<SEC-DOCUMENT>0000875045-15-000034.txt : 20151021
<SEC-HEADER>0000875045-15-000034.hdr.sgml : 20151021
<ACCEPTANCE-DATETIME>20151021161755
ACCESSION NUMBER:		0000875045-15-000034
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		34
CONFORMED PERIOD OF REPORT:	20150930
FILED AS OF DATE:		20151021
DATE AS OF CHANGE:		20151021

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		151168390

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>biib-2015930x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>10-Q</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s18623B1F5833E3206D3DAE73DB681DD0"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="100%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:14pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Washington,&#160;D.C. 20549</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:18pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;font-weight:bold;">Form&#160;10-Q</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="6%"></td><td width="94%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">x</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">For the quarterly period ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">OR</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="6%"></td><td width="94%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Commission File Number 0-19311</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><img src="biogenlogostandard.jpg" style="height:56px;width:173px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:24pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:24pt;font-weight:bold;">BIOGEN INC.</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="49%"></td><td width="4%"></td><td width="47%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">33-0112644</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(State or other jurisdiction of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(I.R.S. Employer</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">225 Binney Street, Cambridge, MA 02142</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">(617)&#160;679-2000</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Address, including zip code, and telephone number, including</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">area code, of registrant&#8217;s principal executive offices)</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days:&#160;&#160;&#160;&#160;Yes</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit and post such files):&#160;&#160;&#160;&#160;Yes</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act (Check One):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="42%"></td><td width="19%"></td><td width="39%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Large&#160;accelerated&#160;filer</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accelerated filer</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-accelerated&#160;filer</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Smaller&#160;reporting&#160;company</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Do not check if a smaller reporting company)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act):&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;No&#160;</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The number of shares of the issuer&#8217;s Common Stock, $0.0005&#160;par value, outstanding as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">October&#160;16, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">222,903,109</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="100%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><br><div></div><hr style="page-break-after:always"><a name="s1524C1338A76B403B4DBAE7421012B3E"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">BIOGEN INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">FORM&#160;10-Q &#8212; Quarterly Report</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">For the Quarterly Period Ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="9%"></td><td width="81%"></td><td width="10%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Page</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;">PART&#160;I&#160;&#8212; </font><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;" href="#s95292127654400789AC7AE742157B8B4"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;">FINANCIAL INFORMATION</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial Statements (unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sEC27577DA9C553FCDF4CAE73DB02E94D"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Income&#160;&#8212; For the Three and Nine Months Ended September 30, 2015 and 2014</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sEC27577DA9C553FCDF4CAE73DB02E94D">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sB7F61FFB18AA6190F2C6AE73D9C26206"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Comprehensive Income &#8212; For the Three and Nine Months Ended September 30, 2015 and 2014</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sB7F61FFB18AA6190F2C6AE73D9C26206">6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sCA343C7D3EBA6C445FEFAE73DB2EB8A3"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Balance Sheets&#160;&#8212; As of September 30, 2015 and December&#160;31, 2014</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sCA343C7D3EBA6C445FEFAE73DB2EB8A3">7</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s2E48925474F92736BC20AE73DB12FFF9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Cash Flows&#160;&#8212; For the Nine Months Ended September 30, 2015 and 2014</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s2E48925474F92736BC20AE73DB12FFF9">8</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sD7F5B705F468B8A491DEAE7422C8A8CA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes to Condensed Consolidated Financial Statements</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sD7F5B705F468B8A491DEAE7422C8A8CA">9</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s5973464BCF9179C4C433AE7426AB4172"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s5973464BCF9179C4C433AE7426AB4172">35</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 3.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sF37A975ECE5C8BE448FBAE742A95D033"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sF37A975ECE5C8BE448FBAE742A95D033">59</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 4.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sB6CD442A03697CCB2441AE742AC53809"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Controls and Procedures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sB6CD442A03697CCB2441AE742AC53809">59</a></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;">PART&#160;II&#160;&#8212; </font><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;" href="#s850E56CD3782C9C8429FAE742AE8EEA8"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;">OTHER INFORMATION</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s565778ED0A04686DC080AE742B1823BD"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Legal Proceedings</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s565778ED0A04686DC080AE742B1823BD">60</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item&#160;1A.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s1ED0177CBD0AE920B3FAAE742B3C9FAA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Risk Factors</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s1ED0177CBD0AE920B3FAAE742B3C9FAA">60</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s70CCD146C84F3CC2FA96AE740F02B0E8"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Unregistered Sales of Equity Securities and Use of Proceeds</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s70CCD146C84F3CC2FA96AE740F02B0E8">72</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 6.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s8B3ADCF1863B6B94C3B8AE742B901855"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Exhibits</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s8B3ADCF1863B6B94C3B8AE742B901855">72</a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s88FAD10395E3771C2718AE742BBF45D7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Signatures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s88FAD10395E3771C2718AE742BBF45D7">73</a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><a name="s78047DD0AAA47626857BAE742125FA7A"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This report contains forward-looking statements that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the &#8220;Act&#8221;) with the intention of obtaining the benefits of the &#8220;Safe Harbor&#8221; provisions of the Act. These forward-looking statements may be accompanied by such words as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;will&#8221; and other words and terms of similar meaning. Reference is made in particular to forward-looking statements regarding:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the anticipated amount, timing and accounting of revenues, contingent payments, milestone, royalty and other payments under licensing, collaboration or acquisition agreements, tax positions and contingencies, collectability of receivables, pre-approval inventory, cost of sales, research and development costs, compensation and other expenses, amortization of intangible assets, foreign currency exchange risk, estimated fair value of assets and liabilities, and impairment assessments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">expectations and plans relating to sales, pricing, growth, launch and prospects of our marketed and pipeline products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact of increased product competition in the markets in which we compete;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the costs and timing of potential trials, filing and approvals, and the potential therapeutic scope of the development and commercialization of our and our collaborators&#8217; pipeline products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our intent to commit resources for research and development opportunities, and expectations relating to selling, general and administrative expense;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the drivers for growing our business, including our plans relating to business development opportunities and research and development programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the anticipated benefits, cost savings, and charges related to our corporate restructuring initiatives; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the expected timing of completion of our 2015 share repurchase program; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the expected timing of the closing our proposed collaboration with Mitsubishi Tanabe Pharma Corporation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our manufacturing capacity, use of third party contract manufacturing and our plans and timing relating to the expansion of our manufacturing capabilities, including anticipated investments and activities in Solothurn, Switzerland and Research Triangle Park, North Carolina;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of the continued uncertainty of the credit and economic conditions in certain countries in Europe and our collection of accounts receivable in such countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact of healthcare reform in the U.S., implementation of provisions of the Patient Protection and Affordable Care Act (also known as the Affordable Care Act or PPACA), and measures being taken worldwide designed to reduce healthcare costs to constrain the overall level of government expenditures, including the impact of pricing actions in Europe and elsewhere, and reduced reimbursement for our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">expectations relating to the timing and execution of our stock repurchase programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to finance our operations and business initiatives and obtain funding for such activities; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of new laws and accounting standards.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These forward-looking statements involve risks and uncertainties, including those that are described in the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; section of this report, and elsewhere in this report that could cause actual results to differ materially from those reflected in such statements. You should not place undue reliance on these statements. Forward-looking statements speak only as of the date of this report. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><a name="s78047DD0AAA47626857BAE742125FA7A"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE REGARDING COMPANY AND PRODUCT REFERENCES</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Throughout this report, &#8220;Biogen,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Biogen Inc. (formerly Biogen Idec Inc.) and its consolidated subsidiaries. References to &#8220;RITUXAN&#8221; refer to both RITUXAN (the trade name for rituximab in the U.S., Canada and Japan) and MabThera (the trade name for rituximab outside the U.S., Canada and Japan), and &#8220;ANGIOMAX&#8221; refers to both ANGIOMAX (the trade name for bivalirudin in the U.S., Canada and Latin America) and ANGIOX (the trade name for bivalirudin in Europe).</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE&#160;REGARDING TRADEMARKS</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ALPROLIX</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">AVONEX</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ELOCTATE</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, PLEGRIDY</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RITUXAN</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, TECFIDERA</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and TYSABRI</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;are registered trademarks of Biogen. BENEPALI</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ELOCTA</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, FLIXABI</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, FUMADERM</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and ZINBRYTA</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;are trademarks of Biogen. The following are trademarks of the respective companies listed: ANGIOMAX</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and ANGIOX</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212;&#160;The Medicines Company; BETASERON</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;&#160;Bayer Pharma AG; BRENZYS</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;&#8212; Merck Sharp &amp; Dohme Corp.; EXTAVIA</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212;&#160;Novartis AG; FAMPYRA</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212;&#160;Acorda Therapeutics, Inc.; GAZYVA</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212;&#160; Genentech, Inc.; and REBIF</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212;&#160;Ares Trading S.A.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><a name="s95292127654400789AC7AE742157B8B4"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">PART&#160;I FINANCIAL INFORMATION</font></div><a name="sEA51917EE053E4D4682BAE742179DF58"></a><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="sEC27577DA9C553FCDF4CAE73DB02E94D"></a><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in thousands, except per share amounts)</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="45%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,391,717</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,117,366</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,762,605</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,916,423</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unconsolidated joint business</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">337,181</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">290,678</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,005,302</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">890,859</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">48,961</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">103,402</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">156,557</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">255,367</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,777,859</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,511,446</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,924,464</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,062,649</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost and expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of sales, excluding amortization of acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">310,028</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">302,639</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">908,579</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">873,771</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">519,863</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">417,174</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,471,140</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,393,331</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">477,827</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">570,436</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,530,083</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,658,732</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">98,065</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">122,431</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">285,972</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">382,515</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Gain) loss on fair value remeasurement of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">244</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(49,433</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,887</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(46,213</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,406,027</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,363,247</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,201,661</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,262,136</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain on sale of rights</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,379</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,138</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,371,832</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,152,578</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,722,803</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,812,651</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(15,413</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16,290</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(41,288</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(17,030</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income before income tax expense and equity in loss of investee, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,356,419</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,136,288</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,681,515</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,795,621</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">330,093</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">274,774</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">904,475</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">721,709</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity in loss of investee, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,833</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,394</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">12,548</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14,932</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,019,493</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">856,120</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,764,492</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,058,980</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">53,871</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(738</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">49,053</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,660</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">965,622</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">856,858</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,715,439</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,051,320</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.16</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.63</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.60</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.67</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.15</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.62</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.57</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.64</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">232,191</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236,217</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">234,134</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236,641</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">232,612</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236,972</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">234,659</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237,449</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><a name="sB7F61FFB18AA6190F2C6AE73D9C26206"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in thousands)</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="45%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">965,622</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">856,858</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,715,439</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,051,320</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on securities available for sale, net of tax of $(1,320) and $(6) for the three months ended September 30, 2015 and 2014, respectively; and $(699) and $(3,021) for the nine months ended September 30, 2015 and 2014, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,239</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1,154</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5,127</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on cash flow hedges, net of tax of $(187) and $302 for the three months ended September 30, 2015 and 2014, respectively; and $(229) and $307 for the nine months ended September 30, 2015 and 2014, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(31,171</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48,242</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(40,084</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64,793</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on pension benefit obligation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">523</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">691</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,632</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,338</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Currency translation adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(23,504</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(60,254</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(61,322</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(71,246</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other comprehensive income (loss), net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(56,391</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11,309</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(97,928</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10,242</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">909,231</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">845,549</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,617,511</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,041,078</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">53,586</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(738</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">49,053</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,660</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">962,817</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">844,811</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,666,564</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,048,738</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><a name="sCA343C7D3EBA6C445FEFAE73DB2EB8A3"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in thousands, except per share amounts)</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="68%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, <br>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, <br>2014</font></div></td></tr><tr><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">ASSETS</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,089,003</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,204,924</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,753,499</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">640,460</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,327,780</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,292,445</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due from unconsolidated joint business, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">319,788</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">283,360</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">918,921</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">804,022</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">861,882</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">446,943</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9,270,873</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,672,154</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,947,354</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,470,652</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,027,821</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,765,683</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,181,245</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,028,507</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,408,854</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,760,249</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">892,221</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">617,536</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20,728,368</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14,314,781</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">LIABILITIES AND EQUITY</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable and other financing arrangements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,171</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,136</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">458,672</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">168,058</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">251,228</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">229,178</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,918,897</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,819,334</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,633,968</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,219,706</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable and other financing arrangements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,529,275</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">580,283</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">136,761</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50,656</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">861,421</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">650,096</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10,161,425</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,500,741</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commitments and contingencies</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc. shareholders&#8217; equity</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Preferred stock, par value $0.001 per share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Common stock, par value $0.0005 per share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">124</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">129</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,342,373</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,196,156</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(157,416</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(59,488</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Retained earnings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11,999,358</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,283,919</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Treasury stock, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,611,713</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,611,706</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total Biogen Inc. shareholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10,572,726</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,809,010</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(5,783</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,030</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10,566,943</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,814,040</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total liabilities and equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20,728,368</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14,314,781</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><a name="s2E48925474F92736BC20AE73DB12FFF9"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in thousands)</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="73%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,764,492</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,058,980</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to reconcile net income to net cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">444,100</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">530,508</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">131,537</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">119,508</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(185,802</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(229,273</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">31,564</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(95,711</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in operating assets and liabilities, net:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(63,608</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(297,057</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(150,387</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(119,890</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(174,532</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19,283</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other changes in operating assets and liabilities, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(121,659</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22,904</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,675,705</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,009,252</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from sales and maturities of marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,363,374</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,942,871</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4,870,142</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,738,584</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquisitions of business, net of cash acquired</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(198,798</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of property, plant and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(456,885</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(180,854</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration related to Fumapharm AG acquisition</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(550,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(175,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(33,620</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13,131</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,746,071</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,164,698</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchase of treasury stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,998,190</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(359,981</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from issuance of stock for share-based compensation arrangements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">45,509</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">44,960</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from borrowings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,930,936</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Repayment of borrowings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,083</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,674</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Excess tax benefit from stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">70,778</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">90,423</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(62,147</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(15,336</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by (used in) financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,984,803</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(242,608</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net increase in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,914,437</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">601,946</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of exchange rate changes on cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(30,358</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(18,227</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents, beginning of the period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,204,924</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">602,562</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,089,003</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,186,281</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><a name="sD7F5B705F468B8A491DEAE7422C8A8CA"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited)</font></div></div><br><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><a name="s731AB998D2B2284807E8AE73DA82BEA7"></a><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">1.&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Overview</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS), ALPROLIX for the treatment of hemophilia B, ELOCTATE for the treatment of hemophilia A and FUMADERM for the treatment of severe plaque psoriasis. We also generate revenue from our collaboration with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin&#8217;s lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, and share profits and losses with Genentech for GAZYVA, which is approved for the treatment of CLL.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our consolidated financial statements and the accompanying notes included in our Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;(</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form&#160;10-K). Our accounting policies are described in the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Notes to Consolidated Financial Statements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form&#160;10-K and updated, as necessary, in this Form&#160;10-Q. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;operating segment, which is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited)</font></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounts Receivable</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our accounts receivable primarily arise from product sales in the U.S.&#160;and Europe and mainly represent amounts due from our wholesale distributors, public hospitals and other government entities. Concentrations of credit risk with respect to our accounts receivable, which are typically unsecured, are limited due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. The majority of our accounts receivable require payment within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30 to 90 days</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We monitor the financial performance and credit worthiness of our customers so that we can properly assess and respond to changes in their credit profile. We provide reserves against trade receivables for estimated losses that may result from a customer&#8217;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve. To date, our historical reserves and write-offs of accounts receivable have not been significant.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year after the time of sale, we discount our receivables and reduce related revenues over the period of time that we estimate those amounts will be paid using the country&#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recognized as a component of other income (expense), net in our condensed consolidated statement of income. To date, our historical discounts of receivables have not been significant.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">New Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. We are currently evaluating the method of adoption and the potential impact that Topic 606 may have on our financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2014, the FASB issued ASU No. 2014-11, Transfers and Servicing (Topic 860): Repurchase-to-Maturity Transactions, Repurchase Financings, and Disclosure. The new standard expanded secured borrowing accounting to include repurchase-to-maturity transactions and repurchase financings and set forth new disclosure requirements for repurchase agreements, securities lending transactions, and repurchase-to-maturity transactions that are accounted for as secured borrowings. We adopted this standard on April 1, 2015 and expanded our disclosures presented in Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these condensed consolidated financial statements. The adoption of this standard did not have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2015, the FASB issued ASU No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. The new standard requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. In August 2015, the FASB issued ASU No. 2015-15, Interest - Imputation of Interest (Subtopic 835-30): Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements, which clarified that debt issuance costs related to line-of-credit arrangements can be presented in the balance sheet as an asset and amortized over the term of the line-of-credit arrangement. We adopted these standards as of September 30, 2015 with retroactive application. The adoption of these standards did not have a significant impact on our financial position or results of operations. For additional information, please read Note 6, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these condensed consolidated financial statements.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited)</font></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2015, the FASB issued ASU No. 2015-05, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer's Accounting for Fees Paid in a Cloud Computing Arrangement. Under this standard, if a cloud computing arrangement includes a software license, the software license element of the arrangement should be accounted for consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the arrangement should be accounted for as a service contract. The new standard will be effective for us on January 1, 2016. The adoption of this standard is not expected to have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2015, the FASB issued ASU No. 2015-07, Fair Value Measurement (Topic 820): Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent). The new standard removes the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient. The new standard will be effective for us on January 1, 2016. Early application is permitted. We maintain investments in certain venture capital funds which primarily invest in small, privately-owned, venture-backed biotechnology companies. The value of our investments in these venture capital funds is estimated using the net asset value of the fund and has been included in the fair value hierarchy disclosure as a Level 3 measurement. These venture capital investments are not material to our financial position or results of operations. We adopted this standard as of June 30, 2015 and our investments in venture capital funds are no longer included in our disclosures reflected in Note 6, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. The new standard applies only to inventory for which cost is determined by methods other than last-in, first-out and the retail inventory method, which includes inventory that is measured using first-in, first-out or average cost. Inventory within the scope of this standard is required to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. The new standard requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined and sets forth new disclosure requirements related to the adjustments. The new standard will be effective for us on January 1, 2016. The adoption of this standard is not expected to have an impact on our financial position or results of operations.</font></div><a name="s65679A6E640FBD92E462AE73D94922E3"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">2.&#160;&#160;&#160;&#160;Acquisitions</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Convergence Pharmaceuticals</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 12, 2015, we completed our acquisition of all of the outstanding stock of Convergence Pharmaceuticals (Convergence), a clinical-stage biopharmaceutical company with a focus on developing product candidates for neuropathic pain. Convergence&#8217;s lead candidate is its Phase 2 clinical candidate Raxatrigine (CNV1014802), which has demonstrated clinical activity in proof-of-concept studies for trigeminal neuralgia (TGN), a chronic orphan disease. Additionally, Raxatrigine has potential applicability in several other neuropathic pain states. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The purchase price consisted of a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$200.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;cash payment at closing, plus contingent consideration in the form of development and approval milestones up to a maximum of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$450.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$350.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;is associated with the development and approval of Raxatrigine for the treatment of TGN. The acquisition was funded from our existing cash on hand and has been accounted for as the acquisition of a business. In addition to obtaining the rights to Raxatrigine and additional product candidates in preclinical development, we retained the services of key employees of Convergence.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Convergence, we recorded a liability of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$274.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;representing the fair value of the contingent consideration.&#160;This amount was estimated through a valuation model that incorporates industry-based probability adjusted assumptions relating to the achievement of these milestones and thus the likelihood of making the contingent payments. This fair value measurement is based upon significant inputs not observable in the market and therefore represents a Level 3 measurement. </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The purchase price, as adjusted, consisted of the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="87%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash portion of consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">200.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">274.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">474.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subsequent changes in the fair value of the contingent consideration obligation will be recognized as adjustments to contingent consideration and reflected in our condensed consolidated statements of income. For additional information related to the fair value of this obligation, please read Note 6,&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the second quarter of 2015, we adjusted our preliminary estimate of the fair value of the assets acquired and contingent consideration as of the date of acquisition to reflect revised estimates to our initial clinical development plans, resulting probabilities of success and the timing of certain milestone payments. The primary effects of these revised estimates resulted in an increase in the value of our estimated contingent consideration and goodwill by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$36.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our revised purchase price allocation is reflected in the chart below. Our purchase price allocation is substantially complete.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the estimated fair values of the separately identifiable assets acquired and liabilities assumed as of February&#160;12, 2015, as adjusted:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="87%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">424.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">128.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(84.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">474.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our estimate of the fair value of the in-process research and development (IPR&amp;D) programs acquired was determined through a probability adjusted discounted cash flow analysis utilizing a discount rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This valuation was primarily driven by the value associated with the lead candidate, Raxatrigine, which is in development for the treatment of TGN and is expected to be completed no earlier than 2020, at a remaining cost of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$145.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair value associated with Raxatrigine for the treatment of TGN was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$200.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have recorded additional IPR&amp;D assets related to the use of Raxatrigine in two additional neuropathic pain indications, with a total estimated value of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$220.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The remaining cost of development for these two indications is approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$415.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, with an expected completion date of no earlier than 2021. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have attributed the goodwill recognized to the Convergence workforce's expertise in chronic pain research and clinical development and to establishing a deferred tax liability for the acquired IPR&amp;D intangible assets which have no tax basis. The goodwill is not tax deductible.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pro forma results of operations would not be materially different as a result of the acquisition of Convergence and therefore are not presented. Subsequent to the acquisition date, our results of operations include the results of operations of Convergence.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><a name="s12D4311010E408CCBCECAE73D985356A"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><br><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">3.&#160;&#160;&#160;&#160;Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="45%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">47.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">387.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">49.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">483.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">332.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,278.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">26.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,636.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(20.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(14.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(37.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(277.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(871.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1,151.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(40.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(271.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(321.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">59.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">500.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">50.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">610.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, included in our condensed consolidated balance sheets, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="73%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>September 30, <br>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">148.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">124.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">462.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">359.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reserves</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">610.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">483.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><a name="sFD199F2A0AA7802DD3F8AE73DA8459FB"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">4.&#160;&#160;&#160;&#160;Inventory</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="73%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>September 30, <br>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">221.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">128.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">537.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">511.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">159.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">164.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">918.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">804.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our inventory included </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$54.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;associated with our ZINBRYTA, FLIXABI and BENEPALI programs, which have been capitalized in advance of regulatory approval. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our inventory included </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;associated with our ZINBRYTA program, which had been capitalized in advance of regulatory approval.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><a name="sD7DEE30031DED236124BAE73D9411F27"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><br><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">5.&#160;&#160;&#160;&#160;Intangible Assets and Goodwill</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"></td></tr><tr><td width="21%"></td><td width="17%"></td><td width="1%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">543.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(499.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">43.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">543.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(481.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-23&#160;years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,005.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,523.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">481.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,005.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,396.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">608.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">735.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">735.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">314.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">314.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks&#160;and&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">tradenames</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed&#160;rights&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and&#160;patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3-17 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,297.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(440.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,856.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,280.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(300.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,980.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,645.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3,464.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,181.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,207.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,178.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,028.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amortization of acquired intangible assets totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$98.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$286.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$122.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$382.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in amortization of acquired intangible assets was primarily driven by higher expected lifetime revenues of AVONEX, partially offset by lower expected lifetime revenues of TYSABRI. Amortization of acquired intangible assets during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;included a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;impairment loss related to one of our IPR&amp;D intangible assets.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in amortization of acquired intangible assets was primarily driven by a decrease in AVONEX revenues during the comparative periods. Amortization of acquired intangible assets during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;included total impairment charges of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to one of our out-licensed patents and one of our IPR&amp;D intangible assets.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Developed Technology</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$472.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">IPR&amp;D</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IPR&amp;D represents the fair value assigned to research and development assets that we acquire that have not reached technological feasibility at the date of acquisition. Upon commercialization, we will determine the estimated useful life. In connection with our acquisition of Convergence in February 2015, we acquired IPR&amp;D programs with an estimated fair value of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$424.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This amount will be adjusted for foreign exchange rate fluctuations. For a more detailed description of this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Acquired and In-licensed Rights and Patents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of the TYSABRI rights from Elan Corporation plc (Elan). Elan was acquired by Perrigo Company plc (Perrigo) in December 2013. The net book value of this asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2,797.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><a name="sD7DEE30031DED236124BAE73D9411F27"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Estimated Future Amortization of Intangible Assets </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption of intangible assets. Our most significant intangible assets are related to our AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of AVONEX and TYSABRI. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of either product.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long range planning cycle was updated in the third quarter of 2015. Based upon this analysis, there was not a significant change in our expected rate of amortization for acquired intangible assets and the estimated future amortization is expected to be as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="87%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>September 30, <br>2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015 (remaining three months)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">94.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">348.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">318.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">291.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">275.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">269.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,596.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="87%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,760.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase to goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">649.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,408.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in goodwill during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was related to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$600.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent payments achieved (exclusive of a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$78.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;tax benefit) to former shareholders of Fumapharm AG or holders of their rights and our acquisition of Convergence. Other includes changes related to foreign exchange rate fluctuations. For additional information related to future contingent payments to the former shareholders of Fumapharm AG or holders of their rights, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these condensed consolidated financial statements. For additional information related to our acquisition of Convergence, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;accumulated impairment losses related to goodwill.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><a name="sD92AF72B4C4CA5234693AE73D95DF6F9"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><br><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">6.&#160;&#160;&#160;&#160;Fair Value Measurements</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</font></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="41%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of September 30, 2015 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,804.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,804.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,039.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,039.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,411.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,411.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">249.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">249.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">25.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">25.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">61.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">61.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">38.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">38.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,630.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">25.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,605.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">31.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">31.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">481.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">481.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">512.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">31.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">481.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="41%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2014 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">716.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">716.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,063.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,063.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">849.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">849.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">198.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">198.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">72.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">72.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,943.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,937.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">220.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;material impairments of our assets measured and carried at fair value during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In addition, there were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;changes in valuation techniques or inputs utilized or transfers between fair value measurement levels during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities was determined through third party pricing services. For a description of our validation procedures related to prices provided by third party pricing services, refer to Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies: Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K. For additional information </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><a name="sD92AF72B4C4CA5234693AE73D95DF6F9"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><br><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">related to our decision to no longer reflect our investments in venture capital funds within the fair value hierarchy, refer to Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies: New Accounting Pronouncements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Instruments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="45%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875% Senior Notes due March&#160;1, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">614.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">566.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">634.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">571.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,514.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,492.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,008.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">991.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,767.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,733.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,766.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,721.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,680.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,514.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">647.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">583.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of our notes payable to Fumedica was estimated using market observable inputs, including current interest and foreign currency exchange rates. The fair values of each of our series of Senior Notes were determined through market, observable, and corroborated sources. In accordance with ASU No. 2015-03, during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we reclassified </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our debt issuance costs related to our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes issued in 2008 from an asset to a reduction to the carrying amount of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes. For additional information related to our notes payable to Fumedica and our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes, please read Note 12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K. For additional information related to our Senior Notes issued on September 15, 2015, please read Note 10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the fair values of our contingent consideration obligations which includes Level 3 measurements:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="45%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">495.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">279.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">215.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">280.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">274.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(49.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(46.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(14.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(14.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(21.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">481.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">213.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">481.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">213.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$301.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$200.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of our contingent consideration obligations valued using Level 3 measurements were reflected as components of other long-term liabilities in our condensed consolidated balance sheets with the remaining balances reflected as a component of accrued expenses and other. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Convergence, we recorded a liability of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$274.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing the fair value of the contingent consideration. This valuation was based on probability weighted net cash outflow projections of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$450.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is the estimated cost of debt financing for market participants. This liability reflects the revised estimate from the date of acquisition for our initial clinical development plans, resulting probabilities of success and the timing of certain milestone payments. For a more detailed description of this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these condensed consolidated financial statements. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$176.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, related to our contingent consideration obligations arising from our acquisition of Convergence, is reflected as a component of accrued expenses and other in our condensed consolidated balance sheets.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><a name="sD92AF72B4C4CA5234693AE73D95DF6F9"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquired IPR&amp;D</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Convergence, we also allocated </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$424.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the total purchase price to acquired IPR&amp;D, which was capitalized as an intangible asset. The amount allocated to acquired IPR&amp;D was based on significant inputs not observable in the market and thus represented a Level 3 fair value measurement. This estimate was also adjusted from our preliminary estimate as of the date of acquisition to reflect revised estimates to our initial clinical development plans, resulting probabilities of success and the timing of certain milestone payments. These assets will be tested for impairment annually until commercialization, after which time the IPR&amp;D will be amortized over its estimated useful life. For a more detailed description of this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these condensed consolidated financial statements.</font></div><a name="sC59C96C33422206F0D2AAE73D96350AB"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">7.&#160;&#160;&#160;&#160;Financial Instruments</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Marketable Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize our marketable debt and equity securities, classified as available-for-sale:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="41%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of September 30, 2015 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">272.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">272.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">767.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">768.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,481.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,480.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">929.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">929.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">249.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">250.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,700.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,700.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">25.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">28.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="41%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2014 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">370.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">370.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">692.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">693.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">269.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">270.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">579.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">580.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">198.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">198.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,111.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,112.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">less than 90&#160;days</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;from the date of purchase included in cash and cash equivalents on the accompanying condensed consolidated balance sheet:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="73%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>September 30, <br>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">21.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">188.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">305.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,119.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">321.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">475.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,804.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">716.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and our short-term debt securities approximate fair value due to their short term maturities. Our overnight reverse repurchase agreements are collateralized with agency-guaranteed mortgage securities and represent approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of total assets as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Contractual Maturities: Available-for-Sale Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities classified as available-for-sale by contractual maturity are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="45%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,753.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,753.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">640.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">640.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,820.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,820.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,343.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,345.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">127.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">127.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">126.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">126.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,700.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,700.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,111.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,112.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The average maturity of our marketable debt securities available-for-sale as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proceeds from Marketable Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="45%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,387.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">625.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,363.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,942.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Strategic Investments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$68.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$47.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which are included in investments and other assets in our accompanying condensed consolidated balance sheets. Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies and investments in venture capital funds where the underlying investments are in equity securities of biotechnology companies. </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><a name="s244AC05043B6781C2673AE73DA7C0B7B"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><br><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">8.&#160;&#160;&#160;&#160;Derivative Instruments</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the global nature of our operations, portions of our revenues are earned in currencies other than the U.S.&#160;dollar. The value of revenues measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign currency forward contracts in effect as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;had durations of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These contracts have been designated as cash flow hedges and accordingly, to the extent effective, any unrealized gains or losses on these foreign currency forward contracts are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses for the effective portion of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized. To the extent ineffective, hedge transaction gains and losses are reported in other income (expense), net.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="69%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Foreign Currency: (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>September 30, <br>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,146.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,174.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">17.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound sterling</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">12.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japanese yen</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Australian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,190.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,302.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The portion of the fair value of these foreign currency forward contracts that was included in accumulated other comprehensive income (loss) in total equity reflected gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$23.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$72.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We expect all contracts to be settled over the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months and any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, credit risk did not change the fair value of our foreign currency forward contracts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments on our condensed consolidated statements of income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td width="20%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="19%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended September 30,</font></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Effective Portion)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized into Net Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Ineffective Portion)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">43.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td width="20%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="19%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months Ended September 30,</font></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Effective Portion)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized into Net Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Ineffective Portion)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">119.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><a name="s244AC05043B6781C2673AE73DA7C0B7B"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may enter into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Interest Rate Lock Contracts</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we entered into treasury rate locks that were designated as cash flow hedges to hedge against changes in the 10-year and 30-year U.S. treasury interest rates that could have impacted our anticipated debt offering. In connection with the issuance of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.05%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes, as described in Note 10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we settled the treasury rate locks and realized an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;gain. As the hedging relationship was effective, the gain was recorded in AOCI and will be recognized in other income (expense), net over the life of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.05%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Interest Rate Swap Contracts</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the issuance of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes,  as described in Note 10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we entered into interest rate swaps with an aggregate notional amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$675.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes attributable to changes in interest rates. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recognized as a component of interest expense in our condensed consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Other Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also enter into other foreign currency forward contracts, usually with one month durations, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate notional amount of these outstanding foreign currency contracts was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$787.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$365.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to these contracts were recognized as a component of other income (expense), net, for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, as compared to net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><a name="s244AC05043B6781C2673AE73DA7C0B7B"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While certain of our derivatives are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivatives including those designated as hedging instruments:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="42%"></td><td width="42%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">Fair Value As of September 30, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">54.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">17.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><a name="sedf41bf01d6f43109ef608c313ac683d"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">9.&#160;&#160;&#160;&#160;Property, Plant and Equipment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are recorded at cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,320.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,186.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Research Triangle Park Facility Purchase</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On August 24, 2015, we purchased from Eisai, Inc. (Eisai) its drug product manufacturing facility and supporting infrastructure in Research Triangle Park (RTP), North Carolina for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$104.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The purchase price consisted of the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="87%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Buildings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">58.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Machinery and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">25.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Land</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">104.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On August 24, 2015, we also amended our existing </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;year lease related to Eisai's oral solid dose products manufacturing facility in RTP, North Carolina where we manufacture our and Eisai's oral solid dose products. As amended, the lease provides for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;year term and our agreement to purchase the facility upon expiration of the lease term and Eisai's completion of certain activities. Accordingly, we recorded the assets along with a corresponding financing obligation on our condensed consolidated balance sheet for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net present value of the future minimum lease payments. The assets were recorded as a component of buildings and machinery and equipment. We expect to complete the purchase of the oral solid products manufacturing facility at the end of the lease term in the third quarter of 2018.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><a name="sd50ae5fd61304a66b20a975a6ad96b9e"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><br><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">10.&#160;&#160;&#160;&#160;Indebtedness</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2015 Senior Notes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On September 15, 2015, we issued senior unsecured notes for an aggregate principal amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, consisting of the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15, 2020, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.792%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">3.625%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15, 2022, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.920%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">4.05%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15, 2025, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.764%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">5.20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15,&#160;2045, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.294%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These notes are senior unsecured obligations and may be redeemed at our option at the greater of (1) </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the principal amount plus accrued and unpaid interest or (2) the sum of the present values of the remaining scheduled payments of interest and principal discounted to the date of redemption on a semi-annual basis at the treasury rate plus an incremental margin, plus, in either case, accrued and unpaid interest. The notes also contain a change of control provision that may require us to purchase the notes at a price equal to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the principal amount plus accrued and unpaid interest to the date of purchase under certain circumstances. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The costs associated with this offering of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$47.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;have been recorded as a reduction to the carrying amount of the debt on our condensed consolidated balance sheet. These costs will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. The discounts will be amortized as additional interest expense over the period from issuance through maturity using the effective interest rate method. Interest on the notes is payable March 15 and September 15 of each year. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additionally, in connection with this offering, we entered into interest rate swaps. The carrying value of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes includes approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to changes in the fair value of the interest rate swaps. For additional information, please read Note 8, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Credit Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2015, we entered into a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;senior unsecured revolving credit facility, under which we are permitted to draw funds for working capital and general corporate purposes for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;years. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of September 30, 2015, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;outstanding borrowings and were in compliance with all covenants under this facility.</font></div><a name="s7A41494EE07E7E0F143EAE73D937516C"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">11.&#160;&#160;&#160;&#160;Equity</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total equity as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;decreased </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$247.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Significant changes were as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additional paid in capital was reduced by share repurchases of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$2,998.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as described below, and activity under our share-based compensation arrangements totaling </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$144.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive losses of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$97.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc. of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$2,715.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchases</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2015, our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock (2015 Share Repurchase Program). This authorization does not have an expiration date. Repurchased shares will be retired. The 2015 Share Repurchase Program is in addition to the approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares remaining under our February 2011 Share Repurchase Program (2011 Share Repurchase Program), which has been used principally to offset common stock issuances under our share-based compensation plans.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2,998.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under our 2015 Share Repurchase Program, which had the effect of reducing additional paid in capital by a similar amount.&#160;We did not repurchase any shares of common stock under our 2011 Share Repurchase Program. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we purchased approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$360.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under our 2011 Share Repurchase Program. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, additional paid in capital totaled approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,342.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Noncontrolling Interests</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table reconciles equity attributable to noncontrolling interests (NCI):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="45%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NCI, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income (loss) attributable to NCI, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">53.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">49.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value of net assets and liabilities acquired and assigned to NCI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Distribution to NCI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(60.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(60.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Translation adjustment and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NCI, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(5.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(5.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, net income (loss) attributable to NCI, net of tax, was related to a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;milestone payment made to Neurimmune SubOne AG. For additional information, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div><a name="s354982014C84B819929EAE73D94FBCA9"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">12.&#160;&#160;&#160;&#160;Accumulated Other Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td width="31%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">71.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(31.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(99.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(59.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">78.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(61.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">19.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(118.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(117.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(40.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(61.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(97.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">31.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(27.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(160.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(157.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td width="31%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(23.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(19.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(27.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(71.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(71.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of September 30, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(18.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(61.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(38.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td width="24%"></td><td width="21%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from Accumulated Other Comprehensive Income</font></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">43.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">119.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">42.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">117.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><a name="s63F990A34C972575180DAE73D9597B41"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">13.&#160;&#160;&#160;&#160;Earnings&#160;per Share</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="45%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">965.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">856.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,715.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,051.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">232.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">234.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">232.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">234.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were not significant.</font></div><a name="s0197C91C9F7A3EC0F765AE73D95BBFCF"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">14. &#160;&#160;&#160;&#160;Share-based Payments</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-based Compensation Expense</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="45%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">68.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">78.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">17.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">99.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">115.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">28.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">167.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">193.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">25.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">159.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">186.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(6.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(46.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(55.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">19.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">113.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">130.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="45%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">33.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">30.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">94.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">86.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(9.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">17.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">28.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">167.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">193.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">25.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">159.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">186.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We estimate the fair value of our obligations associated with our performance and cash settled performance units at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Grants Under Share-based Compensation Plans</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our equity grants to employees, officers and directors under our current stock plans:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td width="73%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">181,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance shares</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">115,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">182,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">89,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">393,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">437,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Employee Stock Purchase Plan (ESPP)</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2015, our stockholders approved the Biogen Inc. 2015 Employee Stock Purchase Plan (ESPP). The ESPP, which became effective on July 1, 2015, replaced the Biogen Idec Inc. 1995 ESPP (1995 ESPP), which expired on June&#160;30, 2015. The maximum aggregate number of shares of our common stock that may be purchased under the ESPP is </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,200,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">98,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares were issued under our 1995 ESPP and 2015 ESPP, respectively, compared to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">150,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;shares issued under our 1995 ESPP in the prior year comparative period.</font></div><a name="s8980C7AB67BF93A32810AE73DAC00794"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">15.&#160;&#160;&#160;&#160;Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="45%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(10.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(10.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Manufacturing deduction</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our effective tax rate benefited from lower anticipated taxes on foreign earnings. Our effective tax rate for the comparative </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;month periods also reflects a benefit, described below, resulting from the remeasurement of one of our uncertain tax positions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in the U.S.&#160;federal jurisdiction, various U.S. states, and foreign jurisdictions. With few exceptions, including the proposed disallowance we discuss below, we are no longer subject to U.S.&#160;federal tax examination for years before 2013 or state, local, or non-U.S.&#160;income tax examinations for years before 2004. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2015, we received a final assessment from the Danish Tax Authority (SKAT) for fiscal 2009, regarding withholding taxes and the treatment of certain intercompany transactions involving our Danish affiliate and another of our affiliates.&#160;The audits of our tax filings for 2010 through 2013 are not completed but have been prepared in a manner consistent with prior filings, with similar transactions, which may result in an assessment for those years.&#160;The total amount assessed for 2009 is </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$49.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, including interest.&#160;For all periods potentially under dispute, we believe that positions taken in our tax filings are valid and we are contesting the assessment vigorously.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Federal Uncertain Tax Positions</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net effect of adjustments to our uncertain tax positions was a net benefit of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$24.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;primarily related to the state impact of a federal uncertain tax item. It is reasonably possible that we will adjust the value of our uncertain tax positions related to our unconsolidated joint business and certain transfer pricing issues as we receive additional information from various taxing authorities, including reaching settlements with the authorities. In addition, the Internal Revenue Service (IRS) and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2011, in conjunction with our examination, the IRS proposed a disallowance of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$130.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in deductions for tax years 2007, 2008 and 2009 related to payments for services provided by our wholly owned Danish subsidiary located in Hiller&#248;d, Denmark. We believe that these items represent valid deductible business expenses and are vigorously defending our position. We have initiated a mutual agreement procedure between the IRS and SKAT for the years 2001 through 2009, in an attempt to reach agreement on the issue. In addition, we have applied for a bilateral advanced pricing agreement for the years 2010 through 2014 to resolve similar issues for the subsequent years.</font></div><a name="sF25BABAA07DC8173DC31AE73D943C0D0"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">16.&#160;&#160;&#160;&#160;Other Consolidated Financial Statement Detail</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Income (Expense), Net</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="45%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">13.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(15.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(28.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(22.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(18.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(7.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(15.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(41.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(17.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accrued Expenses and Other</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="73%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>September 30, <br>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">479.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">265.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related rebates</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">462.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">359.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">214.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">393.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">154.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">172.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">58.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">120.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">549.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">507.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,918.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,819.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Long-Term Liabilities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities consist of the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="73%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>September 30, <br>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">301.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">218.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">341.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">249.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other long-term liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">861.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">650.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Pricing of TYSABRI in Italy - AIFA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2011, Biogen Italia SRL (formerly Biogen Idec Italia SRL), our Italian subsidiary,&#160;received notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) that sales of TYSABRI after mid-February 2009 exceeded a reimbursement limit established pursuant to a Price Determination Resolution granted by AIFA in December 2006. In December 2011, we filed an appeal against AIFA in administrative court in Rome, Italy seeking a ruling that the reimbursement limit is unenforceable. That appeal is pending. </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2014, AIFA eliminated the reimbursement limit from February 2013 going forward. As a result, in June 2014, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$53.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of TYSABRI revenues related to the periods beginning February 2013 that were previously deferred. AIFA and Biogen Italia SRL continue to discuss a possible resolution for the period between February 2009 and January 2013. We have approximately EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">75 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;recorded as accrued expenses and deferred revenue in our long-term liabilities in our condensed consolidated balance sheets for this matter.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information relating to our agreement with AIFA relating to sales of TYSABRI in Italy, please read Note 4, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Accounts Receivable</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><a name="s4DF948E3A03D4AF37C1DAE73DAF309EE"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">17.&#160;&#160;&#160;&#160;Investments in Variable Interest Entities</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Neurimmune SubOne AG</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2007, we entered into a collaboration agreement with Neurimmune SubOne AG (Neurimmune), a subsidiary of Neurimmune AG, for the development and commercialization of antibodies for the treatment of Alzheimer&#8217;s disease. Neurimmune conducts research to identify potential therapeutic antibodies and we are responsible for the development, manufacturing and commercialization of all products. Our anti-amyloid beta antibody, aducanumab (BIIB037), for the treatment of Alzheimer&#8217;s disease resulted from this collaboration. In September 2015, we announced that the first patient had been enrolled in a Phase 3 trial for aducanumab, which triggered a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;milestone payment due to Neurimmune. As we consolidate the financial results of Neurimmune, we recognized this payment as a charge to noncontrolling interest in the third quarter of 2015. Based upon our current development plans, we may pay Neurimmune up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$275.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in remaining milestone payments. We may also pay royalties in the low-to-mid-teens on sales of any resulting commercial products.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts that are incurred by Neurimmune for research and development expenses in support of the collaboration that we reimburse are reflected in research and development expense in our condensed consolidated statements of income. Future milestone payments, if any, will be reflected in our condensed consolidated statements of income as a charge to noncontrolling interest, net of tax, when such milestones are achieved.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the collaboration incurred expenses totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$39.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$87.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which is included in total costs and expenses in our condensed consolidated statements of income, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$29.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Neurimmune are not significant to our financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Unconsolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have relationships with other variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the total carrying value of our investments in biotechnology companies totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our maximum exposure to losses related to these variable interest entities is limited to the carrying value of our investments.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income, as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our investments in variable interest entities, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><a name="s902EFC4D98F84C8C4264AE73D956941A"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><br><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">18.&#160;&#160;&#160;&#160;Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Mitsubishi Tanabe Pharma Corporation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On September 9, 2015, we announced an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) to exclusively license MT-1303, a late stage experimental medicine with potential in multiple autoimmune indications. MT-1303 is an oral compound that targets the sphingosine 1-phosphate (S1P) receptor. Under the terms of the agreement, we will receive worldwide rights to MT-1303, excluding Asia. We will be responsible for global commercialization and development costs except for costs related to the Asian territories, which are the responsibility of MTPC. The transaction is subject to customary closing conditions, including the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the United States, and is expected to close in the fourth quarter of 2015.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon closing, we will pay MTPC an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and in the future may pay up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$484.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in milestone payments for multiple indications and territories, along with average royalties in the mid-teen to high-teen percentages of annual net sales. We will record the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upfront payment as research and development expense in our condensed consolidated statements of income when the agreement closes. MTPC has the right to participate in our global clinical trials related to MT-1303 and has an option to co-promote non-MS indications in the U.S. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Applied Genetic Technologies Corporation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On July 2, 2015, we announced a collaboration and license agreement to develop gene-based therapies for multiple ophthalmic diseases with Applied Genetic Technologies Corporation (AGTC). The collaboration will focus on the development of a portfolio of AGTC&#8217;s therapeutic programs, including both a clinical stage candidate for X-linked Retinoschisis (XLRS) and a pre-clinical candidate for the treatment of X-Linked Retinitis Pigmentosa (XLRP). The agreement also includes options for early stage discovery programs in two ophthalmic diseases and one non-ophthalmic condition, as well as an equity investment in AGTC.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2015, the collaboration became effective and we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$124.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which included a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;equity investment in AGTC, prepaid research and development expenditures of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and total licensing and other fees of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of prepaid research and development expenditures were recorded in investments and other assets in our condensed consolidated balance sheets and will be expensed as the services are provided. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$56.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as research and development expense associated with AGTC in our condensed consolidated statements of income, including the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;total licensing and other fees, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in research and development services, a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;premium on our equity investment and a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;clinical development milestones related to XLRS. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">AGTC is eligible to receive milestone payments aggregating in excess of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which includes up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$472.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;collectively for the two lead programs and up to up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$592.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;across the discovery programs. AGTC is also eligible to receive royalties in the mid-single digit to mid-teen percentages of annual net sales. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We were granted worldwide commercialization rights for the XLRS and XLRP programs. AGTC has an option to share development costs and profits after the initial clinical trial data are available, and an option to co-promote the second of these products to be approved in the U.S. AGTC will lead the clinical development programs of XLRS through product approval and of XLRP through the completion of first-in-human trials. We will support the clinical development costs, subject to certain conditions, following the first-in-human study for XLRS and IND-enabling studies for XLRP. Under the manufacturing license, we have received an exclusive license to use AGTC&#8217;s proprietary technology platform to make AAV vectors for up to six genes, three of which are in AGTC&#8217;s discretion, in exchange for payment of milestones and royalties.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><a name="s902EFC4D98F84C8C4264AE73D956941A"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Swedish Orphan Biovitrum AB</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On July 16, 2015, Swedish Orphan Biovitrum AB (Sobi) exercised its option to assume development and commercialization of ALPROLIX in Europe, Russia, Turkey and certain markets in the Middle East and paid us </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which will be held in escrow pending E.U. regulatory approval.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We collaborate with Sobi to jointly develop and commercialize Factor VIII and Factor IX hemophilia products, including ELOCTATE and ALPROLIX. For more information about our agreement with Sobi, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Joint Venture Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012, we entered into a joint venture agreement with Samsung BioLogics Co. Ltd. (Samsung Biologics), establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals.&#160;Samsung Biologics contributed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">280.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;South Korean won (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$250.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) for an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;stake in Samsung Bioepis and we contributed approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;South Korean won (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) for the remaining </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;ownership interest.&#160;Under the joint venture agreement, we have no obligation to provide any additional funding and our ownership interest may be diluted due to financings in which we do not participate. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership interest is approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which reflects our additional contribution of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.3 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;South Korean won (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) in the first quarter of 2015 and the effect of additional equity financings in which we did not participate. We maintain an option to purchase additional stock in Samsung Bioepis that would allow us to increase our ownership percentage up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;The exercise of this option is within our control and is based on paying for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the total investment made by Samsung Biologics into Samsung Bioepis in excess of what we have already contributed under the agreement plus a rate that will represent their return on capital.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investment in Samsung Bioepis totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.1 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;South Korean won (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets. Based on our level of influence over Samsung Bioepis, we account for this investment under the equity method of accounting and we recognize our share of the results of operations related to our investment in Samsung Bioepis one quarter in arrears when the results of the entity become available, which is reflected as equity in loss of investee, net of tax in our condensed consolidated statements of income. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a loss on our investment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$14.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our share of losses exceeded the carrying value of our investment. We will suspend recognizing additional losses.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Commercial Agreement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On December 17, 2013, pursuant to our rights under the joint venture agreement with Samsung Biologics, we entered into an agreement with Samsung Bioepis to commercialize anti-tumor necrosis factor (TNF) biosimilar product candidates in Europe and, in the case of one anti-TNF biosimilar candidate, Japan.&#160;Under the terms of this agreement, we have paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$46.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which has been recorded as a research and development expense in our condensed consolidated statements of income as the programs they relate to have not achieved regulatory approval. Samsung Bioepis is eligible to receive an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in additional milestones related to regulatory approval of the product candidates. Upon commercialization, there will be a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;profit share with Samsung Bioepis.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Other Services</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement, a technical development services agreement and a manufacturing agreement with Samsung Bioepis. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$47.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in other revenues in relation to these services, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$21.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$57.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our other significant collaboration arrangements, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><a name="s1C1586289CFFD88A32CDAE73D93B9196"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><br><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">19.&#160;&#160;&#160;&#160;Litigation</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">&#32;&#8217;755 Patent Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On May&#160;28, 2010, Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (manufacturer, marketer and seller of REBIF), Pfizer Inc. (co-marketer of REBIF), and Novartis Pharmaceuticals Corp. (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 (&#8217;755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the &#8217;755 Patent and that the patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. The court has consolidated the two lawsuits, and we refer to the two actions as the &#8220;Consolidated &#8217;755 Patent Actions.&#8221;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:12px;text-indent:17px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bayer, Pfizer, Novartis and EMD Serono have all filed counterclaims in the Consolidated &#8217;755 Patent Actions seeking declaratory judgments of patent invalidity and non-infringement, and seeking monetary relief in the form of costs and attorneys' fees, and EMD Serono and Bayer have each filed a counterclaim seeking a declaratory judgment that the &#8217;755 Patent is unenforceable based on alleged inequitable conduct. Bayer has also amended its complaint to seek such a declaration. No trial date has been set.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Italian National Medicines Agency</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2011, Biogen Italia SRL&#160;received notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) that sales of TYSABRI after mid-February 2009 exceeded a reimbursement limit established pursuant to a Price Determination Resolution (Price Resolution) granted by AIFA in December 2006. On December&#160;23, 2011, we filed an appeal in the Regional Administrative Tribunal of Lazio (Il Tribunale Amministrativo Regionale per il Lazio) in Rome, Italy seeking a ruling that the reimbursement limit in the Price Resolution should apply as written to only &#8220;the first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months&#8221; of TYSABRI sales, which ended in mid-February 2009. The appeal is still pending. In June 2014, AIFA approved a resolution affirming that there is no reimbursement limit from and after February 2013. AIFA and Biogen Italia SRL are discussing a possible resolution for the period from mid-February 2009 through January 2013.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Government Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We have also received a subpoena from the federal government for documents relating to our relationship with certain pharmacy benefit managers. We are cooperating with the government in these matters.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Qui Tam Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On July 6, 2015, four qui tam actions filed against us by relators suing on behalf of the United States and certain states were unsealed by the U.S. District Court for the District of Massachusetts. The actions, which have been administratively consolidated, allege sales and promotional activities in violation of the federal False Claims Act and state law counterparts, and seek single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. The United States has declined to intervene in two of the actions and has not made an intervention decision in the other two actions. We have not been served with any of the complaints. We have not formed an opinion that an unfavorable outcome in any of the actions is either &#8220;probable&#8221; or &#8220;remote&#8221; and are unable to estimate the magnitude or range of any potential loss.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Forward Pharma Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On November 18, 2014 Forward Pharma A/S (Forward Pharma) filed suit against us in the Regional Court of Dusseldorf, Germany alleging that TECFIDERA infringes German Utility Model DE&#160;20 2005 022 112&#160;U1, which was issued in April 2014 and expires in October 2015. Forward Pharma subsequently&#160;extended its allegations&#160;to assert that TECFIDERA infringes Forward Pharma's European Patent No. 2,801,355, which was issued in May 2015 and expires in October 2025. Forward Pharma seeks declarations of infringement and damages. A hearing has been scheduled for early 2016.&#160;We have not formed an opinion that an unfavorable outcome is either &#8220;probable&#8221; or &#8220;remote&#8221; and are unable to estimate the magnitude or range of any potential loss.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><a name="s1C1586289CFFD88A32CDAE73D93B9196"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Securities Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On August 18, 2015, Nicole Tehrani filed an action in the U.S. District Court for the District of Massachusetts against Biogen, our Chief Executive Officer, George A. Scangos, and our Chief Financial Officer, Paul J. Clancy, alleging federal securities law violations under 15 U.S.C. &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5. The plaintiff seeks declaration of the action as a class action, certification of the plaintiff as a representative of the class and her counsel as class counsel, and an award to the plaintiff and the class of damages, interest, and attorneys' fees. We have not formed an opinion that an unfavorable outcome is either &#8220;probable&#8221; or &#8220;remote&#8221; and are unable to estimate the magnitude or range of any potential loss.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Patent Matter relating to ALPROLIX</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2015, Pfizer proposed that we discuss taking a license to its U.S. Patent No. 8,603,777&#160;(Expression of Factor VII and IX Activities in Mammalian Cells) and pay&#160;royalties on sales of ALPROLIX. We have not formed an opinion that an unfavorable outcome is either &#8220;probable&#8221; or &#8220;remote&#8221; and are unable to estimate the magnitude or range of any potential loss.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Product Liability and Other Legal Proceedings</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</font></div><a name="s7CCB95580326CBA412A1AE73D9ACCF39"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">20.&#160;&#160;&#160;&#160;Commitments and Contingencies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Fumapharm AG</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2006, we acquired Fumapharm AG. As part of this acquisition we acquired FUMADERM and TECFIDERA (together, Fumapharm Products). We paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$220.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon the closing of the transaction and agreed to pay an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;if a Fumapharm Product was approved for MS in the U.S.&#160;or E.U. In the second quarter of 2013, we paid this </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;contingent payment as TECFIDERA was approved in the U.S. for MS by the U.S. Food and Drug Administration (FDA). We are also required to make additional contingent payments to former shareholders of Fumapharm AG or holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior twelve month period, as defined in the acquisition agreement. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$550.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent payments as we reached the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;cumulative sales levels related to the Fumapharm Products in the fourth quarter of 2014 and second quarter of 2015, respectively, and accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon reaching </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in total cumulative sales of Fumapharm Products in the third quarter of 2015.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We will owe an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;contingent payment for every additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in cumulative sales level of Fumapharm Products reached if the prior 12 months sales of the Fumapharm Products exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, until such time as the cumulative sales level reaches </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, at which time no further contingent payments shall be due. These payments will be accounted for as an increase to goodwill as incurred, in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm. Any portion of the payment which is tax deductible will be recorded as a reduction to goodwill. Payments are due within 60&#160;days following the end of the quarter in which the applicable cumulative sales level has been reached. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On June 30, 2015, we signed an agreement to purchase land in Solothurn, Switzerland for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Swiss Francs. The contract also includes certain environmental remediation costs. Our obligation to purchase the land is subject to customary closing conditions and a condition that no material adverse changes in our business, such as a decision to discontinue our aducanumab program, have occurred during the period. </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><a name="s3f54d4bfb51342d3882419b1569d11e1"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><br><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">21.&#160;&#160;&#160;&#160;Subsequent Events</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Restructuring</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On October 21, 2015, we announced a corporate restructuring, which includes the termination of a number of pipeline programs and an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reduction in workforce. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect to incur a charge related to these restructuring activities in the range of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$85 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$95 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We anticipate making cash payments in the range of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$115 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which includes amounts related to previously accrued incentive compensation. Substantially all of these amounts will be incurred and paid by the end of 2015.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><a name="s5973464BCF9179C4C433AE7426AB4172"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;2.&#160;&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-style:italic;font-weight:bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following discussion should be read in conjunction with our condensed consolidated financial statements and accompanying notes beginning on page&#160;5 of this quarterly report on Form&#160;10-Q and our audited consolidated financial statements and related notes included in our Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;(</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form&#160;10-K). Certain totals may not sum due to rounding.</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Executive Summary</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Introduction</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS), ALPROLIX for the treatment of hemophilia B, ELOCTATE for the treatment of hemophilia A and FUMADERM for the treatment of severe plaque psoriasis. We also generate revenue from our collaboration with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin&#8217;s lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, and share profits and losses with Genentech for GAZYVA, which is approved for the treatment of CLL.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current revenues depend upon continued sales of our principal products. We may be substantially dependent on sales from our principal products for many years, including an increasing reliance on sales and growth of TECFIDERA as we continue to expand into additional markets. In the longer term, our revenue growth will be dependent upon the successful clinical development, regulatory approval and launch of new commercial products as well as additional indications for our existing products, our ability to obtain and maintain patents and other rights related to our marketed products and assets originating from our research and development efforts, and successful execution of external business development opportunities. As part of our ongoing research and development efforts, we have devoted significant resources to conducting clinical studies to advance the development of new pharmaceutical products and to explore the utility of our existing products in treating disorders beyond those currently approved in their labels.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Restructuring</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On October 21, 2015, we announced a corporate restructuring, which includes the termination of a number of pipeline programs and an 11% reduction in workforce. These changes are expected to reduce the current annual run rate of operating expenses by approximately $250 million. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect to reinvest the savings resulting from the restructuring to support key commercial activities, including TECFIDERA, and to support the advancement of our high potential pipeline candidates, including our programs in Alzheimer&#8217;s disease, anti-LINGO for MS, ISIS-SMN</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx </sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">for spinal muscular atrophy (SMA), Raxatrigine (CNV1014802) for trigeminal neuralgia, and subject to the closing of our transaction with Mitsubishi Tanabe Pharma, indications for MT-1303, an oral S1P modulator. We also have discontinued several programs, including our Phase 3 program for TECFIDERA in secondary progressive MS (SPMS), the development of anti-TWEAK in lupus nephritis, and certain activities in immunology and fibrosis research. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect to incur a charge related to these restructuring activities in the range of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$85 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$95 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We anticipate making cash payments in the range of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$115 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which includes amounts related to previously accrued incentive compensation. Substantially all of these amounts will be incurred and paid by the end of 2015.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><a name="s40C1F1855FC334C8E5A4AE7426DC6859"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Financial Highlights</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;"><img src="biib-2015930_highlightschart.jpg" style="height:426px;width:317px;"></div><a name="s350FB423676F81AFE7CBAE7426FE69A0"></a><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, diluted earnings per share attributable to Biogen Inc. was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.15</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.62</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the prior year comparative period.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As described below under </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Results of Operations,&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;our operating results for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reflect the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$2,777.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">third</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 10.6% over the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$2,391.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">third</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 13.0% over the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was driven by a 19.1% increase in worldwide TECFIDERA revenues as well as revenue increases from PLEGRIDY, ALPROLIX and ELOCTATE, which are recent product additions, partially offset by a decrease in worldwide AVONEX and TYSABRI revenues.</font></div></td></tr></table></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of RITUXAN and GAZYVA operating profits totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$337.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">third</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 16.0% over the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.  This increase was due in part to the prior year recognition of additional Branded Pharmaceutical Drug (BPD) fee expense.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues totaled $49.0 million in the </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">third</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing a decrease of 52.6% from the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This decrease was driven by an 86.6% decrease in royalty revenue primarily due to the expiration of U.S. patent rights that gave rise to royalty payments related to ANGIOMAX, partially offset by a 10.3% increase in corporate partner revenue.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1,406.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">third</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">3.1%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was driven by a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">24.6%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;increase in research and development expense, partially offset by a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">19.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;decrease in the amortization of acquired intangible assets, a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">16.2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;decrease in selling, general and administrative expense and a decrease in the gain on fair value remeasurement of contingent consideration. In addition, total costs and expenses in the </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">third</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were lower due to foreign currency translation totaling $40.4 million.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We generated </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2,675.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of net cash flows from operations for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which were primarily driven by earnings. Cash, cash equivalents and marketable securities totaled approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7,789.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2,998.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under our share repurchase programs. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On September 15, 2015, we issued senior unsecured notes for an aggregate principal amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquisitions</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 12, 2015, we completed our acquisition of all of the outstanding stock of Convergence Pharmaceuticals (Convergence), a clinical-stage biopharmaceutical company with a focus on developing product candidates for neuropathic pain. For additional information related to this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Environment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The biopharmaceutical industry and the markets in which we operate are intensely competitive. Many of our competitors are working to develop or have commercialized products similar to those we market or are developing. In addition, the commercialization of certain of our own approved MS products, products of our collaborators and pipeline product candidates may negatively impact future sales of our existing MS products. Our products may also face increased competitive pressures from the introduction of generic versions, related prodrug derivatives or biosimilars of existing products and other technologies, such as gene therapies. For additional information related to competition risk that could negatively impact our products, please read the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Risk Factors&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;section of this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Key Pipeline and Product Developments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">ELOCTATE</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2015, we and Swedish Orphan Biovitrum AB (Sobi) received a positive recommendation from the EMA&#8217;s Committee for Medicinal Products for Human Use (CHMP) for the marketing authorization of&#160;ELOCTA, the approved trade name for ELOCTATE in the E.U., for the treatment of hemophilia A. The CHMP's recommendation was referred to the European Commission, which grants marketing authorizations for medicines in the E.U.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">ALPROLIX</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2015, we and Sobi announced positive top-line results of the Kids B-LONG Phase 3 clinical study that evaluated the safety, efficacy and pharmacokinetics of ALPROLIX in children under age 12 with severe hemophilia B. This data was required as part of our Marketing Authorization Application (MAA) for ALPROLIX for the treatment of hemophilia B in the E.U., which was submitted to the European Medicines Agency (EMA). The EMA validated our MAA for ALPROLIX in June 2015.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">ZINBRYTA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2015, the EMA validated our MAA for ZINBRYTA for the treatment of relapsing forms of MS in the E.U.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2015, the U.S. Food and Drug Administration (FDA) accepted our Biologics License Application for ZINBRYTA for the treatment of relapsing forms of MS in the U.S.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We collaborate with AbbVie Biotherapeutics, Inc. (AbbVie) on the development and commercialization of ZINBRYTA. For additional information about this collaboration, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Aducanumab (BIIB037)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2015, we announced data from a pre-specified interim analysis of PRIME, the Phase 1b study of aducanumab, in which aducanumab demonstrated an acceptable safety profile and positive results on radiologic and clinical measurements in patients with prodromal or mild Alzheimer&#8217;s disease.&#160;Based on results from our Phase 1b study, we advanced the aducanumab clinical program to Phase 3. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2015, we announced new results from a pre-specified interim analysis of PRIME in patients with prodromal or mild Alzheimer&#8217;s disease. In this analysis, which included patients treated up to 54 weeks with the 6 mg/kg dose, aducanumab demonstrated acceptable safety and tolerability, and the findings reinforced the previously reported results from PRIME. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2015, we enrolled our first patient in our two global Phase 3 studies, ENGAGE and EMERGE, to assess the efficacy and safety of aducanumab in people with early Alzheimer's disease and triggered a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;milestone payment due to Neurimmune SubOne AG (Neurimmune). We also received FDA agreement on a special protocol assessment on the aducanumab Phase 3 studies.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Anti-LINGO</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2015, we announced positive top-line results from the Phase 2 acute optic neuritis RENEW trial in which treatment with anti-LINGO-1 showed evidence of biological repair of the visual system. Anti-LINGO-1 demonstrated an improvement in the study&#8217;s primary endpoint, recovery of optic nerve latency (time for a signal to travel from the retina to the visual cortex) relative to placebo. The study showed no effect on secondary endpoints, including change in thickness of the retinal layers (optic nerve neurons and axons) and visual function. Anti-LINGO-1 is also being studied in people with MS through a Phase 2 study, SYNERGY.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Results in our early stage trials for aducanumab and anti-LINGO-1 may not be indicative of results in later stage trials, which, in some cases, may take several years to enroll and complete and may result in the incurrence of significant costs and investment without the assurance of success.&#160;Development of biopharmaceutical products is subject to the risks and uncertainties described in our risk factors. </font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">GAZYVA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2015, the Roche Group announced positive results from the Phase 3 GADOLIN study in non-Hodgkin&#8217;s lymphoma.&#160;At a pre-planned interim analysis, an independent data monitoring committee determined that the study met its primary endpoint early, showing that people lived significantly longer without disease worsening or death (progression-free survival) when treated with GAZYVA plus bendamustine followed by GAZYVA alone, compared to bendamustine alone.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Ocrelizumab</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2015, the Roche Group announced positive results from two Phase 3 studies evaluating ocrelizumab compared with interferon beta-1a in people with relapsing forms of MS. Treatment with ocrelizumab compared with interferon beta-1a significantly reduced the annualized relapse rate over a two-year period; significantly reduced the progression of clinical disability; and led to a significant reduction in the number of lesions in the brain as measured by MRI. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2015, the Roche Group announced positive results from a Phase 3 study evaluating ocrelizumab in people with primary progressive MS. Treatment with ocrelizumab significantly reduced the progression of clinical disability compared with placebo, as measured by the Expanded Disability Status Scale.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Roche Group plans to submit the data for review to regulatory authorities in early 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Genentech, a wholly-owned member of the Roche Group, is solely responsible for development and commercialization of ocrelizumab. If approved for commercial sale by the FDA, we will receive tiered royalties between 13.5% and 24% on U.S. net sales. There will be a 50% reduction to these royalties if a biosimilar to ocrelizumab is approved in the U.S. In addition, we will receive a 3% royalty on worldwide net sales of ocrelizumab outside the U.S.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">ISIS-SMN</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub>&#160;</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2015, Isis Pharmaceuticals, Inc. (Isis) announced additional data from two Phase 2 studies of ISIS-SMN</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the treatment of spinal muscular atrophy in infants and children. There are two Phase 3 studies that are active and currently enrolling patients.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Biosimilars</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2015, the EMA validated and accepted Samsung Bioepis&#8217; MAA for BENEPALI, its etanercept biosimilar candidate. In September 2015, Samsung Bioepis announced that its etanercept biosimilar candidate received regulatory approval for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and psoriasis from the South Korean regulatory authority. In South Korea, etanercept will be marketed as BRENZYS. BRENZYS is expected to launch by the end of this year or early next year.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2015, the EMA validated and accepted Samsung Bioepis&#8217; MAA for FLIXABI, its infliximab biosimilar candidate.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">TYSABRI</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2015, the results of our Phase 2 trial investigating TYSABRI in acute ischemic stroke did not demonstrate an impact on change in infarct volume, the primary endpoint. However, exploratory clinical endpoints suggested that TYSABRI did have a beneficial impact on patient functional deficits. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2015, we announced the top-line results from the Phase 3 ASCEND study evaluating TYSABRI in SPMS. The study did not achieve its primary and secondary endpoints. Based on these results, we have discontinued development of TYSABRI in SPMS.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Neublastin</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2015, the results of our Phase 2 trial investigating Neublastin in neuropathic pain did not meet its primary endpoint or its efficacy criteria. Based on these results, we have discontinued development of Neublastin in neuropathic pain.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Anti-TWEAK</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2015, the results of our interim Phase 2 efficacy results for the development of Anti-TWEAK in lupus nephritis failed to meet the target product profile. Based on these results, we have discontinued development of anti-TWEAK in lupus nephritis.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><a name="s7F23080FE409C93EBDFFAE73DDC8831E"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Results of Operations</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"></td></tr><tr><td width="21%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,721.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">62.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,442.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,820.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">60.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,956.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rest of world</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">670.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">674.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,942.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,960.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,391.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">86.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,117.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,762.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">85.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,916.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">83.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unconsolidated joint business</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">337.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">12.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">290.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,005.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">12.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">890.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">49.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">103.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">156.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">255.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,777.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,511.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,924.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,062.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues are summarized as follows:</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"></td></tr><tr><td width="21%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">937.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">39.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">787.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,645.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">39.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,993.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">784.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">32.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">745.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,229.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">33.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,280.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">479.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">501.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,405.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,475.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">21.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">62.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ALPROLIX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">65.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">163.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ELOCTATE</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">90.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">218.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">12.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">38.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,391.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,117.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,762.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,916.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><a name="sE3196FDD0A352DBC406DAE74275698CD"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Multiple Sclerosis (MS)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">TECFIDERA</font><img src="biib-2015930_tecchart.jpg" style="height:333px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S. TECFIDERA revenues was primarily due to increases in unit sales volume of 8% and 18%, respectively, as TECFIDERA penetrated the U.S. market, and increases in price.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in rest of world TECFIDERA revenues was primarily due to increases in unit sales volume in existing markets and in additional markets as we continue to launch the product and expand our presence around the world. These increases were partially offset by pricing reductions in Germany as described below. &#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rest of world TECFIDERA revenues for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were negatively impacted by foreign currency exchange losses totaling $24.3 million and $53.1 million, respectively.&#160;These foreign currency exchange losses were partially offset by comparative net gains recognized under our foreign currency hedging program totaling $11.9 million and $32.8 million, respectively.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2011, the German government implemented new legislation to manage pricing related to new drug products introduced in the German market. For the first 12 months after launch, pricing is unregulated. We launched TECFIDERA in Germany in February 2014. During the first quarter of 2015, our unregulated pricing ended and we recognized revenue at the fixed price that was established through negotiations with the German authorities. The negotiated annual price is fixed for three years at EUR12,800. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While we continue to see a strong uptake of TECFIDERA in newly launched territories, total market growth and patient switch rates in our maturing markets, such as the U.S. and Germany, are returning to historical averages for MS. During 2015, TECFIDERA's U.S. patient growth versus prior quarters has continued to moderate primarily due to changing physician prescribing patterns. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Interferon</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">PLEGRIDY</font></div><div style="line-height:120%;text-align:left;"><img src="biib-2015930_plegchart.jpg" style="height:333px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales of PLEGRIDY began in the E.U. and the U.S. in the third and fourth quarters of 2014, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect that PLEGRIDY revenues will increase as PLEGRIDY becomes commercially available in additional markets.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><a name="sE3196FDD0A352DBC406DAE74275698CD"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">AVONEX</font></div><div style="line-height:120%;text-align:left;"><img src="biib-2015930_avxchart.jpg" style="height:333px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in U.S. AVONEX revenues was primarily due to decreases in unit sales volume of 12% and 17%, respectively, which was attributable in part to patients transitioning to PLEGRIDY and oral MS therapies, including TECFIDERA, partially offset by price increases. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in rest of world AVONEX revenues was primarily due to decreases in unit sales volume of 6% and 13%, respectively, primarily in Europe, attributable to patients transitioning to PLEGRIDY and oral MS therapies, including TECFIDERA. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rest of world AVONEX revenues for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were negatively impacted by foreign currency exchange losses totaling $38.3 million and $128.7 million, respectively. These foreign currency exchange losses were partially offset by comparative net gains recognized under our foreign currency hedging program totaling $13.8 million and $48.8 million, respectively.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">TYSABRI</font></div><div style="line-height:120%;"><img src="biib-2015930_tyschart.jpg" style="height:333px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S. TYSABRI revenues was primarily due to increases in price, partially offset by a decrease in unit sales volume of 3% related to an extra shipping week in the third quarter of 2014. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S. TYSABRI revenues was primarily due to increases in price and an increase in unit sales volume of 5%. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in rest of world TYSABRI revenues was due to pricing reductions in some European countries, partially offset by increases in unit sales volume of 5% and 4%, respectively, primarily in our emerging markets. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rest of world TYSABRI revenues for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reflects the recognition of $53.5 million of revenues previously deferred in Italy relating to the pricing agreement with the Italian National Medicines Agency (Agenzia Italiana del Farmaco, or AIFA), as discussed below.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><a name="sE3196FDD0A352DBC406DAE74275698CD"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rest of world TYSABRI revenues for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were negatively impacted by foreign currency exchange losses totaling $34.3 million and $112.7 million, respectively. These foreign currency exchange losses were partially offset by comparative net gains recognized under our foreign currency hedging program totaling $11.7 million and $35.1 million respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We remain in discussions with AIFA about a resolution relating to a claim that sales of TYSABRI in Italy exceeded a reimbursement limit established pursuant to a Price Determination Resolution granted by AIFA in December 2006 for the period from mid-February 2009 through January 2013. If AIFA agrees to our current proposal, we could recognize approximately EUR40 million in revenue related to this matter. For information regarding our agreement with AIFA relating to sales of TYSABRI in Italy, please read Note 16, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Consolidated Financial Statement Detail</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Hemophilia</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">ALPROLIX</font></div><div style="line-height:120%;"><img src="biib-2015930_alpchart.jpg" style="height:297px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales of ALPROLIX in the U.S. and Japan began in the second and fourth quarters of 2014, respectively.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">ELOCTATE</font></div><div style="line-height:120%;"><img src="biib-2015930_elochart.jpg" style="height:297px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales of ELOCTATE in the U.S. and Japan began in the third quarter of 2014 and in the first quarter of 2015, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a relatively limited product history for ALPROLIX and ELOCTATE. Therefore, it remains difficult to estimate trends of future sales of these products.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><a name="s946B27796ED131C4E657AE73FD3B1B22"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Unconsolidated Joint Business Revenues</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from unconsolidated joint business are summarized as follows:</font></div><div style="line-height:120%;"><img src="biib-2015930_ujbchart.jpg" style="height:533px;width:317px;"></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Biogen&#8217;s Share of Pre-tax Profits in the U.S. for RITUXAN and GAZYVA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables provide a summary of amounts comprising our share of pre-tax profits on RITUXAN and GAZYVA in the U.S.:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="50%"></td><td width="1%"></td><td width="22%"></td><td width="1%"></td><td width="2%"></td><td width="1%"></td><td width="22%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">959.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">917.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">161.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">244.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax profits in the U.S.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">797.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">673.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits, including the reimbursement of selling and development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">319.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">271.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="50%"></td><td width="1%"></td><td width="22%"></td><td width="1%"></td><td width="2%"></td><td width="1%"></td><td width="22%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,901.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,684.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">516.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">610.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax profits in the U.S.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,384.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,073.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits, including the reimbursement of selling and development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">952.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">831.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S.&#160;product revenues was primarily due to price increases.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S.&#160;product revenues was primarily due to price increases and increases in RITUXAN unit sales volume of 4%, partially offset by higher discounts and allowances.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration costs and expenses for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, decreased in part due to the prior year recognition of $52.5 million of additional BPD fee expense. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the Internal Revenue Service issued final regulations related to the BPD fee, which had the effect of changing the recognition of the fee for accounting purposes, from the period in which the fee was paid, to the period when the sale occurs. As a result of these final regulations, we recognized an incremental BPD fee for the periods 2013 through the end of the third quarter of 2014. The final regulations did not change the timing of payments.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenue on Sales in the Rest of World for RITUXAN</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue on sales in the rest of world for RITUXAN consists of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenue on sales outside the U.S.&#160;and Canada. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, revenue on sales in the rest of world for RITUXAN decreased as a result of lower pre-tax co-promotion profits on RITUXAN in Canada and patent expirations. </font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><a name="sEE5633DA0A73BE2BBE89AE7427A54009"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Revenues</font></div><div style="line-height:120%;"><img src="biib-2015930_otherrevchart.jpg" style="height:400px;width:317px;"></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Royalty Revenues</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We receive royalties from net sales on products related to patents that we have out-licensed. Our most significant source of royalty revenue had been derived from net worldwide sales of ANGIOMAX, which was out-licensed to The Medicines Company. On December 15, 2014 we ceased recognizing royalty revenues from U.S. sales of ANGIOMAX, contemporaneous with the U.S. patent&#8217;s expiration.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, royalty revenues decreased primarily due to the expiration of U.S. patent rights that gave rise to royalty payments related to ANGIOMAX.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Corporate Partner Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our corporate partner revenues include amounts earned under contract manufacturing agreements, revenues related to our arrangement with Samsung Bioepis, and revenues covering products previously included in our product line that we have sold or exclusively licensed to third parties.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in corporate partner revenues was primarily due to higher contract manufacturing revenue and the start of product shipments to Sobi in relation to our collaboration agreement.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our relationship with Samsung Bioepis, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report. For additional information on our relationship with Sobi, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><a name="sD07B36DD50736E32378EAE7427D7DCA7"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recorded net of applicable discounts, allowances and other governmental allowances including those associated with the implementation of pricing actions in certain international markets where we operate.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reserves established for these discounts and allowances are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). These reserves are based on estimates of the amounts earned or to be claimed on the related sales. Our estimates take into consideration our historical experience, current contractual and statutory requirements, specific known market events and trends, and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which will have an effect on earnings in the period of adjustment. To date, such adjustments have not been significant.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reserves for discounts, contractual adjustments and returns that reduced gross product revenues are summarized as follows:</font></div><div style="line-height:120%;text-align:center;"><img src="biib-2015930_reserveschart.jpg" style="height:525px;width:317px;"></div><div style="line-height:120%;text-align:center;"><img src="biib-2015930_reserveperchart.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounts include trade term discounts and wholesaler incentives. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in discounts was primarily driven by our recent product additions and an increase in contractual rates. </font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contractual adjustments relate to Medicaid and managed care rebates, Veterans Administration, Public Health Service discounts, specialty pharmacy program fees and other government rebates or applicable allowances. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in contractual adjustments was primarily due to our recent product additions, higher Medicaid, governmental rebates and allowances and managed care rebates as a result of price increases and an increase in governmental rebates in certain international markets.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product return reserves are established for returns made by wholesalers. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Reserves for product returns are recorded in the period the related revenue is recognized, resulting in a reduction to product sales. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, return reserves decreased primarily due to a reduction in return rates based on recent experiences of returned products.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our reserves, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Reserves for Discounts and Allowances</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><a name="sDDBC52352ECC384670DFAE73E7B83C93"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Cost and Expenses</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of total cost and expenses is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td width="29%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Change&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Change&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of sales, excluding amortization of acquired intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">310.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">302.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">908.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">873.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">519.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">417.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,471.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,393.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">477.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">570.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,530.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,658.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">98.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">122.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(19.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">286.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">382.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(25.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Gain) loss on fair value remeasurement of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(49.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(100.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(46.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(112.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,406.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,363.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,201.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,262.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><a name="sD5A18ADAE5A6BFF1B0EBAE74282A133F"></a><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cost of Sales, Excluding Amortization of Acquired Intangible Assets</font></div><div style="line-height:120%;"><img src="biib-2015930_coschart.jpg" style="height:310px;width:317px;"></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in product cost of sales was primarily driven by higher charges related to inventory write-downs. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in product cost of sales was primarily driven by higher unit sales volume and higher AVONEX production costs. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory amounts written down as a result of  excess, obsolescence, unmarketable or other reasons are included in product cost of sales. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, inventory write-downs totaled $18.6 million and $30.0 million, respectively, compared to $12.3 million and $33.2 million, respectively, in the prior year comparative periods. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in royalty cost of sales was driven by the decrease in TYSABRI revenues and the expiration of third party royalties related to TYSABRI. These decreases were partially offset by an increase in the contractual rate on TYSABRI contingent payments due to Perrigo Company plc (Perrigo), which is based on the expected level of annual worldwide net sales of TYSABRI, and royalties due on increased sales of our hemophilia products. For additional information on the contingent payments due to Perrigo, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><a name="s234595A3B9AFA6ABC396AE74284C9794"></a><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Research and Development</font></div><div style="line-height:120%;"><img src="biib-2015930_rdchart.jpg" style="height:730px;width:317px;"></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expense incurred in support of our marketed products includes costs associated with product lifecycle management activities including, if applicable, costs associated with the development of new indications for existing products. Late stage programs are programs in Phase 3 development or in registration stage. Early stage programs are programs in Phase 1 or Phase 2 development. Research and discovery represents costs incurred to support our discovery research and translational science efforts. Other research and development costs consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as management costs as well as depreciation and other facility-based expenses. For several of our programs, the research and development activities are part of our collaborative and other relationships. Our costs reflect our share of the total costs incurred.</font></div><div style="line-height:120%;text-align:center;"><img src="biib-2015930_15rdpiechart.jpg" style="height:305px;width:317px;"></div><div style="line-height:120%;text-align:center;"><img src="biib-2015930_14rdpiechart.jpg" style="height:305px;width:317px;"></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in research and development expense was primarily related to an increase in milestone and upfront expenses, increases in costs incurred in connection with our late stage programs and higher research and discovery costs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in research and development expense was primarily related to increases in costs incurred in connection with our research and discovery, late stage programs and early stage programs, partially offset by a decrease in milestone and upfront expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in spending associated with our late stage programs for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was driven by costs incurred to advance our aducanumab program for Alzheimer's disease and the ISIS-SMN</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;program for the treatment of SMA, partially offset by a decrease in costs related to ZINBRYTA. The decrease for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months comparative period was also the result of our approvals of PLEGRIDY and ELOCTATE in 2014.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in spending associated with our early stage programs for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was primarily due to costs incurred in connection with our aducanumab program for Alzheimer's disease, which advanced to a late stage program during the third quarter of 2015, the BAN2401 program for Alzheimer&#8217;s disease and our Raxatrigine program for trigeminal neuralgia. These increases were partially offset by a decrease in costs incurred in connection with the ISIS-SMN</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;program for the treatment of SMA as the program advanced to a late stage program during the first quarter of 2015.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in spending associated with milestones and upfront expenses for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was primarily due to $48.1 million recorded upon entering into the collaboration with Applied Genetic Technologies Corporation (AGTC). </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in spending associated with milestones and upfront expenses for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was driven by charges of $117.7 million recorded in the prior year upon entering into the collaboration agreement with Eisai Co., Ltd. (Eisai), $21.6 million as Eisai exercised its option in the collaboration agreement to expand the joint development and commercialization activities to include Japan and $20.0 million related to an upfront payment made to Sangamo BioSciences, Inc. upon entering into an exclusive worldwide collaboration and license agreement in 2014. This decrease in </font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">spending was partially offset by a charge of $48.1 million recorded upon entering into the collaboration with AGTC in the third quarter of 2015 and $16.0 million paid to AbbVie related to milestones for the development of ZINBRYTA as a result of filing with the FDA and EMA in 2015. For additional information about these transactions, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We intend to continue committing significant resources to targeted research and development opportunities where there is a significant unmet need and where the drug candidate has the potential to be highly differentiated. Specifically, we intend to continue to invest in our MS pipeline, our aducanumab program, the BAN2401 and E2609 programs, the ISIS-SMN</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;program, the MT-1303 program and our Raxatrigine program.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Selling, General and Administrative</font></div><div style="line-height:120%;"><img src="biib-2015930_sgachart.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in selling, general and administrative expenses was driven by a decrease in corporate giving, compensation and benefits expense, savings realized through our efforts to control spend associated with our sales and marketing activities and the positive impact of foreign currency translation.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in selling, general and administrative expenses was driven by a decrease in corporate giving and the positive impact of foreign currency translation, partially offset by increased cost related to the BPD fee. </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><a name="sCB830636F366DA91B254AE74287EA94F"></a><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Amortization of Acquired Intangible Assets</font></div><div style="line-height:120%;"><img src="biib-2015930_amortchart.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption of intangible assets. Our most significant intangible assets are related to our AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of AVONEX and TYSABRI. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of either product.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in amortization of acquired intangible assets was primarily driven by higher expected lifetime revenues of AVONEX, as discussed below, partially offset by lower expected lifetime revenues of TYSABRI, as described below. Amortization of acquired intangible assets during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;included a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;impairment loss related to one of our in-process research and development (IPR&amp;D) intangible assets.    </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in amortization of acquired intangible assets was primarily driven by a decrease in AVONEX revenues during the comparative periods. Amortization of acquired intangible assets during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;included total impairment charges of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to one of our out-licensed patents and one of our IPR&amp;D intangible assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long range planning cycle was updated in the third quarter of 2015. Based upon this analysis, there was not a significant change in our expected rate of amortization for acquired intangible assets.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We monitor events and expectations regarding product performance. If there are any indications that the assumptions underlying our most recent analysis would be different than those utilized in our current estimates, our analysis would be updated and may result in a significant change in the anticipated lifetime revenues of the relevant process. The occurrence of an adverse event could substantially increase the amount of amortization expense associated with our acquired intangible assets as compared to previous periods or our current expectations, which may result in a significant negative impact on our future results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to the amortization of acquired intangible assets, please read Note 5, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">IPR&amp;D</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we updated the probabilities of success related to the early stage programs acquired through our acquisitions.&#160;The change in probability of success, combined with a delay in one of the projects, resulted in an impairment loss of $16.2 million in one of our IPR&amp;D assets during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;In addition, we adjusted the value of our contingent consideration liabilities to reflect these lower probabilities of success in connection with these earlier stage programs resulting in net gains of $49.4 million in the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overall, the value of our acquired IPR&amp;D assets is dependent upon a number of variables, including estimates of future revenues and the effects of competition, the level of anticipated development costs and the probability and timing of successfully advancing a particular research program from a clinical trial phase to the next. We are continually reevaluating our estimates concerning these variables and evaluating industry data regarding the productivity of clinical research and the development process. Changes in our estimates of items may result in a significant change in our valuation of these assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Out-licensed Patents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded a charge of $34.7 million related to the impairment of one of our out-licensed patents to reflect a change in its estimated fair value, due to a change in the underlying competitive market for that product, which occurred during the first quarter of 2014. </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><a name="sC332305BD3F15ABA9AF7AE74289F4EF3"></a><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">(Gain) Loss on Fair Value Remeasurement of Contingent Consideration</font></div><div style="line-height:120%;"><img src="biib-2015930_gainlosschart.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The consideration for certain of our business combinations includes future payments that are contingent upon the occurrence of a particular factor or factors. We record an obligation for such contingent consideration payments at fair value on the acquisition date. We then revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations, other than changes due to payments, are recognized as a (gain) loss on fair value remeasurement of contingent consideration in our condensed consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The loss on fair value remeasurement of contingent consideration for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was primarily due to the passage of time and modest changes in the expected timing and probabilities of success related to the achievement of certain developmental milestones.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The gain on fair value remeasurement of contingent consideration for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was primarily due to an adjustment to the value of our contingent consideration liabilities as we updated certain probabilities of success related to the early stage programs we acquired. For additional information, please read Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><a name="s12277DDC03E0E13B6E11AE7428D166DD"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Income (Expense), Net</font></div><div style="line-height:120%;"><img src="biib-2015930_oiechart.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in other income (expense), net was primarily due to an increase in interest expense as a result of our issuance of the Senior Notes issued on September 15, 2015 (2015 Senior Notes), offset by an increase in gains recognized on the sale of our strategic investments and lower non-state income taxes.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in other income (expense), net was primarily due to a decrease in gains recognized on the sale of our strategic investments and marketable securities, higher foreign exchange losses and an increase in interest expense as a result of our issuance of the 2015 Senior Notes. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect interest expense will continue to increase as a result of our issuance of the 2015 Senior Notes. For additional information related to our 2015 Senior Notes, please read Note 10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our condensed consolidated financial statements included in this report.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><a name="sD1EB2DC6E15AA084A887AE7428F25B31"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Income Tax Provision</font></div><div style="line-height:120%;"><img src="biib-2015930_taxexpchart.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:center;"><img src="biib-2015930_taxperchart.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our effective tax rate fluctuates from year to year due to the global nature of our operations. The factors that most significantly impact our effective tax rate include variability in the allocation of our taxable earnings among multiple jurisdictions, changes in tax laws, the amount and characterization of our research and development expenses, the levels of certain deductions and credits, acquisitions, and licensing transactions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our effective tax rate benefited from lower anticipated taxes on foreign earnings. Our effective tax rate for the comparative </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;month periods also reflects a benefit, described below, resulting from the remeasurement of one of our uncertain tax positions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For more information on our uncertain tax positions and income tax rate reconciliation for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note 15, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><a name="s919193E1A3BF5056FBFDAE7429245B80"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Equity in Loss of Investee, Net of Tax</font></div><div style="line-height:120%;"><img src="biib-2015930_investeechart.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012, we entered into an agreement with Samsung BioLogics Co. Ltd. (Samsung Biologics), establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals. We account for this investment under the equity method of accounting. We recognize our share of the results of operations related to our investment in Samsung Bioepis one quarter in arrears. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our share of losses exceeded the carrying value of our investment. We will suspend recognizing additional losses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in our equity in loss of investee, net of tax, was due to increases in the joint venture's clinical activity and milestone revenue earned by the joint venture in the third quarter of 2014, partially offset by a decrease in our ownership interest. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in our equity in loss of investee, net of tax, was due to the suspension of equity method investment losses due to our share of losses exceeding the carrying value of our investment in 2015 and a decrease in our ownership interest. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to this transaction, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><a name="s96e6b3660725423bb50547058e8699e0"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Noncontrolling Interest</font></div><div style="line-height:120%;"><img src="biib-2015930_noncontchart.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in net income (loss) attributable to noncontrolling interests, net of tax, was related to a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;milestone payment made to Neurimmune. For additional information, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our condensed consolidated financial statements included in this report.</font></div><a name="sA91160EE480A2E02D043AE742946BA28"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Quantitative and Qualitative Disclosures About Market Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to certain risks which may affect our results of operations, cash flows and fair values of assets and liabilities, including volatility in foreign currency exchange rates, interest rate movements, pricing pressures worldwide and weak economic conditions in the foreign markets in which we operate. We manage the impact of foreign currency exchange rates and interest rates through various financial instruments, including derivative instruments such as foreign currency forward contracts, interest rate lock contracts and interest rate swap contracts. We do not enter into financial instruments for trading or speculative purposes. Further, we only enter into contracts with parties that have at least an "A" (or equivalent) credit rating. The counter-parties to these contracts are major financial institutions and there is no significant concentration of exposure with any one counter-party.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Exchange Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our results of operations are subject to foreign currency exchange rate fluctuations due to the global nature of our operations. We have operations or maintain distribution relationships in the U.S., Europe, Canada, Switzerland, Australia, New Zealand, Japan and Central and South America. In addition, we receive royalty revenues based on sales of RITUXAN outside the U.S. and Canada. As a result, our financial position, results of operations and cash flows can be affected by market fluctuations in foreign </font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">exchange rates, primarily with respect to the Euro, Canadian dollar, Swiss franc, Danish krone, Japanese yen, Australian dollar and British pound sterling.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While the financial results of our global activities are reported in U.S. dollars, the functional currency for most of our foreign subsidiaries is their respective local currency. Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our operating results, often in ways that are difficult to predict. In particular, as the U.S. dollar strengthens versus other currencies, the value of the non-U.S. revenue will decline when reported in U.S. dollars. The impact to net income as a result of a strengthening U.S. dollar will be partially mitigated by the value of non-U.S. expense which will also decline when reported in U.S. dollars. As the U.S. dollar weakens versus other currencies, the value of the non-U.S. revenue and expenses will increase when reported in U.S. dollars.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have established revenue hedging and balance sheet risk management programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by volatility in foreign exchange rates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Revenue Hedging Program</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our foreign currency hedging program is designed to mitigate, over time, a portion of the impact resulting from volatility in exchange rate changes on revenues. We use foreign currency forward contracts to manage foreign currency risk, with the majority of our forward contracts used to hedge certain forecasted revenue transactions denominated in foreign currencies in the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We do not engage in currency speculation. For a more detailed disclosure of our revenue hedging program, please read Note 8, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our ability to mitigate the impact of exchange rate changes on revenues and net income diminishes as significant exchange rate fluctuations are sustained over extended periods of time. In particular, devaluation or significant deterioration of foreign currency exchange rates are difficult to mitigate and likely to negatively impact earnings. The cash flows from these contracts are reported as operating activities in our condensed consolidated statements of cash flows.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Balance Sheet Risk Management Hedging Program</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also use forward contracts to mitigate the foreign currency exposure related to certain balance sheet items. The primary objective of our balance sheet risk management program is to mitigate the exposure of foreign currency denominated net monetary assets of foreign affiliates. In these instances, we principally utilize currency forward contracts. We have not elected hedge accounting for the balance sheet related items. The cash flows from these contracts are reported as operating activities in our condensed consolidated statement of cash flows.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following quantitative information includes the impact of currency movements on forward contracts used in both our revenue and balance sheet hedging programs. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a hypothetical adverse 10% movement in foreign currency rates compared to the U.S. dollar across all maturities would result in a hypothetical decrease in the fair value of forward contracts of approximately $195.0 million and $160.0 million, respectively. The estimated fair value change was determined by measuring the impact of the hypothetical exchange rate movement on outstanding forward contracts. Our use of this methodology to quantify the market risk of such instruments is subject to assumptions and actual impact could be significantly different. The quantitative information about market risk is limited because it does not take into account all foreign currency operating transactions. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investment portfolio includes cash equivalents and short-term investments. The fair value of our marketable securities is subject to change as a result of potential changes in market interest rates. The potential change in fair value for interest rate sensitive instruments has been assessed on a hypothetical 100 basis point adverse movement across all maturities. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we estimate that such hypothetical 100 basis point adverse movement would result in a hypothetical loss in fair value of approximately $29.6 million and $14.5 million, respectively, to our interest rate sensitive instruments. The fair values of our investments were determined using third party pricing services or other market observable data.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">To achieve a desired mix of fixed and floating interest rate debt, we entered into interest rate swap contracts during 2015 for certain of our fixed-rate debt. These derivative contracts effectively converted a fixed-rate interest coupon to a floating-rate LIBOR-based coupon over the life of the respective note. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a 100 basis-point adverse movement (increase in LIBOR) would increase annual interest expense by approximately $6.8&#160;million. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Pricing Pressure</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Governments in some international markets in which we operate have implemented measures aimed at reducing healthcare costs to constrain the overall level of government expenditures. These implemented measures vary by country and include, among other things, mandatory rebates and discounts, prospective and possible retroactive price reductions and suspensions on price increases of pharmaceuticals. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to secure favorable prices in a particular country may impair our ability to obtain acceptable prices in existing and potential new markets and limit market growth. The continued implementation of pricing actions throughout Europe may also lead to higher levels of parallel trade.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the manner in which our products are prescribed and purchased. It is possible that additional federal health care reform measures will be adopted in the future, which could result in increased pricing pressure and reduced reimbursement for our products and otherwise have an adverse impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. Managed care organizations are also continuing to seek price discounts and, in some cases, to impose restrictions on the coverage of particular drugs.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Credit Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to credit risk from our accounts receivable related to our product sales. The majority of our accounts receivable arise from product sales in the U.S.&#160;and Europe with concentrations of credit risk limited due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. Our accounts receivable are primarily due from wholesale distributors, public hospitals and other government entities. We monitor the financial performance and creditworthiness of our large customers so that we can properly assess and respond to changes in their credit profile. We operate in certain countries where weakness in economic conditions can result in extended collection periods. We continue to monitor these conditions, including the volatility associated with international economies and the relevant financial markets, and assess their possible impact on our business. Our historical write-offs of accounts receivable have not been significant.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credit and economic conditions in the E.U. continue to remain uncertain, which has generally led to long collection periods for our accounts receivable and greater collection risk in certain countries. </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our accounts receivable in Portugal continue to be subject to significant payment delays due to government funding and reimbursement practices, although Portugal has introduced various programs periodically to pay down significantly overdue payables. Our net accounts receivable balance from product sales in Portugal totaled $20.4 million and $22.7 million as of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of which $8.9 million and $7.6 million were classified as non-current and included in investments and other assets in our condensed consolidated balance sheets. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our accounts receivable collection efforts in Spain have improved during the </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. All of our accounts receivable in Spain are expected to be collected within one year and are included in accounts receivable, net in our condensed consolidated balance sheets.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe that our allowance for doubtful accounts was adequate as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. However, if significant changes occur in the availability of government funding or the reimbursement practices of these or other governments, we may not be able to collect on amounts due to us from customers in such countries and our results of operations could be adversely affected.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><a name="s90094E9F9E2E1C545D96AE73E0E9D0BB"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Financial Condition, Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our financial condition is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.875%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td width="56%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>September 30, <br>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Change&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,089.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,204.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">239.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities &#8212; current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,753.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">640.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">173.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities &#8212; non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,947.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,470.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,789.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,316.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">134.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Borrowings:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable and other financing arrangements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable and other financing arrangements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,529.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">580.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total borrowings</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,534.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">583.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Working capital:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9,270.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,672.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">98.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,634.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,219.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total working capital</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,636.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,452.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">170.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">** Percentage not meaningful.</font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><a name="sCEBD4EAD18F9C2214271AE74299C3683"></a><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, certain significant cash flows were as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:67px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:43px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$5,930.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in proceeds from the issuance of our senior unsecured notes (2015 Senior Notes);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:67px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:43px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$2,998.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for share repurchases;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:67px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:43px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion in total payments for income taxes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:67px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:43px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$550.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent payments made to former shareholders of Fumapharm AG and holders of their rights;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:67px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:43px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$456.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for purchases of property, plant and equipment, including </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$104.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to a purchased facility;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:67px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:43px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$198.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;net cash paid for the acquisition of Convergence; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:67px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:43px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$124.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for an upfront payment made to AGTC.</font></div></td></tr></table></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, certain significant cash flows were as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:67px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:43px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$813.5 million in total payments for income taxes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:67px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:43px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;text-transform:default;">$360.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for share repurchases;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:67px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:43px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$180.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for purchases of property, plant and equipment;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:67px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:43px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;text-transform:default;">$175.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent payments made to former shareholders of Fumapharm AG and holders of their rights; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:67px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:43px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$155.0 million used for upfront and milestone payments in collaborative arrangements.</font></div></td></tr></table></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have historically financed our operating and capital expenditures primarily through cash flows earned through our operations. On September 15, 2015, we issued our 2015 Senior Notes for an aggregate principal amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We expect to continue funding our current and planned operating requirements principally through our cash flows from operations, as well as our existing cash resources and proceeds received from our 2015 Senior Notes. We believe that our existing funds, when combined with cash generated from operations and our access to additional financing resources, if needed, are sufficient to satisfy our operating, working capital, strategic alliance, milestone payment, capital expenditure and debt service requirements for the foreseeable future. In addition, we may choose to opportunistically return cash to shareholders and pursue other business initiatives, including acquisition and licensing activities. We may, from time to time, also seek additional funding through a combination of new collaborative agreements, strategic alliances and additional equity and debt financings or from other sources should we identify a significant new opportunity.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The undistributed cumulative foreign earnings of certain of our foreign subsidiaries, exclusive of earnings that would result in little or no net income tax expense under current U.S. tax law or which has already been subject to tax under U.S. tax law, are invested indefinitely outside the U.S. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Of the total cash, cash equivalents and marketable securities at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately $2,925 million was generated in foreign jurisdictions and is primarily intended for use in our foreign operations or in connection with business development transactions outside of the U.S. In managing our day-to-day liquidity in the U.S., we do not rely on the unrepatriated earnings as a source of funds and we have not provided for U.S.&#160;federal or state income taxes on these undistributed foreign earnings. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to certain risks that could negatively impact our financial position or future results of operations, please read the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; and &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Quantitative and Qualitative Disclosures About Market Risk</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; sections of this report.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchase Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2015, our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock (2015 Share Repurchase Program). This authorization does not have an expiration date. Repurchased shares will be retired. The 2015 Share Repurchase Program is in addition to the approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares remaining under our February 2011 Share Repurchase Program (2011 Share Repurchase Program), which has been used principally to offset common stock issuances under our share-based compensation plans.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2,998.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under our 2015 Share Repurchase Program and did not repurchase any shares of common stock under our 2011 Share Repurchase Program. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we purchased approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$360.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under our 2011 Share Repurchase Program. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From October 1, 2015 through October 20, 2015, we repurchased and expect to retire approximately 3.2 million shares of common stock at a cost of $896.3 million under our 2015 Share Repurchase Program. As of October 20, 2015, approximately $1,105.5 million remains available to repurchase shares under this program. We expect to complete the 2015 Share Repurchase Program by the end of 2015.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Marketable Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Until required for another use in our business, we typically invest our cash reserves in bank deposits, certificates of deposit, commercial paper, corporate notes, U.S.&#160;and foreign government instruments and other interest bearing marketable debt instruments in accordance with our investment policy. It is our policy to mitigate credit risk in our cash reserves and marketable securities by maintaining a well-diversified portfolio that limits the amount of exposure as to institution, maturity, and investment type. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in cash, cash equivalents and marketable securities from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, is primarily due to the issuance of our 2015 Senior Notes and net cash flows provided by operating activities, partially offset by purchases of our common stock, net purchases of marketable securities, income tax payments, contingent payments made to former shareholders of Fumapharm AG and holders of their rights, the acquisition of Convergence, net purchases of property, plant and equipment and the upfront payment made to AGTC.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Borrowings</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On September 15, 2015, we issued senior unsecured notes for an aggregate principal amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, consisting of the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15, 2020, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.792%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">3.625%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15, 2022, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.920%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">4.05%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15, 2025, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.764%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">5.20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15,&#160;2045, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.294%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par.</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to the 2015 Senior Notes, we have $550.0 million aggregate principal amount of 6.875% Senior Notes due March 1, 2018 that were originally priced at 99.184% of par. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The discounts will be amortized as additional interest expense over the period from issuance through maturity.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2015, we entered into a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;senior unsecured revolving credit facility, under which we are permitted to draw funds for working capital and general corporate purposes for 5 years. As of </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September 30, 2015, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;outstanding borrowings under this facility.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our 2006 distribution agreement with Fumedica, we issued notes totaling 61.4&#160;million Swiss Francs which were payable to Fumedica in varying amounts from June 2008 through June 2018. Our remaining note payable to Fumedica had a carrying value of 8.8&#160;million Swiss Francs ($9.1&#160;million) and 11.6&#160;million Swiss Francs ($11.7 million) as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a summary of the fair and carrying values of our outstanding borrowings as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note&#160;6, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Working Capital</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We define working capital as current assets less current liabilities. The increase in working capital from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reflects an increase in total current assets of $4,598.7 million, partially offset by an increase in current liabilities of $414.3 million. The increase in total current assets was primarily driven by an increase in cash, cash equivalents and marketable securities due to the issuance of our 2015 Senior Notes, partially offset by purchases of our common stock, and prepaid taxes. The increase in total current liabilities primarily resulted from an increase in taxes payable and accrued expenses and other. </font></div></div></div><br><a name="s584199E7A5C58C5637B0AE73F6A9099D"></a><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash Flows</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our cash flow activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.65625%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="55%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">%&#160;Change</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by operating activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,675.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,009.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in investing activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,746.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,164.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">135.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by (used in) financing activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,984.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(242.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">** Percentage not meaningful.</font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><a name="s2E83444C72525B434EA1AE7429ED8FAD"></a><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Operating Activities</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. We expect cash provided from operating activities will continue to be our primary source of funds to finance operating needs and capital expenditures for the foreseeable future.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating cash flow is derived by adjusting our net income for:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-cash operating items such as depreciation and amortization, impairment charges and share-based compensation charges;</font></div></td></tr></table></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in operating assets and liabilities which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in results of operations;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes associated with the fair value of contingent payments associated with our acquisitions of businesses and payments related to collaborations.</font></div></td></tr></table></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in cash provided by operating activities is primarily driven by higher net income and a decrease in the comparative growth in outstanding accounts receivable balances due to collection efforts, partially offset by a decrease in the change of accrued expenses and other current liabilities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Investing Activities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in net cash flows used in investing activities is primarily due to an increase in net purchases of marketable securities, an increase in the total amount of contingent consideration paid to the former shareholders of Fumapharm AG, an increase in purchases of property, plant and equipment and cash paid for the acquisition of Convergence.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Financing Activities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in net cash flows provided by financing activities is primarily due to the issuance of our 2015 Senior Notes, partially offset by an increase in the amount of common stock we repurchased.</font></div><a name="s2BDA6CEEED303F2D665AAE742A1E8A7E"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Contractual Obligations and Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contractual Obligations</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our contractual obligations primarily consist of our obligations under non-cancellable operating leases, notes payable, and defined benefit and other purchase obligations, excluding amounts related to uncertain tax positions, amounts payable to tax authorities, funding commitments, contingent development, regulatory and commercial milestone payments, TYSABRI contingent payments and contingent consideration related to our business combinations, as described below.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2015, we signed a lease for additional laboratory space in Cambridge, Massachusetts through June 2025. We are subject to future minimum rental commitments related to this lease in the amount of approximately $55.5 million over the term of the lease.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On September 15, 2015, we issued senior unsecured notes for an aggregate principal amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been no other material changes in our contractual obligations since </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Related Obligations</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have approximately $53.9 million of liabilities associated with uncertain tax positions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Funding Commitments</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have several on-going clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to contract research organizations (CROs). The contracts with CROs are generally cancellable, with notice, at our option. We have recorded accrued expenses of approximately $25.0 million on our condensed consolidated balance sheet for expenditures incurred by CROs as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have approximately $680.0 million in cancellable future commitments based on existing CRO contracts as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have planned clinical trials for our ISIS-SMN</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and ISIS-DMPK</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;programs which are managed by Isis. We have agreed to pay up to approximately $140 million in payments to Isis as the trials for these programs proceed. If these trials advance and we continue with our Isis programs, it is possible that we could make a significant amount of additional development payments in the future.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Development, Regulatory and Commercial Milestone Payments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on our development plans as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we could make potential future milestone payments to third parties of up to approximately $2.9 billion as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones had not occurred as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory approval and commercial milestones.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">TYSABRI Contingent Payments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2013, we acquired from Elan Corporation plc (Elan) full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the terms of the acquisition agreement, we are obligated to make contingent payments to Elan of 18% on annual worldwide net sales up to $2.0 billion and 25% on annual worldwide net sales that exceed $2.0 billion. Royalty payments to Elan and other third parties are recognized as cost of sales in our condensed consolidated statements of income. Elan was acquired by Perrigo in December 2013. Following that acquisition, we began making these royalty payments to Perrigo.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration related to Business Combinations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our purchase of the noncontrolling interests in our joint venture investments in Biogen Domp&#233; SRL and Biogen Domp&#233; Switzerland GmbH and our acquisitions of Convergence, Stromedix, Inc. (Stromedix), Biogen International Neuroscience GmbH (formerly Biogen Idec International Neuroscience GmbH) (BIN) and Biogen Hemophilia Inc. (formerly Biogen Idec Hemophilia Inc.) (BIH), we may pay up to approximately $1.3 billion in remaining milestones based upon the achievement of certain events. These milestones may not be achieved.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As the acquisitions of the noncontrolling interests in our joint venture investments and our acquisitions of Convergence, Stromedix and BIN, formerly Panima Pharmaceuticals AG, occurred after January&#160;1, 2009, we record contingent consideration liabilities at their fair value on the acquisition date and revalue these obligations each reporting period. For additional information related to our acquisition of Convergence, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our condensed consolidated financial statements included in this report. For additional information related to our acquisition of Stromedix, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">BIH</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of BIH, formerly Syntonix, in January 2007, we agreed to pay up to an additional $80.0 million if certain milestone events associated with the development of BIH&#8217;s lead product, ALPROLIX are achieved. The final $20.0 million contingent payment will occur if prior to the tenth anniversary of the closing date, a marketing authorization is granted by the EMA for ALPROLIX. This payment will be accounted for as an increase to intangible assets if achieved.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Fumapharm AG</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2006, we acquired Fumapharm AG. As part of this acquisition we acquired FUMADERM and TECFIDERA (together, Fumapharm Products). We are required to make contingent payments to former shareholders of Fumapharm AG or holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior twelve month period, as defined in the acquisition agreement. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$550.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent payments as we reached the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;cumulative sales levels related to the Fumapharm Products in the fourth quarter of 2014 and second quarter of 2015, respectively, and accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon reaching </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in total cumulative sales of Fumapharm Products in the third quarter of 2015.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We will owe an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;contingent payment for every additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in cumulative sales level of Fumapharm Products reached if the prior 12 months sales of the Fumapharm Products exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, until such time as the cumulative sales level reaches </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, at which time no further contingent payments shall be due. These payments will be accounted for as an increase to goodwill as incurred, in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm. Any portion of the payment which is tax deductible will be recorded as a reduction to goodwill. Payments are due within 60&#160;days following the end of the quarter in which the applicable cumulative sales level has been reached. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We do not have any relationships with entities often referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships. We consolidate variable interest entities if we are the primary beneficiary.</font></div><a name="s779A2451CE1089CBCCA9AE742A406D67"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">New Accounting Standards</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of new accounting standards please read Note&#160;1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies - New Accounting Pronouncements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div><a name="s49AFAA8AEB47F848D7C8AE742A716DC3"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Critical Accounting Estimates</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S.&#160;(U.S.&#160;GAAP), requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expenses. Actual results may differ from these estimates under different assumptions or conditions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of our critical accounting estimates, please read Part&#160;II, Item&#160;7 &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form&#160;10-K. There have been no material changes to these critical accounting estimates since our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form&#160;10-K.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><a name="sF37A975ECE5C8BE448FBAE742A95D033"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The information required by this Item is incorporated by reference to the discussion under </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Quantitative and Qualitative Disclosures About Market Risk&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in Item 2. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221;</font></div><a name="sB6CD442A03697CCB2441AE742AC53809"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;4.&#160;&#160;&#160;&#160;Controls and Procedures</font></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Disclosure Controls and Procedures and Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Controls and Procedures</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that (a)&#160;the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities Exchange Commission&#8217;s rules and forms, and (b)&#160;such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There were no changes in our internal control over financial reporting during the quarter ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">59</font></div></div><hr style="page-break-after:always"><a name="s850E56CD3782C9C8429FAE742AE8EEA8"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Part&#160;II&#160;&#8212; OTHER INFORMATION</font></div><a name="s565778ED0A04686DC080AE742B1823BD"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;1.&#160;&#160;&#160;&#160;Legal Proceedings</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Please refer to Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report, which is incorporated into this item by reference.</font></div><a name="s1ED0177CBD0AE920B3FAAE742B3C9FAA"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We are substantially dependent on revenues from our principal products. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current revenues depend upon continued sales of our principal products. We may be substantially dependent on sales from our principal products for many years, including an increasing reliance on sales and growth of TECFIDERA as we continue to expand into additional markets. Any of the following negative developments relating to any of our principal products may adversely affect our revenues and results of operations or could cause a decline in our stock price: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">safety or efficacy issues; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction or greater acceptance of competing products; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">constraints and additional pressures on product pricing or price increases, due to a number of factors, including governmental or regulatory requirements, increased competition, or changes in reimbursement policies and practices of payors and other third parties; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">adverse legal, administrative, regulatory or legislative developments. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we fail to compete effectively, our business and market position would suffer.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The biopharmaceutical industry and the markets in which we operate are intensely competitive. We compete in the marketing and sale of our products, the development of new products and processes, the acquisition of rights to new products with commercial potential and the hiring and retention of personnel. We compete with biotechnology and pharmaceutical companies that have a greater number of products on the market and in the product pipeline, greater financial and other resources and other technological or competitive advantages. One or more of our competitors may benefit from significantly greater sales and marketing capabilities, may develop products that are accepted more widely than ours or may receive patent protection that dominates, blocks or adversely affects our product development or business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our products are also susceptible to competition from generics and biosimilars in many markets.&#160;Generic versions of drugs and biosimilars are likely to be sold at substantially lower prices than branded products.&#160;Accordingly, the introduction of generic or biosimilar versions of our marketed products likely would significantly reduce both the price that we receive for such marketed products and the volume of products that we sell, which may have an adverse impact on our results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the MS market, we face intense competition as the number of products and competitors continues to expand. Due to our significant reliance on sales of our MS products, our business may be harmed if we are unable to successfully compete in the MS market. More specifically, our ability to compete, maintain and grow our share in the MS market may be adversely affected due to a number of factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of more efficacious, safer, less expensive or more convenient alternatives to our MS products, including our own products and products of our collaborators; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of lower-cost biosimilars, follow-on products or generic versions of branded MS products sold by our competitors, and the possibility of future competition from generic versions or related prodrug derivatives or from off-label use by physicians of therapies indicated for other conditions to treat MS patients; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">patient dynamics, including the size of the patient population and our ability to attract new patients to our therapies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">damage to physician and patient confidence in any of our MS products or to our sales and reputation as a result of label changes or adverse experiences or events that may occur with patients treated with our MS products; </font></div></td></tr></table><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">inability to obtain appropriate pricing and reimbursement for our MS products compared to our competitors in key international markets; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to obtain and maintain patent, data or market exclusivity for our MS products.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Similarly, the hemophilia treatment market is highly competitive, with current treatments marketed by companies that have substantially greater financial resources and marketing expertise. Our ability to successfully compete in the hemophilia market and gain share in this market may be adversely affected due to a number of reasons, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">difficulty in penetrating this market if our therapies are not regarded as offering significant benefits over current treatments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction by other companies of longer-lasting or more efficacious, safer, less expensive or more convenient treatments than our therapies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our limited marketing experience within the hemophilia treatment market, which may impact our ability to develop well-established relationships with the associated medical and scientific community; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">if one of several companies that are working to develop additional treatments for hemophilia obtains marketing approval of its treatment in the E.U. before we do, our applications with the EMA could be barred under operation of the EMA&#8217;s orphan medicinal product regulation.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success depends in part on our ability to obtain and defend patent and other intellectual property rights that are important to the commercialization of our products and product candidates. The degree of patent protection that will be afforded to our products and processes in the U.S. and in other important markets remains uncertain and is dependent upon the scope of protection decided upon by the patent offices, courts and lawmakers in these countries. We can provide no assurance that we will successfully obtain or preserve patent protection for the technologies incorporated into our products and processes, or that the protection obtained will be of sufficient breadth and degree to protect our commercial interests in all countries where we conduct business. If we cannot prevent others from exploiting our inventions, we will not derive the benefit from them that we currently expect. Furthermore, we can provide no assurance that our products will not infringe patents or other intellectual property rights held by third parties.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also rely on regulatory exclusivity for protection of our products. Implementation and enforcement of regulatory exclusivity, which may consist of regulatory data protection and market protection, varies widely from country to country.&#160;Failure to qualify for regulatory exclusivity, or failure to obtain or maintain the extent or duration of such protections that we expect in each of the markets for our products, could affect our revenue for our products or our decision on whether to market our products in a particular country or countries or could otherwise have an adverse impact on our results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Litigation, interferences, oppositions, inter partes reviews or other proceedings are, have been and may in the future be necessary in some instances to determine the validity and scope of certain of our proprietary rights, and in other instances to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products.&#160;We may also face challenges to our patent and regulatory protections covering our products by manufacturers of generics and biosimilars that may choose to launch or attempt to launch their products before the expiration of our patent or regulatory exclusivity.&#160;Litigation, interference, oppositions, inter partes reviews or other similar types of proceedings are unpredictable and may be protracted, expensive and distracting to management. The outcome of such proceedings could adversely affect the validity and scope of our patent or other proprietary rights, hinder our ability to manufacture and market our products, require us to seek a license for the infringed product or technology or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our financial statements. An adverse determination in a judicial or administrative proceeding or a failure to obtain necessary licenses could prevent us from manufacturing or selling our products. Furthermore, payments under any licenses that we are able to obtain would reduce our profits derived from the covered products and services.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our long-term success depends upon the successful development of new products and additional indications for existing products. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our long-term viability and growth will depend upon successful development of additional indications for our existing products as well as successful development of new products and technologies resulting from our research and development activities, our biosimilars joint venture with Samsung Biologics or licenses or acquisitions from third parties. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product development is very expensive and involves a high degree of risk. Only a small number of research and development programs result in the commercialization of a product. Clinical trials may indicate that our product candidates lack efficacy, have harmful side effects or raise other concerns that may significantly reduce the likelihood of regulatory approval. This may result in significant restrictions on use and safety warnings in an approved label, adverse placement within the treatment paradigm, or significant reduction in the commercial potential of the product candidate.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Conducting clinical trials is a complex, time-consuming and expensive process. Our ability to complete clinical trials in a timely fashion depends in large part on a number of key factors. These factors include protocol design, regulatory and institutional review board approval, patient enrollment rates, and compliance with extensive current Good Clinical Practices. If we or our third party clinical trial providers or third party contract research organizations, or CROs, do not successfully carry out these clinical activities, our clinical trials or the potential regulatory approval of a product candidate may be delayed or be unsuccessful.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have opened clinical sites and are enrolling patients in a number of countries where our experience is more limited. In most cases, we use the services of third parties to carry out our clinical trial related activities and rely on such parties to accurately report their results. Our reliance on third parties for these activities may impact our ability to control the timing, conduct, expense and quality of our clinical trials. One CRO has responsibility for substantially all of our clinical trial related activities and reporting. If this CRO does not adequately perform, many of our trials may be affected. We may need to replace our CROs. Although we believe there are a number of other CROs we could engage to continue these activities, the replacement of an existing CRO may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and commercialize our product candidates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Successful preclinical work or early stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Positive results in a trial may not be replicated in subsequent or confirmatory trials. Additionally, success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful or that regulatory approval will be obtained. In addition, even if later stage clinical trials are successful, regulatory authorities may delay or decline approval of our product candidates. Regulatory authorities may disagree with our view of the data, require additional studies or disagree with our trial design or endpoints. Regulatory authorities may also fail to approve the facilities or the processes used to manufacture a product candidate, our dosing or delivery methods or companion devices. Regulatory authorities may grant marketing approval that is more restricted than anticipated. These restrictions may include limiting indications to narrow patient populations and the imposition of safety monitoring, educational requirements and risk evaluation and mitigation strategies. The occurrence of any of these events could result in significant costs and expenses, have an adverse effect on our business, financial condition and results of operations and cause our stock price to decline or experience periods of volatility.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Even if we are able to successfully develop new products or indications, sales of new products or products with additional indications may not meet investor expectations.  We may also make a strategic decision to discontinue development of a product or indication if, for example, we believe commercialization will be difficult relative to the standard of care or other opportunities in our pipeline.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adverse safety events involving our marketed products may have a negative impact on our business. Discovery of safety issues with our products could create product liability and could cause additional regulatory scrutiny and requirements for additional labeling, withdrawal of products from the market, and the imposition of fines or criminal penalties. Adverse safety events may also damage physician and patient confidence in our products and our reputation. Any of these could result in liabilities, loss of revenue, material write-offs of inventory, material impairments of intangible assets, goodwill and fixed assets, material restructuring charges and other adverse impacts on our results of operations. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regulatory authorities are making greater amounts of stand-alone safety information directly available to the public through periodic safety update reports, patient registries and other reporting requirements. The reporting of adverse safety events involving our products or products similar to ours and public rumors about such events may increase claims against us and may also cause our product sales or stock price to decline or experience periods of volatility. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restrictions on use or significant safety warnings that may be required to be included in the label of our products, such as the risk of developing progressive multifocal leukoencephalopathy (PML), a serious brain infection, in the label for TYSABRI and in the U.S. label for TECFIDERA, may significantly reduce expected revenues for those products and require significant expense and management time. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third party payors, which are subject to increasing and intense pressure from political, social, competitive and other sources. Our inability to maintain adequate coverage, or a reduction in pricing or reimbursement, could have an adverse effect on our business, revenues and results of operations, and could cause a decline in our stock price.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales of our products are dependent, in large part, on the availability and extent of coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pricing and reimbursement for our products may be adversely affected by a number of factors, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in government regulations or private third-party payors' reimbursement policies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">pressure by employers on private health insurance plans to reduce costs; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">payors, including managed care organizations, health insurers, pharmacy benefit managers, government health administration authorities, private health insurers and other organizations, seeking price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value.&#160; </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our ability to set the price for our products can vary significantly from country to country and as a result so can the price of our products.  Certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to secure adequate prices in a particular country may not only limit the marketing of our products within that country, but may also adversely affect our ability to obtain acceptable prices in other markets. This may create the opportunity for third party cross-border trade or influence our decision to sell or not to sell a product, thus adversely affecting our geographic expansion plans and revenues.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our failure to maintain adequate coverage, pricing, or reimbursement for our products would have an adverse effect on our business, revenues and results of operation, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products, and could cause a decline in our stock price.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Drug prices are under significant scrutiny in the markets in which our products are prescribed.&#160;Drug pricing and other health care costs continues to be subject to intense political and societal pressures which we anticipate will continue and escalate on a global basis.&#160;As a result, our business and reputation may be harmed, our stock price may be adversely impacted and experience periods of volatility, and our results of operations may be adversely impacted.&#160; </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our results of operations may be adversely affected by current and potential future healthcare reforms.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals and enactments to reform health care insurance programs could significantly influence the manner in which our products are prescribed and purchased. For example, provisions of the Patient Protection and Affordable Care Act (PPACA) have resulted in changes in the way health care is paid for by both governmental and private insurers, including increased rebates owed by manufacturers under the Medicaid Drug Rebate Program, annual fees and taxes on manufacturers of certain branded prescription drugs, the requirement that manufacturers participate in a discount program for certain outpatient drugs under Medicare Part D and the expansion of the number of hospitals eligible for discounts under Section 340B of the Public Health Service Act. These changes have had and are expected to continue to have a significant impact on our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. In recent years, some states have considered legislation that would control the prices of drugs, including laws to allow importation of pharmaceutical products from lower cost jurisdictions outside the U.S. State Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding constraint on prices and reimbursement for our products. In addition, under the PPACA, as states implement their health care marketplaces or operate under the federal exchange, the impact on drug manufacturers, including us, will depend in part on the formulary and benefit design decisions made by insurance sponsors or plans participating in these programs. It is possible that we may need to provide discounts or rebates to such plans in order to maintain favorable formulary access for our products for this patient population, which could have an adverse impact on our sales and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the European Union and some other international markets, the government provides health care at low cost to consumers and regulates pharmaceutical prices, patient eligibility or reimbursement levels to control costs for the government-sponsored health care system. Many countries have announced or implemented measures to reduce health care costs to constrain their overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possibly retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases, and greater importation of drugs from lower-cost countries to higher-cost countries. These measures have negatively impacted our revenues, and may continue to adversely affect our revenues and results of operations in the future.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We depend on relationships with collaborators and other third-parties for revenue, and the development, regulatory approval process, commercialization and marketing of certain products, which are outside of our full control.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We rely on a number of significant collaborative relationships for revenue, and the development, regulatory approval process, commercialization, and marketing of certain of our products and product candidates. Reliance on collaborative relationships subjects us to a number of risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">we may be unable to control the resources our collaborator devotes to our programs or products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">disputes may arise with respect to ownership of rights to technology developed with our collaborator, and the underlying contract with our collaborator may fail to provide significant protection or may fail to be effectively enforced if the collaborator fails to perform; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our collaborator&#8217;s interests may not always be aligned with our interests and a collaborator may not pursue regulatory approvals or market a product in the same manner or to the same extent that we would, which could adversely affect our revenues; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">collaborations often require the parties to cooperate, and failure to do so effectively could adversely affect product sales by our collaborator or the clinical development or regulatory approvals of products under joint control or could result in termination of the research, development or commercialization of product candidates or result in litigation or arbitration; and</font></div></td></tr></table><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">any failure on the part of our collaborator to comply with applicable laws and regulatory requirements in the marketing, sale and maintenance of the market authorization of our products or to fulfill any responsibilities our collaborator may have to protect and enforce any intellectual property rights underlying our products could have an adverse effect on our revenues as well as involve us in possible legal proceedings.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Given these risks, there is considerable uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed or revenues from products could decline.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Manufacturing issues could substantially increase our costs, limit supply of our products and reduce our revenues.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The process of manufacturing our products is complex, highly regulated and subject to numerous risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk of Product Loss.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;The manufacturing process for our products is extremely susceptible to product loss due to contamination, oxidation, equipment failure or improper installation or operation of equipment, or vendor or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or manufacturing facilities, we may need to close our manufacturing facilities for an extended period of time to investigate and remediate the contaminant. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risks of Reliance on Third Parties and Single Source Providers.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We rely on third party suppliers and manufacturers for, among other things: manufacturing of RITUXAN and GAZYVA; the majority of our clinical and commercial requirements for TECFIDERA and other small molecule products and product candidates; raw materials and supplies for production of products we manufacture; delivery devices such as syringes and auto-injectors; drug product and fill-finish operations; the majority of our final product storage; and a substantial portion of our packaging operations. In addition, due to the unique manner in which our products are manufactured, we rely on single source providers of several raw materials and manufacturing supplies. These third parties are independent entities subject to their own unique operational and financial risks that are outside of our control. These third parties may not perform their obligations in a timely and cost-effective manner or in compliance with applicable regulations, and they may be unable or unwilling to increase production capacity commensurate with demand for our existing or future products. Finding alternative providers could take a significant amount of time and involve significant expense due to the specialized nature of the services and the need to obtain regulatory approval of any significant changes to our suppliers or manufacturing methods. We cannot be certain that we could reach agreement with alternative providers or that the FDA or other regulatory authorities would approve our use of such alternatives. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Global Bulk Supply Risks.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We rely on our manufacturing facilities in Cambridge, Massachusetts, RTP, North Carolina and Hiller&#248;d, Denmark for the production of drug substance for certain of our large molecule products and product candidates, including AVONEX, TYSABRI, PLEGRIDY, ZINBRYTA, ALPROLIX and ELOCTATE. Our global bulk supply of these products and product candidates depends on the uninterrupted and efficient operation of these facilities, which could be adversely affected by equipment failures, labor shortages, natural disasters, power failures and numerous other factors.   </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risks Relating to Compliance with Current Good Manufacturing Practices.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We and our third party providers are generally required to maintain compliance with current Good Manufacturing Practices and other stringent requirements and are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm such compliance. Any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of our products as a result of a failure of our facilities or the facilities or operations of third parties to pass any regulatory agency inspection could significantly impair our ability to develop and commercialize our products. Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any adverse developments affecting our manufacturing operations or the operations of our third-party suppliers and manufacturers may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the commercial supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenue or market share as patients and physicians turn to competing therapeutics, diminish our profitability or damage our reputation. </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our business may be adversely affected if we do not manage our current growth and do not successfully execute our growth initiatives.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate growth through internal development projects, commercial initiatives, and external opportunities, which may include the acquisition, partnering and in-licensing of products, technologies and companies or the entry into strategic alliances and collaborations. The availability of high quality development opportunities is limited and competitive, and we are not certain that we will be able to identify candidates that we and our shareholders consider suitable or complete transactions on terms that are acceptable to us and our shareholders. In order to pursue such opportunities, we may require significant additional financing, which may not be available to us on favorable terms, if at all. Even if we are able to successfully identify and complete acquisitions and other strategic alliances and collaborations, we may face unanticipated costs or liabilities in connection with the transaction or we may not be able to integrate them or take full advantage of them or otherwise realize the benefits that we expect.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">To manage our current and future potential growth effectively, we need to continue to enhance our operational, financial and management processes and to expand, train and manage our employee base. Our growth is also dependent upon our ability to attract and retain qualified scientific, information technology, manufacturing, sales and marketing and executive personnel and to develop and maintain relationships with qualified clinical researchers and key distributors in a highly competitive environment. Supporting our growth initiatives and the further development of our existing products and potential new products in our pipeline will require significant capital expenditures and management resources, including investments in research and development, sales and marketing, manufacturing capabilities and other areas of our business. If we do not successfully manage our current growth and do not successfully execute our growth initiatives, then our business and financial results may be adversely affected and we may incur asset impairment or restructuring charges.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We may fail to achieve the expected financial and operating benefits of our corporate restructuring and the restructuring may harm our business and financial results. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We face significant risks associated with our corporate restructuring actions that may impair our ability to achieve anticipated savings and operational efficiencies or that may otherwise harm our business. These risks include delays in implementation of anticipated workforce reductions, loss of workforce capabilities, decreases in employee focus and morale, attrition of necessary or key employees, higher than anticipated separation expenses, litigation and the failure to meet financial and operational targets. In addition, the calculation of the anticipated cost savings and other benefits resulting from our corporate restructuring actions are subject to many estimates and assumptions. These estimates and assumptions are subject to significant business, economic, competitive and other uncertainties and contingencies, many of which are beyond our control. If these estimates and assumptions are incorrect or if we experience delays or unforeseen events, our business and financial results could be adversely affected. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our activities, and the activities of our collaborators, distributors and other third party providers, are subject to extensive government regulation and oversight both in the U.S.&#160;and in foreign jurisdictions. The FDA and comparable agencies in other jurisdictions directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting and product risk management. Our interactions in the U.S.&#160;or abroad with physicians and other health care providers that prescribe or purchase our products are also subject to government regulation designed to prevent fraud and abuse in the sale and use of the products and place greater restrictions on the marketing practices of health care companies. Health care companies such as ours are facing heightened scrutiny of their relationships with health care providers from anti-corruption enforcement officials. In addition, we along with many other pharmaceutical and biotechnology companies have been the target of lawsuits and investigations alleging violations of government regulation, including claims asserting submission of incorrect pricing information, impermissible off-label promotion of pharmaceutical products, payments intended to influence the referral of health care business, submission of false claims for government reimbursement, antitrust violations, or violations related to environmental matters. These risks may be heightened as we continue to expand our global operations and introduce additional products to the market.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regulations governing the health care industry are subject to change, with possibly retroactive effect, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to health care availability, pricing or marketing practices, compliance with wage and hour laws and other employment practices, method of delivery, payment for health care products and services, compliance with </font></div></td></tr></table><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">66</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-left:29px;padding-top:12px;text-align:left;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">health information and data privacy and security laws and regulations, tracking and reporting payments and other transfers of value made to physicians and teaching hospitals, extensive anti-bribery and anti-corruption prohibitions, product serialization and labeling requirements, and used product take-back requirements; </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the FDA and foreign regulatory approval processes that may delay or prevent the approval of new products and result in lost market opportunity; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">requirements that provide for increased transparency of clinical trial results and quality data, such as the EMA&#8217;s clinical transparency policy, which could impact our ability to protect trade secrets and competitively-sensitive information contained in approval applications or could be misinterpreted leading to reputational damage, misperception or legal action which could harm our business; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product distribution or use, or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of approved products, or otherwise adversely affect the market for our products.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Examples of previously enacted and possible future changes in laws that could adversely affect our business include the enactment in the U.S.&#160;of health care reform, regulatory pathways easing the entry of competing biosimilars in the marketplace, new legislation or implementation of existing statutory provisions on importation of lower-cost competing drugs from other jurisdictions, enhanced penalties for and investigations into non-compliance with U.S.&#160;fraud and abuse laws, and compliance with the Physician Payment Sunshine Act in the U.S. and similar foreign rules and regulations that require collection and reporting of payments or other transfers of value made to physicians and teaching hospitals.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Violations of governmental regulation may be punishable by criminal and civil sanctions against us, including fines and civil monetary penalties and exclusion from participation in government programs, including Medicare and Medicaid, as well as against executives overseeing our business. In addition to penalties for violation of laws and regulations, we could be required to repay amounts we received from government payors, or pay additional rebates and interest if we are found to have miscalculated the pricing information we have submitted to the government. Whether or not we have complied with the law, an investigation into alleged unlawful conduct could increase our expenses, damage our reputation, divert management time and attention and adversely affect our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">A breakdown or breach of our technology systems could subject us to liability or interrupt the operation of our business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are increasingly dependent upon technology systems and data. Our computer systems continue to increase in multitude and complexity due to the growth in our business, making them potentially vulnerable to breakdown, malicious intrusion and random attack.&#160;Likewise, data privacy or security breaches by individuals authorized to access our technology systems or others may pose a risk that sensitive data, including intellectual property, trade secrets or personal information belonging to us, our patients, customers or other business partners, may be exposed to unauthorized persons or to the public. Cyber-attacks are increasing in their frequency, sophistication and intensity. While we continue to build and improve our systems and infrastructure and believe we have taken appropriate security measures to minimize these risks to our data and information technology systems, there can be no assurance that our efforts will prevent breakdowns or breaches in our systems that could adversely affect our business and operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our indebtedness could adversely affect our business and limit our ability to plan for or respond to changes in our business. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our indebtedness, together with our significant contingent liabilities, including milestone and royalty payment obligations, could have important consequences to our business, for example, it could: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">increase our vulnerability to general adverse economic and industry conditions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limit our ability to access capital markets and incur additional debt in the future;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow for other purposes, including business development efforts, research and development and mergers and acquisitions;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate, thereby placing us at a competitive disadvantage compared to our competitors that have less debt.</font></div></td></tr></table><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our sales and operations are subject to the risks of doing business internationally.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are increasing our presence in international markets, particularly emerging markets, subjecting us to many risks that could adversely affect our business and revenues, such as:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the inability to obtain necessary foreign regulatory or pricing approvals of products in a timely manner; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">collectability of accounts receivable; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">fluctuations in foreign currency exchange rates, in particular the recent strength of the U.S. dollar versus foreign currencies which has adversely impacted our revenues and net income; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">difficulties in staffing and managing international operations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the imposition of governmental controls; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">less favorable intellectual property or other applicable laws; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">increasingly complex standards for complying with foreign laws and regulations that may differ substantially from country to country and may conflict with corresponding U.S. laws and regulations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the far-reaching anti-bribery and anti-corruption legislation in the U.K., including the U.K. Bribery Act 2010, and elsewhere and escalation of investigations and prosecutions pursuant to such laws; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">compliance with complex import and export control laws;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">restrictions on direct investments by foreign entities and trade restrictions; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">greater political or economic instability; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in tax laws and tariffs.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, our international operations are subject to regulation under U.S. law. For example, the Foreign Corrupt Practices Act prohibits U.S. companies and their representatives from offering, promising, authorizing or making payments to foreign officials for the purpose of obtaining or retaining business abroad. In many countries, the health care professionals we regularly interact with may meet the definition of a foreign government official for purposes of the Foreign Corrupt Practices Act. Failure to comply with domestic or foreign laws could result in various adverse consequences, including: possible delay in approval or refusal to approve a product; recalls, seizures or withdrawal of an approved product from the market; disruption in the supply or availability of our products or suspension of export or import privileges; the imposition of civil or criminal sanctions; the prosecution of executives overseeing our international operations; and damage to our reputation.  Any significant impairment of our ability to sell products outside of the U.S. could adversely impact our business and financial results.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our effective tax rate may fluctuate and we may incur obligations in tax jurisdictions in excess of accrued amounts.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a global biopharmaceutical company, we are subject to taxation in numerous countries, states and other jurisdictions. As a result, our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Our effective tax rate, however, may be different than experienced in the past due to numerous factors, including changes in the mix of our profitability from country to country, the results of examinations and audits of our tax filings, adjustments to the value of our uncertain tax positions, changes in accounting for income taxes and changes in tax laws. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, our inability to secure or sustain acceptable arrangements with tax authorities and future changes in the tax laws, among other things, may result in tax obligations in excess of amounts accrued in our financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., there are several proposals under consideration to reform tax law, including proposals that may reduce or eliminate the deferral of U.S.&#160;income tax on our unrepatriated earnings, penalize certain transfer pricing structures, and reduce or eliminate certain foreign or domestic tax credits or deductions. Our future reported financial results may be adversely affected by tax law changes which restrict or eliminate certain foreign tax credits or our ability to deduct expenses attributable to foreign earnings, or otherwise affect the treatment of our unrepatriated earnings.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">68</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to U.S. tax reform proposals, the adoption of some or all of the recommendations set forth in the Organization for Economic Co-operation and Development&#8217;s project on &#8220;Base Erosion and Profit Shifting&#8221; (BEPS) by tax authorities in the countries in which we operate, could negatively impact our effective tax rate.&#160;These recommendations focus on payments from affiliates in high tax jurisdictions to affiliates in lower tax jurisdictions and the activities that give rise to a taxable presence in a particular country.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our operating results are subject to significant fluctuations.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our quarterly revenues, expenses and net income (loss) have fluctuated in the past and are likely to fluctuate significantly in the future due to the risks described in these </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Risk Factors&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as well as the timing of charges and expenses that we may take. We have recorded, or may be required to record, charges that include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the cost of restructurings; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">impairments with respect to investments, fixed assets and long-lived assets, including in-process R&amp;D and other intangible assets; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">inventory write-downs for failed quality specifications, charges for excess or obsolete inventory and charges for inventory write downs relating to product suspensions, expirations or recalls; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the fair value of contingent consideration;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">bad debt expenses and increased bad debt reserves; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">outcomes of litigation and other legal or administrative proceedings, regulatory matters and tax matters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">milestone payments under license and collaboration agreements; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">payments in connection with acquisitions and other business development activities.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our revenues are also subject to foreign exchange rate fluctuations due to the global nature of our operations. Although we have foreign currency forward contracts to hedge specific forecasted transactions denominated in foreign currencies, our efforts to mitigate the impact of fluctuating currency exchange rates may not be successful. As a result, currency fluctuations among our reporting currency, the U.S.&#160;dollar, and the currencies in which we do business will affect our operating results, often in unpredictable ways. Our net income may also fluctuate due to the impact of charges we may be required to take with respect to foreign currency hedge transactions. In particular, we may incur higher than expected charges from hedge ineffectiveness or from the termination of a hedge relationship.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our operating results during any one period do not necessarily suggest the anticipated results of future periods.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We are pursuing opportunities to expand our manufacturing capacity for future clinical and commercial requirements for product candidates, which would result in the incurrence of significant investment with no assurance that such investment will be recouped.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While we believe we currently have sufficient manufacturing capacity to meet our near-term manufacturing requirements, it is probable that we would need additional manufacturing capacity to support future clinical and commercial manufacturing requirements for product candidates in our pipeline, if such candidates are successful and approved. We recently announced our intent to build a biologics manufacturing facility in Solothurn, Switzerland and our acquisition of an additional manufacturing facility in Research Triangle Park, North Carolina. Due to the long lead times necessary for the expansion of manufacturing capacity, we expect to incur significant investment to build or expand our facilities or obtain third party contract manufacturers with no assurance that such investment will be recouped. If we are unable to adequately and timely manufacture and supply our products and product candidates or if we do not fully utilize our manufacturing facilities, our business may be harmed.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our investments in properties may not be fully realized.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We own or lease real estate primarily consisting of buildings that contain research laboratories, office space, and manufacturing operations. For strategic or other operational reasons, we may decide to further consolidate or co-locate certain aspects of our business operations or dispose of one or more of our properties, some of which may be located in markets that are experiencing high vacancy rates and decreasing property values. If we determine that the fair value of any of our owned properties is lower than their book value we may not realize the full investment in these properties and incur significant impairment charges. If we decide to fully or partially vacate a leased property, such as we did following our 2013 relocation of our corporate headquarters from Weston, Massachusetts to Cambridge, Massachusetts, we may incur significant cost, including lease termination fees, rent expense in excess of sublease income and impairment of leasehold improvements. Any of these events may have an adverse impact on our results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our portfolio of marketable securities is subject to market, interest and credit risk that may reduce its value.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a portfolio of marketable securities for investment of our cash. Changes in the value of our portfolio of marketable securities could adversely affect our earnings. In particular, the value of our investments may decline due to increases in interest rates, downgrades of the bonds and other securities included in our portfolio, instability in the global financial markets that reduces the liquidity of securities included in our portfolio, declines in the value of collateral underlying the securities included in our portfolio, and other factors. Each of these events may cause us to record charges to reduce the carrying value of our investment portfolio or sell investments for less than our acquisition cost. Although we attempt to mitigate these risks through diversification of our investments and continuous monitoring of our portfolio's overall risk profile, the value of our investments may nevertheless decline.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">There can be no assurance that we will continue to repurchase stock or that we will repurchase stock at favorable prices.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our Board of Directors has approved stock repurchase programs. The amount and timing of such stock repurchases are subject to capital availability and our determination that stock repurchases are in the best interest of our stockholders and are in compliance with all respective laws and our agreements applicable to the repurchase of stock. Our ability to repurchase stock will depend upon, among other factors, our cash balances and potential future capital requirements for strategic transactions, results of operations, financial condition, and other factors beyond our control that we may deem relevant. A reduction in, or the completion or expiration of, our stock repurchase programs could have a negative effect on our stock price. We can provide no assurance that we will repurchase stock at favorable prices, if at all.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We may not be able to access the capital and credit markets on terms that are favorable to us.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may seek access to the capital markets to supplement our existing funds and cash generated from operations for working capital, capital expenditure and debt service requirements, and other business initiatives. The capital and credit markets have experienced extreme volatility and disruption which leads to uncertainty and liquidity issues for both borrowers and investors. In the event of adverse capital and credit market conditions, we may be unable to obtain capital market financing on favorable terms. Changes in credit ratings issued by nationally recognized credit rating agencies could also adversely affect our cost of financing and the market price of our securities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our business involves environmental risks, which include the cost of compliance and the risk of contamination or injury.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our business and the business of several of our strategic partners involve the controlled use of hazardous materials, chemicals, biologics and radioactive compounds. Although we believe that our safety procedures for handling and disposing of such materials comply with state and federal standards, there will always be the risk of accidental contamination or injury. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. Manufacturing of our products and product candidates also requires permits from government agencies for water supply and wastewater discharge. If we do not obtain appropriate permits, or permits for sufficient quantities of water and wastewater, we could incur significant costs and limits on our manufacturing volumes that could harm our business.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">70</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">The illegal distribution and sale by third parties of counterfeit versions of our products or stolen products could have a negative impact on our reputation and business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Third parties might illegally distribute and sell counterfeit or unfit versions of our products, which do not meet our rigorous manufacturing, distribution and testing standards. A patient who receives a counterfeit or unfit drug may be at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit or unfit drugs sold under our brand name. In addition, thefts of inventory at warehouses, plants or while in-transit, which are not properly stored and which are sold through unauthorized channels, could adversely impact patient safety, our reputation and our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">The increasing use of social media platforms presents new risks and challenges.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Social media is increasingly being used to communicate about our products and the diseases our therapies are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to comment on the effectiveness of a product or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend the company or the public's legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face overly restrictive regulatory actions or incur other harm to our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Some of our collaboration agreements contain change in control provisions that may discourage a third party from attempting to acquire us.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Some of our collaboration agreements include change in control provisions that could reduce the potential acquisition price an acquirer is willing to pay or discourage a takeover attempt that could be viewed as beneficial to shareholders. &#160;Upon a change in control, some of these provisions could trigger reduced milestone, profit or royalty payments to us or give our collaboration partner rights to terminate our collaboration agreement, acquire operational control or force the purchase or sale of the programs that are the subject of the collaboration.&#160; </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71</font></div></div><hr style="page-break-after:always"><a name="s70CCD146C84F3CC2FA96AE740F02B0E8"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;2.&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds</font></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Issuer Purchases of Equity Securities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our common stock repurchase activity under our 2015 Share Repurchase Program during the third quarter of 2015:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td width="17%"></td><td width="19%"></td><td width="1%"></td><td width="1%"></td><td width="19%"></td><td width="1%"></td><td width="1%"></td><td width="19%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="18%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares&#160;Purchased</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average&#160;Price</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Paid&#160;per&#160;Share</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares&#160;Purchased</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">as&#160;Part&#160;of&#160;Publicly</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Announced&#160; Programs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Maximum</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Approximate Dollar Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">of Shares That May Yet Be</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Purchased Under</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Our Programs ($ in millions)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">July&#160;2015</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">145,289</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">351.71</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">145,289</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,906.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">August&#160;2015</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,513,238</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">312.25</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,513,238</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,497.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,892,530</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">305.70</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,892,530</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,001.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9,551,057</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">309.49</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our common stock repurchase activity under our 2011 Share Repurchase Program during the third quarter of 2015:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="17%"></td><td width="19%"></td><td width="1%"></td><td width="1%"></td><td width="19%"></td><td width="1%"></td><td width="1%"></td><td width="19%"></td><td width="1%"></td><td width="1%"></td><td width="19%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares&#160;Purchased</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average&#160;Price</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Paid&#160;per&#160;Share</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares&#160;Purchased</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">as&#160;Part&#160;of&#160;Publicly</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Announced&#160; Programs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Maximum</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Number&#160;of&#160;Shares</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">That May Yet Be</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Purchased Under</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Our Programs (#)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">July&#160;2015</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,264,156</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">August&#160;2015</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,264,156</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,264,156</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2015, our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock (2015 Share Repurchase Program). This authorization does not have an expiration date. Repurchased shares will be retired. The 2015 Share Repurchase Program is in addition to the approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares remaining under our February 2011 Share Repurchase Program (2011 Share Repurchase Program), which has been used principally to offset common stock issuances under our share-based compensation plans.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2,998.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under our 2015 Share Repurchase Program and did not repurchase any shares of common stock under our 2011 Share Repurchase Program. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we purchased approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$360.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under our 2011 Share Repurchase Program. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From October 1, 2015 through October 20, 2015, we repurchased and expect to retire approximately 3.2 million shares of common stock at a cost of $896.3 million under our 2015 Share Repurchase Program. During this time, we paid an average price per share of $276.09. As of October 20, 2015, approximately $1,105.5 million remains available to repurchase shares under this program.</font></div><a name="s8B3ADCF1863B6B94C3B8AE742B901855"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;6.&#160;&#160;&#160;&#160;Exhibits</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The exhibits listed on the Exhibit&#160;Index immediately preceding such exhibits, which is incorporated herein by reference, are filed or furnished as part of this Quarterly Report on Form&#160;10-Q.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">72</font></div></div><hr style="page-break-after:always"><a name="s88FAD10395E3771C2718AE742BBF45D7"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div><div style="line-height:120%;padding-left:492px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:27.34375%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="100%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BIOGEN INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;Paul J. Clancy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Paul J. Clancy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(principal financial officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">October&#160;21, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">73</font></div></div><hr style="page-break-after:always"><a name="sDF91D52450B9BE68B760AE742BE2E24D"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s1524C1338A76B403B4DBAE7421012B3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:18px;text-align:center;padding-left:0px;text-indent:0px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">EXHIBIT&#160;INDEX&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="17%"></td><td width="5%"></td><td width="78%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Exhibit</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description of Exhibit</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.1+++</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indenture, dated September 15, 2015, between Biogen Inc. and U.S. Bank National Association. Filed as Exhibit 4.1 to our Current Report on Form 8-K filed on September 16, 2015.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.2+++</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">First Supplemental Indenture, dated September 15, 2015, between Biogen Inc. and U.S. Bank National Association. Filed as Exhibit 4.2 to our Current Report on Form 8-K filed on September 16, 2015.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.1+++</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credit Agreement, dated August 28, 2015, between Biogen Inc., Bank of America, N.A., as administrative agent, swing line lender and an L/C issuer, and the other lenders party thereto. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on September 1, 2015.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.1+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Executive Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.2+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Financial Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.1++</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101++</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following materials from Biogen Inc.&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended September&#160;30, 2015, formatted in XBRL (Extensible Business Reporting Language): (i)&#160;the Condensed Consolidated Statements of Income, (ii)&#160;the Condensed Consolidated Statements of  Comprehensive Income, (iii) the Condensed Consolidated Balance Sheets, (iv)&#160;the Condensed Consolidated Statements of Cash Flows, and (v)&#160;Notes to Condensed Consolidated Financial Statements.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;&#32;&#32;&#32;+&#160;&#160;&#160;&#160;Filed herewith </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;&#32;++&#160;&#160;&#160;&#160;Furnished herewith</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">+++&#160;&#160;&#160;&#160;Previously filed</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">74</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>biib-2015930xex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s32FCB14D0799B6114294AE741A9122FE"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, George A. Scangos, certify that:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1. I have reviewed this quarterly report of Biogen Inc.;</font></div><div style="line-height:120%;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="52%"></td><td width="3%"></td><td width="45%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: October&#160;21, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ George A. Scangos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">George A. Scangos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>biib-2015930xex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sA223BAA807DF22AFABE6AE741B245DE5"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, Paul J. Clancy, certify that:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1. I have reviewed this quarterly report of Biogen Inc.;</font></div><div style="line-height:120%;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:40px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="52%"></td><td width="3%"></td><td width="45%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: October&#160;21, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Paul J. Clancy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Paul J. Clancy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>biib-2015930xex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sD67766DF8972F62863C6AE741BCCABF9"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Biogen Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that:</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2015 (the &#8220;Form 10-Q&#8221;) of the Company fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="52%"></td><td width="3%"></td><td width="45%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dated: October&#160;21, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ George A. Scangos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">George A. Scangos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">[principal executive officer]</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="52%"></td><td width="3%"></td><td width="45%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dated: October&#160;21, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Paul J. Clancy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Paul J. Clancy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">[principal financial officer]</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>biib-20150930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:0604c53f2fb548edb4f664d10e6bbfb4,x:8b0c1bd108b4428d9859539d4bad4fd6-->
<xbrli:xbrl xmlns:biib="http://www.biogenidec.com/20150930" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2015-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:us-roles="http://fasb.org/us-roles/2015-01-31" xmlns:us-types="http://fasb.org/us-types/2015-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="biib-20150930.xsd" xlink:type="simple" />
	<xbrli:context id="FD2015Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q3SharesOutstanding">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-10-16</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-02-01</xbrli:startDate>
			<xbrli:endDate>2015-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-02-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_biib_RaxatrigineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:RaxatrigineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-02-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_biib_NeuropathicpainindicationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:NeuropathicpainindicationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-02-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_biib_RaxatrigineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:RaxatrigineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-02-01</xbrli:startDate>
			<xbrli:endDate>2015-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-02-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_biib_AVONEXMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:NotesPayableToFumedicaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:NotesPayableToFumedicaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_StrategicInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_StrategicInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_biib_InterestratelocksMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">biib:InterestratelocksMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_CurrencyAxis_currency_AUD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_CurrencyAxis_currency_AUD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_CurrencyAxis_currency_CAD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_CurrencyAxis_currency_GBP_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_CurrencyAxis_currency_EUR_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_CurrencyAxis_currency_JPY_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD_us-gaap_PlanNameAxis_biib_A1995ESPPMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A1995ESPPMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2015ESPPMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_PlanNameAxis_biib_A1995ESPPMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A1995ESPPMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_PlanNameAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD_us-gaap_PlanNameAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD_us-gaap_PlanNameAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_PlanNameAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2011Q4Oct_us-gaap_TaxPeriodAxis_us-gaap_TaxYear2009Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2009Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-10-01</xbrli:startDate>
			<xbrli:endDate>2011-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2011Q4Oct_us-gaap_TaxPeriodAxis_us-gaap_TaxYear2007Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2007Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-10-01</xbrli:startDate>
			<xbrli:endDate>2011-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2011Q4Oct_us-gaap_TaxPeriodAxis_us-gaap_TaxYear2008Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2008Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-10-01</xbrli:startDate>
			<xbrli:endDate>2011-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q2QTD_us-gaap_StatementGeographicalAxis_country_IT">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-04-01</xbrli:startDate>
			<xbrli:endDate>2014-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_StatementGeographicalAxis_country_IT">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2012Q1Feb_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-02-01</xbrli:startDate>
			<xbrli:endDate>2012-02-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2012Q1SD2_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-02-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4QTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-10-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SwedishOrphanBiovitrumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_ProductOrServiceAxis_biib_LeadprogramsMember_us-gaap_TypeOfArrangementAxis_biib_AGTCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:LeadprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AGTCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AGTCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_ProductOrServiceAxis_biib_LeadprogramsMember_us-gaap_TypeOfArrangementAxis_biib_AGTCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:LeadprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AGTCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_TypeOfArrangementAxis_biib_AGTCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AGTCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_TypeOfArrangementAxis_biib_MitsubishiTanabePharmaCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q1QTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_TypeOfArrangementAxis_biib_MitsubishiTanabePharmaCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_ProductOrServiceAxis_biib_DiscoveryprogramsMember_us-gaap_TypeOfArrangementAxis_biib_AGTCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:DiscoveryprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AGTCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_biib_CumulativeSalesLevelAxis_biib_OneBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:OneBillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_biib_CumulativeSalesLevelAxis_biib_SixbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:SixbillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_biib_CumulativeSalesLevelAxis_biib_FourbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:FourbillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_biib_CumulativeSalesLevelAxis_biib_EachAdditionalOneBillionUpToTwentyBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:EachAdditionalOneBillionUpToTwentyBillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2006Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2006-01-01</xbrli:startDate>
			<xbrli:endDate>2006-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q2_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_biib_CumulativeSalesLevelAxis_biib_FivebillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:FivebillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_biib_CumulativeSalesLevelAxis_biib_SixbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:SixbillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q2_us-gaap_StatementGeographicalAxis_country_CH">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_biib_CumulativeSalesLevelAxis_biib_ThreeBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:ThreeBillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_biib_CumulativeSalesLevelAxis_biib_FourbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:FourbillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q3Restructuring_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-10-21</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q3Restructuring_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-10-21</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q3Restructuring_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-10-21</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="segment">
		<xbrli:measure>biib:segment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="EUR">
		<xbrli:measure>iso4217:EUR</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="KRW">
		<xbrli:measure>iso4217:KRW</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="chf">
		<xbrli:measure>iso4217:CHF</xbrli:measure>
	</xbrli:unit>
	<biib:AdditionalMilestonePayment contextRef="FI2013Q4_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-E5CEB9290FDE3D2F5D50AE73D883C149" unitRef="usd">75000000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2015Q3_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember" decimals="-5" id="Fact-4302E9E5F3C4F4E841A83F4E5766B3EF" unitRef="usd">10000000</biib:AdditionalMilestonePayment>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2015Q3YTD" decimals="-5" id="Fact-6FF2565488B386E64AD1AE73D8E2A40C" unitRef="usd">37000000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2015Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-3817EFCF3C7B68433A31AE73D82A5045" unitRef="usd">20900000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2015Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-A55B78AA420CB4584B8EAE73D928AFEF" unitRef="usd">1300000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2015Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-27D1AD4F3FD25D5BDABEAE73D8B8D24F" unitRef="usd">14800000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost contextRef="FI2014Q4" decimals="-5" id="Fact-78269A196511FCE0D1ABAE73D82F1BC1" unitRef="usd">126800000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost contextRef="FI2015Q3" decimals="-5" id="Fact-1D9E8FC73565C1E5C46AAE73D83836D8" unitRef="usd">127500000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue contextRef="FI2014Q4" decimals="-5" id="Fact-73228E4B178E3D2F9D1AAE73D83BCDFA" unitRef="usd">126900000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue contextRef="FI2015Q3" decimals="-5" id="Fact-9B827CB8A605F9F7DE6EAE73D82F71EC" unitRef="usd">127300000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
	<biib:AverageMaturityOfMarketableSecurities contextRef="FD2014Q4YTD" id="Fact-EF32D5636E2DCA6D8E87AE73D91350E8">P15M</biib:AverageMaturityOfMarketableSecurities>
	<biib:AverageMaturityOfMarketableSecurities contextRef="FD2015Q3YTD" id="Fact-835992351B4200A2918DAE73D90808F4">P13M</biib:AverageMaturityOfMarketableSecurities>
	<biib:CumulativeSalesLevel contextRef="FI2015Q3_biib_CumulativeSalesLevelAxis_biib_EachAdditionalOneBillionUpToTwentyBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-8" id="Fact-5EBA2407A6EA1F6B21A3AE73D837237B" unitRef="usd">20000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2015Q3_biib_CumulativeSalesLevelAxis_biib_FivebillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-8" id="Fact-E121B48E107D744FBD9A3F85CFA44D52" unitRef="usd">5000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2015Q3_biib_CumulativeSalesLevelAxis_biib_FourbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-8" id="Fact-DB7D9E4FF8FF5198B247AE73D84F5208" unitRef="usd">4000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2015Q3_biib_CumulativeSalesLevelAxis_biib_OneBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-8" id="Fact-8DFF5F026E278F253611AE73D8536A80" unitRef="usd">1000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2015Q3_biib_CumulativeSalesLevelAxis_biib_SixbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-8" id="Fact-5A6ACC4B49B892497B68AE73D846A3EE" unitRef="usd">6000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2015Q3_biib_CumulativeSalesLevelAxis_biib_ThreeBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-8" id="Fact-905B97586D8F6E4A7CA4AE73D848ED86" unitRef="usd">3000000000</biib:CumulativeSalesLevel>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2015Q3YTD" decimals="-5" id="Fact-4CA5538A0417A3ED526BAE73D85E677E" unitRef="usd">1636400000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2015Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-A47CCEB94F42E7D18940AE73D86ABE40" unitRef="usd">1278000000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2015Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-880A3D7A94A55D5E6E28AE73D8EE8096" unitRef="usd">332000000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2015Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-889B91DDDBA6DE6303B8AE73D8CFF68B" unitRef="usd">26400000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:DebtInstrumentMakeWholeProvisionRedemptionPricePercentage contextRef="FD2015Q3YTD" decimals="INF" id="Fact-11B222506B6A0125908A3EDA3913FA8B" unitRef="number">1.01</biib:DebtInstrumentMakeWholeProvisionRedemptionPricePercentage>
	<biib:DueFromUnconsolidatedJointBusiness contextRef="FI2014Q4" decimals="-3" id="Fact-50875470A57A9CA4C722AE73D8225659" unitRef="usd">283360000</biib:DueFromUnconsolidatedJointBusiness>
	<biib:DueFromUnconsolidatedJointBusiness contextRef="FI2015Q3" decimals="-3" id="Fact-05926DA317DBFE9A5083AE73D8E0F44E" unitRef="usd">319788000</biib:DueFromUnconsolidatedJointBusiness>
	<biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction contextRef="FD2014Q3QTD" decimals="3" id="Fact-D311DE57ACD7F1DC56DEAE73D929FD42" unitRef="number">-0.020</biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction>
	<biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction contextRef="FD2014Q3YTD" decimals="3" id="Fact-5A863CEFDB6C9A0E78AEAE73D81FC9A0" unitRef="number">-0.019</biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction>
	<biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction contextRef="FD2015Q3QTD" decimals="3" id="Fact-762C017B4CBB8CEF4854AE73D8C14BE6" unitRef="number">-0.021</biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction>
	<biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction contextRef="FD2015Q3YTD" decimals="3" id="Fact-E6599A197603F73991D1AE73D92C1EC0" unitRef="number">-0.020</biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction>
	<biib:Employeerelatedliabilitiesnoncurrent contextRef="FI2014Q4" decimals="-5" id="Fact-9456DBF8172FC5E4E08AAE73D86AE4A2" unitRef="usd">200700000</biib:Employeerelatedliabilitiesnoncurrent>
	<biib:Employeerelatedliabilitiesnoncurrent contextRef="FI2015Q3" decimals="-5" id="Fact-9610C1243A594539BFD4AE73D880438B" unitRef="usd">218400000</biib:Employeerelatedliabilitiesnoncurrent>
	<biib:Employeestockpurchaseplanmaximumshares contextRef="FI2015Q3" decimals="0" id="Fact-9D6EBA4BBBBE91325C52AE73D8577FD6" unitRef="shares">6200000</biib:Employeestockpurchaseplanmaximumshares>
	<biib:EquityMethodInvestmentOwnershipPercentageMaximum contextRef="D2012Q1Feb_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="INF" id="Fact-3358E1D37D98FB56677CAE73D89FF565" unitRef="number">0.499</biib:EquityMethodInvestmentOwnershipPercentageMaximum>
	<biib:EquityMethodInvestmentsExpectedProfitShare contextRef="FD2013Q4QTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="INF" id="Fact-4EAEAB698D797A5ADBE1AE73D8875725" unitRef="number">0.5</biib:EquityMethodInvestmentsExpectedProfitShare>
	<biib:Finitelivedintangibleassetsfutureamortization contextRef="FI2015Q3" decimals="-5" id="Fact-A8FCA55AB70806504A73AE73D864835C" unitRef="usd">1596900000</biib:Finitelivedintangibleassetsfutureamortization>
	<biib:GainOnSaleOfRights contextRef="FD2014Q3QTD" decimals="-3" id="Fact-1AE91F82DDED1097FDB6AE73D91B2B60" unitRef="usd">4379000</biib:GainOnSaleOfRights>
	<biib:GainOnSaleOfRights contextRef="FD2014Q3YTD" decimals="-3" id="Fact-91C38BC1A56913828E78AE73D90468F4" unitRef="usd">12138000</biib:GainOnSaleOfRights>
	<biib:GainOnSaleOfRights contextRef="FD2015Q3QTD" decimals="-3" id="Fact-305A8C88B87D6FC03B29AE73D86DD44B" unitRef="usd">0</biib:GainOnSaleOfRights>
	<biib:GainOnSaleOfRights contextRef="FD2015Q3YTD" decimals="-3" id="Fact-642311F8C460D99E155FAE73D8E5ED8D" unitRef="usd">0</biib:GainOnSaleOfRights>
	<biib:IndefiniteLivedIntangibleAssetsUsefulLife contextRef="FD2015Q3YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" id="Fact-033395BFC66B78D8FE21AE73D85F0584">Indefinite until commercialization</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
	<biib:IndefiniteLivedIntangibleAssetsUsefulLife contextRef="FD2015Q3YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" id="Fact-0650F3384B0AB1FA87E6AE73D8E12A4D">Indefinite</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
	<biib:InterestInSubsidiary contextRef="FD2015Q3YTD" decimals="INF" id="Fact-7232DEB6C82BFCA9FAD3AE73D8CAC011" unitRef="number">1.00</biib:InterestInSubsidiary>
	<biib:InventoryVariousProgramsGross contextRef="FI2014Q4" decimals="-5" id="Fact-7EA150043E7F48F5AC64AE73D86B8BA5" unitRef="usd">6300000</biib:InventoryVariousProgramsGross>
	<biib:InventoryVariousProgramsGross contextRef="FI2015Q3" decimals="-5" id="Fact-7BA9AEDD8649B9FB0091AE73D8705470" unitRef="usd">54300000</biib:InventoryVariousProgramsGross>
	<biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities contextRef="FI2014Q4" decimals="-5" id="Fact-E0ACB636455F218D5BF0AE73D880249C" unitRef="usd">7900000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
	<biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities contextRef="FI2015Q3" decimals="-5" id="Fact-7C75E4E4FAA97BBB5288AE73D88299A4" unitRef="usd">10700000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
	<biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement contextRef="I2012Q1SD2_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-8" id="Fact-04BC1E132BBF14D07E0EAE73D88242FB" unitRef="KRW">280500000000</biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement>
	<biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement contextRef="I2012Q1SD2_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-88BCE6ABBC53C0B66911AE73D85D5B8C" unitRef="usd">250000000</biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement>
	<biib:JointVentureOwnerShipPercentageByThirdParty contextRef="D2012Q1Feb_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="INF" id="Fact-2FE45197E6FD42938DD9AE73D85C9688" unitRef="number">0.85</biib:JointVentureOwnerShipPercentageByThirdParty>
	<biib:MaximumTermForAccountsReceivable contextRef="FD2015Q3YTD" id="Fact-63FBB8F0D9BF07B0F9C7AE73D8E95B0F">P90D</biib:MaximumTermForAccountsReceivable>
	<biib:MinimumTermForAccountsReceivable contextRef="FD2015Q3YTD" id="Fact-88979DDFB09ABD3C0357AE73D8587DF4">P30D</biib:MinimumTermForAccountsReceivable>
	<biib:Noncontrollinginterestincreasedecreaseother contextRef="FD2014Q3QTD" decimals="-5" id="Fact-FD502091A1AB2E1F5D02AE73D871961C" unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
	<biib:Noncontrollinginterestincreasedecreaseother contextRef="FD2014Q3YTD" decimals="-5" id="Fact-8C3A59D5733F37FCE25EAE73D907FFE6" unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
	<biib:Noncontrollinginterestincreasedecreaseother contextRef="FD2015Q3QTD" decimals="-5" id="Fact-334963BDB6CC96814855AE73D8F60B51" unitRef="usd">300000</biib:Noncontrollinginterestincreasedecreaseother>
	<biib:Noncontrollinginterestincreasedecreaseother contextRef="FD2015Q3YTD" decimals="-5" id="Fact-62D040026E2B6AA69A90AE73D8880599" unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
	<biib:Overnightreverserepurchaseagreementspercentoftotalassets contextRef="FI2014Q4" decimals="3" id="Fact-1DB33036B51B458C3CEDAE73D90FD3F7" unitRef="number">0.021</biib:Overnightreverserepurchaseagreementspercentoftotalassets>
	<biib:Overnightreverserepurchaseagreementspercentoftotalassets contextRef="FI2015Q3" decimals="3" id="Fact-B0079E66D0CB6F08C2FCAE73D915B5C8" unitRef="number">0.009</biib:Overnightreverserepurchaseagreementspercentoftotalassets>
	<biib:PaymentTermsOfAccountsReceivable contextRef="FD2015Q3YTD" id="Fact-A7504C4A9E7774EA3E8BAE73D8CD8E0F">30 to 90 days</biib:PaymentTermsOfAccountsReceivable>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2015Q3YTD" decimals="-5" id="Fact-BDF9913D05B272CFF7C2AE73D84A5C22" unitRef="usd">1151300000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2015Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-2153DA55BD8A73EC31A4AE73D86DA5D2" unitRef="usd">871800000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2015Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-CB9EF75FAA0CF93B4D57AE73D8B7D6A2" unitRef="usd">277900000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2015Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-FB055E04954B69F6A631AE73D8CA60FA" unitRef="usd">1600000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2015Q3YTD" decimals="-5" id="Fact-BF63DF69C9EFA3D3B198AE73D8E43BCC" unitRef="usd">321200000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2015Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-6491BB3F0FC8AE8CDC95AE73D8DF922A" unitRef="usd">271600000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2015Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-B68DDF3F41B784E3D2B8AE73D8C68ADC" unitRef="usd">40700000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2015Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-2160BB039E03CB5275F2AE73D8860DB5" unitRef="usd">8900000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PercentageParValueOfSeniorNotes contextRef="FI2015Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="INF" id="Fact-1237A0C1E05CDA7A03742ECA427CC663" unitRef="number">0.99294</biib:PercentageParValueOfSeniorNotes>
	<biib:PercentageParValueOfSeniorNotes contextRef="FI2015Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="INF" id="Fact-A457A07561CF9A4097BD2ECA352EC83D" unitRef="number">0.99764</biib:PercentageParValueOfSeniorNotes>
	<biib:PercentageParValueOfSeniorNotes contextRef="FI2015Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="INF" id="Fact-5A202B26D6EFF7E2AFC02EC9A20727D8" unitRef="number">0.99920</biib:PercentageParValueOfSeniorNotes>
	<biib:PercentageParValueOfSeniorNotes contextRef="FI2015Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="INF" id="Fact-F09DBDE48C7494A33D272EC8DD8AB490" unitRef="number">0.99792</biib:PercentageParValueOfSeniorNotes>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F38BE3256274771E6479AE73D854C4A4" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B93CF23EB38D5CBBE0DCAE73D8FBE27F" unitRef="usd">36900000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-75712F81953CD4865D7DAE73D89F43B4" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-37F43A27D5C367FF5D65AE73D8CBD12F" unitRef="usd">36900000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-0670C65DC61B6DA95BC7AE73D90A8270" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-83DFDD2213E7E8F8459BAE73D8F9D1DB" unitRef="usd">38600000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-41206E694DC99F6F478FAE73D8FFC977" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-BE2B9866E8DA8E9522FDAE73D8FD8F20" unitRef="usd">38600000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately contextRef="FI2015Q3_us-gaap_ProductOrServiceAxis_biib_DiscoveryprogramsMember_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-126C0FD06133D07524AD3F498753A458" unitRef="usd">592500000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
	<biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately contextRef="FI2015Q3_us-gaap_ProductOrServiceAxis_biib_LeadprogramsMember_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-CE66D7266E0B392512683F495FEE6068" unitRef="usd">472500000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
	<biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately contextRef="FI2015Q3_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-8" id="Fact-303692CAC16B92E4C3E53F486A645452" unitRef="usd">1000000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
	<biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately contextRef="FI2015Q3_us-gaap_TypeOfArrangementAxis_biib_MitsubishiTanabePharmaCorporationMember" decimals="-5" id="Fact-2E316A95DC8B5C52DF1D3F4108E983BC" unitRef="usd">484000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
	<biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-241B79C779FCF15D1061AE73D8AF484E" unitRef="usd">450000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
	<biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_biib_RaxatrigineMember" decimals="-5" id="Fact-EC156920D0DBEF0081CEAE73D8AE40DC" unitRef="usd">350000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
	<biib:Premiumonequityinvestment contextRef="FD2015Q3QTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-9F6EABA6567643FABD4443A65FD9BBC0" unitRef="usd">7500000</biib:Premiumonequityinvestment>
	<biib:ProposedDisallowanceByTaxAuthoritiesForPaymentForServices contextRef="D2011Q4Oct_us-gaap_TaxPeriodAxis_us-gaap_TaxYear2007Member" decimals="-5" id="Fact-A2070DA53A9352B07631AE73D8C90DC4" unitRef="usd">130000000</biib:ProposedDisallowanceByTaxAuthoritiesForPaymentForServices>
	<biib:ProposedDisallowanceByTaxAuthoritiesForPaymentForServices contextRef="D2011Q4Oct_us-gaap_TaxPeriodAxis_us-gaap_TaxYear2008Member" decimals="-5" id="Fact-64F15B64D735343CE327AE73D8C74F75" unitRef="usd">130000000</biib:ProposedDisallowanceByTaxAuthoritiesForPaymentForServices>
	<biib:ProposedDisallowanceByTaxAuthoritiesForPaymentForServices contextRef="D2011Q4Oct_us-gaap_TaxPeriodAxis_us-gaap_TaxYear2009Member" decimals="-5" id="Fact-2346A9F183164C7B9BA4AE73D8B42B27" unitRef="usd">130000000</biib:ProposedDisallowanceByTaxAuthoritiesForPaymentForServices>
	<biib:Purchaseofcommonstock contextRef="FD2015Q3QTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-93E4EC5BC64F794D49873F44A7F9767B" unitRef="usd">30000000</biib:Purchaseofcommonstock>
	<biib:ReimbursementLimitStatedInResolution contextRef="FD2014Q2QTD_us-gaap_StatementGeographicalAxis_country_IT" id="Fact-E5B8600261E423903849AE73D84DED1E">P24M</biib:ReimbursementLimitStatedInResolution>
	<biib:RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement contextRef="FD2015Q3YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" decimals="-5" id="Fact-E3BE7277ACD5489363C1AE73D880700F" unitRef="usd">275000000</biib:RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement>
	<biib:Researchanddevelopmentservices contextRef="FD2015Q3QTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-CD9143F4AAFF6ADB409C440117883F21" unitRef="usd">8700000</biib:Researchanddevelopmentservices>
	<biib:RestructuringandRelatedCostExpectedCashPayments contextRef="I2015Q3Restructuring_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-6" id="Fact-DA1DA443A00110B09F40879120D8C073" unitRef="usd">120000000</biib:RestructuringandRelatedCostExpectedCashPayments>
	<biib:RestructuringandRelatedCostExpectedCashPayments contextRef="I2015Q3Restructuring_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-6" id="Fact-C77F28224AD11EE1DF9C878FD9F3C386" unitRef="usd">115000000</biib:RestructuringandRelatedCostExpectedCashPayments>
	<biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="FD2014Q3QTD" decimals="-5" id="Fact-C2864E090384289D94E6AE73D875D26C" unitRef="usd">56600000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
	<biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="FD2014Q3YTD" decimals="-5" id="Fact-CC1B2C743C63DC41280DAE73D84EE36B" unitRef="usd">186100000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
	<biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="FD2015Q3QTD" decimals="-5" id="Fact-2E7C26F7725853B76C59AE73D82EDD79" unitRef="usd">25500000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
	<biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="FD2015Q3YTD" decimals="-5" id="Fact-CE7089D25EC5231A6FCBAE73D8C5B64A" unitRef="usd">159200000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
	<biib:StrategicInvestmentPortfolio contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_StrategicInvestmentsMember" decimals="-5" id="Fact-105C69864AB9564DF192AE73D90A5F63" unitRef="usd">47800000</biib:StrategicInvestmentPortfolio>
	<biib:StrategicInvestmentPortfolio contextRef="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_StrategicInvestmentsMember" decimals="-5" id="Fact-59B924EAC3D243E8FBDBAE73D9142FA6" unitRef="usd">68400000</biib:StrategicInvestmentPortfolio>
	<biib:TermOfLease contextRef="FD2015Q3QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" id="Fact-36BEB0790692B35D2757877654A74C48">P3Y</biib:TermOfLease>
	<biib:UnconsolidatedJointBusiness contextRef="FD2014Q3QTD" decimals="-3" id="Fact-61DC54F59666BDAD4C17AE73D8E6CA27" unitRef="usd">290678000</biib:UnconsolidatedJointBusiness>
	<biib:UnconsolidatedJointBusiness contextRef="FD2014Q3YTD" decimals="-3" id="Fact-C58034BD14A75230F487AE73D8F1FB37" unitRef="usd">890859000</biib:UnconsolidatedJointBusiness>
	<biib:UnconsolidatedJointBusiness contextRef="FD2015Q3QTD" decimals="-3" id="Fact-9664B09484BAFA9EBD08AE73D826F0D4" unitRef="usd">337181000</biib:UnconsolidatedJointBusiness>
	<biib:UnconsolidatedJointBusiness contextRef="FD2015Q3YTD" decimals="-3" id="Fact-857DACDE351821E6DC2AAE73D8338BC5" unitRef="usd">1005302000</biib:UnconsolidatedJointBusiness>
	<biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax contextRef="FI2014Q4" decimals="-5" id="Fact-5C61D2F9E906296727A4AE73D8A4F6A5" unitRef="usd">72100000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
	<biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax contextRef="FI2015Q3" decimals="-5" id="Fact-85B5F35F9BDFF96362E4AE73D8D5C4CB" unitRef="usd">23300000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
	<biib:Upfrontmilestonepayment contextRef="FD2015Q3QTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-157BEAE4E3E7269C92B53F43177C092B" unitRef="usd">124000000</biib:Upfrontmilestonepayment>
	<biib:Workforcereductionpercentage contextRef="I2015Q3Restructuring_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-78185973C82EE8AA9EA672222AE0BF9F" unitRef="number">0.11</biib:Workforcereductionpercentage>
	<dei:AmendmentFlag contextRef="FD2015Q3YTD" id="Fact-DE6D9ACC424AC50110E2AE73D91E3016">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2015Q3YTD" id="Fact-7DC18AA0290868CEFECCAE73D9175436">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2015Q3YTD" id="Fact-F23659C32C2AAA51AAD4AE73D914050A">Q3</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2015Q3YTD" id="Fact-14F06722D381A3D7DA4AAE73D905683D">2015</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2015Q3YTD" id="Fact-81C6A4C728BF40456D6AAE73D918224E">2015-09-30</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2015Q3YTD" id="Fact-DEFC026C1496A4CCA3E2AE73D91480EA">10-Q</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2015Q3YTD" id="Fact-677A421698CA621B4223AE73D91BB404">0000875045</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2015Q3SharesOutstanding" decimals="INF" id="Fact-F45AA14C8D0E4B140112AE73D91C6874" unitRef="shares">222903109</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityFilerCategory contextRef="FD2015Q3YTD" id="Fact-BC0247A7BBF8A18B4F2EAE73D90F5601">Large Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityRegistrantName contextRef="FD2015Q3YTD" id="Fact-A44FECEB198A8059AFB3AE73D825C529">BIOGEN INC.</dei:EntityRegistrantName>
	<invest:DerivativeNotionalAmount contextRef="FI2014Q4_us-gaap_CurrencyAxis_currency_AUD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-F7485EFB850C5BA9B677AE73D84D0D4C" unitRef="usd">19900000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2014Q4_us-gaap_CurrencyAxis_currency_CAD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-F3EBEE4E4C082F0D1607AE73D8B0BE4C" unitRef="usd">56700000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2014Q4_us-gaap_CurrencyAxis_currency_EUR_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-B1D5FE957D146E7CF58FAE73D84A3C10" unitRef="usd">1174600000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2014Q4_us-gaap_CurrencyAxis_currency_GBP_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-C49811CFC9D265B80F48AE73D8AC7343" unitRef="usd">34500000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2014Q4_us-gaap_CurrencyAxis_currency_JPY_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-11579BF2B440B1AD5285AE73D8B070D2" unitRef="usd">16600000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2014Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-151BDEF6212769C5ADB3AE73D848EA4F" unitRef="usd">1302300000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2014Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-5071C2271C4A65D86C04AE73D8D5D48C" unitRef="usd">365200000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2015Q3_us-gaap_CurrencyAxis_currency_AUD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-081BD34B351B371ECE6DAE73D8A83435" unitRef="usd">5400000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2015Q3_us-gaap_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-FF1414AF3D5302A93897AE73D8B121D9" unitRef="usd">17400000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2015Q3_us-gaap_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-320CABF05A1816FCAC07AE73D85256C5" unitRef="usd">1146100000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2015Q3_us-gaap_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-27848D458443FE16E7CFAE73D8AD6EE2" unitRef="usd">12000000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2015Q3_us-gaap_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-91E383BCB8493843696DAE73D84CCB5B" unitRef="usd">9300000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2015Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-6C6A6130D0A7854F7955AE73D8AA9495" unitRef="usd">1190200000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2015Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-986DE01E7A1CDACD14A02E8D9CA2182F" unitRef="usd">675000000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2015Q3_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-085D489D1A572E64EF63AE73D8D6FDAE" unitRef="usd">787200000</invest:DerivativeNotionalAmount>
	<us-gaap:AccountsPayableCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-13F6D9747DCF5497D50CAE73D9176215" unitRef="usd">229178000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2015Q3" decimals="-3" id="Fact-A2B04AA25AF16E0A8B89AE73D82A4827" unitRef="usd">251228000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-0B76392486E0BA90611CAE73D8B99431" unitRef="usd">1292445000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2015Q3" decimals="-3" id="Fact-5F3CA0624302907894CEAE73D8BC338C" unitRef="usd">1327780000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccruedRoyaltiesCurrent contextRef="FI2014Q4" decimals="-5" id="Fact-1567071F700E0B073234AE73D842C4DE" unitRef="usd">172400000</us-gaap:AccruedRoyaltiesCurrent>
	<us-gaap:AccruedRoyaltiesCurrent contextRef="FI2015Q3" decimals="-5" id="Fact-8493A451D38F5EA877D0AE73D839ABBC" unitRef="usd">154900000</us-gaap:AccruedRoyaltiesCurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2014Q4" decimals="-5" id="Fact-A1B7725E52A9F27ACF4CAE73D8C293A1" unitRef="usd">1186400000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2015Q3" decimals="-5" id="Fact-0760BE54FE972CBCDBE2AE73D8C07F39" unitRef="usd">1320500000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2013Q4" decimals="-5" id="Fact-9767DFCC20C217032FFAAE73D9054C3B" unitRef="usd">-27700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-87A4A59FB528AE139674AE73D8856CDF" unitRef="usd">-19600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-EE2DB5919FA060C1FF92AE73D9176DA6" unitRef="usd">-23700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-81FA5722602CAA52398CAE73D909AD95" unitRef="usd">5600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-9E3FE0EB76FA34C672A8AE73D91F1320" unitRef="usd">10000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2014Q3" decimals="-5" id="Fact-30067EBF490F30A2C91AAE73D916B18C" unitRef="usd">-38000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2014Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-82C5679FCC7C9231B93AAE73D90063A0" unitRef="usd">-18300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2014Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-A8765984D68CE7B2ACCAAE73D8F5E21A" unitRef="usd">41100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2014Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-B30FC039763A3F8B0772AE73D9169C30" unitRef="usd">500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2014Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-5D0E4EA1B82CD25C3EC4AE73D82BFED3" unitRef="usd">-61200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2014Q4" decimals="-3" id="Fact-8D83CEA743D4CE4F2FF9AE73D82A16F4" unitRef="usd">-59488000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-B6632B29FD0B23C959D1AE73D871C2EB" unitRef="usd">-31600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-3CE9891F8BD7B0929320AE73D89C6036" unitRef="usd">71700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-947D5EB3B707FFE2802FAE73D895333C" unitRef="usd">-400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-51FDDA2C23B4A74452C4AE73D8981FF9" unitRef="usd">-99200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q3" decimals="-3" id="Fact-D82239FA3FF97735860BAE73D8D0CD90" unitRef="usd">-157416000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-2C21AB7B9105C1F961D5AE73D89A040F" unitRef="usd">-27000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-4ECE08C7B3AF35EA0A9BAE73D8969823" unitRef="usd">31600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-1C164D8A808DA472E03EAE73D859DB10" unitRef="usd">-1600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-FC49B5DA71234D94AA1CAE73D85B26F2" unitRef="usd">-160500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2014Q4" decimals="-3" id="Fact-E9805ED17E9448D561EAAE73D857CD6D" unitRef="usd">4196156000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2015Q3" decimals="-3" id="Fact-2B0090E86D5EB0944A36AE73D837168C" unitRef="usd">1342373000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions contextRef="FD2015Q3YTD" decimals="-5" id="Fact-2D4499384E47559F207571BC649639DA" unitRef="usd">144400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" decimals="-5" id="Fact-5C726F2AE2D14C423B91AE73D895733D" unitRef="usd">40000000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-5" id="Fact-2B1C54C2B74DBBF473BCAE73D8969515" unitRef="usd">24200000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-5" id="Fact-5BF44BE3EE91D67C121BAE73D8926D19" unitRef="usd">34700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q3QTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-7893DA00E8E5C720C726AE73D9254D8F" unitRef="usd">15200000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q3QTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember" decimals="-5" id="Fact-9C25087A0ED000B97536AE73D92291B4" unitRef="usd">2700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q3QTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-97E5B10A76D41E558BFEAE73D92D32D6" unitRef="usd">7100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q3QTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-E1C9475EB494BD6FAD9FAE73D911669B" unitRef="usd">28200000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q3QTD_us-gaap_PlanNameAxis_us-gaap_PerformanceSharesMember" decimals="-5" id="Fact-8AF4CA4D50C78005D5DFAE73D924DA69" unitRef="usd">5700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" decimals="-5" id="Fact-1024125820BAF2ED5132AE73D8987AE5" unitRef="usd">130700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-5" id="Fact-370D1D4DCDB21DDDD236AE73D87986DF" unitRef="usd">78100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-5" id="Fact-CD5DE3BD350829A1B92BAE73D893A5B3" unitRef="usd">115500000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q3YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-3069B3E70B95E2D42E13AE73D9283873" unitRef="usd">50600000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q3YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember" decimals="-5" id="Fact-2B3A7EBC7591E7919F58AE73D92B3A23" unitRef="usd">10200000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q3YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-78158C04E4350E95CFF3AE73D921329C" unitRef="usd">30200000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q3YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-91B9FCC965C77068DAFDAE73D92C65E5" unitRef="usd">86600000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q3YTD_us-gaap_PlanNameAxis_us-gaap_PerformanceSharesMember" decimals="-5" id="Fact-A2AD65A6F95692E58525AE73D92416C6" unitRef="usd">16000000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" decimals="-5" id="Fact-0605BC0CBBD98D5F72B2AE73D87F6E81" unitRef="usd">19100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-5" id="Fact-004D24A7870D15C9B948AE73D826ADDE" unitRef="usd">10800000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-5" id="Fact-950CA2BD2B6CA8FC8A16AE73D87ABAA0" unitRef="usd">17500000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3QTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-02A42DC368BDBBD396CEAE73D9212B31" unitRef="usd">-9500000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3QTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember" decimals="-5" id="Fact-7ED67ADB135963AB104CAE73D913705A" unitRef="usd">2900000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3QTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-B51A96DDA98E8CDF37DFAE73D91ABB89" unitRef="usd">7300000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3QTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-980221E1BD07E0D81AEBAE73D927A638" unitRef="usd">30400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3QTD_us-gaap_PlanNameAxis_us-gaap_PerformanceSharesMember" decimals="-5" id="Fact-847F2FE65B1011C598ADAE73D91E3E75" unitRef="usd">-2800000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" decimals="-5" id="Fact-919C48E7D306C2364795AE73D82C7CE1" unitRef="usd">113200000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-5" id="Fact-BEB30FBAE5E41E55845EAE73D86663EB" unitRef="usd">68300000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-5" id="Fact-01A20BC6A62B5FDC9130AE73D87CCF36" unitRef="usd">99300000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-ADC11C7EB863329E354EAE73D9209CE6" unitRef="usd">17500000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember" decimals="-5" id="Fact-FBDCA635758CA6ED56BBAE73D918765C" unitRef="usd">11000000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-7BE84521FDF4A410AFCFAE73D9129830" unitRef="usd">33400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-4E103D4774BF9CE105C8AE73D9108197" unitRef="usd">94100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3YTD_us-gaap_PlanNameAxis_us-gaap_PerformanceSharesMember" decimals="-5" id="Fact-4EC31B318A80C956F6DAAE73D922B7FC" unitRef="usd">11600000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="FD2014Q3QTD" decimals="-5" id="Fact-981E52E898187A98DAEAAE73D894C6A2" unitRef="usd">58900000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
	<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="FD2014Q3YTD" decimals="-5" id="Fact-D8E564F056E45B18D49FAE73D89D7CB2" unitRef="usd">193600000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
	<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="FD2015Q3QTD" decimals="-5" id="Fact-B5DF47E29FDB7A0A0E3CAE73D8B9B968" unitRef="usd">28300000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
	<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="FD2015Q3YTD" decimals="-5" id="Fact-130319695381944020A6AE73D878200E" unitRef="usd">167600000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2014Q3QTD" decimals="-3" id="Fact-A7FF537AE2DD1E2A11B5AE73D8CBB74E" unitRef="usd">122431000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2014Q3YTD" decimals="-3" id="Fact-0FF4816CE72026C576ECAE73D9057B22" unitRef="usd">382515000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2015Q3QTD" decimals="-3" id="Fact-74E0FA897DEE8AD3EF32AE73D8E37BE4" unitRef="usd">98065000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2015Q3YTD" decimals="-3" id="Fact-120CCC41B7B0A0C55995AE73D8DF399D" unitRef="usd">285972000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AssetImpairmentCharges contextRef="FD2015Q3YTD" decimals="-6" id="Fact-C9E00608038A5EAC4623AE73D8F77460" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
	<us-gaap:Assets contextRef="FI2014Q4" decimals="-3" id="Fact-2D6D3EEEEAE38D7B33B8AE73D8B85ADA" unitRef="usd">14314781000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2015Q3" decimals="-3" id="Fact-CDAF59B7030296D52A79AE73D8DB37E8" unitRef="usd">20728368000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-B8C900A4EBB264B36CEFAE73D8C501A1" unitRef="usd">4672154000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2015Q3" decimals="-3" id="Fact-2AAEAC40146EDCEDEFB9AE73D8E12915" unitRef="usd">9270873000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C0DC89767C105A030344AE73D8E9DCF2" unitRef="usd">6900000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-ECE44890644A1BAF13D0AE73D8D78E28" unitRef="usd">2937000000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-21E930B155A92711035BAE73D83851B7" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-8C3011D392A31C1B4FB1AE73D8FCB281" unitRef="usd">2943900000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-9C780EEE687A25BDCBF3AE73D90DE0C3" unitRef="usd">25700000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-7C4C39A28675045D91C9AE73D904150B" unitRef="usd">7605100000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F36FAF6870CC7B470552AE73D907999E" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-0E735324AD50BF65DDD6AE73D8FFC10F" unitRef="usd">7630800000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2014Q4" decimals="-5" id="Fact-47448F39FC5218D1B9D3AE73D833FD44" unitRef="usd">2112800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2015Q3" decimals="-5" id="Fact-AB107858CD8E366DB307AE73D8370E60" unitRef="usd">3700800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4" decimals="-5" id="Fact-98F77EB5EA1D865C7BE9AE73D8356ED2" unitRef="usd">2111100000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-1B258685A4460D8B07C0AE73D8EBB099" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-357D994FC03D6E120478AE73D824B9E9" unitRef="usd">198300000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-864C82FC64509541DD1CAE73D83A5779" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-678DC644F945FED7290EAE73D84B6529" unitRef="usd">198300000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2BB1D359FA2FE740F4DCAE73D8395DF1" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-E5D3B26C98D5C18EA688AE73D8FC00DC" unitRef="usd">1063000000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-14E1767A6BD27D9A5272AE73D841B896" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-89EB887D036DE01D7093AE73D83F3E0F" unitRef="usd">1063000000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A1C0278675CA959A81D9AE73D8EC549D" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-49102AB92B3AA326727EAE73D8C90DB9" unitRef="usd">849800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-839F5BE8E17EF18FCC6EAE73D8EA608F" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-FAF64E8FCB9125EFCD11AE73D8FBD7AF" unitRef="usd">849800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-291F985E175746AEF261AE73D8D015CE" unitRef="usd">370400000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-A27F003E16045A76F9FEAE73D8C343D9" unitRef="usd">692600000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-FFD7DF10AE3BAAE46EA1AE73D91BBD84" unitRef="usd">269900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-D999B085E4DEDE0598C8AE73D860F196" unitRef="usd">579900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-4C46DB3038AD9490D35EAE73D90C2514" unitRef="usd">200000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-FFE1BD597B5E758F283BAE73D8D37BD1" unitRef="usd">198100000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-9D1718398319B7D630BBAE73D9159382" unitRef="usd">6900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q3" decimals="-5" id="Fact-1D8FD0A56EDBDB234DD4AE73D8658D96" unitRef="usd">3700900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-6E32CBE5360FE08B3166AE73D9029473" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-887F90DFCDACBF637F0DAE73D8F8052F" unitRef="usd">249900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-0A86CBC36F0D04EE7495AE73D90B03CF" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F9D4E8BEA93679BF4616AE73D8FD1758" unitRef="usd">249900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-97E346A2EDD77D251C96AE73D9033A72" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-3A054D85D8A415552E6BAE73D9023D83" unitRef="usd">1039900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-9A2B2816C27C0A13F428AE73D906A5E6" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-05367273FAA812EDE307AE73D8FE9C1A" unitRef="usd">1039900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B08A1C91BC16E1EB1D45AE73D90335D1" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-BE9C4F048AC7C2BB6733AE73D8F06C69" unitRef="usd">2411100000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-1013A55EBB75D902E731AE73D8FD7D7F" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-6A5F7F0D96D2892D6261AE73D8F7F949" unitRef="usd">2411100000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-8C57088ED87F33615D09AE73D86CA9A0" unitRef="usd">272100000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-62616FEBF1364877E1E5AE73D86F6217" unitRef="usd">767800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-6C2505D4DEE8BED40424AE73D86387B5" unitRef="usd">1481400000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-626B06A9345C9D86322CAE73D864A787" unitRef="usd">929700000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-F9F48E036044584E0E1FAE73D86F5703" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-79A6E84819265B4D0854AE73D87363C6" unitRef="usd">249900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-DA5B4DCBA173D1D92509AE73D86A739F" unitRef="usd">25700000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2014Q4" decimals="-5" id="Fact-7DA8AEE9C264CB99A866AE73D91F73D6" unitRef="usd">700000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-4052BA5D3025330441BFAE73D8E89F3A" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-C63E6089A9FAC58692B0AE73D90EFBC9" unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-2358C2A763299EDAF523AE73D92372B4" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-7299F74D9BC45932D150AE73D825174F" unitRef="usd">300000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-BC84F28ACF7AF4BC2D26AE73D90C8A0D" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-983C60C6CD3960BE4B81AE73D9252663" unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-1EF3175BBDA7C945855EAE73D90C90AE" unitRef="usd">1200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q3" decimals="-5" id="Fact-8D6E84246483EED288E0AE73D8671347" unitRef="usd">2300000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-4D80189CC3A02944B5C3AE73D86F1060" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-1C2A299F5A54C9D9A864AE73D8635831" unitRef="usd">700000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-4556F6719B4622E5CDD9AE73D869CB4E" unitRef="usd">600000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-C1DC4A5E96C3B065D9B8AE73D870500F" unitRef="usd">800000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-A22FBFA115377022D2B2AE73D86CC680" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-D591542495F28F81E879AE73D8695FC7" unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-DE6886482FF4456A0EFBAE73D8680881" unitRef="usd">900000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2014Q4" decimals="-5" id="Fact-CC68A09824F4E8262596AE73D8E83520" unitRef="usd">2400000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-0C889BF441743628F432AE73D90EE709" unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-EBC8CE7E86DCD457480FAE73D8DCA3A1" unitRef="usd">1500000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-47FC2741A925263CD3B9AE73D91D49A5" unitRef="usd">100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-7F224D29528F2A0FFC4FAE73D8E2694A" unitRef="usd">400000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-241E5FC6C6202D012125AE73D893F79C" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-47C8E12A806B4763C952AE73D91ED8CD" unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-F850F330AF5298132DC4AE73D8CE76EC" unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q3" decimals="-5" id="Fact-45D084B47731874A1467AE73D86226B8" unitRef="usd">2200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-49972DE3A3A0578CB856AE73D870CE28" unitRef="usd">100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-98C7583E6048418ABA78AE73D860DD60" unitRef="usd">1300000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-22D92DEBAC00543F3F11AE73D9181DB3" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-6BB79E50E8C6B8215EFFAE73D864D978" unitRef="usd">300000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-E1D705DEBDD31AA173D1AE73D8677C27" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-91E9D55A33172B0A0D7CAE73D86C4A5A" unitRef="usd">500000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-BC3A04A09BFDAFF93572AE73D8720439" unitRef="usd">3400000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2014Q4" decimals="-5" id="Fact-F690E7DD834126A41717AE73D90F1500" unitRef="usd">2112800000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-3B9AA1A029B18953F25FAE73D8B2263A" unitRef="usd">370600000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-60F3E8A451540171E486AE73D8D1E136" unitRef="usd">693900000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-5181CC36A45883807787AE73D821EC37" unitRef="usd">270000000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-AA7D4A02CB4D97B7A5DDAE73D8D39637" unitRef="usd">580000000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-F3CFEB13872DBF5F2D9CAE73D90DFE1E" unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-974BED07E24261170FA8AE73D8438856" unitRef="usd">198100000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-6AE9A1453FEC44498609AE73D879586E" unitRef="usd">5900000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q3" decimals="-5" id="Fact-59F2253182D99773DB05AE73D865614A" unitRef="usd">3700800000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-B7B56DC1EF89C57209B0AE73D86EA9D5" unitRef="usd">272200000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-71051EF6528B82116030AE73D86549C5" unitRef="usd">768400000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-D1C6C609FA822D07A71CAE73D877EE55" unitRef="usd">1480800000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-04C27CF3C0FBFBCD0777AE73D86A4AEC" unitRef="usd">929200000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-82272CE1F5747BE8C8BEAE73D863E539" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-A2656A9DA47084729A1CAE73D86F62F9" unitRef="usd">250200000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-9589847F93CF0932B4E5AE73D87109F4" unitRef="usd">28200000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-EC5CB0B5DE6004F15DDCAE73D8D1EA06" unitRef="usd">640460000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2015Q3" decimals="-3" id="Fact-00136143D45C04FB464BAE73D8C120A0" unitRef="usd">1753499000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="FI2014Q4" decimals="-5" id="Fact-6DBC1614FE3FEC88EE15AE73D83796D9" unitRef="usd">1345200000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="FI2015Q3" decimals="-5" id="Fact-52D1A02718DDC512CF9DAE73D82DA604" unitRef="usd">1820300000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="FI2014Q4" decimals="-5" id="Fact-3D358F9D49FA900C1083AE73D82DECDD" unitRef="usd">1343700000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="FI2015Q3" decimals="-5" id="Fact-BF8E28A392EB5A4B3C10AE73D82F5B67" unitRef="usd">1820100000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="FI2014Q4" decimals="-5" id="Fact-DBB5A0CD3FB8FBB92513AE73D82F24AD" unitRef="usd">640800000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="FI2015Q3" decimals="-5" id="Fact-9918962274CA9A648393AE73D83170FA" unitRef="usd">1753000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="FI2014Q4" decimals="-5" id="Fact-C6698BAB1A5D08843252AE73D83A37FE" unitRef="usd">640500000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="FI2015Q3" decimals="-5" id="Fact-EFE7BB3DFCD0F685DC91AE73D832AD40" unitRef="usd">1753500000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedGains contextRef="FD2014Q3QTD" decimals="-5" id="Fact-C34C9E143097FB27998AAE73D918ABE3" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedGains contextRef="FD2014Q3YTD" decimals="-5" id="Fact-36D163F6C25236C403ECAE73D92098F0" unitRef="usd">400000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedGains contextRef="FD2015Q3QTD" decimals="-5" id="Fact-BD9B60E0C48914383D7FAE73D91F3934" unitRef="usd">700000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedGains contextRef="FD2015Q3YTD" decimals="-5" id="Fact-B19A71E8086EEFAD4343AE73D8E41755" unitRef="usd">1300000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses contextRef="FD2014Q3QTD" decimals="-5" id="Fact-339D5AFDBBED3BF45F39AE73D91D4D74" unitRef="usd">100000</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses contextRef="FD2014Q3YTD" decimals="-5" id="Fact-536D5F946F6D865D828FAE73D9193BFF" unitRef="usd">300000</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses contextRef="FD2015Q3QTD" decimals="-5" id="Fact-41CD19D04F7A43804306AE73D8EC0238" unitRef="usd">2000000</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses contextRef="FD2015Q3YTD" decimals="-5" id="Fact-610BFF9C3675B9015743AE73D926D92B" unitRef="usd">2900000</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
	<us-gaap:AvailableForSaleSecuritiesNoncurrent contextRef="FI2014Q4" decimals="-3" id="Fact-5CC7AAE1A57E1E0C6C6BAE73D8DBCD78" unitRef="usd">1470652000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
	<us-gaap:AvailableForSaleSecuritiesNoncurrent contextRef="FI2015Q3" decimals="-3" id="Fact-9CB63507B7822FBF669FAE73D83BC1DD" unitRef="usd">1947354000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
	<us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-30CCFE7BCDF31435D1DEAE73D8B8D6CF" unitRef="usd">474600000</us-gaap:BusinessCombinationConsiderationTransferred1>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="FD2015Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-085EFA8659D9235BFECAAE73D8CEBB8E" unitRef="usd">36000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="FI2013Q2_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-3E8255D94192833642FFAE73D8445CFF" unitRef="usd">15000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_biib_NeuropathicpainindicationsMember" decimals="-5" id="Fact-AFA14ACBCA470048EA5EAE73D8B061BA" unitRef="usd">415000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_biib_RaxatrigineMember" decimals="-5" id="Fact-0082CE65F5A229572EFDAE73D8AF4EA1" unitRef="usd">145000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2013Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-4A9553F9175696B3E842AE73D86D30FF" unitRef="usd">280900000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2014Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-FD1AB1AD7B2417F25A8BAE73D8674F6B" unitRef="usd">279100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2014Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-FA01625030D31AF55CC9AE73D874FC43" unitRef="usd">213200000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A560341F75022F3439A6AE73D824F940" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-8C19CCDE40AE7A20BD91AE73D8411740" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-DEBFD6711A1B0760DF78AE73D8FFBF38" unitRef="usd">215500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-CE991496A2A67BBFD8FEAE73D8712862" unitRef="usd">215500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2015Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B49432F9CBAC6E3E1103AE73D876926E" unitRef="usd">495700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2E797B570673FF11D652AE73D9097569" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-16699CFBEBD2E5C229FEAE73D9011FFE" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A10E7A9C0254EB396339AE73D9068D70" unitRef="usd">481400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2015Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-62D2DA88AC4810D3FDEDAE73D86D3C32" unitRef="usd">481400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="FI2014Q4" decimals="-5" id="Fact-128D9DEC818AA3E2D7D9AE73D840AA0A" unitRef="usd">265500000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="FI2015Q3" decimals="-5" id="Fact-BF0B7BD4C699B13E723EAE73D849B420" unitRef="usd">479500000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="FI2015Q3_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-822CA7069560E0B48B664EF1AB72C428" unitRef="usd">176400000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2014Q4" decimals="-5" id="Fact-ACBF9E446DAA207B0BB9AE73D8EC448B" unitRef="usd">200000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2015Q3" decimals="-5" id="Fact-C4F660E50B60F208C77FAE73D8E7FA9E" unitRef="usd">301900000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-72F0E9BF7E9D19C45E7CAE73D88A834E" unitRef="usd">84900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-8ED6644048FDBCB9CE6CAE73D884CFA1" unitRef="usd">424600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-FBCE616716A74CF3722CAE73D8862272" unitRef="usd">424600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_biib_NeuropathicpainindicationsMember" decimals="-5" id="Fact-B2B5AE878675C93C574AAE73D8AF1EDA" unitRef="usd">220000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_biib_RaxatrigineMember" decimals="-5" id="Fact-81FA52C9541F47F17ABDAE73D8B338E0" unitRef="usd">200000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-BFA3BD76F22FCD67A438AE73D892AF97" unitRef="usd">7600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-9A23F7E1C5BAD73C547FAE73D88EC774" unitRef="usd">474600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-AF26C591975E3C0E4E05AE73D88B10DE" unitRef="usd">-1000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets>
	<us-gaap:CapitalLeaseObligations contextRef="FI2015Q3_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-A97C92126DF5DA17277E2EAC36F41265" unitRef="usd">20300000</us-gaap:CapitalLeaseObligations>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2013Q4" decimals="-3" id="Fact-16AC4EC3AFEA6F2663EAAE73D8CCC55B" unitRef="usd">602562000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2014Q3" decimals="-3" id="Fact-C2967EAC96EA7E4F8B17AE73D854273C" unitRef="usd">1186281000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2014Q4" decimals="-3" id="Fact-2FC510C31CE5BADD2F7EAE73D8B9FC39" unitRef="usd">1204924000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q3" decimals="-3" id="Fact-560E1A93A795BEABBAB6AE73D839F950" unitRef="usd">4089003000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-8FD5DABE1C1D4E6D930BAE73D8F57B80" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-5DC3889724784D7F4DACAE73D853DC8F" unitRef="usd">716300000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-BECB9AA83145175EF188AE73D8FDD3C2" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F9E63716A5DD8C9E9D5DAE73D83DBE52" unitRef="usd">716300000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-718801893991004C1EAEAE73D8FE4B48" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-642A6E441815229FE8E2AE73D90D231F" unitRef="usd">3804200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-78BDFBBC3E4B9CB467D3AE73D905399D" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-28155EBEA7A12DDF6B7DAE73D91AF8CA" unitRef="usd">3804200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2014Q3YTD" decimals="-3" id="Fact-0E1ECFE1F550FDA28887AE73D8D00E23" unitRef="usd">601946000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2015Q3YTD" decimals="-3" id="Fact-FB6B6D726D3A70BD2AF9AE73D8BAB7DA" unitRef="usd">2914437000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2014Q4" decimals="-5" id="Fact-026B738D12DEA075479AAE73D8AC1104" unitRef="usd">716300000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2014Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-5" id="Fact-2EC880B2E978916FD1D4AE73D89D4261" unitRef="usd">54200000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2014Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember" decimals="-5" id="Fact-E19AD0414A2E5161E017AE73D8DF2D1A" unitRef="usd">35900000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2014Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-5" id="Fact-9B6CA477BD07C8D4B590AE73D88E1237" unitRef="usd">321200000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2014Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember" decimals="-5" id="Fact-3BC40D903E46B34448B7AE73D894DD69" unitRef="usd">305000000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2015Q3" decimals="-5" id="Fact-09F6921E069695637F56AE73D91198F7" unitRef="usd">3804200000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2015Q3_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-5" id="Fact-4765839B64E9FB094D96AE73D87C7301" unitRef="usd">21400000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2015Q3_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember" decimals="-5" id="Fact-50B17E49D08A65258A75AE73D8609B54" unitRef="usd">475400000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2015Q3_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-5" id="Fact-CDC6480883C6D9590235AE73D8785E9F" unitRef="usd">3119100000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2015Q3_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember" decimals="-5" id="Fact-4026B684B52E9A650F6AAE73D8907AB6" unitRef="usd">188300000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2014Q4" id="Fact-CFB3391191C5FF9A0012AE73D834A577" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2015Q3" id="Fact-3A50DE1EDDB1F7446EC2AE73D8CCCCE1" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2014Q4" decimals="INF" id="Fact-746D581E50E616B55E52AE73D91EE7C6" unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2015Q3" decimals="INF" id="Fact-726E4E46B7827862FAADAE73D917D043" unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockValue contextRef="FI2014Q4" decimals="-3" id="Fact-CE21045611FBD8BF922AAE73D8336954" unitRef="usd">129000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2015Q3" decimals="-3" id="Fact-DE17D81EABBBC9D4E55BAE73D827BB0B" unitRef="usd">124000</us-gaap:CommonStockValue>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2014Q3QTD" decimals="-3" id="Fact-554D54910547107B594DAE73D8DDF9BC" unitRef="usd">845549000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2014Q3YTD" decimals="-3" id="Fact-61E146D11364CC1CA9B2AE73D8D341A5" unitRef="usd">2041078000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2015Q3QTD" decimals="-3" id="Fact-D1C580B27396A287228BAE73D8AE737B" unitRef="usd">909231000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2015Q3YTD" decimals="-3" id="Fact-BD390B2722C6E7D21872AE73D8E04499" unitRef="usd">2617511000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="FD2014Q3QTD" decimals="-3" id="Fact-790C2B5CE450EF16E52DAE73D92A36C3" unitRef="usd">738000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="FD2014Q3YTD" decimals="-3" id="Fact-9537CA5A9E488947CE15AE73D82E19AB" unitRef="usd">-7660000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="FD2015Q3QTD" decimals="-3" id="Fact-8C5AA744C13CAA219DE7AE73D8AB1CFA" unitRef="usd">-53586000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="FD2015Q3YTD" decimals="-3" id="Fact-90652BEA71EF68DB9B8BAE73D9282C71" unitRef="usd">-49053000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2014Q3QTD" decimals="-3" id="Fact-3F79EA9CB7DD6C6CDC74AE73D8BE5748" unitRef="usd">844811000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2014Q3YTD" decimals="-3" id="Fact-F422CFDEA39E05F32CECAE73D834BDFA" unitRef="usd">2048738000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2015Q3QTD" decimals="-3" id="Fact-0694F3786A5C60BCF052AE73D8AA9CB9" unitRef="usd">962817000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2015Q3YTD" decimals="-3" id="Fact-B6AFD890C3E1994959C0AE73D92C7EA2" unitRef="usd">2666564000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:CostOfGoodsSold contextRef="FD2014Q3QTD" decimals="-3" id="Fact-1FB48693BB553F4BBE1AAE73D8FAC61D" unitRef="usd">302639000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2014Q3YTD" decimals="-3" id="Fact-FC0CE14E697B6946733AAE73D8EF3E12" unitRef="usd">873771000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2015Q3QTD" decimals="-3" id="Fact-2B2D05E930F1B2D8DECAAE73D82D2D38" unitRef="usd">310028000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2015Q3YTD" decimals="-3" id="Fact-1E5634C1B408AF0BED0DAE73D8D1F9DA" unitRef="usd">908579000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostsAndExpenses contextRef="FD2014Q3QTD" decimals="-3" id="Fact-59DDCCCA36539ADBA4D6AE73D9256610" unitRef="usd">1363247000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2014Q3YTD" decimals="-3" id="Fact-85012DDD70865A9C70BFAE73D8FF3493" unitRef="usd">4262136000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2015Q3QTD" decimals="-3" id="Fact-94ABE66EE2078021A8B5AE73D8FE06D9" unitRef="usd">1406027000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2015Q3YTD" decimals="-3" id="Fact-5ED67FADBD7A8DDDCBCDAE73D8558DBC" unitRef="usd">4201661000</us-gaap:CostsAndExpenses>
	<us-gaap:DebtCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-D44D4513CDD61B81B491AE73D859762C" unitRef="usd">3136000</us-gaap:DebtCurrent>
	<us-gaap:DebtCurrent contextRef="FI2015Q3" decimals="-3" id="Fact-F235C4C9FF62C72B6D8FAE73D8FDE74C" unitRef="usd">5171000</us-gaap:DebtCurrent>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2015Q3" decimals="-8" id="Fact-A38A52A8C60168D25CE72EB2046CCD67" unitRef="usd">6000000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2015Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-7" id="Fact-FF5A061C6E50100F44632EB63BD9D367" unitRef="usd">1750000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2015Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-7" id="Fact-47E6C34DA632383716AE2EB62C3E1E88" unitRef="usd">1750000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2015Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-8" id="Fact-626A672BD693A3D6E4042EB61AE72F47" unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2015Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-8" id="Fact-0445464D779458D07EF32EB46C94F783" unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFairValue contextRef="FI2014Q4" decimals="-5" id="Fact-ACB8DB60C2996DD235D9AE73D913D2C5" unitRef="usd">647200000</us-gaap:DebtInstrumentFairValue>
	<us-gaap:DebtInstrumentFairValue contextRef="FI2015Q3" decimals="-5" id="Fact-B5FD5B4F4B3C5905AF65AE73D91CA601" unitRef="usd">6680000000</us-gaap:DebtInstrumentFairValue>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2015Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="INF" id="Fact-53D66C218E9E5AD16AD73EA51D86C542" unitRef="number">0.052</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2015Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="INF" id="Fact-230C71A78FC12E6B1C2B3EA50E65581F" unitRef="number">0.0405</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2015Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="INF" id="Fact-9036A5D08C2A1C851AC63EA6C0443686" unitRef="number">0.06875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2015Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="INF" id="Fact-C0202F370FA3585892B93EA4FE0F1757" unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2015Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="INF" id="Fact-68812DED9F46D1042F633EA2A785D7B0" unitRef="number">0.029</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentMaturityDateDescription contextRef="FD2015Q3YTD" id="Fact-AED3E882334F12E265FBAE73D90F2C9D">less than 90&#160;days</us-gaap:DebtInstrumentMaturityDateDescription>
	<us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="FD2015Q3YTD" decimals="INF" id="Fact-19285774975CEF282B963ED24DC2DE90" unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
	<us-gaap:DebtIssuanceCosts contextRef="FD2015Q3QTD" decimals="-5" id="Fact-8B76C1DD1E8E4FECBAA52ECD1E676E44" unitRef="usd">47500000</us-gaap:DebtIssuanceCosts>
	<us-gaap:DebtIssuanceCosts contextRef="FD2015Q3QTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-54B42F747958E1604F6C2E4AA4134603" unitRef="usd">1800000</us-gaap:DebtIssuanceCosts>
	<us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent contextRef="FI2015Q3_us-gaap_StatementGeographicalAxis_country_IT" decimals="-6" id="Fact-DCAB91289D0C04820624AE73D851ECFA" unitRef="EUR">75000000</us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2014Q3YTD" decimals="-3" id="Fact-54777B7EC4093F22FBCEAE73D854719E" unitRef="usd">-229273000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2015Q3YTD" decimals="-3" id="Fact-76F1A84FCE19BDEDE8E3AE73D8CF699C" unitRef="usd">-185802000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2014Q4" decimals="-5" id="Fact-45FCBD8F2EB6424A04E2AE73D8435D7F" unitRef="usd">120900000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2015Q3" decimals="-5" id="Fact-71DC9BF3A93B7D4B5151AE73D83B1AA7" unitRef="usd">58400000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="FI2014Q4" decimals="-3" id="Fact-8BEF9A8C0D486B1F8939AE73D836AEF9" unitRef="usd">50656000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
	<us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="FI2015Q3" decimals="-3" id="Fact-33C3DC3FB76750B17E0CAE73D8287F6F" unitRef="usd">136761000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2014Q3YTD" decimals="-3" id="Fact-359142780517E97B6694AE73D8CA24FF" unitRef="usd">530508000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2015Q3YTD" decimals="-3" id="Fact-086F6DBFD8257FD74986AE73D8D1F90B" unitRef="usd">444100000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2014Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-3A8B6770018F66BC4700AE73D83CAFA4" unitRef="usd">1300000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2014Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-165C61FD7D9A0CC18742AE73D8294B6C" unitRef="usd">69500000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2014Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-590DA6B2FB5AEC0C4ABBAE73D85E917F" unitRef="usd">1900000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2015Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-B59FA69E870D96F67783AE73D8730CB6" unitRef="usd">1700000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2015Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-7865AFD0629A7F5B3600AE73D8567125" unitRef="usd">54100000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2015Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-A7720CA1A7A5AE6922D02ECE2E502E4B" unitRef="usd">5600000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2015Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-1180D15BE2A8DFCC75092E8BA02F87C8" unitRef="usd">5600000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2014Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-4158876D0A73248C751FAE73D89993C8" unitRef="usd">5400000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2015Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-2669875B7A2EA0C8E104AE73D8CB1D88" unitRef="usd">5200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2015Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-A8A26FD909EF25DFB79EAE73D8C228C6" unitRef="usd">17600000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2015Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-2CAC87E214C7CBD18758AE73D8262650" unitRef="usd">8500000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeHigherRemainingMaturityRange1 contextRef="FD2014Q4YTD" id="Fact-AC749C0156E60B5E0CA9AE73D8A43884">P15M</us-gaap:DerivativeHigherRemainingMaturityRange1>
	<us-gaap:DerivativeHigherRemainingMaturityRange1 contextRef="FD2015Q3YTD" id="Fact-75D69B8AFDDAC6B56464AE73D8DC6250">P15M</us-gaap:DerivativeHigherRemainingMaturityRange1>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2014Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" decimals="-5" id="Fact-C44813262BE100D769FBAE73D83E1C97" unitRef="usd">2900000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2014Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" decimals="-5" id="Fact-9C05F68FE4F8AE9BCF08AE73D8776341" unitRef="usd">-7100000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2015Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" decimals="-5" id="Fact-8286BF4316C6BB6154DCAE73D83DE646" unitRef="usd">43900000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2015Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" decimals="-5" id="Fact-32F3AA80E71CDB48CD20AE73D8784E0B" unitRef="usd">119300000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2014Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-CD2B0456FE6C30509568AE73D841C958" unitRef="usd">-500000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2014Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-A769293B16E958924708AE73D877BDEB" unitRef="usd">-1600000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2015Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-9DFDFB39CEEEF3464FF0AE73D83FD3E1" unitRef="usd">2000000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2015Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-682ADCB46A83378C1AE0AE73D87AD1E2" unitRef="usd">5400000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeLowerRemainingMaturityRange1 contextRef="FD2014Q4YTD" id="Fact-FD5DA69E1A15074347CBAE73D8A6C3A8">P1M</us-gaap:DerivativeLowerRemainingMaturityRange1>
	<us-gaap:DerivativeLowerRemainingMaturityRange1 contextRef="FD2015Q3YTD" id="Fact-A0ADC3794BF3546E612AAE73D85A7D1C">P1M</us-gaap:DerivativeLowerRemainingMaturityRange1>
	<us-gaap:EarningsPerShareBasic contextRef="FD2014Q3QTD" decimals="2" id="Fact-2F375CAD3B8B91FE7D12AE73D8FB9F00" unitRef="usdPerShare">3.63</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2014Q3YTD" decimals="2" id="Fact-02292F83B8D909EA0CFFAE73D8FC84AF" unitRef="usdPerShare">8.67</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2015Q3QTD" decimals="2" id="Fact-9BC366513CD454581882AE73D8EE71AB" unitRef="usdPerShare">4.16</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2015Q3YTD" decimals="2" id="Fact-43DBEE1FEE1307E5690FAE73D8FCEB5A" unitRef="usdPerShare">11.60</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2014Q3QTD" decimals="2" id="Fact-C00657B3BA31448EACD7AE73D837AA91" unitRef="usdPerShare">3.62</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2014Q3YTD" decimals="2" id="Fact-0B5927308BEC2608C7ECAE73D8301B1A" unitRef="usdPerShare">8.64</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2015Q3QTD" decimals="2" id="Fact-06E1878BC8801D10D328AE73D91D5290" unitRef="usdPerShare">4.15</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2015Q3YTD" decimals="2" id="Fact-51D09A65F9492620BE80AE73D91E6A8D" unitRef="usdPerShare">11.57</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2014Q3YTD" decimals="-3" id="Fact-44D37584CDCC00324410AE73D8BB5F30" unitRef="usd">-18227000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2015Q3YTD" decimals="-3" id="Fact-74549815C1B3A7F898C5AE73D8A9EE98" unitRef="usd">-30358000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2014Q3QTD" decimals="3" id="Fact-46DB380D50C16D947546AE73D92A36FC" unitRef="number">0.242</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2014Q3YTD" decimals="3" id="Fact-3176182D50C8A83D2BC6AE73D8A780D4" unitRef="number">0.258</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2015Q3QTD" decimals="3" id="Fact-253E03FA30B1BCD78AC0AE73D8B62C35" unitRef="number">0.243</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2015Q3YTD" decimals="3" id="Fact-2435FFA6B74F3A8484E2AE73D9263489" unitRef="number">0.246</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2014Q3QTD" decimals="INF" id="Fact-B7C1C2573C97FD788142AE73D8B53F64" unitRef="number">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2014Q3YTD" decimals="3" id="Fact-BD4A14EF4AB46D4EFF40AE73D8BD13D2" unitRef="number">0.350</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2015Q3QTD" decimals="INF" id="Fact-9D52E8C1969C582B53C5AE73D8BDEC90" unitRef="number">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2015Q3YTD" decimals="3" id="Fact-FA020788F3C3075BB14AAE73D8B6F06D" unitRef="number">0.350</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2014Q3QTD" decimals="3" id="Fact-FD7A8F821668B2CD4186AE73D8A75A06" unitRef="number">-0.093</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2014Q3YTD" decimals="3" id="Fact-ED1FEAD91AF3FF050ADBAE73D8C721EA" unitRef="number">-0.089</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2015Q3QTD" decimals="3" id="Fact-B3C09387AD818B4C32CAAE73D8BD2B47" unitRef="number">-0.107</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2015Q3YTD" decimals="3" id="Fact-4919342A44FADC050723AE73D8BF3281" unitRef="number">-0.101</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="FD2014Q3QTD" decimals="3" id="Fact-FD8A4815C731373EC924AE73D8B9475B" unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="FD2014Q3YTD" decimals="3" id="Fact-0E0D79DB588328CA53BBAE73D81F71F1" unitRef="number">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="FD2015Q3QTD" decimals="3" id="Fact-2D12168BEC642B1FB810AE73D823A58E" unitRef="number">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="FD2015Q3YTD" decimals="3" id="Fact-C023592A8FB9FF6CCD93AE73D8C09AEF" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="FD2014Q3QTD" decimals="3" id="Fact-63AE9B6906825703750CAE73D92B66CF" unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="FD2014Q3YTD" decimals="3" id="Fact-1233869279EDE8E6C4C2AE73D81F4E14" unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="FD2015Q3QTD" decimals="3" id="Fact-27E5F923CF6288E0874DAE73D8BFA9D6" unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="FD2015Q3YTD" decimals="3" id="Fact-C0A45D3FDDB7FE54FD6DAE73D92D055B" unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="FD2014Q3QTD" decimals="3" id="Fact-6202C8C4FAF52E67E6E1AE73D92DF72C" unitRef="number">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="FD2014Q3YTD" decimals="3" id="Fact-DBE0978E1A4F95967FB8AE73D8C16848" unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="FD2015Q3QTD" decimals="3" id="Fact-A347549BBCB6DA1A6A7EAE73D8AD0F5D" unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="FD2015Q3YTD" decimals="3" id="Fact-137FDE9CFE3F16E3656CAE73D8B5DCF4" unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2014Q3QTD" decimals="3" id="Fact-73FB993961E93EC64F98AE73D8BD4BD8" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2014Q3YTD" decimals="3" id="Fact-7E80C2261ADE8219900CAE73D8B8C755" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2015Q3QTD" decimals="3" id="Fact-957E95DF561740F37EE7AE73D8BB7F1F" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2015Q3YTD" decimals="3" id="Fact-3ED6A7F3FCD6F8B6C006AE73D9283524" unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2014Q3QTD" decimals="3" id="Fact-96C26DB8BC21DE438501AE73D92A8768" unitRef="number">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2014Q3YTD" decimals="3" id="Fact-8F528E90EFF8FD0A14ACAE73D88D55F8" unitRef="number">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2015Q3QTD" decimals="3" id="Fact-CE84EFF6CFC95E5C056DAE73D81FBC12" unitRef="number">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2015Q3YTD" decimals="3" id="Fact-769F8227FD7E54A89FE7AE73D8B6A950" unitRef="number">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2014Q4" decimals="-5" id="Fact-B87587D222DE01EA6F96AE73D83F3FAC" unitRef="usd">393800000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2015Q3" decimals="-5" id="Fact-A55E2C3700546A4CC10BAE73D835F8D3" unitRef="usd">214200000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="FD2014Q3QTD" decimals="-5" id="Fact-CDC14037FBD8A2ECEE81AE73D88B3105" unitRef="usd">2300000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
	<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="FD2014Q3YTD" decimals="-5" id="Fact-6B9965C5471744D0E647AE73D8928746" unitRef="usd">7500000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
	<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="FD2015Q3QTD" decimals="-5" id="Fact-D64B66025F9CF2DCBBA4AE73D875503D" unitRef="usd">2800000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
	<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="FD2015Q3YTD" decimals="-5" id="Fact-6D8FA8D86743027030FFAE73D8D2E072" unitRef="usd">8400000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="FD2014Q3QTD" decimals="-5" id="Fact-762D4747523B69E08D97AE73D8941397" unitRef="usd">16600000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="FD2014Q3YTD" decimals="-5" id="Fact-C1780A53BE12634710D8AE73D87EA146" unitRef="usd">55400000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="FD2015Q3QTD" decimals="-5" id="Fact-6E65E398A434A3E89FEFAE73D84D3772" unitRef="usd">6400000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="FD2015Q3YTD" decimals="-5" id="Fact-30573F806D1EC90CDB47AE73D88CF4D3" unitRef="usd">46000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
	<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="FI2015Q3_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="INF" id="Fact-941B9814FC50FE19F9E8AE73D87EC0C7" unitRef="number">0.10</us-gaap:EquityMethodInvestmentOwnershipPercentage>
	<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="I2012Q1SD2_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="INF" id="Fact-35CBB84131C26B6FD579AE73D85C430A" unitRef="number">0.15</us-gaap:EquityMethodInvestmentOwnershipPercentage>
	<us-gaap:EquityMethodInvestments contextRef="FI2014Q4_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-8" id="Fact-F88B9FD03E3F036723A2AE73D8823CAC" unitRef="KRW">9100000000</us-gaap:EquityMethodInvestments>
	<us-gaap:EquityMethodInvestments contextRef="FI2014Q4_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-D428590936869178969FAE73D86258E2" unitRef="usd">8600000</us-gaap:EquityMethodInvestments>
	<us-gaap:EquityMethodInvestments contextRef="FI2015Q3_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-340DB7CF12EC89744E3CAE73D8865F99" unitRef="usd">0</us-gaap:EquityMethodInvestments>
	<us-gaap:EquityMethodInvestments contextRef="FI2015Q3_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-8" id="Fact-8D089541092E5D4FC0C6AE73D8639CDA" unitRef="KRW">0</us-gaap:EquityMethodInvestments>
	<us-gaap:EquityMethodInvestments contextRef="I2012Q1SD2_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-8" id="Fact-AF8D701AB212FF8A713EAE73D85E6EF3" unitRef="KRW">49500000000</us-gaap:EquityMethodInvestments>
	<us-gaap:EquityMethodInvestments contextRef="I2012Q1SD2_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-7A8D9EF1F9CD533A8127AE73D886E7E8" unitRef="usd">45000000</us-gaap:EquityMethodInvestments>
	<us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities contextRef="FD2014Q3YTD" decimals="-3" id="Fact-019B2A3D44F31DF5D2FCAE73D8D4642B" unitRef="usd">90423000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
	<us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities contextRef="FD2015Q3YTD" decimals="-3" id="Fact-0325BE87507026F8EE41AE73D8557522" unitRef="usd">70778000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
	<us-gaap:FairValueInputsDiscountRate contextRef="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="INF" id="Fact-A2AA66929771D07157E5AE73D8F9A8CE" unitRef="number">0.02</us-gaap:FairValueInputsDiscountRate>
	<us-gaap:FairValueInputsDiscountRate contextRef="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_biib_RaxatrigineMember" decimals="2" id="Fact-4C071745D24380EE77D3AE73D8B2C380" unitRef="number">0.11</us-gaap:FairValueInputsDiscountRate>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2014Q3QTD" decimals="-3" id="Fact-C8BF25B462B707EA49BFAE73D8F08204" unitRef="usd">49433000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2014Q3YTD" decimals="-3" id="Fact-8A0213B209E31E7424B9AE73D901C891" unitRef="usd">46213000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2015Q3QTD" decimals="-3" id="Fact-47DA35434A079936C678AE73D8496862" unitRef="usd">-244000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2015Q3YTD" decimals="-3" id="Fact-317ABB74834B9D788116AE73D88A3ECB" unitRef="usd">-5887000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-82779FC7B10B5913B47EAE73D8BCC420" unitRef="usd">274500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="FD2014Q3QTD" decimals="-5" id="Fact-B23C197445C7DA481641AE73D86ED4D8" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="FD2014Q3YTD" decimals="-5" id="Fact-AF9C0D2766185E003F83AE73D86846BE" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="FD2015Q3QTD" decimals="-5" id="Fact-FE9C5714C9FAFC43C0DFAE73D86C8533" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="FD2015Q3YTD" decimals="-5" id="Fact-D515E3B97B4A90C04E68AE73D86DD305" unitRef="usd">274500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2014Q3QTD" decimals="-5" id="Fact-711955E2C8E41FC8AB2BAE73D8699782" unitRef="usd">16500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2014Q3YTD" decimals="-5" id="Fact-DBD6438E400F91535247AE73D8761AA5" unitRef="usd">21500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2015Q3QTD" decimals="-5" id="Fact-2AF05697BF9F205D5857AE73D86B48C2" unitRef="usd">14500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2015Q3YTD" decimals="-5" id="Fact-93F90556B448793EF916AE73D869EC63" unitRef="usd">14500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementsChangesInValuationTechniques contextRef="FD2015Q3YTD" id="Fact-3EEC76825A6FEBA915E1AE73D8F3D58C">0</us-gaap:FairValueMeasurementsChangesInValuationTechniques>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2015Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-41A6DEB10A7658FF5406AE73D85C3FA0">P17Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2015Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-0F904A741D2983093B5DAE73D86E17F5">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2015Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-38DCEDAEF6C045ADD913AE73D85AF15D">P23Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2015Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-E41EF95A552C320EC266AE73D89BCF0B">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2015Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-B485E6CC8946AD603D78AE73D89A5C33">P23Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2015Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-38AE39FD9D7B34DE166CAE73D85B7EB4">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2014Q4" decimals="-5" id="Fact-09DD86BCB2420253F72DAE73D8E47F44" unitRef="usd">3178600000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2014Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-430DE53742840B1CC213AE73D8A28439" unitRef="usd">300100000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2014Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-3B4129070A32A91936A7AE73D8E18BBF" unitRef="usd">481700000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2014Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-C28068A77E3962D27400AE73D8F219C1" unitRef="usd">2396800000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2014Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-40C65531CF963D5ACF5CAE73D8EB245B" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2014Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-3B29A59552ED372023F7AE73D8F7766B" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2015Q3" decimals="-5" id="Fact-EBEB785CC23ECF9246ECAE73D8F1E930" unitRef="usd">3464600000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2015Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-0710F22879E7F1ED33E7AE73D8E4DCE5" unitRef="usd">440900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2015Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-D6E8C7737A885DD6E667AE73D8F44BF0" unitRef="usd">499900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2015Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-8F3D9AB36FE164C56102AE73D8E589F5" unitRef="usd">2523800000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2015Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-0F2126D01B58179A7EA6AE73D8F4D0A3" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2015Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-ABEFA6CBF3CABCD8DD5EAE73D8A54BB9" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="FI2015Q3" decimals="-5" id="Fact-3CA8182912F3E9E6D44CAE73D86479D6" unitRef="usd">348800000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="FI2015Q3" decimals="-5" id="Fact-2C6DAF4B992F2752AD3EAE73D861383C" unitRef="usd">94300000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="FI2015Q3" decimals="-5" id="Fact-5D0B74629CE6EB6FDADBAE73D86761B6" unitRef="usd">269100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="FI2015Q3" decimals="-5" id="Fact-33D6449789491713D9B5AE73D8628A5B" unitRef="usd">275100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="FI2015Q3" decimals="-5" id="Fact-00E6BC6192B3374D94A9AE73D86042CC" unitRef="usd">291000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="FI2015Q3" decimals="-5" id="Fact-5515FF6CF857763B6920AE73D865DD10" unitRef="usd">318600000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2014Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-B1D5BB64E75C4FA64BA2AE73D8EBE3A0" unitRef="usd">3280400000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2014Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-3AE7C2C50FF3D3C3E4BDAE73D8A694B5" unitRef="usd">543300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2014Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-348715BE6A985C3E9517AE73D8E3970C" unitRef="usd">3005300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2015Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-FD35683F8A9337941B9EAE73D8EB6753" unitRef="usd">3297600000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2015Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-1C89D56113AE98353D82AE73D8A1FE9D" unitRef="usd">543300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2015Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-6D755B2B7596BDDE8F40AE73D8E35513" unitRef="usd">3005300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2014Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-DC11039D240E6AE2937DAE73D8E4383D" unitRef="usd">2980300000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2014Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-93CD1FFDFFAF7F762FC4AE73D8E5651C" unitRef="usd">61600000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2014Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-B6DAA63FFEA640115C92AE73D8A41196" unitRef="usd">608500000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2015Q3_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-07E41D0DB8CB6EC9F493AE73D8821C17" unitRef="usd">2797500000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2015Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-BBC5B7785241C7809EB5AE73D8A13130" unitRef="usd">2856700000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2015Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-A78AFBA914D0C883F2C7AE73D8A4D7C4" unitRef="usd">43400000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2015Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-D208631EE9860A64F39EAE73D8E6E226" unitRef="usd">481500000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2015Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_biib_AVONEXMember" decimals="-5" id="Fact-CF0945C6756EA54C05EDAE73D8856ECC" unitRef="usd">472900000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-EDCCC82D4DAC637BA5DBAE73D8EC4B10" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-5B92C909D248AC65C642AE73D8F5852E" unitRef="usd">72700000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-15328A0F808511324FD0AE73D8EBFCEA" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-65147FF5BF442E1EB2EDAE73D842D120" unitRef="usd">72700000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B6F4CCB1C353A10AAF45AE73D901F728" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-FA7A5FED00E82C4FB157AE73D9099927" unitRef="usd">61400000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-58A5E158EC0A3C661497AE73D8FC3EC3" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2236C792C38F061F5C0DAE73D904C669" unitRef="usd">61400000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-332EED75230C3CCD4FACAE73D8F50615" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-8100BC45DFB7197FEC7BAE73D8FA695C" unitRef="usd">5400000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-6D9EBED2BA22218F4DABAE73D83620FC" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-8E309F4DC310CE17327AAE73D8D27556" unitRef="usd">5400000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-7ADAE6830F03200F50AEAE73D8FE3706" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-3CE435C3F12D879B9C31AE73D900F1EC" unitRef="usd">31300000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-1CF78A3D9277B3E317D2AE73D9091E8C" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A4539AFA057E5CA3619AAE73D8F9423C" unitRef="usd">31300000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2014Q3QTD" decimals="-5" id="Fact-DFD327200F0F5E512EA3AE73D861D5AD" unitRef="usd">-4800000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2014Q3YTD" decimals="-5" id="Fact-CD87A0D7FD875F19E04CAE73D85B8EA0" unitRef="usd">-9500000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2015Q3QTD" decimals="-5" id="Fact-C51693B6CC9B4A7C3F44AE73D878DCC7" unitRef="usd">-4300000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2015Q3YTD" decimals="-5" id="Fact-6C0E8CE4D935DEC8D8A4AE73D87DD00A" unitRef="usd">-18800000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="FD2014Q3QTD" decimals="-5" id="Fact-988F3263F07EB4D7E867AE73D8D55AE0" unitRef="usd">7700000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
	<us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="FD2014Q3YTD" decimals="-5" id="Fact-DA105DB8475B4B1709BAAE73D8D91658" unitRef="usd">11500000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
	<us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="FD2015Q3QTD" decimals="-5" id="Fact-DC6E51346EC4E19CF245AE73D8D9D4C1" unitRef="usd">8100000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
	<us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="FD2015Q3YTD" decimals="-5" id="Fact-1FF67ADBEDEC798AB7B2AE73D8D643E6" unitRef="usd">4200000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
	<us-gaap:GainLossOnSaleOfInvestments contextRef="FD2014Q3QTD" decimals="-5" id="Fact-F730E83E7B8B467BEB54AE73D8E1DBD3" unitRef="usd">-3100000</us-gaap:GainLossOnSaleOfInvestments>
	<us-gaap:GainLossOnSaleOfInvestments contextRef="FD2014Q3YTD" decimals="-5" id="Fact-EABC3642553777088E8BAE73D8E2C174" unitRef="usd">13500000</us-gaap:GainLossOnSaleOfInvestments>
	<us-gaap:GainLossOnSaleOfInvestments contextRef="FD2015Q3QTD" decimals="-5" id="Fact-5B2E00329ADF36D2DE61AE73D87BFDBB" unitRef="usd">1100000</us-gaap:GainLossOnSaleOfInvestments>
	<us-gaap:GainLossOnSaleOfInvestments contextRef="FD2015Q3YTD" decimals="-5" id="Fact-7AFC935BA00A1054CE7FAE73D87BD580" unitRef="usd">-300000</us-gaap:GainLossOnSaleOfInvestments>
	<us-gaap:Goodwill contextRef="FI2014Q4" decimals="-3" id="Fact-66BAACFD4A9E6267F707AE73D8B68751" unitRef="usd">1760249000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2015Q3" decimals="-3" id="Fact-CFCF9CE5AED5B30AA7A2AE73D826DBCB" unitRef="usd">2408854000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-E1CE881B97BBC844DCA2AE73D8819FE6" unitRef="usd">128300000</us-gaap:Goodwill>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2015Q3YTD" decimals="-5" id="Fact-622226CA0F1D7848F122AE73D8E8FEA1" unitRef="usd">649400000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2015Q3YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-5AE18A45C973E20A312EAE73D889E4FC" unitRef="usd">600000000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillImpairedAccumulatedImpairmentLoss contextRef="FI2015Q3" decimals="-6" id="Fact-931597C639655CF06D0CAE73D8924149" unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
	<us-gaap:GoodwillOtherChanges contextRef="FD2015Q3YTD" decimals="-5" id="Fact-00FEEA6929E1490A9F70AE73D852D4E3" unitRef="usd">-700000</us-gaap:GoodwillOtherChanges>
	<us-gaap:GoodwillPeriodIncreaseDecrease contextRef="FD2015Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-AD66851AC9EAD6E2F1FFAE73D8AFC29C" unitRef="usd">36000000</us-gaap:GoodwillPeriodIncreaseDecrease>
	<us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="FD2014Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-5D98050A9879598C16CC4EED0E2A0367" unitRef="usd">50900000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
	<us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="FD2014Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-DF2EA1161F00F26FE1242E3749FCAB72" unitRef="usd">16200000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2014Q3QTD" decimals="-3" id="Fact-255AE3FA27D20E81E65FAE73D8352FEE" unitRef="usd">1136288000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2014Q3YTD" decimals="-3" id="Fact-0DA74D6E272AD591A438AE73D8AE81E6" unitRef="usd">2795621000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2015Q3QTD" decimals="-3" id="Fact-8DFFF886C7CDED7992E7AE73D8EAD47B" unitRef="usd">1356419000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2015Q3YTD" decimals="-3" id="Fact-C867E89D15568ABFAC1CAE73D858598A" unitRef="usd">3681515000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2014Q3QTD" decimals="-3" id="Fact-37695282E9A98459E7FAAE73D8EB30DE" unitRef="usd">-5394000</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2014Q3QTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-0462BDC8EFC374912F12AE73D8886D0B" unitRef="usd">-5400000</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2014Q3YTD" decimals="-3" id="Fact-EF27B1A4F7175ED0F69EAE73D8389BB3" unitRef="usd">-14932000</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2014Q3YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-1EAB185837A40DF74A76AE73D89EC03B" unitRef="usd">-14900000</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2015Q3QTD" decimals="-3" id="Fact-08EB45053FEE90B522B2AE73D84FE920" unitRef="usd">-6833000</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2015Q3QTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-3E1F97B05632294EBFC7AE73D85BFB1C" unitRef="usd">-6800000</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2015Q3YTD" decimals="-3" id="Fact-D63B084486FBFF7684AFAE73D8F47221" unitRef="usd">-12548000</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2015Q3YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-500AFC1BA0E0A0D0DC2BAE73D8A76FD6" unitRef="usd">-12500000</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="FI2015Q1" decimals="-5" id="Fact-CCF82AAFDBC217955438AE73D92C9280" unitRef="usd">49300000</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2014Q3QTD" decimals="-3" id="Fact-B00224A3EB1750D0A7A7AE73D926E436" unitRef="usd">274774000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2014Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-DEC2BA6E26BCF886EA38AE73D8751AB7" unitRef="usd">-100000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2014Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-9748CDF12218B27A4A6EAE73D8666980" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2014Q3YTD" decimals="-3" id="Fact-2C102501DCC304EBF981AE73D8ECC257" unitRef="usd">721709000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2014Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-2F0C8D17D4FEBA9708A3AE73D8992F03" unitRef="usd">-200000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2014Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-CA49226D1EE9FBAE858FAE73D868FE31" unitRef="usd">-3600000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2015Q3QTD" decimals="-3" id="Fact-4E5706F99FA51C16793AAE73D8F9A189" unitRef="usd">330093000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2015Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-603098262A5519DF7301AE73D866A7B3" unitRef="usd">-200000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2015Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-EC261C2A6CCCACF2962EAE73D86404C1" unitRef="usd">500000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2015Q3YTD" decimals="-3" id="Fact-9F980F883AD0D17E97CCAE73D8921F71" unitRef="usd">904475000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2015Q3YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-AD06B02DF9EB35129532AE73D88C3F61" unitRef="usd">78900000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2015Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-AEDCE9EBAD54DA446EBDAE73D8696DF2" unitRef="usd">-600000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2015Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-308EB7210CE07B79246BAE73D8A2C25B" unitRef="usd">600000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2014Q3YTD" decimals="-3" id="Fact-59018828FF371F261759AE73D8440B04" unitRef="usd">297057000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2015Q3YTD" decimals="-3" id="Fact-198A2EE64B82A5E59396AE73D84735E9" unitRef="usd">63608000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2014Q3YTD" decimals="-3" id="Fact-E675F5BBC1A12D2B5707AE73D8DA0C40" unitRef="usd">19283000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2015Q3YTD" decimals="-3" id="Fact-FEEC91973EE10D8B55A0AE73D8B7B908" unitRef="usd">-174532000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2014Q3YTD" decimals="-3" id="Fact-0B516AD743C931B8510CAE73D8487581" unitRef="usd">119890000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2015Q3YTD" decimals="-3" id="Fact-4B6F80340ABA060C7F99AE73D845E128" unitRef="usd">150387000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="FD2014Q3YTD" decimals="-3" id="Fact-722C10D9903B570FFF42AE73D8DCA549" unitRef="usd">-22904000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
	<us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="FD2015Q3YTD" decimals="-3" id="Fact-3090E9561D776BAA0F87AE73D8D2B041" unitRef="usd">121659000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2014Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-77B3D9182C122E280368AE73D88CF596" unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2014Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" decimals="-5" id="Fact-6527A54B8A2863EC074AAE73D8BF52F7" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2014Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-3CB2CD978D645C359459AE73D8ADFFCC" unitRef="shares">500000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2014Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-B70C128D2EAD6A8F58CEAE73D8ABD109" unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2014Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" decimals="-5" id="Fact-B8B38AD4F0C8F13292E6AE73D85F44F0" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2014Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-9A80EE42FBB34F1EA909AE73D89CDE58" unitRef="shares">500000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2015Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-2E61B0AF43031AE57D6CAE73D8915198" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2015Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" decimals="-5" id="Fact-1927E79B43E1AB1331DBAE73D8AC83EE" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2015Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-6384E87738AF463D45B9AE73D8ABACB5" unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2015Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-3861218A28560B4C2293AE73D8C9F04F" unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2015Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" decimals="-5" id="Fact-C8DCDB1D720890780545AE73D8D99BBD" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2015Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-A936C604ED09610FF73DAE73D88E5B4B" unitRef="shares">300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2014Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-EFBF2A9D681F52649065AE73D8A38805" unitRef="usd">314100000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2014Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-EDFEC6FDF1DE5DFE87F9AE73D8A6E51A" unitRef="usd">64000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2015Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-D932E9A6CDE3CDD61560AE73D8E8D3A7" unitRef="usd">735600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2015Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-612158C12D8CA1C10FD0AE73D8E27CBC" unitRef="usd">64000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="FI2014Q4" decimals="-5" id="Fact-B4DA9B0F44D88AD08135AE73D8E8BB23" unitRef="usd">7207100000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
	<us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="FI2015Q3" decimals="-5" id="Fact-6BB9BB1640F4DF91BD31AE73D8F1D0B3" unitRef="usd">7645800000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2014Q4" decimals="-3" id="Fact-AA64A3904F2B85805B1AAE73D847E8D9" unitRef="usd">4028507000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2015Q3" decimals="-3" id="Fact-EE8A522B48EFE853CA7EAE73D8C9AF63" unitRef="usd">4181245000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:InterestExpense contextRef="FD2014Q3QTD" decimals="-5" id="Fact-F590B01BA0D46D15E368AE73D8DD695D" unitRef="usd">7400000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2014Q3YTD" decimals="-5" id="Fact-34C8CE471892F7FD72AFAE73D86237A1" unitRef="usd">22100000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2015Q3QTD" decimals="-5" id="Fact-0477C1BB138493324D6BAE73D876740E" unitRef="usd">15600000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2015Q3YTD" decimals="-5" id="Fact-4384CCD5DB541EEF1F5DAE73D87F5BB9" unitRef="usd">28100000</us-gaap:InterestExpense>
	<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="FI2014Q4" decimals="-5" id="Fact-5AB212B2D26898334C6DAE73D8E481E3" unitRef="usd">164200000</us-gaap:InventoryFinishedGoodsNetOfReserves>
	<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="FI2015Q3" decimals="-5" id="Fact-9EA81865BF75E2FE469CAE73D8C4C6A0" unitRef="usd">159700000</us-gaap:InventoryFinishedGoodsNetOfReserves>
	<us-gaap:InventoryNet contextRef="FI2014Q4" decimals="-3" id="Fact-F3020CB7E80DBCB7571EAE73D8991A0D" unitRef="usd">804022000</us-gaap:InventoryNet>
	<us-gaap:InventoryNet contextRef="FI2015Q3" decimals="-3" id="Fact-9327D92F1E035E014109AE73D8393644" unitRef="usd">918921000</us-gaap:InventoryNet>
	<us-gaap:InventoryRawMaterialsNetOfReserves contextRef="FI2014Q4" decimals="-5" id="Fact-3A28A7220A375F1B43F4AE73D8E6B0CB" unitRef="usd">128300000</us-gaap:InventoryRawMaterialsNetOfReserves>
	<us-gaap:InventoryRawMaterialsNetOfReserves contextRef="FI2015Q3" decimals="-5" id="Fact-1AC4BE23A9FCDE507B65AE73D8E94800" unitRef="usd">221500000</us-gaap:InventoryRawMaterialsNetOfReserves>
	<us-gaap:InventoryWorkInProcessNetOfReserves contextRef="FI2014Q4" decimals="-5" id="Fact-5B948E92B28EAA9430E4AE73D8F7695A" unitRef="usd">511500000</us-gaap:InventoryWorkInProcessNetOfReserves>
	<us-gaap:InventoryWorkInProcessNetOfReserves contextRef="FI2015Q3" decimals="-5" id="Fact-E1B5BA09847A2DAAA6CEAE73D8E73354" unitRef="usd">537700000</us-gaap:InventoryWorkInProcessNetOfReserves>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2014Q3QTD" decimals="-5" id="Fact-16CDAE34FC52DFA7F602AE73D8DCFC0D" unitRef="usd">3600000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2014Q3YTD" decimals="-5" id="Fact-C803D2A89C2EC4108173AE73D87D4DC1" unitRef="usd">8700000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2015Q3QTD" decimals="-5" id="Fact-D069562F3A75FF9A8DFCAE73D8E1ACF1" unitRef="usd">5400000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2015Q3YTD" decimals="-5" id="Fact-7D0042C6106112D5A54AAE73D87DB762" unitRef="usd">13000000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-6BF3527CA6B4877D81C4AE73D82D6D12" unitRef="usd">6900000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2B4E9F0B00C0C95EF859AE73D8CBD4ED" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-7E657C57D3F37482A210AE73D8365A47" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A86418857030743817A2AE73D8F374E0" unitRef="usd">6900000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C206566A5D7DB962E9B3AE73D90B6FDB" unitRef="usd">25700000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-CC59B445CBBACD65E5EEAE73D9028582" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C73351DA7E6AEA7639ADAE73D904539C" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-E4463661C90B48BDDE0BAE73D905F173" unitRef="usd">25700000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:Land contextRef="FI2015Q2_us-gaap_StatementGeographicalAxis_country_CH" decimals="-5" id="Fact-81187C526283B1FFAF67AE73D849B147" unitRef="chf">65100000</us-gaap:Land>
	<us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract contextRef="FD2015Q3QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" id="Fact-7BF023A380767A7F4F5A877691472CE5">P10Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
	<us-gaap:Liabilities contextRef="FI2014Q4" decimals="-3" id="Fact-8F3E9731DC4E70104295AE73D857EC27" unitRef="usd">3500741000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2015Q3" decimals="-3" id="Fact-64EE8AE99BF14E763BE7AE73D8C81663" unitRef="usd">10161425000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2014Q4" decimals="-3" id="Fact-720E8924F073DAA9DF82AE73D8C3F156" unitRef="usd">14314781000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2015Q3" decimals="-3" id="Fact-16D8306C18CA5458AF59AE73D833316D" unitRef="usd">20728368000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-BB9BA5F067450DDF4AE4AE73D8BE3D27" unitRef="usd">2219706000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2015Q3" decimals="-3" id="Fact-17ECFDB1CC1DE1303DDDAE73D8E57C84" unitRef="usd">2633968000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-7AB4DB1EACF012DCA5EEAE73D844E345" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-FF00D444DCE40F9EE74CAE73D8CD2325" unitRef="usd">5400000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-22962BE24582E70A1686AE73D8FA97E4" unitRef="usd">215500000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2A03BA109095A801D5C8AE73D901975B" unitRef="usd">220900000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-764CE3C8D4FA8A8430AFAE73D905BAC0" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-24BB1589EF6F1570F85EAE73D90231D1" unitRef="usd">31300000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-5BB2CB8C397E1CF69FCBAE73D90BD2A5" unitRef="usd">481400000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A4B0EC91800BA19A4579AE73D908695D" unitRef="usd">512700000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LicenseCosts contextRef="FD2015Q3QTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-17710A90468D2F7353933F474A05A0F3" unitRef="usd">35600000</us-gaap:LicenseCosts>
	<us-gaap:LineOfCreditFacilityExpirationPeriod contextRef="FD2015Q3QTD" id="Fact-3F85AE478A9857C89BB03EDFB6F33DDE">P5Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
	<us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding contextRef="FI2015Q3" decimals="0" id="Fact-682BC585C8E762859B182ED7DC4320AE" unitRef="usd">0</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="FI2015Q3" decimals="-8" id="Fact-060E74A405D961763C072ED0DBD6C75F" unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LongTermDebt contextRef="FI2014Q4" decimals="-3" id="Fact-99EDE2E10748905315C2AE73D88ADAE9" unitRef="usd">580283000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2015Q3" decimals="-3" id="Fact-CF04D268CEAF09599BFFAE73D82695A1" unitRef="usd">6529275000</us-gaap:LongTermDebt>
	<us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1 contextRef="FD2015Q3YTD" id="Fact-668662C306DF0B099021AE73D8D963B8">P15M</us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1>
	<us-gaap:MinorityInterest contextRef="FI2013Q4" decimals="-5" id="Fact-D54007F6E46986A1DC08AE73D898C3E0" unitRef="usd">600000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2014Q2" decimals="-5" id="Fact-E72EC4B226FCF52CFE7AAE73D890367F" unitRef="usd">3900000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2014Q3" decimals="-5" id="Fact-D731B7EA09250DEB7004AE73D880ADBD" unitRef="usd">3200000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2014Q4" decimals="-3" id="Fact-EDE77715C3D3606518D5AE73D840FCE2" unitRef="usd">5030000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2015Q2" decimals="-5" id="Fact-87ECE31C97804AF38F0AAE73D8F022CC" unitRef="usd">400000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2015Q3" decimals="-3" id="Fact-FAA52F67B477732CDB42AE73D8516CE9" unitRef="usd">-5783000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="FD2014Q3QTD" decimals="-5" id="Fact-B6B59666F706C278AA36AE73D86FF22A" unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
	<us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="FD2014Q3YTD" decimals="-5" id="Fact-84863FE9E28A9040DA8CAE73D8A00A10" unitRef="usd">9100000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
	<us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="FD2015Q3QTD" decimals="-5" id="Fact-15D614B65E3FA6D5A1DB4F0BCA7970B9" unitRef="usd">60000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
	<us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="FD2015Q3YTD" decimals="-5" id="Fact-C68B98AF6A5CDA84C3434F0C08BF03F1" unitRef="usd">60000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2014Q3YTD" decimals="-3" id="Fact-B02E1E8C3215CF44417CAE73D8CFF13E" unitRef="usd">-242608000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2015Q3YTD" decimals="-3" id="Fact-2276DAEE8B4B57B28D81AE73D8B6646D" unitRef="usd">2984803000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2014Q3YTD" decimals="-3" id="Fact-E9A1DDC2B092A5B480DEAE73D8B8B0C6" unitRef="usd">-1164698000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2015Q3YTD" decimals="-3" id="Fact-14CEBF92806F06D1D61DAE73D8D86050" unitRef="usd">-2746071000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2014Q3YTD" decimals="-3" id="Fact-D098DFD40D696EC23EDDAE73D8B955A5" unitRef="usd">2009252000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2015Q3YTD" decimals="-3" id="Fact-B17DAF11E08DAA1CE4CDAE73D8C2B62B" unitRef="usd">2675705000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q3QTD" decimals="-3" id="Fact-C20A169BC75FFC78ADA3AE73D82D00E5" unitRef="usd">856858000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-D7E24318AD28277AEA99AE73D89B1A0B" unitRef="usd">2700000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q3YTD" decimals="-3" id="Fact-F7F6D5B5B8C69DCD7E90AE73D8ED42DC" unitRef="usd">2051320000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-54B1CFF60E0FDB68CF53AE73D85AD2C1" unitRef="usd">-800000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q3QTD" decimals="-3" id="Fact-907F679DA8B1BE0E1E62AE73D8D32708" unitRef="usd">965622000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-472E5E25A5EC87AA9D5CAE73D89B3C2A" unitRef="usd">42900000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q3YTD" decimals="-3" id="Fact-D3ED9DDBEA7CF31572CDAE73D9030680" unitRef="usd">2715439000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-40E34D2BBE895232538BAE73D89B4782" unitRef="usd">117700000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2014Q3QTD" decimals="-3" id="Fact-8D83F6F56894AA7242B4AE73D8A92A07" unitRef="usd">-738000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2014Q3YTD" decimals="-3" id="Fact-4D7D4657F93F79D1BA03AE73D927834C" unitRef="usd">7660000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2015Q3QTD" decimals="-3" id="Fact-CE957CED6FB15505C130AE73D82424C6" unitRef="usd">53871000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2015Q3YTD" decimals="-3" id="Fact-BBDAE3ACC6C202975B8BAE73D91D8287" unitRef="usd">49053000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2015Q3YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" decimals="-5" id="Fact-E5F356575A647A60A600AE73D87A491E" unitRef="usd">60000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination contextRef="FD2014Q3QTD" decimals="-5" id="Fact-A8CC7C8505E201DB1087AE73D89D3DC7" unitRef="usd">0</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
	<us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination contextRef="FD2014Q3YTD" decimals="-5" id="Fact-AC632346A8C8F1E6DA8FAE73D87C6CEE" unitRef="usd">4000000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
	<us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination contextRef="FD2015Q3QTD" decimals="-5" id="Fact-F3D89378D7B70BAA765AAE73D882364D" unitRef="usd">200000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
	<us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination contextRef="FD2015Q3YTD" decimals="-5" id="Fact-AFEF20D4C721CA7D3814AE73D8760D83" unitRef="usd">100000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2014Q3QTD" decimals="-3" id="Fact-102D7F34C73AC3337550AE73D9026C75" unitRef="usd">-16290000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2014Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-E28E8DB9A2F976F4F8C03EEF07027DEB" unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2014Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-B67355F55428325B7C57AE73D8A0D0A4" unitRef="usd">-100000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2014Q3YTD" decimals="-3" id="Fact-4599041933D177D2F0BEAE73D924F02F" unitRef="usd">-17030000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2014Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-C3E6BE18A8977054F5513EEF7C3A65BC" unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2014Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-3FBD243901CE5803C74EAE73D8979F73" unitRef="usd">10100000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2015Q3QTD" decimals="-3" id="Fact-00C2384D9DDB82089ED2AE73D90DA8B9" unitRef="usd">-15413000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2015Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-1C757119042144BF74A83EEC0E3149F1" unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2015Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-CFA32C6A355C42893BC6AE73D89EB07A" unitRef="usd">-1300000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2015Q3YTD" decimals="-3" id="Fact-297B54AD978A9B8A6212AE73D90C78ED" unitRef="usd">-41288000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2015Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-1876791FE0A47A39ADAA3EEF50207ACD" unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2015Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-E737D3E426E013F88128AE73D8A8E75C" unitRef="usd">-1600000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NotesPayable contextRef="FI2014Q4" decimals="-5" id="Fact-2643F6BFBBF0EF380D00AE73D8B471C7" unitRef="usd">583400000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember" decimals="-5" id="Fact-92DEE160A94746F6F457AE73D921EC3F" unitRef="usd">11700000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-BA01723451144A6C02C42E4707315D3F" unitRef="usd">0</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-C7958C6BBEE4BF4B27282E46E940E6C3" unitRef="usd">0</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-FD6A86EE3EFD4B3A7EECAE73D8B470DD" unitRef="usd">571700000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-B2AB1D7FEFEC193C616A2E46CFF7D5C3" unitRef="usd">0</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-AC90D8DAB1047447854F2E46B436AFD1" unitRef="usd">0</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2015Q3" decimals="-5" id="Fact-91D26E0F1B586133F937AE73D90E3576" unitRef="usd">6514300000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2015Q3_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember" decimals="-5" id="Fact-D16589C5AE354B6B4BA9AE73D9165506" unitRef="usd">9100000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2015Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-37B2A443E669104B4F882E45B065B461" unitRef="usd">1721000000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2015Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-1CDA2D77D37E94AA637F2E459F532EF3" unitRef="usd">1733100000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2015Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-40C4C9DCC4F247495479AE73D91B0108" unitRef="usd">566900000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2015Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-F6AFB20700D9D47796C92E4590361D79" unitRef="usd">991900000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2015Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-77BA1AAAD862646AF8A42E457EC86894" unitRef="usd">1492300000</us-gaap:NotesPayable>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember" decimals="-5" id="Fact-4EE181E448EE2F8EB37CAE73D88E45B6" unitRef="usd">12600000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-BBF0E878D35A5EB597712E44E836017D" unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-86DD4D42B898C4F69D072E44CECB21AE" unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-A6CB4E48F5CEEF08628BAE73D8E13F4C" unitRef="usd">634600000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-38841A6ADC68CDBAC6FC2E44B225F3C0" unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-2CCA9208E41B49B1582F2E449304958F" unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2015Q3_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember" decimals="-5" id="Fact-590AB115261AACCC9A44AE73D91C6939" unitRef="usd">9500000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2015Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-7685AEEBAE6DCF2972632E3DE013B435" unitRef="usd">1766900000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2015Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-B9858C0A03C47B72A8A82E3DCA663896" unitRef="usd">1767100000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2015Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-3701329C78C944246BBCAE73D9171BD2" unitRef="usd">614000000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2015Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-98FD657DB2AC71F72C4B2E3DB86182FC" unitRef="usd">1008400000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2015Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-15B4A2BBF295B78BB7C42E3DA5FE8604" unitRef="usd">1514100000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NumberOfReportableSegments contextRef="FD2015Q3YTD" decimals="0" id="Fact-344F36BD342F572BA232AE73D8C83B00" unitRef="segment">1</us-gaap:NumberOfReportableSegments>
	<us-gaap:OperatingIncomeLoss contextRef="FD2014Q3QTD" decimals="-3" id="Fact-17D353D45CBD8996CDBEAE73D83D976B" unitRef="usd">1152578000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2014Q3YTD" decimals="-3" id="Fact-EA7CEF4A598F03E7F4C8AE73D83394BF" unitRef="usd">2812651000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q3QTD" decimals="-3" id="Fact-E3C7A9C2E7032305AB0AAE73D927211E" unitRef="usd">1371832000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q3YTD" decimals="-3" id="Fact-2662F978F07BD5D23898AE73D923DD82" unitRef="usd">3722803000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2014Q4" decimals="-5" id="Fact-8F110F95063320148539AE73D83C4E55" unitRef="usd">507500000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2015Q3" decimals="-5" id="Fact-99267B96155176A101BBAE73D8466A7E" unitRef="usd">549200000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesNoncurrent contextRef="FI2014Q4" decimals="-5" id="Fact-2504EBEDD9CF0259A78DAE73D87D1443" unitRef="usd">249400000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
	<us-gaap:OtherAccruedLiabilitiesNoncurrent contextRef="FI2015Q3" decimals="-5" id="Fact-A29424F5FC3F2626F667AE73D88187A9" unitRef="usd">341100000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
	<us-gaap:OtherAssetsCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-8B308B13A7A9271156EEAE73D85686E0" unitRef="usd">446943000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="FI2015Q3" decimals="-3" id="Fact-1A8335C0A6F0D646AB40AE73D8287EF5" unitRef="usd">861882000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2014Q4" decimals="-3" id="Fact-28FA324186E02D5E9AA6AE73D8DD9ACE" unitRef="usd">617536000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2015Q3" decimals="-3" id="Fact-45B75669CE821ECE4E7EAE73D8882F79" unitRef="usd">892221000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2014Q3QTD" decimals="-3" id="Fact-3C7FF678410392CD15CAAE73D8E0FDCF" unitRef="usd">12000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2014Q3YTD" decimals="-3" id="Fact-723FF358B4E160991871AE73D8D4A282" unitRef="usd">-5127000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2015Q3QTD" decimals="-3" id="Fact-DCEF0C06E4BC8BEC9C32AE73D8387BBC" unitRef="usd">-2239000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2015Q3YTD" decimals="-3" id="Fact-1E47C9FAA0314805A67EAE73D8AD59FD" unitRef="usd">-1154000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax contextRef="FD2014Q3QTD" decimals="-3" id="Fact-C356B3495F7445EAA427AE73D84D70DB" unitRef="usd">-6000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax contextRef="FD2014Q3YTD" decimals="-3" id="Fact-51324EC87CE6F9B6D229AE73D84FE60A" unitRef="usd">-3021000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax contextRef="FD2015Q3QTD" decimals="-3" id="Fact-FBD8B66330659C079510AE73D855F2CF" unitRef="usd">-1320000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax contextRef="FD2015Q3YTD" decimals="-3" id="Fact-9E95566971093B9155B7AE73D851945E" unitRef="usd">-699000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2014Q3YTD" decimals="-5" id="Fact-E7A40A205661C9CCC0F4AE73D913858C" unitRef="usd">-11000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2014Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-2C3666F327FE39A0BBCAAE73D8583D16" unitRef="usd">1300000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2014Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-EC4BBD794834AD0C965CAE73D8EEBCD4" unitRef="usd">57500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2014Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-CABF34A1553AB9433CA5AE73D82BF30A" unitRef="usd">1400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2014Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-35B4AA7A2FC05E289DCFAE73D9108127" unitRef="usd">-71200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2015Q3YTD" decimals="-5" id="Fact-C3EB05F083C65BD73DDBAE73D85E2A0C" unitRef="usd">19700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2015Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_biib_InterestratelocksMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-03835E7E931B7A31648571A6213F7DEB" unitRef="usd">8500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-83513C491C716547E246AE73D89069BD" unitRef="usd">4600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-CA96868F3A9A565B7BC3AE73D85B22FE" unitRef="usd">78600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-812EEB63E4F25BA4E6A8AE73D89F272E" unitRef="usd">-2200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-3D382EC50A2CBD7C97D7AE73D88CC525" unitRef="usd">-61300000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax contextRef="FD2014Q3QTD" decimals="-3" id="Fact-7874F81386250FABBC94AE73D8B4C90B" unitRef="usd">48242000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax contextRef="FD2014Q3YTD" decimals="-3" id="Fact-8F37C085713AED1C8C3DAE73D8DB4804" unitRef="usd">64793000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax contextRef="FD2015Q3QTD" decimals="-3" id="Fact-34DCF4FFF1D26D2650A4AE73D8D514B6" unitRef="usd">-31171000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax contextRef="FD2015Q3YTD" decimals="-3" id="Fact-A7B3F5AB280F13E59072AE73D90A126D" unitRef="usd">-40084000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax contextRef="FD2014Q3QTD" decimals="-3" id="Fact-C0F12A8D1AF28F176129AE73D850917E" unitRef="usd">302000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax contextRef="FD2014Q3YTD" decimals="-3" id="Fact-CC350260E1882E151832AE73D8522013" unitRef="usd">307000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax contextRef="FD2015Q3QTD" decimals="-3" id="Fact-AFA6D557D125DA721CCEAE73D8578B24" unitRef="usd">-187000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax contextRef="FD2015Q3YTD" decimals="-3" id="Fact-2D04A1EA4F6391CD2B15AE73D854D013" unitRef="usd">-229000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2014Q3QTD" decimals="-3" id="Fact-249AFA88B5F48E51C47DAE73D8A91FBD" unitRef="usd">-60254000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2014Q3YTD" decimals="-3" id="Fact-CE97EC08C94CEB340DFCAE73D8D9766A" unitRef="usd">-71246000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2015Q3QTD" decimals="-3" id="Fact-DA3811F086E6E3D93861AE73D92686B6" unitRef="usd">-23504000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2015Q3YTD" decimals="-3" id="Fact-03D180377B48D2843CCFAE73D92A3AB9" unitRef="usd">-61322000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2014Q3QTD" decimals="-3" id="Fact-45A0939CA38750A32144AE73D8A7F0F7" unitRef="usd">-11309000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2014Q3YTD" decimals="-3" id="Fact-FCC705BC15376545F13FAE73D8C46CFF" unitRef="usd">-10242000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2014Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-0A03E12A7E32813C05D4AE73D903D009" unitRef="usd">1300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2014Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-CF7974A5A66C09CE83A0AE73D919FC37" unitRef="usd">64800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2014Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-8CC2E0D4A8752523A1F3AE73D83EFB34" unitRef="usd">-5100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2014Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-F48FDEB10AE51B43D56EAE73D90BC297" unitRef="usd">-71200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2015Q3QTD" decimals="-3" id="Fact-69B8AAC84EFFB178F4FEAE73D9114CC0" unitRef="usd">-56391000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2015Q3YTD" decimals="-3" id="Fact-B8CEAFEBE0E97C77551EAE73D8322E28" unitRef="usd">-97928000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-C29E6BD5E6485986A742AE73D85C71AD" unitRef="usd">4600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-7542E0315BC488A35A4CAE73D85A72A2" unitRef="usd">-40100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-2F46A565DF68115D8879AE73D873ABFD" unitRef="usd">-1200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-8FBA19AB347C75919F8EAE73D85DEA5A" unitRef="usd">-61300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="FD2014Q3QTD" decimals="-3" id="Fact-416E1AFD76B65CDC49CCAE73D8D93A88" unitRef="usd">-691000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="FD2014Q3YTD" decimals="-3" id="Fact-1B7A7FEBC07EC8DAFC33AE73D8DBDF5F" unitRef="usd">-1338000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="FD2015Q3QTD" decimals="-3" id="Fact-F41FAD2E652634503D15AE73D92AAE54" unitRef="usd">-523000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="FD2015Q3YTD" decimals="-3" id="Fact-1065849114A8A3161B36AE73D8366F57" unitRef="usd">-4632000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-2F4660E48B56A308B829AE73D8D75350" unitRef="usd">1819334000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2015Q3" decimals="-3" id="Fact-0DAD65CE8F260BD7AC23AE73D8D1C6C2" unitRef="usd">1918897000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2014Q4" decimals="-3" id="Fact-F2500F7DE79658A5419AAE73D8C30CD2" unitRef="usd">650096000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2015Q3" decimals="-3" id="Fact-2440925617A793A769E1AE73D8D8E51B" unitRef="usd">861421000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherNoncashIncomeExpense contextRef="FD2014Q3YTD" decimals="-3" id="Fact-402924AA3E6E988A6788AE73D8D0648F" unitRef="usd">95711000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNoncashIncomeExpense contextRef="FD2015Q3YTD" decimals="-3" id="Fact-CC00D0EC1F982AF5BB24AE73D8DA334A" unitRef="usd">-31564000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2014Q3QTD" decimals="-5" id="Fact-7E20AFDCF86B0A16C758AE73D8DFF346" unitRef="usd">-4600000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2014Q3YTD" decimals="-5" id="Fact-5EA61B8251F8CCFA7B6FAE73D85CB8E0" unitRef="usd">-7600000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2015Q3QTD" decimals="-5" id="Fact-5EA8E29701FB0C83908FAE73D8E20BE2" unitRef="usd">-2000000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2015Q3YTD" decimals="-5" id="Fact-4A42D9AC830B9434F5FFAE73D85A7B86" unitRef="usd">-7100000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2014Q3QTD" decimals="-3" id="Fact-F1934F1B24BFE214A1BBAE73D82EB7F8" unitRef="usd">103402000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2014Q3QTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-3148C6504FAE07B6ACAAAE73D8890911" unitRef="usd">21300000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2014Q3YTD" decimals="-3" id="Fact-39C9C4A33587CE1CBCDFAE73D83EE518" unitRef="usd">255367000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2014Q3YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-FEA5CDD34FD4AA76CA30AE73D884656A" unitRef="usd">57800000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q3QTD" decimals="-3" id="Fact-F3B8F2A6F4B03011C043AE73D8CBEDF1" unitRef="usd">48961000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q3QTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-4E7C2FC64F8C44E081CDAE73D8887272" unitRef="usd">10900000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q3YTD" decimals="-3" id="Fact-E391C78DC63E2D491505AE73D9208206" unitRef="usd">156557000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q3YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-ED12E3D0902F65D76211AE73D8A67DDC" unitRef="usd">47000000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="FD2014Q3YTD" decimals="-3" id="Fact-7882CD4A2039F0F6767DAE73D8CACCC9" unitRef="usd">13131000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
	<us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="FD2015Q3YTD" decimals="-3" id="Fact-76911B5460BAF47910DBAE73D8DA54FB" unitRef="usd">33620000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2014Q3YTD" decimals="-3" id="Fact-8410D1A10FBE5C88BF21AE73D8CD763B" unitRef="usd">359981000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2015Q3YTD" decimals="-3" id="Fact-7A139DB2C5E2A3A8E1D4AE73D8B935CB" unitRef="usd">2998190000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="FD2014Q3YTD" decimals="-3" id="Fact-F187358C77BF78C01A43AE73D8BD1A74" unitRef="usd">2738584000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="FD2015Q3YTD" decimals="-3" id="Fact-DAA380B1718425A4EA2FAE73D8DC07D5" unitRef="usd">4870142000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
	<us-gaap:PaymentsToAcquireBusinessesGross contextRef="D2006Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-5" id="Fact-90D57F85F1587D4EFE41AE73D844EBA7" unitRef="usd">220000000</us-gaap:PaymentsToAcquireBusinessesGross>
	<us-gaap:PaymentsToAcquireBusinessesGross contextRef="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-EBFF25B640BED91D3865AE73D8BAEF67" unitRef="usd">200100000</us-gaap:PaymentsToAcquireBusinessesGross>
	<us-gaap:PaymentsToAcquireBusinessesGross contextRef="FD2015Q3YTD_biib_CumulativeSalesLevelAxis_biib_FourbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-5" id="Fact-7CFD66233CFA06FA8F24AE73D856D82F" unitRef="usd">550000000</us-gaap:PaymentsToAcquireBusinessesGross>
	<us-gaap:PaymentsToAcquireBusinessesGross contextRef="FD2015Q3YTD_biib_CumulativeSalesLevelAxis_biib_SixbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-5" id="Fact-6F24198017F01743D697AE73D851AB05" unitRef="usd">300000000</us-gaap:PaymentsToAcquireBusinessesGross>
	<us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="FD2014Q3YTD" decimals="-3" id="Fact-58BC868689D62B046A33AE73D8C703B4" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
	<us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="FD2015Q3YTD" decimals="-3" id="Fact-7DC7C191BFBDEF33A7D6AE73D8C4A11D" unitRef="usd">198798000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
	<us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="FD2015Q1QTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-6F9A1BD7802735FD9EAEAE73D85E4311" unitRef="usd">5700000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
	<us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="FD2015Q1QTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-8" id="Fact-4D08AADCE8FB5D4090FFAE73D893C9A5" unitRef="KRW">6300000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
	<us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="FD2014Q3YTD" decimals="-3" id="Fact-AA8AC6BDFC268FE11B1AAE73D85690B0" unitRef="usd">175000000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
	<us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="FD2015Q3YTD" decimals="-3" id="Fact-490C1C70A7909B69D830AE73D8C68F7F" unitRef="usd">550000000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2014Q3YTD" decimals="-3" id="Fact-2493B096B4DE587677B2AE73D8CD98F2" unitRef="usd">180854000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2015Q3YTD" decimals="-3" id="Fact-9E06FAA45F567FBC1ACCAE73D8D06D72" unitRef="usd">456885000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2014Q4" decimals="INF" id="Fact-EC0D7C2E91A5AEBB0021AE73D897BF90" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2015Q3" decimals="INF" id="Fact-3B69ADD118A12DCEFD4DAE73D916BC87" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockValue contextRef="FI2014Q4" decimals="-3" id="Fact-72B95E3DC63CA4AC8602AE73D828B81F" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2015Q3" decimals="-3" id="Fact-0FC252D74C38D5005BA1AE73D92974FD" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidExpenseAndOtherAssets contextRef="FI2015Q3_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-65E8AA5ED3EFD1C14BE73F45D71AE240" unitRef="usd">58400000</us-gaap:PrepaidExpenseAndOtherAssets>
	<us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="FD2014Q3YTD" decimals="-3" id="Fact-D49A3B25C97C777D8B83AE73D8CFEBAB" unitRef="usd">44960000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
	<us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="FD2015Q3YTD" decimals="-3" id="Fact-DF3C983F9FCCFAD9F865AE73D84C9662" unitRef="usd">45509000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
	<us-gaap:ProceedsFromNotesPayable contextRef="FD2014Q3YTD" decimals="-3" id="Fact-AF59BAEA7972E88E4CCE2E24ED2B6AE7" unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
	<us-gaap:ProceedsFromNotesPayable contextRef="FD2015Q3YTD" decimals="-3" id="Fact-65306AF51F6C2F9D55092E24ED398F1F" unitRef="usd">5930936000</us-gaap:ProceedsFromNotesPayable>
	<us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="FD2014Q3YTD" decimals="-3" id="Fact-F9510FB5DF6EBE278825AE73D8A776C1" unitRef="usd">-15336000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
	<us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="FD2015Q3YTD" decimals="-3" id="Fact-6414104BF18337B0385EAE73D8CB7699" unitRef="usd">-62147000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2014Q3QTD" decimals="-5" id="Fact-944564710FCAE661C88EAE73D9233514" unitRef="usd">625400000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2014Q3YTD" decimals="-3" id="Fact-A8E45CBBA6DA694EA1EDAE73D8DB7CCB" unitRef="usd">1942871000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2015Q3QTD" decimals="-5" id="Fact-7FDE57AAD20CD707693DAE73D91FB048" unitRef="usd">2387900000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2015Q3YTD" decimals="-3" id="Fact-86517DF09632F8EF9D6CAE73D8C03B37" unitRef="usd">3363374000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProfitLoss contextRef="FD2014Q3QTD" decimals="-3" id="Fact-1C7E264BBD82E248014DAE73D8FA834F" unitRef="usd">856120000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2014Q3YTD" decimals="-3" id="Fact-9DFDD45775D36FC92012AE73D8AE9F93" unitRef="usd">2058980000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2015Q3QTD" decimals="-3" id="Fact-39693D8225A3E23A0036AE73D91F3E7B" unitRef="usd">1019493000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2015Q3YTD" decimals="-3" id="Fact-B40CAC0162B3023C6410AE73D8E837A5" unitRef="usd">2764492000</us-gaap:ProfitLoss>
	<us-gaap:PropertyPlantAndEquipmentAdditions contextRef="FD2015Q3QTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-6C4C7A6CB1D027CB06762EA1B2200020" unitRef="usd">58600000</us-gaap:PropertyPlantAndEquipmentAdditions>
	<us-gaap:PropertyPlantAndEquipmentAdditions contextRef="FD2015Q3QTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-02F011217BBE66013CEC71B2C4289066" unitRef="usd">20300000</us-gaap:PropertyPlantAndEquipmentAdditions>
	<us-gaap:PropertyPlantAndEquipmentAdditions contextRef="FD2015Q3QTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-33C048880DBB0A53E1BD2EA3A6A1C49E" unitRef="usd">25900000</us-gaap:PropertyPlantAndEquipmentAdditions>
	<us-gaap:PropertyPlantAndEquipmentAdditions contextRef="FD2015Q3QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-21A7F0CE56B8658E9FD871B34E27E6D7" unitRef="usd">104800000</us-gaap:PropertyPlantAndEquipmentAdditions>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2014Q4" decimals="-3" id="Fact-7981802EA47ED8F01DEEAE73D8B75B92" unitRef="usd">1765683000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2015Q3" decimals="-3" id="Fact-F09B431C11CF7741BC8BAE73D8DDC491" unitRef="usd">2027821000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2014Q3YTD" decimals="-5" id="Fact-E24CE53A2C7854709627AE73D91DA001" unitRef="usd">800000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2014Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-9AF117346B87158DA68AAE73D90640AB" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2014Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-0070A907CAC778C5811EAE73D858D38A" unitRef="usd">7300000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2014Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-70A9C4C8F3ED41CC0CCAAE73D834E914" unitRef="usd">-6500000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2014Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-460FCF42B480A905750AAE73D911C087" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2015Q3YTD" decimals="-5" id="Fact-5A6117E69C37770391BBAE73D89EA9D4" unitRef="usd">-117700000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-82E88DF754556540BEF7AE73D8A3488A" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-0E9978CDE1DA5C5C1D48AE73D896591E" unitRef="usd">-118700000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-6A5C19D31A1B21F0D18BAE73D8C88293" unitRef="usd">1000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-9F46F250E0D2F158FAEDAE73D8550FC2" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:RepaymentsOfNotesPayable contextRef="FD2014Q3YTD" decimals="-3" id="Fact-03D53A8924045637A5712E26F069F1E1" unitRef="usd">2674000</us-gaap:RepaymentsOfNotesPayable>
	<us-gaap:RepaymentsOfNotesPayable contextRef="FD2015Q3YTD" decimals="-3" id="Fact-374DCDAD5A55143389D22E26F066CF24" unitRef="usd">2083000</us-gaap:RepaymentsOfNotesPayable>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2013Q4QTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-AB9F9E32C5A293E04924AE73D88F1EEE" unitRef="usd">46000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2014Q3QTD" decimals="-3" id="Fact-039540CEE0DB8F63B6A5AE73D820DCB4" unitRef="usd">417174000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2014Q3QTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" decimals="-5" id="Fact-AB0BC5F45B8EB9572A0AAE73D88F24A9" unitRef="usd">7400000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2014Q3YTD" decimals="-3" id="Fact-4B0E21C7E9CDC22A9AD2AE73D905252E" unitRef="usd">1393331000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2014Q3YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" decimals="-5" id="Fact-EC5759F1E406480CAD26AE73D881DA72" unitRef="usd">29100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q3QTD" decimals="-3" id="Fact-E6289C8A85D1BB0081CFAE73D85B4A20" unitRef="usd">519863000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q3QTD_us-gaap_ProductOrServiceAxis_biib_LeadprogramsMember_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-A6A3B8C68094DFF6EBCF439F7BC2C420" unitRef="usd">5000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q3QTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-2C583D17702A40C76DAE439C5886FBA5" unitRef="usd">56800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q3QTD_us-gaap_TypeOfArrangementAxis_biib_MitsubishiTanabePharmaCorporationMember" decimals="-5" id="Fact-48C8AD78479BC2A5AA893F3DDC2CCAAF" unitRef="usd">60000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q3QTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" decimals="-5" id="Fact-912FE8A4F1B09323C9E9AE73D87F169C" unitRef="usd">39700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q3YTD" decimals="-3" id="Fact-16E3E5627EC36FCA4FDFAE73D8FC6272" unitRef="usd">1471140000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q3YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" decimals="-5" id="Fact-A1A371B75030E084B872AE73D886DEF8" unitRef="usd">87500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="I2015Q3Restructuring_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-6" id="Fact-90F16DA285A459703D9B8AB62B29CAC1" unitRef="usd">95000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
	<us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="I2015Q3Restructuring_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-6" id="Fact-3334C5A243DFFC68BEE58AB68D5C83A9" unitRef="usd">85000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2014Q4" decimals="-3" id="Fact-C593EB2F21A23CC71B9AAE73D83C4FBD" unitRef="usd">9283919000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2015Q3" decimals="-3" id="Fact-EAA54BB3FBCED53ACBCCAE73D8D49061" unitRef="usd">11999358000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:Revenues contextRef="FD2014Q3QTD" decimals="-3" id="Fact-140565E4DCC07887DB53AE73D8FB6D31" unitRef="usd">2511446000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2014Q3YTD" decimals="-3" id="Fact-7B5CD37C2892D56CC8AFAE73D85521DE" unitRef="usd">7062649000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2015Q3QTD" decimals="-3" id="Fact-C02118D6AA54769AB3D5AE73D859538A" unitRef="usd">2777859000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2015Q3YTD" decimals="-3" id="Fact-FC294489EA6C9DE7E430AE73D853BABE" unitRef="usd">7924464000</us-gaap:Revenues>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q2QTD_us-gaap_StatementGeographicalAxis_country_IT" decimals="-5" id="Fact-78748D5F1102AEA18B67AE73D8228B49" unitRef="usd">53500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q3QTD" decimals="-3" id="Fact-AFC240E6EEF2DF951D34AE73D920F64C" unitRef="usd">2117366000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-AE29E257FC3E499CB2D9AE73D8A14E62" unitRef="usd">2900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q3YTD" decimals="-3" id="Fact-EFC4033889BF45A778FEAE73D8D1C507" unitRef="usd">5916423000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-AA492253F35F20CFE796AE73D865F1EF" unitRef="usd">7100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q3QTD" decimals="-3" id="Fact-FE43E4B5E029853A68FAAE73D8F2973A" unitRef="usd">2391717000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-FF76BDD18615102DB144AE73D86AF9D3" unitRef="usd">43900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q3YTD" decimals="-3" id="Fact-2B44266EA0A5E17DD592AE73D82C4011" unitRef="usd">6762605000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-12F64B96046D0521997FAE73D859C7B9" unitRef="usd">119300000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2014Q3QTD" decimals="-3" id="Fact-D06E76EA1DDF9287F186AE73D8FF8EB8" unitRef="usd">570436000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2014Q3YTD" decimals="-3" id="Fact-21801389F07F7D5B4522AE73D8A7FE4E" unitRef="usd">1658732000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2015Q3QTD" decimals="-3" id="Fact-515BD72CB505A3AADF35AE73D8353D80" unitRef="usd">477827000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2015Q3YTD" decimals="-3" id="Fact-AED8A84F1754189E90C9AE73D8EDAEDA" unitRef="usd">1530083000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:ShareBasedCompensation contextRef="FD2014Q3YTD" decimals="-3" id="Fact-564F99B94639F18971CEAE73D8A8F9CF" unitRef="usd">119508000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2015Q3YTD" decimals="-3" id="Fact-30BE941A2FAA393FE600AE73D8D59D54" unitRef="usd">131537000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2014Q3YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember" decimals="0" id="Fact-0A47407C7805649B33C1AE73D87E0847" unitRef="shares">182000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2014Q3YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember" decimals="0" id="Fact-A8573CAC80D72AD27B4DAE73D84F252C" unitRef="shares">236000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2014Q3YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="0" id="Fact-1AD8AB6966768B523BBCAE73D874F244" unitRef="shares">437000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2014Q3YTD_us-gaap_PlanNameAxis_us-gaap_PerformanceSharesMember" decimals="0" id="Fact-DDFCF290E5E0DA8A9EC9AE73D88A8034" unitRef="shares">57000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2015Q3YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember" decimals="0" id="Fact-FFFA555E99E7C10E5D7DAE73D84BF988" unitRef="shares">115000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2015Q3YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember" decimals="0" id="Fact-A7C656FAC570E7B6F50CAE73D889213E" unitRef="shares">181000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2015Q3YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="0" id="Fact-9ADCE131E60F49B75B69AE73D8C154E3" unitRef="shares">393000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2015Q3YTD_us-gaap_PlanNameAxis_us-gaap_PerformanceSharesMember" decimals="0" id="Fact-061AB3A0843E01E95E43AE73D84B74AF" unitRef="shares">89000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2014Q3YTD_us-gaap_PlanNameAxis_biib_A1995ESPPMember" decimals="INF" id="Fact-8A59EAB40841A08098DCAE73D8AD7418" unitRef="shares">150000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2015Q3YTD_us-gaap_PlanNameAxis_biib_A1995ESPPMember" decimals="INF" id="Fact-A97BD70FF18BDB3B6F1BAE73D8968B1F" unitRef="shares">98000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2015Q3YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember" decimals="INF" id="Fact-815440213D1ED316D1373EF39DB3AD1A" unitRef="shares">43000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="FI2015Q3" decimals="-8" id="Fact-F54E084EE9BFB9E41A2CAE73D915D15A" unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
	<us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased contextRef="FI2015Q3" decimals="-5" id="Fact-59B6FC716F4AF457888AAE73D8596711" unitRef="shares">1300000</us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4" decimals="-3" id="Fact-95D171D84965E7075AB0AE73D83C8FE0" unitRef="usd">10809010000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q3" decimals="-3" id="Fact-F371C489F21270E823B1AE73D8E06B1D" unitRef="usd">10572726000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4" decimals="-3" id="Fact-C115B2B7985AD9DA53D7AE73D8BB6BD0" unitRef="usd">10814040000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q3" decimals="-3" id="Fact-6E87F5A9E30EA0B7FCD3AE73D846551D" unitRef="usd">10566943000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityPeriodIncreaseDecrease contextRef="FD2015Q3YTD" decimals="-5" id="Fact-FE639D5B6D2D60E87BF1AE73D850CAAA" unitRef="usd">247100000</us-gaap:StockholdersEquityPeriodIncreaseDecrease>
	<us-gaap:TaxesPayableCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-7AF0D1A2E07DFF96FE19AE73D8D37A70" unitRef="usd">168058000</us-gaap:TaxesPayableCurrent>
	<us-gaap:TaxesPayableCurrent contextRef="FI2015Q3" decimals="-3" id="Fact-C91CBB58D4A17C2F0D62AE73D842C0D1" unitRef="usd">458672000</us-gaap:TaxesPayableCurrent>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2014Q3YTD" decimals="-5" id="Fact-A767B8A984879C5A07A8AE73D869B2CE" unitRef="shares">1200000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2015Q3YTD" decimals="-5" id="Fact-5979FF4D64E6CDDA3777AE73D85D29F5" unitRef="shares">9700000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockValue contextRef="FI2014Q4" decimals="-3" id="Fact-A81837F88B2F1BDE4ECAAE73D83465EB" unitRef="usd">2611706000</us-gaap:TreasuryStockValue>
	<us-gaap:TreasuryStockValue contextRef="FI2015Q3" decimals="-3" id="Fact-4E84ECD5B3376721F70CAE73D82B20B0" unitRef="usd">2611713000</us-gaap:TreasuryStockValue>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2015Q3" decimals="-5" id="Fact-D49802A097E0A9B74708AE73D8ADBE34" unitRef="usd">24000000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2014Q4" decimals="-5" id="Fact-9106F718683C7CF39F04AE73D833B175" unitRef="usd">483800000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2014Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" decimals="-5" id="Fact-82338E96089C550A0164AE73D83184B8" unitRef="usd">124600000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2014Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" decimals="-5" id="Fact-BB86960148A01BFDB3F4AE73D830D549" unitRef="usd">359200000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2014Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-4FEF636C119AF2C7CA71AE73D85D8EE1" unitRef="usd">387100000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2014Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-CF722EFB720AA108C362AE73D8ED69BA" unitRef="usd">47600000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2014Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-8CC8CF75567402659148AE73D8667778" unitRef="usd">49100000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q3" decimals="-5" id="Fact-EEB3094D5B8B7DAF9BBAAE73D82F6F39" unitRef="usd">610700000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" decimals="-5" id="Fact-37D0F95CD17609FD4836AE73D8309027" unitRef="usd">148000000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" decimals="-5" id="Fact-71788572643C16154F3FAE73D83535A3" unitRef="usd">462700000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-10DE59B8F2383A8971B7AE73D82978FA" unitRef="usd">500800000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-CA8C267CD47E1B58ED35AE73D8972B9F" unitRef="usd">59700000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-FD179A322B2FEC31F583AE73D8DE57DD" unitRef="usd">50200000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2014Q3QTD" decimals="-5" id="Fact-B739E8A4F2B78518C173AE73D8EAAADB" unitRef="shares">800000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2014Q3YTD" decimals="-5" id="Fact-9657485EEC68A556DED1AE73D8D2AF7A" unitRef="shares">800000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2015Q3QTD" decimals="-5" id="Fact-550600E82C488EEA237DAE73D8B3DFF8" unitRef="shares">400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2015Q3YTD" decimals="-5" id="Fact-4D5590A7379EC18CE71CAE73D8A92FA4" unitRef="shares">600000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2014Q3QTD" decimals="-3" id="Fact-0070CC658A5992C79E00AE73D90CDE99" unitRef="shares">236972000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2014Q3YTD" decimals="-3" id="Fact-29C5887F12F428A8A3BFAE73D8A57120" unitRef="shares">237449000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2015Q3QTD" decimals="-3" id="Fact-24546B4FE64735DF3E79AE73D83FBCA7" unitRef="shares">232612000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2015Q3YTD" decimals="-3" id="Fact-42A368F7A9B5D4AF050FAE73D84855C2" unitRef="shares">234659000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2014Q3QTD" decimals="-3" id="Fact-60EB64FDF3052F366B73AE73D8A706CC" unitRef="shares">236217000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2014Q3YTD" decimals="-3" id="Fact-3E4D30D7FF98CD811FC1AE73D90C6D7E" unitRef="shares">236641000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2015Q3QTD" decimals="-3" id="Fact-92D301BB1F16AE199A22AE73D82BE44E" unitRef="shares">232191000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2015Q3YTD" decimals="-3" id="Fact-EF95C4E8094874166AB9AE73D8FF15BB" unitRef="shares">234134000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock contextRef="FD2015Q3YTD" id="Fact-8DBE50463C88E93AC51BAE73D87D1E4F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;47.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;387.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;49.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;483.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;332.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,278.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;26.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,636.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(20.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(14.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(37.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(277.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(871.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1,151.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(40.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(271.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(8.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(321.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of September 30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;59.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;500.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;50.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;610.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock>
	<biib:BusinessOverviewPolicyTextBlock contextRef="FD2015Q3YTD" id="Fact-98AE6DDBFFF5A875FC9EAE73D8CC566D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS), ALPROLIX for the treatment of hemophilia B, ELOCTATE for the treatment of hemophilia A and FUMADERM for the treatment of severe plaque psoriasis. We also generate revenue from our collaboration with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin&amp;#8217;s lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, and share profits and losses with Genentech for GAZYVA, which is approved for the treatment of CLL.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</biib:BusinessOverviewPolicyTextBlock>
	<biib:IntangibleAssetsExcludingGoodwillTableTextBlock contextRef="FD2015Q3YTD" id="Fact-B0E0CA978BA1EE101C2FAE73D884A670">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="21%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="17%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="7%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="7%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="7%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="7%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of September 30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Out-licensed patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13-23 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(499.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;43.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(481.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;61.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;technology&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15-23&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2,523.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;481.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2,396.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;608.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite until commercialization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;735.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;735.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;314.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;314.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Trademarks&amp;#160;and&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;tradenames&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed&amp;#160;rights&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;and&amp;#160;patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3-17 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,297.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(440.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,856.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,280.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(300.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,980.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7,645.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(3,464.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4,181.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,207.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3,178.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,028.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:IntangibleAssetsExcludingGoodwillTableTextBlock>
	<biib:PropertyplantandequipmentpurchasepriceallocationTableTextBlock contextRef="FD2015Q3YTD" id="Fact-10BF1632E57ED330923771AF3F19C1A2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The purchase price consisted of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="87%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Buildings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;58.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Machinery and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;25.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Land&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;20.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total purchase price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;104.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:PropertyplantandequipmentpurchasepriceallocationTableTextBlock>
	<biib:ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock contextRef="FD2015Q3YTD" id="Fact-B8359697B1E6076C2B25AE73D8556E99">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table reconciles equity attributable to noncontrolling interests (NCI):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;NCI, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income (loss) attributable to NCI, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;53.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;49.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value of net assets and liabilities acquired and assigned to NCI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Distribution to NCI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(60.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(60.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Translation adjustment and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;NCI, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(5.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(5.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock>
	<biib:ScheduleOfRestrictedStockUnitGrantsTableTextBlock contextRef="FD2015Q3YTD" id="Fact-A02C09F2ECD730AFBC2BAE73D89F7567">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our equity grants to employees, officers and directors under our current stock plans:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="73%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;181,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;236,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash settled performance shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;115,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;182,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;89,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;57,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;393,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;437,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:ScheduleOfRestrictedStockUnitGrantsTableTextBlock>
	<biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock contextRef="FD2015Q3YTD" id="Fact-5C3925F1307CCCD95C40AE73D87CDFED">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total reserves above, included in our condensed consolidated balance sheets, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="73%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reduction of accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;148.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;124.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Component of accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;462.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;359.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reserves&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;610.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;483.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock>
	<us-gaap:AdditionalFinancialInformationDisclosureTextBlock contextRef="FD2015Q3YTD" id="Fact-46F6D5EA2C44E72FA80CAE73D84EC8D4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Other Consolidated Financial Statement Detail&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Income (Expense), Net&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Components of other income (expense), net, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;13.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(15.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(7.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(28.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(22.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign exchange gains (losses), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(4.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(18.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(7.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(7.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(15.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(16.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(41.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(17.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accrued Expenses and Other&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other consists of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="73%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;479.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;265.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue-related rebates&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;462.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;359.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee compensation and benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;214.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;393.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalties and licensing fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;154.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;172.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;58.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;120.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;549.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;507.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,918.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,819.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Long-Term Liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities consist of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="73%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;301.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;200.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee compensation and benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;218.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;200.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;341.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;249.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;861.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;650.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Pricing of TYSABRI in Italy - AIFA&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the fourth quarter of 2011, Biogen Italia SRL (formerly Biogen Idec Italia SRL), our Italian subsidiary,&amp;#160;received notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) that sales of TYSABRI after mid-February 2009 exceeded a reimbursement limit established pursuant to a Price Determination Resolution granted by AIFA in December 2006. In December 2011, we filed an appeal against AIFA in administrative court in Rome, Italy seeking a ruling that the reimbursement limit is unenforceable. That appeal is pending. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2014, AIFA eliminated the reimbursement limit from February 2013 going forward. As a result, in June 2014, we recognized &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$53.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of TYSABRI revenues related to the periods beginning February 2013 that were previously deferred. AIFA and Biogen Italia SRL continue to discuss a possible resolution for the period between February 2009 and January 2013. We have approximately EUR&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;75 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; recorded as accrued expenses and deferred revenue in our long-term liabilities in our condensed consolidated balance sheets for this matter.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information relating to our agreement with AIFA relating to sales of TYSABRI in Italy, please read Note 4, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Accounts Receivable&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
	<us-gaap:AvailableForSaleSecuritiesTextBlock contextRef="FD2015Q3YTD" id="Fact-4C79DD5A9D8FD6D436A1AE73D9160A46">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize our marketable debt and equity securities, classified as available-for-sale:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of September 30, 2015 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;272.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;272.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;767.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;768.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,481.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,480.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;929.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;929.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;249.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;250.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,700.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,700.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;25.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;28.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2014 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;370.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;370.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;692.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;693.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;269.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;270.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;579.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;580.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;198.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;198.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,111.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,112.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2015Q3YTD" id="Fact-99F4E9D8B82EF13E321FAE73D8BFE001">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&amp;#160;GAAP). The information included in this quarterly report on Form&amp;#160;10-Q should be read in conjunction with our consolidated financial statements and the accompanying notes included in our Annual Report on Form&amp;#160;10-K for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&amp;#160;10-K). Our accounting policies are described in the &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Notes to Consolidated Financial Statements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8221; in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&amp;#160;10-K and updated, as necessary, in this Form&amp;#160;10-Q. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&amp;#160;GAAP. The results of operations for the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="FD2015Q3YTD" id="Fact-E08756ECE5CF8C9E9124AE73D91021A3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Marketable Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize our marketable debt and equity securities, classified as available-for-sale:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of September 30, 2015 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;272.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;272.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;767.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;768.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,481.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,480.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;929.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;929.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;249.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;250.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,700.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,700.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;25.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;28.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2014 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;370.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;370.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;692.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;693.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;269.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;270.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;579.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;580.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;198.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;198.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,111.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,112.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our financial assets with maturities of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;less than 90&amp;#160;days&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; from the date of purchase included in cash and cash equivalents on the accompanying condensed consolidated balance sheet:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="73%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;21.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;54.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Overnight reverse repurchase agreements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;188.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;305.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,119.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;321.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Short-term debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;475.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,804.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;716.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and our short-term debt securities approximate fair value due to their short term maturities. Our overnight reverse repurchase agreements are collateralized with agency-guaranteed mortgage securities and represent approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.9%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.1%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of total assets as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Summary of Contractual Maturities: Available-for-Sale Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The estimated fair value and amortized cost of our marketable debt securities classified as available-for-sale by contractual maturity are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of September 30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due in one year or less&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,753.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,753.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;640.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;640.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,820.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,820.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,343.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,345.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;127.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;127.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;126.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;126.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total available-for-sale securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,700.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,700.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,111.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,112.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The average maturity of our marketable debt securities available-for-sale as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Proceeds from Marketable Debt Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Proceeds from maturities and sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,387.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;625.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,363.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,942.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Strategic Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our strategic investment portfolio was comprised of investments totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$68.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$47.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, which are included in investments and other assets in our accompanying condensed consolidated balance sheets. Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies and investments in venture capital funds where the underlying investments are in equity securities of biotechnology companies.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
	<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="FD2015Q3YTD" id="Fact-963939DCD59E6CF52E68AE73D887C745">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Mitsubishi Tanabe Pharma Corporation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On September 9, 2015, we announced an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) to exclusively license MT-1303, a late stage experimental medicine with potential in multiple autoimmune indications. MT-1303 is an oral compound that targets the sphingosine 1-phosphate (S1P) receptor. Under the terms of the agreement, we will receive worldwide rights to MT-1303, excluding Asia. We will be responsible for global commercialization and development costs except for costs related to the Asian territories, which are the responsibility of MTPC. The transaction is subject to customary closing conditions, including the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the United States, and is expected to close in the fourth quarter of 2015.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon closing, we will pay MTPC an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and in the future may pay up to approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$484.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in milestone payments for multiple indications and territories, along with average royalties in the mid-teen to high-teen percentages of annual net sales. We will record the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upfront payment as research and development expense in our condensed consolidated statements of income when the agreement closes. MTPC has the right to participate in our global clinical trials related to MT-1303 and has an option to co-promote non-MS indications in the U.S. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Applied Genetic Technologies Corporation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On July 2, 2015, we announced a collaboration and license agreement to develop gene-based therapies for multiple ophthalmic diseases with Applied Genetic Technologies Corporation (AGTC). The collaboration will focus on the development of a portfolio of AGTC&amp;#8217;s therapeutic programs, including both a clinical stage candidate for X-linked Retinoschisis (XLRS) and a pre-clinical candidate for the treatment of X-Linked Retinitis Pigmentosa (XLRP). The agreement also includes options for early stage discovery programs in two ophthalmic diseases and one non-ophthalmic condition, as well as an equity investment in AGTC.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the third quarter of 2015, the collaboration became effective and we made an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$124.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which included a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$30.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; equity investment in AGTC, prepaid research and development expenditures of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$58.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and total licensing and other fees of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$35.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$58.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of prepaid research and development expenditures were recorded in investments and other assets in our condensed consolidated balance sheets and will be expensed as the services are provided. During the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recorded &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$56.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as research and development expense associated with AGTC in our condensed consolidated statements of income, including the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$35.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; total licensing and other fees, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$8.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in research and development services, a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$7.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; premium on our equity investment and a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; clinical development milestones related to XLRS. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;AGTC is eligible to receive milestone payments aggregating in excess of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which includes up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$472.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; collectively for the two lead programs and up to up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$592.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; across the discovery programs. AGTC is also eligible to receive royalties in the mid-single digit to mid-teen percentages of annual net sales. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We were granted worldwide commercialization rights for the XLRS and XLRP programs. AGTC has an option to share development costs and profits after the initial clinical trial data are available, and an option to co-promote the second of these products to be approved in the U.S. AGTC will lead the clinical development programs of XLRS through product approval and of XLRP through the completion of first-in-human trials. We will support the clinical development costs, subject to certain conditions, following the first-in-human study for XLRS and IND-enabling studies for XLRP. Under the manufacturing license, we have received an exclusive license to use AGTC&amp;#8217;s proprietary technology platform to make AAV vectors for up to six genes, three of which are in AGTC&amp;#8217;s discretion, in exchange for payment of milestones and royalties.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Swedish Orphan Biovitrum AB&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On July 16, 2015, Swedish Orphan Biovitrum AB (Sobi) exercised its option to assume development and commercialization of ALPROLIX in Europe, Russia, Turkey and certain markets in the Middle East and paid us &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which will be held in escrow pending E.U. regulatory approval.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We collaborate with Sobi to jointly develop and commercialize Factor VIII and Factor IX hemophilia products, including ELOCTATE and ALPROLIX. For more information about our agreement with Sobi, please read Note 20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Samsung Bioepis&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"&gt;Joint Venture Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2012, we entered into a joint venture agreement with Samsung BioLogics Co. Ltd. (Samsung Biologics), establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals.&amp;#160;Samsung Biologics contributed &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;280.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$250.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) for an &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;85%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; stake in Samsung Bioepis and we contributed approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$45.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) for the remaining &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; ownership interest.&amp;#160;Under the joint venture agreement, we have no obligation to provide any additional funding and our ownership interest may be diluted due to financings in which we do not participate. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our ownership interest is approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which reflects our additional contribution of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.3 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) in the first quarter of 2015 and the effect of additional equity financings in which we did not participate. We maintain an option to purchase additional stock in Samsung Bioepis that would allow us to increase our ownership percentage up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.9%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&amp;#160;The exercise of this option is within our control and is based on paying for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.9%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the total investment made by Samsung Biologics into Samsung Bioepis in excess of what we have already contributed under the agreement plus a rate that will represent their return on capital.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the carrying value of our investment in Samsung Bioepis totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.1 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$8.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets. Based on our level of influence over Samsung Bioepis, we account for this investment under the equity method of accounting and we recognize our share of the results of operations related to our investment in Samsung Bioepis one quarter in arrears when the results of the entity become available, which is reflected as equity in loss of investee, net of tax in our condensed consolidated statements of income. During the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized a loss on our investment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$6.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, as compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$14.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in the prior year comparative periods. During the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our share of losses exceeded the carrying value of our investment. We will suspend recognizing additional losses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"&gt;Commercial Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On December 17, 2013, pursuant to our rights under the joint venture agreement with Samsung Biologics, we entered into an agreement with Samsung Bioepis to commercialize anti-tumor necrosis factor (TNF) biosimilar product candidates in Europe and, in the case of one anti-TNF biosimilar candidate, Japan.&amp;#160;Under the terms of this agreement, we have paid &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$46.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which has been recorded as a research and development expense in our condensed consolidated statements of income as the programs they relate to have not achieved regulatory approval. Samsung Bioepis is eligible to receive an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$75.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional milestones related to regulatory approval of the product candidates. Upon commercialization, there will be a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; profit share with Samsung Bioepis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"&gt;Other Services&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement, a technical development services agreement and a manufacturing agreement with Samsung Bioepis. For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$47.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in other revenues in relation to these services, as compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$21.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$57.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in the prior year comparative periods. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information related to our other significant collaboration arrangements, please read Note 20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2015Q3YTD" id="Fact-CA5107ED85231DF8AE32AE73D83D6D32">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Fumapharm AG&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2006, we acquired Fumapharm AG. As part of this acquisition we acquired FUMADERM and TECFIDERA (together, Fumapharm Products). We paid &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$220.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon the closing of the transaction and agreed to pay an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; if a Fumapharm Product was approved for MS in the U.S.&amp;#160;or E.U. In the second quarter of 2013, we paid this &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; contingent payment as TECFIDERA was approved in the U.S. for MS by the U.S. Food and Drug Administration (FDA). We are also required to make additional contingent payments to former shareholders of Fumapharm AG or holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior twelve month period, as defined in the acquisition agreement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we paid &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$550.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in contingent payments as we reached the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$4.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; cumulative sales levels related to the Fumapharm Products in the fourth quarter of 2014 and second quarter of 2015, respectively, and accrued &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon reaching &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$6.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in total cumulative sales of Fumapharm Products in the third quarter of 2015.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We will owe an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; contingent payment for every additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in cumulative sales level of Fumapharm Products reached if the prior 12 months sales of the Fumapharm Products exceed &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, until such time as the cumulative sales level reaches &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, at which time no further contingent payments shall be due. These payments will be accounted for as an increase to goodwill as incurred, in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm. Any portion of the payment which is tax deductible will be recorded as a reduction to goodwill. Payments are due within 60&amp;#160;days following the end of the quarter in which the applicable cumulative sales level has been reached. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Solothurn, Switzerland Facility&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On June 30, 2015, we signed an agreement to purchase land in Solothurn, Switzerland for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;65.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Swiss Francs. The contract also includes certain environmental remediation costs. Our obligation to purchase the land is subject to customary closing conditions and a condition that no material adverse changes in our business, such as a decision to discontinue our aducanumab program, have occurred during the period.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ComprehensiveIncomeNoteTextBlock contextRef="FD2015Q3YTD" id="Fact-EF9863BF6BC0F5CE80BAAE73D8BB7CEB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="31%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;71.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(31.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(99.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(59.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;78.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(61.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;19.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(118.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(117.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(40.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(61.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(97.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of September 30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;31.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(27.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(160.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(157.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="31%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(23.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(19.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(27.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;57.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(71.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(5.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(71.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of September 30, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;41.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(18.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(61.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(38.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="24%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="21%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on securities available for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on cash flow hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;43.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;119.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(7.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reclassifications, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;42.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;117.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="FD2015Q3YTD" id="Fact-2485A72104CEEE444E1BAE73D8BE4D5B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We operate as &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; operating segment, which is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2015Q3YTD" id="Fact-A309E8C82ED52939A9F52EBC7989FC67">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Indebtedness&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;2015 Senior Notes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On September 15, 2015, we issued senior unsecured notes for an aggregate principal amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$6.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, consisting of the following:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$1.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due September 15, 2020, valued at &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;99.792%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of par;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$1.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;3.625%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due September 15, 2022, valued at &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;99.920%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of par;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$1.75 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;4.05%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due September 15, 2025, valued at &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;99.764%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of par; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$1.75 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;5.20%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due September 15,&amp;#160;2045, valued at &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;99.294%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of par.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;These notes are senior unsecured obligations and may be redeemed at our option at the greater of (1) &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the principal amount plus accrued and unpaid interest or (2) the sum of the present values of the remaining scheduled payments of interest and principal discounted to the date of redemption on a semi-annual basis at the treasury rate plus an incremental margin, plus, in either case, accrued and unpaid interest. The notes also contain a change of control provision that may require us to purchase the notes at a price equal to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;101%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the principal amount plus accrued and unpaid interest to the date of purchase under certain circumstances. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The costs associated with this offering of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$47.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; have been recorded as a reduction to the carrying amount of the debt on our condensed consolidated balance sheet. These costs will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. The discounts will be amortized as additional interest expense over the period from issuance through maturity using the effective interest rate method. Interest on the notes is payable March 15 and September 15 of each year. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additionally, in connection with this offering, we entered into interest rate swaps. The carrying value of the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes includes approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to changes in the fair value of the interest rate swaps. For additional information, please read Note 8, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivative Instruments, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Credit Facility&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2015, we entered into a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; senior unsecured revolving credit facility, under which we are permitted to draw funds for working capital and general corporate purposes for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; years. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of September 30, 2015, we had &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; outstanding borrowings and were in compliance with all covenants under this facility.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="FD2015Q3YTD" id="Fact-8B5C40FD756EB9764A99AE73D8D32158">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Derivative Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Foreign Currency Forward Contracts - Hedging Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due to the global nature of our operations, portions of our revenues are earned in currencies other than the U.S.&amp;#160;dollar. The value of revenues measured in U.S.&amp;#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign currency forward contracts in effect as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; had durations of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. These contracts have been designated as cash flow hedges and accordingly, to the extent effective, any unrealized gains or losses on these foreign currency forward contracts are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses for the effective portion of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized. To the extent ineffective, hedge transaction gains and losses are reported in other income (expense), net.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="69%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Notional Amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Foreign Currency: (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Euro&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,146.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,174.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Canadian dollar&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;17.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;56.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;British pound sterling&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;12.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;34.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Japanese yen&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;9.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;16.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Australian dollar&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;19.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total foreign currency forward contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,190.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,302.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The portion of the fair value of these foreign currency forward contracts that was included in accumulated other comprehensive income (loss) in total equity reflected gains of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$23.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$72.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. We expect all contracts to be settled over the next &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months and any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue. We consider the impact of our and our counterparties&amp;#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, credit risk did not change the fair value of our foreign currency forward contracts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments on our condensed consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="20%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="19%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Effective Portion)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized into Net Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Ineffective Portion)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;43.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="20%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="19%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Effective Portion)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized into Net Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Ineffective Portion)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;119.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(7.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Interest Rate Contracts - Hedging Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We may enter into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"&gt;Interest Rate Lock Contracts&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we entered into treasury rate locks that were designated as cash flow hedges to hedge against changes in the 10-year and 30-year U.S. treasury interest rates that could have impacted our anticipated debt offering. In connection with the issuance of our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.05%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.20%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes, as described in Note 10, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Indebtedness&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we settled the treasury rate locks and realized an &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$8.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; gain. As the hedging relationship was effective, the gain was recorded in AOCI and will be recognized in other income (expense), net over the life of the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.05%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.20%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"&gt;Interest Rate Swap Contracts&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the issuance of our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes,  as described in Note 10, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Indebtedness&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we entered into interest rate swaps with an aggregate notional amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$675.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes attributable to changes in interest rates. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recognized as a component of interest expense in our condensed consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Foreign Currency Forward Contracts - Other Derivatives&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also enter into other foreign currency forward contracts, usually with one month durations, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The aggregate notional amount of these outstanding foreign currency contracts was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$787.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$365.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Net losses of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$8.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$4.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to these contracts were recognized as a component of other income (expense), net, for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, as compared to net losses of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$7.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$11.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in the prior year comparative periods.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Summary of Derivatives&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;While certain of our derivatives are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivatives including those designated as hedging instruments:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="42%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="42%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;Fair Value As of September 30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;54.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;17.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;8.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value As of December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;69.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2015Q3YTD" id="Fact-AFD0D8FFC88C14BB3AB7AE73D8255211">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Share-based Payments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share-based Compensation Expense&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;10.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;68.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;78.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;17.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;34.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;99.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;115.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;28.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;58.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;167.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;193.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(8.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(7.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;25.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;56.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;159.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;186.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax effect&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(6.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(16.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(46.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(55.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;19.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;40.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;113.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;130.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;33.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;30.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;28.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;94.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;86.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash settled performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(9.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;17.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;11.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;16.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;11.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;28.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;58.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;167.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;193.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(8.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(7.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;25.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;56.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;159.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;186.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We estimate the fair value of our obligations associated with our performance and cash settled performance units at the end of each reporting period through expected settlement.&amp;#160;Cumulative adjustments to these obligations are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Grants Under Share-based Compensation Plans&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our equity grants to employees, officers and directors under our current stock plans:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="73%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;181,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;236,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash settled performance shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;115,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;182,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;89,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;57,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;393,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;437,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Employee Stock Purchase Plan (ESPP)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2015, our stockholders approved the Biogen Inc. 2015 Employee Stock Purchase Plan (ESPP). The ESPP, which became effective on July 1, 2015, replaced the Biogen Idec Inc. 1995 ESPP (1995 ESPP), which expired on June&amp;#160;30, 2015. The maximum aggregate number of shares of our common stock that may be purchased under the ESPP is &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,200,000&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;98,000&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;43,000&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares were issued under our 1995 ESPP and 2015 ESPP, respectively, compared to approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;150,000&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;shares issued under our 1995 ESPP in the prior year comparative period.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2015Q3YTD" id="Fact-6917FAA0422998EC4F42AE73D8392D78">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Earnings&amp;#160;per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;965.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;856.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,715.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,051.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average number of common shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;232.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;236.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;234.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;236.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Stock options and employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Dilutive potential common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares used in calculating diluted earnings per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;232.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;237.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;234.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;237.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were not significant.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="FD2015Q3YTD" id="Fact-D42C845952AB7624D3AAAE73D8F9FE1C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of September 30, 2015 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&amp;#160;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,804.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,804.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,039.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,039.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,411.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,411.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;249.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;249.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;25.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;25.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;61.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;61.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;38.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;38.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7,630.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;25.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7,605.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;31.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;31.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;481.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;481.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;512.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;31.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;481.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2014 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&amp;#160;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;716.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;716.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,063.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,063.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;849.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;849.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;198.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;198.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;72.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;72.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;36.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;36.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,943.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,937.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;215.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;215.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;220.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;215.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;There have been &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; material impairments of our assets measured and carried at fair value during the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. In addition, there were &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; changes in valuation techniques or inputs utilized or transfers between fair value measurement levels during the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities was determined through third party pricing services. For a description of our validation procedures related to prices provided by third party pricing services, refer to Note 1, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies: Fair Value Measurements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K. For additional information related to our decision to no longer reflect our investments in venture capital funds within the fair value hierarchy, refer to Note 1, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies: New Accounting Pronouncements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Debt Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair and carrying values of our debt instruments, which are Level&amp;#160;2 liabilities, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of September 30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Notes payable to Fumedica&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;9.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;9.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875% Senior Notes due March&amp;#160;1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;614.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;566.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;634.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;571.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,514.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,492.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,008.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;991.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,767.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,733.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,766.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,721.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6,680.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6,514.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;647.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;583.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair value of our notes payable to Fumedica was estimated using market observable inputs, including current interest and foreign currency exchange rates. The fair values of each of our series of Senior Notes were determined through market, observable, and corroborated sources. In accordance with ASU No. 2015-03, during the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we reclassified &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our debt issuance costs related to our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes issued in 2008 from an asset to a reduction to the carrying amount of the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes. For additional information related to our notes payable to Fumedica and our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes, please read Note 12, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Indebtedness&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K. For additional information related to our Senior Notes issued on September 15, 2015, please read Note 10, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Indebtedness&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingent Consideration Obligations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the fair values of our contingent consideration obligations which includes Level 3 measurements:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;495.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;279.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;215.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;280.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;274.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Changes in fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(49.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(46.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(14.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(16.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(14.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(21.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;481.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;213.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;481.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;213.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$301.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$200.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of our contingent consideration obligations valued using Level 3 measurements were reflected as components of other long-term liabilities in our condensed consolidated balance sheets with the remaining balances reflected as a component of accrued expenses and other. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisition of Convergence, we recorded a liability of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$274.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, representing the fair value of the contingent consideration. This valuation was based on probability weighted net cash outflow projections of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$450.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, discounted using a rate of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which is the estimated cost of debt financing for market participants. This liability reflects the revised estimate from the date of acquisition for our initial clinical development plans, resulting probabilities of success and the timing of certain milestone payments. For a more detailed description of this transaction, please read Note 2, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$176.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, related to our contingent consideration obligations arising from our acquisition of Convergence, is reflected as a component of accrued expenses and other in our condensed consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Acquired IPR&amp;amp;D&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisition of Convergence, we also allocated &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$424.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the total purchase price to acquired IPR&amp;amp;D, which was capitalized as an intangible asset. The amount allocated to acquired IPR&amp;amp;D was based on significant inputs not observable in the market and thus represented a Level 3 fair value measurement. This estimate was also adjusted from our preliminary estimate as of the date of acquisition to reflect revised estimates to our initial clinical development plans, resulting probabilities of success and the timing of certain milestone payments. These assets will be tested for impairment annually until commercialization, after which time the IPR&amp;amp;D will be amortized over its estimated useful life. For a more detailed description of this transaction, please read Note 2, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2015Q3YTD" id="Fact-C08555AE2F69D363D898AE73D8EE7441">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the fair values of our contingent consideration obligations which includes Level 3 measurements:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;495.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;279.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;215.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;280.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;274.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Changes in fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(49.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(46.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(14.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(16.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(14.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(21.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;481.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;213.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;481.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;213.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="FD2015Q3YTD" id="Fact-AFF4B6DD5696E1F2F260AE73D88B12C6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Intangible Assets and Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="21%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="17%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="7%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="7%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="7%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="7%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of September 30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Out-licensed patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13-23 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(499.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;43.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(481.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;61.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;technology&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15-23&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2,523.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;481.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2,396.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;608.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite until commercialization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;735.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;735.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;314.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;314.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Trademarks&amp;#160;and&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;tradenames&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed&amp;#160;rights&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;and&amp;#160;patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3-17 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,297.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(440.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,856.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,280.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(300.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,980.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7,645.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(3,464.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4,181.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,207.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3,178.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,028.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, amortization of acquired intangible assets totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$98.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$286.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, as compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$122.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$382.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in the prior year comparative periods. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, compared to the same period in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the decrease in amortization of acquired intangible assets was primarily driven by higher expected lifetime revenues of AVONEX, partially offset by lower expected lifetime revenues of TYSABRI. Amortization of acquired intangible assets during the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; included a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$16.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; impairment loss related to one of our IPR&amp;amp;D intangible assets.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, compared to the same period in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the decrease in amortization of acquired intangible assets was primarily driven by a decrease in AVONEX revenues during the comparative periods. Amortization of acquired intangible assets during the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; included total impairment charges of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to one of our out-licensed patents and one of our IPR&amp;amp;D intangible assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"&gt;Developed Technology&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$472.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"&gt;IPR&amp;amp;D&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;IPR&amp;amp;D represents the fair value assigned to research and development assets that we acquire that have not reached technological feasibility at the date of acquisition. Upon commercialization, we will determine the estimated useful life. In connection with our acquisition of Convergence in February 2015, we acquired IPR&amp;amp;D programs with an estimated fair value of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$424.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This amount will be adjusted for foreign exchange rate fluctuations. For a more detailed description of this transaction, please read Note 2, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"&gt;Acquired and In-licensed Rights and Patents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed rights and patents primarily relate to our acquisition of the TYSABRI rights from Elan Corporation plc (Elan). Elan was acquired by Perrigo Company plc (Perrigo) in December 2013. The net book value of this asset as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2,797.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"&gt;Estimated Future Amortization of Intangible Assets &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our amortization expense is based on the economic consumption of intangible assets. Our most significant intangible assets are related to our AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of AVONEX and TYSABRI. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of either product.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our most recent long range planning cycle was updated in the third quarter of 2015. Based upon this analysis, there was not a significant change in our expected rate of amortization for acquired intangible assets and the estimated future amortization is expected to be as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="87%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015 (remaining three months)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;94.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;348.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;318.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;291.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;275.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;269.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,596.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="87%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,760.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Increase to goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;649.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of September 30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,408.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The increase in goodwill during the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was related to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$600.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in contingent payments achieved (exclusive of a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$78.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; tax benefit) to former shareholders of Fumapharm AG or holders of their rights and our acquisition of Convergence. Other includes changes related to foreign exchange rate fluctuations. For additional information related to future contingent payments to the former shareholders of Fumapharm AG or holders of their rights, please read Note 20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements. For additional information related to our acquisition of Convergence, please read Note 2, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; accumulated impairment losses related to goodwill.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2015Q3YTD" id="Fact-9C779532C6B39F4B9053AE73D8B21C3A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation between the U.S.&amp;#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Taxes on foreign earnings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(10.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(10.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(8.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Credits and net operating loss utilization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Manufacturing deduction&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other permanent items&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effective tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;24.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;24.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;25.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, compared to the same periods in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our effective tax rate benefited from lower anticipated taxes on foreign earnings. Our effective tax rate for the comparative &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; month periods also reflects a benefit, described below, resulting from the remeasurement of one of our uncertain tax positions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accounting for Uncertainty in Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in the U.S.&amp;#160;federal jurisdiction, various U.S. states, and foreign jurisdictions. With few exceptions, including the proposed disallowance we discuss below, we are no longer subject to U.S.&amp;#160;federal tax examination for years before 2013 or state, local, or non-U.S.&amp;#160;income tax examinations for years before 2004. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2015, we received a final assessment from the Danish Tax Authority (SKAT) for fiscal 2009, regarding withholding taxes and the treatment of certain intercompany transactions involving our Danish affiliate and another of our affiliates.&amp;#160;The audits of our tax filings for 2010 through 2013 are not completed but have been prepared in a manner consistent with prior filings, with similar transactions, which may result in an assessment for those years.&amp;#160;The total amount assessed for 2009 is &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$49.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, including interest.&amp;#160;For all periods potentially under dispute, we believe that positions taken in our tax filings are valid and we are contesting the assessment vigorously.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"&gt;Federal Uncertain Tax Positions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the net effect of adjustments to our uncertain tax positions was a net benefit of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$24.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; primarily related to the state impact of a federal uncertain tax item. It is reasonably possible that we will adjust the value of our uncertain tax positions related to our unconsolidated joint business and certain transfer pricing issues as we receive additional information from various taxing authorities, including reaching settlements with the authorities. In addition, the Internal Revenue Service (IRS) and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2011, in conjunction with our examination, the IRS proposed a disallowance of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$130.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in deductions for tax years 2007, 2008 and 2009 related to payments for services provided by our wholly owned Danish subsidiary located in Hiller&amp;#248;d, Denmark. We believe that these items represent valid deductible business expenses and are vigorously defending our position. We have initiated a mutual agreement procedure between the IRS and SKAT for the years 2001 through 2009, in an attempt to reach agreement on the issue. In addition, we have applied for a bilateral advanced pricing agreement for the years 2010 through 2014 to resolve similar issues for the subsequent years.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:InventoryDisclosureTextBlock contextRef="FD2015Q3YTD" id="Fact-AA631F8BBEF33DEF7F96AE73D86B8CF1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The components of inventory are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="73%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;221.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;128.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Work in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;537.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;511.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;159.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;164.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;918.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;804.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our inventory included &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$54.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; associated with our ZINBRYTA, FLIXABI and BENEPALI programs, which have been capitalized in advance of regulatory approval. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our inventory included &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$6.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; associated with our ZINBRYTA program, which had been capitalized in advance of regulatory approval.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
	<us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="FD2015Q3YTD" id="Fact-52818D7EA7837DCC9B6FAE73D90E1C2F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The estimated fair value and amortized cost of our marketable debt securities classified as available-for-sale by contractual maturity are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of September 30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due in one year or less&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,753.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,753.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;640.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;640.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,820.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,820.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,343.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,345.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;127.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;127.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;126.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;126.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total available-for-sale securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,700.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,700.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,111.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,112.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
	<us-gaap:LegalMattersAndContingenciesTextBlock contextRef="FD2015Q3YTD" id="Fact-EE14B4AFAD09148443EAAE73D88F8D06">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt; &amp;#8217;755 Patent Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On May&amp;#160;28, 2010, Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&amp;#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (manufacturer, marketer and seller of REBIF), Pfizer Inc. (co-marketer of REBIF), and Novartis Pharmaceuticals Corp. (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 (&amp;#8217;755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the &amp;#8217;755 Patent and that the patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. The court has consolidated the two lawsuits, and we refer to the two actions as the &amp;#8220;Consolidated &amp;#8217;755 Patent Actions.&amp;#8221;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:12px;text-indent:17px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Bayer, Pfizer, Novartis and EMD Serono have all filed counterclaims in the Consolidated &amp;#8217;755 Patent Actions seeking declaratory judgments of patent invalidity and non-infringement, and seeking monetary relief in the form of costs and attorneys' fees, and EMD Serono and Bayer have each filed a counterclaim seeking a declaratory judgment that the &amp;#8217;755 Patent is unenforceable based on alleged inequitable conduct. Bayer has also amended its complaint to seek such a declaration. No trial date has been set.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Italian National Medicines Agency&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the fourth quarter of 2011, Biogen Italia SRL&amp;#160;received notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) that sales of TYSABRI after mid-February 2009 exceeded a reimbursement limit established pursuant to a Price Determination Resolution (Price Resolution) granted by AIFA in December 2006. On December&amp;#160;23, 2011, we filed an appeal in the Regional Administrative Tribunal of Lazio (Il Tribunale Amministrativo Regionale per il Lazio) in Rome, Italy seeking a ruling that the reimbursement limit in the Price Resolution should apply as written to only &amp;#8220;the first &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months&amp;#8221; of TYSABRI sales, which ended in mid-February 2009. The appeal is still pending. In June 2014, AIFA approved a resolution affirming that there is no reimbursement limit from and after February 2013. AIFA and Biogen Italia SRL are discussing a possible resolution for the period from mid-February 2009 through January 2013.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Government Matters&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We have also received a subpoena from the federal government for documents relating to our relationship with certain pharmacy benefit managers. We are cooperating with the government in these matters.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Qui Tam Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On July 6, 2015, four qui tam actions filed against us by relators suing on behalf of the United States and certain states were unsealed by the U.S. District Court for the District of Massachusetts. The actions, which have been administratively consolidated, allege sales and promotional activities in violation of the federal False Claims Act and state law counterparts, and seek single and treble damages, civil penalties, interest, attorneys&amp;#8217; fees and costs. The United States has declined to intervene in two of the actions and has not made an intervention decision in the other two actions. We have not been served with any of the complaints. We have not formed an opinion that an unfavorable outcome in any of the actions is either &amp;#8220;probable&amp;#8221; or &amp;#8220;remote&amp;#8221; and are unable to estimate the magnitude or range of any potential loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Forward Pharma Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On November 18, 2014 Forward Pharma A/S (Forward Pharma) filed suit against us in the Regional Court of Dusseldorf, Germany alleging that TECFIDERA infringes German Utility Model DE&amp;#160;20 2005 022 112&amp;#160;U1, which was issued in April 2014 and expires in October 2015. Forward Pharma subsequently&amp;#160;extended its allegations&amp;#160;to assert that TECFIDERA infringes Forward Pharma's European Patent No. 2,801,355, which was issued in May 2015 and expires in October 2025. Forward Pharma seeks declarations of infringement and damages. A hearing has been scheduled for early 2016.&amp;#160;We have not formed an opinion that an unfavorable outcome is either &amp;#8220;probable&amp;#8221; or &amp;#8220;remote&amp;#8221; and are unable to estimate the magnitude or range of any potential loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Securities Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On August 18, 2015, Nicole Tehrani filed an action in the U.S. District Court for the District of Massachusetts against Biogen, our Chief Executive Officer, George A. Scangos, and our Chief Financial Officer, Paul J. Clancy, alleging federal securities law violations under 15 U.S.C. &amp;#167;78j(b) and &amp;#167;78t(a) and 17 C.F.R. &amp;#167;240.10b-5. The plaintiff seeks declaration of the action as a class action, certification of the plaintiff as a representative of the class and her counsel as class counsel, and an award to the plaintiff and the class of damages, interest, and attorneys' fees. We have not formed an opinion that an unfavorable outcome is either &amp;#8220;probable&amp;#8221; or &amp;#8220;remote&amp;#8221; and are unable to estimate the magnitude or range of any potential loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Patent Matter relating to ALPROLIX&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In September 2015, Pfizer proposed that we discuss taking a license to its U.S. Patent No. 8,603,777&amp;#160;(Expression of Factor VII and IX Activities in Mammalian Cells) and pay&amp;#160;royalties on sales of ALPROLIX. We have not formed an opinion that an unfavorable outcome is either &amp;#8220;probable&amp;#8221; or &amp;#8220;remote&amp;#8221; and are unable to estimate the magnitude or range of any potential loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Product Liability and Other Legal Proceedings&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
	<us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock contextRef="FD2015Q3YTD" id="Fact-DC4AC3339E21DE38BD3FAE73D8B25B4B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Acquisitions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Convergence Pharmaceuticals&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On February 12, 2015, we completed our acquisition of all of the outstanding stock of Convergence Pharmaceuticals (Convergence), a clinical-stage biopharmaceutical company with a focus on developing product candidates for neuropathic pain. Convergence&amp;#8217;s lead candidate is its Phase 2 clinical candidate Raxatrigine (CNV1014802), which has demonstrated clinical activity in proof-of-concept studies for trigeminal neuralgia (TGN), a chronic orphan disease. Additionally, Raxatrigine has potential applicability in several other neuropathic pain states. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The purchase price consisted of a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$200.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; cash payment at closing, plus contingent consideration in the form of development and approval milestones up to a maximum of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$450.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, of which &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$350.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; is associated with the development and approval of Raxatrigine for the treatment of TGN. The acquisition was funded from our existing cash on hand and has been accounted for as the acquisition of a business. In addition to obtaining the rights to Raxatrigine and additional product candidates in preclinical development, we retained the services of key employees of Convergence.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisition of Convergence, we recorded a liability of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$274.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; representing the fair value of the contingent consideration.&amp;#160;This amount was estimated through a valuation model that incorporates industry-based probability adjusted assumptions relating to the achievement of these milestones and thus the likelihood of making the contingent payments. This fair value measurement is based upon significant inputs not observable in the market and therefore represents a Level 3 measurement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The purchase price, as adjusted, consisted of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="87%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash portion of consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;200.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;274.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total purchase price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;474.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subsequent changes in the fair value of the contingent consideration obligation will be recognized as adjustments to contingent consideration and reflected in our condensed consolidated statements of income. For additional information related to the fair value of this obligation, please read Note 6,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the second quarter of 2015, we adjusted our preliminary estimate of the fair value of the assets acquired and contingent consideration as of the date of acquisition to reflect revised estimates to our initial clinical development plans, resulting probabilities of success and the timing of certain milestone payments. The primary effects of these revised estimates resulted in an increase in the value of our estimated contingent consideration and goodwill by &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$36.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Our revised purchase price allocation is reflected in the chart below. Our purchase price allocation is substantially complete.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the estimated fair values of the separately identifiable assets acquired and liabilities assumed as of February&amp;#160;12, 2015, as adjusted:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="87%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;424.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;128.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred tax liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(84.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total purchase price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;474.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our estimate of the fair value of the in-process research and development (IPR&amp;amp;D) programs acquired was determined through a probability adjusted discounted cash flow analysis utilizing a discount rate of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This valuation was primarily driven by the value associated with the lead candidate, Raxatrigine, which is in development for the treatment of TGN and is expected to be completed no earlier than 2020, at a remaining cost of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$145.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The fair value associated with Raxatrigine for the treatment of TGN was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$200.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We have recorded additional IPR&amp;amp;D assets related to the use of Raxatrigine in two additional neuropathic pain indications, with a total estimated value of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$220.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The remaining cost of development for these two indications is approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$415.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, with an expected completion date of no earlier than 2021. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have attributed the goodwill recognized to the Convergence workforce's expertise in chronic pain research and clinical development and to establishing a deferred tax liability for the acquired IPR&amp;amp;D intangible assets which have no tax basis. The goodwill is not tax deductible.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Pro forma results of operations would not be materially different as a result of the acquisition of Convergence and therefore are not presented. Subsequent to the acquisition date, our results of operations include the results of operations of Convergence.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2015Q3YTD" id="Fact-286E4CB906FA37C6B99CAE73D8C3070A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. We are currently evaluating the method of adoption and the potential impact that Topic 606 may have on our financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2014, the FASB issued ASU No. 2014-11, Transfers and Servicing (Topic 860): Repurchase-to-Maturity Transactions, Repurchase Financings, and Disclosure. The new standard expanded secured borrowing accounting to include repurchase-to-maturity transactions and repurchase financings and set forth new disclosure requirements for repurchase agreements, securities lending transactions, and repurchase-to-maturity transactions that are accounted for as secured borrowings. We adopted this standard on April 1, 2015 and expanded our disclosures presented in Note 7, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Financial Instruments&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements. The adoption of this standard did not have an impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In April 2015, the FASB issued ASU No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. The new standard requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. In August 2015, the FASB issued ASU No. 2015-15, Interest - Imputation of Interest (Subtopic 835-30): Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements, which clarified that debt issuance costs related to line-of-credit arrangements can be presented in the balance sheet as an asset and amortized over the term of the line-of-credit arrangement. We adopted these standards as of September 30, 2015 with retroactive application. The adoption of these standards did not have a significant impact on our financial position or results of operations. For additional information, please read Note 6, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In April 2015, the FASB issued ASU No. 2015-05, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer's Accounting for Fees Paid in a Cloud Computing Arrangement. Under this standard, if a cloud computing arrangement includes a software license, the software license element of the arrangement should be accounted for consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the arrangement should be accounted for as a service contract. The new standard will be effective for us on January 1, 2016. The adoption of this standard is not expected to have an impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2015, the FASB issued ASU No. 2015-07, Fair Value Measurement (Topic 820): Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent). The new standard removes the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient. The new standard will be effective for us on January 1, 2016. Early application is permitted. We maintain investments in certain venture capital funds which primarily invest in small, privately-owned, venture-backed biotechnology companies. The value of our investments in these venture capital funds is estimated using the net asset value of the fund and has been included in the fair value hierarchy disclosure as a Level 3 measurement. These venture capital investments are not material to our financial position or results of operations. We adopted this standard as of June 30, 2015 and our investments in venture capital funds are no longer included in our disclosures reflected in Note 6, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. The new standard applies only to inventory for which cost is determined by methods other than last-in, first-out and the retail inventory method, which includes inventory that is measured using first-in, first-out or average cost. Inventory within the scope of this standard is required to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have an impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. The new standard requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined and sets forth new disclosure requirements related to the adjustments. The new standard will be effective for us on January 1, 2016. The adoption of this standard is not expected to have an impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:OtherNoncurrentLiabilitiesTableTextBlock contextRef="FD2015Q3YTD" id="Fact-057D6043973BFC216B20AE73D8461FA2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities consist of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="73%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;301.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;200.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee compensation and benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;218.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;200.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;341.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;249.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;861.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;650.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OtherNoncurrentLiabilitiesTableTextBlock>
	<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="FD2015Q3YTD" id="Fact-651AA1D73F0777F32EA72E9BF16C4276">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Property, Plant and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment are recorded at cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1,320.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1,186.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Research Triangle Park Facility Purchase&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On August 24, 2015, we purchased from Eisai, Inc. (Eisai) its drug product manufacturing facility and supporting infrastructure in Research Triangle Park (RTP), North Carolina for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$104.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The purchase price consisted of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="87%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Buildings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;58.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Machinery and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;25.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Land&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;20.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total purchase price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;104.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On August 24, 2015, we also amended our existing &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; year lease related to Eisai's oral solid dose products manufacturing facility in RTP, North Carolina where we manufacture our and Eisai's oral solid dose products. As amended, the lease provides for a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; year term and our agreement to purchase the facility upon expiration of the lease term and Eisai's completion of certain activities. Accordingly, we recorded the assets along with a corresponding financing obligation on our condensed consolidated balance sheet for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the net present value of the future minimum lease payments. The assets were recorded as a component of buildings and machinery and equipment. We expect to complete the purchase of the oral solid products manufacturing facility at the end of the lease term in the third quarter of 2018.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
	<us-gaap:RealizedGainLossOnInvestmentsTableTextBlock contextRef="FD2015Q3YTD" id="Fact-109D3BE6920A28719B1AAE73D90F6DF1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Proceeds from maturities and sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,387.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;625.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,363.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,942.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RealizedGainLossOnInvestmentsTableTextBlock>
	<us-gaap:ReceivablesPolicyTextBlock contextRef="FD2015Q3YTD" id="Fact-5965046E4CCAEC5493EBAE73D8C54C5A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our accounts receivable primarily arise from product sales in the U.S.&amp;#160;and Europe and mainly represent amounts due from our wholesale distributors, public hospitals and other government entities. Concentrations of credit risk with respect to our accounts receivable, which are typically unsecured, are limited due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. The majority of our accounts receivable require payment within &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30 to 90 days&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We monitor the financial performance and credit worthiness of our customers so that we can properly assess and respond to changes in their credit profile. We provide reserves against trade receivables for estimated losses that may result from a customer&amp;#8217;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve. To date, our historical reserves and write-offs of accounts receivable have not been significant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year after the time of sale, we discount our receivables and reduce related revenues over the period of time that we estimate those amounts will be paid using the country&amp;#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recognized as a component of other income (expense), net in our condensed consolidated statement of income. To date, our historical discounts of receivables have not been significant.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
	<us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock contextRef="FD2015Q3YTD" id="Fact-AC287B2F8B410F8F55F1AE73D8BBB489">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="24%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="21%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on securities available for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on cash flow hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;43.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;119.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(7.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reclassifications, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;42.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;117.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
	<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="FD2015Q3YTD" id="Fact-53E88B91A49913B692F4AE73D8B3BCF6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other consists of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="73%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;479.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;265.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue-related rebates&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;462.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;359.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee compensation and benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;214.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;393.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalties and licensing fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;154.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;172.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;58.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;120.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;549.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;507.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,918.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,819.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="FD2015Q3YTD" id="Fact-9A2984E86264537EB5C7AE73D8B943A2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="31%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;71.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(31.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(99.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(59.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;78.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(61.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;19.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(118.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(117.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(40.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(61.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(97.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of September 30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;31.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(27.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(160.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(157.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="31%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(23.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(19.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(27.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;57.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(71.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(5.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(71.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of September 30, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;41.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(18.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(61.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(38.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
	<us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="FD2015Q3YTD" id="Fact-BD4BC54F0B73AAC89AD1AE73D8AFB48B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The purchase price, as adjusted, consisted of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="87%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash portion of consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;200.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;274.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total purchase price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;474.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
	<us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock contextRef="FD2015Q3YTD" id="Fact-E113BD4568BD2B803026AE73D8F63258">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair and carrying values of our debt instruments, which are Level&amp;#160;2 liabilities, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of September 30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Notes payable to Fumedica&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;9.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;9.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875% Senior Notes due March&amp;#160;1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;614.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;566.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;634.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;571.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,514.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,492.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,008.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;991.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,767.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,733.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,766.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,721.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6,680.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6,514.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;647.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;583.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
	<us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="FD2015Q3YTD" id="Fact-48DE3047C8123FF77652AE73D90E3D33">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our financial assets with maturities of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;less than 90&amp;#160;days&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; from the date of purchase included in cash and cash equivalents on the accompanying condensed consolidated balance sheet:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="73%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;21.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;54.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Overnight reverse repurchase agreements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;188.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;305.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,119.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;321.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Short-term debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;475.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,804.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;716.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
	<us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="FD2015Q3YTD" id="Fact-1D29B1F970A9C1AB2C45AE73D89D54D0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;33.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;30.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;28.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;94.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;86.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash settled performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(9.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;17.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;11.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;16.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;11.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;28.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;58.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;167.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;193.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(8.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(7.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;25.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;56.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;159.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;186.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
	<us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock contextRef="FD2015Q3YTD" id="Fact-CB051CC7401083182DC7AE73D8A52F6B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments on our condensed consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="20%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="19%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Effective Portion)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized into Net Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Ineffective Portion)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;43.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="20%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="19%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Effective Portion)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized into Net Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Ineffective Portion)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;119.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(7.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
	<us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock contextRef="FD2015Q3YTD" id="Fact-CB680C770EB99B38B2C2AE73D8D62137">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivatives including those designated as hedging instruments:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="42%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="42%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;Fair Value As of September 30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;54.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;17.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;8.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value As of December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;69.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="FD2015Q3YTD" id="Fact-7BE7BA500A68BFC9D51FAE73D85640C1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;965.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;856.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,715.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,051.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average number of common shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;232.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;236.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;234.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;236.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Stock options and employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Dilutive potential common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares used in calculating diluted earnings per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;232.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;237.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;234.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;237.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="FD2015Q3YTD" id="Fact-AAB7C6188C629E6F6E78AE73D8DA9C98">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation between the U.S.&amp;#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Taxes on foreign earnings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(10.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(10.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(8.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Credits and net operating loss utilization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Manufacturing deduction&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other permanent items&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effective tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;24.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;24.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;25.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2015Q3YTD" id="Fact-5A83A8142B9642DF44DAAE73D8A39334">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;10.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;68.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;78.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;17.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;34.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;99.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;115.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;28.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;58.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;167.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;193.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(8.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(7.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;25.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;56.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;159.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;186.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax effect&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(6.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(16.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(46.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(55.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;19.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;40.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;113.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;130.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="FD2015Q3YTD" id="Fact-B9A2B61A4A36C662D765AE73D8F37583">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of September 30, 2015 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&amp;#160;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,804.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,804.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,039.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,039.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,411.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,411.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;249.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;249.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;25.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;25.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;61.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;61.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;38.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;38.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7,630.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;25.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7,605.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;31.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;31.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;481.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;481.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;512.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;31.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;481.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2014 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&amp;#160;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;716.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;716.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,063.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,063.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;849.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;849.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;198.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;198.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;72.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;72.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;36.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;36.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,943.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,937.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;215.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;215.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;220.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;215.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
	<us-gaap:ScheduleOfGoodwillTextBlock contextRef="FD2015Q3YTD" id="Fact-B9D1C4025D0E1BA63DC9AE73D8932644">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="87%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,760.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Increase to goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;649.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of September 30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,408.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
	<us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="FD2015Q3YTD" id="Fact-E39CCE59BE0627BB895BAE73D86C74E3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The components of inventory are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="73%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;221.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;128.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Work in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;537.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;511.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;159.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;164.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;918.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;804.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
	<us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock contextRef="FD2015Q3YTD" id="Fact-1888F5D119874F0FBE58AE73D8DBB838">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="69%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Notional Amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Foreign Currency: (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Euro&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,146.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,174.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Canadian dollar&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;17.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;56.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;British pound sterling&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;12.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;34.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Japanese yen&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;9.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;16.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Australian dollar&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;19.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total foreign currency forward contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,190.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,302.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock>
	<us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="FD2015Q3YTD" id="Fact-AA8135EEC74C330AA1F1AE73D84E29E4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Components of other income (expense), net, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;13.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(15.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(7.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(28.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(22.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign exchange gains (losses), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(4.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(18.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(7.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(7.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(15.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(16.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(41.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(17.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
	<us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="FD2015Q3YTD" id="Fact-35CD4862F203C0AA9E93AE73D8B03359">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the estimated fair values of the separately identifiable assets acquired and liabilities assumed as of February&amp;#160;12, 2015, as adjusted:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="87%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;424.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;128.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred tax liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(84.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total purchase price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;474.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
	<us-gaap:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock contextRef="FD2015Q3YTD" id="Fact-ABF0A7B27180BF9FA0B2AE73D87F0100">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Reserves for Discounts and Allowances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;47.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;387.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;49.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;483.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;332.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,278.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;26.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,636.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(20.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(14.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(37.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(277.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(871.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1,151.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(40.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(271.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(8.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(321.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of September 30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;59.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;500.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;50.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;610.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total reserves above, included in our condensed consolidated balance sheets, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="73%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reduction of accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;148.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;124.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Component of accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;462.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;359.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reserves&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;610.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;483.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
	<us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="FD2015Q3YTD" id="Fact-10E026F3DF6A5E3EF67FAE73D8875E35">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Based upon this analysis, there was not a significant change in our expected rate of amortization for acquired intangible assets and the estimated future amortization is expected to be as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="87%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015 (remaining three months)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;94.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;348.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;318.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;291.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;275.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;269.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,596.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2015Q3YTD" id="Fact-E0D735CE6E7FDBEA44B9AE73D8C8931D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Business Overview&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS), ALPROLIX for the treatment of hemophilia B, ELOCTATE for the treatment of hemophilia A and FUMADERM for the treatment of severe plaque psoriasis. We also generate revenue from our collaboration with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin&amp;#8217;s lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, and share profits and losses with Genentech for GAZYVA, which is approved for the treatment of CLL.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&amp;#160;GAAP). The information included in this quarterly report on Form&amp;#160;10-Q should be read in conjunction with our consolidated financial statements and the accompanying notes included in our Annual Report on Form&amp;#160;10-K for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&amp;#160;10-K). Our accounting policies are described in the &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Notes to Consolidated Financial Statements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8221; in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&amp;#160;10-K and updated, as necessary, in this Form&amp;#160;10-Q. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&amp;#160;GAAP. The results of operations for the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We operate as &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; operating segment, which is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accounts Receivable&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our accounts receivable primarily arise from product sales in the U.S.&amp;#160;and Europe and mainly represent amounts due from our wholesale distributors, public hospitals and other government entities. Concentrations of credit risk with respect to our accounts receivable, which are typically unsecured, are limited due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. The majority of our accounts receivable require payment within &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30 to 90 days&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We monitor the financial performance and credit worthiness of our customers so that we can properly assess and respond to changes in their credit profile. We provide reserves against trade receivables for estimated losses that may result from a customer&amp;#8217;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve. To date, our historical reserves and write-offs of accounts receivable have not been significant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year after the time of sale, we discount our receivables and reduce related revenues over the period of time that we estimate those amounts will be paid using the country&amp;#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recognized as a component of other income (expense), net in our condensed consolidated statement of income. To date, our historical discounts of receivables have not been significant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;New Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. We are currently evaluating the method of adoption and the potential impact that Topic 606 may have on our financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2014, the FASB issued ASU No. 2014-11, Transfers and Servicing (Topic 860): Repurchase-to-Maturity Transactions, Repurchase Financings, and Disclosure. The new standard expanded secured borrowing accounting to include repurchase-to-maturity transactions and repurchase financings and set forth new disclosure requirements for repurchase agreements, securities lending transactions, and repurchase-to-maturity transactions that are accounted for as secured borrowings. We adopted this standard on April 1, 2015 and expanded our disclosures presented in Note 7, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Financial Instruments&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements. The adoption of this standard did not have an impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In April 2015, the FASB issued ASU No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. The new standard requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. In August 2015, the FASB issued ASU No. 2015-15, Interest - Imputation of Interest (Subtopic 835-30): Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements, which clarified that debt issuance costs related to line-of-credit arrangements can be presented in the balance sheet as an asset and amortized over the term of the line-of-credit arrangement. We adopted these standards as of September 30, 2015 with retroactive application. The adoption of these standards did not have a significant impact on our financial position or results of operations. For additional information, please read Note 6, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In April 2015, the FASB issued ASU No. 2015-05, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer's Accounting for Fees Paid in a Cloud Computing Arrangement. Under this standard, if a cloud computing arrangement includes a software license, the software license element of the arrangement should be accounted for consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the arrangement should be accounted for as a service contract. The new standard will be effective for us on January 1, 2016. The adoption of this standard is not expected to have an impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2015, the FASB issued ASU No. 2015-07, Fair Value Measurement (Topic 820): Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent). The new standard removes the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient. The new standard will be effective for us on January 1, 2016. Early application is permitted. We maintain investments in certain venture capital funds which primarily invest in small, privately-owned, venture-backed biotechnology companies. The value of our investments in these venture capital funds is estimated using the net asset value of the fund and has been included in the fair value hierarchy disclosure as a Level 3 measurement. These venture capital investments are not material to our financial position or results of operations. We adopted this standard as of June 30, 2015 and our investments in venture capital funds are no longer included in our disclosures reflected in Note 6, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. The new standard applies only to inventory for which cost is determined by methods other than last-in, first-out and the retail inventory method, which includes inventory that is measured using first-in, first-out or average cost. Inventory within the scope of this standard is required to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have an impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. The new standard requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined and sets forth new disclosure requirements related to the adjustments. The new standard will be effective for us on January 1, 2016. The adoption of this standard is not expected to have an impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2015Q3YTD" id="Fact-FC8D6930EE4476F1861FAE73D82657BD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total equity as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; decreased &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$247.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Significant changes were as follows:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additional paid in capital was reduced by share repurchases of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$2,998.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, as described below, and activity under our share-based compensation arrangements totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$144.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive losses of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$97.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;; and &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc. of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$2,715.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share Repurchases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2015, our Board of Directors authorized a program to repurchase up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our common stock (2015 Share Repurchase Program). This authorization does not have an expiration date. Repurchased shares will be retired. The 2015 Share Repurchase Program is in addition to the approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares remaining under our February 2011 Share Repurchase Program (2011 Share Repurchase Program), which has been used principally to offset common stock issuances under our share-based compensation plans.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we repurchased and retired approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of common stock at a cost of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2,998.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; under our 2015 Share Repurchase Program, which had the effect of reducing additional paid in capital by a similar amount.&amp;#160;We did not repurchase any shares of common stock under our 2011 Share Repurchase Program. During the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we purchased approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of common stock at a cost of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$360.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; under our 2011 Share Repurchase Program. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, additional paid in capital totaled approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1,342.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Noncontrolling Interests&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table reconciles equity attributable to noncontrolling interests (NCI):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;NCI, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income (loss) attributable to NCI, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;53.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;49.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value of net assets and liabilities acquired and assigned to NCI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Distribution to NCI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(60.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(60.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Translation adjustment and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;NCI, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(5.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(5.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, net income (loss) attributable to NCI, net of tax, was related to a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; milestone payment made to Neurimmune SubOne AG. For additional information, please read Note 17, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Investments in Variable Interest Entities&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:SubsequentEventsTextBlock contextRef="FD2015Q3YTD" id="Fact-786A0C73CE0701FBCC92721DC870E4A7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Subsequent Events&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Restructuring&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On October 21, 2015, we announced a corporate restructuring, which includes the termination of a number of pipeline programs and an &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reduction in workforce. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We expect to incur a charge related to these restructuring activities in the range of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$85 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$95 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We anticipate making cash payments in the range of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$115 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$120 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which includes amounts related to previously accrued incentive compensation. Substantially all of these amounts will be incurred and paid by the end of 2015.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:UseOfEstimates contextRef="FD2015Q3YTD" id="Fact-D6CB377B44563CC29348AE73D8C9D5FE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<us-gaap:VariableInterestEntityDisclosureTextBlock contextRef="FD2015Q3YTD" id="Fact-778FEF696BE4555384C4AE73D890FF4F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Investments in Variable Interest Entities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Consolidated Variable Interest Entities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"&gt;Neurimmune SubOne AG&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2007, we entered into a collaboration agreement with Neurimmune SubOne AG (Neurimmune), a subsidiary of Neurimmune AG, for the development and commercialization of antibodies for the treatment of Alzheimer&amp;#8217;s disease. Neurimmune conducts research to identify potential therapeutic antibodies and we are responsible for the development, manufacturing and commercialization of all products. Our anti-amyloid beta antibody, aducanumab (BIIB037), for the treatment of Alzheimer&amp;#8217;s disease resulted from this collaboration. In September 2015, we announced that the first patient had been enrolled in a Phase 3 trial for aducanumab, which triggered a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; milestone payment due to Neurimmune. As we consolidate the financial results of Neurimmune, we recognized this payment as a charge to noncontrolling interest in the third quarter of 2015. Based upon our current development plans, we may pay Neurimmune up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$275.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in remaining milestone payments. We may also pay royalties in the low-to-mid-teens on sales of any resulting commercial products.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts that are incurred by Neurimmune for research and development expenses in support of the collaboration that we reimburse are reflected in research and development expense in our condensed consolidated statements of income. Future milestone payments, if any, will be reflected in our condensed consolidated statements of income as a charge to noncontrolling interest, net of tax, when such milestones are achieved.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the collaboration incurred expenses totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$39.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$87.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, which is included in total costs and expenses in our condensed consolidated statements of income, as compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$7.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$29.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in the prior year comparative periods. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The assets and liabilities of Neurimmune are not significant to our financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Unconsolidated Variable Interest Entities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have relationships with other variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the total carrying value of our investments in biotechnology companies totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$7.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Our maximum exposure to losses related to these variable interest entities is limited to the carrying value of our investments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income, as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information related to our investments in variable interest entities, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Investments in Variable Interest Entities&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>biib-20150930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biogenidec.com/20150930" xmlns:biib="http://www.biogenidec.com/20150930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2015-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-roles-2015-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-types-2015-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2015-01-31" schemaLocation="http://xbrl.sec.gov/exch/2015/exch-2015-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20150930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20150930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20150930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20150930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss">
        <link:definition>2118100 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2418402 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1">
        <link:definition>2418403 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables">
        <link:definition>2318301 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAcquisitions" roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitions">
        <link:definition>2104100 - Disclosure - Acquisitions Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAcquisitionsDetails" roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails">
        <link:definition>2404402 - Disclosure - Acquisitions  Acquisitions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAcquisitionsDetails1" roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails1">
        <link:definition>2404403 - Disclosure - Acquisitions Acquisitions (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAcquisitionsDetailsTextual" roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetailsTextual">
        <link:definition>2404404 - Disclosure - Acquisitions Acquisitions (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAcquisitionsTables" roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsTables">
        <link:definition>2304301 - Disclosure - Acquisitions Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationships" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships">
        <link:definition>2124100 - Disclosure - Collaborative and Other Relationships</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails">
        <link:definition>2424401 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships - Collaborations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails">
        <link:definition>2424402 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships - Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencesDetails" roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencesDetails">
        <link:definition>2426401 - Disclosure - Commitments and Contingences (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencies">
        <link:definition>2126100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1">
        <link:definition>2426402 - Disclosure - Commitments and Contingencies Commitments and Contingencies (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>1003000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1003501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited">
        <link:definition>1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedParenthetical" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedParenthetical">
        <link:definition>1002501 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited">
        <link:definition>1001000 - Statement - Condensed Consolidated Statements of Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstruments" roleURI="http://www.biogenidec.com/role/DerivativeInstruments">
        <link:definition>2112100 - Disclosure - Derivative Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails">
        <link:definition>2412402 - Disclosure - Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsTables" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables">
        <link:definition>2312301 - Disclosure - Derivative Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.biogenidec.com/role/EarningsPerShare">
        <link:definition>2119100 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails">
        <link:definition>2419402 - Disclosure - Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.biogenidec.com/role/EarningsPerShareTables">
        <link:definition>2319301 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.biogenidec.com/role/Equity">
        <link:definition>2117100 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityDetails" roleURI="http://www.biogenidec.com/role/EquityDetails">
        <link:definition>2417402 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityDetailsTextual" roleURI="http://www.biogenidec.com/role/EquityDetailsTextual">
        <link:definition>2417403 - Disclosure - Equity (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.biogenidec.com/role/EquityTables">
        <link:definition>2317301 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.biogenidec.com/role/FairValueMeasurements">
        <link:definition>2109100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails">
        <link:definition>2409402 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1">
        <link:definition>2409403 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails2" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2">
        <link:definition>2409404 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetailsTextual" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual">
        <link:definition>2409405 - Disclosure - Fair Value Measurements (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables">
        <link:definition>2309301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.biogenidec.com/role/FinancialInstruments">
        <link:definition>2110100 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails">
        <link:definition>2410402 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails1" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1">
        <link:definition>2410403 - Disclosure - Financial Instruments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2">
        <link:definition>2410404 - Disclosure - Financial Instruments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails3" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3">
        <link:definition>2410405 - Disclosure - Financial Instruments (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetailsTextual" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual">
        <link:definition>2410406 - Disclosure - Financial Instruments (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialInstrumentsDetailsTextual2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2">
        <link:definition>2410407 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables">
        <link:definition>2310301 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.biogenidec.com/role/IncomeTaxes">
        <link:definition>2121100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails">
        <link:definition>2421402 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual">
        <link:definition>2421403 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.biogenidec.com/role/IncomeTaxesTables">
        <link:definition>2321301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessIdebtednessDetails" roleURI="http://www.biogenidec.com/role/IndebtednessIdebtednessDetails">
        <link:definition>2416401 - Disclosure - Indebtedness Idebtedness (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessIndebtedness" roleURI="http://www.biogenidec.com/role/IndebtednessIndebtedness">
        <link:definition>2116100 - Disclosure - Indebtedness Indebtedness</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwill" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill">
        <link:definition>2108100 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails">
        <link:definition>2408402 - Disclosure - Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillDetails1" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1">
        <link:definition>2408403 - Disclosure - Intangible Assets and Goodwill (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillTables" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables">
        <link:definition>2308301 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.biogenidec.com/role/Inventory">
        <link:definition>2107100 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.biogenidec.com/role/InventoryDetails">
        <link:definition>2407402 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryInventoryDetailsTextual" roleURI="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual">
        <link:definition>2407403 - Disclosure - Inventory Inventory (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.biogenidec.com/role/InventoryTables">
        <link:definition>2307301 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInVariableInterestEntities" roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities">
        <link:definition>2123100 - Disclosure - Investments in Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInVariableInterestEntitiesDetails" roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails">
        <link:definition>2423401 - Disclosure - Investments in Variable Interest Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigation" roleURI="http://www.biogenidec.com/role/Litigation">
        <link:definition>2125100 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationDetails" roleURI="http://www.biogenidec.com/role/LitigationDetails">
        <link:definition>2425401 - Disclosure - Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetail" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail">
        <link:definition>2122100 - Disclosure - Other Consolidated Financial Statement Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails">
        <link:definition>2422402 - Disclosure - Other Consolidated Financial Statement Detail (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual">
        <link:definition>2422403 - Disclosure - Other Consolidated Financial Statement Detail Other Consolidated Financial Statement (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailTables" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables">
        <link:definition>2322301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentPropertyPlantAndEquipment" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment">
        <link:definition>2114100 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails">
        <link:definition>2414402 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetailsTextual" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetailsTextual">
        <link:definition>2414403 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentPropertyPlantAndEquipmentTables" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentTables">
        <link:definition>2314301 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesForDiscountsAndAllowances" roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances">
        <link:definition>2106100 - Disclosure - Reserves for Discounts and Allowances</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesForDiscountsAndAllowancesDetails" roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails">
        <link:definition>2406402 - Disclosure - Reserves for Discounts and Allowances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesForDiscountsAndAllowancesDetails1" roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1">
        <link:definition>2406403 - Disclosure - Reserves for Discounts and Allowances (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesForDiscountsAndAllowancesDetails1Calc2" roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1Calc2">
        <link:definition>2406403 - Disclosure - Reserves for Discounts and Allowances (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesForDiscountsAndAllowancesTables" roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables">
        <link:definition>2306301 - Disclosure - Reserves for Discounts and Allowances (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPayments" roleURI="http://www.biogenidec.com/role/ShareBasedPayments">
        <link:definition>2120100 - Disclosure - Share-based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails">
        <link:definition>2420402 - Disclosure - Share-Based Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails1" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1">
        <link:definition>2420403 - Disclosure - Share-Based Payments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails2" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2">
        <link:definition>2420404 - Disclosure - Share-Based Payments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetailsTextual" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual">
        <link:definition>2420405 - Disclosure - Share-Based Payments (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables">
        <link:definition>2320301 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsSubsequentEvents" roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents">
        <link:definition>2127100 - Disclosure - Subsequent Events Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsSubsequentEventsDetails" roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails">
        <link:definition>2427401 - Disclosure - Subsequent Events Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2101100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>2401402 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2201201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="biib_A1995ESPPMember" name="A1995ESPPMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2015ESPPMember" name="A2015ESPPMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AGTCMember" name="AGTCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AVONEXMember" name="AVONEXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AdditionalMilestonePayment" name="AdditionalMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" name="AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_AverageMaturityOfMarketableSecurities" name="AverageMaturityOfMarketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BasicAndDilutedEarningsPerShareAbstract" name="BasicAndDilutedEarningsPerShareAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_BusinessOverviewPolicyTextBlock" name="BusinessOverviewPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashSettledPerformanceSharesMember" name="CashSettledPerformanceSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ContractualAdjustmentsMember" name="ContractualAdjustmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ConvergencePharmaceuticalsMember" name="ConvergencePharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CorporateDebtSecuritiesCurrentMember" name="CorporateDebtSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CorporateDebtSecuritiesNonCurrentMember" name="CorporateDebtSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CumulativeSalesLevel" name="CumulativeSalesLevel" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_CumulativeSalesLevelAxis" name="CumulativeSalesLevelAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CumulativeSalesLevelDomain" name="CumulativeSalesLevelDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" name="CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" name="DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DerivativeInstrumentsTextualAbstract" name="DerivativeInstrumentsTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DiscoveryprogramsMember" name="DiscoveryprogramsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_DueFromUnconsolidatedJointBusiness" name="DueFromUnconsolidatedJointBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_EachAdditionalOneBillionUpToTwentyBillionMember" name="EachAdditionalOneBillionUpToTwentyBillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" name="EffectiveIncomeTaxRateReconciliationManufacturingDeduction" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EisaiMember" name="EisaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Employeerelatedliabilitiesnoncurrent" name="Employeerelatedliabilitiesnoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_Employeestockpurchaseplanmaximumshares" name="Employeestockpurchaseplanmaximumshares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_EquityMethodInvestmentOwnershipPercentageMaximum" name="EquityMethodInvestmentOwnershipPercentageMaximum" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EquityMethodInvestmentsExpectedProfitShare" name="EquityMethodInvestmentsExpectedProfitShare" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EquityTextualAbstract" name="EquityTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Finitelivedintangibleassetsfutureamortization" name="Finitelivedintangibleassetsfutureamortization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_FivebillionMember" name="FivebillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FourbillionMember" name="FourbillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FumapharmAgMember" name="FumapharmAgMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_GainOnSaleOfRights" name="GainOnSaleOfRights" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_GovernmentSecuritiesCurrentMember" name="GovernmentSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_GovernmentSecuritiesNonCurrentMember" name="GovernmentSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_InLicensedPatentsMember" name="InLicensedPatentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_IndefiniteLivedIntangibleAssetsUsefulLife" name="IndefiniteLivedIntangibleAssetsUsefulLife" nillable="true" substitutionGroup="xbrli:item" type="us-types:durationStringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_IntangibleAssetsExcludingGoodwillTableTextBlock" name="IntangibleAssetsExcludingGoodwillTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_InterestInSubsidiary" name="InterestInSubsidiary" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_InterestratelocksMember" name="InterestratelocksMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_InventoryVariousProgramsGross" name="InventoryVariousProgramsGross" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" name="InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_InvestmentInVariableInterestEntitiesTextualAbstract" name="InvestmentInVariableInterestEntitiesTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" name="InvestmentsByThirdPartyInJointVentureAsPerAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_InvestmentsInVariableInterestEntitiesAbstract" name="InvestmentsInVariableInterestEntitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_JointVentureOwnerShipPercentageByThirdParty" name="JointVentureOwnerShipPercentageByThirdParty" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_LeadprogramsMember" name="LeadprogramsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MarketStockUnitsMember" name="MarketStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_MaximumTermForAccountsReceivable" name="MaximumTermForAccountsReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_MinimumTermForAccountsReceivable" name="MinimumTermForAccountsReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MitsubishiTanabePharmaCorporationMember" name="MitsubishiTanabePharmaCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" name="MortgageAndOtherAssetBackedSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" name="MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NeurimmuneMember" name="NeurimmuneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NeuropathicpainindicationsMember" name="NeuropathicpainindicationsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Noncontrollinginterestincreasedecreaseother" name="Noncontrollinginterestincreasedecreaseother" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NotesPayableToFumedicaMember" name="NotesPayableToFumedicaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OneBillionMember" name="OneBillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OutLicensedPatentsMember" name="OutLicensedPatentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Overnightreverserepurchaseagreementspercentoftotalassets" name="Overnightreverserepurchaseagreementspercentoftotalassets" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PaymentTermsOfAccountsReceivable" name="PaymentTermsOfAccountsReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageParValueOfSeniorNotes" name="PercentageParValueOfSeniorNotes" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PlanAssetsForDeferredCompensationFairValueDisclosure" name="PlanAssetsForDeferredCompensationFairValueDisclosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" name="PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_Premiumonequityinvestment" name="Premiumonequityinvestment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock" name="PropertyplantandequipmentpurchasepriceallocationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices" name="ProposedDisallowanceByTaxAuthoritiesForPaymentForServices" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_Purchaseofcommonstock" name="Purchaseofcommonstock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RaxatrigineMember" name="RaxatrigineMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract" name="ReconciliationOfEquityAttributableToNonControllingInterestsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock" name="ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ReimbursementLimitStatedInResolution" name="ReimbursementLimitStatedInResolution" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement" name="RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_Researchanddevelopmentservices" name="Researchanddevelopmentservices" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_RestructuringandRelatedCostExpectedCashPayments" name="RestructuringandRelatedCostExpectedCashPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_SamsungBiosimilarAgreementMember" name="SamsungBiosimilarAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock" name="ScheduleOfRestrictedStockUnitGrantsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ScheduleOfStockOptionGrantsAbstract" name="ScheduleOfStockOptionGrantsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" name="SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" name="SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" name="SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" name="SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" name="SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" name="ShareBasedCompensationExpenseIncludedInCostsAndExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SixbillionMember" name="SixbillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_StockOptionsAndEmployeeStockPurchasePlanMember" name="StockOptionsAndEmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_StrategicInvestmentPortfolio" name="StrategicInvestmentPortfolio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_StrategicInvestmentsMember" name="StrategicInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract" name="SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" name="SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" name="SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SwedishOrphanBiovitrumMember" name="SwedishOrphanBiovitrumMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TecfideraMember" name="TecfideraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_TermOfLease" name="TermOfLease" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ThreeBillionMember" name="ThreeBillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TimeVestedRestrictedStockUnitsMember" name="TimeVestedRestrictedStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TysabriProductMember" name="TysabriProductMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_UnconsolidatedJointBusiness" name="UnconsolidatedJointBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" name="UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_Upfrontmilestonepayment" name="Upfrontmilestonepayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_Workforcereductionpercentage" name="Workforcereductionpercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>biib-20150930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:href="biib-20150930.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20150930.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:href="biib-20150930.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20150930.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitions" xlink:href="biib-20150930.xsd#AcquisitionsAcquisitions" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails" xlink:href="biib-20150930.xsd#AcquisitionsAcquisitionsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails1" xlink:href="biib-20150930.xsd#AcquisitionsAcquisitionsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetailsTextual" xlink:href="biib-20150930.xsd#AcquisitionsAcquisitionsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsTables" xlink:href="biib-20150930.xsd#AcquisitionsAcquisitionsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20150930.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:href="biib-20150930.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:href="biib-20150930.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencesDetails" xlink:href="biib-20150930.xsd#CommitmentsAndContingencesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:href="biib-20150930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:href="biib-20150930.xsd#CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="biib-20150930.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="biib-20150930.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="biib-20150930.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="biib-20150930.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedParenthetical" xlink:href="biib-20150930.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:href="biib-20150930.xsd#CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20150930.xsd#DerivativeInstruments" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20150930.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20150930.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:href="biib-20150930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20150930.xsd#EarningsPerShare" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20150930.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20150930.xsd#EarningsPerShareTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20150930.xsd#Equity" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EquityDetails" xlink:href="biib-20150930.xsd#EquityDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:href="biib-20150930.xsd#EquityDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:href="biib-20150930.xsd#EquityTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20150930.xsd#FairValueMeasurements" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20150930.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20150930.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20150930.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20150930.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20150930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20150930.xsd#FinancialInstruments" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20150930.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20150930.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20150930.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20150930.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:href="biib-20150930.xsd#FinancialInstrumentsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:href="biib-20150930.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20150930.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20150930.xsd#IncomeTaxes" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20150930.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20150930.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20150930.xsd#IncomeTaxesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IndebtednessIdebtednessDetails" xlink:href="biib-20150930.xsd#IndebtednessIdebtednessDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IndebtednessIndebtedness" xlink:href="biib-20150930.xsd#IndebtednessIndebtedness" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20150930.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20150930.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20150930.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20150930.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20150930.xsd#Inventory" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20150930.xsd#InventoryDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual" xlink:href="biib-20150930.xsd#InventoryInventoryDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20150930.xsd#InventoryTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20150930.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20150930.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20150930.xsd#Litigation" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:href="biib-20150930.xsd#LitigationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20150930.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20150930.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:href="biib-20150930.xsd#OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20150930.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:href="biib-20150930.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:href="biib-20150930.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetailsTextual" xlink:href="biib-20150930.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentTables" xlink:href="biib-20150930.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipmentTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances" xlink:href="biib-20150930.xsd#ReservesForDiscountsAndAllowances" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails" xlink:href="biib-20150930.xsd#ReservesForDiscountsAndAllowancesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20150930.xsd#ReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1Calc2" xlink:href="biib-20150930.xsd#ReservesForDiscountsAndAllowancesDetails1Calc2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables" xlink:href="biib-20150930.xsd#ReservesForDiscountsAndAllowancesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20150930.xsd#ShareBasedPayments" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20150930.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20150930.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:href="biib-20150930.xsd#ShareBasedPaymentsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:href="biib-20150930.xsd#ShareBasedPaymentsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20150930.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents" xlink:href="biib-20150930.xsd#SubsequentEventsSubsequentEvents" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails" xlink:href="biib-20150930.xsd#SubsequentEventsSubsequentEventsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20150930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20150930.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20150930.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitions" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_7482f468-ad2c-9a86-91bc-7630d59b2e7f" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_109615d2-1833-125a-1bfc-cb072e58e440" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_7482f468-ad2c-9a86-91bc-7630d59b2e7f" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_109615d2-1833-125a-1bfc-cb072e58e440" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_606e9f3e-262e-f1b7-9864-37b9aab5c800" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_7482f468-ad2c-9a86-91bc-7630d59b2e7f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_606e9f3e-262e-f1b7-9864-37b9aab5c800" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8e82af62-5d0c-8a44-003d-d4557b49ee76" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_3a587fe4-d426-9267-7729-fe8f09d606cf" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8e82af62-5d0c-8a44-003d-d4557b49ee76" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_3a587fe4-d426-9267-7729-fe8f09d606cf" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_b108d604-1348-4e65-3817-2944b734c65a" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8e82af62-5d0c-8a44-003d-d4557b49ee76" xlink:to="loc_us-gaap_Goodwill_b108d604-1348-4e65-3817-2944b734c65a" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_b0419091-032e-c384-ce03-ca388d51379a" xlink:type="locator" />
    <calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8e82af62-5d0c-8a44-003d-d4557b49ee76" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_b0419091-032e-c384-ce03-ca388d51379a" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_b00c3cef-b479-982f-a9af-358785626dd3" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8e82af62-5d0c-8a44-003d-d4557b49ee76" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_b00c3cef-b479-982f-a9af-358785626dd3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_38b908d0-3ddf-2ab7-5076-d76b2cb8c9a7" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8e82af62-5d0c-8a44-003d-d4557b49ee76" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_38b908d0-3ddf-2ab7-5076-d76b2cb8c9a7" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitionsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingencesDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_effc14df-fd72-eec8-ede9-64e0071b91bc" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_39eaeb62-7ee3-5503-48f5-08c2dff05e50" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_effc14df-fd72-eec8-ede9-64e0071b91bc" xlink:to="loc_us-gaap_AssetsCurrent_39eaeb62-7ee3-5503-48f5-08c2dff05e50" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_eae794c2-73ec-cd91-efb3-99a2ff1f24cf" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_39eaeb62-7ee3-5503-48f5-08c2dff05e50" xlink:to="loc_us-gaap_InventoryNet_eae794c2-73ec-cd91-efb3-99a2ff1f24cf" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cd34decb-53b6-e0a9-28d5-0a9741c4b0f8" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_39eaeb62-7ee3-5503-48f5-08c2dff05e50" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cd34decb-53b6-e0a9-28d5-0a9741c4b0f8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_222b5a74-9526-7448-da46-fccf1775d7c0" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_39eaeb62-7ee3-5503-48f5-08c2dff05e50" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_222b5a74-9526-7448-da46-fccf1775d7c0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4d24e56f-a5cb-07ba-0508-f5f1533ae24e" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_39eaeb62-7ee3-5503-48f5-08c2dff05e50" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4d24e56f-a5cb-07ba-0508-f5f1533ae24e" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_DueFromUnconsolidatedJointBusiness" xlink:label="loc_biib_DueFromUnconsolidatedJointBusiness_cf573ba9-04a8-7ac8-507a-d4ecccd56637" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_39eaeb62-7ee3-5503-48f5-08c2dff05e50" xlink:to="loc_biib_DueFromUnconsolidatedJointBusiness_cf573ba9-04a8-7ac8-507a-d4ecccd56637" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_33278e4f-d71c-924a-f185-bd5aaa288d0b" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_39eaeb62-7ee3-5503-48f5-08c2dff05e50" xlink:to="loc_us-gaap_OtherAssetsCurrent_33278e4f-d71c-924a-f185-bd5aaa288d0b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_392a46ef-05fd-68f8-e487-35e85a8f15a1" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_effc14df-fd72-eec8-ede9-64e0071b91bc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_392a46ef-05fd-68f8-e487-35e85a8f15a1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7ce178a4-245f-fa78-36a1-552609a67554" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_effc14df-fd72-eec8-ede9-64e0071b91bc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7ce178a4-245f-fa78-36a1-552609a67554" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_894a128f-2068-d267-1e3e-64c93d0ed5ca" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_effc14df-fd72-eec8-ede9-64e0071b91bc" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_894a128f-2068-d267-1e3e-64c93d0ed5ca" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_b108d604-1348-4e65-3817-2944b734c65a" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_effc14df-fd72-eec8-ede9-64e0071b91bc" xlink:to="loc_us-gaap_Goodwill_b108d604-1348-4e65-3817-2944b734c65a" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9b98e689-e6db-3e5b-e5c3-3324fffb4edf" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_effc14df-fd72-eec8-ede9-64e0071b91bc" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9b98e689-e6db-3e5b-e5c3-3324fffb4edf" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4a314f0d-c6fa-5cf2-0be1-add747465af3" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9a5c5aff-ee63-a4f2-571a-3515b5d26a3b" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4a314f0d-c6fa-5cf2-0be1-add747465af3" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9a5c5aff-ee63-a4f2-571a-3515b5d26a3b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_d0f349aa-18e3-6323-86ad-665f8773c064" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9a5c5aff-ee63-a4f2-571a-3515b5d26a3b" xlink:to="loc_us-gaap_StockholdersEquity_d0f349aa-18e3-6323-86ad-665f8773c064" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_359b0ac4-80ce-a291-f73b-cff103b81eae" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d0f349aa-18e3-6323-86ad-665f8773c064" xlink:to="loc_us-gaap_PreferredStockValue_359b0ac4-80ce-a291-f73b-cff103b81eae" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_ce40a301-9b6b-9fc3-bfb6-dfbb8fcdf29b" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d0f349aa-18e3-6323-86ad-665f8773c064" xlink:to="loc_us-gaap_CommonStockValue_ce40a301-9b6b-9fc3-bfb6-dfbb8fcdf29b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_9158c8ad-1189-2464-9c41-553e6a22df6c" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d0f349aa-18e3-6323-86ad-665f8773c064" xlink:to="loc_us-gaap_AdditionalPaidInCapital_9158c8ad-1189-2464-9c41-553e6a22df6c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dd6b7206-c19f-4dd5-339b-1369c57cfe0f" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d0f349aa-18e3-6323-86ad-665f8773c064" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dd6b7206-c19f-4dd5-339b-1369c57cfe0f" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1d565cd0-d7bf-de89-4dbe-a484007b1fe8" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d0f349aa-18e3-6323-86ad-665f8773c064" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1d565cd0-d7bf-de89-4dbe-a484007b1fe8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_0b2a392d-b5d5-0c30-4a0c-bcaab86d8160" xlink:type="locator" />
    <calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d0f349aa-18e3-6323-86ad-665f8773c064" xlink:to="loc_us-gaap_TreasuryStockValue_0b2a392d-b5d5-0c30-4a0c-bcaab86d8160" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_be52b263-dda5-21e0-250c-b71c8efa5893" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9a5c5aff-ee63-a4f2-571a-3515b5d26a3b" xlink:to="loc_us-gaap_MinorityInterest_be52b263-dda5-21e0-250c-b71c8efa5893" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_4e70462c-e5f6-e2d9-0cf5-7f1332ddbc05" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4a314f0d-c6fa-5cf2-0be1-add747465af3" xlink:to="loc_us-gaap_Liabilities_4e70462c-e5f6-e2d9-0cf5-7f1332ddbc05" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_1de50dbc-01a9-6657-f83f-d1e74edfdf18" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4e70462c-e5f6-e2d9-0cf5-7f1332ddbc05" xlink:to="loc_us-gaap_LiabilitiesCurrent_1de50dbc-01a9-6657-f83f-d1e74edfdf18" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_22caddf9-3843-6329-6e39-dc458323b572" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1de50dbc-01a9-6657-f83f-d1e74edfdf18" xlink:to="loc_us-gaap_AccountsPayableCurrent_22caddf9-3843-6329-6e39-dc458323b572" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_7432ef68-60ae-faca-f534-19eb617f5674" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1de50dbc-01a9-6657-f83f-d1e74edfdf18" xlink:to="loc_us-gaap_TaxesPayableCurrent_7432ef68-60ae-faca-f534-19eb617f5674" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0d8009a1-9f3a-b52e-6afc-03d7b3b4df06" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1de50dbc-01a9-6657-f83f-d1e74edfdf18" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_0d8009a1-9f3a-b52e-6afc-03d7b3b4df06" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_e290f5d1-6cff-e2db-d278-97a30e8ccd78" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1de50dbc-01a9-6657-f83f-d1e74edfdf18" xlink:to="loc_us-gaap_DebtCurrent_e290f5d1-6cff-e2db-d278-97a30e8ccd78" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_9210187e-cdda-2312-446f-000237db141c" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4e70462c-e5f6-e2d9-0cf5-7f1332ddbc05" xlink:to="loc_us-gaap_LongTermDebt_9210187e-cdda-2312-446f-000237db141c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_d3900b70-6aae-8c94-5a39-4a06f81c5d62" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4e70462c-e5f6-e2d9-0cf5-7f1332ddbc05" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_d3900b70-6aae-8c94-5a39-4a06f81c5d62" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7f5c7cfd-4659-429c-35ab-266d67961421" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4e70462c-e5f6-e2d9-0cf5-7f1332ddbc05" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7f5c7cfd-4659-429c-35ab-266d67961421" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_53d4115f-c3d1-6e9c-3f23-fd144b27061e" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4a314f0d-c6fa-5cf2-0be1-add747465af3" xlink:to="loc_us-gaap_CommitmentsAndContingencies_53d4115f-c3d1-6e9c-3f23-fd144b27061e" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ff5db18e-7b91-5a5d-e914-0527b02a8012" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_916e1eb7-21fa-e5f0-a15f-0b05ed633776" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ff5db18e-7b91-5a5d-e914-0527b02a8012" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_916e1eb7-21fa-e5f0-a15f-0b05ed633776" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_bfab8b08-4541-18e9-28b5-5802fef422a3" xlink:type="locator" />
    <calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_916e1eb7-21fa-e5f0-a15f-0b05ed633776" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_bfab8b08-4541-18e9-28b5-5802fef422a3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_91d80b53-6368-7466-a11d-02030d33de5c" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_916e1eb7-21fa-e5f0-a15f-0b05ed633776" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_91d80b53-6368-7466-a11d-02030d33de5c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_5f8983ec-dfa4-10d0-f53d-c0676300a16f" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_916e1eb7-21fa-e5f0-a15f-0b05ed633776" xlink:to="loc_us-gaap_ProfitLoss_5f8983ec-dfa4-10d0-f53d-c0676300a16f" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_783b94c5-664a-4bc7-f813-8c258cc934b7" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_916e1eb7-21fa-e5f0-a15f-0b05ed633776" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_783b94c5-664a-4bc7-f813-8c258cc934b7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_d4c99b59-c44a-c4ac-309f-0bddfdb944a5" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_916e1eb7-21fa-e5f0-a15f-0b05ed633776" xlink:to="loc_us-gaap_ShareBasedCompensation_d4c99b59-c44a-c4ac-309f-0bddfdb944a5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8b437d2d-6bbf-1f71-a341-6d3ac2b36703" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_916e1eb7-21fa-e5f0-a15f-0b05ed633776" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8b437d2d-6bbf-1f71-a341-6d3ac2b36703" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_8a9fbf97-3c14-4351-6d6b-553e136a9df1" xlink:type="locator" />
    <calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_916e1eb7-21fa-e5f0-a15f-0b05ed633776" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_8a9fbf97-3c14-4351-6d6b-553e136a9df1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_59947135-2495-391e-9e35-ed6effebb894" xlink:type="locator" />
    <calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_916e1eb7-21fa-e5f0-a15f-0b05ed633776" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_59947135-2495-391e-9e35-ed6effebb894" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1ea297cc-8653-7155-6fa9-a3af7df49950" xlink:type="locator" />
    <calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_916e1eb7-21fa-e5f0-a15f-0b05ed633776" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1ea297cc-8653-7155-6fa9-a3af7df49950" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_58a5bd26-e5f4-de8f-6118-f713733148b8" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ff5db18e-7b91-5a5d-e914-0527b02a8012" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_58a5bd26-e5f4-de8f-6118-f713733148b8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_0ff68e79-9d67-8dd3-0a29-1b2e1239e793" xlink:type="locator" />
    <calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_58a5bd26-e5f4-de8f-6118-f713733148b8" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_0ff68e79-9d67-8dd3-0a29-1b2e1239e793" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_11bab1ef-563b-9c08-d855-5223ff2c6591" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_58a5bd26-e5f4-de8f-6118-f713733148b8" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_11bab1ef-563b-9c08-d855-5223ff2c6591" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_198988d2-2f05-3f47-d4f0-bce81f98eaf0" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_58a5bd26-e5f4-de8f-6118-f713733148b8" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_198988d2-2f05-3f47-d4f0-bce81f98eaf0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_386292ff-155c-0309-455a-2b91b395b3da" xlink:type="locator" />
    <calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_58a5bd26-e5f4-de8f-6118-f713733148b8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_386292ff-155c-0309-455a-2b91b395b3da" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4852d3ee-c33e-1b07-798c-41e651367343" xlink:type="locator" />
    <calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_58a5bd26-e5f4-de8f-6118-f713733148b8" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4852d3ee-c33e-1b07-798c-41e651367343" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_b6ed717f-2ece-aa81-6051-41cf1a876a59" xlink:type="locator" />
    <calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_58a5bd26-e5f4-de8f-6118-f713733148b8" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_b6ed717f-2ece-aa81-6051-41cf1a876a59" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a678c20d-a481-ef6a-800a-4bd566075d81" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ff5db18e-7b91-5a5d-e914-0527b02a8012" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a678c20d-a481-ef6a-800a-4bd566075d81" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_03b01b21-9333-5ba7-dbad-c8702c225fae" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a678c20d-a481-ef6a-800a-4bd566075d81" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_03b01b21-9333-5ba7-dbad-c8702c225fae" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_fdef3cb2-ec10-67c4-c0cc-b6e268faa4f7" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a678c20d-a481-ef6a-800a-4bd566075d81" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_fdef3cb2-ec10-67c4-c0cc-b6e268faa4f7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_9dbeb004-67a9-1b19-c357-8b5cbf0013ee" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a678c20d-a481-ef6a-800a-4bd566075d81" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_9dbeb004-67a9-1b19-c357-8b5cbf0013ee" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4c2e87e5-41d0-b35b-6dfd-e3ab5b253709" xlink:type="locator" />
    <calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a678c20d-a481-ef6a-800a-4bd566075d81" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4c2e87e5-41d0-b35b-6dfd-e3ab5b253709" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_ae38354d-77f5-8db7-0abd-f1fc628a19a0" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a678c20d-a481-ef6a-800a-4bd566075d81" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_ae38354d-77f5-8db7-0abd-f1fc628a19a0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_e62f836f-8946-6184-26d1-70135f5dd38d" xlink:type="locator" />
    <calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a678c20d-a481-ef6a-800a-4bd566075d81" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_e62f836f-8946-6184-26d1-70135f5dd38d" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_038f4602-9abc-1f60-05a2-6f69306a77ae" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_640557c9-9806-6bef-9084-9cc792948f77" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_038f4602-9abc-1f60-05a2-6f69306a77ae" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_640557c9-9806-6bef-9084-9cc792948f77" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e716acb8-9d7f-1564-a267-c0491db420a5" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_640557c9-9806-6bef-9084-9cc792948f77" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e716acb8-9d7f-1564-a267-c0491db420a5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8449f638-e094-e8fc-6726-9e09a5f21c54" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e716acb8-9d7f-1564-a267-c0491db420a5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8449f638-e094-e8fc-6726-9e09a5f21c54" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_7443b8c0-35a8-1f56-7e6b-5e71bdbce930" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e716acb8-9d7f-1564-a267-c0491db420a5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_7443b8c0-35a8-1f56-7e6b-5e71bdbce930" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_a8fa6c6f-a6dd-0012-f55c-e82fc2a06223" xlink:type="locator" />
    <calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e716acb8-9d7f-1564-a267-c0491db420a5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_a8fa6c6f-a6dd-0012-f55c-e82fc2a06223" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_fbd5cad0-09ca-a68e-f9d5-77ff2ba61ae4" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e716acb8-9d7f-1564-a267-c0491db420a5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_fbd5cad0-09ca-a68e-f9d5-77ff2ba61ae4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e62ce8b8-4401-2622-8598-3e644745e95e" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_640557c9-9806-6bef-9084-9cc792948f77" xlink:to="loc_us-gaap_NetIncomeLoss_e62ce8b8-4401-2622-8598-3e644745e95e" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_560dfcb1-0fb6-5ffa-6e3b-8257ed923a94" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_038f4602-9abc-1f60-05a2-6f69306a77ae" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_560dfcb1-0fb6-5ffa-6e3b-8257ed923a94" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedParenthetical" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e62ce8b8-4401-2622-8598-3e644745e95e" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_5f8983ec-dfa4-10d0-f53d-c0676300a16f" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e62ce8b8-4401-2622-8598-3e644745e95e" xlink:to="loc_us-gaap_ProfitLoss_5f8983ec-dfa4-10d0-f53d-c0676300a16f" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_f0ea1b66-a9f7-f42c-6882-4cca5faefea1" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_5f8983ec-dfa4-10d0-f53d-c0676300a16f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_f0ea1b66-a9f7-f42c-6882-4cca5faefea1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_0ea1551e-1643-5e21-4c6e-6431fd87aa68" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_f0ea1b66-a9f7-f42c-6882-4cca5faefea1" xlink:to="loc_us-gaap_OperatingIncomeLoss_0ea1551e-1643-5e21-4c6e-6431fd87aa68" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_ba59260a-e348-d7f8-5375-fde11baf79c1" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0ea1551e-1643-5e21-4c6e-6431fd87aa68" xlink:to="loc_us-gaap_Revenues_ba59260a-e348-d7f8-5375-fde11baf79c1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_ca646ab3-5159-77d2-80af-f70eebc0f27d" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_ba59260a-e348-d7f8-5375-fde11baf79c1" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_ca646ab3-5159-77d2-80af-f70eebc0f27d" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_UnconsolidatedJointBusiness" xlink:label="loc_biib_UnconsolidatedJointBusiness_9d7213e3-e33d-5fcd-5a5d-d4ecccc4667d" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_ba59260a-e348-d7f8-5375-fde11baf79c1" xlink:to="loc_biib_UnconsolidatedJointBusiness_9d7213e3-e33d-5fcd-5a5d-d4ecccc4667d" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_104a708e-80a2-fec9-83a4-0bfbe74de8c9" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_ba59260a-e348-d7f8-5375-fde11baf79c1" xlink:to="loc_us-gaap_OtherSalesRevenueNet_104a708e-80a2-fec9-83a4-0bfbe74de8c9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_8281466b-86c7-ec9c-c7fc-3723705ba526" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0ea1551e-1643-5e21-4c6e-6431fd87aa68" xlink:to="loc_us-gaap_CostsAndExpenses_8281466b-86c7-ec9c-c7fc-3723705ba526" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_47bf16bc-113d-838a-56d3-e154f0f2a154" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8281466b-86c7-ec9c-c7fc-3723705ba526" xlink:to="loc_us-gaap_CostOfGoodsSold_47bf16bc-113d-838a-56d3-e154f0f2a154" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ec32a100-932a-145a-1c30-859c3cf9ce96" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8281466b-86c7-ec9c-c7fc-3723705ba526" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ec32a100-932a-145a-1c30-859c3cf9ce96" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_37d23128-e0be-7b8b-d6c6-f3d1ac14cac9" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8281466b-86c7-ec9c-c7fc-3723705ba526" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_37d23128-e0be-7b8b-d6c6-f3d1ac14cac9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_682e13ed-74ef-f976-16fa-3796f1bc898f" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8281466b-86c7-ec9c-c7fc-3723705ba526" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_682e13ed-74ef-f976-16fa-3796f1bc898f" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8d928bd0-3555-e21c-4646-ebe154fbdd5d" xlink:type="locator" />
    <calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8281466b-86c7-ec9c-c7fc-3723705ba526" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8d928bd0-3555-e21c-4646-ebe154fbdd5d" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_GainOnSaleOfRights" xlink:label="loc_biib_GainOnSaleOfRights_c3d7f6e7-1c4d-b587-6955-d4ecccf10a0d" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0ea1551e-1643-5e21-4c6e-6431fd87aa68" xlink:to="loc_biib_GainOnSaleOfRights_c3d7f6e7-1c4d-b587-6955-d4ecccf10a0d" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_915682f7-b9cc-2ed3-6852-178ddfcb101f" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_f0ea1b66-a9f7-f42c-6882-4cca5faefea1" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_915682f7-b9cc-2ed3-6852-178ddfcb101f" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b8dcf191-083d-828d-7b9f-e2d2969b89f4" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_5f8983ec-dfa4-10d0-f53d-c0676300a16f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b8dcf191-083d-828d-7b9f-e2d2969b89f4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b71b86f8-adb0-6f61-c3a9-37e1e67b4d68" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_5f8983ec-dfa4-10d0-f53d-c0676300a16f" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b71b86f8-adb0-6f61-c3a9-37e1e67b4d68" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6e1329dd-9911-a537-956e-8ca9c6805be6" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e62ce8b8-4401-2622-8598-3e644745e95e" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6e1329dd-9911-a537-956e-8ca9c6805be6" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ca9bebe4-4073-b721-7b75-1a0086593d58" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8afbf9ec-40f2-ac04-dde9-64f96fdfbf74" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ca9bebe4-4073-b721-7b75-1a0086593d58" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8afbf9ec-40f2-ac04-dde9-64f96fdfbf74" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_58a1745d-db2b-3ff9-104d-4b3f9664d3ce" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ca9bebe4-4073-b721-7b75-1a0086593d58" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_58a1745d-db2b-3ff9-104d-4b3f9664d3ce" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0449447d-2475-b5e7-892e-ced6d0229840" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_58a1745d-db2b-3ff9-104d-4b3f9664d3ce" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0449447d-2475-b5e7-892e-ced6d0229840" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/EquityDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_190f7f5c-4b8c-bf2f-74c0-cab5f1deb02f" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0fe5317b-bdcf-7a27-121f-55fe035264d7" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_190f7f5c-4b8c-bf2f-74c0-cab5f1deb02f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0fe5317b-bdcf-7a27-121f-55fe035264d7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_72dfc996-2bdc-a5c2-43c9-885b6330f5bb" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_190f7f5c-4b8c-bf2f-74c0-cab5f1deb02f" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_72dfc996-2bdc-a5c2-43c9-885b6330f5bb" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_fc1c6482-bc06-c49d-f5fe-3b9e6e37b9c3" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_a6e76a34-fa42-d66f-a2a4-5865ce92446b" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_fc1c6482-bc06-c49d-f5fe-3b9e6e37b9c3" xlink:to="loc_us-gaap_AvailableForSaleSecurities_a6e76a34-fa42-d66f-a2a4-5865ce92446b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d5cbedb3-d62c-f015-a49f-ef377e438819" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_fc1c6482-bc06-c49d-f5fe-3b9e6e37b9c3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d5cbedb3-d62c-f015-a49f-ef377e438819" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_258c41aa-2b09-923b-df97-cb86ef48f935" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_fc1c6482-bc06-c49d-f5fe-3b9e6e37b9c3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_258c41aa-2b09-923b-df97-cb86ef48f935" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9361d00b-bf28-09e2-175e-2f8c5c8d39ac" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_0c84ece3-1f8c-2bb3-6d4d-e7a215e4c9c1" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9361d00b-bf28-09e2-175e-2f8c5c8d39ac" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_0c84ece3-1f8c-2bb3-6d4d-e7a215e4c9c1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0936fe34-b1c6-5f4e-1eee-fa338ed8b930" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9361d00b-bf28-09e2-175e-2f8c5c8d39ac" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0936fe34-b1c6-5f4e-1eee-fa338ed8b930" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_a142b19a-8793-4b19-f90e-d4ecccce4f97" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9361d00b-bf28-09e2-175e-2f8c5c8d39ac" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_a142b19a-8793-4b19-f90e-d4ecccce4f97" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_a6e76a34-fa42-d66f-a2a4-5865ce92446b" xlink:type="locator" />
    <loc xlink:href="biib-20150930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_bf13782d-1724-0c45-a352-d4ecccf5eb0b" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_a6e76a34-fa42-d66f-a2a4-5865ce92446b" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_bf13782d-1724-0c45-a352-d4ecccf5eb0b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_73b022da-9054-5e1b-96dd-04e339313a48" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_a6e76a34-fa42-d66f-a2a4-5865ce92446b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_73b022da-9054-5e1b-96dd-04e339313a48" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_465ba6e6-2b33-45fe-3e73-c5293643fc38" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_a6e76a34-fa42-d66f-a2a4-5865ce92446b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_465ba6e6-2b33-45fe-3e73-c5293643fc38" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_037594ef-c95d-7169-0f2c-0d9bf9c6587e" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_9c55f220-92b5-d322-b264-8565d6f98283" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_037594ef-c95d-7169-0f2c-0d9bf9c6587e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_9c55f220-92b5-d322-b264-8565d6f98283" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_decf3e7b-8400-73a7-9168-2d6d4804b247" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_037594ef-c95d-7169-0f2c-0d9bf9c6587e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_decf3e7b-8400-73a7-9168-2d6d4804b247" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_acf5d13d-61d7-58c0-7f7b-a5c0f7cb7066" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_037594ef-c95d-7169-0f2c-0d9bf9c6587e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_acf5d13d-61d7-58c0-7f7b-a5c0f7cb7066" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4b3be44f-5687-e783-ac34-c53c5c3f10e0" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_037594ef-c95d-7169-0f2c-0d9bf9c6587e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4b3be44f-5687-e783-ac34-c53c5c3f10e0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_79b52493-ed4b-fb62-5daf-e1982275e67b" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_037594ef-c95d-7169-0f2c-0d9bf9c6587e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_79b52493-ed4b-fb62-5daf-e1982275e67b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_b7dc579f-e75c-078b-3163-aa7cbf10455d" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_037594ef-c95d-7169-0f2c-0d9bf9c6587e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_b7dc579f-e75c-078b-3163-aa7cbf10455d" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_750737d4-a9f6-ddcb-7238-bbe8eadd7390" xlink:type="locator" />
    <calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_037594ef-c95d-7169-0f2c-0d9bf9c6587e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_750737d4-a9f6-ddcb-7238-bbe8eadd7390" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_827805f6-6e2a-818b-c1dc-d4eccd3a9153" xlink:type="locator" />
    <calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_037594ef-c95d-7169-0f2c-0d9bf9c6587e" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_827805f6-6e2a-818b-c1dc-d4eccd3a9153" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/IndebtednessIdebtednessDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/IndebtednessIndebtedness" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_894a128f-2068-d267-1e3e-64c93d0ed5ca" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5fad788a-33b8-6ace-c3c4-7d91cd9f63e4" xlink:type="locator" />
    <calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_894a128f-2068-d267-1e3e-64c93d0ed5ca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5fad788a-33b8-6ace-c3c4-7d91cd9f63e4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_ba3ee58c-a1d2-0b1b-d8ba-aeea5e112c4e" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_894a128f-2068-d267-1e3e-64c93d0ed5ca" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_ba3ee58c-a1d2-0b1b-d8ba-aeea5e112c4e" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d1f67248-e9b5-f4cc-7b0f-6057f1a3d17a" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_37242da4-8bd9-8845-4f04-4d33ee3aa769" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d1f67248-e9b5-f4cc-7b0f-6057f1a3d17a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_37242da4-8bd9-8845-4f04-4d33ee3aa769" xlink:type="arc" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d1f67248-e9b5-f4cc-7b0f-6057f1a3d17a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5fad788a-33b8-6ace-c3c4-7d91cd9f63e4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0b66a991-68b5-43d2-3cb3-4ea68bba2b7e" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d1f67248-e9b5-f4cc-7b0f-6057f1a3d17a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0b66a991-68b5-43d2-3cb3-4ea68bba2b7e" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_Finitelivedintangibleassetsfutureamortization" xlink:label="loc_biib_Finitelivedintangibleassetsfutureamortization_7f8164a6-3307-f223-f76d-d4ecccfc5814" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_d2ae3101-f749-ffd5-b93e-6f07027013ae" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Finitelivedintangibleassetsfutureamortization_7f8164a6-3307-f223-f76d-d4ecccfc5814" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_d2ae3101-f749-ffd5-b93e-6f07027013ae" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2249ecdd-108d-3264-e1fb-82dc2f8b7f93" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Finitelivedintangibleassetsfutureamortization_7f8164a6-3307-f223-f76d-d4ecccfc5814" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2249ecdd-108d-3264-e1fb-82dc2f8b7f93" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0395a918-3975-df2b-2aff-c690ea9ff6a6" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Finitelivedintangibleassetsfutureamortization_7f8164a6-3307-f223-f76d-d4ecccfc5814" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0395a918-3975-df2b-2aff-c690ea9ff6a6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_522cf592-49df-8430-14fb-ace2b07d08a6" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Finitelivedintangibleassetsfutureamortization_7f8164a6-3307-f223-f76d-d4ecccfc5814" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_522cf592-49df-8430-14fb-ace2b07d08a6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_f9536b4e-5267-6ef8-a509-7c8008810f55" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Finitelivedintangibleassetsfutureamortization_7f8164a6-3307-f223-f76d-d4ecccfc5814" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_f9536b4e-5267-6ef8-a509-7c8008810f55" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1435205b-5a1f-afbc-0b39-6d638729472e" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Finitelivedintangibleassetsfutureamortization_7f8164a6-3307-f223-f76d-d4ecccfc5814" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1435205b-5a1f-afbc-0b39-6d638729472e" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_eae794c2-73ec-cd91-efb3-99a2ff1f24cf" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_52e0aebe-a03f-09bd-b0a5-024dc9cc6bc5" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_eae794c2-73ec-cd91-efb3-99a2ff1f24cf" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_52e0aebe-a03f-09bd-b0a5-024dc9cc6bc5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_8162f0c6-3901-3410-efb8-4a460fb9898c" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_eae794c2-73ec-cd91-efb3-99a2ff1f24cf" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_8162f0c6-3901-3410-efb8-4a460fb9898c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_67158a47-96e7-9b0f-c6d4-8e2f09cc69df" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_eae794c2-73ec-cd91-efb3-99a2ff1f24cf" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_67158a47-96e7-9b0f-c6d4-8e2f09cc69df" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_915682f7-b9cc-2ed3-6852-178ddfcb101f" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_f41ffc72-ebad-5797-e151-38939dd37877" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_915682f7-b9cc-2ed3-6852-178ddfcb101f" xlink:to="loc_us-gaap_InvestmentIncomeInterest_f41ffc72-ebad-5797-e151-38939dd37877" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_8d3aa4ad-dbea-9eba-4578-5d3b83ba3bc6" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_915682f7-b9cc-2ed3-6852-178ddfcb101f" xlink:to="loc_us-gaap_InterestExpense_8d3aa4ad-dbea-9eba-4578-5d3b83ba3bc6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_a9b00820-766d-4f93-08eb-06a6be9e0e6b" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_915682f7-b9cc-2ed3-6852-178ddfcb101f" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_a9b00820-766d-4f93-08eb-06a6be9e0e6b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_7d95006c-ae0a-39bc-bb82-9715342e9a83" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_915682f7-b9cc-2ed3-6852-178ddfcb101f" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_7d95006c-ae0a-39bc-bb82-9715342e9a83" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_51486ac3-3cfb-dff4-43ca-0d3980775a1d" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_915682f7-b9cc-2ed3-6852-178ddfcb101f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_51486ac3-3cfb-dff4-43ca-0d3980775a1d" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7f5c7cfd-4659-429c-35ab-266d67961421" xlink:type="locator" />
    <loc xlink:href="biib-20150930.xsd#biib_Employeerelatedliabilitiesnoncurrent" xlink:label="loc_biib_Employeerelatedliabilitiesnoncurrent_f92e99ca-128a-38fa-2b71-d4ecccd8d600" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_7f5c7cfd-4659-429c-35ab-266d67961421" xlink:to="loc_biib_Employeerelatedliabilitiesnoncurrent_f92e99ca-128a-38fa-2b71-d4ecccd8d600" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_966acde3-4f37-c9e4-23af-34b57d61d82f" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_7f5c7cfd-4659-429c-35ab-266d67961421" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_966acde3-4f37-c9e4-23af-34b57d61d82f" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_c1cdcecb-6358-aee2-3913-b09d3829a3a8" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_7f5c7cfd-4659-429c-35ab-266d67961421" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_c1cdcecb-6358-aee2-3913-b09d3829a3a8" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1Calc2" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_ed55a377-3e01-611f-cd7f-0fbe24ab1ea8" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_7668125b-8e16-a6bf-5206-b61c4942c5e3" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_ed55a377-3e01-611f-cd7f-0fbe24ab1ea8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_7668125b-8e16-a6bf-5206-b61c4942c5e3" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_33deb27f-5bc5-f719-f29b-d4eccd282105" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_ed55a377-3e01-611f-cd7f-0fbe24ab1ea8" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_33deb27f-5bc5-f719-f29b-d4eccd282105" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>biib-20150930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:href="biib-20150930.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20150930.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:href="biib-20150930.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20150930.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitions" xlink:href="biib-20150930.xsd#AcquisitionsAcquisitions" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails" xlink:href="biib-20150930.xsd#AcquisitionsAcquisitionsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails1" xlink:href="biib-20150930.xsd#AcquisitionsAcquisitionsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetailsTextual" xlink:href="biib-20150930.xsd#AcquisitionsAcquisitionsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsTables" xlink:href="biib-20150930.xsd#AcquisitionsAcquisitionsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20150930.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:href="biib-20150930.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:href="biib-20150930.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencesDetails" xlink:href="biib-20150930.xsd#CommitmentsAndContingencesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:href="biib-20150930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:href="biib-20150930.xsd#CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="biib-20150930.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="biib-20150930.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="biib-20150930.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="biib-20150930.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedParenthetical" xlink:href="biib-20150930.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:href="biib-20150930.xsd#CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20150930.xsd#DerivativeInstruments" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20150930.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20150930.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:href="biib-20150930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20150930.xsd#EarningsPerShare" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20150930.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20150930.xsd#EarningsPerShareTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20150930.xsd#Equity" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EquityDetails" xlink:href="biib-20150930.xsd#EquityDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:href="biib-20150930.xsd#EquityDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:href="biib-20150930.xsd#EquityTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20150930.xsd#FairValueMeasurements" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20150930.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20150930.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20150930.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20150930.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20150930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20150930.xsd#FinancialInstruments" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20150930.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20150930.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20150930.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20150930.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:href="biib-20150930.xsd#FinancialInstrumentsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:href="biib-20150930.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20150930.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20150930.xsd#IncomeTaxes" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20150930.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20150930.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20150930.xsd#IncomeTaxesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IndebtednessIdebtednessDetails" xlink:href="biib-20150930.xsd#IndebtednessIdebtednessDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IndebtednessIndebtedness" xlink:href="biib-20150930.xsd#IndebtednessIndebtedness" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20150930.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20150930.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20150930.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20150930.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20150930.xsd#Inventory" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20150930.xsd#InventoryDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual" xlink:href="biib-20150930.xsd#InventoryInventoryDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20150930.xsd#InventoryTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20150930.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20150930.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20150930.xsd#Litigation" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:href="biib-20150930.xsd#LitigationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20150930.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20150930.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:href="biib-20150930.xsd#OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20150930.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:href="biib-20150930.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:href="biib-20150930.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetailsTextual" xlink:href="biib-20150930.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentTables" xlink:href="biib-20150930.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipmentTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances" xlink:href="biib-20150930.xsd#ReservesForDiscountsAndAllowances" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails" xlink:href="biib-20150930.xsd#ReservesForDiscountsAndAllowancesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20150930.xsd#ReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables" xlink:href="biib-20150930.xsd#ReservesForDiscountsAndAllowancesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20150930.xsd#ShareBasedPayments" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20150930.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20150930.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:href="biib-20150930.xsd#ShareBasedPaymentsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:href="biib-20150930.xsd#ShareBasedPaymentsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20150930.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents" xlink:href="biib-20150930.xsd#SubsequentEventsSubsequentEvents" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails" xlink:href="biib-20150930.xsd#SubsequentEventsSubsequentEventsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20150930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20150930.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20150930.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A71D09DF5D4DAE13144AAE73DAC88E12" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_B073DB90F67EB6FFA3C8AE73DAC75079" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A71D09DF5D4DAE13144AAE73DAC88E12" xlink:to="loc_us-gaap_StatementTable_B073DB90F67EB6FFA3C8AE73DAC75079" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1FFD3CEDCFB69DC17F51AE73DAC71386" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_B073DB90F67EB6FFA3C8AE73DAC75079" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1FFD3CEDCFB69DC17F51AE73DAC71386" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_C0AFF8C03C07EDC0F9F4AE73DAC74078_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1FFD3CEDCFB69DC17F51AE73DAC71386" xlink:to="loc_us-gaap_EquityComponentDomain_C0AFF8C03C07EDC0F9F4AE73DAC74078_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_C0AFF8C03C07EDC0F9F4AE73DAC74078" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1FFD3CEDCFB69DC17F51AE73DAC71386" xlink:to="loc_us-gaap_EquityComponentDomain_C0AFF8C03C07EDC0F9F4AE73DAC74078" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_B3F82AEED4FEF94D3195AE73DAC86B32" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_C0AFF8C03C07EDC0F9F4AE73DAC74078" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_B3F82AEED4FEF94D3195AE73DAC86B32" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_51398B047631C4D2CB1FAE73DAC89CD8" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_C0AFF8C03C07EDC0F9F4AE73DAC74078" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_51398B047631C4D2CB1FAE73DAC89CD8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_BA43F811940A123FC9E5AE73DAC83528" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_C0AFF8C03C07EDC0F9F4AE73DAC74078" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_BA43F811940A123FC9E5AE73DAC83528" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_B6A817B389E0EC44A451AE73DAC86BE2" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_C0AFF8C03C07EDC0F9F4AE73DAC74078" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_B6A817B389E0EC44A451AE73DAC86BE2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_AFB961221FB32CDA3BA6AE73DAC8B410" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A71D09DF5D4DAE13144AAE73DAC88E12" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_AFB961221FB32CDA3BA6AE73DAC8B410" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_B22267E37C86E622B459AE73DAC827EA" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A71D09DF5D4DAE13144AAE73DAC88E12" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_B22267E37C86E622B459AE73DAC827EA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_A31DB94F1AAE78803289AE73DAC84FE3" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A71D09DF5D4DAE13144AAE73DAC88E12" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_A31DB94F1AAE78803289AE73DAC84FE3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_000A265A83FFB3A59AECAE73DAC831B7" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A71D09DF5D4DAE13144AAE73DAC88E12" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_000A265A83FFB3A59AECAE73DAC831B7" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_8C9067EFF8FEB6CE75273F3E22CAB8CB" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_E10F703D4FBFA00363723F3E22CA7D08" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_8C9067EFF8FEB6CE75273F3E22CAB8CB" xlink:to="loc_us-gaap_StatementTable_E10F703D4FBFA00363723F3E22CA7D08" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5B09CE218CDB50EA54743F3E22CAFCBC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_E10F703D4FBFA00363723F3E22CA7D08" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5B09CE218CDB50EA54743F3E22CAFCBC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_C55EFB1C97B84D096E753F3E22CAFD7C_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5B09CE218CDB50EA54743F3E22CAFCBC" xlink:to="loc_us-gaap_EquityComponentDomain_C55EFB1C97B84D096E753F3E22CAFD7C_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_C55EFB1C97B84D096E753F3E22CAFD7C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5B09CE218CDB50EA54743F3E22CAFCBC" xlink:to="loc_us-gaap_EquityComponentDomain_C55EFB1C97B84D096E753F3E22CAFD7C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_D209FE9D8C2FB1EDEFAD3F3E22CAD475" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_C55EFB1C97B84D096E753F3E22CAFD7C" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_D209FE9D8C2FB1EDEFAD3F3E22CAD475" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_93139726C20451F7C40D3F3E22CA047B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_C55EFB1C97B84D096E753F3E22CAFD7C" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_93139726C20451F7C40D3F3E22CA047B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_E12648F30DED21B8FB7C3F3E22CA4571" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_E10F703D4FBFA00363723F3E22CA7D08" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_E12648F30DED21B8FB7C3F3E22CA4571" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_79579F456B13957A78473F3E22CA4961_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_E12648F30DED21B8FB7C3F3E22CA4571" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_79579F456B13957A78473F3E22CA4961_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_79579F456B13957A78473F3E22CA4961" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_E12648F30DED21B8FB7C3F3E22CA4571" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_79579F456B13957A78473F3E22CA4961" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_F985421BE347DDB8E87E3F3E22CA6BD5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_79579F456B13957A78473F3E22CA4961" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_F985421BE347DDB8E87E3F3E22CA6BD5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_F438B2155987471462FC3F3E22CA6C65" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_8C9067EFF8FEB6CE75273F3E22CAB8CB" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_F438B2155987471462FC3F3E22CA6C65" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_DEC0507AAA6907BC1EC33F3E22CACA2A" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_8C9067EFF8FEB6CE75273F3E22CAB8CB" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_DEC0507AAA6907BC1EC33F3E22CACA2A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_CD7023CD582889D514883F3E22CA1A32" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_8C9067EFF8FEB6CE75273F3E22CAB8CB" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_CD7023CD582889D514883F3E22CA1A32" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_D3C32535CB0332415D863F3E22CA03D0" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_8C9067EFF8FEB6CE75273F3E22CAB8CB" xlink:to="loc_us-gaap_NetIncomeLoss_D3C32535CB0332415D863F3E22CA03D0" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitions" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_F7DC79D95934D85AF4EFAE73D98F1B1F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6539D1F992E2E43976D7AE73D98E06A8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_F7DC79D95934D85AF4EFAE73D98F1B1F" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6539D1F992E2E43976D7AE73D98E06A8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5559ACA89EED988F6FC7AE73D98EA694" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6539D1F992E2E43976D7AE73D98E06A8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5559ACA89EED988F6FC7AE73D98EA694" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9A9FA6D0B01DD51D54E9AE73D98E8CC5_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5559ACA89EED988F6FC7AE73D98EA694" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9A9FA6D0B01DD51D54E9AE73D98E8CC5_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9A9FA6D0B01DD51D54E9AE73D98E8CC5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5559ACA89EED988F6FC7AE73D98EA694" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9A9FA6D0B01DD51D54E9AE73D98E8CC5" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_362D0C06803EFE4D68E5AE73D98FD750" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9A9FA6D0B01DD51D54E9AE73D98E8CC5" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_362D0C06803EFE4D68E5AE73D98FD750" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_8FFCFCF03A1C5D8813C6AE73D98F4EF4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_F7DC79D95934D85AF4EFAE73D98F1B1F" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_8FFCFCF03A1C5D8813C6AE73D98F4EF4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_082BE282BE9279C442DBAE73D98F6937" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_F7DC79D95934D85AF4EFAE73D98F1B1F" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_082BE282BE9279C442DBAE73D98F6937" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_C77348E6510F7F513EAFAE73D98F860C" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_F7DC79D95934D85AF4EFAE73D98F1B1F" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_C77348E6510F7F513EAFAE73D98F860C" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_61C0CDAFA79297C91B07AE73DAD83871" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1ACFD8A35556A2DA2974AE73DAD80F35" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_61C0CDAFA79297C91B07AE73DAD83871" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1ACFD8A35556A2DA2974AE73DAD80F35" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_DC63467ABC4F3AA5B6D6AE73DAD84FCD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1ACFD8A35556A2DA2974AE73DAD80F35" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_DC63467ABC4F3AA5B6D6AE73DAD84FCD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17035937EB437A2A904AAE73DAD81490_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_DC63467ABC4F3AA5B6D6AE73DAD84FCD" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17035937EB437A2A904AAE73DAD81490_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17035937EB437A2A904AAE73DAD81490" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_DC63467ABC4F3AA5B6D6AE73DAD84FCD" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17035937EB437A2A904AAE73DAD81490" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_FC2503F1E3E8A36B5D04AE73DAD82C58" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17035937EB437A2A904AAE73DAD81490" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_FC2503F1E3E8A36B5D04AE73DAD82C58" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_954FAF1B3D7EB1C795F5AE73DAD97F14" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_61C0CDAFA79297C91B07AE73DAD83871" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_954FAF1B3D7EB1C795F5AE73DAD97F14" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_48C28D5CC4D69A5FA60DAE73DAD9995B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_61C0CDAFA79297C91B07AE73DAD83871" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_48C28D5CC4D69A5FA60DAE73DAD9995B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_FF2D33449CA53C08E4D9AE73DAD93992" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_61C0CDAFA79297C91B07AE73DAD83871" xlink:to="loc_us-gaap_Goodwill_FF2D33449CA53C08E4D9AE73DAD93992" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_6AF0007A0C5E0909F8EFAE73DAD97B49" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_61C0CDAFA79297C91B07AE73DAD83871" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_6AF0007A0C5E0909F8EFAE73DAD97B49" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_4CC4F48AA710F6C39361AE73DAD9DE67" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_61C0CDAFA79297C91B07AE73DAD83871" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_4CC4F48AA710F6C39361AE73DAD9DE67" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_B555EC941B8F504AE48EAE73DAD9810A" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_61C0CDAFA79297C91B07AE73DAD83871" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_B555EC941B8F504AE48EAE73DAD9810A" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_F778C55D46CCA913817571883E1EEB85" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0B07D458439ACEB1B60371883E1D3DFE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_F778C55D46CCA913817571883E1EEB85" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0B07D458439ACEB1B60371883E1D3DFE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2D9C4242B02CE80D05DC71883E1D057E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0B07D458439ACEB1B60371883E1D3DFE" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2D9C4242B02CE80D05DC71883E1D057E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B7C5B1C061072C5417EB71883E1D7276_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2D9C4242B02CE80D05DC71883E1D057E" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B7C5B1C061072C5417EB71883E1D7276_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B7C5B1C061072C5417EB71883E1D7276" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2D9C4242B02CE80D05DC71883E1D057E" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B7C5B1C061072C5417EB71883E1D7276" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_477C66E5148D216012EE71883E1D54BF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B7C5B1C061072C5417EB71883E1D7276" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_477C66E5148D216012EE71883E1D54BF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_19B5892897ABBFE8B4C971883E1D5BA7" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0B07D458439ACEB1B60371883E1D3DFE" xlink:to="loc_us-gaap_ProductOrServiceAxis_19B5892897ABBFE8B4C971883E1D5BA7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_CAD0C13B87366566E73871883E1D330A_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_19B5892897ABBFE8B4C971883E1D5BA7" xlink:to="loc_us-gaap_ProductsAndServicesDomain_CAD0C13B87366566E73871883E1D330A_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_CAD0C13B87366566E73871883E1D330A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_19B5892897ABBFE8B4C971883E1D5BA7" xlink:to="loc_us-gaap_ProductsAndServicesDomain_CAD0C13B87366566E73871883E1D330A" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_RaxatrigineMember" xlink:label="loc_biib_RaxatrigineMember_1D85FF1DAA07723F644271883E1ED9A6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_CAD0C13B87366566E73871883E1D330A" xlink:to="loc_biib_RaxatrigineMember_1D85FF1DAA07723F644271883E1ED9A6" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_NeuropathicpainindicationsMember" xlink:label="loc_biib_NeuropathicpainindicationsMember_AD648A403DA02AAEFEF671883E1EDF28" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_CAD0C13B87366566E73871883E1D330A" xlink:to="loc_biib_NeuropathicpainindicationsMember_AD648A403DA02AAEFEF671883E1EDF28" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_C7670D61D9D5D4024BFC71883E1EEC2E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_F778C55D46CCA913817571883E1EEB85" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_C7670D61D9D5D4024BFC71883E1EEC2E" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_2EACD7FC1BF7B97D77DC71883E1ECDB4" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_F778C55D46CCA913817571883E1EEB85" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_2EACD7FC1BF7B97D77DC71883E1ECDB4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_DA2CDAACB2242088FC0571883E1E4630" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_F778C55D46CCA913817571883E1EEB85" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_DA2CDAACB2242088FC0571883E1E4630" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_CA2BBFE40549412982E371883E1EFE57" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_F778C55D46CCA913817571883E1EEB85" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_CA2BBFE40549412982E371883E1EFE57" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease_80D5DEEDF5274F9AA59171883E1E26C5" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_F778C55D46CCA913817571883E1EEB85" xlink:to="loc_us-gaap_GoodwillPeriodIncreaseDecrease_80D5DEEDF5274F9AA59171883E1E26C5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_F841767D78C843CA950671883E1E7224" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_F778C55D46CCA913817571883E1EEB85" xlink:to="loc_us-gaap_FairValueInputsDiscountRate_F841767D78C843CA950671883E1E7224" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_1BDBB106DFA6051338B171883E1EEF46" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_F778C55D46CCA913817571883E1EEB85" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_1BDBB106DFA6051338B171883E1EEF46" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_46BCE14ABC5413D47CE871883E1E04A8" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_F778C55D46CCA913817571883E1EEB85" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_46BCE14ABC5413D47CE871883E1E04A8" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitionsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFB5CBE92E7DF9AAC1DF43FEA0E2F5B2" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1C7D9DA5FF00719A3A7F43FEA0E22DF6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFB5CBE92E7DF9AAC1DF43FEA0E2F5B2" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1C7D9DA5FF00719A3A7F43FEA0E22DF6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_9351AE7B1E141C965F3043FEA0E2A527" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1C7D9DA5FF00719A3A7F43FEA0E22DF6" xlink:to="loc_us-gaap_ProductOrServiceAxis_9351AE7B1E141C965F3043FEA0E2A527" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_95270CF13AE5B400A2DC43FEA0E25E27_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_9351AE7B1E141C965F3043FEA0E2A527" xlink:to="loc_us-gaap_ProductsAndServicesDomain_95270CF13AE5B400A2DC43FEA0E25E27_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_95270CF13AE5B400A2DC43FEA0E25E27" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_9351AE7B1E141C965F3043FEA0E2A527" xlink:to="loc_us-gaap_ProductsAndServicesDomain_95270CF13AE5B400A2DC43FEA0E25E27" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_LeadprogramsMember" xlink:label="loc_biib_LeadprogramsMember_38CE7703D191A10C6C9E43FEA0E2E2FB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_95270CF13AE5B400A2DC43FEA0E25E27" xlink:to="loc_biib_LeadprogramsMember_38CE7703D191A10C6C9E43FEA0E2E2FB" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_DiscoveryprogramsMember" xlink:label="loc_biib_DiscoveryprogramsMember_ADFBCDFA6E51CBEA090B43FEA0E2DF9D" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_95270CF13AE5B400A2DC43FEA0E25E27" xlink:to="loc_biib_DiscoveryprogramsMember_ADFBCDFA6E51CBEA090B43FEA0E2DF9D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7A4680417DAE3E8BE4F343FEA0E2E172" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1C7D9DA5FF00719A3A7F43FEA0E22DF6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7A4680417DAE3E8BE4F343FEA0E2E172" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_73DDC09B68A92D43B73B43FEA0E27B6D_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7A4680417DAE3E8BE4F343FEA0E2E172" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_73DDC09B68A92D43B73B43FEA0E27B6D_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_73DDC09B68A92D43B73B43FEA0E27B6D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7A4680417DAE3E8BE4F343FEA0E2E172" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_73DDC09B68A92D43B73B43FEA0E27B6D" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_MitsubishiTanabePharmaCorporationMember" xlink:label="loc_biib_MitsubishiTanabePharmaCorporationMember_E907908813EF53B1142443FEA0E2DD23" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_73DDC09B68A92D43B73B43FEA0E27B6D" xlink:to="loc_biib_MitsubishiTanabePharmaCorporationMember_E907908813EF53B1142443FEA0E2DD23" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_AGTCMember" xlink:label="loc_biib_AGTCMember_A48444DC4304BE35A81343FEA0E284CD" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_73DDC09B68A92D43B73B43FEA0E27B6D" xlink:to="loc_biib_AGTCMember_A48444DC4304BE35A81343FEA0E284CD" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SwedishOrphanBiovitrumMember" xlink:label="loc_biib_SwedishOrphanBiovitrumMember_15DEEDB40CEB2F4049E043FEA0E2EEDE" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_73DDC09B68A92D43B73B43FEA0E27B6D" xlink:to="loc_biib_SwedishOrphanBiovitrumMember_15DEEDB40CEB2F4049E043FEA0E2EEDE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_B5C40E0FE58D77541A4843FEA0E29286" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFB5CBE92E7DF9AAC1DF43FEA0E2F5B2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_B5C40E0FE58D77541A4843FEA0E29286" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_C209A469CD947B3EF4DE43FEA0E38EBA" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFB5CBE92E7DF9AAC1DF43FEA0E2F5B2" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_C209A469CD947B3EF4DE43FEA0E38EBA" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_Upfrontmilestonepayment" xlink:label="loc_biib_Upfrontmilestonepayment_CDB681C346A41E52E37C43FEA0E3FC0D" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFB5CBE92E7DF9AAC1DF43FEA0E2F5B2" xlink:to="loc_biib_Upfrontmilestonepayment_CDB681C346A41E52E37C43FEA0E3FC0D" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_Purchaseofcommonstock" xlink:label="loc_biib_Purchaseofcommonstock_4F73654FF98DE600327243FEA0E3BDBB" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFB5CBE92E7DF9AAC1DF43FEA0E2F5B2" xlink:to="loc_biib_Purchaseofcommonstock_4F73654FF98DE600327243FEA0E3BDBB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_0228242BB5B82764A3DA43FEA0E31B71" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFB5CBE92E7DF9AAC1DF43FEA0E2F5B2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_0228242BB5B82764A3DA43FEA0E31B71" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicenseCosts" xlink:label="loc_us-gaap_LicenseCosts_C3DAE20AAC0A7F66F37643FEA0E35AEF" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFB5CBE92E7DF9AAC1DF43FEA0E2F5B2" xlink:to="loc_us-gaap_LicenseCosts_C3DAE20AAC0A7F66F37643FEA0E35AEF" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_Researchanddevelopmentservices" xlink:label="loc_biib_Researchanddevelopmentservices_90145527D86F6321C5D44401170FE736" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFB5CBE92E7DF9AAC1DF43FEA0E2F5B2" xlink:to="loc_biib_Researchanddevelopmentservices_90145527D86F6321C5D44401170FE736" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_Premiumonequityinvestment" xlink:label="loc_biib_Premiumonequityinvestment_F51FE72C5F2EC2B916D743FEA0E3115F" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFB5CBE92E7DF9AAC1DF43FEA0E2F5B2" xlink:to="loc_biib_Premiumonequityinvestment_F51FE72C5F2EC2B916D743FEA0E3115F" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_6C8EC7F3DC2DFF2B73A943FEA0E32983" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFB5CBE92E7DF9AAC1DF43FEA0E2F5B2" xlink:to="loc_biib_AdditionalMilestonePayment_6C8EC7F3DC2DFF2B73A943FEA0E32983" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3597189B2BCE41228AD8AE73D9573E41" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_FBEBB55F50E93B5597F5AE73D95781A1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3597189B2BCE41228AD8AE73D9573E41" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_FBEBB55F50E93B5597F5AE73D95781A1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4E207D692DF211677B4AAE73D957B789" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_FBEBB55F50E93B5597F5AE73D95781A1" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4E207D692DF211677B4AAE73D957B789" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_B8880A517D22D6DB4D2DAE73D9572C54_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4E207D692DF211677B4AAE73D957B789" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_B8880A517D22D6DB4D2DAE73D9572C54_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_B8880A517D22D6DB4D2DAE73D9572C54" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4E207D692DF211677B4AAE73D957B789" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_B8880A517D22D6DB4D2DAE73D9572C54" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_7E0E37069767CDBF8963AE73D957397B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_B8880A517D22D6DB4D2DAE73D9572C54" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_7E0E37069767CDBF8963AE73D957397B" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" xlink:label="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_41AF7C69484757FFC14FAE73D957F097" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3597189B2BCE41228AD8AE73D9573E41" xlink:to="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_41AF7C69484757FFC14FAE73D957F097" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_JointVentureOwnerShipPercentageByThirdParty" xlink:label="loc_biib_JointVentureOwnerShipPercentageByThirdParty_54B2C72B65B4C378328AAE73D95767EC" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3597189B2BCE41228AD8AE73D9573E41" xlink:to="loc_biib_JointVentureOwnerShipPercentageByThirdParty_54B2C72B65B4C378328AAE73D95767EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_9CB4FFA9B459E1C56B74AE73D95733DE" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3597189B2BCE41228AD8AE73D9573E41" xlink:to="loc_us-gaap_EquityMethodInvestments_9CB4FFA9B459E1C56B74AE73D95733DE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_888EC4F26F6E9E901D71AE73D957C129" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3597189B2BCE41228AD8AE73D9573E41" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_888EC4F26F6E9E901D71AE73D957C129" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_EAB11AABB378F83B4233AE73D957729F" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3597189B2BCE41228AD8AE73D9573E41" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_EAB11AABB378F83B4233AE73D957729F" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_EquityMethodInvestmentOwnershipPercentageMaximum" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_B73581D89CB97F0C9A56AE73D95734CC" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3597189B2BCE41228AD8AE73D9573E41" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_B73581D89CB97F0C9A56AE73D95734CC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_517D388A11C0C5EFFF5DAE73D958823A" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3597189B2BCE41228AD8AE73D9573E41" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_517D388A11C0C5EFFF5DAE73D958823A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1621F5F278CE78216F5FAE73D958D7EF" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3597189B2BCE41228AD8AE73D9573E41" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1621F5F278CE78216F5FAE73D958D7EF" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_BF482127EE2A9E03F9DEAE73D958AEF3" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3597189B2BCE41228AD8AE73D9573E41" xlink:to="loc_biib_AdditionalMilestonePayment_BF482127EE2A9E03F9DEAE73D958AEF3" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_EquityMethodInvestmentsExpectedProfitShare" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_F3453C5ABEE1D8DC309CAE73D9588530" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3597189B2BCE41228AD8AE73D9573E41" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_F3453C5ABEE1D8DC309CAE73D9588530" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_56DCEE9C060367D8575DAE73D9589E90" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3597189B2BCE41228AD8AE73D9573E41" xlink:to="loc_us-gaap_OtherSalesRevenueNet_56DCEE9C060367D8575DAE73D9589E90" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingencesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4C856771F8E500FF08E03F3E2282BF88" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1D7B087FDA3E1516FF833F3E228126DF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4C856771F8E500FF08E03F3E2282BF88" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1D7B087FDA3E1516FF833F3E228126DF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="biib-20150930.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_4C55D43A856D54B327833F3E2281BB66" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1D7B087FDA3E1516FF833F3E228126DF" xlink:to="loc_biib_CumulativeSalesLevelAxis_4C55D43A856D54B327833F3E2281BB66" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_AA077F9E992D4AEF0EDD3F3E228163D9_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_CumulativeSalesLevelAxis_4C55D43A856D54B327833F3E2281BB66" xlink:to="loc_biib_CumulativeSalesLevelDomain_AA077F9E992D4AEF0EDD3F3E228163D9_default" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_AA077F9E992D4AEF0EDD3F3E228163D9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_CumulativeSalesLevelAxis_4C55D43A856D54B327833F3E2281BB66" xlink:to="loc_biib_CumulativeSalesLevelDomain_AA077F9E992D4AEF0EDD3F3E228163D9" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_FourbillionMember" xlink:label="loc_biib_FourbillionMember_14DC9D8041A1E7118E3C3F3E2281E4EA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_AA077F9E992D4AEF0EDD3F3E228163D9" xlink:to="loc_biib_FourbillionMember_14DC9D8041A1E7118E3C3F3E2281E4EA" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_FivebillionMember" xlink:label="loc_biib_FivebillionMember_A5E161E412B2A7F2267B3F3E22812D39" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_AA077F9E992D4AEF0EDD3F3E228163D9" xlink:to="loc_biib_FivebillionMember_A5E161E412B2A7F2267B3F3E22812D39" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SixbillionMember" xlink:label="loc_biib_SixbillionMember_EDB968E377305E3F9CB13F86E28D0F6E" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_AA077F9E992D4AEF0EDD3F3E228163D9" xlink:to="loc_biib_SixbillionMember_EDB968E377305E3F9CB13F86E28D0F6E" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_056AD91582DBEAF306CA3F3E22811482" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_AA077F9E992D4AEF0EDD3F3E228163D9" xlink:to="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_056AD91582DBEAF306CA3F3E22811482" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_OneBillionMember" xlink:label="loc_biib_OneBillionMember_5E71E2F114E6D418BDBD3F3E2281FDAA" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_AA077F9E992D4AEF0EDD3F3E228163D9" xlink:to="loc_biib_OneBillionMember_5E71E2F114E6D418BDBD3F3E2281FDAA" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_ThreeBillionMember" xlink:label="loc_biib_ThreeBillionMember_448C062CF29247EA488D3F3E2281B6C7" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_AA077F9E992D4AEF0EDD3F3E228163D9" xlink:to="loc_biib_ThreeBillionMember_448C062CF29247EA488D3F3E2281B6C7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_382AF231A839F8B0B71B3F3E2282BE2D" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1D7B087FDA3E1516FF833F3E228126DF" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_382AF231A839F8B0B71B3F3E2282BE2D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_41D96D74E15383526D533F3E2282F556_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_382AF231A839F8B0B71B3F3E2282BE2D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_41D96D74E15383526D533F3E2282F556_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_41D96D74E15383526D533F3E2282F556" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_382AF231A839F8B0B71B3F3E2282BE2D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_41D96D74E15383526D533F3E2282F556" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_10CAD5AAAF1763C484F73F3E228259EE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_41D96D74E15383526D533F3E2282F556" xlink:to="loc_biib_FumapharmAgMember_10CAD5AAAF1763C484F73F3E228259EE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_44629A458C7F34A71AD63F3E228291D5" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1D7B087FDA3E1516FF833F3E228126DF" xlink:to="loc_us-gaap_ProductOrServiceAxis_44629A458C7F34A71AD63F3E228291D5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_E189B96F16593FF691033F3E22822D47_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_44629A458C7F34A71AD63F3E228291D5" xlink:to="loc_us-gaap_ProductsAndServicesDomain_E189B96F16593FF691033F3E22822D47_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_E189B96F16593FF691033F3E22822D47" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_44629A458C7F34A71AD63F3E228291D5" xlink:to="loc_us-gaap_ProductsAndServicesDomain_E189B96F16593FF691033F3E22822D47" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_1ED6A605267E6BD2BBC03F3E2282C2D3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E189B96F16593FF691033F3E22822D47" xlink:to="loc_biib_TecfideraMember_1ED6A605267E6BD2BBC03F3E2282C2D3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_6D4FFB2D0B7CEC2828C63F3E2282E1B3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4C856771F8E500FF08E03F3E2282BF88" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_6D4FFB2D0B7CEC2828C63F3E2282E1B3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4E4B8BC8CB30ACEEE5B03F3E22825CB9" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4C856771F8E500FF08E03F3E2282BF88" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4E4B8BC8CB30ACEEE5B03F3E22825CB9" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_5AD055203F8A4FD3DDF73F3E2282683D" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4C856771F8E500FF08E03F3E2282BF88" xlink:to="loc_biib_CumulativeSalesLevel_5AD055203F8A4FD3DDF73F3E2282683D" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0B7581993C9B0E2EA9F3AE73DA92C287" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_4C01FBFF5C55DDEB033FAE73DA92FF86" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0B7581993C9B0E2EA9F3AE73DA92C287" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_4C01FBFF5C55DDEB033FAE73DA92FF86" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_C459EB3083ED884B30BFAE73DA929D47" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_4C01FBFF5C55DDEB033FAE73DA92FF86" xlink:to="loc_us-gaap_StatementGeographicalAxis_C459EB3083ED884B30BFAE73DA929D47" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_1C9E18AEFAA00CE82453AE73DA928913_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_C459EB3083ED884B30BFAE73DA929D47" xlink:to="loc_us-gaap_SegmentGeographicalDomain_1C9E18AEFAA00CE82453AE73DA928913_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_1C9E18AEFAA00CE82453AE73DA928913" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_C459EB3083ED884B30BFAE73DA929D47" xlink:to="loc_us-gaap_SegmentGeographicalDomain_1C9E18AEFAA00CE82453AE73DA928913" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_CH" xlink:label="loc_country_CH_57E9FB756D275CEEC7E3AE73DA927ECA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_1C9E18AEFAA00CE82453AE73DA928913" xlink:to="loc_country_CH_57E9FB756D275CEEC7E3AE73DA927ECA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Land" xlink:label="loc_us-gaap_Land_A3900C5EBEFDDC62286FAE73DA928955" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0B7581993C9B0E2EA9F3AE73DA92C287" xlink:to="loc_us-gaap_Land_A3900C5EBEFDDC62286FAE73DA928955" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedParenthetical" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_ADEB9161A70F9F58000871883D97BF43" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5661B9FC8ECA81734BBF71883D903FD8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ADEB9161A70F9F58000871883D97BF43" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5661B9FC8ECA81734BBF71883D903FD8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_F9137E129C4289F7E1E571883D902F8F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5661B9FC8ECA81734BBF71883D903FD8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_F9137E129C4289F7E1E571883D902F8F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_E630E70D56D556D4882B71883D905E60_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_F9137E129C4289F7E1E571883D902F8F" xlink:to="loc_us-gaap_EquityComponentDomain_E630E70D56D556D4882B71883D905E60_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_E630E70D56D556D4882B71883D905E60" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_F9137E129C4289F7E1E571883D902F8F" xlink:to="loc_us-gaap_EquityComponentDomain_E630E70D56D556D4882B71883D905E60" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_6437FDB9E33F4EECA8A471883D90075C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_E630E70D56D556D4882B71883D905E60" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_6437FDB9E33F4EECA8A471883D90075C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_62AF664553A6FF4AE35471883D90550D" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5661B9FC8ECA81734BBF71883D903FD8" xlink:to="loc_us-gaap_DebtInstrumentAxis_62AF664553A6FF4AE35471883D90550D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5999F17314350458F9EC71883D90E54F_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_62AF664553A6FF4AE35471883D90550D" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5999F17314350458F9EC71883D90E54F_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5999F17314350458F9EC71883D90E54F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_62AF664553A6FF4AE35471883D90550D" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5999F17314350458F9EC71883D90E54F" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_54977BD726433157B60771883D904E2C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5999F17314350458F9EC71883D90E54F" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_54977BD726433157B60771883D904E2C" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_847DA85D41DAC8B9057C71883D9068A6" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5999F17314350458F9EC71883D90E54F" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_847DA85D41DAC8B9057C71883D9068A6" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_DA2FEA6B56321AB78A8D71883D90749A" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5999F17314350458F9EC71883D90E54F" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_DA2FEA6B56321AB78A8D71883D90749A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaap_CurrencyAxis_F88AE216C787925E4AB471883D90AC24" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5661B9FC8ECA81734BBF71883D903FD8" xlink:to="loc_us-gaap_CurrencyAxis_F88AE216C787925E4AB471883D90AC24" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_3C4DFE46ADCF99F2254771883D906B05_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CurrencyAxis_F88AE216C787925E4AB471883D90AC24" xlink:to="loc_currency_AllCurrenciesDomain_3C4DFE46ADCF99F2254771883D906B05_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_3C4DFE46ADCF99F2254771883D906B05" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CurrencyAxis_F88AE216C787925E4AB471883D90AC24" xlink:to="loc_currency_AllCurrenciesDomain_3C4DFE46ADCF99F2254771883D906B05" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_BB987EC231F3BCA7841271883D9016D7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_3C4DFE46ADCF99F2254771883D906B05" xlink:to="loc_currency_EUR_BB987EC231F3BCA7841271883D9016D7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_9214581F3388E20CF22E71883D900F73" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_3C4DFE46ADCF99F2254771883D906B05" xlink:to="loc_currency_CAD_9214581F3388E20CF22E71883D900F73" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_54673D65504D10AC046F71883D90E6D4" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_3C4DFE46ADCF99F2254771883D906B05" xlink:to="loc_currency_GBP_54673D65504D10AC046F71883D90E6D4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_JPY" xlink:label="loc_currency_JPY_6A890CB159A3ECADA30271883D917A3D" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_3C4DFE46ADCF99F2254771883D906B05" xlink:to="loc_currency_JPY_6A890CB159A3ECADA30271883D917A3D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AUD" xlink:label="loc_currency_AUD_11DAED1BE65F6D65A5C371883D9148D3" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_3C4DFE46ADCF99F2254771883D906B05" xlink:to="loc_currency_AUD_11DAED1BE65F6D65A5C371883D9148D3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_70C5DC0DB328D1CB3F4B71883D91D928" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5661B9FC8ECA81734BBF71883D903FD8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_70C5DC0DB328D1CB3F4B71883D91D928" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C9DCAD0AE89887F23AD771883D91A2F4_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_70C5DC0DB328D1CB3F4B71883D91D928" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_C9DCAD0AE89887F23AD771883D91A2F4_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C9DCAD0AE89887F23AD771883D91A2F4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_70C5DC0DB328D1CB3F4B71883D91D928" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_C9DCAD0AE89887F23AD771883D91A2F4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_F9CA5412A296A741E5F671883D917EB0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C9DCAD0AE89887F23AD771883D91A2F4" xlink:to="loc_us-gaap_SalesMember_F9CA5412A296A741E5F671883D917EB0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_DBAA740734B5288BCC1471883D916303" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C9DCAD0AE89887F23AD771883D91A2F4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_DBAA740734B5288BCC1471883D916303" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_7559A45E2BE627CC0C0871883D918DD5" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5661B9FC8ECA81734BBF71883D903FD8" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_7559A45E2BE627CC0C0871883D918DD5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_15A4CFCAAAFC153D2E0671883D913F2F_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7559A45E2BE627CC0C0871883D918DD5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_15A4CFCAAAFC153D2E0671883D913F2F_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_15A4CFCAAAFC153D2E0671883D913F2F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7559A45E2BE627CC0C0871883D918DD5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_15A4CFCAAAFC153D2E0671883D913F2F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_591E016BC232CB22A9E971883D916DF1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_15A4CFCAAAFC153D2E0671883D913F2F" xlink:to="loc_us-gaap_ForeignExchangeContractMember_591E016BC232CB22A9E971883D916DF1" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_InterestratelocksMember" xlink:label="loc_biib_InterestratelocksMember_3B0D41ABD32C1ECAE60B71883D916591" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_15A4CFCAAAFC153D2E0671883D913F2F" xlink:to="loc_biib_InterestratelocksMember_3B0D41ABD32C1ECAE60B71883D916591" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_4B7121D80409244270B871883D91D2BF" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_15A4CFCAAAFC153D2E0671883D913F2F" xlink:to="loc_us-gaap_InterestRateSwapMember_4B7121D80409244270B871883D91D2BF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_D23194920FDEDCC6BCB071883D91A24B" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5661B9FC8ECA81734BBF71883D903FD8" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_D23194920FDEDCC6BCB071883D91A24B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8787B6B7DACE435004FE71883D91D512_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_D23194920FDEDCC6BCB071883D91A24B" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8787B6B7DACE435004FE71883D91D512_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8787B6B7DACE435004FE71883D91D512" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_D23194920FDEDCC6BCB071883D91A24B" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8787B6B7DACE435004FE71883D91D512" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_A1A8587FE0475B354F2D71883D910A5F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8787B6B7DACE435004FE71883D91D512" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_A1A8587FE0475B354F2D71883D910A5F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="loc_us-gaap_OtherInvestmentsMember_F4CF7731752451F96FD971883D913A04" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8787B6B7DACE435004FE71883D91D512" xlink:to="loc_us-gaap_OtherInvestmentsMember_F4CF7731752451F96FD971883D913A04" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_3B69F2E0A5072BDCC72D71883D92D09A" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8787B6B7DACE435004FE71883D91D512" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_3B69F2E0A5072BDCC72D71883D92D09A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_7CAD6154F6535306734771883D92BC31" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8787B6B7DACE435004FE71883D91D512" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_7CAD6154F6535306734771883D92BC31" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_DFCF0CA186418E91EE6C71883D92E3D5" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5661B9FC8ECA81734BBF71883D903FD8" xlink:to="loc_us-gaap_HedgingDesignationAxis_DFCF0CA186418E91EE6C71883D92E3D5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_B1E0C97B80B357052D2571883D92F408_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_DFCF0CA186418E91EE6C71883D92E3D5" xlink:to="loc_us-gaap_HedgingDesignationDomain_B1E0C97B80B357052D2571883D92F408_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_B1E0C97B80B357052D2571883D92F408" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_DFCF0CA186418E91EE6C71883D92E3D5" xlink:to="loc_us-gaap_HedgingDesignationDomain_B1E0C97B80B357052D2571883D92F408" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_951EDFEFFD4AF905DDD271883D923A00" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_B1E0C97B80B357052D2571883D92F408" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_951EDFEFFD4AF905DDD271883D923A00" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_2431FDFAB5771274CAC271883D97F720" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_B1E0C97B80B357052D2571883D92F408" xlink:to="loc_us-gaap_NondesignatedMember_2431FDFAB5771274CAC271883D97F720" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_27B3206A552A8630A9DD71883D9C0319" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ADEB9161A70F9F58000871883D97BF43" xlink:to="loc_us-gaap_DerivativeAssetFairValueNetAbstract_27B3206A552A8630A9DD71883D9C0319" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_DD771838E0898A2A9ADB71883D9C289A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_27B3206A552A8630A9DD71883D9C0319" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_DD771838E0898A2A9ADB71883D9C289A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_75E28D89FF67069FE30B71883D9C67E3" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_27B3206A552A8630A9DD71883D9C0319" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_75E28D89FF67069FE30B71883D9C67E3" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_DerivativeInstrumentsTextualAbstract" xlink:label="loc_biib_DerivativeInstrumentsTextualAbstract_2B95F15DCB5BD88DD2BA71883D9C4459" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ADEB9161A70F9F58000871883D97BF43" xlink:to="loc_biib_DerivativeInstrumentsTextualAbstract_2B95F15DCB5BD88DD2BA71883D9C4459" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLowerRemainingMaturityRange1" xlink:label="loc_us-gaap_DerivativeLowerRemainingMaturityRange1_2F4F94091B01D8CBD56271883D9C5635" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_2B95F15DCB5BD88DD2BA71883D9C4459" xlink:to="loc_us-gaap_DerivativeLowerRemainingMaturityRange1_2F4F94091B01D8CBD56271883D9C5635" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeHigherRemainingMaturityRange1" xlink:label="loc_us-gaap_DerivativeHigherRemainingMaturityRange1_33C68787831D3B5F059671883D9CA55C" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_2B95F15DCB5BD88DD2BA71883D9C4459" xlink:to="loc_us-gaap_DerivativeHigherRemainingMaturityRange1_33C68787831D3B5F059671883D9CA55C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_11EA4347461178D2E37771883D9C8FCB" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_2B95F15DCB5BD88DD2BA71883D9C4459" xlink:to="loc_invest_DerivativeNotionalAmount_11EA4347461178D2E37771883D9C8FCB" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_7BCEF77576DE56DBA48671883D9DB5CF" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_2B95F15DCB5BD88DD2BA71883D9C4459" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_7BCEF77576DE56DBA48671883D9DB5CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_D71F5765F0FFB218B16271883D9DD75F" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_2B95F15DCB5BD88DD2BA71883D9C4459" xlink:to="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_D71F5765F0FFB218B16271883D9DD75F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_98D0B672259F876B715D71883D9DC172" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_2B95F15DCB5BD88DD2BA71883D9C4459" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_98D0B672259F876B715D71883D9DC172" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_DCB5C27FBF090C1156F271883D9D7036" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_2B95F15DCB5BD88DD2BA71883D9C4459" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_DCB5C27FBF090C1156F271883D9D7036" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_BD54A25A007AC78DBB8671883D9D9D70" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_2B95F15DCB5BD88DD2BA71883D9C4459" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_BD54A25A007AC78DBB8671883D9D9D70" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8F6AA8B2E295D3CAB45271883D9D62CA" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_2B95F15DCB5BD88DD2BA71883D9C4459" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8F6AA8B2E295D3CAB45271883D9D62CA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_923D865BE31BCD18A94B71883D9D1BCE" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_2B95F15DCB5BD88DD2BA71883D9C4459" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_923D865BE31BCD18A94B71883D9D1BCE" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3D70FBF4CCD77D11A581AE73DAAD41BB" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_332E799A3E6482108ED8AE73DAAC42BF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3D70FBF4CCD77D11A581AE73DAAD41BB" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_332E799A3E6482108ED8AE73DAAC42BF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6279105BFE54D83B5FA7AE73DAAC09D7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_332E799A3E6482108ED8AE73DAAC42BF" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6279105BFE54D83B5FA7AE73DAAC09D7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3E467AF57B45B70425A2AE73DAACD1F9_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6279105BFE54D83B5FA7AE73DAAC09D7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3E467AF57B45B70425A2AE73DAACD1F9_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3E467AF57B45B70425A2AE73DAACD1F9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6279105BFE54D83B5FA7AE73DAAC09D7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3E467AF57B45B70425A2AE73DAACD1F9" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E1544BD1DACAADCE3A1FAE73DAACB3FF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3E467AF57B45B70425A2AE73DAACD1F9" xlink:to="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E1544BD1DACAADCE3A1FAE73DAACB3FF" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_26EAC58710C7B644C55DAE73DAADEC2B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3E467AF57B45B70425A2AE73DAACD1F9" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_26EAC58710C7B644C55DAE73DAADEC2B" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_F98DE2956AFC73D09645AE73DAAD9E47" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3E467AF57B45B70425A2AE73DAACD1F9" xlink:to="loc_biib_MarketStockUnitsMember_F98DE2956AFC73D09645AE73DAAD9E47" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_8F8947208496BFDAC620AE73DAADBF57" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3D70FBF4CCD77D11A581AE73DAAD41BB" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_8F8947208496BFDAC620AE73DAADBF57" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_0D1D5138AACEF5657D5EAE73DAADDC4E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_8F8947208496BFDAC620AE73DAADBF57" xlink:to="loc_us-gaap_NetIncomeLossAbstract_0D1D5138AACEF5657D5EAE73DAADDC4E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_FD82AA7CBF17BDA4E04AAE73DAADDAF0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_0D1D5138AACEF5657D5EAE73DAADDC4E" xlink:to="loc_us-gaap_NetIncomeLoss_FD82AA7CBF17BDA4E04AAE73DAADDAF0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_FB599B4976B87AB09F90AE73DAADF303" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_8F8947208496BFDAC620AE73DAADBF57" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_FB599B4976B87AB09F90AE73DAADF303" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_230376A524458ECA756AAE73DAADDE33" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_FB599B4976B87AB09F90AE73DAADF303" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_230376A524458ECA756AAE73DAADDE33" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_05ABFE26BFFE1BA748F9AE73DAAD7AB7" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_FB599B4976B87AB09F90AE73DAADF303" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_05ABFE26BFFE1BA748F9AE73DAAD7AB7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8121223E6DAA46EBA951AE73DAAD2EAD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_05ABFE26BFFE1BA748F9AE73DAAD7AB7" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8121223E6DAA46EBA951AE73DAAD2EAD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_0C9B6310E7F2AB72BEF0AE73DAAD9D38" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_05ABFE26BFFE1BA748F9AE73DAAD7AB7" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_0C9B6310E7F2AB72BEF0AE73DAAD9D38" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_68DFD58195CDAA9C52C4AE73DAAD1368" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_FB599B4976B87AB09F90AE73DAADF303" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_68DFD58195CDAA9C52C4AE73DAAD1368" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/EquityDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="loc_us-gaap_MinorityInterestLineItems_C40F61420DE540DBD7BD875A3D37AC18" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="loc_us-gaap_MinorityInterestTable_4B2EA797A70E840641DD875A3D37E63D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_C40F61420DE540DBD7BD875A3D37AC18" xlink:to="loc_us-gaap_MinorityInterestTable_4B2EA797A70E840641DD875A3D37E63D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_1138872278EA1825B0DF875A3D37D13E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_4B2EA797A70E840641DD875A3D37E63D" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_1138872278EA1825B0DF875A3D37D13E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_EE444E617E2859599921875A3D37A337_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_1138872278EA1825B0DF875A3D37D13E" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_EE444E617E2859599921875A3D37A337_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_EE444E617E2859599921875A3D37A337" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_1138872278EA1825B0DF875A3D37D13E" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_EE444E617E2859599921875A3D37A337" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_92D63231C9308DF0800F875A3D37BB74" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_EE444E617E2859599921875A3D37A337" xlink:to="loc_biib_NeurimmuneMember_92D63231C9308DF0800F875A3D37BB74" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_E57813F252C74B61C141875A3D37FA83" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_C40F61420DE540DBD7BD875A3D37AC18" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_E57813F252C74B61C141875A3D37FA83" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_66D3A98DBC6B29FF514B875A3D379699" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_C40F61420DE540DBD7BD875A3D37AC18" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_66D3A98DBC6B29FF514B875A3D379699" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_12C172F3CEBBE24ABE9C875A3D37EA66" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_C40F61420DE540DBD7BD875A3D37AC18" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_12C172F3CEBBE24ABE9C875A3D37EA66" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A7B8DBB15892F754C4C4AE73D99CE7A5" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FC11D69342D83B7B8E93AE73D99A4E69" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A7B8DBB15892F754C4C4AE73D99CE7A5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FC11D69342D83B7B8E93AE73D99A4E69" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A52BE0D26FAD476CB8B3AE73D99B25AC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FC11D69342D83B7B8E93AE73D99A4E69" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A52BE0D26FAD476CB8B3AE73D99B25AC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9803B66CB35D93C2148FAE73D99B75FB_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A52BE0D26FAD476CB8B3AE73D99B25AC" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9803B66CB35D93C2148FAE73D99B75FB_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9803B66CB35D93C2148FAE73D99B75FB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A52BE0D26FAD476CB8B3AE73D99B25AC" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9803B66CB35D93C2148FAE73D99B75FB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9CA31CE67376E2434B65AE73D99BED67" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9803B66CB35D93C2148FAE73D99B75FB" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9CA31CE67376E2434B65AE73D99BED67" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_A18377FD0173C450F956AE73D99B7805" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9803B66CB35D93C2148FAE73D99B75FB" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_A18377FD0173C450F956AE73D99B7805" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2E0077E5FE6AE5E7E803AE73D99BBE58" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9803B66CB35D93C2148FAE73D99B75FB" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2E0077E5FE6AE5E7E803AE73D99BBE58" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6850FA8AE469DB795836AE73D99B801C" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FC11D69342D83B7B8E93AE73D99A4E69" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6850FA8AE469DB795836AE73D99B801C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8EED916F6EF2EE9A9B7FAE73D99BD82E_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6850FA8AE469DB795836AE73D99B801C" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8EED916F6EF2EE9A9B7FAE73D99BD82E_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8EED916F6EF2EE9A9B7FAE73D99BD82E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6850FA8AE469DB795836AE73D99B801C" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8EED916F6EF2EE9A9B7FAE73D99BD82E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_CBDAF0D76DFECE6A2292AE73D99B40AD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_8EED916F6EF2EE9A9B7FAE73D99BD82E" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_CBDAF0D76DFECE6A2292AE73D99B40AD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_21C87B041BB4778C46E1AE73D99BBBD5" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FC11D69342D83B7B8E93AE73D99A4E69" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_21C87B041BB4778C46E1AE73D99BBBD5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_FA84A1598394A8DC0394AE73D99B81A6_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_21C87B041BB4778C46E1AE73D99BBBD5" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_FA84A1598394A8DC0394AE73D99B81A6_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_FA84A1598394A8DC0394AE73D99B81A6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_21C87B041BB4778C46E1AE73D99BBBD5" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_FA84A1598394A8DC0394AE73D99B81A6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9C76A7B5FBF2DBD17144AE73D99B2DF7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_FA84A1598394A8DC0394AE73D99B81A6" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9C76A7B5FBF2DBD17144AE73D99B2DF7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_394D48A9FBAF5FAEF294AE73D99C6BF2" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_FA84A1598394A8DC0394AE73D99B81A6" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_394D48A9FBAF5FAEF294AE73D99C6BF2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_4B9939D775B16BFEBA06AE73D99CAA7E" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_FA84A1598394A8DC0394AE73D99B81A6" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_4B9939D775B16BFEBA06AE73D99CAA7E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_9EAFC26590F174F9D423AE73D99CAA00" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A7B8DBB15892F754C4C4AE73D99CE7A5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_9EAFC26590F174F9D423AE73D99CAA00" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_C73496645E029C24B696AE73D99CACA6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_9EAFC26590F174F9D423AE73D99CAA00" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_C73496645E029C24B696AE73D99CACA6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_DDB99059D33C19042470AE73D99CE832" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_C73496645E029C24B696AE73D99CACA6" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_DDB99059D33C19042470AE73D99CE832" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_435F75EA1A094B99D241AE73D99CE778" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_C73496645E029C24B696AE73D99CACA6" xlink:to="loc_us-gaap_AvailableForSaleSecurities_435F75EA1A094B99D241AE73D99CE778" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_679942340E194E852910AE73D99C0187" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_C73496645E029C24B696AE73D99CACA6" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_679942340E194E852910AE73D99C0187" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_F317E08BCF09618832BDAE73D99C8596" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_C73496645E029C24B696AE73D99CACA6" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_F317E08BCF09618832BDAE73D99C8596" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_E97E431AD6C8252F6670AE73D99C7011" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_C73496645E029C24B696AE73D99CACA6" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_E97E431AD6C8252F6670AE73D99C7011" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8D0093057C4319AE34EFAE73D99C051B" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_C73496645E029C24B696AE73D99CACA6" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_8D0093057C4319AE34EFAE73D99C051B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_CA4A28F1D156793C8DDFAE73D99C0BAD" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_9EAFC26590F174F9D423AE73D99CAA00" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_CA4A28F1D156793C8DDFAE73D99C0BAD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_C56C6D6643740FAAF87AAE73D99C4CC0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_CA4A28F1D156793C8DDFAE73D99C0BAD" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_C56C6D6643740FAAF87AAE73D99C4CC0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_171D35C5DD79E5989571AE73D99D5857" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_CA4A28F1D156793C8DDFAE73D99C0BAD" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_171D35C5DD79E5989571AE73D99D5857" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_E08E6026A0CC0668C3E1AE73D99DF94C" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_CA4A28F1D156793C8DDFAE73D99C0BAD" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_E08E6026A0CC0668C3E1AE73D99DF94C" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_A83892476EEA39CBAAA82E2530685161" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_CAAB3ECA7F5022FE9E242E253067BAFE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A83892476EEA39CBAAA82E2530685161" xlink:to="loc_us-gaap_DebtInstrumentTable_CAAB3ECA7F5022FE9E242E253067BAFE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_A40416B24C3B45654FC32E253067DCB5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_CAAB3ECA7F5022FE9E242E253067BAFE" xlink:to="loc_us-gaap_DebtInstrumentAxis_A40416B24C3B45654FC32E253067DCB5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_EA1DDF68FD1F5462EB1A2E253067AA31_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_A40416B24C3B45654FC32E253067DCB5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_EA1DDF68FD1F5462EB1A2E253067AA31_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_EA1DDF68FD1F5462EB1A2E253067AA31" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_A40416B24C3B45654FC32E253067DCB5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_EA1DDF68FD1F5462EB1A2E253067AA31" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_NotesPayableToFumedicaMember" xlink:label="loc_biib_NotesPayableToFumedicaMember_6011038135E308B348D92E2530673CD5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_EA1DDF68FD1F5462EB1A2E253067AA31" xlink:to="loc_biib_NotesPayableToFumedicaMember_6011038135E308B348D92E2530673CD5" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_FE84211CF90B8C1421582E253068B9F0" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_EA1DDF68FD1F5462EB1A2E253067AA31" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_FE84211CF90B8C1421582E253068B9F0" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_67F532469C70FF144FB32E3F7265C450" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_EA1DDF68FD1F5462EB1A2E253067AA31" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_67F532469C70FF144FB32E3F7265C450" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_B862861C424B2708D0192E41431E9125" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_EA1DDF68FD1F5462EB1A2E253067AA31" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_B862861C424B2708D0192E41431E9125" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_8CBA50488B91F2C97AA72E42BB1E2358" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_EA1DDF68FD1F5462EB1A2E253067AA31" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_8CBA50488B91F2C97AA72E42BB1E2358" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_B9F21E726FA51CD45C8E2E43F7DC2BB4" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_EA1DDF68FD1F5462EB1A2E253067AA31" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_B9F21E726FA51CD45C8E2E43F7DC2BB4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_28BB50082A9FC84B84042E253068D881" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A83892476EEA39CBAAA82E2530685161" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_28BB50082A9FC84B84042E253068D881" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_45B9E442B3B3B92FCD692E253068B9EB" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A83892476EEA39CBAAA82E2530685161" xlink:to="loc_us-gaap_NotesPayable_45B9E442B3B3B92FCD692E253068B9EB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_57D6C7784B7E2F6136402E25306871FE" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A83892476EEA39CBAAA82E2530685161" xlink:to="loc_us-gaap_DebtInstrumentFairValue_57D6C7784B7E2F6136402E25306871FE" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_CBA66B786B665AD3DC13AE73DA993053" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6A9993956C3B48EAEA68AE73DA982B5B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_CBA66B786B665AD3DC13AE73DA993053" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6A9993956C3B48EAEA68AE73DA982B5B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4C59EEFB7D930A600FD8AE73DA9849D9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6A9993956C3B48EAEA68AE73DA982B5B" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4C59EEFB7D930A600FD8AE73DA9849D9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_473E913192FA04DA4116AE73DA99B699_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4C59EEFB7D930A600FD8AE73DA9849D9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_473E913192FA04DA4116AE73DA99B699_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_473E913192FA04DA4116AE73DA99B699" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4C59EEFB7D930A600FD8AE73DA9849D9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_473E913192FA04DA4116AE73DA99B699" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_28CB3C6AEE76FC24A198AE73DA99C5B3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_473E913192FA04DA4116AE73DA99B699" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_28CB3C6AEE76FC24A198AE73DA99C5B3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_D1D8DDBA9609EED54F24AE73DA99744A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_CBA66B786B665AD3DC13AE73DA993053" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_D1D8DDBA9609EED54F24AE73DA99744A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_139F904B44A811F4F2B2AE73DA998843" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_CBA66B786B665AD3DC13AE73DA993053" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_139F904B44A811F4F2B2AE73DA998843" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_89BAFA8F73DE08D5719BAE73DA99CAD6" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_CBA66B786B665AD3DC13AE73DA993053" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_89BAFA8F73DE08D5719BAE73DA99CAD6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_94638A156ACA64B01178AE73DA996094" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_CBA66B786B665AD3DC13AE73DA993053" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_94638A156ACA64B01178AE73DA996094" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_9D2EC17A38522B49B0384EEFD7CE7932" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_54D89D2755318A55C9534EEFD7CDE112" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_9D2EC17A38522B49B0384EEFD7CE7932" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_54D89D2755318A55C9534EEFD7CDE112" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9D6FAEAC8C3E887697354EEFD7CD57BE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_54D89D2755318A55C9534EEFD7CDE112" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9D6FAEAC8C3E887697354EEFD7CD57BE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_BEE47F91328439D4AEB44EEFD7CD14BA_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9D6FAEAC8C3E887697354EEFD7CD57BE" xlink:to="loc_us-gaap_TypeOfAdoptionMember_BEE47F91328439D4AEB44EEFD7CD14BA_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_BEE47F91328439D4AEB44EEFD7CD14BA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9D6FAEAC8C3E887697354EEFD7CD57BE" xlink:to="loc_us-gaap_TypeOfAdoptionMember_BEE47F91328439D4AEB44EEFD7CD14BA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember_D97C1C8215015DEA4B374EEFD7CDB903" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_BEE47F91328439D4AEB44EEFD7CD14BA" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember_D97C1C8215015DEA4B374EEFD7CDB903" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_02519EA8E87D5F442DE94EEFD7CD5F03" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_54D89D2755318A55C9534EEFD7CDE112" xlink:to="loc_us-gaap_DebtInstrumentAxis_02519EA8E87D5F442DE94EEFD7CD5F03" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_600E466A136DE445CB0F4EEFD7CDF4D1_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_02519EA8E87D5F442DE94EEFD7CD5F03" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_600E466A136DE445CB0F4EEFD7CDF4D1_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_600E466A136DE445CB0F4EEFD7CDF4D1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_02519EA8E87D5F442DE94EEFD7CD5F03" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_600E466A136DE445CB0F4EEFD7CDF4D1" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_A5234F2BB0FD4DFE26484EEFD7CD7219" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_600E466A136DE445CB0F4EEFD7CDF4D1" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_A5234F2BB0FD4DFE26484EEFD7CD7219" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_808604F38D2F60122E6E4EEFD7CD058E" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_600E466A136DE445CB0F4EEFD7CDF4D1" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_808604F38D2F60122E6E4EEFD7CD058E" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D5B161C9C6D82A3E978E4EEFD7CDDE8A" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_600E466A136DE445CB0F4EEFD7CDF4D1" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D5B161C9C6D82A3E978E4EEFD7CDDE8A" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_B38514DD4265224884D44EEFD7CE9549" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_600E466A136DE445CB0F4EEFD7CDF4D1" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_B38514DD4265224884D44EEFD7CE9549" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_815F4D724694A342003D4EEFD7CE3DFD" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_600E466A136DE445CB0F4EEFD7CDF4D1" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_815F4D724694A342003D4EEFD7CE3DFD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_CAFC3C3C34AA2280283C4EEFD7CE3FA1" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_54D89D2755318A55C9534EEFD7CDE112" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_CAFC3C3C34AA2280283C4EEFD7CE3FA1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AAA77350EEFA4C2DC7914EEFD7CE76F7_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_CAFC3C3C34AA2280283C4EEFD7CE3FA1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AAA77350EEFA4C2DC7914EEFD7CE76F7_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AAA77350EEFA4C2DC7914EEFD7CE76F7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_CAFC3C3C34AA2280283C4EEFD7CE3FA1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AAA77350EEFA4C2DC7914EEFD7CE76F7" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_EEA9DD1833B1BB7258FC4EEFD7CE4BA1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AAA77350EEFA4C2DC7914EEFD7CE76F7" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_EEA9DD1833B1BB7258FC4EEFD7CE4BA1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_47D2AEB9EC89F1B9C6D54EEFD7CE5619" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_9D2EC17A38522B49B0384EEFD7CE7932" xlink:to="loc_us-gaap_AssetImpairmentCharges_47D2AEB9EC89F1B9C6D54EEFD7CE5619" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsChangesInValuationTechniques" xlink:label="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_113D5FAD98080D4DCAD54EEFD7CE65E4" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_9D2EC17A38522B49B0384EEFD7CE7932" xlink:to="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_113D5FAD98080D4DCAD54EEFD7CE65E4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtIssuanceCosts" xlink:label="loc_us-gaap_DebtIssuanceCosts_311FD69AC90FBD64FC4D4EEFD7CEF3AC" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_9D2EC17A38522B49B0384EEFD7CE7932" xlink:to="loc_us-gaap_DebtIssuanceCosts_311FD69AC90FBD64FC4D4EEFD7CEF3AC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_FCFD2014FA2C33BD69124EEFD7CE5BE6" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_9D2EC17A38522B49B0384EEFD7CE7932" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_FCFD2014FA2C33BD69124EEFD7CE5BE6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_BDE67515C98601A561964EEFD7CE23FB" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_9D2EC17A38522B49B0384EEFD7CE7932" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_BDE67515C98601A561964EEFD7CE23FB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_2EB37210E097D3F682E64EEFD7CEB86A" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_9D2EC17A38522B49B0384EEFD7CE7932" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_2EB37210E097D3F682E64EEFD7CEB86A" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_68339E8DEBE9AB78AE334EEFD7CE0442" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_9D2EC17A38522B49B0384EEFD7CE7932" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_68339E8DEBE9AB78AE334EEFD7CE0442" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_D8412F708C55D646540E4EEFD7CEAAF9" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_9D2EC17A38522B49B0384EEFD7CE7932" xlink:to="loc_us-gaap_FairValueInputsDiscountRate_D8412F708C55D646540E4EEFD7CEAAF9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_E3F8677105501A771D0A4EF25CA61338" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_9D2EC17A38522B49B0384EEFD7CE7932" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_E3F8677105501A771D0A4EF25CA61338" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_5A29A0253C8BD58F64604EEFD7CE92EB" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_9D2EC17A38522B49B0384EEFD7CE7932" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_5A29A0253C8BD58F64604EEFD7CE92EB" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_54FDB2B9D48F1AFBFF9BAE73D9A5DAAF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_ED9CA85CE95F36E483B2AE73D9A48278" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_54FDB2B9D48F1AFBFF9BAE73D9A5DAAF" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_ED9CA85CE95F36E483B2AE73D9A48278" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_8326487E1588232A56EEAE73D9A4EB2D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_ED9CA85CE95F36E483B2AE73D9A48278" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_8326487E1588232A56EEAE73D9A4EB2D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4DFE5FC8086B3BB807ADAE73D9A4CB15_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_8326487E1588232A56EEAE73D9A4EB2D" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4DFE5FC8086B3BB807ADAE73D9A4CB15_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4DFE5FC8086B3BB807ADAE73D9A4CB15" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_8326487E1588232A56EEAE73D9A4EB2D" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4DFE5FC8086B3BB807ADAE73D9A4CB15" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_374E4E2C08490C41076AAE73D9A49648" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4DFE5FC8086B3BB807ADAE73D9A4CB15" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_374E4E2C08490C41076AAE73D9A49648" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_27E75F2C13EC955A4924AE73D9A4D1C6" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4DFE5FC8086B3BB807ADAE73D9A4CB15" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_27E75F2C13EC955A4924AE73D9A4D1C6" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_B1674D3481D22C3B4BC3AE73D9A42278" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4DFE5FC8086B3BB807ADAE73D9A4CB15" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_B1674D3481D22C3B4BC3AE73D9A42278" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_958621CF5BA86EC61F7AAE73D9A4D105" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4DFE5FC8086B3BB807ADAE73D9A4CB15" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_958621CF5BA86EC61F7AAE73D9A4D105" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_05CC0345B3296F797184AE73D9A4E889" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4DFE5FC8086B3BB807ADAE73D9A4CB15" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_05CC0345B3296F797184AE73D9A4E889" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_7EBAD2F6926B49F8C584AE73D9A428BD" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4DFE5FC8086B3BB807ADAE73D9A4CB15" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_7EBAD2F6926B49F8C584AE73D9A428BD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_00CC927FCC7085DC955BAE73D9A4E424" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4DFE5FC8086B3BB807ADAE73D9A4CB15" xlink:to="loc_us-gaap_EquitySecuritiesMember_00CC927FCC7085DC955BAE73D9A4E424" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3EB914A7B704BA087A93AE73D9A53814" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_54FDB2B9D48F1AFBFF9BAE73D9A5DAAF" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3EB914A7B704BA087A93AE73D9A53814" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_677B8F2E20F595AE4473AE73D9A551A2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3EB914A7B704BA087A93AE73D9A53814" xlink:to="loc_us-gaap_AvailableForSaleSecurities_677B8F2E20F595AE4473AE73D9A551A2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8FF6A868AAB4DCF9DD98AE73D9A5960F" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3EB914A7B704BA087A93AE73D9A53814" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8FF6A868AAB4DCF9DD98AE73D9A5960F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_37769FBAF9C1AEDDBFE3AE73D9A571A9" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3EB914A7B704BA087A93AE73D9A53814" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_37769FBAF9C1AEDDBFE3AE73D9A571A9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_C3EECE13BEBD95AC7174AE73D9A5957B" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3EB914A7B704BA087A93AE73D9A53814" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_C3EECE13BEBD95AC7174AE73D9A5957B" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_A30E4615E1893A77C7E4AE73DACD79B9" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_93D314DEB1CA91939C8FAE73DACCC1FD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_A30E4615E1893A77C7E4AE73DACD79B9" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_93D314DEB1CA91939C8FAE73DACCC1FD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_D2EF599BE5C945B82C31AE73DACC46AA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_93D314DEB1CA91939C8FAE73DACCC1FD" xlink:to="loc_us-gaap_InvestmentTypeAxis_D2EF599BE5C945B82C31AE73DACC46AA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_772F0F232C62A72AEF18AE73DACD8490_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_D2EF599BE5C945B82C31AE73DACC46AA" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_772F0F232C62A72AEF18AE73DACD8490_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_772F0F232C62A72AEF18AE73DACD8490" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_D2EF599BE5C945B82C31AE73DACC46AA" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_772F0F232C62A72AEF18AE73DACD8490" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_2F51F3EE5696BA2E607BAE73DACDAD90" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_772F0F232C62A72AEF18AE73DACD8490" xlink:to="loc_us-gaap_CommercialPaperMember_2F51F3EE5696BA2E607BAE73DACDAD90" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_85A5F3810445AD5D1B98AE73DACD5DC9" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_772F0F232C62A72AEF18AE73DACD8490" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_85A5F3810445AD5D1B98AE73DACD5DC9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7A2D5CEADE62DA2A57B8AE73DACD0AF4" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_772F0F232C62A72AEF18AE73DACD8490" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7A2D5CEADE62DA2A57B8AE73DACD0AF4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_BDA880F00B02902C131DAE73DACD8A18" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_772F0F232C62A72AEF18AE73DACD8490" xlink:to="loc_us-gaap_DebtSecuritiesMember_BDA880F00B02902C131DAE73DACD8A18" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_1E0C2BC409729050D38AAE73DACDF66D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_A30E4615E1893A77C7E4AE73DACD79B9" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_1E0C2BC409729050D38AAE73DACDF66D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_833E1E6F7651F9EC2E38AE73DACD5A5E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_1E0C2BC409729050D38AAE73DACDF66D" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_833E1E6F7651F9EC2E38AE73DACD5A5E" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_E3AE1614C6A04E3D3804AE73DB601A9E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_35BB631EF1E757A4A161AE73DB60094F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E3AE1614C6A04E3D3804AE73DB601A9E" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_35BB631EF1E757A4A161AE73DB60094F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_27D079A2BE9D74DF9D75AE73DB6012B7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_35BB631EF1E757A4A161AE73DB60094F" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_27D079A2BE9D74DF9D75AE73DB6012B7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EB3B38DC4336DC08ABCCAE73DB6050F9_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_27D079A2BE9D74DF9D75AE73DB6012B7" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EB3B38DC4336DC08ABCCAE73DB6050F9_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EB3B38DC4336DC08ABCCAE73DB6050F9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_27D079A2BE9D74DF9D75AE73DB6012B7" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EB3B38DC4336DC08ABCCAE73DB6050F9" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_84F8BB0DB4C3ECFD7167AE73DB606C24" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EB3B38DC4336DC08ABCCAE73DB6050F9" xlink:to="loc_biib_StrategicInvestmentsMember_84F8BB0DB4C3ECFD7167AE73DB606C24" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_4665EBB3735364C37D9DAE73DB60F307" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E3AE1614C6A04E3D3804AE73DB601A9E" xlink:to="loc_biib_StrategicInvestmentPortfolio_4665EBB3735364C37D9DAE73DB60F307" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_CE13D21A11109AB590E0875A3D058FF8" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_5458054DD6F927104863875A3D05FE7F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_CE13D21A11109AB590E0875A3D058FF8" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_5458054DD6F927104863875A3D05FE7F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_5DFF0136A150E0F4E565875A3D051236" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_5458054DD6F927104863875A3D05FE7F" xlink:to="loc_us-gaap_TaxPeriodAxis_5DFF0136A150E0F4E565875A3D051236" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_C0F1B5E66AF59A94CB0E875A3D050753_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_5DFF0136A150E0F4E565875A3D051236" xlink:to="loc_us-gaap_TaxPeriodDomain_C0F1B5E66AF59A94CB0E875A3D050753_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_C0F1B5E66AF59A94CB0E875A3D050753" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_5DFF0136A150E0F4E565875A3D051236" xlink:to="loc_us-gaap_TaxPeriodDomain_C0F1B5E66AF59A94CB0E875A3D050753" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxYear2007Member" xlink:label="loc_us-gaap_TaxYear2007Member_DA33D9164D8653247DBB875A3D05D6FA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_C0F1B5E66AF59A94CB0E875A3D050753" xlink:to="loc_us-gaap_TaxYear2007Member_DA33D9164D8653247DBB875A3D05D6FA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxYear2008Member" xlink:label="loc_us-gaap_TaxYear2008Member_F2A1D0915449C95C8FB2875A3D05D892" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_C0F1B5E66AF59A94CB0E875A3D050753" xlink:to="loc_us-gaap_TaxYear2008Member_F2A1D0915449C95C8FB2875A3D05D892" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxYear2009Member" xlink:label="loc_us-gaap_TaxYear2009Member_5D329BA9C9F85758BC4F875A3D05DD9F" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_C0F1B5E66AF59A94CB0E875A3D050753" xlink:to="loc_us-gaap_TaxYear2009Member_5D329BA9C9F85758BC4F875A3D05DD9F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_CBF99875A6ACA1E5D3C9875A3D06BF04" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_CE13D21A11109AB590E0875A3D058FF8" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_CBF99875A6ACA1E5D3C9875A3D06BF04" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_90D87F1297F743020253875A3D06A2F5" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_CE13D21A11109AB590E0875A3D058FF8" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_90D87F1297F743020253875A3D06A2F5" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices" xlink:label="loc_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_D01220AF41A31016451C875A3D06F04E" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_CE13D21A11109AB590E0875A3D058FF8" xlink:to="loc_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_D01220AF41A31016451C875A3D06F04E" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessIdebtednessDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_F05A3A29B2F81DAC6D8D3EA2E589BB05" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_80DC13D589A8C003FFD33EA2E58890B3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F05A3A29B2F81DAC6D8D3EA2E589BB05" xlink:to="loc_us-gaap_DebtInstrumentTable_80DC13D589A8C003FFD33EA2E58890B3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5B4268666FB4C8A280D33EA2E5886D39" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_80DC13D589A8C003FFD33EA2E58890B3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5B4268666FB4C8A280D33EA2E5886D39" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_E224BBC70F21A0E580A93EA2E588E0D0_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5B4268666FB4C8A280D33EA2E5886D39" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_E224BBC70F21A0E580A93EA2E588E0D0_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_E224BBC70F21A0E580A93EA2E588E0D0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5B4268666FB4C8A280D33EA2E5886D39" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_E224BBC70F21A0E580A93EA2E588E0D0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_325FFF9386D7AB95D1853EA2E5889F4D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_E224BBC70F21A0E580A93EA2E588E0D0" xlink:to="loc_us-gaap_InterestRateSwapMember_325FFF9386D7AB95D1853EA2E5889F4D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_92910DA5D12E9A30EFE73EA2E588B51F" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_80DC13D589A8C003FFD33EA2E58890B3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_92910DA5D12E9A30EFE73EA2E588B51F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0FE0CC493C857A4C12C73EA2E588B9CD_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_92910DA5D12E9A30EFE73EA2E588B51F" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0FE0CC493C857A4C12C73EA2E588B9CD_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0FE0CC493C857A4C12C73EA2E588B9CD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_92910DA5D12E9A30EFE73EA2E588B51F" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0FE0CC493C857A4C12C73EA2E588B9CD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="loc_us-gaap_OtherInvestmentsMember_E81E4B8627F40A4618073EA2E58858F3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0FE0CC493C857A4C12C73EA2E588B9CD" xlink:to="loc_us-gaap_OtherInvestmentsMember_E81E4B8627F40A4618073EA2E58858F3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_9A6D567CF915C7D17FCF3EA2E5888E8C" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_80DC13D589A8C003FFD33EA2E58890B3" xlink:to="loc_us-gaap_HedgingDesignationAxis_9A6D567CF915C7D17FCF3EA2E5888E8C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_0E0CFAED9E3343B49B3B3EA2E5884EC2_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_9A6D567CF915C7D17FCF3EA2E5888E8C" xlink:to="loc_us-gaap_HedgingDesignationDomain_0E0CFAED9E3343B49B3B3EA2E5884EC2_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_0E0CFAED9E3343B49B3B3EA2E5884EC2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_9A6D567CF915C7D17FCF3EA2E5888E8C" xlink:to="loc_us-gaap_HedgingDesignationDomain_0E0CFAED9E3343B49B3B3EA2E5884EC2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_660ECC04DFCB94B9BE553EA2E5880F47" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_0E0CFAED9E3343B49B3B3EA2E5884EC2" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_660ECC04DFCB94B9BE553EA2E5880F47" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_4FC58F9C7050049B3AFE3EA2E588494F" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_80DC13D589A8C003FFD33EA2E58890B3" xlink:to="loc_us-gaap_DebtInstrumentAxis_4FC58F9C7050049B3AFE3EA2E588494F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_C370E8D56BE62ECC01C03EA2E5895444_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_4FC58F9C7050049B3AFE3EA2E588494F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_C370E8D56BE62ECC01C03EA2E5895444_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_C370E8D56BE62ECC01C03EA2E5895444" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_4FC58F9C7050049B3AFE3EA2E588494F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_C370E8D56BE62ECC01C03EA2E5895444" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E204A8979420E3C138BB3EA2E5893178" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C370E8D56BE62ECC01C03EA2E5895444" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E204A8979420E3C138BB3EA2E5893178" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D4C5E89F3D784FBBF3203EA2E58913E9" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C370E8D56BE62ECC01C03EA2E5895444" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D4C5E89F3D784FBBF3203EA2E58913E9" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_D3D08C9A18F45932F03A3EA2E589CCFC" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C370E8D56BE62ECC01C03EA2E5895444" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_D3D08C9A18F45932F03A3EA2E589CCFC" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_E515C44A59266B22DC373EA2E589F340" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C370E8D56BE62ECC01C03EA2E5895444" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_E515C44A59266B22DC373EA2E589F340" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_AD265A1C38DC158C664D3EA2E5897AA3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F05A3A29B2F81DAC6D8D3EA2E589BB05" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_AD265A1C38DC158C664D3EA2E5897AA3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_260D33B45699151D76053EA2E58941C6" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F05A3A29B2F81DAC6D8D3EA2E589BB05" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_260D33B45699151D76053EA2E58941C6" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_PercentageParValueOfSeniorNotes" xlink:label="loc_biib_PercentageParValueOfSeniorNotes_3159AEB89C7D2EECA8883EA2E5892694" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F05A3A29B2F81DAC6D8D3EA2E589BB05" xlink:to="loc_biib_PercentageParValueOfSeniorNotes_3159AEB89C7D2EECA8883EA2E5892694" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_7BC864566EF8B02E108B3ED24CF69702" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F05A3A29B2F81DAC6D8D3EA2E589BB05" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_7BC864566EF8B02E108B3ED24CF69702" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:label="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_4C98B93F8A4F05F68B043EDA38E8BE8A" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F05A3A29B2F81DAC6D8D3EA2E589BB05" xlink:to="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_4C98B93F8A4F05F68B043EDA38E8BE8A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtIssuanceCosts" xlink:label="loc_us-gaap_DebtIssuanceCosts_71A0D4D1F9B1077938E13EA2E589972F" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F05A3A29B2F81DAC6D8D3EA2E589BB05" xlink:to="loc_us-gaap_DebtIssuanceCosts_71A0D4D1F9B1077938E13EA2E589972F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_A2B3D1BEC77C49BA55AE3EA2E589B87A" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F05A3A29B2F81DAC6D8D3EA2E589BB05" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_A2B3D1BEC77C49BA55AE3EA2E589B87A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_D2440943128BB65837B93EA2E5893DCD" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F05A3A29B2F81DAC6D8D3EA2E589BB05" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_D2440943128BB65837B93EA2E5893DCD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_8AF1637588B4D86183B43EDFB6D37C1C" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F05A3A29B2F81DAC6D8D3EA2E589BB05" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_8AF1637588B4D86183B43EDFB6D37C1C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_7D3A090F1CE00FCD99643EA2E589EE42" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F05A3A29B2F81DAC6D8D3EA2E589BB05" xlink:to="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_7D3A090F1CE00FCD99643EA2E589EE42" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessIndebtedness" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_EF1C5EDF74FBC37059A771883DFF11B4" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CABFE49CB6EB23EB605A71883DFDE3C5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_EF1C5EDF74FBC37059A771883DFF11B4" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CABFE49CB6EB23EB605A71883DFDE3C5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2B170BDA2F0AEC36A47271883DFD899B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CABFE49CB6EB23EB605A71883DFDE3C5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2B170BDA2F0AEC36A47271883DFD899B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2799B2DD8B691DBCBF0171883DFE34B0_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2B170BDA2F0AEC36A47271883DFD899B" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2799B2DD8B691DBCBF0171883DFE34B0_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2799B2DD8B691DBCBF0171883DFE34B0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2B170BDA2F0AEC36A47271883DFD899B" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2799B2DD8B691DBCBF0171883DFE34B0" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_4817EAB40B39441A426B71883DFE6AAA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2799B2DD8B691DBCBF0171883DFE34B0" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_4817EAB40B39441A426B71883DFE6AAA" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_FF1C1FB26C128A882CE971883DFEE5EE" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2799B2DD8B691DBCBF0171883DFE34B0" xlink:to="loc_biib_TysabriProductMember_FF1C1FB26C128A882CE971883DFEE5EE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_179F4A91155553B5C1C271883DFED735" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CABFE49CB6EB23EB605A71883DFDE3C5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_179F4A91155553B5C1C271883DFED735" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5FEC4020D776C7599B9171883DFEB40D_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_179F4A91155553B5C1C271883DFED735" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5FEC4020D776C7599B9171883DFEB40D_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5FEC4020D776C7599B9171883DFEB40D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_179F4A91155553B5C1C271883DFED735" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5FEC4020D776C7599B9171883DFEB40D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_CF6E8882414F6CC91DDD71883DFE5F9E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5FEC4020D776C7599B9171883DFEB40D" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_CF6E8882414F6CC91DDD71883DFE5F9E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_6FBBCDD266ADEF989CF971883DFE445C" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5FEC4020D776C7599B9171883DFEB40D" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_6FBBCDD266ADEF989CF971883DFE445C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_31B9B5E4ED398FEBEEF971883DFE6552" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CABFE49CB6EB23EB605A71883DFDE3C5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_31B9B5E4ED398FEBEEF971883DFE6552" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0DB8811CC9C93AAB403571883DFE8C46_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_31B9B5E4ED398FEBEEF971883DFE6552" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0DB8811CC9C93AAB403571883DFE8C46_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0DB8811CC9C93AAB403571883DFE8C46" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_31B9B5E4ED398FEBEEF971883DFE6552" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0DB8811CC9C93AAB403571883DFE8C46" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_99B3E62E513208503E6371883DFE0DDE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0DB8811CC9C93AAB403571883DFE8C46" xlink:to="loc_biib_OutLicensedPatentsMember_99B3E62E513208503E6371883DFE0DDE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_247D6E64D0931069D83271883DFEF565" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0DB8811CC9C93AAB403571883DFE8C46" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_247D6E64D0931069D83271883DFEF565" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_27AAAAF30384BD473EAB71883DFEDB8E" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0DB8811CC9C93AAB403571883DFE8C46" xlink:to="loc_biib_InLicensedPatentsMember_27AAAAF30384BD473EAB71883DFEDB8E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_FF5E212D9C564718790C71883DFEF1F6" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CABFE49CB6EB23EB605A71883DFDE3C5" xlink:to="loc_us-gaap_ProductOrServiceAxis_FF5E212D9C564718790C71883DFEF1F6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_D04D7C9530029BDB5C1671883DFE3A3A_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_FF5E212D9C564718790C71883DFEF1F6" xlink:to="loc_us-gaap_ProductsAndServicesDomain_D04D7C9530029BDB5C1671883DFE3A3A_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_D04D7C9530029BDB5C1671883DFE3A3A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_FF5E212D9C564718790C71883DFEF1F6" xlink:to="loc_us-gaap_ProductsAndServicesDomain_D04D7C9530029BDB5C1671883DFE3A3A" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_3ADDA49194495D55F80371883DFE6E4D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D04D7C9530029BDB5C1671883DFE3A3A" xlink:to="loc_biib_AVONEXMember_3ADDA49194495D55F80371883DFE6E4D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_0E4B67AD9BD6E87DA5B971883DFE27EF" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CABFE49CB6EB23EB605A71883DFDE3C5" xlink:to="loc_us-gaap_RangeAxis_0E4B67AD9BD6E87DA5B971883DFE27EF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_28E33F0E9EC5F24C956F71883DFEBF31_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_0E4B67AD9BD6E87DA5B971883DFE27EF" xlink:to="loc_us-gaap_RangeMember_28E33F0E9EC5F24C956F71883DFEBF31_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_28E33F0E9EC5F24C956F71883DFEBF31" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_0E4B67AD9BD6E87DA5B971883DFE27EF" xlink:to="loc_us-gaap_RangeMember_28E33F0E9EC5F24C956F71883DFEBF31" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_2DBF40525671E540809E71883DFE3878" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_28E33F0E9EC5F24C956F71883DFEBF31" xlink:to="loc_us-gaap_MinimumMember_2DBF40525671E540809E71883DFE3878" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_2431B1EBEBFC4DBB770F71883DFE172F" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_28E33F0E9EC5F24C956F71883DFEBF31" xlink:to="loc_us-gaap_MaximumMember_2431B1EBEBFC4DBB770F71883DFE172F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2DFBD573E3940E6DC20571883DFF1B68" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_EF1C5EDF74FBC37059A771883DFF11B4" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2DFBD573E3940E6DC20571883DFF1B68" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6F4CEE519FC97588E1D471883DFFB99A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2DFBD573E3940E6DC20571883DFF1B68" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6F4CEE519FC97588E1D471883DFFB99A" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_A3E74ED2BBCC6BF9FA7471883DFFF37C" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2DFBD573E3940E6DC20571883DFF1B68" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_A3E74ED2BBCC6BF9FA7471883DFFF37C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_236DFD33697423108D6D71883DFF035F" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2DFBD573E3940E6DC20571883DFF1B68" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_236DFD33697423108D6D71883DFF035F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9EE13335C84BEABFD76371883DFF87B8" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2DFBD573E3940E6DC20571883DFF1B68" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9EE13335C84BEABFD76371883DFF87B8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_D372EABDB43F1C65FB2D71883DFF5237" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2DFBD573E3940E6DC20571883DFF1B68" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_D372EABDB43F1C65FB2D71883DFF5237" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_D91B2181CF37F1B3E6E371883DFFD5D4" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2DFBD573E3940E6DC20571883DFF1B68" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_D91B2181CF37F1B3E6E371883DFFD5D4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_13EBC3B213E8DACC39DF71883DFF8D1A" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2DFBD573E3940E6DC20571883DFF1B68" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_13EBC3B213E8DACC39DF71883DFF8D1A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0682AB8510D7E6677E4071883DFF6ED8" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2DFBD573E3940E6DC20571883DFF1B68" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0682AB8510D7E6677E4071883DFF6ED8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_70AAAE099F946162EBF071883DFFF077" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2DFBD573E3940E6DC20571883DFF1B68" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_70AAAE099F946162EBF071883DFFF077" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2F081D8A4124F7ED146471883DFF36B1" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2DFBD573E3940E6DC20571883DFF1B68" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2F081D8A4124F7ED146471883DFF36B1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_0A77D613BAF6B0113CF971883DFFE029" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2DFBD573E3940E6DC20571883DFF1B68" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_0A77D613BAF6B0113CF971883DFFE029" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_8F2775182217F0F734A4AE73DAE817A3" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_534D6F0935EA4F14CB72AE73DAE7FBE9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_8F2775182217F0F734A4AE73DAE817A3" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_534D6F0935EA4F14CB72AE73DAE7FBE9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_6B4DE970DCE257634D1EAE73DAE7DBC9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_534D6F0935EA4F14CB72AE73DAE7FBE9" xlink:to="loc_us-gaap_ProductOrServiceAxis_6B4DE970DCE257634D1EAE73DAE7DBC9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_167240C91CF34B5BE746AE73DAE7DA86_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_6B4DE970DCE257634D1EAE73DAE7DBC9" xlink:to="loc_us-gaap_ProductsAndServicesDomain_167240C91CF34B5BE746AE73DAE7DA86_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_167240C91CF34B5BE746AE73DAE7DA86" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_6B4DE970DCE257634D1EAE73DAE7DBC9" xlink:to="loc_us-gaap_ProductsAndServicesDomain_167240C91CF34B5BE746AE73DAE7DA86" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_590E29752ABFF86B7FA2AE73DAE7EEE5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_167240C91CF34B5BE746AE73DAE7DA86" xlink:to="loc_biib_TecfideraMember_590E29752ABFF86B7FA2AE73DAE7EEE5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_D08026252B5634564138AE73DAE7D90F" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_534D6F0935EA4F14CB72AE73DAE7FBE9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_D08026252B5634564138AE73DAE7D90F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6E43D9534DD0F5351333AE73DAE77CD6_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_D08026252B5634564138AE73DAE7D90F" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6E43D9534DD0F5351333AE73DAE77CD6_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6E43D9534DD0F5351333AE73DAE77CD6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_D08026252B5634564138AE73DAE7D90F" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6E43D9534DD0F5351333AE73DAE77CD6" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_43A6F9E77E85B589D10BAE73DAE8AD5F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6E43D9534DD0F5351333AE73DAE77CD6" xlink:to="loc_biib_FumapharmAgMember_43A6F9E77E85B589D10BAE73DAE8AD5F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_59D8F4660310F1B3898BAE73DAE84BD3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_8F2775182217F0F734A4AE73DAE817A3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_59D8F4660310F1B3898BAE73DAE84BD3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_CFF32E507952DC831B22AE73DAE83BEA" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_8F2775182217F0F734A4AE73DAE817A3" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_CFF32E507952DC831B22AE73DAE83BEA" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_4FBC2578998B70ABCC0543C3DB775412" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_0BCFE8363A5D99A2C61043C3DB77BD80" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_4FBC2578998B70ABCC0543C3DB775412" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_0BCFE8363A5D99A2C61043C3DB77BD80" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_52B77B940A44F21481D043C3DB7753B9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_0BCFE8363A5D99A2C61043C3DB77BD80" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_52B77B940A44F21481D043C3DB7753B9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_F3F6EF94FDFC2E824F8443C3DB77DE6B_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_52B77B940A44F21481D043C3DB7753B9" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_F3F6EF94FDFC2E824F8443C3DB77DE6B_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_F3F6EF94FDFC2E824F8443C3DB77DE6B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_52B77B940A44F21481D043C3DB7753B9" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_F3F6EF94FDFC2E824F8443C3DB77DE6B" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_B9499F44AF20ECE8992D43C3DB77C61C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_F3F6EF94FDFC2E824F8443C3DB77DE6B" xlink:to="loc_biib_NeurimmuneMember_B9499F44AF20ECE8992D43C3DB77C61C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9FB61CD643519FF01B5343C3DB77E733" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_4FBC2578998B70ABCC0543C3DB775412" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9FB61CD643519FF01B5343C3DB77E733" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_InvestmentInVariableInterestEntitiesTextualAbstract" xlink:label="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_6D826EA9CBC48DDEA6EB43C3DB773CD9" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_4FBC2578998B70ABCC0543C3DB775412" xlink:to="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_6D826EA9CBC48DDEA6EB43C3DB773CD9" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement" xlink:label="loc_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_18C5103EDF71FCFC104743C3DB774EC1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_6D826EA9CBC48DDEA6EB43C3DB773CD9" xlink:to="loc_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_18C5103EDF71FCFC104743C3DB774EC1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_EFD7388D3156A382F82C43C3DB7763CB" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_6D826EA9CBC48DDEA6EB43C3DB773CD9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_EFD7388D3156A382F82C43C3DB7763CB" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_67A7AF45A19ECAF825B743C3DB783C03" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_6D826EA9CBC48DDEA6EB43C3DB773CD9" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_67A7AF45A19ECAF825B743C3DB783C03" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_11020AA57F9FCA5BD9C0AE73D93CC9B6" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_219CAEB8764319694740AE73D93C86F5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_11020AA57F9FCA5BD9C0AE73D93CC9B6" xlink:to="loc_us-gaap_LossContingenciesTable_219CAEB8764319694740AE73D93C86F5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_55B51BFA7415B7F320D0AE73D93CBE95" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_219CAEB8764319694740AE73D93C86F5" xlink:to="loc_us-gaap_StatementGeographicalAxis_55B51BFA7415B7F320D0AE73D93CBE95" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_8A28995B29561FD23C44AE73D93C75D2_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_55B51BFA7415B7F320D0AE73D93CBE95" xlink:to="loc_us-gaap_SegmentGeographicalDomain_8A28995B29561FD23C44AE73D93C75D2_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_8A28995B29561FD23C44AE73D93C75D2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_55B51BFA7415B7F320D0AE73D93CBE95" xlink:to="loc_us-gaap_SegmentGeographicalDomain_8A28995B29561FD23C44AE73D93C75D2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_IT" xlink:label="loc_country_IT_D38D251D6016C83DB244AE73D93CEACD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_8A28995B29561FD23C44AE73D93C75D2" xlink:to="loc_country_IT_D38D251D6016C83DB244AE73D93CEACD" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_ReimbursementLimitStatedInResolution" xlink:label="loc_biib_ReimbursementLimitStatedInResolution_9AF23B05A4509ED60F25AE73D93CB0B4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_11020AA57F9FCA5BD9C0AE73D93CC9B6" xlink:to="loc_biib_ReimbursementLimitStatedInResolution_9AF23B05A4509ED60F25AE73D93CB0B4" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_9AE166CC2FD57A566E7C720464D53C9B" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1EA2FFC510071A9A01AF720464D4C1EC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_9AE166CC2FD57A566E7C720464D53C9B" xlink:to="loc_us-gaap_StatementTable_1EA2FFC510071A9A01AF720464D4C1EC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_C55D4DA7F6BD95936494720464D588AD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1EA2FFC510071A9A01AF720464D4C1EC" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_C55D4DA7F6BD95936494720464D588AD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0F9B45BE453839D28919720464D56F75_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_C55D4DA7F6BD95936494720464D588AD" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0F9B45BE453839D28919720464D56F75_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0F9B45BE453839D28919720464D56F75" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_C55D4DA7F6BD95936494720464D588AD" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0F9B45BE453839D28919720464D56F75" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_82F24D4E1D73B658E3B7720464D5F818" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0F9B45BE453839D28919720464D56F75" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_82F24D4E1D73B658E3B7720464D5F818" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="loc_us-gaap_ProductLiabilityContingencyLineItems_7A6A0542911CBD03E69E720464CFC65E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="loc_us-gaap_ProductLiabilityContingencyTable_F214774A207C40BD9FE4720464CFEBE6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_7A6A0542911CBD03E69E720464CFC65E" xlink:to="loc_us-gaap_ProductLiabilityContingencyTable_F214774A207C40BD9FE4720464CFEBE6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_027EAF1712FF8FA66EF5720464CF4BC6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ProductLiabilityContingencyTable_F214774A207C40BD9FE4720464CFEBE6" xlink:to="loc_us-gaap_StatementGeographicalAxis_027EAF1712FF8FA66EF5720464CF4BC6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_3B48B489E61753812851720464CFDEC6_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_027EAF1712FF8FA66EF5720464CF4BC6" xlink:to="loc_us-gaap_SegmentGeographicalDomain_3B48B489E61753812851720464CFDEC6_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_3B48B489E61753812851720464CFDEC6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_027EAF1712FF8FA66EF5720464CF4BC6" xlink:to="loc_us-gaap_SegmentGeographicalDomain_3B48B489E61753812851720464CFDEC6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_IT" xlink:label="loc_country_IT_3548DE6FFC06331FDCD9720464CF0269" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_3B48B489E61753812851720464CFDEC6" xlink:to="loc_country_IT_3548DE6FFC06331FDCD9720464CF0269" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_A2DCA7751EB432CD5E44720464CFEA54" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_7A6A0542911CBD03E69E720464CFC65E" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_A2DCA7751EB432CD5E44720464CFEA54" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_43AD76CEE1681453C89E720464CF7A4C" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_7A6A0542911CBD03E69E720464CFC65E" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_43AD76CEE1681453C89E720464CF7A4C" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_952983D8BDD7FF6AA0BC71B13DBFD104" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_C204A33BE7334E5FF96071B13DBED8DD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_952983D8BDD7FF6AA0BC71B13DBFD104" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_C204A33BE7334E5FF96071B13DBED8DD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_BF185DF12ABE10C94FBD71B22FF806F1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_C204A33BE7334E5FF96071B13DBED8DD" xlink:to="loc_us-gaap_TypeOfArrangementAxis_BF185DF12ABE10C94FBD71B22FF806F1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DC6B36A2CF724DF2468371B23005AF2C_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_BF185DF12ABE10C94FBD71B22FF806F1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DC6B36A2CF724DF2468371B23005AF2C_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DC6B36A2CF724DF2468371B23005AF2C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_BF185DF12ABE10C94FBD71B22FF806F1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DC6B36A2CF724DF2468371B23005AF2C" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_BBCDE800707FB0F280B471B2302A9A35" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DC6B36A2CF724DF2468371B23005AF2C" xlink:to="loc_biib_EisaiMember_BBCDE800707FB0F280B471B2302A9A35" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0B1BCFA3CAE4A9B77A5771B13DBE577A" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_C204A33BE7334E5FF96071B13DBED8DD" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0B1BCFA3CAE4A9B77A5771B13DBE577A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_A05E477D4D3BF298720A71B13DBE1F13_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0B1BCFA3CAE4A9B77A5771B13DBE577A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_A05E477D4D3BF298720A71B13DBE1F13_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_A05E477D4D3BF298720A71B13DBE1F13" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0B1BCFA3CAE4A9B77A5771B13DBE577A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_A05E477D4D3BF298720A71B13DBE1F13" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_F42CFF8EF018DCE2693B71B23037A3F3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_A05E477D4D3BF298720A71B13DBE1F13" xlink:to="loc_us-gaap_BuildingMember_F42CFF8EF018DCE2693B71B23037A3F3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_41EE4E3543585545902E71B261861B7E" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_A05E477D4D3BF298720A71B13DBE1F13" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_41EE4E3543585545902E71B261861B7E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_BF687AD09D8D91C667F471B30678C6F2" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_A05E477D4D3BF298720A71B13DBE1F13" xlink:to="loc_us-gaap_LandMember_BF687AD09D8D91C667F471B30678C6F2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_FE3B7CF505A43D6F8FF371B14293A0BD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_952983D8BDD7FF6AA0BC71B13DBFD104" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_FE3B7CF505A43D6F8FF371B14293A0BD" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_BDA1852A96809CC1ACED875A3D498823" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A0989F4B3EC49892890B875A3D4917ED" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_BDA1852A96809CC1ACED875A3D498823" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A0989F4B3EC49892890B875A3D4917ED" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6E887704B4C66091A415875A3D494B48" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A0989F4B3EC49892890B875A3D4917ED" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6E887704B4C66091A415875A3D494B48" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6A38ABBA6E22D04AF3C8875A3D497D58_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6E887704B4C66091A415875A3D494B48" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6A38ABBA6E22D04AF3C8875A3D497D58_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6A38ABBA6E22D04AF3C8875A3D497D58" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6E887704B4C66091A415875A3D494B48" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6A38ABBA6E22D04AF3C8875A3D497D58" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_E0952C67FB3AA0381890875A3D49F499" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6A38ABBA6E22D04AF3C8875A3D497D58" xlink:to="loc_biib_EisaiMember_E0952C67FB3AA0381890875A3D49F499" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_A133B037092426ABB472875A3D4A3BB0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_BDA1852A96809CC1ACED875A3D498823" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_A133B037092426ABB472875A3D4A3BB0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_91361D31174AEDBAD046875A3D4A1D48" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_BDA1852A96809CC1ACED875A3D498823" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_91361D31174AEDBAD046875A3D4A1D48" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_B70C546A5B1E2530F12A875A3D4AB537" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_BDA1852A96809CC1ACED875A3D498823" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_B70C546A5B1E2530F12A875A3D4AB537" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_TermOfLease" xlink:label="loc_biib_TermOfLease_5FBE1A0A4781A816BE90875A3D4A1AB7" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_BDA1852A96809CC1ACED875A3D498823" xlink:to="loc_biib_TermOfLease_5FBE1A0A4781A816BE90875A3D4A1AB7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="loc_us-gaap_CapitalLeaseObligations_1318D9DE25D697AFC4D3875A3D4A90FE" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_BDA1852A96809CC1ACED875A3D498823" xlink:to="loc_us-gaap_CapitalLeaseObligations_1318D9DE25D697AFC4D3875A3D4A90FE" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_307A1C9A227B211CF60A2E2530935C91" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_E60431B9377B9A488E9D2E2530939BAD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_307A1C9A227B211CF60A2E2530935C91" xlink:to="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_E60431B9377B9A488E9D2E2530939BAD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_947311637BA834AB68B12E253093189C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_E60431B9377B9A488E9D2E2530939BAD" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_947311637BA834AB68B12E253093189C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_8011D080F63E94FF01372E253093B700_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_947311637BA834AB68B12E253093189C" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_8011D080F63E94FF01372E253093B700_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_8011D080F63E94FF01372E253093B700" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_947311637BA834AB68B12E253093189C" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_8011D080F63E94FF01372E253093B700" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReserveForCashDiscountMember" xlink:label="loc_us-gaap_ReserveForCashDiscountMember_09510A56CA45DB49B3292E25309375C6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8011D080F63E94FF01372E253093B700" xlink:to="loc_us-gaap_ReserveForCashDiscountMember_09510A56CA45DB49B3292E25309375C6" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_EF6E5811B4AE2C27C0602E25309379EE" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8011D080F63E94FF01372E253093B700" xlink:to="loc_biib_ContractualAdjustmentsMember_EF6E5811B4AE2C27C0602E25309379EE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_758964C09BA113A2C30D2E25309388BD" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8011D080F63E94FF01372E253093B700" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_758964C09BA113A2C30D2E25309388BD" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_B85CB23882F68CA3C33E2E253093D5B7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_307A1C9A227B211CF60A2E2530935C91" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_B85CB23882F68CA3C33E2E253093D5B7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_69E7CEE8EDB9BC05A7B32E253093ABF2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_B85CB23882F68CA3C33E2E253093D5B7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_69E7CEE8EDB9BC05A7B32E253093ABF2" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_D0CF3AD88EFF1B85CC9E2E253093BF17" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_B85CB23882F68CA3C33E2E253093D5B7" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_D0CF3AD88EFF1B85CC9E2E253093BF17" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_85EFC725114DEC1AD30D2E25309388AC" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_B85CB23882F68CA3C33E2E253093D5B7" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_85EFC725114DEC1AD30D2E25309388AC" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_A8A56D465FCD07F73D7F2E253093D955" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_B85CB23882F68CA3C33E2E253093D5B7" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_A8A56D465FCD07F73D7F2E253093D955" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_6D17D82BE78FCE2A06C62E253093A345" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_B85CB23882F68CA3C33E2E253093D5B7" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_6D17D82BE78FCE2A06C62E253093A345" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_D9453522CB4F596DCBB8AE73DB5B1044" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_733E6463D87D8DCA2B72AE73DB5B8C8D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_D9453522CB4F596DCBB8AE73DB5B1044" xlink:to="loc_us-gaap_StatementTable_733E6463D87D8DCA2B72AE73DB5B8C8D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2F2CB41B710E02B5D608AE73DB5BBAE8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_733E6463D87D8DCA2B72AE73DB5B8C8D" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2F2CB41B710E02B5D608AE73DB5BBAE8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_B882ECA7810379A64E5AAE73DB5B0AD5_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2F2CB41B710E02B5D608AE73DB5BBAE8" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_B882ECA7810379A64E5AAE73DB5B0AD5_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_B882ECA7810379A64E5AAE73DB5B0AD5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2F2CB41B710E02B5D608AE73DB5BBAE8" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_B882ECA7810379A64E5AAE73DB5B0AD5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_1E0F4A5FA2857119D82CAE73DB5BE9BC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_B882ECA7810379A64E5AAE73DB5B0AD5" xlink:to="loc_us-gaap_AccountsReceivableMember_1E0F4A5FA2857119D82CAE73DB5BE9BC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_F93BB9DD1345FF18EB72AE73DB5B891F" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_B882ECA7810379A64E5AAE73DB5B0AD5" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_F93BB9DD1345FF18EB72AE73DB5B891F" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_02C0E577788EB3E31AAFAE73DB5B37A6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D9453522CB4F596DCBB8AE73DB5B1044" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_02C0E577788EB3E31AAFAE73DB5B37A6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_9B6E6FCC21C3B1C60377AE73DB5C7085" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_02C0E577788EB3E31AAFAE73DB5B37A6" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_9B6E6FCC21C3B1C60377AE73DB5C7085" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1D55D1B09A240BB3883AAE73DB561448" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_26D5F461409E00AA72B8AE73DB56150C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1D55D1B09A240BB3883AAE73DB561448" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_26D5F461409E00AA72B8AE73DB56150C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1D60CBA97E32368DA909AE73DB56A339" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_26D5F461409E00AA72B8AE73DB56150C" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1D60CBA97E32368DA909AE73DB56A339" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1F05255FAAE6BDCCD99EAE73DB56CDEB_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1D60CBA97E32368DA909AE73DB56A339" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1F05255FAAE6BDCCD99EAE73DB56CDEB_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1F05255FAAE6BDCCD99EAE73DB56CDEB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1D60CBA97E32368DA909AE73DB56A339" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1F05255FAAE6BDCCD99EAE73DB56CDEB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2138FDBD24834F5371E2AE73DB564B16" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1F05255FAAE6BDCCD99EAE73DB56CDEB" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2138FDBD24834F5371E2AE73DB564B16" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_BE721F9EDBE1D1659E50AE73DB561952" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1F05255FAAE6BDCCD99EAE73DB56CDEB" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_BE721F9EDBE1D1659E50AE73DB561952" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_261905DAAEAB0C109727AE73DB56BBEF" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1F05255FAAE6BDCCD99EAE73DB56CDEB" xlink:to="loc_us-gaap_ParentMember_261905DAAEAB0C109727AE73DB56BBEF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_29C53B869AC3406E9DC5AE73DB563A03" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1D55D1B09A240BB3883AAE73DB561448" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_29C53B869AC3406E9DC5AE73DB563A03" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_A890705399D96BD0B860AE73DB560E34" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_29C53B869AC3406E9DC5AE73DB563A03" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_A890705399D96BD0B860AE73DB560E34" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_C25FF2E74EB99E9D829AAE73DB56471B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_29C53B869AC3406E9DC5AE73DB563A03" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_C25FF2E74EB99E9D829AAE73DB56471B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_AA1FE99A37D66A18CB0AAE73DB57A40F" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_29C53B869AC3406E9DC5AE73DB563A03" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_AA1FE99A37D66A18CB0AAE73DB57A40F" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_8668398966772FE9BEECAE73DB577428" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_29C53B869AC3406E9DC5AE73DB563A03" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_8668398966772FE9BEECAE73DB577428" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_23FB7FC5BB62C16CDB50AE73DB572404" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_29C53B869AC3406E9DC5AE73DB563A03" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_23FB7FC5BB62C16CDB50AE73DB572404" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_63AFB2B620C82B063BBBAE73DB3D7CEA" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_410A4A6CCD4894503C61AE73DB3C53FC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_63AFB2B620C82B063BBBAE73DB3D7CEA" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_410A4A6CCD4894503C61AE73DB3C53FC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_16D9C787CAC86A8AB972AE73DB3C10F6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_410A4A6CCD4894503C61AE73DB3C53FC" xlink:to="loc_us-gaap_PlanNameAxis_16D9C787CAC86A8AB972AE73DB3C10F6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_67BF43482EBFE0E6444EAE73DB3D8F6B_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_16D9C787CAC86A8AB972AE73DB3C10F6" xlink:to="loc_us-gaap_PlanNameDomain_67BF43482EBFE0E6444EAE73DB3D8F6B_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_67BF43482EBFE0E6444EAE73DB3D8F6B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_16D9C787CAC86A8AB972AE73DB3C10F6" xlink:to="loc_us-gaap_PlanNameDomain_67BF43482EBFE0E6444EAE73DB3D8F6B" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_CF5B2E674F01E41D6C78AE73DB3DA3FD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_67BF43482EBFE0E6444EAE73DB3D8F6B" xlink:to="loc_biib_MarketStockUnitsMember_CF5B2E674F01E41D6C78AE73DB3DA3FD" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_3ED6F667D6EE3EA1A301AE73DB3D0D03" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_67BF43482EBFE0E6444EAE73DB3D8F6B" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_3ED6F667D6EE3EA1A301AE73DB3D0D03" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_A4A72F8F82C0D6928C01AE73DB3D65E5" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_67BF43482EBFE0E6444EAE73DB3D8F6B" xlink:to="loc_biib_CashSettledPerformanceSharesMember_A4A72F8F82C0D6928C01AE73DB3D65E5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_1B4E6CC07F7DC4B6F121AE73DB3DF9BF" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_67BF43482EBFE0E6444EAE73DB3D8F6B" xlink:to="loc_us-gaap_PerformanceSharesMember_1B4E6CC07F7DC4B6F121AE73DB3DF9BF" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_E565765DDBCFAABB2F9FAE73DB3D7963" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_67BF43482EBFE0E6444EAE73DB3D8F6B" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_E565765DDBCFAABB2F9FAE73DB3D7963" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18F9D0853DE50D6225CFAE73DB3D606A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_63AFB2B620C82B063BBBAE73DB3D7CEA" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18F9D0853DE50D6225CFAE73DB3D606A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_73B1C8DF0FB9BB63ABFDAE73DB3D3599" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18F9D0853DE50D6225CFAE73DB3D606A" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_73B1C8DF0FB9BB63ABFDAE73DB3D3599" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_2CFD69F50BFF9650A936AE73DB3DDD80" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18F9D0853DE50D6225CFAE73DB3D606A" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_2CFD69F50BFF9650A936AE73DB3DDD80" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_75997AAB9B30748DD8B5AE73DB3D62FC" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18F9D0853DE50D6225CFAE73DB3D606A" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_75997AAB9B30748DD8B5AE73DB3D62FC" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_9FB75CA349F848D7CB5BAE73DB3DCCED" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18F9D0853DE50D6225CFAE73DB3D606A" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_9FB75CA349F848D7CB5BAE73DB3DCCED" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E8D76486BEC6EFF715BCAE73DADFEF6C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E5771B9D160DF86C507CAE73DADFB42B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E8D76486BEC6EFF715BCAE73DADFEF6C" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E5771B9D160DF86C507CAE73DADFB42B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_F4FA66DA04C3D442CDFDAE73DADF8D8F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E5771B9D160DF86C507CAE73DADFB42B" xlink:to="loc_us-gaap_PlanNameAxis_F4FA66DA04C3D442CDFDAE73DADF8D8F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_97B771C3F71F7C020588AE73DADF34A8_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_F4FA66DA04C3D442CDFDAE73DADF8D8F" xlink:to="loc_us-gaap_PlanNameDomain_97B771C3F71F7C020588AE73DADF34A8_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_97B771C3F71F7C020588AE73DADF34A8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_F4FA66DA04C3D442CDFDAE73DADF8D8F" xlink:to="loc_us-gaap_PlanNameDomain_97B771C3F71F7C020588AE73DADF34A8" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_D62CEC66F51F78A83AF5AE73DADFD767" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_97B771C3F71F7C020588AE73DADF34A8" xlink:to="loc_biib_MarketStockUnitsMember_D62CEC66F51F78A83AF5AE73DADFD767" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_A66E609D3B5C03138D63AE73DADF43A7" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_97B771C3F71F7C020588AE73DADF34A8" xlink:to="loc_biib_CashSettledPerformanceSharesMember_A66E609D3B5C03138D63AE73DADF43A7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_361A823BF2B5732B2E6EAE73DADFA299" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_97B771C3F71F7C020588AE73DADF34A8" xlink:to="loc_us-gaap_PerformanceSharesMember_361A823BF2B5732B2E6EAE73DADFA299" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_6C3EC5331BB1CA68C116AE73DADF66C5" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_97B771C3F71F7C020588AE73DADF34A8" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_6C3EC5331BB1CA68C116AE73DADF66C5" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_ScheduleOfStockOptionGrantsAbstract" xlink:label="loc_biib_ScheduleOfStockOptionGrantsAbstract_2B608E2213BDBC28C519AE73DADFC947" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E8D76486BEC6EFF715BCAE73DADFEF6C" xlink:to="loc_biib_ScheduleOfStockOptionGrantsAbstract_2B608E2213BDBC28C519AE73DADFC947" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_747858BD316986D444A4AE73DADF10C8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfStockOptionGrantsAbstract_2B608E2213BDBC28C519AE73DADFC947" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_747858BD316986D444A4AE73DADF10C8" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_2DABCF06F103985390273EFA95B09FA3" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_2151E59E038D0F39BE9D3EFA95A9BDB2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_2DABCF06F103985390273EFA95B09FA3" xlink:to="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_2151E59E038D0F39BE9D3EFA95A9BDB2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_25A2BC4D4AA5BECEF2B13EFAC2BA0F8C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_2151E59E038D0F39BE9D3EFA95A9BDB2" xlink:to="loc_us-gaap_PlanNameAxis_25A2BC4D4AA5BECEF2B13EFAC2BA0F8C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_4821F631872A9E6DF7513EFAC2BF45E4_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_25A2BC4D4AA5BECEF2B13EFAC2BA0F8C" xlink:to="loc_us-gaap_PlanNameDomain_4821F631872A9E6DF7513EFAC2BF45E4_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_4821F631872A9E6DF7513EFAC2BF45E4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_25A2BC4D4AA5BECEF2B13EFAC2BA0F8C" xlink:to="loc_us-gaap_PlanNameDomain_4821F631872A9E6DF7513EFAC2BF45E4" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_A1995ESPPMember" xlink:label="loc_biib_A1995ESPPMember_3CAA199F9B075388839F3EFB47ED7066" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4821F631872A9E6DF7513EFAC2BF45E4" xlink:to="loc_biib_A1995ESPPMember_3CAA199F9B075388839F3EFB47ED7066" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_A2015ESPPMember" xlink:label="loc_biib_A2015ESPPMember_CD85549E8C7A70F7E4953F00A93D0C9C" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4821F631872A9E6DF7513EFAC2BF45E4" xlink:to="loc_biib_A2015ESPPMember_CD85549E8C7A70F7E4953F00A93D0C9C" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_Employeestockpurchaseplanmaximumshares" xlink:label="loc_biib_Employeestockpurchaseplanmaximumshares_6F0476F71E940862D1DB3EA2E554FBC3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_2DABCF06F103985390273EFA95B09FA3" xlink:to="loc_biib_Employeestockpurchaseplanmaximumshares_6F0476F71E940862D1DB3EA2E554FBC3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5D616C13D4205D0F62783EA2E5548387" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_2DABCF06F103985390273EFA95B09FA3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5D616C13D4205D0F62783EA2E5548387" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_E7078D41B59EE3DB36348AB77623365D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_F4AAA2673C4D7862CDF78AB77622B70E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_E7078D41B59EE3DB36348AB77623365D" xlink:to="loc_us-gaap_SubsequentEventTable_F4AAA2673C4D7862CDF78AB77622B70E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_539C6C9B4DA9971E48568AB776236093" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_F4AAA2673C4D7862CDF78AB77622B70E" xlink:to="loc_us-gaap_RangeAxis_539C6C9B4DA9971E48568AB776236093" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_5D42BA188B753CC3F9E18AB7762346E4_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_539C6C9B4DA9971E48568AB776236093" xlink:to="loc_us-gaap_RangeMember_5D42BA188B753CC3F9E18AB7762346E4_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_5D42BA188B753CC3F9E18AB7762346E4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_539C6C9B4DA9971E48568AB776236093" xlink:to="loc_us-gaap_RangeMember_5D42BA188B753CC3F9E18AB7762346E4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_9F645CE026CC1A303A498AB77623A2D3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_5D42BA188B753CC3F9E18AB7762346E4" xlink:to="loc_us-gaap_MinimumMember_9F645CE026CC1A303A498AB77623A2D3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_5CA87F10342FA59300878AB77623DD68" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_5D42BA188B753CC3F9E18AB7762346E4" xlink:to="loc_us-gaap_MaximumMember_5CA87F10342FA59300878AB77623DD68" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_221C48C7B0785339C3078AB776230BC6" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_F4AAA2673C4D7862CDF78AB77622B70E" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_221C48C7B0785339C3078AB776230BC6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_AF04598060F0EC0827958AB77623F40F_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_221C48C7B0785339C3078AB776230BC6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_AF04598060F0EC0827958AB77623F40F_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_AF04598060F0EC0827958AB77623F40F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_221C48C7B0785339C3078AB776230BC6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_AF04598060F0EC0827958AB77623F40F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_92244E1920C8B1FCD6B48AB776232DE2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_AF04598060F0EC0827958AB77623F40F" xlink:to="loc_us-gaap_SubsequentEventMember_92244E1920C8B1FCD6B48AB776232DE2" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_Workforcereductionpercentage" xlink:label="loc_biib_Workforcereductionpercentage_AE3C65828B5B190475EA8AB776230359" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_E7078D41B59EE3DB36348AB77623365D" xlink:to="loc_biib_Workforcereductionpercentage_AE3C65828B5B190475EA8AB776230359" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_367A46A44E559142ABDB8AB776233036" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_E7078D41B59EE3DB36348AB77623365D" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_367A46A44E559142ABDB8AB776233036" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_RestructuringandRelatedCostExpectedCashPayments" xlink:label="loc_biib_RestructuringandRelatedCostExpectedCashPayments_4927C426B50D2099D7BA8AB77623E005" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_E7078D41B59EE3DB36348AB77623365D" xlink:to="loc_biib_RestructuringandRelatedCostExpectedCashPayments_4927C426B50D2099D7BA8AB77623E005" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>biib-20150930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_7E1052F92309394760E2AE73DA8260D5_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_7E1052F92309394760E2AE73DA8260D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7E1052F92309394760E2AE73DA8260D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7E1052F92309394760E2AE73DA8260D5" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_7E1052F92309394760E2AE73DA8260D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_ADE4B526EC08068BBEB6AE73DA82E9B3_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_ADE4B526EC08068BBEB6AE73DA82E9B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_ADE4B526EC08068BBEB6AE73DA82E9B3_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_ADE4B526EC08068BBEB6AE73DA82E9B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_ADE4B526EC08068BBEB6AE73DA82E9B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_ADE4B526EC08068BBEB6AE73DA82E9B3" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_ADE4B526EC08068BBEB6AE73DA82E9B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_92CAD7756C760A6209D63F3E22C907D1_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_92CAD7756C760A6209D63F3E22C907D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_92CAD7756C760A6209D63F3E22C907D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_92CAD7756C760A6209D63F3E22C907D1" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_92CAD7756C760A6209D63F3E22C907D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_E10F703D4FBFA00363723F3E22CA7D08_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_E10F703D4FBFA00363723F3E22CA7D08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_E10F703D4FBFA00363723F3E22CA7D08_label_en-US" xlink:label="lab_us-gaap_StatementTable_E10F703D4FBFA00363723F3E22CA7D08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_E10F703D4FBFA00363723F3E22CA7D08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_E10F703D4FBFA00363723F3E22CA7D08" xlink:to="lab_us-gaap_StatementTable_E10F703D4FBFA00363723F3E22CA7D08" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_5B09CE218CDB50EA54743F3E22CAFCBC_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_5B09CE218CDB50EA54743F3E22CAFCBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_5B09CE218CDB50EA54743F3E22CAFCBC_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_5B09CE218CDB50EA54743F3E22CAFCBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5B09CE218CDB50EA54743F3E22CAFCBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5B09CE218CDB50EA54743F3E22CAFCBC" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_5B09CE218CDB50EA54743F3E22CAFCBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_C55EFB1C97B84D096E753F3E22CAFD7C_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_C55EFB1C97B84D096E753F3E22CAFD7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_C55EFB1C97B84D096E753F3E22CAFD7C_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_C55EFB1C97B84D096E753F3E22CAFD7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_C55EFB1C97B84D096E753F3E22CAFD7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_C55EFB1C97B84D096E753F3E22CAFD7C" xlink:to="lab_us-gaap_EquityComponentDomain_C55EFB1C97B84D096E753F3E22CAFD7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_D209FE9D8C2FB1EDEFAD3F3E22CAD475_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_D209FE9D8C2FB1EDEFAD3F3E22CAD475" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Net Unrealized Investment Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_D209FE9D8C2FB1EDEFAD3F3E22CAD475_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_D209FE9D8C2FB1EDEFAD3F3E22CAD475" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_D209FE9D8C2FB1EDEFAD3F3E22CAD475" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_D209FE9D8C2FB1EDEFAD3F3E22CAD475" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_D209FE9D8C2FB1EDEFAD3F3E22CAD475" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_93139726C20451F7C40D3F3E22CA047B_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_93139726C20451F7C40D3F3E22CA047B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_93139726C20451F7C40D3F3E22CA047B_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_93139726C20451F7C40D3F3E22CA047B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_93139726C20451F7C40D3F3E22CA047B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_93139726C20451F7C40D3F3E22CA047B" xlink:to="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_93139726C20451F7C40D3F3E22CA047B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_E12648F30DED21B8FB7C3F3E22CA4571_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_E12648F30DED21B8FB7C3F3E22CA4571" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_E12648F30DED21B8FB7C3F3E22CA4571_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_E12648F30DED21B8FB7C3F3E22CA4571" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_E12648F30DED21B8FB7C3F3E22CA4571" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_E12648F30DED21B8FB7C3F3E22CA4571" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_E12648F30DED21B8FB7C3F3E22CA4571" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_79579F456B13957A78473F3E22CA4961_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_79579F456B13957A78473F3E22CA4961" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_79579F456B13957A78473F3E22CA4961_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_79579F456B13957A78473F3E22CA4961" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_79579F456B13957A78473F3E22CA4961" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_79579F456B13957A78473F3E22CA4961" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_79579F456B13957A78473F3E22CA4961" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_F985421BE347DDB8E87E3F3E22CA6BD5_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_F985421BE347DDB8E87E3F3E22CA6BD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_F985421BE347DDB8E87E3F3E22CA6BD5_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_F985421BE347DDB8E87E3F3E22CA6BD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_F985421BE347DDB8E87E3F3E22CA6BD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_F985421BE347DDB8E87E3F3E22CA6BD5" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_F985421BE347DDB8E87E3F3E22CA6BD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_8C9067EFF8FEB6CE75273F3E22CAB8CB_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_8C9067EFF8FEB6CE75273F3E22CAB8CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_8C9067EFF8FEB6CE75273F3E22CAB8CB_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_8C9067EFF8FEB6CE75273F3E22CAB8CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_8C9067EFF8FEB6CE75273F3E22CAB8CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_8C9067EFF8FEB6CE75273F3E22CAB8CB" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_8C9067EFF8FEB6CE75273F3E22CAB8CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_F438B2155987471462FC3F3E22CA6C65_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_F438B2155987471462FC3F3E22CA6C65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_F438B2155987471462FC3F3E22CA6C65_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_F438B2155987471462FC3F3E22CA6C65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_F438B2155987471462FC3F3E22CA6C65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_F438B2155987471462FC3F3E22CA6C65" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_F438B2155987471462FC3F3E22CA6C65" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_DEC0507AAA6907BC1EC33F3E22CACA2A_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_DEC0507AAA6907BC1EC33F3E22CACA2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit (expense)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_DEC0507AAA6907BC1EC33F3E22CACA2A_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_DEC0507AAA6907BC1EC33F3E22CACA2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_DEC0507AAA6907BC1EC33F3E22CACA2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_DEC0507AAA6907BC1EC33F3E22CACA2A" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_DEC0507AAA6907BC1EC33F3E22CACA2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_CD7023CD582889D514883F3E22CA1A32_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_CD7023CD582889D514883F3E22CA1A32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product, net</link:label>
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_CD7023CD582889D514883F3E22CA1A32_label_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_CD7023CD582889D514883F3E22CA1A32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_CD7023CD582889D514883F3E22CA1A32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNet_CD7023CD582889D514883F3E22CA1A32" xlink:to="lab_us-gaap_SalesRevenueGoodsNet_CD7023CD582889D514883F3E22CA1A32" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_D3C32535CB0332415D863F3E22CA03D0_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_D3C32535CB0332415D863F3E22CA03D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_D3C32535CB0332415D863F3E22CA03D0_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_D3C32535CB0332415D863F3E22CA03D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_D3C32535CB0332415D863F3E22CA03D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_D3C32535CB0332415D863F3E22CA03D0" xlink:to="lab_us-gaap_NetIncomeLoss_D3C32535CB0332415D863F3E22CA03D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_47952D058D4BA63D06CBAE73D9430CFD_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_47952D058D4BA63D06CBAE73D9430CFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_47952D058D4BA63D06CBAE73D9430CFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_47952D058D4BA63D06CBAE73D9430CFD" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_47952D058D4BA63D06CBAE73D9430CFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_57C79E0857DFA3D310ACAE73D9431A1B_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_57C79E0857DFA3D310ACAE73D9431A1B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Consolidated Financial Statement Detail</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_57C79E0857DFA3D310ACAE73D9431A1B_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_57C79E0857DFA3D310ACAE73D9431A1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_57C79E0857DFA3D310ACAE73D9431A1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_57C79E0857DFA3D310ACAE73D9431A1B" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_57C79E0857DFA3D310ACAE73D9431A1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_F6A56287303757D28588AE73DAF8AF46_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_F6A56287303757D28588AE73DAF8AF46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_F6A56287303757D28588AE73DAF8AF46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_F6A56287303757D28588AE73DAF8AF46" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_F6A56287303757D28588AE73DAF8AF46" xlink:type="arc" />
    <link:label id="lab_biib_InventoryVariousProgramsGross_97981A16C26D9549F83DAE73DAF8A166_terseLabel_en-US" xlink:label="lab_biib_InventoryVariousProgramsGross_97981A16C26D9549F83DAE73DAF8A166" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Various Programs, Gross</link:label>
    <link:label id="lab_biib_InventoryVariousProgramsGross_97981A16C26D9549F83DAE73DAF8A166_label_en-US" xlink:label="lab_biib_InventoryVariousProgramsGross_97981A16C26D9549F83DAE73DAF8A166" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Various Programs, Gross</link:label>
    <link:label id="lab_biib_InventoryVariousProgramsGross_97981A16C26D9549F83DAE73DAF8A166_documentation_en-US" xlink:label="lab_biib_InventoryVariousProgramsGross_97981A16C26D9549F83DAE73DAF8A166" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gross inventory of various programs which have been capitalized in advance of regulatory approval.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_InventoryVariousProgramsGross" xlink:label="loc_biib_InventoryVariousProgramsGross_97981A16C26D9549F83DAE73DAF8A166" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InventoryVariousProgramsGross_97981A16C26D9549F83DAE73DAF8A166" xlink:to="lab_biib_InventoryVariousProgramsGross_97981A16C26D9549F83DAE73DAF8A166" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_D0F49AC9E142AEAF2AE3AE73DAACD062_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_D0F49AC9E142AEAF2AE3AE73DAACD062" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_D0F49AC9E142AEAF2AE3AE73DAACD062" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_D0F49AC9E142AEAF2AE3AE73DAACD062" xlink:to="lab_us-gaap_EarningsPerShareAbstract_D0F49AC9E142AEAF2AE3AE73DAACD062" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_332E799A3E6482108ED8AE73DAAC42BF_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_332E799A3E6482108ED8AE73DAAC42BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_332E799A3E6482108ED8AE73DAAC42BF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_332E799A3E6482108ED8AE73DAAC42BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_332E799A3E6482108ED8AE73DAAC42BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_332E799A3E6482108ED8AE73DAAC42BF" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_332E799A3E6482108ED8AE73DAAC42BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6279105BFE54D83B5FA7AE73DAAC09D7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6279105BFE54D83B5FA7AE73DAAC09D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6279105BFE54D83B5FA7AE73DAAC09D7_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6279105BFE54D83B5FA7AE73DAAC09D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6279105BFE54D83B5FA7AE73DAAC09D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6279105BFE54D83B5FA7AE73DAAC09D7" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6279105BFE54D83B5FA7AE73DAAC09D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_3E467AF57B45B70425A2AE73DAACD1F9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_3E467AF57B45B70425A2AE73DAACD1F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_3E467AF57B45B70425A2AE73DAACD1F9_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_3E467AF57B45B70425A2AE73DAACD1F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3E467AF57B45B70425A2AE73DAACD1F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3E467AF57B45B70425A2AE73DAACD1F9" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_3E467AF57B45B70425A2AE73DAACD1F9" xlink:type="arc" />
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E1544BD1DACAADCE3A1FAE73DAACB3FF_verboseLabel_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E1544BD1DACAADCE3A1FAE73DAACB3FF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan</link:label>
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E1544BD1DACAADCE3A1FAE73DAACB3FF_label_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E1544BD1DACAADCE3A1FAE73DAACB3FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan [Member]</link:label>
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E1544BD1DACAADCE3A1FAE73DAACB3FF_documentation_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E1544BD1DACAADCE3A1FAE73DAACB3FF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E1544BD1DACAADCE3A1FAE73DAACB3FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E1544BD1DACAADCE3A1FAE73DAACB3FF" xlink:to="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E1544BD1DACAADCE3A1FAE73DAACB3FF" xlink:type="arc" />
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_26EAC58710C7B644C55DAE73DAADEC2B_verboseLabel_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_26EAC58710C7B644C55DAE73DAADEC2B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Time-vested restricted stock units</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_26EAC58710C7B644C55DAE73DAADEC2B_label_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_26EAC58710C7B644C55DAE73DAADEC2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Vested Restricted Stock Units [Member]</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_26EAC58710C7B644C55DAE73DAADEC2B_documentation_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_26EAC58710C7B644C55DAE73DAADEC2B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time vested restricted stock units.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_26EAC58710C7B644C55DAE73DAADEC2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimeVestedRestrictedStockUnitsMember_26EAC58710C7B644C55DAE73DAADEC2B" xlink:to="lab_biib_TimeVestedRestrictedStockUnitsMember_26EAC58710C7B644C55DAE73DAADEC2B" xlink:type="arc" />
    <link:label id="lab_biib_MarketStockUnitsMember_F98DE2956AFC73D09645AE73DAAD9E47_verboseLabel_en-US" xlink:label="lab_biib_MarketStockUnitsMember_F98DE2956AFC73D09645AE73DAAD9E47" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Market stock units</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_F98DE2956AFC73D09645AE73DAAD9E47_label_en-US" xlink:label="lab_biib_MarketStockUnitsMember_F98DE2956AFC73D09645AE73DAAD9E47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Stock Units [Member]</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_F98DE2956AFC73D09645AE73DAAD9E47_documentation_en-US" xlink:label="lab_biib_MarketStockUnitsMember_F98DE2956AFC73D09645AE73DAAD9E47" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market stock units.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_F98DE2956AFC73D09645AE73DAAD9E47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketStockUnitsMember_F98DE2956AFC73D09645AE73DAAD9E47" xlink:to="lab_biib_MarketStockUnitsMember_F98DE2956AFC73D09645AE73DAAD9E47" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3D70FBF4CCD77D11A581AE73DAAD41BB_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3D70FBF4CCD77D11A581AE73DAAD41BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3D70FBF4CCD77D11A581AE73DAAD41BB_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3D70FBF4CCD77D11A581AE73DAAD41BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3D70FBF4CCD77D11A581AE73DAAD41BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3D70FBF4CCD77D11A581AE73DAAD41BB" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3D70FBF4CCD77D11A581AE73DAAD41BB" xlink:type="arc" />
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_8F8947208496BFDAC620AE73DAADBF57_verboseLabel_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_8F8947208496BFDAC620AE73DAADBF57" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_8F8947208496BFDAC620AE73DAADBF57_label_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_8F8947208496BFDAC620AE73DAADBF57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic And Diluted Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_8F8947208496BFDAC620AE73DAADBF57_documentation_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_8F8947208496BFDAC620AE73DAADBF57" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_8F8947208496BFDAC620AE73DAADBF57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_8F8947208496BFDAC620AE73DAADBF57" xlink:to="lab_biib_BasicAndDilutedEarningsPerShareAbstract_8F8947208496BFDAC620AE73DAADBF57" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_0D1D5138AACEF5657D5EAE73DAADDC4E_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract_0D1D5138AACEF5657D5EAE73DAADDC4E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_0D1D5138AACEF5657D5EAE73DAADDC4E_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract_0D1D5138AACEF5657D5EAE73DAADDC4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_0D1D5138AACEF5657D5EAE73DAADDC4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract_0D1D5138AACEF5657D5EAE73DAADDC4E" xlink:to="lab_us-gaap_NetIncomeLossAbstract_0D1D5138AACEF5657D5EAE73DAADDC4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_FD82AA7CBF17BDA4E04AAE73DAADDAF0_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_FD82AA7CBF17BDA4E04AAE73DAADDAF0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_FD82AA7CBF17BDA4E04AAE73DAADDAF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_FD82AA7CBF17BDA4E04AAE73DAADDAF0" xlink:to="lab_us-gaap_NetIncomeLoss_FD82AA7CBF17BDA4E04AAE73DAADDAF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_FB599B4976B87AB09F90AE73DAADF303_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_FB599B4976B87AB09F90AE73DAADF303" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used in calculating:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_FB599B4976B87AB09F90AE73DAADF303_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_FB599B4976B87AB09F90AE73DAADF303" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_FB599B4976B87AB09F90AE73DAADF303" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_FB599B4976B87AB09F90AE73DAADF303" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_FB599B4976B87AB09F90AE73DAADF303" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_230376A524458ECA756AAE73DAADDE33_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_230376A524458ECA756AAE73DAADDE33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_230376A524458ECA756AAE73DAADDE33_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_230376A524458ECA756AAE73DAADDE33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_230376A524458ECA756AAE73DAADDE33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_230376A524458ECA756AAE73DAADDE33" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_230376A524458ECA756AAE73DAADDE33" xlink:type="arc" />
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_05ABFE26BFFE1BA748F9AE73DAAD7AB7_verboseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_05ABFE26BFFE1BA748F9AE73DAAD7AB7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_05ABFE26BFFE1BA748F9AE73DAAD7AB7_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_05ABFE26BFFE1BA748F9AE73DAAD7AB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_05ABFE26BFFE1BA748F9AE73DAAD7AB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_05ABFE26BFFE1BA748F9AE73DAAD7AB7" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract_05ABFE26BFFE1BA748F9AE73DAAD7AB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8121223E6DAA46EBA951AE73DAAD2EAD_verboseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8121223E6DAA46EBA951AE73DAAD2EAD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock units</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8121223E6DAA46EBA951AE73DAAD2EAD_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8121223E6DAA46EBA951AE73DAAD2EAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8121223E6DAA46EBA951AE73DAAD2EAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8121223E6DAA46EBA951AE73DAAD2EAD" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8121223E6DAA46EBA951AE73DAAD2EAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_0C9B6310E7F2AB72BEF0AE73DAAD9D38_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_0C9B6310E7F2AB72BEF0AE73DAAD9D38" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Dilutive potential common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_0C9B6310E7F2AB72BEF0AE73DAAD9D38_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_0C9B6310E7F2AB72BEF0AE73DAAD9D38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_0C9B6310E7F2AB72BEF0AE73DAAD9D38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_0C9B6310E7F2AB72BEF0AE73DAAD9D38" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_0C9B6310E7F2AB72BEF0AE73DAAD9D38" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_68DFD58195CDAA9C52C4AE73DAAD1368_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_68DFD58195CDAA9C52C4AE73DAAD1368" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Shares used in calculating diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_68DFD58195CDAA9C52C4AE73DAAD1368_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_68DFD58195CDAA9C52C4AE73DAAD1368" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_68DFD58195CDAA9C52C4AE73DAAD1368" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_68DFD58195CDAA9C52C4AE73DAAD1368" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_68DFD58195CDAA9C52C4AE73DAAD1368" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_F18ABE00735F498C3A9271AC05A1DDA6_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_F18ABE00735F498C3A9271AC05A1DDA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_F18ABE00735F498C3A9271AC05A1DDA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_F18ABE00735F498C3A9271AC05A1DDA6" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_F18ABE00735F498C3A9271AC05A1DDA6" xlink:type="arc" />
    <link:label id="lab_biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock_8B99BF48A6E5B8401D3371AF3F09EE91_terseLabel_en-US" xlink:label="lab_biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock_8B99BF48A6E5B8401D3371AF3F09EE91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property plant and equipment purchase price allocation [Table Text Block]</link:label>
    <link:label id="lab_biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock_8B99BF48A6E5B8401D3371AF3F09EE91_label_en-US" xlink:label="lab_biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock_8B99BF48A6E5B8401D3371AF3F09EE91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property plant and equipment purchase price allocation [Table Text Block]</link:label>
    <link:label id="lab_biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock_8B99BF48A6E5B8401D3371AF3F09EE91_documentation_en-US" xlink:label="lab_biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock_8B99BF48A6E5B8401D3371AF3F09EE91" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property plant and equipment purchase price allocation [Table]</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock" xlink:label="loc_biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock_8B99BF48A6E5B8401D3371AF3F09EE91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock_8B99BF48A6E5B8401D3371AF3F09EE91" xlink:to="lab_biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock_8B99BF48A6E5B8401D3371AF3F09EE91" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_CB8C217453BE52BEA7DD2E2244F373F0_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_CB8C217453BE52BEA7DD2E2244F373F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_CB8C217453BE52BEA7DD2E2244F373F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_CB8C217453BE52BEA7DD2E2244F373F0" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_CB8C217453BE52BEA7DD2E2244F373F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_DE64FD6F8082B4D8B6272E2244F388AE_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_DE64FD6F8082B4D8B6272E2244F388AE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_DE64FD6F8082B4D8B6272E2244F388AE_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_DE64FD6F8082B4D8B6272E2244F388AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_DE64FD6F8082B4D8B6272E2244F388AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_DE64FD6F8082B4D8B6272E2244F388AE" xlink:to="lab_us-gaap_AssetsAbstract_DE64FD6F8082B4D8B6272E2244F388AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_3C79A0AD8E586210AD5B2E2244F3A3DB_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_3C79A0AD8E586210AD5B2E2244F3A3DB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_3C79A0AD8E586210AD5B2E2244F3A3DB_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_3C79A0AD8E586210AD5B2E2244F3A3DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3C79A0AD8E586210AD5B2E2244F3A3DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3C79A0AD8E586210AD5B2E2244F3A3DB" xlink:to="lab_us-gaap_AssetsCurrentAbstract_3C79A0AD8E586210AD5B2E2244F3A3DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_67A0828651AC8A5AE2BB2E2244F33101_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_67A0828651AC8A5AE2BB2E2244F33101" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_67A0828651AC8A5AE2BB2E2244F33101_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_67A0828651AC8A5AE2BB2E2244F33101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_67A0828651AC8A5AE2BB2E2244F33101" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_67A0828651AC8A5AE2BB2E2244F33101" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_67A0828651AC8A5AE2BB2E2244F33101" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_B6F24448B49FA8ADE4C82E2244F33201_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent_B6F24448B49FA8ADE4C82E2244F33201" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_B6F24448B49FA8ADE4C82E2244F33201_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent_B6F24448B49FA8ADE4C82E2244F33201" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_B6F24448B49FA8ADE4C82E2244F33201" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesCurrent_B6F24448B49FA8ADE4C82E2244F33201" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesCurrent_B6F24448B49FA8ADE4C82E2244F33201" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_367852297D788C3010BC2E2244F39F2C_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_367852297D788C3010BC2E2244F39F2C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_367852297D788C3010BC2E2244F39F2C_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_367852297D788C3010BC2E2244F39F2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_367852297D788C3010BC2E2244F39F2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_367852297D788C3010BC2E2244F39F2C" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_367852297D788C3010BC2E2244F39F2C" xlink:type="arc" />
    <link:label id="lab_biib_DueFromUnconsolidatedJointBusiness_7C2ED3D238B91159F68C2E2244F4189B_verboseLabel_en-US" xlink:label="lab_biib_DueFromUnconsolidatedJointBusiness_7C2ED3D238B91159F68C2E2244F4189B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due from unconsolidated joint business, net</link:label>
    <link:label id="lab_biib_DueFromUnconsolidatedJointBusiness_7C2ED3D238B91159F68C2E2244F4189B_label_en-US" xlink:label="lab_biib_DueFromUnconsolidatedJointBusiness_7C2ED3D238B91159F68C2E2244F4189B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due from unconsolidated joint business</link:label>
    <link:label id="lab_biib_DueFromUnconsolidatedJointBusiness_7C2ED3D238B91159F68C2E2244F4189B_documentation_en-US" xlink:label="lab_biib_DueFromUnconsolidatedJointBusiness_7C2ED3D238B91159F68C2E2244F4189B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Receivable from unconsolidated joint business for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_DueFromUnconsolidatedJointBusiness" xlink:label="loc_biib_DueFromUnconsolidatedJointBusiness_7C2ED3D238B91159F68C2E2244F4189B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DueFromUnconsolidatedJointBusiness_7C2ED3D238B91159F68C2E2244F4189B" xlink:to="lab_biib_DueFromUnconsolidatedJointBusiness_7C2ED3D238B91159F68C2E2244F4189B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_530F84625F46856321192E2244F42FBF_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_530F84625F46856321192E2244F42FBF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_530F84625F46856321192E2244F42FBF_label_en-US" xlink:label="lab_us-gaap_InventoryNet_530F84625F46856321192E2244F42FBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_530F84625F46856321192E2244F42FBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_530F84625F46856321192E2244F42FBF" xlink:to="lab_us-gaap_InventoryNet_530F84625F46856321192E2244F42FBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsCurrent_DD75DFCC4FFBF73A93A52E2244F4FF5D_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_DD75DFCC4FFBF73A93A52E2244F4FF5D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_DD75DFCC4FFBF73A93A52E2244F4FF5D_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_DD75DFCC4FFBF73A93A52E2244F4FF5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_DD75DFCC4FFBF73A93A52E2244F4FF5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_DD75DFCC4FFBF73A93A52E2244F4FF5D" xlink:to="lab_us-gaap_OtherAssetsCurrent_DD75DFCC4FFBF73A93A52E2244F4FF5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_9B8DC736B64201D7DFE42E2244F41248_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_9B8DC736B64201D7DFE42E2244F41248" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_9B8DC736B64201D7DFE42E2244F41248_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_9B8DC736B64201D7DFE42E2244F41248" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_9B8DC736B64201D7DFE42E2244F41248" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_9B8DC736B64201D7DFE42E2244F41248" xlink:to="lab_us-gaap_AssetsCurrent_9B8DC736B64201D7DFE42E2244F41248" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_CB64E1E67A7940103A212E2244F42BFE_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_CB64E1E67A7940103A212E2244F42BFE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_CB64E1E67A7940103A212E2244F42BFE_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_CB64E1E67A7940103A212E2244F42BFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_CB64E1E67A7940103A212E2244F42BFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_CB64E1E67A7940103A212E2244F42BFE" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_CB64E1E67A7940103A212E2244F42BFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3FC902DB8C222077A87F2E2244F40BD1_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_3FC902DB8C222077A87F2E2244F40BD1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3FC902DB8C222077A87F2E2244F40BD1_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_3FC902DB8C222077A87F2E2244F40BD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3FC902DB8C222077A87F2E2244F40BD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_3FC902DB8C222077A87F2E2244F40BD1" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_3FC902DB8C222077A87F2E2244F40BD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_38BED52BCBF2719F5C332E2244F44B3A_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_38BED52BCBF2719F5C332E2244F44B3A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_38BED52BCBF2719F5C332E2244F44B3A_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_38BED52BCBF2719F5C332E2244F44B3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_38BED52BCBF2719F5C332E2244F44B3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_38BED52BCBF2719F5C332E2244F44B3A" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_38BED52BCBF2719F5C332E2244F44B3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_62ACDD4180DABB4E16C52E2244F49C29_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_62ACDD4180DABB4E16C52E2244F49C29" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_62ACDD4180DABB4E16C52E2244F49C29_label_en-US" xlink:label="lab_us-gaap_Goodwill_62ACDD4180DABB4E16C52E2244F49C29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_62ACDD4180DABB4E16C52E2244F49C29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_62ACDD4180DABB4E16C52E2244F49C29" xlink:to="lab_us-gaap_Goodwill_62ACDD4180DABB4E16C52E2244F49C29" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_D3D60BB03E3F07326C222E2244F407A4_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_D3D60BB03E3F07326C222E2244F407A4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_D3D60BB03E3F07326C222E2244F407A4_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_D3D60BB03E3F07326C222E2244F407A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_D3D60BB03E3F07326C222E2244F407A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_D3D60BB03E3F07326C222E2244F407A4" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_D3D60BB03E3F07326C222E2244F407A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_5632F78EA45FE84073D52E2244F4652D_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_5632F78EA45FE84073D52E2244F4652D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_5632F78EA45FE84073D52E2244F4652D_label_en-US" xlink:label="lab_us-gaap_Assets_5632F78EA45FE84073D52E2244F4652D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_5632F78EA45FE84073D52E2244F4652D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_5632F78EA45FE84073D52E2244F4652D" xlink:to="lab_us-gaap_Assets_5632F78EA45FE84073D52E2244F4652D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3CC79BFA1BD8AF38EEF52E2244F4BD08_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3CC79BFA1BD8AF38EEF52E2244F4BD08" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3CC79BFA1BD8AF38EEF52E2244F4BD08_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3CC79BFA1BD8AF38EEF52E2244F4BD08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3CC79BFA1BD8AF38EEF52E2244F4BD08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3CC79BFA1BD8AF38EEF52E2244F4BD08" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3CC79BFA1BD8AF38EEF52E2244F4BD08" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_F75621576EB537BA2D9B2E2244F49570_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_F75621576EB537BA2D9B2E2244F49570" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_F75621576EB537BA2D9B2E2244F49570_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_F75621576EB537BA2D9B2E2244F49570" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_F75621576EB537BA2D9B2E2244F49570" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F75621576EB537BA2D9B2E2244F49570" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_F75621576EB537BA2D9B2E2244F49570" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtCurrent_8AE4CE8E979A1D6CCF902E2244F400DA_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent_8AE4CE8E979A1D6CCF902E2244F400DA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of notes payable and other financing arrangements</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_8AE4CE8E979A1D6CCF902E2244F400DA_label_en-US" xlink:label="lab_us-gaap_DebtCurrent_8AE4CE8E979A1D6CCF902E2244F400DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_8AE4CE8E979A1D6CCF902E2244F400DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent_8AE4CE8E979A1D6CCF902E2244F400DA" xlink:to="lab_us-gaap_DebtCurrent_8AE4CE8E979A1D6CCF902E2244F400DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxesPayableCurrent_BA430734BF0EBA8B772A2E2244F5A865_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_BA430734BF0EBA8B772A2E2244F5A865" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_BA430734BF0EBA8B772A2E2244F5A865_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_BA430734BF0EBA8B772A2E2244F5A865" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_BA430734BF0EBA8B772A2E2244F5A865" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent_BA430734BF0EBA8B772A2E2244F5A865" xlink:to="lab_us-gaap_TaxesPayableCurrent_BA430734BF0EBA8B772A2E2244F5A865" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_CB9FC6A2FA35B6EE8ABC2E2244F59A96_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_CB9FC6A2FA35B6EE8ABC2E2244F59A96" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_CB9FC6A2FA35B6EE8ABC2E2244F59A96_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_CB9FC6A2FA35B6EE8ABC2E2244F59A96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_CB9FC6A2FA35B6EE8ABC2E2244F59A96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_CB9FC6A2FA35B6EE8ABC2E2244F59A96" xlink:to="lab_us-gaap_AccountsPayableCurrent_CB9FC6A2FA35B6EE8ABC2E2244F59A96" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_6547B666B8C863F35FB12E2244F5BF49_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_6547B666B8C863F35FB12E2244F5BF49" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_6547B666B8C863F35FB12E2244F5BF49_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_6547B666B8C863F35FB12E2244F5BF49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_6547B666B8C863F35FB12E2244F5BF49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_6547B666B8C863F35FB12E2244F5BF49" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_6547B666B8C863F35FB12E2244F5BF49" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_304C46EA002A90CA41CE2E2244F58888_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_304C46EA002A90CA41CE2E2244F58888" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_304C46EA002A90CA41CE2E2244F58888_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_304C46EA002A90CA41CE2E2244F58888" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_304C46EA002A90CA41CE2E2244F58888" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_304C46EA002A90CA41CE2E2244F58888" xlink:to="lab_us-gaap_LiabilitiesCurrent_304C46EA002A90CA41CE2E2244F58888" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_6C5616D15D1735DF552D2E2244F5383C_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_6C5616D15D1735DF552D2E2244F5383C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable and other financing arrangements</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_6C5616D15D1735DF552D2E2244F5383C_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_6C5616D15D1735DF552D2E2244F5383C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_6C5616D15D1735DF552D2E2244F5383C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_6C5616D15D1735DF552D2E2244F5383C" xlink:to="lab_us-gaap_LongTermDebt_6C5616D15D1735DF552D2E2244F5383C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_926E5BE5CEE6704FE0062E2244F579B8_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_926E5BE5CEE6704FE0062E2244F579B8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_926E5BE5CEE6704FE0062E2244F579B8_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_926E5BE5CEE6704FE0062E2244F579B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_926E5BE5CEE6704FE0062E2244F579B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_926E5BE5CEE6704FE0062E2244F579B8" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_926E5BE5CEE6704FE0062E2244F579B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_03AC0BCAAB831455EA0B2E2244F54558_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_03AC0BCAAB831455EA0B2E2244F54558" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_03AC0BCAAB831455EA0B2E2244F54558_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_03AC0BCAAB831455EA0B2E2244F54558" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_03AC0BCAAB831455EA0B2E2244F54558" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_03AC0BCAAB831455EA0B2E2244F54558" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_03AC0BCAAB831455EA0B2E2244F54558" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_4B62AEA0D69F6CE7E2002E2244F51E07_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_4B62AEA0D69F6CE7E2002E2244F51E07" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_4B62AEA0D69F6CE7E2002E2244F51E07_label_en-US" xlink:label="lab_us-gaap_Liabilities_4B62AEA0D69F6CE7E2002E2244F51E07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_4B62AEA0D69F6CE7E2002E2244F51E07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_4B62AEA0D69F6CE7E2002E2244F51E07" xlink:to="lab_us-gaap_Liabilities_4B62AEA0D69F6CE7E2002E2244F51E07" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_AAAABC8F618AA33D91B32E2244F55FB6_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_AAAABC8F618AA33D91B32E2244F55FB6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_AAAABC8F618AA33D91B32E2244F55FB6_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_AAAABC8F618AA33D91B32E2244F55FB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_AAAABC8F618AA33D91B32E2244F55FB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_AAAABC8F618AA33D91B32E2244F55FB6" xlink:to="lab_us-gaap_CommitmentsAndContingencies_AAAABC8F618AA33D91B32E2244F55FB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3F21C88AC001FDCC7EFD2E2244F56319_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3F21C88AC001FDCC7EFD2E2244F56319" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3F21C88AC001FDCC7EFD2E2244F56319_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3F21C88AC001FDCC7EFD2E2244F56319" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3F21C88AC001FDCC7EFD2E2244F56319" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3F21C88AC001FDCC7EFD2E2244F56319" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3F21C88AC001FDCC7EFD2E2244F56319" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_1773B6488BE46E0BA7272E2244F5D1E1_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_1773B6488BE46E0BA7272E2244F5D1E1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Biogen Idec Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_1773B6488BE46E0BA7272E2244F5D1E1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_1773B6488BE46E0BA7272E2244F5D1E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_1773B6488BE46E0BA7272E2244F5D1E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1773B6488BE46E0BA7272E2244F5D1E1" xlink:to="lab_us-gaap_StockholdersEquityAbstract_1773B6488BE46E0BA7272E2244F5D1E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_8C25F97A4FF49F8796202E2244F5E623_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_8C25F97A4FF49F8796202E2244F5E623" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value $0.001 per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_8C25F97A4FF49F8796202E2244F5E623_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_8C25F97A4FF49F8796202E2244F5E623" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_8C25F97A4FF49F8796202E2244F5E623" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_8C25F97A4FF49F8796202E2244F5E623" xlink:to="lab_us-gaap_PreferredStockValue_8C25F97A4FF49F8796202E2244F5E623" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_DC78F34165E7759584D02E2244F5AA88_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_DC78F34165E7759584D02E2244F5AA88" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value $0.0005 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_DC78F34165E7759584D02E2244F5AA88_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_DC78F34165E7759584D02E2244F5AA88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_DC78F34165E7759584D02E2244F5AA88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_DC78F34165E7759584D02E2244F5AA88" xlink:to="lab_us-gaap_CommonStockValue_DC78F34165E7759584D02E2244F5AA88" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_E190859FBB9E9CA4D3412E2244F5EA4D_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_E190859FBB9E9CA4D3412E2244F5EA4D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_E190859FBB9E9CA4D3412E2244F5EA4D_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_E190859FBB9E9CA4D3412E2244F5EA4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_E190859FBB9E9CA4D3412E2244F5EA4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_E190859FBB9E9CA4D3412E2244F5EA4D" xlink:to="lab_us-gaap_AdditionalPaidInCapital_E190859FBB9E9CA4D3412E2244F5EA4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_15E0C9C74C4F4C0188ED2E2244F5BB2C_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_15E0C9C74C4F4C0188ED2E2244F5BB2C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_15E0C9C74C4F4C0188ED2E2244F5BB2C_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_15E0C9C74C4F4C0188ED2E2244F5BB2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_15E0C9C74C4F4C0188ED2E2244F5BB2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_15E0C9C74C4F4C0188ED2E2244F5BB2C" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_15E0C9C74C4F4C0188ED2E2244F5BB2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2E2B7F8478A32D65F2132E2244F521AB_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2E2B7F8478A32D65F2132E2244F521AB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2E2B7F8478A32D65F2132E2244F521AB_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2E2B7F8478A32D65F2132E2244F521AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2E2B7F8478A32D65F2132E2244F521AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2E2B7F8478A32D65F2132E2244F521AB" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2E2B7F8478A32D65F2132E2244F521AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValue_95E4F44BF83A123699FA2E2244F6593E_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_95E4F44BF83A123699FA2E2244F6593E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_95E4F44BF83A123699FA2E2244F6593E_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_95E4F44BF83A123699FA2E2244F6593E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_95E4F44BF83A123699FA2E2244F6593E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_95E4F44BF83A123699FA2E2244F6593E" xlink:to="lab_us-gaap_TreasuryStockValue_95E4F44BF83A123699FA2E2244F6593E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_3F5F3C10D84D4933BF462E2244F6EA36_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_3F5F3C10D84D4933BF462E2244F6EA36" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Biogen Inc. shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_3F5F3C10D84D4933BF462E2244F6EA36_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_3F5F3C10D84D4933BF462E2244F6EA36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_3F5F3C10D84D4933BF462E2244F6EA36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_3F5F3C10D84D4933BF462E2244F6EA36" xlink:to="lab_us-gaap_StockholdersEquity_3F5F3C10D84D4933BF462E2244F6EA36" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_E97F296EFEE92A4EE90C2E2244F6ECF9_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_E97F296EFEE92A4EE90C2E2244F6ECF9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_E97F296EFEE92A4EE90C2E2244F6ECF9_label_en-US" xlink:label="lab_us-gaap_MinorityInterest_E97F296EFEE92A4EE90C2E2244F6ECF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_E97F296EFEE92A4EE90C2E2244F6ECF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_E97F296EFEE92A4EE90C2E2244F6ECF9" xlink:to="lab_us-gaap_MinorityInterest_E97F296EFEE92A4EE90C2E2244F6ECF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_CF8DBF43B823CE769DB32E2244F64E90_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_CF8DBF43B823CE769DB32E2244F64E90" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_CF8DBF43B823CE769DB32E2244F64E90_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_CF8DBF43B823CE769DB32E2244F64E90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_CF8DBF43B823CE769DB32E2244F64E90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_CF8DBF43B823CE769DB32E2244F64E90" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_CF8DBF43B823CE769DB32E2244F64E90" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_004C73CCD3281FBB7C6B2E2244F66CD3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_004C73CCD3281FBB7C6B2E2244F66CD3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_004C73CCD3281FBB7C6B2E2244F66CD3_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_004C73CCD3281FBB7C6B2E2244F66CD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_004C73CCD3281FBB7C6B2E2244F66CD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_004C73CCD3281FBB7C6B2E2244F66CD3" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_004C73CCD3281FBB7C6B2E2244F66CD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_DDB628E2FF2F0197C58371883D8FFED9_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_DDB628E2FF2F0197C58371883D8FFED9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_DDB628E2FF2F0197C58371883D8FFED9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_DDB628E2FF2F0197C58371883D8FFED9" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_DDB628E2FF2F0197C58371883D8FFED9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5661B9FC8ECA81734BBF71883D903FD8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5661B9FC8ECA81734BBF71883D903FD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5661B9FC8ECA81734BBF71883D903FD8_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5661B9FC8ECA81734BBF71883D903FD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5661B9FC8ECA81734BBF71883D903FD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5661B9FC8ECA81734BBF71883D903FD8" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5661B9FC8ECA81734BBF71883D903FD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_62AF664553A6FF4AE35471883D90550D_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_62AF664553A6FF4AE35471883D90550D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_62AF664553A6FF4AE35471883D90550D_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_62AF664553A6FF4AE35471883D90550D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_62AF664553A6FF4AE35471883D90550D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_62AF664553A6FF4AE35471883D90550D" xlink:to="lab_us-gaap_DebtInstrumentAxis_62AF664553A6FF4AE35471883D90550D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_5999F17314350458F9EC71883D90E54F_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_5999F17314350458F9EC71883D90E54F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_5999F17314350458F9EC71883D90E54F_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_5999F17314350458F9EC71883D90E54F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5999F17314350458F9EC71883D90E54F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5999F17314350458F9EC71883D90E54F" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_5999F17314350458F9EC71883D90E54F" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_54977BD726433157B60771883D904E2C_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_54977BD726433157B60771883D904E2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.050% Senior Notes due 2025</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_54977BD726433157B60771883D904E2C_label_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_54977BD726433157B60771883D904E2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_54977BD726433157B60771883D904E2C_documentation_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_54977BD726433157B60771883D904E2C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_54977BD726433157B60771883D904E2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_54977BD726433157B60771883D904E2C" xlink:to="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_54977BD726433157B60771883D904E2C" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_847DA85D41DAC8B9057C71883D9068A6_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_847DA85D41DAC8B9057C71883D9068A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">5.200% Senior Notes due 2045</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_847DA85D41DAC8B9057C71883D9068A6_label_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_847DA85D41DAC8B9057C71883D9068A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_847DA85D41DAC8B9057C71883D9068A6_documentation_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_847DA85D41DAC8B9057C71883D9068A6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_847DA85D41DAC8B9057C71883D9068A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_847DA85D41DAC8B9057C71883D9068A6" xlink:to="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_847DA85D41DAC8B9057C71883D9068A6" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_DA2FEA6B56321AB78A8D71883D90749A_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_DA2FEA6B56321AB78A8D71883D90749A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.900% Senior Notes due 2020</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_DA2FEA6B56321AB78A8D71883D90749A_label_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_DA2FEA6B56321AB78A8D71883D90749A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_DA2FEA6B56321AB78A8D71883D90749A_documentation_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_DA2FEA6B56321AB78A8D71883D90749A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_DA2FEA6B56321AB78A8D71883D90749A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_DA2FEA6B56321AB78A8D71883D90749A" xlink:to="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_DA2FEA6B56321AB78A8D71883D90749A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrencyAxis_F88AE216C787925E4AB471883D90AC24_terseLabel_en-US" xlink:label="lab_us-gaap_CurrencyAxis_F88AE216C787925E4AB471883D90AC24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_us-gaap_CurrencyAxis_F88AE216C787925E4AB471883D90AC24_label_en-US" xlink:label="lab_us-gaap_CurrencyAxis_F88AE216C787925E4AB471883D90AC24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaap_CurrencyAxis_F88AE216C787925E4AB471883D90AC24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencyAxis_F88AE216C787925E4AB471883D90AC24" xlink:to="lab_us-gaap_CurrencyAxis_F88AE216C787925E4AB471883D90AC24" xlink:type="arc" />
    <link:label id="lab_currency_AllCurrenciesDomain_3C4DFE46ADCF99F2254771883D906B05_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain_3C4DFE46ADCF99F2254771883D906B05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_3C4DFE46ADCF99F2254771883D906B05_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain_3C4DFE46ADCF99F2254771883D906B05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_3C4DFE46ADCF99F2254771883D906B05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain_3C4DFE46ADCF99F2254771883D906B05" xlink:to="lab_currency_AllCurrenciesDomain_3C4DFE46ADCF99F2254771883D906B05" xlink:type="arc" />
    <link:label id="lab_currency_EUR_BB987EC231F3BCA7841271883D9016D7_verboseLabel_en-US" xlink:label="lab_currency_EUR_BB987EC231F3BCA7841271883D9016D7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Euro</link:label>
    <link:label id="lab_currency_EUR_BB987EC231F3BCA7841271883D9016D7_label_en-US" xlink:label="lab_currency_EUR_BB987EC231F3BCA7841271883D9016D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_BB987EC231F3BCA7841271883D9016D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR_BB987EC231F3BCA7841271883D9016D7" xlink:to="lab_currency_EUR_BB987EC231F3BCA7841271883D9016D7" xlink:type="arc" />
    <link:label id="lab_currency_CAD_9214581F3388E20CF22E71883D900F73_verboseLabel_en-US" xlink:label="lab_currency_CAD_9214581F3388E20CF22E71883D900F73" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Canadian Dollar</link:label>
    <link:label id="lab_currency_CAD_9214581F3388E20CF22E71883D900F73_label_en-US" xlink:label="lab_currency_CAD_9214581F3388E20CF22E71883D900F73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canada, Dollars</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_9214581F3388E20CF22E71883D900F73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CAD_9214581F3388E20CF22E71883D900F73" xlink:to="lab_currency_CAD_9214581F3388E20CF22E71883D900F73" xlink:type="arc" />
    <link:label id="lab_currency_GBP_54673D65504D10AC046F71883D90E6D4_terseLabel_en-US" xlink:label="lab_currency_GBP_54673D65504D10AC046F71883D90E6D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">British Pound Sterling</link:label>
    <link:label id="lab_currency_GBP_54673D65504D10AC046F71883D90E6D4_label_en-US" xlink:label="lab_currency_GBP_54673D65504D10AC046F71883D90E6D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_54673D65504D10AC046F71883D90E6D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP_54673D65504D10AC046F71883D90E6D4" xlink:to="lab_currency_GBP_54673D65504D10AC046F71883D90E6D4" xlink:type="arc" />
    <link:label id="lab_currency_JPY_6A890CB159A3ECADA30271883D917A3D_terseLabel_en-US" xlink:label="lab_currency_JPY_6A890CB159A3ECADA30271883D917A3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Japanese Yen</link:label>
    <link:label id="lab_currency_JPY_6A890CB159A3ECADA30271883D917A3D_label_en-US" xlink:label="lab_currency_JPY_6A890CB159A3ECADA30271883D917A3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Japan, Yen</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_JPY" xlink:label="loc_currency_JPY_6A890CB159A3ECADA30271883D917A3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_JPY_6A890CB159A3ECADA30271883D917A3D" xlink:to="lab_currency_JPY_6A890CB159A3ECADA30271883D917A3D" xlink:type="arc" />
    <link:label id="lab_currency_AUD_11DAED1BE65F6D65A5C371883D9148D3_terseLabel_en-US" xlink:label="lab_currency_AUD_11DAED1BE65F6D65A5C371883D9148D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Australian Dollar</link:label>
    <link:label id="lab_currency_AUD_11DAED1BE65F6D65A5C371883D9148D3_label_en-US" xlink:label="lab_currency_AUD_11DAED1BE65F6D65A5C371883D9148D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Australia, Dollars</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AUD" xlink:label="loc_currency_AUD_11DAED1BE65F6D65A5C371883D9148D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AUD_11DAED1BE65F6D65A5C371883D9148D3" xlink:to="lab_currency_AUD_11DAED1BE65F6D65A5C371883D9148D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_70C5DC0DB328D1CB3F4B71883D91D928_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_70C5DC0DB328D1CB3F4B71883D91D928" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_70C5DC0DB328D1CB3F4B71883D91D928_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_70C5DC0DB328D1CB3F4B71883D91D928" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_70C5DC0DB328D1CB3F4B71883D91D928" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_70C5DC0DB328D1CB3F4B71883D91D928" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_70C5DC0DB328D1CB3F4B71883D91D928" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_C9DCAD0AE89887F23AD771883D91A2F4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_C9DCAD0AE89887F23AD771883D91A2F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_C9DCAD0AE89887F23AD771883D91A2F4_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_C9DCAD0AE89887F23AD771883D91A2F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C9DCAD0AE89887F23AD771883D91A2F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C9DCAD0AE89887F23AD771883D91A2F4" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_C9DCAD0AE89887F23AD771883D91A2F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesMember_F9CA5412A296A741E5F671883D917EB0_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember_F9CA5412A296A741E5F671883D917EB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesMember_F9CA5412A296A741E5F671883D917EB0_label_en-US" xlink:label="lab_us-gaap_SalesMember_F9CA5412A296A741E5F671883D917EB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_F9CA5412A296A741E5F671883D917EB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember_F9CA5412A296A741E5F671883D917EB0" xlink:to="lab_us-gaap_SalesMember_F9CA5412A296A741E5F671883D917EB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_DBAA740734B5288BCC1471883D916303_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_DBAA740734B5288BCC1471883D916303" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_DBAA740734B5288BCC1471883D916303_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_DBAA740734B5288BCC1471883D916303" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_DBAA740734B5288BCC1471883D916303" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_DBAA740734B5288BCC1471883D916303" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_DBAA740734B5288BCC1471883D916303" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_7559A45E2BE627CC0C0871883D918DD5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_7559A45E2BE627CC0C0871883D918DD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_7559A45E2BE627CC0C0871883D918DD5_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_7559A45E2BE627CC0C0871883D918DD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_7559A45E2BE627CC0C0871883D918DD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7559A45E2BE627CC0C0871883D918DD5" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis_7559A45E2BE627CC0C0871883D918DD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_15A4CFCAAAFC153D2E0671883D913F2F_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_15A4CFCAAAFC153D2E0671883D913F2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_15A4CFCAAAFC153D2E0671883D913F2F_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_15A4CFCAAAFC153D2E0671883D913F2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_15A4CFCAAAFC153D2E0671883D913F2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_15A4CFCAAAFC153D2E0671883D913F2F" xlink:to="lab_us-gaap_DerivativeContractTypeDomain_15A4CFCAAAFC153D2E0671883D913F2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_591E016BC232CB22A9E971883D916DF1_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_591E016BC232CB22A9E971883D916DF1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange contract</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_591E016BC232CB22A9E971883D916DF1_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_591E016BC232CB22A9E971883D916DF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_591E016BC232CB22A9E971883D916DF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember_591E016BC232CB22A9E971883D916DF1" xlink:to="lab_us-gaap_ForeignExchangeContractMember_591E016BC232CB22A9E971883D916DF1" xlink:type="arc" />
    <link:label id="lab_biib_InterestratelocksMember_3B0D41ABD32C1ECAE60B71883D916591_terseLabel_en-US" xlink:label="lab_biib_InterestratelocksMember_3B0D41ABD32C1ECAE60B71883D916591" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate locks</link:label>
    <link:label id="lab_biib_InterestratelocksMember_3B0D41ABD32C1ECAE60B71883D916591_label_en-US" xlink:label="lab_biib_InterestratelocksMember_3B0D41ABD32C1ECAE60B71883D916591" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest rate locks [Member]</link:label>
    <link:label id="lab_biib_InterestratelocksMember_3B0D41ABD32C1ECAE60B71883D916591_documentation_en-US" xlink:label="lab_biib_InterestratelocksMember_3B0D41ABD32C1ECAE60B71883D916591" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest rate locks [Member]</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_InterestratelocksMember" xlink:label="loc_biib_InterestratelocksMember_3B0D41ABD32C1ECAE60B71883D916591" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterestratelocksMember_3B0D41ABD32C1ECAE60B71883D916591" xlink:to="lab_biib_InterestratelocksMember_3B0D41ABD32C1ECAE60B71883D916591" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestRateSwapMember_4B7121D80409244270B871883D91D2BF_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_4B7121D80409244270B871883D91D2BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_4B7121D80409244270B871883D91D2BF_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_4B7121D80409244270B871883D91D2BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_4B7121D80409244270B871883D91D2BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember_4B7121D80409244270B871883D91D2BF" xlink:to="lab_us-gaap_InterestRateSwapMember_4B7121D80409244270B871883D91D2BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_D23194920FDEDCC6BCB071883D91A24B_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_D23194920FDEDCC6BCB071883D91A24B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_D23194920FDEDCC6BCB071883D91A24B_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_D23194920FDEDCC6BCB071883D91A24B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_D23194920FDEDCC6BCB071883D91A24B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_D23194920FDEDCC6BCB071883D91A24B" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_D23194920FDEDCC6BCB071883D91A24B" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_8787B6B7DACE435004FE71883D91D512_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_8787B6B7DACE435004FE71883D91D512" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_8787B6B7DACE435004FE71883D91D512_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_8787B6B7DACE435004FE71883D91D512" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8787B6B7DACE435004FE71883D91D512" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8787B6B7DACE435004FE71883D91D512" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_8787B6B7DACE435004FE71883D91D512" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_A1A8587FE0475B354F2D71883D910A5F_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_A1A8587FE0475B354F2D71883D910A5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_A1A8587FE0475B354F2D71883D910A5F_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_A1A8587FE0475B354F2D71883D910A5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_A1A8587FE0475B354F2D71883D910A5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember_A1A8587FE0475B354F2D71883D910A5F" xlink:to="lab_us-gaap_OtherCurrentAssetsMember_A1A8587FE0475B354F2D71883D910A5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherInvestmentsMember_F4CF7731752451F96FD971883D913A04_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember_F4CF7731752451F96FD971883D913A04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentsMember_F4CF7731752451F96FD971883D913A04_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember_F4CF7731752451F96FD971883D913A04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Investments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="loc_us-gaap_OtherInvestmentsMember_F4CF7731752451F96FD971883D913A04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentsMember_F4CF7731752451F96FD971883D913A04" xlink:to="lab_us-gaap_OtherInvestmentsMember_F4CF7731752451F96FD971883D913A04" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_3B69F2E0A5072BDCC72D71883D92D09A_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember_3B69F2E0A5072BDCC72D71883D92D09A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_3B69F2E0A5072BDCC72D71883D92D09A_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember_3B69F2E0A5072BDCC72D71883D92D09A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_3B69F2E0A5072BDCC72D71883D92D09A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember_3B69F2E0A5072BDCC72D71883D92D09A" xlink:to="lab_us-gaap_AccruedLiabilitiesMember_3B69F2E0A5072BDCC72D71883D92D09A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_7CAD6154F6535306734771883D92BC31_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_7CAD6154F6535306734771883D92BC31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_7CAD6154F6535306734771883D92BC31_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_7CAD6154F6535306734771883D92BC31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_7CAD6154F6535306734771883D92BC31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember_7CAD6154F6535306734771883D92BC31" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember_7CAD6154F6535306734771883D92BC31" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationAxis_DFCF0CA186418E91EE6C71883D92E3D5_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_DFCF0CA186418E91EE6C71883D92E3D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_DFCF0CA186418E91EE6C71883D92E3D5_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_DFCF0CA186418E91EE6C71883D92E3D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_DFCF0CA186418E91EE6C71883D92E3D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis_DFCF0CA186418E91EE6C71883D92E3D5" xlink:to="lab_us-gaap_HedgingDesignationAxis_DFCF0CA186418E91EE6C71883D92E3D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationDomain_B1E0C97B80B357052D2571883D92F408_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_B1E0C97B80B357052D2571883D92F408" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_B1E0C97B80B357052D2571883D92F408_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_B1E0C97B80B357052D2571883D92F408" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_B1E0C97B80B357052D2571883D92F408" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain_B1E0C97B80B357052D2571883D92F408" xlink:to="lab_us-gaap_HedgingDesignationDomain_B1E0C97B80B357052D2571883D92F408" xlink:type="arc" />
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_951EDFEFFD4AF905DDD271883D923A00_verboseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_951EDFEFFD4AF905DDD271883D923A00" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_951EDFEFFD4AF905DDD271883D923A00_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_951EDFEFFD4AF905DDD271883D923A00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_951EDFEFFD4AF905DDD271883D923A00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember_951EDFEFFD4AF905DDD271883D923A00" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember_951EDFEFFD4AF905DDD271883D923A00" xlink:type="arc" />
    <link:label id="lab_us-gaap_NondesignatedMember_2431FDFAB5771274CAC271883D97F720_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember_2431FDFAB5771274CAC271883D97F720" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_2431FDFAB5771274CAC271883D97F720_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember_2431FDFAB5771274CAC271883D97F720" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_2431FDFAB5771274CAC271883D97F720" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember_2431FDFAB5771274CAC271883D97F720" xlink:to="lab_us-gaap_NondesignatedMember_2431FDFAB5771274CAC271883D97F720" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_ADEB9161A70F9F58000871883D97BF43_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_ADEB9161A70F9F58000871883D97BF43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_ADEB9161A70F9F58000871883D97BF43_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_ADEB9161A70F9F58000871883D97BF43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_ADEB9161A70F9F58000871883D97BF43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ADEB9161A70F9F58000871883D97BF43" xlink:to="lab_us-gaap_DerivativesFairValueLineItems_ADEB9161A70F9F58000871883D97BF43" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeAssetFairValueNetAbstract_27B3206A552A8630A9DD71883D9C0319_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueNetAbstract_27B3206A552A8630A9DD71883D9C0319" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Derivatives designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueNetAbstract_27B3206A552A8630A9DD71883D9C0319_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueNetAbstract_27B3206A552A8630A9DD71883D9C0319" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Fair Value, Amount Not Offset Against Collateral [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_27B3206A552A8630A9DD71883D9C0319" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_27B3206A552A8630A9DD71883D9C0319" xlink:to="lab_us-gaap_DerivativeAssetFairValueNetAbstract_27B3206A552A8630A9DD71883D9C0319" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_DD771838E0898A2A9ADB71883D9C289A_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_DD771838E0898A2A9ADB71883D9C289A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative asset, fair value, net</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_DD771838E0898A2A9ADB71883D9C289A_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_DD771838E0898A2A9ADB71883D9C289A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_DD771838E0898A2A9ADB71883D9C289A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_DD771838E0898A2A9ADB71883D9C289A" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_DD771838E0898A2A9ADB71883D9C289A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_75E28D89FF67069FE30B71883D9C67E3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_75E28D89FF67069FE30B71883D9C67E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability, fair value, net</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_75E28D89FF67069FE30B71883D9C67E3_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_75E28D89FF67069FE30B71883D9C67E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_75E28D89FF67069FE30B71883D9C67E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_75E28D89FF67069FE30B71883D9C67E3" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_75E28D89FF67069FE30B71883D9C67E3" xlink:type="arc" />
    <link:label id="lab_biib_DerivativeInstrumentsTextualAbstract_2B95F15DCB5BD88DD2BA71883D9C4459_verboseLabel_en-US" xlink:label="lab_biib_DerivativeInstrumentsTextualAbstract_2B95F15DCB5BD88DD2BA71883D9C4459" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_DerivativeInstrumentsTextualAbstract_2B95F15DCB5BD88DD2BA71883D9C4459_label_en-US" xlink:label="lab_biib_DerivativeInstrumentsTextualAbstract_2B95F15DCB5BD88DD2BA71883D9C4459" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_DerivativeInstrumentsTextualAbstract_2B95F15DCB5BD88DD2BA71883D9C4459_documentation_en-US" xlink:label="lab_biib_DerivativeInstrumentsTextualAbstract_2B95F15DCB5BD88DD2BA71883D9C4459" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Instruments.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_DerivativeInstrumentsTextualAbstract" xlink:label="loc_biib_DerivativeInstrumentsTextualAbstract_2B95F15DCB5BD88DD2BA71883D9C4459" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_2B95F15DCB5BD88DD2BA71883D9C4459" xlink:to="lab_biib_DerivativeInstrumentsTextualAbstract_2B95F15DCB5BD88DD2BA71883D9C4459" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeLowerRemainingMaturityRange1_2F4F94091B01D8CBD56271883D9C5635_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLowerRemainingMaturityRange1_2F4F94091B01D8CBD56271883D9C5635" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Lower range of durations of foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeLowerRemainingMaturityRange1_2F4F94091B01D8CBD56271883D9C5635_label_en-US" xlink:label="lab_us-gaap_DerivativeLowerRemainingMaturityRange1_2F4F94091B01D8CBD56271883D9C5635" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Lower Remaining Maturity Range</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLowerRemainingMaturityRange1" xlink:label="loc_us-gaap_DerivativeLowerRemainingMaturityRange1_2F4F94091B01D8CBD56271883D9C5635" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLowerRemainingMaturityRange1_2F4F94091B01D8CBD56271883D9C5635" xlink:to="lab_us-gaap_DerivativeLowerRemainingMaturityRange1_2F4F94091B01D8CBD56271883D9C5635" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeHigherRemainingMaturityRange1_33C68787831D3B5F059671883D9CA55C_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeHigherRemainingMaturityRange1_33C68787831D3B5F059671883D9CA55C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Higher range of durations of foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeHigherRemainingMaturityRange1_33C68787831D3B5F059671883D9CA55C_label_en-US" xlink:label="lab_us-gaap_DerivativeHigherRemainingMaturityRange1_33C68787831D3B5F059671883D9CA55C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Higher Remaining Maturity Range</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeHigherRemainingMaturityRange1" xlink:label="loc_us-gaap_DerivativeHigherRemainingMaturityRange1_33C68787831D3B5F059671883D9CA55C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeHigherRemainingMaturityRange1_33C68787831D3B5F059671883D9CA55C" xlink:to="lab_us-gaap_DerivativeHigherRemainingMaturityRange1_33C68787831D3B5F059671883D9CA55C" xlink:type="arc" />
    <link:label id="lab_invest_DerivativeNotionalAmount_11EA4347461178D2E37771883D9C8FCB_terseLabel_en-US" xlink:label="lab_invest_DerivativeNotionalAmount_11EA4347461178D2E37771883D9C8FCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate notional amount</link:label>
    <link:label id="lab_invest_DerivativeNotionalAmount_11EA4347461178D2E37771883D9C8FCB_label_en-US" xlink:label="lab_invest_DerivativeNotionalAmount_11EA4347461178D2E37771883D9C8FCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_11EA4347461178D2E37771883D9C8FCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_DerivativeNotionalAmount_11EA4347461178D2E37771883D9C8FCB" xlink:to="lab_invest_DerivativeNotionalAmount_11EA4347461178D2E37771883D9C8FCB" xlink:type="arc" />
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_7BCEF77576DE56DBA48671883D9DB5CF_verboseLabel_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_7BCEF77576DE56DBA48671883D9DB5CF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gain/Loss on fair value of foreign currency forward contracts</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_7BCEF77576DE56DBA48671883D9DB5CF_label_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_7BCEF77576DE56DBA48671883D9DB5CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Losses) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_7BCEF77576DE56DBA48671883D9DB5CF_documentation_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_7BCEF77576DE56DBA48671883D9DB5CF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_7BCEF77576DE56DBA48671883D9DB5CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_7BCEF77576DE56DBA48671883D9DB5CF" xlink:to="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_7BCEF77576DE56DBA48671883D9DB5CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_D71F5765F0FFB218B16271883D9DD75F_verboseLabel_en-US" xlink:label="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_D71F5765F0FFB218B16271883D9DD75F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected settlement time for contracts, in months</link:label>
    <link:label id="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_D71F5765F0FFB218B16271883D9DD75F_label_en-US" xlink:label="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_D71F5765F0FFB218B16271883D9DD75F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Remaining Maturity of Foreign Currency Derivatives</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_D71F5765F0FFB218B16271883D9DD75F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_D71F5765F0FFB218B16271883D9DD75F" xlink:to="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_D71F5765F0FFB218B16271883D9DD75F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_98D0B672259F876B715D71883D9DC172_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_98D0B672259F876B715D71883D9DC172" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) in product revenue for the settlement of certain effective cash flow hedge instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_98D0B672259F876B715D71883D9DC172_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_98D0B672259F876B715D71883D9DC172" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_98D0B672259F876B715D71883D9DC172" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_98D0B672259F876B715D71883D9DC172" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_98D0B672259F876B715D71883D9DC172" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_DCB5C27FBF090C1156F271883D9D7036_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_DCB5C27FBF090C1156F271883D9D7036" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) in earnings of Foreign currency forward contracts due to hedge ineffectiveness</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_DCB5C27FBF090C1156F271883D9D7036_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_DCB5C27FBF090C1156F271883D9D7036" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_DCB5C27FBF090C1156F271883D9D7036" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_DCB5C27FBF090C1156F271883D9D7036" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_DCB5C27FBF090C1156F271883D9D7036" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_BD54A25A007AC78DBB8671883D9D9D70_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_BD54A25A007AC78DBB8671883D9D9D70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_BD54A25A007AC78DBB8671883D9D9D70_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_BD54A25A007AC78DBB8671883D9D9D70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_BD54A25A007AC78DBB8671883D9D9D70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_BD54A25A007AC78DBB8671883D9D9D70" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_BD54A25A007AC78DBB8671883D9D9D70" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8F6AA8B2E295D3CAB45271883D9D62CA_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8F6AA8B2E295D3CAB45271883D9D62CA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gain for treasury rate lock settlement</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8F6AA8B2E295D3CAB45271883D9D62CA_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8F6AA8B2E295D3CAB45271883D9D62CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8F6AA8B2E295D3CAB45271883D9D62CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8F6AA8B2E295D3CAB45271883D9D62CA" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8F6AA8B2E295D3CAB45271883D9D62CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_923D865BE31BCD18A94B71883D9D1BCE_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_923D865BE31BCD18A94B71883D9D1BCE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) of other income (expense) related to foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_923D865BE31BCD18A94B71883D9D1BCE_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_923D865BE31BCD18A94B71883D9D1BCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_923D865BE31BCD18A94B71883D9D1BCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_923D865BE31BCD18A94B71883D9D1BCE" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_923D865BE31BCD18A94B71883D9D1BCE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A0989F4B3EC49892890B875A3D4917ED_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A0989F4B3EC49892890B875A3D4917ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A0989F4B3EC49892890B875A3D4917ED_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A0989F4B3EC49892890B875A3D4917ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A0989F4B3EC49892890B875A3D4917ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A0989F4B3EC49892890B875A3D4917ED" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A0989F4B3EC49892890B875A3D4917ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_6E887704B4C66091A415875A3D494B48_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_6E887704B4C66091A415875A3D494B48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_6E887704B4C66091A415875A3D494B48_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_6E887704B4C66091A415875A3D494B48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6E887704B4C66091A415875A3D494B48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6E887704B4C66091A415875A3D494B48" xlink:to="lab_us-gaap_TypeOfArrangementAxis_6E887704B4C66091A415875A3D494B48" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6A38ABBA6E22D04AF3C8875A3D497D58_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6A38ABBA6E22D04AF3C8875A3D497D58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6A38ABBA6E22D04AF3C8875A3D497D58_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6A38ABBA6E22D04AF3C8875A3D497D58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6A38ABBA6E22D04AF3C8875A3D497D58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6A38ABBA6E22D04AF3C8875A3D497D58" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6A38ABBA6E22D04AF3C8875A3D497D58" xlink:type="arc" />
    <link:label id="lab_biib_EisaiMember_E0952C67FB3AA0381890875A3D49F499_terseLabel_en-US" xlink:label="lab_biib_EisaiMember_E0952C67FB3AA0381890875A3D49F499" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eisai</link:label>
    <link:label id="lab_biib_EisaiMember_E0952C67FB3AA0381890875A3D49F499_label_en-US" xlink:label="lab_biib_EisaiMember_E0952C67FB3AA0381890875A3D49F499" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eisai [Member]</link:label>
    <link:label id="lab_biib_EisaiMember_E0952C67FB3AA0381890875A3D49F499_documentation_en-US" xlink:label="lab_biib_EisaiMember_E0952C67FB3AA0381890875A3D49F499" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eisai [Member]</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_E0952C67FB3AA0381890875A3D49F499" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EisaiMember_E0952C67FB3AA0381890875A3D49F499" xlink:to="lab_biib_EisaiMember_E0952C67FB3AA0381890875A3D49F499" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_BDA1852A96809CC1ACED875A3D498823_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_BDA1852A96809CC1ACED875A3D498823" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_BDA1852A96809CC1ACED875A3D498823_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_BDA1852A96809CC1ACED875A3D498823" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_BDA1852A96809CC1ACED875A3D498823" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_BDA1852A96809CC1ACED875A3D498823" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_BDA1852A96809CC1ACED875A3D498823" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_A133B037092426ABB472875A3D4A3BB0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_A133B037092426ABB472875A3D4A3BB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_A133B037092426ABB472875A3D4A3BB0_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_A133B037092426ABB472875A3D4A3BB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_A133B037092426ABB472875A3D4A3BB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_A133B037092426ABB472875A3D4A3BB0" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_A133B037092426ABB472875A3D4A3BB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_91361D31174AEDBAD046875A3D4A1D48_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions_91361D31174AEDBAD046875A3D4A1D48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Triangle Park facility purchase</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_91361D31174AEDBAD046875A3D4A1D48_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions_91361D31174AEDBAD046875A3D4A1D48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Additions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_91361D31174AEDBAD046875A3D4A1D48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAdditions_91361D31174AEDBAD046875A3D4A1D48" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAdditions_91361D31174AEDBAD046875A3D4A1D48" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_B70C546A5B1E2530F12A875A3D4AB537_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_B70C546A5B1E2530F12A875A3D4AB537" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of lease</link:label>
    <link:label id="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_B70C546A5B1E2530F12A875A3D4AB537_label_en-US" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_B70C546A5B1E2530F12A875A3D4AB537" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Leasing Arrangements, Operating Leases, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_B70C546A5B1E2530F12A875A3D4AB537" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_B70C546A5B1E2530F12A875A3D4AB537" xlink:to="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_B70C546A5B1E2530F12A875A3D4AB537" xlink:type="arc" />
    <link:label id="lab_biib_TermOfLease_5FBE1A0A4781A816BE90875A3D4A1AB7_terseLabel_en-US" xlink:label="lab_biib_TermOfLease_5FBE1A0A4781A816BE90875A3D4A1AB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of amended lease</link:label>
    <link:label id="lab_biib_TermOfLease_5FBE1A0A4781A816BE90875A3D4A1AB7_label_en-US" xlink:label="lab_biib_TermOfLease_5FBE1A0A4781A816BE90875A3D4A1AB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Of Lease</link:label>
    <link:label id="lab_biib_TermOfLease_5FBE1A0A4781A816BE90875A3D4A1AB7_documentation_en-US" xlink:label="lab_biib_TermOfLease_5FBE1A0A4781A816BE90875A3D4A1AB7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Of Lease.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_TermOfLease" xlink:label="loc_biib_TermOfLease_5FBE1A0A4781A816BE90875A3D4A1AB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TermOfLease_5FBE1A0A4781A816BE90875A3D4A1AB7" xlink:to="lab_biib_TermOfLease_5FBE1A0A4781A816BE90875A3D4A1AB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeaseObligations_1318D9DE25D697AFC4D3875A3D4A90FE_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligations_1318D9DE25D697AFC4D3875A3D4A90FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital lease obligation</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligations_1318D9DE25D697AFC4D3875A3D4A90FE_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligations_1318D9DE25D697AFC4D3875A3D4A90FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Lease Obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="loc_us-gaap_CapitalLeaseObligations_1318D9DE25D697AFC4D3875A3D4A90FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligations_1318D9DE25D697AFC4D3875A3D4A90FE" xlink:to="lab_us-gaap_CapitalLeaseObligations_1318D9DE25D697AFC4D3875A3D4A90FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0B1BCFA3CAE4A9B77A5771B13DBE577A_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0B1BCFA3CAE4A9B77A5771B13DBE577A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0B1BCFA3CAE4A9B77A5771B13DBE577A_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0B1BCFA3CAE4A9B77A5771B13DBE577A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0B1BCFA3CAE4A9B77A5771B13DBE577A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0B1BCFA3CAE4A9B77A5771B13DBE577A" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0B1BCFA3CAE4A9B77A5771B13DBE577A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_A05E477D4D3BF298720A71B13DBE1F13_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_A05E477D4D3BF298720A71B13DBE1F13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_A05E477D4D3BF298720A71B13DBE1F13_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_A05E477D4D3BF298720A71B13DBE1F13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_A05E477D4D3BF298720A71B13DBE1F13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_A05E477D4D3BF298720A71B13DBE1F13" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_A05E477D4D3BF298720A71B13DBE1F13" xlink:type="arc" />
    <link:label id="lab_us-gaap_BuildingMember_F42CFF8EF018DCE2693B71B23037A3F3_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember_F42CFF8EF018DCE2693B71B23037A3F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_F42CFF8EF018DCE2693B71B23037A3F3_label_en-US" xlink:label="lab_us-gaap_BuildingMember_F42CFF8EF018DCE2693B71B23037A3F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_F42CFF8EF018DCE2693B71B23037A3F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember_F42CFF8EF018DCE2693B71B23037A3F3" xlink:to="lab_us-gaap_BuildingMember_F42CFF8EF018DCE2693B71B23037A3F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_41EE4E3543585545902E71B261861B7E_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_41EE4E3543585545902E71B261861B7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Machinery and Equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_41EE4E3543585545902E71B261861B7E_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_41EE4E3543585545902E71B261861B7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_41EE4E3543585545902E71B261861B7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember_41EE4E3543585545902E71B261861B7E" xlink:to="lab_us-gaap_MachineryAndEquipmentMember_41EE4E3543585545902E71B261861B7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LandMember_BF687AD09D8D91C667F471B30678C6F2_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember_BF687AD09D8D91C667F471B30678C6F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_BF687AD09D8D91C667F471B30678C6F2_label_en-US" xlink:label="lab_us-gaap_LandMember_BF687AD09D8D91C667F471B30678C6F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_BF687AD09D8D91C667F471B30678C6F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember_BF687AD09D8D91C667F471B30678C6F2" xlink:to="lab_us-gaap_LandMember_BF687AD09D8D91C667F471B30678C6F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9B439715B10A78809F913F3E22812BB3_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9B439715B10A78809F913F3E22812BB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9B439715B10A78809F913F3E22812BB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9B439715B10A78809F913F3E22812BB3" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9B439715B10A78809F913F3E22812BB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1D7B087FDA3E1516FF833F3E228126DF_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1D7B087FDA3E1516FF833F3E228126DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1D7B087FDA3E1516FF833F3E228126DF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1D7B087FDA3E1516FF833F3E228126DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1D7B087FDA3E1516FF833F3E228126DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1D7B087FDA3E1516FF833F3E228126DF" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1D7B087FDA3E1516FF833F3E228126DF" xlink:type="arc" />
    <link:label id="lab_biib_CumulativeSalesLevelAxis_4C55D43A856D54B327833F3E2281BB66_terseLabel_en-US" xlink:label="lab_biib_CumulativeSalesLevelAxis_4C55D43A856D54B327833F3E2281BB66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Axis]</link:label>
    <link:label id="lab_biib_CumulativeSalesLevelAxis_4C55D43A856D54B327833F3E2281BB66_label_en-US" xlink:label="lab_biib_CumulativeSalesLevelAxis_4C55D43A856D54B327833F3E2281BB66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Axis]</link:label>
    <link:label id="lab_biib_CumulativeSalesLevelAxis_4C55D43A856D54B327833F3E2281BB66_documentation_en-US" xlink:label="lab_biib_CumulativeSalesLevelAxis_4C55D43A856D54B327833F3E2281BB66" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Axis]</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_4C55D43A856D54B327833F3E2281BB66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CumulativeSalesLevelAxis_4C55D43A856D54B327833F3E2281BB66" xlink:to="lab_biib_CumulativeSalesLevelAxis_4C55D43A856D54B327833F3E2281BB66" xlink:type="arc" />
    <link:label id="lab_biib_CumulativeSalesLevelDomain_AA077F9E992D4AEF0EDD3F3E228163D9_terseLabel_en-US" xlink:label="lab_biib_CumulativeSalesLevelDomain_AA077F9E992D4AEF0EDD3F3E228163D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Domain]</link:label>
    <link:label id="lab_biib_CumulativeSalesLevelDomain_AA077F9E992D4AEF0EDD3F3E228163D9_label_en-US" xlink:label="lab_biib_CumulativeSalesLevelDomain_AA077F9E992D4AEF0EDD3F3E228163D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Domain]</link:label>
    <link:label id="lab_biib_CumulativeSalesLevelDomain_AA077F9E992D4AEF0EDD3F3E228163D9_documentation_en-US" xlink:label="lab_biib_CumulativeSalesLevelDomain_AA077F9E992D4AEF0EDD3F3E228163D9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Cumulative sales level [Axis]</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_AA077F9E992D4AEF0EDD3F3E228163D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CumulativeSalesLevelDomain_AA077F9E992D4AEF0EDD3F3E228163D9" xlink:to="lab_biib_CumulativeSalesLevelDomain_AA077F9E992D4AEF0EDD3F3E228163D9" xlink:type="arc" />
    <link:label id="lab_biib_FourbillionMember_14DC9D8041A1E7118E3C3F3E2281E4EA_terseLabel_en-US" xlink:label="lab_biib_FourbillionMember_14DC9D8041A1E7118E3C3F3E2281E4EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Four billion</link:label>
    <link:label id="lab_biib_FourbillionMember_14DC9D8041A1E7118E3C3F3E2281E4EA_label_en-US" xlink:label="lab_biib_FourbillionMember_14DC9D8041A1E7118E3C3F3E2281E4EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Four billion [Member]</link:label>
    <link:label id="lab_biib_FourbillionMember_14DC9D8041A1E7118E3C3F3E2281E4EA_documentation_en-US" xlink:label="lab_biib_FourbillionMember_14DC9D8041A1E7118E3C3F3E2281E4EA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Four billion [Member]</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_FourbillionMember" xlink:label="loc_biib_FourbillionMember_14DC9D8041A1E7118E3C3F3E2281E4EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FourbillionMember_14DC9D8041A1E7118E3C3F3E2281E4EA" xlink:to="lab_biib_FourbillionMember_14DC9D8041A1E7118E3C3F3E2281E4EA" xlink:type="arc" />
    <link:label id="lab_biib_FivebillionMember_A5E161E412B2A7F2267B3F3E22812D39_terseLabel_en-US" xlink:label="lab_biib_FivebillionMember_A5E161E412B2A7F2267B3F3E22812D39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Five billion</link:label>
    <link:label id="lab_biib_FivebillionMember_A5E161E412B2A7F2267B3F3E22812D39_label_en-US" xlink:label="lab_biib_FivebillionMember_A5E161E412B2A7F2267B3F3E22812D39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Five billion [Member]</link:label>
    <link:label id="lab_biib_FivebillionMember_A5E161E412B2A7F2267B3F3E22812D39_documentation_en-US" xlink:label="lab_biib_FivebillionMember_A5E161E412B2A7F2267B3F3E22812D39" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Five billion [Member]</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_FivebillionMember" xlink:label="loc_biib_FivebillionMember_A5E161E412B2A7F2267B3F3E22812D39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FivebillionMember_A5E161E412B2A7F2267B3F3E22812D39" xlink:to="lab_biib_FivebillionMember_A5E161E412B2A7F2267B3F3E22812D39" xlink:type="arc" />
    <link:label id="lab_biib_SixbillionMember_EDB968E377305E3F9CB13F86E28D0F6E_terseLabel_en-US" xlink:label="lab_biib_SixbillionMember_EDB968E377305E3F9CB13F86E28D0F6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Six billion</link:label>
    <link:label id="lab_biib_SixbillionMember_EDB968E377305E3F9CB13F86E28D0F6E_label_en-US" xlink:label="lab_biib_SixbillionMember_EDB968E377305E3F9CB13F86E28D0F6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Six billion [Member]</link:label>
    <link:label id="lab_biib_SixbillionMember_EDB968E377305E3F9CB13F86E28D0F6E_documentation_en-US" xlink:label="lab_biib_SixbillionMember_EDB968E377305E3F9CB13F86E28D0F6E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Six billion [Member]</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_SixbillionMember" xlink:label="loc_biib_SixbillionMember_EDB968E377305E3F9CB13F86E28D0F6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SixbillionMember_EDB968E377305E3F9CB13F86E28D0F6E" xlink:to="lab_biib_SixbillionMember_EDB968E377305E3F9CB13F86E28D0F6E" xlink:type="arc" />
    <link:label id="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_056AD91582DBEAF306CA3F3E22811482_terseLabel_en-US" xlink:label="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_056AD91582DBEAF306CA3F3E22811482" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Each additional one billion up to twenty billion</link:label>
    <link:label id="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_056AD91582DBEAF306CA3F3E22811482_label_en-US" xlink:label="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_056AD91582DBEAF306CA3F3E22811482" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Each additional one billion up to twenty billion [Member]</link:label>
    <link:label id="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_056AD91582DBEAF306CA3F3E22811482_documentation_en-US" xlink:label="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_056AD91582DBEAF306CA3F3E22811482" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Each additional one billion up to twenty billion [Member]</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_056AD91582DBEAF306CA3F3E22811482" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_056AD91582DBEAF306CA3F3E22811482" xlink:to="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_056AD91582DBEAF306CA3F3E22811482" xlink:type="arc" />
    <link:label id="lab_biib_OneBillionMember_5E71E2F114E6D418BDBD3F3E2281FDAA_terseLabel_en-US" xlink:label="lab_biib_OneBillionMember_5E71E2F114E6D418BDBD3F3E2281FDAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">One billion</link:label>
    <link:label id="lab_biib_OneBillionMember_5E71E2F114E6D418BDBD3F3E2281FDAA_label_en-US" xlink:label="lab_biib_OneBillionMember_5E71E2F114E6D418BDBD3F3E2281FDAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">One billion [Member]</link:label>
    <link:label id="lab_biib_OneBillionMember_5E71E2F114E6D418BDBD3F3E2281FDAA_documentation_en-US" xlink:label="lab_biib_OneBillionMember_5E71E2F114E6D418BDBD3F3E2281FDAA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">One billion [Member]</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_OneBillionMember" xlink:label="loc_biib_OneBillionMember_5E71E2F114E6D418BDBD3F3E2281FDAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OneBillionMember_5E71E2F114E6D418BDBD3F3E2281FDAA" xlink:to="lab_biib_OneBillionMember_5E71E2F114E6D418BDBD3F3E2281FDAA" xlink:type="arc" />
    <link:label id="lab_biib_ThreeBillionMember_448C062CF29247EA488D3F3E2281B6C7_terseLabel_en-US" xlink:label="lab_biib_ThreeBillionMember_448C062CF29247EA488D3F3E2281B6C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Three billion</link:label>
    <link:label id="lab_biib_ThreeBillionMember_448C062CF29247EA488D3F3E2281B6C7_label_en-US" xlink:label="lab_biib_ThreeBillionMember_448C062CF29247EA488D3F3E2281B6C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Three billion [Member]</link:label>
    <link:label id="lab_biib_ThreeBillionMember_448C062CF29247EA488D3F3E2281B6C7_documentation_en-US" xlink:label="lab_biib_ThreeBillionMember_448C062CF29247EA488D3F3E2281B6C7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Three billion [Member]</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_ThreeBillionMember" xlink:label="loc_biib_ThreeBillionMember_448C062CF29247EA488D3F3E2281B6C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ThreeBillionMember_448C062CF29247EA488D3F3E2281B6C7" xlink:to="lab_biib_ThreeBillionMember_448C062CF29247EA488D3F3E2281B6C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_382AF231A839F8B0B71B3F3E2282BE2D_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_382AF231A839F8B0B71B3F3E2282BE2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_382AF231A839F8B0B71B3F3E2282BE2D_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_382AF231A839F8B0B71B3F3E2282BE2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_382AF231A839F8B0B71B3F3E2282BE2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_382AF231A839F8B0B71B3F3E2282BE2D" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_382AF231A839F8B0B71B3F3E2282BE2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_41D96D74E15383526D533F3E2282F556_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_41D96D74E15383526D533F3E2282F556" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_41D96D74E15383526D533F3E2282F556_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_41D96D74E15383526D533F3E2282F556" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_41D96D74E15383526D533F3E2282F556" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_41D96D74E15383526D533F3E2282F556" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_41D96D74E15383526D533F3E2282F556" xlink:type="arc" />
    <link:label id="lab_biib_FumapharmAgMember_10CAD5AAAF1763C484F73F3E228259EE_terseLabel_en-US" xlink:label="lab_biib_FumapharmAgMember_10CAD5AAAF1763C484F73F3E228259EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fumapharm AG</link:label>
    <link:label id="lab_biib_FumapharmAgMember_10CAD5AAAF1763C484F73F3E228259EE_label_en-US" xlink:label="lab_biib_FumapharmAgMember_10CAD5AAAF1763C484F73F3E228259EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fumapharm AG [Member]</link:label>
    <link:label id="lab_biib_FumapharmAgMember_10CAD5AAAF1763C484F73F3E228259EE_documentation_en-US" xlink:label="lab_biib_FumapharmAgMember_10CAD5AAAF1763C484F73F3E228259EE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fumapharm AG [Member]</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_10CAD5AAAF1763C484F73F3E228259EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FumapharmAgMember_10CAD5AAAF1763C484F73F3E228259EE" xlink:to="lab_biib_FumapharmAgMember_10CAD5AAAF1763C484F73F3E228259EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductOrServiceAxis_44629A458C7F34A71AD63F3E228291D5_terseLabel_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_44629A458C7F34A71AD63F3E228291D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:label id="lab_us-gaap_ProductOrServiceAxis_44629A458C7F34A71AD63F3E228291D5_label_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_44629A458C7F34A71AD63F3E228291D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_44629A458C7F34A71AD63F3E228291D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductOrServiceAxis_44629A458C7F34A71AD63F3E228291D5" xlink:to="lab_us-gaap_ProductOrServiceAxis_44629A458C7F34A71AD63F3E228291D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_E189B96F16593FF691033F3E22822D47_terseLabel_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_E189B96F16593FF691033F3E22822D47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_E189B96F16593FF691033F3E22822D47_label_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_E189B96F16593FF691033F3E22822D47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_E189B96F16593FF691033F3E22822D47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E189B96F16593FF691033F3E22822D47" xlink:to="lab_us-gaap_ProductsAndServicesDomain_E189B96F16593FF691033F3E22822D47" xlink:type="arc" />
    <link:label id="lab_biib_TecfideraMember_1ED6A605267E6BD2BBC03F3E2282C2D3_terseLabel_en-US" xlink:label="lab_biib_TecfideraMember_1ED6A605267E6BD2BBC03F3E2282C2D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TECFIDERA</link:label>
    <link:label id="lab_biib_TecfideraMember_1ED6A605267E6BD2BBC03F3E2282C2D3_label_en-US" xlink:label="lab_biib_TecfideraMember_1ED6A605267E6BD2BBC03F3E2282C2D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:label id="lab_biib_TecfideraMember_1ED6A605267E6BD2BBC03F3E2282C2D3_documentation_en-US" xlink:label="lab_biib_TecfideraMember_1ED6A605267E6BD2BBC03F3E2282C2D3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_1ED6A605267E6BD2BBC03F3E2282C2D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TecfideraMember_1ED6A605267E6BD2BBC03F3E2282C2D3" xlink:to="lab_biib_TecfideraMember_1ED6A605267E6BD2BBC03F3E2282C2D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4C856771F8E500FF08E03F3E2282BF88_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4C856771F8E500FF08E03F3E2282BF88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4C856771F8E500FF08E03F3E2282BF88_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4C856771F8E500FF08E03F3E2282BF88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4C856771F8E500FF08E03F3E2282BF88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4C856771F8E500FF08E03F3E2282BF88" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4C856771F8E500FF08E03F3E2282BF88" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_6D4FFB2D0B7CEC2828C63F3E2282E1B3_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_6D4FFB2D0B7CEC2828C63F3E2282E1B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash portion of consideration</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_6D4FFB2D0B7CEC2828C63F3E2282E1B3_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_6D4FFB2D0B7CEC2828C63F3E2282E1B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_6D4FFB2D0B7CEC2828C63F3E2282E1B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_6D4FFB2D0B7CEC2828C63F3E2282E1B3" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_6D4FFB2D0B7CEC2828C63F3E2282E1B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4E4B8BC8CB30ACEEE5B03F3E22825CB9_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4E4B8BC8CB30ACEEE5B03F3E22825CB9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum contingent consideration in the form of development and approval milestones</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4E4B8BC8CB30ACEEE5B03F3E22825CB9_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4E4B8BC8CB30ACEEE5B03F3E22825CB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4E4B8BC8CB30ACEEE5B03F3E22825CB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4E4B8BC8CB30ACEEE5B03F3E22825CB9" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4E4B8BC8CB30ACEEE5B03F3E22825CB9" xlink:type="arc" />
    <link:label id="lab_biib_CumulativeSalesLevel_5AD055203F8A4FD3DDF73F3E2282683D_terseLabel_en-US" xlink:label="lab_biib_CumulativeSalesLevel_5AD055203F8A4FD3DDF73F3E2282683D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative sales level</link:label>
    <link:label id="lab_biib_CumulativeSalesLevel_5AD055203F8A4FD3DDF73F3E2282683D_label_en-US" xlink:label="lab_biib_CumulativeSalesLevel_5AD055203F8A4FD3DDF73F3E2282683D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative sales level</link:label>
    <link:label id="lab_biib_CumulativeSalesLevel_5AD055203F8A4FD3DDF73F3E2282683D_documentation_en-US" xlink:label="lab_biib_CumulativeSalesLevel_5AD055203F8A4FD3DDF73F3E2282683D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cumulative sales level</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_5AD055203F8A4FD3DDF73F3E2282683D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CumulativeSalesLevel_5AD055203F8A4FD3DDF73F3E2282683D" xlink:to="lab_biib_CumulativeSalesLevel_5AD055203F8A4FD3DDF73F3E2282683D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_3D6AB69635F6A3FDB6F0875A3CD10E5F_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_3D6AB69635F6A3FDB6F0875A3CD10E5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_3D6AB69635F6A3FDB6F0875A3CD10E5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_3D6AB69635F6A3FDB6F0875A3CD10E5F" xlink:to="lab_us-gaap_SubsequentEventsAbstract_3D6AB69635F6A3FDB6F0875A3CD10E5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_D75A5B38DC5483E98580875A3CD103C1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_D75A5B38DC5483E98580875A3CD103C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_D75A5B38DC5483E98580875A3CD103C1_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_D75A5B38DC5483E98580875A3CD103C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_D75A5B38DC5483E98580875A3CD103C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_D75A5B38DC5483E98580875A3CD103C1" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_D75A5B38DC5483E98580875A3CD103C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_BA43F811940A123FC9E5AE73DAC83528_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_BA43F811940A123FC9E5AE73DAC83528" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_BA43F811940A123FC9E5AE73DAC83528_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_BA43F811940A123FC9E5AE73DAC83528" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_BA43F811940A123FC9E5AE73DAC83528" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_BA43F811940A123FC9E5AE73DAC83528" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_BA43F811940A123FC9E5AE73DAC83528" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_B6A817B389E0EC44A451AE73DAC86BE2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_B6A817B389E0EC44A451AE73DAC86BE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Translation Adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_B6A817B389E0EC44A451AE73DAC86BE2_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_B6A817B389E0EC44A451AE73DAC86BE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_B6A817B389E0EC44A451AE73DAC86BE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember_B6A817B389E0EC44A451AE73DAC86BE2" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember_B6A817B389E0EC44A451AE73DAC86BE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A71D09DF5D4DAE13144AAE73DAC88E12_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A71D09DF5D4DAE13144AAE73DAC88E12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A71D09DF5D4DAE13144AAE73DAC88E12_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A71D09DF5D4DAE13144AAE73DAC88E12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A71D09DF5D4DAE13144AAE73DAC88E12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A71D09DF5D4DAE13144AAE73DAC88E12" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A71D09DF5D4DAE13144AAE73DAC88E12" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_AFB961221FB32CDA3BA6AE73DAC8B410_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_AFB961221FB32CDA3BA6AE73DAC8B410" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_AFB961221FB32CDA3BA6AE73DAC8B410" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_AFB961221FB32CDA3BA6AE73DAC8B410" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_AFB961221FB32CDA3BA6AE73DAC8B410" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_B22267E37C86E622B459AE73DAC827EA_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_B22267E37C86E622B459AE73DAC827EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income loss before reclassifications</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_B22267E37C86E622B459AE73DAC827EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_B22267E37C86E622B459AE73DAC827EA" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_B22267E37C86E622B459AE73DAC827EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_A31DB94F1AAE78803289AE73DAC84FE3_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_A31DB94F1AAE78803289AE73DAC84FE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_A31DB94F1AAE78803289AE73DAC84FE3_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_A31DB94F1AAE78803289AE73DAC84FE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_A31DB94F1AAE78803289AE73DAC84FE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_A31DB94F1AAE78803289AE73DAC84FE3" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_A31DB94F1AAE78803289AE73DAC84FE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_000A265A83FFB3A59AECAE73DAC831B7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_000A265A83FFB3A59AECAE73DAC831B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net current period other comprehensive income loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_000A265A83FFB3A59AECAE73DAC831B7_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_000A265A83FFB3A59AECAE73DAC831B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_000A265A83FFB3A59AECAE73DAC831B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_000A265A83FFB3A59AECAE73DAC831B7" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_000A265A83FFB3A59AECAE73DAC831B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_383BE862344E3FF52951AE73DAF9145F_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_383BE862344E3FF52951AE73DAF9145F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_383BE862344E3FF52951AE73DAF9145F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_383BE862344E3FF52951AE73DAF9145F" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_383BE862344E3FF52951AE73DAF9145F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_B071C33EF0C113A616CBAE73DAF93B62_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_B071C33EF0C113A616CBAE73DAF93B62" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_B071C33EF0C113A616CBAE73DAF93B62_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_B071C33EF0C113A616CBAE73DAF93B62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_B071C33EF0C113A616CBAE73DAF93B62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_B071C33EF0C113A616CBAE73DAF93B62" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_B071C33EF0C113A616CBAE73DAF93B62" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_FC71DA3DE54F2495B341AE73DAF602C5_label_en-US" xlink:label="lab_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_FC71DA3DE54F2495B341AE73DAF602C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Discounts, Returns and Allowances, Goods [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_FC71DA3DE54F2495B341AE73DAF602C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_FC71DA3DE54F2495B341AE73DAF602C5" xlink:to="lab_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_FC71DA3DE54F2495B341AE73DAF602C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_EBCCE181B7C2B8EADB76AE73DAF637EF_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_EBCCE181B7C2B8EADB76AE73DAF637EF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reserves for discounts and allowances</link:label>
    <link:label id="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_EBCCE181B7C2B8EADB76AE73DAF637EF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_EBCCE181B7C2B8EADB76AE73DAF637EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="loc_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_EBCCE181B7C2B8EADB76AE73DAF637EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_EBCCE181B7C2B8EADB76AE73DAF637EF" xlink:to="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_EBCCE181B7C2B8EADB76AE73DAF637EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_4F20CCC111C00BBE370D4EEFD7CDD8DD_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_4F20CCC111C00BBE370D4EEFD7CDD8DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4F20CCC111C00BBE370D4EEFD7CDD8DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4F20CCC111C00BBE370D4EEFD7CDD8DD" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_4F20CCC111C00BBE370D4EEFD7CDD8DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9D6FAEAC8C3E887697354EEFD7CD57BE_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9D6FAEAC8C3E887697354EEFD7CD57BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9D6FAEAC8C3E887697354EEFD7CD57BE_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9D6FAEAC8C3E887697354EEFD7CD57BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9D6FAEAC8C3E887697354EEFD7CD57BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9D6FAEAC8C3E887697354EEFD7CD57BE" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9D6FAEAC8C3E887697354EEFD7CD57BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_BEE47F91328439D4AEB44EEFD7CD14BA_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_BEE47F91328439D4AEB44EEFD7CD14BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_BEE47F91328439D4AEB44EEFD7CD14BA_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_BEE47F91328439D4AEB44EEFD7CD14BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_BEE47F91328439D4AEB44EEFD7CD14BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_BEE47F91328439D4AEB44EEFD7CD14BA" xlink:to="lab_us-gaap_TypeOfAdoptionMember_BEE47F91328439D4AEB44EEFD7CD14BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember_D97C1C8215015DEA4B374EEFD7CDB903_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember_D97C1C8215015DEA4B374EEFD7CDB903" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment for new accounting principle, early adoption</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember_D97C1C8215015DEA4B374EEFD7CDB903_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember_D97C1C8215015DEA4B374EEFD7CDB903" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Principle, Early Adoption [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember_D97C1C8215015DEA4B374EEFD7CDB903" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember_D97C1C8215015DEA4B374EEFD7CDB903" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember_D97C1C8215015DEA4B374EEFD7CDB903" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_A5234F2BB0FD4DFE26484EEFD7CD7219_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_A5234F2BB0FD4DFE26484EEFD7CD7219" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">6.875% Senior Notes due 2018</link:label>
    <link:label id="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_A5234F2BB0FD4DFE26484EEFD7CD7219_label_en-US" xlink:label="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_A5234F2BB0FD4DFE26484EEFD7CD7219" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Six Point Eight Seven Five Percent Due Twenty Eighteen [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_A5234F2BB0FD4DFE26484EEFD7CD7219_documentation_en-US" xlink:label="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_A5234F2BB0FD4DFE26484EEFD7CD7219" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Six Point Eight Seven Five Percent Due Twenty Eighteen.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_A5234F2BB0FD4DFE26484EEFD7CD7219" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_A5234F2BB0FD4DFE26484EEFD7CD7219" xlink:to="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_A5234F2BB0FD4DFE26484EEFD7CD7219" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D5B161C9C6D82A3E978E4EEFD7CDDE8A_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D5B161C9C6D82A3E978E4EEFD7CDDE8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.625% Senior Notes due 2022</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D5B161C9C6D82A3E978E4EEFD7CDDE8A_label_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D5B161C9C6D82A3E978E4EEFD7CDDE8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D5B161C9C6D82A3E978E4EEFD7CDDE8A_documentation_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D5B161C9C6D82A3E978E4EEFD7CDDE8A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D5B161C9C6D82A3E978E4EEFD7CDDE8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D5B161C9C6D82A3E978E4EEFD7CDDE8A" xlink:to="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D5B161C9C6D82A3E978E4EEFD7CDDE8A" xlink:type="arc" />
    <link:label id="lab_biib_ConvergencePharmaceuticalsMember_EEA9DD1833B1BB7258FC4EEFD7CE4BA1_terseLabel_en-US" xlink:label="lab_biib_ConvergencePharmaceuticalsMember_EEA9DD1833B1BB7258FC4EEFD7CE4BA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convergence Pharmaceuticals</link:label>
    <link:label id="lab_biib_ConvergencePharmaceuticalsMember_EEA9DD1833B1BB7258FC4EEFD7CE4BA1_label_en-US" xlink:label="lab_biib_ConvergencePharmaceuticalsMember_EEA9DD1833B1BB7258FC4EEFD7CE4BA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convergence Pharmaceuticals [Member]</link:label>
    <link:label id="lab_biib_ConvergencePharmaceuticalsMember_EEA9DD1833B1BB7258FC4EEFD7CE4BA1_documentation_en-US" xlink:label="lab_biib_ConvergencePharmaceuticalsMember_EEA9DD1833B1BB7258FC4EEFD7CE4BA1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convergence Pharmaceuticals [Member]</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_EEA9DD1833B1BB7258FC4EEFD7CE4BA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ConvergencePharmaceuticalsMember_EEA9DD1833B1BB7258FC4EEFD7CE4BA1" xlink:to="lab_biib_ConvergencePharmaceuticalsMember_EEA9DD1833B1BB7258FC4EEFD7CE4BA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetImpairmentCharges_47D2AEB9EC89F1B9C6D54EEFD7CE5619_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_47D2AEB9EC89F1B9C6D54EEFD7CE5619" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_47D2AEB9EC89F1B9C6D54EEFD7CE5619_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_47D2AEB9EC89F1B9C6D54EEFD7CE5619" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_47D2AEB9EC89F1B9C6D54EEFD7CE5619" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges_47D2AEB9EC89F1B9C6D54EEFD7CE5619" xlink:to="lab_us-gaap_AssetImpairmentCharges_47D2AEB9EC89F1B9C6D54EEFD7CE5619" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_113D5FAD98080D4DCAD54EEFD7CE65E4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_113D5FAD98080D4DCAD54EEFD7CE65E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in valuation techniques</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_113D5FAD98080D4DCAD54EEFD7CE65E4_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_113D5FAD98080D4DCAD54EEFD7CE65E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Changes in Valuation Techniques</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsChangesInValuationTechniques" xlink:label="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_113D5FAD98080D4DCAD54EEFD7CE65E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_113D5FAD98080D4DCAD54EEFD7CE65E4" xlink:to="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_113D5FAD98080D4DCAD54EEFD7CE65E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtIssuanceCosts_311FD69AC90FBD64FC4D4EEFD7CEF3AC_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCosts_311FD69AC90FBD64FC4D4EEFD7CEF3AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCosts_311FD69AC90FBD64FC4D4EEFD7CEF3AC_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCosts_311FD69AC90FBD64FC4D4EEFD7CEF3AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtIssuanceCosts" xlink:label="loc_us-gaap_DebtIssuanceCosts_311FD69AC90FBD64FC4D4EEFD7CEF3AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCosts_311FD69AC90FBD64FC4D4EEFD7CEF3AC" xlink:to="lab_us-gaap_DebtIssuanceCosts_311FD69AC90FBD64FC4D4EEFD7CEF3AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_BDE67515C98601A561964EEFD7CE23FB_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_BDE67515C98601A561964EEFD7CE23FB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_BDE67515C98601A561964EEFD7CE23FB_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_BDE67515C98601A561964EEFD7CE23FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_BDE67515C98601A561964EEFD7CE23FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_BDE67515C98601A561964EEFD7CE23FB" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_BDE67515C98601A561964EEFD7CE23FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_2EB37210E097D3F682E64EEFD7CEB86A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_2EB37210E097D3F682E64EEFD7CEB86A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_2EB37210E097D3F682E64EEFD7CEB86A_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_2EB37210E097D3F682E64EEFD7CEB86A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_2EB37210E097D3F682E64EEFD7CEB86A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_2EB37210E097D3F682E64EEFD7CEB86A" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_2EB37210E097D3F682E64EEFD7CEB86A" xlink:type="arc" />
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_68339E8DEBE9AB78AE334EEFD7CE0442_terseLabel_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_68339E8DEBE9AB78AE334EEFD7CE0442" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential future milestone payments</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_68339E8DEBE9AB78AE334EEFD7CE0442_label_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_68339E8DEBE9AB78AE334EEFD7CE0442" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Future Milestone Payments Commitment To Third Party Approximately</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_68339E8DEBE9AB78AE334EEFD7CE0442_documentation_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_68339E8DEBE9AB78AE334EEFD7CE0442" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential future milestone payments commitment to third party approximately.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_68339E8DEBE9AB78AE334EEFD7CE0442" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_68339E8DEBE9AB78AE334EEFD7CE0442" xlink:to="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_68339E8DEBE9AB78AE334EEFD7CE0442" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsDiscountRate_D8412F708C55D646540E4EEFD7CEAAF9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsDiscountRate_D8412F708C55D646540E4EEFD7CEAAF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_FairValueInputsDiscountRate_D8412F708C55D646540E4EEFD7CEAAF9_label_en-US" xlink:label="lab_us-gaap_FairValueInputsDiscountRate_D8412F708C55D646540E4EEFD7CEAAF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Inputs, Discount Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_D8412F708C55D646540E4EEFD7CEAAF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsDiscountRate_D8412F708C55D646540E4EEFD7CEAAF9" xlink:to="lab_us-gaap_FairValueInputsDiscountRate_D8412F708C55D646540E4EEFD7CEAAF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_E3F8677105501A771D0A4EF25CA61338_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_E3F8677105501A771D0A4EF25CA61338" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_E3F8677105501A771D0A4EF25CA61338_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_E3F8677105501A771D0A4EF25CA61338" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_E3F8677105501A771D0A4EF25CA61338" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_E3F8677105501A771D0A4EF25CA61338" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_E3F8677105501A771D0A4EF25CA61338" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_5A29A0253C8BD58F64604EEFD7CE92EB_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_5A29A0253C8BD58F64604EEFD7CE92EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development and other intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_5A29A0253C8BD58F64604EEFD7CE92EB_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_5A29A0253C8BD58F64604EEFD7CE92EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_5A29A0253C8BD58F64604EEFD7CE92EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_5A29A0253C8BD58F64604EEFD7CE92EB" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_5A29A0253C8BD58F64604EEFD7CE92EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_22CA7967DDA3B73458DDAE73DAD8577F_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_22CA7967DDA3B73458DDAE73DAD8577F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_22CA7967DDA3B73458DDAE73DAD8577F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_22CA7967DDA3B73458DDAE73DAD8577F" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_22CA7967DDA3B73458DDAE73DAD8577F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1ACFD8A35556A2DA2974AE73DAD80F35_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1ACFD8A35556A2DA2974AE73DAD80F35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1ACFD8A35556A2DA2974AE73DAD80F35_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1ACFD8A35556A2DA2974AE73DAD80F35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1ACFD8A35556A2DA2974AE73DAD80F35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1ACFD8A35556A2DA2974AE73DAD80F35" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1ACFD8A35556A2DA2974AE73DAD80F35" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_61C0CDAFA79297C91B07AE73DAD83871_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_61C0CDAFA79297C91B07AE73DAD83871" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_61C0CDAFA79297C91B07AE73DAD83871_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_61C0CDAFA79297C91B07AE73DAD83871" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_61C0CDAFA79297C91B07AE73DAD83871" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_61C0CDAFA79297C91B07AE73DAD83871" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_61C0CDAFA79297C91B07AE73DAD83871" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_48C28D5CC4D69A5FA60DAE73DAD9995B_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_48C28D5CC4D69A5FA60DAE73DAD9995B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_48C28D5CC4D69A5FA60DAE73DAD9995B_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_48C28D5CC4D69A5FA60DAE73DAD9995B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_48C28D5CC4D69A5FA60DAE73DAD9995B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_48C28D5CC4D69A5FA60DAE73DAD9995B" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_48C28D5CC4D69A5FA60DAE73DAD9995B" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_FF2D33449CA53C08E4D9AE73DAD93992_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_FF2D33449CA53C08E4D9AE73DAD93992" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_FF2D33449CA53C08E4D9AE73DAD93992" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_FF2D33449CA53C08E4D9AE73DAD93992" xlink:to="lab_us-gaap_Goodwill_FF2D33449CA53C08E4D9AE73DAD93992" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_6AF0007A0C5E0909F8EFAE73DAD97B49_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_6AF0007A0C5E0909F8EFAE73DAD97B49" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_6AF0007A0C5E0909F8EFAE73DAD97B49_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_6AF0007A0C5E0909F8EFAE73DAD97B49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_6AF0007A0C5E0909F8EFAE73DAD97B49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_6AF0007A0C5E0909F8EFAE73DAD97B49" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_6AF0007A0C5E0909F8EFAE73DAD97B49" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_4CC4F48AA710F6C39361AE73DAD9DE67_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_4CC4F48AA710F6C39361AE73DAD9DE67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_4CC4F48AA710F6C39361AE73DAD9DE67_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_4CC4F48AA710F6C39361AE73DAD9DE67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_4CC4F48AA710F6C39361AE73DAD9DE67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_4CC4F48AA710F6C39361AE73DAD9DE67" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_4CC4F48AA710F6C39361AE73DAD9DE67" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_B555EC941B8F504AE48EAE73DAD9810A_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_B555EC941B8F504AE48EAE73DAD9810A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_B555EC941B8F504AE48EAE73DAD9810A_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_B555EC941B8F504AE48EAE73DAD9810A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_B555EC941B8F504AE48EAE73DAD9810A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_B555EC941B8F504AE48EAE73DAD9810A" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_B555EC941B8F504AE48EAE73DAD9810A" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D44EED643D26CB5191E771883DFD74AB_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D44EED643D26CB5191E771883DFD74AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D44EED643D26CB5191E771883DFD74AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D44EED643D26CB5191E771883DFD74AB" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D44EED643D26CB5191E771883DFD74AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CABFE49CB6EB23EB605A71883DFDE3C5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CABFE49CB6EB23EB605A71883DFDE3C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CABFE49CB6EB23EB605A71883DFDE3C5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CABFE49CB6EB23EB605A71883DFDE3C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CABFE49CB6EB23EB605A71883DFDE3C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CABFE49CB6EB23EB605A71883DFDE3C5" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CABFE49CB6EB23EB605A71883DFDE3C5" xlink:type="arc" />
    <link:label id="lab_biib_TysabriProductMember_FF1C1FB26C128A882CE971883DFEE5EE_terseLabel_en-US" xlink:label="lab_biib_TysabriProductMember_FF1C1FB26C128A882CE971883DFEE5EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TYSABRI product</link:label>
    <link:label id="lab_biib_TysabriProductMember_FF1C1FB26C128A882CE971883DFEE5EE_label_en-US" xlink:label="lab_biib_TysabriProductMember_FF1C1FB26C128A882CE971883DFEE5EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:label id="lab_biib_TysabriProductMember_FF1C1FB26C128A882CE971883DFEE5EE_documentation_en-US" xlink:label="lab_biib_TysabriProductMember_FF1C1FB26C128A882CE971883DFEE5EE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_FF1C1FB26C128A882CE971883DFEE5EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TysabriProductMember_FF1C1FB26C128A882CE971883DFEE5EE" xlink:to="lab_biib_TysabriProductMember_FF1C1FB26C128A882CE971883DFEE5EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_179F4A91155553B5C1C271883DFED735_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_179F4A91155553B5C1C271883DFED735" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_179F4A91155553B5C1C271883DFED735_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_179F4A91155553B5C1C271883DFED735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_179F4A91155553B5C1C271883DFED735" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_179F4A91155553B5C1C271883DFED735" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_179F4A91155553B5C1C271883DFED735" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5FEC4020D776C7599B9171883DFEB40D_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5FEC4020D776C7599B9171883DFEB40D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5FEC4020D776C7599B9171883DFEB40D_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5FEC4020D776C7599B9171883DFEB40D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5FEC4020D776C7599B9171883DFEB40D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5FEC4020D776C7599B9171883DFEB40D" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5FEC4020D776C7599B9171883DFEB40D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_CF6E8882414F6CC91DDD71883DFE5F9E_verboseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_CF6E8882414F6CC91DDD71883DFE5F9E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_CF6E8882414F6CC91DDD71883DFE5F9E_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_CF6E8882414F6CC91DDD71883DFE5F9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_CF6E8882414F6CC91DDD71883DFE5F9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember_CF6E8882414F6CC91DDD71883DFE5F9E" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember_CF6E8882414F6CC91DDD71883DFE5F9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_6FBBCDD266ADEF989CF971883DFE445C_verboseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember_6FBBCDD266ADEF989CF971883DFE445C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Trademarks and trade names</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_6FBBCDD266ADEF989CF971883DFE445C_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember_6FBBCDD266ADEF989CF971883DFE445C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_6FBBCDD266ADEF989CF971883DFE445C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember_6FBBCDD266ADEF989CF971883DFE445C" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember_6FBBCDD266ADEF989CF971883DFE445C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_31B9B5E4ED398FEBEEF971883DFE6552_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_31B9B5E4ED398FEBEEF971883DFE6552" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_31B9B5E4ED398FEBEEF971883DFE6552_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_31B9B5E4ED398FEBEEF971883DFE6552" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_31B9B5E4ED398FEBEEF971883DFE6552" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_31B9B5E4ED398FEBEEF971883DFE6552" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_31B9B5E4ED398FEBEEF971883DFE6552" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0DB8811CC9C93AAB403571883DFE8C46_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0DB8811CC9C93AAB403571883DFE8C46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0DB8811CC9C93AAB403571883DFE8C46_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0DB8811CC9C93AAB403571883DFE8C46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0DB8811CC9C93AAB403571883DFE8C46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0DB8811CC9C93AAB403571883DFE8C46" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0DB8811CC9C93AAB403571883DFE8C46" xlink:type="arc" />
    <link:label id="lab_biib_OutLicensedPatentsMember_99B3E62E513208503E6371883DFE0DDE_terseLabel_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_99B3E62E513208503E6371883DFE0DDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Out-licensed patents</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_99B3E62E513208503E6371883DFE0DDE_label_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_99B3E62E513208503E6371883DFE0DDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Out Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_99B3E62E513208503E6371883DFE0DDE_documentation_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_99B3E62E513208503E6371883DFE0DDE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Out-licensed patents.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_99B3E62E513208503E6371883DFE0DDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OutLicensedPatentsMember_99B3E62E513208503E6371883DFE0DDE" xlink:to="lab_biib_OutLicensedPatentsMember_99B3E62E513208503E6371883DFE0DDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_247D6E64D0931069D83271883DFEF565_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_247D6E64D0931069D83271883DFEF565" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_247D6E64D0931069D83271883DFEF565_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_247D6E64D0931069D83271883DFEF565" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_247D6E64D0931069D83271883DFEF565" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember_247D6E64D0931069D83271883DFEF565" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember_247D6E64D0931069D83271883DFEF565" xlink:type="arc" />
    <link:label id="lab_biib_InLicensedPatentsMember_27AAAAF30384BD473EAB71883DFEDB8E_terseLabel_en-US" xlink:label="lab_biib_InLicensedPatentsMember_27AAAAF30384BD473EAB71883DFEDB8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired and in-licensed rights and patents</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_27AAAAF30384BD473EAB71883DFEDB8E_label_en-US" xlink:label="lab_biib_InLicensedPatentsMember_27AAAAF30384BD473EAB71883DFEDB8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_27AAAAF30384BD473EAB71883DFEDB8E_documentation_en-US" xlink:label="lab_biib_InLicensedPatentsMember_27AAAAF30384BD473EAB71883DFEDB8E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In-licensed patents.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_27AAAAF30384BD473EAB71883DFEDB8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InLicensedPatentsMember_27AAAAF30384BD473EAB71883DFEDB8E" xlink:to="lab_biib_InLicensedPatentsMember_27AAAAF30384BD473EAB71883DFEDB8E" xlink:type="arc" />
    <link:label id="lab_biib_AVONEXMember_3ADDA49194495D55F80371883DFE6E4D_terseLabel_en-US" xlink:label="lab_biib_AVONEXMember_3ADDA49194495D55F80371883DFE6E4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:label id="lab_biib_AVONEXMember_3ADDA49194495D55F80371883DFE6E4D_label_en-US" xlink:label="lab_biib_AVONEXMember_3ADDA49194495D55F80371883DFE6E4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AVONEX [Member]</link:label>
    <link:label id="lab_biib_AVONEXMember_3ADDA49194495D55F80371883DFE6E4D_documentation_en-US" xlink:label="lab_biib_AVONEXMember_3ADDA49194495D55F80371883DFE6E4D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_3ADDA49194495D55F80371883DFE6E4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AVONEXMember_3ADDA49194495D55F80371883DFE6E4D" xlink:to="lab_biib_AVONEXMember_3ADDA49194495D55F80371883DFE6E4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_0E4B67AD9BD6E87DA5B971883DFE27EF_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_0E4B67AD9BD6E87DA5B971883DFE27EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_0E4B67AD9BD6E87DA5B971883DFE27EF_label_en-US" xlink:label="lab_us-gaap_RangeAxis_0E4B67AD9BD6E87DA5B971883DFE27EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_0E4B67AD9BD6E87DA5B971883DFE27EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_0E4B67AD9BD6E87DA5B971883DFE27EF" xlink:to="lab_us-gaap_RangeAxis_0E4B67AD9BD6E87DA5B971883DFE27EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_28E33F0E9EC5F24C956F71883DFEBF31_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_28E33F0E9EC5F24C956F71883DFEBF31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_28E33F0E9EC5F24C956F71883DFEBF31_label_en-US" xlink:label="lab_us-gaap_RangeMember_28E33F0E9EC5F24C956F71883DFEBF31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_28E33F0E9EC5F24C956F71883DFEBF31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_28E33F0E9EC5F24C956F71883DFEBF31" xlink:to="lab_us-gaap_RangeMember_28E33F0E9EC5F24C956F71883DFEBF31" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_2DBF40525671E540809E71883DFE3878_verboseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_2DBF40525671E540809E71883DFE3878" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_us-gaap_MinimumMember_2DBF40525671E540809E71883DFE3878_label_en-US" xlink:label="lab_us-gaap_MinimumMember_2DBF40525671E540809E71883DFE3878" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_2DBF40525671E540809E71883DFE3878" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_2DBF40525671E540809E71883DFE3878" xlink:to="lab_us-gaap_MinimumMember_2DBF40525671E540809E71883DFE3878" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_2431B1EBEBFC4DBB770F71883DFE172F_verboseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_2431B1EBEBFC4DBB770F71883DFE172F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_us-gaap_MaximumMember_2431B1EBEBFC4DBB770F71883DFE172F_label_en-US" xlink:label="lab_us-gaap_MaximumMember_2431B1EBEBFC4DBB770F71883DFE172F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_2431B1EBEBFC4DBB770F71883DFE172F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_2431B1EBEBFC4DBB770F71883DFE172F" xlink:to="lab_us-gaap_MaximumMember_2431B1EBEBFC4DBB770F71883DFE172F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_EF1C5EDF74FBC37059A771883DFF11B4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_EF1C5EDF74FBC37059A771883DFF11B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_EF1C5EDF74FBC37059A771883DFF11B4_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_EF1C5EDF74FBC37059A771883DFF11B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_EF1C5EDF74FBC37059A771883DFF11B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_EF1C5EDF74FBC37059A771883DFF11B4" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_EF1C5EDF74FBC37059A771883DFF11B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2DFBD573E3940E6DC20571883DFF1B68_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2DFBD573E3940E6DC20571883DFF1B68" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2DFBD573E3940E6DC20571883DFF1B68_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2DFBD573E3940E6DC20571883DFF1B68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2DFBD573E3940E6DC20571883DFF1B68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2DFBD573E3940E6DC20571883DFF1B68" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2DFBD573E3940E6DC20571883DFF1B68" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6F4CEE519FC97588E1D471883DFFB99A_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6F4CEE519FC97588E1D471883DFFB99A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated life, (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6F4CEE519FC97588E1D471883DFFB99A_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6F4CEE519FC97588E1D471883DFFB99A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6F4CEE519FC97588E1D471883DFFB99A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6F4CEE519FC97588E1D471883DFFB99A" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6F4CEE519FC97588E1D471883DFFB99A" xlink:type="arc" />
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_A3E74ED2BBCC6BF9FA7471883DFFF37C_terseLabel_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_A3E74ED2BBCC6BF9FA7471883DFFF37C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite lived intangible assets useful life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_A3E74ED2BBCC6BF9FA7471883DFFF37C_label_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_A3E74ED2BBCC6BF9FA7471883DFFF37C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite Lived Intangible Assets Useful Life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_A3E74ED2BBCC6BF9FA7471883DFFF37C_documentation_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_A3E74ED2BBCC6BF9FA7471883DFFF37C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Indefinite lived intangible assets useful life.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_A3E74ED2BBCC6BF9FA7471883DFFF37C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_A3E74ED2BBCC6BF9FA7471883DFFF37C" xlink:to="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_A3E74ED2BBCC6BF9FA7471883DFFF37C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_236DFD33697423108D6D71883DFF035F_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_236DFD33697423108D6D71883DFF035F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_236DFD33697423108D6D71883DFF035F_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_236DFD33697423108D6D71883DFF035F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_236DFD33697423108D6D71883DFF035F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_236DFD33697423108D6D71883DFF035F" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_236DFD33697423108D6D71883DFF035F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9EE13335C84BEABFD76371883DFF87B8_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9EE13335C84BEABFD76371883DFF87B8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and Net</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9EE13335C84BEABFD76371883DFF87B8_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9EE13335C84BEABFD76371883DFF87B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9EE13335C84BEABFD76371883DFF87B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9EE13335C84BEABFD76371883DFF87B8" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9EE13335C84BEABFD76371883DFF87B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_D372EABDB43F1C65FB2D71883DFF5237_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_D372EABDB43F1C65FB2D71883DFF5237" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_D372EABDB43F1C65FB2D71883DFF5237_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_D372EABDB43F1C65FB2D71883DFF5237" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_D372EABDB43F1C65FB2D71883DFF5237" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_D372EABDB43F1C65FB2D71883DFF5237" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_D372EABDB43F1C65FB2D71883DFF5237" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_D91B2181CF37F1B3E6E371883DFFD5D4_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_D91B2181CF37F1B3E6E371883DFFD5D4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_D91B2181CF37F1B3E6E371883DFFD5D4_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_D91B2181CF37F1B3E6E371883DFFD5D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_D91B2181CF37F1B3E6E371883DFFD5D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_D91B2181CF37F1B3E6E371883DFFD5D4" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_D91B2181CF37F1B3E6E371883DFFD5D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_13EBC3B213E8DACC39DF71883DFF8D1A_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_13EBC3B213E8DACC39DF71883DFF8D1A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_13EBC3B213E8DACC39DF71883DFF8D1A_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_13EBC3B213E8DACC39DF71883DFF8D1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_13EBC3B213E8DACC39DF71883DFF8D1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_13EBC3B213E8DACC39DF71883DFF8D1A" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_13EBC3B213E8DACC39DF71883DFF8D1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_0682AB8510D7E6677E4071883DFF6ED8_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_0682AB8510D7E6677E4071883DFF6ED8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0682AB8510D7E6677E4071883DFF6ED8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0682AB8510D7E6677E4071883DFF6ED8" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_0682AB8510D7E6677E4071883DFF6ED8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_70AAAE099F946162EBF071883DFFF077_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_70AAAE099F946162EBF071883DFFF077" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of IPR&amp;D intangible asset</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_70AAAE099F946162EBF071883DFFF077_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_70AAAE099F946162EBF071883DFFF077" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_70AAAE099F946162EBF071883DFFF077" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_70AAAE099F946162EBF071883DFFF077" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_70AAAE099F946162EBF071883DFFF077" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2F081D8A4124F7ED146471883DFF36B1_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2F081D8A4124F7ED146471883DFF36B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total impairment charges</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2F081D8A4124F7ED146471883DFF36B1_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2F081D8A4124F7ED146471883DFF36B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2F081D8A4124F7ED146471883DFF36B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2F081D8A4124F7ED146471883DFF36B1" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2F081D8A4124F7ED146471883DFF36B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_92A8BE98907459DAC0B971883DFF4F22_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_92A8BE98907459DAC0B971883DFF4F22" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill (Textual) [Abstract]</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_92A8BE98907459DAC0B971883DFF4F22_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_92A8BE98907459DAC0B971883DFF4F22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Including Goodwill) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_92A8BE98907459DAC0B971883DFF4F22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_92A8BE98907459DAC0B971883DFF4F22" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_92A8BE98907459DAC0B971883DFF4F22" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_FF913A3958EFF24576C771883DFFA2CC_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_FF913A3958EFF24576C771883DFFA2CC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_FF913A3958EFF24576C771883DFFA2CC_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_FF913A3958EFF24576C771883DFFA2CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_FF913A3958EFF24576C771883DFFA2CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_FF913A3958EFF24576C771883DFFA2CC" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_FF913A3958EFF24576C771883DFFA2CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_755A661097FC7B0AAD7D71883DFFF936_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_755A661097FC7B0AAD7D71883DFFF936" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated impairment losses related to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_755A661097FC7B0AAD7D71883DFFF936_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_755A661097FC7B0AAD7D71883DFFF936" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_755A661097FC7B0AAD7D71883DFFF936" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_755A661097FC7B0AAD7D71883DFFF936" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_755A661097FC7B0AAD7D71883DFFF936" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5D17B3AE9C8C83D3C8F071883DFF7DD9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5D17B3AE9C8C83D3C8F071883DFF7DD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2015 (remaining three months)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5D17B3AE9C8C83D3C8F071883DFF7DD9_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5D17B3AE9C8C83D3C8F071883DFF7DD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5D17B3AE9C8C83D3C8F071883DFF7DD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5D17B3AE9C8C83D3C8F071883DFF7DD9" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5D17B3AE9C8C83D3C8F071883DFF7DD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_289AF34B9E1F6519D7DB71883DFF5A65_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_289AF34B9E1F6519D7DB71883DFF5A65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2016</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_289AF34B9E1F6519D7DB71883DFF5A65_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_289AF34B9E1F6519D7DB71883DFF5A65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_289AF34B9E1F6519D7DB71883DFF5A65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_289AF34B9E1F6519D7DB71883DFF5A65" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_289AF34B9E1F6519D7DB71883DFF5A65" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_F7D57461AFBE86421D3C71883E00CB82_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_F7D57461AFBE86421D3C71883E00CB82" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2017</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_F7D57461AFBE86421D3C71883E00CB82_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_F7D57461AFBE86421D3C71883E00CB82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_F7D57461AFBE86421D3C71883E00CB82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_F7D57461AFBE86421D3C71883E00CB82" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_F7D57461AFBE86421D3C71883E00CB82" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_326E61273B38CF56084071883E00A54C_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_326E61273B38CF56084071883E00A54C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2018</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_326E61273B38CF56084071883E00A54C_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_326E61273B38CF56084071883E00A54C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_326E61273B38CF56084071883E00A54C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_326E61273B38CF56084071883E00A54C" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_326E61273B38CF56084071883E00A54C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_EAF5ECCF5F49D840AC9571883E000DEC_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_EAF5ECCF5F49D840AC9571883E000DEC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2019</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_EAF5ECCF5F49D840AC9571883E000DEC_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_EAF5ECCF5F49D840AC9571883E000DEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_EAF5ECCF5F49D840AC9571883E000DEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_EAF5ECCF5F49D840AC9571883E000DEC" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_EAF5ECCF5F49D840AC9571883E000DEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_075789BDDC45CD8EE88F71883E00E619_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_075789BDDC45CD8EE88F71883E00E619" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_075789BDDC45CD8EE88F71883E00E619_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_075789BDDC45CD8EE88F71883E00E619" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_075789BDDC45CD8EE88F71883E00E619" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_075789BDDC45CD8EE88F71883E00E619" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_075789BDDC45CD8EE88F71883E00E619" xlink:type="arc" />
    <link:label id="lab_biib_Finitelivedintangibleassetsfutureamortization_0A2FB105A5B0C95A615171883E00D5B3_totalLabel_en-US" xlink:label="lab_biib_Finitelivedintangibleassetsfutureamortization_0A2FB105A5B0C95A615171883E00D5B3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_biib_Finitelivedintangibleassetsfutureamortization_0A2FB105A5B0C95A615171883E00D5B3_label_en-US" xlink:label="lab_biib_Finitelivedintangibleassetsfutureamortization_0A2FB105A5B0C95A615171883E00D5B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FiniteLivedIntangibleAssetsFutureAmortization</link:label>
    <link:label id="lab_biib_Finitelivedintangibleassetsfutureamortization_0A2FB105A5B0C95A615171883E00D5B3_documentation_en-US" xlink:label="lab_biib_Finitelivedintangibleassetsfutureamortization_0A2FB105A5B0C95A615171883E00D5B3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FiniteLivedIntangibleAssetsFutureAmortization</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_Finitelivedintangibleassetsfutureamortization" xlink:label="loc_biib_Finitelivedintangibleassetsfutureamortization_0A2FB105A5B0C95A615171883E00D5B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Finitelivedintangibleassetsfutureamortization_0A2FB105A5B0C95A615171883E00D5B3" xlink:to="lab_biib_Finitelivedintangibleassetsfutureamortization_0A2FB105A5B0C95A615171883E00D5B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_5AD7F181A13F39700016AE73DB03F624_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_5AD7F181A13F39700016AE73DB03F624" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_5AD7F181A13F39700016AE73DB03F624" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_5AD7F181A13F39700016AE73DB03F624" xlink:to="lab_us-gaap_IncomeStatementAbstract_5AD7F181A13F39700016AE73DB03F624" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_0917FADCB333E3659FCAAE73DB032669_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_0917FADCB333E3659FCAAE73DB032669" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_0917FADCB333E3659FCAAE73DB032669_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_0917FADCB333E3659FCAAE73DB032669" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_0917FADCB333E3659FCAAE73DB032669" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_0917FADCB333E3659FCAAE73DB032669" xlink:to="lab_us-gaap_RevenuesAbstract_0917FADCB333E3659FCAAE73DB032669" xlink:type="arc" />
    <link:label id="lab_biib_UnconsolidatedJointBusiness_341BB8D745D2D0718C95AE73DB034C41_verboseLabel_en-US" xlink:label="lab_biib_UnconsolidatedJointBusiness_341BB8D745D2D0718C95AE73DB034C41" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unconsolidated joint business</link:label>
    <link:label id="lab_biib_UnconsolidatedJointBusiness_341BB8D745D2D0718C95AE73DB034C41_label_en-US" xlink:label="lab_biib_UnconsolidatedJointBusiness_341BB8D745D2D0718C95AE73DB034C41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unconsolidated Joint Business</link:label>
    <link:label id="lab_biib_UnconsolidatedJointBusiness_341BB8D745D2D0718C95AE73DB034C41_documentation_en-US" xlink:label="lab_biib_UnconsolidatedJointBusiness_341BB8D745D2D0718C95AE73DB034C41" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from unconsolidated joint business consists of our share of pre-tax co-promotion profits in the U.S.; reimbursement of selling and development expense in the U.S.; and revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_UnconsolidatedJointBusiness" xlink:label="loc_biib_UnconsolidatedJointBusiness_341BB8D745D2D0718C95AE73DB034C41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnconsolidatedJointBusiness_341BB8D745D2D0718C95AE73DB034C41" xlink:to="lab_biib_UnconsolidatedJointBusiness_341BB8D745D2D0718C95AE73DB034C41" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherSalesRevenueNet_616F03B15306DEE3CEA7AE73DB04F6D0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherSalesRevenueNet_616F03B15306DEE3CEA7AE73DB04F6D0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSalesRevenueNet_616F03B15306DEE3CEA7AE73DB04F6D0_label_en-US" xlink:label="lab_us-gaap_OtherSalesRevenueNet_616F03B15306DEE3CEA7AE73DB04F6D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Revenue, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_616F03B15306DEE3CEA7AE73DB04F6D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSalesRevenueNet_616F03B15306DEE3CEA7AE73DB04F6D0" xlink:to="lab_us-gaap_OtherSalesRevenueNet_616F03B15306DEE3CEA7AE73DB04F6D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_DFF56A14797E61FAC277AE73DB041DA2_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues_DFF56A14797E61FAC277AE73DB041DA2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_DFF56A14797E61FAC277AE73DB041DA2_label_en-US" xlink:label="lab_us-gaap_Revenues_DFF56A14797E61FAC277AE73DB041DA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_DFF56A14797E61FAC277AE73DB041DA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_DFF56A14797E61FAC277AE73DB041DA2" xlink:to="lab_us-gaap_Revenues_DFF56A14797E61FAC277AE73DB041DA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_B921A60251F176A99EA6AE73DB0493BC_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_B921A60251F176A99EA6AE73DB0493BC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_B921A60251F176A99EA6AE73DB0493BC_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_B921A60251F176A99EA6AE73DB0493BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_B921A60251F176A99EA6AE73DB0493BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_B921A60251F176A99EA6AE73DB0493BC" xlink:to="lab_us-gaap_CostsAndExpensesAbstract_B921A60251F176A99EA6AE73DB0493BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsSold_BD35B39F8B63CD4CF688AE73DB04F1E7_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_BD35B39F8B63CD4CF688AE73DB04F1E7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales, excluding amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsSold_BD35B39F8B63CD4CF688AE73DB04F1E7_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_BD35B39F8B63CD4CF688AE73DB04F1E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_BD35B39F8B63CD4CF688AE73DB04F1E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsSold_BD35B39F8B63CD4CF688AE73DB04F1E7" xlink:to="lab_us-gaap_CostOfGoodsSold_BD35B39F8B63CD4CF688AE73DB04F1E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_21CD4395A89527B428C6AE73DB04FBB9_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_21CD4395A89527B428C6AE73DB04FBB9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_21CD4395A89527B428C6AE73DB04FBB9_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_21CD4395A89527B428C6AE73DB04FBB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_21CD4395A89527B428C6AE73DB04FBB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_21CD4395A89527B428C6AE73DB04FBB9" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_21CD4395A89527B428C6AE73DB04FBB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_5B309260C272ACDB5E1BAE73DB046AE9_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_5B309260C272ACDB5E1BAE73DB046AE9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_5B309260C272ACDB5E1BAE73DB046AE9_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_5B309260C272ACDB5E1BAE73DB046AE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_5B309260C272ACDB5E1BAE73DB046AE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_5B309260C272ACDB5E1BAE73DB046AE9" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_5B309260C272ACDB5E1BAE73DB046AE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_D21FB4CEA2672D724D1DAE73DB04765A_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_D21FB4CEA2672D724D1DAE73DB04765A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">(Gain) loss on fair value remeasurement of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_D21FB4CEA2672D724D1DAE73DB04765A_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_D21FB4CEA2672D724D1DAE73DB04765A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_D21FB4CEA2672D724D1DAE73DB04765A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_D21FB4CEA2672D724D1DAE73DB04765A" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_D21FB4CEA2672D724D1DAE73DB04765A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_B263B7FC51105131E1BBAE73DB0454D0_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_B263B7FC51105131E1BBAE73DB0454D0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cost and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_B263B7FC51105131E1BBAE73DB0454D0_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_B263B7FC51105131E1BBAE73DB0454D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_B263B7FC51105131E1BBAE73DB0454D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_B263B7FC51105131E1BBAE73DB0454D0" xlink:to="lab_us-gaap_CostsAndExpenses_B263B7FC51105131E1BBAE73DB0454D0" xlink:type="arc" />
    <link:label id="lab_biib_GainOnSaleOfRights_A453F3AC198A99B44419AE73DB04B854_terseLabel_en-US" xlink:label="lab_biib_GainOnSaleOfRights_A453F3AC198A99B44419AE73DB04B854" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of rights</link:label>
    <link:label id="lab_biib_GainOnSaleOfRights_A453F3AC198A99B44419AE73DB04B854_label_en-US" xlink:label="lab_biib_GainOnSaleOfRights_A453F3AC198A99B44419AE73DB04B854" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain on sale of rights</link:label>
    <link:label id="lab_biib_GainOnSaleOfRights_A453F3AC198A99B44419AE73DB04B854_documentation_en-US" xlink:label="lab_biib_GainOnSaleOfRights_A453F3AC198A99B44419AE73DB04B854" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain on sale of our royalty and other rights related to future sales of BENLYSTA recognized in our consolidated statement of income.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_GainOnSaleOfRights" xlink:label="loc_biib_GainOnSaleOfRights_A453F3AC198A99B44419AE73DB04B854" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GainOnSaleOfRights_A453F3AC198A99B44419AE73DB04B854" xlink:to="lab_biib_GainOnSaleOfRights_A453F3AC198A99B44419AE73DB04B854" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_B36C1C3A0965401FD065AE73DB048F60_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_B36C1C3A0965401FD065AE73DB048F60" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_B36C1C3A0965401FD065AE73DB048F60_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_B36C1C3A0965401FD065AE73DB048F60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_B36C1C3A0965401FD065AE73DB048F60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_B36C1C3A0965401FD065AE73DB048F60" xlink:to="lab_us-gaap_OperatingIncomeLoss_B36C1C3A0965401FD065AE73DB048F60" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_946C67FE798C884A8DC6AE73DB05EC0D_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_946C67FE798C884A8DC6AE73DB05EC0D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_946C67FE798C884A8DC6AE73DB05EC0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_946C67FE798C884A8DC6AE73DB05EC0D" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_946C67FE798C884A8DC6AE73DB05EC0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3CEAAECB8355C87D8DF5AE73DB055B1F_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3CEAAECB8355C87D8DF5AE73DB055B1F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before income tax expense and equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3CEAAECB8355C87D8DF5AE73DB055B1F_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3CEAAECB8355C87D8DF5AE73DB055B1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3CEAAECB8355C87D8DF5AE73DB055B1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3CEAAECB8355C87D8DF5AE73DB055B1F" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3CEAAECB8355C87D8DF5AE73DB055B1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_03A34D5D4948DB32F88EAE73DB050493_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_03A34D5D4948DB32F88EAE73DB050493" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_03A34D5D4948DB32F88EAE73DB050493" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_03A34D5D4948DB32F88EAE73DB050493" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_03A34D5D4948DB32F88EAE73DB050493" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_99E0E90AF0D364AAD7AEAE73DB05B6A3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_99E0E90AF0D364AAD7AEAE73DB05B6A3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_99E0E90AF0D364AAD7AEAE73DB05B6A3_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_99E0E90AF0D364AAD7AEAE73DB05B6A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_99E0E90AF0D364AAD7AEAE73DB05B6A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_99E0E90AF0D364AAD7AEAE73DB05B6A3" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_99E0E90AF0D364AAD7AEAE73DB05B6A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_691741C877E5C9611AE1AE73DB05F47B_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_691741C877E5C9611AE1AE73DB05F47B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_691741C877E5C9611AE1AE73DB05F47B_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_691741C877E5C9611AE1AE73DB05F47B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_691741C877E5C9611AE1AE73DB05F47B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_691741C877E5C9611AE1AE73DB05F47B" xlink:to="lab_us-gaap_ProfitLoss_691741C877E5C9611AE1AE73DB05F47B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_D63C4D116C7262C29587AE73DB05512B_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_D63C4D116C7262C29587AE73DB05512B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_D63C4D116C7262C29587AE73DB05512B_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_D63C4D116C7262C29587AE73DB05512B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_D63C4D116C7262C29587AE73DB05512B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_D63C4D116C7262C29587AE73DB05512B" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_D63C4D116C7262C29587AE73DB05512B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_416F83B7E692F7CB1E45AE73DB054491_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_416F83B7E692F7CB1E45AE73DB054491" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_416F83B7E692F7CB1E45AE73DB054491" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_416F83B7E692F7CB1E45AE73DB054491" xlink:to="lab_us-gaap_NetIncomeLoss_416F83B7E692F7CB1E45AE73DB054491" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_3B938C11DAE0BA4CF827AE73DB058464_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_3B938C11DAE0BA4CF827AE73DB058464" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income per share:</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3B938C11DAE0BA4CF827AE73DB058464" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3B938C11DAE0BA4CF827AE73DB058464" xlink:to="lab_us-gaap_EarningsPerShareAbstract_3B938C11DAE0BA4CF827AE73DB058464" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_19D8319CF5678ADBD6DFAE73DB05674A_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_19D8319CF5678ADBD6DFAE73DB05674A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_19D8319CF5678ADBD6DFAE73DB05674A_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_19D8319CF5678ADBD6DFAE73DB05674A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_19D8319CF5678ADBD6DFAE73DB05674A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_19D8319CF5678ADBD6DFAE73DB05674A" xlink:to="lab_us-gaap_EarningsPerShareBasic_19D8319CF5678ADBD6DFAE73DB05674A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_727663ECCA566594DF0FAE73DB053284_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_727663ECCA566594DF0FAE73DB053284" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_727663ECCA566594DF0FAE73DB053284_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_727663ECCA566594DF0FAE73DB053284" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_727663ECCA566594DF0FAE73DB053284" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_727663ECCA566594DF0FAE73DB053284" xlink:to="lab_us-gaap_EarningsPerShareDiluted_727663ECCA566594DF0FAE73DB053284" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_CC50E41EDC3FDB46A014AE73DB069680_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_CC50E41EDC3FDB46A014AE73DB069680" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_CC50E41EDC3FDB46A014AE73DB069680" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_CC50E41EDC3FDB46A014AE73DB069680" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_CC50E41EDC3FDB46A014AE73DB069680" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_068F6E3F0D3EF9D505B0AE73DB065718_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_068F6E3F0D3EF9D505B0AE73DB065718" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_068F6E3F0D3EF9D505B0AE73DB065718" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_068F6E3F0D3EF9D505B0AE73DB065718" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_068F6E3F0D3EF9D505B0AE73DB065718" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0C38DC0EAE82D936DD81AE73DB652126_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0C38DC0EAE82D936DD81AE73DB652126" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0C38DC0EAE82D936DD81AE73DB652126_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0C38DC0EAE82D936DD81AE73DB652126" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0C38DC0EAE82D936DD81AE73DB652126" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0C38DC0EAE82D936DD81AE73DB652126" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0C38DC0EAE82D936DD81AE73DB652126" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_4C59EEFB7D930A600FD8AE73DA9849D9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_4C59EEFB7D930A600FD8AE73DA9849D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_4C59EEFB7D930A600FD8AE73DA9849D9_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_4C59EEFB7D930A600FD8AE73DA9849D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4C59EEFB7D930A600FD8AE73DA9849D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4C59EEFB7D930A600FD8AE73DA9849D9" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_4C59EEFB7D930A600FD8AE73DA9849D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_473E913192FA04DA4116AE73DA99B699_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_473E913192FA04DA4116AE73DA99B699" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_473E913192FA04DA4116AE73DA99B699_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_473E913192FA04DA4116AE73DA99B699" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_473E913192FA04DA4116AE73DA99B699" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_473E913192FA04DA4116AE73DA99B699" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_473E913192FA04DA4116AE73DA99B699" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_28CB3C6AEE76FC24A198AE73DA99C5B3_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_28CB3C6AEE76FC24A198AE73DA99C5B3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_28CB3C6AEE76FC24A198AE73DA99C5B3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_28CB3C6AEE76FC24A198AE73DA99C5B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_28CB3C6AEE76FC24A198AE73DA99C5B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_28CB3C6AEE76FC24A198AE73DA99C5B3" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_28CB3C6AEE76FC24A198AE73DA99C5B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_D1D8DDBA9609EED54F24AE73DA99744A_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_D1D8DDBA9609EED54F24AE73DA99744A" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value, beginning of period</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_D1D8DDBA9609EED54F24AE73DA99744A_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_D1D8DDBA9609EED54F24AE73DA99744A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_D1D8DDBA9609EED54F24AE73DA99744A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_D1D8DDBA9609EED54F24AE73DA99744A" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_D1D8DDBA9609EED54F24AE73DA99744A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_139F904B44A811F4F2B2AE73DA998843_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_139F904B44A811F4F2B2AE73DA998843" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_139F904B44A811F4F2B2AE73DA998843" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_139F904B44A811F4F2B2AE73DA998843" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_139F904B44A811F4F2B2AE73DA998843" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_89BAFA8F73DE08D5719BAE73DA99CAD6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_89BAFA8F73DE08D5719BAE73DA99CAD6" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Changes in fair value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_89BAFA8F73DE08D5719BAE73DA99CAD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_89BAFA8F73DE08D5719BAE73DA99CAD6" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_89BAFA8F73DE08D5719BAE73DA99CAD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_94638A156ACA64B01178AE73DA996094_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_94638A156ACA64B01178AE73DA996094" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_94638A156ACA64B01178AE73DA996094_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_94638A156ACA64B01178AE73DA996094" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_94638A156ACA64B01178AE73DA996094" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_94638A156ACA64B01178AE73DA996094" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_94638A156ACA64B01178AE73DA996094" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_8D56060853F7873F59D1AE73DA99D0EA_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_8D56060853F7873F59D1AE73DA99D0EA" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8D56060853F7873F59D1AE73DA99D0EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8D56060853F7873F59D1AE73DA99D0EA" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_8D56060853F7873F59D1AE73DA99D0EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_397ED4CE953868FB23EC3EA2E588C6DB_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_397ED4CE953868FB23EC3EA2E588C6DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_397ED4CE953868FB23EC3EA2E588C6DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_397ED4CE953868FB23EC3EA2E588C6DB" xlink:to="lab_us-gaap_DebtDisclosureAbstract_397ED4CE953868FB23EC3EA2E588C6DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_80DC13D589A8C003FFD33EA2E58890B3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_80DC13D589A8C003FFD33EA2E58890B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_80DC13D589A8C003FFD33EA2E58890B3_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_80DC13D589A8C003FFD33EA2E58890B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_80DC13D589A8C003FFD33EA2E58890B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_80DC13D589A8C003FFD33EA2E58890B3" xlink:to="lab_us-gaap_DebtInstrumentTable_80DC13D589A8C003FFD33EA2E58890B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_660ECC04DFCB94B9BE553EA2E5880F47_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_660ECC04DFCB94B9BE553EA2E5880F47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Designated as hedging instrument</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_660ECC04DFCB94B9BE553EA2E5880F47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember_660ECC04DFCB94B9BE553EA2E5880F47" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember_660ECC04DFCB94B9BE553EA2E5880F47" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_F05A3A29B2F81DAC6D8D3EA2E589BB05_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_F05A3A29B2F81DAC6D8D3EA2E589BB05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_F05A3A29B2F81DAC6D8D3EA2E589BB05_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_F05A3A29B2F81DAC6D8D3EA2E589BB05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_F05A3A29B2F81DAC6D8D3EA2E589BB05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F05A3A29B2F81DAC6D8D3EA2E589BB05" xlink:to="lab_us-gaap_DebtInstrumentLineItems_F05A3A29B2F81DAC6D8D3EA2E589BB05" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_AD265A1C38DC158C664D3EA2E5897AA3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_AD265A1C38DC158C664D3EA2E5897AA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes principle amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_AD265A1C38DC158C664D3EA2E5897AA3_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_AD265A1C38DC158C664D3EA2E5897AA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_AD265A1C38DC158C664D3EA2E5897AA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_AD265A1C38DC158C664D3EA2E5897AA3" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_AD265A1C38DC158C664D3EA2E5897AA3" xlink:type="arc" />
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_3159AEB89C7D2EECA8883EA2E5892694_terseLabel_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes_3159AEB89C7D2EECA8883EA2E5892694" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage par value of Senior Notes</link:label>
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_3159AEB89C7D2EECA8883EA2E5892694_label_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes_3159AEB89C7D2EECA8883EA2E5892694" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Par Value Of Senior Notes</link:label>
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_3159AEB89C7D2EECA8883EA2E5892694_documentation_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes_3159AEB89C7D2EECA8883EA2E5892694" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Par Value Of Senior Notes</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_PercentageParValueOfSeniorNotes" xlink:label="loc_biib_PercentageParValueOfSeniorNotes_3159AEB89C7D2EECA8883EA2E5892694" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageParValueOfSeniorNotes_3159AEB89C7D2EECA8883EA2E5892694" xlink:to="lab_biib_PercentageParValueOfSeniorNotes_3159AEB89C7D2EECA8883EA2E5892694" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_7BC864566EF8B02E108B3ED24CF69702_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_7BC864566EF8B02E108B3ED24CF69702" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption percentage of 2015 Senior Notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_7BC864566EF8B02E108B3ED24CF69702_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_7BC864566EF8B02E108B3ED24CF69702" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_7BC864566EF8B02E108B3ED24CF69702" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_7BC864566EF8B02E108B3ED24CF69702" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_7BC864566EF8B02E108B3ED24CF69702" xlink:type="arc" />
    <link:label id="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_4C98B93F8A4F05F68B043EDA38E8BE8A_terseLabel_en-US" xlink:label="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_4C98B93F8A4F05F68B043EDA38E8BE8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption percentage for change in control provision on the 2015 Senior Notes</link:label>
    <link:label id="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_4C98B93F8A4F05F68B043EDA38E8BE8A_label_en-US" xlink:label="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_4C98B93F8A4F05F68B043EDA38E8BE8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Make Whole Provision Redemption Price, Percentage</link:label>
    <link:label id="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_4C98B93F8A4F05F68B043EDA38E8BE8A_documentation_en-US" xlink:label="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_4C98B93F8A4F05F68B043EDA38E8BE8A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Make Whole Provision Redemption Price, Percentage</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:label="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_4C98B93F8A4F05F68B043EDA38E8BE8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_4C98B93F8A4F05F68B043EDA38E8BE8A" xlink:to="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_4C98B93F8A4F05F68B043EDA38E8BE8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtIssuanceCosts_71A0D4D1F9B1077938E13EA2E589972F_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCosts_71A0D4D1F9B1077938E13EA2E589972F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtIssuanceCosts" xlink:label="loc_us-gaap_DebtIssuanceCosts_71A0D4D1F9B1077938E13EA2E589972F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCosts_71A0D4D1F9B1077938E13EA2E589972F" xlink:to="lab_us-gaap_DebtIssuanceCosts_71A0D4D1F9B1077938E13EA2E589972F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_D2440943128BB65837B93EA2E5893DCD_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_D2440943128BB65837B93EA2E5893DCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum senior unsecured revolving credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_D2440943128BB65837B93EA2E5893DCD_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_D2440943128BB65837B93EA2E5893DCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_D2440943128BB65837B93EA2E5893DCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_D2440943128BB65837B93EA2E5893DCD" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_D2440943128BB65837B93EA2E5893DCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_8AF1637588B4D86183B43EDFB6D37C1C_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_8AF1637588B4D86183B43EDFB6D37C1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit facility term</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_8AF1637588B4D86183B43EDFB6D37C1C_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_8AF1637588B4D86183B43EDFB6D37C1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_8AF1637588B4D86183B43EDFB6D37C1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_8AF1637588B4D86183B43EDFB6D37C1C" xlink:to="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_8AF1637588B4D86183B43EDFB6D37C1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_7D3A090F1CE00FCD99643EA2E589EE42_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_7D3A090F1CE00FCD99643EA2E589EE42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding credit facility borrowings</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_7D3A090F1CE00FCD99643EA2E589EE42_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_7D3A090F1CE00FCD99643EA2E589EE42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Fair Value of Amount Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_7D3A090F1CE00FCD99643EA2E589EE42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_7D3A090F1CE00FCD99643EA2E589EE42" xlink:to="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_7D3A090F1CE00FCD99643EA2E589EE42" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D17437132B8426153600AE73DAD20EBA_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D17437132B8426153600AE73DAD20EBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D17437132B8426153600AE73DAD20EBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D17437132B8426153600AE73DAD20EBA" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D17437132B8426153600AE73DAD20EBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_470F137BF5E40CCCBFE0AE73DAD235F7_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_470F137BF5E40CCCBFE0AE73DAD235F7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_470F137BF5E40CCCBFE0AE73DAD235F7_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_470F137BF5E40CCCBFE0AE73DAD235F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_470F137BF5E40CCCBFE0AE73DAD235F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_470F137BF5E40CCCBFE0AE73DAD235F7" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_470F137BF5E40CCCBFE0AE73DAD235F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_CDD217D5A6FEE5B3547471883E4C11BC_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_CDD217D5A6FEE5B3547471883E4C11BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_CDD217D5A6FEE5B3547471883E4C11BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_CDD217D5A6FEE5B3547471883E4C11BC" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_CDD217D5A6FEE5B3547471883E4C11BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6DDACD248415A2CDF5DB71883E4D16C4_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6DDACD248415A2CDF5DB71883E4D16C4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6DDACD248415A2CDF5DB71883E4D16C4_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6DDACD248415A2CDF5DB71883E4D16C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6DDACD248415A2CDF5DB71883E4D16C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6DDACD248415A2CDF5DB71883E4D16C4" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6DDACD248415A2CDF5DB71883E4D16C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4D564ACB633496C5A7E171883E4D9B16_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4D564ACB633496C5A7E171883E4D9B16" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on securities available for sale, net of tax of $(1,320) and $(6) for the three months ended September 30, 2015 and 2014, respectively; and $(699) and $(3,021) for the nine months ended September 30, 2015 and 2014, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4D564ACB633496C5A7E171883E4D9B16_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4D564ACB633496C5A7E171883E4D9B16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4D564ACB633496C5A7E171883E4D9B16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4D564ACB633496C5A7E171883E4D9B16" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4D564ACB633496C5A7E171883E4D9B16" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_63AC91730DDB249CCA8171883E4D2BB0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_63AC91730DDB249CCA8171883E4D2BB0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges, net of tax of $(187) and $302 for the three months ended September 30, 2015 and 2014, respectively; and $(229) and $307 for the nine months ended September 30, 2015 and 2014, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_63AC91730DDB249CCA8171883E4D2BB0_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_63AC91730DDB249CCA8171883E4D2BB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_63AC91730DDB249CCA8171883E4D2BB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_63AC91730DDB249CCA8171883E4D2BB0" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_63AC91730DDB249CCA8171883E4D2BB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_C70D522DEF04086B28B571883E4D4FF2_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_C70D522DEF04086B28B571883E4D4FF2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on pension benefit obligation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_C70D522DEF04086B28B571883E4D4FF2_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_C70D522DEF04086B28B571883E4D4FF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_C70D522DEF04086B28B571883E4D4FF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_C70D522DEF04086B28B571883E4D4FF2" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_C70D522DEF04086B28B571883E4D4FF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6EE1B6C3470969345EE071883E4D2DD0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6EE1B6C3470969345EE071883E4D2DD0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6EE1B6C3470969345EE071883E4D2DD0_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6EE1B6C3470969345EE071883E4D2DD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6EE1B6C3470969345EE071883E4D2DD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6EE1B6C3470969345EE071883E4D2DD0" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6EE1B6C3470969345EE071883E4D2DD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_32AAF3D5B4B414E141AA71883E4D6EB2_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_32AAF3D5B4B414E141AA71883E4D6EB2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive income (loss), net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_32AAF3D5B4B414E141AA71883E4D6EB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_32AAF3D5B4B414E141AA71883E4D6EB2" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_32AAF3D5B4B414E141AA71883E4D6EB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_1F2ED52FCE9902C06BB571883E4DC367_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_1F2ED52FCE9902C06BB571883E4DC367" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_1F2ED52FCE9902C06BB571883E4DC367_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_1F2ED52FCE9902C06BB571883E4DC367" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1F2ED52FCE9902C06BB571883E4DC367" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_1F2ED52FCE9902C06BB571883E4DC367" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_1F2ED52FCE9902C06BB571883E4DC367" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_D329F59DB83424AF08FA71883E4D3A44_negatedLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_D329F59DB83424AF08FA71883E4D3A44" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_D329F59DB83424AF08FA71883E4D3A44_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_D329F59DB83424AF08FA71883E4D3A44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_D329F59DB83424AF08FA71883E4D3A44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_D329F59DB83424AF08FA71883E4D3A44" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_D329F59DB83424AF08FA71883E4D3A44" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_DF20FF739776680105AB71883E4D7654_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_DF20FF739776680105AB71883E4D7654" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_DF20FF739776680105AB71883E4D7654_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_DF20FF739776680105AB71883E4D7654" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_DF20FF739776680105AB71883E4D7654" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_DF20FF739776680105AB71883E4D7654" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_DF20FF739776680105AB71883E4D7654" xlink:type="arc" />
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_C26E3C3441291F16B8DD2E2530AE5031_verboseLabel_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_C26E3C3441291F16B8DD2E2530AE5031" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Overview</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_C26E3C3441291F16B8DD2E2530AE5031_label_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_C26E3C3441291F16B8DD2E2530AE5031" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Overview [Policy Text Block]</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_C26E3C3441291F16B8DD2E2530AE5031_documentation_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_C26E3C3441291F16B8DD2E2530AE5031" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Describes an overview of the company and its operations.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_BusinessOverviewPolicyTextBlock" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_C26E3C3441291F16B8DD2E2530AE5031" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessOverviewPolicyTextBlock_C26E3C3441291F16B8DD2E2530AE5031" xlink:to="lab_biib_BusinessOverviewPolicyTextBlock_C26E3C3441291F16B8DD2E2530AE5031" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_503E3C49F9974F1EAFDA2E2530AE1994_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_503E3C49F9974F1EAFDA2E2530AE1994" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_503E3C49F9974F1EAFDA2E2530AE1994_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_503E3C49F9974F1EAFDA2E2530AE1994" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_503E3C49F9974F1EAFDA2E2530AE1994" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_503E3C49F9974F1EAFDA2E2530AE1994" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_503E3C49F9974F1EAFDA2E2530AE1994" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_224D88C86F220F587E572E2530AE3373_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_224D88C86F220F587E572E2530AE3373" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_224D88C86F220F587E572E2530AE3373_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_224D88C86F220F587E572E2530AE3373" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_224D88C86F220F587E572E2530AE3373" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_224D88C86F220F587E572E2530AE3373" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_224D88C86F220F587E572E2530AE3373" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_B6862FE7559A00F8ECC32E2530AF73C7_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_B6862FE7559A00F8ECC32E2530AF73C7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_B6862FE7559A00F8ECC32E2530AF73C7_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_B6862FE7559A00F8ECC32E2530AF73C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_B6862FE7559A00F8ECC32E2530AF73C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_B6862FE7559A00F8ECC32E2530AF73C7" xlink:to="lab_us-gaap_UseOfEstimates_B6862FE7559A00F8ECC32E2530AF73C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_7B6B0FE7856AD585AD772E2530AF0237_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock_7B6B0FE7856AD585AD772E2530AF0237" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_7B6B0FE7856AD585AD772E2530AF0237_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock_7B6B0FE7856AD585AD772E2530AF0237" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_7B6B0FE7856AD585AD772E2530AF0237" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock_7B6B0FE7856AD585AD772E2530AF0237" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock_7B6B0FE7856AD585AD772E2530AF0237" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_646ADDE34A390B8967682E2530AFB8DB_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_646ADDE34A390B8967682E2530AFB8DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_646ADDE34A390B8967682E2530AFB8DB_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_646ADDE34A390B8967682E2530AFB8DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_646ADDE34A390B8967682E2530AFB8DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_646ADDE34A390B8967682E2530AFB8DB" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_646ADDE34A390B8967682E2530AFB8DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_C71DAE43F246DCE5CD03AE73DACC91A5_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_C71DAE43F246DCE5CD03AE73DACC91A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_C71DAE43F246DCE5CD03AE73DACC91A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_C71DAE43F246DCE5CD03AE73DACC91A5" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_C71DAE43F246DCE5CD03AE73DACC91A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_93D314DEB1CA91939C8FAE73DACCC1FD_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_93D314DEB1CA91939C8FAE73DACCC1FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_93D314DEB1CA91939C8FAE73DACCC1FD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_93D314DEB1CA91939C8FAE73DACCC1FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_93D314DEB1CA91939C8FAE73DACCC1FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_93D314DEB1CA91939C8FAE73DACCC1FD" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_93D314DEB1CA91939C8FAE73DACCC1FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeAxis_D2EF599BE5C945B82C31AE73DACC46AA_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_D2EF599BE5C945B82C31AE73DACC46AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_D2EF599BE5C945B82C31AE73DACC46AA_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_D2EF599BE5C945B82C31AE73DACC46AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_D2EF599BE5C945B82C31AE73DACC46AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis_D2EF599BE5C945B82C31AE73DACC46AA" xlink:to="lab_us-gaap_InvestmentTypeAxis_D2EF599BE5C945B82C31AE73DACC46AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_772F0F232C62A72AEF18AE73DACD8490_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_772F0F232C62A72AEF18AE73DACD8490" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type Categorization [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_772F0F232C62A72AEF18AE73DACD8490_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_772F0F232C62A72AEF18AE73DACD8490" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_772F0F232C62A72AEF18AE73DACD8490" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_772F0F232C62A72AEF18AE73DACD8490" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember_772F0F232C62A72AEF18AE73DACD8490" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_2F51F3EE5696BA2E607BAE73DACDAD90_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_2F51F3EE5696BA2E607BAE73DACDAD90" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_2F51F3EE5696BA2E607BAE73DACDAD90_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_2F51F3EE5696BA2E607BAE73DACDAD90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_2F51F3EE5696BA2E607BAE73DACDAD90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_2F51F3EE5696BA2E607BAE73DACDAD90" xlink:to="lab_us-gaap_CommercialPaperMember_2F51F3EE5696BA2E607BAE73DACDAD90" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_85A5F3810445AD5D1B98AE73DACD5DC9_verboseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember_85A5F3810445AD5D1B98AE73DACD5DC9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Overnight reverse repurchase agreements</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_85A5F3810445AD5D1B98AE73DACD5DC9_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember_85A5F3810445AD5D1B98AE73DACD5DC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repurchase Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_85A5F3810445AD5D1B98AE73DACD5DC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementsMember_85A5F3810445AD5D1B98AE73DACD5DC9" xlink:to="lab_us-gaap_RepurchaseAgreementsMember_85A5F3810445AD5D1B98AE73DACD5DC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_7A2D5CEADE62DA2A57B8AE73DACD0AF4_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_7A2D5CEADE62DA2A57B8AE73DACD0AF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_7A2D5CEADE62DA2A57B8AE73DACD0AF4_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_7A2D5CEADE62DA2A57B8AE73DACD0AF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7A2D5CEADE62DA2A57B8AE73DACD0AF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_7A2D5CEADE62DA2A57B8AE73DACD0AF4" xlink:to="lab_us-gaap_MoneyMarketFundsMember_7A2D5CEADE62DA2A57B8AE73DACD0AF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesMember_BDA880F00B02902C131DAE73DACD8A18_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_BDA880F00B02902C131DAE73DACD8A18" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_BDA880F00B02902C131DAE73DACD8A18_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_BDA880F00B02902C131DAE73DACD8A18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_BDA880F00B02902C131DAE73DACD8A18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember_BDA880F00B02902C131DAE73DACD8A18" xlink:to="lab_us-gaap_DebtSecuritiesMember_BDA880F00B02902C131DAE73DACD8A18" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_A30E4615E1893A77C7E4AE73DACD79B9_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_A30E4615E1893A77C7E4AE73DACD79B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_A30E4615E1893A77C7E4AE73DACD79B9_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_A30E4615E1893A77C7E4AE73DACD79B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_A30E4615E1893A77C7E4AE73DACD79B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_A30E4615E1893A77C7E4AE73DACD79B9" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems_A30E4615E1893A77C7E4AE73DACD79B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_1E0C2BC409729050D38AAE73DACDF66D_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_1E0C2BC409729050D38AAE73DACDF66D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_1E0C2BC409729050D38AAE73DACDF66D_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_1E0C2BC409729050D38AAE73DACDF66D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_1E0C2BC409729050D38AAE73DACDF66D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_1E0C2BC409729050D38AAE73DACDF66D" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_1E0C2BC409729050D38AAE73DACDF66D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_833E1E6F7651F9EC2E38AE73DACD5A5E_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_833E1E6F7651F9EC2E38AE73DACD5A5E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_833E1E6F7651F9EC2E38AE73DACD5A5E_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_833E1E6F7651F9EC2E38AE73DACD5A5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_833E1E6F7651F9EC2E38AE73DACD5A5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue_833E1E6F7651F9EC2E38AE73DACD5A5E" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue_833E1E6F7651F9EC2E38AE73DACD5A5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_3BC2324CD57A25414C0EAE73DAC0BE69_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_3BC2324CD57A25414C0EAE73DAC0BE69" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_3BC2324CD57A25414C0EAE73DAC0BE69_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_3BC2324CD57A25414C0EAE73DAC0BE69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_3BC2324CD57A25414C0EAE73DAC0BE69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_3BC2324CD57A25414C0EAE73DAC0BE69" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_3BC2324CD57A25414C0EAE73DAC0BE69" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_82F24D4E1D73B658E3B7720464D5F818_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_82F24D4E1D73B658E3B7720464D5F818" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Component of accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_82F24D4E1D73B658E3B7720464D5F818_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_82F24D4E1D73B658E3B7720464D5F818" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_82F24D4E1D73B658E3B7720464D5F818" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember_82F24D4E1D73B658E3B7720464D5F818" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember_82F24D4E1D73B658E3B7720464D5F818" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_9AE166CC2FD57A566E7C720464D53C9B_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_9AE166CC2FD57A566E7C720464D53C9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_9AE166CC2FD57A566E7C720464D53C9B_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_9AE166CC2FD57A566E7C720464D53C9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_9AE166CC2FD57A566E7C720464D53C9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_9AE166CC2FD57A566E7C720464D53C9B" xlink:to="lab_us-gaap_StatementLineItems_9AE166CC2FD57A566E7C720464D53C9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_3B76604B1A0ABE15B840720464D522D6_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_3B76604B1A0ABE15B840720464D522D6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses and Other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_3B76604B1A0ABE15B840720464D522D6_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_3B76604B1A0ABE15B840720464D522D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_3B76604B1A0ABE15B840720464D522D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_3B76604B1A0ABE15B840720464D522D6" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_3B76604B1A0ABE15B840720464D522D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_54E8CBA70650B73AB6A9720464D52756_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_54E8CBA70650B73AB6A9720464D52756" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of contingent consideration obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_54E8CBA70650B73AB6A9720464D52756" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_54E8CBA70650B73AB6A9720464D52756" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_54E8CBA70650B73AB6A9720464D52756" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_BEF2EE30D4125FC9BF78720464D5A615_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_BEF2EE30D4125FC9BF78720464D5A615" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue-related rebates</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_BEF2EE30D4125FC9BF78720464D5A615_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_BEF2EE30D4125FC9BF78720464D5A615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves, Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_BEF2EE30D4125FC9BF78720464D5A615" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_BEF2EE30D4125FC9BF78720464D5A615" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_BEF2EE30D4125FC9BF78720464D5A615" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_954FE3DF7F2D3B2A8487720464D57278_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_954FE3DF7F2D3B2A8487720464D57278" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_954FE3DF7F2D3B2A8487720464D57278_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_954FE3DF7F2D3B2A8487720464D57278" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_954FE3DF7F2D3B2A8487720464D57278" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_954FE3DF7F2D3B2A8487720464D57278" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_954FE3DF7F2D3B2A8487720464D57278" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_4700170E8F9D39546546720464D51CB8_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_4700170E8F9D39546546720464D51CB8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalties and licensing fees</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_4700170E8F9D39546546720464D51CB8_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_4700170E8F9D39546546720464D51CB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_4700170E8F9D39546546720464D51CB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent_4700170E8F9D39546546720464D51CB8" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent_4700170E8F9D39546546720464D51CB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_DFF132AB176578486BC0720464D50611_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_DFF132AB176578486BC0720464D50611" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_DFF132AB176578486BC0720464D50611_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_DFF132AB176578486BC0720464D50611" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_DFF132AB176578486BC0720464D50611" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent_DFF132AB176578486BC0720464D50611" xlink:to="lab_us-gaap_DeferredRevenueCurrent_DFF132AB176578486BC0720464D50611" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_B5E89677048F4793CE80720464D59BFE_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_B5E89677048F4793CE80720464D59BFE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_B5E89677048F4793CE80720464D59BFE_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_B5E89677048F4793CE80720464D59BFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_B5E89677048F4793CE80720464D59BFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_B5E89677048F4793CE80720464D59BFE" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_B5E89677048F4793CE80720464D59BFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_18AC07230704BAE180B2720464D59A06_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_18AC07230704BAE180B2720464D59A06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses and other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_18AC07230704BAE180B2720464D59A06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_18AC07230704BAE180B2720464D59A06" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_18AC07230704BAE180B2720464D59A06" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_E3E5997D2B8079CB3764720464D59652_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract_E3E5997D2B8079CB3764720464D59652" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Income (Expense), Net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_E3E5997D2B8079CB3764720464D59652_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract_E3E5997D2B8079CB3764720464D59652" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_E3E5997D2B8079CB3764720464D59652" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_E3E5997D2B8079CB3764720464D59652" xlink:to="lab_us-gaap_InterestIncomeExpenseNetAbstract_E3E5997D2B8079CB3764720464D59652" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_01845E4732C7A848E6AB720464D57D28_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_01845E4732C7A848E6AB720464D57D28" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_01845E4732C7A848E6AB720464D57D28_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_01845E4732C7A848E6AB720464D57D28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_01845E4732C7A848E6AB720464D57D28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_01845E4732C7A848E6AB720464D57D28" xlink:to="lab_us-gaap_InvestmentIncomeInterest_01845E4732C7A848E6AB720464D57D28" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_7313CFDB155C8CA52FFB720464D52B74_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_7313CFDB155C8CA52FFB720464D52B74" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_7313CFDB155C8CA52FFB720464D52B74_label_en-US" xlink:label="lab_us-gaap_InterestExpense_7313CFDB155C8CA52FFB720464D52B74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_7313CFDB155C8CA52FFB720464D52B74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_7313CFDB155C8CA52FFB720464D52B74" xlink:to="lab_us-gaap_InterestExpense_7313CFDB155C8CA52FFB720464D52B74" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_E04873D614B2E1FAFAA7720464D516C0_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments_E04873D614B2E1FAFAA7720464D516C0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on sales of investments, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_E04873D614B2E1FAFAA7720464D516C0_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments_E04873D614B2E1FAFAA7720464D516C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Sale of Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_E04873D614B2E1FAFAA7720464D516C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfInvestments_E04873D614B2E1FAFAA7720464D516C0" xlink:to="lab_us-gaap_GainLossOnSaleOfInvestments_E04873D614B2E1FAFAA7720464D516C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_B0468164B7D2334742FB720464D6C0DC_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_B0468164B7D2334742FB720464D6C0DC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange gains (losses), net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_B0468164B7D2334742FB720464D6C0DC_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_B0468164B7D2334742FB720464D6C0DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_B0468164B7D2334742FB720464D6C0DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_B0468164B7D2334742FB720464D6C0DC" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_B0468164B7D2334742FB720464D6C0DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_4E194CC0B8EEEABB49A4720464D6A532_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_4E194CC0B8EEEABB49A4720464D6A532" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_4E194CC0B8EEEABB49A4720464D6A532_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_4E194CC0B8EEEABB49A4720464D6A532" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4E194CC0B8EEEABB49A4720464D6A532" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_4E194CC0B8EEEABB49A4720464D6A532" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_4E194CC0B8EEEABB49A4720464D6A532" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_40BC119D5DCC35F2DCBB720464D6F712_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_40BC119D5DCC35F2DCBB720464D6F712" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_40BC119D5DCC35F2DCBB720464D6F712" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_40BC119D5DCC35F2DCBB720464D6F712" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_40BC119D5DCC35F2DCBB720464D6F712" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_EE4F15CF9F53A54AEC91720464D6DB0C_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_EE4F15CF9F53A54AEC91720464D6DB0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_EE4F15CF9F53A54AEC91720464D6DB0C_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_EE4F15CF9F53A54AEC91720464D6DB0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_EE4F15CF9F53A54AEC91720464D6DB0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_EE4F15CF9F53A54AEC91720464D6DB0C" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_EE4F15CF9F53A54AEC91720464D6DB0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7A5BC6DBD1289C837C77720464D6CAEC_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7A5BC6DBD1289C837C77720464D6CAEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7A5BC6DBD1289C837C77720464D6CAEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7A5BC6DBD1289C837C77720464D6CAEC" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7A5BC6DBD1289C837C77720464D6CAEC" xlink:type="arc" />
    <link:label id="lab_biib_Employeerelatedliabilitiesnoncurrent_CB79B85C7D0515B6745E720464D6DAA3_terseLabel_en-US" xlink:label="lab_biib_Employeerelatedliabilitiesnoncurrent_CB79B85C7D0515B6745E720464D6DAA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee related liabilities noncurrent</link:label>
    <link:label id="lab_biib_Employeerelatedliabilitiesnoncurrent_CB79B85C7D0515B6745E720464D6DAA3_label_en-US" xlink:label="lab_biib_Employeerelatedliabilitiesnoncurrent_CB79B85C7D0515B6745E720464D6DAA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee related liabilities noncurrent</link:label>
    <link:label id="lab_biib_Employeerelatedliabilitiesnoncurrent_CB79B85C7D0515B6745E720464D6DAA3_documentation_en-US" xlink:label="lab_biib_Employeerelatedliabilitiesnoncurrent_CB79B85C7D0515B6745E720464D6DAA3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee related liabilities noncurrent</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_Employeerelatedliabilitiesnoncurrent" xlink:label="loc_biib_Employeerelatedliabilitiesnoncurrent_CB79B85C7D0515B6745E720464D6DAA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Employeerelatedliabilitiesnoncurrent_CB79B85C7D0515B6745E720464D6DAA3" xlink:to="lab_biib_Employeerelatedliabilitiesnoncurrent_CB79B85C7D0515B6745E720464D6DAA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesNoncurrent_AB335796064748E6F854720464D6CB63_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesNoncurrent_AB335796064748E6F854720464D6CB63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesNoncurrent_AB335796064748E6F854720464D6CB63_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesNoncurrent_AB335796064748E6F854720464D6CB63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_AB335796064748E6F854720464D6CB63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_AB335796064748E6F854720464D6CB63" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesNoncurrent_AB335796064748E6F854720464D6CB63" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_C633756CA6BE54BF3FDC720464D65046_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_C633756CA6BE54BF3FDC720464D65046" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other long-term liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_C633756CA6BE54BF3FDC720464D65046" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_C633756CA6BE54BF3FDC720464D65046" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_C633756CA6BE54BF3FDC720464D65046" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_76CB6728FFF29DA0525FAE73D98A7E97_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_76CB6728FFF29DA0525FAE73D98A7E97" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_76CB6728FFF29DA0525FAE73D98A7E97_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_76CB6728FFF29DA0525FAE73D98A7E97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_76CB6728FFF29DA0525FAE73D98A7E97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_76CB6728FFF29DA0525FAE73D98A7E97" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_76CB6728FFF29DA0525FAE73D98A7E97" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_48EE6CAB9D1EE44BBC92AE73D98A9BDD_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_48EE6CAB9D1EE44BBC92AE73D98A9BDD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_48EE6CAB9D1EE44BBC92AE73D98A9BDD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_48EE6CAB9D1EE44BBC92AE73D98A9BDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_48EE6CAB9D1EE44BBC92AE73D98A9BDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_48EE6CAB9D1EE44BBC92AE73D98A9BDD" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_48EE6CAB9D1EE44BBC92AE73D98A9BDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_12B18C707FE56C49B705AE73D98AE33E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_12B18C707FE56C49B705AE73D98AE33E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_12B18C707FE56C49B705AE73D98AE33E_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_12B18C707FE56C49B705AE73D98AE33E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_12B18C707FE56C49B705AE73D98AE33E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_12B18C707FE56C49B705AE73D98AE33E" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_12B18C707FE56C49B705AE73D98AE33E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_B13FFF4879118506DAF8AE73D93CA5D5_label_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_B13FFF4879118506DAF8AE73D93CA5D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_B13FFF4879118506DAF8AE73D93CA5D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_B13FFF4879118506DAF8AE73D93CA5D5" xlink:to="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_B13FFF4879118506DAF8AE73D93CA5D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesTable_219CAEB8764319694740AE73D93C86F5_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_219CAEB8764319694740AE73D93C86F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_219CAEB8764319694740AE73D93C86F5_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_219CAEB8764319694740AE73D93C86F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_219CAEB8764319694740AE73D93C86F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable_219CAEB8764319694740AE73D93C86F5" xlink:to="lab_us-gaap_LossContingenciesTable_219CAEB8764319694740AE73D93C86F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementGeographicalAxis_55B51BFA7415B7F320D0AE73D93CBE95_terseLabel_en-US" xlink:label="lab_us-gaap_StatementGeographicalAxis_55B51BFA7415B7F320D0AE73D93CBE95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementGeographicalAxis_55B51BFA7415B7F320D0AE73D93CBE95_label_en-US" xlink:label="lab_us-gaap_StatementGeographicalAxis_55B51BFA7415B7F320D0AE73D93CBE95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_55B51BFA7415B7F320D0AE73D93CBE95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementGeographicalAxis_55B51BFA7415B7F320D0AE73D93CBE95" xlink:to="lab_us-gaap_StatementGeographicalAxis_55B51BFA7415B7F320D0AE73D93CBE95" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentGeographicalDomain_8A28995B29561FD23C44AE73D93C75D2_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentGeographicalDomain_8A28995B29561FD23C44AE73D93C75D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentGeographicalDomain_8A28995B29561FD23C44AE73D93C75D2_label_en-US" xlink:label="lab_us-gaap_SegmentGeographicalDomain_8A28995B29561FD23C44AE73D93C75D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_8A28995B29561FD23C44AE73D93C75D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentGeographicalDomain_8A28995B29561FD23C44AE73D93C75D2" xlink:to="lab_us-gaap_SegmentGeographicalDomain_8A28995B29561FD23C44AE73D93C75D2" xlink:type="arc" />
    <link:label id="lab_country_IT_D38D251D6016C83DB244AE73D93CEACD_terseLabel_en-US" xlink:label="lab_country_IT_D38D251D6016C83DB244AE73D93CEACD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Italy</link:label>
    <link:label id="lab_country_IT_D38D251D6016C83DB244AE73D93CEACD_label_en-US" xlink:label="lab_country_IT_D38D251D6016C83DB244AE73D93CEACD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ITALY</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_IT" xlink:label="loc_country_IT_D38D251D6016C83DB244AE73D93CEACD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IT_D38D251D6016C83DB244AE73D93CEACD" xlink:to="lab_country_IT_D38D251D6016C83DB244AE73D93CEACD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesLineItems_11020AA57F9FCA5BD9C0AE73D93CC9B6_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_11020AA57F9FCA5BD9C0AE73D93CC9B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_11020AA57F9FCA5BD9C0AE73D93CC9B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems_11020AA57F9FCA5BD9C0AE73D93CC9B6" xlink:to="lab_us-gaap_LossContingenciesLineItems_11020AA57F9FCA5BD9C0AE73D93CC9B6" xlink:type="arc" />
    <link:label id="lab_biib_ReimbursementLimitStatedInResolution_9AF23B05A4509ED60F25AE73D93CB0B4_terseLabel_en-US" xlink:label="lab_biib_ReimbursementLimitStatedInResolution_9AF23B05A4509ED60F25AE73D93CB0B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reimbursement limit stated in the resolution</link:label>
    <link:label id="lab_biib_ReimbursementLimitStatedInResolution_9AF23B05A4509ED60F25AE73D93CB0B4_label_en-US" xlink:label="lab_biib_ReimbursementLimitStatedInResolution_9AF23B05A4509ED60F25AE73D93CB0B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursement Limit Stated In Resolution</link:label>
    <link:label id="lab_biib_ReimbursementLimitStatedInResolution_9AF23B05A4509ED60F25AE73D93CB0B4_documentation_en-US" xlink:label="lab_biib_ReimbursementLimitStatedInResolution_9AF23B05A4509ED60F25AE73D93CB0B4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reimbursement limit stated in the resolution.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_ReimbursementLimitStatedInResolution" xlink:label="loc_biib_ReimbursementLimitStatedInResolution_9AF23B05A4509ED60F25AE73D93CB0B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReimbursementLimitStatedInResolution_9AF23B05A4509ED60F25AE73D93CB0B4" xlink:to="lab_biib_ReimbursementLimitStatedInResolution_9AF23B05A4509ED60F25AE73D93CB0B4" xlink:type="arc" />
    <link:label id="lab_biib_RaxatrigineMember_1D85FF1DAA07723F644271883E1ED9A6_terseLabel_en-US" xlink:label="lab_biib_RaxatrigineMember_1D85FF1DAA07723F644271883E1ED9A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raxatrigine</link:label>
    <link:label id="lab_biib_RaxatrigineMember_1D85FF1DAA07723F644271883E1ED9A6_label_en-US" xlink:label="lab_biib_RaxatrigineMember_1D85FF1DAA07723F644271883E1ED9A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Raxatrigine [Member]</link:label>
    <link:label id="lab_biib_RaxatrigineMember_1D85FF1DAA07723F644271883E1ED9A6_documentation_en-US" xlink:label="lab_biib_RaxatrigineMember_1D85FF1DAA07723F644271883E1ED9A6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Raxatrigine [Member]</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_RaxatrigineMember" xlink:label="loc_biib_RaxatrigineMember_1D85FF1DAA07723F644271883E1ED9A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RaxatrigineMember_1D85FF1DAA07723F644271883E1ED9A6" xlink:to="lab_biib_RaxatrigineMember_1D85FF1DAA07723F644271883E1ED9A6" xlink:type="arc" />
    <link:label id="lab_biib_NeuropathicpainindicationsMember_AD648A403DA02AAEFEF671883E1EDF28_terseLabel_en-US" xlink:label="lab_biib_NeuropathicpainindicationsMember_AD648A403DA02AAEFEF671883E1EDF28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Neuropathic pain indications</link:label>
    <link:label id="lab_biib_NeuropathicpainindicationsMember_AD648A403DA02AAEFEF671883E1EDF28_label_en-US" xlink:label="lab_biib_NeuropathicpainindicationsMember_AD648A403DA02AAEFEF671883E1EDF28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neuropathic pain indications [Member]</link:label>
    <link:label id="lab_biib_NeuropathicpainindicationsMember_AD648A403DA02AAEFEF671883E1EDF28_documentation_en-US" xlink:label="lab_biib_NeuropathicpainindicationsMember_AD648A403DA02AAEFEF671883E1EDF28" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Neuropathic pain indications [Member]</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_NeuropathicpainindicationsMember" xlink:label="loc_biib_NeuropathicpainindicationsMember_AD648A403DA02AAEFEF671883E1EDF28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NeuropathicpainindicationsMember_AD648A403DA02AAEFEF671883E1EDF28" xlink:to="lab_biib_NeuropathicpainindicationsMember_AD648A403DA02AAEFEF671883E1EDF28" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_CA2BBFE40549412982E371883E1EFE57_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_CA2BBFE40549412982E371883E1EFE57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in the value of our estimated contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_CA2BBFE40549412982E371883E1EFE57_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_CA2BBFE40549412982E371883E1EFE57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_CA2BBFE40549412982E371883E1EFE57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_CA2BBFE40549412982E371883E1EFE57" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_CA2BBFE40549412982E371883E1EFE57" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillPeriodIncreaseDecrease_80D5DEEDF5274F9AA59171883E1E26C5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease_80D5DEEDF5274F9AA59171883E1E26C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillPeriodIncreaseDecrease_80D5DEEDF5274F9AA59171883E1E26C5_label_en-US" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease_80D5DEEDF5274F9AA59171883E1E26C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease_80D5DEEDF5274F9AA59171883E1E26C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPeriodIncreaseDecrease_80D5DEEDF5274F9AA59171883E1E26C5" xlink:to="lab_us-gaap_GoodwillPeriodIncreaseDecrease_80D5DEEDF5274F9AA59171883E1E26C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_1BDBB106DFA6051338B171883E1EEF46_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_1BDBB106DFA6051338B171883E1EEF46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining cost to complete CNV1014802</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_1BDBB106DFA6051338B171883E1EEF46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_1BDBB106DFA6051338B171883E1EEF46" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_1BDBB106DFA6051338B171883E1EEF46" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_3C25733B9E8D56A0C36CAE73DB642E9F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_3C25733B9E8D56A0C36CAE73DB642E9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price schedule</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_3C25733B9E8D56A0C36CAE73DB642E9F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_3C25733B9E8D56A0C36CAE73DB642E9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_3C25733B9E8D56A0C36CAE73DB642E9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_3C25733B9E8D56A0C36CAE73DB642E9F" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_3C25733B9E8D56A0C36CAE73DB642E9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_359AE44678116F757837AE73DB64D019_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_359AE44678116F757837AE73DB64D019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair values of the separately identifiable assets acquired and liabilities assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_359AE44678116F757837AE73DB64D019_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_359AE44678116F757837AE73DB64D019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_359AE44678116F757837AE73DB64D019" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_359AE44678116F757837AE73DB64D019" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_359AE44678116F757837AE73DB64D019" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_8BAC38370D114D6CB05AAE73DA860FDF_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_8BAC38370D114D6CB05AAE73DA860FDF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_8BAC38370D114D6CB05AAE73DA860FDF_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_8BAC38370D114D6CB05AAE73DA860FDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_8BAC38370D114D6CB05AAE73DA860FDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_8BAC38370D114D6CB05AAE73DA860FDF" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_8BAC38370D114D6CB05AAE73DA860FDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_713998584FE4A5FC61AC3E9CFBF2C987_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_713998584FE4A5FC61AC3E9CFBF2C987" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Tax effect on net unrealized gains (losses) recognized on securities available for sale</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_713998584FE4A5FC61AC3E9CFBF2C987_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_713998584FE4A5FC61AC3E9CFBF2C987" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_713998584FE4A5FC61AC3E9CFBF2C987" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_713998584FE4A5FC61AC3E9CFBF2C987" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_713998584FE4A5FC61AC3E9CFBF2C987" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax_9D3F047A4D3E831BDF2D3E9CFBF20708_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax_9D3F047A4D3E831BDF2D3E9CFBF20708" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Tax effect of net unrealized gains (losses) recognized on cash flow hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax_9D3F047A4D3E831BDF2D3E9CFBF20708_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax_9D3F047A4D3E831BDF2D3E9CFBF20708" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax_9D3F047A4D3E831BDF2D3E9CFBF20708" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax_9D3F047A4D3E831BDF2D3E9CFBF20708" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax_9D3F047A4D3E831BDF2D3E9CFBF20708" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_26D5F461409E00AA72B8AE73DB56150C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_26D5F461409E00AA72B8AE73DB56150C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_26D5F461409E00AA72B8AE73DB56150C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_26D5F461409E00AA72B8AE73DB56150C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_26D5F461409E00AA72B8AE73DB56150C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_26D5F461409E00AA72B8AE73DB56150C" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_26D5F461409E00AA72B8AE73DB56150C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_2138FDBD24834F5371E2AE73DB564B16_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_2138FDBD24834F5371E2AE73DB564B16" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_2138FDBD24834F5371E2AE73DB564B16_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_2138FDBD24834F5371E2AE73DB564B16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2138FDBD24834F5371E2AE73DB564B16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2138FDBD24834F5371E2AE73DB564B16" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_2138FDBD24834F5371E2AE73DB564B16" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_BE721F9EDBE1D1659E50AE73DB561952_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_BE721F9EDBE1D1659E50AE73DB561952" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_BE721F9EDBE1D1659E50AE73DB561952_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_BE721F9EDBE1D1659E50AE73DB561952" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_BE721F9EDBE1D1659E50AE73DB561952" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_BE721F9EDBE1D1659E50AE73DB561952" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_BE721F9EDBE1D1659E50AE73DB561952" xlink:type="arc" />
    <link:label id="lab_us-gaap_ParentMember_261905DAAEAB0C109727AE73DB56BBEF_verboseLabel_en-US" xlink:label="lab_us-gaap_ParentMember_261905DAAEAB0C109727AE73DB56BBEF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense, net of tax</link:label>
    <link:label id="lab_us-gaap_ParentMember_261905DAAEAB0C109727AE73DB56BBEF_label_en-US" xlink:label="lab_us-gaap_ParentMember_261905DAAEAB0C109727AE73DB56BBEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_261905DAAEAB0C109727AE73DB56BBEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember_261905DAAEAB0C109727AE73DB56BBEF" xlink:to="lab_us-gaap_ParentMember_261905DAAEAB0C109727AE73DB56BBEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1D55D1B09A240BB3883AAE73DB561448_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1D55D1B09A240BB3883AAE73DB561448" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1D55D1B09A240BB3883AAE73DB561448_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1D55D1B09A240BB3883AAE73DB561448" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1D55D1B09A240BB3883AAE73DB561448" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1D55D1B09A240BB3883AAE73DB561448" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1D55D1B09A240BB3883AAE73DB561448" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_29C53B869AC3406E9DC5AE73DB563A03_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_29C53B869AC3406E9DC5AE73DB563A03" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Expense included in consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_29C53B869AC3406E9DC5AE73DB563A03_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_29C53B869AC3406E9DC5AE73DB563A03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_29C53B869AC3406E9DC5AE73DB563A03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_29C53B869AC3406E9DC5AE73DB563A03" xlink:to="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_29C53B869AC3406E9DC5AE73DB563A03" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_A890705399D96BD0B860AE73DB560E34_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_A890705399D96BD0B860AE73DB560E34" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_A890705399D96BD0B860AE73DB560E34_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_A890705399D96BD0B860AE73DB560E34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_A890705399D96BD0B860AE73DB560E34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_A890705399D96BD0B860AE73DB560E34" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_A890705399D96BD0B860AE73DB560E34" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_C25FF2E74EB99E9D829AAE73DB56471B_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_C25FF2E74EB99E9D829AAE73DB56471B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_C25FF2E74EB99E9D829AAE73DB56471B_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_C25FF2E74EB99E9D829AAE73DB56471B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_C25FF2E74EB99E9D829AAE73DB56471B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_C25FF2E74EB99E9D829AAE73DB56471B" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_C25FF2E74EB99E9D829AAE73DB56471B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_AA1FE99A37D66A18CB0AAE73DB57A40F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_AA1FE99A37D66A18CB0AAE73DB57A40F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Capitalized share-based compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_AA1FE99A37D66A18CB0AAE73DB57A40F_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_AA1FE99A37D66A18CB0AAE73DB57A40F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_AA1FE99A37D66A18CB0AAE73DB57A40F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_AA1FE99A37D66A18CB0AAE73DB57A40F" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_AA1FE99A37D66A18CB0AAE73DB57A40F" xlink:type="arc" />
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_8668398966772FE9BEECAE73DB577428_terseLabel_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_8668398966772FE9BEECAE73DB577428" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in total costs and expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_8668398966772FE9BEECAE73DB577428_label_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_8668398966772FE9BEECAE73DB577428" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Expense Included In Costs And Expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_8668398966772FE9BEECAE73DB577428_documentation_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_8668398966772FE9BEECAE73DB577428" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation expense included in costs and expenses.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_8668398966772FE9BEECAE73DB577428" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_8668398966772FE9BEECAE73DB577428" xlink:to="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_8668398966772FE9BEECAE73DB577428" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_23FB7FC5BB62C16CDB50AE73DB572404_negatedLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_23FB7FC5BB62C16CDB50AE73DB572404" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax effect</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_23FB7FC5BB62C16CDB50AE73DB572404_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_23FB7FC5BB62C16CDB50AE73DB572404" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Tax Benefit from Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_23FB7FC5BB62C16CDB50AE73DB572404" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_23FB7FC5BB62C16CDB50AE73DB572404" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_23FB7FC5BB62C16CDB50AE73DB572404" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_5458054DD6F927104863875A3D05FE7F_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable_5458054DD6F927104863875A3D05FE7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_5458054DD6F927104863875A3D05FE7F_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable_5458054DD6F927104863875A3D05FE7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_5458054DD6F927104863875A3D05FE7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_5458054DD6F927104863875A3D05FE7F" xlink:to="lab_us-gaap_IncomeTaxContingencyTable_5458054DD6F927104863875A3D05FE7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxPeriodAxis_5DFF0136A150E0F4E565875A3D051236_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis_5DFF0136A150E0F4E565875A3D051236" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_5DFF0136A150E0F4E565875A3D051236_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis_5DFF0136A150E0F4E565875A3D051236" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_5DFF0136A150E0F4E565875A3D051236" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis_5DFF0136A150E0F4E565875A3D051236" xlink:to="lab_us-gaap_TaxPeriodAxis_5DFF0136A150E0F4E565875A3D051236" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxPeriodDomain_C0F1B5E66AF59A94CB0E875A3D050753_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain_C0F1B5E66AF59A94CB0E875A3D050753" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_C0F1B5E66AF59A94CB0E875A3D050753_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain_C0F1B5E66AF59A94CB0E875A3D050753" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_C0F1B5E66AF59A94CB0E875A3D050753" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain_C0F1B5E66AF59A94CB0E875A3D050753" xlink:to="lab_us-gaap_TaxPeriodDomain_C0F1B5E66AF59A94CB0E875A3D050753" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxYear2007Member_DA33D9164D8653247DBB875A3D05D6FA_terseLabel_en-US" xlink:label="lab_us-gaap_TaxYear2007Member_DA33D9164D8653247DBB875A3D05D6FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Year 2007</link:label>
    <link:label id="lab_us-gaap_TaxYear2007Member_DA33D9164D8653247DBB875A3D05D6FA_label_en-US" xlink:label="lab_us-gaap_TaxYear2007Member_DA33D9164D8653247DBB875A3D05D6FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2007 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxYear2007Member" xlink:label="loc_us-gaap_TaxYear2007Member_DA33D9164D8653247DBB875A3D05D6FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxYear2007Member_DA33D9164D8653247DBB875A3D05D6FA" xlink:to="lab_us-gaap_TaxYear2007Member_DA33D9164D8653247DBB875A3D05D6FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxYear2008Member_F2A1D0915449C95C8FB2875A3D05D892_terseLabel_en-US" xlink:label="lab_us-gaap_TaxYear2008Member_F2A1D0915449C95C8FB2875A3D05D892" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Year 2008</link:label>
    <link:label id="lab_us-gaap_TaxYear2008Member_F2A1D0915449C95C8FB2875A3D05D892_label_en-US" xlink:label="lab_us-gaap_TaxYear2008Member_F2A1D0915449C95C8FB2875A3D05D892" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2008 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxYear2008Member" xlink:label="loc_us-gaap_TaxYear2008Member_F2A1D0915449C95C8FB2875A3D05D892" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxYear2008Member_F2A1D0915449C95C8FB2875A3D05D892" xlink:to="lab_us-gaap_TaxYear2008Member_F2A1D0915449C95C8FB2875A3D05D892" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxYear2009Member_5D329BA9C9F85758BC4F875A3D05DD9F_terseLabel_en-US" xlink:label="lab_us-gaap_TaxYear2009Member_5D329BA9C9F85758BC4F875A3D05DD9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Year 2009</link:label>
    <link:label id="lab_us-gaap_TaxYear2009Member_5D329BA9C9F85758BC4F875A3D05DD9F_label_en-US" xlink:label="lab_us-gaap_TaxYear2009Member_5D329BA9C9F85758BC4F875A3D05DD9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2009 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxYear2009Member" xlink:label="loc_us-gaap_TaxYear2009Member_5D329BA9C9F85758BC4F875A3D05DD9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxYear2009Member_5D329BA9C9F85758BC4F875A3D05DD9F" xlink:to="lab_us-gaap_TaxYear2009Member_5D329BA9C9F85758BC4F875A3D05DD9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_CE13D21A11109AB590E0875A3D058FF8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems_CE13D21A11109AB590E0875A3D058FF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_CE13D21A11109AB590E0875A3D058FF8_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems_CE13D21A11109AB590E0875A3D058FF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_CE13D21A11109AB590E0875A3D058FF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_CE13D21A11109AB590E0875A3D058FF8" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems_CE13D21A11109AB590E0875A3D058FF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_CBF99875A6ACA1E5D3C9875A3D06BF04_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_CBF99875A6ACA1E5D3C9875A3D06BF04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notice of assessment of corporate withholding tax including penalties and interest</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_CBF99875A6ACA1E5D3C9875A3D06BF04_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_CBF99875A6ACA1E5D3C9875A3D06BF04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination, Penalties and Interest Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_CBF99875A6ACA1E5D3C9875A3D06BF04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_CBF99875A6ACA1E5D3C9875A3D06BF04" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_CBF99875A6ACA1E5D3C9875A3D06BF04" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_90D87F1297F743020253875A3D06A2F5_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_90D87F1297F743020253875A3D06A2F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net benefit for a previously unrecognized position</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_90D87F1297F743020253875A3D06A2F5_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_90D87F1297F743020253875A3D06A2F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_90D87F1297F743020253875A3D06A2F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_90D87F1297F743020253875A3D06A2F5" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_90D87F1297F743020253875A3D06A2F5" xlink:type="arc" />
    <link:label id="lab_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_D01220AF41A31016451C875A3D06F04E_verboseLabel_en-US" xlink:label="lab_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_D01220AF41A31016451C875A3D06F04E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proposed deduction disallowance by tax authorities</link:label>
    <link:label id="lab_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_D01220AF41A31016451C875A3D06F04E_label_en-US" xlink:label="lab_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_D01220AF41A31016451C875A3D06F04E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proposed Disallowance By Tax Authorities For Payment For Services</link:label>
    <link:label id="lab_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_D01220AF41A31016451C875A3D06F04E_documentation_en-US" xlink:label="lab_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_D01220AF41A31016451C875A3D06F04E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proposed disallowance by tax authorities for payment for services.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices" xlink:label="loc_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_D01220AF41A31016451C875A3D06F04E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_D01220AF41A31016451C875A3D06F04E" xlink:to="lab_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_D01220AF41A31016451C875A3D06F04E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1C7D9DA5FF00719A3A7F43FEA0E22DF6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1C7D9DA5FF00719A3A7F43FEA0E22DF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1C7D9DA5FF00719A3A7F43FEA0E22DF6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1C7D9DA5FF00719A3A7F43FEA0E22DF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1C7D9DA5FF00719A3A7F43FEA0E22DF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1C7D9DA5FF00719A3A7F43FEA0E22DF6" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1C7D9DA5FF00719A3A7F43FEA0E22DF6" xlink:type="arc" />
    <link:label id="lab_biib_LeadprogramsMember_38CE7703D191A10C6C9E43FEA0E2E2FB_terseLabel_en-US" xlink:label="lab_biib_LeadprogramsMember_38CE7703D191A10C6C9E43FEA0E2E2FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lead programs</link:label>
    <link:label id="lab_biib_LeadprogramsMember_38CE7703D191A10C6C9E43FEA0E2E2FB_label_en-US" xlink:label="lab_biib_LeadprogramsMember_38CE7703D191A10C6C9E43FEA0E2E2FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lead programs [Member]</link:label>
    <link:label id="lab_biib_LeadprogramsMember_38CE7703D191A10C6C9E43FEA0E2E2FB_documentation_en-US" xlink:label="lab_biib_LeadprogramsMember_38CE7703D191A10C6C9E43FEA0E2E2FB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lead programs [Member]</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_LeadprogramsMember" xlink:label="loc_biib_LeadprogramsMember_38CE7703D191A10C6C9E43FEA0E2E2FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LeadprogramsMember_38CE7703D191A10C6C9E43FEA0E2E2FB" xlink:to="lab_biib_LeadprogramsMember_38CE7703D191A10C6C9E43FEA0E2E2FB" xlink:type="arc" />
    <link:label id="lab_biib_DiscoveryprogramsMember_ADFBCDFA6E51CBEA090B43FEA0E2DF9D_terseLabel_en-US" xlink:label="lab_biib_DiscoveryprogramsMember_ADFBCDFA6E51CBEA090B43FEA0E2DF9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discovery programs</link:label>
    <link:label id="lab_biib_DiscoveryprogramsMember_ADFBCDFA6E51CBEA090B43FEA0E2DF9D_label_en-US" xlink:label="lab_biib_DiscoveryprogramsMember_ADFBCDFA6E51CBEA090B43FEA0E2DF9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discovery programs [Member]</link:label>
    <link:label id="lab_biib_DiscoveryprogramsMember_ADFBCDFA6E51CBEA090B43FEA0E2DF9D_documentation_en-US" xlink:label="lab_biib_DiscoveryprogramsMember_ADFBCDFA6E51CBEA090B43FEA0E2DF9D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Discovery programs [Member]</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_DiscoveryprogramsMember" xlink:label="loc_biib_DiscoveryprogramsMember_ADFBCDFA6E51CBEA090B43FEA0E2DF9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DiscoveryprogramsMember_ADFBCDFA6E51CBEA090B43FEA0E2DF9D" xlink:to="lab_biib_DiscoveryprogramsMember_ADFBCDFA6E51CBEA090B43FEA0E2DF9D" xlink:type="arc" />
    <link:label id="lab_biib_MitsubishiTanabePharmaCorporationMember_E907908813EF53B1142443FEA0E2DD23_terseLabel_en-US" xlink:label="lab_biib_MitsubishiTanabePharmaCorporationMember_E907908813EF53B1142443FEA0E2DD23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation</link:label>
    <link:label id="lab_biib_MitsubishiTanabePharmaCorporationMember_E907908813EF53B1142443FEA0E2DD23_label_en-US" xlink:label="lab_biib_MitsubishiTanabePharmaCorporationMember_E907908813EF53B1142443FEA0E2DD23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation [Member]</link:label>
    <link:label id="lab_biib_MitsubishiTanabePharmaCorporationMember_E907908813EF53B1142443FEA0E2DD23_documentation_en-US" xlink:label="lab_biib_MitsubishiTanabePharmaCorporationMember_E907908813EF53B1142443FEA0E2DD23" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mitsubishi Tanabe Pharmaceutical Corporation [Member]</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_MitsubishiTanabePharmaCorporationMember" xlink:label="loc_biib_MitsubishiTanabePharmaCorporationMember_E907908813EF53B1142443FEA0E2DD23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MitsubishiTanabePharmaCorporationMember_E907908813EF53B1142443FEA0E2DD23" xlink:to="lab_biib_MitsubishiTanabePharmaCorporationMember_E907908813EF53B1142443FEA0E2DD23" xlink:type="arc" />
    <link:label id="lab_biib_AGTCMember_A48444DC4304BE35A81343FEA0E284CD_terseLabel_en-US" xlink:label="lab_biib_AGTCMember_A48444DC4304BE35A81343FEA0E284CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGTC</link:label>
    <link:label id="lab_biib_AGTCMember_A48444DC4304BE35A81343FEA0E284CD_label_en-US" xlink:label="lab_biib_AGTCMember_A48444DC4304BE35A81343FEA0E284CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGTC [Member]</link:label>
    <link:label id="lab_biib_AGTCMember_A48444DC4304BE35A81343FEA0E284CD_documentation_en-US" xlink:label="lab_biib_AGTCMember_A48444DC4304BE35A81343FEA0E284CD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGTC [Member]</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_AGTCMember" xlink:label="loc_biib_AGTCMember_A48444DC4304BE35A81343FEA0E284CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AGTCMember_A48444DC4304BE35A81343FEA0E284CD" xlink:to="lab_biib_AGTCMember_A48444DC4304BE35A81343FEA0E284CD" xlink:type="arc" />
    <link:label id="lab_biib_SwedishOrphanBiovitrumMember_15DEEDB40CEB2F4049E043FEA0E2EEDE_terseLabel_en-US" xlink:label="lab_biib_SwedishOrphanBiovitrumMember_15DEEDB40CEB2F4049E043FEA0E2EEDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Swedish Orphan Biovitrum</link:label>
    <link:label id="lab_biib_SwedishOrphanBiovitrumMember_15DEEDB40CEB2F4049E043FEA0E2EEDE_label_en-US" xlink:label="lab_biib_SwedishOrphanBiovitrumMember_15DEEDB40CEB2F4049E043FEA0E2EEDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Swedish Orphan Biovitrum [Member]</link:label>
    <link:label id="lab_biib_SwedishOrphanBiovitrumMember_15DEEDB40CEB2F4049E043FEA0E2EEDE_documentation_en-US" xlink:label="lab_biib_SwedishOrphanBiovitrumMember_15DEEDB40CEB2F4049E043FEA0E2EEDE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Swedish orphan biovitrum.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_SwedishOrphanBiovitrumMember" xlink:label="loc_biib_SwedishOrphanBiovitrumMember_15DEEDB40CEB2F4049E043FEA0E2EEDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SwedishOrphanBiovitrumMember_15DEEDB40CEB2F4049E043FEA0E2EEDE" xlink:to="lab_biib_SwedishOrphanBiovitrumMember_15DEEDB40CEB2F4049E043FEA0E2EEDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFB5CBE92E7DF9AAC1DF43FEA0E2F5B2_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFB5CBE92E7DF9AAC1DF43FEA0E2F5B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFB5CBE92E7DF9AAC1DF43FEA0E2F5B2_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFB5CBE92E7DF9AAC1DF43FEA0E2F5B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFB5CBE92E7DF9AAC1DF43FEA0E2F5B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFB5CBE92E7DF9AAC1DF43FEA0E2F5B2" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFB5CBE92E7DF9AAC1DF43FEA0E2F5B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_B5C40E0FE58D77541A4843FEA0E29286_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_B5C40E0FE58D77541A4843FEA0E29286" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_B5C40E0FE58D77541A4843FEA0E29286" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_B5C40E0FE58D77541A4843FEA0E29286" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_B5C40E0FE58D77541A4843FEA0E29286" xlink:type="arc" />
    <link:label id="lab_biib_Upfrontmilestonepayment_CDB681C346A41E52E37C43FEA0E3FC0D_terseLabel_en-US" xlink:label="lab_biib_Upfrontmilestonepayment_CDB681C346A41E52E37C43FEA0E3FC0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront milestone payment</link:label>
    <link:label id="lab_biib_Upfrontmilestonepayment_CDB681C346A41E52E37C43FEA0E3FC0D_label_en-US" xlink:label="lab_biib_Upfrontmilestonepayment_CDB681C346A41E52E37C43FEA0E3FC0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront milestone payment</link:label>
    <link:label id="lab_biib_Upfrontmilestonepayment_CDB681C346A41E52E37C43FEA0E3FC0D_documentation_en-US" xlink:label="lab_biib_Upfrontmilestonepayment_CDB681C346A41E52E37C43FEA0E3FC0D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront milestone payment</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_Upfrontmilestonepayment" xlink:label="loc_biib_Upfrontmilestonepayment_CDB681C346A41E52E37C43FEA0E3FC0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Upfrontmilestonepayment_CDB681C346A41E52E37C43FEA0E3FC0D" xlink:to="lab_biib_Upfrontmilestonepayment_CDB681C346A41E52E37C43FEA0E3FC0D" xlink:type="arc" />
    <link:label id="lab_biib_Purchaseofcommonstock_4F73654FF98DE600327243FEA0E3BDBB_terseLabel_en-US" xlink:label="lab_biib_Purchaseofcommonstock_4F73654FF98DE600327243FEA0E3BDBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase of common stock</link:label>
    <link:label id="lab_biib_Purchaseofcommonstock_4F73654FF98DE600327243FEA0E3BDBB_label_en-US" xlink:label="lab_biib_Purchaseofcommonstock_4F73654FF98DE600327243FEA0E3BDBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of common stock</link:label>
    <link:label id="lab_biib_Purchaseofcommonstock_4F73654FF98DE600327243FEA0E3BDBB_documentation_en-US" xlink:label="lab_biib_Purchaseofcommonstock_4F73654FF98DE600327243FEA0E3BDBB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase of common stock</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_Purchaseofcommonstock" xlink:label="loc_biib_Purchaseofcommonstock_4F73654FF98DE600327243FEA0E3BDBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Purchaseofcommonstock_4F73654FF98DE600327243FEA0E3BDBB" xlink:to="lab_biib_Purchaseofcommonstock_4F73654FF98DE600327243FEA0E3BDBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_0228242BB5B82764A3DA43FEA0E31B71_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets_0228242BB5B82764A3DA43FEA0E31B71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid research and development</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_0228242BB5B82764A3DA43FEA0E31B71_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets_0228242BB5B82764A3DA43FEA0E31B71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_0228242BB5B82764A3DA43FEA0E31B71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_0228242BB5B82764A3DA43FEA0E31B71" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets_0228242BB5B82764A3DA43FEA0E31B71" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicenseCosts_C3DAE20AAC0A7F66F37643FEA0E35AEF_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseCosts_C3DAE20AAC0A7F66F37643FEA0E35AEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total licensing and fees</link:label>
    <link:label id="lab_us-gaap_LicenseCosts_C3DAE20AAC0A7F66F37643FEA0E35AEF_label_en-US" xlink:label="lab_us-gaap_LicenseCosts_C3DAE20AAC0A7F66F37643FEA0E35AEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicenseCosts" xlink:label="loc_us-gaap_LicenseCosts_C3DAE20AAC0A7F66F37643FEA0E35AEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseCosts_C3DAE20AAC0A7F66F37643FEA0E35AEF" xlink:to="lab_us-gaap_LicenseCosts_C3DAE20AAC0A7F66F37643FEA0E35AEF" xlink:type="arc" />
    <link:label id="lab_biib_Researchanddevelopmentservices_90145527D86F6321C5D44401170FE736_terseLabel_en-US" xlink:label="lab_biib_Researchanddevelopmentservices_90145527D86F6321C5D44401170FE736" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development services</link:label>
    <link:label id="lab_biib_Researchanddevelopmentservices_90145527D86F6321C5D44401170FE736_label_en-US" xlink:label="lab_biib_Researchanddevelopmentservices_90145527D86F6321C5D44401170FE736" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development services</link:label>
    <link:label id="lab_biib_Researchanddevelopmentservices_90145527D86F6321C5D44401170FE736_documentation_en-US" xlink:label="lab_biib_Researchanddevelopmentservices_90145527D86F6321C5D44401170FE736" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and development services</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_Researchanddevelopmentservices" xlink:label="loc_biib_Researchanddevelopmentservices_90145527D86F6321C5D44401170FE736" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Researchanddevelopmentservices_90145527D86F6321C5D44401170FE736" xlink:to="lab_biib_Researchanddevelopmentservices_90145527D86F6321C5D44401170FE736" xlink:type="arc" />
    <link:label id="lab_biib_Premiumonequityinvestment_F51FE72C5F2EC2B916D743FEA0E3115F_terseLabel_en-US" xlink:label="lab_biib_Premiumonequityinvestment_F51FE72C5F2EC2B916D743FEA0E3115F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Premium on equity investment</link:label>
    <link:label id="lab_biib_Premiumonequityinvestment_F51FE72C5F2EC2B916D743FEA0E3115F_label_en-US" xlink:label="lab_biib_Premiumonequityinvestment_F51FE72C5F2EC2B916D743FEA0E3115F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Premium on equity investment</link:label>
    <link:label id="lab_biib_Premiumonequityinvestment_F51FE72C5F2EC2B916D743FEA0E3115F_documentation_en-US" xlink:label="lab_biib_Premiumonequityinvestment_F51FE72C5F2EC2B916D743FEA0E3115F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Premium on equity investment</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_Premiumonequityinvestment" xlink:label="loc_biib_Premiumonequityinvestment_F51FE72C5F2EC2B916D743FEA0E3115F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Premiumonequityinvestment_F51FE72C5F2EC2B916D743FEA0E3115F" xlink:to="lab_biib_Premiumonequityinvestment_F51FE72C5F2EC2B916D743FEA0E3115F" xlink:type="arc" />
    <link:label id="lab_biib_AdditionalMilestonePayment_6C8EC7F3DC2DFF2B73A943FEA0E32983_terseLabel_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_6C8EC7F3DC2DFF2B73A943FEA0E32983" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional milestone payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_6C8EC7F3DC2DFF2B73A943FEA0E32983_label_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_6C8EC7F3DC2DFF2B73A943FEA0E32983" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Milestone Payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_6C8EC7F3DC2DFF2B73A943FEA0E32983_documentation_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_6C8EC7F3DC2DFF2B73A943FEA0E32983" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional milestone payment.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_6C8EC7F3DC2DFF2B73A943FEA0E32983" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdditionalMilestonePayment_6C8EC7F3DC2DFF2B73A943FEA0E32983" xlink:to="lab_biib_AdditionalMilestonePayment_6C8EC7F3DC2DFF2B73A943FEA0E32983" xlink:type="arc" />
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_8CE95D985089CFC2ACE5AE73DAEB66D9_verboseLabel_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_8CE95D985089CFC2ACE5AE73DAEB66D9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_8CE95D985089CFC2ACE5AE73DAEB66D9_label_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_8CE95D985089CFC2ACE5AE73DAEB66D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Excluding Goodwill [Table Text Block]</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_8CE95D985089CFC2ACE5AE73DAEB66D9_documentation_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_8CE95D985089CFC2ACE5AE73DAEB66D9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible assets excluding goodwill.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_8CE95D985089CFC2ACE5AE73DAEB66D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_8CE95D985089CFC2ACE5AE73DAEB66D9" xlink:to="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_8CE95D985089CFC2ACE5AE73DAEB66D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BCE465CEAD0984FC3FEBAE73DAEB8C97_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BCE465CEAD0984FC3FEBAE73DAEB8C97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated future amortization for acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BCE465CEAD0984FC3FEBAE73DAEB8C97_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BCE465CEAD0984FC3FEBAE73DAEB8C97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BCE465CEAD0984FC3FEBAE73DAEB8C97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BCE465CEAD0984FC3FEBAE73DAEB8C97" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BCE465CEAD0984FC3FEBAE73DAEB8C97" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_2345C7E20E1027435A01AE73DAEB3FD4_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_2345C7E20E1027435A01AE73DAEB3FD4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_2345C7E20E1027435A01AE73DAEB3FD4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_2345C7E20E1027435A01AE73DAEB3FD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_2345C7E20E1027435A01AE73DAEB3FD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock_2345C7E20E1027435A01AE73DAEB3FD4" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock_2345C7E20E1027435A01AE73DAEB3FD4" xlink:type="arc" />
    <link:label id="lab_biib_DocumentAndEntityInformationAbstract_8A2C1C098326A87A273DAE73DB1E438D_label_en-US" xlink:label="lab_biib_DocumentAndEntityInformationAbstract_8A2C1C098326A87A273DAE73DB1E438D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:label id="lab_biib_DocumentAndEntityInformationAbstract_8A2C1C098326A87A273DAE73DB1E438D_documentation_en-US" xlink:label="lab_biib_DocumentAndEntityInformationAbstract_8A2C1C098326A87A273DAE73DB1E438D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document and Entity Information.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_DocumentAndEntityInformationAbstract" xlink:label="loc_biib_DocumentAndEntityInformationAbstract_8A2C1C098326A87A273DAE73DB1E438D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_8A2C1C098326A87A273DAE73DB1E438D" xlink:to="lab_biib_DocumentAndEntityInformationAbstract_8A2C1C098326A87A273DAE73DB1E438D" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_9792297EEB6A8AFAF563AE73DB1F572A_label_en-US" xlink:label="lab_dei_EntityRegistrantName_9792297EEB6A8AFAF563AE73DB1F572A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_9792297EEB6A8AFAF563AE73DB1F572A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_9792297EEB6A8AFAF563AE73DB1F572A" xlink:to="lab_dei_EntityRegistrantName_9792297EEB6A8AFAF563AE73DB1F572A" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_4A97C03D6767032EB08DAE73DB1F12F3_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_4A97C03D6767032EB08DAE73DB1F12F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_4A97C03D6767032EB08DAE73DB1F12F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_4A97C03D6767032EB08DAE73DB1F12F3" xlink:to="lab_dei_EntityCentralIndexKey_4A97C03D6767032EB08DAE73DB1F12F3" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_BAACAD6319E7D7BC09FDAE73DB1F31AF_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_BAACAD6319E7D7BC09FDAE73DB1F31AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_BAACAD6319E7D7BC09FDAE73DB1F31AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_BAACAD6319E7D7BC09FDAE73DB1F31AF" xlink:to="lab_dei_CurrentFiscalYearEndDate_BAACAD6319E7D7BC09FDAE73DB1F31AF" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_0112C9B72E7742456572AE73DB1FD9E1_label_en-US" xlink:label="lab_dei_EntityFilerCategory_0112C9B72E7742456572AE73DB1FD9E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_0112C9B72E7742456572AE73DB1FD9E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_0112C9B72E7742456572AE73DB1FD9E1" xlink:to="lab_dei_EntityFilerCategory_0112C9B72E7742456572AE73DB1FD9E1" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_0382B5D13D024D2BF57AAE73DB1F5058_label_en-US" xlink:label="lab_dei_DocumentType_0382B5D13D024D2BF57AAE73DB1F5058" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_0382B5D13D024D2BF57AAE73DB1F5058" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_0382B5D13D024D2BF57AAE73DB1F5058" xlink:to="lab_dei_DocumentType_0382B5D13D024D2BF57AAE73DB1F5058" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_3F6A964D94A90D9A0B02AE73DB1F6D5E_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_3F6A964D94A90D9A0B02AE73DB1F6D5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_3F6A964D94A90D9A0B02AE73DB1F6D5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_3F6A964D94A90D9A0B02AE73DB1F6D5E" xlink:to="lab_dei_DocumentPeriodEndDate_3F6A964D94A90D9A0B02AE73DB1F6D5E" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_490A2D94EA2908FF55BDAE73DB1F9781_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_490A2D94EA2908FF55BDAE73DB1F9781" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_490A2D94EA2908FF55BDAE73DB1F9781" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_490A2D94EA2908FF55BDAE73DB1F9781" xlink:to="lab_dei_DocumentFiscalYearFocus_490A2D94EA2908FF55BDAE73DB1F9781" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_A2B934C0311261FD5330AE73DB1FF73C_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_A2B934C0311261FD5330AE73DB1FF73C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_A2B934C0311261FD5330AE73DB1FF73C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_A2B934C0311261FD5330AE73DB1FF73C" xlink:to="lab_dei_DocumentFiscalPeriodFocus_A2B934C0311261FD5330AE73DB1FF73C" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_00B79227110F252F9D3CAE73DB1FEBAD_label_en-US" xlink:label="lab_dei_AmendmentFlag_00B79227110F252F9D3CAE73DB1FEBAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_00B79227110F252F9D3CAE73DB1FEBAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_00B79227110F252F9D3CAE73DB1FEBAD" xlink:to="lab_dei_AmendmentFlag_00B79227110F252F9D3CAE73DB1FEBAD" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_05CF129616C095A1FE3BAE73DB1F9B74_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_05CF129616C095A1FE3BAE73DB1F9B74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_05CF129616C095A1FE3BAE73DB1F9B74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_05CF129616C095A1FE3BAE73DB1F9B74" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_05CF129616C095A1FE3BAE73DB1F9B74" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_C334159063D7445D7E1A43C3DB77E8D3_label_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_C334159063D7445D7E1A43C3DB77E8D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_C334159063D7445D7E1A43C3DB77E8D3_documentation_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_C334159063D7445D7E1A43C3DB77E8D3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments In Variable Interest Entities.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_C334159063D7445D7E1A43C3DB77E8D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_C334159063D7445D7E1A43C3DB77E8D3" xlink:to="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_C334159063D7445D7E1A43C3DB77E8D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_0BCFE8363A5D99A2C61043C3DB77BD80_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_0BCFE8363A5D99A2C61043C3DB77BD80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_0BCFE8363A5D99A2C61043C3DB77BD80_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_0BCFE8363A5D99A2C61043C3DB77BD80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_0BCFE8363A5D99A2C61043C3DB77BD80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_0BCFE8363A5D99A2C61043C3DB77BD80" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_0BCFE8363A5D99A2C61043C3DB77BD80" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_52B77B940A44F21481D043C3DB7753B9_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_52B77B940A44F21481D043C3DB7753B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entities [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_52B77B940A44F21481D043C3DB7753B9_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_52B77B940A44F21481D043C3DB7753B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_52B77B940A44F21481D043C3DB7753B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_52B77B940A44F21481D043C3DB7753B9" xlink:to="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_52B77B940A44F21481D043C3DB7753B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_F3F6EF94FDFC2E824F8443C3DB77DE6B_terseLabel_en-US" xlink:label="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_F3F6EF94FDFC2E824F8443C3DB77DE6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_F3F6EF94FDFC2E824F8443C3DB77DE6B_label_en-US" xlink:label="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_F3F6EF94FDFC2E824F8443C3DB77DE6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Classification [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_F3F6EF94FDFC2E824F8443C3DB77DE6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_F3F6EF94FDFC2E824F8443C3DB77DE6B" xlink:to="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_F3F6EF94FDFC2E824F8443C3DB77DE6B" xlink:type="arc" />
    <link:label id="lab_biib_NeurimmuneMember_B9499F44AF20ECE8992D43C3DB77C61C_verboseLabel_en-US" xlink:label="lab_biib_NeurimmuneMember_B9499F44AF20ECE8992D43C3DB77C61C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Neurimmune</link:label>
    <link:label id="lab_biib_NeurimmuneMember_B9499F44AF20ECE8992D43C3DB77C61C_label_en-US" xlink:label="lab_biib_NeurimmuneMember_B9499F44AF20ECE8992D43C3DB77C61C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neurimmune [Member]</link:label>
    <link:label id="lab_biib_NeurimmuneMember_B9499F44AF20ECE8992D43C3DB77C61C_documentation_en-US" xlink:label="lab_biib_NeurimmuneMember_B9499F44AF20ECE8992D43C3DB77C61C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Neurimmune.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_B9499F44AF20ECE8992D43C3DB77C61C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NeurimmuneMember_B9499F44AF20ECE8992D43C3DB77C61C" xlink:to="lab_biib_NeurimmuneMember_B9499F44AF20ECE8992D43C3DB77C61C" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_4FBC2578998B70ABCC0543C3DB775412_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems_4FBC2578998B70ABCC0543C3DB775412" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_4FBC2578998B70ABCC0543C3DB775412_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems_4FBC2578998B70ABCC0543C3DB775412" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_4FBC2578998B70ABCC0543C3DB775412" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_4FBC2578998B70ABCC0543C3DB775412" xlink:to="lab_us-gaap_VariableInterestEntityLineItems_4FBC2578998B70ABCC0543C3DB775412" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_6D826EA9CBC48DDEA6EB43C3DB773CD9_verboseLabel_en-US" xlink:label="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_6D826EA9CBC48DDEA6EB43C3DB773CD9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment in Variable Interest Entities (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_6D826EA9CBC48DDEA6EB43C3DB773CD9_label_en-US" xlink:label="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_6D826EA9CBC48DDEA6EB43C3DB773CD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in Variable Interest Entities (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_6D826EA9CBC48DDEA6EB43C3DB773CD9_documentation_en-US" xlink:label="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_6D826EA9CBC48DDEA6EB43C3DB773CD9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in Variable Interest Entities.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_InvestmentInVariableInterestEntitiesTextualAbstract" xlink:label="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_6D826EA9CBC48DDEA6EB43C3DB773CD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_6D826EA9CBC48DDEA6EB43C3DB773CD9" xlink:to="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_6D826EA9CBC48DDEA6EB43C3DB773CD9" xlink:type="arc" />
    <link:label id="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_18C5103EDF71FCFC104743C3DB774EC1_verboseLabel_en-US" xlink:label="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_18C5103EDF71FCFC104743C3DB774EC1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Remaining potential development milestone payments and royalties on commercial sales under the terms of collaboration agreement</link:label>
    <link:label id="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_18C5103EDF71FCFC104743C3DB774EC1_label_en-US" xlink:label="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_18C5103EDF71FCFC104743C3DB774EC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remaining Potential Development Milestone Payments And Royalties On Commercial Sales Under Terms Of Collaboration Agreement</link:label>
    <link:label id="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_18C5103EDF71FCFC104743C3DB774EC1_documentation_en-US" xlink:label="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_18C5103EDF71FCFC104743C3DB774EC1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected total payments including upfront and milestone payments as well as the greater of an annual maintenance fee or usage-based royalty payments under the terms of collaboration agreement.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement" xlink:label="loc_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_18C5103EDF71FCFC104743C3DB774EC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_18C5103EDF71FCFC104743C3DB774EC1" xlink:to="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_18C5103EDF71FCFC104743C3DB774EC1" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_67A7AF45A19ECAF825B743C3DB783C03_verboseLabel_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_67A7AF45A19ECAF825B743C3DB783C03" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_67A7AF45A19ECAF825B743C3DB783C03_label_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_67A7AF45A19ECAF825B743C3DB783C03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_67A7AF45A19ECAF825B743C3DB783C03_documentation_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_67A7AF45A19ECAF825B743C3DB783C03" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_67A7AF45A19ECAF825B743C3DB783C03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_67A7AF45A19ECAF825B743C3DB783C03" xlink:to="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_67A7AF45A19ECAF825B743C3DB783C03" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_4E851FC5671C73BAD9AFAE73D95E26BB_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_4E851FC5671C73BAD9AFAE73D95E26BB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative and Other Relationships</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_4E851FC5671C73BAD9AFAE73D95E26BB_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_4E851FC5671C73BAD9AFAE73D95E26BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_4E851FC5671C73BAD9AFAE73D95E26BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_4E851FC5671C73BAD9AFAE73D95E26BB" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_4E851FC5671C73BAD9AFAE73D95E26BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_6F85B0DEAD17AE1E9314AE73DAA1016A_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_6F85B0DEAD17AE1E9314AE73DAA1016A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_6F85B0DEAD17AE1E9314AE73DAA1016A_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_6F85B0DEAD17AE1E9314AE73DAA1016A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_6F85B0DEAD17AE1E9314AE73DAA1016A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_6F85B0DEAD17AE1E9314AE73DAA1016A" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_6F85B0DEAD17AE1E9314AE73DAA1016A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0BE7FD13DDD14D13BE00AE73DB51C132_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0BE7FD13DDD14D13BE00AE73DB51C132" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0BE7FD13DDD14D13BE00AE73DB51C132_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0BE7FD13DDD14D13BE00AE73DB51C132" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0BE7FD13DDD14D13BE00AE73DB51C132" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0BE7FD13DDD14D13BE00AE73DB51C132" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0BE7FD13DDD14D13BE00AE73DB51C132" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_59FA8E50AFC8003A8F8EAE73DB514FA5_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_59FA8E50AFC8003A8F8EAE73DB514FA5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with each of our share-based compensating programs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_59FA8E50AFC8003A8F8EAE73DB514FA5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_59FA8E50AFC8003A8F8EAE73DB514FA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_59FA8E50AFC8003A8F8EAE73DB514FA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_59FA8E50AFC8003A8F8EAE73DB514FA5" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_59FA8E50AFC8003A8F8EAE73DB514FA5" xlink:type="arc" />
    <link:label id="lab_biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock_C70D57F4327DF227492EAE73DB51BA40_verboseLabel_en-US" xlink:label="lab_biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock_C70D57F4327DF227492EAE73DB51BA40" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of equity grants to employees, officers and directors under our current stock plans</link:label>
    <link:label id="lab_biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock_C70D57F4327DF227492EAE73DB51BA40_label_en-US" xlink:label="lab_biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock_C70D57F4327DF227492EAE73DB51BA40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Restricted Stock Unit Grants [Table Text Block]</link:label>
    <link:label id="lab_biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock_C70D57F4327DF227492EAE73DB51BA40_documentation_en-US" xlink:label="lab_biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock_C70D57F4327DF227492EAE73DB51BA40" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of restricted stock unit grants.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock" xlink:label="loc_biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock_C70D57F4327DF227492EAE73DB51BA40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock_C70D57F4327DF227492EAE73DB51BA40" xlink:to="lab_biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock_C70D57F4327DF227492EAE73DB51BA40" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_534D6F0935EA4F14CB72AE73DAE7FBE9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_534D6F0935EA4F14CB72AE73DAE7FBE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_534D6F0935EA4F14CB72AE73DAE7FBE9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_534D6F0935EA4F14CB72AE73DAE7FBE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_534D6F0935EA4F14CB72AE73DAE7FBE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_534D6F0935EA4F14CB72AE73DAE7FBE9" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable_534D6F0935EA4F14CB72AE73DAE7FBE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillLineItems_8F2775182217F0F734A4AE73DAE817A3_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_8F2775182217F0F734A4AE73DAE817A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_8F2775182217F0F734A4AE73DAE817A3_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_8F2775182217F0F734A4AE73DAE817A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_8F2775182217F0F734A4AE73DAE817A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems_8F2775182217F0F734A4AE73DAE817A3" xlink:to="lab_us-gaap_GoodwillLineItems_8F2775182217F0F734A4AE73DAE817A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_CFF32E507952DC831B22AE73DAE83BEA_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_CFF32E507952DC831B22AE73DAE83BEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_CFF32E507952DC831B22AE73DAE83BEA_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_CFF32E507952DC831B22AE73DAE83BEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_CFF32E507952DC831B22AE73DAE83BEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod_CFF32E507952DC831B22AE73DAE83BEA" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod_CFF32E507952DC831B22AE73DAE83BEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillRollForward_15C8E4AC4D84050AF701AE73DAE8A668_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_15C8E4AC4D84050AF701AE73DAE8A668" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_15C8E4AC4D84050AF701AE73DAE8A668_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_15C8E4AC4D84050AF701AE73DAE8A668" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_15C8E4AC4D84050AF701AE73DAE8A668" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward_15C8E4AC4D84050AF701AE73DAE8A668" xlink:to="lab_us-gaap_GoodwillRollForward_15C8E4AC4D84050AF701AE73DAE8A668" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_03B860FB5CF6CF27B069AE73DAE84141_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill_03B860FB5CF6CF27B069AE73DAE84141" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Goodwill, beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_03B860FB5CF6CF27B069AE73DAE84141" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_03B860FB5CF6CF27B069AE73DAE84141" xlink:to="lab_us-gaap_Goodwill_03B860FB5CF6CF27B069AE73DAE84141" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillOtherChanges_D8D9A000C110090ADCB2AE73DAE89C1B_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherChanges_D8D9A000C110090ADCB2AE73DAE89C1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherChanges_D8D9A000C110090ADCB2AE73DAE89C1B_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherChanges_D8D9A000C110090ADCB2AE73DAE89C1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Other Changes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillOtherChanges" xlink:label="loc_us-gaap_GoodwillOtherChanges_D8D9A000C110090ADCB2AE73DAE89C1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherChanges_D8D9A000C110090ADCB2AE73DAE89C1B" xlink:to="lab_us-gaap_GoodwillOtherChanges_D8D9A000C110090ADCB2AE73DAE89C1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_C672BA0653B196E8FD96AE73DAE8B5C5_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill_C672BA0653B196E8FD96AE73DAE8B5C5" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Goodwill, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_C672BA0653B196E8FD96AE73DAE8B5C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_C672BA0653B196E8FD96AE73DAE8B5C5" xlink:to="lab_us-gaap_Goodwill_C672BA0653B196E8FD96AE73DAE8B5C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_C77348E6510F7F513EAFAE73D98F860C_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_C77348E6510F7F513EAFAE73D98F860C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_C77348E6510F7F513EAFAE73D98F860C_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_C77348E6510F7F513EAFAE73D98F860C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_C77348E6510F7F513EAFAE73D98F860C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_C77348E6510F7F513EAFAE73D98F860C" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1_C77348E6510F7F513EAFAE73D98F860C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_FDC6BF465BBA3F41473DAE73DA9E5EDD_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_FDC6BF465BBA3F41473DAE73DA9E5EDD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_FDC6BF465BBA3F41473DAE73DA9E5EDD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_FDC6BF465BBA3F41473DAE73DA9E5EDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_FDC6BF465BBA3F41473DAE73DA9E5EDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_FDC6BF465BBA3F41473DAE73DA9E5EDD" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_FDC6BF465BBA3F41473DAE73DA9E5EDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_A5CBD0E18E1E710B1140AE73DA9E3FA4_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_A5CBD0E18E1E710B1140AE73DA9E3FA4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair and carrying value of debt instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_A5CBD0E18E1E710B1140AE73DA9E3FA4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_A5CBD0E18E1E710B1140AE73DA9E3FA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_A5CBD0E18E1E710B1140AE73DA9E3FA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_A5CBD0E18E1E710B1140AE73DA9E3FA4" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_A5CBD0E18E1E710B1140AE73DA9E3FA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_271E0E8BA37BD321D9B0AE73DA9EB233_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_271E0E8BA37BD321D9B0AE73DA9EB233" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_271E0E8BA37BD321D9B0AE73DA9EB233_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_271E0E8BA37BD321D9B0AE73DA9EB233" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_271E0E8BA37BD321D9B0AE73DA9EB233" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_271E0E8BA37BD321D9B0AE73DA9EB233" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_271E0E8BA37BD321D9B0AE73DA9EB233" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_F6C4852CF9669185B4ECAE73DA9BEE0F_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_F6C4852CF9669185B4ECAE73DA9BEE0F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency forward contracts that were entered into to hedge forecasted revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_F6C4852CF9669185B4ECAE73DA9BEE0F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_F6C4852CF9669185B4ECAE73DA9BEE0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_F6C4852CF9669185B4ECAE73DA9BEE0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_F6C4852CF9669185B4ECAE73DA9BEE0F" xlink:to="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_F6C4852CF9669185B4ECAE73DA9BEE0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_9158D2FBD517910D7B82AE73DA9C2CDF_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_9158D2FBD517910D7B82AE73DA9C2CDF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of the effect of derivatives designated as hedging instruments on the condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_9158D2FBD517910D7B82AE73DA9C2CDF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_9158D2FBD517910D7B82AE73DA9C2CDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_9158D2FBD517910D7B82AE73DA9C2CDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_9158D2FBD517910D7B82AE73DA9C2CDF" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_9158D2FBD517910D7B82AE73DA9C2CDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_ACFF57CA619E5B155CE5AE73DA9CEF61_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_ACFF57CA619E5B155CE5AE73DA9CEF61" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair value and presentation of derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_ACFF57CA619E5B155CE5AE73DA9CEF61_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_ACFF57CA619E5B155CE5AE73DA9CEF61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_ACFF57CA619E5B155CE5AE73DA9CEF61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_ACFF57CA619E5B155CE5AE73DA9CEF61" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_ACFF57CA619E5B155CE5AE73DA9CEF61" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_4A4883B44537EE264AE6AE73DAE17992_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_4A4883B44537EE264AE6AE73DAE17992" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_4A4883B44537EE264AE6AE73DAE17992_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_4A4883B44537EE264AE6AE73DAE17992" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_4A4883B44537EE264AE6AE73DAE17992" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_4A4883B44537EE264AE6AE73DAE17992" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_4A4883B44537EE264AE6AE73DAE17992" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_E26AE0C245072A6BD776AE73DAB268D7_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_E26AE0C245072A6BD776AE73DAB268D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_E26AE0C245072A6BD776AE73DAB268D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_E26AE0C245072A6BD776AE73DAB268D7" xlink:to="lab_us-gaap_EquityAbstract_E26AE0C245072A6BD776AE73DAB268D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7E941F48FF0E1171B0F5AE73DAB235BB_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7E941F48FF0E1171B0F5AE73DAB235BB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7E941F48FF0E1171B0F5AE73DAB235BB_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7E941F48FF0E1171B0F5AE73DAB235BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7E941F48FF0E1171B0F5AE73DAB235BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7E941F48FF0E1171B0F5AE73DAB235BB" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7E941F48FF0E1171B0F5AE73DAB235BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_9DA31E9A79087DA9627DAE73DB6005F2_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_9DA31E9A79087DA9627DAE73DB6005F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_9DA31E9A79087DA9627DAE73DB6005F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_9DA31E9A79087DA9627DAE73DB6005F2" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_9DA31E9A79087DA9627DAE73DB6005F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_27D079A2BE9D74DF9D75AE73DB6012B7_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_27D079A2BE9D74DF9D75AE73DB6012B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_27D079A2BE9D74DF9D75AE73DB6012B7_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_27D079A2BE9D74DF9D75AE73DB6012B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_27D079A2BE9D74DF9D75AE73DB6012B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_27D079A2BE9D74DF9D75AE73DB6012B7" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_27D079A2BE9D74DF9D75AE73DB6012B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EB3B38DC4336DC08ABCCAE73DB6050F9_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EB3B38DC4336DC08ABCCAE73DB6050F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EB3B38DC4336DC08ABCCAE73DB6050F9_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EB3B38DC4336DC08ABCCAE73DB6050F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EB3B38DC4336DC08ABCCAE73DB6050F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EB3B38DC4336DC08ABCCAE73DB6050F9" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EB3B38DC4336DC08ABCCAE73DB6050F9" xlink:type="arc" />
    <link:label id="lab_biib_StrategicInvestmentsMember_84F8BB0DB4C3ECFD7167AE73DB606C24_terseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_84F8BB0DB4C3ECFD7167AE73DB606C24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Strategic Investments</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_84F8BB0DB4C3ECFD7167AE73DB606C24_label_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_84F8BB0DB4C3ECFD7167AE73DB606C24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investments [Member]</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_84F8BB0DB4C3ECFD7167AE73DB606C24_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_84F8BB0DB4C3ECFD7167AE73DB606C24" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investments.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_84F8BB0DB4C3ECFD7167AE73DB606C24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentsMember_84F8BB0DB4C3ECFD7167AE73DB606C24" xlink:to="lab_biib_StrategicInvestmentsMember_84F8BB0DB4C3ECFD7167AE73DB606C24" xlink:type="arc" />
    <link:label id="lab_biib_StrategicInvestmentPortfolio_4665EBB3735364C37D9DAE73DB60F307_verboseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_4665EBB3735364C37D9DAE73DB60F307" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_4665EBB3735364C37D9DAE73DB60F307_label_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_4665EBB3735364C37D9DAE73DB60F307" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investment Portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_4665EBB3735364C37D9DAE73DB60F307_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_4665EBB3735364C37D9DAE73DB60F307" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_4665EBB3735364C37D9DAE73DB60F307" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentPortfolio_4665EBB3735364C37D9DAE73DB60F307" xlink:to="lab_biib_StrategicInvestmentPortfolio_4665EBB3735364C37D9DAE73DB60F307" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8A3E9C156FAA7412FEB7AE73DB48F487_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8A3E9C156FAA7412FEB7AE73DB48F487" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8A3E9C156FAA7412FEB7AE73DB48F487_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8A3E9C156FAA7412FEB7AE73DB48F487" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8A3E9C156FAA7412FEB7AE73DB48F487" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8A3E9C156FAA7412FEB7AE73DB48F487" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8A3E9C156FAA7412FEB7AE73DB48F487" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_A9ACD2E1380B732950C7AE73DB489D6D_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_A9ACD2E1380B732950C7AE73DB489D6D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_A9ACD2E1380B732950C7AE73DB489D6D_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_A9ACD2E1380B732950C7AE73DB489D6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_A9ACD2E1380B732950C7AE73DB489D6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_A9ACD2E1380B732950C7AE73DB489D6D" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_A9ACD2E1380B732950C7AE73DB489D6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_E120B9E404A2DFC64BC0AE73DB48E531_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_E120B9E404A2DFC64BC0AE73DB48E531" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_E120B9E404A2DFC64BC0AE73DB48E531_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_E120B9E404A2DFC64BC0AE73DB48E531" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_E120B9E404A2DFC64BC0AE73DB48E531" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_E120B9E404A2DFC64BC0AE73DB48E531" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_E120B9E404A2DFC64BC0AE73DB48E531" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B87A72D68EBB151459C3AE73DB485B49_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B87A72D68EBB151459C3AE73DB485B49" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes on foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B87A72D68EBB151459C3AE73DB485B49_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B87A72D68EBB151459C3AE73DB485B49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B87A72D68EBB151459C3AE73DB485B49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B87A72D68EBB151459C3AE73DB485B49" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B87A72D68EBB151459C3AE73DB485B49" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_AF97477796468513CA0CAE73DB49D6E2_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_AF97477796468513CA0CAE73DB49D6E2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Credits and net operating loss utilization</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_AF97477796468513CA0CAE73DB49D6E2_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_AF97477796468513CA0CAE73DB49D6E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_AF97477796468513CA0CAE73DB49D6E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_AF97477796468513CA0CAE73DB49D6E2" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_AF97477796468513CA0CAE73DB49D6E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_B2F93BE48820FBC58F2FAE73DB498EDA_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_B2F93BE48820FBC58F2FAE73DB498EDA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Purchased intangible assets</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_B2F93BE48820FBC58F2FAE73DB498EDA_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_B2F93BE48820FBC58F2FAE73DB498EDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_B2F93BE48820FBC58F2FAE73DB498EDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_B2F93BE48820FBC58F2FAE73DB498EDA" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_B2F93BE48820FBC58F2FAE73DB498EDA" xlink:type="arc" />
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_759173C74B53FC23E3FFAE73DB49270B_terseLabel_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_759173C74B53FC23E3FFAE73DB49270B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing deduction</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_759173C74B53FC23E3FFAE73DB49270B_label_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_759173C74B53FC23E3FFAE73DB49270B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation manufacturing deduction</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_759173C74B53FC23E3FFAE73DB49270B_documentation_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_759173C74B53FC23E3FFAE73DB49270B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation manufacturing deduction</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_759173C74B53FC23E3FFAE73DB49270B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_759173C74B53FC23E3FFAE73DB49270B" xlink:to="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_759173C74B53FC23E3FFAE73DB49270B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_3B967C3A5CFEFE13DF72AE73DB49DB4D_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_3B967C3A5CFEFE13DF72AE73DB49DB4D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Permanent items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_3B967C3A5CFEFE13DF72AE73DB49DB4D_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_3B967C3A5CFEFE13DF72AE73DB49DB4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_3B967C3A5CFEFE13DF72AE73DB49DB4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_3B967C3A5CFEFE13DF72AE73DB49DB4D" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_3B967C3A5CFEFE13DF72AE73DB49DB4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2845529838CE9DA23B0AAE73DB496F03_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2845529838CE9DA23B0AAE73DB496F03" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2845529838CE9DA23B0AAE73DB496F03_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2845529838CE9DA23B0AAE73DB496F03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2845529838CE9DA23B0AAE73DB496F03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2845529838CE9DA23B0AAE73DB496F03" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2845529838CE9DA23B0AAE73DB496F03" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B6DAF90E54594B34ABE5AE73DB499F7A_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B6DAF90E54594B34ABE5AE73DB499F7A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B6DAF90E54594B34ABE5AE73DB499F7A_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B6DAF90E54594B34ABE5AE73DB499F7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B6DAF90E54594B34ABE5AE73DB499F7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B6DAF90E54594B34ABE5AE73DB499F7A" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B6DAF90E54594B34ABE5AE73DB499F7A" xlink:type="arc" />
    <link:label id="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_65CD16814045F6F794344EEFD6A9CDCA_verboseLabel_en-US" xlink:label="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_65CD16814045F6F794344EEFD6A9CDCA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of equity attributable to non-controlling interests</link:label>
    <link:label id="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_65CD16814045F6F794344EEFD6A9CDCA_label_en-US" xlink:label="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_65CD16814045F6F794344EEFD6A9CDCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation Of Equity Attributable To Non Controlling Interests [Abstract]</link:label>
    <link:label id="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_65CD16814045F6F794344EEFD6A9CDCA_documentation_en-US" xlink:label="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_65CD16814045F6F794344EEFD6A9CDCA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reconciliation of equity attributable to non-controlling interests.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract" xlink:label="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_65CD16814045F6F794344EEFD6A9CDCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_65CD16814045F6F794344EEFD6A9CDCA" xlink:to="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_65CD16814045F6F794344EEFD6A9CDCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_E2471CECDFBC38D731434EEFD6A9D04D_periodStartLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_E2471CECDFBC38D731434EEFD6A9D04D" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">NCI, beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_E2471CECDFBC38D731434EEFD6A9D04D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_E2471CECDFBC38D731434EEFD6A9D04D" xlink:to="lab_us-gaap_MinorityInterest_E2471CECDFBC38D731434EEFD6A9D04D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_B9D0E08AF730E0519E2B4EEFD6A9BF6B_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_B9D0E08AF730E0519E2B4EEFD6A9BF6B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to NCI, net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_B9D0E08AF730E0519E2B4EEFD6A9BF6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_B9D0E08AF730E0519E2B4EEFD6A9BF6B" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_B9D0E08AF730E0519E2B4EEFD6A9BF6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_B0B744D9C13C64AEFA294EEFD6A9BEB0_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_B0B744D9C13C64AEFA294EEFD6A9BEB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of net assets and liabilities acquired and assigned to NCI</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_B0B744D9C13C64AEFA294EEFD6A9BEB0_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_B0B744D9C13C64AEFA294EEFD6A9BEB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Increase from Business Combination</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_B0B744D9C13C64AEFA294EEFD6A9BEB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_B0B744D9C13C64AEFA294EEFD6A9BEB0" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_B0B744D9C13C64AEFA294EEFD6A9BEB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_9CC50651B579446A67E74EEFD6A992F9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_9CC50651B579446A67E74EEFD6A992F9" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Distribution to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_9CC50651B579446A67E74EEFD6A992F9_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_9CC50651B579446A67E74EEFD6A992F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_9CC50651B579446A67E74EEFD6A992F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_9CC50651B579446A67E74EEFD6A992F9" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_9CC50651B579446A67E74EEFD6A992F9" xlink:type="arc" />
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_BDA51E3889DD2F221C504EEFD6A9E85B_negatedTerseLabel_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_BDA51E3889DD2F221C504EEFD6A9E85B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Translation adjustment and other</link:label>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_BDA51E3889DD2F221C504EEFD6A9E85B_label_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_BDA51E3889DD2F221C504EEFD6A9E85B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_BDA51E3889DD2F221C504EEFD6A9E85B_documentation_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_BDA51E3889DD2F221C504EEFD6A9E85B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_BDA51E3889DD2F221C504EEFD6A9E85B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Noncontrollinginterestincreasedecreaseother_BDA51E3889DD2F221C504EEFD6A9E85B" xlink:to="lab_biib_Noncontrollinginterestincreasedecreaseother_BDA51E3889DD2F221C504EEFD6A9E85B" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_A22F8EB2FCDE7D3A35AD4EEFD6AA126E_periodEndLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_A22F8EB2FCDE7D3A35AD4EEFD6AA126E" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">NCI, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_A22F8EB2FCDE7D3A35AD4EEFD6AA126E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_A22F8EB2FCDE7D3A35AD4EEFD6AA126E" xlink:to="lab_us-gaap_MinorityInterest_A22F8EB2FCDE7D3A35AD4EEFD6AA126E" xlink:type="arc" />
    <link:label id="lab_biib_NotesPayableToFumedicaMember_6011038135E308B348D92E2530673CD5_verboseLabel_en-US" xlink:label="lab_biib_NotesPayableToFumedicaMember_6011038135E308B348D92E2530673CD5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes Payable to Fumedica</link:label>
    <link:label id="lab_biib_NotesPayableToFumedicaMember_6011038135E308B348D92E2530673CD5_label_en-US" xlink:label="lab_biib_NotesPayableToFumedicaMember_6011038135E308B348D92E2530673CD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable To Fumedica [Member]</link:label>
    <link:label id="lab_biib_NotesPayableToFumedicaMember_6011038135E308B348D92E2530673CD5_documentation_en-US" xlink:label="lab_biib_NotesPayableToFumedicaMember_6011038135E308B348D92E2530673CD5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Notes payable.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_NotesPayableToFumedicaMember" xlink:label="loc_biib_NotesPayableToFumedicaMember_6011038135E308B348D92E2530673CD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NotesPayableToFumedicaMember_6011038135E308B348D92E2530673CD5" xlink:to="lab_biib_NotesPayableToFumedicaMember_6011038135E308B348D92E2530673CD5" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_FE84211CF90B8C1421582E253068B9F0_verboseLabel_en-US" xlink:label="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_FE84211CF90B8C1421582E253068B9F0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">6.875% Senior Notes due 2018</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_FE84211CF90B8C1421582E253068B9F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_FE84211CF90B8C1421582E253068B9F0" xlink:to="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_FE84211CF90B8C1421582E253068B9F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_28BB50082A9FC84B84042E253068D881_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_28BB50082A9FC84B84042E253068D881" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, fair value</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_28BB50082A9FC84B84042E253068D881_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_28BB50082A9FC84B84042E253068D881" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_28BB50082A9FC84B84042E253068D881" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure_28BB50082A9FC84B84042E253068D881" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure_28BB50082A9FC84B84042E253068D881" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayable_45B9E442B3B3B92FCD692E253068B9EB_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable_45B9E442B3B3B92FCD692E253068B9EB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, carrying value</link:label>
    <link:label id="lab_us-gaap_NotesPayable_45B9E442B3B3B92FCD692E253068B9EB_label_en-US" xlink:label="lab_us-gaap_NotesPayable_45B9E442B3B3B92FCD692E253068B9EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_45B9E442B3B3B92FCD692E253068B9EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable_45B9E442B3B3B92FCD692E253068B9EB" xlink:to="lab_us-gaap_NotesPayable_45B9E442B3B3B92FCD692E253068B9EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_57D6C7784B7E2F6136402E25306871FE_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_57D6C7784B7E2F6136402E25306871FE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt instruments, fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_57D6C7784B7E2F6136402E25306871FE_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_57D6C7784B7E2F6136402E25306871FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_57D6C7784B7E2F6136402E25306871FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue_57D6C7784B7E2F6136402E25306871FE" xlink:to="lab_us-gaap_DebtInstrumentFairValue_57D6C7784B7E2F6136402E25306871FE" xlink:type="arc" />
    <link:label id="lab_biib_InterestInSubsidiary_7AABD4B1346609D0DDDA8B8034C0BDC0_verboseLabel_en-US" xlink:label="lab_biib_InterestInSubsidiary_7AABD4B1346609D0DDDA8B8034C0BDC0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest in subsidiary (less than given percentage)</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_7AABD4B1346609D0DDDA8B8034C0BDC0_label_en-US" xlink:label="lab_biib_InterestInSubsidiary_7AABD4B1346609D0DDDA8B8034C0BDC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest In Subsidiary</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_7AABD4B1346609D0DDDA8B8034C0BDC0_documentation_en-US" xlink:label="lab_biib_InterestInSubsidiary_7AABD4B1346609D0DDDA8B8034C0BDC0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest in subsidiary.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_InterestInSubsidiary" xlink:label="loc_biib_InterestInSubsidiary_7AABD4B1346609D0DDDA8B8034C0BDC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterestInSubsidiary_7AABD4B1346609D0DDDA8B8034C0BDC0" xlink:to="lab_biib_InterestInSubsidiary_7AABD4B1346609D0DDDA8B8034C0BDC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfReportableSegments_898160E9B6992B14EB978B8034C0DC8E_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_898160E9B6992B14EB978B8034C0DC8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_898160E9B6992B14EB978B8034C0DC8E_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_898160E9B6992B14EB978B8034C0DC8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_898160E9B6992B14EB978B8034C0DC8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments_898160E9B6992B14EB978B8034C0DC8E" xlink:to="lab_us-gaap_NumberOfReportableSegments_898160E9B6992B14EB978B8034C0DC8E" xlink:type="arc" />
    <link:label id="lab_biib_PaymentTermsOfAccountsReceivable_EB35E0D254E7795359CA8B8034C07220_verboseLabel_en-US" xlink:label="lab_biib_PaymentTermsOfAccountsReceivable_EB35E0D254E7795359CA8B8034C07220" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Payment terms of accounts receivable arising from product sales</link:label>
    <link:label id="lab_biib_PaymentTermsOfAccountsReceivable_EB35E0D254E7795359CA8B8034C07220_label_en-US" xlink:label="lab_biib_PaymentTermsOfAccountsReceivable_EB35E0D254E7795359CA8B8034C07220" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment Terms Of Accounts Receivable</link:label>
    <link:label id="lab_biib_PaymentTermsOfAccountsReceivable_EB35E0D254E7795359CA8B8034C07220_documentation_en-US" xlink:label="lab_biib_PaymentTermsOfAccountsReceivable_EB35E0D254E7795359CA8B8034C07220" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment  terms of accounts receivable.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_PaymentTermsOfAccountsReceivable" xlink:label="loc_biib_PaymentTermsOfAccountsReceivable_EB35E0D254E7795359CA8B8034C07220" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentTermsOfAccountsReceivable_EB35E0D254E7795359CA8B8034C07220" xlink:to="lab_biib_PaymentTermsOfAccountsReceivable_EB35E0D254E7795359CA8B8034C07220" xlink:type="arc" />
    <link:label id="lab_biib_MinimumTermForAccountsReceivable_DA42E5BE7668294D50BB8B8034C03403_verboseLabel_en-US" xlink:label="lab_biib_MinimumTermForAccountsReceivable_DA42E5BE7668294D50BB8B8034C03403" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum term for accounts receivable</link:label>
    <link:label id="lab_biib_MinimumTermForAccountsReceivable_DA42E5BE7668294D50BB8B8034C03403_label_en-US" xlink:label="lab_biib_MinimumTermForAccountsReceivable_DA42E5BE7668294D50BB8B8034C03403" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Term For Accounts Receivable</link:label>
    <link:label id="lab_biib_MinimumTermForAccountsReceivable_DA42E5BE7668294D50BB8B8034C03403_documentation_en-US" xlink:label="lab_biib_MinimumTermForAccountsReceivable_DA42E5BE7668294D50BB8B8034C03403" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum term for accounts receivable.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_MinimumTermForAccountsReceivable" xlink:label="loc_biib_MinimumTermForAccountsReceivable_DA42E5BE7668294D50BB8B8034C03403" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MinimumTermForAccountsReceivable_DA42E5BE7668294D50BB8B8034C03403" xlink:to="lab_biib_MinimumTermForAccountsReceivable_DA42E5BE7668294D50BB8B8034C03403" xlink:type="arc" />
    <link:label id="lab_biib_MaximumTermForAccountsReceivable_8FCEC2C3F87C64D5EFB38B8034C0A479_verboseLabel_en-US" xlink:label="lab_biib_MaximumTermForAccountsReceivable_8FCEC2C3F87C64D5EFB38B8034C0A479" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum term for accounts receivable</link:label>
    <link:label id="lab_biib_MaximumTermForAccountsReceivable_8FCEC2C3F87C64D5EFB38B8034C0A479_label_en-US" xlink:label="lab_biib_MaximumTermForAccountsReceivable_8FCEC2C3F87C64D5EFB38B8034C0A479" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Term For Accounts Receivable</link:label>
    <link:label id="lab_biib_MaximumTermForAccountsReceivable_8FCEC2C3F87C64D5EFB38B8034C0A479_documentation_en-US" xlink:label="lab_biib_MaximumTermForAccountsReceivable_8FCEC2C3F87C64D5EFB38B8034C0A479" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum term for accounts receivable.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_MaximumTermForAccountsReceivable" xlink:label="loc_biib_MaximumTermForAccountsReceivable_8FCEC2C3F87C64D5EFB38B8034C0A479" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MaximumTermForAccountsReceivable_8FCEC2C3F87C64D5EFB38B8034C0A479" xlink:to="lab_biib_MaximumTermForAccountsReceivable_8FCEC2C3F87C64D5EFB38B8034C0A479" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_0AF4DF56AFC9CE356948AE73DAD0749D_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_0AF4DF56AFC9CE356948AE73DAD0749D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable debt and equity securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_0AF4DF56AFC9CE356948AE73DAD0749D_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_0AF4DF56AFC9CE356948AE73DAD0749D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_0AF4DF56AFC9CE356948AE73DAD0749D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_0AF4DF56AFC9CE356948AE73DAD0749D" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_0AF4DF56AFC9CE356948AE73DAD0749D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_CC809B69BD1D4A216246AE73DAD039AF_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_CC809B69BD1D4A216246AE73DAD039AF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_CC809B69BD1D4A216246AE73DAD039AF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_CC809B69BD1D4A216246AE73DAD039AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_CC809B69BD1D4A216246AE73DAD039AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_CC809B69BD1D4A216246AE73DAD039AF" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_CC809B69BD1D4A216246AE73DAD039AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_4AEBC5E3593908850C7FAE73DAD0989C_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_4AEBC5E3593908850C7FAE73DAD0989C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of contractual maturities: available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_4AEBC5E3593908850C7FAE73DAD0989C_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_4AEBC5E3593908850C7FAE73DAD0989C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_4AEBC5E3593908850C7FAE73DAD0989C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_4AEBC5E3593908850C7FAE73DAD0989C" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_4AEBC5E3593908850C7FAE73DAD0989C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_19954C1672624514EFA8AE73DAD016D4_verboseLabel_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_19954C1672624514EFA8AE73DAD016D4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from marketable debt securities</link:label>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_19954C1672624514EFA8AE73DAD016D4_label_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_19954C1672624514EFA8AE73DAD016D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_19954C1672624514EFA8AE73DAD016D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_19954C1672624514EFA8AE73DAD016D4" xlink:to="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_19954C1672624514EFA8AE73DAD016D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_711340CE2372DA30D60A71883E38C1B2_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_711340CE2372DA30D60A71883E38C1B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_711340CE2372DA30D60A71883E38C1B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_711340CE2372DA30D60A71883E38C1B2" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_711340CE2372DA30D60A71883E38C1B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_86AC88793704770CF26571883E3894DF_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_86AC88793704770CF26571883E3894DF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_86AC88793704770CF26571883E3894DF_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_86AC88793704770CF26571883E3894DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_86AC88793704770CF26571883E3894DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_86AC88793704770CF26571883E3894DF" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_86AC88793704770CF26571883E3894DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_C6384953A2A6E2A5D06F71883E38D70A_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_C6384953A2A6E2A5D06F71883E38D70A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_C6384953A2A6E2A5D06F71883E38D70A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_C6384953A2A6E2A5D06F71883E38D70A" xlink:to="lab_us-gaap_ProfitLoss_C6384953A2A6E2A5D06F71883E38D70A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDA35972990BD0280FC471883E38A66C_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDA35972990BD0280FC471883E38A66C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDA35972990BD0280FC471883E38A66C_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDA35972990BD0280FC471883E38A66C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDA35972990BD0280FC471883E38A66C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDA35972990BD0280FC471883E38A66C" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDA35972990BD0280FC471883E38A66C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_56F810AEBEF3756056B971883E3807F8_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_56F810AEBEF3756056B971883E3807F8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_56F810AEBEF3756056B971883E3807F8_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_56F810AEBEF3756056B971883E3807F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_56F810AEBEF3756056B971883E3807F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_56F810AEBEF3756056B971883E3807F8" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_56F810AEBEF3756056B971883E3807F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_0D8432A273C672CF3E6771883E388824_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_0D8432A273C672CF3E6771883E388824" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_0D8432A273C672CF3E6771883E388824_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_0D8432A273C672CF3E6771883E388824" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_0D8432A273C672CF3E6771883E388824" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_0D8432A273C672CF3E6771883E388824" xlink:to="lab_us-gaap_ShareBasedCompensation_0D8432A273C672CF3E6771883E388824" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_D047BE6885FDD2318BD571883E383FD1_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_D047BE6885FDD2318BD571883E383FD1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_D047BE6885FDD2318BD571883E383FD1_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_D047BE6885FDD2318BD571883E383FD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_D047BE6885FDD2318BD571883E383FD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_D047BE6885FDD2318BD571883E383FD1" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_D047BE6885FDD2318BD571883E383FD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_C46A62AC1DED1A7ADDA271883E382611_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_C46A62AC1DED1A7ADDA271883E382611" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_C46A62AC1DED1A7ADDA271883E382611_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_C46A62AC1DED1A7ADDA271883E382611" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_C46A62AC1DED1A7ADDA271883E382611" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_C46A62AC1DED1A7ADDA271883E382611" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_C46A62AC1DED1A7ADDA271883E382611" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8B748038B4AD249A4A0871883E38B883_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8B748038B4AD249A4A0871883E38B883" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities, net:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8B748038B4AD249A4A0871883E38B883_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8B748038B4AD249A4A0871883E38B883" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8B748038B4AD249A4A0871883E38B883" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8B748038B4AD249A4A0871883E38B883" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8B748038B4AD249A4A0871883E38B883" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6426EEB437FF11D6938D71883E384E7E_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6426EEB437FF11D6938D71883E384E7E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6426EEB437FF11D6938D71883E384E7E_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6426EEB437FF11D6938D71883E384E7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6426EEB437FF11D6938D71883E384E7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6426EEB437FF11D6938D71883E384E7E" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6426EEB437FF11D6938D71883E384E7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_4665E16D98F729A9306771883E380BAF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_4665E16D98F729A9306771883E380BAF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_4665E16D98F729A9306771883E380BAF_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_4665E16D98F729A9306771883E380BAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_4665E16D98F729A9306771883E380BAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_4665E16D98F729A9306771883E380BAF" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_4665E16D98F729A9306771883E380BAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_2FDA9A527A01A1E13CB771883E39A4E3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_2FDA9A527A01A1E13CB771883E39A4E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_2FDA9A527A01A1E13CB771883E39A4E3_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_2FDA9A527A01A1E13CB771883E39A4E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2FDA9A527A01A1E13CB771883E39A4E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2FDA9A527A01A1E13CB771883E39A4E3" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_2FDA9A527A01A1E13CB771883E39A4E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_62B14FE540818E00FC9171883E395903_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_62B14FE540818E00FC9171883E395903" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other changes in operating assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_62B14FE540818E00FC9171883E395903_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_62B14FE540818E00FC9171883E395903" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_62B14FE540818E00FC9171883E395903" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_62B14FE540818E00FC9171883E395903" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_62B14FE540818E00FC9171883E395903" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_964DD2FD05859AAC2A2971883E393BFC_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_964DD2FD05859AAC2A2971883E393BFC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_964DD2FD05859AAC2A2971883E393BFC_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_964DD2FD05859AAC2A2971883E393BFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_964DD2FD05859AAC2A2971883E393BFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_964DD2FD05859AAC2A2971883E393BFC" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_964DD2FD05859AAC2A2971883E393BFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A87D9CDCAD7FAAECBC4571883E393364_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A87D9CDCAD7FAAECBC4571883E393364" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A87D9CDCAD7FAAECBC4571883E393364_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A87D9CDCAD7FAAECBC4571883E393364" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A87D9CDCAD7FAAECBC4571883E393364" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A87D9CDCAD7FAAECBC4571883E393364" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A87D9CDCAD7FAAECBC4571883E393364" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_22BB4F92F4B13F1329BD71883E393121_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_22BB4F92F4B13F1329BD71883E393121" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_22BB4F92F4B13F1329BD71883E393121_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_22BB4F92F4B13F1329BD71883E393121" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_22BB4F92F4B13F1329BD71883E393121" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_22BB4F92F4B13F1329BD71883E393121" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_22BB4F92F4B13F1329BD71883E393121" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_1E8ECD466C6B1C8364AF71883E39BE12_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_1E8ECD466C6B1C8364AF71883E39BE12" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_1E8ECD466C6B1C8364AF71883E39BE12_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_1E8ECD466C6B1C8364AF71883E39BE12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_1E8ECD466C6B1C8364AF71883E39BE12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_1E8ECD466C6B1C8364AF71883E39BE12" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_1E8ECD466C6B1C8364AF71883E39BE12" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_FBA85EF469326E7313DE71883E39E2AD_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_FBA85EF469326E7313DE71883E39E2AD" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of business, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_FBA85EF469326E7313DE71883E39E2AD_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_FBA85EF469326E7313DE71883E39E2AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_FBA85EF469326E7313DE71883E39E2AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_FBA85EF469326E7313DE71883E39E2AD" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_FBA85EF469326E7313DE71883E39E2AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C6637885FD3882E75DD071883E3983AD_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C6637885FD3882E75DD071883E3983AD" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C6637885FD3882E75DD071883E3983AD_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C6637885FD3882E75DD071883E3983AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C6637885FD3882E75DD071883E3983AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C6637885FD3882E75DD071883E3983AD" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C6637885FD3882E75DD071883E3983AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_D57D659C6108D5EA59E971883E395086_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_D57D659C6108D5EA59E971883E395086" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration related to Fumapharm AG acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_D57D659C6108D5EA59E971883E395086_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_D57D659C6108D5EA59E971883E395086" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_D57D659C6108D5EA59E971883E395086" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_D57D659C6108D5EA59E971883E395086" xlink:to="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_D57D659C6108D5EA59E971883E395086" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_20B4D9670B5C43FDE91771883E3998E7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_20B4D9670B5C43FDE91771883E3998E7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_20B4D9670B5C43FDE91771883E3998E7_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_20B4D9670B5C43FDE91771883E3998E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_20B4D9670B5C43FDE91771883E3998E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_20B4D9670B5C43FDE91771883E3998E7" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_20B4D9670B5C43FDE91771883E3998E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_EE459034572DD33763C171883E399D9F_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_EE459034572DD33763C171883E399D9F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_EE459034572DD33763C171883E399D9F_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_EE459034572DD33763C171883E399D9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_EE459034572DD33763C171883E399D9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_EE459034572DD33763C171883E399D9F" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_EE459034572DD33763C171883E399D9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3D04F8D1230F83DA075471883E39B828_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3D04F8D1230F83DA075471883E39B828" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3D04F8D1230F83DA075471883E39B828_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3D04F8D1230F83DA075471883E39B828" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3D04F8D1230F83DA075471883E39B828" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3D04F8D1230F83DA075471883E39B828" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3D04F8D1230F83DA075471883E39B828" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_4D4D947218D9EE083A0F71883E39A26A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_4D4D947218D9EE083A0F71883E39A26A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_4D4D947218D9EE083A0F71883E39A26A_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_4D4D947218D9EE083A0F71883E39A26A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4D4D947218D9EE083A0F71883E39A26A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4D4D947218D9EE083A0F71883E39A26A" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_4D4D947218D9EE083A0F71883E39A26A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_3AF45795A4861087F4D971883E39244D_negatedLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_3AF45795A4861087F4D971883E39244D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of stock for share-based compensation arrangements</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_3AF45795A4861087F4D971883E39244D_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_3AF45795A4861087F4D971883E39244D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_3AF45795A4861087F4D971883E39244D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_3AF45795A4861087F4D971883E39244D" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_3AF45795A4861087F4D971883E39244D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_BD871ED31DE39577CB8271883E394DAA_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable_BD871ED31DE39577CB8271883E394DAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_BD871ED31DE39577CB8271883E394DAA_label_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable_BD871ED31DE39577CB8271883E394DAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_BD871ED31DE39577CB8271883E394DAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable_BD871ED31DE39577CB8271883E394DAA" xlink:to="lab_us-gaap_ProceedsFromNotesPayable_BD871ED31DE39577CB8271883E394DAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_28AA1A4D5EF7C10CF33371883E39255B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable_28AA1A4D5EF7C10CF33371883E39255B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_28AA1A4D5EF7C10CF33371883E39255B_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable_28AA1A4D5EF7C10CF33371883E39255B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_28AA1A4D5EF7C10CF33371883E39255B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable_28AA1A4D5EF7C10CF33371883E39255B" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable_28AA1A4D5EF7C10CF33371883E39255B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_CE5D9D2839896CA798B771883E390E5F_terseLabel_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_CE5D9D2839896CA798B771883E390E5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Excess tax benefit from stock options</link:label>
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_CE5D9D2839896CA798B771883E390E5F_label_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_CE5D9D2839896CA798B771883E390E5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Excess Tax Benefit from Share-based Compensation, Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_CE5D9D2839896CA798B771883E390E5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_CE5D9D2839896CA798B771883E390E5F" xlink:to="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_CE5D9D2839896CA798B771883E390E5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9C6758C5F7C4F0546D5A71883E390762_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9C6758C5F7C4F0546D5A71883E390762" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9C6758C5F7C4F0546D5A71883E390762_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9C6758C5F7C4F0546D5A71883E390762" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9C6758C5F7C4F0546D5A71883E390762" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9C6758C5F7C4F0546D5A71883E390762" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9C6758C5F7C4F0546D5A71883E390762" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_89F1048F1E2031E61EF071883E3A5788_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_89F1048F1E2031E61EF071883E3A5788" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_89F1048F1E2031E61EF071883E3A5788_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_89F1048F1E2031E61EF071883E3A5788" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_89F1048F1E2031E61EF071883E3A5788" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_89F1048F1E2031E61EF071883E3A5788" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_89F1048F1E2031E61EF071883E3A5788" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_8A2A82FC8C75BA07129671883E3AB178_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_8A2A82FC8C75BA07129671883E3AB178" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_8A2A82FC8C75BA07129671883E3AB178_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_8A2A82FC8C75BA07129671883E3AB178" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_8A2A82FC8C75BA07129671883E3AB178" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_8A2A82FC8C75BA07129671883E3AB178" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_8A2A82FC8C75BA07129671883E3AB178" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_2B173DA8E3E2D12E242F71883E3A3023_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_2B173DA8E3E2D12E242F71883E3A3023" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_2B173DA8E3E2D12E242F71883E3A3023_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_2B173DA8E3E2D12E242F71883E3A3023" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_2B173DA8E3E2D12E242F71883E3A3023" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_2B173DA8E3E2D12E242F71883E3A3023" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_2B173DA8E3E2D12E242F71883E3A3023" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_04B258A88E3A1317BD7671883E3AE57E_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_04B258A88E3A1317BD7671883E3AE57E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_04B258A88E3A1317BD7671883E3AE57E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_04B258A88E3A1317BD7671883E3AE57E" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_04B258A88E3A1317BD7671883E3AE57E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0ED3300AEB99BAFAB57471883E3A26D3_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0ED3300AEB99BAFAB57471883E3A26D3" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0ED3300AEB99BAFAB57471883E3A26D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0ED3300AEB99BAFAB57471883E3A26D3" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0ED3300AEB99BAFAB57471883E3A26D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_255BEE4320D7C840B2192EBC79537768_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_255BEE4320D7C840B2192EBC79537768" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_255BEE4320D7C840B2192EBC79537768_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_255BEE4320D7C840B2192EBC79537768" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_255BEE4320D7C840B2192EBC79537768" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_255BEE4320D7C840B2192EBC79537768" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_255BEE4320D7C840B2192EBC79537768" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_ED9CA85CE95F36E483B2AE73D9A48278_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_ED9CA85CE95F36E483B2AE73D9A48278" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_ED9CA85CE95F36E483B2AE73D9A48278_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_ED9CA85CE95F36E483B2AE73D9A48278" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_ED9CA85CE95F36E483B2AE73D9A48278" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_ED9CA85CE95F36E483B2AE73D9A48278" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_ED9CA85CE95F36E483B2AE73D9A48278" xlink:type="arc" />
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_374E4E2C08490C41076AAE73D9A49648_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_374E4E2C08490C41076AAE73D9A49648" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities Current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_374E4E2C08490C41076AAE73D9A49648_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_374E4E2C08490C41076AAE73D9A49648" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_374E4E2C08490C41076AAE73D9A49648_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_374E4E2C08490C41076AAE73D9A49648" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate debt securities Current.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_374E4E2C08490C41076AAE73D9A49648" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesCurrentMember_374E4E2C08490C41076AAE73D9A49648" xlink:to="lab_biib_CorporateDebtSecuritiesCurrentMember_374E4E2C08490C41076AAE73D9A49648" xlink:type="arc" />
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_27E75F2C13EC955A4924AE73D9A4D1C6_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_27E75F2C13EC955A4924AE73D9A4D1C6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities Non-current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_27E75F2C13EC955A4924AE73D9A4D1C6_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_27E75F2C13EC955A4924AE73D9A4D1C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_27E75F2C13EC955A4924AE73D9A4D1C6_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_27E75F2C13EC955A4924AE73D9A4D1C6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_27E75F2C13EC955A4924AE73D9A4D1C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesNonCurrentMember_27E75F2C13EC955A4924AE73D9A4D1C6" xlink:to="lab_biib_CorporateDebtSecuritiesNonCurrentMember_27E75F2C13EC955A4924AE73D9A4D1C6" xlink:type="arc" />
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_B1674D3481D22C3B4BC3AE73D9A42278_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_B1674D3481D22C3B4BC3AE73D9A42278" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities Current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_B1674D3481D22C3B4BC3AE73D9A42278_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_B1674D3481D22C3B4BC3AE73D9A42278" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Securities Current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_B1674D3481D22C3B4BC3AE73D9A42278_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_B1674D3481D22C3B4BC3AE73D9A42278" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government securities Current.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_B1674D3481D22C3B4BC3AE73D9A42278" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesCurrentMember_B1674D3481D22C3B4BC3AE73D9A42278" xlink:to="lab_biib_GovernmentSecuritiesCurrentMember_B1674D3481D22C3B4BC3AE73D9A42278" xlink:type="arc" />
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_958621CF5BA86EC61F7AAE73D9A4D105_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_958621CF5BA86EC61F7AAE73D9A4D105" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities Non-current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_958621CF5BA86EC61F7AAE73D9A4D105_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_958621CF5BA86EC61F7AAE73D9A4D105" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Securities Non-current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_958621CF5BA86EC61F7AAE73D9A4D105_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_958621CF5BA86EC61F7AAE73D9A4D105" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_958621CF5BA86EC61F7AAE73D9A4D105" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesNonCurrentMember_958621CF5BA86EC61F7AAE73D9A4D105" xlink:to="lab_biib_GovernmentSecuritiesNonCurrentMember_958621CF5BA86EC61F7AAE73D9A4D105" xlink:type="arc" />
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_05CC0345B3296F797184AE73D9A4E889_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_05CC0345B3296F797184AE73D9A4E889" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_05CC0345B3296F797184AE73D9A4E889_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_05CC0345B3296F797184AE73D9A4E889" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_05CC0345B3296F797184AE73D9A4E889_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_05CC0345B3296F797184AE73D9A4E889" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Current.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_05CC0345B3296F797184AE73D9A4E889" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_05CC0345B3296F797184AE73D9A4E889" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_05CC0345B3296F797184AE73D9A4E889" xlink:type="arc" />
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_7EBAD2F6926B49F8C584AE73D9A428BD_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_7EBAD2F6926B49F8C584AE73D9A428BD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Non-current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_7EBAD2F6926B49F8C584AE73D9A428BD_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_7EBAD2F6926B49F8C584AE73D9A428BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_7EBAD2F6926B49F8C584AE73D9A428BD_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_7EBAD2F6926B49F8C584AE73D9A428BD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_7EBAD2F6926B49F8C584AE73D9A428BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_7EBAD2F6926B49F8C584AE73D9A428BD" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_7EBAD2F6926B49F8C584AE73D9A428BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesMember_00CC927FCC7085DC955BAE73D9A4E424_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember_00CC927FCC7085DC955BAE73D9A4E424" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_00CC927FCC7085DC955BAE73D9A4E424_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember_00CC927FCC7085DC955BAE73D9A4E424" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_00CC927FCC7085DC955BAE73D9A4E424" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember_00CC927FCC7085DC955BAE73D9A4E424" xlink:to="lab_us-gaap_EquitySecuritiesMember_00CC927FCC7085DC955BAE73D9A4E424" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_54FDB2B9D48F1AFBFF9BAE73D9A5DAAF_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_54FDB2B9D48F1AFBFF9BAE73D9A5DAAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_54FDB2B9D48F1AFBFF9BAE73D9A5DAAF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_54FDB2B9D48F1AFBFF9BAE73D9A5DAAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_54FDB2B9D48F1AFBFF9BAE73D9A5DAAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_54FDB2B9D48F1AFBFF9BAE73D9A5DAAF" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_54FDB2B9D48F1AFBFF9BAE73D9A5DAAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_3EB914A7B704BA087A93AE73D9A53814_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract_3EB914A7B704BA087A93AE73D9A53814" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable Debt and Equity Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_3EB914A7B704BA087A93AE73D9A53814_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract_3EB914A7B704BA087A93AE73D9A53814" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3EB914A7B704BA087A93AE73D9A53814" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3EB914A7B704BA087A93AE73D9A53814" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract_3EB914A7B704BA087A93AE73D9A53814" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_677B8F2E20F595AE4473AE73D9A551A2_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_677B8F2E20F595AE4473AE73D9A551A2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_677B8F2E20F595AE4473AE73D9A551A2_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_677B8F2E20F595AE4473AE73D9A551A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_677B8F2E20F595AE4473AE73D9A551A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_677B8F2E20F595AE4473AE73D9A551A2" xlink:to="lab_us-gaap_AvailableForSaleSecurities_677B8F2E20F595AE4473AE73D9A551A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8FF6A868AAB4DCF9DD98AE73D9A5960F_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8FF6A868AAB4DCF9DD98AE73D9A5960F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8FF6A868AAB4DCF9DD98AE73D9A5960F_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8FF6A868AAB4DCF9DD98AE73D9A5960F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8FF6A868AAB4DCF9DD98AE73D9A5960F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8FF6A868AAB4DCF9DD98AE73D9A5960F" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8FF6A868AAB4DCF9DD98AE73D9A5960F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_37769FBAF9C1AEDDBFE3AE73D9A571A9_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_37769FBAF9C1AEDDBFE3AE73D9A571A9" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_37769FBAF9C1AEDDBFE3AE73D9A571A9_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_37769FBAF9C1AEDDBFE3AE73D9A571A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_37769FBAF9C1AEDDBFE3AE73D9A571A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_37769FBAF9C1AEDDBFE3AE73D9A571A9" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_37769FBAF9C1AEDDBFE3AE73D9A571A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_C3EECE13BEBD95AC7174AE73D9A5957B_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_C3EECE13BEBD95AC7174AE73D9A5957B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_C3EECE13BEBD95AC7174AE73D9A5957B_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_C3EECE13BEBD95AC7174AE73D9A5957B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_C3EECE13BEBD95AC7174AE73D9A5957B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_C3EECE13BEBD95AC7174AE73D9A5957B" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_C3EECE13BEBD95AC7174AE73D9A5957B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_5EAA1F29086B450E8DF22E9BF14CB4E4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_5EAA1F29086B450E8DF22E9BF14CB4E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_5EAA1F29086B450E8DF22E9BF14CB4E4_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_5EAA1F29086B450E8DF22E9BF14CB4E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_5EAA1F29086B450E8DF22E9BF14CB4E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_5EAA1F29086B450E8DF22E9BF14CB4E4" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_5EAA1F29086B450E8DF22E9BF14CB4E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_E60431B9377B9A488E9D2E2530939BAD_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_E60431B9377B9A488E9D2E2530939BAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_E60431B9377B9A488E9D2E2530939BAD_label_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_E60431B9377B9A488E9D2E2530939BAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_E60431B9377B9A488E9D2E2530939BAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_E60431B9377B9A488E9D2E2530939BAD" xlink:to="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_E60431B9377B9A488E9D2E2530939BAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_947311637BA834AB68B12E253093189C_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_947311637BA834AB68B12E253093189C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_947311637BA834AB68B12E253093189C_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_947311637BA834AB68B12E253093189C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_947311637BA834AB68B12E253093189C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_947311637BA834AB68B12E253093189C" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_947311637BA834AB68B12E253093189C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_8011D080F63E94FF01372E253093B700_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_8011D080F63E94FF01372E253093B700" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_8011D080F63E94FF01372E253093B700_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_8011D080F63E94FF01372E253093B700" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_8011D080F63E94FF01372E253093B700" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8011D080F63E94FF01372E253093B700" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain_8011D080F63E94FF01372E253093B700" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReserveForCashDiscountMember_09510A56CA45DB49B3292E25309375C6_verboseLabel_en-US" xlink:label="lab_us-gaap_ReserveForCashDiscountMember_09510A56CA45DB49B3292E25309375C6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Discounts</link:label>
    <link:label id="lab_us-gaap_ReserveForCashDiscountMember_09510A56CA45DB49B3292E25309375C6_label_en-US" xlink:label="lab_us-gaap_ReserveForCashDiscountMember_09510A56CA45DB49B3292E25309375C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve for Cash Discount [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReserveForCashDiscountMember" xlink:label="loc_us-gaap_ReserveForCashDiscountMember_09510A56CA45DB49B3292E25309375C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReserveForCashDiscountMember_09510A56CA45DB49B3292E25309375C6" xlink:to="lab_us-gaap_ReserveForCashDiscountMember_09510A56CA45DB49B3292E25309375C6" xlink:type="arc" />
    <link:label id="lab_biib_ContractualAdjustmentsMember_EF6E5811B4AE2C27C0602E25309379EE_verboseLabel_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_EF6E5811B4AE2C27C0602E25309379EE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contractual Adjustments</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_EF6E5811B4AE2C27C0602E25309379EE_label_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_EF6E5811B4AE2C27C0602E25309379EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Adjustments [Member]</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_EF6E5811B4AE2C27C0602E25309379EE_documentation_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_EF6E5811B4AE2C27C0602E25309379EE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual adjustments.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_EF6E5811B4AE2C27C0602E25309379EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractualAdjustmentsMember_EF6E5811B4AE2C27C0602E25309379EE" xlink:to="lab_biib_ContractualAdjustmentsMember_EF6E5811B4AE2C27C0602E25309379EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_758964C09BA113A2C30D2E25309388BD_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_758964C09BA113A2C30D2E25309388BD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_758964C09BA113A2C30D2E25309388BD_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_758964C09BA113A2C30D2E25309388BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_758964C09BA113A2C30D2E25309388BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember_758964C09BA113A2C30D2E25309388BD" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember_758964C09BA113A2C30D2E25309388BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_307A1C9A227B211CF60A2E2530935C91_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_307A1C9A227B211CF60A2E2530935C91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_307A1C9A227B211CF60A2E2530935C91_label_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_307A1C9A227B211CF60A2E2530935C91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_307A1C9A227B211CF60A2E2530935C91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_307A1C9A227B211CF60A2E2530935C91" xlink:to="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_307A1C9A227B211CF60A2E2530935C91" xlink:type="arc" />
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_B85CB23882F68CA3C33E2E253093D5B7_verboseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_B85CB23882F68CA3C33E2E253093D5B7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Analysis of the amount of, and change in, reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_B85CB23882F68CA3C33E2E253093D5B7_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_B85CB23882F68CA3C33E2E253093D5B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Abstract]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_B85CB23882F68CA3C33E2E253093D5B7_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_B85CB23882F68CA3C33E2E253093D5B7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Analysis of the amount of, and change in product revenue reserves.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_B85CB23882F68CA3C33E2E253093D5B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_B85CB23882F68CA3C33E2E253093D5B7" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_B85CB23882F68CA3C33E2E253093D5B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_69E7CEE8EDB9BC05A7B32E253093ABF2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_69E7CEE8EDB9BC05A7B32E253093ABF2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance as of December 31, 2014</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_69E7CEE8EDB9BC05A7B32E253093ABF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_69E7CEE8EDB9BC05A7B32E253093ABF2" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_69E7CEE8EDB9BC05A7B32E253093ABF2" xlink:type="arc" />
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_D0CF3AD88EFF1B85CC9E2E253093BF17_verboseLabel_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_D0CF3AD88EFF1B85CC9E2E253093BF17" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current provisions relating to sales in current year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_D0CF3AD88EFF1B85CC9E2E253093BF17_label_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_D0CF3AD88EFF1B85CC9E2E253093BF17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Provisions To Product Revenue Reserves Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_D0CF3AD88EFF1B85CC9E2E253093BF17_documentation_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_D0CF3AD88EFF1B85CC9E2E253093BF17" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current provisions to product revenue reserves relating to sales in current year.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_D0CF3AD88EFF1B85CC9E2E253093BF17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_D0CF3AD88EFF1B85CC9E2E253093BF17" xlink:to="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_D0CF3AD88EFF1B85CC9E2E253093BF17" xlink:type="arc" />
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_85EFC725114DEC1AD30D2E25309388AC_negatedLabel_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_85EFC725114DEC1AD30D2E25309388AC" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Adjustments relating to prior years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_85EFC725114DEC1AD30D2E25309388AC_label_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_85EFC725114DEC1AD30D2E25309388AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Product Revenue Reserves Relating To Sales In Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_85EFC725114DEC1AD30D2E25309388AC_documentation_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_85EFC725114DEC1AD30D2E25309388AC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to product revenue reserves relating to sales in prior years.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_85EFC725114DEC1AD30D2E25309388AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_85EFC725114DEC1AD30D2E25309388AC" xlink:to="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_85EFC725114DEC1AD30D2E25309388AC" xlink:type="arc" />
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_A8A56D465FCD07F73D7F2E253093D955_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_A8A56D465FCD07F73D7F2E253093D955" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/credits relating to sales in current year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_A8A56D465FCD07F73D7F2E253093D955_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_A8A56D465FCD07F73D7F2E253093D955" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_A8A56D465FCD07F73D7F2E253093D955_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_A8A56D465FCD07F73D7F2E253093D955" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to current year.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_A8A56D465FCD07F73D7F2E253093D955" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_A8A56D465FCD07F73D7F2E253093D955" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_A8A56D465FCD07F73D7F2E253093D955" xlink:type="arc" />
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_6D17D82BE78FCE2A06C62E253093A345_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_6D17D82BE78FCE2A06C62E253093A345" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/credits relating to sales in prior years</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_6D17D82BE78FCE2A06C62E253093A345_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_6D17D82BE78FCE2A06C62E253093A345" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_6D17D82BE78FCE2A06C62E253093A345_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_6D17D82BE78FCE2A06C62E253093A345" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to prior year.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_6D17D82BE78FCE2A06C62E253093A345" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_6D17D82BE78FCE2A06C62E253093A345" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_6D17D82BE78FCE2A06C62E253093A345" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_780B3D030560B2D54E502E2530945271_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_780B3D030560B2D54E502E2530945271" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance as of September 30, 2015</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_780B3D030560B2D54E502E2530945271" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_780B3D030560B2D54E502E2530945271" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_780B3D030560B2D54E502E2530945271" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNetAbstract_DE3D8A3D4DC1D7038A99AE73DABB0BD2_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_DE3D8A3D4DC1D7038A99AE73DABB0BD2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_DE3D8A3D4DC1D7038A99AE73DABB0BD2_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_DE3D8A3D4DC1D7038A99AE73DABB0BD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_DE3D8A3D4DC1D7038A99AE73DABB0BD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract_DE3D8A3D4DC1D7038A99AE73DABB0BD2" xlink:to="lab_us-gaap_InventoryNetAbstract_DE3D8A3D4DC1D7038A99AE73DABB0BD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_C4F7B5CA55C21E159AAFAE73DABBE7F7_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_C4F7B5CA55C21E159AAFAE73DABBE7F7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_C4F7B5CA55C21E159AAFAE73DABBE7F7_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_C4F7B5CA55C21E159AAFAE73DABBE7F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_C4F7B5CA55C21E159AAFAE73DABBE7F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves_C4F7B5CA55C21E159AAFAE73DABBE7F7" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves_C4F7B5CA55C21E159AAFAE73DABBE7F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_95D576CE08FCD77FF03EAE73DABB4178_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_95D576CE08FCD77FF03EAE73DABB4178" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_95D576CE08FCD77FF03EAE73DABB4178_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_95D576CE08FCD77FF03EAE73DABB4178" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_95D576CE08FCD77FF03EAE73DABB4178" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves_95D576CE08FCD77FF03EAE73DABB4178" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves_95D576CE08FCD77FF03EAE73DABB4178" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_B2A146856E067EB5B621AE73DABB7DCC_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_B2A146856E067EB5B621AE73DABB7DCC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_B2A146856E067EB5B621AE73DABB7DCC_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_B2A146856E067EB5B621AE73DABB7DCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_B2A146856E067EB5B621AE73DABB7DCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_B2A146856E067EB5B621AE73DABB7DCC" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_B2A146856E067EB5B621AE73DABB7DCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_C201385C3B69265998D3AE73DABBB3B9_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_C201385C3B69265998D3AE73DABBB3B9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_C201385C3B69265998D3AE73DABBB3B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_C201385C3B69265998D3AE73DABBB3B9" xlink:to="lab_us-gaap_InventoryNet_C201385C3B69265998D3AE73DABBB3B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E5771B9D160DF86C507CAE73DADFB42B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E5771B9D160DF86C507CAE73DADFB42B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E5771B9D160DF86C507CAE73DADFB42B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E5771B9D160DF86C507CAE73DADFB42B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E5771B9D160DF86C507CAE73DADFB42B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E5771B9D160DF86C507CAE73DADFB42B" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E5771B9D160DF86C507CAE73DADFB42B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_F4FA66DA04C3D442CDFDAE73DADF8D8F_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_F4FA66DA04C3D442CDFDAE73DADF8D8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_F4FA66DA04C3D442CDFDAE73DADF8D8F_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_F4FA66DA04C3D442CDFDAE73DADF8D8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_F4FA66DA04C3D442CDFDAE73DADF8D8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_F4FA66DA04C3D442CDFDAE73DADF8D8F" xlink:to="lab_us-gaap_PlanNameAxis_F4FA66DA04C3D442CDFDAE73DADF8D8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_97B771C3F71F7C020588AE73DADF34A8_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_97B771C3F71F7C020588AE73DADF34A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_97B771C3F71F7C020588AE73DADF34A8_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_97B771C3F71F7C020588AE73DADF34A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_97B771C3F71F7C020588AE73DADF34A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_97B771C3F71F7C020588AE73DADF34A8" xlink:to="lab_us-gaap_PlanNameDomain_97B771C3F71F7C020588AE73DADF34A8" xlink:type="arc" />
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_A66E609D3B5C03138D63AE73DADF43A7_terseLabel_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_A66E609D3B5C03138D63AE73DADF43A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash settled performance shares</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_A66E609D3B5C03138D63AE73DADF43A7_label_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_A66E609D3B5C03138D63AE73DADF43A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_A66E609D3B5C03138D63AE73DADF43A7_documentation_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_A66E609D3B5C03138D63AE73DADF43A7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_A66E609D3B5C03138D63AE73DADF43A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashSettledPerformanceSharesMember_A66E609D3B5C03138D63AE73DADF43A7" xlink:to="lab_biib_CashSettledPerformanceSharesMember_A66E609D3B5C03138D63AE73DADF43A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PerformanceSharesMember_361A823BF2B5732B2E6EAE73DADFA299_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_361A823BF2B5732B2E6EAE73DADFA299" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_361A823BF2B5732B2E6EAE73DADFA299_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_361A823BF2B5732B2E6EAE73DADFA299" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_361A823BF2B5732B2E6EAE73DADFA299" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember_361A823BF2B5732B2E6EAE73DADFA299" xlink:to="lab_us-gaap_PerformanceSharesMember_361A823BF2B5732B2E6EAE73DADFA299" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E8D76486BEC6EFF715BCAE73DADFEF6C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E8D76486BEC6EFF715BCAE73DADFEF6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E8D76486BEC6EFF715BCAE73DADFEF6C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E8D76486BEC6EFF715BCAE73DADFEF6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E8D76486BEC6EFF715BCAE73DADFEF6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E8D76486BEC6EFF715BCAE73DADFEF6C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E8D76486BEC6EFF715BCAE73DADFEF6C" xlink:type="arc" />
    <link:label id="lab_biib_ScheduleOfStockOptionGrantsAbstract_2B608E2213BDBC28C519AE73DADFC947_verboseLabel_en-US" xlink:label="lab_biib_ScheduleOfStockOptionGrantsAbstract_2B608E2213BDBC28C519AE73DADFC947" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of stock option grants</link:label>
    <link:label id="lab_biib_ScheduleOfStockOptionGrantsAbstract_2B608E2213BDBC28C519AE73DADFC947_label_en-US" xlink:label="lab_biib_ScheduleOfStockOptionGrantsAbstract_2B608E2213BDBC28C519AE73DADFC947" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Stock Option Grants [Abstract]</link:label>
    <link:label id="lab_biib_ScheduleOfStockOptionGrantsAbstract_2B608E2213BDBC28C519AE73DADFC947_documentation_en-US" xlink:label="lab_biib_ScheduleOfStockOptionGrantsAbstract_2B608E2213BDBC28C519AE73DADFC947" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of stock option grants.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_ScheduleOfStockOptionGrantsAbstract" xlink:label="loc_biib_ScheduleOfStockOptionGrantsAbstract_2B608E2213BDBC28C519AE73DADFC947" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ScheduleOfStockOptionGrantsAbstract_2B608E2213BDBC28C519AE73DADFC947" xlink:to="lab_biib_ScheduleOfStockOptionGrantsAbstract_2B608E2213BDBC28C519AE73DADFC947" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_747858BD316986D444A4AE73DADF10C8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_747858BD316986D444A4AE73DADF10C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_747858BD316986D444A4AE73DADF10C8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_747858BD316986D444A4AE73DADF10C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_747858BD316986D444A4AE73DADF10C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_747858BD316986D444A4AE73DADF10C8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_747858BD316986D444A4AE73DADF10C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4BA5101F19F1C83331A3AE73D959EBFA_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4BA5101F19F1C83331A3AE73D959EBFA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4BA5101F19F1C83331A3AE73D959EBFA_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4BA5101F19F1C83331A3AE73D959EBFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4BA5101F19F1C83331A3AE73D959EBFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4BA5101F19F1C83331A3AE73D959EBFA" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4BA5101F19F1C83331A3AE73D959EBFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDateDescription_ADDE165AB68F07DCDBBCAE73DAC2F625_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateDescription_ADDE165AB68F07DCDBBCAE73DAC2F625" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Original maturities of commercial paper and short-term debt securities</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDateDescription_ADDE165AB68F07DCDBBCAE73DAC2F625_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateDescription_ADDE165AB68F07DCDBBCAE73DAC2F625" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Maturity Date, Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_ADDE165AB68F07DCDBBCAE73DAC2F625" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDateDescription_ADDE165AB68F07DCDBBCAE73DAC2F625" xlink:to="lab_us-gaap_DebtInstrumentMaturityDateDescription_ADDE165AB68F07DCDBBCAE73DAC2F625" xlink:type="arc" />
    <link:label id="lab_biib_Overnightreverserepurchaseagreementspercentoftotalassets_3E9E1C5C93AEDF6A9EE7AE73DAC2CD9D_terseLabel_en-US" xlink:label="lab_biib_Overnightreverserepurchaseagreementspercentoftotalassets_3E9E1C5C93AEDF6A9EE7AE73DAC2CD9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Overnight reverse repurchase agreements, percent of total assets</link:label>
    <link:label id="lab_biib_Overnightreverserepurchaseagreementspercentoftotalassets_3E9E1C5C93AEDF6A9EE7AE73DAC2CD9D_label_en-US" xlink:label="lab_biib_Overnightreverserepurchaseagreementspercentoftotalassets_3E9E1C5C93AEDF6A9EE7AE73DAC2CD9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Overnight reverse repurchase agreements, percent of total assets</link:label>
    <link:label id="lab_biib_Overnightreverserepurchaseagreementspercentoftotalassets_3E9E1C5C93AEDF6A9EE7AE73DAC2CD9D_documentation_en-US" xlink:label="lab_biib_Overnightreverserepurchaseagreementspercentoftotalassets_3E9E1C5C93AEDF6A9EE7AE73DAC2CD9D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Overnight reverse repurchase agreements, percent of total assets</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_Overnightreverserepurchaseagreementspercentoftotalassets" xlink:label="loc_biib_Overnightreverserepurchaseagreementspercentoftotalassets_3E9E1C5C93AEDF6A9EE7AE73DAC2CD9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Overnightreverserepurchaseagreementspercentoftotalassets_3E9E1C5C93AEDF6A9EE7AE73DAC2CD9D" xlink:to="lab_biib_Overnightreverserepurchaseagreementspercentoftotalassets_3E9E1C5C93AEDF6A9EE7AE73DAC2CD9D" xlink:type="arc" />
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_EE116E00A72ED8AEF6EEAE73DAC2BA9A_verboseLabel_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_EE116E00A72ED8AEF6EEAE73DAC2BA9A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average maturity of marketable securities, months</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_EE116E00A72ED8AEF6EEAE73DAC2BA9A_label_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_EE116E00A72ED8AEF6EEAE73DAC2BA9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average Maturity Of Marketable Securities</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_EE116E00A72ED8AEF6EEAE73DAC2BA9A_documentation_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_EE116E00A72ED8AEF6EEAE73DAC2BA9A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average remaining time to maturity of marketable debt securities, available-for-sale securities.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_AverageMaturityOfMarketableSecurities" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_EE116E00A72ED8AEF6EEAE73DAC2BA9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageMaturityOfMarketableSecurities_EE116E00A72ED8AEF6EEAE73DAC2BA9A" xlink:to="lab_biib_AverageMaturityOfMarketableSecurities_EE116E00A72ED8AEF6EEAE73DAC2BA9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_B235768672D7FF49B019AE73D95DD5F5_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_B235768672D7FF49B019AE73D95DD5F5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_B235768672D7FF49B019AE73D95DD5F5_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_B235768672D7FF49B019AE73D95DD5F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_B235768672D7FF49B019AE73D95DD5F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_B235768672D7FF49B019AE73D95DD5F5" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_B235768672D7FF49B019AE73D95DD5F5" xlink:type="arc" />
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_5029A6EA577A15AAFE8BAE73DAA0C0F0_verboseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_5029A6EA577A15AAFE8BAE73DAA0C0F0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Analysis of the changes in reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_5029A6EA577A15AAFE8BAE73DAA0C0F0_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_5029A6EA577A15AAFE8BAE73DAA0C0F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_5029A6EA577A15AAFE8BAE73DAA0C0F0_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_5029A6EA577A15AAFE8BAE73DAA0C0F0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Analysis of amount of and change in product revenue reserves.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_5029A6EA577A15AAFE8BAE73DAA0C0F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_5029A6EA577A15AAFE8BAE73DAA0C0F0" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_5029A6EA577A15AAFE8BAE73DAA0C0F0" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_DA3EDDE447F2BDC55529AE73DAA02646_verboseLabel_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_DA3EDDE447F2BDC55529AE73DAA02646" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total reserves included in condensed consolidated balance sheets</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_DA3EDDE447F2BDC55529AE73DAA02646_label_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_DA3EDDE447F2BDC55529AE73DAA02646" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_DA3EDDE447F2BDC55529AE73DAA02646_documentation_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_DA3EDDE447F2BDC55529AE73DAA02646" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of total product revenue reserves included in consolidated balance sheets.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_DA3EDDE447F2BDC55529AE73DAA02646" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_DA3EDDE447F2BDC55529AE73DAA02646" xlink:to="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_DA3EDDE447F2BDC55529AE73DAA02646" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterestTable_4B2EA797A70E840641DD875A3D37E63D_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable_4B2EA797A70E840641DD875A3D37E63D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_4B2EA797A70E840641DD875A3D37E63D_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable_4B2EA797A70E840641DD875A3D37E63D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="loc_us-gaap_MinorityInterestTable_4B2EA797A70E840641DD875A3D37E63D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable_4B2EA797A70E840641DD875A3D37E63D" xlink:to="lab_us-gaap_MinorityInterestTable_4B2EA797A70E840641DD875A3D37E63D" xlink:type="arc" />
    <link:label id="lab_biib_NeurimmuneMember_92D63231C9308DF0800F875A3D37BB74_terseLabel_en-US" xlink:label="lab_biib_NeurimmuneMember_92D63231C9308DF0800F875A3D37BB74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Neurimmune</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_92D63231C9308DF0800F875A3D37BB74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NeurimmuneMember_92D63231C9308DF0800F875A3D37BB74" xlink:to="lab_biib_NeurimmuneMember_92D63231C9308DF0800F875A3D37BB74" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterestLineItems_C40F61420DE540DBD7BD875A3D37AC18_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems_C40F61420DE540DBD7BD875A3D37AC18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_C40F61420DE540DBD7BD875A3D37AC18_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems_C40F61420DE540DBD7BD875A3D37AC18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="loc_us-gaap_MinorityInterestLineItems_C40F61420DE540DBD7BD875A3D37AC18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems_C40F61420DE540DBD7BD875A3D37AC18" xlink:to="lab_us-gaap_MinorityInterestLineItems_C40F61420DE540DBD7BD875A3D37AC18" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_66D3A98DBC6B29FF514B875A3D379699_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_66D3A98DBC6B29FF514B875A3D379699" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock shares repurchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_66D3A98DBC6B29FF514B875A3D379699_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_66D3A98DBC6B29FF514B875A3D379699" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_66D3A98DBC6B29FF514B875A3D379699" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired_66D3A98DBC6B29FF514B875A3D379699" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired_66D3A98DBC6B29FF514B875A3D379699" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_12C172F3CEBBE24ABE9C875A3D37EA66_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_12C172F3CEBBE24ABE9C875A3D37EA66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase of treasury stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_12C172F3CEBBE24ABE9C875A3D37EA66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_12C172F3CEBBE24ABE9C875A3D37EA66" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_12C172F3CEBBE24ABE9C875A3D37EA66" xlink:type="arc" />
    <link:label id="lab_biib_EquityTextualAbstract_BE16C65CB2B12D6C0B9E875A3D38CC5A_verboseLabel_en-US" xlink:label="lab_biib_EquityTextualAbstract_BE16C65CB2B12D6C0B9E875A3D38CC5A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_EquityTextualAbstract_BE16C65CB2B12D6C0B9E875A3D38CC5A_label_en-US" xlink:label="lab_biib_EquityTextualAbstract_BE16C65CB2B12D6C0B9E875A3D38CC5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_EquityTextualAbstract_BE16C65CB2B12D6C0B9E875A3D38CC5A_documentation_en-US" xlink:label="lab_biib_EquityTextualAbstract_BE16C65CB2B12D6C0B9E875A3D38CC5A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_EquityTextualAbstract" xlink:label="loc_biib_EquityTextualAbstract_BE16C65CB2B12D6C0B9E875A3D38CC5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityTextualAbstract_BE16C65CB2B12D6C0B9E875A3D38CC5A" xlink:to="lab_biib_EquityTextualAbstract_BE16C65CB2B12D6C0B9E875A3D38CC5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease_AE753208DF47CE0CCC99875A3D38215C_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease_AE753208DF47CE0CCC99875A3D38215C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity increase during the period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease_AE753208DF47CE0CCC99875A3D38215C_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease_AE753208DF47CE0CCC99875A3D38215C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease_AE753208DF47CE0CCC99875A3D38215C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease_AE753208DF47CE0CCC99875A3D38215C" xlink:to="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease_AE753208DF47CE0CCC99875A3D38215C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_B1A12F1CC38F1C434351875A3D38CAFC_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_B1A12F1CC38F1C434351875A3D38CAFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to additional paid in capital, share-based compensation and exercise of stock options</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_B1A12F1CC38F1C434351875A3D38CAFC_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_B1A12F1CC38F1C434351875A3D38CAFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation and Exercise of Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_B1A12F1CC38F1C434351875A3D38CAFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_B1A12F1CC38F1C434351875A3D38CAFC" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_B1A12F1CC38F1C434351875A3D38CAFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_FFA80AA01758C28FB0B7875A3D3844DD_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_FFA80AA01758C28FB0B7875A3D3844DD" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net current period other comprehensive income loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_FFA80AA01758C28FB0B7875A3D3844DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_FFA80AA01758C28FB0B7875A3D3844DD" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_FFA80AA01758C28FB0B7875A3D3844DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_9FB8D99CF7A02DFA1883875A3D38CF65_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_9FB8D99CF7A02DFA1883875A3D38CF65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock value authorized for repurchase</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_9FB8D99CF7A02DFA1883875A3D38CF65_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_9FB8D99CF7A02DFA1883875A3D38CF65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_9FB8D99CF7A02DFA1883875A3D38CF65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_9FB8D99CF7A02DFA1883875A3D38CF65" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_9FB8D99CF7A02DFA1883875A3D38CF65" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_1E57862DFCD42942374E875A3D38A8EF_verboseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_1E57862DFCD42942374E875A3D38A8EF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock shares authorized remaining or repurchase</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_1E57862DFCD42942374E875A3D38A8EF_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_1E57862DFCD42942374E875A3D38A8EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_1E57862DFCD42942374E875A3D38A8EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_1E57862DFCD42942374E875A3D38A8EF" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_1E57862DFCD42942374E875A3D38A8EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_93E8CCA0DAAD5ADE34AD875A3D381EBA_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_93E8CCA0DAAD5ADE34AD875A3D381EBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_93E8CCA0DAAD5ADE34AD875A3D381EBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_93E8CCA0DAAD5ADE34AD875A3D381EBA" xlink:to="lab_us-gaap_AdditionalPaidInCapital_93E8CCA0DAAD5ADE34AD875A3D381EBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_A9F839C62C0B8257C6F4AE73D9519FCF_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_A9F839C62C0B8257C6F4AE73D9519FCF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_A9F839C62C0B8257C6F4AE73D9519FCF_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_A9F839C62C0B8257C6F4AE73D9519FCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_A9F839C62C0B8257C6F4AE73D9519FCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_A9F839C62C0B8257C6F4AE73D9519FCF" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_A9F839C62C0B8257C6F4AE73D9519FCF" xlink:type="arc" />
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_B6BAEE2A2E24B7DC9AD1AE73DB6746F8_terseLabel_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_B6BAEE2A2E24B7DC9AD1AE73DB6746F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_B6BAEE2A2E24B7DC9AD1AE73DB6746F8_label_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_B6BAEE2A2E24B7DC9AD1AE73DB6746F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_B6BAEE2A2E24B7DC9AD1AE73DB6746F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_B6BAEE2A2E24B7DC9AD1AE73DB6746F8" xlink:to="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_B6BAEE2A2E24B7DC9AD1AE73DB6746F8" xlink:type="arc" />
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_E565765DDBCFAABB2F9FAE73DB3D7963_verboseLabel_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_E565765DDBCFAABB2F9FAE73DB3D7963" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_E565765DDBCFAABB2F9FAE73DB3D7963_label_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_E565765DDBCFAABB2F9FAE73DB3D7963" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_E565765DDBCFAABB2F9FAE73DB3D7963_documentation_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_E565765DDBCFAABB2F9FAE73DB3D7963" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_E565765DDBCFAABB2F9FAE73DB3D7963" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeStockPurchasePlanMember_E565765DDBCFAABB2F9FAE73DB3D7963" xlink:to="lab_biib_EmployeeStockPurchasePlanMember_E565765DDBCFAABB2F9FAE73DB3D7963" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18F9D0853DE50D6225CFAE73DB3D606A_verboseLabel_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18F9D0853DE50D6225CFAE73DB3D606A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of share based compensation expense associated with different programs</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18F9D0853DE50D6225CFAE73DB3D606A_label_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18F9D0853DE50D6225CFAE73DB3D606A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18F9D0853DE50D6225CFAE73DB3D606A_documentation_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18F9D0853DE50D6225CFAE73DB3D606A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with different programs.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18F9D0853DE50D6225CFAE73DB3D606A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18F9D0853DE50D6225CFAE73DB3D606A" xlink:to="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18F9D0853DE50D6225CFAE73DB3D606A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_2CFD69F50BFF9650A936AE73DB3DDD80_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_2CFD69F50BFF9650A936AE73DB3DDD80" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_2CFD69F50BFF9650A936AE73DB3DDD80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_2CFD69F50BFF9650A936AE73DB3DDD80" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_2CFD69F50BFF9650A936AE73DB3DDD80" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_DEE14ED176B916331CB1AE73DB1B4A21_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_DEE14ED176B916331CB1AE73DB1B4A21" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_DEE14ED176B916331CB1AE73DB1B4A21_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_DEE14ED176B916331CB1AE73DB1B4A21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_DEE14ED176B916331CB1AE73DB1B4A21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_DEE14ED176B916331CB1AE73DB1B4A21" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_DEE14ED176B916331CB1AE73DB1B4A21" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_12CF505977340C3B40A3AE73D963055F_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_12CF505977340C3B40A3AE73D963055F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Contractual Maturities: Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_12CF505977340C3B40A3AE73D963055F_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_12CF505977340C3B40A3AE73D963055F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_12CF505977340C3B40A3AE73D963055F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_12CF505977340C3B40A3AE73D963055F" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_12CF505977340C3B40A3AE73D963055F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6F90F0C0B71F0F9875E8AE73D963F6AC_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6F90F0C0B71F0F9875E8AE73D963F6AC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6F90F0C0B71F0F9875E8AE73D963F6AC_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6F90F0C0B71F0F9875E8AE73D963F6AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6F90F0C0B71F0F9875E8AE73D963F6AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6F90F0C0B71F0F9875E8AE73D963F6AC" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6F90F0C0B71F0F9875E8AE73D963F6AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_9FD670ED9577765F4378AE73D96307F0_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_9FD670ED9577765F4378AE73D96307F0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_9FD670ED9577765F4378AE73D96307F0_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_9FD670ED9577765F4378AE73D96307F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Next Twelve Months, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_9FD670ED9577765F4378AE73D96307F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_9FD670ED9577765F4378AE73D96307F0" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_9FD670ED9577765F4378AE73D96307F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_A68B959CBEB6B04A12BDAE73D963A48C_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_A68B959CBEB6B04A12BDAE73D963A48C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_A68B959CBEB6B04A12BDAE73D963A48C_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_A68B959CBEB6B04A12BDAE73D963A48C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_A68B959CBEB6B04A12BDAE73D963A48C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_A68B959CBEB6B04A12BDAE73D963A48C" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_A68B959CBEB6B04A12BDAE73D963A48C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_8AB419B82678FFFF1F87AE73D964EECE_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_8AB419B82678FFFF1F87AE73D964EECE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_8AB419B82678FFFF1F87AE73D964EECE_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_8AB419B82678FFFF1F87AE73D964EECE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Year Two Through Five, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_8AB419B82678FFFF1F87AE73D964EECE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_8AB419B82678FFFF1F87AE73D964EECE" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_8AB419B82678FFFF1F87AE73D964EECE" xlink:type="arc" />
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_43559E1D95092B2B1AE9AE73D964F537_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_43559E1D95092B2B1AE9AE73D964F537" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after five years, estimated fair value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_43559E1D95092B2B1AE9AE73D964F537_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_43559E1D95092B2B1AE9AE73D964F537" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Fair Value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_43559E1D95092B2B1AE9AE73D964F537_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_43559E1D95092B2B1AE9AE73D964F537" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_43559E1D95092B2B1AE9AE73D964F537" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_43559E1D95092B2B1AE9AE73D964F537" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_43559E1D95092B2B1AE9AE73D964F537" xlink:type="arc" />
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_1BD18E70E711FD5C2FA5AE73D96419B7_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_1BD18E70E711FD5C2FA5AE73D96419B7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after five years, amortized cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_1BD18E70E711FD5C2FA5AE73D96419B7_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_1BD18E70E711FD5C2FA5AE73D96419B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Amortized Cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_1BD18E70E711FD5C2FA5AE73D96419B7_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_1BD18E70E711FD5C2FA5AE73D96419B7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_1BD18E70E711FD5C2FA5AE73D96419B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_1BD18E70E711FD5C2FA5AE73D96419B7" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_1BD18E70E711FD5C2FA5AE73D96419B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_480A186F616EF96CA261AE73D9642B43_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_480A186F616EF96CA261AE73D9642B43" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total available-for-sale securities, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_480A186F616EF96CA261AE73D9642B43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_480A186F616EF96CA261AE73D9642B43" xlink:to="lab_us-gaap_AvailableForSaleSecurities_480A186F616EF96CA261AE73D9642B43" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D315C8AD079670AE7D3AAE73D9645160_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D315C8AD079670AE7D3AAE73D9645160" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total available-for-sale securities, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D315C8AD079670AE7D3AAE73D9645160_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D315C8AD079670AE7D3AAE73D9645160" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D315C8AD079670AE7D3AAE73D9645160" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D315C8AD079670AE7D3AAE73D9645160" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D315C8AD079670AE7D3AAE73D9645160" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_685936B82FE48BE361F2AE73D94F825C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_685936B82FE48BE361F2AE73D94F825C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_685936B82FE48BE361F2AE73D94F825C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_685936B82FE48BE361F2AE73D94F825C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_685936B82FE48BE361F2AE73D94F825C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_685936B82FE48BE361F2AE73D94F825C" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_685936B82FE48BE361F2AE73D94F825C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_5365D2891DE42591E72CAE73D94F32F2_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_5365D2891DE42591E72CAE73D94F32F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_5365D2891DE42591E72CAE73D94F32F2_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_5365D2891DE42591E72CAE73D94F32F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_5365D2891DE42591E72CAE73D94F32F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_5365D2891DE42591E72CAE73D94F32F2" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_5365D2891DE42591E72CAE73D94F32F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentTable_4C01FBFF5C55DDEB033FAE73DA92FF86_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentTable_4C01FBFF5C55DDEB033FAE73DA92FF86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Purchase Commitment [Table]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentTable_4C01FBFF5C55DDEB033FAE73DA92FF86_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentTable_4C01FBFF5C55DDEB033FAE73DA92FF86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Purchase Commitment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_4C01FBFF5C55DDEB033FAE73DA92FF86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_4C01FBFF5C55DDEB033FAE73DA92FF86" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentTable_4C01FBFF5C55DDEB033FAE73DA92FF86" xlink:type="arc" />
    <link:label id="lab_country_CH_57E9FB756D275CEEC7E3AE73DA927ECA_terseLabel_en-US" xlink:label="lab_country_CH_57E9FB756D275CEEC7E3AE73DA927ECA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Switzerland</link:label>
    <link:label id="lab_country_CH_57E9FB756D275CEEC7E3AE73DA927ECA_label_en-US" xlink:label="lab_country_CH_57E9FB756D275CEEC7E3AE73DA927ECA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SWITZERLAND</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_CH" xlink:label="loc_country_CH_57E9FB756D275CEEC7E3AE73DA927ECA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CH_57E9FB756D275CEEC7E3AE73DA927ECA" xlink:to="lab_country_CH_57E9FB756D275CEEC7E3AE73DA927ECA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentLineItems_0B7581993C9B0E2EA9F3AE73DA92C287_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentLineItems_0B7581993C9B0E2EA9F3AE73DA92C287" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Purchase Commitment [Line Items]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentLineItems_0B7581993C9B0E2EA9F3AE73DA92C287_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentLineItems_0B7581993C9B0E2EA9F3AE73DA92C287" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Purchase Commitment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0B7581993C9B0E2EA9F3AE73DA92C287" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0B7581993C9B0E2EA9F3AE73DA92C287" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentLineItems_0B7581993C9B0E2EA9F3AE73DA92C287" xlink:type="arc" />
    <link:label id="lab_us-gaap_Land_A3900C5EBEFDDC62286FAE73DA928955_terseLabel_en-US" xlink:label="lab_us-gaap_Land_A3900C5EBEFDDC62286FAE73DA928955" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_Land_A3900C5EBEFDDC62286FAE73DA928955_label_en-US" xlink:label="lab_us-gaap_Land_A3900C5EBEFDDC62286FAE73DA928955" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Land" xlink:label="loc_us-gaap_Land_A3900C5EBEFDDC62286FAE73DA928955" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land_A3900C5EBEFDDC62286FAE73DA928955" xlink:to="lab_us-gaap_Land_A3900C5EBEFDDC62286FAE73DA928955" xlink:type="arc" />
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_277B7950268FF17F8DCBAE73D94DC495_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_277B7950268FF17F8DCBAE73D94DC495" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_277B7950268FF17F8DCBAE73D94DC495_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_277B7950268FF17F8DCBAE73D94DC495" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_277B7950268FF17F8DCBAE73D94DC495" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock_277B7950268FF17F8DCBAE73D94DC495" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock_277B7950268FF17F8DCBAE73D94DC495" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_B9D4C431A33F6D8EB26BAE73DA8459A0_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_B9D4C431A33F6D8EB26BAE73DA8459A0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_B9D4C431A33F6D8EB26BAE73DA8459A0_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_B9D4C431A33F6D8EB26BAE73DA8459A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_B9D4C431A33F6D8EB26BAE73DA8459A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_B9D4C431A33F6D8EB26BAE73DA8459A0" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_B9D4C431A33F6D8EB26BAE73DA8459A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_282DB7A17BFE387C8626AE73D941B3FA_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_282DB7A17BFE387C8626AE73D941B3FA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_282DB7A17BFE387C8626AE73D941B3FA_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_282DB7A17BFE387C8626AE73D941B3FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_282DB7A17BFE387C8626AE73D941B3FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_282DB7A17BFE387C8626AE73D941B3FA" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_282DB7A17BFE387C8626AE73D941B3FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_9D7E065A1A87703155C0AE73DB62AB3C_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_9D7E065A1A87703155C0AE73DB62AB3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities and sales</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_9D7E065A1A87703155C0AE73DB62AB3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_9D7E065A1A87703155C0AE73DB62AB3C" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_9D7E065A1A87703155C0AE73DB62AB3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_1BA1386C0A3C9A14AA41AE73DB62EBA3_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_1BA1386C0A3C9A14AA41AE73DB62EBA3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Realized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_1BA1386C0A3C9A14AA41AE73DB62EBA3_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_1BA1386C0A3C9A14AA41AE73DB62EBA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Gross Realized Gains</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_1BA1386C0A3C9A14AA41AE73DB62EBA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_1BA1386C0A3C9A14AA41AE73DB62EBA3" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_1BA1386C0A3C9A14AA41AE73DB62EBA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_729DC1E4182EF726C105AE73DB626A08_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_729DC1E4182EF726C105AE73DB626A08" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Realized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_729DC1E4182EF726C105AE73DB626A08_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_729DC1E4182EF726C105AE73DB626A08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Gross Realized Losses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_729DC1E4182EF726C105AE73DB626A08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_729DC1E4182EF726C105AE73DB626A08" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_729DC1E4182EF726C105AE73DB626A08" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6ADABC5987D621C99AB4AE73D93EE52A_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6ADABC5987D621C99AB4AE73D93EE52A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6ADABC5987D621C99AB4AE73D93EE52A_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6ADABC5987D621C99AB4AE73D93EE52A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6ADABC5987D621C99AB4AE73D93EE52A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6ADABC5987D621C99AB4AE73D93EE52A" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6ADABC5987D621C99AB4AE73D93EE52A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_889A5721E2BA0EF631CBAE73D93FD617_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_889A5721E2BA0EF631CBAE73D93FD617" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_889A5721E2BA0EF631CBAE73D93FD617_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_889A5721E2BA0EF631CBAE73D93FD617" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_889A5721E2BA0EF631CBAE73D93FD617" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_889A5721E2BA0EF631CBAE73D93FD617" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_889A5721E2BA0EF631CBAE73D93FD617" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTable_F4AAA2673C4D7862CDF78AB77622B70E_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_F4AAA2673C4D7862CDF78AB77622B70E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_F4AAA2673C4D7862CDF78AB77622B70E_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_F4AAA2673C4D7862CDF78AB77622B70E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_F4AAA2673C4D7862CDF78AB77622B70E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_F4AAA2673C4D7862CDF78AB77622B70E" xlink:to="lab_us-gaap_SubsequentEventTable_F4AAA2673C4D7862CDF78AB77622B70E" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_9F645CE026CC1A303A498AB77623A2D3_terseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_9F645CE026CC1A303A498AB77623A2D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_9F645CE026CC1A303A498AB77623A2D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_9F645CE026CC1A303A498AB77623A2D3" xlink:to="lab_us-gaap_MinimumMember_9F645CE026CC1A303A498AB77623A2D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_5CA87F10342FA59300878AB77623DD68_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_5CA87F10342FA59300878AB77623DD68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_5CA87F10342FA59300878AB77623DD68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_5CA87F10342FA59300878AB77623DD68" xlink:to="lab_us-gaap_MaximumMember_5CA87F10342FA59300878AB77623DD68" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_221C48C7B0785339C3078AB776230BC6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_221C48C7B0785339C3078AB776230BC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_221C48C7B0785339C3078AB776230BC6_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_221C48C7B0785339C3078AB776230BC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_221C48C7B0785339C3078AB776230BC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_221C48C7B0785339C3078AB776230BC6" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_221C48C7B0785339C3078AB776230BC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_AF04598060F0EC0827958AB77623F40F_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_AF04598060F0EC0827958AB77623F40F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_AF04598060F0EC0827958AB77623F40F_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_AF04598060F0EC0827958AB77623F40F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_AF04598060F0EC0827958AB77623F40F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_AF04598060F0EC0827958AB77623F40F" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_AF04598060F0EC0827958AB77623F40F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_92244E1920C8B1FCD6B48AB776232DE2_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_92244E1920C8B1FCD6B48AB776232DE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_92244E1920C8B1FCD6B48AB776232DE2_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_92244E1920C8B1FCD6B48AB776232DE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_92244E1920C8B1FCD6B48AB776232DE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_92244E1920C8B1FCD6B48AB776232DE2" xlink:to="lab_us-gaap_SubsequentEventMember_92244E1920C8B1FCD6B48AB776232DE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventLineItems_E7078D41B59EE3DB36348AB77623365D_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_E7078D41B59EE3DB36348AB77623365D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_E7078D41B59EE3DB36348AB77623365D_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_E7078D41B59EE3DB36348AB77623365D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_E7078D41B59EE3DB36348AB77623365D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_E7078D41B59EE3DB36348AB77623365D" xlink:to="lab_us-gaap_SubsequentEventLineItems_E7078D41B59EE3DB36348AB77623365D" xlink:type="arc" />
    <link:label id="lab_biib_Workforcereductionpercentage_AE3C65828B5B190475EA8AB776230359_terseLabel_en-US" xlink:label="lab_biib_Workforcereductionpercentage_AE3C65828B5B190475EA8AB776230359" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Workforce reduction percentage</link:label>
    <link:label id="lab_biib_Workforcereductionpercentage_AE3C65828B5B190475EA8AB776230359_label_en-US" xlink:label="lab_biib_Workforcereductionpercentage_AE3C65828B5B190475EA8AB776230359" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Workforce reduction percentage</link:label>
    <link:label id="lab_biib_Workforcereductionpercentage_AE3C65828B5B190475EA8AB776230359_documentation_en-US" xlink:label="lab_biib_Workforcereductionpercentage_AE3C65828B5B190475EA8AB776230359" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Workforce reduction percentage</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_Workforcereductionpercentage" xlink:label="loc_biib_Workforcereductionpercentage_AE3C65828B5B190475EA8AB776230359" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Workforcereductionpercentage_AE3C65828B5B190475EA8AB776230359" xlink:to="lab_biib_Workforcereductionpercentage_AE3C65828B5B190475EA8AB776230359" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_367A46A44E559142ABDB8AB776233036_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_367A46A44E559142ABDB8AB776233036" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_367A46A44E559142ABDB8AB776233036_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_367A46A44E559142ABDB8AB776233036" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_367A46A44E559142ABDB8AB776233036" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_367A46A44E559142ABDB8AB776233036" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_367A46A44E559142ABDB8AB776233036" xlink:type="arc" />
    <link:label id="lab_biib_RestructuringandRelatedCostExpectedCashPayments_4927C426B50D2099D7BA8AB77623E005_terseLabel_en-US" xlink:label="lab_biib_RestructuringandRelatedCostExpectedCashPayments_4927C426B50D2099D7BA8AB77623E005" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected cash payments</link:label>
    <link:label id="lab_biib_RestructuringandRelatedCostExpectedCashPayments_4927C426B50D2099D7BA8AB77623E005_label_en-US" xlink:label="lab_biib_RestructuringandRelatedCostExpectedCashPayments_4927C426B50D2099D7BA8AB77623E005" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cash Payments</link:label>
    <link:label id="lab_biib_RestructuringandRelatedCostExpectedCashPayments_4927C426B50D2099D7BA8AB77623E005_documentation_en-US" xlink:label="lab_biib_RestructuringandRelatedCostExpectedCashPayments_4927C426B50D2099D7BA8AB77623E005" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cash Payments</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_RestructuringandRelatedCostExpectedCashPayments" xlink:label="loc_biib_RestructuringandRelatedCostExpectedCashPayments_4927C426B50D2099D7BA8AB77623E005" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RestructuringandRelatedCostExpectedCashPayments_4927C426B50D2099D7BA8AB77623E005" xlink:to="lab_biib_RestructuringandRelatedCostExpectedCashPayments_4927C426B50D2099D7BA8AB77623E005" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_189915F009BCD22BE154AE73DB196C01_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_189915F009BCD22BE154AE73DB196C01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_189915F009BCD22BE154AE73DB196C01_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_189915F009BCD22BE154AE73DB196C01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_189915F009BCD22BE154AE73DB196C01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_189915F009BCD22BE154AE73DB196C01" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_189915F009BCD22BE154AE73DB196C01" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FC11D69342D83B7B8E93AE73D99A4E69_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FC11D69342D83B7B8E93AE73D99A4E69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FC11D69342D83B7B8E93AE73D99A4E69_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FC11D69342D83B7B8E93AE73D99A4E69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FC11D69342D83B7B8E93AE73D99A4E69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FC11D69342D83B7B8E93AE73D99A4E69" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FC11D69342D83B7B8E93AE73D99A4E69" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_A52BE0D26FAD476CB8B3AE73D99B25AC_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_A52BE0D26FAD476CB8B3AE73D99B25AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_A52BE0D26FAD476CB8B3AE73D99B25AC_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_A52BE0D26FAD476CB8B3AE73D99B25AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A52BE0D26FAD476CB8B3AE73D99B25AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A52BE0D26FAD476CB8B3AE73D99B25AC" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_A52BE0D26FAD476CB8B3AE73D99B25AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9803B66CB35D93C2148FAE73D99B75FB_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9803B66CB35D93C2148FAE73D99B75FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9803B66CB35D93C2148FAE73D99B75FB_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9803B66CB35D93C2148FAE73D99B75FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9803B66CB35D93C2148FAE73D99B75FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9803B66CB35D93C2148FAE73D99B75FB" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9803B66CB35D93C2148FAE73D99B75FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_9CA31CE67376E2434B65AE73D99BED67_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_9CA31CE67376E2434B65AE73D99BED67" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_9CA31CE67376E2434B65AE73D99BED67_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_9CA31CE67376E2434B65AE73D99BED67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9CA31CE67376E2434B65AE73D99BED67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_9CA31CE67376E2434B65AE73D99BED67" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_9CA31CE67376E2434B65AE73D99BED67" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_A18377FD0173C450F956AE73D99B7805_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_A18377FD0173C450F956AE73D99B7805" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_A18377FD0173C450F956AE73D99B7805_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_A18377FD0173C450F956AE73D99B7805" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_A18377FD0173C450F956AE73D99B7805" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_A18377FD0173C450F956AE73D99B7805" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_A18377FD0173C450F956AE73D99B7805" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_2E0077E5FE6AE5E7E803AE73D99BBE58_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_2E0077E5FE6AE5E7E803AE73D99BBE58" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_2E0077E5FE6AE5E7E803AE73D99BBE58_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_2E0077E5FE6AE5E7E803AE73D99BBE58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2E0077E5FE6AE5E7E803AE73D99BBE58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_2E0077E5FE6AE5E7E803AE73D99BBE58" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_2E0077E5FE6AE5E7E803AE73D99BBE58" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_21C87B041BB4778C46E1AE73D99BBBD5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_21C87B041BB4778C46E1AE73D99BBBD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_21C87B041BB4778C46E1AE73D99BBBD5_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_21C87B041BB4778C46E1AE73D99BBBD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_21C87B041BB4778C46E1AE73D99BBBD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_21C87B041BB4778C46E1AE73D99BBBD5" xlink:to="lab_us-gaap_FairValueByAssetClassAxis_21C87B041BB4778C46E1AE73D99BBBD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_FA84A1598394A8DC0394AE73D99B81A6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_FA84A1598394A8DC0394AE73D99B81A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_FA84A1598394A8DC0394AE73D99B81A6_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_FA84A1598394A8DC0394AE73D99B81A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_FA84A1598394A8DC0394AE73D99B81A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_FA84A1598394A8DC0394AE73D99B81A6" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_FA84A1598394A8DC0394AE73D99B81A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_9C76A7B5FBF2DBD17144AE73D99B2DF7_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_9C76A7B5FBF2DBD17144AE73D99B2DF7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_9C76A7B5FBF2DBD17144AE73D99B2DF7_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_9C76A7B5FBF2DBD17144AE73D99B2DF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9C76A7B5FBF2DBD17144AE73D99B2DF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_9C76A7B5FBF2DBD17144AE73D99B2DF7" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_9C76A7B5FBF2DBD17144AE73D99B2DF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_394D48A9FBAF5FAEF294AE73D99C6BF2_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_394D48A9FBAF5FAEF294AE73D99C6BF2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_394D48A9FBAF5FAEF294AE73D99C6BF2_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_394D48A9FBAF5FAEF294AE73D99C6BF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_394D48A9FBAF5FAEF294AE73D99C6BF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember_394D48A9FBAF5FAEF294AE73D99C6BF2" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember_394D48A9FBAF5FAEF294AE73D99C6BF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_4B9939D775B16BFEBA06AE73D99CAA7E_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_4B9939D775B16BFEBA06AE73D99CAA7E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_4B9939D775B16BFEBA06AE73D99CAA7E_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_4B9939D775B16BFEBA06AE73D99CAA7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_4B9939D775B16BFEBA06AE73D99CAA7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember_4B9939D775B16BFEBA06AE73D99CAA7E" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember_4B9939D775B16BFEBA06AE73D99CAA7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A7B8DBB15892F754C4C4AE73D99CE7A5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A7B8DBB15892F754C4C4AE73D99CE7A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A7B8DBB15892F754C4C4AE73D99CE7A5_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A7B8DBB15892F754C4C4AE73D99CE7A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A7B8DBB15892F754C4C4AE73D99CE7A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A7B8DBB15892F754C4C4AE73D99CE7A5" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A7B8DBB15892F754C4C4AE73D99CE7A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_9EAFC26590F174F9D423AE73D99CAA00_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_9EAFC26590F174F9D423AE73D99CAA00" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_9EAFC26590F174F9D423AE73D99CAA00_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_9EAFC26590F174F9D423AE73D99CAA00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets, Liabilities and Stockholders' Equity Measured on Recurring Basis [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_9EAFC26590F174F9D423AE73D99CAA00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_9EAFC26590F174F9D423AE73D99CAA00" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_9EAFC26590F174F9D423AE73D99CAA00" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_C73496645E029C24B696AE73D99CACA6_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_C73496645E029C24B696AE73D99CACA6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_C73496645E029C24B696AE73D99CACA6_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_C73496645E029C24B696AE73D99CACA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_C73496645E029C24B696AE73D99CACA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_C73496645E029C24B696AE73D99CACA6" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_C73496645E029C24B696AE73D99CACA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_DDB99059D33C19042470AE73D99CE832_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_DDB99059D33C19042470AE73D99CE832" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_DDB99059D33C19042470AE73D99CE832_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_DDB99059D33C19042470AE73D99CE832" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_DDB99059D33C19042470AE73D99CE832" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_DDB99059D33C19042470AE73D99CE832" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_DDB99059D33C19042470AE73D99CE832" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_435F75EA1A094B99D241AE73D99CE778_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_435F75EA1A094B99D241AE73D99CE778" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable debt securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_435F75EA1A094B99D241AE73D99CE778" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_435F75EA1A094B99D241AE73D99CE778" xlink:to="lab_us-gaap_AvailableForSaleSecurities_435F75EA1A094B99D241AE73D99CE778" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_679942340E194E852910AE73D99C0187_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_679942340E194E852910AE73D99C0187" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_679942340E194E852910AE73D99C0187_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_679942340E194E852910AE73D99C0187" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_679942340E194E852910AE73D99C0187" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_679942340E194E852910AE73D99C0187" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure_679942340E194E852910AE73D99C0187" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_F317E08BCF09618832BDAE73D99C8596_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_F317E08BCF09618832BDAE73D99C8596" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_F317E08BCF09618832BDAE73D99C8596_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_F317E08BCF09618832BDAE73D99C8596" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_F317E08BCF09618832BDAE73D99C8596" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_F317E08BCF09618832BDAE73D99C8596" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_F317E08BCF09618832BDAE73D99C8596" xlink:type="arc" />
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_E97E431AD6C8252F6670AE73D99C7011_verboseLabel_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_E97E431AD6C8252F6670AE73D99C7011" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Plan assets for deferred compensation</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_E97E431AD6C8252F6670AE73D99C7011_label_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_E97E431AD6C8252F6670AE73D99C7011" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Assets For Deferred Compensation Fair Value Disclosure</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_E97E431AD6C8252F6670AE73D99C7011_documentation_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_E97E431AD6C8252F6670AE73D99C7011" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair values as of the balance sheet date of all assets of deferred compensation plans.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_E97E431AD6C8252F6670AE73D99C7011" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_E97E431AD6C8252F6670AE73D99C7011" xlink:to="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_E97E431AD6C8252F6670AE73D99C7011" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_8D0093057C4319AE34EFAE73D99C051B_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_8D0093057C4319AE34EFAE73D99C051B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_8D0093057C4319AE34EFAE73D99C051B_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_8D0093057C4319AE34EFAE73D99C051B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8D0093057C4319AE34EFAE73D99C051B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_8D0093057C4319AE34EFAE73D99C051B" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_8D0093057C4319AE34EFAE73D99C051B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_CA4A28F1D156793C8DDFAE73D99C0BAD_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_CA4A28F1D156793C8DDFAE73D99C0BAD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_CA4A28F1D156793C8DDFAE73D99C0BAD_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_CA4A28F1D156793C8DDFAE73D99C0BAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_CA4A28F1D156793C8DDFAE73D99C0BAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_CA4A28F1D156793C8DDFAE73D99C0BAD" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_CA4A28F1D156793C8DDFAE73D99C0BAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_C56C6D6643740FAAF87AAE73D99C4CC0_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_C56C6D6643740FAAF87AAE73D99C4CC0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_C56C6D6643740FAAF87AAE73D99C4CC0_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_C56C6D6643740FAAF87AAE73D99C4CC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_C56C6D6643740FAAF87AAE73D99C4CC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_C56C6D6643740FAAF87AAE73D99C4CC0" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_C56C6D6643740FAAF87AAE73D99C4CC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_171D35C5DD79E5989571AE73D99D5857_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_171D35C5DD79E5989571AE73D99D5857" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_171D35C5DD79E5989571AE73D99D5857" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_171D35C5DD79E5989571AE73D99D5857" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_171D35C5DD79E5989571AE73D99D5857" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_E08E6026A0CC0668C3E1AE73D99DF94C_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_E08E6026A0CC0668C3E1AE73D99DF94C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_E08E6026A0CC0668C3E1AE73D99DF94C_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_E08E6026A0CC0668C3E1AE73D99DF94C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_E08E6026A0CC0668C3E1AE73D99DF94C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_E08E6026A0CC0668C3E1AE73D99DF94C" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure_E08E6026A0CC0668C3E1AE73D99DF94C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_1E0F4A5FA2857119D82CAE73DB5BE9BC_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_1E0F4A5FA2857119D82CAE73DB5BE9BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction of accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_1E0F4A5FA2857119D82CAE73DB5BE9BC_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_1E0F4A5FA2857119D82CAE73DB5BE9BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_1E0F4A5FA2857119D82CAE73DB5BE9BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_1E0F4A5FA2857119D82CAE73DB5BE9BC" xlink:to="lab_us-gaap_AccountsReceivableMember_1E0F4A5FA2857119D82CAE73DB5BE9BC" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_02C0E577788EB3E31AAFAE73DB5B37A6_verboseLabel_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_02C0E577788EB3E31AAFAE73DB5B37A6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of total product revenue reserves included in consolidated balance sheets</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_02C0E577788EB3E31AAFAE73DB5B37A6_label_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_02C0E577788EB3E31AAFAE73DB5B37A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_02C0E577788EB3E31AAFAE73DB5B37A6_documentation_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_02C0E577788EB3E31AAFAE73DB5B37A6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of product revenue reserves included in consolidated balance sheets.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_02C0E577788EB3E31AAFAE73DB5B37A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_02C0E577788EB3E31AAFAE73DB5B37A6" xlink:to="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_02C0E577788EB3E31AAFAE73DB5B37A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_9B6E6FCC21C3B1C60377AE73DB5C7085_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_9B6E6FCC21C3B1C60377AE73DB5C7085" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_9B6E6FCC21C3B1C60377AE73DB5C7085" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_9B6E6FCC21C3B1C60377AE73DB5C7085" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_9B6E6FCC21C3B1C60377AE73DB5C7085" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesAbstract_C0F25214255C304D0969720464CE7ECF_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesAbstract_C0F25214255C304D0969720464CE7ECF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesAbstract_C0F25214255C304D0969720464CE7ECF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesAbstract_C0F25214255C304D0969720464CE7ECF" xlink:to="lab_us-gaap_OtherLiabilitiesAbstract_C0F25214255C304D0969720464CE7ECF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductLiabilityContingencyTable_F214774A207C40BD9FE4720464CFEBE6_terseLabel_en-US" xlink:label="lab_us-gaap_ProductLiabilityContingencyTable_F214774A207C40BD9FE4720464CFEBE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Liability Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_ProductLiabilityContingencyTable_F214774A207C40BD9FE4720464CFEBE6_label_en-US" xlink:label="lab_us-gaap_ProductLiabilityContingencyTable_F214774A207C40BD9FE4720464CFEBE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Liability Contingency [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="loc_us-gaap_ProductLiabilityContingencyTable_F214774A207C40BD9FE4720464CFEBE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductLiabilityContingencyTable_F214774A207C40BD9FE4720464CFEBE6" xlink:to="lab_us-gaap_ProductLiabilityContingencyTable_F214774A207C40BD9FE4720464CFEBE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductLiabilityContingencyLineItems_7A6A0542911CBD03E69E720464CFC65E_terseLabel_en-US" xlink:label="lab_us-gaap_ProductLiabilityContingencyLineItems_7A6A0542911CBD03E69E720464CFC65E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Liability Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_ProductLiabilityContingencyLineItems_7A6A0542911CBD03E69E720464CFC65E_label_en-US" xlink:label="lab_us-gaap_ProductLiabilityContingencyLineItems_7A6A0542911CBD03E69E720464CFC65E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Liability Contingency [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="loc_us-gaap_ProductLiabilityContingencyLineItems_7A6A0542911CBD03E69E720464CFC65E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_7A6A0542911CBD03E69E720464CFC65E" xlink:to="lab_us-gaap_ProductLiabilityContingencyLineItems_7A6A0542911CBD03E69E720464CFC65E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_43AD76CEE1681453C89E720464CF7A4C_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_43AD76CEE1681453C89E720464CF7A4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount reserved for this matter</link:label>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_43AD76CEE1681453C89E720464CF7A4C_label_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_43AD76CEE1681453C89E720464CF7A4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Credits and Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_43AD76CEE1681453C89E720464CF7A4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_43AD76CEE1681453C89E720464CF7A4C" xlink:to="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_43AD76CEE1681453C89E720464CF7A4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_2151E59E038D0F39BE9D3EFA95A9BDB2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_2151E59E038D0F39BE9D3EFA95A9BDB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_2151E59E038D0F39BE9D3EFA95A9BDB2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_2151E59E038D0F39BE9D3EFA95A9BDB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_2151E59E038D0F39BE9D3EFA95A9BDB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_2151E59E038D0F39BE9D3EFA95A9BDB2" xlink:to="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_2151E59E038D0F39BE9D3EFA95A9BDB2" xlink:type="arc" />
    <link:label id="lab_biib_A1995ESPPMember_3CAA199F9B075388839F3EFB47ED7066_terseLabel_en-US" xlink:label="lab_biib_A1995ESPPMember_3CAA199F9B075388839F3EFB47ED7066" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1995 ESPP</link:label>
    <link:label id="lab_biib_A1995ESPPMember_3CAA199F9B075388839F3EFB47ED7066_label_en-US" xlink:label="lab_biib_A1995ESPPMember_3CAA199F9B075388839F3EFB47ED7066" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1995 ESPP [Member]</link:label>
    <link:label id="lab_biib_A1995ESPPMember_3CAA199F9B075388839F3EFB47ED7066_documentation_en-US" xlink:label="lab_biib_A1995ESPPMember_3CAA199F9B075388839F3EFB47ED7066" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">1995 ESPP [Member]</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_A1995ESPPMember" xlink:label="loc_biib_A1995ESPPMember_3CAA199F9B075388839F3EFB47ED7066" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A1995ESPPMember_3CAA199F9B075388839F3EFB47ED7066" xlink:to="lab_biib_A1995ESPPMember_3CAA199F9B075388839F3EFB47ED7066" xlink:type="arc" />
    <link:label id="lab_biib_A2015ESPPMember_CD85549E8C7A70F7E4953F00A93D0C9C_terseLabel_en-US" xlink:label="lab_biib_A2015ESPPMember_CD85549E8C7A70F7E4953F00A93D0C9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015 ESPP</link:label>
    <link:label id="lab_biib_A2015ESPPMember_CD85549E8C7A70F7E4953F00A93D0C9C_label_en-US" xlink:label="lab_biib_A2015ESPPMember_CD85549E8C7A70F7E4953F00A93D0C9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2015 ESPP [Member]</link:label>
    <link:label id="lab_biib_A2015ESPPMember_CD85549E8C7A70F7E4953F00A93D0C9C_documentation_en-US" xlink:label="lab_biib_A2015ESPPMember_CD85549E8C7A70F7E4953F00A93D0C9C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2015 ESPP [Member]</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_A2015ESPPMember" xlink:label="loc_biib_A2015ESPPMember_CD85549E8C7A70F7E4953F00A93D0C9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2015ESPPMember_CD85549E8C7A70F7E4953F00A93D0C9C" xlink:to="lab_biib_A2015ESPPMember_CD85549E8C7A70F7E4953F00A93D0C9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_2DABCF06F103985390273EFA95B09FA3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_2DABCF06F103985390273EFA95B09FA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_2DABCF06F103985390273EFA95B09FA3_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_2DABCF06F103985390273EFA95B09FA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_2DABCF06F103985390273EFA95B09FA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_2DABCF06F103985390273EFA95B09FA3" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_2DABCF06F103985390273EFA95B09FA3" xlink:type="arc" />
    <link:label id="lab_biib_Employeestockpurchaseplanmaximumshares_6F0476F71E940862D1DB3EA2E554FBC3_terseLabel_en-US" xlink:label="lab_biib_Employeestockpurchaseplanmaximumshares_6F0476F71E940862D1DB3EA2E554FBC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan maximum shares</link:label>
    <link:label id="lab_biib_Employeestockpurchaseplanmaximumshares_6F0476F71E940862D1DB3EA2E554FBC3_label_en-US" xlink:label="lab_biib_Employeestockpurchaseplanmaximumshares_6F0476F71E940862D1DB3EA2E554FBC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan maximum shares</link:label>
    <link:label id="lab_biib_Employeestockpurchaseplanmaximumshares_6F0476F71E940862D1DB3EA2E554FBC3_documentation_en-US" xlink:label="lab_biib_Employeestockpurchaseplanmaximumshares_6F0476F71E940862D1DB3EA2E554FBC3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan maximum shares</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_Employeestockpurchaseplanmaximumshares" xlink:label="loc_biib_Employeestockpurchaseplanmaximumshares_6F0476F71E940862D1DB3EA2E554FBC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Employeestockpurchaseplanmaximumshares_6F0476F71E940862D1DB3EA2E554FBC3" xlink:to="lab_biib_Employeestockpurchaseplanmaximumshares_6F0476F71E940862D1DB3EA2E554FBC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5D616C13D4205D0F62783EA2E5548387_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5D616C13D4205D0F62783EA2E5548387" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued under ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5D616C13D4205D0F62783EA2E5548387_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5D616C13D4205D0F62783EA2E5548387" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5D616C13D4205D0F62783EA2E5548387" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5D616C13D4205D0F62783EA2E5548387" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5D616C13D4205D0F62783EA2E5548387" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_FBEBB55F50E93B5597F5AE73D95781A1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_FBEBB55F50E93B5597F5AE73D95781A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_FBEBB55F50E93B5597F5AE73D95781A1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_FBEBB55F50E93B5597F5AE73D95781A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_FBEBB55F50E93B5597F5AE73D95781A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_FBEBB55F50E93B5597F5AE73D95781A1" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_FBEBB55F50E93B5597F5AE73D95781A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4E207D692DF211677B4AAE73D957B789_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4E207D692DF211677B4AAE73D957B789" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investee, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4E207D692DF211677B4AAE73D957B789_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4E207D692DF211677B4AAE73D957B789" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4E207D692DF211677B4AAE73D957B789" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4E207D692DF211677B4AAE73D957B789" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4E207D692DF211677B4AAE73D957B789" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvesteeNameDomain_B8880A517D22D6DB4D2DAE73D9572C54_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeNameDomain_B8880A517D22D6DB4D2DAE73D9572C54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investee, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvesteeNameDomain_B8880A517D22D6DB4D2DAE73D9572C54_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeNameDomain_B8880A517D22D6DB4D2DAE73D9572C54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_B8880A517D22D6DB4D2DAE73D9572C54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_B8880A517D22D6DB4D2DAE73D9572C54" xlink:to="lab_us-gaap_EquityMethodInvesteeNameDomain_B8880A517D22D6DB4D2DAE73D9572C54" xlink:type="arc" />
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_7E0E37069767CDBF8963AE73D957397B_terseLabel_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_7E0E37069767CDBF8963AE73D957397B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Samsung Biosimilar Agreement [Member]</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_7E0E37069767CDBF8963AE73D957397B_label_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_7E0E37069767CDBF8963AE73D957397B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Samsung Biosimilar Agreement [Member]</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_7E0E37069767CDBF8963AE73D957397B_documentation_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_7E0E37069767CDBF8963AE73D957397B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Samsung bio-similar agreement.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_7E0E37069767CDBF8963AE73D957397B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SamsungBiosimilarAgreementMember_7E0E37069767CDBF8963AE73D957397B" xlink:to="lab_biib_SamsungBiosimilarAgreementMember_7E0E37069767CDBF8963AE73D957397B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3597189B2BCE41228AD8AE73D9573E41_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3597189B2BCE41228AD8AE73D9573E41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3597189B2BCE41228AD8AE73D9573E41_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3597189B2BCE41228AD8AE73D9573E41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3597189B2BCE41228AD8AE73D9573E41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3597189B2BCE41228AD8AE73D9573E41" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3597189B2BCE41228AD8AE73D9573E41" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_41AF7C69484757FFC14FAE73D957F097_verboseLabel_en-US" xlink:label="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_41AF7C69484757FFC14FAE73D957F097" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contribution from Samsung to develop, manufacture and market biosimilar pharmaceuticals</link:label>
    <link:label id="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_41AF7C69484757FFC14FAE73D957F097_label_en-US" xlink:label="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_41AF7C69484757FFC14FAE73D957F097" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments By Third Party In Joint Venture As Per Agreement.</link:label>
    <link:label id="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_41AF7C69484757FFC14FAE73D957F097_documentation_en-US" xlink:label="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_41AF7C69484757FFC14FAE73D957F097" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments by third party in joint venture as per agreement</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" xlink:label="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_41AF7C69484757FFC14FAE73D957F097" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_41AF7C69484757FFC14FAE73D957F097" xlink:to="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_41AF7C69484757FFC14FAE73D957F097" xlink:type="arc" />
    <link:label id="lab_biib_JointVentureOwnerShipPercentageByThirdParty_54B2C72B65B4C378328AAE73D95767EC_verboseLabel_en-US" xlink:label="lab_biib_JointVentureOwnerShipPercentageByThirdParty_54B2C72B65B4C378328AAE73D95767EC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Variable interest entity, qualitative or quantitative information, ownership percentage</link:label>
    <link:label id="lab_biib_JointVentureOwnerShipPercentageByThirdParty_54B2C72B65B4C378328AAE73D95767EC_label_en-US" xlink:label="lab_biib_JointVentureOwnerShipPercentageByThirdParty_54B2C72B65B4C378328AAE73D95767EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Joint Venture Owner Ship Percentage By Third Party.</link:label>
    <link:label id="lab_biib_JointVentureOwnerShipPercentageByThirdParty_54B2C72B65B4C378328AAE73D95767EC_documentation_en-US" xlink:label="lab_biib_JointVentureOwnerShipPercentageByThirdParty_54B2C72B65B4C378328AAE73D95767EC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Joint venture owner ship percentage by third party.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_JointVentureOwnerShipPercentageByThirdParty" xlink:label="loc_biib_JointVentureOwnerShipPercentageByThirdParty_54B2C72B65B4C378328AAE73D95767EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_JointVentureOwnerShipPercentageByThirdParty_54B2C72B65B4C378328AAE73D95767EC" xlink:to="lab_biib_JointVentureOwnerShipPercentageByThirdParty_54B2C72B65B4C378328AAE73D95767EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestments_9CB4FFA9B459E1C56B74AE73D95733DE_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_9CB4FFA9B459E1C56B74AE73D95733DE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contribution from Biogen to develop, manufacture and market biosimilar pharmaceuticals</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_9CB4FFA9B459E1C56B74AE73D95733DE_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_9CB4FFA9B459E1C56B74AE73D95733DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_9CB4FFA9B459E1C56B74AE73D95733DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments_9CB4FFA9B459E1C56B74AE73D95733DE" xlink:to="lab_us-gaap_EquityMethodInvestments_9CB4FFA9B459E1C56B74AE73D95733DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_888EC4F26F6E9E901D71AE73D957C129_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_888EC4F26F6E9E901D71AE73D957C129" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of stake in entity minimum</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_888EC4F26F6E9E901D71AE73D957C129_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_888EC4F26F6E9E901D71AE73D957C129" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_888EC4F26F6E9E901D71AE73D957C129" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_888EC4F26F6E9E901D71AE73D957C129" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_888EC4F26F6E9E901D71AE73D957C129" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_EAB11AABB378F83B4233AE73D957729F_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_EAB11AABB378F83B4233AE73D957729F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional contribution made to Samsung Bioepis</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_EAB11AABB378F83B4233AE73D957729F_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_EAB11AABB378F83B4233AE73D957729F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_EAB11AABB378F83B4233AE73D957729F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_EAB11AABB378F83B4233AE73D957729F" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_EAB11AABB378F83B4233AE73D957729F" xlink:type="arc" />
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_B73581D89CB97F0C9A56AE73D95734CC_verboseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_B73581D89CB97F0C9A56AE73D95734CC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of stake in entity maximum</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_B73581D89CB97F0C9A56AE73D95734CC_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_B73581D89CB97F0C9A56AE73D95734CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment Ownership Percentage Maximum</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_B73581D89CB97F0C9A56AE73D95734CC_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_B73581D89CB97F0C9A56AE73D95734CC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity method investment ownership percentage maximum.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_EquityMethodInvestmentOwnershipPercentageMaximum" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_B73581D89CB97F0C9A56AE73D95734CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_B73581D89CB97F0C9A56AE73D95734CC" xlink:to="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_B73581D89CB97F0C9A56AE73D95734CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_517D388A11C0C5EFFF5DAE73D958823A_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_517D388A11C0C5EFFF5DAE73D958823A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognized loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_517D388A11C0C5EFFF5DAE73D958823A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_517D388A11C0C5EFFF5DAE73D958823A" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_517D388A11C0C5EFFF5DAE73D958823A" xlink:type="arc" />
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_F3453C5ABEE1D8DC309CAE73D9588530_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare_F3453C5ABEE1D8DC309CAE73D9588530" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected profit share with Samsung Bioepis</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_F3453C5ABEE1D8DC309CAE73D9588530_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare_F3453C5ABEE1D8DC309CAE73D9588530" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_F3453C5ABEE1D8DC309CAE73D9588530_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare_F3453C5ABEE1D8DC309CAE73D9588530" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_EquityMethodInvestmentsExpectedProfitShare" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_F3453C5ABEE1D8DC309CAE73D9588530" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentsExpectedProfitShare_F3453C5ABEE1D8DC309CAE73D9588530" xlink:to="lab_biib_EquityMethodInvestmentsExpectedProfitShare_F3453C5ABEE1D8DC309CAE73D9588530" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherSalesRevenueNet_56DCEE9C060367D8575DAE73D9589E90_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSalesRevenueNet_56DCEE9C060367D8575DAE73D9589E90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue related to technical development and technology transfer services</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_56DCEE9C060367D8575DAE73D9589E90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSalesRevenueNet_56DCEE9C060367D8575DAE73D9589E90" xlink:to="lab_us-gaap_OtherSalesRevenueNet_56DCEE9C060367D8575DAE73D9589E90" xlink:type="arc" />
    <link:label id="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_9918DA1CB2294982F10CAE73DABE1716_verboseLabel_en-US" xlink:label="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_9918DA1CB2294982F10CAE73DABE1716" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of equity attributable to noncontrolling interests</link:label>
    <link:label id="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_9918DA1CB2294982F10CAE73DABE1716_label_en-US" xlink:label="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_9918DA1CB2294982F10CAE73DABE1716" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation Of Equity Attributable To Noncontrolling Interests [Table Text Block]</link:label>
    <link:label id="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_9918DA1CB2294982F10CAE73DABE1716_documentation_en-US" xlink:label="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_9918DA1CB2294982F10CAE73DABE1716" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reconciliation of equity attributable to noncontrolling interests.</link:label>
    <link:loc xlink:href="biib-20150930.xsd#biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock" xlink:label="loc_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_9918DA1CB2294982F10CAE73DABE1716" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_9918DA1CB2294982F10CAE73DABE1716" xlink:to="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_9918DA1CB2294982F10CAE73DABE1716" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>biib-20150930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:href="biib-20150930.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20150930.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:href="biib-20150930.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20150930.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitions" xlink:href="biib-20150930.xsd#AcquisitionsAcquisitions" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails" xlink:href="biib-20150930.xsd#AcquisitionsAcquisitionsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails1" xlink:href="biib-20150930.xsd#AcquisitionsAcquisitionsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetailsTextual" xlink:href="biib-20150930.xsd#AcquisitionsAcquisitionsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsTables" xlink:href="biib-20150930.xsd#AcquisitionsAcquisitionsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20150930.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:href="biib-20150930.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:href="biib-20150930.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencesDetails" xlink:href="biib-20150930.xsd#CommitmentsAndContingencesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:href="biib-20150930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:href="biib-20150930.xsd#CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="biib-20150930.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="biib-20150930.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="biib-20150930.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="biib-20150930.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedParenthetical" xlink:href="biib-20150930.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:href="biib-20150930.xsd#CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20150930.xsd#DerivativeInstruments" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20150930.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20150930.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:href="biib-20150930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20150930.xsd#EarningsPerShare" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20150930.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20150930.xsd#EarningsPerShareTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20150930.xsd#Equity" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EquityDetails" xlink:href="biib-20150930.xsd#EquityDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:href="biib-20150930.xsd#EquityDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:href="biib-20150930.xsd#EquityTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20150930.xsd#FairValueMeasurements" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20150930.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20150930.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20150930.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20150930.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20150930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20150930.xsd#FinancialInstruments" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20150930.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20150930.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20150930.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20150930.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:href="biib-20150930.xsd#FinancialInstrumentsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:href="biib-20150930.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20150930.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20150930.xsd#IncomeTaxes" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20150930.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20150930.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20150930.xsd#IncomeTaxesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IndebtednessIdebtednessDetails" xlink:href="biib-20150930.xsd#IndebtednessIdebtednessDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IndebtednessIndebtedness" xlink:href="biib-20150930.xsd#IndebtednessIndebtedness" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20150930.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20150930.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20150930.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20150930.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20150930.xsd#Inventory" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20150930.xsd#InventoryDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual" xlink:href="biib-20150930.xsd#InventoryInventoryDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20150930.xsd#InventoryTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20150930.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20150930.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20150930.xsd#Litigation" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:href="biib-20150930.xsd#LitigationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20150930.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20150930.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:href="biib-20150930.xsd#OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20150930.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:href="biib-20150930.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:href="biib-20150930.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetailsTextual" xlink:href="biib-20150930.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentTables" xlink:href="biib-20150930.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipmentTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances" xlink:href="biib-20150930.xsd#ReservesForDiscountsAndAllowances" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails" xlink:href="biib-20150930.xsd#ReservesForDiscountsAndAllowancesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20150930.xsd#ReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables" xlink:href="biib-20150930.xsd#ReservesForDiscountsAndAllowancesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20150930.xsd#ShareBasedPayments" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20150930.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20150930.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:href="biib-20150930.xsd#ShareBasedPaymentsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:href="biib-20150930.xsd#ShareBasedPaymentsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20150930.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents" xlink:href="biib-20150930.xsd#SubsequentEventsSubsequentEvents" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails" xlink:href="biib-20150930.xsd#SubsequentEventsSubsequentEventsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20150930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20150930.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20150930.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_0F8E9F53EF38B0AFD31FAE73D9516791" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_A9F839C62C0B8257C6F4AE73D9519FCF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_0F8E9F53EF38B0AFD31FAE73D9516791" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_A9F839C62C0B8257C6F4AE73D9519FCF" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_4E23E2D2E95C4E76493DAE73DAC75A23" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_B073DB90F67EB6FFA3C8AE73DAC75079" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_4E23E2D2E95C4E76493DAE73DAC75A23" xlink:to="loc_us-gaap_StatementTable_B073DB90F67EB6FFA3C8AE73DAC75079" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1FFD3CEDCFB69DC17F51AE73DAC71386" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_B073DB90F67EB6FFA3C8AE73DAC75079" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1FFD3CEDCFB69DC17F51AE73DAC71386" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_C0AFF8C03C07EDC0F9F4AE73DAC74078" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1FFD3CEDCFB69DC17F51AE73DAC71386" xlink:to="loc_us-gaap_EquityComponentDomain_C0AFF8C03C07EDC0F9F4AE73DAC74078" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_B3F82AEED4FEF94D3195AE73DAC86B32" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_C0AFF8C03C07EDC0F9F4AE73DAC74078" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_B3F82AEED4FEF94D3195AE73DAC86B32" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_51398B047631C4D2CB1FAE73DAC89CD8" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_C0AFF8C03C07EDC0F9F4AE73DAC74078" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_51398B047631C4D2CB1FAE73DAC89CD8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_BA43F811940A123FC9E5AE73DAC83528" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_C0AFF8C03C07EDC0F9F4AE73DAC74078" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_BA43F811940A123FC9E5AE73DAC83528" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_B6A817B389E0EC44A451AE73DAC86BE2" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_C0AFF8C03C07EDC0F9F4AE73DAC74078" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_B6A817B389E0EC44A451AE73DAC86BE2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A71D09DF5D4DAE13144AAE73DAC88E12" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_B073DB90F67EB6FFA3C8AE73DAC75079" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A71D09DF5D4DAE13144AAE73DAC88E12" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_AFB961221FB32CDA3BA6AE73DAC8B410" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A71D09DF5D4DAE13144AAE73DAC88E12" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_AFB961221FB32CDA3BA6AE73DAC8B410" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_B22267E37C86E622B459AE73DAC827EA" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A71D09DF5D4DAE13144AAE73DAC88E12" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_B22267E37C86E622B459AE73DAC827EA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_A31DB94F1AAE78803289AE73DAC84FE3" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A71D09DF5D4DAE13144AAE73DAC88E12" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_A31DB94F1AAE78803289AE73DAC84FE3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_000A265A83FFB3A59AECAE73DAC831B7" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A71D09DF5D4DAE13144AAE73DAC88E12" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_000A265A83FFB3A59AECAE73DAC831B7" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_92CAD7756C760A6209D63F3E22C907D1" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_E10F703D4FBFA00363723F3E22CA7D08" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_92CAD7756C760A6209D63F3E22C907D1" xlink:to="loc_us-gaap_StatementTable_E10F703D4FBFA00363723F3E22CA7D08" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5B09CE218CDB50EA54743F3E22CAFCBC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_E10F703D4FBFA00363723F3E22CA7D08" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5B09CE218CDB50EA54743F3E22CAFCBC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_C55EFB1C97B84D096E753F3E22CAFD7C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5B09CE218CDB50EA54743F3E22CAFCBC" xlink:to="loc_us-gaap_EquityComponentDomain_C55EFB1C97B84D096E753F3E22CAFD7C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_D209FE9D8C2FB1EDEFAD3F3E22CAD475" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_C55EFB1C97B84D096E753F3E22CAFD7C" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_D209FE9D8C2FB1EDEFAD3F3E22CAD475" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_93139726C20451F7C40D3F3E22CA047B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_C55EFB1C97B84D096E753F3E22CAFD7C" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_93139726C20451F7C40D3F3E22CA047B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_E12648F30DED21B8FB7C3F3E22CA4571" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_E10F703D4FBFA00363723F3E22CA7D08" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_E12648F30DED21B8FB7C3F3E22CA4571" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_79579F456B13957A78473F3E22CA4961" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_E12648F30DED21B8FB7C3F3E22CA4571" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_79579F456B13957A78473F3E22CA4961" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_F985421BE347DDB8E87E3F3E22CA6BD5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_79579F456B13957A78473F3E22CA4961" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_F985421BE347DDB8E87E3F3E22CA6BD5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_8C9067EFF8FEB6CE75273F3E22CAB8CB" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_E10F703D4FBFA00363723F3E22CA7D08" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_8C9067EFF8FEB6CE75273F3E22CAB8CB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_F438B2155987471462FC3F3E22CA6C65" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_8C9067EFF8FEB6CE75273F3E22CAB8CB" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_F438B2155987471462FC3F3E22CA6C65" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_DEC0507AAA6907BC1EC33F3E22CACA2A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_8C9067EFF8FEB6CE75273F3E22CAB8CB" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_DEC0507AAA6907BC1EC33F3E22CACA2A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_CD7023CD582889D514883F3E22CA1A32" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_8C9067EFF8FEB6CE75273F3E22CAB8CB" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_CD7023CD582889D514883F3E22CA1A32" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_D3C32535CB0332415D863F3E22CA03D0" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_8C9067EFF8FEB6CE75273F3E22CAB8CB" xlink:to="loc_us-gaap_NetIncomeLoss_D3C32535CB0332415D863F3E22CA03D0" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_785640D40F9F329619B4AE73D94F9031" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_685936B82FE48BE361F2AE73D94F825C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_785640D40F9F329619B4AE73D94F9031" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_685936B82FE48BE361F2AE73D94F825C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_5365D2891DE42591E72CAE73D94F32F2" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_785640D40F9F329619B4AE73D94F9031" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_5365D2891DE42591E72CAE73D94F32F2" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitions" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_C36BCFB8618CC12435D6AE73DB670372" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_B6BAEE2A2E24B7DC9AD1AE73DB6746F8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_C36BCFB8618CC12435D6AE73DB670372" xlink:to="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_B6BAEE2A2E24B7DC9AD1AE73DB6746F8" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_DEF9AC9E02C50BA2F7AAAE73D98EFC63" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6539D1F992E2E43976D7AE73D98E06A8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_DEF9AC9E02C50BA2F7AAAE73D98EFC63" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6539D1F992E2E43976D7AE73D98E06A8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5559ACA89EED988F6FC7AE73D98EA694" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6539D1F992E2E43976D7AE73D98E06A8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5559ACA89EED988F6FC7AE73D98EA694" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9A9FA6D0B01DD51D54E9AE73D98E8CC5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5559ACA89EED988F6FC7AE73D98EA694" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9A9FA6D0B01DD51D54E9AE73D98E8CC5" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_362D0C06803EFE4D68E5AE73D98FD750" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9A9FA6D0B01DD51D54E9AE73D98E8CC5" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_362D0C06803EFE4D68E5AE73D98FD750" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_F7DC79D95934D85AF4EFAE73D98F1B1F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6539D1F992E2E43976D7AE73D98E06A8" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_F7DC79D95934D85AF4EFAE73D98F1B1F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_8FFCFCF03A1C5D8813C6AE73D98F4EF4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_F7DC79D95934D85AF4EFAE73D98F1B1F" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_8FFCFCF03A1C5D8813C6AE73D98F4EF4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_082BE282BE9279C442DBAE73D98F6937" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_F7DC79D95934D85AF4EFAE73D98F1B1F" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_082BE282BE9279C442DBAE73D98F6937" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_C77348E6510F7F513EAFAE73D98F860C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_F7DC79D95934D85AF4EFAE73D98F1B1F" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_C77348E6510F7F513EAFAE73D98F860C" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_22CA7967DDA3B73458DDAE73DAD8577F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1ACFD8A35556A2DA2974AE73DAD80F35" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_22CA7967DDA3B73458DDAE73DAD8577F" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1ACFD8A35556A2DA2974AE73DAD80F35" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_DC63467ABC4F3AA5B6D6AE73DAD84FCD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1ACFD8A35556A2DA2974AE73DAD80F35" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_DC63467ABC4F3AA5B6D6AE73DAD84FCD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17035937EB437A2A904AAE73DAD81490" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_DC63467ABC4F3AA5B6D6AE73DAD84FCD" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17035937EB437A2A904AAE73DAD81490" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_FC2503F1E3E8A36B5D04AE73DAD82C58" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17035937EB437A2A904AAE73DAD81490" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_FC2503F1E3E8A36B5D04AE73DAD82C58" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_61C0CDAFA79297C91B07AE73DAD83871" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1ACFD8A35556A2DA2974AE73DAD80F35" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_61C0CDAFA79297C91B07AE73DAD83871" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_954FAF1B3D7EB1C795F5AE73DAD97F14" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_61C0CDAFA79297C91B07AE73DAD83871" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_954FAF1B3D7EB1C795F5AE73DAD97F14" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_48C28D5CC4D69A5FA60DAE73DAD9995B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_61C0CDAFA79297C91B07AE73DAD83871" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_48C28D5CC4D69A5FA60DAE73DAD9995B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_FF2D33449CA53C08E4D9AE73DAD93992" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_61C0CDAFA79297C91B07AE73DAD83871" xlink:to="loc_us-gaap_Goodwill_FF2D33449CA53C08E4D9AE73DAD93992" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_6AF0007A0C5E0909F8EFAE73DAD97B49" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_61C0CDAFA79297C91B07AE73DAD83871" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_6AF0007A0C5E0909F8EFAE73DAD97B49" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_4CC4F48AA710F6C39361AE73DAD9DE67" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_61C0CDAFA79297C91B07AE73DAD83871" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_4CC4F48AA710F6C39361AE73DAD9DE67" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_B555EC941B8F504AE48EAE73DAD9810A" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_61C0CDAFA79297C91B07AE73DAD83871" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_B555EC941B8F504AE48EAE73DAD9810A" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_F1349A5A64CD9BA9D8F171883E1DB692" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0B07D458439ACEB1B60371883E1D3DFE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_F1349A5A64CD9BA9D8F171883E1DB692" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0B07D458439ACEB1B60371883E1D3DFE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2D9C4242B02CE80D05DC71883E1D057E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0B07D458439ACEB1B60371883E1D3DFE" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2D9C4242B02CE80D05DC71883E1D057E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B7C5B1C061072C5417EB71883E1D7276" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2D9C4242B02CE80D05DC71883E1D057E" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B7C5B1C061072C5417EB71883E1D7276" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_477C66E5148D216012EE71883E1D54BF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B7C5B1C061072C5417EB71883E1D7276" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_477C66E5148D216012EE71883E1D54BF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_19B5892897ABBFE8B4C971883E1D5BA7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0B07D458439ACEB1B60371883E1D3DFE" xlink:to="loc_us-gaap_ProductOrServiceAxis_19B5892897ABBFE8B4C971883E1D5BA7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_CAD0C13B87366566E73871883E1D330A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_19B5892897ABBFE8B4C971883E1D5BA7" xlink:to="loc_us-gaap_ProductsAndServicesDomain_CAD0C13B87366566E73871883E1D330A" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_RaxatrigineMember" xlink:label="loc_biib_RaxatrigineMember_1D85FF1DAA07723F644271883E1ED9A6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_CAD0C13B87366566E73871883E1D330A" xlink:to="loc_biib_RaxatrigineMember_1D85FF1DAA07723F644271883E1ED9A6" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_NeuropathicpainindicationsMember" xlink:label="loc_biib_NeuropathicpainindicationsMember_AD648A403DA02AAEFEF671883E1EDF28" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_CAD0C13B87366566E73871883E1D330A" xlink:to="loc_biib_NeuropathicpainindicationsMember_AD648A403DA02AAEFEF671883E1EDF28" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_F778C55D46CCA913817571883E1EEB85" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0B07D458439ACEB1B60371883E1D3DFE" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_F778C55D46CCA913817571883E1EEB85" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_C7670D61D9D5D4024BFC71883E1EEC2E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_F778C55D46CCA913817571883E1EEB85" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_C7670D61D9D5D4024BFC71883E1EEC2E" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_2EACD7FC1BF7B97D77DC71883E1ECDB4" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_F778C55D46CCA913817571883E1EEB85" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_2EACD7FC1BF7B97D77DC71883E1ECDB4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_DA2CDAACB2242088FC0571883E1E4630" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_F778C55D46CCA913817571883E1EEB85" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_DA2CDAACB2242088FC0571883E1E4630" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_CA2BBFE40549412982E371883E1EFE57" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_F778C55D46CCA913817571883E1EEB85" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_CA2BBFE40549412982E371883E1EFE57" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease_80D5DEEDF5274F9AA59171883E1E26C5" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_F778C55D46CCA913817571883E1EEB85" xlink:to="loc_us-gaap_GoodwillPeriodIncreaseDecrease_80D5DEEDF5274F9AA59171883E1E26C5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_F841767D78C843CA950671883E1E7224" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_F778C55D46CCA913817571883E1EEB85" xlink:to="loc_us-gaap_FairValueInputsDiscountRate_F841767D78C843CA950671883E1E7224" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_1BDBB106DFA6051338B171883E1EEF46" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_F778C55D46CCA913817571883E1EEB85" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_1BDBB106DFA6051338B171883E1EEF46" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_46BCE14ABC5413D47CE871883E1E04A8" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_F778C55D46CCA913817571883E1EEB85" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_46BCE14ABC5413D47CE871883E1E04A8" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitionsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_C74560DD02974BB35E05AE73DB649504" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_3C25733B9E8D56A0C36CAE73DB642E9F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_C74560DD02974BB35E05AE73DB649504" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_3C25733B9E8D56A0C36CAE73DB642E9F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_359AE44678116F757837AE73DB64D019" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_C74560DD02974BB35E05AE73DB649504" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_359AE44678116F757837AE73DB64D019" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1AA97253FA1CB4C7FA2EAE73D95E6E3F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_4E851FC5671C73BAD9AFAE73D95E26BB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1AA97253FA1CB4C7FA2EAE73D95E6E3F" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_4E851FC5671C73BAD9AFAE73D95E26BB" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_CF828DA4417B439E4E3543FEA0E2B82C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1C7D9DA5FF00719A3A7F43FEA0E22DF6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_CF828DA4417B439E4E3543FEA0E2B82C" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1C7D9DA5FF00719A3A7F43FEA0E22DF6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_9351AE7B1E141C965F3043FEA0E2A527" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1C7D9DA5FF00719A3A7F43FEA0E22DF6" xlink:to="loc_us-gaap_ProductOrServiceAxis_9351AE7B1E141C965F3043FEA0E2A527" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_95270CF13AE5B400A2DC43FEA0E25E27" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_9351AE7B1E141C965F3043FEA0E2A527" xlink:to="loc_us-gaap_ProductsAndServicesDomain_95270CF13AE5B400A2DC43FEA0E25E27" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_LeadprogramsMember" xlink:label="loc_biib_LeadprogramsMember_38CE7703D191A10C6C9E43FEA0E2E2FB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_95270CF13AE5B400A2DC43FEA0E25E27" xlink:to="loc_biib_LeadprogramsMember_38CE7703D191A10C6C9E43FEA0E2E2FB" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_DiscoveryprogramsMember" xlink:label="loc_biib_DiscoveryprogramsMember_ADFBCDFA6E51CBEA090B43FEA0E2DF9D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_95270CF13AE5B400A2DC43FEA0E25E27" xlink:to="loc_biib_DiscoveryprogramsMember_ADFBCDFA6E51CBEA090B43FEA0E2DF9D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7A4680417DAE3E8BE4F343FEA0E2E172" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1C7D9DA5FF00719A3A7F43FEA0E22DF6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7A4680417DAE3E8BE4F343FEA0E2E172" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_73DDC09B68A92D43B73B43FEA0E27B6D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7A4680417DAE3E8BE4F343FEA0E2E172" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_73DDC09B68A92D43B73B43FEA0E27B6D" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_MitsubishiTanabePharmaCorporationMember" xlink:label="loc_biib_MitsubishiTanabePharmaCorporationMember_E907908813EF53B1142443FEA0E2DD23" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_73DDC09B68A92D43B73B43FEA0E27B6D" xlink:to="loc_biib_MitsubishiTanabePharmaCorporationMember_E907908813EF53B1142443FEA0E2DD23" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_AGTCMember" xlink:label="loc_biib_AGTCMember_A48444DC4304BE35A81343FEA0E284CD" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_73DDC09B68A92D43B73B43FEA0E27B6D" xlink:to="loc_biib_AGTCMember_A48444DC4304BE35A81343FEA0E284CD" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SwedishOrphanBiovitrumMember" xlink:label="loc_biib_SwedishOrphanBiovitrumMember_15DEEDB40CEB2F4049E043FEA0E2EEDE" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_73DDC09B68A92D43B73B43FEA0E27B6D" xlink:to="loc_biib_SwedishOrphanBiovitrumMember_15DEEDB40CEB2F4049E043FEA0E2EEDE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFB5CBE92E7DF9AAC1DF43FEA0E2F5B2" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1C7D9DA5FF00719A3A7F43FEA0E22DF6" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFB5CBE92E7DF9AAC1DF43FEA0E2F5B2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_B5C40E0FE58D77541A4843FEA0E29286" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFB5CBE92E7DF9AAC1DF43FEA0E2F5B2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_B5C40E0FE58D77541A4843FEA0E29286" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_C209A469CD947B3EF4DE43FEA0E38EBA" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFB5CBE92E7DF9AAC1DF43FEA0E2F5B2" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_C209A469CD947B3EF4DE43FEA0E38EBA" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_Upfrontmilestonepayment" xlink:label="loc_biib_Upfrontmilestonepayment_CDB681C346A41E52E37C43FEA0E3FC0D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFB5CBE92E7DF9AAC1DF43FEA0E2F5B2" xlink:to="loc_biib_Upfrontmilestonepayment_CDB681C346A41E52E37C43FEA0E3FC0D" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_Purchaseofcommonstock" xlink:label="loc_biib_Purchaseofcommonstock_4F73654FF98DE600327243FEA0E3BDBB" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFB5CBE92E7DF9AAC1DF43FEA0E2F5B2" xlink:to="loc_biib_Purchaseofcommonstock_4F73654FF98DE600327243FEA0E3BDBB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_0228242BB5B82764A3DA43FEA0E31B71" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFB5CBE92E7DF9AAC1DF43FEA0E2F5B2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_0228242BB5B82764A3DA43FEA0E31B71" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicenseCosts" xlink:label="loc_us-gaap_LicenseCosts_C3DAE20AAC0A7F66F37643FEA0E35AEF" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFB5CBE92E7DF9AAC1DF43FEA0E2F5B2" xlink:to="loc_us-gaap_LicenseCosts_C3DAE20AAC0A7F66F37643FEA0E35AEF" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_Researchanddevelopmentservices" xlink:label="loc_biib_Researchanddevelopmentservices_90145527D86F6321C5D44401170FE736" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFB5CBE92E7DF9AAC1DF43FEA0E2F5B2" xlink:to="loc_biib_Researchanddevelopmentservices_90145527D86F6321C5D44401170FE736" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_Premiumonequityinvestment" xlink:label="loc_biib_Premiumonequityinvestment_F51FE72C5F2EC2B916D743FEA0E3115F" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFB5CBE92E7DF9AAC1DF43FEA0E2F5B2" xlink:to="loc_biib_Premiumonequityinvestment_F51FE72C5F2EC2B916D743FEA0E3115F" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_6C8EC7F3DC2DFF2B73A943FEA0E32983" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFB5CBE92E7DF9AAC1DF43FEA0E2F5B2" xlink:to="loc_biib_AdditionalMilestonePayment_6C8EC7F3DC2DFF2B73A943FEA0E32983" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FF0E026BC5CE1E92EE3DAE73D957DDA2" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_FBEBB55F50E93B5597F5AE73D95781A1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FF0E026BC5CE1E92EE3DAE73D957DDA2" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_FBEBB55F50E93B5597F5AE73D95781A1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4E207D692DF211677B4AAE73D957B789" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_FBEBB55F50E93B5597F5AE73D95781A1" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4E207D692DF211677B4AAE73D957B789" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_B8880A517D22D6DB4D2DAE73D9572C54" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4E207D692DF211677B4AAE73D957B789" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_B8880A517D22D6DB4D2DAE73D9572C54" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_7E0E37069767CDBF8963AE73D957397B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_B8880A517D22D6DB4D2DAE73D9572C54" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_7E0E37069767CDBF8963AE73D957397B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3597189B2BCE41228AD8AE73D9573E41" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_FBEBB55F50E93B5597F5AE73D95781A1" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3597189B2BCE41228AD8AE73D9573E41" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" xlink:label="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_41AF7C69484757FFC14FAE73D957F097" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3597189B2BCE41228AD8AE73D9573E41" xlink:to="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_41AF7C69484757FFC14FAE73D957F097" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_JointVentureOwnerShipPercentageByThirdParty" xlink:label="loc_biib_JointVentureOwnerShipPercentageByThirdParty_54B2C72B65B4C378328AAE73D95767EC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3597189B2BCE41228AD8AE73D9573E41" xlink:to="loc_biib_JointVentureOwnerShipPercentageByThirdParty_54B2C72B65B4C378328AAE73D95767EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_9CB4FFA9B459E1C56B74AE73D95733DE" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3597189B2BCE41228AD8AE73D9573E41" xlink:to="loc_us-gaap_EquityMethodInvestments_9CB4FFA9B459E1C56B74AE73D95733DE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_888EC4F26F6E9E901D71AE73D957C129" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3597189B2BCE41228AD8AE73D9573E41" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_888EC4F26F6E9E901D71AE73D957C129" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_EAB11AABB378F83B4233AE73D957729F" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3597189B2BCE41228AD8AE73D9573E41" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_EAB11AABB378F83B4233AE73D957729F" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_EquityMethodInvestmentOwnershipPercentageMaximum" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_B73581D89CB97F0C9A56AE73D95734CC" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3597189B2BCE41228AD8AE73D9573E41" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_B73581D89CB97F0C9A56AE73D95734CC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_517D388A11C0C5EFFF5DAE73D958823A" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3597189B2BCE41228AD8AE73D9573E41" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_517D388A11C0C5EFFF5DAE73D958823A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1621F5F278CE78216F5FAE73D958D7EF" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3597189B2BCE41228AD8AE73D9573E41" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1621F5F278CE78216F5FAE73D958D7EF" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_BF482127EE2A9E03F9DEAE73D958AEF3" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3597189B2BCE41228AD8AE73D9573E41" xlink:to="loc_biib_AdditionalMilestonePayment_BF482127EE2A9E03F9DEAE73D958AEF3" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_EquityMethodInvestmentsExpectedProfitShare" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_F3453C5ABEE1D8DC309CAE73D9588530" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3597189B2BCE41228AD8AE73D9573E41" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_F3453C5ABEE1D8DC309CAE73D9588530" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_56DCEE9C060367D8575DAE73D9589E90" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3597189B2BCE41228AD8AE73D9573E41" xlink:to="loc_us-gaap_OtherSalesRevenueNet_56DCEE9C060367D8575DAE73D9589E90" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingencesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9B439715B10A78809F913F3E22812BB3" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1D7B087FDA3E1516FF833F3E228126DF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9B439715B10A78809F913F3E22812BB3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1D7B087FDA3E1516FF833F3E228126DF" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_4C55D43A856D54B327833F3E2281BB66" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1D7B087FDA3E1516FF833F3E228126DF" xlink:to="loc_biib_CumulativeSalesLevelAxis_4C55D43A856D54B327833F3E2281BB66" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_AA077F9E992D4AEF0EDD3F3E228163D9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelAxis_4C55D43A856D54B327833F3E2281BB66" xlink:to="loc_biib_CumulativeSalesLevelDomain_AA077F9E992D4AEF0EDD3F3E228163D9" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_FourbillionMember" xlink:label="loc_biib_FourbillionMember_14DC9D8041A1E7118E3C3F3E2281E4EA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_AA077F9E992D4AEF0EDD3F3E228163D9" xlink:to="loc_biib_FourbillionMember_14DC9D8041A1E7118E3C3F3E2281E4EA" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_FivebillionMember" xlink:label="loc_biib_FivebillionMember_A5E161E412B2A7F2267B3F3E22812D39" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_AA077F9E992D4AEF0EDD3F3E228163D9" xlink:to="loc_biib_FivebillionMember_A5E161E412B2A7F2267B3F3E22812D39" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SixbillionMember" xlink:label="loc_biib_SixbillionMember_EDB968E377305E3F9CB13F86E28D0F6E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_AA077F9E992D4AEF0EDD3F3E228163D9" xlink:to="loc_biib_SixbillionMember_EDB968E377305E3F9CB13F86E28D0F6E" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_056AD91582DBEAF306CA3F3E22811482" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_AA077F9E992D4AEF0EDD3F3E228163D9" xlink:to="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_056AD91582DBEAF306CA3F3E22811482" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_OneBillionMember" xlink:label="loc_biib_OneBillionMember_5E71E2F114E6D418BDBD3F3E2281FDAA" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_AA077F9E992D4AEF0EDD3F3E228163D9" xlink:to="loc_biib_OneBillionMember_5E71E2F114E6D418BDBD3F3E2281FDAA" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_ThreeBillionMember" xlink:label="loc_biib_ThreeBillionMember_448C062CF29247EA488D3F3E2281B6C7" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_AA077F9E992D4AEF0EDD3F3E228163D9" xlink:to="loc_biib_ThreeBillionMember_448C062CF29247EA488D3F3E2281B6C7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_382AF231A839F8B0B71B3F3E2282BE2D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1D7B087FDA3E1516FF833F3E228126DF" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_382AF231A839F8B0B71B3F3E2282BE2D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_41D96D74E15383526D533F3E2282F556" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_382AF231A839F8B0B71B3F3E2282BE2D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_41D96D74E15383526D533F3E2282F556" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_10CAD5AAAF1763C484F73F3E228259EE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_41D96D74E15383526D533F3E2282F556" xlink:to="loc_biib_FumapharmAgMember_10CAD5AAAF1763C484F73F3E228259EE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_44629A458C7F34A71AD63F3E228291D5" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1D7B087FDA3E1516FF833F3E228126DF" xlink:to="loc_us-gaap_ProductOrServiceAxis_44629A458C7F34A71AD63F3E228291D5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_E189B96F16593FF691033F3E22822D47" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_44629A458C7F34A71AD63F3E228291D5" xlink:to="loc_us-gaap_ProductsAndServicesDomain_E189B96F16593FF691033F3E22822D47" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_1ED6A605267E6BD2BBC03F3E2282C2D3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E189B96F16593FF691033F3E22822D47" xlink:to="loc_biib_TecfideraMember_1ED6A605267E6BD2BBC03F3E2282C2D3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4C856771F8E500FF08E03F3E2282BF88" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1D7B087FDA3E1516FF833F3E228126DF" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4C856771F8E500FF08E03F3E2282BF88" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_6D4FFB2D0B7CEC2828C63F3E2282E1B3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4C856771F8E500FF08E03F3E2282BF88" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_6D4FFB2D0B7CEC2828C63F3E2282E1B3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4E4B8BC8CB30ACEEE5B03F3E22825CB9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4C856771F8E500FF08E03F3E2282BF88" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4E4B8BC8CB30ACEEE5B03F3E22825CB9" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_5AD055203F8A4FD3DDF73F3E2282683D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4C856771F8E500FF08E03F3E2282BF88" xlink:to="loc_biib_CumulativeSalesLevel_5AD055203F8A4FD3DDF73F3E2282683D" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2AFE87A156F66A0EF6F7AE73DB1985B4" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_189915F009BCD22BE154AE73DB196C01" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2AFE87A156F66A0EF6F7AE73DB1985B4" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_189915F009BCD22BE154AE73DB196C01" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_40391494B1C690920F13AE73DA92F227" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_4C01FBFF5C55DDEB033FAE73DA92FF86" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_40391494B1C690920F13AE73DA92F227" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_4C01FBFF5C55DDEB033FAE73DA92FF86" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_C459EB3083ED884B30BFAE73DA929D47" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_4C01FBFF5C55DDEB033FAE73DA92FF86" xlink:to="loc_us-gaap_StatementGeographicalAxis_C459EB3083ED884B30BFAE73DA929D47" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_1C9E18AEFAA00CE82453AE73DA928913" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_C459EB3083ED884B30BFAE73DA929D47" xlink:to="loc_us-gaap_SegmentGeographicalDomain_1C9E18AEFAA00CE82453AE73DA928913" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_CH" xlink:label="loc_country_CH_57E9FB756D275CEEC7E3AE73DA927ECA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_1C9E18AEFAA00CE82453AE73DA928913" xlink:to="loc_country_CH_57E9FB756D275CEEC7E3AE73DA927ECA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0B7581993C9B0E2EA9F3AE73DA92C287" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_4C01FBFF5C55DDEB033FAE73DA92FF86" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0B7581993C9B0E2EA9F3AE73DA92C287" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Land" xlink:label="loc_us-gaap_Land_A3900C5EBEFDDC62286FAE73DA928955" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0B7581993C9B0E2EA9F3AE73DA92C287" xlink:to="loc_us-gaap_Land_A3900C5EBEFDDC62286FAE73DA928955" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_CB8C217453BE52BEA7DD2E2244F373F0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_DE64FD6F8082B4D8B6272E2244F388AE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_CB8C217453BE52BEA7DD2E2244F373F0" xlink:to="loc_us-gaap_AssetsAbstract_DE64FD6F8082B4D8B6272E2244F388AE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3C79A0AD8E586210AD5B2E2244F3A3DB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_DE64FD6F8082B4D8B6272E2244F388AE" xlink:to="loc_us-gaap_AssetsCurrentAbstract_3C79A0AD8E586210AD5B2E2244F3A3DB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_67A0828651AC8A5AE2BB2E2244F33101" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3C79A0AD8E586210AD5B2E2244F3A3DB" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_67A0828651AC8A5AE2BB2E2244F33101" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_B6F24448B49FA8ADE4C82E2244F33201" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3C79A0AD8E586210AD5B2E2244F3A3DB" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_B6F24448B49FA8ADE4C82E2244F33201" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_367852297D788C3010BC2E2244F39F2C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3C79A0AD8E586210AD5B2E2244F3A3DB" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_367852297D788C3010BC2E2244F39F2C" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_DueFromUnconsolidatedJointBusiness" xlink:label="loc_biib_DueFromUnconsolidatedJointBusiness_7C2ED3D238B91159F68C2E2244F4189B" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3C79A0AD8E586210AD5B2E2244F3A3DB" xlink:to="loc_biib_DueFromUnconsolidatedJointBusiness_7C2ED3D238B91159F68C2E2244F4189B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_530F84625F46856321192E2244F42FBF" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3C79A0AD8E586210AD5B2E2244F3A3DB" xlink:to="loc_us-gaap_InventoryNet_530F84625F46856321192E2244F42FBF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_DD75DFCC4FFBF73A93A52E2244F4FF5D" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3C79A0AD8E586210AD5B2E2244F3A3DB" xlink:to="loc_us-gaap_OtherAssetsCurrent_DD75DFCC4FFBF73A93A52E2244F4FF5D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_9B8DC736B64201D7DFE42E2244F41248" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3C79A0AD8E586210AD5B2E2244F3A3DB" xlink:to="loc_us-gaap_AssetsCurrent_9B8DC736B64201D7DFE42E2244F41248" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_CB64E1E67A7940103A212E2244F42BFE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_DE64FD6F8082B4D8B6272E2244F388AE" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_CB64E1E67A7940103A212E2244F42BFE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3FC902DB8C222077A87F2E2244F40BD1" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_DE64FD6F8082B4D8B6272E2244F388AE" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3FC902DB8C222077A87F2E2244F40BD1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_38BED52BCBF2719F5C332E2244F44B3A" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_DE64FD6F8082B4D8B6272E2244F388AE" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_38BED52BCBF2719F5C332E2244F44B3A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_62ACDD4180DABB4E16C52E2244F49C29" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_DE64FD6F8082B4D8B6272E2244F388AE" xlink:to="loc_us-gaap_Goodwill_62ACDD4180DABB4E16C52E2244F49C29" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_D3D60BB03E3F07326C222E2244F407A4" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_DE64FD6F8082B4D8B6272E2244F388AE" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_D3D60BB03E3F07326C222E2244F407A4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_5632F78EA45FE84073D52E2244F4652D" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_DE64FD6F8082B4D8B6272E2244F388AE" xlink:to="loc_us-gaap_Assets_5632F78EA45FE84073D52E2244F4652D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3CC79BFA1BD8AF38EEF52E2244F4BD08" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_CB8C217453BE52BEA7DD2E2244F373F0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3CC79BFA1BD8AF38EEF52E2244F4BD08" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_F75621576EB537BA2D9B2E2244F49570" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3CC79BFA1BD8AF38EEF52E2244F4BD08" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_F75621576EB537BA2D9B2E2244F49570" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_8AE4CE8E979A1D6CCF902E2244F400DA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F75621576EB537BA2D9B2E2244F49570" xlink:to="loc_us-gaap_DebtCurrent_8AE4CE8E979A1D6CCF902E2244F400DA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_BA430734BF0EBA8B772A2E2244F5A865" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F75621576EB537BA2D9B2E2244F49570" xlink:to="loc_us-gaap_TaxesPayableCurrent_BA430734BF0EBA8B772A2E2244F5A865" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_CB9FC6A2FA35B6EE8ABC2E2244F59A96" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F75621576EB537BA2D9B2E2244F49570" xlink:to="loc_us-gaap_AccountsPayableCurrent_CB9FC6A2FA35B6EE8ABC2E2244F59A96" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_6547B666B8C863F35FB12E2244F5BF49" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F75621576EB537BA2D9B2E2244F49570" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_6547B666B8C863F35FB12E2244F5BF49" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_304C46EA002A90CA41CE2E2244F58888" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F75621576EB537BA2D9B2E2244F49570" xlink:to="loc_us-gaap_LiabilitiesCurrent_304C46EA002A90CA41CE2E2244F58888" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_6C5616D15D1735DF552D2E2244F5383C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3CC79BFA1BD8AF38EEF52E2244F4BD08" xlink:to="loc_us-gaap_LongTermDebt_6C5616D15D1735DF552D2E2244F5383C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_926E5BE5CEE6704FE0062E2244F579B8" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3CC79BFA1BD8AF38EEF52E2244F4BD08" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_926E5BE5CEE6704FE0062E2244F579B8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_03AC0BCAAB831455EA0B2E2244F54558" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3CC79BFA1BD8AF38EEF52E2244F4BD08" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_03AC0BCAAB831455EA0B2E2244F54558" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_4B62AEA0D69F6CE7E2002E2244F51E07" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3CC79BFA1BD8AF38EEF52E2244F4BD08" xlink:to="loc_us-gaap_Liabilities_4B62AEA0D69F6CE7E2002E2244F51E07" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_AAAABC8F618AA33D91B32E2244F55FB6" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3CC79BFA1BD8AF38EEF52E2244F4BD08" xlink:to="loc_us-gaap_CommitmentsAndContingencies_AAAABC8F618AA33D91B32E2244F55FB6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3F21C88AC001FDCC7EFD2E2244F56319" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3CC79BFA1BD8AF38EEF52E2244F4BD08" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3F21C88AC001FDCC7EFD2E2244F56319" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_1773B6488BE46E0BA7272E2244F5D1E1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3F21C88AC001FDCC7EFD2E2244F56319" xlink:to="loc_us-gaap_StockholdersEquityAbstract_1773B6488BE46E0BA7272E2244F5D1E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_8C25F97A4FF49F8796202E2244F5E623" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1773B6488BE46E0BA7272E2244F5D1E1" xlink:to="loc_us-gaap_PreferredStockValue_8C25F97A4FF49F8796202E2244F5E623" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_DC78F34165E7759584D02E2244F5AA88" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1773B6488BE46E0BA7272E2244F5D1E1" xlink:to="loc_us-gaap_CommonStockValue_DC78F34165E7759584D02E2244F5AA88" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_E190859FBB9E9CA4D3412E2244F5EA4D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1773B6488BE46E0BA7272E2244F5D1E1" xlink:to="loc_us-gaap_AdditionalPaidInCapital_E190859FBB9E9CA4D3412E2244F5EA4D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_15E0C9C74C4F4C0188ED2E2244F5BB2C" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1773B6488BE46E0BA7272E2244F5D1E1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_15E0C9C74C4F4C0188ED2E2244F5BB2C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2E2B7F8478A32D65F2132E2244F521AB" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1773B6488BE46E0BA7272E2244F5D1E1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2E2B7F8478A32D65F2132E2244F521AB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_95E4F44BF83A123699FA2E2244F6593E" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1773B6488BE46E0BA7272E2244F5D1E1" xlink:to="loc_us-gaap_TreasuryStockValue_95E4F44BF83A123699FA2E2244F6593E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_3F5F3C10D84D4933BF462E2244F6EA36" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1773B6488BE46E0BA7272E2244F5D1E1" xlink:to="loc_us-gaap_StockholdersEquity_3F5F3C10D84D4933BF462E2244F6EA36" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_E97F296EFEE92A4EE90C2E2244F6ECF9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3F21C88AC001FDCC7EFD2E2244F56319" xlink:to="loc_us-gaap_MinorityInterest_E97F296EFEE92A4EE90C2E2244F6ECF9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_CF8DBF43B823CE769DB32E2244F64E90" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3F21C88AC001FDCC7EFD2E2244F56319" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_CF8DBF43B823CE769DB32E2244F64E90" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_004C73CCD3281FBB7C6B2E2244F66CD3" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3CC79BFA1BD8AF38EEF52E2244F4BD08" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_004C73CCD3281FBB7C6B2E2244F66CD3" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9B24488F2AF56ACD376AAE73D93E75F7" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6ADABC5987D621C99AB4AE73D93EE52A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9B24488F2AF56ACD376AAE73D93E75F7" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6ADABC5987D621C99AB4AE73D93EE52A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_889A5721E2BA0EF631CBAE73D93FD617" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9B24488F2AF56ACD376AAE73D93E75F7" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_889A5721E2BA0EF631CBAE73D93FD617" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_711340CE2372DA30D60A71883E38C1B2" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_86AC88793704770CF26571883E3894DF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_711340CE2372DA30D60A71883E38C1B2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_86AC88793704770CF26571883E3894DF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_C6384953A2A6E2A5D06F71883E38D70A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_86AC88793704770CF26571883E3894DF" xlink:to="loc_us-gaap_ProfitLoss_C6384953A2A6E2A5D06F71883E38D70A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDA35972990BD0280FC471883E38A66C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_86AC88793704770CF26571883E3894DF" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDA35972990BD0280FC471883E38A66C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_56F810AEBEF3756056B971883E3807F8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDA35972990BD0280FC471883E38A66C" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_56F810AEBEF3756056B971883E3807F8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_0D8432A273C672CF3E6771883E388824" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDA35972990BD0280FC471883E38A66C" xlink:to="loc_us-gaap_ShareBasedCompensation_0D8432A273C672CF3E6771883E388824" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_D047BE6885FDD2318BD571883E383FD1" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDA35972990BD0280FC471883E38A66C" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_D047BE6885FDD2318BD571883E383FD1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_C46A62AC1DED1A7ADDA271883E382611" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDA35972990BD0280FC471883E38A66C" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_C46A62AC1DED1A7ADDA271883E382611" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8B748038B4AD249A4A0871883E38B883" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDA35972990BD0280FC471883E38A66C" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8B748038B4AD249A4A0871883E38B883" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6426EEB437FF11D6938D71883E384E7E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8B748038B4AD249A4A0871883E38B883" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6426EEB437FF11D6938D71883E384E7E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_4665E16D98F729A9306771883E380BAF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8B748038B4AD249A4A0871883E38B883" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_4665E16D98F729A9306771883E380BAF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2FDA9A527A01A1E13CB771883E39A4E3" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8B748038B4AD249A4A0871883E38B883" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2FDA9A527A01A1E13CB771883E39A4E3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_62B14FE540818E00FC9171883E395903" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8B748038B4AD249A4A0871883E38B883" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_62B14FE540818E00FC9171883E395903" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_964DD2FD05859AAC2A2971883E393BFC" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDA35972990BD0280FC471883E38A66C" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_964DD2FD05859AAC2A2971883E393BFC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A87D9CDCAD7FAAECBC4571883E393364" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_711340CE2372DA30D60A71883E38C1B2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A87D9CDCAD7FAAECBC4571883E393364" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_22BB4F92F4B13F1329BD71883E393121" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A87D9CDCAD7FAAECBC4571883E393364" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_22BB4F92F4B13F1329BD71883E393121" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_1E8ECD466C6B1C8364AF71883E39BE12" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A87D9CDCAD7FAAECBC4571883E393364" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_1E8ECD466C6B1C8364AF71883E39BE12" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_FBA85EF469326E7313DE71883E39E2AD" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A87D9CDCAD7FAAECBC4571883E393364" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_FBA85EF469326E7313DE71883E39E2AD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C6637885FD3882E75DD071883E3983AD" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A87D9CDCAD7FAAECBC4571883E393364" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C6637885FD3882E75DD071883E3983AD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_D57D659C6108D5EA59E971883E395086" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A87D9CDCAD7FAAECBC4571883E393364" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_D57D659C6108D5EA59E971883E395086" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_20B4D9670B5C43FDE91771883E3998E7" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A87D9CDCAD7FAAECBC4571883E393364" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_20B4D9670B5C43FDE91771883E3998E7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_EE459034572DD33763C171883E399D9F" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A87D9CDCAD7FAAECBC4571883E393364" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_EE459034572DD33763C171883E399D9F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3D04F8D1230F83DA075471883E39B828" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_711340CE2372DA30D60A71883E38C1B2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3D04F8D1230F83DA075471883E39B828" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4D4D947218D9EE083A0F71883E39A26A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3D04F8D1230F83DA075471883E39B828" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4D4D947218D9EE083A0F71883E39A26A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_3AF45795A4861087F4D971883E39244D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3D04F8D1230F83DA075471883E39B828" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_3AF45795A4861087F4D971883E39244D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_BD871ED31DE39577CB8271883E394DAA" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3D04F8D1230F83DA075471883E39B828" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_BD871ED31DE39577CB8271883E394DAA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_28AA1A4D5EF7C10CF33371883E39255B" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3D04F8D1230F83DA075471883E39B828" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_28AA1A4D5EF7C10CF33371883E39255B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_CE5D9D2839896CA798B771883E390E5F" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3D04F8D1230F83DA075471883E39B828" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_CE5D9D2839896CA798B771883E390E5F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9C6758C5F7C4F0546D5A71883E390762" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3D04F8D1230F83DA075471883E39B828" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9C6758C5F7C4F0546D5A71883E390762" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_89F1048F1E2031E61EF071883E3A5788" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3D04F8D1230F83DA075471883E39B828" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_89F1048F1E2031E61EF071883E3A5788" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_8A2A82FC8C75BA07129671883E3AB178" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_711340CE2372DA30D60A71883E38C1B2" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_8A2A82FC8C75BA07129671883E3AB178" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_2B173DA8E3E2D12E242F71883E3A3023" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_711340CE2372DA30D60A71883E38C1B2" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_2B173DA8E3E2D12E242F71883E3A3023" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_04B258A88E3A1317BD7671883E3AE57E" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_711340CE2372DA30D60A71883E38C1B2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_04B258A88E3A1317BD7671883E3AE57E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0ED3300AEB99BAFAB57471883E3A26D3" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_711340CE2372DA30D60A71883E38C1B2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0ED3300AEB99BAFAB57471883E3A26D3" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_CDD217D5A6FEE5B3547471883E4C11BC" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_490BC66F53EFA83A6D7B71883E4C3542" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_CDD217D5A6FEE5B3547471883E4C11BC" xlink:to="loc_us-gaap_NetIncomeLoss_490BC66F53EFA83A6D7B71883E4C3542" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6DDACD248415A2CDF5DB71883E4D16C4" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_CDD217D5A6FEE5B3547471883E4C11BC" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6DDACD248415A2CDF5DB71883E4D16C4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4D564ACB633496C5A7E171883E4D9B16" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6DDACD248415A2CDF5DB71883E4D16C4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4D564ACB633496C5A7E171883E4D9B16" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_63AC91730DDB249CCA8171883E4D2BB0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6DDACD248415A2CDF5DB71883E4D16C4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_63AC91730DDB249CCA8171883E4D2BB0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_C70D522DEF04086B28B571883E4D4FF2" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6DDACD248415A2CDF5DB71883E4D16C4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_C70D522DEF04086B28B571883E4D4FF2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6EE1B6C3470969345EE071883E4D2DD0" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6DDACD248415A2CDF5DB71883E4D16C4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6EE1B6C3470969345EE071883E4D2DD0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_32AAF3D5B4B414E141AA71883E4D6EB2" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6DDACD248415A2CDF5DB71883E4D16C4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_32AAF3D5B4B414E141AA71883E4D6EB2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1F2ED52FCE9902C06BB571883E4DC367" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6DDACD248415A2CDF5DB71883E4D16C4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_1F2ED52FCE9902C06BB571883E4DC367" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_D329F59DB83424AF08FA71883E4D3A44" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6DDACD248415A2CDF5DB71883E4D16C4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_D329F59DB83424AF08FA71883E4D3A44" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_DF20FF739776680105AB71883E4D7654" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6DDACD248415A2CDF5DB71883E4D16C4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_DF20FF739776680105AB71883E4D7654" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedParenthetical" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4464FA92D002B9CA56C33E9CFBF2DBA5" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_713998584FE4A5FC61AC3E9CFBF2C987" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4464FA92D002B9CA56C33E9CFBF2DBA5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_713998584FE4A5FC61AC3E9CFBF2C987" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax_9D3F047A4D3E831BDF2D3E9CFBF20708" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4464FA92D002B9CA56C33E9CFBF2DBA5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax_9D3F047A4D3E831BDF2D3E9CFBF20708" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_5AD7F181A13F39700016AE73DB03F624" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_0917FADCB333E3659FCAAE73DB032669" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5AD7F181A13F39700016AE73DB03F624" xlink:to="loc_us-gaap_RevenuesAbstract_0917FADCB333E3659FCAAE73DB032669" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_D6B6EA589A0F1170ECF1AE73DB037DDE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_0917FADCB333E3659FCAAE73DB032669" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_D6B6EA589A0F1170ECF1AE73DB037DDE" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_UnconsolidatedJointBusiness" xlink:label="loc_biib_UnconsolidatedJointBusiness_341BB8D745D2D0718C95AE73DB034C41" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_0917FADCB333E3659FCAAE73DB032669" xlink:to="loc_biib_UnconsolidatedJointBusiness_341BB8D745D2D0718C95AE73DB034C41" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_616F03B15306DEE3CEA7AE73DB04F6D0" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_0917FADCB333E3659FCAAE73DB032669" xlink:to="loc_us-gaap_OtherSalesRevenueNet_616F03B15306DEE3CEA7AE73DB04F6D0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_DFF56A14797E61FAC277AE73DB041DA2" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_0917FADCB333E3659FCAAE73DB032669" xlink:to="loc_us-gaap_Revenues_DFF56A14797E61FAC277AE73DB041DA2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_B921A60251F176A99EA6AE73DB0493BC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5AD7F181A13F39700016AE73DB03F624" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_B921A60251F176A99EA6AE73DB0493BC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_BD35B39F8B63CD4CF688AE73DB04F1E7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_B921A60251F176A99EA6AE73DB0493BC" xlink:to="loc_us-gaap_CostOfGoodsSold_BD35B39F8B63CD4CF688AE73DB04F1E7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_21CD4395A89527B428C6AE73DB04FBB9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_B921A60251F176A99EA6AE73DB0493BC" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_21CD4395A89527B428C6AE73DB04FBB9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_5B309260C272ACDB5E1BAE73DB046AE9" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_B921A60251F176A99EA6AE73DB0493BC" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_5B309260C272ACDB5E1BAE73DB046AE9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4EAED753D628C0BE0E67AE73DB04E67D" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_B921A60251F176A99EA6AE73DB0493BC" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_4EAED753D628C0BE0E67AE73DB04E67D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_D21FB4CEA2672D724D1DAE73DB04765A" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_B921A60251F176A99EA6AE73DB0493BC" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_D21FB4CEA2672D724D1DAE73DB04765A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_B263B7FC51105131E1BBAE73DB0454D0" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_B921A60251F176A99EA6AE73DB0493BC" xlink:to="loc_us-gaap_CostsAndExpenses_B263B7FC51105131E1BBAE73DB0454D0" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_GainOnSaleOfRights" xlink:label="loc_biib_GainOnSaleOfRights_A453F3AC198A99B44419AE73DB04B854" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5AD7F181A13F39700016AE73DB03F624" xlink:to="loc_biib_GainOnSaleOfRights_A453F3AC198A99B44419AE73DB04B854" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_B36C1C3A0965401FD065AE73DB048F60" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5AD7F181A13F39700016AE73DB03F624" xlink:to="loc_us-gaap_OperatingIncomeLoss_B36C1C3A0965401FD065AE73DB048F60" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_946C67FE798C884A8DC6AE73DB05EC0D" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5AD7F181A13F39700016AE73DB03F624" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_946C67FE798C884A8DC6AE73DB05EC0D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3CEAAECB8355C87D8DF5AE73DB055B1F" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5AD7F181A13F39700016AE73DB03F624" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3CEAAECB8355C87D8DF5AE73DB055B1F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_03A34D5D4948DB32F88EAE73DB050493" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5AD7F181A13F39700016AE73DB03F624" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_03A34D5D4948DB32F88EAE73DB050493" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_99E0E90AF0D364AAD7AEAE73DB05B6A3" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5AD7F181A13F39700016AE73DB03F624" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_99E0E90AF0D364AAD7AEAE73DB05B6A3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_691741C877E5C9611AE1AE73DB05F47B" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5AD7F181A13F39700016AE73DB03F624" xlink:to="loc_us-gaap_ProfitLoss_691741C877E5C9611AE1AE73DB05F47B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_D63C4D116C7262C29587AE73DB05512B" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5AD7F181A13F39700016AE73DB03F624" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_D63C4D116C7262C29587AE73DB05512B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_416F83B7E692F7CB1E45AE73DB054491" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5AD7F181A13F39700016AE73DB03F624" xlink:to="loc_us-gaap_NetIncomeLoss_416F83B7E692F7CB1E45AE73DB054491" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3B938C11DAE0BA4CF827AE73DB058464" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5AD7F181A13F39700016AE73DB03F624" xlink:to="loc_us-gaap_EarningsPerShareAbstract_3B938C11DAE0BA4CF827AE73DB058464" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_19D8319CF5678ADBD6DFAE73DB05674A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3B938C11DAE0BA4CF827AE73DB058464" xlink:to="loc_us-gaap_EarningsPerShareBasic_19D8319CF5678ADBD6DFAE73DB05674A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_727663ECCA566594DF0FAE73DB053284" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3B938C11DAE0BA4CF827AE73DB058464" xlink:to="loc_us-gaap_EarningsPerShareDiluted_727663ECCA566594DF0FAE73DB053284" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7826DB244ED88F115928AE73DB05B253" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5AD7F181A13F39700016AE73DB03F624" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7826DB244ED88F115928AE73DB05B253" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_CC50E41EDC3FDB46A014AE73DB069680" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7826DB244ED88F115928AE73DB05B253" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_CC50E41EDC3FDB46A014AE73DB069680" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_068F6E3F0D3EF9D505B0AE73DB065718" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7826DB244ED88F115928AE73DB05B253" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_068F6E3F0D3EF9D505B0AE73DB065718" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3B950B9AE05D1B32F5FDAE73DAE1C976" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_4A4883B44537EE264AE6AE73DAE17992" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3B950B9AE05D1B32F5FDAE73DAE1C976" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_4A4883B44537EE264AE6AE73DAE17992" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_DDB628E2FF2F0197C58371883D8FFED9" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5661B9FC8ECA81734BBF71883D903FD8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_DDB628E2FF2F0197C58371883D8FFED9" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5661B9FC8ECA81734BBF71883D903FD8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_F9137E129C4289F7E1E571883D902F8F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5661B9FC8ECA81734BBF71883D903FD8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_F9137E129C4289F7E1E571883D902F8F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_E630E70D56D556D4882B71883D905E60" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_F9137E129C4289F7E1E571883D902F8F" xlink:to="loc_us-gaap_EquityComponentDomain_E630E70D56D556D4882B71883D905E60" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_6437FDB9E33F4EECA8A471883D90075C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_E630E70D56D556D4882B71883D905E60" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_6437FDB9E33F4EECA8A471883D90075C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_62AF664553A6FF4AE35471883D90550D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5661B9FC8ECA81734BBF71883D903FD8" xlink:to="loc_us-gaap_DebtInstrumentAxis_62AF664553A6FF4AE35471883D90550D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5999F17314350458F9EC71883D90E54F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_62AF664553A6FF4AE35471883D90550D" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5999F17314350458F9EC71883D90E54F" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_54977BD726433157B60771883D904E2C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5999F17314350458F9EC71883D90E54F" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_54977BD726433157B60771883D904E2C" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_847DA85D41DAC8B9057C71883D9068A6" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5999F17314350458F9EC71883D90E54F" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_847DA85D41DAC8B9057C71883D9068A6" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_DA2FEA6B56321AB78A8D71883D90749A" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5999F17314350458F9EC71883D90E54F" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_DA2FEA6B56321AB78A8D71883D90749A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaap_CurrencyAxis_F88AE216C787925E4AB471883D90AC24" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5661B9FC8ECA81734BBF71883D903FD8" xlink:to="loc_us-gaap_CurrencyAxis_F88AE216C787925E4AB471883D90AC24" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_3C4DFE46ADCF99F2254771883D906B05" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrencyAxis_F88AE216C787925E4AB471883D90AC24" xlink:to="loc_currency_AllCurrenciesDomain_3C4DFE46ADCF99F2254771883D906B05" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_BB987EC231F3BCA7841271883D9016D7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_3C4DFE46ADCF99F2254771883D906B05" xlink:to="loc_currency_EUR_BB987EC231F3BCA7841271883D9016D7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_9214581F3388E20CF22E71883D900F73" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_3C4DFE46ADCF99F2254771883D906B05" xlink:to="loc_currency_CAD_9214581F3388E20CF22E71883D900F73" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_54673D65504D10AC046F71883D90E6D4" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_3C4DFE46ADCF99F2254771883D906B05" xlink:to="loc_currency_GBP_54673D65504D10AC046F71883D90E6D4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_JPY" xlink:label="loc_currency_JPY_6A890CB159A3ECADA30271883D917A3D" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_3C4DFE46ADCF99F2254771883D906B05" xlink:to="loc_currency_JPY_6A890CB159A3ECADA30271883D917A3D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AUD" xlink:label="loc_currency_AUD_11DAED1BE65F6D65A5C371883D9148D3" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_3C4DFE46ADCF99F2254771883D906B05" xlink:to="loc_currency_AUD_11DAED1BE65F6D65A5C371883D9148D3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_70C5DC0DB328D1CB3F4B71883D91D928" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5661B9FC8ECA81734BBF71883D903FD8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_70C5DC0DB328D1CB3F4B71883D91D928" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C9DCAD0AE89887F23AD771883D91A2F4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_70C5DC0DB328D1CB3F4B71883D91D928" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_C9DCAD0AE89887F23AD771883D91A2F4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_F9CA5412A296A741E5F671883D917EB0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C9DCAD0AE89887F23AD771883D91A2F4" xlink:to="loc_us-gaap_SalesMember_F9CA5412A296A741E5F671883D917EB0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_DBAA740734B5288BCC1471883D916303" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C9DCAD0AE89887F23AD771883D91A2F4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_DBAA740734B5288BCC1471883D916303" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_7559A45E2BE627CC0C0871883D918DD5" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5661B9FC8ECA81734BBF71883D903FD8" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_7559A45E2BE627CC0C0871883D918DD5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_15A4CFCAAAFC153D2E0671883D913F2F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7559A45E2BE627CC0C0871883D918DD5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_15A4CFCAAAFC153D2E0671883D913F2F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_591E016BC232CB22A9E971883D916DF1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_15A4CFCAAAFC153D2E0671883D913F2F" xlink:to="loc_us-gaap_ForeignExchangeContractMember_591E016BC232CB22A9E971883D916DF1" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_InterestratelocksMember" xlink:label="loc_biib_InterestratelocksMember_3B0D41ABD32C1ECAE60B71883D916591" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_15A4CFCAAAFC153D2E0671883D913F2F" xlink:to="loc_biib_InterestratelocksMember_3B0D41ABD32C1ECAE60B71883D916591" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_4B7121D80409244270B871883D91D2BF" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_15A4CFCAAAFC153D2E0671883D913F2F" xlink:to="loc_us-gaap_InterestRateSwapMember_4B7121D80409244270B871883D91D2BF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_D23194920FDEDCC6BCB071883D91A24B" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5661B9FC8ECA81734BBF71883D903FD8" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_D23194920FDEDCC6BCB071883D91A24B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8787B6B7DACE435004FE71883D91D512" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_D23194920FDEDCC6BCB071883D91A24B" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8787B6B7DACE435004FE71883D91D512" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_A1A8587FE0475B354F2D71883D910A5F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8787B6B7DACE435004FE71883D91D512" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_A1A8587FE0475B354F2D71883D910A5F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="loc_us-gaap_OtherInvestmentsMember_F4CF7731752451F96FD971883D913A04" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8787B6B7DACE435004FE71883D91D512" xlink:to="loc_us-gaap_OtherInvestmentsMember_F4CF7731752451F96FD971883D913A04" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_3B69F2E0A5072BDCC72D71883D92D09A" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8787B6B7DACE435004FE71883D91D512" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_3B69F2E0A5072BDCC72D71883D92D09A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_7CAD6154F6535306734771883D92BC31" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8787B6B7DACE435004FE71883D91D512" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_7CAD6154F6535306734771883D92BC31" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_DFCF0CA186418E91EE6C71883D92E3D5" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5661B9FC8ECA81734BBF71883D903FD8" xlink:to="loc_us-gaap_HedgingDesignationAxis_DFCF0CA186418E91EE6C71883D92E3D5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_B1E0C97B80B357052D2571883D92F408" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_DFCF0CA186418E91EE6C71883D92E3D5" xlink:to="loc_us-gaap_HedgingDesignationDomain_B1E0C97B80B357052D2571883D92F408" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_951EDFEFFD4AF905DDD271883D923A00" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_B1E0C97B80B357052D2571883D92F408" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_951EDFEFFD4AF905DDD271883D923A00" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_2431FDFAB5771274CAC271883D97F720" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_B1E0C97B80B357052D2571883D92F408" xlink:to="loc_us-gaap_NondesignatedMember_2431FDFAB5771274CAC271883D97F720" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_ADEB9161A70F9F58000871883D97BF43" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5661B9FC8ECA81734BBF71883D903FD8" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_ADEB9161A70F9F58000871883D97BF43" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_27B3206A552A8630A9DD71883D9C0319" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ADEB9161A70F9F58000871883D97BF43" xlink:to="loc_us-gaap_DerivativeAssetFairValueNetAbstract_27B3206A552A8630A9DD71883D9C0319" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_DD771838E0898A2A9ADB71883D9C289A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_27B3206A552A8630A9DD71883D9C0319" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_DD771838E0898A2A9ADB71883D9C289A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_75E28D89FF67069FE30B71883D9C67E3" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_27B3206A552A8630A9DD71883D9C0319" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_75E28D89FF67069FE30B71883D9C67E3" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_DerivativeInstrumentsTextualAbstract" xlink:label="loc_biib_DerivativeInstrumentsTextualAbstract_2B95F15DCB5BD88DD2BA71883D9C4459" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ADEB9161A70F9F58000871883D97BF43" xlink:to="loc_biib_DerivativeInstrumentsTextualAbstract_2B95F15DCB5BD88DD2BA71883D9C4459" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLowerRemainingMaturityRange1" xlink:label="loc_us-gaap_DerivativeLowerRemainingMaturityRange1_2F4F94091B01D8CBD56271883D9C5635" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_2B95F15DCB5BD88DD2BA71883D9C4459" xlink:to="loc_us-gaap_DerivativeLowerRemainingMaturityRange1_2F4F94091B01D8CBD56271883D9C5635" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeHigherRemainingMaturityRange1" xlink:label="loc_us-gaap_DerivativeHigherRemainingMaturityRange1_33C68787831D3B5F059671883D9CA55C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_2B95F15DCB5BD88DD2BA71883D9C4459" xlink:to="loc_us-gaap_DerivativeHigherRemainingMaturityRange1_33C68787831D3B5F059671883D9CA55C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_11EA4347461178D2E37771883D9C8FCB" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_2B95F15DCB5BD88DD2BA71883D9C4459" xlink:to="loc_invest_DerivativeNotionalAmount_11EA4347461178D2E37771883D9C8FCB" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_7BCEF77576DE56DBA48671883D9DB5CF" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_2B95F15DCB5BD88DD2BA71883D9C4459" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_7BCEF77576DE56DBA48671883D9DB5CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_D71F5765F0FFB218B16271883D9DD75F" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_2B95F15DCB5BD88DD2BA71883D9C4459" xlink:to="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_D71F5765F0FFB218B16271883D9DD75F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_98D0B672259F876B715D71883D9DC172" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_2B95F15DCB5BD88DD2BA71883D9C4459" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_98D0B672259F876B715D71883D9DC172" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_DCB5C27FBF090C1156F271883D9D7036" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_2B95F15DCB5BD88DD2BA71883D9C4459" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_DCB5C27FBF090C1156F271883D9D7036" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_BD54A25A007AC78DBB8671883D9D9D70" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_2B95F15DCB5BD88DD2BA71883D9C4459" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_BD54A25A007AC78DBB8671883D9D9D70" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8F6AA8B2E295D3CAB45271883D9D62CA" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_2B95F15DCB5BD88DD2BA71883D9C4459" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8F6AA8B2E295D3CAB45271883D9D62CA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_923D865BE31BCD18A94B71883D9D1BCE" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_2B95F15DCB5BD88DD2BA71883D9C4459" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_923D865BE31BCD18A94B71883D9D1BCE" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_AE580D96A0D8DA9D671EAE73DA9BB95E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_F6C4852CF9669185B4ECAE73DA9BEE0F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_AE580D96A0D8DA9D671EAE73DA9BB95E" xlink:to="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_F6C4852CF9669185B4ECAE73DA9BEE0F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_9158D2FBD517910D7B82AE73DA9C2CDF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_AE580D96A0D8DA9D671EAE73DA9BB95E" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_9158D2FBD517910D7B82AE73DA9C2CDF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_ACFF57CA619E5B155CE5AE73DA9CEF61" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_AE580D96A0D8DA9D671EAE73DA9BB95E" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_ACFF57CA619E5B155CE5AE73DA9CEF61" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:href="biib-20150930.xsd#biib_DocumentAndEntityInformationAbstract" xlink:label="loc_biib_DocumentAndEntityInformationAbstract_8A2C1C098326A87A273DAE73DB1E438D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_9792297EEB6A8AFAF563AE73DB1F572A" xlink:type="locator" />
    <presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_8A2C1C098326A87A273DAE73DB1E438D" xlink:to="loc_dei_EntityRegistrantName_9792297EEB6A8AFAF563AE73DB1F572A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_4A97C03D6767032EB08DAE73DB1F12F3" xlink:type="locator" />
    <presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_8A2C1C098326A87A273DAE73DB1E438D" xlink:to="loc_dei_EntityCentralIndexKey_4A97C03D6767032EB08DAE73DB1F12F3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_BAACAD6319E7D7BC09FDAE73DB1F31AF" xlink:type="locator" />
    <presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_8A2C1C098326A87A273DAE73DB1E438D" xlink:to="loc_dei_CurrentFiscalYearEndDate_BAACAD6319E7D7BC09FDAE73DB1F31AF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_0112C9B72E7742456572AE73DB1FD9E1" xlink:type="locator" />
    <presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_8A2C1C098326A87A273DAE73DB1E438D" xlink:to="loc_dei_EntityFilerCategory_0112C9B72E7742456572AE73DB1FD9E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_0382B5D13D024D2BF57AAE73DB1F5058" xlink:type="locator" />
    <presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_8A2C1C098326A87A273DAE73DB1E438D" xlink:to="loc_dei_DocumentType_0382B5D13D024D2BF57AAE73DB1F5058" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_3F6A964D94A90D9A0B02AE73DB1F6D5E" xlink:type="locator" />
    <presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_8A2C1C098326A87A273DAE73DB1E438D" xlink:to="loc_dei_DocumentPeriodEndDate_3F6A964D94A90D9A0B02AE73DB1F6D5E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_490A2D94EA2908FF55BDAE73DB1F9781" xlink:type="locator" />
    <presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_8A2C1C098326A87A273DAE73DB1E438D" xlink:to="loc_dei_DocumentFiscalYearFocus_490A2D94EA2908FF55BDAE73DB1F9781" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_A2B934C0311261FD5330AE73DB1FF73C" xlink:type="locator" />
    <presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_8A2C1C098326A87A273DAE73DB1E438D" xlink:to="loc_dei_DocumentFiscalPeriodFocus_A2B934C0311261FD5330AE73DB1FF73C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_00B79227110F252F9D3CAE73DB1FEBAD" xlink:type="locator" />
    <presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_8A2C1C098326A87A273DAE73DB1E438D" xlink:to="loc_dei_AmendmentFlag_00B79227110F252F9D3CAE73DB1FEBAD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_05CF129616C095A1FE3BAE73DB1F9B74" xlink:type="locator" />
    <presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_8A2C1C098326A87A273DAE73DB1E438D" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_05CF129616C095A1FE3BAE73DB1F9B74" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_01CB173C6940F7FCBF28AE73DB1B18BE" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_DEE14ED176B916331CB1AE73DB1B4A21" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_01CB173C6940F7FCBF28AE73DB1B18BE" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_DEE14ED176B916331CB1AE73DB1B4A21" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_D0F49AC9E142AEAF2AE3AE73DAACD062" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_332E799A3E6482108ED8AE73DAAC42BF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_D0F49AC9E142AEAF2AE3AE73DAACD062" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_332E799A3E6482108ED8AE73DAAC42BF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6279105BFE54D83B5FA7AE73DAAC09D7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_332E799A3E6482108ED8AE73DAAC42BF" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6279105BFE54D83B5FA7AE73DAAC09D7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3E467AF57B45B70425A2AE73DAACD1F9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6279105BFE54D83B5FA7AE73DAAC09D7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3E467AF57B45B70425A2AE73DAACD1F9" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E1544BD1DACAADCE3A1FAE73DAACB3FF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3E467AF57B45B70425A2AE73DAACD1F9" xlink:to="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E1544BD1DACAADCE3A1FAE73DAACB3FF" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_26EAC58710C7B644C55DAE73DAADEC2B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3E467AF57B45B70425A2AE73DAACD1F9" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_26EAC58710C7B644C55DAE73DAADEC2B" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_F98DE2956AFC73D09645AE73DAAD9E47" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3E467AF57B45B70425A2AE73DAACD1F9" xlink:to="loc_biib_MarketStockUnitsMember_F98DE2956AFC73D09645AE73DAAD9E47" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3D70FBF4CCD77D11A581AE73DAAD41BB" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_332E799A3E6482108ED8AE73DAAC42BF" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3D70FBF4CCD77D11A581AE73DAAD41BB" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_8F8947208496BFDAC620AE73DAADBF57" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3D70FBF4CCD77D11A581AE73DAAD41BB" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_8F8947208496BFDAC620AE73DAADBF57" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_0D1D5138AACEF5657D5EAE73DAADDC4E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_8F8947208496BFDAC620AE73DAADBF57" xlink:to="loc_us-gaap_NetIncomeLossAbstract_0D1D5138AACEF5657D5EAE73DAADDC4E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_FD82AA7CBF17BDA4E04AAE73DAADDAF0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_0D1D5138AACEF5657D5EAE73DAADDC4E" xlink:to="loc_us-gaap_NetIncomeLoss_FD82AA7CBF17BDA4E04AAE73DAADDAF0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_FB599B4976B87AB09F90AE73DAADF303" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_8F8947208496BFDAC620AE73DAADBF57" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_FB599B4976B87AB09F90AE73DAADF303" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_230376A524458ECA756AAE73DAADDE33" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_FB599B4976B87AB09F90AE73DAADF303" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_230376A524458ECA756AAE73DAADDE33" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_05ABFE26BFFE1BA748F9AE73DAAD7AB7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_FB599B4976B87AB09F90AE73DAADF303" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_05ABFE26BFFE1BA748F9AE73DAAD7AB7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8121223E6DAA46EBA951AE73DAAD2EAD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_05ABFE26BFFE1BA748F9AE73DAAD7AB7" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8121223E6DAA46EBA951AE73DAAD2EAD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_0C9B6310E7F2AB72BEF0AE73DAAD9D38" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_05ABFE26BFFE1BA748F9AE73DAAD7AB7" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_0C9B6310E7F2AB72BEF0AE73DAAD9D38" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_68DFD58195CDAA9C52C4AE73DAAD1368" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_FB599B4976B87AB09F90AE73DAADF303" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_68DFD58195CDAA9C52C4AE73DAAD1368" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_700772EFF5CD7E45E1FBAE73D95997A0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4BA5101F19F1C83331A3AE73D959EBFA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_700772EFF5CD7E45E1FBAE73D95997A0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4BA5101F19F1C83331A3AE73D959EBFA" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_E26AE0C245072A6BD776AE73DAB268D7" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7E941F48FF0E1171B0F5AE73DAB235BB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_E26AE0C245072A6BD776AE73DAB268D7" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7E941F48FF0E1171B0F5AE73DAB235BB" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/EquityDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_7EAE43F27972C2DEA8EC4EEFD6A9F553" xlink:type="locator" />
    <loc xlink:href="biib-20150930.xsd#biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract" xlink:label="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_65CD16814045F6F794344EEFD6A9CDCA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7EAE43F27972C2DEA8EC4EEFD6A9F553" xlink:to="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_65CD16814045F6F794344EEFD6A9CDCA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_E2471CECDFBC38D731434EEFD6A9D04D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_65CD16814045F6F794344EEFD6A9CDCA" xlink:to="loc_us-gaap_MinorityInterest_E2471CECDFBC38D731434EEFD6A9D04D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_B9D0E08AF730E0519E2B4EEFD6A9BF6B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_65CD16814045F6F794344EEFD6A9CDCA" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_B9D0E08AF730E0519E2B4EEFD6A9BF6B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_B0B744D9C13C64AEFA294EEFD6A9BEB0" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_65CD16814045F6F794344EEFD6A9CDCA" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_B0B744D9C13C64AEFA294EEFD6A9BEB0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_9CC50651B579446A67E74EEFD6A992F9" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_65CD16814045F6F794344EEFD6A9CDCA" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_9CC50651B579446A67E74EEFD6A992F9" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_BDA51E3889DD2F221C504EEFD6A9E85B" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_65CD16814045F6F794344EEFD6A9CDCA" xlink:to="loc_biib_Noncontrollinginterestincreasedecreaseother_BDA51E3889DD2F221C504EEFD6A9E85B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_A22F8EB2FCDE7D3A35AD4EEFD6AA126E" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_65CD16814045F6F794344EEFD6A9CDCA" xlink:to="loc_us-gaap_MinorityInterest_A22F8EB2FCDE7D3A35AD4EEFD6AA126E" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_72FB8CD5282EC03C2260875A3D3733E8" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="loc_us-gaap_MinorityInterestTable_4B2EA797A70E840641DD875A3D37E63D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_72FB8CD5282EC03C2260875A3D3733E8" xlink:to="loc_us-gaap_MinorityInterestTable_4B2EA797A70E840641DD875A3D37E63D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_1138872278EA1825B0DF875A3D37D13E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_4B2EA797A70E840641DD875A3D37E63D" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_1138872278EA1825B0DF875A3D37D13E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_EE444E617E2859599921875A3D37A337" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_1138872278EA1825B0DF875A3D37D13E" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_EE444E617E2859599921875A3D37A337" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_92D63231C9308DF0800F875A3D37BB74" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_EE444E617E2859599921875A3D37A337" xlink:to="loc_biib_NeurimmuneMember_92D63231C9308DF0800F875A3D37BB74" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="loc_us-gaap_MinorityInterestLineItems_C40F61420DE540DBD7BD875A3D37AC18" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_4B2EA797A70E840641DD875A3D37E63D" xlink:to="loc_us-gaap_MinorityInterestLineItems_C40F61420DE540DBD7BD875A3D37AC18" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_E57813F252C74B61C141875A3D37FA83" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_C40F61420DE540DBD7BD875A3D37AC18" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_E57813F252C74B61C141875A3D37FA83" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_66D3A98DBC6B29FF514B875A3D379699" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_C40F61420DE540DBD7BD875A3D37AC18" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_66D3A98DBC6B29FF514B875A3D379699" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_12C172F3CEBBE24ABE9C875A3D37EA66" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_C40F61420DE540DBD7BD875A3D37AC18" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_12C172F3CEBBE24ABE9C875A3D37EA66" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_EquityTextualAbstract" xlink:label="loc_biib_EquityTextualAbstract_BE16C65CB2B12D6C0B9E875A3D38CC5A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_72FB8CD5282EC03C2260875A3D3733E8" xlink:to="loc_biib_EquityTextualAbstract_BE16C65CB2B12D6C0B9E875A3D38CC5A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease_AE753208DF47CE0CCC99875A3D38215C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EquityTextualAbstract_BE16C65CB2B12D6C0B9E875A3D38CC5A" xlink:to="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease_AE753208DF47CE0CCC99875A3D38215C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_B1A12F1CC38F1C434351875A3D38CAFC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EquityTextualAbstract_BE16C65CB2B12D6C0B9E875A3D38CC5A" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_B1A12F1CC38F1C434351875A3D38CAFC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_FFA80AA01758C28FB0B7875A3D3844DD" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EquityTextualAbstract_BE16C65CB2B12D6C0B9E875A3D38CC5A" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_FFA80AA01758C28FB0B7875A3D3844DD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_6D28C5010124A470B982875A3D38EC9D" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EquityTextualAbstract_BE16C65CB2B12D6C0B9E875A3D38CC5A" xlink:to="loc_us-gaap_NetIncomeLoss_6D28C5010124A470B982875A3D38EC9D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_9FB8D99CF7A02DFA1883875A3D38CF65" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EquityTextualAbstract_BE16C65CB2B12D6C0B9E875A3D38CC5A" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_9FB8D99CF7A02DFA1883875A3D38CF65" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_1E57862DFCD42942374E875A3D38A8EF" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EquityTextualAbstract_BE16C65CB2B12D6C0B9E875A3D38CC5A" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_1E57862DFCD42942374E875A3D38A8EF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_93E8CCA0DAAD5ADE34AD875A3D381EBA" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EquityTextualAbstract_BE16C65CB2B12D6C0B9E875A3D38CC5A" xlink:to="loc_us-gaap_AdditionalPaidInCapital_93E8CCA0DAAD5ADE34AD875A3D381EBA" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_5D98F60A1D5120E6E716AE73DABEFF2D" xlink:type="locator" />
    <loc xlink:href="biib-20150930.xsd#biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock" xlink:label="loc_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_9918DA1CB2294982F10CAE73DABE1716" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5D98F60A1D5120E6E716AE73DABEFF2D" xlink:to="loc_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_9918DA1CB2294982F10CAE73DABE1716" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_08CB7FFD09820708C359AE73D95D2D04" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_B235768672D7FF49B019AE73D95DD5F5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_08CB7FFD09820708C359AE73D95D2D04" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_B235768672D7FF49B019AE73D95DD5F5" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_D593AA21D84B05BB3803AE73D99A3533" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FC11D69342D83B7B8E93AE73D99A4E69" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_D593AA21D84B05BB3803AE73D99A3533" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FC11D69342D83B7B8E93AE73D99A4E69" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A52BE0D26FAD476CB8B3AE73D99B25AC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FC11D69342D83B7B8E93AE73D99A4E69" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A52BE0D26FAD476CB8B3AE73D99B25AC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9803B66CB35D93C2148FAE73D99B75FB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A52BE0D26FAD476CB8B3AE73D99B25AC" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9803B66CB35D93C2148FAE73D99B75FB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9CA31CE67376E2434B65AE73D99BED67" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9803B66CB35D93C2148FAE73D99B75FB" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9CA31CE67376E2434B65AE73D99BED67" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_A18377FD0173C450F956AE73D99B7805" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9803B66CB35D93C2148FAE73D99B75FB" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_A18377FD0173C450F956AE73D99B7805" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2E0077E5FE6AE5E7E803AE73D99BBE58" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9803B66CB35D93C2148FAE73D99B75FB" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2E0077E5FE6AE5E7E803AE73D99BBE58" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6850FA8AE469DB795836AE73D99B801C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FC11D69342D83B7B8E93AE73D99A4E69" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6850FA8AE469DB795836AE73D99B801C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8EED916F6EF2EE9A9B7FAE73D99BD82E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6850FA8AE469DB795836AE73D99B801C" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8EED916F6EF2EE9A9B7FAE73D99BD82E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_CBDAF0D76DFECE6A2292AE73D99B40AD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_8EED916F6EF2EE9A9B7FAE73D99BD82E" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_CBDAF0D76DFECE6A2292AE73D99B40AD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_21C87B041BB4778C46E1AE73D99BBBD5" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FC11D69342D83B7B8E93AE73D99A4E69" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_21C87B041BB4778C46E1AE73D99BBBD5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_FA84A1598394A8DC0394AE73D99B81A6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_21C87B041BB4778C46E1AE73D99BBBD5" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_FA84A1598394A8DC0394AE73D99B81A6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9C76A7B5FBF2DBD17144AE73D99B2DF7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_FA84A1598394A8DC0394AE73D99B81A6" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9C76A7B5FBF2DBD17144AE73D99B2DF7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_394D48A9FBAF5FAEF294AE73D99C6BF2" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_FA84A1598394A8DC0394AE73D99B81A6" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_394D48A9FBAF5FAEF294AE73D99C6BF2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_4B9939D775B16BFEBA06AE73D99CAA7E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_FA84A1598394A8DC0394AE73D99B81A6" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_4B9939D775B16BFEBA06AE73D99CAA7E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A7B8DBB15892F754C4C4AE73D99CE7A5" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FC11D69342D83B7B8E93AE73D99A4E69" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A7B8DBB15892F754C4C4AE73D99CE7A5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_9EAFC26590F174F9D423AE73D99CAA00" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A7B8DBB15892F754C4C4AE73D99CE7A5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_9EAFC26590F174F9D423AE73D99CAA00" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_C73496645E029C24B696AE73D99CACA6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_9EAFC26590F174F9D423AE73D99CAA00" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_C73496645E029C24B696AE73D99CACA6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_DDB99059D33C19042470AE73D99CE832" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_C73496645E029C24B696AE73D99CACA6" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_DDB99059D33C19042470AE73D99CE832" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_435F75EA1A094B99D241AE73D99CE778" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_C73496645E029C24B696AE73D99CACA6" xlink:to="loc_us-gaap_AvailableForSaleSecurities_435F75EA1A094B99D241AE73D99CE778" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_679942340E194E852910AE73D99C0187" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_C73496645E029C24B696AE73D99CACA6" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_679942340E194E852910AE73D99C0187" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_F317E08BCF09618832BDAE73D99C8596" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_C73496645E029C24B696AE73D99CACA6" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_F317E08BCF09618832BDAE73D99C8596" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_E97E431AD6C8252F6670AE73D99C7011" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_C73496645E029C24B696AE73D99CACA6" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_E97E431AD6C8252F6670AE73D99C7011" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8D0093057C4319AE34EFAE73D99C051B" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_C73496645E029C24B696AE73D99CACA6" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_8D0093057C4319AE34EFAE73D99C051B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_CA4A28F1D156793C8DDFAE73D99C0BAD" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_9EAFC26590F174F9D423AE73D99CAA00" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_CA4A28F1D156793C8DDFAE73D99C0BAD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_C56C6D6643740FAAF87AAE73D99C4CC0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_CA4A28F1D156793C8DDFAE73D99C0BAD" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_C56C6D6643740FAAF87AAE73D99C4CC0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_171D35C5DD79E5989571AE73D99D5857" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_CA4A28F1D156793C8DDFAE73D99C0BAD" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_171D35C5DD79E5989571AE73D99D5857" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_E08E6026A0CC0668C3E1AE73D99DF94C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_CA4A28F1D156793C8DDFAE73D99C0BAD" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_E08E6026A0CC0668C3E1AE73D99DF94C" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_48238C1F1F64409A1BA52E253067D02B" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_CAAB3ECA7F5022FE9E242E253067BAFE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_48238C1F1F64409A1BA52E253067D02B" xlink:to="loc_us-gaap_DebtInstrumentTable_CAAB3ECA7F5022FE9E242E253067BAFE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_A40416B24C3B45654FC32E253067DCB5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_CAAB3ECA7F5022FE9E242E253067BAFE" xlink:to="loc_us-gaap_DebtInstrumentAxis_A40416B24C3B45654FC32E253067DCB5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_EA1DDF68FD1F5462EB1A2E253067AA31" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_A40416B24C3B45654FC32E253067DCB5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_EA1DDF68FD1F5462EB1A2E253067AA31" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_NotesPayableToFumedicaMember" xlink:label="loc_biib_NotesPayableToFumedicaMember_6011038135E308B348D92E2530673CD5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_EA1DDF68FD1F5462EB1A2E253067AA31" xlink:to="loc_biib_NotesPayableToFumedicaMember_6011038135E308B348D92E2530673CD5" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_FE84211CF90B8C1421582E253068B9F0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_EA1DDF68FD1F5462EB1A2E253067AA31" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_FE84211CF90B8C1421582E253068B9F0" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_67F532469C70FF144FB32E3F7265C450" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_EA1DDF68FD1F5462EB1A2E253067AA31" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_67F532469C70FF144FB32E3F7265C450" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_B862861C424B2708D0192E41431E9125" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_EA1DDF68FD1F5462EB1A2E253067AA31" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_B862861C424B2708D0192E41431E9125" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_8CBA50488B91F2C97AA72E42BB1E2358" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_EA1DDF68FD1F5462EB1A2E253067AA31" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_8CBA50488B91F2C97AA72E42BB1E2358" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_B9F21E726FA51CD45C8E2E43F7DC2BB4" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_EA1DDF68FD1F5462EB1A2E253067AA31" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_B9F21E726FA51CD45C8E2E43F7DC2BB4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_A83892476EEA39CBAAA82E2530685161" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_CAAB3ECA7F5022FE9E242E253067BAFE" xlink:to="loc_us-gaap_DebtInstrumentLineItems_A83892476EEA39CBAAA82E2530685161" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_28BB50082A9FC84B84042E253068D881" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A83892476EEA39CBAAA82E2530685161" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_28BB50082A9FC84B84042E253068D881" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_45B9E442B3B3B92FCD692E253068B9EB" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A83892476EEA39CBAAA82E2530685161" xlink:to="loc_us-gaap_NotesPayable_45B9E442B3B3B92FCD692E253068B9EB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_57D6C7784B7E2F6136402E25306871FE" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A83892476EEA39CBAAA82E2530685161" xlink:to="loc_us-gaap_DebtInstrumentFairValue_57D6C7784B7E2F6136402E25306871FE" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_565C46726ECF308E05C8AE73DA98B7A0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6A9993956C3B48EAEA68AE73DA982B5B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_565C46726ECF308E05C8AE73DA98B7A0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6A9993956C3B48EAEA68AE73DA982B5B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4C59EEFB7D930A600FD8AE73DA9849D9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6A9993956C3B48EAEA68AE73DA982B5B" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4C59EEFB7D930A600FD8AE73DA9849D9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_473E913192FA04DA4116AE73DA99B699" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4C59EEFB7D930A600FD8AE73DA9849D9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_473E913192FA04DA4116AE73DA99B699" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_28CB3C6AEE76FC24A198AE73DA99C5B3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_473E913192FA04DA4116AE73DA99B699" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_28CB3C6AEE76FC24A198AE73DA99C5B3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_CBA66B786B665AD3DC13AE73DA993053" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6A9993956C3B48EAEA68AE73DA982B5B" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_CBA66B786B665AD3DC13AE73DA993053" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_D1D8DDBA9609EED54F24AE73DA99744A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_CBA66B786B665AD3DC13AE73DA993053" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_D1D8DDBA9609EED54F24AE73DA99744A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_139F904B44A811F4F2B2AE73DA998843" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_CBA66B786B665AD3DC13AE73DA993053" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_139F904B44A811F4F2B2AE73DA998843" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_89BAFA8F73DE08D5719BAE73DA99CAD6" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_CBA66B786B665AD3DC13AE73DA993053" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_89BAFA8F73DE08D5719BAE73DA99CAD6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_94638A156ACA64B01178AE73DA996094" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_CBA66B786B665AD3DC13AE73DA993053" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_94638A156ACA64B01178AE73DA996094" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8D56060853F7873F59D1AE73DA99D0EA" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_CBA66B786B665AD3DC13AE73DA993053" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8D56060853F7873F59D1AE73DA99D0EA" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4F20CCC111C00BBE370D4EEFD7CDD8DD" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_54D89D2755318A55C9534EEFD7CDE112" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4F20CCC111C00BBE370D4EEFD7CDD8DD" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_54D89D2755318A55C9534EEFD7CDE112" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9D6FAEAC8C3E887697354EEFD7CD57BE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_54D89D2755318A55C9534EEFD7CDE112" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9D6FAEAC8C3E887697354EEFD7CD57BE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_BEE47F91328439D4AEB44EEFD7CD14BA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9D6FAEAC8C3E887697354EEFD7CD57BE" xlink:to="loc_us-gaap_TypeOfAdoptionMember_BEE47F91328439D4AEB44EEFD7CD14BA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember_D97C1C8215015DEA4B374EEFD7CDB903" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_BEE47F91328439D4AEB44EEFD7CD14BA" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember_D97C1C8215015DEA4B374EEFD7CDB903" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_02519EA8E87D5F442DE94EEFD7CD5F03" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_54D89D2755318A55C9534EEFD7CDE112" xlink:to="loc_us-gaap_DebtInstrumentAxis_02519EA8E87D5F442DE94EEFD7CD5F03" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_600E466A136DE445CB0F4EEFD7CDF4D1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_02519EA8E87D5F442DE94EEFD7CD5F03" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_600E466A136DE445CB0F4EEFD7CDF4D1" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_A5234F2BB0FD4DFE26484EEFD7CD7219" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_600E466A136DE445CB0F4EEFD7CDF4D1" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_A5234F2BB0FD4DFE26484EEFD7CD7219" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_808604F38D2F60122E6E4EEFD7CD058E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_600E466A136DE445CB0F4EEFD7CDF4D1" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_808604F38D2F60122E6E4EEFD7CD058E" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D5B161C9C6D82A3E978E4EEFD7CDDE8A" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_600E466A136DE445CB0F4EEFD7CDF4D1" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D5B161C9C6D82A3E978E4EEFD7CDDE8A" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_B38514DD4265224884D44EEFD7CE9549" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_600E466A136DE445CB0F4EEFD7CDF4D1" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_B38514DD4265224884D44EEFD7CE9549" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_815F4D724694A342003D4EEFD7CE3DFD" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_600E466A136DE445CB0F4EEFD7CDF4D1" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_815F4D724694A342003D4EEFD7CE3DFD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_CAFC3C3C34AA2280283C4EEFD7CE3FA1" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_54D89D2755318A55C9534EEFD7CDE112" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_CAFC3C3C34AA2280283C4EEFD7CE3FA1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AAA77350EEFA4C2DC7914EEFD7CE76F7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_CAFC3C3C34AA2280283C4EEFD7CE3FA1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AAA77350EEFA4C2DC7914EEFD7CE76F7" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_EEA9DD1833B1BB7258FC4EEFD7CE4BA1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AAA77350EEFA4C2DC7914EEFD7CE76F7" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_EEA9DD1833B1BB7258FC4EEFD7CE4BA1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_9D2EC17A38522B49B0384EEFD7CE7932" xlink:type="locator" />
    <presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_54D89D2755318A55C9534EEFD7CDE112" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_9D2EC17A38522B49B0384EEFD7CE7932" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_47D2AEB9EC89F1B9C6D54EEFD7CE5619" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_9D2EC17A38522B49B0384EEFD7CE7932" xlink:to="loc_us-gaap_AssetImpairmentCharges_47D2AEB9EC89F1B9C6D54EEFD7CE5619" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsChangesInValuationTechniques" xlink:label="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_113D5FAD98080D4DCAD54EEFD7CE65E4" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_9D2EC17A38522B49B0384EEFD7CE7932" xlink:to="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_113D5FAD98080D4DCAD54EEFD7CE65E4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtIssuanceCosts" xlink:label="loc_us-gaap_DebtIssuanceCosts_311FD69AC90FBD64FC4D4EEFD7CEF3AC" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_9D2EC17A38522B49B0384EEFD7CE7932" xlink:to="loc_us-gaap_DebtIssuanceCosts_311FD69AC90FBD64FC4D4EEFD7CEF3AC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_FCFD2014FA2C33BD69124EEFD7CE5BE6" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_9D2EC17A38522B49B0384EEFD7CE7932" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_FCFD2014FA2C33BD69124EEFD7CE5BE6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_BDE67515C98601A561964EEFD7CE23FB" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_9D2EC17A38522B49B0384EEFD7CE7932" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_BDE67515C98601A561964EEFD7CE23FB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_2EB37210E097D3F682E64EEFD7CEB86A" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_9D2EC17A38522B49B0384EEFD7CE7932" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_2EB37210E097D3F682E64EEFD7CEB86A" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_68339E8DEBE9AB78AE334EEFD7CE0442" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_9D2EC17A38522B49B0384EEFD7CE7932" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_68339E8DEBE9AB78AE334EEFD7CE0442" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_D8412F708C55D646540E4EEFD7CEAAF9" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_9D2EC17A38522B49B0384EEFD7CE7932" xlink:to="loc_us-gaap_FairValueInputsDiscountRate_D8412F708C55D646540E4EEFD7CEAAF9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_E3F8677105501A771D0A4EF25CA61338" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_9D2EC17A38522B49B0384EEFD7CE7932" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_E3F8677105501A771D0A4EF25CA61338" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_5A29A0253C8BD58F64604EEFD7CE92EB" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_9D2EC17A38522B49B0384EEFD7CE7932" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_5A29A0253C8BD58F64604EEFD7CE92EB" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_DFCD87DCB1079B6CC8E2AE73DA9E8605" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_FDC6BF465BBA3F41473DAE73DA9E5EDD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_DFCD87DCB1079B6CC8E2AE73DA9E8605" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_FDC6BF465BBA3F41473DAE73DA9E5EDD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_A5CBD0E18E1E710B1140AE73DA9E3FA4" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_DFCD87DCB1079B6CC8E2AE73DA9E8605" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_A5CBD0E18E1E710B1140AE73DA9E3FA4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_271E0E8BA37BD321D9B0AE73DA9EB233" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_DFCD87DCB1079B6CC8E2AE73DA9E8605" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_271E0E8BA37BD321D9B0AE73DA9EB233" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_E2A2C00EF2A0721CD35FAE73DA866A7E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_8BAC38370D114D6CB05AAE73DA860FDF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_E2A2C00EF2A0721CD35FAE73DA866A7E" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_8BAC38370D114D6CB05AAE73DA860FDF" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_C2B0B6DA34D921E010EBAE73D9A4F998" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_ED9CA85CE95F36E483B2AE73D9A48278" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_C2B0B6DA34D921E010EBAE73D9A4F998" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_ED9CA85CE95F36E483B2AE73D9A48278" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_8326487E1588232A56EEAE73D9A4EB2D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_ED9CA85CE95F36E483B2AE73D9A48278" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_8326487E1588232A56EEAE73D9A4EB2D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4DFE5FC8086B3BB807ADAE73D9A4CB15" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_8326487E1588232A56EEAE73D9A4EB2D" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4DFE5FC8086B3BB807ADAE73D9A4CB15" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_374E4E2C08490C41076AAE73D9A49648" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4DFE5FC8086B3BB807ADAE73D9A4CB15" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_374E4E2C08490C41076AAE73D9A49648" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_27E75F2C13EC955A4924AE73D9A4D1C6" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4DFE5FC8086B3BB807ADAE73D9A4CB15" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_27E75F2C13EC955A4924AE73D9A4D1C6" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_B1674D3481D22C3B4BC3AE73D9A42278" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4DFE5FC8086B3BB807ADAE73D9A4CB15" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_B1674D3481D22C3B4BC3AE73D9A42278" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_958621CF5BA86EC61F7AAE73D9A4D105" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4DFE5FC8086B3BB807ADAE73D9A4CB15" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_958621CF5BA86EC61F7AAE73D9A4D105" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_05CC0345B3296F797184AE73D9A4E889" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4DFE5FC8086B3BB807ADAE73D9A4CB15" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_05CC0345B3296F797184AE73D9A4E889" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_7EBAD2F6926B49F8C584AE73D9A428BD" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4DFE5FC8086B3BB807ADAE73D9A4CB15" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_7EBAD2F6926B49F8C584AE73D9A428BD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_00CC927FCC7085DC955BAE73D9A4E424" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4DFE5FC8086B3BB807ADAE73D9A4CB15" xlink:to="loc_us-gaap_EquitySecuritiesMember_00CC927FCC7085DC955BAE73D9A4E424" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_54FDB2B9D48F1AFBFF9BAE73D9A5DAAF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_ED9CA85CE95F36E483B2AE73D9A48278" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_54FDB2B9D48F1AFBFF9BAE73D9A5DAAF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3EB914A7B704BA087A93AE73D9A53814" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_54FDB2B9D48F1AFBFF9BAE73D9A5DAAF" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3EB914A7B704BA087A93AE73D9A53814" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_677B8F2E20F595AE4473AE73D9A551A2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3EB914A7B704BA087A93AE73D9A53814" xlink:to="loc_us-gaap_AvailableForSaleSecurities_677B8F2E20F595AE4473AE73D9A551A2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8FF6A868AAB4DCF9DD98AE73D9A5960F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3EB914A7B704BA087A93AE73D9A53814" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8FF6A868AAB4DCF9DD98AE73D9A5960F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_37769FBAF9C1AEDDBFE3AE73D9A571A9" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3EB914A7B704BA087A93AE73D9A53814" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_37769FBAF9C1AEDDBFE3AE73D9A571A9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_C3EECE13BEBD95AC7174AE73D9A5957B" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3EB914A7B704BA087A93AE73D9A53814" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_C3EECE13BEBD95AC7174AE73D9A5957B" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_C71DAE43F246DCE5CD03AE73DACC91A5" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_93D314DEB1CA91939C8FAE73DACCC1FD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_C71DAE43F246DCE5CD03AE73DACC91A5" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_93D314DEB1CA91939C8FAE73DACCC1FD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_D2EF599BE5C945B82C31AE73DACC46AA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_93D314DEB1CA91939C8FAE73DACCC1FD" xlink:to="loc_us-gaap_InvestmentTypeAxis_D2EF599BE5C945B82C31AE73DACC46AA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_772F0F232C62A72AEF18AE73DACD8490" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_D2EF599BE5C945B82C31AE73DACC46AA" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_772F0F232C62A72AEF18AE73DACD8490" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_2F51F3EE5696BA2E607BAE73DACDAD90" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_772F0F232C62A72AEF18AE73DACD8490" xlink:to="loc_us-gaap_CommercialPaperMember_2F51F3EE5696BA2E607BAE73DACDAD90" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_85A5F3810445AD5D1B98AE73DACD5DC9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_772F0F232C62A72AEF18AE73DACD8490" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_85A5F3810445AD5D1B98AE73DACD5DC9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7A2D5CEADE62DA2A57B8AE73DACD0AF4" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_772F0F232C62A72AEF18AE73DACD8490" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7A2D5CEADE62DA2A57B8AE73DACD0AF4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_BDA880F00B02902C131DAE73DACD8A18" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_772F0F232C62A72AEF18AE73DACD8490" xlink:to="loc_us-gaap_DebtSecuritiesMember_BDA880F00B02902C131DAE73DACD8A18" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_A30E4615E1893A77C7E4AE73DACD79B9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_93D314DEB1CA91939C8FAE73DACCC1FD" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_A30E4615E1893A77C7E4AE73DACD79B9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_1E0C2BC409729050D38AAE73DACDF66D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_A30E4615E1893A77C7E4AE73DACD79B9" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_1E0C2BC409729050D38AAE73DACDF66D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_833E1E6F7651F9EC2E38AE73DACD5A5E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_1E0C2BC409729050D38AAE73DACDF66D" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_833E1E6F7651F9EC2E38AE73DACD5A5E" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_BE02647978B448602098AE73D96326D9" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_12CF505977340C3B40A3AE73D963055F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_BE02647978B448602098AE73D96326D9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_12CF505977340C3B40A3AE73D963055F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6F90F0C0B71F0F9875E8AE73D963F6AC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_12CF505977340C3B40A3AE73D963055F" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6F90F0C0B71F0F9875E8AE73D963F6AC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_9FD670ED9577765F4378AE73D96307F0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_12CF505977340C3B40A3AE73D963055F" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_9FD670ED9577765F4378AE73D96307F0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_A68B959CBEB6B04A12BDAE73D963A48C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_12CF505977340C3B40A3AE73D963055F" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_A68B959CBEB6B04A12BDAE73D963A48C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_8AB419B82678FFFF1F87AE73D964EECE" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_12CF505977340C3B40A3AE73D963055F" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_8AB419B82678FFFF1F87AE73D964EECE" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_43559E1D95092B2B1AE9AE73D964F537" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_12CF505977340C3B40A3AE73D963055F" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_43559E1D95092B2B1AE9AE73D964F537" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_1BD18E70E711FD5C2FA5AE73D96419B7" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_12CF505977340C3B40A3AE73D963055F" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_1BD18E70E711FD5C2FA5AE73D96419B7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_480A186F616EF96CA261AE73D9642B43" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_12CF505977340C3B40A3AE73D963055F" xlink:to="loc_us-gaap_AvailableForSaleSecurities_480A186F616EF96CA261AE73D9642B43" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D315C8AD079670AE7D3AAE73D9645160" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_12CF505977340C3B40A3AE73D963055F" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D315C8AD079670AE7D3AAE73D9645160" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4C701FFAA5F879D395B1AE73DB627FC4" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_9D7E065A1A87703155C0AE73DB62AB3C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4C701FFAA5F879D395B1AE73DB627FC4" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_9D7E065A1A87703155C0AE73DB62AB3C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_1BA1386C0A3C9A14AA41AE73DB62EBA3" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4C701FFAA5F879D395B1AE73DB627FC4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_1BA1386C0A3C9A14AA41AE73DB62EBA3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_729DC1E4182EF726C105AE73DB626A08" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4C701FFAA5F879D395B1AE73DB627FC4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_729DC1E4182EF726C105AE73DB626A08" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_B73BF0F222BE8A7A0DEEAE73DAC29704" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_ADDE165AB68F07DCDBBCAE73DAC2F625" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_B73BF0F222BE8A7A0DEEAE73DAC29704" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateDescription_ADDE165AB68F07DCDBBCAE73DAC2F625" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_Overnightreverserepurchaseagreementspercentoftotalassets" xlink:label="loc_biib_Overnightreverserepurchaseagreementspercentoftotalassets_3E9E1C5C93AEDF6A9EE7AE73DAC2CD9D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_B73BF0F222BE8A7A0DEEAE73DAC29704" xlink:to="loc_biib_Overnightreverserepurchaseagreementspercentoftotalassets_3E9E1C5C93AEDF6A9EE7AE73DAC2CD9D" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_AverageMaturityOfMarketableSecurities" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_EE116E00A72ED8AEF6EEAE73DAC2BA9A" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_B73BF0F222BE8A7A0DEEAE73DAC29704" xlink:to="loc_biib_AverageMaturityOfMarketableSecurities_EE116E00A72ED8AEF6EEAE73DAC2BA9A" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_9DA31E9A79087DA9627DAE73DB6005F2" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_35BB631EF1E757A4A161AE73DB60094F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_9DA31E9A79087DA9627DAE73DB6005F2" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_35BB631EF1E757A4A161AE73DB60094F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_27D079A2BE9D74DF9D75AE73DB6012B7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_35BB631EF1E757A4A161AE73DB60094F" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_27D079A2BE9D74DF9D75AE73DB6012B7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EB3B38DC4336DC08ABCCAE73DB6050F9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_27D079A2BE9D74DF9D75AE73DB6012B7" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EB3B38DC4336DC08ABCCAE73DB6050F9" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_84F8BB0DB4C3ECFD7167AE73DB606C24" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EB3B38DC4336DC08ABCCAE73DB6050F9" xlink:to="loc_biib_StrategicInvestmentsMember_84F8BB0DB4C3ECFD7167AE73DB606C24" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_E3AE1614C6A04E3D3804AE73DB601A9E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_35BB631EF1E757A4A161AE73DB60094F" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_E3AE1614C6A04E3D3804AE73DB601A9E" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_4665EBB3735364C37D9DAE73DB60F307" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E3AE1614C6A04E3D3804AE73DB601A9E" xlink:to="loc_biib_StrategicInvestmentPortfolio_4665EBB3735364C37D9DAE73DB60F307" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_797756497FA909B0BAF1AE73DACFF111" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_0AF4DF56AFC9CE356948AE73DAD0749D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_797756497FA909B0BAF1AE73DACFF111" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_0AF4DF56AFC9CE356948AE73DAD0749D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_CC809B69BD1D4A216246AE73DAD039AF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_797756497FA909B0BAF1AE73DACFF111" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_CC809B69BD1D4A216246AE73DAD039AF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_4AEBC5E3593908850C7FAE73DAD0989C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_797756497FA909B0BAF1AE73DACFF111" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_4AEBC5E3593908850C7FAE73DAD0989C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_19954C1672624514EFA8AE73DAD016D4" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_797756497FA909B0BAF1AE73DACFF111" xlink:to="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_19954C1672624514EFA8AE73DAD016D4" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_54E524E4F78A9BAAC7A5AE73DAC0FE14" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_3BC2324CD57A25414C0EAE73DAC0BE69" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_54E524E4F78A9BAAC7A5AE73DAC0FE14" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_3BC2324CD57A25414C0EAE73DAC0BE69" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7C1C156D765DFE04B720AE73DB48A926" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8A3E9C156FAA7412FEB7AE73DB48F487" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7C1C156D765DFE04B720AE73DB48A926" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8A3E9C156FAA7412FEB7AE73DB48F487" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_A9ACD2E1380B732950C7AE73DB489D6D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8A3E9C156FAA7412FEB7AE73DB48F487" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_A9ACD2E1380B732950C7AE73DB489D6D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_E120B9E404A2DFC64BC0AE73DB48E531" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8A3E9C156FAA7412FEB7AE73DB48F487" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_E120B9E404A2DFC64BC0AE73DB48E531" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B87A72D68EBB151459C3AE73DB485B49" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8A3E9C156FAA7412FEB7AE73DB48F487" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B87A72D68EBB151459C3AE73DB485B49" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_AF97477796468513CA0CAE73DB49D6E2" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8A3E9C156FAA7412FEB7AE73DB48F487" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_AF97477796468513CA0CAE73DB49D6E2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_B2F93BE48820FBC58F2FAE73DB498EDA" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8A3E9C156FAA7412FEB7AE73DB48F487" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_B2F93BE48820FBC58F2FAE73DB498EDA" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_759173C74B53FC23E3FFAE73DB49270B" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8A3E9C156FAA7412FEB7AE73DB48F487" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_759173C74B53FC23E3FFAE73DB49270B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_3B967C3A5CFEFE13DF72AE73DB49DB4D" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8A3E9C156FAA7412FEB7AE73DB48F487" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_3B967C3A5CFEFE13DF72AE73DB49DB4D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2845529838CE9DA23B0AAE73DB496F03" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8A3E9C156FAA7412FEB7AE73DB48F487" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2845529838CE9DA23B0AAE73DB496F03" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B6DAF90E54594B34ABE5AE73DB499F7A" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8A3E9C156FAA7412FEB7AE73DB48F487" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B6DAF90E54594B34ABE5AE73DB499F7A" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_440EC49720BA6CEB1FBB875A3D0570C6" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_5458054DD6F927104863875A3D05FE7F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_440EC49720BA6CEB1FBB875A3D0570C6" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_5458054DD6F927104863875A3D05FE7F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_5DFF0136A150E0F4E565875A3D051236" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_5458054DD6F927104863875A3D05FE7F" xlink:to="loc_us-gaap_TaxPeriodAxis_5DFF0136A150E0F4E565875A3D051236" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_C0F1B5E66AF59A94CB0E875A3D050753" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_5DFF0136A150E0F4E565875A3D051236" xlink:to="loc_us-gaap_TaxPeriodDomain_C0F1B5E66AF59A94CB0E875A3D050753" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxYear2007Member" xlink:label="loc_us-gaap_TaxYear2007Member_DA33D9164D8653247DBB875A3D05D6FA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_C0F1B5E66AF59A94CB0E875A3D050753" xlink:to="loc_us-gaap_TaxYear2007Member_DA33D9164D8653247DBB875A3D05D6FA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxYear2008Member" xlink:label="loc_us-gaap_TaxYear2008Member_F2A1D0915449C95C8FB2875A3D05D892" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_C0F1B5E66AF59A94CB0E875A3D050753" xlink:to="loc_us-gaap_TaxYear2008Member_F2A1D0915449C95C8FB2875A3D05D892" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxYear2009Member" xlink:label="loc_us-gaap_TaxYear2009Member_5D329BA9C9F85758BC4F875A3D05DD9F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_C0F1B5E66AF59A94CB0E875A3D050753" xlink:to="loc_us-gaap_TaxYear2009Member_5D329BA9C9F85758BC4F875A3D05DD9F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_CE13D21A11109AB590E0875A3D058FF8" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_5458054DD6F927104863875A3D05FE7F" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_CE13D21A11109AB590E0875A3D058FF8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_CBF99875A6ACA1E5D3C9875A3D06BF04" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_CE13D21A11109AB590E0875A3D058FF8" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_CBF99875A6ACA1E5D3C9875A3D06BF04" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_90D87F1297F743020253875A3D06A2F5" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_CE13D21A11109AB590E0875A3D058FF8" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_90D87F1297F743020253875A3D06A2F5" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices" xlink:label="loc_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_D01220AF41A31016451C875A3D06F04E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_CE13D21A11109AB590E0875A3D058FF8" xlink:to="loc_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_D01220AF41A31016451C875A3D06F04E" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_383BE862344E3FF52951AE73DAF9145F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_B071C33EF0C113A616CBAE73DAF93B62" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_383BE862344E3FF52951AE73DAF9145F" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_B071C33EF0C113A616CBAE73DAF93B62" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessIdebtednessDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_397ED4CE953868FB23EC3EA2E588C6DB" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_80DC13D589A8C003FFD33EA2E58890B3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_397ED4CE953868FB23EC3EA2E588C6DB" xlink:to="loc_us-gaap_DebtInstrumentTable_80DC13D589A8C003FFD33EA2E58890B3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5B4268666FB4C8A280D33EA2E5886D39" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_80DC13D589A8C003FFD33EA2E58890B3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5B4268666FB4C8A280D33EA2E5886D39" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_E224BBC70F21A0E580A93EA2E588E0D0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5B4268666FB4C8A280D33EA2E5886D39" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_E224BBC70F21A0E580A93EA2E588E0D0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_325FFF9386D7AB95D1853EA2E5889F4D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_E224BBC70F21A0E580A93EA2E588E0D0" xlink:to="loc_us-gaap_InterestRateSwapMember_325FFF9386D7AB95D1853EA2E5889F4D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_92910DA5D12E9A30EFE73EA2E588B51F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_80DC13D589A8C003FFD33EA2E58890B3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_92910DA5D12E9A30EFE73EA2E588B51F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0FE0CC493C857A4C12C73EA2E588B9CD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_92910DA5D12E9A30EFE73EA2E588B51F" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0FE0CC493C857A4C12C73EA2E588B9CD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="loc_us-gaap_OtherInvestmentsMember_E81E4B8627F40A4618073EA2E58858F3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0FE0CC493C857A4C12C73EA2E588B9CD" xlink:to="loc_us-gaap_OtherInvestmentsMember_E81E4B8627F40A4618073EA2E58858F3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_9A6D567CF915C7D17FCF3EA2E5888E8C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_80DC13D589A8C003FFD33EA2E58890B3" xlink:to="loc_us-gaap_HedgingDesignationAxis_9A6D567CF915C7D17FCF3EA2E5888E8C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_0E0CFAED9E3343B49B3B3EA2E5884EC2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_9A6D567CF915C7D17FCF3EA2E5888E8C" xlink:to="loc_us-gaap_HedgingDesignationDomain_0E0CFAED9E3343B49B3B3EA2E5884EC2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_660ECC04DFCB94B9BE553EA2E5880F47" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_0E0CFAED9E3343B49B3B3EA2E5884EC2" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_660ECC04DFCB94B9BE553EA2E5880F47" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_4FC58F9C7050049B3AFE3EA2E588494F" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_80DC13D589A8C003FFD33EA2E58890B3" xlink:to="loc_us-gaap_DebtInstrumentAxis_4FC58F9C7050049B3AFE3EA2E588494F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_C370E8D56BE62ECC01C03EA2E5895444" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4FC58F9C7050049B3AFE3EA2E588494F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_C370E8D56BE62ECC01C03EA2E5895444" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E204A8979420E3C138BB3EA2E5893178" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C370E8D56BE62ECC01C03EA2E5895444" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E204A8979420E3C138BB3EA2E5893178" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D4C5E89F3D784FBBF3203EA2E58913E9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C370E8D56BE62ECC01C03EA2E5895444" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D4C5E89F3D784FBBF3203EA2E58913E9" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_D3D08C9A18F45932F03A3EA2E589CCFC" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C370E8D56BE62ECC01C03EA2E5895444" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_D3D08C9A18F45932F03A3EA2E589CCFC" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_E515C44A59266B22DC373EA2E589F340" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C370E8D56BE62ECC01C03EA2E5895444" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_E515C44A59266B22DC373EA2E589F340" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_F05A3A29B2F81DAC6D8D3EA2E589BB05" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_80DC13D589A8C003FFD33EA2E58890B3" xlink:to="loc_us-gaap_DebtInstrumentLineItems_F05A3A29B2F81DAC6D8D3EA2E589BB05" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_AD265A1C38DC158C664D3EA2E5897AA3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F05A3A29B2F81DAC6D8D3EA2E589BB05" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_AD265A1C38DC158C664D3EA2E5897AA3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_260D33B45699151D76053EA2E58941C6" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F05A3A29B2F81DAC6D8D3EA2E589BB05" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_260D33B45699151D76053EA2E58941C6" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_PercentageParValueOfSeniorNotes" xlink:label="loc_biib_PercentageParValueOfSeniorNotes_3159AEB89C7D2EECA8883EA2E5892694" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F05A3A29B2F81DAC6D8D3EA2E589BB05" xlink:to="loc_biib_PercentageParValueOfSeniorNotes_3159AEB89C7D2EECA8883EA2E5892694" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_7BC864566EF8B02E108B3ED24CF69702" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F05A3A29B2F81DAC6D8D3EA2E589BB05" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_7BC864566EF8B02E108B3ED24CF69702" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:label="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_4C98B93F8A4F05F68B043EDA38E8BE8A" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F05A3A29B2F81DAC6D8D3EA2E589BB05" xlink:to="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_4C98B93F8A4F05F68B043EDA38E8BE8A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtIssuanceCosts" xlink:label="loc_us-gaap_DebtIssuanceCosts_71A0D4D1F9B1077938E13EA2E589972F" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F05A3A29B2F81DAC6D8D3EA2E589BB05" xlink:to="loc_us-gaap_DebtIssuanceCosts_71A0D4D1F9B1077938E13EA2E589972F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_A2B3D1BEC77C49BA55AE3EA2E589B87A" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F05A3A29B2F81DAC6D8D3EA2E589BB05" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_A2B3D1BEC77C49BA55AE3EA2E589B87A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_D2440943128BB65837B93EA2E5893DCD" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F05A3A29B2F81DAC6D8D3EA2E589BB05" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_D2440943128BB65837B93EA2E5893DCD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_8AF1637588B4D86183B43EDFB6D37C1C" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F05A3A29B2F81DAC6D8D3EA2E589BB05" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_8AF1637588B4D86183B43EDFB6D37C1C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_7D3A090F1CE00FCD99643EA2E589EE42" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F05A3A29B2F81DAC6D8D3EA2E589BB05" xlink:to="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_7D3A090F1CE00FCD99643EA2E589EE42" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessIndebtedness" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7C53BC01966014C946D22EBAB66EB23C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_255BEE4320D7C840B2192EBC79537768" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7C53BC01966014C946D22EBAB66EB23C" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_255BEE4320D7C840B2192EBC79537768" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_A77809BDFF7A8DEEBF2EAE73D9416D04" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_282DB7A17BFE387C8626AE73D941B3FA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_A77809BDFF7A8DEEBF2EAE73D9416D04" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_282DB7A17BFE387C8626AE73D941B3FA" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D44EED643D26CB5191E771883DFD74AB" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CABFE49CB6EB23EB605A71883DFDE3C5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D44EED643D26CB5191E771883DFD74AB" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CABFE49CB6EB23EB605A71883DFDE3C5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2B170BDA2F0AEC36A47271883DFD899B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CABFE49CB6EB23EB605A71883DFDE3C5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2B170BDA2F0AEC36A47271883DFD899B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2799B2DD8B691DBCBF0171883DFE34B0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2B170BDA2F0AEC36A47271883DFD899B" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2799B2DD8B691DBCBF0171883DFE34B0" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_4817EAB40B39441A426B71883DFE6AAA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2799B2DD8B691DBCBF0171883DFE34B0" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_4817EAB40B39441A426B71883DFE6AAA" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_FF1C1FB26C128A882CE971883DFEE5EE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2799B2DD8B691DBCBF0171883DFE34B0" xlink:to="loc_biib_TysabriProductMember_FF1C1FB26C128A882CE971883DFEE5EE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_179F4A91155553B5C1C271883DFED735" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CABFE49CB6EB23EB605A71883DFDE3C5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_179F4A91155553B5C1C271883DFED735" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5FEC4020D776C7599B9171883DFEB40D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_179F4A91155553B5C1C271883DFED735" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5FEC4020D776C7599B9171883DFEB40D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_CF6E8882414F6CC91DDD71883DFE5F9E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5FEC4020D776C7599B9171883DFEB40D" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_CF6E8882414F6CC91DDD71883DFE5F9E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_6FBBCDD266ADEF989CF971883DFE445C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5FEC4020D776C7599B9171883DFEB40D" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_6FBBCDD266ADEF989CF971883DFE445C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_31B9B5E4ED398FEBEEF971883DFE6552" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CABFE49CB6EB23EB605A71883DFDE3C5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_31B9B5E4ED398FEBEEF971883DFE6552" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0DB8811CC9C93AAB403571883DFE8C46" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_31B9B5E4ED398FEBEEF971883DFE6552" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0DB8811CC9C93AAB403571883DFE8C46" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_99B3E62E513208503E6371883DFE0DDE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0DB8811CC9C93AAB403571883DFE8C46" xlink:to="loc_biib_OutLicensedPatentsMember_99B3E62E513208503E6371883DFE0DDE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_247D6E64D0931069D83271883DFEF565" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0DB8811CC9C93AAB403571883DFE8C46" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_247D6E64D0931069D83271883DFEF565" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_27AAAAF30384BD473EAB71883DFEDB8E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0DB8811CC9C93AAB403571883DFE8C46" xlink:to="loc_biib_InLicensedPatentsMember_27AAAAF30384BD473EAB71883DFEDB8E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_FF5E212D9C564718790C71883DFEF1F6" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CABFE49CB6EB23EB605A71883DFDE3C5" xlink:to="loc_us-gaap_ProductOrServiceAxis_FF5E212D9C564718790C71883DFEF1F6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_D04D7C9530029BDB5C1671883DFE3A3A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_FF5E212D9C564718790C71883DFEF1F6" xlink:to="loc_us-gaap_ProductsAndServicesDomain_D04D7C9530029BDB5C1671883DFE3A3A" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_3ADDA49194495D55F80371883DFE6E4D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D04D7C9530029BDB5C1671883DFE3A3A" xlink:to="loc_biib_AVONEXMember_3ADDA49194495D55F80371883DFE6E4D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_0E4B67AD9BD6E87DA5B971883DFE27EF" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CABFE49CB6EB23EB605A71883DFDE3C5" xlink:to="loc_us-gaap_RangeAxis_0E4B67AD9BD6E87DA5B971883DFE27EF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_28E33F0E9EC5F24C956F71883DFEBF31" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_0E4B67AD9BD6E87DA5B971883DFE27EF" xlink:to="loc_us-gaap_RangeMember_28E33F0E9EC5F24C956F71883DFEBF31" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_2DBF40525671E540809E71883DFE3878" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_28E33F0E9EC5F24C956F71883DFEBF31" xlink:to="loc_us-gaap_MinimumMember_2DBF40525671E540809E71883DFE3878" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_2431B1EBEBFC4DBB770F71883DFE172F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_28E33F0E9EC5F24C956F71883DFEBF31" xlink:to="loc_us-gaap_MaximumMember_2431B1EBEBFC4DBB770F71883DFE172F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_EF1C5EDF74FBC37059A771883DFF11B4" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_CABFE49CB6EB23EB605A71883DFDE3C5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_EF1C5EDF74FBC37059A771883DFF11B4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2DFBD573E3940E6DC20571883DFF1B68" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_EF1C5EDF74FBC37059A771883DFF11B4" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2DFBD573E3940E6DC20571883DFF1B68" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6F4CEE519FC97588E1D471883DFFB99A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2DFBD573E3940E6DC20571883DFF1B68" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6F4CEE519FC97588E1D471883DFFB99A" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_A3E74ED2BBCC6BF9FA7471883DFFF37C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2DFBD573E3940E6DC20571883DFF1B68" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_A3E74ED2BBCC6BF9FA7471883DFFF37C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_236DFD33697423108D6D71883DFF035F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2DFBD573E3940E6DC20571883DFF1B68" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_236DFD33697423108D6D71883DFF035F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9EE13335C84BEABFD76371883DFF87B8" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2DFBD573E3940E6DC20571883DFF1B68" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9EE13335C84BEABFD76371883DFF87B8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_D372EABDB43F1C65FB2D71883DFF5237" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2DFBD573E3940E6DC20571883DFF1B68" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_D372EABDB43F1C65FB2D71883DFF5237" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_D91B2181CF37F1B3E6E371883DFFD5D4" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2DFBD573E3940E6DC20571883DFF1B68" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_D91B2181CF37F1B3E6E371883DFFD5D4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_13EBC3B213E8DACC39DF71883DFF8D1A" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2DFBD573E3940E6DC20571883DFF1B68" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_13EBC3B213E8DACC39DF71883DFF8D1A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0682AB8510D7E6677E4071883DFF6ED8" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2DFBD573E3940E6DC20571883DFF1B68" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0682AB8510D7E6677E4071883DFF6ED8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_70AAAE099F946162EBF071883DFFF077" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2DFBD573E3940E6DC20571883DFF1B68" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_70AAAE099F946162EBF071883DFFF077" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2F081D8A4124F7ED146471883DFF36B1" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2DFBD573E3940E6DC20571883DFF1B68" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2F081D8A4124F7ED146471883DFF36B1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_0A77D613BAF6B0113CF971883DFFE029" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2DFBD573E3940E6DC20571883DFF1B68" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_0A77D613BAF6B0113CF971883DFFE029" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_92A8BE98907459DAC0B971883DFF4F22" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D44EED643D26CB5191E771883DFD74AB" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_92A8BE98907459DAC0B971883DFF4F22" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_FF913A3958EFF24576C771883DFFA2CC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_92A8BE98907459DAC0B971883DFF4F22" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_FF913A3958EFF24576C771883DFFA2CC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_755A661097FC7B0AAD7D71883DFFF936" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_92A8BE98907459DAC0B971883DFF4F22" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_755A661097FC7B0AAD7D71883DFFF936" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5D17B3AE9C8C83D3C8F071883DFF7DD9" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D44EED643D26CB5191E771883DFD74AB" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5D17B3AE9C8C83D3C8F071883DFF7DD9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_289AF34B9E1F6519D7DB71883DFF5A65" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D44EED643D26CB5191E771883DFD74AB" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_289AF34B9E1F6519D7DB71883DFF5A65" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_F7D57461AFBE86421D3C71883E00CB82" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D44EED643D26CB5191E771883DFD74AB" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_F7D57461AFBE86421D3C71883E00CB82" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_326E61273B38CF56084071883E00A54C" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D44EED643D26CB5191E771883DFD74AB" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_326E61273B38CF56084071883E00A54C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_EAF5ECCF5F49D840AC9571883E000DEC" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D44EED643D26CB5191E771883DFD74AB" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_EAF5ECCF5F49D840AC9571883E000DEC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_075789BDDC45CD8EE88F71883E00E619" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D44EED643D26CB5191E771883DFD74AB" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_075789BDDC45CD8EE88F71883E00E619" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_Finitelivedintangibleassetsfutureamortization" xlink:label="loc_biib_Finitelivedintangibleassetsfutureamortization_0A2FB105A5B0C95A615171883E00D5B3" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D44EED643D26CB5191E771883DFD74AB" xlink:to="loc_biib_Finitelivedintangibleassetsfutureamortization_0A2FB105A5B0C95A615171883E00D5B3" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_81C3A10B89C4891D2BEEAE73DAE70FED" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_534D6F0935EA4F14CB72AE73DAE7FBE9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_81C3A10B89C4891D2BEEAE73DAE70FED" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_534D6F0935EA4F14CB72AE73DAE7FBE9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_6B4DE970DCE257634D1EAE73DAE7DBC9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_534D6F0935EA4F14CB72AE73DAE7FBE9" xlink:to="loc_us-gaap_ProductOrServiceAxis_6B4DE970DCE257634D1EAE73DAE7DBC9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_167240C91CF34B5BE746AE73DAE7DA86" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_6B4DE970DCE257634D1EAE73DAE7DBC9" xlink:to="loc_us-gaap_ProductsAndServicesDomain_167240C91CF34B5BE746AE73DAE7DA86" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_590E29752ABFF86B7FA2AE73DAE7EEE5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_167240C91CF34B5BE746AE73DAE7DA86" xlink:to="loc_biib_TecfideraMember_590E29752ABFF86B7FA2AE73DAE7EEE5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_D08026252B5634564138AE73DAE7D90F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_534D6F0935EA4F14CB72AE73DAE7FBE9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_D08026252B5634564138AE73DAE7D90F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6E43D9534DD0F5351333AE73DAE77CD6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_D08026252B5634564138AE73DAE7D90F" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6E43D9534DD0F5351333AE73DAE77CD6" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_43A6F9E77E85B589D10BAE73DAE8AD5F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6E43D9534DD0F5351333AE73DAE77CD6" xlink:to="loc_biib_FumapharmAgMember_43A6F9E77E85B589D10BAE73DAE8AD5F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_8F2775182217F0F734A4AE73DAE817A3" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_534D6F0935EA4F14CB72AE73DAE7FBE9" xlink:to="loc_us-gaap_GoodwillLineItems_8F2775182217F0F734A4AE73DAE817A3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_59D8F4660310F1B3898BAE73DAE84BD3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_8F2775182217F0F734A4AE73DAE817A3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_59D8F4660310F1B3898BAE73DAE84BD3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_CFF32E507952DC831B22AE73DAE83BEA" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_8F2775182217F0F734A4AE73DAE817A3" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_CFF32E507952DC831B22AE73DAE83BEA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_15C8E4AC4D84050AF701AE73DAE8A668" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_81C3A10B89C4891D2BEEAE73DAE70FED" xlink:to="loc_us-gaap_GoodwillRollForward_15C8E4AC4D84050AF701AE73DAE8A668" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_03B860FB5CF6CF27B069AE73DAE84141" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_15C8E4AC4D84050AF701AE73DAE8A668" xlink:to="loc_us-gaap_Goodwill_03B860FB5CF6CF27B069AE73DAE84141" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillOtherChanges" xlink:label="loc_us-gaap_GoodwillOtherChanges_D8D9A000C110090ADCB2AE73DAE89C1B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_15C8E4AC4D84050AF701AE73DAE8A668" xlink:to="loc_us-gaap_GoodwillOtherChanges_D8D9A000C110090ADCB2AE73DAE89C1B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_C672BA0653B196E8FD96AE73DAE8B5C5" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_15C8E4AC4D84050AF701AE73DAE8A668" xlink:to="loc_us-gaap_Goodwill_C672BA0653B196E8FD96AE73DAE8B5C5" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D6886609AE92C5A9F821AE73DAEA3B58" xlink:type="locator" />
    <loc xlink:href="biib-20150930.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_8CE95D985089CFC2ACE5AE73DAEB66D9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D6886609AE92C5A9F821AE73DAEA3B58" xlink:to="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_8CE95D985089CFC2ACE5AE73DAEB66D9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BCE465CEAD0984FC3FEBAE73DAEB8C97" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D6886609AE92C5A9F821AE73DAEA3B58" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BCE465CEAD0984FC3FEBAE73DAEB8C97" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_2345C7E20E1027435A01AE73DAEB3FD4" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D6886609AE92C5A9F821AE73DAEA3B58" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_2345C7E20E1027435A01AE73DAEB3FD4" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_E1F2F0B274D2F2AE9379AE73DA8467A6" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_B9D4C431A33F6D8EB26BAE73DA8459A0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_E1F2F0B274D2F2AE9379AE73DA8467A6" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_B9D4C431A33F6D8EB26BAE73DA8459A0" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_BFA44CB5E7283E22AD8FAE73DABB22AD" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_DE3D8A3D4DC1D7038A99AE73DABB0BD2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_BFA44CB5E7283E22AD8FAE73DABB22AD" xlink:to="loc_us-gaap_InventoryNetAbstract_DE3D8A3D4DC1D7038A99AE73DABB0BD2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_C4F7B5CA55C21E159AAFAE73DABBE7F7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_DE3D8A3D4DC1D7038A99AE73DABB0BD2" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_C4F7B5CA55C21E159AAFAE73DABBE7F7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_95D576CE08FCD77FF03EAE73DABB4178" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_DE3D8A3D4DC1D7038A99AE73DABB0BD2" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_95D576CE08FCD77FF03EAE73DABB4178" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_B2A146856E067EB5B621AE73DABB7DCC" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_DE3D8A3D4DC1D7038A99AE73DABB0BD2" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_B2A146856E067EB5B621AE73DABB7DCC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_C201385C3B69265998D3AE73DABBB3B9" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_DE3D8A3D4DC1D7038A99AE73DABB0BD2" xlink:to="loc_us-gaap_InventoryNet_C201385C3B69265998D3AE73DABBB3B9" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_F6A56287303757D28588AE73DAF8AF46" xlink:type="locator" />
    <loc xlink:href="biib-20150930.xsd#biib_InventoryVariousProgramsGross" xlink:label="loc_biib_InventoryVariousProgramsGross_97981A16C26D9549F83DAE73DAF8A166" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_F6A56287303757D28588AE73DAF8AF46" xlink:to="loc_biib_InventoryVariousProgramsGross_97981A16C26D9549F83DAE73DAF8A166" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_3852EE39523E473B4BC1AE73DB65E9F7" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0C38DC0EAE82D936DD81AE73DB652126" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3852EE39523E473B4BC1AE73DB65E9F7" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0C38DC0EAE82D936DD81AE73DB652126" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended">
    <loc xlink:href="biib-20150930.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_B1CF06598721E36880BDAE73DAA146EB" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_6F85B0DEAD17AE1E9314AE73DAA1016A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_B1CF06598721E36880BDAE73DAA146EB" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_6F85B0DEAD17AE1E9314AE73DAA1016A" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended">
    <loc xlink:href="biib-20150930.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_C334159063D7445D7E1A43C3DB77E8D3" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_0BCFE8363A5D99A2C61043C3DB77BD80" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_C334159063D7445D7E1A43C3DB77E8D3" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_0BCFE8363A5D99A2C61043C3DB77BD80" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_52B77B940A44F21481D043C3DB7753B9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_0BCFE8363A5D99A2C61043C3DB77BD80" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_52B77B940A44F21481D043C3DB7753B9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_F3F6EF94FDFC2E824F8443C3DB77DE6B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_52B77B940A44F21481D043C3DB7753B9" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_F3F6EF94FDFC2E824F8443C3DB77DE6B" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_B9499F44AF20ECE8992D43C3DB77C61C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_F3F6EF94FDFC2E824F8443C3DB77DE6B" xlink:to="loc_biib_NeurimmuneMember_B9499F44AF20ECE8992D43C3DB77C61C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_4FBC2578998B70ABCC0543C3DB775412" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_0BCFE8363A5D99A2C61043C3DB77BD80" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_4FBC2578998B70ABCC0543C3DB775412" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9FB61CD643519FF01B5343C3DB77E733" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_4FBC2578998B70ABCC0543C3DB775412" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9FB61CD643519FF01B5343C3DB77E733" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_InvestmentInVariableInterestEntitiesTextualAbstract" xlink:label="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_6D826EA9CBC48DDEA6EB43C3DB773CD9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_4FBC2578998B70ABCC0543C3DB775412" xlink:to="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_6D826EA9CBC48DDEA6EB43C3DB773CD9" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement" xlink:label="loc_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_18C5103EDF71FCFC104743C3DB774EC1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_6D826EA9CBC48DDEA6EB43C3DB773CD9" xlink:to="loc_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_18C5103EDF71FCFC104743C3DB774EC1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_EFD7388D3156A382F82C43C3DB7763CB" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_6D826EA9CBC48DDEA6EB43C3DB773CD9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_EFD7388D3156A382F82C43C3DB7763CB" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_67A7AF45A19ECAF825B743C3DB783C03" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_6D826EA9CBC48DDEA6EB43C3DB773CD9" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_67A7AF45A19ECAF825B743C3DB783C03" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_AE18BA6FE8AB848AFCBCAE73D94D4D3D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_277B7950268FF17F8DCBAE73D94DC495" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_AE18BA6FE8AB848AFCBCAE73D94D4D3D" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_277B7950268FF17F8DCBAE73D94DC495" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_B13FFF4879118506DAF8AE73D93CA5D5" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_219CAEB8764319694740AE73D93C86F5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_B13FFF4879118506DAF8AE73D93CA5D5" xlink:to="loc_us-gaap_LossContingenciesTable_219CAEB8764319694740AE73D93C86F5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_55B51BFA7415B7F320D0AE73D93CBE95" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_219CAEB8764319694740AE73D93C86F5" xlink:to="loc_us-gaap_StatementGeographicalAxis_55B51BFA7415B7F320D0AE73D93CBE95" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_8A28995B29561FD23C44AE73D93C75D2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_55B51BFA7415B7F320D0AE73D93CBE95" xlink:to="loc_us-gaap_SegmentGeographicalDomain_8A28995B29561FD23C44AE73D93C75D2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_IT" xlink:label="loc_country_IT_D38D251D6016C83DB244AE73D93CEACD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_8A28995B29561FD23C44AE73D93C75D2" xlink:to="loc_country_IT_D38D251D6016C83DB244AE73D93CEACD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_11020AA57F9FCA5BD9C0AE73D93CC9B6" xlink:type="locator" />
    <presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_219CAEB8764319694740AE73D93C86F5" xlink:to="loc_us-gaap_LossContingenciesLineItems_11020AA57F9FCA5BD9C0AE73D93CC9B6" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_ReimbursementLimitStatedInResolution" xlink:label="loc_biib_ReimbursementLimitStatedInResolution_9AF23B05A4509ED60F25AE73D93CB0B4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_11020AA57F9FCA5BD9C0AE73D93CC9B6" xlink:to="loc_biib_ReimbursementLimitStatedInResolution_9AF23B05A4509ED60F25AE73D93CB0B4" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_47952D058D4BA63D06CBAE73D9430CFD" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_57C79E0857DFA3D310ACAE73D9431A1B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_47952D058D4BA63D06CBAE73D9430CFD" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_57C79E0857DFA3D310ACAE73D9431A1B" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_13138B8992B4B490B887720464D4662A" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1EA2FFC510071A9A01AF720464D4C1EC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_13138B8992B4B490B887720464D4662A" xlink:to="loc_us-gaap_StatementTable_1EA2FFC510071A9A01AF720464D4C1EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_C55D4DA7F6BD95936494720464D588AD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1EA2FFC510071A9A01AF720464D4C1EC" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_C55D4DA7F6BD95936494720464D588AD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0F9B45BE453839D28919720464D56F75" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_C55D4DA7F6BD95936494720464D588AD" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0F9B45BE453839D28919720464D56F75" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_82F24D4E1D73B658E3B7720464D5F818" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0F9B45BE453839D28919720464D56F75" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_82F24D4E1D73B658E3B7720464D5F818" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_9AE166CC2FD57A566E7C720464D53C9B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1EA2FFC510071A9A01AF720464D4C1EC" xlink:to="loc_us-gaap_StatementLineItems_9AE166CC2FD57A566E7C720464D53C9B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_3B76604B1A0ABE15B840720464D522D6" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_13138B8992B4B490B887720464D4662A" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_3B76604B1A0ABE15B840720464D522D6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_54E8CBA70650B73AB6A9720464D52756" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_3B76604B1A0ABE15B840720464D522D6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_54E8CBA70650B73AB6A9720464D52756" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_BEF2EE30D4125FC9BF78720464D5A615" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_3B76604B1A0ABE15B840720464D522D6" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_BEF2EE30D4125FC9BF78720464D5A615" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_954FE3DF7F2D3B2A8487720464D57278" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_3B76604B1A0ABE15B840720464D522D6" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_954FE3DF7F2D3B2A8487720464D57278" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_4700170E8F9D39546546720464D51CB8" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_3B76604B1A0ABE15B840720464D522D6" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_4700170E8F9D39546546720464D51CB8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_DFF132AB176578486BC0720464D50611" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_3B76604B1A0ABE15B840720464D522D6" xlink:to="loc_us-gaap_DeferredRevenueCurrent_DFF132AB176578486BC0720464D50611" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_B5E89677048F4793CE80720464D59BFE" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_3B76604B1A0ABE15B840720464D522D6" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_B5E89677048F4793CE80720464D59BFE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_18AC07230704BAE180B2720464D59A06" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_3B76604B1A0ABE15B840720464D522D6" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_18AC07230704BAE180B2720464D59A06" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_E3E5997D2B8079CB3764720464D59652" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_13138B8992B4B490B887720464D4662A" xlink:to="loc_us-gaap_InterestIncomeExpenseNetAbstract_E3E5997D2B8079CB3764720464D59652" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_01845E4732C7A848E6AB720464D57D28" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_E3E5997D2B8079CB3764720464D59652" xlink:to="loc_us-gaap_InvestmentIncomeInterest_01845E4732C7A848E6AB720464D57D28" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_7313CFDB155C8CA52FFB720464D52B74" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_E3E5997D2B8079CB3764720464D59652" xlink:to="loc_us-gaap_InterestExpense_7313CFDB155C8CA52FFB720464D52B74" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_E04873D614B2E1FAFAA7720464D516C0" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_E3E5997D2B8079CB3764720464D59652" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_E04873D614B2E1FAFAA7720464D516C0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_B0468164B7D2334742FB720464D6C0DC" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_E3E5997D2B8079CB3764720464D59652" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_B0468164B7D2334742FB720464D6C0DC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4E194CC0B8EEEABB49A4720464D6A532" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_E3E5997D2B8079CB3764720464D59652" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4E194CC0B8EEEABB49A4720464D6A532" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_40BC119D5DCC35F2DCBB720464D6F712" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_E3E5997D2B8079CB3764720464D59652" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_40BC119D5DCC35F2DCBB720464D6F712" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_EE4F15CF9F53A54AEC91720464D6DB0C" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_13138B8992B4B490B887720464D4662A" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_EE4F15CF9F53A54AEC91720464D6DB0C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7A5BC6DBD1289C837C77720464D6CAEC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_EE4F15CF9F53A54AEC91720464D6DB0C" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7A5BC6DBD1289C837C77720464D6CAEC" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_Employeerelatedliabilitiesnoncurrent" xlink:label="loc_biib_Employeerelatedliabilitiesnoncurrent_CB79B85C7D0515B6745E720464D6DAA3" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_EE4F15CF9F53A54AEC91720464D6DB0C" xlink:to="loc_biib_Employeerelatedliabilitiesnoncurrent_CB79B85C7D0515B6745E720464D6DAA3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_AB335796064748E6F854720464D6CB63" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_EE4F15CF9F53A54AEC91720464D6DB0C" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_AB335796064748E6F854720464D6CB63" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_C633756CA6BE54BF3FDC720464D65046" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_EE4F15CF9F53A54AEC91720464D6DB0C" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_C633756CA6BE54BF3FDC720464D65046" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesAbstract_C0F25214255C304D0969720464CE7ECF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="loc_us-gaap_ProductLiabilityContingencyTable_F214774A207C40BD9FE4720464CFEBE6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesAbstract_C0F25214255C304D0969720464CE7ECF" xlink:to="loc_us-gaap_ProductLiabilityContingencyTable_F214774A207C40BD9FE4720464CFEBE6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_027EAF1712FF8FA66EF5720464CF4BC6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductLiabilityContingencyTable_F214774A207C40BD9FE4720464CFEBE6" xlink:to="loc_us-gaap_StatementGeographicalAxis_027EAF1712FF8FA66EF5720464CF4BC6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_3B48B489E61753812851720464CFDEC6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_027EAF1712FF8FA66EF5720464CF4BC6" xlink:to="loc_us-gaap_SegmentGeographicalDomain_3B48B489E61753812851720464CFDEC6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_IT" xlink:label="loc_country_IT_3548DE6FFC06331FDCD9720464CF0269" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_3B48B489E61753812851720464CFDEC6" xlink:to="loc_country_IT_3548DE6FFC06331FDCD9720464CF0269" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="loc_us-gaap_ProductLiabilityContingencyLineItems_7A6A0542911CBD03E69E720464CFC65E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductLiabilityContingencyTable_F214774A207C40BD9FE4720464CFEBE6" xlink:to="loc_us-gaap_ProductLiabilityContingencyLineItems_7A6A0542911CBD03E69E720464CFC65E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_A2DCA7751EB432CD5E44720464CFEA54" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_7A6A0542911CBD03E69E720464CFC65E" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_A2DCA7751EB432CD5E44720464CFEA54" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_43AD76CEE1681453C89E720464CF7A4C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_7A6A0542911CBD03E69E720464CFC65E" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_43AD76CEE1681453C89E720464CF7A4C" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B0BDBA030B26D4F75C8EAE73D98A9F79" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_76CB6728FFF29DA0525FAE73D98A7E97" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B0BDBA030B26D4F75C8EAE73D98A9F79" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_76CB6728FFF29DA0525FAE73D98A7E97" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_48EE6CAB9D1EE44BBC92AE73D98A9BDD" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B0BDBA030B26D4F75C8EAE73D98A9F79" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_48EE6CAB9D1EE44BBC92AE73D98A9BDD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_12B18C707FE56C49B705AE73D98AE33E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B0BDBA030B26D4F75C8EAE73D98A9F79" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_12B18C707FE56C49B705AE73D98AE33E" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_31D2A4FE9E2E1CFDDE162E9B992B0FB8" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_5EAA1F29086B450E8DF22E9BF14CB4E4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_31D2A4FE9E2E1CFDDE162E9B992B0FB8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_5EAA1F29086B450E8DF22E9BF14CB4E4" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_D3D7CE9F79BC8C5CF8B071B1374A4B91" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_C204A33BE7334E5FF96071B13DBED8DD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_D3D7CE9F79BC8C5CF8B071B1374A4B91" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_C204A33BE7334E5FF96071B13DBED8DD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_BF185DF12ABE10C94FBD71B22FF806F1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_C204A33BE7334E5FF96071B13DBED8DD" xlink:to="loc_us-gaap_TypeOfArrangementAxis_BF185DF12ABE10C94FBD71B22FF806F1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DC6B36A2CF724DF2468371B23005AF2C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_BF185DF12ABE10C94FBD71B22FF806F1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DC6B36A2CF724DF2468371B23005AF2C" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_BBCDE800707FB0F280B471B2302A9A35" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DC6B36A2CF724DF2468371B23005AF2C" xlink:to="loc_biib_EisaiMember_BBCDE800707FB0F280B471B2302A9A35" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0B1BCFA3CAE4A9B77A5771B13DBE577A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_C204A33BE7334E5FF96071B13DBED8DD" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0B1BCFA3CAE4A9B77A5771B13DBE577A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_A05E477D4D3BF298720A71B13DBE1F13" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0B1BCFA3CAE4A9B77A5771B13DBE577A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_A05E477D4D3BF298720A71B13DBE1F13" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_F42CFF8EF018DCE2693B71B23037A3F3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_A05E477D4D3BF298720A71B13DBE1F13" xlink:to="loc_us-gaap_BuildingMember_F42CFF8EF018DCE2693B71B23037A3F3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_41EE4E3543585545902E71B261861B7E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_A05E477D4D3BF298720A71B13DBE1F13" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_41EE4E3543585545902E71B261861B7E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_BF687AD09D8D91C667F471B30678C6F2" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_A05E477D4D3BF298720A71B13DBE1F13" xlink:to="loc_us-gaap_LandMember_BF687AD09D8D91C667F471B30678C6F2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_952983D8BDD7FF6AA0BC71B13DBFD104" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_C204A33BE7334E5FF96071B13DBED8DD" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_952983D8BDD7FF6AA0BC71B13DBFD104" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_FE3B7CF505A43D6F8FF371B14293A0BD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_952983D8BDD7FF6AA0BC71B13DBFD104" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_FE3B7CF505A43D6F8FF371B14293A0BD" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_66334D1588281582A893875A3D497074" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A0989F4B3EC49892890B875A3D4917ED" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_66334D1588281582A893875A3D497074" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A0989F4B3EC49892890B875A3D4917ED" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6E887704B4C66091A415875A3D494B48" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A0989F4B3EC49892890B875A3D4917ED" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6E887704B4C66091A415875A3D494B48" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6A38ABBA6E22D04AF3C8875A3D497D58" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6E887704B4C66091A415875A3D494B48" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6A38ABBA6E22D04AF3C8875A3D497D58" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_E0952C67FB3AA0381890875A3D49F499" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6A38ABBA6E22D04AF3C8875A3D497D58" xlink:to="loc_biib_EisaiMember_E0952C67FB3AA0381890875A3D49F499" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_BDA1852A96809CC1ACED875A3D498823" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A0989F4B3EC49892890B875A3D4917ED" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_BDA1852A96809CC1ACED875A3D498823" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_A133B037092426ABB472875A3D4A3BB0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_BDA1852A96809CC1ACED875A3D498823" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_A133B037092426ABB472875A3D4A3BB0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_91361D31174AEDBAD046875A3D4A1D48" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_BDA1852A96809CC1ACED875A3D498823" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_91361D31174AEDBAD046875A3D4A1D48" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_B70C546A5B1E2530F12A875A3D4AB537" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_BDA1852A96809CC1ACED875A3D498823" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_B70C546A5B1E2530F12A875A3D4AB537" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_TermOfLease" xlink:label="loc_biib_TermOfLease_5FBE1A0A4781A816BE90875A3D4A1AB7" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_BDA1852A96809CC1ACED875A3D498823" xlink:to="loc_biib_TermOfLease_5FBE1A0A4781A816BE90875A3D4A1AB7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="loc_us-gaap_CapitalLeaseObligations_1318D9DE25D697AFC4D3875A3D4A90FE" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_BDA1852A96809CC1ACED875A3D498823" xlink:to="loc_us-gaap_CapitalLeaseObligations_1318D9DE25D697AFC4D3875A3D4A90FE" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_F18ABE00735F498C3A9271AC05A1DDA6" xlink:type="locator" />
    <loc xlink:href="biib-20150930.xsd#biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock" xlink:label="loc_biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock_8B99BF48A6E5B8401D3371AF3F09EE91" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_F18ABE00735F498C3A9271AC05A1DDA6" xlink:to="loc_biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock_8B99BF48A6E5B8401D3371AF3F09EE91" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_FC71DA3DE54F2495B341AE73DAF602C5" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="loc_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_EBCCE181B7C2B8EADB76AE73DAF637EF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_FC71DA3DE54F2495B341AE73DAF602C5" xlink:to="loc_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_EBCCE181B7C2B8EADB76AE73DAF637EF" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_3689CEFFB0EAD1A10C0E2E2530939F93" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_E60431B9377B9A488E9D2E2530939BAD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_3689CEFFB0EAD1A10C0E2E2530939F93" xlink:to="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_E60431B9377B9A488E9D2E2530939BAD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_947311637BA834AB68B12E253093189C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_E60431B9377B9A488E9D2E2530939BAD" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_947311637BA834AB68B12E253093189C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_8011D080F63E94FF01372E253093B700" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_947311637BA834AB68B12E253093189C" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_8011D080F63E94FF01372E253093B700" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReserveForCashDiscountMember" xlink:label="loc_us-gaap_ReserveForCashDiscountMember_09510A56CA45DB49B3292E25309375C6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8011D080F63E94FF01372E253093B700" xlink:to="loc_us-gaap_ReserveForCashDiscountMember_09510A56CA45DB49B3292E25309375C6" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_EF6E5811B4AE2C27C0602E25309379EE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8011D080F63E94FF01372E253093B700" xlink:to="loc_biib_ContractualAdjustmentsMember_EF6E5811B4AE2C27C0602E25309379EE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_758964C09BA113A2C30D2E25309388BD" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8011D080F63E94FF01372E253093B700" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_758964C09BA113A2C30D2E25309388BD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_307A1C9A227B211CF60A2E2530935C91" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_E60431B9377B9A488E9D2E2530939BAD" xlink:to="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_307A1C9A227B211CF60A2E2530935C91" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_B85CB23882F68CA3C33E2E253093D5B7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_307A1C9A227B211CF60A2E2530935C91" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_B85CB23882F68CA3C33E2E253093D5B7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_69E7CEE8EDB9BC05A7B32E253093ABF2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_B85CB23882F68CA3C33E2E253093D5B7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_69E7CEE8EDB9BC05A7B32E253093ABF2" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_D0CF3AD88EFF1B85CC9E2E253093BF17" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_B85CB23882F68CA3C33E2E253093D5B7" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_D0CF3AD88EFF1B85CC9E2E253093BF17" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_85EFC725114DEC1AD30D2E25309388AC" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_B85CB23882F68CA3C33E2E253093D5B7" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_85EFC725114DEC1AD30D2E25309388AC" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_A8A56D465FCD07F73D7F2E253093D955" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_B85CB23882F68CA3C33E2E253093D5B7" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_A8A56D465FCD07F73D7F2E253093D955" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_6D17D82BE78FCE2A06C62E253093A345" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_B85CB23882F68CA3C33E2E253093D5B7" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_6D17D82BE78FCE2A06C62E253093A345" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_780B3D030560B2D54E502E2530945271" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_B85CB23882F68CA3C33E2E253093D5B7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_780B3D030560B2D54E502E2530945271" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_841811EE8781848D7B31AE73DB5B186E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_733E6463D87D8DCA2B72AE73DB5B8C8D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_841811EE8781848D7B31AE73DB5B186E" xlink:to="loc_us-gaap_StatementTable_733E6463D87D8DCA2B72AE73DB5B8C8D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2F2CB41B710E02B5D608AE73DB5BBAE8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_733E6463D87D8DCA2B72AE73DB5B8C8D" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2F2CB41B710E02B5D608AE73DB5BBAE8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_B882ECA7810379A64E5AAE73DB5B0AD5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2F2CB41B710E02B5D608AE73DB5BBAE8" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_B882ECA7810379A64E5AAE73DB5B0AD5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_1E0F4A5FA2857119D82CAE73DB5BE9BC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_B882ECA7810379A64E5AAE73DB5B0AD5" xlink:to="loc_us-gaap_AccountsReceivableMember_1E0F4A5FA2857119D82CAE73DB5BE9BC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_F93BB9DD1345FF18EB72AE73DB5B891F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_B882ECA7810379A64E5AAE73DB5B0AD5" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_F93BB9DD1345FF18EB72AE73DB5B891F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_D9453522CB4F596DCBB8AE73DB5B1044" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_733E6463D87D8DCA2B72AE73DB5B8C8D" xlink:to="loc_us-gaap_StatementLineItems_D9453522CB4F596DCBB8AE73DB5B1044" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_02C0E577788EB3E31AAFAE73DB5B37A6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D9453522CB4F596DCBB8AE73DB5B1044" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_02C0E577788EB3E31AAFAE73DB5B37A6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_9B6E6FCC21C3B1C60377AE73DB5C7085" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_02C0E577788EB3E31AAFAE73DB5B37A6" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_9B6E6FCC21C3B1C60377AE73DB5C7085" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_1A31BA5893AF9FA39744AE73DAA053C3" xlink:type="locator" />
    <loc xlink:href="biib-20150930.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_5029A6EA577A15AAFE8BAE73DAA0C0F0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_1A31BA5893AF9FA39744AE73DAA053C3" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_5029A6EA577A15AAFE8BAE73DAA0C0F0" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_DA3EDDE447F2BDC55529AE73DAA02646" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_1A31BA5893AF9FA39744AE73DAA053C3" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_DA3EDDE447F2BDC55529AE73DAA02646" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D17437132B8426153600AE73DAD20EBA" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_470F137BF5E40CCCBFE0AE73DAD235F7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D17437132B8426153600AE73DAD20EBA" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_470F137BF5E40CCCBFE0AE73DAD235F7" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F88CDFB03989757907ECAE73DB56109F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_26D5F461409E00AA72B8AE73DB56150C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F88CDFB03989757907ECAE73DB56109F" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_26D5F461409E00AA72B8AE73DB56150C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1D60CBA97E32368DA909AE73DB56A339" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_26D5F461409E00AA72B8AE73DB56150C" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1D60CBA97E32368DA909AE73DB56A339" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1F05255FAAE6BDCCD99EAE73DB56CDEB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1D60CBA97E32368DA909AE73DB56A339" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1F05255FAAE6BDCCD99EAE73DB56CDEB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2138FDBD24834F5371E2AE73DB564B16" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1F05255FAAE6BDCCD99EAE73DB56CDEB" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2138FDBD24834F5371E2AE73DB564B16" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_BE721F9EDBE1D1659E50AE73DB561952" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1F05255FAAE6BDCCD99EAE73DB56CDEB" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_BE721F9EDBE1D1659E50AE73DB561952" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_261905DAAEAB0C109727AE73DB56BBEF" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1F05255FAAE6BDCCD99EAE73DB56CDEB" xlink:to="loc_us-gaap_ParentMember_261905DAAEAB0C109727AE73DB56BBEF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1D55D1B09A240BB3883AAE73DB561448" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_26D5F461409E00AA72B8AE73DB56150C" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1D55D1B09A240BB3883AAE73DB561448" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_29C53B869AC3406E9DC5AE73DB563A03" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1D55D1B09A240BB3883AAE73DB561448" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_29C53B869AC3406E9DC5AE73DB563A03" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_A890705399D96BD0B860AE73DB560E34" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_29C53B869AC3406E9DC5AE73DB563A03" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_A890705399D96BD0B860AE73DB560E34" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_C25FF2E74EB99E9D829AAE73DB56471B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_29C53B869AC3406E9DC5AE73DB563A03" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_C25FF2E74EB99E9D829AAE73DB56471B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_AA1FE99A37D66A18CB0AAE73DB57A40F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_29C53B869AC3406E9DC5AE73DB563A03" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_AA1FE99A37D66A18CB0AAE73DB57A40F" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_8668398966772FE9BEECAE73DB577428" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_29C53B869AC3406E9DC5AE73DB563A03" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_8668398966772FE9BEECAE73DB577428" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_23FB7FC5BB62C16CDB50AE73DB572404" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_29C53B869AC3406E9DC5AE73DB563A03" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_23FB7FC5BB62C16CDB50AE73DB572404" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_57977664DBCA63E4C346AE73DB3C5D8D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_410A4A6CCD4894503C61AE73DB3C53FC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_57977664DBCA63E4C346AE73DB3C5D8D" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_410A4A6CCD4894503C61AE73DB3C53FC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_16D9C787CAC86A8AB972AE73DB3C10F6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_410A4A6CCD4894503C61AE73DB3C53FC" xlink:to="loc_us-gaap_PlanNameAxis_16D9C787CAC86A8AB972AE73DB3C10F6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_67BF43482EBFE0E6444EAE73DB3D8F6B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_16D9C787CAC86A8AB972AE73DB3C10F6" xlink:to="loc_us-gaap_PlanNameDomain_67BF43482EBFE0E6444EAE73DB3D8F6B" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_CF5B2E674F01E41D6C78AE73DB3DA3FD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_67BF43482EBFE0E6444EAE73DB3D8F6B" xlink:to="loc_biib_MarketStockUnitsMember_CF5B2E674F01E41D6C78AE73DB3DA3FD" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_3ED6F667D6EE3EA1A301AE73DB3D0D03" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_67BF43482EBFE0E6444EAE73DB3D8F6B" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_3ED6F667D6EE3EA1A301AE73DB3D0D03" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_A4A72F8F82C0D6928C01AE73DB3D65E5" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_67BF43482EBFE0E6444EAE73DB3D8F6B" xlink:to="loc_biib_CashSettledPerformanceSharesMember_A4A72F8F82C0D6928C01AE73DB3D65E5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_1B4E6CC07F7DC4B6F121AE73DB3DF9BF" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_67BF43482EBFE0E6444EAE73DB3D8F6B" xlink:to="loc_us-gaap_PerformanceSharesMember_1B4E6CC07F7DC4B6F121AE73DB3DF9BF" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_E565765DDBCFAABB2F9FAE73DB3D7963" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_67BF43482EBFE0E6444EAE73DB3D8F6B" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_E565765DDBCFAABB2F9FAE73DB3D7963" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_63AFB2B620C82B063BBBAE73DB3D7CEA" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_410A4A6CCD4894503C61AE73DB3C53FC" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_63AFB2B620C82B063BBBAE73DB3D7CEA" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18F9D0853DE50D6225CFAE73DB3D606A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_63AFB2B620C82B063BBBAE73DB3D7CEA" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18F9D0853DE50D6225CFAE73DB3D606A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_73B1C8DF0FB9BB63ABFDAE73DB3D3599" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18F9D0853DE50D6225CFAE73DB3D606A" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_73B1C8DF0FB9BB63ABFDAE73DB3D3599" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_2CFD69F50BFF9650A936AE73DB3DDD80" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18F9D0853DE50D6225CFAE73DB3D606A" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_2CFD69F50BFF9650A936AE73DB3DDD80" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_75997AAB9B30748DD8B5AE73DB3D62FC" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18F9D0853DE50D6225CFAE73DB3D606A" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_75997AAB9B30748DD8B5AE73DB3D62FC" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_9FB75CA349F848D7CB5BAE73DB3DCCED" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18F9D0853DE50D6225CFAE73DB3D606A" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_9FB75CA349F848D7CB5BAE73DB3DCCED" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_45A1119DCCE1CAB6C173AE73DADFBDF1" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E5771B9D160DF86C507CAE73DADFB42B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_45A1119DCCE1CAB6C173AE73DADFBDF1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E5771B9D160DF86C507CAE73DADFB42B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_F4FA66DA04C3D442CDFDAE73DADF8D8F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E5771B9D160DF86C507CAE73DADFB42B" xlink:to="loc_us-gaap_PlanNameAxis_F4FA66DA04C3D442CDFDAE73DADF8D8F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_97B771C3F71F7C020588AE73DADF34A8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_F4FA66DA04C3D442CDFDAE73DADF8D8F" xlink:to="loc_us-gaap_PlanNameDomain_97B771C3F71F7C020588AE73DADF34A8" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_D62CEC66F51F78A83AF5AE73DADFD767" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_97B771C3F71F7C020588AE73DADF34A8" xlink:to="loc_biib_MarketStockUnitsMember_D62CEC66F51F78A83AF5AE73DADFD767" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_A66E609D3B5C03138D63AE73DADF43A7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_97B771C3F71F7C020588AE73DADF34A8" xlink:to="loc_biib_CashSettledPerformanceSharesMember_A66E609D3B5C03138D63AE73DADF43A7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_361A823BF2B5732B2E6EAE73DADFA299" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_97B771C3F71F7C020588AE73DADF34A8" xlink:to="loc_us-gaap_PerformanceSharesMember_361A823BF2B5732B2E6EAE73DADFA299" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_6C3EC5331BB1CA68C116AE73DADF66C5" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_97B771C3F71F7C020588AE73DADF34A8" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_6C3EC5331BB1CA68C116AE73DADF66C5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E8D76486BEC6EFF715BCAE73DADFEF6C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E5771B9D160DF86C507CAE73DADFB42B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E8D76486BEC6EFF715BCAE73DADFEF6C" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_ScheduleOfStockOptionGrantsAbstract" xlink:label="loc_biib_ScheduleOfStockOptionGrantsAbstract_2B608E2213BDBC28C519AE73DADFC947" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E8D76486BEC6EFF715BCAE73DADFEF6C" xlink:to="loc_biib_ScheduleOfStockOptionGrantsAbstract_2B608E2213BDBC28C519AE73DADFC947" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_747858BD316986D444A4AE73DADF10C8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfStockOptionGrantsAbstract_2B608E2213BDBC28C519AE73DADFC947" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_747858BD316986D444A4AE73DADF10C8" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_AEDD3FAC4C69F9808A413EA2E55401F3" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_2151E59E038D0F39BE9D3EFA95A9BDB2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_AEDD3FAC4C69F9808A413EA2E55401F3" xlink:to="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_2151E59E038D0F39BE9D3EFA95A9BDB2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_25A2BC4D4AA5BECEF2B13EFAC2BA0F8C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_2151E59E038D0F39BE9D3EFA95A9BDB2" xlink:to="loc_us-gaap_PlanNameAxis_25A2BC4D4AA5BECEF2B13EFAC2BA0F8C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_4821F631872A9E6DF7513EFAC2BF45E4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_25A2BC4D4AA5BECEF2B13EFAC2BA0F8C" xlink:to="loc_us-gaap_PlanNameDomain_4821F631872A9E6DF7513EFAC2BF45E4" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_A1995ESPPMember" xlink:label="loc_biib_A1995ESPPMember_3CAA199F9B075388839F3EFB47ED7066" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4821F631872A9E6DF7513EFAC2BF45E4" xlink:to="loc_biib_A1995ESPPMember_3CAA199F9B075388839F3EFB47ED7066" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_A2015ESPPMember" xlink:label="loc_biib_A2015ESPPMember_CD85549E8C7A70F7E4953F00A93D0C9C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4821F631872A9E6DF7513EFAC2BF45E4" xlink:to="loc_biib_A2015ESPPMember_CD85549E8C7A70F7E4953F00A93D0C9C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_2DABCF06F103985390273EFA95B09FA3" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_2151E59E038D0F39BE9D3EFA95A9BDB2" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_2DABCF06F103985390273EFA95B09FA3" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_Employeestockpurchaseplanmaximumshares" xlink:label="loc_biib_Employeestockpurchaseplanmaximumshares_6F0476F71E940862D1DB3EA2E554FBC3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_2DABCF06F103985390273EFA95B09FA3" xlink:to="loc_biib_Employeestockpurchaseplanmaximumshares_6F0476F71E940862D1DB3EA2E554FBC3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5D616C13D4205D0F62783EA2E5548387" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_2DABCF06F103985390273EFA95B09FA3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5D616C13D4205D0F62783EA2E5548387" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_370293A71B77D41C4C6CAE73DB5180F8" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0BE7FD13DDD14D13BE00AE73DB51C132" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_370293A71B77D41C4C6CAE73DB5180F8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0BE7FD13DDD14D13BE00AE73DB51C132" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_59FA8E50AFC8003A8F8EAE73DB514FA5" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_370293A71B77D41C4C6CAE73DB5180F8" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_59FA8E50AFC8003A8F8EAE73DB514FA5" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock" xlink:label="loc_biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock_C70D57F4327DF227492EAE73DB51BA40" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_370293A71B77D41C4C6CAE73DB5180F8" xlink:to="loc_biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock_C70D57F4327DF227492EAE73DB51BA40" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_3D6AB69635F6A3FDB6F0875A3CD10E5F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_D75A5B38DC5483E98580875A3CD103C1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_3D6AB69635F6A3FDB6F0875A3CD10E5F" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_D75A5B38DC5483E98580875A3CD103C1" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1E671F6F7338319F1E458AB776202C53" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_F4AAA2673C4D7862CDF78AB77622B70E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1E671F6F7338319F1E458AB776202C53" xlink:to="loc_us-gaap_SubsequentEventTable_F4AAA2673C4D7862CDF78AB77622B70E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_539C6C9B4DA9971E48568AB776236093" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_F4AAA2673C4D7862CDF78AB77622B70E" xlink:to="loc_us-gaap_RangeAxis_539C6C9B4DA9971E48568AB776236093" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_5D42BA188B753CC3F9E18AB7762346E4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_539C6C9B4DA9971E48568AB776236093" xlink:to="loc_us-gaap_RangeMember_5D42BA188B753CC3F9E18AB7762346E4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_9F645CE026CC1A303A498AB77623A2D3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_5D42BA188B753CC3F9E18AB7762346E4" xlink:to="loc_us-gaap_MinimumMember_9F645CE026CC1A303A498AB77623A2D3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_5CA87F10342FA59300878AB77623DD68" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_5D42BA188B753CC3F9E18AB7762346E4" xlink:to="loc_us-gaap_MaximumMember_5CA87F10342FA59300878AB77623DD68" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_221C48C7B0785339C3078AB776230BC6" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_F4AAA2673C4D7862CDF78AB77622B70E" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_221C48C7B0785339C3078AB776230BC6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_AF04598060F0EC0827958AB77623F40F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_221C48C7B0785339C3078AB776230BC6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_AF04598060F0EC0827958AB77623F40F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_92244E1920C8B1FCD6B48AB776232DE2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_AF04598060F0EC0827958AB77623F40F" xlink:to="loc_us-gaap_SubsequentEventMember_92244E1920C8B1FCD6B48AB776232DE2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_E7078D41B59EE3DB36348AB77623365D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_F4AAA2673C4D7862CDF78AB77622B70E" xlink:to="loc_us-gaap_SubsequentEventLineItems_E7078D41B59EE3DB36348AB77623365D" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_Workforcereductionpercentage" xlink:label="loc_biib_Workforcereductionpercentage_AE3C65828B5B190475EA8AB776230359" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_E7078D41B59EE3DB36348AB77623365D" xlink:to="loc_biib_Workforcereductionpercentage_AE3C65828B5B190475EA8AB776230359" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_367A46A44E559142ABDB8AB776233036" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_E7078D41B59EE3DB36348AB77623365D" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_367A46A44E559142ABDB8AB776233036" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_RestructuringandRelatedCostExpectedCashPayments" xlink:label="loc_biib_RestructuringandRelatedCostExpectedCashPayments_4927C426B50D2099D7BA8AB77623E005" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_E7078D41B59EE3DB36348AB77623365D" xlink:to="loc_biib_RestructuringandRelatedCostExpectedCashPayments_4927C426B50D2099D7BA8AB77623E005" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7E1052F92309394760E2AE73DA8260D5" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_ADE4B526EC08068BBEB6AE73DA82E9B3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7E1052F92309394760E2AE73DA8260D5" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_ADE4B526EC08068BBEB6AE73DA82E9B3" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_177F0E60C1FF5D67F00B8B8034C0D249" xlink:type="locator" />
    <loc xlink:href="biib-20150930.xsd#biib_InterestInSubsidiary" xlink:label="loc_biib_InterestInSubsidiary_7AABD4B1346609D0DDDA8B8034C0BDC0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_177F0E60C1FF5D67F00B8B8034C0D249" xlink:to="loc_biib_InterestInSubsidiary_7AABD4B1346609D0DDDA8B8034C0BDC0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_898160E9B6992B14EB978B8034C0DC8E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_177F0E60C1FF5D67F00B8B8034C0D249" xlink:to="loc_us-gaap_NumberOfReportableSegments_898160E9B6992B14EB978B8034C0DC8E" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_PaymentTermsOfAccountsReceivable" xlink:label="loc_biib_PaymentTermsOfAccountsReceivable_EB35E0D254E7795359CA8B8034C07220" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_177F0E60C1FF5D67F00B8B8034C0D249" xlink:to="loc_biib_PaymentTermsOfAccountsReceivable_EB35E0D254E7795359CA8B8034C07220" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_MinimumTermForAccountsReceivable" xlink:label="loc_biib_MinimumTermForAccountsReceivable_DA42E5BE7668294D50BB8B8034C03403" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_177F0E60C1FF5D67F00B8B8034C0D249" xlink:to="loc_biib_MinimumTermForAccountsReceivable_DA42E5BE7668294D50BB8B8034C03403" xlink:type="arc" />
    <loc xlink:href="biib-20150930.xsd#biib_MaximumTermForAccountsReceivable" xlink:label="loc_biib_MaximumTermForAccountsReceivable_8FCEC2C3F87C64D5EFB38B8034C0A479" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_177F0E60C1FF5D67F00B8B8034C0D249" xlink:to="loc_biib_MaximumTermForAccountsReceivable_8FCEC2C3F87C64D5EFB38B8034C0A479" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_A4ECDAAD51B25885E8DC2E2530AE235F" xlink:type="locator" />
    <loc xlink:href="biib-20150930.xsd#biib_BusinessOverviewPolicyTextBlock" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_C26E3C3441291F16B8DD2E2530AE5031" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_A4ECDAAD51B25885E8DC2E2530AE235F" xlink:to="loc_biib_BusinessOverviewPolicyTextBlock_C26E3C3441291F16B8DD2E2530AE5031" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_503E3C49F9974F1EAFDA2E2530AE1994" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_A4ECDAAD51B25885E8DC2E2530AE235F" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_503E3C49F9974F1EAFDA2E2530AE1994" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_224D88C86F220F587E572E2530AE3373" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_A4ECDAAD51B25885E8DC2E2530AE235F" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_224D88C86F220F587E572E2530AE3373" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_B6862FE7559A00F8ECC32E2530AF73C7" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_A4ECDAAD51B25885E8DC2E2530AE235F" xlink:to="loc_us-gaap_UseOfEstimates_B6862FE7559A00F8ECC32E2530AF73C7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_7B6B0FE7856AD585AD772E2530AF0237" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_A4ECDAAD51B25885E8DC2E2530AE235F" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_7B6B0FE7856AD585AD772E2530AF0237" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_646ADDE34A390B8967682E2530AFB8DB" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_A4ECDAAD51B25885E8DC2E2530AE235F" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_646ADDE34A390B8967682E2530AFB8DB" xlink:type="arc" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>biib-2015930_14rdpiechart.jpg
<TEXT>
begin 644 biib-2015930_14rdpiechart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $Q 3T# 2(  A$! Q$!_\0
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M-&\3^%H9=5TLZYKLM]I^M^)$M/%B@'TK\-_^"EOP"\=Z?\1;K4=)^+7A'4/
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M#P_KGA?P5X^^+>@^,=&?4]5C\5'Q1J4/A_PSK7=_##_@H?\ M<OXS^"_P_\
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M,?@]'XM\/WWA/PM<_#+_ (7K\:?A?J/BCPCK?BB#7-&D\9^'_#=GXTM^#_\
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M%:=O;P6D$%K:PQ6UM;0Q6]O;P1)#!!!"BQPPPPQ*D<444:K'''&JI&BJB*%
M  )J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[4GCNRU2.T:^FLOB]\.OV3OAIH_@BQ.GVEWI?BG6OB1JOB"=8/'%\\'*V/\
MP21^*]K9^()9OBOX:BOXS\,O$7ART\+^(?B#X)&L>)/A;_P4._:V_;/T_0/$
M7BGP]IT/B+P]X=UKPW^T-X:\/+XA\.1ZAK?ACX@>%$\56VBZ[IFDV.GZQZUX
MC_X*M^(?#G@'P;\4)?V>;>_\(?'+P[8>./V=+>T^*4B^)_$OA%?VI?V?OV;-
M6C^+&FW'P]@TSX6>*GM_VBO!OQ T72K#6_'.E2Q6FN^#-:UK2=?TVWGU6UX$
M_;Q_:&^)7[</P5_9ZL_A]\+?"OA+3=7_ &U_AY^TA:#QMXD\1WQ\;_L[Z?\
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M[7XC^+_#.C>&[S5_#WASQ)XE^ B>'OABFE#5+_7]/^)G@#Q3KL>DV.I3Z?
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MTZ44 %%%% !1110 4444 %%%% !1110 A /4 _4 _P Z,#C@<=.!Q]/2EHH
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M$LF%XW2,>22:^R/&&H_V5X6U^_#%7M]*O#$P.")Y86@M\'U\^6/'OTKX2 P
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MZKX;1M4\/"VO+V*PU)KNU_/C6?\ @DK\>_&5O=:EXO\ C7X,N?%VG_LX:/\
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MO#/_ )>KYJ2_.*/N*BOCFU_;@^$$PA^T:5X\LBX_>[]$TNZ6 \\,UMKI,HX
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MQ32^:(;B&&'W+XH1Z+XH\/[[&\CFU;2I&O+&-(;AI+F-E"7=F@$))::(+)&
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M8_B?=>()=9\%:U\/_$FB^(]!TQ])UU?#U[KGAS4_9?A)_P $_$^#\LNAZ/\
MM!?%?Q+\./&FB^%8?CIX4\<1>'_%'B#XT^(O"7PN3X-V^I:Y\1M0M6\3Z#H>
MN_#^P\+:%XC\.Z2LMW)!X#\'KX<\2>&4B\3)XH /9? '[;G[,GQ.\3^$_!WA
M#X@SW/B#Q[]BN/ MGJ_@7XA>%8?&VB:QX8\9^,=!\9>$-0\5^$]#T_Q-\/?%
M/A[X=>-K[PG\1M%NK[P1XJE\,:I8:#KU_J,45K++H7[:_P"S9XFUG3-$T7QU
M?W[ZO:64]CJT?@#XCCPFVIZEX!'Q3TOP?/XUD\(IX/L_B1J7PW,/CK3OAE>:
MY!\0+WPM=6&L6_AQ[:_L3<_*DG_!+W3=1\"2>&M<_:!^(>H>+O"?PQ^$7P/^
M!_Q,L_#'@G0_%/PA^%'P;\6_\)%HUC:0Z79QZ9XG\;^*M*FN_"'COQMJ$&GP
MZMX>D2'1/#'AN>;5Y-8ZNV_X)C_!31OCSXE^,WAFS\&:-;^)?$-YX\?2KGX-
M?#7Q!XST#Q[/\(K'X,6]SX1^+VM:=<^-_#'@ZS\-Z3I.M6OA32C!J>G^)[2=
M]%\8Z1X7U35?"MV ?1?P[_;*_9S^*FB6_B+P+X]FUC0[_1_A)XBT/49O!WCG
M1;?Q/X:^.?BK_A"/A1XE\(_V[X;TUO%?AOQ?XM#:#8Z_X>74M(MM01TU"\M(
ME$S>C:3\2Y/B5\+-0^('P3TRW\1ZE<CQ9IOA'2_BA9>/_@Y8:GXC\)>(]8\)
M7EGXA_M_X?:CXY\.:(^OZ'J$=MKT/@#68]5TH6?B'P[::UH>J:9?W?QAX._8
MJN_!?Q"_85\+:?+?WGPO_8M_9PTCX;W_ (UO;_0+2X^,NI^$_#GA'P9\-/#7
MB/P;9V]Q?0CP-JWA!OC';ZT+^RTO1_%%SI>F:)%K!N]8;2?NGX<^&O&_AGP/
M::!X]^(]S\3/%T-YXFGN/'=SX4\/>$9[JTU3Q+K.J>'+(^&_#J+H< \)Z!>Z
M1X8AN(D\[68]"CUC5-VI:C>D@'CO[+OQH^)WQLT'XA:U\1/A]\/?!]EX4^)O
MB/X=>%M8^&OQ+\3_ !,\->/4\&/#H?C/Q!INH>*_A1\)]0M-.T/X@P>)_ <3
MKI-_;:Q?>$M7U:PNVTJ?3Y;OXP\"_P#!4NQ\>7VOZ?I/PY\#+J>GSZ_::IX/
MM_C?::C\3/@%-H/QH\-?!F>Y_;:\!6_@"&?]F33Q=Z_?>*I[I-6^(OV?P_X/
M\9,!<IH<VHG[5\%_L]Z[\,O@K^S[\%?AO\5=7\+:3\'5\!Z5XSUO_A&-"U/6
M?B]X4\-^']0TSQ=HNJW%Y+Y_@[5/B%K5Y'XIU3QAX5NH_$>C:M#+_9%TBWEQ
M)7S[\*O^"?,?PI\3^!?$6C?&767D^!_P@^(/P>^ ,]M\._ FC:_X8TGX@V&A
MVEWKOQ5\2:5!#>_''7-*NO#>E:S:)X@M_#NBZOXA^W>*_%FD>(?&-S#XCLP#
MZ,_9P_:)M_VBM$O?$>F>$=1\*Z7IVF>&H+N+6[V,:L/&=U975QXUT"+2VM;6
MZ?1_!UY_9^AQ^)I(X8-=US^W].AT^PG\-WJ2?2E?&_P5_8R\$_ SXJ7?Q)\*
M^)O$EW%+X,F\+0Z+JK0W-S->:MI'PMTKQ)K6O>(PZZGXD.IW/PETGQ59:;J,
M2V^C^./&GQ6\4Q375WX\FBTO[(H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
DB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>biib-2015930_15rdpiechart.jpg
<TEXT>
begin 644 biib-2015930_15rdpiechart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $Q 3T# 2(  A$! Q$!_\0
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M-&\3^%H9=5TLZYKLM]I^M^)$M/%B@'TK\-_^"EOP"\=Z?\1;K4=)^+7A'4/
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MO%.MS0?$#P_8^*M>T6^TC7?A3XI\*-;Z+INHBZA\4P:OIM]I+Z/J?+?LP?\
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M8K>WMX(DA@@@A18X8888E2.***-5CCCC54C151%"@  $U%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445^<'[>O[2OQ
M6_9R\6_LLZQX#N-*/@"Z^)/CCQ)^T5I-[H$.L:EK'P#^'_PUU;6_'DWAN\::
M&YT/6O!=K>1_$_[;:&234-,\"ZCX?FB-OJ\LD0!^C]%?AU:_M]_%JX_;(^(_
M@;5->6'X&ZQ\;OV&O 'P$L_"GACPA>:CJ.@_%GQO^VM\)OB-X@\3>)]7%TVL
M^$/B!XV_9?O=;\/:GH)AU/1_"T.@W'ARYN(]<U"ZE@_9%_X*Y:?\1/!_[+WA
M#XDZ/+XL^*OCOX=_LS3_ !CU_P -0KI,NF>/OVEK"TO_  H?"OP]T_1+W^W/
M#F@:;JN@^)/BAK$>M:!IW@'PSK<&JV<?B8:7XCM]$ /W,HK\2?C!_P %5/B7
MIWP:^(_BWX1_ #P_8_%7P9\0?@#HMK\*_C1\4M$\,^/-.\*?%;]J'PA^SUKB
M?$KX76=G;_$/X>^,K9_$MG?:*\>F^*_ALEMX@T?6U^(>O7^EWO@;4_;?B9_P
M4XT'X6:5\2O&^N_!KQ7>_"GP)XB_:-^%>F^/])\5^&9$\6?';]F#X0_$GXN_
M$3P#9^%[N.U\0Z5X9O;?X/\ Q+\&>%/B#?P.-4\7^$[A=2\):)X=U?PYK^L
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M@+Q/XKT;PQ\*?$FLV_AV#]N*S_:R\<^"]#^)5Q;6^H:?I@_9S\1:^#>>"O\
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MZFB@ HHH) &20!ZG@4 %%%% !102 ,D@#U/ HH **** "BBB@ HHHH ****
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M\(/">DV?C?\ :-^'7[,GPFF^(GBOQ'H\Y\7?$']E7P3^V#/XG^)=GI?AJ_\
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MQXS^#VJ:H]MI%W).T?VGQ#X/NYH[J/PEXQ5$YOK> Z3KHQ;>([*Y*V>HZ;\
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MI.=*)_IA Y&1T/(HKYO_ &1?C_I7[4'[./PG^-^F>1#-XV\+6L_B#3H9$?\
ML7QCI<DNC>,M%=48LG]F>);#4K>$2+&SV@MIPBI*F?I"O\K\?@<5EF.QN6XV
MDZ&,R_%8C!8NC+XJ6)PM6="O3;6C<*D)1NM':ZT/]-,#C<-F6"P>8X.JJV$Q
M^%H8S"UH_#5P^)I0K4:B\ITYQE;=7L]0HHHKD.H**** "BBB@ HHHH ****
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MXQ?&+6+'XP?"WQ1X&^,&C_L#/^R5X ;X0^))&-U\?/@%\0_BMXNU#PQ-XO\
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MP]N]B>(/!_B_0G. \MC)I/B"U7ID@+<:5=E02<8MF8J.F[ K_17%>(,J\>3
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M.<=,]\>U?(/AP_L9_&+5]"UO0/#OPJ\6^)/$?Q8D^,.C7S>!XD\37'Q>\#^
M/ ]M'\5"=1T.TUNQ\367PM?X:VVE^/+M;3^U_A_JO@&WTS5=1\.:]X;34/KZ
M@#@?BA;FY\"^(%52S0V\%T #CBTO+:X<G@Y"QQNQ'&<<$=1\6U^@.J62ZEIF
MH:>^-M]975FVX9 %S!)#D\'IOSG!QC-? 4L,MO++;SJ4FMY)()E/59H7:*5?
MPD1A^% $=%%% !1110 4444 %?CA_P %9?'^RT^$/PLMISFXGUWXAZS IX,5
ML@\,>'1+[&:X\1S1J3UC#$<*1^QYZ' R>P'4^WXU_,Q^WUX^'C[]J7XC-!<"
MXTWP6^E_#O3"AS$%\*VFS5BG8[_$=[K6]@!EE[X!KZS@S"?6,[IU6KPP=&KB
M&^G.TJ%->MZSFO\ KVVM4CX;Q"QWU3AZK04K5,PQ%#"I)VER1E]9JOOR\M!4
MY>56SW/Q?_:(\(?V5XCM?%-I$%L?$:&.]*#"QZW9QCS78< &_LA%/D??FM[I
MCAF.?G:OTK^(7A1/&GA+5M""I]LEB%UI4LG2'5K0F6R;.1M69MUI*1_RQN9"
M<@8K\UG1XW>.1&CDC=XY(W!#QR1L4DC8'HT;JR,.S*17]-Y'B_K&$5*3O4PU
MJ;ONZ;7[J7R2<._N7>Y_(F?X/ZOC'6A&U+%7J+LJJM[9>KDU4?\ U\LMM&Y/
MJ:6,F&19HB8IE(*S1$Q2J1T*RQE9%(Z@A@<]Z2BO9/#/1=!^+OQ2\,;1H/Q#
M\8:=&GW8%UZ^NK4< 8^QZA)>6A&  %\G ':O8]#_ &R/CAI.Q+W5= \21*?F
M77/#MFL[CT-YH[Z5,#Z/AF'H><_*]%:1K58?#4G%=E)V^Z]C2-6K#X:DUY*3
MMTZ7MT70_0K0_P!O6^4HGB;X;6<P 'F7'ASQ#/:NQXR5L]7LKN,<\[?MPQT#
M=<>Q:'^VO\'-3"+JL/B[PS*V-WV_1(]4MD.<$&YT2\O)"!UW&T3([ \5^2=%
M=$<=B([RC-=I17YQY7^)O''8B.\E+_%&/YI)O[^I_2[^Q#\3OA;\6/VI_P!G
MSPUX3\;Z#K6J7WQ3\*ZA'HT=U/8:O-;>'[IO$M^T5CJ-M:W,IMK#1[FYF2*)
MSY4,F<*&=?[0A@@$=#S^?-?PA_\ !N]\';SX@_M[O\2'MUDT;X#_  I\8^)[
MBYF0211^(_'L:?#WPU;INSMN9M.U'QA>1.!E$TV5LJQ0U_=[7\W^,>9_7N(<
M#A?=3P&60511;TK8FO6K---NS]BJ$M]5)=+']2>"U"JN&L9CZL5%X[-*JI63
M49T,+0H4>=7;;_VCZQ3>K2=-VZA1117Y&?L(A4'!.<CT)7IG@X(R.3P<CVI:
M** "BBB@ HHHH **** $8$JP4X8@@'T)'!_ \U^-/Q+_ &7?VFM?\:?M>W/A
MGP]J4/QC^)__  NJX^ O[7<7QF?PAH_P\^''BSX":7X/^&GP6/@_0]9N_&27
M7AOX@P:E'-IG_"&0^ _#MU?K^T;H?BN_^+EK%X6E_9>B@#\!/%?[&/QIUVRU
MV^T#X"_$'P'\'+KXC^$_$'@;]E2S^(WP5^(\'A;6K'X#ZUX%^('CWQM\/_&G
MQ7TGX1^-M"\9>+M6TJ_T33O#GQW\%>/?!WBWP9:_M :?>Q?$/QIXGT.#G]=_
M8(^-S_$#XD?$[Q-\ O[7\>?'CX!?\$_(OB-XA^!_Q&^&U]!;>/?V9V\:V7QD
M^%?BQ/VBO$8UGXY>!_&\VI?#B\7P1\0-5;PG\7/#7@^]M/B'\6?#WBWP[X9U
M#Q+_ $-T4 ?G-^Q[\)_'O@;4_AS<?%7]G2V\)^.?#GP5^)?@BT^+NB?$2&_T
M/0O 4_Q]NM>^'WP:U3X?7GQ;^)NHZ7XQU?P@N@^/?$4OAK5O&OPV\#:AIM]\
M/O!/CV7PY;:%HR<Y\>/A)\>/BQ^T3\(=5TWX9^(M'T;X4_'WX=^,K3Q'=?%G
MP-K7[,?B;X:Z!J2:OXD\7>,OA#>+8_$J?]HVTTG4=>T7X<S6'A"[T+PCXTTO
MP-XUB^)4NG:/<V%?IY10!^&WPC_9B_:5^$?C?X4>.=.^&OQ<\2>#OV'/@#^T
M#\,/@)\'/$7Q9_9U6^^(5K\1)OA7H/@7X6> O%?AD>&++6/"/AOPM\+XYT^*
M'[14W@7Q:LL?@K1KCPA+J5KXU\:ZSK^(OV0OVA-0_:HU'X@Q>&_$[6OBK]KK
MPM\5/$R6'Q$\#0_L5>(O@;HNG:7X2FN_'_P U35KGXAZ]^U+'\+=/@T^W\:V
M'A*73Y_C!X;\!^-'\;P>"_#-EX<LOVRHH _*#X<_LU?';X0_'+2O'/PL\,Z=
MX4\#^*/$]MX5U?0=7\1:/XPO?#7PD\ >(_!7@_38_%6O^)M0UGQ-.?&WPA\+
M7^M^%[/X>7YO/#OB72_@UX$\5(O@SP%=,WZO+G:-WWL#..F<<_K2T4 %?'/Q
M7T%M$\77<Z#_ $76P=5MVQP)9&V7L7  RERIEP/^6=Q'WS7V-7F7Q5\+MXC\
M-O/:Q[]2T4R7]HH +S0!,7MJO?=+"HEC4 EI[>% /FH ^/**.N#Z@$?0\C]*
M* "BBB@ HHHH Y[Q=XGL/!/A3Q/XSU1UCT[PCX>UKQ->LV,?9]"TZYU-T(/4
MRFV$*C^)I%7DD _R :OJ]_X@U;5-?U61I=4U[4]1UO4I7.7DU#6+V?4KUF/<
MFZNI?H, <"OZ-?\ @HSX^_X0K]E[Q3I<$YAU'XC:QH7@*T"-M>2QO+E];\0X
MYSL_L31;FVEP#E;Q4. X-?S='DD^M?J? 6$]G@L9C91M+$5XT(-[NGAX<UXN
MVTJE:<7KO378_%?$['>US# 9?&5XX3#3Q$TGHJN+FHJ,EWC3P\)*^J55V=F%
M?"'Q[\(?\(]XQ;5[6/9IOBE)-10*FV.'5(F5-5MUP-H\UVBOU7.<74G4*37W
M?7FGQ:\(?\)CX+U*R@C\S5-.!UC2-HR[WEE'(9+5>^+ZT:>UP#DRM >2@%?I
MV5XOZIC*<Y.U.I^ZJWV4)M6D^W))1DWORJ26Y^/9O@_KF"J0BKU:?[VEW<H)
MWCW?/!RBEMS.+>Q^=5%'Y_B,'\0>0?4'D'@\T5]^?G04444 %* 20!R20 /<
M\"DKZQ_8B_92\4_MI_M+_#7]G_PT+FULO%&IMJ/COQ!;Q,Z>$?AIH7E7OC?Q
M)-)Q'#/%I;+H^A^<\:7/BC6M!L@V;FL,3B:&#P]?%XFI&EA\-2J5Z]66T*5*
M+G.3[VBF[+5O17;1T8/"8C'XO#8+"4I5L3BZ]+#T*4/BJ5JTU3IP717E)*[T
M2U;239_7M_P;Q_LPS_!S]CG4OC=KMO)!XG_:?\21>+K."9$1[3X:^#AJ'AOP
M"NTQB=3K<LGB/Q8I>5HY;+7M,>-%*EG_ 'YKPGQ[\0?@[^R'\$M-U[Q7->>#
MOA1\/8?AK\-M"L?#OA7Q;XVU&WD\1^(O"_PG^&7A'P]X2\$Z-XD\6:[J.L>)
M-=\,>%M)T_1](O[F6\OX&D5(!-/'UWPS^*7AWXK>')?%'A[2?B#H6GQ:O>:(
MUG\3?A7\2?@_XB:]LEMFEDA\*_%3PMX0\2SZ=+]JC2RU>'2I-+U"5+F&QN[B
M:TNDA_CO.\TJYUFV/S2JG&6,Q$ZL8-ING15H8>DVM'[&A"G2OUY+]3^[N'<G
MI</Y)EF3T6I1P&%ITIS2LJM=WJ8FO;I[?$SJUFNCG9:)'I%%><^/?BU\/OAC
M??#O3?'/B*/0KWXK_$/2_A3X @?3]5OSX@\?:UH/B7Q-IGA]'TRQO8].DNM#
M\(>(KX7^K/8Z7$NG&":]CN;JSAN/1%=6&5(/RAL#KM894[>O(SCCG!'4&O*/
M:'45Q?BOXB^!O UQX/M/%_BK0_#ES\0/&5C\/?!,.KW\-E)XI\<:EINM:Q8>
M%=$64@W^N76E^'==U"+3X-T[6ND:A*5"VTF.O$T1WX<?N\%_5,J'&\=4RA#@
M, 2AWXV\T 2T5CZ9XBT'6VU%-&UK2=6;1]6O- U9=,U&SU Z9KFGK%)?Z-J(
MLYIC9:M91SP27>FW7E7MM'-&\T"(ZD[% !1110 4444 %%%% !1110 4444
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M9_M?2I;775T]H-1LIS'<Q_!'[1?[+7[37[1?PO\ "?@+3?@OXI\)Z-HWPO\
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M)T+P/\,_&?P.B_X6WX-N?@XG@2Z/BC2=WB+3/Z@5! P3D\Y/KSU]L]<=LX'
M%<+X7\5:]KOB/X@:+J7P^\3^%-(\(ZWHFF>&/%VN:AX5NM&^)VFZIX1T+Q%>
M^(_"=IHGB+5O$.F:9H.L:M?^"M2M?&^D>%M9F\0>'=4N],TV^\-W&D:YJ/YO
M:!^U9^U=X@TK_@I+HEWX$\"V7Q/_ &:=>^'FC?!7PG\.M"\9?%Z\MK7XB_L_
M_#KXGVG_  DUC8-H6K_%CQ3HVI^,=0U&[T?P;HOA.QOX;2+PKI#WXM3XKU4
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M+8M 'BBU;5Y\WPA^Q=\'?!E]>:GI]]\4]5U*#X=^*/A-X'U#Q9\8/B)XPO\
MX2?#SQG!HL/B/PY\)KWQ+KVIW?@EM2_X1KPVTVOVDUSXJ\OP[H-D->_LW2+"
MRA^M:* / O /[,OP;^&'CJ7X@>!_"BZ#K/\ PB]OX2L;2UO[YM!T;3$T#X>>
M%+V71=#EF>PTW4-9\,?"/X6Z!K-_ GGWVF^ ?#T3&.2._EO_ 'VBB@ HHHH
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M6Z#9!:6=O#;PI\L<:KQ6S0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !0>A[^WK110!^6,/PX_:>MO^"A/COXWI^SWX'?X
M(Z]^SNO[/%IJ*_&GP]'K>I2Z%\4OB;\65\<WW@D^"3'%IWC6X\7V7A^]T>;5
M;C5++4+G4-5U0WMLC/<9G[)7A/\ ;1^#B?M8:GXE_9M^'$&K_&?]J#4?C_X+
MTMOVD;";38=!^)%_\(?!?BCPSK6JZ5\+]1N-/USP!X*\*^)_&E@UMI-_I'B[
M4;/1_!D5_H?]K3^(-)_6&B@#\H-,_8Q^*&I>(O ?P<\=Z)X!UK]F_P"%7[5_
MQ]_:KL_&$GBW6-7\8_$K3OC3=?M :_I_P=\2?#[4O#R6%F^B^)?VB/$MEXI\
M1:AXNU70==\'>$O#\&G:1%J7BK5K?P?V'[/7[,7Q[^#WQ>T#Q9'KWAC1O OC
M.WO/&7Q>\*Z+JMUJ%E!XBU33?B3!>>!K235=*N-<\87&FZKK'P>U+1OBCJ^L
M6NJW<G@GXJZEK.GOK?Q;U.YO?TOHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
7 HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>biib-2015930_alpchart.jpg
<TEXT>
begin 644 biib-2015930_alpchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $I 3T# 2(  A$! Q$!_\0
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M8^._'_Q \6?$[6_B)XE^)?P-^"?Q,BU+1OBSJ?A'Q#XBTOPAX;\=^&-?\,^
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M/XQ\9:-X\U'1[VQT7PSI^IV":;H=OI4J7=QJQM)6EEAFD,J& !1&0 K?-G-
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MY^(-?MY'_JX_]Q?_ $$4 /HHHH **** "BBB@ HHHH **** "BBB@ K\]/\
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M &W16)_9-W_T,6M_]\:'_P#*6C^R;O\ Z&+6_P#OC0__ )2T ;=%8G]DW?\
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M ).;PC_V'8K_ -5F./ZVZ*Q/[)N_^ABUO_OC0_\ Y2T?V3=_]#%K?_?&A_\
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MO^R=1?\ J4^'*_0NOST_X*M_\H\_VIO^R=1?^I3X<KZK@7_DM^#?^RJX>_\
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MJ5)K$4XR4,31:PU=5,-&-*/TQ:_M/>*=,^"4_P %]$T)-)M=1\&OX UK7_\
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MCCEEEC14DDD5G=%5'8J !IT4 -C1(D2.-%CCC541$541$4!55%4!550 %50
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M /P139C_ ,%"_A<"Q(_X0?XO\$D_\R1<U^B^J?\ !O!-J6J:KJ7_  UHL/\
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MN/!\Z^,QX3_X12'78BAT'^VOMW]M2:5)NW?VOIGV?[/_ &;C&)O-\[.8]F'
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$H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>biib-2015930_amortchart.jpg
<TEXT>
begin 644 biib-2015930_amortchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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M;KXE_$#2FD\&6?A[5?!%N@\3V7A34M=U33/JK]B3XAZAXO\  G_!2_6_B/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9XJFE)SC+F4ERJUVM%%%?$GV04444 %%%% !1110 4444 ?B!_P4G_Y22?\
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M7QX\4ZC\4/$&I?%OQI:>*;'P3K?AKP)HNO\ BGX-77A?5M T?QVMYI?AN?\
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M4FXINM65+#\M9_V0?\-]_L4_]'K?!/\ \+GP%_\ $4?\-]_L4_\ 1ZWP3_\
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M6W_QV@#0HK/_ +6TS_H(6/\ X&6W_P =H_M;3/\ H(6/_@9;?_': -"BL_\
MM;3/^@A8_P#@9;?_ !VC^UM,_P"@A8_^!EM_\=H T**S_P"UM,_Z"%C_ .!E
MM_\ ':/[6TS_ *"%C_X&6W_QV@#0HK/_ +6TS_H(6/\ X&6W_P =H_M;3/\
MH(6/_@9;?_': -"OST_X*M_\H\_VIO\ LG47_J4^'*^^_P"UM,_Z"%C_ .!E
MM_\ ':_/C_@JMJ%A/_P3V_:ECAO;261OAW&%CCNK=W8_\)1X=.%1)"S' /0&
MOJN!?^2WX-_[*KA[_P!6^#/F.-O^2-XM_P"R:SW_ -5F*/XI/@;\89?@C\0+
M#QF? _@KXAV-M=64U]X:\;:4;J"8Z9>B_L+S0]<LY+;7?".NV=TO[G6]#NXI
M)[*:\TO4[74=-O);4>J7/[7WB#6_#7C7P[XO^%7PN\23?$6\TEO&VOVES\3/
M ^M>(?#WA?0=%\,^!OAYJ$W@;Q_HJW/PS\!:+X>TBV\,^"KCSM-FNK*'6O%#
M>)?$$<.K1?([_?;_ 'F_F:;7^HV)R'*<;B?KV(PBEBY0PT'B(5L10J\N%JJO
M0Y94*U-Q<*T:=5N-G.I0PLZCG+"85T?\T\-G>:83#1P=#%..%C*O)4)T</6I
M7Q-/V-;FC7I5%)3I.I22E=0IU\5&FH+%8E5?J*#]K/X@V=I=W^G:#X+TOXF7
M_P ,_#7P=O/C1I]OXGA\?R_#CPA%X:M?#^APZ<WBF3X>V-_8Z?X.\,::?$=E
MX*@U>2VTF.Y5XM8N;W5KFOXG_:<U/Q9+.FI_"7X/1:-KWQ)U?XR?$?PSI^D^
M,K71?BK\4]6\.^(?#J^+_%P/C>;4=.31QXIU_6]!\,^"]0\,>&-.U_5;^^;3
M+FWN38Q_,M%*/#V30FJD,#"$TI1C*%2M"4(.$(0IP<:J<*.'5*F\'1ARTL#4
MA&K@X4*L5-4\^S>4>2>,G.#<92C.G1G&<U.4YU)J5-J=7$.<UBZL[U<;"<J>
M+G6IR<7[]<?M%>,+GP _@N70?!W]NW/PNT?X'ZE\5%T_6!\1M5^#N@ZE9ZCI
MO@"]N&UQO"HM533=+T.Z\16OA:W\67_A'2K#PG=ZU)I$4D<W[$_\&\YS^T%^
MT(3U/P:\+$_^%X]?S\5_0#_P;VW$%M^T!^T&]Q/# K?!OPL%::6.%21X[<D
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M ,_^R=,_Z!]C_P" =M_\:H_LG3/^@?8_^ =M_P#&JT** ,_^R=,_Z!]C_P"
M=M_\:K\^/^"JVGV$'_!/;]J62&RM(I%^'<962.UMT=3_ ,)1X=&5=(PRG!/0
MBOT7K\]/^"K?_*//]J;_ +)U%_ZE/AROJN!?^2WX-_[*KA[_ -6^#/F.-O\
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MA'Z4W_);Y%_V2N'_ /5OFY_;/T9O^2.SO_LI\1_ZJ<G-&BBBOYE/Z/"BBB@
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M#6HZ3K=Q;-9K=*JZ?J%M+]I:!G=H%EB?\U_V=OV,/VE_@E^S?\&O@WJ?C_\
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M^++^+PQX0T>SBUCQ7=:+K%SKEGIGA[^P-6_5NB@#SWXHVGQ(N_ VM6GPDNO
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>biib-2015930_avxchart.jpg
<TEXT>
begin 644 biib-2015930_avxchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %- 3T# 2(  A$! Q$!_\0
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M++7]J'P-^S1I7P;TGPG_ ,)G\7=&\-?%K]C'X,_'74_C;I>H3^.-+L?%%G\
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MMKX6\ O+=&6&Z$,7GI)Y:8 /P*\1?\%)_P!J'P1HGAOQ)J"_"#7M/^+/B/\
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MBLTT^.TDM(X%MY+6.QC2S2W>-H4M$2V5! JQ@ _G)M/BIX5U[1_&GC?]FO\
M:'\37O['NM^(/V1/ OQ,U?5/VI-9\<_$;QC\/M2_:'L;;X_?M?R7+^-O$?Q%
M^"?@+Q1X!U'2OASK?Q":X^'.H^-?"VM>+/BO)I7@SPSX1^'WC;6Z_P"UA\5Q
MX1_8._;/U#PA^UAXJ\ _!_X=?M$KH?[)WB:Q^-UGINI?%?P=IWAW]G;5_%G@
MCP_\6_%%U+X^\8_#GX<_&;6_C1X8M+/P5XUG?4=!\/MX U+7KWP)H,FAWO\
M1)HGP^\"^&YKZX\/>#/"FA7&J0-;:E/HWAO1-*FU"W=S(\%]+I]A;27<#N2[
MPW#21NQ)9"234VI^!_!FM6.EZ7K'A/PSJFFZ&J)HUAJ6@:1?V6DI';K:(FF6
MEW936^GHELBVZK9Q0JL"K"H$8"T ?AE_P42_:H\5W7CC]G^^\$:/^T3>?!7P
M3^U?^P?K?A'XD_ ;0]5\2?##X^:SX]_:5\#:3XUT:\^(/P_\3M8>)/!^@>!;
MZ^\ Z7\.[YY;'X@?$SQC?0:KI5Q!X-\-3ZA^^BG*J<$9 .&&&&0#@@]".X['
M(K&M/#?AZPTZQT>QT+1K/2M,>WDT[3+72["VT^P>TG%U:O964-O':VC6UR!<
M6[6\4;0S@31%)!NK;H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M(+FYM[."6ZNYX;:V@C:6>>XEC@AAB09>26:5DCCC0<L[LJJ.214VX8SR1DC@
M%N1D$' .,$$'/0\'GBOQ@_X+7^&O'_BG]FW4K3P;XD\(>(=)TKP!\8O$7CK]
MF[Q!\4==^$^M_&+PU9:#X>TNU\;^&M8\+6^H:IXFD^!OB+6=)UR_\"^(-/'P
MY\0'Q=87/BW5]&U31_"4T]YO%/[)/C;]F_X?_&/X^V'QVN_!WP4^(GQX^!EO
M^RE\4_$NJ?'+6_%'[25M\4=5\!7GPTM?"'AN^\::K^U-\2/ FL^$?%'@7]G6
M.Q\0>.-/@\%Z]JGB&>S76]/;Q%X/ /V1!R 1GGGD$'\00"/H0#0&!./FSSU5
M@...I&/ISSU&17Q#^P%X!^,/PU_9>\(>%/CG+JWAWQEJWBCXN>*O"_P\UWQ<
MGC_Q+\$_A9XV^)_C#QC\&_@/J7CJ\O-:/CC6O@7\*M:\)?#S4M;&HZ_IWVWP
M[-INF:QKV@:;IVJWWQ3X%^$OA"+]KWX!>"OV.T\=ZFW[,_C'QY=?M\_M=:[X
MEUO7$^,::M\+/&?AVX_9O^)OC2XD@T3X^?'CQ3\7?%7@CXQ^,[?3K.YTO]FF
MU^':V*/\/-1\4^%/ &I@'[9"16. 'R?6.11Z\EE 'XGVZT"16. 'R?6.11Z\
MEE 'XGVZU^,'[-/[&O[,NG?M^?%+QM\&OA1#\/= _8UL-*^' U32?%_Q)O&\
M;_M"?&KX=:?X\\<3:U#K'CW5M&OM!^%GP4\;^ M,\/:9-I4T,WB_XL>,=4OU
M74_!OA:>R/V:/V-OV9=-_;\^*7C;X,?"B'X>:!^QK8Z1\-TU/2?%WQ(O6\;_
M +0GQH^'>G>/O&\^M0ZSX\U?1;_0?A9\%?&_@'2_#VF3:3-!/XO^*_C/4]01
M=2\'>%9K$ _:$D 9/Z DGOP!DDX[ $TM?D?_ ,%L]&\8:C_P34_;#\;^#?BW
M\1O -I\._P!EWX^^+9-*^%^K1>&;OQEK^F^"I)O"XUSQQI$!\9Z5X=\,WMG?
MZGJ&@>$=:\/+XMEDATSQ3J5WX8M=2T#6/U>T99%TG34E6594L+))%F5TE$BV
ML*N)%D <.&!#[ANW @\YH TJ*** "BBB@ HHHH **** "BBB@#YC^,_[67PP
M^!7QF_9;^!7C2S\6W'C3]KOQWXX^'?PLGT'1[*_T&SU[X?\ P[U7XFZY)XOU
M"YU>PN-'TZ3P[H]W%I]Q8V&L37.IM%;2VUO TEW']-@A@&'0@$?0C-?B#_P4
MG_Y22?\ !"G_ +.M_:@_]8Y^(-?MY'_JX_\ <7_T$4 /HHHH **** "BBB@
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M2!_PT=\*>!_R'=1[?]2SKU?T&KT'T'\J %HHHH **** "BBB@ HHHH ****
M/P[_ ."EPG/_  4?_P""%@MGACG/[5O[3_EO<1R31#_C#OX@;M\<4L#ME-P7
M$JX<J6W*"I_:2.'Q)Y:?Z=HGW%Z:7J..@]=:S^?-?C!_P4G_ .4DG_!"G_LZ
MW]J#_P!8Y^(-?MY'_JX_]Q?_ $$4 8OD^)/^?[1/_!7J/_RZH\GQ)_S_ &B?
M^"O4?_EU6[10!A>3XD_Y_M$_\%>H_P#RZH\GQ)_S_:)_X*]1_P#EU6[10!A>
M3XD_Y_M$_P#!7J/_ ,NJ/)\2?\_VB?\ @KU'_P"75;M% &%Y/B3_ )_M$_\
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M: -RBL/_ (2+3?[NJ?\ @AUW_P"5M'_"1:;_ '=4_P#!#KO_ ,K: -RBL/\
MX2+3?[NJ?^"'7?\ Y6T?\)%IO]W5/_!#KO\ \K: -RBL/_A(M-_NZI_X(==_
M^5M'_"1:;_=U3_P0Z[_\K: -RBL/_A(M-_NZI_X(==_^5M'_  D6F_W=4_\
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MO%.A_P#"V?%7B=/!/[1/PWUWP->>!O!'[8GQ"L?A9XT\3W_[,EYXETWQ=?\
MPZ^$?B'X!>!==^%WPA^'OB?PGX5\.W7CF71]>L/VFO&7BGXN1>!(I?$4OBS]
M\EZ<Y/)Z_4\<@9 Z XY !K\%OB3XX;PI^V%\3/$6B_%#Q9X/T.P_:?\ @?X!
M\6? ZP_:XU3PG\4_B1XH\;6?PETRS\:?#?\ 9IA^&NI^'M4\"WUCXEL&OM+?
MQ%_;7Q.\-^%_&.OS>)M DTJTL*_>E3D9^OOW/0]QZ'N,4 ?B#_P4G_Y22?\
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M?_\ HJGB7_OWHO\ \J:?_$K'&W_0^X4_\*,X_P#G-Z_TM3_B9G@[_H1\3_\
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M?AO0+*2>&+P!XQO$1;JTL8KB'$]M"Y:*16(4H249@?[6%.54GJ5!_2OX+?\
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MW_\ \HJVZ* ,3SO$?_0.T3_P<W__ ,HJ/.\1_P#0.T3_ ,'-_P#_ "BK;HH
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MBUK\1^B?_"XZ_P"OG#G_ *3G9^Q?2B_C\$_]>^(__2LB'T445_8!_*(4444
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M]F^']W%97-_JM[.][J=D7O\ P1XC\*64PTJX-I-=:5?:\%BUJUDG'R262@K
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MI\+?B/H/ASX3^#$^'5\?^%M:7KU_XA\&V.I?$?Q;8QQC3_A?X7DTSQ/-XO\
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MJ_V1D_,L/_:"6.Y.7D=3ZRN;ZPZRI?N%2-"BBBOYZ/WP**** "BBB@ HHHH
M**** /Q _P""D_\ RDD_X(4_]G6_M0?K^QS\0<UL?\%#"3\:_#1)/_),]$Y/
M./\ BH?%!_F2?<UC_P#!2?\ Y22?\$*?^SK?VH/_ %CGX@U^;7_!=GXB^/\
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M:_I;_B:OA[_HD\Y_\+,#Y?U\O2_\[?\ $L6>_P#14Y3_ .$>-_S_ *L_*_\
M+:L42(L:11)&ARD:QHL:$'<&1 H5&#?,&4 AOF!SS2/%#)N$D,,@=0CB2*.3
M>@;<$?>IW(K?,JME0WS !N:_H(^!'_!N;^Q?\2/%_P"U!H6N?'[]OL6?P?\
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M]?>OZC_^(7C]@[_HO_\ P4._\2[UC_YC*/\ B%X_8._Z+_\ \%#O_$N]8_\
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MOPO\/HXOB9XYT/PQ;I<Z)X%U#1[C29?$GB?5+7PH^GKO[89\,?'?P+\(]?\
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M"R?%Z+Q&NN11:BX_X1T::+ -J*:A8?-7[2G[ 5_\>U_;8FT_XK6GA.]_:W^
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M;Q/=:QIG@G1/"6L>(+"S\3:CXUU_7=,\+>#/ ][=>*?%FJZ?I6BZI<PMM_\
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0 !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>biib-2015930_coschart.jpg
<TEXT>
begin 644 biib-2015930_coschart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $V 3T# 2(  A$! Q$!_\0
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MYXU7X9>-/%6BOI&E_$J*?5#=>./AS;Z#=_4_[$GPI^(?P?\ @_JOAOQ];_\
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M !1110 5\X?M=?\ )M_Q9_[%I/\ T[:97T?7SA^UU_R;?\6?^Q:3_P!.VF4
M?D!^S'<3V_Q.MOLUI;W=Q<006R/#KFCZ)XCLD;4[2:>\\+/KEM<VFH78B@-K
MK&F6_P!GU&?0KJ\DLKF+RIVKTKP?!X,TOQ=XUB7XC^%-0\2>)=(^(MAK=_?Z
M)<63V6@?\*LU.X%E9'PIH>J>#6U:^\13M)XNOO#^I&"X/A@6F@I?2ZW<0S_%
MRN\<BR1N\<D;AXY(V:.2-U)VO'(A5T=><.C*PR<$9J/:N NU=HP N!M 7&T
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M0-7YS;$W;]B>9C;OVKO*]-I?&XC'&,X]N*_1C_@G!_R4;XC_ /8DZ3_ZD#4
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M/^$?@_Z"6O?^#O4/_CU &[D>H_,49'J/S%87_"/P?]!+7O\ P=ZA_P#'J/\
MA'X/^@EKW_@[U#_X]0!NY'J/S%&1ZC\Q6%_PC\'_ $$M>_\ !WJ'_P >H_X1
M^#_H):]_X.]0_P#CU &[D>H_,49'J/S%87_"/P?]!+7O_!WJ'_QZC_A'X/\
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MG37Z%_\ !.RS2]^(7Q%C>>[@"^"M)(>SNI[20D^(.C/ Z,P^7 5B0,M@9.:
M/U[U<C^R]2Y'_'A>]Q_SZS5_+NGW%_W5_D*_ILU7085TS43_ &CKIQ87O#:U
M?D<VDPY!FP<=1GC-?S)I]U?]T?R% #J*** "BBB@#Z+_ &2?^3C?A3_V'=1_
M]1G7J_H,4@@8(/ _E7\]W[*$(G_:(^%D+/+&'UV_R\$KP2C;X;UQODEC*R)D
MKABK E2RDX)K^@*PT]+$/LN;^X\T)G[=?7%YLV;L>7Y[OY>[=\^W&["YSM%
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M /%4?:K;_GX@_P"_T?\ \50!/14'VJV_Y^(/^_T?_P 51]JMO^?B#_O]'_\
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M+68G^+L.37\OB?<7_=7^0KY0^G'4444 %%%% 'T7^R3_ ,G&_"G_ +#NH_\
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M]^VEIOPQT/X6^!_B'K/_  2M^);_  O\/?L975Q#X77]GSX?_'7P18^,M?\
MC%I6EZ%H6OZ1\:-/^'GBO4=/_9=G\+V%QI$.FVOQRTOPEK$NL6\$,?VQX_\
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M^$VH_#OP;X4UN#1M1\+7>NV/Q9U:XM]1\?V%_;Z1:P:#<??7_!OC9VMY\?\
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M/A3QM\5?#/@7XMZK+\:O ?CZ>ZT:_P#&7AG3?AO9?!+QJECH/@_XE>#;G5O
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M^SA=8_\ 5;?#FOM[_@JW_P H\_VIO^R=1?\ J4^'*_A'BO\ Y2&?_9?\/?\
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M445_8!_*(4444 ?H)_P2K_Y2$?LO?]CMX@_]5MXYK^])/N+_ +J_R%?P6_\
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M4\9_:E7%UZF8?6Z,H2HXGZY.I+$>WI2IPE3K>T]I!PBXR3BK?0TLKRVAE_\
M9-#+\%1ROV%3"_V;2PM"G@/JU52C5P_U2,%A_85(SG&I2]GR34I*46I._P#(
MH?\ @V"^-!))_P""L'C3).3_ ,87?!'J?^YUI/\ B&!^-'_26#QI_P"(7?!'
M_P";:OZ[**^D_P"(C^(/_1<\7_\ B1YO_P#-GE^?=GS_ /Q#_@/_ *(KA/\
M\1W*/_F3R_J[/XK?B;_P;L?&_P"'WCK]GCP;#_P5$\6ZK'\<OBSK_P -+K4)
M?V/?@O:2>&H-%^!GQA^,2:Q;6\?BV:/4Y;FX^%L'A]K.>6UCC@UJ?4%F::QB
MMKCV;_B&!^-'_26#QI_XA=\$?_FVK^L/7_!7A?Q1J_@G7M>T>VU+5_AUXCO/
M%O@J^G:X67P_XBU#PCXG\"7FJV8AFBC>XG\)>,O$VB.MU'<0"UU>Y98EN5MY
MX>IH_P"(C^(7_1<\7?\ B1YO_P#-@O\ B'_ ?_1%<*?^(]E/E_U">7Y]W?\
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M /Q(\W_^;/+\^[/(_P"(?\!_]$5PG_XCV4__ #(?R@+_ ,&P?QG;<1_P5?\
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M@^!O#NJ>*)9/$.J>%_AQH&K:7\/O"^IZTEIJ6H>'O#&F7EWIVERS'3;3Z!H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>biib-2015930_elochart.jpg
<TEXT>
begin 644 biib-2015930_elochart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $I 3T# 2(  A$! Q$!_\0
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M8^._'_Q \6?$[6_B)XE^)?P-^"?Q,BU+1OBSJ?A'Q#XBTOPAX;\=^&-?\,^
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M_P#9UO[4'_K'/Q!K]O(_]7'_ +B_^@B@!]%%% !1110 4444 %%%% !1110
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M#-_#7C/PK\1/$U[JFC^!?B'\*-,T#1O"'B"P^&>@'0?#G@/Q/I<WASQO9?\
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M?^87J'H/^HU7XP?\%)_^4DG_  0I_P"SK?VH/_6.?B#7[>1_ZN/_ '%_]!%
M&+Y/B3_G^T3_ ,%>H_\ RZH\GQ)_S_:)_P""O4?_ )=5NT4 87D^)/\ G^T3
M_P %>H__ "ZH\GQ)_P _VB?^"O4?_EU6[10!A>3XD_Y_M$_\%>H__+JCR?$G
M_/\ :)_X*]1_^75;M% &%Y/B3_G^T3_P5ZC_ /+JCR?$G_/]HG_@KU'_ .75
M;M% &%Y/B3_G^T3_ ,%>H_\ RZH\GQ)_S_:)_P""O4?_ )=5NT4 87D^)/\
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MJ/\ \NJO62:DGF?VA/8SYV>5]CM;BVVXW;_,\^]O-^?DV[/+VX;=NR-M^B@
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M!_T ]'_\%EE_\8K8HH Q_P#A'M _Z >C_P#@LLO_ (Q1_P (]H'_ $ ]'_\
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M"K?_ "CS_:F_[)U%_P"I3X<K[L_M/5_^A=G_ /!GIG_Q^OS]_P""J-]J$_\
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MKXJ^%_CVGQB^'/@[QEXHU/P3\-E^+/PET#7/C=\1_%_PZT'3?&U]\=;R37O
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M7C[]HSQ/\0?"?P5TW2O#^CZEX2MK_P !3V>@VU[\2M3OM5LM:M+#QEX\O/\
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MT\,I8>)Y;[0[9+#59==OK;3X=&5IM6F9Y+J*R>PM[B[B]FE]'GBZO&,Z/$7
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M?S\5_0/_ ,&\_P#R<%^T)_V1KPM_ZGCU^6^-?_)K>,/^P'"?^K7+S],\'/\
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M*,@C8G((^ZO<?2OU3_B9'Q._Z"LD_P##/3_^7?U=^5OS+_B7KPW_ .@7./\
MP[5?_E7]7?E;_,OT+X=?MF^)KOQ/8>'O^";/[?\ K5[X+\12>$?%MKIWP.TB
MYG\.^)XM%T3Q')H6K(OCL&UU)=!\2Z!JYMVSFPU>PG#$3 #H?^%&_MZ?](N_
M^"B?_AA-+_\ F[K_ $-_@Q\(=1^&7BG]HK7M2U/3M3@^,_QWN_BUI$%G!<QR
MZ/IES\)/@_\ #L:7J+7**DU^+_X;W^H-+:%K8V>H6:;C<1W 7WGRX_\ GFG_
M 'RO^%'_ !,EXG?]!.2?^&BGY?\ 3[^K^@?\2]>&_P#T"YO_ .':K]W\+^ON
MM_FH+\#OV\PRD_\ !+O_ (**8# G'P#TO. ><?\ %>=:_I[_ &/O^"E_Q)^
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M*LOK'*G[1QK3Y9\MXNSL[:_YJ#? []O0LQ'_  2Z_P""B>"21GX":7G!/?\
MXKND_P"%&_MZ?](N_P#@HG_X832__F[K_2P\N/\ YYI_WRO^%'EQ_P#/-/\
MOE?\*_55])'Q.7_,3DFG_4GI^7_3_P#J[\K?F7_$O7AO_P! N;_^':K_ /*O
MZOZ6_P S#6/AO^VAX?U+PMH^M_\ !-?_ (* Z5JOCC6[KPWX/T^^^!FDPW?B
M77[+PYKWC"[T?1XCX[)N]0M_"WA?Q%X@E@7!72]$U&YSMMR#O_\ "C?V]/\
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MQ&#_ "")\#/V]$6,?\.N_P#@HG\BHI(^ FEY^50"1_Q78].,X_"O]+'RX_\
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MWB)T,/AY.,Y1BXP=/#4O=M924G?WK"T445\>?6!1110 4444 %%%% !1110
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M+>0"1E+@$:T4$,/F>3%'%YLC32^7&D?F2L%5I)-BKOD8*H+MEB% )( Q+10
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M3%U>Z-N;U+%K=;QH,(^\6[7=N)>FTS)USP >AT5\_P#_  U1^SP?^:N^"_\
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M^UQ>(R^K1HT_:ULLIT8.=648<]2I"G'XI34=3^&^#_![Q&ROC+AW-<?P\Z&
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>biib-2015930_gainlosschart.jpg
<TEXT>
begin 644 biib-2015930_gainlosschart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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M;KXE_$#2FD\&6?A[5?!%N@\3V7A34M=U33/JK]B3XAZAXO\  G_!2_6_B/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8EO!)<L92LEPR&5T2-&.V- /RP_X*3_\I)/^"%/_ &=;^U!_ZQS\0:_;R/\
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M^&M"T?PSX>\):!X<TC2=1/[<S7_H-J_=#_Y$?]B97_T!TOOGTM_>_NH^F_\
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MK!X'/.G _F ?:OQA_P""D_\ RDD_X(4_]G6_M0?^L<_$&OV\CYC0GKL7^0H
MQ/\ A)-+];[_ ,$^M?\ RNH_X2/2QG!OADY/_$GUGD^I_P")=R>!6]10!@_\
M))I?K??^"?6O_E=1_P ))I?K??\ @GUK_P"5U;U% &#_ ,))I?K??^"?6O\
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M_>3I^I6NH*XMC.?)6/?YUG>VGWP=I3[9;6_F?=.?+W;>-^W*Y_@\_P""5?\
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MB7_G\T/_ ,%^H_\ RVH WJ*P?*\2_P#/YH?_ (+]1_\ EM1Y7B7_ )_-#_\
M!?J/_P MJ -ZBL'RO$O_ #^:'_X+]1_^6U'E>)?^?S0__!?J/_RVH _ W_@X
M:_Y(#^S_ /\ 9<-1_P#5:^*:_DWK^KC_ (.#4U5?@'\ O[0GTZ5#\;M1V"SM
MKN!P_P#PK?Q1RYN+RY5EV[LA54YV'=PP/\H]?Z,?1V_Y-;E'_8=G'_JQKG^?
M_C]_R<O-O^P/*?\ U6X8****_<#\7"BBB@#^N_\ X-\O^34_BY_V<+K'_JMO
MAS7[TU^ O_!O^FK-^RM\6CI\^FQ1#]H+5]XO+6[GE,G_  KCX=9*M!>VR!-N
MT!2A;=O)<@J%_=SRO$O_ #^:'_X+]1_^6U?YB>,O_)S^,O\ L:_^ZN&/](?"
M/_DV_"7_ &+%_P"GZQO45@^5XE_Y_-#_ /!?J/\ \MJ/*\2_\_FA_P#@OU'_
M .6U?F1^CF]16#Y7B7_G\T/_ ,%^H_\ RVH\KQ+_ ,_FA_\ @OU'_P"6U &]
M16#Y7B7_ )_-#_\ !?J/_P MJ/*\2_\ /YH?_@OU'_Y;4 -\6?\ (K^(_P#L
M ZS_ .FVZK_-$C_U47_7*+_T6M?Z3_BJ+Q)_PC'B+==Z&1_8.L9']GZB"1_9
MMSG!_M4X_+IGOBO\V"/_ %47_7*+_P!%K7]D?1/_ (7'7_7SAS_TG.S^1?I1
M?Q^"?^O?$?\ Z5D0^BBBO[ /Y1"BBB@#]!/^"5?_ "D(_9>_[';Q!_ZK;QS7
M]Z2?<7_=7^0K^"C_ ()9"<_\% _V81:M"DY\:^(/+:X222%3_P *X\<9+I%)
M#(WR[@H65,-M))4%3_>1IZ:FBO\ VC-83 K'Y/V*WN8-N V_S/M-W=%P?EV;
M=A&&W;LC'\(_2F_Y+?(O^R5P_P#ZM\W/[9^C-_R1V=_]E/B/_53DYHT445_,
MI_1X4444 %%%% !52_MFO;&\LTN;NR:ZM+FV6\L)(XKVU:>&2(7-G++%-''=
M0%Q+;R20RHDR(SQNH*&W2$9!'J"/SH _#KQ5X[\7Z5^UY=_#^Z_:BLOA[9^#
M?B1\)/"EGX!^.'_!0_P)\+OB!\3M*;PYX!E/BCPK^SYIG[*7C:[\0Z!X^O;C
M5--TFPN_BGH6J?$/Q5:>)(T7P3;WUG'9?N*/KGD]\]SQT'3ICMTR<9K\ZM=^
M!B>"OV@_$7BS0_VMO#7PL@^*'Q(\-_$O6O@U>?#']G2XO_$VK_8?#/A2[,'B
M;Q7I,GQ,N[GQ=8^$=/T?^U+?4);NTDMX8?#HLY;..,_HL/KGD_SZ?AT_#F@#
M\0/^"D__ "DD_P""%/\ V=;^U!_ZQS\0:_;R/_5Q_P"XO_H(K\0_^"D__*23
M_@A3U_Y.M_:@Z G_ )LY^(/I^M?MW&<1H"""$4$%6R#@<'B@"2BDR/?\C_A1
MD>_Y'_"@!:*3(]_R/^%&1[_D?\* %HI,CW_(_P"%&1[_ )'_  H _GP_X.&O
M^2 _L_\ _9<-1_\ 5:^*:_DWK^LC_@X9_P"2 _L_G!Q_PO#4>2"!S\-O%7J/
M8_D:_DWK_1CZ._\ R:W)_P#L.SC_ -6-<_S_ /'[_DY>;?\ 8'E/_JMPP444
M5^X'XN%%%% ']=__  ;Y?\FI_%S_ +.%UC_U6WPYK]Z:_!;_ (-\^/V4_BX<
M''_#0NL<X)''PV^'&>0,<9&?J/45^]&1[_D?\*_S$\9?^3G\9?\ 8U_]U<,?
MZ0^$?_)M^$O^Q8O_ $_6%HI,CW_(_P"%&1[_ )'_  K\R/T<6BDR/?\ (_X4
M9'O^1_PH 6BDR/?\C_A1D>_Y'_"@# \6?\BOXC_[ .L_^FVZK_-$C_U47_7*
M+_T6M?Z77BLY\+^(\ G_ (D.L_PM_P! VZ]J_P T6/\ U47_ %RB_P#1:U_9
M'T3_ .%QU_U\X<_])SL_D7Z47\?@G_KWQ'_Z5D0^BBBO[ /Y1"BBB@#]!/\
M@E7_ ,I"/V7O^QV\0?\ JMO'-?WI)]Q?]U?Y"OX+?^"5?_*0C]E[_L=O$)XY
MZ?#;QR3^E?WI)]U>HPHSD$=O<"OX1^E-_P EOD7_ &2N'_\ 5OFY_;/T9O\
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M_P!C7_W5PQ_I#X1_\FWX2_[%B_\ 3]8PO^$8\/?] >P_\!T_PH_X1CP]_P!
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M6S[QC<0(RH5DPY)8+^[G]LW/_0OZY_WZTS_Y;5^&G_!OE_R:G\7/^SA=8_\
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MMM3BU_0?B5J_Q+;08Y+W41<Z*EO)\+TN-2MKR2SUKR?#6N1I"FI6D"?UH?\
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MQ!/VQ_LK5/\ H8[[_P  -%_^5]?+?[:_C?X@_!S]E7XY?$WP'XXNM#\8>#?
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M$WB7P?>Z#<37>A:KX?>/4K73_ NEWTT*66KW#QK!J%LXN(X7:1D5XY/UR P
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M/&6GZ;8:C?W6F^'O%_AKQGH.O:'8>($TOQ/:65XL'B#1-(U%)K&( ^I****
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M#48O"_A*QT;01J6H'3S>S^Y444 %?'7[2_P<^*^I^*?"7[1O[.>H^#(_C_\
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MY:B*TUB[T$7=@^IKIMRD5Y';QWUG-YT4<D%S!-&DB_3U% 'RU\4/V=;GQ_\
MM$?LG_&ZQ\2V&B:;^S9?_&F[NO"QT66XF\3P_%3X7CX>65OI^HP7]K;:&N@2
M!=1E\ZPU!+VW464"6; 3CY)_9<_8)^,'PO\ "?[*7PR^-'Q8^&/C'X8_L8:M
M=^)OA9H_P[^&_BCPWXA\<>,X?!_CGP)X5\4_$?7O%OCKQ1:V-KX2T'XB^++^
M+PQX0T>SBUCQ7=:+K%SKEGIGA[^P-6_5NB@#SWXHVGQ(N_ VM6GPDNO UEX[
MF2RBT:?XCV'B35/!R0M?6ZZHNK6'A+5M#UZ?S-)-['9?8=3MME\UM)<&2V26
M)_RQ\-_\$QOB%K_[&_P:_9M^+'[0&I>'_&G[.?P,\4?L_P#PK\>?L\-K_@7P
MOK'A?7O@_P"&OA6?$OQ)\">/KCXAC5_%,]OH^J)<S:#JVBR:=X=\2^(_#OA_
M4M.M?$.LFZ_9"B@#PW]F?X/WG[/_ .S[\&?@EJ'C'6/B!>_"KX;>#O =SXRU
MWRAJ7B";PQH5EI+W\D<,,*V]JS6IBTRS99)K'2XK*RN+J]N+>6]N/<J** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
L* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>biib-2015930_highlightschart.jpg
<TEXT>
begin 644 biib-2015930_highlightschart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &J 3T# 2(  A$! Q$!_\0
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M_'+]G*[N/V6? 7A7]GS6_ L7C#5OBS^TQ=^#?C)XH\':[\"-!^/OC/QW\/\
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M? 'PP\4#Q+82>&;GXDF&\N?'?Q"NO#FL>/=>ANK/P]=:P_@W0M%\-6;/AO\
ML0:C\*CHEQX8^./B?4;WX._!_P 4_ W]E+_A+O!G@_7-/^ O@/Q5=^$KFYAO
M;6QCT*^^*>KZ?8> / O@_3-7\1ZMI-Q!X&\*6.DRI/KVJ^*/%6O@'DB?\%%_
M%FK_ ++WP7^.NG_"/P3X+\9_%WX\_&SX)3^ _B=\5?$ T+PC=_!#Q7\?O#>M
MNWB?X6_"GXE>(?&OBG6F^!DT>B^$_ _@+65N]2\021V6KWNDZ(^L:A]N^#/C
MIX?U'X ^'/CIXHUCPCJ.C7_A73]?U;4/@O?>+/C#X7N+N[N4TZ6R\"W&D>#=
M/\:^-/\ B;2#2;.S@\"V'B.XU)9-/G\/VFH136L?RW\"/V*OC=\!_A(/AEX=
M_; \033Z-\4/'?Q1\):[#\%OA[8VT5Y\6/&_Q)^(OQ*\->-?#MSJ>L6OB_PY
MJWC#XF:EK'APZ9J'@SQ!X4DT;0[:'7=3L1K%KJWK6N?L?:%J?[*NN_LP6?Q'
M\>Z=!XBU75_%>M_$93X>F\4>(/&?B;XO7/QQ\:W_ (DT>#2+#PEJWA7XA>.=
M1UJP\>?#N+2-/\)Z_P##_P 0ZY\/TM;'0[X&( Q]0_X*(?LJ:5%9Q:AXT\70
M:_=WOQ/TN7P(GP=^,5W\2M+U;X->'_ WB[XF:1KOPWLO ESXVT35/"?@WXD>
M"O&E[8ZEH=O-=>#M=MO%&F"^T59;Q./^)G_!1GX.>&O$OP=\+_#1;GXNW'Q2
M_:$^ 7P*O/$&AZ?XRL?A]X>D^/7AC_A.]'U&U^)Z>"]2^'?B#Q3IO@&]\.^-
MI/AS;>)[7Q'-X;\3Z+J5V--@O;=Y/-_A1_P2K^&7PI^(-[\1M&\;WEKJ.LZA
M\>M=U?P[X6^'GP]^'O@>/7?V@O@3^SK\#/%DOASPCX+TW3-)\-Z5ING?L[:'
MXAT?3+>*[NIM6\1:T^O:OK5T1J=S6^''_!*_PM\,=%^"_@?P_P#&WQ[_ ,*R
M^#OQ2_9Z^/,'@B;PWX+V>)?C3\"/AUX2^&-QXJU+Q ME_;EGH7Q T7P=IVOZ
M]X1LIS;:7XUNM0U?1]5CT6>+PS  ?0W[4O[3_P 2?V<]$\;?$6S^"%CXL^#O
MPF\!:5\0?B)XQUCXGZ?X-U[78=0U;4-/N? _P5\(CPOXD/CSXC:;:65K=+HW
MBW6?AMH_B#6/$?@_P=X6UW6-<UK4G\.\OI/[;MY??$K1[:^^&VG:7\!?%?[3
M/CK]C[PC\5I?'\<_BR^^.'P]?QCHFK-JWPVC\+"QTKX?ZK\1?A]XQ^%V@:U!
MX]U+Q5+XJT[2[W5/!FG>'M<&HZ9=_:)_9-^+?QK^+_@;XD:%^TA%X3\)_#?3
M=&N_!GP@\3_!/PC\3/ FB_$[2]6O=0'QG$>H>)?#5[JWQ%LK233M*\(7?B-M
M;TKX=K8W.N>"-,T;Q5J]_KS7[#]B71[+XGV7BA_B5XINOA?H7QN\6_M/>%_@
MG<:-X;?PYH?[0GCBR\2)K_C$>)VM&\6W_AA?$GC'Q9\1M)\"75ZMKIWQ%\17
MNM2:U>Z-8Z!X:T8 E^!?[:%A\3M+_:T\1_$OX<ZW\ - _94^*/\ PA.O?\)Y
MK.F:GX@N_"C? 7X2_'F+QIXBT;PTFH6OA.^GT+XI0VO_  A5MJ_B;6+/^SH(
M[^ZM]?O[KP[I70?L<_M0:S^U)X6^+FN^(/AA=_"75OA;^T'\4?@E-X7U'Q'%
MXCU6>T\"2:%=:/KFMM!I&E0:#K^KZ+XBTZ;Q!X1@?6(O"FM1W^B+X@UO[(;^
M3POP#_P3WU?^T_VD;7]H/XXW7QV\ _M0^./"/Q6^(?@C3_ #_!.:U^*/P^\/
M?!GPGX&\2^&O&OPS^(=OXNT:P\/Z+\#?!EPNB6]^IN_$$=UJ\VJ+!(-+KWG]
MDS]COP)^R%!\<+;P+XH^(?B:'XX_'3QE\<]:/Q \=^-?'-SI.K>+K72+232;
M"^\:>)_$U].MM'I*M>:]<W U_P 23RQW'B.\U*XLK*6$ ^N:*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \=^-'
MQ/\ $'POT#2]0\+_  O\4_%/6=9UD:1!I>@ZMX1\+Z1HD*Z=?:E/KWC'QCXX
MUS0O#_AK0$^PII5O.9=2U74=>U31]*TW1[K[5<7-EXW=?MC^%I_V18OVMO#W
M@CQ=?Z-J&BV%UI/@+7;GPSX/\22Z]J?C:V^'5OH.I:[J^M2^"--LX_%ER(9O
M&<?B+4?!5QH,?_"6:1K>K>';FQO[OT']HSX5^-?BWX1M/#/A?5/A3<Z/-=7$
M?C7X=?'/X2V?Q?\ A3\2] GMU:VT?Q+H/]L^'=7LKC1-;M]-\1:1?V&J7%FU
MU8O9ZMHNHQSVMUI?S_X5_96^+W@GX,>'OV<-(^(GPR\0?#G1OA_XBD;4_B)\
M&T\=647Q*NOC9IGQ)\*>&-(\ :WX^N-&L?V>_!GA*37/AKX5^&LEU-XE\'^#
M[#P##X7^)-IJGA..\E )]!_;CEU[P#\.=7TKX4)XO^)OQC^(OC'P#\+/AG\+
M_C5\&_B58>)K?P%X;O?%GB[Q=>?%70O$4'PZT'P]X>T?2M135H[S4IM:MM:D
MT3P_'I=QJNOV4"8NI_\ !1[P _ANW\6^"OA3\6O'6C>&OA-J?QQ^.D6GV'A;
M1M:^ OP\T#QGX\^'7B6/Q=I&O>);)_$WCK0/&OPH^+6DW?@;P!<^([Z[@^%?
MC6\TJ^OI#X2LO%F9%^Q)\2K3Q;%^T!I_Q,^&6G_M-P?&G5_B_!>6WPIUR/X(
M1VOB3X!^'_V>?%'@A_!,?Q$C\<3+XA\+^%/#'BG5O'!\?1>(;[QOX:T*22P7
MPC8CPI)Q;?\ !-OQ-X7\)>*/"WPR^-^EZ--\=?@IXI^!W[4?B#Q-\+;/6+_Q
MS9>./B=\:OB]XF^(_P -[/2/%.@V7@/QPOBW]H[XVVVAZ;XD/C_PI8Z3XH\-
MI?V.JS>"0OB4 _5'3-3L-9TZPU?2KNWU#3-4L[74=.OK25)[6]L+Z".ZL[RV
MFC)26WNK:6*>"125DBD1QP:NDXYY_ $_H 36'X8\-Z/X.\.:!X3\/6::?H/A
MC1=*\/:)81L[1V6D:)I]MI>F6:,Y9V6UL;2W@5G8LPC#,<DUE>.O 7AKXCZ$
MWASQ7;ZE<Z4UY:7YCTKQ%XE\+W7VFR9WMV&J>%-8T/51&K.QDMQ?"VN!A;B&
M554  [$$'IG\58?S I:_"K[%J'PQ_P""Y7P3^!?@SQC\2]-^#GBW_@F?\>OB
M1XE^&=Y\5OB;X@\%:SX_\._M&?#'P]H/C.\\/^)/%VL:>_B71]"U74M(T[65
MB6_M-/OKJU@G2&9T/[;?\(SI/_/.[_\ !KJ__P GT ;]%8'_  C.D_\ /.[_
M /!KJ_\ \GT?\(SI/_/.[_\ !KJ__P GT ;]%8'_  C.D_\ /.[_ /!KJ_\
M\GT?\(SI/_/.[_\ !KJ__P GT ;]%8'_  C.D_\ /.[_ /!KJ_\ \GT?\(SI
M/_/.[_\ !KJ__P GT ;]%8'_  C.D_\ /.[_ /!KJ_\ \GT?\(SI/_/.[_\
M!KJ__P GT ;]%8'_  C.D_\ /.[_ /!KJ_\ \GT?\(SI/_/.[_\ !KJ__P G
MT ;]%8'_  C.D_\ /.[_ /!KJ_\ \GT?\(SI/_/.[_\ !KJ__P GT ;]%8'_
M  C.D_\ /.[_ /!KJ_\ \GT?\(SI/_/.[_\ !KJ__P GT ;]%8'_  C.D_\
M/.[_ /!KJ_\ \GT?\(SI/_/.[_\ !KJ__P GT ;]%8'_  C.D_\ /.[_ /!K
MJ_\ \GT?\(SI/_/.[_\ !KJ__P GT ;]%8'_  C.D_\ /.[_ /!KJ_\ \GT?
M\(SI/_/.[_\ !KJ__P GT ;]%8'_  C.D_\ /.[_ /!KJ_\ \GU?L=,M-.\W
M[*LR^=LW^;=WESG9NV[?M5Q/L^^V=FW=QNSA< &A1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 ?AWX__ .5B#]G#_M$W^TE_ZU)\(:_<2OP[\?\
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M2-+U[1;V#4M'UK3K'5M*U"V;?;7^FZE:Q7MA>V[X&^"[M)X;B%L M'(I(!)
MT20!DY_ %C^2@G]*R?#^@Z1X6T+1O#7A^P@TK0O#VE:=H>BZ9;;_ +/I^DZ1
M90:=IMC!YC/)Y-G8VT%M%O=G\N)=S%LDX?COX>^#?B;H+>&?'6@V?B/0FO+3
M4&TZ^>Z2 WE@[26D^ZTN+:;? [LR#S=N6.Y6H _&WQ\0?^#B#]G \_\ *)O]
MI/JK _\ )TGPA[$ ]O3T]17[B9'O^1_PK^?6X^$?PX^'/_!P9^SWHO@KPGIO
MA_2[[_@E'^TE=W=G9M>/'/<C]I[X3VPG<W5U<R&007$L0(D&%;C&U-O[V?\
M"+:!_P! R#_OJ7_XY0!O9'O^1_PHR/?\C_A6#_PBV@?] R#_ +ZE_P#CE'_"
M+:!_T#(/^^I?_CE &]D>_P"1_P *,CW_ "/^%8/_  BV@?\ 0,@_[ZE_^.4?
M\(MH'_0,@_[ZE_\ CE &]D>_Y'_"C(]_R/\ A6#_ ,(MH'_0,@_[ZE_^.4?\
M(MH'_0,@_P"^I?\ XY0!O9'O^1_PHR/?\C_A6#_PBV@?] R#_OJ7_P".4?\
M"+:!_P! R#_OJ7_XY0!O9'O^1_PHR/?\C_A6#_PBV@?] R#_ +ZE_P#CE'_"
M+:!_T#(/^^I?_CE &]D>_P"1_P *,CW_ "/^%8/_  BV@?\ 0,@_[ZE_^.4?
M\(MH'_0,@_[ZE_\ CE &]D>_Y'_"C(]_R/\ A6#_ ,(MH'_0,@_[ZE_^.4?\
M(MH'_0,@_P"^I?\ XY0!O9'O^1_PHR/?\C_A6#_PBV@?] R#_OJ7_P".4?\
M"+^'_P#H&0?]]2__ !R@#>R/?\C_ (49'O\ D?\ "L'_ (1;0/\ H&0?]]2_
M_'*/^$6T#_H&0?\ ?4O_ ,<H WLCW_(_X49'O^1_PK!_X1;0/^@9!_WU+_\
M'*/^$6T#_H&0?]]2_P#QR@#>R/?\C_A2YSZ_B"/YU@?\(MH'_0,@_P"^I?\
MXY5^QTO3]-\W[#:QVWG;/-V%SOV;MF=S-]W>V,8ZF@#0HHHH **** "BBB@
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M$%E\"+_P$/A*=:\M_AW??#G3M/%U:2^/)/&LOBW3M,\2OXZ:+3K31H^1N_\
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MS;1MHB(JHB[410BHJE45% 555  BJ   %4 #@ 4X;1T&/HI']*PO^$6\/_\
M0*MORD_^+H_X1;P__P! JV_*3_XNO/.XWLCW_(_X49'O^1_PK!_X1;P__P!
MJV_*3_XNC_A%O#__ $"K;\I/_BZ -[(]_P C_A1D>_Y'_"L'_A%O#_\ T"K;
M\I/_ (NC_A%O#_\ T"K;\I/_ (N@#>R/?\C_ (49'O\ D?\ "L'_ (1;P_\
M] JV_*3_ .+H_P"$6\/_ /0*MORD_P#BZ -[(]_R/^%&1[_D?\*P?^$6\/\
M_0*MORD_^+H_X1;P_P#] JV_*3_XN@#>R/?\C_A2YSZ_B"/YU@?\(MX?_P"@
M5;?E)_\ %U?L=*T_3?-^PVL5MYVSS?+W?/LW;,[F/W=[8QZF@#0HHHH ****
M "BBB@ I#G!QUP<?6EJI?W:V-C>7KPW=PEI:W-TT%A;37E[,MO"\S16=I;J\
M]U=2A"EO;0HTL\S)%&K.Z@@'XK>-(I9?VZ?'5OXOT']HK1_$>O?%SX.:KX0;
MX0_LX_L9WW@+XA> ?AMIGA&3P?XD\8^,/B3X%\7_ +1WBU/AUXKU+QHGB#QU
M9ZWI6F^ [&[)^&$?AV]TF;5&_;,=/S]!QGV[>GM7X.?$3P5%XG_:@U6XL_AU
M\14T7XG?'GX ?&;4OBGK7_!/SX\>(/CMX#U7P[8?"6\TSPAX'_:+MY;?P1X6
M\%V=MX<@T34==UNTM[CX/:3K7Q)\)WFA:^YN+RQ_>,=._4]?J>GMZ>V* %HH
MHH **** "BBB@#\._'__ "L0?LX?]HF_VDO_ %J3X0U^XE?AWX__ .5B#]G#
M_M$W^TE_ZU)\(:_<2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "L7Q&AD\/ZXBVS7C/H^J*+1+.74
M'N2UA<*+=+"&^TR:]:<GREM(M1L);DN(([VT:07$>U2-]UN,\'CD9XZ9&2,^
MP)H _FU\+_ E?AU\</ACH^I_!3P7;7=AXR^%.K1:SIO[$?QE\-6\2:A>^%]:
M2XT[7O$W_!5O7FTFXT&:[?2]0U:Z\!^,+#0/$&D:G$^@>+8=+>QU+^DH?U/\
MS[G_ #V'2OPH\3^'?!5M^W)\4=3\0^'?@KH^NZO^T%\,]0TNY\<_\$V/VC_V
MHO'GB!+;PE\+M.LO$&B_M;6=SX?\ _#H37=@VE>'])LK37/#7P2N='77KO5;
MR"^NK"R_=<?U/;'<_P"2>YY[T >,?&/Q7\8?#]OX9T[X,_#;P[XXU[Q!JM]!
MJ^N>._'+> _A]X$T/3-)N=2EU?Q%J&E:%XO\7ZI>:K>QV>A:%I'AOPE?H;F[
MNM4UW5=$TK2G>^^>K#]MRPU7]C'P;^UC9?#K4!J7Q#N/ ?A7P5\-KKQ1I=O;
M^(?B/\4/BUI'P.^'^F:9X]>Q&GWOP_\ %GCW7M'U/0OB/;:%(-4^&VHV?C>R
M\,2R7,.A-W7[6_[-OBK]ISPAX<\#Z1\;?$?PH\*VFORZGX_\,Z5X-\&>,O#G
MQBT#^SIK6#X??$;3?%5L;F^\ R7\L>J:[X;TK4]+L_&*VL/AWQ>NM^#[K6/#
MNJ\_XB_98\9?$'P)HGPM^)7QR\0ZSX*TOX<:=I$K>$O!7P[^'FJP_%[P;\4/
M!WQ(^$?QI\,IHGAN\L_"FN_">?P7IEIX<\+6CWG@+4F$<VO^%M1%N(W /)Q^
MV[\29?&</[-\'PQ^&Y_:X_X7!J'POO/"L_Q4UV/X06_A_3?@7IG[0;?%5?&D
M?PZF\<2>';[P?K.F>%[3PX/A[_;\/Q#GN--NIU\*V1\7W'&/_P %)/$GB?PK
MXE\5?#+X(Z;K?_"C/@CXB^.?[4F@>)?BC9Z+JO@.R\&_$WXT?"/Q3\./AS<:
M1X7U^P\>^.;;Q9^SG\;KC2=0\1-X \*:EI?A3PY]IU#3)O&XD\->TC]AN)3'
MX]B^-?CR+]I1/BK<_%]OV@E\-_#LZK+KUW\*;;X'3^%I/A\WAIO 9^&__"K+
M*QT"'PH+ 7D.L65OXV'B ^,!-JTW.:E_P3B\!Q^&8?"?@KXL?%GP+IOBCX4Z
MS\$OCK=Z?=^$]9UKX\_#[Q/XT\>_$;Q3+XMU+7O#-XGAGQUK?C;XL?%K5V\<
M> ;/PY=Z9#\4_&=GI6G6A7PG<^% #[]\->(M'\7>'M"\5>'KV/4M!\2Z/I>O
MZ)J,(<0W^D:U86^IZ9>Q"14<1W=C=6]P@=58+( P!!K;SC_]1/\ *J&E:7I^
MAZ9I^C:39P:?I>DV-IINFV%K&L-K9:?86\=I96=M$H"QV]K:PQ6\$8X2*-%Y
MQFL+QGX"\$?$;13X<^('A#PUXW\/M=VM^VB>*]$TWQ!I)OK)F>SO#I^JVUU:
MFYM7=VMYS%YD+,QC9230!^,_C[_E8@_9P_[1-_M)?^M2?"&OW$K^?W4/A3\,
M/A__ ,'!_P"SUH_@7X=^!_!NDWO_  2C_:1O+W3?"_A70]!L;R[7]I_X2VZW
M=W:Z78VL-S=);S26ZW$R/,L#F%7$6$'[S_\ "->'?^@%I'_@NM/_ (U0!MT5
MB?\ "->'?^@%I'_@NM/_ (U1_P (UX=_Z 6D?^"ZT_\ C5 &W16)_P (UX=_
MZ 6D?^"ZT_\ C5'_  C7AW_H!:1_X+K3_P"-4 ;=%8G_  C7AW_H!:1_X+K3
M_P"-4?\ "->'?^@%I'_@NM/_ (U0!MT5B?\ "->'?^@%I'_@NM/_ (U1_P (
MUX=_Z 6D?^"ZT_\ C5 &W16)_P (UX=_Z 6D?^"ZT_\ C5'_  C7AW_H!:1_
MX+K3_P"-4 ;=%8G_  C7AW_H!:1_X+K3_P"-4?\ "->'?^@%I'_@NM/_ (U0
M!MT5B?\ "->'?^@%I'_@NM/_ (U1_P (UX=_Z 6D?^"ZT_\ C5 &W16)_P (
MUX=_Z 6D?^"ZT_\ C5'_  C7AW_H!:1_X+K3_P"-4 ;=%8G_  C7AW_H!:1_
MX+K3_P"-4?\ "->'?^@%I'_@NM/_ (U0!MT5B?\ "->'?^@%I'_@NM/_ (U1
M_P (UX=_Z 6D?^"ZT_\ C5 &W16)_P (UX=_Z 6D?^"ZT_\ C57;/3-.T[S/
ML%A9V7G;?-^RVT-OYFS=LW^4B[]F]MN[.W<V,9- %ZBBB@ HHHH **** "D8
MX!/H">PZ#/4\?GQ2U5OK9KVRN[-+NZL7NK6XMEO;%XH[VT:>%X5NK22:&XA2
MZMRXFMWE@FC69$9XI$!1@#\S?$O[<FOI^TYXK^".E>._V&O =AX(^)W@GX=7
M_A;XT_M3+X;_ &@O%2^)-(\(:Y)K7A7X4Z#X>U.T@;7D\43Z+\/=#U379-3\
M1ZMI+-J0T9KY=.L_T['X=3T]B1^?KZ'-? 6H_![P'_PM?X=W][^W#\7K7Q'X
MMU*QNO _PSF^)G[/RV?Q(G^%EAH]KXOM=%T2\^$DOC#Q4LQT*;4?B/\ \(YK
M+7EC>:GJ\R7'AV!K.#3_ +^'USU/Y\_EZ>U !1110 4444 %%%% 'X=^/_\
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M?^*?%7AOPM'J>MV/@^UO_%5_I&A_\) VL:AI_AVUGUF_M=/DL]/Q=3QNM/\
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MW\R/(.&3(.#C-?A!XN\<^+CXM\6?9/%7BJVM?^$I\2?9;9M7UJQ:VM?[;O\
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M^!EM_P#':/[6TS_H(6/_ (&6W_QVC^R=,_Z!]C_X!VW_ ,:H_LG3/^@?8_\
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M>Q]G?VMIG_00L?\ P,MO_CM']K:9_P!!"Q_\#+;_ ..U\;W7QP^.MV /#W[
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M.Q%%2JT'=*I%:0Q4*<FZE"&)C:K&A5_>4E+E;DN6<C^UM,_Z"%C_ .!EM_\
M':/[6TS_ *"%C_X&6W_QVC^R=,_Z!]C_ . =M_\ &J/[)TS_ *!]C_X!VW_Q
MJO"/HP_M;3/^@A8_^!EM_P#':L07=K=;OLUQ!/LQO\F:*7;NSMW>6[;<[3C.
M,X.,X-5_[)TS_H'V/_@';?\ QJK$%I:VN[[-;P0;\;_)ABBW;<[=WEHN[&XX
MSG&3C&30!8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /P[\?_\
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MUNK>R;6?%>O:3X<TH7EXS):6AU'6;RQLA<W3(RV\!G\V=E81(Y4@=,JJ@"J
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M]O\ _%4 ?C!_Q$)_\$AO^CLY_P#Q'O\ :H_^<=1_Q$)_\$AO^CLY_P#Q'O\
M:H_^<=7[/[1ZM_WV_P#\51M'JW_?;_\ Q5 'XP?\1"?_  2&_P"CLY__ !'O
M]JC_ .<=1_Q$)_\ !(;_ *.SG_\ $>_VJ/\ YQU?L_M'JW_?;_\ Q5&T>K?]
M]O\ _%4 ?C!_Q$)_\$AO^CLY_P#Q'O\ :H_^<=1_Q$)_\$AO^CLY_P#Q'O\
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M_MO_ (1W!^)G@;P8-4_M#_A'-8S_ &,=1-G]C_T_[+]IM/M'VCM'JW_?;_\
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MX0^&FL^(Y?@C\0/#5[X\OK[Q1K]SX=U'5->T/Q<NJ:CJP!^TA90-Q90N<9)
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M[6_M)(KJWAE3SJT_8[_9=L_AO/\ "!?@3\-+GX97/BV3QY+X*U+PS9ZOH/\
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MC::_KD$GBB#;KDT>L:D)K^3[;<&0 _)O4?\ @K9\0(/A9\<_C5IO[-?B*Y\
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MLGH,9SF@!U%%!(&,D#)P,]SZ#U/!H **** "BBB@ HHH!!Z$'DCCU'4?4=Z
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MOK7A7P_ D>G^'M7M[?4M)AM+V"*=.OTGX._";0? VL?#'1?AGX!TKX;^(?\
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MHMW^V/X@L/A[H]Y\4O&'CK4_AG^Q9\;O'/P4\9>,-7AT/PU9>%/ ^@^-M?\
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M.=5U'QIK-V)#)J/BZ\G\2W._6I#?5[[_ )_/K0 4444 %%%% !1110 4444
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L@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>biib-2015930_investeechart.jpg
<TEXT>
begin 644 biib-2015930_investeechart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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M;KXE_$#2FD\&6?A[5?!%N@\3V7A34M=U33/JK]B3XAZAXO\  G_!2_6_B/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB,+E^+H4Z.'SB52M',J\<-0IT8RSB*K3C7E&E6G1E4P].I*-/VTIWB?U?_\
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MO^2WR+_LE</_ .K?-S^R_HS?\D=G?_93XG_U4Y..HHHK^93^CPHHHH ****
M"HIYDMX99Y2PCAC>60I')*P2-2[%8XD>61MJG"1H[L<*BLQ ,M(>AYV\'GTX
MZ\\<=: /GF?X]ZNIEO;/]GS]H/4?#,5P\8\4P>%?!EHLENDBH;V'P-K'Q"TO
MXM36Y3=,D2_#P:C+&N(=/DE9(V]YTS4+;5M.L=4LQ<BTU&TM[VV%Y8WVF78@
MN8DFB%UIVIV]GJ-A<!' FL[^UMKRVE#0W,$,R/&OX-?&G_A)/%/[9'B/PT_Q
MJUW6_P#A#/VA?ASX@\!OX*TG]L#QQ:?#7Q;XKU']F677=&\91?#3X/\ B#X%
M>!M:^&/P@\!^-?#GAGPEJ_CR[T/QC;_M.>)_&'Q6A^'L4NMWOB+]\ES@9SWZ
MYXY/&3R<=,]\9[T ?B#_ ,%)_P#E))_P0I_[.M_:@_\ 6.?B#7[>1_ZN/_<7
M_P!!%?A]_P %+3,O_!1__@A6;>.*68?M6_M/;(YIG@B;_C#OX@!MTJ07+IA=
MQ&(7W, IV@EE_:B.?Q#Y:?\ $KT;[B_\QV^]!_U+E &Y16-Y_B'_ *!>C?\
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MD_\ RDD_X(4_]G6_M0?^L<_$&OV\C_U<?^XO_H(K\0_^"D__ "DD_P""%/\
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M?$G@_3O&/P@\<>*[/X;S-K'BW2M&.C6FB^&?B/X:\-Z)J6M>"-&U2^_I+//
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MGT!/\@<?C2;AZ-_WP_\ \37\RV?;^OZ:/Z-'44W</1O^^'_^)HW#T;_OA_\
MXFG9]G_7_#K[Q77=?U_PZ^\=13=P]&_[X?\ ^)HW#T;_ +X?_P")HL^S_K_A
MU]X77=?U_P .OO'5^>G_  5;_P"4>?[4W_9.HO\ U*?#E?H4#GIG\01_,"OS
MU_X*M_\ *//]J;_LG47_ *E/AROJ>!?^2WX-_P"RJX>_]6^#/F>-O^2-XL_[
M)K//_59BC^#1_OM_O-_,TVG/]]O]YOYFFU_J['9>B_(_R^"BBBF 5_0/_P &
M\_\ R<%^T)_V1KPM_P"IX]?S\5_0/_P;S_\ )P7[0G_9&O"W_J>/7Y;XU_\
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MFGVMU&/W9'3\3V*]SV/.?4]SSWKYSE_9G\)->*+7QW\<M,\,A!&W@?2_C?\
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M2?#?PY^RBWP:O]!^(WBWQ*/$,,^G^%?$^O>'M6^'_A#4DL;:Y'Q6^&?B*_\
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MX@U^5'_!?G_D\OX?_P#9N?@[_P!3WXEU^]_1N_Y.9A_^Q-FO_I- _#?I#?\
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M3_ZJ<G'4445_,I_1X4444 %%%% !1110 4444 ?B!_P4H('_  4C_P""%))
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M6J,*D^:5UR^[;>[1_)]D>H_,49'J/S%?T^_\0M_[%_\ T=U_P4R_\2=\'_\
MSF*0_P#!KA^Q> 3_ ,-=?\%,N 3_ ,G.^#^PSW^"Y_D:_IO_ (FJX7_Z)CB'
M_P &99Y?]1GK_6_\X_\ $L?$O_129#_X+S'_ .9?7^EK_,'D>H_,49'J/S%?
MOK\"_P#@W'_92^)?B[]IS0=>_:U_X*,QV?P;_:&N_A5X6;2OVE/"MO<2^'(/
M@M\$_B$DNN/+\(KE;O6#K?Q%UR,W4*641TR/3+<VGFV\ES<_1'_$+?\ L7_]
M'=?\%,O_ !)WP?\ _.8H_P")JN%_^B8XA_\ !F6>7_47Z_UN?\2Q\2_]%)D/
M_@O,?_F7U_I:_P PB$;UY'WE[CU%?WV?\$S'3_A@;]D_YE_Y(QX4_B'_ #SN
M/>OR/'_!K?\ L7@@C]KO_@ID"#D'_AIWP?P1_P!T8KZ3\*?\$.=$\">&]%\'
M>"O^"IG_  63\*^$_#>GP:3X?\.:'^V;X<L='T73+5=EMI^G6<?P7\NVM+=/
MDAA3Y47@<5^1^,'C+D_B1DF695EV49GEU7 YHL?4JXZ6$E3G36$Q&'Y(+#UZ
MLN?FK*7O)148O5NU_P!5\)O"/-O#W.<QS/,,URW'TL;ECP,*>"ABHU(5'BL-
MB/:3=>C3CR<M"4;1;E>2TLFSS7_@X993\ ?V?\,I_P"+X:CW'_1-O%/O7\G&
M1ZC\Q7]<WQ._X-__ (8?&K2]-T3XP?\ !2+_ (*[_$S1M'U$ZOI.E^,_VP/#
M.M66FZJUI<6#:C9P3_!?;#>&QN[JT,R_-]GN)H_NR-GQ;_B%O_8O_P"CNO\
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M1ZC\Q7] _P#P;SLH_:"_:$RP'_%FO"W<?]#X]>[?\0M_[%__ $=U_P %,O\
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M*T?\%II(I4>.2-OVV- *O&ZE71@/@N"5925/(X)KY._XA;OV+N!_PUU_P4R
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M^.O$GPA\>_#3Q9\%OC'X7\'^'OB%=>!_%6K>#?$]GKO@3Q+K&M^';+Q7X/\
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MN=0L],\:>&],\2V%I?FSFN+3[;;6FJ0P7?V:>:W^T1R>3+)'M=O0* "BBB@
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MVCJ]S#%;)=:A?/%]KU">."%9[J6:5(H@ZHFM10!^47@_]A_X^^*M=_;(T_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
7!1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>biib-2015930_noncontchart.jpg
<TEXT>
begin 644 biib-2015930_noncontchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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M;KXE_$#2FD\&6?A[5?!%N@\3V7A34M=U33/JK]B3XAZAXO\  G_!2_6_B/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=,]\9[T ?B!_P4I94_X*1?\ !"IF954?M6_M099B% S^QU\00,DD 9. /4D
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M8&A_] ;2O_!;9?\ QBOX6/[5-#[5;?\ /Q!_W^C_ /BJ/M5M_P _$'_?Z/\
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M^-E_^(6<8VW^HX3?_L:Y>?IG@Y_R<WA'_L.Q/_JLQQ_6G]JMO^?B#_O]'_\
M%4?:K;_GX@_[_1__ !59_P#8&A_] ;2O_!;9?_&*/[ T/_H#:5_X+;+_ .,5
M_F2?Z.&A]JMO^?B#_O\ 1_\ Q5'VJV_Y^(/^_P!'_P#%5G_V!H?_ $!M*_\
M!;9?_&*/[ T/_H#:5_X+;+_XQ0!H?:K;_GX@_P"_T?\ \51]JMO^?B#_ +_1
M_P#Q59_]@:'_ - ;2O\ P6V7_P 8H_L#0_\ H#:5_P""VR_^,4 :'VJV_P"?
MB#_O]'_\53TEBDSY<D<F,9V.KXSG&=I.,X.,]<&LS^P-#_Z VE?^"VR_^,5;
MM=/L;'S/L5E:6GF[?,^RVT%OYFS.S?Y,:;]NYMN[.W)QC)R 7**** "BBB@
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M'6_^@#_Y5K+_ .-T?VCK?_0!_P#*M9?_ !N@#H**Y_\ M'6_^@#_ .5:R_\
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M0?\ K'/Q!K\J/^"_/_)Y?P__ .S<_!W_ *GOQ+K][^C=_P G,P__ &)LU_\
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MOYFFTY_OM_O-_,TVO]78[+T7Y'^7P4444P"OZ!_^#>?_ )."_:$_[(UX6_\
M4\>OY^*_H'_X-Y_^3@OVA/\ LC7A;_U/'K\M\:_^36\8?]@.$_\ 5KEY^F>#
MG_)S>$?^P[$_^JS'']:-%%%?YDG^C@4444 %%%% !1110 4444 %%%% !111
M0 57O+A+2TN;J1+B2.VMYIWCM;:XO+J1(8GE9+>TM4DN;F=U0K#;V\;SSR%8
MH4:1U4V*CFABN(I8)XUEAFC>*6)P&22*12DD;J>&5T8JP/!4D'@T ?A3IL.C
M:W^U%XB^).B?#"QU/3?BK\9? GC-+SXZ?\$<_P!M?Q-\6/"MW:Z7X+\)SPVO
M[1'B/7M#T#PE96<7AJUO/#>LWOA73?"GPU.=2;3I-/M;J,?NR.GXGL5[GL><
M^I[GGO7SG+^S/X2:\46OCOXY:9X9""-O ^E_&_XC67A<1C:#;6WEZX?$FFZ=
MM41II&D^)+#28+<FSM[&&T/D5[]I>F6&BZ;8:1I=M'9:;I=G;:?86D6[RK:S
MLX4M[:"/>SN5BAC1 79G.,LS,22 ?B5_P4MA2?\ X*/_ /!"N)S*J/\ M6_M
M/9,,\UM*-O['?Q 8;9K>2*9.0 =DB[ERK95F!_*3_@O?:16?[8_@"*%[EU/[
M.O@]R;J]O+Z3)\>?$I2!->SW$JIA1B,.$!W,%#,Q/ZP?\%)_^4DG_!"G_LZW
M]J#_ -8Y^(-?E1_P7Y_Y/+^'_P#V;GX._P#4]^)=?O?T;O\ DYF'_P"Q-FO_
M *30/PWZ0W_)N<1_V-LK_P#3LS\/:***_P!#3^"0HHHH <GWU_WE_F*_O9_X
M)I:1:7'[!7[*4TDNJ*[_  :\*LP@UO6K:($I<$A(+:_BAC7T6.-5 X  XK^"
M9/OK_O+_ #%?WV_\$S/^3!?V3_\ LC'A3_T7<5_,'TI_^20X>_[*-?\ JMQQ
M_2?T9?\ DJ\^_P"R>G_ZLLO/M#^PK'_GOK/_ (4?B'_Y:4?V%8_\]]9_\*/Q
M#_\ +2MFBOX6/[5,;^PK'_GOK/\ X4?B'_Y:4?V%8_\ /?6?_"C\0_\ RTK9
MHH QO["L?^>^L_\ A1^(?_EI1_85C_SWUG_PH_$/_P M*V:* ,;^PK'_ )[Z
MS_X4?B'_ .6E?GU_P54TFUMO^"?'[4DT<NILZ?#N(@7&M:S=1$_\)1X<^_!=
M7\T$@]GC8>U?H]7YZ?\ !5O_ )1Y_M3?]DZB_P#4I\.5]5P+_P EOP;_ -E5
MP]_ZM\&?,<;?\D;Q;_V36>_^JS%'\&C_ 'V_WF_F:;3G^^W^\W\S3:_U=CLO
M1?D?Y?!1113 *_?W_@WQLXKSX_\ [04<SW2*OP;\+,#:WU[8N2?';CYI+&XM
MY'7CA79E!R0 237X!5_0/_P;S_\ )P7[0G_9&O"W_J>/7Y;XU_\ )K>,/^P'
M"?\ JUR\_3/!S_DYO"/_ &'8G_U68X_JX_L*Q_Y[ZS_X4?B'_P"6E']A6/\
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MNC=_MC^ 9#;7EKM_9V\()Y=];_9I3M\>_$KYU3S),H<[=VX?.KKCY<G]8?\
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M;'1P\:D*L\;C<*Z<%AZ=*'LU'"QFG*+ES3EK:R7[GX3\?8_Q"R/,,US# X/
M5<'F]7+H4L%*O*G.G3P6!Q*J2=>I4ESN6+E%V:CRPCI>[;J***_)C]3"BBB@
M HHHH **** "BBB@#\0/^"E! _X*1_\ !"DD@#_AJW]J#D\#_DSGX@U\/_\
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MOV/_ ,Z*D/\ P1KG4$_\/7O^"SQP"<?\-OV/;G_HD5?N7_$U7%'_ $3'#_\
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M>_X+/?\ B;]C_P#.BI_\35<4?]$QP_\ ^#<Q_P#FC^KORL?\2Q\-?]%)GO\
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ML !7]/B_\$;)W!/_  ]=_P""SP^9UP/VW[' VNR_]$BSV[Y/J2>2[_AS5/\
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M'X'\6ZWK/P_\5^(?"/A#Q9XA\-Z9XFTJ/3M2A\,:SI$FMVGB4:5HNJ@'Z)8
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MQG/+'_OIBQ_ $X'MUS2T4 %?,/[:/[/!_:R_93^/G[-RZUI?AN3XT?#'Q-X
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MRN+J]N+>6]N/<J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
-HHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>biib-2015930_oiechart.jpg
<TEXT>
begin 644 biib-2015930_oiechart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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M;KXE_$#2FD\&6?A[5?!%N@\3V7A34M=U33/JK]B3XAZAXO\  G_!2_6_B/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]G_7_#K[PNNZ_K_AU]XZBF[T_O+_ -]#_&E#*>A!^A!_E2L^W]?TU]X[KO\
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M+9H;?_@H_P#\$*YIY8X8D_:M_:?+RS2)%&N?V._B HW22,J+EB%&6&6(49)
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M=,\*>*[+6=;DU3PSXBT25XK^_P!1ELXKJ2\UL7UQ+<1.D@290!)(I']%JC
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M5/\ Y)H_L"W_ .@AKO\ X/=4_P#DFMVBO\S3_1@PO[ M_P#H(:[_ .#W5/\
MY)H_L"W_ .@AKO\ X/=4_P#DFMVB@#"_L"W_ .@AKO\ X/=4_P#DFC^P+?\
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MJG_0QWW_ ( :+_\ *^C^RM4_Z&.^_P# #1?_ )7T ;U?GI_P5;!/_!/3]J8
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M_E?5^QM+JV\W[3J4^H;]FSSK>R@\K;NW;?L=O;[M^1GS-^-HV[<MD OT444
M%%%% !1110 4444 %%%% !1110 45\3?&#]MSPG\)O%/Q/TN/X:_$KQ[X0_9
M]\.^'_%?[27Q&\&V_A:3P_\ !?0?$VCW7B>UGO\ 2]<\2Z/XH\;ZAH/@FV7X
MC>-M&\ :+K^I>%_A_>:;K+0ZAJNK:5X?O-?7?VO+'PO\9O!?PN\1_!WXJZ/X
M:^(OQ#_X5-X(^*LZ>";GP]XC\</X4UWQE:WECX0T_P 7WGQ,7X;WVF^&]:TN
MU^)]SX/@\-_\)!8LERMMX;FMO%$X!]7:=H>BZ//J]SI.D:7I=SK^J-K>NW&G
M:?:64^M:RUAI^E-JVK2VT,4FI:FVF:3I>G-?WK3W9L--L+,S?9K.VBBU*\"\
M8_'NS\#?$#7?!^L_#WXEW6AZ%\*M-^);>//#GA2]\6:)JNH:MXYF\#6/PWT+
M0_#*:KXRUGX@7%TMIJL6EV/A^6S;2]0M9GOHV%QY'RQ<?\%'O"-]^S'\ ?VE
M?"_PN\2R:?\ M!ZKK5EH7A#X@^/_ (0?"2]\&67AS3O&VI:]?_$#QEXU\:6_
MP\T9]-'@N;3VL-.\3:O<76J:I96]BUS;Q7UY;@'Z245QWP]\3WOC3P-X0\7:
MAHT?AZ\\3^'-'U^?18?$&A>*X=-;5K&&^6T@\3>&+J^\.Z_!'',AAU?0[RZT
MK4(F2YL;B:WDCD;L: "BBOG?XT_M +\+?$O@/X=>%_AUXQ^+WQ8^)=CXPUWP
MIX \&W7A71I%\(_#O_A&U\<^,_$7BCQQKWAOPOX>\/:%>>,O!V@0R76HS:EJ
M_BCQ?X=TG3=.E@FU34M( /HBLI-"T2/6I_$D>CZ6GB*ZTNUT2ZUY-/LUUJYT
M6QO+W4+'2)]56$7\VF6=_J6HWMKI\EPUI;W=_>W,,*374[R?!WBW_@H/X4T/
MX0Z9\>_#OP4^-7C+X36O@;7_ (@?$;Q+:V?@#PS=_#2R\&ZWXH\->// ]_X=
M\9>/-#UOQI\8?!/B#P7XITO7OA?\.K7Q3K!N=$EM=,O-0U+6O".G>)/K;QO\
M2I/".I?"*QL?!GBWQ=!\5?B)%X$EU+P]:6@M/ =E+\/O'GCT>-O&J:I=6%U9
M>%U/@F'PO(UE!=ZHGB/Q3X>MFT\02WL]J >H45\G? ?]L'X<_'NZ_:&.D:)X
MV\!Z-^SEX\TWP5XIUWXK:"?A_#J]EJGPD\#?&:U\<Z=I&OSVWB+0_!DWA'QY
MIMS!>>-]*\+ZM)!:7>JR:/;Z--I]]>7?V5OVJO"W[5VA?%3Q!X4\(>-/!UI\
M+OC5XQ^#5U:^.K33=.U37I/#&C^%/$>F>,M/TVPU&_NM-\/>+_#7C/0=>T.P
M\0)I?B>TLKQ8/$&B:1J*36,0!]24444 %%?*'Q<_:[\ _!'X@:Q\/?'^A>+;
M'5)/A-)\4/AM<6-E8W\/QFO]/\76'@;7OA=\.(4O8[J_^*6C^)O%?POL5\,Z
ME%IZ:Q%\5/"U[HM[>V=AXKE\/_)?Q._X*<>)?@[KO[2FE^/OV0OBE8V/[+_P
MR\"?%7QUK&F?%+X$ZQ#J7ASXM:Y\0?#'PI@\/V-OXUCOY-3\5^(/AKXBLKZW
MU2+38O#%J^G:EJTYM+LM$ ?JC?:+H^IW>CW^I:5INH7WA[4)M6T"\OK&UN[K
M0]5N-*U+0I]2T>XN(I)M,U";1-8U;1Y;VR>"YDTO5-1T]Y6L[ZZAETJ^9/@[
M^T@?B'XZ\2?"'Q[\-/%GP6^,?A?P?X>^(5UX'\5:MX-\3V>N^!/$NL:WX=LO
M%?@_QAX#U_7_  _KUCIWB/P_J/A[Q+IT[Z3XB\-:K_9KZGHL>D>(O#.K:QY9
M\7OV\O"/P0^%4WQ0\>?"+XUVJGXX^(_@O8>%].\)VVHZI<6V@_M Z?\  "#X
MJ:EK4.HKX/\ "_PRUS4=:T'QGH6I^)O$.EZWK/A;7-,M-%T+5/%5RN@4 ?=U
M%?$OQ&_;%_X0S]I+0?V=-&^&\7B*_P!1'P^34O%&J_&3X,_#Q(;OQ]J.MQ)I
MWA?P5XX\5Z9X\^(6HZ#HFBR:_JEKX0T*^::*\M--TTWFIBZ@M_MH?Y_I^= !
M117AOQF^/'AKX%WWPNE\<:9JUMX.^)'Q#T[X8WOQ!A:P'A;X>^)/$VGWY\"7
M'CV>YNH+G2?#_C?Q7:6'PZTG7((;FTM/'/B?PEIFJ_8K/6QJ%L >Y5E:WH6B
M>)M)OM!\1Z/I6OZ'JD#6NI:-K>GV>JZ5J%JS*S6U]IU_#<6=W S(K-#<0R1D
MJI*Y4$?G/JW_  4'\1'XE?LZ^"/!W[+7Q-\7>'OVIY?%UQ\'?'C^/?A'X4T_
M6/#G@G3+SQ1J_BO5?#7B;Q19^+=&T?4O 4%GXX\+Q3Z7)J>LZ/K.E6LUCINJ
MRW%E;;?[.7_!0C1_CMI_P.\1Z_\ !'XF_"'P/^T]<ZO9_L_>.?%.L?#CQ+H'
MC75-*\.^(_&-OX9U^/P/XMUO6?A_XK\0^$?"'BSQ#X;TSQ-I4>G:E#X8UG2)
M-;M/$HTK1=5 /T2P!T&.I_$G)/XGD^]%?//BG]H2S\&>(OB[H^M_#3XK3Z9\
M+/"7PK\1V&O>&?"%SXQ3XG:K\5-4\:Z+8>"OAQH?AE]1\0ZMXG\/ZIX3L+;Q
M*NI:=I6BZ5%XOT#4[S6+;1HM:U+2_*9/VZ/ARG[$/@O]MY?"?C67PW\1O@GX
M?^,?@3X4PKX<E^*?B>X\4^ Y/'^B?#K3+5-=;PM-XSETJ"\_M&=?$;>%M%M-
M+UKQ%JFOV_A;1M1UFW /MRBO/_A/\1-*^+OPN^''Q5T.TO;#1?B7X"\'?$#2
M+'4C;G4+/3/&GAO3/$MA:7YLYKBT^VVUIJD,%W]FGFM_M$<GDRR1[7;T"@ H
MHHH **** "BBB@ HHHH **** "BBB@#\L_VJ_P!E3XN:C>?M 2_!N[AUWX9_
MML0^$? W[5O@BT\/^'KSXIZ/X:C^&MW\%_%/CSX(:[XK\>>!_!,FN^(?AG9>
M#O!>NZ%X\:]M_#-CI-U\1O"(\0>(+%_A]XF[[Q'^QEXT\7?'WX:_%#5_&OPG
MTG2?A%X]L/%O@GQKX-^"R^%OVEH_A_I/]OQZ?^S;JWQ>LO%\FFZA\%IX_$%S
M8^([:3PJUSXK\,A]&U+2(/$MQ+X]'Z'44 <9X^A\>2>#M;B^&-UX3M/'AM(A
MX<NO'=GKNH^%([U;JV,CZY9^&M1TG6[BV:S6Z55T_4+:7[2T#.[0++$_YK_L
M[?L8?M+_  2_9O\ @U\&]3\?_LM>,?$O[/WB?6-2\!ZMKOP%\7:_X:UC2/$=
MKXLBU*:[M=>^(L_BGP)XUT^X\9:DNF>*/!'B 07>@B_\-:QI-U9Z[/<Z?^K=
M% 'AO[-_P5A_9[^#GA3X40ZY#XC;0+GQ7JEYJMEH%GX2T=]5\:^-?$GCS6;/
MPQX2T^ZO[+PCX-TK5O$][I/@KPC;ZAJ,7A?PE8Z-H(U+4#IYO9_<J** "OCK
M]I?X.?%?4_%/A+]HW]G/4?!D?Q_^$7PW^+O@+PYX2^(^DW=[X#^)OA#XH3>
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MBF>WT?5$N9M!U;19-.\.^)?$?AWP_J6G6OB'63=?LA10!X;^S/\ !^\_9_\
MV??@S\$M0\8ZQ\0+WX5?#;P=X#N?&6N^4-2\03>&-"LM)>_DCAAA6WM6:U,6
MF6;+)-8Z7%965Q=7MQ;RWMQ[E110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
61110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>biib-2015930_otherrevchart.jpg
<TEXT>
begin 644 biib-2015930_otherrevchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &0 3T# 2(  A$! Q$!_\0
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M;KXE_$#2FD\&6?A[5?!%N@\3V7A34M=U33/JK]B3XAZAXO\  G_!2_6_B/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 49'KUZ>]%?A_^VE^V[\<?@K^V=\'?A7J'
MQ(\$?LM?";5?$,UIX0\8_&3X6^)O$'P5_:!.J? [QSKUW'XU^.=CK>B^&?A=
M!X2^*-AX>\$+X.M]2T;QSIL]U:?%"_D\4>#M1L?#1 /W HK\L?VZOBG^T]^S
MK\-?V@OVDM/^-G@+PIIWP\M-!LOV6?V>M+^'=EXX;]HOX@7&BZ,GAOX4_$K5
M-4M;7Q_<_$7X]_%[4;OX2?#KPS\$]1T*3PCI+>'?&=Y>^-M3OM=\/:+X;\</
MVA_VH-)^/?QKU77/C/\ %C]G#X _ _4OA;)XJ_X1S]BC2?C;\._#?@G4/@W\
M._B3X^\<>-?CIK%U:RW&E:3XB\2>,?#GBJ_^'^C>)+#X<^'_  D?%/B=-(T]
M[N\MP#]P**_$GX^?M#_M%:3^T/\ '75A\?\ XH_!']F?X(:Y\-7U/7?"?[$>
MF?&;X8VGPTU#X0?#SXD^+?B;XN^-VMWL-TVAIJWB7Q7I/B2Z\ Z7XHLOAIX;
M\-#Q-XI.E6)O+Z#]7?BZ?B)J_P ,M9'P8\9>#?"/B[4DT8Z9XY\5^&[_ ,>:
M%X?\.W.K:=+XH\0Z=X7T;4]+/B;7[/P8=9O/!5C<ZE'H5YXG&B2:XE]H0OK&
M[ /6:*_-/]A+]HWQO\:OBC^U%X)D^(\OQM^#GPEN_@]#\.?B[XK\!:=\)/BK
MJ'BSQMX;\3ZO\2O 7B_X<6FB^"IIO#O@V#3O ^L>"OB5_P *U\$Z=XM/C3Q'
MX4L1XFN_AUJOB"?]+* "BBB@ HHHH **** "BBB@ HHHH ^9?C-^UA\+_@7\
M9?V7?@9XUM_%<WC3]KGQWXW^'GPKET/1K;4-#MM?\ ?#S5?B9KK^+=1FU2RF
MT73W\.:/=I87%I9:K+<ZB8[9[>"$R74?TR"& 8=" 1]",U^'G_!2YY8_^"C_
M /P0L>"#[3*O[5G[3^R'S4@WY_8[^( /[V0%%VJ2^",OMV+AF!K]HDU#6PB#
M^P?X5_YB]B>P[B/!^HX/44 =%17/_P!HZW_T ?\ RK67_P ;H_M'6_\ H _^
M5:R_^-T =!17/_VCK?\ T ?_ "K67_QNC^T=;_Z /_E6LO\ XW0!T%%<_P#V
MCK?_ $ ?_*M9?_&Z/[1UO_H _P#E6LO_ (W0!T%%<_\ VCK?_0!_\JUE_P#&
MZ/[1UO\ Z /_ )5K+_XW0!T%%<__ &CK?_0!_P#*M9?_ !NC^T=;_P"@#_Y5
MK+_XW0!T%%<__:.M_P#0!_\ *M9?_&Z/[1UO_H _^5:R_P#C= '045S_ /:.
MM_\ 0!_\JUE_\;H_M'6_^@#_ .5:R_\ C= '045S_P#:.M_] '_RK67_ ,;H
M_M'6_P#H _\ E6LO_C= '045S_\ :.M_] '_ ,JUE_\ &Z/[1UO_ * /_E6L
MO_C= '045S_]HZW_ - '_P JUE_\;H_M'6_^@#_Y5K+_ .-T =!7YL_M8_L
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M10 4444 %%%% !1110!G:O\ \@O4O^O"]_\ 26:OY=D^XO\ NK_(5_43J_\
MR"]2_P"O"]_])9J_EV3[B_[J_P A0 ZBBB@ HHHH ^B_V2?^3C?A3_V'=1_]
M1G7J_H,7H/H/Y5_/G^R3_P G&_"G_L.ZC_ZC.O5_08O0?0?RH 6BBB@ HHHH
M **** "BBB@ HHHH _$#_@I/_P I)/\ @A3_ -G6_M0?^L<_$&OV\C_U<?\
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MJ#_UCGX@U^WD?^KC_P!Q?_010!D^1XA_Z"FC?^"*^_\ FCH\CQ#_ -!31O\
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M6KS:2+V34AI4VJ7\NF#497>274!ISW#60OI)))))+OR/M#RR22-(9)'9IO\
MA)O$HEUB<>(_$ F\0JR^()AK>J"77E?<'76Y!=A]7#!W5O[1:YW*[HV5D<,
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M^PC_ -!C7?\ P9'_ .,4 ;V1ZC\Q1D>H_,5@_P!A'_H,:[_X,C_\8H_L(_\
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M0YK<\;_4M%?+G_#9/[/_ /T-&M_^$;XB_P#D2C_ALG]G_P#Z&C6__"-\1?\
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MR%?P6_\ !*O_ )2$?LO?]CMX@_\ 5;>.:_O23[B_[J_R%?PC]*;_ )+?(O\
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MP2IVD'##JIP3AAW!P1W% "U^BW_!.#_DHWQ'_P"Q)TG_ -2!J_.C<NXKN7<
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M=TV"[A]^_P""==C8W_Q#^(L=]96MY''X+TITCN[>*Y2-SK[ LJS(X5B/E+
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MR :_O+L=.T^P5OL-A9V7FK'YOV2U@MO,V [/,\E$W[=S;=V=NYL8R<_P<_\
M!*O_ )2$?LO?]CMX@_\ 5;>.:_O23[B_[J_R%?PC]*;_ )+?(O\ LE</_P"K
M?-S^V?HS?\D=G?\ V4^)_P#53DXZBBBOYE/Z/"BBB@ HHHH **** "BBB@#\
M0/\ @I/_ ,I)/^"%/_9UO[4'_K'/Q!K]O(_]7'_N+_Z"*_$/_@I/_P I)/\
M@A3_ -G6_M0?^L<_$&OV[3/E+M(#>6-I/0':,$^V>M #\C(&>3T_GC/3..<9
MSC)Q@&ER,@9&3T'<XZX^E?SX?%KXN?&GX/\ _!3CPIJG[1/CKX_^!?A/JEC\
M0[+X3_$CX0:CX(\8_LUVOPR\0?&G]D#P7X0\*_%_X7/::AXI\&7DWC'6_$OP
MV^+OQ2\5^'-6ETG7_'GA'Q/X(^(?@KPSIFH0^$L'X\_\%%/#GC#]MG]BN\\$
M?M<>"OA[\'M#_;X\9?LR^)_AAI?QE\"Z-+\5-!\.?LV_M/R?$WXC?&3PW+KB
M:S9^ ]/^/?@GP%\,_@WI^NVFFV6H^(/#VJ^-X9M5M_B-\.?* /Z+-RYQD9SC
MKWQG'UQSCKCG&*4D#D\?_7. /J3P!W/%?SQ^,_BS^T-\&O"GCOXG^.[/]J^]
M_;/\-?MW:'I+Z&)?B9;_ +)VO?LL>/OVP_#_ ,,_AYH/@B*=X?V;-2\!:Y^R
MUXO\/VMA';>;^T5_PT#+>W.HJGB2UN%C_1K]M?QAXQ?Q_P#L0? 71/$7C#P-
MX/\ VF/VG]:\ _%3QCX)UFY\*^)1X&^''[.GQU^/J>!]'\8:;<66O^$[CXE^
M)?A/X>\-:IKOA:^T_P 2CP@WBO3=!U32-1U*'5+, _0$$'H<]OQ'4'T([CM2
MU^<O[&/C'QGI7[0/[='[,^I>(/&7C3X;_L^_$?X,ZE\(O$WCWQ#J?C/Q-H?A
MWXW_  1T#XB:]\*KWQMKUYJ'B;Q;:> _%2:EK/AW4?%NH:IXET[PGX\T#PY=
MZOJ6GZ)I,X_1J@#\Y?\ @I!_R3OX=_\ 8^7/_J,:M7Y%6=Y>:==07VGWEWI]
M]:2K/:7UA<SV=[:3I]R>UN[:2*XMYD))26&1'7)PV"<_7G_!=OXG>./A?\$/
M@=J?@;6O[$O=3^,=_IU]-_9^FZAY]FGP^\27:P[-2M+N./%Q#')OB5)#MVEB
MA*G^8K_AKC]H+_H??_+<\+?_ "FK]HX-\"^+>.,APW$64YAP]0P6*JXFC3I9
MABLQI8F,L+7G0J.<,/E6*I).<&X.-:3<6G)1=TOQ_B_QJX6X+SS$9!FF SZO
MC,-2PU6I5P&%R^KAG'%4:=>FH3Q&:86KS1A42FI48I23LY))O][KCXI_$:Y\
M0:EXID\:>(1KNL110:C?1ZA(OVFUMY/-MK-K1M]BMG:39GL[5+8065P\EQ:I
M#/+)(^=8^/O'&F?VP=/\7^)+-O$-Q-=ZY)!K%ZLNK7EQ%-!<7M[.TK3O?3V\
M\]O-?))'>2VTTML\[6[F.OPB_P"&N/V@O^A]_P#+<\+?_*:C_AKC]H+_ *'W
M_P MSPM_\IJ^J_XE=\0/^AMPC_X7YQ_\XO/\^S/F/^)E>!O^A7Q5T_Y@<I\O
M^IYYO\>VO[O:?X^\;Z3-;SZ9XKUVQEM=%T_PY ;>_=4CT'29))M+TCR&#6SV
M.FS2RS:?#+#)]BED>6V:*1BU<U>WMYJ-W=:AJ%W<W]_>SRW5[>WL\MU>7=U.
MYDGN;JYG>2:>>:1F>265W=V))8U^(W_#7'[07_0^_P#EN>%O_E-1_P -<?M!
M?]#[_P"6YX6_^4U'_$KOB!_T-N$?_"_./_G%Y_GV8?\ $RO W_0KXJZ?\P.4
M^7_4\\W^/;7^T+_@G-_R2/QC_P!E(O?_ %%_#->[_M=?\FW_ !9_[%I/_3MI
ME?F]_P $+_B1XS^)W[,_Q1UKQOK']M:E8_';5=+M;G[#I]AY5C'\/O -VD'E
M:=:VD+XN+NXD\QXVD/F;2Y555?TA_:Z_Y-O^+/\ V+2?^G;3*_"N)N'\9PKG
MN9\/9A4PU;&Y5B/JV(J8.=6IAIS]G"I>C.M1P]64>6HE>=&F[I^[:S?[9PYG
MV$XGR3+L^P%/$TL)F=!8BA3Q<*5/$PASRA:K"C6Q%*,KP;M"M45K:WNE_/NW
M4_4_SI*5NI^I_G25X1[84444 %?HM_P3@_Y*-\1_^Q)TG_U(&K\Z:_1;_@G!
M_P E&^(__8DZ3_ZD#4 ?K%XL_P"17\1_]@'6?_3;=5_F\_#/PG8>._''@WP9
MJ?B73_!UAXFU6TTFZ\3ZH;,66CI/;2R1S/\ VEJ6C:8;F[GBBTS35U36='TI
M]5OK%-4U?2].:ZO[?_2&\6?\BOXC_P"P#K/_ *;;JO\ -@\+Z_<^%]7TK7K3
M3O#VL3:>LA.D>+= L?%'AC5;>\T^XTZ]TW7O#^I*;35=+OK*\N;:YMF>"X19
M!<V%Y8:C!:7UM_8/T6(UI8'Q"CAI^SQ$H9%'#U+1?LZ\J.>JE.TXS@^2HXRM
M.$X.WO0E&\7_ "7])F5&./X"EB(>TP\99[*O33DN>BJN0.K"\)0FN:"E&\)P
MDK^[.+M)?H-KO[&?PSL_VOO#G[/=]X]^*/PT\.>*FT"'2X_B%\-5G\>:IJOB
M"2.RTW2_!%_HVHWG@/QEHEW/YFJW?Q GU71M T&QM-;T5[+6O$&EV5GJ_P ]
M_LV? '2_C3>ZG<^,/%=SX'\,II?B_3O#5[8VMA>ZKXO^).@_#+Q5\3K7PKI%
MKJ<T,#:3I'A[PI=ZWX]UL++_ ,(_I-YH5I$AU;Q/HZ'O]4_;=\2ZC\9_!WQ?
M_P"%3_#$Q_#"[?4_A/X$FG\>6_A?P'K5[?VFKZ[KQFT7Q=I&M>*]6\0:K:QS
MZE_PDVH7NEI:P6-G8Z79_8S/<</\.?VN_B[\'M=MKKX57\7@CP9IS^*[C2/A
M1;:AKNO^ M(O_&?A"X\(Z]JEE_PE>IZUXI_M&[66WUY[B7Q&_FZUIFE"Y2XT
MJPBTROZ$H8?CE937P_M;9G/(\!3HU\5B<OC0H9E0>9/%.E4P^%Q59XC%4ZF5
MPJK%4<3AZ=2EC(TL=45.EB\9^$5J_!3S2A7]E_PFPSG'3JT,+A\=*O6RZM'+
MEA55A7Q&&H*AAJD,RG3^K5L-B)PGA75P4/:5<+A-+Q)^SYHVD_!#P[\1-%M?
M&?B3Q'J7P?\ AY\7/$$^F>/O@M=^'_"^C^-)[*.^OM1^&]E<W'QCA\*:'/?V
M>@S^*[FW@TZ+Q!>6\EZT&EY>1O[,7P"\'?'W5?\ A%;[5OB?:^)[C5;B&_OO
M!WAGPG?>#_AEX0ATA[P?$GX@W?B/7K#6O$FD+J$-]#=^$/ =@OB:VTK1[[4;
M>\U'4K[1]"N//U^.NIV_A'6M!TWX?_#'1O%'BGP2WPY\8_%/1]!U:P\=>*_!
MMS>6-YK-GJEK%KX\#6VO>*AIEA8^,O&FD>#M.\4^)]-MWM;_ %$2WNI75[M^
M%?VB8_!GB>U\7Z!\#?@9::]X:^(,_P 3/AA>KH7C1)_A7XD:32[FPM] NK?Q
MU;WWBOPYH&IZ-I^M>'?#WQ+NO&5II&JI=20RM8ZEJ.G77H5J'%#RW,L/2G-8
M^I7Q,\!C*<L-^Z_=T50]K2Q&*J0J45B)2G3=.6%_V>E.=;!1J)8#&\%*MPW_
M &CEU>I",L#3H8>&.PE2.(7M'SS=9TZU##4YPK*A%1FJD<2EB*D84<7*#>.P
M?N__  2KQ_P\(_9>PRL/^$V\08=0X5Q_PK?QSAT$BI(J2##HLB)*JL!(B2!E
M']Z2?<7_ '5_D*_@T_X);75Q??\ !1/]FB^O)FN+R^^(/BJ^O+APBO<7E[\/
MO'MW=W#K&J1J\]S-+,ZQQQQJSD1HB!5']Y:?<7_=7^0K^0_I2W_UVR&^_P#J
MIA[V=U?^ULWOJTF]>ME?>RV/ZL^C/;_4_/+:K_6?$V;5O^93D_2\K>G,_5CJ
M***_F8_HX**** "BBB@ HHHH **** /PZ_X*7SQVW_!1[_@A9/*6$:?M6_M/
M;BD4LS?-^QW\0$&(X(Y96RS ?*C8'S-A06'[,R>,_#5J$AN]22VD:)6$=U:W
M]M(T9&T.([BSCD,;$, VW:2&&<J0/QL_X*3_ /*23_@A3_V=;^U!_P"L<_$&
MM?\ X*&@'XU^&RP5C_PK/1.64,?^1@\4'J03UR?J30!]*>)/V*_V._%7[0&G
M_M!:K;:@=4MTU[4]5^'%KXL\9V?P?\3^/M;\>?"GXC+\3O$?PTM-3A\):GXR
ML_%7P@\+:W/)-I)T?Q%XA@MO%WBO2==\6:-H6MZ;[G\2OA;^SE\6_%?P:\:^
M-]-TK4?$7P&^*$WQA^'%];/?:9_9OCN?X>>//A?)J6IPV$$$7B"U/A#XD>*K
M,:5K2WFGK>W5EJRP#4M*TZXM_P !]J_W$_[X7_"C:O\ <3_OA?\ "@#]PK;]
MG+]F*#XBO\1I;WQ;J,P^(=Q\7[/P-K7Q1^*&M_"72OBY<W5U?2_$S1_A5JVO
M7G@C3/%<>HW<^M6,EIH\>D:1XH<^,M&TC3O&'_$]J75_V>?V:?$/A[X@^'/$
M>I>,?$-M\0/C>/VBEU/7/BE\3]4\2?#SXM6UKH%MHWB/X,>)KK77USX-6GAL
M^';2;P[X;^'-]X?\,Z4^H>)(H=(-GXK\2VNJ?AQM7^XG_?"_X4;5_N)_WPO^
M% ']"'P>\'?!+X&Z%K.B>!+VY$WBGQ)>>-?&WB;Q-X@\2^,?&OCSQKJ.GZ7I
M-]XL\:^,/$T^IZ]XBUN72-#T31+6:]O&M='\.Z)HGAK0K32_#VBZ5I=G[1'X
MHT:9%EAFN9XI &CE@TO5IHI%/1HY8[!HW4]F1B#V-?S$*JY'R)U'\"^OTK^A
MO]EK_DWGX0>G_"$:1P. /EDZ#H* /Q<_X.#=4L[_ . ?P"2V:<LGQNU%V$UE
M?VHV_P#"M_%"G#7=K C$$K\J,S8.<85L?RCU_61_P<-$_P#"@?V?^?\ FN&H
M_P#JMO%/^)_,U_)O7^C'T=O^36Y1_P!AV<_^K&O;\#_/_P ?O^3EYM_V!Y3_
M .JW#!10/FQM^8$9!7D$>H(SD>XXI0K'HI/;@$\^E?N!^+B44 $\ 9/H** /
MZW?^#?\ U6SL/V5_BU%<-<!W_:"U>0"&PU"Z&T_#CX=*"7M+2>-22K?(SAP!
MDJ%9"WZJ_M8ZYI]U^SM\5;>%KOS)?#BJ@DTS5($)_M733\TL]E%"@XZO(HSC
MFOR\_P"#?+_DU/XN?]G"ZQ_ZK;X<5^K?[7()_9P^+(4$D^&EX4$D_P#$UTWH
M!R>,U_F)XR_\G/XR_P"QK_[JX8_TA\(_^3;\)6_Z%B^_ZQ7_ . ?S[-U/U/\
MZ2I&CER?W4O4_P#+*3U_W:3RY?\ GE+_ -^I/_B:_,;KNOO1^D6?9_U_PZ^\
M913_ "Y?^>4O_?J3_P")H\N7_GE+_P!^I/\ XFBZ[K[T%GV?]?\ #K[QE?H5
M_P $[+^WL/B%\1)+DS!9/!>E(ODVMW=,6&O,QREI!.Z#&,,ZJI)P#G-?GQY<
MO_/*7_OU)_\ $U^BO_!.%77XB_$?<CJ#X)TG[RLN?^)^W3<!GBBZ[K[Q6?;^
MOZ:^\_4/Q5XCTQO#'B(!KT$Z#K YTC60.=-NNI.G8'^>]?YL,?\ JHO^N47_
M *+6O]+OQ9_R*_B/_L ZS_Z;;JO\T2/_ %47_7*+_P!%K7]D_1/_ (7'7_7S
MAS_TG.S^1?I1?Q^"?^O?$?\ Z5D7]=!]%%%?V ?RB%%%% 'W]_P2SGCMO^"@
M?[,,\I<1Q^-=?+>7%+,_/PX\<* L4$<LKDLP&$C8@98X4$C^\G3]2M=05Q;&
M<^2L>_SK.]M/O@[2GVRVM_,^Z<^7NV\;]N5S_!Y_P2K_ .4A'[+W_8[>(/\
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MOYY$!&W)+-QN8@ LW&YB!P"QRV!P,X' K^AO]EK_ )-Y^$/_ &)&D?\ H,E
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MA[HWBGXJ?!+2M;\7VVJOXJTK5?',FD7/PLNM%U/QQI^IKXNBO=)6\U72;5O
M6M6"Z]X+LO$=I>^+XE\%:7#J&JWF@3Z__>6*I<-8">&HXO!Y91JXN-=X>#P-
M&4JBPM'V]=I0H2M&G32O*5HN<Z=*+=6K3A/^'\+5XAQM.O5PN+S*K3PKH*O-
M8ZM&--XFJJ-!-SKQO*I4VC&[4(3J22ITJDX^!?\ "QOB'_T/WCC_ ,+#Q'_\
MLZ/^%C?$/_H?O''_ (6'B/\ ^6=>LW/[/#V'B/P/HM[\5? (TKXJ>$]'\7?"
MKQ3I>@_%?Q#9?$"WUKQ?JW@2WT73/#>C_#V?QSHWB2+Q5H>IZ3)IGB7PUI45
MS)#!/IEYJ-K>VD\GEWBWP%J'AKXCZY\,M(U/2OB#K.D>+9?!-CJ'@0:EJ>E^
M*O$$>H1Z,EKX6%]8:=J6I?:=;D;1[$O80&^O8R;436TMO<3+#T^&L5-TZ.!P
M#DJ,Z[<\K5&FJ=*HJ-:]6MA:=)5*%:]'$47/VU"K&K3K4X3IU8QJO+B+#052
MMC<=&+K0H)0S)U9NI5I^VH\M.EB9U'3K4>6K0K*+I5J4J=2E.<*E.4J__"QO
MB'_T/WCC_P +#Q'_ /+.OWS_ .#?WQ3XGU[X^?'^WUWQ+XAUNW@^#WA>:"#6
M-<U35(8)F\=2(TL,5_=W$<4K(=C2(JN4^0MMXK\,OC/\'?$7P-\8V?@GQ1JO
MAG6M2O?!O@_QK'?>$=3EUG1!8>,=,;4;6QCU.2TLX[R^TR2*YT[4YK)+C3'O
M;:5],O\ 4+%X+N7]K_\ @WG_ .3@OVA/^R->%O\ U/'K\Z\7<+DU;PHXHS#+
M\)@'3JY;@JV&Q-#"T(-TZF9Y>XSA.-.,X\T'Y.S:>[/T'PIQ&;T?%'AG X_%
M8Y3I9CBZ.(PU?$UIJ,Z>78WFA4A*I*+Y916CNKI-;(_JQ\6?\BOXC_[ .L_^
MFVZK_-$C_P!5%_URB_\ 1:U_I=^+/^17\1_]@'6?_3;=5_FB1_ZJ+_KE%_Z+
M6OR;Z)_\+CK_ *^<.?\ I.=GZ?\ 2B_C\$_]>^(__2LA'T445_8!_*(4444
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MJV^'-?;W_!5O_E'G^U-_V3J+_P!2GPY7Y$?\$_\ PE_P68_82^%7BWX8P?\
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M^!- GGT3P/XL\1_#JU\*>(_&'@S2OL^G^%/%.JZQH%KI^F1:>NFVGT;0  ,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=%4=.@ Z=.W;M2X&<X&>N<#.<8SGZ<?3BEHH 3:N0=JY'0X&1UZ'MU/YFE
MX P/0444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
7 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>biib-2015930_plegchart.jpg
<TEXT>
begin 644 biib-2015930_plegchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %- 3T# 2(  A$! Q$!_\0
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M++7]J'P-^S1I7P;TGPG_ ,)G\7=&\-?%K]C'X,_'74_C;I>H3^.-+L?%%G\
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MMKX6\ O+=&6&Z$,7GI)Y:8 /P*\1?\%)_P!J'P1HGAOQ)J"_"#7M/^+/B/\
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MBLTT^.TDM(X%MY+6.QC2S2W>-H4M$2V5! JQ@ _G)M/BIX5U[1_&GC?]FO\
M:'\37O['NM^(/V1/ OQ,U?5/VI-9\<_$;QC\/M2_:'L;;X_?M?R7+^-O$?Q%
M^"?@+Q1X!U'2OASK?Q":X^'.H^-?"VM>+/BO)I7@SPSX1^'WC;6Z_P"UA\5Q
MX1_8._;/U#PA^UAXJ\ _!_X=?M$KH?[)WB:Q^-UGINI?%?P=IWAW]G;5_%G@
MCP_\6_%%U+X^\8_#GX<_&;6_C1X8M+/P5XUG?4=!\/MX U+7KWP)H,FAWO\
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M3_@A3_V=;^U!_P"L<_$&OV\C_P!7'_N+_P"@B@!]%%% !1110 4444 %%%%
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M_9?\^NM_^$[KW_RNH_M^R_Y]=;_\)W7O_E=6W10!B?V_9?\ /KK?_A.Z]_\
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MOV7_ #ZZW_X3NO?_ "NH_M^R_P"?76__  G=>_\ E=6W10!B?V_9?\^NM_\
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MZ5_X'VW_ ,<K;HH Q/\ A)?#W_0;TK_P/MO_ (Y1_P )+X>_Z#>E?^!]M_\
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M?=G5_P#">>.O^AW\9_\ A6>(?_EE7[U_\$!?&6JW?QZ^/J^)_%>JWEJGP?\
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MX22>>1L#=)+([GNQH ^B?,C_ .>B?]]+_C1YD?\ ST3_ +Z7_&LK_A'M _Z
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M=OX>M+/5-2^'_A?X@_$GQKH?A/Q'XM?5_%.K65F#K^M3ZM'=V5B ?JG1110
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M4I1Y:34^:5TD]EK<_DUHK^I#_B%X_8._Z+__ ,%#O_$N]8_^8RD;_@UX_8.
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M7\(>)/%5YJ?P^\%+J6I7NFZ+_9UQ^=O_ !#_ 'P._P"C]/\ @KE_XL)^)O\
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MCSG*:=6%&IFF59AE].M4C*4*4\;A*V'A4G&/O2A"512DH^\TFEJ?QYO]]O\
M>;^9IM?U(?\ $+Q^P<>OQ_\ ^"AW_B7>L?\ S&4?\0O'[!W_ $7_ /X*'?\
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M<9&5E93_ ,%'_BH0RL"K C^Q^002"/0UP'_$/[\#AT_;S_X*Y?\ BPGXF_\
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MW9Q:9X$^'/B6*[\8?$?4=&TG1UU.>#18[1=4N[^VT+2I)]1BO#;?=(.?U]Z
M"BBO!/CE\?= ^ $WPRU3QSI-];_#WQW\0]-^&_B3XDB[L;?PS\+-6\465[#X
M$UGQX]T\4EAX4\6^-(=)^',>OQ.UKHOBWQ;X5&L+;Z1J%WJ>G 'O=9^JZ1I6
MNZ==Z1K>FZ?K&E7\)M[[3-4LK;4=/O(&*LT-W97D4UM<Q%E5C'-$Z$JI*Y Q
M^:^K_M^_$5OB?^S7X)\'?LL:_P"(O#'[5TGC.[^$WC76?BWX(\%SS^&? VDW
MGB_4?$_B+P7JVDW?B'0[/6OA[%I_C+POIQ:ZU>]MM:T_2M9L_#^IK>16VO\
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M&/QB\86WB2^A@\5Z+/XKLO%%Q\4X+*XT2WN/#<^E0:%-+%K%W)J:#3_TEHH
M^2?@]^SYXYT3XP>)_P!H?XX^/O"7C_XM:Y\.]#^$F@6_P[\!:K\._ '@7X?Z
M3XFU7QGJEEH^E^(O'7Q&\3ZQX@\9^*M1M-4\4Z[J_B<60LO#GA71M#T#25TS
M5-0U_G?V[OV<OBU^U5\&E^#?PU^)/PY^&6F:QXH\$>)?%NL^._AOXJ^(][<'
MX;_$CP+\4/"]GX=M?#OQ/^&]OI@NM<\%#3M>GU-M9:;2=18:6FG7=N9Y_MBB
M@#\__BM^RA\8OC9I.O\ AGQU\6?A':>&OBSX0^'GACXW+X:_9ZA@\92-X&UN
MZUJZD^$7CW5/B)>ZIX6M=5ENY9/#Y^)%E\5]5^&>LO<>)_ VJV>ISPQ6?W^J
M[1@>K-^+,6/X9)QWQU)/-+10 5\U_MB?L\P?M8_LO?'?]FZXU^T\*Q?&KX9^
M)_AXWB2^\/Q>*[70F\167V6/5IO#L]_I<6L"QD"7"V+:C9&5T0I=0.JN/I2B
M@#YD^)W[.Q^(?[0G[+7QRB\51Z+#^S;J'QEOCX6&A_;/^$N3XL?#3_A7L<$>
MK+J=HF@C0#C5-W]FZH-14"Q5+'_CYKY1_9D_8"^)7PF\+_LL?#;XN?&SP-\1
MOAC^QMJ&H^(OA%H'@CX0:MX"USQ-XS_X13QAX&\+^+/BCXB\1_$_XAQZB?!_
MAKX@^,Y=.T#P=HWA+3[[Q1J6F>(-1N9(- L='E_4FB@#@_B5I_Q#U+P7K%A\
M*M9\$^'_ !O<):1:1JGQ#\,^(/&'A"VA-[;_ -IIJGA[POXP\!ZW?&?2OMEO
M9&S\4Z9]FOI+:ZG^UV\$EG/^7WA[_@EYK^L_L@?"#]FCXN_M Z]_PE'[/7P.
M\3?L^_"3XF? %?'?P8TZ7P5X@^%?ACX:/J_Q'\ :E\1OB!8>,/%$\7AZ:>_N
MK75]$M4T76-8\-:)%HUAK>O/JGZ^T4 >)?LV_!S_ (9[^ ?P>^!Y\7:]X\/P
MI^'7A+P&WC#Q+<37&L^(6\,Z+9Z4^I7)N)[J6WBG:V/V#3VNKK^R]-6STM+F
MY2S6>3VVBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ I#Q^8_4@4M(>GXK_ #% '\7.M_\ !;[]O6PUO7+"
MW\0?",6]AKFMV%L'^%,#.+:QU:\L[<.W_"2?.XA@0.^!O;+8&<#[=_X)K_\
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M!ETSP';_ !5^*7QJ^(5I#XD>WAUK7K"^^(ESX9LM0CAB\*^'- B.ISZQ]=T
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ML+QC=?M9W/[1G@_Q;IVE7.HB'Q;X9^/MA#/H&IWO@"^\/W7A61 @!]9_!_\
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H0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>biib-2015930_rdchart.jpg
<TEXT>
begin 644 biib-2015930_rdchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" +: 3T# 2(  A$! Q$!_\0
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M9H/P]7Q7X<E\7:YJ6F/X=T"SU_09-6UFSN]9TZQG^H/VFO@?I?[3'[/'QO\
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MC-;S^(_BK<>#=0\7_%2S\*>./"FAP^&M \:2R>'-2\)VI\/?$;3/B$XM=5M
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MM_<Z1K'PNB\*:GX5"0:)K_@[Q5XBM);C3=5_LK5M/YO5O^".7PE\1>*O$OQ
M\6^.8O'_ (^^(/B[XD:[\0/$7Q-^"/P0^)=M?Z1\4[[PKKFO:7X1\,^-_"FM
M^&O!&K>'M>\/ZE)X&\1VFFZHVG:%XGU30/%>C^-H[/1KZP /J7QC^WI\+=*^
M.7P2^!?@:VU#X@:W\4/VC?$'[.WB;Q!:Z5XQT?P;X+\0>%_@1\8?C1XC_L?Q
MU=^#IO 'Q"\2>&9_A?IWA/Q5X+\.>+?[5\-7GBE[C59H+WP[JFCU]T Y /J
M?S&:_/S2OV!])T/XI?#OQ;I'Q<\9V/PU^$_[3'Q _:M\!?!F/P_X,_L#2/B9
M\6O!'QH\)?$>TN/%"Z7'XJO_  EJ6I?'/QMXP\/:$]U$WA?6]3NK.*\U+08]
M#TOP]^@8& !Z #\J %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7\.O@EXSDU+Q#?:S\.="\.?"7]H+4]=M=*^)'@/XA:_X%U_PGKGCR/P7X/\
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MP/\ $SXI>-OC#_PH"?Q+\6O#?@J3XX^,_"^D?$O6(/#.A_&K4O#_ (>_9N\
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ML7RUVMN6@&Q7&\ \D#O7T+7"?$S_ )$7Q)_UX#_TJMJ /PA;]FKXH L3!X;
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M_8@^#GB3P5XV\;WOB^QT*>SOO"NG6MFL%Y;ZLRW,>LM+(6B>U40@Q$8D&2Q
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M?$.PU2'P9X@DGUM[J);(%X#IUC")5^T0#:98D$B<D'*$'B@#\[/C5\#OA/\
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M3=8&F:@6\0R$"QO"1_96F\@6TI(.8^A'^%?S*)]Q?]U?Y"@!2 >H!^HS_.C
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M6_M/;))83<1KC]COX@%MT*S0%]R;E&)4VL0_S;=K?M+':^(?+3_B<Z7]Q?\
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MG=N^4 O4444 %%%% !1110 4444 %%%% 'X@?\%)_P#E))_P0I_[.M_:@_\
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MR?\ ]-]Y7VQ7Q/\ #7_D>_#?_7Y/_P"F^\K[8H **** "BBB@ HHHH ****
M"BBB@#\._P#@I=,MO_P4?_X(63.DTBI^U;^T^2EO!+<S'/['?Q 4;(8$>5\$
M@MM4[4#.V%5B/VFCU^T"(/L>N<(H_P"1?UKT'_3C7XO?\%)_^4DG_!"G_LZW
M]J#_ -8Y^(-?MY'_ *N/_<7_ -!% &-_;]I_SYZY_P"$_K7_ ,@T?V_:?\^>
MN?\ A/ZU_P#(-;E% &'_ &_:?\^>N?\ A/ZU_P#(-']OVG_/GKG_ (3^M?\
MR#6Y10!A_P!OVG_/GKG_ (3^M?\ R#1_;]I_SYZY_P"$_K7_ ,@UN44 8?\
M;]I_SYZY_P"$_K7_ ,@T?V_:?\^>N?\ A/ZU_P#(-;E% &'_ &_:?\^>N?\
MA/ZU_P#(-']OVG_/GKG_ (3^M?\ R#6Y10!A_P!OVG_/GKG_ (3^M?\ R#1_
M;]I_SYZY_P"$_K7_ ,@UN44 8?\ ;]I_SYZY_P"$_K7_ ,@UQ7Q$UBWN?!?B
M"%+75D:2R"A[C1=4MH5_TF!LR3W%I'#&,*?F=U&<#.2 ?4:X3XF?\B+XD_Z\
M!_Z56U 'Q6W4_4_SI*5NI^I_G24 %%%% !7L_P %KV.RUG67EBO)0^EVZ@6=
MC=WS@B]+9=+2&9XU('#N%4G@$GBO&*]R^!?_ "'-<_[!-M_Z7T >^7&O6K6\
MZBSUS)AE _XI_61R48=38@#ZD@>I%?""]!]!_*OT*NO^/:X_ZX3?^BVK\]5Z
M#Z#^5 "T444 %%%% '9?#V9;?QKX>G=)G6.[G8I;P2W,S V-V/W<$"232')!
M(1&(4%B,*2/M"RU"*^\SRH;Z'RMN[[;I][8[M^['E_;((?-QM.[R]VS*[L;A
MGXU^&O\ R/?AO_K\G_\ 3?>5]L4 %%%% !1110 4444 %13O)'#+)%$9Y4CD
M>. .D9F=49DB$DA$:&1@$#N0BEMS$*":EI& ((.<$$''7&.V.<^E 'PWXI_:
M"^(WA/QCX>T/Q%X\_8[\(ZUXI\:6'@#P[\(_$WQ6\2Q>.-:\9:EH^G^)-.\'
MKXL@TZ*WL_%NH>']5TK4X-'A^&>K*T>MZ$;2YU&WUK2;B_\ M72;B^N],T^Z
MU*P72]1N+*VFOM-6\BU!;"\DA1[FS6_@2.&\6VF+PK=11QQW"H)5CC#[%_$/
MQC\&=4^(7[7'QB;P9\//B=K_ ((A^,_@6P\;WNN_%/X&_#FPT#6=1\0?LQ_%
MWXHZCX,\.ZIX5UCXL^,/!_CP_ OX)V4NK>(M9LM1L[7P5XET'X/C0],U:TUV
M/]RU&!CW)/N222?;/7';I0!^(/\ P4G_ .4DG_!"G_LZW]J#_P!8Y^(-?MY'
M_JX_]Q?_ $$5^(?_  4G_P"4DG_!"G_LZW]J#]/V.?B#FOV\C!$: C!"*"#U
M!P.#0 ^BBB@ HHHH **** "BBB@ HHHH **** "N$^)G_(B^)/\ KP'_ *56
MU=W7"?$S_D1?$G_7@/\ TJMJ /BMNI^I_G24K=3]3_.DH **** "O<O@7_R'
M-<_[!-M_Z7UX;7N7P+_Y#FN?]@FV_P#2Z@#Z7NO^/:X_ZX3?^BVK\]5Z#Z#^
M5?H5<\VUP!U\B7_T6U?GJO0?0?RH 6BBB@ HHHH [CX:_P#(]^&_^OR?_P!-
M]Y7VQ7Q/\-?^1[\-_P#7Y/\ II]X3^0K[8H **** "BBB@ HHHH *1NAP 3@
M\'H>.AZ\'Z4M8WB.V^V>']<M#:I?"YT?5+<V4EI;7Z78GL+B+[*]C>7=A:7B
M7&_R6M;F^L[>Y5S#/=6T4CS( ?B'\7O@SJ&I?MF>(_B!+^SE#KWQ<'Q\^#,G
MPRBM_P!B'X.^,/@UXX^#\"_#X^*/BI\4/VM-5^$6K>-_#'Q*\'P+X[U#3KR?
MXU>"/$7@K5?"/A31_"'PT\<V5Y%<>-/W47.!GKS[=^I [GJ?<FOYS_!GP(^*
MVJ_&CX<^,/&G[)%M_:EAXS^&IN_%^K?\$^?V--!U32-+\*W?A[2](NQXKT?_
M (*'^)_$/AV'PSX?TFPMM+UC1O#'B+5- T_3+.XTC0M8N+*UT^Y_HP']3V Z
MD^F?SZGJ<'B@#\._^"E\$5U_P4>_X(603+OBD_:M_:>W*'DC)V_L=_$!U.^)
MXW&&4'AP#C# J2I_:./PQHI1#]ED&44X%]J.!P.!F\/'XU^,7_!2?_E))_P0
MI_[.M_:@_P#6.?B#7[>1_P"KC_W%_P#010!A?\(OHW_/K)_X':C_ /)E'_"+
MZ-_SZR?^!VH__)E=!10!S_\ PB^C?\^LG_@=J/\ \F4?\(OHW_/K)_X':C_\
MF5T%% '/_P#"+Z-_SZR?^!VH_P#R91_PB^C?\^LG_@=J/_R97044 <__ ,(O
MHW_/K)_X':C_ /)E'_"+Z-_SZR?^!VH__)E=!10!S_\ PB^C?\^LG_@=J/\
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M)X \-?%+X@^,([[4_B$GB#X%ZKK.OS)K/AR_U^]\-P:?X-\3:'X$\5^.9/\
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MZN;:RMM4N;F)GDMK">]O+.SBN9X8XVNKNVMP?-GB5OT1_P""3O[3/Q>_:/\
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M0P/[1I'XFV)BZT'&U>EEJ6.@Z9U+./3//K0!T-%8'E>)_P#GZT+_ , M2_\
MEC1Y7B?_ )^M"_\  +4O_EC0!OT5@>5XG_Y^M"_\ M2_^6-'E>)_^?K0O_ +
M4O\ Y8T ;]%8'E>)_P#GZT+_ , M2_\ EC1Y7B?_ )^M"_\  +4O_EC0!OT5
M@>5XG_Y^M"_\ M2_^6-'E>)_^?K0O_ +4O\ Y8T ;]%8'E>)_P#GZT+_ , M
M2_\ EC1Y7B?_ )^M"_\  +4O_EC0!OT5@>5XG_Y^M"_\ M2_^6-'E>)_^?K0
MO_ +4O\ Y8T ;]?"G_!3'_DQ3]I+_L0H_P#U)- K[,\KQ/\ \_6A?^ 6I?\
MRQKX<_X*4)KH_8:_:/-Y<:0]N/ <?F+;VM]'.5_X2/0O]6\M[+$ISCEXV[8'
M4UWY5_R-,M_[#\'_ .I%,\O._P#D39M_V+<=_P"HU4_C#?EFR ?F;@C(ZGL>
M*0,PZ,1WX)'/K2O]]O\ >;^9IM?T MEZ(_EL7)QC)QG.,\9]?K[T%F/5F/U)
MI**8!7[C_P#!"G_DN7QT_P"R3>&O_4V>OPXK]N_^"&JW[?&[XXC3Y+..7_A5
M'AS>;V*XE0K_ ,)H^T(MO/ P;.<EF*_=XP#7@<4?\B#,O^O5/_T_2/I^#/\
MDI\H_P"O]3_U&K']/UU_Q[7'_7";_P!%M7YZKT'T'\J^[+B/Q+Y$^ZYT(KY,
MNX?8]2&1L;/34<]/2OA->@^@_E7X<?TB+1110 4444 =Q\-?^1[\-_\ 7Y/_
M .F^\K[8KXA^'HN#XT\/BU:!+@W4_E-<I)) &^P7>?,2*2*1AMW!=LBX?:2=
MH(/V=8KJB^;_ &C+829V>3]B@N8=OWM_F?:+FXW9^7;LV8PV[=D8 -"BBB@
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MEI/C/P%9V^DZEK6E:]I][!9PQZ,E[Y/KG[4OQN\2>#_"/@76O$OAZ\T'X?\
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MBB@ HHHH **** "BBB@#\0/^"D__ "DD_P""%/\ V=;^U!_ZQS\0:^\?VY?
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MY\0VOC/]CSX56_[5_@OX6:Q^V?X?^,5AX*\3_"SP7I'PO\!:9'^UAX=_:O\
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M\2L+.^'DI*LZL**O#V7.J;G.+]JTJ?)+VG-R69P+-<R=6G1^JX)SJ85XR/\
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M4_@M\5_!T \)7OBGP[XV\=^&_!5]\.O#^N^#/#$O_"UO &H6_P /M!1;B_M
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M^+K/PK<^)M$UOX:Z1\1)]VFZC\2M)GT!M&L]'NM,\37WU8/V?_A"0"/",9!
M(/\ :NM=#T_YB% 'ZF>"=*L?#_A70?#FG^(-8\46_AW2=/T,:]XCU^7Q1XCU
M0Z=:16XOO$/B"X>2ZU?6KM%6XU#4+MOM-Y<2/<2C=(<_GI_P61_Y1D_M@_\
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MBO91K7E"K%*C.480K7=-?NI3G&$:GP2E*,8R;E%/\5*_I>_X-DO^3D_VE_\
MLA?@[_U9$U?,EQ_P3W\!6GA:'QM=?"SQC;>$[FSMM1M]?G\6:M%83V%[<BSM
M+R%7U47DMM<W1\B"9+1HY7!*$H"X_73_ ((E?!+P1\*OC1\:]4^'>AM9ZCJG
MPM\.:?J+ZQXBUN^B>S@\927420I,EZL<@N"2SB-"1M4L5R!\AQY0OP9Q!5A6
MP]6%&C2IU/8U55<*D<=A%*G+E34:D7+WH2:E'2Z5T?:^'>78K"\;\.SK0]FI
M5ZM2*FIP<J<L%BN6I!3A'GA)W491;C*SLW8_I#\:?\BCXH_[%W7?_33>5_E!
M1_ZJ+_KE%_Z+6O\ 5A\8R^)/^$2\3[K/0PO_  CNN9/]H:D2/^)5>= -*&??
M)Z9QSBO\IZ/_ %47_7*+_P!%K7YSX-?P^(?\>5_^DY@?>^/?\3A;_!G7_I65
MCZ***_;3^>@HHHH _2__ ((Z?\I,OV1?^Q_\2_\ JJOB'7^C>GW%_P!U?Y"O
M\XO_ ((]F<?\%+?V2#;+"\X\?>)/+6X>2.$G_A5GQ"R'>*.:1?EW%=L;9<*"
M I+#_1ET]]3=7_M&&PA 6/R?L5Q<S[LAM_F?:;2U* ?+LV[R<MNVX&?YW\7_
M /D?Y=_V)Z7_ *FXT_J/P+_Y)O-?^Q[6_P#5=EIHT445^3G[:%%%% !1110
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MX[?]B:O_ *?=&KW.&/\ DI>'O^QYE/\ ZGX<\;B/_DGL^_[$V:?^H-<_G?\
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M?"?]G/P/8>+?'<GAWXA_&OPYXQ^*6C:)\0/BIXK\9ZKI'B7Q=X!NOB8_P]\
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MI!(9-JE&_(-_^"N7AZ-6>3X$:^B(I=W?XBZ(B(B@EF=V\+A550"69B H!)(
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M^?E0B0RB&$2DDF411B4DKM),FW>25^4G=DK\I)'%?T%_\&\Y _:"_:$R<?\
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MS83#\\ZM".)E&$7YG PD,$@! D$,@#<,!(%<!AV8!@&'KFOZT/V(_P#DTWX
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MYTJV*YZ%.&)C*<IP=2.55ZF'C*"3A&M*$G>45^]7_!L[_P F<?&S_LYK6_\
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M[*?$?^JG)S2HHHK^93^CPHHHH **** "BBB@ HHHH _$#_@I/_RDD_X(4_\
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MDA /N,R1@X+H#Z%E!].A.>O%*&5L[65L<'!!P?0X/%?B]\3?!_[0>B?M5?\
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MI5NY6:U\-:!X:T?PG83Q02Z;H%F\,17Z-95=61@"K JP/0A@0P/U!(/UIU%
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M@WP?<^(+SPKX8\8?:[:0Z]H?AR[\5^);K0].U S6^EW.NZK/9I%)?3L_KE%
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M-0TW1;=]0C^$_P 3[JW:UUBTEOXOZE:\5NOV;OV?KW15\.W?P4^%EQHB^#/
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M-&M+F#2G:S(!]$@@@$$$$ @CD$'D$'TI:.G2B@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BL75/$?A_19(H=8US1]*EG
M1I88M2U2PL))8T8(TD:7=Q"TB*Y"LZ!E#$*2#Q69_P )[X(_Z'#PM_X46B__
M "=6L:%>45*-&K*+VE&G-Q?31I-/4SE6HQ;C*K3BUNI5(IK;=-IK=?>NYUM%
M103P74$-S;317%O<11S03P2)-#-#*H>.6*6-FCDCD1E=)$9D=2&4D$&I:R::
M;35FM&GNGV9HFFKIW3U36S7<*** 01D$$'H1R#^- !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 ?S^?\%@HH9/BO\'C)##(1\.O$@!DBCD(!\5VN0"ZL0#U('&>
M>M?D&UM;;7_T6U^X_P#R[0?W#_TSK^C?]O;]C#XK_M-^./ /B/X?:IX(L+#P
MQX3U?0]13Q5J^KZ=<R7E]K<.I0O:1Z=H&KQR0"",K(\DL+K)A1&RG?7P8?\
M@DQ^TN0P_P"$C^#_ "K ?\51XGZE2!_S)'J:_JS@+C+AC+>$<CP..SS X7%8
M?#UHU\/5JN-2E*6-Q-1*4>5V;A.,O22/YFXVX2XCS#B?.,9@\EQF)PU>M1E1
MKTZ490J*.$PU-N+YM4IQDO6+['[I?LW@#]GGX%  *!\'OAJ J@!0!X.T8
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M_P#!7C]H*]\6:[\8;CX;^'Y/@7H'[*VJ:_>? JTTWQ%/\4Y_V@_#W[=?CO\
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MY+OPGX8\,:/HV@7LNJPK;ZI/?Z796<5IJ%QJ<")#J-Q?1W,]]$JQ74DL:J@
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M>-V5@39K+;<U332::::NFM4T]FGU3"BBFJZ,<*ZL1R0K D#IG .>M QU%!(
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M-$T/1-/M-)T?1]*T^!+6PTS2],L(;>QT_3[&UBBMK.RM((;:V@CCAAB2-%4
M&I1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-W?B_P 4S>'[B%EDT5O$.LKIK6R:A<J^F_[-G[/<FH^+]6?X'_"9M4^(&O\
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MTF61['0AKNKC38+?^T;KS0#\3-0_X*\_$/2M0ALH?@SX4\46WQ*\#_!7XO?
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M?#6MI:^+3K?@NTT'Q2?&%]XP\6>%I-!O++[T_8U_:=\:_'@>._"OQ9\.>%_
M/Q7\"Z?X!\3ZW\/-.LOBAH7B?P_X8^)5EX@.@W.NZ)\2/!NA6FIZ4VO^#_&/
MASP]\1/A[XJ\<^ _'TOA?6KW3+S0;K3[K0XO9K7]EC]FJR\.>%O"%G\ O@[:
M^%_!'B1_&7A#0+?X;^$8M*\->+9;<6=QXFT6S321%8:_>68^QW^KP*M]J%FS
M6=]/<6K>375_#'X)?!SX*66JZ9\'OA5\._A9IVMWB:AK%A\//!GA[P=::G>1
M"9;>>^@T#3[".Z:TBN)H+)9E>.QMG-M9I!!^[H ]0HHHH **** "BBB@ HHH
MH **** "BBB@ HK(U+Q!H6CR10ZMK.DZ7+,C20QZCJ5E8R2QJP5GC2ZGB>1%
M8A2R*5#<$@\5G?\ ";^#/^AM\,_^#_2/_DR@#J**BAFAN88KBWECGMYXTF@G
MAD26&:&50\<L4L99)(Y$8.CHS(ZD,I((-2T %%%-W+MW;EVGHV1MY.!SG')X
M^O% #J*0,I. 03SP"">"0?R((/N".HI: "BBB@ HHHH ***0$$ @@@\@@Y!'
MJ".M "T44F020""1C(R,C/3(ZC/;/6@!:*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH _'W_ (*11QO\0OAJ7CC<CP9K
M6"\:.0/[>AX!920/4#BOSB>"#8W[B#[K?\L8O0_[%?M=^UK^S#X^^._BGPCK
M?A#5?"FGVF@^']0TJ\C\07NJ6L\EQ=ZG'>QO;K8:/J2/"(D*NTDD;A^ A7YJ
M^36_X)V?&PJP'B3X:Y(('_$W\1]Q_P!BM0!^JGP3 'P;^$X   ^&W@@
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M*^!O#/A_Q+XB?4KY-4U)M9UO2M,M=1U ZEJD::IJ7VBX?^T=35=1OOM%ZHG
M!ZO1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>biib-2015930_reserveperchart.jpg
<TEXT>
begin 644 biib-2015930_reserveperchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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M;KXE_$#2FD\&6?A[5?!%N@\3V7A34M=U33/JK]B3XAZAXO\  G_!2_6_B/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'O"_ARU:2[\1ZSIMO"S-\77_ /P3G^)/B?X%? ;X1>-?BM\!-:UWX(?""_\
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MH-0CL?#-_?6JR7=A:ZC#Y-W"PCF!MKR$L5'RN60\J:X__AOK]GO_ *"'B_\
M\([4_P#XJ@#S[P)_P3LT/X>> O@OX5\.?M&_M Z=XO\ @#\*=0_9]^&WQDTV
M/X':7\2[#]GK4M)^'>DS?![57M/@O_PAFLZ1:O\ "_PEK^E>+[KP?_PL;2/%
M&GG5['Q=''=7ME==Y=?L*?#27P)H7POL/&OQ.T;X>_#:T_9W/[/GA6PU+PA-
M:?LV>(OV:;6XL_ _C+X4:AJO@K4]9O?$6MV[V=OXZ7XGZC\1-$\36.GKI;:-
M9Z9JNOVFK2_\-]?L]_\ 00\7_P#A':G_ /%4?\-]?L]_]!#Q?_X1VI__ !5
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M10 C=#]#_*OPQ_X)X_\ *7C_ (+[?]E7_P"">G_K%6DU^YS=#]#_ "K\,?\
M@GC_ ,I>/^"^W_95_P#@GI_ZQ5I- '@OQM_Y+-\6O^RD^-O_ %(]1KS"O3_C
M;_R6;XM?]E)\;?\ J1ZC7F% !1110 4444 ?H=_P3B_Y*AX__P"Q!M/_ %)+
M.OV);H?H?Y5^.W_!.+_DJ'C_ /[$&T_]22SK]B6Z'Z'^5 '\[/[3'_)P/Q@_
M['?4/_2:RKPZO<?VF/\ DX'XP?\ 8[ZA_P"DUE7AU !1110 4444 ?=?_!/7
M_DN6L?\ 9.-?_P#3YX7K]K&Z'Z'^5?BG_P $]?\ DN6L?]DXU_\ ]/GA>OVL
M;H?H?Y4 ?SU?M6?\G%_%O_L9K?\ ]1_1*^?:^@OVK/\ DXOXM_\ 8S6__J/Z
M)7S[0 4444 %%%% 'VQ^P%_R< O_ &(?BO\ ]*M K]OVZ'Z'^5?B!^P%_P G
M +_V(?BO_P!*M K]OVZ'Z'^5 '\_G[8'_)R7Q2_["6A_^HEX?KYKKZ4_; _Y
M.2^*7_82T/\ ]1+P_7S70 4444 %%%% 'V/^P?\ \G%:-_V*7C#_ -)+*OW1
MK\+OV#_^3BM&_P"Q2\8?^DEE7[HT %%%% !1110 4444 (W0_0_RK\,?^">/
M_*7C_@OM_P!E7_X)Z?\ K%6DU^YS=#]#_*OPQ_X)X_\ *7C_ (+[?]E7_P""
M>G_K%6DT >"_&W_DLWQ:_P"RD^-O_4CU&O,*]/\ C;_R6;XM?]E)\;?^I'J-
M>84 %%%% !1110!^AW_!.+_DJ'C_ /[$&T_]22SK]B6Z'Z'^5?CM_P $XO\
MDJ'C_P#[$&T_]22SK]B6Z'Z'^5 '\[/[3'_)P/Q@_P"QWU#_ -)K*O#J]Q_:
M8_Y.!^,'_8[ZA_Z365>'4 %%%% !1110!]U_\$]?^2Y:Q_V3C7__ $^>%Z_:
MQNA^A_E7XI_\$]?^2Y:Q_P!DXU__ -/GA>OVL;H?H?Y4 ?SU?M6?\G%_%O\
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MAS^RTFBKX;/@)O /[4MC^TD?&S:@=<'B5=56R^$GPN_X0\>'A9Z&;-I#K?\
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MA-Q%T7[,OA3Q7\._C[X0\/\ PXT;XMWVB7OB']I!_P!H.S^+?[+W@;X3Z/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %<'\3/B+H'PI\%ZOX[\3IJ,FB:*; 7B:3:)>WY.H
MZC::9;^1;//;+)BYO(C)F9-D0=QN*[3WE?*?[;/_ ";5\0O^NGA3_P!3'0:
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MWIU% &;8Z-I&ESZI<Z;I>G:?<:WJ)U?69[*QM;2;5M5-C9:6=2U.6WACDO\
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(4 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>biib-2015930_reserveschart.jpg
<TEXT>
begin 644 biib-2015930_reserveschart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (- 3T# 2(  A$! Q$!_\0
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M2_B;X*T?1O%'Q&^$LNGPKXPM_AWXWB\1W.G>-+31)['Q>- \-Z%H%CTWB?\
MX)W?"+Q%^U9<_M4D>'AXC\0^,/AE\1/%]IKWPC^%/C?Q)=^.O@_H?ASP]X(U
M;P;\2O&7A?6/&?PVLGTGP;X0B\0Z9X9E\ZXNO#=EK?A;4O!FO7FM:KJ8!TOA
M[_@H]^QYXJ\-KXLT#XJ7U_HUYX8\.^+O#;_\*U^*MM>^/]'\5>.]+^%NB_\
M"K=+N_!,&I?%35;CXFZWHOP[N=!^'EKXDUK3/&NL:3X=U2QL]0U2QCG\]^&/
M_!3?X&^+S\63XUAU_P"'Z_#;XT?&?X<P0IX2^)GBK4SX!^",/@./QA\9OB-H
MVE_#R'5/@MX)T36?'-OH/BG4OB-:Z1H?A74;&XCO]?E$5^=/\ZTO_@D]X%T7
MPW^S/I>G_&;X@1>(/V4?@]-\._A1XJ.@>$9[JW\867QR^%7QT\+_ !)UC2Y;
M233;^XTG6/A=%X4U/PJ$@T37O!_BOQ%:27.FZM_9.K:=S>K?\$<OA-XB\5>)
M?B!XN\=0^/\ Q]\0/%WQ)UWX@>(OB;\$?@C\2K:_TCXJ7OA76]>TOPCX8\;>
M%M:\->"-6\/:]X?U*3P/XCM=-U8Z=H?B?4] \5Z-XVCLM&OK  ^I?&/[>GPM
MTKXX_!+X%^![;4/B!KGQ0_:-U_\ 9V\3>(+72O&.C^#?!?B'PO\  CXP_&CQ
M&-(\<W?@Z;P#\0O$GAF;X7Z=X3\5>"_#GBS^U?#5WXJ:XU6:"]\/:GH]?= .
M0#Z@'\QFOS\TK]@?2=#^*7PZ\6Z1\7/&=C\-/A-^TS\0?VK? 7P9C\/>#/[
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M?PC%X.\1Z+>QQ1ZKI_C6YT?3#Y!^S!_P49_:EOM/_9%^'-_JO@SXH->?!?\
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M-.O?AIJFC7$NA6WB9=<"Z1P'A']OW]H/X%_#GXO>,_!>L>%?VAO$&I?M0?\
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M;XOL-7B^#EEXY^*\_A/]AOXH_M._&R]N/#US^U+?>(-0^#&B:!^SGX33X'?
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MNV\?>._A9\)OB1XI^/'A$67AGQQ=Z-/X>L7\(>*=6U/P1X5MM&F_HDT+X?\
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M)#H/_0:TG_P96/\ \D5I?9[?_GA#_P!^D_\ B:/L]O\ \\(?^_2?_$T 9O\
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MT4 8'V/Q#_T'+3_P2+_\M*/L?B'_ *#EI_X)%_\ EI6_10!@?8_$/_0<M/\
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M9IW^;]COX@*-L4$<LKY9@#L1MHRS84,P_:2/Q%IOEIQJ)^1>?[$UST'KIN:
M.@HK"_X2+3?34?\ P2:Y_P#*VC_A(M-]-1_\$FN?_*V@#=HK"_X2+3?34?\
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M_P $*?\ LZW]J#_UCGX@U^WD?^KC_P!Q?_010 ^BBB@ HHHH **** "BBB@
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M4#_;NNG%C>''VJS&<6TIP?\ B7=\?UK^9-/N+_NK_(4 .HHHH **** /HO\
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MO^O"]_\ 26:OY=D^XO\ NK_(4 .HHHH **** /HO]DG_ ).-^%/_ &'=1_\
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MZE_UX7O_ *2S5_+LGW%_W5_D*_J)U<$Z7J.!G_0+W_TEEK^79/N+_NK_ "%
M#J*** "BBB@#Z+_9)_Y.-^%/_8=U'_U&=>K^@Q>@^@_E7\^?[)/_ "<;\*?^
MP[J/Z>&=>S7]!@Z#Z"@!:*** "BBB@ HHHH *0C((]01^=+5:\N%M+2ZNGCN
M)DM[>>=HK2WFN[J588GE:.WM;<-/<3N$*0P0JTLTI2.,%V4$ _/77OA;H_P]
M_:"\0:SH_P"VMI_P=?XI_$?PW\2-;^!#^%/V6('\7:W<6/AGPG<;-2\8>"[K
MXL:A<>-K#PEINB2ZG;Z[+J0:WBA\.36,]K$!^B8^N>3_ #Z?AT_#FOPHT62/
M5?VG/$?Q$\/_  WUV/2/BS\9/ _C6XC^,O\ P1W_ &FO%/Q"\.7T&F>#?"-V
MJ_M%Z]\5?#]AX9LX[3PS8W>CZ_>^"8/#WPW53>0Z+-INGRP2_NL#D9]SV([G
ML>?\>N!F@#\._P#@I?!%<_\ !1[_ ((603*6CD_:L_:?#*LDL1.W]COX@,,/
M"\<BX90?E<9QALJ2I_:-/#.CE$/D7 RJG U+5<#('K?D_F:_&+_@I/\ \I)/
M^"%/_9UO[4'_ *QS\0:_;R/_ %<?^XO_ *"* ,+_ (1C1_\ GA<?^#+5?_DZ
MC_A&-'_YX7'_ (,M5_\ DZN@HH Y_P#X1C1_^>%Q_P"#+5?_ ).H_P"$8T?_
M )X7'_@RU7_Y.KH** .?_P"$8T?_ )X7'_@RU7_Y.H_X1C1_^>%Q_P"#+5?_
M ).KH** .?\ ^$8T?_GA<?\ @RU7_P"3J/\ A&-'_P">%Q_X,M5_^3JZ"B@#
MG_\ A&-'_P">%Q_X,M5_^3J/^$8T?_GA<?\ @RU7_P"3JZ"B@#G_ /A&-'_Y
MX7'_ (,M5_\ DZC_ (1C1_\ GA<?^#+5?_DZN@HH Y__ (1C1_\ GA<?^#+5
M?_DZOGC]K#0=-L_V=OBM<013++%X<1D+WVH2J#_:NG#F.:[DB8<GAT89QQ7U
M/7SA^UU_R;?\6?\ L6D_].VF4 ?S[MU/U/\ .DI6ZGZG^=)0 4444 %?H3_P
M3MT^UU'XA?$2*Z1W2/P9I3J$N+FW(8Z\RDEK::%F&,8#,R@C(&<U^>U?HM_P
M3@_Y*-\1_P#L2=)_]2!J /U3U7PUI"Z9J+""?(L+P\ZCJI'%M*>1]NZ'&#[5
M_,HG*IC^ZO\ (5_43J__ ""]2_Z\+W_TEFK^:'P':6U[XL\.VU[H-[XHLY+S
M-UX>TV);C4-6@BL[F=[6TM&NK(7\R^4+D:6+RU?5E@;2H[B*2]5P <M[CD=<
M@Y&/7(X_^O2X/H>N/Q]/K7WOXR\%Z'I/B#QOXPUC2O#.FZ5/X:T6WT/6M&^%
MUSK>NZ-K,_B&.Q;4-5^#&IROI=Z^H66F:IHZ>*;62TT&WLTM)+2>^U^26.:K
MI?@7PBOCQ?#(\->&+.QN_BW-IOBZ+5?!>MZQ'JO@34_"_A75M.L_!NK0Z/+:
M>!]2TVPOM:\1>(](FOO"NI^#[S4+*:[OY]'T VR@'PC1D=,\^E?3S^ M!L/@
MWX_GTP^#O$.HVUKX'\4-XK3Q)X7OM6TR/4_%MS:P>&M.@34_[2TUX_#20OK4
M<EE;W/B'Q)J,^DV,5RNBVL<G%?#V?4/#=AX^O]9T#1+BQ\#Z6MW=Z+XH\%:#
MJ%]<>*_$5[;>&?#>DWUQKND3:SI]C;WDT^N7]A#<6C20:+/;QK"]]-+0!N?L
MHV\5U^T/\+;>=2T4NN:@KJLDD3''AK7&&)(7CE4AE!RCJ3C!RI(/] 5AIEGI
MPD-JDB><$\S?<W5QG9NVX^TSS;,;CG9MS_%G Q^ ?[)/_)QOPIYS_P 3W4,D
M@ D_\(SKV20H"C/7"@*.B@# K^@Q>@^@_E0 M%%% !1110 4444 %1S0Q7$4
ML$\:30S1O%-%(H>.6*12DD;HP*LCHS*ZD$,I*D$$BI** /G-_P!F+P$;G9;>
M)_C-IGAPQO$W@C2?CG\6-,\'"*3):UM])M/%D5SI^F8/EKHFEZC8Z&EN6M$T
MU;1W@;W[2],T_1=-L-(TJT@L-,TNSMM/T^QMD$=O:65G"EO;6T$8R$BAAC2-
M%R<*HY)YJ]10!^('_!2?_E))_P $*?\ LZW]J#_UCGX@U^W:$")"?[B_^@C_
M #[=3Q7X?_\ !2YIU_X*/_\ !"QK>*.:8?M6_M/;(Y9C;QMG]COX@!MTRPSE
M-J;F&(GW, GR[MR_9W[>6D_$SQ9\#+#PQX+\7_#WP3KVM?$#P5$G@SQK\5O$
MOPVTG]H'2-.EOM<\3?L\Q>/?!^AMXY\,W_Q+\,Z5JZ6M[X+LM6UF[&C2Z3>:
M/J'AK4=?MW /NVVO+6]M+>^L[B&\L[N"&YM;JTD2ZM[FVN(UF@N+>:W,D<\$
MT3I+#-$SQ2QNLD;LC*QL!@PR,@?[2LI_)@#CWQBOY=?V;O"__#3G[!O[._[+
MVD>!-"\%:[\//BC^R?#\4/@E^TK^T;XMU7X8>.M"UG]C>Q^)_ARV^$&K>"FU
M?7M:\/\ B+PW=Z!\;+?X :)>>$]1T7Q%X<\7IJVB^$_#L4>MZE]&>%?CL_[)
M?PR^+7[(WPV^">C?!OQWX3_:-\+?"7Q5\3OV>O"/QR^,'PE\'V/Q;^"_A_XT
MZU\?/^$>M_!OQ'\<>%?&'ASX9O9>&M(^'7BR37M/E^,=_P##&*ZUF_\  OBN
M[U.Q /W^!!&>0.>H*GCV8 _CCGJ* 01D9_$%3Q[, ?TY[5_,-^Q%^UU_PKO]
MA;Q/X ^$TOQAN+OQ%_P4,_;B^#&A_$_5?AG^TQ\4[WX&?"RZ_:E^.VOV7Q&\
M1W>H?"77O$6N:UX5^%>C6^D>!-.U2SO%N_C)J_@OPIX]L/#2?\)7IVB_9'_!
M$WXF:#KG[*OQ-\,>$;[Q'JVD>!/VV_VX_"^BS_$C4?BG:ZW;^%KW]KWXT'X;
MZ0?$7Q4\'Z=JWB;48O"-OIMO=PQ75UK.D7D;:7XET[P_X@6ZT.R /VQW#..>
MN.AQTSUQC [G. >"<\4M?AE^T1\(]!USXW:/\(?V9-'\3^*/VX=1_:3^%W[0
MWQ:_:DF\7:KX@U/]E/X.1?$[2/'?B;PO\0/B"FBZ?I6C>$O'?P9T/5?V?_@;
M^R181W#>.?"?B%/&/B7PE)X8T3QK\3+K]L%N?$0 SH^F=SSKT^1DD@<:%CY1
MP/8<DGF@#=HK#^U>(O\ H#Z7_P"#VX_^45'VKQ%_T!]+_P#![<?_ "BH W**
MP_M7B+_H#Z7_ .#VX_\ E%1]J\1?] ?2_P#P>W'_ ,HJ -RBL/[5XB_Z ^E_
M^#VX_P#E%1]J\1?] ?2__![<?_**@#<KYP_:Z_Y-O^+/_8M)_P"G;3*]S^U>
M(O\ H#Z7_P"#VX_^45?._P"UE<:T_P"SK\5ENM,T^" ^&T$DL.KS7$J+_:NF
M\I VD6ZR'..#-&,9^;.* /P,;J?J?YTE*W4_4_SI* "BBB@ K]%O^"<'_)1O
MB/\ ]B3I/_J0-7YTU^A?_!.N2^C^(7Q%-C:V]W(?!>E!TN;U[)53^WVPRNEG
M>EV)X*%$ '(8DX !^OFK_P#(+U+_ *\+W_TEFK^79"0J$%E("$,K,C*RX961
MU*LCJP#(Z,K(P#*0P!']-VJW/B$Z9J.[1]+ ^PWF2-=GR!]FER0#H8R<=LCZ
M@5_,BGW%_P!U?Y"@#HI?%GBF;6[CQ(_B77QXANU"7.N1:QJ-MJ\T:Q10+%)J
M%M<0W1A$,,4?DB01;8T^3(S5.+7-<@AU*W@UO68(-9W?VQ!#J^HPPZP6+ESJ
MT4=TL>IES)(7-^MP7\Q]Y;>V<NB@":.YN(HKBWBGGB@N_(^U01S21PW7V67S
M[;[3"CK'<?9I_P!];^<K^1-^]AV2?-5BXU34[M[^2[U+4;N35)HKC5)+J_O+
MB34[B!VDAN-1>:9VOYX9'=XIKPS2QN[NCJS,31HH ^B_V2?^3C?A3_V'=1_]
M1G7J_H,7H/H/Y5_/=^R@TZ_M$?"QK:*.><:YJ'EQ33&WC<_\(UKH(>98;AHP
M%RP(AD)("X&[</Z [&749 _V^SM;3:$\K[-?R7WF9#;]^^PLA'MPNW;YF_)S
MLVC< 7Z*** "BBB@ HHHH **** "BBB@#\0/^"D__*23_@A3_P!G6_M0?^L<
M_$&OTW^.?B/]FK5-!O\ X3?M":M\,+W1/$^D6MY?^"OB*^BW5KJ.G_:I/[/U
M(:9K$4\8DM-3L&N=+U**-;K3]3L8KRQG@O+6*5/S(_X*3_\ *23_ ((4_P#9
MUO[4'_K'/Q!K9_X*%NZ_&KPV%9E'_"L]$. Q S_PD'B?G@TX\J?O)M=HR47]
M[C-?@3)2:]R48NZUE%R5NJLI0W[W/H7PGX3_ ."9W@WX$>&_V;-'7]G<_![P
MM%X=DTSPI?7'AV\#Z]X6TG3=&T;QQ?ZHZ)JU[\1;:UTC3Y#\0I;P>,6O+:*\
M&LI.B,OL/PT^*'[%/P<\,CP=\+O&_P %O GALZA>:Q<:7X;UC2--BO\ 6M2,
M;:GKNK312&[UG7=4>**34]<U>XOM6U%XT:]O9RB%?PK5W+*#*4#, 7=W"("0
M"[D;B$0'<Y568*"0K$!3].>)?@3I.AWGA>%/$OB;^S[KPGXE\6>(]>E\.6\^
MBWVC>$K?7]0U/5? VK6.LW6DZJ][:Z7I]OINA7][!?1QZQI6M7T\=K<7MEI]
MWI?\^ZG_ (.CY?\ 3CU_#S(Y:_\ S]I?^"9?_+_ZOZ6_4#P!\7/V-?A9H^J:
M!\//B%\(/"&C:UXR\<?$'5=-T/Q#I]G:W_C7XE>+=8\>>/?$UU&+AO-U?Q9X
MQU_6O$>MW1(:]U;4[R[=0\S"O.+I?^"=%]X>T#PG>7/[/EUX<\+?'E_VG_#N
MC7%_I4UAHW[04GQ"U?XKR?%VPADN6\CQR_Q'U[6?&;:TI\UO$&I7E^4WS,M?
ME3X@\'&VO?!/_",WM_J6F?$33K*]\-?VNMM8ZI!>3^(;WPG>:/K LY[BP6XL
M-?T^:'[?:2?9+NPFM;U(H'::VBZ7XG?#%/A_9I+%<^+)Y[;Q+J7A6^N=7TC3
M+71;Z[TRT6>:]TFZTO6-1O-*\R593;^'?%EIIOB&XTI[37(HS;27-O:EZ7_/
MNI_X.CY?]./7\/,.6O\ \_:?_@F7E_T_]?O]+?;UG\%_^"56F>-_$'Q%T>#X
M+:'XQ\6_$75/BWXHUC0/B'XET)O$GQ+US5(=7UCQOKMCH_BZQTO5O$>J7UM:
M/J&HWUA/+=P6EG93[[&TMK:+].O#^OZ)XIT73?$7AO5+'6M"UBUCO]+U;3;A
M+JQO[2?+1W-K<1DI-#)@E'0E3@XK^8-9),C]X_4?Q-Z_6OZ&/V6R3^SU\(22
M23X(TG)/)/RR=ZF3@U[L91?7FFIJUNRIPMKUN].A4543]^<)*VBC3<'?35MU
M)WZZ66KWZ'OE%'^?7^5<SX;\9^$?&+>($\)^)]!\2MX4\2ZGX-\3C0=6LM6/
MA[Q;HJVSZOX9UO[%--_9>OZ8E[:/?Z3>>3?6JW,#30()4)DLZ:BLFTU_0[_5
M-7T2RUC2[O6/#ZZ>^NZ5:ZC97&I:,FK02W6EOJMA#.]WIJZC;0S7%@U[# M[
M!%)-:F6-'86+34].OI-0ALKZSO)M)O1INJ0VMU!<RZ=J!L[34!8W\4,DCV=Z
M;'4+&]%I<K%<&TO;2Y$?DW,#R %ZBN*\'?$CX>_$/^V1X"\=>#O&W_".Z@=)
MU_\ X1'Q1H7B;^P]54.6TS6/[$U"_P#[,U!1'(397WD7.$<^5A&P>+?B1\/?
M -QH%IXY\=>#?!MUXJU Z3X8MO%?BG0?#D_B/5%:!6TW08=:U"QEUB_5KFV!
ML].6YN0;B$&/,L88 [6OG#]KK_DV_P"+/_8M)_Z=M,KZ/!SS_G_/M7SA^UU_
MR;?\6?\ L6D_].VF4 ?S[MU/U/\ .DI6ZGZG^=)0 4444 %?HM_P3@_Y*-\1
M_P#L2=)_]2!J_.FOT6_X)P?\E&^(_P#V).D_^I U 'ZXZO\ \@O4O^O"]_\
M26:OY=D^XO\ NK_(5_43J_\ R"]2_P"O"]_])9J_EV3[B_[J_P A0 ZBBB@
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M_.OZ"OV7])TN?]GWX1RS:=82ROX)TEGDDLK5Y'8K)EG=XF9F/4EB23DDY)H
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M_L93_%74E\:MJ7B3QQ>>)]=\&2^/+S4_'CRZYXI/B"[O-:$MYK2I$W[&:_\
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MHA12X/7!QZXI* /T$_X)5_\ *0C]E[_L=O$'_JMO'-?WI)]Q?]U?Y"OX)_\
M@EG<0VO_  4#_9AN+B010Q>-=?+R,&(4'X<>.%&0H8\LRJ,#J1G R:_O)T_5
M-/U)7%C<I<^2L?F[%D 7S VS.]$SNV-C&>G.*_A'Z4W_ "6^1?\ 9*X?_P!6
M^;G]L_1F_P"2.SO_ +*?$?\ JIR<T:***_F4_H\**** "BBB@ HHHH ****
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MC@Y1:P+3^MU5*GAU>]6=XTU)Q/LO_AOWP+_T3OQI_P"#3PY_\=H_X;]\"_\
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MS96-I:PZ.M?M*_&WQ'K7A[Q!KOC5-6U3PQJ?B'7=-DO?"7@66SNO$OBS1?\
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MZO4Y49R2>WN37\%G_!*H ?\ !0?]ET   >-=?  Z #X;>.0 /8"O[TT^XO\
MNK_(5_'_ -*6ZXVR%-IO_53#W:32;_M;-[M)N32;V3DVNK>Y_6'T9[?ZGYY:
MZ7^M&)LF[M+^R<GM=I)-I=;*_9;#J***_F8_HX**** "BBB@ HHHH **** /
MQ _X*3_\I(_^"%/_ &=;^U!T&?\ FSGX@^E?E3_P7Y!'[9?P_)# #]G3P=V(
M/'C[XE@\D<<\9QUK^B+]MW_@GI\)?V[)?@MJGQ ^(O[07PE\8?L_>+O$GC?X
M6?$3]F[XN:E\&_B%X:UWQ;X9?P?KLUIXKTG3=1U"&.^\/2W.F/\ 8S:3_9;R
M]MS<&WO+F&3\Y/B%_P &Y'[+7Q;UJW\2?%7]L+_@J'\2O$5GIL.C6FN^.OVW
M_%OBG5[;1[:XNKNWTJWU#6/"MW=1:?!=WMY<Q6B2"".>[N)50/,Y/Z-X6\;8
M3@#BNEQ#C<#B,PH4\#C,(\/A:E*E5<L2J:C-2J^YRPY+R6[3T/S_ ,2^#<3Q
MWPQ4R'"8VA@*M3&X3%?6,33J5::CAYRE*/+2:GS2NDGLM;GX7Z'^T-\(;?\
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M"U\5^*K?64N5TF6]-Y"^FK:K)%:?99V#3C^V+_@F9Q^P-^R?D'_DC'A3L?\
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M-[:6R?4;"UUKPW>0VMZUG//:-=0HDQMII82_ER.I\AD_X-<_V"Y4>*7X^_\
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MW]E;V]]=6WR1+_P4BT/4?V7?V=?VD_#OPQ73(_VBM9UK3M)\)?%SXO\ PO\
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M:1Z;X%^'7B9+KQA\1M1T;2='&J3P:)%:KJ=W?VVA:5)/J,5X;?[I'^?Z?G0
M445X)\<?C[H'P!F^&6J>.=)O[?X?>._B%IOPW\1_$@75C;^&?A;JWBBRO8?
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M6U9K:2[L[?5([:Y>W9H7FBD:(F,J:]$H **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOA5I-AHN@2_$GQWXWUGXH_$75?VSDU6Y-II=MX \,VGAC5[VTU+2PFD^&-2
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M^)G[,^@:%=:U\6/CE\9?'-O>^'[+XD7OB6+7-3\6ZW!%96J^#=(T32=.9-2
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MRMI^@3>._B!XU\3M;M(MUKOV%=/TO3 #Z'HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH 8\<<@ D1) #D!U5@#TR P(!QWJ/[+;?\
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M;(_9?T2RN-1U?XW> M,L+2;X\6]W=W^JR6MO:2_LPZG_ &/^T MU++;*MO\
M\*EU,-9^-6F*)I4JOEI41V7X1\!?\$J!X ^%.H>#-)^*/A>#QQHNJ?LCZE\.
M_'\/@+XD7VU/V-?C)HOQL^&^F?$S2O&?[0/C6^\2:#K_ (FT*VM_$OA;X<Z_
M\)O">D0WVL7_ ()T30-2O_-APOBE_P $E-8^*&D?$SP[<_M!V.C>'?&_A_\
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M'%%%"@CAC2*-<X2-%C09))PJ!5&223@#)))YJ2BBD/;8**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
@B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>biib-2015930_sgachart.jpg
<TEXT>
begin 644 biib-2015930_sgachart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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M;KXE_$#2FD\&6?A[5?!%N@\3V7A34M=U33/JK]B3XAZAXO\  G_!2_6_B/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)XA_Z#5C_P""-O\ Y<5O44 8/V3Q#_T&K'_P1M_\N*/LGB'_ *#5C_X(V_\
MEQ6]10!@_9/$/_0:L?\ P1M_\N*/LGB'_H-6/_@C;_Y<5O44 8/V3Q#_ -!J
MQ_\ !&W_ ,N*^'/^"E'B;XA^ /V&OVC_ !AX3\<ZGX7\1Z#X$CO=)U_PHM_X
M=\1:7<_\)'H4!N-*UK3=8^WZ?<F&:6$2VO[UHY9(P"&*G] :_/7_ (*M;?\
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MLW/_ $+^N?\ ?K3/_EM6]10!@_VS<_\ 0OZY_P!^M,_^6U']LW/_ $+^N?\
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M]I\/%-&DL;8_8[^(##='(K(V& 894X8!A@@$?(O_  6)_;&_:5_9L_:=\&>
M_@9\4;SX=>$=2^"7AGQ1?:'I'A7P#?6UQK]]XP\=:==:DTNO>$]7O%FFL=)T
MZV:..Y2V$=K&4@5S([_8<#<%YEQ[GU/A_*L3@<)BZF%Q&+5;,9XBGAE3PRBY
MQ<L-AL55YY<Z4$J3CO>2Z_)\:<89=P/DD\]S3#XW$X6&)P^&=+ 0H5,1SXB3
MC"2CB,1AJ?(FGS/VO,KJT9'].GVVS_Y^[;_O_%_\71]ML_\ G[MO^_\ %_\
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MVB[:_P!ROVVS_P"?NV_[_P 7_P 73A=6IY%S 1ZB:/\ ^*K^%[QI_P %!O\
M@IA\-]7M-%\=_&OQ=X<U"^L(-6L(KKP?\%KVTU32;BXN+6+4M)U?1O!FIZ+J
M]@UW9WEF]WI>HWD,-[:75E.\5W;3PQ_UN?L(^)=8^+7['O[.WQ)^(L]GXI\<
M>,_A?X=U[Q1XBO=&T.UN]8U>\28W5]<0:9IMC812S%%+):6=O""/EB7)S\7Q
MYX19YP!E&7YUF.;9!F>"S+&+!8>638K&8ENHZ%7$*HY5\!A:,J/+1G'FIU9O
MF<4HM7DOL."/%7)>.LUQV3Y?E>>9=C,OP;QF(CF^&PF&2@JU"@Z:A0QV*JQJ
M\]>,G&I3@E%/WKV3\+_X*?\ [<_C_P#8=^&GPS\:_#;PKX%\9ZCXV^(5WX0U
M&S\9SZV+.SL+?PIK.OK=6?\ PCVH6-Q]K:ZTZ&!OM#R0>1(Y""0HP_%Z+_@X
M*_:HFCO)H?@3\")8=.M5OM0EB?XER16%B]Y:Z<E[?2)X@9+.S?4+ZQL%NKEH
MH&OKVSLUD-S=012?8O\ P<(:=I]E\ O@"UG8V=HS_&_45=K:TM[=F7_A6_BA
MMK-#&C,N0"0Q(RJG^$8_*?\ 8 U%Y?@]\<_#DWBC0?ASH=[ ;SQ/\3],\8?#
M--=\'Z9>>+?@SHLEY\6OA9\2]/-IX_\ A+IVG_VKJ>C"PU(QW!E^)7A*WTZZ
M\9>)?"2G]K\->#>"*_A7EW$V=<)Y=G>8U,TQ&$KU\5B\9A7*C/-WA(2E*A*H
MY.C1:4*5##5:]:2C3I4ZE244_P <\1>+>,J'B;F'#N3\48_)\!3RW#XFC1PN
M%PF)2K1RJEBY1C&O&FHJM53=2K6Q-*A1@Y5*E2G3C*4?I/\ XB"/VJ_*%Q_P
MH3X'?9R0!<[/BA]F8LP10MQ_;ODL6<A% <EG(1<L0*)O^#@C]JNV"FZ^ OP.
MM Y 0W:?$^U#EFVJ$,^NQARS?* N26^4 GBOC+QOJ%YKW[.H_MJ?Q/X(\$^"
M?@%\(?\ A6OB[0OVF9/$W@#XE?$;P?>>$-%M?!5C\#;6XM;+2-7U2 :[XJU2
MS_L6V\=?#'Q1X<N=7\7ZQ=VK00OT.@?%'Q&GCCX-_##7?BCJ/B;Q3H_[-7CW
MXC^#/%?CSQY)XBL[;]KKXZ_!_4]<^'-Q_P )%XLUB^TGP]?>!M$O_"GP\\%/
M>7EE8^&/'S7>KW366LZE<WD/Z%_J#X;NA5K4_#K**D\/4S)8BBLTQD_9T<!@
MJ6*]O[;"U,51LZU>AAL31E*.*P<JZE/#R=.<%\#_ *\>(4:U*C4X_P UA&O3
MRYT*KRO"0]I5QV->&]C['$T\-6NJ5"OB<-6498;%QHN,*\%.$W]3G_@X1_:B
M5F5O@?\  -71VCD1Y_B0KQR(2KQR(WB$-'(C J\;A71@590011_Q$(_M18#?
M\*.^ FTDJ&\_XD;2RXW*&_X2':63<N]025W+N W#/YS?'GPKK/C"Y^$MQXQU
MFUB\?>!O@KX#MOVJ_&]YJVC^*-=\)WGB'XP>)_#/@C4O&-OI^L7&J_$#XA>&
M_AGJ_@*U\7Z9H#^(?%86UTVR\2R0WMGJ-W:]U^UAJ7PUU;]G/X 6OPU^(W@S
M7O"?@?XK_M ^%/ 7A+1=(\:Z=XBL? 3:5\&)+/5O$I\2^$?#SR>(]3U6TU/Q
M7XTU74/)@UWQ5XROH?!\FJZ5H5_'HW92\//"VM7R6A#@# U'FF,QF$Q-?#UL
MUQ&$P+PN$Q.)HU/K5*4J=6.81H4:^!5;ZI[7+<3',92IP]A1K\E3CWQ+I4<X
MKSXYQE-9;@\'B\-1KT<LP^+QWUG%83#U:?U:K&-2E+ .K6H8YTOK?LLQP\L!
M!5)>UJX?^IS_ ()D?MK^.OVW/@SXW^)'Q(\,>"?!FK^&/B??>![+3O!L^LG3
M[G3;7PIX5UY+VY_X2"_O;O[:UUKUS WDR+;^1!#M3S/-8[/_  59G@?_ ()Z
M?M3*DT+,?AU$ JRH6)_X2CP[T4-D].P]!W%?#/\ P;^:;IU[^RM\6Y+RPLKI
MU_:#UA%>YM+:=U0?#?X=,$#S1.X4,6(4-M!9B "S9^VO^"JFCZ3:_P#!/C]J
M2:VTS3H)D^'<126&QM(I4/\ PE'AT922.%74\]58?H*_E?-LKR_)/';"Y5E6
M%IX++\%QWP[1PN%I.;IT:?U_+9<L74E.;7-*4O>DW=O4_IO*\SQV<>">(S/,
M\34QF/QG!6>5<3B:J@IUJGU''QYI*G&$$^6,5[L5ML?PBO\ ?;_>;^9IM.?[
M[?[S?S--K_1^.R]%^1_GN%%%%, K^@7_ (-ZI(X_V@?V@S(Z1@_!KPL 7=4!
M/_">.< L1D_3V]17\_5?O]_P;X6=I>_'_P#:"CO+6VNT7X-^%V5+FWAN$5CX
M[<%E69'56(QD@ \#G@5^6^-E_P#B%G&-M_J.$W_[&N7GZ9X.?\G-X1_[#L3_
M .JS'']6?BNYMCX7\1_Z1!_R =9_Y;1_] VZ_P!JO\TN/_51?]<HO_1:U_I2
M^*M!T1?#'B(KH^E C0=9((TVRR/^);=?],/\]*_S6H_]5%_URB_]%K7XC]$_
M^%QU_P!?.'/_ $G.S]B^E%_'X)_Z]\1W_P# LB'T445_8!_*(4444 ?H'_P2
MM95_X*#_ ++S,RJH\;>(,LQ"@?\ %MO'/4D@#G@>IXK^]"&6*10(Y(Y-JKN\
MMU?&1QG:3UP<'OCBOX+/^"6,,-Q_P4$_9@AGBBGAD\:^( \4T:2QN!\-_'#
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ME[_L=O$'_JMO'-?WI)]Q?]U?Y"OX1^E-_P EOD7_ &2N'_\ 5OFY_;/T9O\
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M,4J^+55T5'#SE*46J,*D^:5UR^[;>[1_)]D>H_,49'J/S%?T^_\ $+?^Q?\
M]'=?\%,O_$G?!_\ \YBD/_!KA^Q> 3_PUU_P4RX!/_)SO@_L,]_@N?Y&OZ;_
M .)JN%_^B8XA_P#!F6>7_49Z_P!;_P X_P#$L?$O_129#_X+S'_YE]?Z6O\
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? HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>biib-2015930_taxexpchart.jpg
<TEXT>
begin 644 biib-2015930_taxexpchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M /GS]K+XZG]F#]F']H/]HP>&D\9'X%_!GXC_ !:'A.76AX;B\1GP!X5U/Q*-
M$F\0'3=8&B0ZD=/^RRZL=)U+^SXY&NOL%WY7D/\ .7@G]O\ ^'FG^"Y/%WQJ
M\>_L]W4%Z?%FIZ'<?LC?$?XC?M=Z+%X/^'6E^'M1^)GB[QGJ/@SX,:'=^"]!
M^'B>*O#DOB_7=2TR3PUX?LO$&@S:OKEE=ZUIUC<?3W[37P/TS]IC]G?XX?L\
MZUKVI>%M(^-WPI\=_"O4_$FC6MC>ZMH5AXZ\.7_AVZU;3K/4E?3[J]L(;][F
MVM[Y6M)I8U2=3$S ^1?'G]CNP^+7B+1/&7@GXD>(/@IXOM_A7\1_@-XEUKP=
MX8\&:RGB3X/_ !8NO">H^+=&32O$NE7>FZ+XLL-8\%:%J_@WQC9P7!T&Z.IP
M:IH7B73;\6%N >K^!?VEO@[\4-7^)6A_#GQ'J7C:^^$5_<:1X^E\.>$/&.HZ
M1I&MP:-HGB.+P_9^(8M!_L#Q#XAU+PWXCT'Q)H^@^'-3U;5=7T#6M)UBPM)]
M/U.PN;G\\OA/_P %C_@G\1A\-_$_B#X>_$OX5_"OQY^S7\7_ -HW4/%_CCPC
MXWD\0^"=%^#OQF\)?"?Q(_B;P5X=\$ZO=6G@*QL?$TOC77_BW+J4/@KPQI.E
MW4&J768;ZZL?N#]EW]E3P9^RGH_Q2\.>!=6U2]\.?$7XJ)\1].T?4(+9(O!M
MC9?"WX5?"?1?!VE7$)>ZU/2])\/?";1IDU+59)M6O+J]O6NI65(2/C3P_P#\
M$G?"/A_PA\1/ -O\;?',OA+Q)^R)^U!^Q?X&M6\+^$XM4\ _"C]I3Q=IWC5[
MZ?5(U \8>+O &JP:A;Z)JNJV.GV^MZ=?01^(+&>^LY-1O@#[M\,?M2_ WQE\
M2KSX3^'/&4VH>+;;5/$OA^UN#X6\8VG@O7_%'@J W7C7PAX1^)-]X?MOAWXR
M\8>#+59;CQ9X5\*^*-8UWP_'9:Q_:5C ^@:^FE_,WQR_:X_: ^$O[2T/P9TG
MX)_![Q1X%OO@!\:/VD]/\:WWQR\<:#XP?P'\ M1^$&@^.=#N? UO\!=<T2'Q
MCJNN?%VQ'A&WB\>3Z'=Z5HE[=ZWK&C7MU;:?2? #_@FS\(/V>/C7-\7/![>&
MI%M];\?^,-$MI_@[\)H_'>G^,/BK_:<WCR[O/C6?#ES\3]1\.W-]XA\47GA_
MPY'J^FRZ+!XBO= O=<U[PM::3H=A[M\6?V6]#^+'Q;L/BU?^+=;TB_L?V8OV
MA?V9DT>PL=+N+"71/VA/$'PB\0:MXJ:XND:[&L^')?A)I]OI-DK?V9>1:S?O
M?JTEO:$ 'BGPL_X*;_LS^.?A/\*_B#XK\0:OX!\3?$GP;^SSXA'P[N/!'Q/U
MO7!K7[2O@/Q'XR^&>C>"A;^ ;34/B?H_BN^\#?$#PAX,\9>#-'O]!\8^*_!F
MK>']*D&N^5I;^OQ?MQ?LQO!XOOKCXCOIFD>#-'\9:[>^(M9\&^/M'\+^(-.^
M'GB?3O _CMOAWXHU'PO;Z#\5;OPAXWUG1_!7B#3?AG?^+-2T_P 7ZOI/AMK1
M]6U*QM9_G*P_X)B^"K#Q=^S=XM7XK>-9KC]G#X>?L2?#[1[1]%\-B#Q/:_L4
M+^T"OAS4]8E$7G6=WX\_X7_JI\2PZ<4M]._X1S2AHX07=^&X'3O^"-7[-%GX
M=^*/@7[-H47@KQII?B#3O"XT_P"#OP>LOB%X7EUWXJ^'?C/;S^)/BI<^$]1\
M6?%.S\*>-_"FB0>'- \8,/#NJ>$K4^'OB/IOQ"E%KJ]H ?I)X#^-_P ./B/X
M2\1^,_#>K:K%IG@R^U/2O&FG>)_"7B_P3XM\&:OH^CV/B'4-(\6^!O&.@Z'X
MS\.ZG'H&J:5KUM9:IH5O/J>@ZMI&MZ4M]I6K:==W/A#_ /!0/]EBUV0:KXV\
M5:!K,_BWP!X)L_"/B7X._&?PWX^U+7_BQ9>.K[X61:7\/M=\ :?XUU*P^)"_
M#7QO9>"=7LM!GTSQ!K/AW4= L[EM<A.GF]\(/V/?"GPF^ OQ-^"6B:Y!X1?X
MN+XSE\3^+_@7X"\!?L\:AH&J>,/!]GX&&O?#W3?AMH]O;^&O$?AW1-,TRY\.
M^)M7O/%7B:SUFRMKR;6KBQLM+TK3?DGX??\ !)+X>^!?B7X*^*\?Q)F@\4^%
M_%/[-7B;4[7P3\(_A;\,_#GBF?\ 9BN_VAW\)3ZWI/A#3+>XO=>\4V7[0NM6
M_CCQ?J^I:SX@U:;P[HSV=WIVG :1: 'I7Q^_X*D?L]?"CX%^+_B]\/KK4OC%
MJ_ASX>V7Q#M_!ND^&_B-HD-GIVH_$?4_A38:?\2_$[?#_5[+X*ZQ?^._#?C/
MPE8:-\3[3P]K=WXJ\%^*/#Z:8M[H>J?8_9_CW^UM%\!?CO\ LY?"O6? 5QJW
M@?XUVGQ$F\9_%*W\0Q6D7P>/ASQ=\&_AWX%U'6?##Z3<2Z[X9\;_ !&^,_A;
MP7J^O0:QI:>!KW5=%U;4[:_T*ZU?4-#^1]4_X)(^%I/ /QF^&_ASX_\ Q'\+
M^'/VCAXU7XY"S\+^!=0O/%ZZK^T'\8/V@? ITJ\U&QF?PK/X.O?C/KW@'59;
M'[2?&O@;2M!CNDT/Q%;7&O7/Z!_$?]GGP7\5/B'H?C3QL9-9T73_ (*_'#X&
MZWX%NK>!]!\4^%?CKKWPBUGQ&^J7"F/4H9[*/X36>G645E-$DD6N7UQ(Z7=G
M82Q@'RWX%_X*2?"G4M2U&V^*#:/\,D@O/"_AZPT:WN/'_CGQK>>+_'G[47[3
M/[,?P]TA_#_A_P"&(TYK?X@>(OV<M2/A<:3X@UCQ ?$>HZCX8UOPWH]M8>&_
M$'C+U^+]O3]EJ>W\/7,7Q&OGAUV'4+G4)!\/?B85^'EII/Q UWX4:K=_&DCP
M<1\#+73?B=X7\2^ ;ZX^+Y\%Q6OBKPUXETR5E/AO79=.^4/ 7_!)WPCX)N_A
MYJ-U\?/BGXQU/P!K/[-&LMK7BG2?"-SK_BR^_9L_:B_:;_:@TR]\4ZA96-G]
MLU?QQK?[3&M>'?%^J06MO/+9^&].URSBBU;5=6+5[C_@C_\ !&X^(FN?$>[U
MS2O$6N>.OB!\3O%7Q G^('P6^#GQ0N=0\/\ CS]HOXM?M&:3X=\%W/Q!\,^(
MHOAY?^%-9^,WB_P8/%.E66H2^(_"$NGOK6C_ /"3Z5I'B#3P#ZK_ &BOVNU_
M9\^.O[)_PIU#P!+XA\*_M'>+O&7A/Q1\0K?Q&NGM\)6TMO WAKP/J]YX;;1;
MT^)],\:?%7XE^ _AQ=R)K.AGPU<^)['6I#J=O'/9KY-X'_X*3?#O7/C+^U-\
M-O&7A35?"'ASX$?$OX5?"_X8^)=$7Q+\2_%O[1.O_$3PQX]U"_A\#?"SP+X-
MU3Q4;O0O$WPJ^)FCVFGZ,WBN35O#'@S5OB!>3:'H-O=+:>W?M+_LD^&?VF;F
MUD\0^+_$_A5K/X._'7X36=QX9M=,&H:9<?&=OAGJ%AX^T;4M1MKDZ9XQ^&7B
M3X6>&_%O@>[CBEMX/$-M;WM[%,;&W4_/FF_\$TM$\*>+8OB1X!^-OCOPW\1_
M#9_9YOOAYXEO_#7@KQ-;^'==^!7P2^+_ , -5U/Q#HVHV,-MXT7XL^ OCE\0
M9/'$-S<:/>6WB74;7Q)X>U33=2M%D< ]OM/^"@G[).H:EHNF:=\5UU%]<TKX
M0ZY'?V'@KXAWFAZ-H_QY\7>)/A[\)]0\7^((/";Z-X%A\7?$7PCX@^'4"^-+
MW0)],\?Z?)X-UR+3-?86(^6_!_\ P5\^#/B6\^&FJ:S\-?C!\/?A]XXTS]NJ
M]UOQ!XW^&OQ,@\7^%I?V'OC#\-OA;XHN8OAMH7@'6_$?B'PWKMCXYUCQCKOB
M;3_*L_AE:^#=:\->,(X_%&GZ_IV@]!#_ ,$K_A[8^#OB_P"$-.^*_C^-?C)H
M7[+UGXEUN]TOPI=ZN_BC]G3]IKXK?M5:QXWE$%AI^ESZQ\7OB3\7_%+>*].M
M]-T_0?#^G-:VOA+3K"&%85WM*_X)NZ#I?B/6;]/C!XL;PPGA?]OSPCX+\-#P
MQX:AN/"FE?\ !0KXD>#?C#\4Q=>(58W7B>3P?\1/#6I7W@*2]LK(VVA:ZNAZ
M\=9GTF'5[D ^H_!?[6GP(^(WQ#N?AGX#\7:CXPUNSU&/0[C7?#G@?Q_J_P -
M8_$DG@33?B>/"9^+MEX7F^%H\7#X?:UHWB__ (1@^+QK3:)JEI<QV<DCO#'H
MZ]^U#\$?#7Q2A^#NK^+[B+QLVH>$-$OQ:^%/&6I^%/#?B/XA2"/X?>%/&?Q"
MTSP]>> /!/BWQZSPKX+\+^+/$NCZ[XF>^T>+2K&XE\0: FJ?*'PG_P""<NC?
M"OXE?!CQY8?%[7IH?@OX>\":+8#1/A[\.? 7C?QM:^!?@O;_  5L/"'Q-^)G
M@K2M'\2_$;X32V$">,;?X>^.(/$=YIOC.ST.:Q\9#P_X;T/0;+I?%'_!.[X2
M>(OVK;K]J@_\(Z/$7B'QC\,?B+XOM-?^$?PK\<>);OQU\'M#\.>'O!&J^#/B
M3XQ\-:MXP^&]B^D^#?"$7B'3/#;M//=^&[+6_"VJ>#-=O-9U34@#I_#_ /P4
M=_8[\5>&QXLT#XJWE_HUWX9\.^+?#DG_  K?XJVU[X^T?Q5X[TSX6Z(/A;I=
MWX)@U'XJ:K<?$W6M&^'=SH/P\MO$NM:9XUUC2/#FJ6-GJ.J6,4_GWPQ_X*;?
M SQ@?BRWC2'7O "?#?XT?&?X<P1+X3^)GBK4F\!_!&'P''XQ^,WQ%T;2_AW#
MJGP6\$:)K/CJVT+Q5J7Q'M=(T/PIJ-C<1ZCX@D$5\=/\VTS_ ().^!]%\-_L
MS:7I_P 9_'\/B']E'X/3?#OX4^*CX?\ "4]S!XQLOCG\*OCKX7^).LZ5+;2:
M;?S:3J_PNC\)ZIX4"P:+K_@_Q7XBM7NM+U8:3JVG\WJW_!'+X4>(_%?B;X@^
M+O'5O\0/'WQ"\7?$G7?B#XA^)OP0^"OQ)M+[1_BI?>%=;U[2O"/A?QIX:UGP
MUX)U;P]KOA_4G\#^([?3M8%AH7B?4] \6Z+XW2RT>_L0#ZH\9?MZ?"S2?CC\
M$O@7X'M[_P"(&N_%#]HW7_V=?$VO6FE^,-'\'>"O$/A?X$?&#XT^(_[)\<7?
M@Z?P#\0?$?AF7X8:=X3\5>"_#GBT:MX:O/%1N=6EM[OP_J>D'[G!R ?4 _F,
MU^?>E?L#Z7H7Q2^'7BS1_B[XQL?AG\)_VF?B!^U=X"^#,?ASP;_8>D_$SXM^
M"/C3X3^(]G<^*ETZ/Q3?^$M1U/XY^-O&'AS0WGB?POK6IW-C'>ZIH,6A:9X>
M_00#  ] !^5 "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!\*?\%"UU"7X$Z5:V'QLT3X'F\^+/PP@O=5\8Z[XY\#_  \\>Z8FO-=:A\(O
MB-\5/ARUOXL^$GA#XEV]NWA^?Q[8:C80P:P^C>&[]-=L?$UQX5U_\F6_X*+_
M !F^%6CZ=\-?@_X)TJQT?PG'^T#K+>.?B%^T)\.OCE\&?''C'X;Z[X ;1/A5
M\&/VCOC?\8/V>;[Q/\&+73/'L0\1ZMIUKX]^,/PWOUF\ Z/X$N8? ^I!_P"D
MF[M+6_M;BRO;>"\L[R":UN[2ZACN+:ZMKB-H9[>YMYE>&>":)WCEAE1XI$9E
M=64D5F'PUX>-EI.FG0]'_L_0;BSN]#L?[,L1::-=Z<C1Z?=:3;?9_(TRXL4=
MULY[&."6U5V$#QAFR ?AAXM_;L_:3\8^,OC=\+O!/C?X8Z'XOT_]ICXY?LK^
M'/AOX7\%OXD^-'@[P]IG['4'Q]\-_'^'SO'\$6NGX;^.KJT\-:Q WA&+P?XC
MT6\C6'5]/\9W&D:6_D'[,'_!1O\ :EO]._9'^'6H:GX,^*#W?P6_8BO?%/Q%
M\7:W\%O#&H?'GQ!\?+N#1OBU>0WWB/\ :"\,>,(?$GPD*7G@R&P^%WPM^*^K
M>(?C-X7\1V/Q!M/"T6L6FEZ=^^OP^^"?PP^%NM_$3Q)X&\*6FBZ[\5?'FN?$
MOQUJIN;_ %&^UGQCXDTKPMHNMZC'<:I=7LNDVFH6'@KPRDVB:.UAH?VC2HKY
M-.6^EN+B7MK;PMX:LY[&YM/#VAVUQIEUK%[IL]OI&G03:?>>()9)M=NK&6*V
M22TN=:FEEEU:XMVCFU*21WOGG9V) /Y^3_P4F_:U?X5^)OB5:ZO\#BUC^Q[_
M ,%#?VL-*TRX^&GB.6"%O^">/[2%A\*W\%7=Q!\4;1[_ $_XX^%_$6FR:[KR
M+IUY\,M4T:YDT2S\4+KBKI'G_A'_ (* ?M _ OX<?%[QKX.UCPI^T/KNH_M0
M_P#!2J[T[]EN^CU_5/C=X/\ !/@[Q+^TA\8/A_\ $F?Q5>>//MB?"'PQ<>%O
M!WP^GTFV\%Z7X0C\%^+?"EGX&\1V_B*VLM)UG^DH>'/#XA-N-$T@0-9:GIIA
M&EV B.GZS.MUJ]B8_L^PV>J7*)<:C:E3;WTRK+=QS2*&$\&BZ1;7G]HVVEZ=
M;WYLETXWL%C:PWAT]+F:]2Q-U%$DYLTO+FXNTM?,\A;F>:X6,32.Y /Q/^&7
M[<?[4/Q&\0? 7X=6NJ_!JUG^+O[4FL_!5?B=%%\+O'QD\)V7[''QD_:3U:?_
M (1'X$?M'?&#P1HOBW1/$OPUT_1_#T5S\5+O^V/!/BG2=9U_0;*^TVZ.O^E?
M\%1_$/AO3_!?B8Z3\9-+\$_&?PQ\'?%GBSP=X=\4?M0?$?\ 9T@T+3&L_$YB
M^+?PCT7P;IR:+\9/CMX8\2:+IFF>%/"/BK6(M$M5N+73-:OO"NF^,9)_$7ZP
M67AW0=-AL+?3]%TFQM]*N;N]TR"STRQM8=/N[\7:WUU8Q06\<=G<W@O[T7<]
MLL4UR+RZ$[R"XF#SZAHVD:M)I\NJ:7IVHRZ3?1:GI<E_8VMX^G:E &6#4+!K
MF*5K*^A5W6*[MC%<1J[!) ": /P97XL^)=5^(^N^+KSXD?$;3/VL8_VOOV.O
M!GP+^#7B7QWXG\)ZWXF_9,^(?A3]F6_^(?\ PD?[/MG-!X3NM)U?P%XF_:,^
M(?Q6\2_\(5J:^"?BEX+U^UC\7:;-\)-"T_0_U%_:)^+'[/+_ +-GC?XD?$/]
MHFU^&OP(T35QIOC?XM^ ?B1;>'663P=\28O"/BCX<6/CCP^]UK%AKWB3QIHM
M_P#!O7-'\%7-G\26UW4-4\'^$;S1O'4EC/9_4CZ7ILFHPZN]A9OJMM:3V%OJ
M;6L#:A!8W,L$]S9PWIC-U%:7$]M;37%M'*L$\L$,DL;O&A&&O@7P:OA^?PHW
MA?09O#5S?ZAJESH5WI5E?:5<ZEJVM77B/4[^YL;Z&YMKB\O]>OKS6+JYGCDE
MFU*YFO&8SN7H _!GP=XOL]63X-V'COXKWGA+]A[XI_M/?&R]ET"\_:EO]>U;
MX-Z'H'[.GA-/@=\"OC)\</"WQ!U/4?"Z^//B#H?Q4^/<?PZO?BS-9^#M>UWX
M=_"3^V]5CTNR\-76.?C_ *IH"_\ !)KQO\7_ -KK6?"[:O\ M-_$#PU-X%\=
M?%GPKX&LOB1^SM;?"_\ ;RC^$'QU^+-MK+>&O&/Q NOB%X#\'? W5+;5?&]W
M/X0/BLPZ]8Z,_CO76U-?WWTSX=^ =%T6^\-Z1X)\(Z5X>U.<76I:%IOAG0[#
M1M0N0MNHGOM*M+"&PO)@MI:J);FWED MK<;OW,6QOB+X<?#[Q=>KJ/BKP/X/
M\2Z@EFFGK?>(/"^A:U>+81SO<QV2W6J:?=SK:)<2R3I;"00),[RK&)&9B ?C
MMX:U;0_ O[<,/C2/QI\)?C/XY^(7[4WC7X9OX$\-?%CX[:E\=/AOX8USP5K<
MEIXKU?X<:IXVC^%^E^$?AYX=TF*QUK18_A%9>&3X/NK3XD^'_BEJOB'4]/TO
M7-[]LK_@HG\0/@#^T /!?@&7POK^C^ /%7[+.B_$;X?^(/#WAOP]K6H:-^T3
M\4= \#ZOK6A>(O$OQ@T;QYXS'A_PYXABUG3+OX5?!OQ)X3\+:YI]Y9^//%.I
M"W\0Z-X4_8R/1M(AU)]9ATO3XM7DL8M+DU2.RM4U%]-@E:>#3WOEB%V]C#,[
MS0V;3&VBE9I(XE<[J;=Z%HM_>1ZA>Z3IEY?Q6DMA%>W6GV=S=QV,T\%S-9QW
M,\,DT=I-<VMM<2VR.L,D\$,SH98HW4 _G^M/^"EO[4FF>#/@WXAU^\^"TZ?M
M#:'^T*D/B#_A ==T_P ,?L[Z9\ /V[_@I^RMK?QH\=3-\3%D\:^!M(^&_P :
M;KXE_$#2FD\&6?A[5?!%N@\3V7A34M=U33/JK]B3XAZAXO\  G_!2_6_B/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%-=TB1Y)'6.-%9W=V5$15!9F9F(55502S,0  22 * '45\ZW/[6'P
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MS_$/_0+T;_P>WW_S.4>?XA_Z!>C?^#V^_P#F<K9HH QO/\0_] O1O_![??\
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M/ KXX'_!1C]C@@$?M/\ [-1! (/_  NC2N01D$?\2?H1R*^Q?%G_ "*_B/\
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M!YEN+B#S/-0 _!VYM_$/Q+_:<\'?%+4?@UXUM)=3\>?"75]?@\2_\$[OVT]
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M&EC_ /'ZV:* ,;_A(_#W_0=T;_P:6/\ \?H_X2/P]_T'=&_\&EC_ /'ZV:*
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MWL;.VM'U'5)H[C4K]K>%(FO+^>&"VAEO+ED,US)%;P1/,[F.&)"L:WZ* /Q
M_P""D_\ RDD_X(4_]G6_M0?^L<_$&ORH_P""_/\ R>7\/_\ LW/P=_ZGOQ+K
M]C?^"GW[/W[6/COXV?\ !/']I;]D_P"%'P\^.'B3]CKXW?%KXA>)_A=X^^,D
M?P.B\3Z1\1O@CKWPKLETSQM<^"?'=K:2:;=Z[+J=TLFB7,LB6MO;10.MW-<V
M7XZ?M[_LE?\ !93]N7XQZ!\6YOV!OV=_A@VA?#O2/  T!/V^M#\8BZ72=?\
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MT*."2&&2!-)DLUADAA>,*\497[(_X<_?\%C_ /HTW]GK_P 3.T/_ .=90?\
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M]2?S_K6R_P"(%>*7_1,QZ?\ ,[X>\O\ J;>;^YGPQ7] _P#P;S_\G!?M"?\
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MS%9=#.5C&\=EV#]B\9+*?J_^_P"+POM.=8:N_P!U[11Y/?Y>:/-\,T5]S_\
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M+2:*GAK_ (0)O '[4MC^TD?&S7YUL>)5U1;/X2?"_P#X0\>'EL]#-D9&UO\
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M\%4O@Q\)_"O[*,7A#P9\*?B5XC\6:E^T7X9^-?@OP?\ "KX;?&WXHZ?/X_\
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MY[*263ZGHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y/Q[XRTCX=>!O&GQ!\0+>OH
M/@3PGXB\9:VFG6ZW>H/I'AC1[S6]26PM7E@2YO6L[&86MNT\*S3F.-I8PQ<=
M97@7[5W_ ":Y^TG_ -D"^,7_ *KOQ'7;EF'IXO,LOPM7F]EB<;A,/4Y7RR]G
M6KTZ<^5V=I<LG9V=GK9G%F5>IA<OQV)I<OM</@\36I\RO'GI49SAS*ZNN:*N
MKJZT/S)3_@OC^PZZ(XT?X_;9$1US\,M,SM=0PSCQD1G!&1DX/%?5/[)'_!3#
M]G7]M'X@:_\ #7X06'Q-M?$/ASP=<^.-0D\:^$+/P_IK:-:ZUH^@RI;7=OK^
MJO+??;M;LF6V-O&K6XFE\X&,(_\ !7;?\>UM_P!>\'_HI*_>3_@WT_Y.Y^+7
M_9N>K_\ JR_AY7]C^(G@/P'PQP5Q%GV6+.OK^68'ZQA?K&90K4?:>WHT_P!Y
M36%@YQY9RT4HZVUTU_DC@#QOXXXDXPX?R3,991]2S+&JAB?89?.E6=-T:DW[
M.H\5-0ES03ORRT;5NI_7U1117\5G]B&'?>)_#>F:WHGAK4O$&AZ?XB\2Q:O/
MX<T&^U;3[36M?@T""UN==FT72KBXCO\ 58M%MKVSN-6DL+>X338+NVEO6@CN
M(F?:WIC.Y<9QG<,9QG&<]<<X].:_&7_@JIX$_:,UCQ1\._B'^S;X2^(^J_$#
MX=_LA_\ !2F'P;XM^&NCS:AKWA'XM>+O@E\.K3X/0:1=1))]E\6>)/%>CS6O
MA"T*.=5U/3Y;8)(L;H>#\<:=^UMX4^/?Q9\ ^(+K]MG7OV/=!^(+ZSX8\4?"
M'4/$'B#XYZQXN\8?LV_#O5O#%EX>\7VZ1^(-3^#ND?&&#XJ#5=*M73P5X2^)
M>I>#M"\8V^F?!J&\TC30#]U]RYQN&?3(STSTZ].?I2;ESC<N<XQD9SZ=>OM7
MX%?%]OV_5U#XPR>%!^U2WQCM=7^.S:2FF+(_P4G_ &8?^&//&#?"=?"B>&=O
MPWG_ &CV^/8\"AQX1Q\3A\:/^$G%ML^ #:8#C6N@_P#!1#P]K>J:MH&K_M.:
MUJ?A[QW_ ,$S?$?@RP\9ZMKFI^#-4U'XWRV?A3]N>Q\66!MBFM_#CP?IL<.N
M>*?#5RDND_!"\_M+Q+\/[;PU=S2Q. ?T'AE.<,#CK@@XZ]<=.A_(U!%=VL_F
M&"YMYA#-);2F*:*3RKB$XE@DV,VR:(G$D3XD0_>45^2O_!-BR_;*2Z\0W'[3
MGB?QY?WK?"OP'#X]T#QKX&^*6DV4'[07V_5)/'VI^$?%7Q-\9:KH=]I<B>?8
M7.C? ?P[9_L_C3(O"VI^"[V*\FU6P?XH\.?"']HCX/:O\;O@WX7\*_M>>&K7
MXA_MQ?M7_%C5_BIIOB#]I'QSX,MO#_Q!O;'Q#^SRVC0_#7QGX5\6>*+7QW:Z
MOKTWB/5M!^+G@CP!\./$GA2ZM?VA$N;[7? \,@!_21D'H0?Q]L_R(/T.:-RY
MV[AN],C/3/3KTY^E?CA^Q+KO[<6I>+?V?==_:6T?XRP>'_%G[.WPZMOBCI^M
MV,FDCPQ^VOIGP6\+O\5K_7?#]FH32O@7X@\/V,MCX=^S7,G@VR_:6LO']U86
M31^*_!FI-D:_!^V[)^VM\1+GQ3XC^)6E_"&U^)MQ=>$])^'O@?XW>(O#6M?L
MK6WP+M6U;2+#6O#7C'0_@WH?Q&U+XB?\)5);:M<Z/J?[1VG?$.#PY;>$+2^^
M&]W8"( _:;<HY+#'U'IG^1!^AHW+D#<,GD#(R1UR!] 3^%?SIZQ\2/VH?!7B
MK]CSX5_M)>(OVK=.U3QO\6/VG]!^+=G\)=4UZY\7?$OX;^'/V4[+QK\$;[P$
MOPW@MO$M]JWA;3K#PM:_&$_#M6U*W_:9T[XM:M8*?AUX@L;F;J_V?+'_ (*A
MR?&KX/#]HCQ3XYTG5K=_@-]KM=*\$_$#Q)X'U?X20?!SPQ_PN&R^(&L>#O%^
M@?LVZ+\3]7^(;?$"#QCK/B+2-2^(VA>+T\-ZA\'K'5?A^;#3Y #^@#<O)W+@
M8R<CC)P,\\9/ ]31N7@[EP>AR.><<<\\D#CN:_F^\#:+_P %#=,^$/P8T[QC
MXO\ VRK*^^(/[$'[-7Q"_:"\0:CX<\8?$;Q/H'[1/ACXR^"M/^(/@%=$\*:_
MX.^(OP_'B[X9ZIXATGXKZ=\"-7L_BI9Z#IL?COPII'B'QKIFM3Z[N^)+K_@I
M-X@C^$W]C?\ "Z_A;X5M/AYXPT3X:W-]I7QJ^,'B^_\ C+I/Q_\ '5CH_COX
MHVN@7_PHU@>$O$7P>@^%6N^ /!W[8=M:^&[#PM>>,M!^*NK7/Q)M)/$6H ']
M$U%-3=M7?@MCYL @9[X!).W.=N3G;C/.33J "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ KD_'O@W2/B+X&\:?#[Q UZF@^._"?B
M+P;K;Z=<+::@FD>)]'O-$U)K"Z>*=+:]6SOIC:W#03+#.(Y&BD"E#UE%72JU
M*-6G6I3E3JTIPJTZD7:4*E.2E"<7TE&24D^C1%6G3K4ZE&K"-2E5A*G4A)7C
M.$XN,XR752BVFNS/Q,3_ (('?L.HB(-8^/VV-$1<_$W3,[44*,X\&@9P!DX&
M3S7U3^R1_P $S_V=?V+OB!K_ ,2OA!?_ !-NO$/B/P=<^!]0C\:^+[/Q!IJZ
M-=:UH^O2O;6EOH&E/%??;M$LE6Y-Q(JVYFB\DF0.GZ%45]IF/B3QYF^!Q.6Y
MGQ7G6.P&,I^RQ6$Q&+G4HUZ?-&7)4@])1YHQ=GUBNQ\?E_AWP/E6,PV89=PQ
ME&#QN$G[7#8JAA(4ZU"HH\BG3FM8RY6U?LV%%%%?$'V8A /4 ]1R.QZC\>]!
M53U4'OR ><8SS[<?3BEHH 3:N<[5R>IP,GC'7KTX^G%&!Z#MV].GY=O2EHH
M0*JYPH&>N !GKUQ]3^9I"JGDJI.<Y('7IGIUQQ3J* $P!T 'X>V/Y #Z#%&U
M<YVC/K@9Z8Z]>A(^E+10!EWFAZ+J%_I>JWVDZ9>ZGH;WDNC:C=Z?9W-]I,FH
MVC6%_)IEY/#)<Z>][8LUG=O9RPM<VK-;3F2$E#I[5R#M7(Z' R,=,'MBEHH
M0JIX*@C@8(!X!! _ @$>X![4FU>/E7CIP.,G)QQQD\_7FG44 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
(% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>biib-2015930_taxperchart.jpg
<TEXT>
begin 644 biib-2015930_taxperchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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M;KXE_$#2FD\&6?A[5?!%N@\3V7A34M=U33/JK]B3XAZAXO\  G_!2_6_B/\
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M<CKD>V 3GVI: "BBB@ HHI"0!DY_ $D_0 $D^P!- "T4TL -W./0*Q;_ +Y
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M1>'OBU/K6BVMAX:N;_XU?#>'XI>#SX/U:'5;R?6X(O#4Z1ZT]WI^D2:?J?\
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M+O+O39KRTCAN);"ZN;.21K>>6-P#^?C]LS]J_P#::^ _['?@KP-\0_&7QY\
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M+\<QZ[XQTO3Q_P 4EH&O:3#X6N]9GM[OQ+<SZ187.CZM[#>>+?"VG7,ME?\
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MBB@ HHHH _0[_@G%_P E0\?_ /8@VG_J26=?L2W0_0_RK\=O^"<7_)4/'_\
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M,OV2O^"B'_!1S]H7]GK]C?X(_M2?"C]M;Q1^S)XK\,ZKXG_;)LOV?O$/@_\
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MN)4,85_L\_M7_P#!9X@C_AT=^SKS_P!91]"_^A+H ^??VK/^3B_BW_V,UO\
M^H_HE?/M.^*GP^_X++_$[XA^+/'[?\$WOV==$;Q3J4>HMI7_  \3T;4?L)CT
M^RL/*^W#]G>Q%SN^Q^:9!:0 &0H$PFYO/_\ A0?_  65_P"D>7[.O_BP;1O_
M )P- '?45P/_  H/_@LK_P!(\OV=?_%@VC?_ #@:X;3O _\ P5QU3XD^+/A3
M:?\ !/C]G]O%W@KP5X \?:[ _P"W]HBV,7A[XE:W\1_#_A>6WO!\!V\^[FU'
MX6>+5O;0PQM900Z?.SR)J,00 ]WHK@?^%!_\%E?^D>7[.O\ XL&T;_YP-'_"
M@_\ @LK_ -(\OV=?_%@VC?\ S@: /T6_8"_Y. 7_ +$/Q7_Z5:!7[?MT/T/\
MJ_F3^ FB_P#!9CX&^/O^$Y3_ ()H_LZ^)V&A:IH@TP_\%'-%T;C4YK"4W/VP
M_LX:H/W/V';Y)M?W@E)\V,H-WVR?VK_^"SQ!'_#H[]G7G_K*/H7_ -"70!X?
M^V!_R<E\4O\ L):'_P"HEX?KYKJU\7O W_!9?XK_ !'\4?$)O^";?[.N@MXE
MN+&X.D_\/%=&U/[']BTC3]*V_;A^SM8"X\W[!]H+"S@"&7R@K;-[>;_\*#_X
M+*_](\OV=?\ Q8-HW_S@: .^HK@?^%!_\%E?^D>7[.O_ (L&T;_YP-<#:>#?
M^"MU]\4/$'PA@_X)\_L_GQGX9\!>#_B1JEL_[?NB)8IX8\<>(O'/A?09[>]/
MP')N+N35OAYXDCO+5(!]BABL99)6-_%&H![Y17 _\*#_ ."RO_2/+]G7_P 6
M#:-_\X&C_A0?_!97_I'E^SK_ .+!M&_^<#0!^@O[!_\ R<5HW_8I>,/_ $DL
MJ_=&OYBO@5X=_P""S'P3^(=GX^3_ ()I_LZ^)6M-)U?2QI7_  \:T71]XU:*
M",S_ &T_LXZF%\CR<^7]D;S0Y&^,@$_M3^R5\6/VTOB<_CL?M=?LB_#G]EI-
M%7PV? 3> ?VI;']I(^-FU ZX/$JZJME\)/A=_P (>/#PL]#-FTAUO^W3K-T$
M&G_V23>@'V91110 4444 %%%% !1110 445S?B'QCX3\)'2%\4^)O#WALZ_J
MUKH.A#7];TO13K.N7N[['HVD_P!IW=K_ &EJMUL;[/IMEY][/M/E0/@T =)7
MD/@7X.Z)X#^(_P :?B5I^JZO>ZI\;=>\$Z_KVGWWV'^SM(N/ _P]T/X=V$&C
M?9K6&[\B\TW0K>_O?[0N+N3^T)I_L[PVOEP)W-[XR\(Z;XCT?P?J'BCP[8^+
M/$%M=WF@^&+W7-+M/$.M6FGJSWUUI.B7%W'JFIV]DB.UW/8VD\5L$<SO'M;&
MG/K.D6NJ:=H=SJFG6^LZO:ZC>Z5I,]]:Q:GJ=GH[6*ZK=:?I\DRWE[;:8VIZ
M<NH3VL,L5DU_9"Z>(W=N) #2HKB==^)7P[\+^&]6\8^)?'?@WP]X2T'4IM&U
MSQ/KGBG0=(\/:-JUMJ@T2XTO5=;U'4+;2]-U&#66729K&]NX+N+4V&GR0K=D
M0UI>$O&/A+Q]X?L/%?@;Q1X=\9>%]4^T_P!F>(_"FN:7XCT'4/L=W/8W?V'6
M-%N[[3;O[+>VUQ:7'V>ZE\BZ@FMY=DT4B* =)1110 445SGB3QAX3\'0Z=<>
M+/$WA_PQ!J^JV>A:5/XAUO2]$AU/6]0+BPT?3Y=4N[2.]U6],<@M-.M6EO+G
M8_DP/M. #HZ\E\.?"'1O#?QC^)_QGM=4U6XUSXI>$?A5X/U;2;C[%_8^G67P
MGG^(UQH]UIGE6T=_]KU-OB3JBZI]LN[F#;I^G?8HK8_:S<=IJ/C/PCI&OZ)X
M5U7Q1X=TSQ-XE6Z?P[X=U#7-+L==UY+&,RWK:+H]U=PZEJJV<8+W1T^UN1;H
M"TQ0 D:5UK>C66IZ9HUYJVF6NKZU'J$NCZ7<W]I!J.JQ:5%!/J<FFV,LR7=^
MFG0W-O+?O:0S+9Q3PR7)B26-F -2BLW3M9TG6%O6TK4]/U,:;J-WI&H'3[VU
MO?L.JV#K'?:9>?999?LNHV<CJEW8W'EW5L[*D\,;$ PZ#XAT'Q3ID.M^&=:T
MCQ#H]Q/?VL&JZ'J=CJ^FS7.E:A=:3J=O%?Z=/<VDD^G:I8WNG7T*3-)9W]I<
MV=RL5S;S1( ;%%%% !117'ZG\0O >B>';KQ?K'C3PEI7A2RN-1M+SQ-J7B31
M+#P]:76D7=[8:K;7.MW=]#I<$^FWVFZA9:A#+=I)97=A>VURL4UI<)& =A7E
M^C_"O2-&^,GC[XT0:EJ<NN_$'X<_"KX;:EI,WV/^Q['2_A-XB^+OB/1[^P\N
MV2__ +1U.Z^,&M0:K]INY[3[/I>D_8K>VE^W277*Q?M3_LSSZ?)JT/[0WP,F
MTN+4++29=2B^+WPZDL(]4U&WN+O3]-DO4\2FV2_OK6UNKFSLVE%S=06\\T$4
MD<,C+['<Z_H5GH5QXHN]9TJU\-VFDRZ]=>(+G4;*WT2WT2"S;4)M8GU::=-/
MATJ*P5KV349+E;)+0&Z:<0 R4 :]%9<FN:-#?:5IDNK:9%J.N07ESHMA)?VB
M7NKV^GQ03W\^F6K3"?4(;*&ZMI;N6SCG2UBN())VC2:)GXK0/C+\(_%7C#6/
MA[X8^*/PZ\1>/?#W]H_V]X*T+QSX6UCQ=HG]CWD6GZM_:_AK3M6N=;TS^S+^
M>"RU#[=80?8KN:*VNO*GD2-@#TFBBB@ HHKE-1\=^"=(T&_\4ZKXO\+Z9X9T
MN\U'3]2\0ZAXAT>RT/3[[1]0NM)U6ROM7NKV+3K2[TS5+*\TW4+:YN8I[+4+
M2YL[J.*Y@EB0 ZNO*+#X2:-I_P </%7QTCU357\0>*_A5X!^$]YHTGV+^Q+;
M1_A_XP^)7C+3=3M=MJNH_P!J7U]\3-5M+_SKR6R^QZ?IOV6V@G^URW'-1?M5
M_LQSZ?<:M#^T3\"I=+M+W3M-NM1B^,'PYDL+;4-7AO;G2K&>\3Q,;:&\U.WT
MW4)]/M995GO8;&\EM8Y8[6X:/V637]#BT)_%$NLZ5%X;BTEM?D\02:C9)HD>
MAI9G47UE]7:<:<NE+8 WK:DUR+);0&Y,X@!DH UZ*QSXAT%9]%M6UK25N?$:
M32^'[<ZE9";7([:R_M*X?1XC.'U1(-/Q?3M8+<+%9D74A6W(DHD\0Z#%KUKX
M6EUK28_$M]I5]KEEX?DU*R37+S1=,N[&PU+5[72&G&HW&EZ?>ZIIMG>ZA#;/
M9VEUJ%E;7$\<UW;QR &Q1110 4444 %%%% !1110 4444 %?D9^V!I?@/PG^
MT%\3?B#^TI\)->^+GP;^(W[)G@OX%_!&"Q^&^H?$S2],^,FN?%#XFZ?X_P#A
M@$LH=4M/AYXK_:"?QU\ -&\+^,?$2^$O"^NWG@F/1]6\;Z/-X:L4G_7.L/Q)
MX9\.>,M"U3POXNT#1/%/AK7+*;3=:\/>(]*L-<T/6-.N !<6&J:1JEO=Z?J%
ME.%436MY;S02@#?&<# !^"7Q$^#?C\>%/V6?!NJ?"KQ9XR_:>^'UQ^PM?_&K
M48O@#JVL?\-+^,/A--\"[[6?'>A_MVZ%-J]C\(?#7PMO-)\47/B >(=7T;5/
M$TVB^)]$_P"$;O?#_P 0H]3\6?L_\4?AK\+]9N$^*WCK0]6GUWX<_#3XN>%]
M*\3^%AXN/CCP[X*^)%AX;G^(]KX+/@%7\;1:YKEMX#\-2V'_  AL3^+5U'2+
M!?#8_M;[.&]AM+*SL+6VL;&UMK*RLX(+6TM+2"*VM;6VM8TAMK>WMX42&&"W
MACCB@BB18X8T2.-510!9H _G<_9P\,> ]1_90^(OPLA^'G[1WPX\*_#W_@HM
M\;OC1I.F6'[&_P 1-8U32_@_XT_:?^*?BSX8^,M-^'WQQ^%LEMXYT74O"M_I
M_B&]O?#_ (0^*OC?P=>:AI'C'Q%X(GO;>[GA_6W]C"?XAM\)=5L_'.D:II^C
M:7\3/B+IWPHU/Q-\.]$^$?C;Q9\(XM?>?P=XK\<?#+P[H?A32?!_B359+C5X
MVM(?!G@B[UC1K/1O%.J^"_"^K:_?:/:_6N!]?J2?Q&>A]Q2X Z#'4_B3DG\3
MR?>@ HHHH *_*']K2S\!>"?VG+[XM_M/?"O6OBW^SGKG[+%I\&? %C:_#34?
MBYH^@?&'Q5\7M4LO&O@N\T*RL]5MO">N_M#:-XG^#W@_PKXKURTT7PS?WG@>
MZ\.:WXU\/F73[?5/U>K&\0^'= \6Z)JOAKQ3HFD>)/#NNZ?=:3K>@Z_IECK.
MBZQI=]$8;W3=5TK4H+JPU'3[R%FBNK.\MYK:XC)26)U.* /Y\/B'\$OB-'\%
M?V9/ASKGPD\9>+?VI_ G@[]BU?BG-%\!]4\4R?M+^(_A5??";6[*UT/]N?PM
MJ6OV'P.T_P"$6KZ3XHM_$WB[Q#K>C:A>WH\0>(++2]3TCQ1;:QXC_<'XF_"_
MX9^([W2OBCXVT+4+CQ'\+?"7Q1L_#7B?P\?$P\9>&-#\?^'K33O'A\(/X.67
MQ7'K6L:-H5A'9?\ ",Q2^(UO+.S70D;5!:J?6M.TW3M(L+'2M*L++3-+TRTM
M=/T[3=/M8+*PL+"Q@CMK*RLK.VCBMK6TL[:**WM;:"*.&WACCBA1(T51=H _
MGV_9'B^)NG?LY_M5_!W]EOX1?$'POKFO?MQ?&_Q?I.C_ !+\*?&?]EZ[?]F7
MXG_$A;VZ\:?#KXB?%WX12VFH_$#Q7X8L]0@T:\N7O/%6CZQXAE\>>(&&LZ?!
M#JGVS_P27\&_$/X=?LAOX#^(?P+'[.\WAO\ :/\ VR/^$2^'"ZM#J<-AX$\1
M?M8_&3Q?X6GL$A\/>&Q;:"+#Q MCX4O!930^+/"ECHOCNRN?[/\ %-I;6_Z8
M8QZ_B2?YT4 %%%%  0""#T(P?H:_+CP9^S<^G_M_?&C3=0\-:]??LU)\.O!/
M[37@GPKK/AI9_A-:?M7?'K7/B]\*?V@=5T.\FM3I%_J[_#SX=>&?%>H^#G6X
MCT/Q5\>/BA\0+V&34?B?!/:_J/10!_-)X$^"UA\&_P#AW[XM^(W[-WBG3_!W
MA']LS_@K)K7Q*M]"_9D\7>.Y_#^D_$3XG?M31?!/Q%XG\$_#[X<^*=?M] \3
M:?X@\.R>!M>N/#SZ3)HNLZ7/IUY#IE_;-+^HW[(GP*77?V9/C?\ "[XJ?#N_
M\-_ _P".?Q/_ &E&\"? OQ;I$WAR^\'_ +-?Q?US5K/3O 6K>$V<3^";#Q+9
M:EXH\66'@!X].N_A_P"'_&^F^#+K1O#M]H4^@Z7^BN/K^9H  &  !Z#@4 ?C
M'\=Q\/O _P#P5/\ V/?'VE?#_P"-6I7OA3X:_M _#WXC^.M&^"7[1WQ!\">#
M;;Q_X5^!^F_"#PKIOC#1O GB/X=^%?#^MWNCZY>ZQ;>#]2L]$M-;LM1UKX@2
MVFJPFXBZ+]F7PIXK^'?Q]\(>'_AQHWQ;OM$O?$/[2#_M!V?Q;_9>\#?"?1_A
M[I&L>*?$7C#P1K/@SXR:%X,T6^^)'B;Q/XXO-%TXQZ9\5?C5I?CGP?JFL^/=
M:C\$ZKH5K;2?KSCOS^9_EG% 4#H .OX9.3CTR>3CJ>3S0 M%%%  0""#R",$
M>H-?EEHG[/5[;_\ !1/XC:9<^%M=N?V8M2^&7AW]JBR\.:AX4CF^%,G[8WCW
M5O&_P+^)&OVFKO9#2[K6+OX/^&="\1ZIX!E^TV</C'QQXG^+%W;OXD\6G45_
M4VB@#^;;0?@KI7PAO_V2?&7Q _9N\1V?@;PI_P %4_\ @J?XQ\?Q>'/V9?%/
MCJYTWP#X]N_V]-,^"OC+7/!GP[^'/B?Q%<>#/$,OCGP='X'\3/X?NM%.G>)=
M"ETV\@TJ_M7;]-/V0_@G%K7P+_:0\">/_AQJ_A'X"_'7XS_'JZ^&?P2\8Z/=
M^%[[PQ^SY\3-*TOP]J?AS4/!-UY5[X#TSXA>*#\3/B3IO@6ZMM)U'PIH/Q'L
M=(U'0/#6J07GA_2_T5Q]?S-& .@QU/XDY)_$\GWH _%']H_3/AE\.?\ @H]^
MP3XNT+X<_&F_?X7:)\9O!7CGQAX:^"'[1WQ,\%_#CP/XO^!]MX/^&'A[2/$/
MAWP+XG^'_A?2-<\2);IK]IX3O+8RZM:VFJ>/WB.G6EQ9Y7P_\ ?M:1_\%3?@
M]\8_BS^S9I\%KKGP4_;=\'>)_C1X<^+]EXS\*>$?AY??$W]E>\^"?@2RM6^&
MNA7?AX6.B>$;F_@\$7FK1ZIX]\<^+_B_\1K:[33/"%QHT/[A8^OYG_&EH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KP'XS?M(?#[X%7N@6'C6#Q)-/XCM-1O-/.A:3#J4:PZ
M9/:6]R+EI;^R,+E[V$Q*!)O4.25VX/OU?DK_ ,%)?^1F^$__ & ?&'_IS\/4
M ?07_#PGX$?\^7Q"_P#"7M/_ )>U]B>#_%.F>-_"OA[QAHRW2:3XFT?3]<TY
M;Z%;:\6SU*W2YMQ<P+),L,XC=?-C$L@1LJ';&:_F+K^C']G7_DA'P@_[)UX2
M_P#31;4 >ST$@=3CH.?4G 'XG@>]%,D!*@ 9^>(_@)4)/X $GV% 'A?A;]J7
M]F7QSJVO:!X)_:)^!7C#7O"ND:WX@\3:)X6^+OP^\0:OX=T+PU,EOXBUK7=-
MTGQ%=WFD:3H,\D<.M:EJ,-M9:5-(D=_/;NP4]OX0^+/PL^(5U/8^ OB5X \;
MWMMH'AKQ7<6GA'QEX<\2W4'A;QG:SWWA#Q+-;Z+J5]-%H'BJSM;JZ\-ZS(BZ
M=KMM;7%QI=S=PPR.O\P7A'X'?&[Q!_P2;^/_ .ROJ7AC]K>;XP2_ _Q5;>'_
M (.1_LN>./@A;>'KW3_C)=:A=^#_  M\=?#?@_PQ#\8(_%.D:Q:/<^&[_P <
M>(T\8^'8M1N)K*^M%UA(_1[']F_]K[X$>,OCT_PJ7]HC0/@]X[_;C^.VI>.-
M9UOQ'^T]\5?'_BGPIHOP"^!6D?LX>)O#DGP\\;-\:;KP)>^(_P#A:6D:[XK\
M,:DVG:KK_A7X;:'\3#??#_PX(=/ /Z="Z#JRC R<L!Q@G/)Z8!.>F 3VK!T_
MQ9X6U;6=1\.:7XET#4O$.D:1H.OZMH5AK.FWFLZ7H7BJ368?#&M:CI=M<RWU
MEI/B*;P[X@BT+4KF"*RUB30]8CTZ>Y;3+X0?D7\/?"W[3_BOQSJ'@K]I'6OV
MMM2\;^(_"?@/POX3\2?"X1?#']G>]^%NL_LHZ%IGQ1USXF)X>U_4M"\!?$^?
M]HRX^)]UJ@T3Q-?_ !G\+:FWPHD^#^LS?#VSUZ];X\_9'\(_MB?L^_!/PO?>
M'O 7[5]Q;_LE_LB_\$S[:[^"?B*Q\67>H_%CXB?#9OVJ/ 7[:_P8\"R>.IV?
MQLMEX>\5^$]<\ Q:)JM_\/X[[PI\'7^'UW'X:AT_(!_2MN7.-PR>@R,GJ>G7
MH"?P-0&ZM1<&T-Q +H0_:3;F:,3BWW^5YYAW>8(?,!C\W;Y>\;-V[BOP_P#A
M'X4_X*&>'?VLM!T+XH_$?QQJ>@:/\0?!CP:I:>$/BSXK^'/BWX'S_!K1]4^(
M5IJFOP>,M#^ .@ZG/\9]1\?6=IJ/B/1-2^.>@W>E>#;'PCIU]\,#9P*W]L?X
M9_&GP+^VSX[_ &BOAG\/?VC_ !S=>.OV&="^#?@V[^$?C/X@P>'=*\;:'\=]
M3UCQ\=<L- B\1Z-X6E\/?"3Q)/X^\.VS>'+;7_'^LZ/K?AOX4:E#\9-6T.X8
M _<D,IZ,#UZ$'IC/Y9&?J*"0.I STR<9K^>[P!<_\%!=*_X2ZTE7]H_Q%X%\
M#?M#OJMA=S^'OBEX6U_QQ^PSXD^#_P"S[K?Q&TOP59_%[QM\2/BKJ?QZT;XU
M3^*I/A+;>+_&#?$ZT\,:/\:?"]L/!\.N>"_#UK]]?M=6W[15S\=_@E=_"6P^
M-.M_#[P[^S?^V;XX\5>$_A;XKM/ 6E^.OC;X-NOV<M6_9P\!>)?&6KV5_HN@
MZEXKOW^(]EX7CUZWDT+48HM>M?%5GJ_A*/Q!H6I@'Z(37=K L;37$$2RS0V\
M32S11B2>X8)!"A=U#RS.0L42DR2,0J*Q(%3AE)P&!(Z@$$CG'0>_'UK^6SQ=
M\)/VP/BD-/;XBZ3^UIXN^!_PP^,G_!.#]I?18M.M?VH?#'Q'T?7-!^,7QET'
M]K32O#]KXQ\?Z[\;/B%J?@SPE%\*_$ZZ'H&C>$-%!A'BWX._#&PFDN;W5_T'
M_84M?VZ'^.6O7G[27B3Q2B_V1\9#\2_#5[X&^+<?P\F\0W'Q-TY_@Y/\/O&'
MC/Q@WPELM)T;P(+^WT'3_@)X39==\,W\DGQJETOXA:-:?;@#]C-RYQN&?3(S
MTSTZ] 3]* 0>A!^A!_E7XD_&X_MKM\9OB[_PB(_:-_X3&#XN^(7^'P\)C7E_
M9ME_8W;]F6\.RW-H5\,2?&\_&3^TET;+#XW1_%;_ (1@Z<4^"7GD^W_L(6'[
M47AGQ?::'\:KSXU:[X:\1?L.?L1?$?Q'K?Q?O-0U=[+]J_Q!+\8]"_:-\.:1
M>7T<<7AO4K;2_#_PPU#Q9\.](2U\/^'=3O+?5],TO3KOQ'JSWP!^H^Y>?F7C
MKR./KZ4!E)P&!/7 (SC@YQ]"#^(K^6;X-?$;]N_XN_LA_#[XE_!GQ?\ MB^*
M?%WB[X!>#6^+7B_5FGUG3M3^)[_MH?L_Z3\/?$/P!.K0WFCZC';_ +/%I^T7
M=?%BY\&07/ANX\)KX5F^*=K<^-GF@/VM\)_#/_!0S1/VG/&^B7/CCQ)#8Z!X
M^^-.E>$(?B7X7^._C_X0Z[^S[9>']4L/V=7\1>/)?B)IWPOG\1,$\#:_XN\0
M>#+*_P#VB=4\>0^-M#\<;?!^J'6-. /V]2ZMI))XH[B!Y;61(KF-)8VDMY9(
MDGCCF16+12/#+',B2!6:)TD4%'5C-D'&"#G!'(Y!R01ZY )'T-?SP>(?A;^T
M7\+/C[^U9:6OAG]IA;[]I?\ :>^$_P 2?%/Q7^'.M?M/>*/@]H?@/3_V(_AE
MX-NM9\/>'_AMXQL?'\]G>_M(>&?%'P^MO 7@CX@_#KQ9X(\)Z5\.]7^(&O/\
M%?#6D:;=^Q_L8ZM^WQ)XH_9CU7]I72?CDWAZ;P3J'@?XYV>HVUSI\MI\?/#U
M[\5=,^%?C:_T2"XU@_\ "H]8^$%C8P?&._TK6-1\/ZA\<=:^!OB.WNM1_L_X
MI:TX!^T-KXG\-7VOZSX5LO$.AWGB?P[8:)JOB#PY:ZMI]QKVAZ9XE?5H_#FH
MZQH\-P^HZ98:_)H&NQZ+>7UM!;ZJ^BZLMA)<-IUX(=K<O'S+\W3D<_3GG\*_
M%C]HOP[^V'KW[<,NE>!)_P!H#0O@%XG^)'[ VB^(?$'P[EOM#T-/A[_PA/\
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MC#ME@BYQ7244 %%%% ";5]!SUX%!53P5!&<\@'G&,_7'&?2EHH 3:N0=HR.
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M*HSUP ,\YY_'GZ\T;5/4#OV'?K^??U[TM% "  <  #K@ #GUXI:** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>biib-2015930_tecchart.jpg
<TEXT>
begin 644 biib-2015930_tecchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %- 3T# 2(  A$! Q$!_\0
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M8TM?VM-;TG1?A)<Z1\%_A]^W'JOAC2=7\0_"2+5X-+_9?^''Q&\3?"7XQ?\
M"/:#\?-?^,7BO0?C5?>$/#7BV^TO5/@SX$\#VWPW^)_@[6?!WCO4K.SL]6\>
MK\5/V\_VH](O/C!X.UW7_AC=^'O"GQ6_9S^$.HOX5\$Z[X9\5ZOH'[</P,?Q
M7H%QHVO2?$+45\*>(_@CXEU**31-<AL=5/Q TB!;35M+\.:HJ:PW[_1>&O#L
M"SK#H6CQ+<Z5;Z%<K%I=A&MQHEI%-#::/.$MP)M*M8;B>*VTV4/901S2QQ0(
MCLIFDT+193(TND:7(TTMG/*TFGV;F6;3XQ#832%H"7ELH@(K21\O;1_) T:8
M% '\UGPT_P""B?[2WPJ_9V_9P\(:+K'@/X]G7_V9?V)+WQY\5M/M-'L]3_9:
M\4_$;0!X5\6^'/CGK'Q8^-_A;PGX@\;^)I?#4J^"[KXJ>.OAAK%I\19M;D^(
MEI>V%_X?T"?[S_98_:__ &B/CO\ M ?#7X9>*+CX4>'O#3_LRZO\=/&,GA>V
MT3QOJGBVYTG]I?XO_ GPY_8'B?P5\3/&/P_T/3O%WACPQX5\<^(8O#_B+XC6
M/AKQ!#J/A/P_XBU[3[F37;;]86T31WM]5M'TK36M=<>XDUJV:PM#;ZO)=VL5
MC=/JD!A\K4'N;*"&TG:\29IK:**WD+0QHBS0:9IUK+'/;6%G!-#91:;#-#:P
M12Q:? YD@L8Y$C5X[*%R6BM$86\3<QQJ>: /QG_:D\8>'-,_:K^%^L_#SXO3
M2>.M/_:B_9Z\#_$OPOIW[1'Q(MOCCH&D^(O$_P .] O?AO\ #/\ 9)OK73/A
M?XV^!_B[PUKMAXI^-/C2\DO;[P]X&U7XF?%/P_-K'B?X?^'I-!\[_90^+VIZ
M1XZ_9G\7:W\6M4O_ (I>)?AQ^U)XI_X*8:)XS^*>OZMH/PAO_ATEI=OKGC+P
MCXAU*3PY\&K?X7_%"V7X;?#G[+H_@>QO?A7?:ZMC%XFT#0DU33/W9?2-*EU.
M'6I--L'UBWM)+"#57L[9M2@L9I%FELH;]HC=Q6DLJ+++:QS+!)( \D;-S5.^
M\,>'M2@\06U[HVFSP^*K%]-\2 VD*/KEC)82:6UMJD\21SWL8TZ:6RC^T2NT
M-J[0PM'&=M 'P=^W+\6/V:/#OP^^%7B7XR?%O73X<\9:[*OPH^$OP^^,^E_"
MY/VF/%>K^%WU'P[HT?B:#Q7X$;4O#^@:1)-XV.K:C\1O"GPR\,0"U\>_$'4F
MTO0M(GM?S)\8>*_%_ACX7ZU9_'3]J;6M>^(7P_\ ^">7AKXA?L>>-_ 7QY\1
MSZ+\3?VIY_&G[0T/BNV\%>(O#-UI5I^TY\1?AY=:=^S'\)+.#Q/:>,]9\>Z=
MK-WJ&K>"#-\6O%MC>?T-:MX&\%Z]IUAI&M^$O#.L:5I<20:;IFJZ!I&I6&GP
M1Q0PQPV5G?6=Q;VL4<-O;Q(D$<:K'!"@&V) MVT\,>'+"QTG3+'0-%L].T&<
M76AV-II6GVUGHUR$N8Q<:5:P6\=OILXCO+N,364<$H2ZN%#[9I0X!^./A'XX
MVVC_ /!5#1/"?CW]IBSN?$?C+]A+Q)-K_P #+GXN>$[CPA\,_C'!\8OA(D/@
M?P5\+M$NK"2?QE:VEYXCG;4M<T[Q!\3O%FGRM9G4G\/Z9I6D6#O^"<5WX>\&
M?$C1? .@>,/@W\;-1\=_LXP^/?&WQ5^#GQ2^-_Q#OO!WB+P;KW@;0Y-#^+L7
MQ5\;>+;&#Q!\5=0\::[XI\,7\7A_X2>)?M?@?QWH.I?#QK;1WO=/_7EOA[X#
M;6_^$E;P7X2;Q#]N34_[=/AK0SK/]I1((X]0_M4V!U#[:D8")=_:?M")\JR!
M>*Z&RTK3-.>]DT_3[*Q?4KN34-1>TM+>V:_OYDCCEOKUH(XVN[R6.**.2ZN#
M+.Z1HC2%5  !\:?"'PM??%S48?BSXG\:^-=+U[X7?M;?M,ZA;>&]/\2W5IX;
MO=*\))\5/V8O"OACQ+H=E?+INH^%X/ R:/\ $BQT>_BEMT\<R67B^2WBUAOM
M<?Y=^"?B;X-\7:'_ ,%3OA-_PVUX2^)LMC^T]^SMJ6G>-OB?^T 1IL7P[U#X
M+?L5:K\2XFNO@9?V&I_"[X/:GXI\0^+/!>I3_#32_!W@OPG=Z[J=OJFNZ!=_
M\))XEB_?K0_"'ASPW>^)]0T/2X=.N?&6N?\ "2^)/(DG,&I:\VD:7H<VJ-:R
M2O;6UU=Z9HNEPWILX;=+V:U%[=)-?3W-S-GZ-\./A_X=N9;S0/ _A#1+N:SN
M-.FNM(\,:%I=Q+I]U*L]U8R3V&GV\LEG<S(LMQ:N[6\\BAY8W8 @ _);X"^/
M3X1\+^'O#_PX/A/6=.^&W[<O@#X46GC_ .#OC/Q_XG^$?QS\-?&'P)X<G\=7
MFB3?$CQ]\1M5D?X>V/BZ?_A)]#L/'_C;2-#\7_"\7VE:K9ZA_;OAK1JW[?W_
M  44^(G[,?Q/U;1/AN_AK78_A3X5^"OCGQW\._$OAWPYH%WXJT'XJ?$+6?"N
MIMX?\6>*/BQH'B_Q:]CH&C7MW:0_![X3>+K?P-K5I]L^(.OWMG?CPUI_Z[7/
M@'PA=77@V[ET*S5OA]?7>J>#;:V5[+3= U*\T/4O#4M_8Z59O!IJW4>@ZSK&
MEVDKVKFQM=6U$6?D/=RNV]>:-I.H7$5W?:9I]Y=06UY907-W8VMS/#9ZB(1?
MVL4T\,DD=M?"W@%Y;HRPW0AB\])/+3 !^!7B+_@I/^U#X(T3PWXDU!?A!KVG
M_%GQ'^WWX&\.L/ NOZ?IWP8LOV._VX=)_9V@^-/CN]MOB!)<^-O!^A?";7=8
M^)7Q;\.:=!X5-LG@D3:/XAT;3FUR\;ZA_8G^(FL>,?$/_!334/&G[1FE>,?#
MOAOX_>#=-T?XV^$K^PT3P+X9\,6W[!_[,FH:OXJ\%6GB+7O'?@3PI8:%KUQX
MB\1:W+I]]J7@*7QA;^(=>N[0_:M8LT_51=&TA&A9-+TY&MFU%K=DL;56@;5Y
MFN-5:$B$&(ZE.S3:@4*F]E9I+KSG8L60:'HUK8RZ9;:3IEOIL]K'8S:?!I]G
M#92V45FFGQVDEI' MO):QV,:6:6[QM"EHB6RH(%6, '\Y-I\5/"NO:/XT\;_
M +-?[0_B:]_8]UOQ!^R)X%^)FKZI^U)K/CGXC>,?A]J7[0]C;?'[]K^2Y?QM
MXC^(OP3\!>*/ .HZ5\.=;^(37'PYU'QKX6UKQ9\5Y-*\&>&?"/P^\;:W7_:P
M^*X\(_L'?MGZAX0_:P\5> ?@_P##K]HE=#_9.\36/QNL]-U+XK^#M.\._L[:
MOXL\$>'_ (M^*+J7Q]XQ^'/PY^,VM_&CPQ:6?@KQK.^HZ#X?;P!J6O7O@309
M-#O?Z)-$^'W@7PW-?7'A[P9X4T*XU2!K;4I]&\-Z)I4VH6[N9'@OI=/L+:2[
M@=R7>&X:2-V)+(22:FU/P/X,UJQTO2]8\)^&=4TW0U1-&L-2T#2+^RTE([=;
M1$TRTN[*:WT]$MD6W5;.*%5@585 C 6@#\,O^"B7[5'BNZ\<?L_WW@C1_P!H
MF\^"O@G]J_\ 8/UOPC\2?@-H>J^)/AA\?-9\>_M*^!M)\:Z->?$'X?\ B=K#
MQ)X/T#P+?7W@'2_AW?/+8_$#XF>,;Z#5=*N(/!OAJ?4/U6^)E[JNN_M!_!3X
M:2:MK.B>%-<^%?[0_CF^FTG4O[+EU#Q1X9_X5)X"\/Z;/);W$5]-]AT'XN^,
M_$EK:A7MHM6TC3-6;9>:-92Q_0MIX;\/6&G6.CV.A:-9Z5ICV\FG:9:Z786V
MGV#VDXNK5[*RAMX[6T:VN0+BW:WBC:&<":(I(-U5M9\(^'=?U?POKVK:9#=:
MSX+U*]U;PSJ6^:&[TJ\U/1M0\/ZEY<MO+$9[74-(U.[M+VPNO/L+D_9;F6V:
M[L+"XM@#\<_CEXE\'_LO_M7_ /!*OX;:W^V+KEEH/A#5/%7PK\0_#GXA_&_P
MMH%EKOA?P]^Q-\>;#0_B5\6-,O\ 4['Q7\1/%7C#QKX;\*M:>*_B-JNNZ-IW
MB:USX5L+/Q+X@U+4=2X2_P#CY\3O&G_!5K]G'PYX[\"?M2>!/"?B;P[^W%\+
M-$\!:CX4\8:!\++_ , ^$D^"&EZ%\2=2NM)US_A%_%>H>*M9B\0>,QX]$<]U
M\/\ P?XI^''@ZS72-9N?$]UJ_P"W6M?#WP'XDU#^U?$/@OPEKNI^3!;?VAK/
MAK0]4OOL]K*9[:#[9?V%Q<^3;SL9H(O-\N&4F2-5<EJW;_1=-U)7^U6J><UI
M?V4=];YM=2M(-2B6&].GZG;&*_T^:9$C)N+*Y@F$D4,JR"2&)D / ?V1/%_B
M/QS^SO\ #77_ !5<7E_K TW5]#?6=1G2YO\ Q'8^$_%.O^$=%\5WMS%)+'<W
M7BS0]"TWQ+<7*.1<RZJ\^%,A4?258OAOPYH?A#P]H?A3PSIMMHWAWPUI&FZ#
MH6D62LEIIFCZ19PZ?IMA;*[.RP6EG;PP1!G=]D8+NS$L=J@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *,C
MCGKP/<X)P/P!/T!HK\._^"A7[7'Q]^ O[4?P*T#5/B/=_LN?LXW'B/3KO3?C
MA?\ P5USXO?!SQWK%S\"/VI-;\9>'_CWXET2>.3P%X7\!^)O!WPHOAX;DO?A
M]-?>'M7U_P"*47Q*&G>!M7@\(@'[B45^5'[;_P 0?C[\&OA+\=/VD[?]J/1_
MA]H_A7P%X=@_93^%?PW^'_A#QM:?&;XSZEX5E?PWX,\>67B_PWXF\9_%+6_C
M=\5]4TOX=?#CX<_!GQ#X&U-?#!L-6LO$5WXLU6XU'P[['^UG^TA\1/@/^QG9
M_%G5;7P[\,_B]XHNOV>OAQ>?VI8ZG\0?"WPJ^(OQ_P#B1\.?A1J6KW.G:!$=
M1\=6'PUUKQUJ6IZ9HEDL,WCV_P! TSP];R1RZ_&: /O2BORN^%O[5$'PFN_C
MW=?&KXU_&OQ%I/P]^'/@'Q]I_P *?V@O@5X2\ ?M$M)XI\4^)/"6G:O\.;WX
M:Z+X+\%_%;PM\7_%S^'? 'PY^'VG^%Y/B%X1^**KX3\1ZI$OC3PIX?TWYM\,
M?M2?MVZKX+_X*PZ!K^H74OQG_9^^(_P T3X/>%?A+\*M"^(WB7X/:=\;OV>O
M@/\ %CQ+X1\+:!INCZRWQP\1?#"3XF^(&L-9\1Z7JL'BW5]#FO9-*MO#%Q;:
M1: '[QT5^='[&/Q"\:VWCSXH_!_XW_'3]H?Q]\6[#PYX2^(6C>!?VDOA)^S?
M\+-=TOX;7NI^(/#R^-_ =Y^S9X>T_P *>,O#VN^(+==(\1PZQKVJ^)O!.J:=
MHEIK6A>%#XFL/[;^9/C9^UQ\2]8^+O[8^F^&OC+\6_A#X4_9)UOPWX%CN_A5
M^SCH_P :O!'@[5#\$O _QH\3?&3]J9=?\,ZCXJ\0?#>6'XG6>A67PR^"NO\
MAGQU:^"_ OB'QZ=4BF\2:#K/AT _;*BL;P[JMOKF@Z+K-IJ>E:U::MI.FZG;
M:QH<HGT75;>_LH+N#4M(F6>Z6;2[^*9+O3I1=7(ELIH'%Q-N\U]F@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** /F/XS_M9?##X%?&;]EOX%>-+
M/Q;<>-/VN_'?CCX=_"R?0='LK_0;/7OA_P##O5?B;KDGB_4+G5["XT?3I/#N
MCW<6GW%C8:Q-<ZFT5M+;6\#27<?TV"& 8=" 1]",U^(/_!2?_E))_P $*?\
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M6='_  C^G_\ /75__"A\0?\ RSK:R/?\C_A1D>_Y'_"@#%_X1_3_ /GKJ_\
MX4/B#_Y9T?\ "/Z?_P ]=7_\*'Q!_P#+.MK(]_R/^%&1[_D?\* ,7_A']/\
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M?$C ./\ A"=)[$_\S Y[9["@#]9_^$?T_P#YZZO_ .%#X@_^6='_  C^G_\
M/75__"A\0?\ RSK:R/?\C_A1D>_Y'_"@#%_X1_3_ /GKJ_\ X4/B#_Y9T?\
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M!E?\(OH'_0-B_P"_D_\ \=H_X1?0/^@;%_W\G_\ CM:OVZR_Y_+7_P "(O\
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MY?C\?,W'_"8>(/4_]1"F_P#"V/BG_P!%+\?_ /A8>(/_ )/K^FE]%3/6D_\
M6W*=?^I=C/+_ *?>O]+7^<?^)G<D_P"B6S7_ ,+L)_\ *_7^GI_0)MD_NO\
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M_A)?#W_0;TK_ ,#[;_XY0!-_86B_] G3/_!?9_\ QBC^PM%_Z!.F?^"^S_\
MC%0_\)+X>_Z#>E?^!]M_\<H_X27P]_T&]*_\#[;_ ..4 3?V%HO_ $"=,_\
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M35/B#XDMM=N-1'A:'7+>TL_W8']3WSW/\O3MTYQ0!^(/_!2?_E))_P $*?\
MLZW]J#_UCGX@U^WD?^K3_<7^0K\/?^"ETI@_X*/?\$+)1#-.4_:L_:?(BMT6
M29\_L=_$!?E1Y(U(7.YR7&U S ,0%/[2)K<P1!_86O<*HYL[4'@#J/[0.#ZC
M)Q0!T-%8']N3?] +7?\ P$M?_D^C^W)O^@%KO_@):_\ R?0!OT5@?VY-_P!
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M^+/&-K%XA\<:;;S_ !(6#^T;:[T'P_XPT#PKJ]C'KVAZO-/PW_##EQ>_!O\
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MYKMI^RI\<?'GQ@\3>*/BY_PCT7CO2O@1INE>./@+\+$F\3_\*WET[QQXFNM
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MRZQLP-WF",'<-F[#;?X1^E-_R6^1?]DKA_\ U;YN?VS]&;_DCL[_ .RGQ/\
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MDTVD>*+>Z6-[+3-/N[;3TU<#Q T_V=KC1YR'_@J7\#=)N_A_?Z)\(/C/)=^
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M>G!Y^E?Z&G\$B44I!!P003T!!R?PI,'.,'.<8[Y],>M #D^^O^\O\Q7]]O\
MP3,_Y,%_9/\ ^R,>%/\ T7<5_ DH(=000=R\'@]17]ZO_!-5->/[!?[*9M)M
M'2W_ .%->%?*6>WOWF">7<;?,:.\CC+8ZE$4;LX&, ?S!]*?_DC^'O/B-?\
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M)0ACLM@G4ITIU*?MI<O-7J0E:M6E.LHPYW"/YX?\'#7_ "0']G__ ++AJ/\
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M+IU(*A3J96X2K*HJZFE4HSIMU(PC*4:L;>TS!1C[&,<5*C/^TG_2'_P;Y?\
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M\FLXQ_[ <)_ZM<O/TSP<_P"3F\(_]AV)_P#59CC^KWQ9_P BOXC_ .P#K/\
MZ;;JO\T2/_51?]<HO_1:U_I.^*;'7AX9\1%M>C*C0M8R/[&MN1_9USD<W?\
M^OH>":_S8H_]5%_URB_]%K7XC]$_^%QU_P!?.'/_ $G.S]B^E%_'X)_Z]\1_
M^E9$/HHHK^P#^40HHHH _03_ ()5_P#*0C]E[_L=O$'_ *K;QS7]Z2?<7_=7
M^0K^"?\ X)9I,_\ P4#_ &84MYA;S-XU\0".8Q+.$/\ PK?QP23$[(K[E!7E
MEVEMXR5 /]Y.GP7\*O\ ;K];[<(_*VV45GY6 V_(CFEW[\K@'&S;QG=Q_"/T
MIO\ DM\B_P"R5P__ *M\W/[9^C-_R1V>?]E/B/\ U4Y.:-%%%?S*?T>%%%%
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MN+O_ (1$F73&TSP1HWV*V^SHL%RM_)YTS7&(?T#_ (FKX?\ ^B4SK_PLP/\
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M#KQ<HW<FHNSNT?QYO]]O]YOYFFU_4A_Q"\?L''K\?_\ @H=_XEWK'_S&4?\
M$+Q^P=_T7_\ X*'?^)=ZQ_\ ,97],KZ5?#Z27^JF=:)+_?,#Y?U\GY7_ )T_
MXEASS_HJ<H_\(L;_ )_U;TO_ "WT5_0?\8?^#<;]BSP)\2?V5?"6C_'[]O[^
MSOC-\<?$_P //%1O?VM=6FN?[!T?]FOX_?%>V&D.?!Z&TU$^)_AMX=:6Y439
MTA-5LS!_I@N;7Z!_XA>/V#O^B_\ _!0[_P 2[UC_ .8RG_Q-7P]_T2>=?^%F
M!_K^GY77_$L6>_\ 14Y1_P"$>-\M]?7OMYG\M]?T#_\ !O/_ ,G!?M"<'_DC
M7A;H"?\ F?)/3Z'\J^B?^(7C]@[_ *+_ /\ !0[_ ,2[UC_YC*]#^'7_  ;J
M?LR_!_4=1UCX2_ME_P#!4OX8ZMJ]C%IFK:GX!_;F\9>$[_4].@N/M<%AJ%UH
MOABSFN[.&Z_TF*WG=XHYRTJ*'8D_(<>?2'R;B_A#.^&\-P[FF#KYKAZ-&GB:
M^*PE2C2E2QF&Q+<X4_?DG&A**Y=>9I['U? _@'F_"G%>3<18CB#+<71RO$5:
MU3#4<+BJ=6JJF%KX=1A.;<(M.NI-RT:BUNT?O)XK.?"_B/ )_P")#K/\+?\
M0-NO:O\ -%C_ -5%_P!<H_\ T!:_LPF_X(H>&+B&6WN/^"E__!9J:">.2&:&
M7_@H[\4WCEBE0QR1R(VCE721&9'5@0RD@@@FOF+_ (A=_P!@T8 ^/W_!0X
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M\0=3N]:^&7@[Q)X-O?!?B3Q1X0\>?"C1/!WB/QG%K?Q/^.WA#Q)X*\5:3?\
MPV\")?6^HWNEV]CH/BK5=4\0>&=.UG[+\;_$34_"NI_"*RTCP%XH\8VOQ.^(
ML7@K5]2T9+6U@^'&BR_#[Q[XW_X3OQ?!J;6]TF@)?>#=.\'R6UI&^J)XA\7Z
M'&UN(5O#& >HT5\B? O]L3P/\;[O]I9CX5\;?"S0OV9O'VG^#?$^M?%[3(/
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M@#^+G6_^"WW[>MAK>N6%OX@^$8M[#7-;L+8/\*8&<6UCJUY9VX=O^$D^=Q#
M@=\#>V6P,X'V[_P37_X*D?M:?M/?M=>!_@[\5]8^'EWX)UWPQ\0M5U"W\/>
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M5\.Z+I/A]].7Q)K%UX@T&&Y\3:"VE:/>6^L^%+.^\5Z;/<^&["]U6W^#]?\
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MXVNU_P"$?$5KX(DC\9SRQ^%Y(]6;\]+'_@BW\(M/^$&F_#JP\3>'M!\6>(?
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M'V6V_P"?>#_OU'_\34RJJ@*H"J!@*H   Z  < >PI:* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
-HH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>biib-2015930_tyschart.jpg
<TEXT>
begin 644 biib-2015930_tyschart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %- 3T# 2(  A$! Q$!_\0
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M[-];Z;807IM$L#>0V=M#=&QCN)KN.S-S%$DQM4NKFXN4MB_DI<32SJ@ED=V
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M/^!7P=\3^.?%'A77_$G[)/Q \*_LRWWQ%'B+X V4T/A*ZT75/ 7B3]H[Q_\
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MN7?_ (,=(_\ DVC^U-6_Z%R[_P#!CI'_ ,FUOT4 8']J:M_T+EW_ .#'2/\
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M_$_QG@MH98O#OBC18+'4O .G:5X%N_B%XOFU2UT@^"]!GL/$U]X<ZW_@HY\
M_CE^T?\ LW>/_AM\&+CX5Z^_B?P5XP\,Z]\)_C%X5@U/PCX_EU:31I/#NH6O
MBS[5'=^"?$W@Z]TFYN=(O+O3/$?AK5;?6-3LM:T2.]CT+7=%^:?C1_P3_P#C
M[<?\$X?BW^P;\$]5^!EU_P +^\+_ +3OAKQ)K7C#4O'_ ,./A[\#M*_:"\0>
M)O$.B^$?@9\/_"OA+XEW4OP[^&2>+[SP]X7\(:QX@\.P6.CZ'IPT^:PLK_\
ML+0P#];=-\0:O?Z=87S>&;F-KRRM+ID75-(=4:YMXIC&KF\4L$:0HK$ L &
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M\5_$+P5XS\-6?@+PJEYJ>H>'O$UAK2>)/B/H,=MIECJFBZKIOTC^RC\";_\
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MR+R-"UW'0?\ 4-H Z"BL+_A(]+]-3_\ !%KO_P K:/\ A(]+]-3_ /!%KO\
M\K: -VBL+_A(]+]-3_\ !%KO_P K:/\ A(]+]-3_ /!%KO\ \K: -VBL+_A(
M]+]-3_\ !%KO_P K:/\ A(]+]-3_ /!%KO\ \K: -VBL+_A(]+]-3_\ !%KO
M_P K:/\ A(]+]-3_ /!%KO\ \K: -VBL+_A(]+]-3_\ !%KO_P K:/\ A(]+
M]-3_ /!%KO\ \K: -VBL+_A(]+]-3_\ !%KO_P K:/\ A(]+]-3_ /!%KO\
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M]$U7QY::I\0?$EMKMQJ(\+0ZY;VEG^[ _J>^>Y_EZ=NG.* /P]_X*62Q0_\
M!2#_ ((5RS21Q1I^U;^T^6DED2*-<_L=?$!1N>1E098A5!(+,0HRQ /[6QZW
MHX1 =5TW(10?^)A9GH!W$^#^%?BI_P %*D23_@I%_P $*DD1)$;]JW]I_*.J
MNIQ^QU\02,JP(." 1D<$ C! -?MG'I]@40FQL\E%)_T6 =0.PCP/PH A_MO1
M_P#H*Z;_ .!]G_\ 'J/[;T?_ *"NF_\ @?9__'JL?V=I_P#SXV?_ (#0?_$4
M?V=I_P#SXV?_ (#0?_$4 5_[;T?_ *"NF_\ @?9__'J/[;T?_H*Z;_X'V?\
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M3ZYJ\"Z3HWA)+J^:P,>I7BPG6])A!@L;65KBY??*@V1*6P2V, U];?V=I_\
MSXV?_@-!_P#$5^>__!5>SLXO^">O[4KQ6EM&X^'<1#I;Q(ZG_A*/#HR&5 PZ
MGH1_*O;X:RZAG'$?#^4XJ56.%S3.\JR[$RHRC"M&AC<?0PU:5*<X5(1JJG5D
MZ<I0G&,[.4))-/QN(\PKY3P_GN:894Y8G+<GS/'X>-:,IT95\'@J^(HJK",Z
M<I4W4IQ52,:D)2C=1G%M-?SI-^VA\ <G_B?^).I_YDS6O7_=I/\ AM#X _\
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M2&)_\.>1?_/3S7WGR_\ Q&KPP_Z*O#_^&W.__G9YK[S]!**_/O\ X> ^&/\
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M^YOV*?VG/%'QG\2_M0?"^X\3:7\8+7]G7XN^&?!WA7XVQ0:?X=L_BKX*\?\
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MCW4MCH?B/6='M)+I]=\2127,EKI][;0O</'#%$\S(9&2&-&8K&H !Z3\!_\
M@ES^SQX$^#_A3P/\=_#N@_M/^/;#3_A=<^)/'_Q1\*^'KJ(>*/AA\#O"?P"T
M:X\ ^'].TG3+#P1H5AX!\+C0-/M[=+OQ'?:9J>J?\)9XD\1W^IWUU++\,_\
M@E_\"_@W^R?^U+^RA\+;_5O F@?M5:E^TO=^+?&OAO1_#]CXJT"R_:,\1_$#
M5_[(T.)K*?29[#X8:+\0+SP?X"&J6MS+#X>TO3H]3:ZNOM$TGYM?\+@^+?\
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M5P__ *M\W/[9^C-_R1V=_P#93XC_ -5.3CJ***_F4_H\**** "BBB@ HHHH
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M$(SBI0E*AB,13JQC.,HR@W%*46FFTT?HM/IGBS3/ALI\5>!(;RRUO2_!EO\
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M"&8\'C@9_ 2OZ!_^#>?_ )."_:$_[(UX6_\ 4\>ORWQL_P"36<8ZV_V'"?\
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MXIU>UTBVN+J[M]+M]0UGPM=W46GP75[>7,5HDH@CGN[B54#S2%OT;PMXVPG
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M;*V74YM+M+FZO;73I=0$0O)+"VO+Z]NK>S>9K:&YN[J>*));B9W_ #S\:_\
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MW+/.0C2875HH _+;PG^PI\8O$.O?M>6W[0OQF^'WB7X>?MA>+/!'Q \9Z/\
M SP+\4/@GXZ\->*?AS\/O@I\,O#5CH'CR^^-WC^.;PCJ'A[X,6-UXNT6_P##
MTLOB.Z\0ZOH]Y=MX6FN-&N_;OV,_V-A^R'/^T1(/C%\2OBXOQX^.VM?&5)/B
M/KE_KE_X7CU3PQX7\.KHWVZ^N[I]6U:1O#SW6L^)A'I[ZU"VCV<NFVXT..>[
M^VZ* "BBB@#YO^/'[/=K\;?&W[+'C&?6[+1W_9H_:(/QZAM;OP[!K<OB5_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6%]*W@J]US2F\=2>&;&Y-Y'E?LU_L@^,/V>/B?KOCV[^.6J_%R+Q]\"_@/\
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=44 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>biib-2015930_ujbchart.jpg
<TEXT>
begin 644 biib-2015930_ujbchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (5 3T# 2(  A$! Q$!_\0
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MH?@SI'P4^#GB?P+?? #XT?M)Z?XTO_CAXYT'QC)X#^ 6H_!_0?'.AW/@>V^
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M%L5M]4\:^+-!UF;Q;\/_  39>$/$GP<^,WASQ_J6O_%FR\=7WPKBTOX?:YX
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MR>!--^)X\)M\7;'PO-\+AXN'P^UK1O%__",MXO767T75+.XBM))7>"/0U_\
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M(B/!Y;*I&S0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 > _%C]HSP3\(/B;^SI\
M)/$&F^)M1\7_ +4'C[QI\.?AJNB6.GSZ3;Z_X#^$/CKXVZ[-XIU*_P!5T_\
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M%%% !1110 4444 %%%% !1110 4444 ?E/\ MSVT-W^W/_P1OMYP[1/^U?\
MM+[@DLT#97_@GA^U.RD2V\D4JX90?ED ;&U@REE/Z<#PUI.!^[N^@_YBNK__
M "PK\SOVWO\ D^W_ ((V?]G7_M,_^N[_ -JBOU07H/H/Y4 8/_",Z3_SSN__
M  :ZO_\ )]'_  C.D_\ /.[_ /!KJ_\ \GUOT4 8'_",Z3_SSN__  :ZO_\
M)]'_  C.D_\ /.[_ /!KJ_\ \GUOT4 8'_",Z3_SSN__  :ZO_\ )]'_  C.
MD_\ /.[_ /!KJ_\ \GUOT4 8'_",Z3_SSN__  :ZO_\ )]'_  C.D_\ /.[_
M /!KJ_\ \GUOT4 8'_",Z3_SSN__  :ZO_\ )]'_  C.D_\ /.[_ /!KJ_\
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M%EJ=FNJ02:,9/MJ1_:/D,_M ? [<=WQ6\!LN[YD;7H0KKGYD8JN0KC*L5^8
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M3O-^RK,OG;-_FW=Y=9V;MNW[7<3[/O'/E[=W&[.!B^"#G!!P<'!S@^A]Z6@
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M/_/.[_\ !KJ__P GT?\ ",Z3_P \[O\ \&NK_P#R?0!OT5@?\(SI/_/.[_\
M!KJ__P GT?\ ",Z3_P \[O\ \&NK_P#R?0!OT5@?\(SI/_/.[_\ !KJ__P G
MT?\ ",Z3_P \[O\ \&NK_P#R?0!OU^>G_!5L'_AWG^U/Q_S3J+_U*/#O^!_(
MU]V?\(SI/_/.[_\ !KJ__P GU^?G_!5+0].L_P#@GS^U'<01W EC^'<3(9-0
MU*90?^$H\.CF.>\DB8<]'C8<"OJN!?\ DM^#?^RJX>_]6^#/F.-O^2-XM_[)
MK/?_ %5XH_A+?[[?[S?S--IS_?;_ 'F_F:;7^KL=EZ+\C_+X****8!7] _\
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M/M_X(V?]G7_M,_\ KN_]JBOU07H/H/Y4 +1110 4444 %%%% !1110 4444
M%%%% !7YZ?\ !5O_ )1Y_M3?]DZB_P#4I\.5^A=?GI_P5;_Y1Y_M3?\ 9.HO
M_4I\.5]5P+_R6_!O_95</?\ JWP9\QQM_P D;Q;_ -DUGO\ ZK,4?P:/]]O]
MYOYFFTY_OM_O-_,TVO\ 5V.R]%^1_E\%%%%, K^@?_@WG_Y."_:$_P"R->%O
M_4\>OY^*_H'_ .#>?_DX+]H3_LC7A;_U/'K\M\:_^36\8?\ 8#A/_5KEY^F>
M#G_)S>$?^P[$_P#JLQQ_5CXL_P"17\1_]@'6?_3;=5_FB1_ZJ+_KE%_Z+6O]
M+OQ9_P BOXC_ .P#K/\ Z;;JO\T2/_51?]<HO_1:U^(_1/\ X7'7_7SAS_TG
M.S]B^E%_'X)_Z]\1_P#I60CZ***_L _E$**** /T$_X)5_\ *0C]E[_L=O$'
M_JMO'-?WI)]Q?]U?Y"OX+?\ @E7_ ,I"/V7O^QV\0?\ JMO'-?WI)]Q?]U?Y
M"OX1^E-_R6^1?]DKA_\ U;YN?VS]&;_DCL[_ .RGQ/\ ZJ<G'4445_,I_1X4
M444 %%%% !1110 4444 ?E/^W/+-#^W-_P $;Y(+9KN5?VK_ -I?;;I-# SY
M_P"">'[4X)$L[)$NQ27PS OMV+EF45^G U35\#_BG+GH/^8EI)_]NJ_,[]M[
M_D^W_@C9_P!G7_M,_P#KN_\ :HK]4%Z#Z#^5 &#_ &IJ_P#T+MS_ .#+2O\
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MZB_]2GPY7Z%U^>G_  5;!_X=Y_M3\?\ -.HO_4H\._X'\C7U7 O_ "6_!O\
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M'Z)_\+CK_KYPY_Z3G9^Q?2B_C\$_]>^(_P#TK(A]%%%?V ?RB%%%% 'Z"?\
M!*O_ )2$?LO?]CMX@_\ 5;>.:_O23[B_[J_R%?P3_P#!+.26+_@H%^S%)# U
MS*GC7Q 4@66.%I#_ ,*W\< @23%8UV@E_F8;@I4'<17]Y.GW5Y<J_P!JTV33
M]@C\O?=6ESYN0V[!M9'V[,#)?;NW?+T./X1^E-_R6^1?]DKA_P#U;YN?VS]&
M;_DCL[_[*?$?^JG)S1HHHK^93^CPHHHH **** "JM]<?9+*[NO)DN/LUK<7'
MV>*2TADG\B%Y?)CEOKBTLHGEV;$DN[JVM49@UQ/#"'E2U36575D=5=&!5E8!
ME92""K*00002"",$$@\4 ?C_ .%[?]I:/XV:UXV\$> ?VZ_A'\//BS\5/#/Q
M \9>";;PG_P2PUOX7PW-QIWA/PWXBUO4O%=M\:?%'Q9N]'UW0?#MC<>)]7TC
M4]>\1"R@DN/"5NM\MO%<_KU:75M?6MO>V=Q!=VEW$EQ:W5M-%<6]Q;S*'AF@
MG@=X9H9(V5XY8W9'0AE8@YKP"Z_90_9YO-6?5I_A9X;*S7'VNYT*/^U+?P;>
MW1E6:2YO_ 5MJ4/@:^GFF433RWGAR=YY<O,9&))]_M+2UL+6WLK*V@L[.T@B
MMK6TM88[>VMK>"-8H8+>"%4BAAAB18XHHD2.-%5$55   /RV_;>_Y/M_X(V?
M]G7_ +3/_KN_]JBOU07H/H/Y5^5_[;W_ "?;_P $;/\ LZ_]IG_UW?\ M45^
MJ"]!]!_*@!:*** "BBB@ HHHH **** "BBB@ HHHH *_/3_@JW_RCS_:F_[)
MU%_ZE/AROT+K\]/^"K?_ "CS_:F_[)U%_P"I3X<KZK@7_DM^#?\ LJN'O_5O
M@SYCC;_DC>+?^R:SW_U68H_C[_8>\)_"SQ;\<;&R^+.A6^NZ)$-*BT:+Q%I?
MC'4OAK#XBU/Q%IUE%'\2I? \;:M8:7J&B?VW:>&)KZ2#P]<>,/[*MM<:2V9(
MV^HOAG^S;\&=5^(?@#X3^)_!7PITG7/B%\9M7\*_$W3]?^-_BC4?&'PY^&WB
MKP1X#\1?!SQ)^S5=MJ'ANZ^*&GZWI/BG4?'?]O:AX5\<:Y;@:1X6^)>D^&-&
MM;_6[[\V/AE\5_B)\&/&-EX[^&'BW5_!_B?3V=([_2[EDAO+5I%DDT[6-/<M
M8:WI,LL4,\FEZK;W5B]S;VUUY(N+:"6/7T_X^_'#2]-\4:18?%OX@PV'C6]U
M?4_%B2>);Z[N=>U/Q#IT>C^(M3N]3OFNM6@U+Q'H\46D>(M0TV_L;O7M)BAT
MO5YKRPABMD_TCSGA_B#'9AC\3EV;SP>'Q678;#X>#S',**H8J$,51G7AA\-!
M4H1H+$1QE-*<ZN)QM+#*57"X:EB:6._SSR?/LBP.78##8_*88O$8;'XC$8B?
M]GX"K[?#3EA*D:$L1B)RJSE6>&>$FW"%/#8.KB'"EB<35P]7!?1\W@[X,:O\
M,[/1O"D7P]U/QAX$^!'A/XQ?%N!_ ?Q3\-_$_4?#^AZSI5Q\4M4\*_%37_%<
MOPUM=:O-'U2TNO#%N?AK>^#[[PY<QOH?B75];D@T^?B?CUHGP[TKX=^"]1_X
M5KX:^"WQ:U[QKX@U33_ACX<\2^*M9U:T_9[N=!T^?P/XD^+&E>+?$/B+4/#_
M ([U;Q%+-'X=NW;PWJ?C3PJM]XHU/PAI6F3^%[O4/)+3X\_&FP\,:)X+L_BC
MXS@\)^')=$DT/0%U17L--C\,ZQ%XA\.6$1FMY+J?0] UZ"#6=%\-7MS=>&=+
MU."&\LM'AFBC9=G6_P!I?X^>)/$.F^+=<^*GB/4?%6DZKJVNV'B62T\-6^OQ
M:UKVDZAH.M:I/J]CH%I?ZC?:IH^JZEI]]/JL]\T\%Y,QQ/Y<T?1A\FSVAC*=
M5XR.(H4<7C<7&-?.<?&K556A&%##5*=#+*>#EA9U[U:D*^'Q-; QC%8;$XEW
MOA7S;)*^$J4EA'0KU<+@L*W1RC!2I4_95^>OB*<ZV93Q<<3"BO9TZE'$8>CC
M92D\3AL/N=?')X1LOV8+[Q+K_P *?AHOB7Q5XPB^%7PQ\5Z?9>,[/QF)_!>G
MZ+XM^*'Q#UJ^?QU<^']0N+2QU[PCX*TRQC\+VVG7&J^*M9U.2VB;P]:P3?K-
M_P &\_\ R<%^T)_V1KPM_P"IX]?@C<^(M=O/#V@>$KK5KZX\,^%;K7;WPWH4
MLV[3=#N_$[Z9)XBN=.@V@PS:T^BZ2^H.SN9SIUIC:(@#^]W_  ;S_P#)P7[0
MG_9&O"W_ *GCU\AXMX.IA/"OCMU:LZD\4H8FSK5JM.E2>;Y?2PU*DJTI.BEA
MJ5&=:E3M2^MSQ$Z=XS3?UGA5BX8KQ.X'5.G"G##-X>ZHT:52K5658^IB:E65
M&,56;Q-2K"C5FO:_5(8>G/WH,_JQ\6?\BOXC_P"P#K/_ *;;JO\ -$C_ -5%
M_P!<HO\ T6M?Z7?BS_D5_$?_ & =9_\ 3;=5_FB1_P"JB_ZY1?\ HM:_(?HG
M_P +CK_KYPY_Z3G9^J?2B_C\$_\ 7OB/_P!*R$?1117]@'\HA1110!^@G_!*
MO_E(1^R]_P!CMX@_]5MXYK^])/N+_NK_ "%?P6_\$J_^4A'[+W_8[>(/_5;>
M.:_O23[B_P"ZO\A7\(_2F_Y+?(O^R5P__JWS<_MGZ,W_ "1V=_\ 93XG_P!5
M.3CJ***_F4_H\**** "BBB@ HHHH **** /RN_;=_P"3[?\ @C;_ -G7_M,_
MI_P3N_:H)_(5^J Z#Z"ORH_;GMH;S]N;_@C?;W"EXI/VK_VE]RK)+$25_P""
M>/[4[J1)!)%(,,H/RN <88,I*GZW_:/^+W@;]G'P)I7BO6/#^K^)M9\7>-O"
M/PN^'_A33O$$.B-XI^(WCZ^DTOPCH-YXG\3:YI7ACPIIMY>12OJ'B#7]2MK2
MSMH'ALH=5URZTG1=3 /J&BOSL^$'[1GQ1^+7[-'P>^+NC_LA^/$^)WQ5A^%Z
M1^ ;[XE:!I7P_P!+L/B!\.=(^)-W\3[GXJ)K&MW2_![1M)O[C2FU*#P1J'Q*
MG\7Q6OA$?#(WMU]L2/P+^U%XL^(NB_%#P_X1_9DU_7_CK\&_VDX?V9/B'X'T
MKXN6,WPI\/Z]/\.O"?Q@_P"%ES_&ZZLK*6Y^%-K\./&OAV34Y].^&U]\2]+^
M(%^OPVO/AE'K4<US$ ?HO17YM>&OVG/BC\1?!OQFMOA7^RS9^,OCS^SS^T*?
MV?OBM\+;S]HJU\,^!%OC\._"7Q2B\8^ ?C3=^$;ZR\8:+-X3^(?@1)M%O_!7
MA?Q7H_B+4=?\-^(]'T74_#%PE[Z7^QG\:?%/[3_PU\2?$+QW\#K;X-1Z7\1O
M%W@;PO'HGQJM?C)X>^(.D^"[F'0]7\=>%O%FA:5X8MIO#<OC.V\3>%=+FFTU
M%UAO"]UK^E3WOAS5-%U*^ /MJBOS;^*'[6FO_!Z#5/B3\0/V9?%OAC]FW1?C
M[X1^ %_\1];^(MQI_P 4I[SQO\5?#OP*\/?%C1_@8VBRR:E\&]2^*_BC1]-T
MK6&^(=KX\U_P5<Q?$70/AUJ6@7FDKJ?Z"#PUH[#(@GZD?\A'4^""01_Q^\X(
M//>@#H**P/\ A&=(_P">$_\ X,=3_P#DVC_A&=(_YX3_ /@QU/\ ^3: -^BL
M#_A&=(_YX3_^#'4__DVC_A&=(_YX3_\ @QU/_P"3: -^BL#_ (1G2/\ GA/_
M .#'4_\ Y-H_X1G2/^>$_P#X,=3_ /DV@#?K\]/^"K8/_#O/]J?C_FG47_J4
M>'?\#^1K[L_X1G2/^>$__@QU/_Y-K\_/^"J6A:;:?\$^OVH[B"&598_AW$R,
MU[?R@'_A*/#HYCFNY(F'/1T8<5]5P+_R6_!O_95</?\ JWP9\QQM_P D;Q;?
M_HFL]_\ 57BK?B?PEO\ ?;_>;^9IM.?[[?[S?S--K_5V.R]%^1_E\%%%%, K
M^@?_ (-YP3^T%^T)@?\ -&O"W_J>.?Y G\*_GXK]^_\ @WTL+74/C]^T#'=(
MTB1_!SPNZA)[B AF\=NI):VFA9N@P&8J".G)S^6^-G_)K.,;?] .$_\ 5KE_
M]?JC],\'/^3F\(_]AV)_]5F./ZO?%8)\+^(\#/\ Q(=9_P#3;=5_F[_#;1?"
MGB/QKX0T+QSXJC\$>#]5U*VM/$7BV62T@BT+3FM9I#=R7>H17&G:<DUS';:>
M=7U.WN-+T7[;_;.J6]QIUA=02?Z-?BKPWI"^&?$3""8D:%K!&=0U0CC3;KJ/
MMW(/0^U?YO\ X3\3Z[X+UK1_%'AF^33==T<F?3[R73]-U:W1KBPGL+J&\TG6
M;/4-'U6PO;"\N[#4=+U6PO-.U&PNKFSO+::WGD0_A7T6(5:F!\0H8>?L\1.&
M10H5.94^2M*CGL:<_:.CB%#DFXRYGAZZC:[HU4O9R_:?I,RI4\?P#.O#VE"$
ML]G7I\KGSTHUL@=2'(JN'<^>"<>58BBY7LJU)OGC^H7C']BWX;Z=\6/BOI^G
M>#/'FA^&/"OPV\.^+O ^A>-_C7\,O!OPP\::]JGB_1O"VHVVG?M43Z5K/@S2
M](L]/N=1U"PT'Q/IVC^+M:\7Z=JOAJSN5TZULY+KSGP9^S%\&]4_:-\<?L[Z
MQ!\2)=4TCXBMX<;6[WXB?#SP)>^#?!EQH%E=6FK>&_"6O^'I?$?[0_CIO$$^
MI6VA>%?"6D>&X?B%X9L/#VK>%+8W?CNQ.C^*>-?VQ_BYX^U777\2:=\,]4\#
MZ\--:;X-ZI\./#FH_!^SN]*FN;RSUFP\'&WM#;^)UU'4-6O9O%B:@GB2[35[
M[2;[4KO0C!I<.3!^UI\85\0'Q9J!^'7B'Q59^*8/&GA3Q'XE^%/@75]6^''B
M6RTG0-#TJ_\ AI,VDP0^$K;0M*\)^%;7P[H:6]_X<\/OX:T6]TC1[34;,WDW
M[UA<EXYC@ZE/$YEAW7GE<<-2E#,LQYL/C(T<OAAJ\JC4I5I4:U'&5L5>?/4G
MB+UL7FN&]G@,/^(8G-^"GBZ53#Y?B%1AF;Q%93R[+^7$81U<9+$4(TTXJC&K
M2JX2GAFH<E.&'Y:.%RS$>TQM>KK_ ,,/AW8_LS^'_BIH6N^,M7^(3?&M/AMX
MVLM4T:V\/>%-"AN?AMJ7C2'1=%T^66]UW5=7TRXL84UOQ'J,^F6,EQ=RZ/IF
MAF/39-8OX_A%\-/ASXX^&W[0&OZ_K_BQ?'_PX^$VO?$'P9X:T;2[.W\-^7H'
MB?X>:+<:OXL\1WLL]Q?)>?\ "976GZ5X4T/38+A9K&;6M7UZVMDL-,O\6;X]
M>*+GX7W/PDN?"'PFN?#E[KS>+KS6+CX?13>.+SQO)HT_A^7QW=>+I-8:\F\8
MSZ3<W-I<:N]N89O/EFDL&N',U:GAO]H_Q1X6N_B3=Z9\._@+*?BO;:QI7B^U
MO?A!I+Z8WAG7;S0-1U#P7H.E6&IZ=I_AOP8VI^&-'U*WT+2;>'[+>V\DD%VD
M=Q-"WT<Z'$/U/$T8SF\0\T6)H5WC**F\%'&X2M]4DU@^6%*I0^LTN6$83C"-
M.FZDO:5)Q\"%?(?K6&J2A!45EOU:O26#K.,<9+"8BC]:C_M;E.K3K_5ZO-4G
M.$IRJSY(^SA"7T)_P2M&/^"A7[+ZC/'C?Q"/? ^&_CGK] .:_O07A5S_ '1_
M*OX+/^"72Q:C_P %"OV://@BCBN_'GB:9[>T$EI;P^;\/?'4XAM4BE$EO;0,
M1';PK*?+@1(2[J"6_O#T_3+/3E<VD;Q^<L>_?<W5QG8&V@?:9Y]F-S?<VYS\
MV<#'\=?2EO\ Z[9#??\ U4P]_7^ULWN?UE]&:W^IV>?]E1B+>G]DY/\ UO\
M\#2HHHK^9C^CPHHHH **** "BBB@ HHHH _*[]M[_D^W_@C9_P!G7_M,_P#K
MN_\ :HKZ^_:O^'GBSXI_!3Q%X&\,> ?@W\6+37'MH/&'PJ^.>FW5YX+^(G@Y
M8KE]3\.6NI0Z=XAL_#'BI+X:5K?A7Q'K/@_QEHUIJ^C0V=]H=N-0C\0Z%\@_
MMO?\GV_\$;/^SK_VF?\ UW?^U17=_M9?M8_$#X&_$?2/"/A6'P3)IU]X.T[7
MY3XCL[NXOA=W6K:U8R"-X-=TQ!:^5IT.Q3;LPD,I,K A4:3D[13;[)-O[D)M
M)7;26BN]-]$?)_[$G[)/[5/[.7[&^A?#W4?AQ\,O%'A7QQI?PUM_&W[&GQ"^
M*GC76]/\"_#YOV9?"W@+XG>%_!'Q+UO1]4T;PUXV\:?&73;_ ,?^*?AS_8-]
M\&=*L=3\1>&O">MZ;J^KWGC2[].^#/[,7[1GP5^&OQJT#0/A'\!;WX+?&#XV
M:OXCLOV&]0\?:Y<>%_AE\"_$WP<TKPOXX\)> OBI_P (G%H=MXW^(WQLM-;^
M,7BOPEJ7A2^^&%K9^,/$GA70/$-AJM[+XNFWO@M^VO\ $WXC>+QH&KS_  WM
MT2S-S:Z1HUG%;Z_X@E\P12VNCOK?C>WLB^G0O_:5]%%'?7\MI$4LK&4&XGM7
M)^VC\2QHGQ5O9M1\&6^N_#^VM+NR\,:IX!UK0]66SD\5^&/#EQ=>,H[OQK/#
MHET6\1&.ST?3I]0GDN[*:ZN;RUL)+*._KV<]N25][<KOO;MW:$IP:NIQM_B7
M:]M][-.W8ROA9^RS^TQ\(?V6_P!NWPI\);7P+\'/$WQH'Q,\0?L<_L_^&?'%
MYJG@7]F;7?$WP5T?PK"A^(\OA>P>WO/&OQMM_$OQL\1:7H&A7GA+P9KGB>YL
MO#UQK+/J6I7GVY;^$_&WP!^$WP"^%/[/'PX\)^,?#_@;5/@M\)-9TWQ3X\N/
M ,7@OX&Z';:=X5\5^-M#GMO"OBH^*_%7@_PSIT.HZ'X&F30X?&%_OL;CQ5H>
MXWA^)1^WQXU;X=7GBI]/\,V6KKJFG^&M'>X%I<:'KOB,00ZGXA%O91:I!J-M
MI>AZ++!<SR-J<]S'>ZMH=DWF_:9Y8MCX8_MI_$GX@1W5E(OA9-6MX]9N=1O]
M*T*UDT'PII^GZ1<ZEI]_JME=>-W\1^*&U.6SNH;C3?#-I#>Z;;1QSQ?VE-.(
M$/9SWY)V6[Y7TWZ=!>TAMSQOIU775???3N<3XR\!_MC_ !A_:OT_QK\>OV:M
M)\7? /X+?%JQU;]FGX;^$/VC/ ]IX%BO/#NH?9] _:A^.&B:UX5T_P 2^/OB
M[I#RW/B3X9_#)63X>_!J2*QUJR7QQ\5X-'\=>$_V(' QC&,C&<\ \'/N.?7G
MGFOQ)C_X*,?&5UC8VGPJ&]48@:=J+;2ZABN1XMP<9QD<'K7ZR_!+QKJ?Q&^$
MW@'QSK*Z>NJ>*/#=AJ]\NE(\6G"XN0Y<6<<ES=ND VC8K7,[ 9S(U)QE'XHR
MCZIK\T-2C+X9)^C3[?YH]2I 0<^WKD?CSU'N.#V-<!\6%^(;_"[XCI\([GPS
M9?%9_ ?C!/AE>>-%N'\'6OQ";P[J2^"KCQ8EHKW;^&8?$QTN37DM$>Y?2UNE
M@5I2H/X>_L!?$?XL>.O$7[6WP%\1_'#]JOX(?M(^)]?^/\OA/1OVC?#7PO\
MC%HNAZUX=/PG\.^)?BC\&/&?A&S7X9^*K[X/^)O&&GP>(?A9H7B6T\$06OCC
MP%K+?#C1[%KT:A)1_0#N4C(((P&SD8VG.#]#@X/0X- (/0@\ \$'@]#]#V/>
MOY__ (F>*_VG=+\4?M;^!O\ @FY\2?C1\;]-^#G['OQ \)^/_$OQ"\?S?&NP
ML_VY[/QMX!?P+X8^!_B_XI76J:;?_'CPU\(/^%WZM\7/AUH^H#X.^&O'^I_
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MC_?;_>;^9IM.?[[?[S?S--K_ %=CLO1?D?Y?!1113 *_H'_X-Y_^3@OVA/\
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M9_\ 3;=5_FB1_P"JB_ZY1?\ HM:_$?HG_P +CK_KYPY_Z3G9^Q?2B_C\$_\
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M^Y\>6,=KX0T;X9?&K7=1TZ;2=.\'7%Y%X9U&P7Q)KEO8P6W@FX@UO^YZ?%6
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M@X/0X./SH*L.H(^H(_G7[@?BXE%'3K2D$=01GID8S0!_6Y_P;_Z18:A^RO\
M%J6ZA>1T_:"U>-66YNX?D'PX^'3 %8+B)#@LQW%"QW8+$!0OVQ_P52T+3+3_
M ()\_M1W$$$BRQ_#N)D9KN^D /\ PE'AT?<ENGC;KT9&''UKXY_X-\O^34_B
MY_V<+K'_ *K;X<U]O?\ !5O_ )1Y_M3?]DZB_P#4I\.5_G=Q7_RD,_\ LO\
MA[_U-RL_OKAAO_B J_[(;/%\G@\P_P V?P:/]]O]YOYFFTY_OM_O-_,TVO\
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M//\ @E7_ ,I"/V7O^QV\0?\ JMO'-?WI)]Q?]U?Y"OX1^E-_R6^1?]DKA_\
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M3ZEX;.CZ,EO'H^DG1+W5)]-_LO28K2TBTO3_ +-]CT^*UMHK.&&.")5P=/\
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MDXG!Q_Q:30^N/;G\N?2OZ$_XFPJ_]$)#_P 25^7_ %(/)_?Y'X+_ ,2NT_\
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M:CXG\.6,LG[06L2)%=:_H\$K1CX<?#E?,$4M\DGEELJLFW8S*ZJQ*.%^V/\
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M7M4\6>+?%'B+7-2DDO-7\1^+/%NNZYXG\0:C*4%WK&KWLT4%M T5M%Z-110
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MQKUG0-=^*_PXT_2)(5-WX/\ '>H>';6/7X]9NM4\076E7>J>'T\0QZ!?R:8
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M-BO;ZPM)7\E??J "BBB@ HHHH **** "BBB@ K^'G_@M+_RD2^,7_8J_!_\
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M75I[7P3XA^&WP'^'^G>&/B-\5=%\=S_#:X\/^"XIKM+.?1?&OCJY31M$\,>
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MTOQ(WQ>\*:WXLL+6RT:\M['Q'HMWHEEHZ+J%MX@TZQGNH]2T^^L8I+&XCFD
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
+%%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>biogenlogostandard.jpg
<TEXT>
begin 644 biogenlogostandard.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(                  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
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M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
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MQQMEM;KJT---(4XZZXI*&VVT)-2UK6HR2A"$D9F9GH1#Z 7$-:*N*^$@"IV
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MC)(CTM-?,>D'L-"L[%<JI 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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MIH;9K7%C2 YW$]K-A.S>ZOF4*_\ 2'=FOF[;G?QIQ7^]#87]E74'TK9_BY%
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MUOC/M9\HF/";O#S[T[+U-S[!ZAKGY[LKSUUO[9BI!#HNN?R B B B B B B
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M_81+HOR9]V6)]5)[>52("*E)Z B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B BYYY4[4KWEV+SK#H;'CWZ*\K_%2)*ENG
MDF/J_",",P23Z.6R&G()F9'VHE*/34B&4:,S0P.H[:_D-+;BX)/5O]%Q/VM0
M_P K5CFK<0<W@+BR8*W'#QQ_;L]( ?;;6^1RK!,S5MJ-"^Y"TF:5)41I4E23
MT4E23T-)I/74O48W =&"*C<M5@\C8=Z^^FQ/3WWH+[/NCR,07IWB^%VQZ'[7
MV>D?IL2_)D7@RY^B5&:B)):F9F>A$7K,SZ:=!4LC7B^1:UOLQB0R6B,E4Y\B
M/0FS)+"5%_9OGKK_ .82OND*MK"T;0J4O!.Q:*R.RN;U2BFR%%'UU3#8U:BI
MZZEW-D9FZI/J-9J,NNF@\I YVP[EZ,+6[1O6"/5/]K^D*<Q+V$B^D=1_:_U!
M^.Z7[,E%_:*C^U'T1+X9.E>FQ4]2]GW/4/V(E^"]=,;$<6MUM^K1$;",><12
MLR$,VF86Z7H&+5/5/B$]8FTLYLMM"B/X-%0_)T/7L).JBP377,S1_+JS,^H;
MD?/2VL=M'1]Q)OIPQU'"TD$=Y(61UV<5=BOV!TQF=2S=WCHCW -'2NV1MZZN
MIM/V+:N[**>CCEPSVOX\QXUNAE.8[B^"12LTMXK9*@..-&V^QB]:I3S5'&6E
M:DFX2G);B5&2W>PR0GGWS1YZ:JYC.?8 FQTQ79:QN/I@&H-Q)L,IK0\-&QM(
M!#.(<1V%TMH3$Z::+BG?Y2FV5P^+U]VW;P#MVN/2:;%UBZ[Z>OZGZH@M[UG*
MYMW'V9A7*W[C%4,5]JM2W9-;[+,">M7M*4P?1$*4M7I]#2S/KVGJHX_S^E(;
MPF[QW#'<G:6[FN[1]:?J'LWJAGLP_P!.+8[JZ#^\N495?-K)CT*QBOPY<=9H
M>CR&U-NH47NI41:I474C+4E%U(S(1I+!-;RF&=I9*#M!&W_3ZBMA:6GA<*%?
M<CH]'V?='HP+]A9'$;] K8VKU:LKA->]Z"XQ-7NT+,H#7O1<X6JH:%M+"\=D
MY)>5=)$+1VPDMLJ<[343#):KD25EZ31'82I9EZR2,KTYAI\[E[?$VW\[/(&U
MW\+=[G'L:T%Q\B]QZ(JI,(4./7PXD"(V346%&8B1FB]#;$=I++2"]'O6T$0W
MIM+6&RM8[.V'#;Q1M8T=36@- \P"IR:FIWK[0J$0$447G6?1Z[K?&?:SY1,>
M$W>'GWIV7J;GV#U#7/SW97GKK?VS%2"'1=<_D!$!%/+Q/\DC\Z#CUMIOQ^<U
M_ ?_ #B5EI9?P5_S,?PE_ _X-R*XH/!_#G^=C'_PAXWX)\7N^!L=OB=NA]O<
M>L^M_$5^ANJKS3/YG^<_-'M;WGSON^/BC8^O!\V?PTXJ?'.ZO31;&:,Y ?I=
MIFTU'^=OF_SICG=W\U[SAX7N93C^<,XJ\-?BC?3HJNB/Z.9_]8W_ -O?_P \
M!BO[6'_T'_KO_9K)_P!EW_[S_P!%_P"[3^CF?_6-_P#;W_\ / /VL/\ Z#_U
MW_LT_9=_^\_]%_[M/Z.9_P#6-_\ ;W_\\ _:P_\ H/\ UW_LT_9=_P#O/_1?
M^[7QN_5S72:<-CF&VX\3:S9;=X_J9:6Z23-M#CR-ZWUM-J7H1J)"S274DGZ!
M];XL!4<6 (;7;2]K]3YH*_"/*OA\+IH>'. NIL_Y.GU?G1_<*YJW9\@KE5AT
M&39[8YQMCN^U&2M2:1N988'E<PR2:D%"AY"S(Q8]>TR/QKEDR4:="41F:<OP
M?B=T5?RB',VUY8./RZ-FB'E+")/@B/3NZ<4S/AOUC8QF;$7%I?-'R*NAD/D#
MP8_AE'GZ(;MS]IMS-E<MFX)NQ@V3;?9=7D3C]'E%5)JY;D93CC;-A!4^@F+.
MJE*95X$N,MV,^DNYMQ1=1/N&SF'U#8MR6#N8;JQ=N?&X.%>EIIM:X5VM< X=
M("@O+X7+8"]=CLU;RVUZW>R1I::=!%=CFFFQS26GH)6O!=5;$!$!%*GY07*N
M7QNY9XSCMO8.L[:;[/UNV6915OFB##N[&;X> 94XVI:&"?I<BEE%<>69)9KK
M*6KJ?:0A7GOHIFKM#S7<# <OC0ZXB--I8T?AX^NCXQQ #?)'&.M3%R1UB_2N
MM(K6=Q&)R);!**[ ]Q_ R=56O/"2=S'O*O#CG(N@B BCO\V#Z/7DM\6,7^43
M#A*O)'WIX?UTGL)5&'.;W99;U4?MXE0U'3!<Z$!$!%?*\I_Z/7C3\6,H^43,
M1S/YW>]/,>NC]A$NB_)GW98GU4GMY5(@(J4GH"("("("("("("("("("("("
M("("("("("("("("("("("("("("("("("("("("("("("("("("("("("("
M("("("("("("("("("("("("("("("("("("("("("*MQS]V07LSO=/NJF"J
M/A&YQR\KH%MM&B'"MUO)/*J)M1$EI*H5E(3);;21):BS64%[TQM?RSU",_IY
MMO.ZN1LZ1OV[2VGX-_G:.$G>7-<3O6LO,+!'"9UT\+:6-U61G4'5_"-\SCQ
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M>V9ME0EXR"U[6]>U7K6D>,_A1NF_]-G(WFGRK0LV]&ZX?L[?J%>T/B@MG?\
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MJZZZ^ZX^^XX\\\XMUYYU:G'777%&MQQQQ9FM;BUF9F9F9F9ZF)3:T- :T -
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M;3#'3W>/?/9MWR6Y$[:=)+6?A6@;R71M%.G?22]/<X.7^I'M@M;]D%V[='<
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M6S;N9$QK&^4AH%2>EQJ2=I)*U?R>6RF:NG7V7N)KF\=O?(]SW>0%Q- .@"@
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MCY.\.'3#DC[K,/ZF3V\JYS\Y?>;EO71^QB4=XE51B@(KE_D+?R'[;_3KGO\
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M>J'$NQW'F'(^YB<N<)S$PQL,@!'D8P3!<  OB?\ 4XHW?+C)HX;06O#7#/-
M<P,SH#+B^L"9,>\@3P$D,E;]7AD;\B0"H.PAS2YIO0\?]_-M>3.U6,;P[4W1
M7&*9-'49LO$TS<4%O&[46N-9' ;>?.LOJ>0KL?:-2D*2:76EN,.-.KYMZHTQ
ME]'YN; YN/N[V$[Q4M>T_%DC=0<3'C:#OWM< X. Z&::U)BM68:'.8:3CLY1
MN.QS'#XT;Q4\+VG81NW%I+2"=SC'U?D!$!%5P\Y[S(+F=D&0<.=CL@=KJ&H2
M]4[]995/K:FWMPO0I.UU;,:[51J2I:]F\4VLUS9*U0%^&S'E(E;F^'WE+;QV
ML6OM1Q!]U)1UE$X5#&=%RX'>]Q_F:BC&@2BKG,+-0N>_-.>2YET-IZ4MMF5;
M>2-.U[NFW:>AC?\ :T-7./=FC6O#ZV@VX6JR B BVOM-L5O+OM=+Q[9S;'-=
MR+5CPSFM8GC]A:QJMMWN\)^ZL6&3K:2*X:#)+LMYEHU=.[4R(63.:ET_IJW^
M=9^\M[2 [C*]K2[L8TGB>>QH)[%><+IW.ZBN/FV#M+BZF&\1L<X-[7. X6#M
M<0%(=CGDG>8%>P$3INV^(XHMQ*%HK\CW+PXY_8LU]IK;Q^ROV&5$A)*-"W$K
M22R(R)1*2F*KOQ$<KK:4QQW<\X'RH[>7A_CM83Y0*;.JA,G6O(+F5<1]Y):P
M0D_)?/%7^(YX'D)KMZZT\G,O)C\P/$8:Y\?:2GS*.RTEV06&[@87/F,D:EH-
M"*RTN::TG.I-*3-,9E]6BR,M=%]OOC_$#RNOY.Z??26[R:#O8)6@_P )K'M
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MH.:&;K<D^;4FHV-TGJ22N<C9^ E<=MPQHVM>>F9@VUWR,!)]-KB^? :QK8]
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M]KFU-*KFD9>L40$4AOEB<JY_%/E=@M[-LE1=M]Q)\';?=*(ZZ2(!8YD4]B-
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M6.4V2YTJ.I78:6)DV46&1DOH(U$OP?A#9*3HE:R/N* \EXI],P3%F*QM[<1
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M/.YSYWN+G.<27.<34N<3M))VDG:3M*WXBBB@B;#"UK(6-#6M: &M:!0  ;
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MCJ=):QLH'8XJ ?$7A(\AH9N6#1\XL+ICN*FT1S'NGM[ Y[HB>UH5-D;^K1=
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M+*,/<=[I(QW;W'[9["?.N9?,/$1X+7&4Q<(#;>.\D+ -S6//>,:/(UP'F7*
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M /@KOI_R6 ?CB+3^RSJ_Z1QO_'_JE=/VF=)_^0R/_!_K4_I"?&?_ ,%=]/\
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MI_+UQ_\ T8[D?Y.AB!?$A[LI?[9!_**G#P]^\>+^R3_R0KJPYZ+?9 1 1 1
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M_P XB_PUVMAO#3_WU=_Y3+_B+57"!H8MX$!$!$!$!%1<\X[Z1_D9_JB^0C;
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MQ)FRW&X[*W%$VA1DA"E'T(S$F\F[NUL>9F*N[V6.&U9-(7/>X,8VL,H%7.(
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M)\1QY:42K1Y"'GTH2W'CQ^>?-;FOD^9&1;&UKK?3EN\F&&NUQW=[+389"W8
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M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(HT>=_P#@3OT;?^"L?RX?^*1^P?\
MZ?\ \T2_RT_G!_W=\8__ (C_ %__ .7G44<Q?YL_]J[A_P#EO)T?ZO,JE')O
M_"+7^15_<OY,G^#_ /O*'_[J_P#2_P#9O$&\FCOBL_[AZ?\ \AO^*?C?ZOLJ
M+2W5OQG_ /X#^X;OC#XO^GQ:KBH2$L"0$0$6Q-KO^M\#_N\_N?\ WH_]4/\
M#(G^'_\ I?\  ^(+5F?^@=_U?]W_ )W<?B_Z;Z*YXC_KF_\ 2_WC^:WC?_IN
MJK,? S_"<?\ H9_\*K_^I'_?S^QI_9O_ &K_ -1_PWBC3_F9\27W@;G?SW_1
M>;LZ^SA6V/+GX\?_ &)O;_-?]9Y^WJ[:JQ<Q^PL_L7[$W^P?L/O"_8?^"_L?
MM#5%WQCOW]._S]JVA;\4;MW1N\R^4?E?4!$!$!$!$!$!$!$!$!$!$!$!$!$!
C$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!%__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129194414064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of accumulated other comprehensive income (loss)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td width="31%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">71.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(31.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(99.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(59.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">78.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(61.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">19.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(118.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(117.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(40.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(61.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(97.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">31.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(27.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(160.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(157.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td width="31%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(23.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(19.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(27.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(71.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(71.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of September 30, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(18.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(61.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(38.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Reclassification out of accumulated other comprehensive income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td width="24%" rowspan="1" colspan="1"></td><td width="21%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from Accumulated Other Comprehensive Income</font></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">43.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">119.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">42.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">117.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129118126384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 3,700.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,111.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">3,804.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">25.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">61.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">38.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">7,630.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,943.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">31.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">481.4<span></span>
</td>
<td class="nump">$ 495.7<span></span>
</td>
<td class="nump">215.5<span></span>
</td>
<td class="nump">$ 213.2<span></span>
</td>
<td class="nump">$ 279.1<span></span>
</td>
<td class="nump">$ 280.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">512.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,039.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,063.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">2,411.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">849.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">249.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets, Level 1 | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">25.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">25.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets, Level 1 | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets, Level 1 | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets, Level 1 | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">3,804.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">61.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">38.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">7,605.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,937.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">31.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">31.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,039.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,063.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">2,411.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">849.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">249.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">481.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">481.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of all assets of deferred compensation plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PlanAssetsForDeferredCompensationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph (aa)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26610-111562<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph b<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Trading Securities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6526789<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27723805&amp;loc=d3e24584-111560<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Available-for-Sale Securities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505594<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph a, f, g<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129188113120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Discounts and Allowances (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract', window );"><strong>Analysis of the amount of, and change in, reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance as of December 31, 2014</a></td>
<td class="nump">$ 483.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">1,636.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="num">(37.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/credits relating to sales in current year</a></td>
<td class="num">(1,151.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/credits relating to sales in prior years</a></td>
<td class="num">(321.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance as of September 30, 2015</a></td>
<td class="nump">610.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ReserveForCashDiscountMember', window );">Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract', window );"><strong>Analysis of the amount of, and change in, reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance as of December 31, 2014</a></td>
<td class="nump">47.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">332.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/credits relating to sales in current year</a></td>
<td class="num">(277.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/credits relating to sales in prior years</a></td>
<td class="num">(40.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance as of September 30, 2015</a></td>
<td class="nump">59.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember', window );">Contractual Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract', window );"><strong>Analysis of the amount of, and change in, reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance as of December 31, 2014</a></td>
<td class="nump">387.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">1,278.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="num">(20.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/credits relating to sales in current year</a></td>
<td class="num">(871.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/credits relating to sales in prior years</a></td>
<td class="num">(271.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance as of September 30, 2015</a></td>
<td class="nump">500.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract', window );"><strong>Analysis of the amount of, and change in, reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance as of December 31, 2014</a></td>
<td class="nump">49.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">26.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="num">(14.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/credits relating to sales in current year</a></td>
<td class="num">(1.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/credits relating to sales in prior years</a></td>
<td class="num">(8.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance as of September 30, 2015</a></td>
<td class="nump">$ 50.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to product revenue reserves relating to sales in prior years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Analysis of the amount of, and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current provisions to product revenue reserves relating to sales in current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to prior year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 09<br><br><br><br> -Article 12<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ReserveForCashDiscountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ReserveForCashDiscountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>38
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0````(`%>"54<=SB.R60(``.@R```3````6T-O;G1E;G1?5'EP97-=
M+GAM;,W;W6Z;,!3`\5>)<CL%!P.&54UOUMUNE;87\,!)4/B2[:;IV\^0=MJB
M;&K71OK?A)!CGW/@P.\NU]\?!^-FA[;IW&J^]7ZX$L*56]-J%_6#Z4)DW=M6
M^W!J-V+0Y4YOC)#+I1)EWWG3^84?<\QOKK_NC;5U96:?CH$Q]VJNAZ&I2^WK
MOA/[KCK)NNC7Z[HT55_>MV%+Y$-I\R'$Y[,[;?T7W884XM"(*7#\C*,Q+MZG
MH!NLT97;&N/;)G+^L3'N7/UCY+GRK5GK^\:_JO#3O8NL::8U;EL/3Z4^'T(6
M%WY;S4/4O:C"Z<9_=5:WX]"&;O/'CO'\/Z_EY";NV^;6ZH?ZI,#^8F,:CU&K
MZ^[<J!YZN_O1][OW?$S,>%65J1:##0NMK\\\)6'Q78@Z$5*_J?;SDU+VUKRH
MX+CP@B_%5EM3??,VS/?\N_'[@LOU,<YU^OZWH4]!)Z;#!9%X51\2TD<"Z2.%
M])%!^E"0/G)('P6DCX^0/N(EI1&*J#&%U)AB:DQ!-::H&E-8C2FNQA188XJL
MDB*KI,@J*;)*BJR2(JNDR"HILDJ*K)(BJZ3(FE!D32BR)A19$XJL"476A")K
M0I$UH<B:4&1-*+*F%%E3BJPI1=:4(FM*D36ER)I29$TILJ8465.*K!E%UHPB
M:T:1-:/(FE%DS2BR9A19,XJL&476C"*KHLBJ*+(JBJR*(JNBR*HHLBJ*K(HB
MJZ+(JBBRYA19<XJL.476G")K3I$UI\B:4V3-*;+F%%ESBJP%1=:"(FM!D;6@
MR%I09"THLA8468M?LHKI#RXW/P%02P,$%`````@`5X)51TAU!>[%````*P(`
M``L```!?<F5L<R\N<F5L<ZV2RV["0`Q%?R6:?7%*)1818<6&'4+\@#OC/)3,
M>.0Q(OW[CMB`PD.MQ-*O>X^NO`ZIK`XTHO8<4M?'5$Q^#*G*_=ITJK$"2+8C
MCVG!D4*>-BP>-9?20D0[8$NP+,L5R*V.V:SGVL7.U49V[M,41Y26M#;3"&>6
MX9MY6&3I//B)]!=C;IK>TI;MR5/0!_ZS#0//>997'L=V+YRO+0O]C^AY%.!)
MT:'B1?4C9@,2[2F]@OIZ`(4QOCLEFI2"(S>C@KN_V/P"4$L#!!0````(`%>"
M54<(76=8I`(``/(S```:````>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/%
MV\MNVD`8AN%;0;Z`F#E/4,@JFVR;WH`%PT$!&]FNVMQ]7!85/?A3%TCO!H0M
MS;RK1];XYZD=EJLOY=2,QZX=#L?+L/AQ/K7#:KJ^K@[C>%G5];`YE',S/'27
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MZ.T9O;W0VS-Z>Z&W9_3V0F_/Z!V$WH'1.PB]`Z-W$'H'1N\@]`Z,WD'H':!W
ME>IE):-W$'H'1N\@]`Z,WD'H'1B]@]`[,'I'H7=D](Y"[\CH'87>D=$["KTC
MHW<4>D=&[RCTCM"LB1HV8?2.0N_(Z!V%WI'1.PJ](Z-W$GHG1N\D]$Z,WDGH
MG1B]D]`[,7HGH7=B]$Y"[\3HG83>"9H55,."C-Y)Z)T8O9/0.S%Z9Z%W9O3.
M0N_,Z)V%WIG1.PN],Z-W%GIG1N\L],Z,WEGHG1F]L]`[0[/>-WH/AZ8OV[>Q
M/[;[X=XUORTNBV[P'L:/4[E_RG55.7!^H_4X[53JZ^?=4;RN^C.D_NOO/<^?
M4$L#!!0````(`%>"54>/*Y"7_P,```@4```0````9&]C4')O<',O87!P+GAM
M;+U847/:.!#^*QJ>KC/7FA(2N`SU#(6TS4P[90J7/@M[`4UER95D#OKKN[:!
MV,E:J?UP>8DD[[=:[;??2L-$V?[MPN@4C!-@V2&1RM[BXKO>SKGT-@ALM(.$
MVS=HHO#K1IN$.YR:;:`W&Q'!7$=9`LH%@W[_)H"#`Q5#_#J]..V%DWR7:9I*
M$7$GM`J_B,AHJS>.W1TBD)/@J4&!0,]+B#(CW#'LES;5I<)F&7$),]PKW'!I
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M^`]]=<!<=<`,VV#><\E5!*P#YJ9#;",2L\R2A)LCTQNV%%LED$(L&C:-(IUA
MYDG,-/J9"2MR+BRK3DCK;V#![+'[(8%L+FSAV!;<3J74).9>[9%_;8X-7QVJ
M7:PEL*FU<'+V4>OX/R$E"?F`M<X>N,R`?0%N,Y,7A:,#_B`4YEAPB46'\ZS9
M<@Y&[+$F]_"BZ>D6./[-%I*?2QLSEQ:%OF@X9PQK9%"!M:PZ(:US;XY.&+*9
M)9DLJN&KVX%A>=,VL,-JP>!I=]PH;!*68=BL:,IT_>1?7N>RCMF"'YL3<*\B
MG0!;\0/0!N?`*I7[R,32-=:)=<6F3"@D&%M>7A98(6`:]IEI*?E:FY*WG(=R
MYV\@\_9"8CYC?6]]S2=)Q"F,W"$>PF'N`&-O"&*9K2W\S'+N[_8%KK;27JJ#
M?]I)E?VUPDRU%^S56[]@2[]@7W50+MT)&Z1[WNC/)>P/C=:R'^,5]17=<$N9
M^OUZ]7I%,_U<K_X]2N&^KPGW)?(>%>RW]$IY2%^LWNH>TA=KK:"?E/<<Z);A
M401">'O,D.;9JZ+AN`.&YKVBO#Q^(1O9.]L]1[`5W=R]<KT>=,#0W#=*O(RO
M/>;ZN@.&?E3Y,33W#>W'RX\?T]`:?9B;?@<,W=W]&+H.:,QEM54//B6A?0^^
MH>O`CZ'KH/X8JXS+Z+R]WDO\$R/4XL%E7':X&48TXWX,S3AUFWA/05\GW2&,
MCLN/H2O1CUG]P5WW0F,E3/TL>N_'$=WGO9@QS;SW>3RF,^Q]'H_I#/LQ=,]_
M?%*_D-_FQW61[_8/<C9K_R0?UQK]LU]4GOQ^$M1_]PM_`U!+`P04````"`!7
M@E5'4SJPUCX!``!I`P``$0```&1O8U!R;W!S+V-O<F4N>&ULS9--3\,P#(;_
M"NJ]2[/!A**N!T"<F(3$$(A;EGA;6/.AQ%/7?T^6=2T#+KMQJVN_CU_'22D<
M$];#L[<./"H(5WM=F\"$FV4;1,<("6(#FH=1K#`QN;)><XRA7Q/'Q9:O@8R+
M8DHT()<<.3D`<]<3LZJ4@@D/'*WO\%+T>+?S=8))0:`&#08#H2-*LNK5;(UM
M3$D&?55&QS4/.+=2K13(NW8H^YV*G1&\#D<YR+Y]^ONGAY0A65>Y#ZJO:IIF
MU$Q271R8DO?YTTLZFUR9@-P(B*J@&+8.9MFI\]OD_F'QF%7C@M[DM,C'=$&G
MC-ZRZ^+C,-F9O\&P[H;XMXY/!M-V46$-%^XV:61:;OI,(`E!>.5067,1+F&^
MB1,L[):?(/!R4"=,EVT+;6.]#%6Z7T-T>#EQ96OKVV/J1W3VJJHO4$L#!!0`
M```(`%>"54>97)PC$`8``)PG```3````>&PO=&AE;64O=&AE;64Q+GAM;.U:
M6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?A1%8C6QY9)&$?[]'-A#+
ME@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@V2_;UKNW+][@5S(D$4$P
M&:>O\,`*I4Q>M5II`,,X?<D3$L/<@HL(2W@4R]9<X%L:+R/6ZK3;W5:$:6RA
M&$=D8'U>+&A`T%116F]?(+3E'S/X%<M4C66C`1-702:YB+3R^6S%_-K>/F7/
MZ3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1TDB`@LE]E`6Z2?:CTQ4(
M,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP'`3@4;N>PIWT;+^D00FT
MHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG`J-6T_3:W?=TXZ)QJW0>`V^\4^'PZZ)
MQJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@`%AP=M;,T@.67BGZ=90:V1V[
MW4%<\%CN.8D1_L;%!-9ITAF6-$9RG9`%#@`WQ-%,4'RO0;:*X,*2TER0UL\I
MM5`:")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']IJP&G[;N;SY/\<^CDGZ>3
MUTU"SG"\+`GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E,L_O^0KK3CQG'U:6L%W/
MS^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZY!$XM4D-,A,_")V&F&I0
M'`*D"3&6H8;XM,:L$>`3?;>^",C?C8CWJV^:/5>A6$G:A/@01AKBG'/F<]%L
M^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\'1,2S90+!D&&ER0F$JDY
M?DU($_XKI=K^G--`\)0O)/I*D8]ILR.G=";-Z#,:P4:O&W6':-(\>OX%^9PU
M"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:<K46@;9QJ81@6A+&T7A.
MTK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY`1OQZ&.$J:[:)Q6`3]GE[#
M2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR-`>CFED)O816:I^JAS0^J!XR
M"@7QN1X^Y7IX"C>6QKQ0KH)[`?_1VC?"J_B"P#E_+GW/I>^Y]#VATK<W(WUG
MP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?P.S]:#Z>\>WZV22$KYI9
M+2,6D$N!LT$DN/R+RO`JQ`GH9%LE"<M4TV4WBA*>0AMNZ5/U2I77Y:^Y*+@\
M6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KTL<QP3A[+##MG/)(=MG>@
M'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K34I!OP_GIQ7@:XCG9!+E]
MF%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'>7M?F&>5QE`T%&ULK"0L
M1K=@N-?Q+!3@9&`MH`>#KU$"\E)58#%;Q@,KD*)\3(Q%Z'#GEUQ?X]&2X]NF
M9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^:CVT%4[/_EFMR)\,$4X6
M"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'<4Y3N!)VM@\",KF[.:EZ
M93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!8/+]<,E'#^4[YU_T74.N
M?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0!A,!S93)1/`"@F2F'("8
M^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L`P%(1=RX^_ODVIWC-?Z+(%MA%0R
M9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+PWING2TG_]M>U#VT%SU&
M\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83+$.D?L%]BHJ`$:MBOKJO
M3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'?!^2!F.,6_0T7X\48JVF
ML:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5`Y3_;U`UH]@TT')$%7C&9
MMC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%`````@`5X)51U!D.+NN`@``>Q``
M``T```!X;"]S='EL97,N>&ULS9C=:MLP%,=?1:ACM#!B)VV3=G4,HQ`8;&60
M7.RNR+&<"/3AR7*7]')O,]A3[4FF#R=*3)TT65O<&\OG'/W.7\>2.&E4J"7%
MXSG&"BP8Y<40SI7*/P9!,9UCAHJ.R#'7GDQ(AI1^E;.@R"5&:6$F,1KTPK`?
M,$0XC"->LA%3!9B*DJLA[(9K&W"`6Y'B(;P_??^C%.KF'7#/DP\G)^']V4W=
M?FH=9Q`XQN=4(_N7,'@^M!,V<[6OANX?B-[)KL,'A\)WT^OXJ\/P.]@U\'4#
MV(.>GC@(]RCZ^^M/P_?WGJ=VP*"[%_R[<;'>UZ"Z=QA\![H&/M\#'H]DHVKO
M:U!]8>!!=?SB*!/<G\(>=(8X*A[!`Z(ZWE9P*JB00.ECKE6XFB*&7<0MHB21
MQ!@SQ`A=.K,MCKT9JCA&N)`VM\M0S],)?28Y2X8PK/Z>GR[Q=/LPRR.4;B]/
M&^(H1TIAR4?Z!53CR3+7B^."8R?2QNV)GDFT[/8N-R;8A\Z;")EBZ:\WN#+%
M$<69TA,DF<W-4XG<2!=*":8'*4$SP1$UR-6,:J"Q4TSIV-S#W[,M]B(#+L9\
MXQ`"HV(UU(6HAGX;V*(&FS3'WL0.CN*"1;9.H&>C/*?+3Y3,.,-.K#.-1/6V
M#]]MP,<16E'!7$CRJ./-1IAJ`Y80/&"IR'33\E.B?((7JMK!P2)K4GCLDE]3
MT\M7S:O16_"MRW-T<FNZ*UF"Y<A>C8=+.A_L_V3V=,*:S+?=-4=(>('BF*ZI
MM=+Z[97V.GOJ1:1=M5?:=6NE#=I[0G57VUIIO?9*.V^OM(O_E!94O=M&@[C5
M'JZM("D)582O-"#3T-\9W72K<_.MH6:F"]\56J]""<7;630LQ1DJJ?I&'H2R
MSB'TXR]&?K>_CIJL$4/HQU]Q2DIF?T8&_M\-\3]02P,$%`````@`5X)51V6#
MQ</I!0``X1H```\```!X;"]W;W)K8F]O:RYX;6R5F5USTS@4AO^*QE>[,[N;
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MR3MQPY?S9)HPWCO]5BHGS`5WXIW1_59VMYZ5L+4TUBU"=X=_MK*3K?P6VNVW
M[$;?_ZN-_*8[Q]5B9;12PU'AA^$@?P;[8X]OHY.KT1\=7WX*5V*>E%,/O)-6
M+J62[G&>#-^5"#V9/.G*,/P_O[%N&)S#)6:\:]AEYSR%776[B^>')K3!__FJ
M&4YLSJ3_8JZ:V6ZH$/1&=XWHK&B8_V:UDHT?E88MG/_P)P!0"J#T5%`&H`Q`
MV:F@'$`Y@/+?!KWFBG<KP0!4`*@X%50"J`10>6K7*@!5`*J>@Q9]VW+SR/2:
M+>1M)_VLYUZ&\]5*]UX&`-4`JI^#SE=?>^_>D`\,-P#Q`A`OGB,^"2O,G;#,
MV\<NI!V:8`<QSY72J.(479P^1UUU=]YI;1[QH)'`A,%7?CYVMV'ZL'-KQ?[4
M[[1N[J522$*#9X3";[DT[#-7O6`?!+>]"3/`X5#,T-T9(>];V7DG)%=^-EIG
M^F<`='9&2'LAC+SC(;".$5#6&6'KM?%1;MSC7^Q:\4-"^`N['?+B&E&HZXSP
M]<KKNO2&=L):AAL(055GA*OAW&YT1=')&2FE#[=>#7/CH]L(XZ=+Z^]%&S]W
M_,`@"MV<$7)><M/Y>+?,#PE;;+C!HU/T,25\'`[X>\G#C+WFCT\O18IJIJ2:
M*]T*=L,?Q.BX4902(AXZ#1GQ4ZR%0Q0*F1)"ABEEW=!R)CMOMY$\3!4_:X09
MMPK53,D\58HOM=G9&;3:M?/3KL!`%#J:$HZ^]R%S^_1.E:*.*1F?;2OW?0FG
M]P/D_,45?ES&/4$E4S(^EU9\[<-\N+P;<*,]B$)74\+5:!*G+Q"%KJ:$JT>S
MF/WA2PM,L@S%S0AQHYF<S1"%#F>DP_M,WK5"V#_Q:#0Y(TR.AS/>@[-164!%
M*YW.AV8A"DW.")/)E";[AR)GA,AT7),HM#LC[([F=H;%089^9T<CEVP%^IR=
MFKT9^IRAS]EO92_5HAQ=SH^&\.M1"),@-#G_11J3`)0Y/S66<RQQ<Y0Y)V2.
MQD8^*G)'52XA\R@IGN3&A<";18XVYX3-D03R)(XHM#DG;(ZB<K0Y1YMSPN9H
MF.4UHM#NG+`[CD*[<[0[)^R&7`QC(]7(I0*M+F*E+GL.8C=8I13H=7%J`5RD
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MO=<\_&]//KR8>?4=4$L#!!0````(`%>"54<H3D]U/P(``(X'```8````>&PO
M=V]R:W-H965T<R]S:&5E=#$N>&ULC979;J,P%(9?Q>(!BFV6+")(2495YV*D
MJA<SUT[B!%3`C.V$SMN/-RBI7,(-M@__?[YC\))UC+^+@E()/NJJ$9N@D+)=
MAZ$X%K0FXHFUM%%OSHS71*HAOX2BY92<C*FN0@QA&M:D;((\,[%7GF?L*JNR
MH:\<B&M=$_YO1RO6;0(4](&W\E)('0CS+!Q\I[*FC2A9`S@];X(M6N]1I"5&
M\;NDG1CU@2[^P-B['OP\;0*H:Z`5/4J=@JCF1O>TJG0F1?[KDGXRM7'<[[,_
MF^FJ\@]$T#VK_I0G6:AJ80!.]$RNE7QCW0MU<TATPB.KA'F"XU5(5O>6`-3D
MP[9E8]K.OHDC9_,;L#/@P8#C24/D#-%@0,80VLK,O'X02?*,LPZ(ENB_C=9*
MSG42E1D(DTU-29C@5D=O.<S"FT[C%'BDV%D%&A2ARNT%X,!GQ\:.OP?LK2)Z
M#(AZ0#2>063L\6-[W-OCL3TV]N2^OK%B9Q7I8T#B!23&OK@')$;16(!5+!<)
MC)/'E-1+26V.B6E8Q>HQ8.$%+.PR@!,$)YFQ5)9>Q-+Z\03"268LEI47L;+^
M>`+A)#/^!()>A@FK#.G$+W<:#&=QD)_C=N:7I97>;5ZG6<Z@8#_%;D^TFOAD
M3H/A#$KDI]A=C-'WWVS?:S!>P0C!KRLY'!U_->47<RT(<&371MK3;X@.5\\6
MF^/S4YYG+;G07X1?RD:``Y/J$#8GYIDQ2545\$G55*C+<1A4]"QU=Z'ZW%X7
M=B!9V]]^PQ6<_P=02P,$%`````@`5X)51P@0P@U@!0``B1D``!@```!X;"]W
M;W)K<VAE971S+W-H965T,BYX;6R-F4USXC@0AO\*Q7U`K6^E"%7QQ];N8:NF
MYK!S=A(GH09P%CO)[+]?V6HY0$3C.0S@/-WJ5Y*[V_+JHSG\:E_JNIO]WFWW
M[>W\I>M>;Y;+]N&EWE7MHGFM]_XO3\UA5W7^Y^%YV;X>ZNIQ,-IMEYPQO=Q5
MF_U\O1JN?3^L5\U;M]WLZ^^'6?NVVU6'_[)ZVWS<SF$>+_S8/+]T_87E>K4<
M[1XWNWK?;IK][%`_W<[OX*;DKD<&XI]-_=$>?9_UP=\WS:_^QU^/MW/6QU!O
MZX>N=U'YC_<ZK[?;WI,?^5]T^CEF;WC\/7K_8Y#KP[^OVCIOMC\WC]V+CY;-
M9X_U4_6V[7XT'W_6J$'U#A^:;3O\/WMX:[MF%TWFLUWU.WQN]L/G1_B+96B6
M-N!HP$>#<9RT@4`#\6D@20.)!G+J"`H-U-D(RZ!]F+FBZJKUZM!\S-K7JM]/
M<./Q0^_$>YZU@S<_:>UP\:Z_^K[F?+5\[_T@PH^0#!%Q&2D"`B.Q].,G@^#S
MU`@\C'!Y@!P)2<1PU4GYQ<G%,$4,4QS/E0CVZKJ]C/;RV%X&>WT:HAF0?9@)
M1(0#`^8RER,'8(0F_!6!TT9SS=1EK@R<<J#ET4)?U*>2^E0(ZBQN=:PO($(8
ML'`9R]&38]K8RU@1,&!,"<8O<V7@K&-6N>OB=%*<#B$1X60!D=9I2IO&H(6D
M8BX04UHI8D)+#$LIH<UU:28IS>!L$](0,<8<3^%7<<@I`"DUH2YPQG&/24(>
M<LSO7SEAZ6SROK5AT['K]BXY/R[8$XN:180Q:H?DB#&N!3&+1<#Z[6H(K`R8
M-<*8":D76%+<<-G'1.S%#!D%SFI!R$-.]LF+6-4".9#&[Q-&*(R@<$*(*1HA
MK1$P[5`:`R/]#J<R6(Z<,DP*:H<C!SXU,4L,7$90*[^2?()&GM88JIL@YCU#
MQEFF%24Q8,"YI#9]@1SW*<%0Z3>&9GU>F%`\0:0%AO(KB,@S9'Q6H>0%Z)MT
MDMH1!7+*6BH!C]XTAPF5$]*M`80"3.VH#!E_QVA&;U$$A19<$F"!H.0,-%6S
MRA'L1>H)*M,-`F#YISH$9(BLD",B!94=B^N.2D3`B[(31*4;`]"XNRE16,W[
MOH?*M'D$07%%MCYQ5,.Y961ZB8T+<*VFI-!TCP"A$E-E*T/F&R@)9)F(G/8=
M'J41.0G<$G-1COX,FU+DP:85AC:!JD<9,B"4ED#U01'T=PL9>X&@T!:.DV-"
MI,46S"E_$TY0F>YEP&&)IE1BF^(KER/7T6%(OFB2Y3[V,U(:4F+@#/<+.:'9
MX^F&AF,30C4TR&A+%8`<*24<I0XIX$I2FS1BTDTI\CS=R'!L4JA&!AE@X"2Y
M?`A:I8%3MR%RW&@I'57G(\B4]2W&!)'I3H:'=H&JX1DR2EA#/6LA]LU0V;F(
M`SK_'$G)"YC1>HJV=!/#0[<@B6?Q#!FG_8W.+W,Y<G[]K+*7N0(Y;GQ>/L_?
M)X<`$60*!)^B<>QE3AZW.#8+$_H$GNX3.!;XLS[!GLP2,@O0EZD<*;$X?VZQ
M)S.$?0`L"%\E4G8QY4F;IYL%'L\(*&4Z*E.4,AV5<4I9["<6YZ<(I])TE";9
MT;\I!WHFO0<,WE(3/*3+,;?)/7":!;`F"@Z.3`.1\Y63ZH='SO<OU*G$IS\M
MI\Q1NA1SE]P+IPI=5.B3-*4P<II\%"M&3FKJ'*<<.2._K.'RZ)QY5Q^>AQ/^
M=O;0O.V[<'0Z7AW?(MSQ_ISZ['H&-SDDKA=P4X9W!)_NUZO7ZKG^NSH\;_;M
M[+[INF8W'&4_-4U7^Y#9P@MXJ:O'\<>V?NKZKZ9?A?"F(/SHFM?XXF-\^[+^
M'U!+`P04````"`!7@E5'86/3L4(#``":#```&````'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;(V779.:,!2&_PK#O4N^`XXZLX*=]J(S.[UHKUF-RBP0"[AN
M_WT3$EAT(7HC<'S.QWL(Y+"XR.JM/@K1>!]%7M9+_]@TIWD0U-NC*-+Z29Y$
MJ?[9RZI(&W59'8+Z5(ETUSH5>8``8$&19J6_6K2VEVJUD.<FSTKQ4GGUN2C2
MZM]:Y/*R]*'?&7YEAV.C#<%J$?1^NZP099W)TJO$?ND_P_D&8HVTQ.],7.K!
MN:>+?Y7R35_\V"U]H&L0N=@V.D2J#N\B%GFN(ZG,?VW0SYS:<7C>1?_6RE7E
MOZ:UB&7^)]LU1U4M\+V=V*?GO/DE+]^%U4!UP*W,Z_;7VY[K1A:=B^\5Z8<Y
M9F5[O)A_0F#=QAV0=4"]0Y]GW`%;!_SI0)P.Q#J01S-0ZT!O,@1&>]NY)&W2
MU:*2%Z\^I7H]P;G"*QU$1?;J-IIJ6MT:G[7U?47!(GC7<2R"!LC:(`A/(XE!
M8$\$*O]H$<@?RX!,AND$L26(HX:[039?@DR6B;LR\;!7V/3J`9FD\R=#?]+Z
M$WI=(F^1TG3"(!&C#*%I+#982%E(PVDL,1CBD!(<37,;RP$*,0+WU='1[E#3
M'73?GXUVAQG_FV5&A]TQR`RA6S5#*C841--(8@-!U9AI:F,I"A&_+XJ/BN)&
ME"/+VB`S#"&'#E4&(R$B+F$V&`$@="DS&",\PO>5A:/*0J.,.I19Y/;-<27+
M,"QR2$\,0QAV*-\8"&(<WE<4C2J*3+G,H2BR"Q!3X&AO;#$&D.O.)QVFGCJ7
M,HMQB`B[KPV"47&M6:GC#G66F5&&7?<C[C@(,7`\B$G'13Q"H4-@'P\,%_>T
M0CBNT&YECDQKRT0@0MBIT'`AH90X%=J]D4%.H2/@I@,!@8`_L$(A&M=HMC#J
MJ&G=,9B&CJ4<6VS&L:-AB:5(!%POYHW%.&,/;!\0CVLSVRN[&46NMD?+1`R%
MD$]SL>5"0L+;VW*U05H.,:9V7#(-;CH0D)!_><,$@\&K$-6A'7EK;RO/96-F
MB=[:C]7/2`]N-_8UG,=PQ)[H,;P=]#[#KQ:G]"!^IM4A*VOO539J7&QGN[V4
MC5`U@R?5[J/Z4.@O<K%O]"G7]\&,SN:BD:?N2Z#_'%G]!U!+`P04````"`!7
M@E5'^6G*)10"```^!@``&````'AL+W=O<FMS:&5E=',O<VAE970T+GAM;(U5
M38^;,!#]*Q;WKL%`LAL1I'Q5[:'2:@_MV4F<@-;&K.V$[;^OOR`H!387;`_O
MO9DWP9.LX>)=%H0H\,EH)9=!H52]@%`>"L*P?.(UJ?2;$Q<,*WT49RAK0?#1
MDAB%*`QGD.&R"O+,QEY%GO&+HF5%7@60%\:P^+LFE#?+(`K:P%MY+I0)P#R#
M'>]8,E+)DE=`D-,R6$6+76H0%O"[)(WL[8&I?<_YNSG\/"Z#T)1`*#DHHX#U
M<B4;0JD1THD_O.8MI2'V]ZWZ=^M65[_'DFPX_5,>5:&+#0-P)"=\H>J--S^(
MMV`K/'`J[1,<+E)QUE("P/"G6\O*KHU[\QQZVC`!>0+J"%V>84+L"?&-D$P2
M$D]('LV0>D)ZEP$Z[[9S6ZQPG@G>`%EC\SE%"PT71D0K`VG5=-.D#:Y,])K/
MH@Q>C8Z'H!YD[2`H'H=L'>0F`G7^P2)0,)0!N0SC"38>D4S4\*7([C^1T3+C
MMLRXWZO8\M,';"8M/^GS$]?KNQ+G%E*Y3CC(MRA&X3AJXU&S<<BVA;R\C(-V
M'A2'Z`%/Z:"GU'F*)SREWM/S?,*2`^E*)CQY(82F/+5"\SM'L'<[&!%G.Y<D
M./!+I=P/WD6[T;="YG;=Q=?18A,-Q+=Z5+K)=I//LQJ?R2\LSF4EP9XK?:?M
M!3QQKH@N-WS2S2WT,.\.E)R4V<Y-U]U\<P?%ZW9:=W\9^3]02P,$%`````@`
M5X)51Z.E>5:B!```<A8``!@```!X;"]W;W)K<VAE971S+W-H965T-2YX;6R-
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M[_IF/Q69S_;E3_K='<;?$_W'3L72!3`6P',!4&P!&0O(3P46E&Q\KE_*OEPM
MV^8TZX[ET-OP&/!VJ"34/.O&VL(C=>/%K\/5CY51R\7'4$]$\`)9$X*WB2)6
MHL_((MP_&0*G$/(R!%)Y<[^\G,JKR_*2RMOKB'9$#O00A"CAO!#R-E<0!RB4
M1W4_CTKF493'7=]'7^8A!*R6ROO;7!&K4D(9<3^.3L;15`=SFS4A(-%:)Y@X
MD</0."JCNTTRCQDKL<Q]UH1(\-8QK5@0AD[*G-:QR326T@"3AA`/SB.#%80Y
MH03B_30NF<91&F32$.(,.,=@!6%*&:_D_30^F<93&LFD(<2C%8[C"N*4L0@Z
M8V"!2`8:+]\96I$!KZS4BHDT@<H*HS-Z#""=B?1GF5NM(X,"K6/?H0B"-=JX
MC'X#3&<BI5K-92)&@0-4#%A,H$"GA<W(E+8TD%NMX3(1@T'4CN\[.;630.4S
M,J5-#>17:[E,Q(3!CWS715</4L^8RB`M:R#%6O8-U_%MLD%]W%@H(@E*AK?<
M04:JL[*O9FB(SLYIZ;1F8;(C]US$:.!L7$1*0E8KIS4+4:*<]2.CM#.<CXO(
M@7%"NXQ$:=4""9)3^CHRJ`&1[?7(H0>;D0C3KD72H^/LCY-KPV3DF4%43*`#
M+V6&_S'M6B0].LZUD4$CI6<'QP1B6&:(C'<)TZY%TJ/C7!N9,,V$F9)S;02U
M"[+-T#^F58LRKA&X2-&@TEC##;?(Z3!'YK11VK,8'<IY=F(,*-:SD3-:")^3
M*.U9)#-^7EY>?31$!@0,F?1MLHBD#)FLRM`LIE?&:.)4<WVK2V8=&2]N,\7_
MF=M)SKJ^_B2;UKP9-:05BRZN#+D&)D9P+?L9N9TC+5:,*U168SY^UW!+CC.4
M,0G*M%(E6=!S^HH,2(6275%'4($WD#,T95JIDBSH.7U%Y@%T>+L9J103J+UR
M&3./3!M5D@0]IZ_(`'COI>8T/]46A.HAI^]N;#*0![E9;AV9!S00UC!LYUV2
M.9./3(M5D@P]MUR,#`AMT2+;?1/IA!>0,>9D6JZ2=,CM;*PC\Z`MM\(H(J:%
MS(F3UJHT\;&XQ><9TN;JDSD1:2(=J/"QGQ$KO226=II>N(TKRZSUK[>N++?6
M7USL#A[+M^J/LGW;';K9<]/WS7[<%7QMFKX*-8DOX7&W5;DYG]35:S\<VG#<
MTI8HG?3-<=KA/6\SK_X%4$L#!!0````(`%>"54=ZA@58LP$``$0$```8````
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&ULA53;;J,P$/T5BP^(S26M&A&DEE75
M?5BIZD/[[(0AH/K"VD[H_OWZ!J4KFGW!,^-SSIR1;<I1JG?=`1CTP9G0^Z0S
M9MAAK(\=<*HW<@!A=UJI.#4V52>L!P6T\23.<$;(#>:T%TE5^MJSJDIY-JP7
M\*R0/G-.U9\'8'+<)VDR%5[Z4V=<`5<EGGE-ST'H7@JDH-TG]^FN+AS"`UY[
M&/4B1L[[0<IWE_QL]@EQ%H#!T3@%:I<+U,"8$[*-?T?-SY:.N(PG]4<_K75_
MH!IJR=[ZQG36+$E0`RT],_,BQR>((VR=X%$R[;_H>-9&\HF2($X_PMH+OXYA
MY_8NTM8)621D,R$MKA+R2,C_(>#@S,_U@QI:E4J.2`_4'7:ZLW#E1*PRTE[-
MCJ1]\=Y5+U5*LA)?G%#$9`O,0\!<0=0!<;.=(=@:6'6132[RI8LLNLC_+Y!/
M`L52((\"Q5>3=QXCPA@!0S:$I-^CZC74MV:*53-%-+/]VL9=K4\WQ=SG*JY>
MQ05#>''@`SW!+ZI.O=#H((V]._Z@6RD-6!FRV2:HLT]Z3ABTQH6W-E;AEH?$
MR&%ZL_./H_H+4$L#!!0````(`%>"54>`H6-_@@0``,\4```8````>&PO=V]R
M:W-H965T<R]S:&5E=#<N>&ULC9A-;^,V$(;_BN"[UN3P.W`,Q"J*]E!@L8?V
MK,1*;*QDN9*RWO[[4M)0<;+,F)=88AX.7TK#ER-N+FWWO3]4U9#];.I3?[\Z
M#,/Y;KWNGPY54_9?VG-U\O]Y;KNF'/QM][+NSUU5[J=.3;T&QO2Z*8^GU78S
MM7WMMIOV=:B/I^IKE_6O35-V_^VJNKW<K_@J-'P[OAR&L6&]W:R7?OMC4YWZ
M8WO*NNKY?O7`[PJA1F0B_CY6E_[J.AO%/[;M]_'FS_W]BHT:JKIZ&L80I?_Y
M415578^1_,C_8M"W,<>.U]<A^N_3=+W\Q[*OBK;^Y[@?#EXM6V7[ZKE\K8=O
M[>6/"N<P*7QJZW[ZFSV]]D/;A"ZKK"E_SK_'T_1[F?]C&7:+=P#L`$N'99QX
M!X$=Q%L'.<UT5C;-Z[=R*+>;KKUD_;D<WS:_\W@W!O&1LWZ*YJ?43XT/8^N/
M+6=ZL_XQ!D(&KI@=,@NQ]M&C0\`JUAVF[O#Y``42\O8((HP@KB<A<!+F=@`9
M`LCK`'(*(,5[C69"3O,L9@2,EM+!YUR!'%/6679;CXI.2.&$[.T`.CHAC0'<
M>Z7J>D8S(Z7DC'V.%3.F!%,I<DQ4CIGE<&*<'3*"*V$(.2&42Y)CHW(LQN"$
MG)G)N566`:$'.0`'1MP6Y**"W)PTEM`S(_[I:$FHF:G<*<,3UBMGT>R;FL?G
M`PDA>'1"'#V#"V)*".5::$9,O0@<.,-4PAKG$-<TVXRAWCHR.5=,6"H-%Y`[
MZQ+6.1=Q36A=G'BI.X1R;J025"Z&:`YL0BKRN!=RB9(4)4FB).!:$293(.B7
M!TNP=Z[BDM`/N:8DS1!HHWR:4)(09,R!2DEQ'5\EZ+$\)2/CMLB#F5$+'R$A
MM!"&6OLAFI-@3<KJCYLC#^Y([1T(Y=(:QB69D\$@C?!6FI(#<8ODL[5QH/80
MA'*_*(TC+64&$Q8NL*@<0(\$RDT0RJ72UE(I&4!NF54)SPCBK@OHND"\D!U"
M2C%&[OLAF%'7W.>2XJ8+<'MK0R;W*4Z]W2)POD80*=5HW'(!31*HK0DAG[52
M,VK'*`+IS4EJEU"2@(S:":#MIE3!$+=)0)L$RKD1\INIL]R1CQM)H48T056\
M%`7T2:#,&R&_4A15LQ8+)YU.2<JX[P(Z)1`[_`XAY01S@M!>()@B)^ZX@(Y+
M+Y+@H\P2B5LLF#8IB13W6@A>2VT!"!EF#.6TB/GM'Q)J$A%W6\%NNP@RN08N
MJ<HM</X[X^JU?JXH;K4"W5%0VQ%"X*RTC'IK(E2X$G3*9XV(FZV`\`U%B4)'
M=EQ*\DL+0<U\19'RH.)V*]!NJ<)UAU`NF%!4,@6.6X"$LDO$*UR!5BNH'2!`
MP/SW/E5V(:@9*)U038JX=POT;O%AJ'=G$`A)YC\Y/N;3NT.($(U;#;]8]_KJ
MG*BINI?I_*S/GMK7TS"?X2RMRQG=`XSG3!_:=_RNF$_:WL)L-^?RI?JK[%Z.
MISY[;(>A;:8CI^>V'2JOC7WQ3^]0E?OEIJZ>A_'2^.MN/F^;;X;V'(X/ES/,
M[?]02P,$%`````@`5X)51[+0E-"E`0``L0,``!@```!X;"]W;W)K<VAE971S
M+W-H965T."YX;6R%4]MNW"`0_17$!P2O[4VBE=?2;J*J?:@4Y:%]9NVQC0*,
M`WB=_GT!7^)6*^7%S(S/.7-@H!C1O-D.P)$/);4]TLZY_L"8K3I0W-YA#]K_
M:=`H[GQJ6F9[`[R.)"59FB3W3'&A:5G$VHLI"QR<%!I>#+&#4MS\.8/$\4AW
M="F\BK9SH<#*@JV\6BC05J`F!IHC/>T.YSP@(N"7@-%N8A*\7Q#?0O*C/M(D
M6``)E0L*W"]7>`(I@Y!O_#YK?K8,Q&V\J'^+N_7N+]S"$\K?HG:=-YM04D/#
M!^E><?P.\Q;V0;!":>.75(-UJ!8*)8I_3*O0<1VG/WDVTVX3TIF0KH3')!J?
M&D6;S]SQLC`X$MOS,+O=P<--$/'*Q$8U[]#&XBE4K^4NVQ?L&H1F3+K!G&?,
MBF!>_6:+E-ZBIY&>?DW/%GJV=9C-#N^_%L@7@7PKD,\"#_]N<8LY+YC'_YJP
MS9DJ,&V\.I94.&@W'>E:76_G*8TS^8271<];^,E-*[0E%W1^LG$,#:(#WSZY
MVU/2^?>S)A(:%\(''YOI2DV)PWYY(.LK+?\"4$L#!!0````(`%>"54>.F-I!
MHP$``+$#```8````>&PO=V]R:W-H965T<R]S:&5E=#DN>&ULA5/;;MP@$/T5
MQ`<$W]++RFMI-U'5/E2*\M`^L_;81@'&`;Q._[Z`+W&KE?)B9L;GG#DP4$YH
M7FP/X,B;DMH>:>_<<&#,UCTH;N]P`.W_M&@4=SXU';.#`=Y$DI(L2Y)/3'&A
M:57&VI.I2AR=%!J>#+&C4MS\.8/$Z4A3NA:>1=>[4&!5R39>(Q1H*U`3`^V1
MGM+#N0B("/@E8+*[F`3O%\27D/QHCC0)%D!"[8("]\L5'D#*(.0;ORZ:[RT#
M<1^OZM_B;KW["[?P@/*W:%SOS2:4--#R4;IGG+[#LH7[(%BCM/%+ZM$Z5"N%
M$L7?YE7HN$[SGSQ?:+<)V4+(-L*7)!J?&T6;C]SQJC0X$3OP,+OTX.$FB'AE
M8J.:=VAC\12JURK-OY;L&H063+;#G!?,AF!>_6:+C-ZB9Y&>?4S/5WJ^=YC/
MW8OD8X%B%2CV`L4BD/Z[Q3WFO&+^=\EV9ZK`=/'J6%+CJ-U\I%MUNYVG+,[D
M'5Z5`^_@)S>=T)9<T/G)QC&TB`Y\^^3NGI+>OY\MD="Z$'[VL9FOU)PX'-8'
MLKW2ZB]02P,$%`````@`5X)51RQM90RD`0``L0,``!D```!X;"]W;W)K<VAE
M971S+W-H965T,3`N>&ULA5/;;N,@$/T5Q`<4QW&Z5>182EI5[<-*51]VGXD]
MME&!<0''W;]?P)>Z5:2^F)GQ.6<.#.0#FC?;`CCRH:2V!]HZU^T9LV4+BML;
M[$#[/S4:Q9U/3<-L9X!7D:0D2Y/DEBDN-"WR6'LQ18Z]DT+#BR&V5XJ;?R>0
M.!SHALZ%5]&T+A18D;.%5PD%V@K4Q$!]H,?-_I0%1`3\$3#854R"]S/B6TB>
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M^/;)S8Z2UK^?)9%0NQ#^\K$9K]28..SF![*\TN(_4$L#!!0````(`%>"54>&
M$HVWH@$``*\#```9````>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;(53VV[C
M(!#]%<0'%,=QFRIR+"5=5>U#I:H/N\_$'MNHP+B`X^[?+^!+K%6DOIB9\3EG
M#@SD`YI/VP(X\JVDM@?:.M?M&;-E"XK;.^Q`^S\U&L6=3TW#;&>`5Y&D)$N3
MY($I+C0M\EA[-T6.O9-"P[LAME>*F[\GD#@<Z(;.A0_1M"X46)&SA5<)!=H*
MU,1`?:#'S?Z4!40$_!8PV%5,@O<SXF=(7JL#38(%D%"ZH,#]<H$GD#((^<9?
MD^:U92"NXUG].>[6NS]S"T\H_XC*M=YL0DD%->^E^\#A!:8MW`?!$J6-7U+V
MUJ&:*90H_CVN0L=U&/]LTXEVFY!.A'0A/";1^-@HVOS%'2]R@P.Q'0^SV^P]
MW`01KTQL5/,.;2P>0_52[#8YNP2="9*N(*<1<D4P+WZS0TIOT=-(3W^F;V?Z
M=FUP.W;/=C\+9+-`MA;(;NYP#3EE4X_'_WJPU8DJ,$V\.):4V&LW'NA27>[F
M,8Z07>%%WO$&WKAIA+;DC,[/-0ZA1G3@VR=W]Y2T_O4LB83:A7#G8S->J#%Q
MV,W/8WFCQ3]02P,$%`````@`5X)51QE*UR*B`0``L0,``!D```!X;"]W;W)K
M<VAE971S+W-H965T,3(N>&ULA5/;;J,P$/T5RQ]0$P)[B0A2TM6J?5BIZL/N
MLP,#6+4]K&U"^_>US:6HBM07/#.<<^:,+\6(YL5V`(Z\*JGMD7;.]0?&;-6!
MXO8.>]#^3X-&<>=3TS+;&^!U)"G)TB3YQA07FI9%K#V9LL#!2:'AR1`[*,7-
MVQDDCD>ZHTOA6;2="P56%FSEU4*!M@(U,=`<Z6EW.&<!$0%_!8QV$Y/@_8+X
M$I+'^DB38`$D5"XH<+]<X1ZD#$*^\?]9\Z-E(&[C1?UWG-:[OW`+]RC_B=IU
MWFQ"20T-'Z1[QO$!YA'R(%BAM/%+JL$Z5`N%$L5?IU7HN([3GWP_TVX3TIF0
MKH0?230^-8HV?W''R\+@2&S/P]GM#AYN@HA7)C:J>8<V%D^A>BUWV<^"78/0
MC$DWF/.,61',J]]LD=);]#32TZ_I^X6^WSK<3]WSY&N!;!'(M@+9[1&WF/.,
MR3\/R39[JL"T\>I84N&@W;2E:W6]G:<TGLD'O"QZWL(?;EJA+;F@\R<;CZ%!
M=.#;)W<Y)9U_/VLBH7$A_.YC,UVI*7'8+P]D?:7E.U!+`P04````"`!7@E5'
ML%=BS*$!``"Q`P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6R%4]MN
MXR`0_17$!Q3'=K95Y%A*NJIV'U:J^K#[3.RQC0J,"SAN_[Z`+[56D?IB9L;G
MG#DP4(QH7FT'X,B[DMH>:>=<?V#,5ATH;N^P!^W_-&@4=SXU+;.]`5Y'DI(L
M39(?3'&A:5G$VK,I"QR<%!J>#;&#4MQ\G$'B>*0[NA1>1-NY4&!EP59>+11H
M*U`3`\V1GG:'<QX0$?!7P&@W,0G>+XBO(?E='VD2+("$R@4%[I<K/(*40<@W
M?ILUOUH&XC9>U)_B;KW["[?PB/*?J%WGS2:4U-#P0;H7''_!O(5]$*Q0VO@E
MU6`=JH5"B>+OTRIT7,?I3Y;/M-N$=":D*^$AB<:G1M'F3^YX61@<B>UYF-WN
MX.$FB'AE8J.:=VAC\12JUW*W3PMV#4(S)MU@SC-F13"O?K-%2F_1TTA/OZ=G
M"SW;.LQFA]GW`ODBD&\%\MM;W&+."R;_KPG;G*D"T\:K8TF%@W;3D:[5]7:>
MTCB3+WA9]+R%/]RT0EMR0><G&\?0(#KP[9.[/26=?S]K(J%Q(;SWL9FNU)0X
M[)<'LK[2\A-02P,$%`````@`5X)51R$O9!:B`0``L0,``!D```!X;"]W;W)K
M<VAE971S+W-H965T,30N>&ULA5/;;N,@$/T5Q`<4VXG;*G(L)5VM=A]6JOK0
M/A-[;*,"XP4<=_^^@"^U5I'Z8F;&YYPY,%",:-YM!^#(AY+:'FGG7']@S%8=
M*&[OL`?M_S1H%'<^-2VSO0%>1Y*2+$N2>Z:XT+0L8NW9E`4.3@H-SX;802EN
M_IU!XGBD*5T*+Z+M7"BPLF`KKQ8*M!6HB8'F2$_IX;P/B`AX%3#:34R"]POB
M>TA^UT>:!`L@H7)!@?OE"D\@91#RC?_.FE\M`W$;+^H_XVZ]^PNW\(3R3=2N
M\V832FIH^"#="XZ_8-Y"'@0KE#9^2358AVJA4*+XQ[0*'==Q^I.G,^TV(9L)
MV4IX3*+QJ5&T^8,[7A8&1V)['F:7'CS<!!&O3&Q4\PYM+)Y"]5JF>5ZP:Q":
M,=D&<YXQ*X)Y]9LM,GJ+GD5Z]CU]M]!W6X>[V>']]P+[16"_%=C?WN(6<UXP
M#_\U89LS56#:>'4LJ7#0;CK2M;K>SE,69_(%+XN>M_"'FU9H2R[H_&3C&!I$
M![Y]<I=3TOGWLR82&A?"!Q^;Z4I-B<-^>2#K*RT_`5!+`P04````"`!7@E5'
MOLU[,J(!``"Q`P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6R%4]MN
MXR`0_17$!Q3'N6PV<BPEK:KNPTI5'[K/Q![;J,"X@./NWQ?PI585J2]F9GS.
MF0,#68_FS38`CGPHJ>V1-LZU!\9LT8#B]@Y;T/Y/A49QYU-3,]L:X&4D*<G2
M)-DQQ86F>19KSR;/L'-2:'@VQ'9*<?/_#!+[(UW1J?`BZL:%`LLS-O-*H4!;
M@9H8J([TM#J<-P$1`:\">KN(2?!^07P+R9_R2)-@`204+BAPOUSA'J0,0K[Q
M^ZCYU3(0E_&D_AAWZ]U?N(5[E/]$Z1IO-J&DA(IWTKU@_P3C%K9!L$!IXY<4
MG76H)@HEBG\,J]!Q[8<_N_U(NTU(1T(Z$_9)-#XTBC8?N.-Y9K`GMN5A=JN#
MAYL@XI6)C6K>H8W%4ZA>\]5VG[%K$!HQZ0)S'C$S@GGUFRU2>HN>1GKZ,WT]
MT==+A^O1X>^?!3:3P&8IL+F]Q27F/&)VR;<F;'&F"DP=KXXE!7;:#4<Z5^?;
M>4KC3+[@>=;R&OYR4PMMR06=GVP<0X7HP+=/[K:4-/[]S(F$RH7PEX_-<*6&
MQ&$[/9#YE>:?4$L#!!0````(`%>"54?4;U]PI`$``+$#```9````>&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;(U3VV[<(!#]%<0'!-OK;*N5U])NJBAYB!3E
MH7UF[;&-`HP+>)W^?0%?XE8KM2]F9GS.F0,#Q8CFW78`CGPHJ>V1=L[U!\9L
MU8'B]@Y[T/Y/@T9QYU/3,ML;X'4D*<FR)-DSQ86F91%KKZ8L<'!2:'@UQ`Y*
M<?/K#!+'(TWI4G@3;>="@94%6WFU4*"M0$T,-$=Z2@_G/"`BX+N`T6YB$KQ?
M$-]#\EP?:1(L@(3*!07NERL\@)1!R#?^.6M^M@S$;;RH/\;=>O<7;N$!Y0]1
MN\Z;32BIH>&#=&\X/L&\A?L@6*&T\4NJP3I4"X42Q3^F5>BXCM.??3+3;A.R
MF9"MA*^1P*9&T>8W[GA9&!R)[7F877KP<!-$O#*Q4<T[M+%X"M5KF>[3@EV#
MT(S)-ICSC%D1S*O?;)'16_0LTK-_TW<+?;=UN)L=_H=`O@CD6X%\%MC]N<4M
MYKQ@\K^:L,V9*C!MO#J65#AH-QWI6EUOYRF+,_F$ET7/6WCAIA7:D@LZ/]DX
MA@;1@6^?W-U3TOGWLR82&A?"+SXVTY6:$H?]\D#65UK^!E!+`P04````"`!7
M@E5'2`BN3:0!``"Q`P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6R%
M4]MNXR`0_17$!Q3'N5618REI5;4/E:H^[#X3>VRC`N,"CKM_OX`O]:XB]<7,
MC,\Y<V`@Z]%\V`;`D2\EM3W2QKGVP)@M&E#<WF$+VO^IT"CN?&IJ9EL#O(PD
M)5F:)#NFN-`TSV+MS>09=DX*#6^&V$XI;OZ<06)_I"LZ%=Y%W;A08'G&9EXI
M%&@K4!,#U9&>5H?S)B`BX)>`WBYB$KQ?$#]"\E(>:1(L@(3"!07NERL\@)1!
MR#?^'#6_6P;B,I[4G^)NO?L+M_"`\K<H7>/-)I244/%.NG?LGV'<PC8(%BAM
M_)*BLP[51*%$\:]A%3JN_?`GW8^TVX1T)*0SX3Z)QH=&T>8C=SS/#/;$MCS,
M;G7P<!-$O#*Q4<T[M+%X"M5KOMIM,W8-0B,F76#.(V9&,*]^LT5*;]'32$]_
MIJ\G^GKI<#TZW/TLL)D$-DN!S2BP_W>+2\QYPMS_UX0MSE2!J>/5L:3`3KOA
M2.?J?#M/:9S)-SS/6E[#*S>UT)9<T/G)QC%4B`Y\^^1N2TGCW\^<2*A<"/<^
M-L.5&A*'[?1`YE>:_P502P,$%`````@`5X)51[MFG*VB`0``L0,``!D```!X
M;"]W;W)K<VAE971S+W-H965T,3@N>&ULA5/;3N,P$/T5RQ^`T[10MDHCM2`$
M#RLA'MAG-YDD%K8GV$[#_CVV<R%"E?H2STS..7/&EZQ'\V$;`$>^E-1V3QOG
MVAUCMFA`<7N#+6C_IT*CN/.IJ9EM#?`RDI1D:9+<,<6%IGD6:Z\FS[!S4FAX
M-<1V2G'S_P@2^SU=T:GP)NK&A0++,S;S2J%`6X&:&*CV]+#:'3<!$0'O`GJ[
MB$GP?D+\",E+N:=)L``2"A<4N%_.\`!2!B'?^'/4_&D9B,MX4G^*TWKW)V[A
M`>4_4;K&FTTH*:'BG71OV#_#.,)M$"Q0VO@E16<=JHE"B>)?PRIT7/OQS_U(
MNTQ(1T(Z$^Z3:'QH%&T^<L?SS&!/;,O#V:UV'FZ"B%<F-JIYAS86#Z%ZSE=W
M?S)V#D(C)EU@CB-F1C"O?K%%2B_1TTA/K]/7$WV]=+@>NF^3ZP*;26"S%-A<
M'G&).8Z8[>\AV6)/%9@Z7AU+"NRT&[9TKLZW\Y#&,_F!YUG+:_C+32VT)2=T
M_F3C,52(#GS[Y.:6DL:_GSF14+D0;GULABLU)`[;Z8',KS3_!E!+`P04````
M"`!7@E5'%P],6:(!``"Q`P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6R%4]MNXR`0_17$!Q3'<;95Y%A*NJJZ#RM5?6B?B3VV48'Q`HZ[?U_`E[I5
MI+Z8F?$Y9PX,Y`.:-]L"./*NI+8'VCK7[1FS90N*VQOL0/L_-1K%G4]-PVQG
M@%>1I"1+D^074UQH6N2Q]F2*''LGA88G0VRO%#?_3R!Q.-`-G0O/HFE=*+`B
M9PNO$@JT%:B)@?I`CYO]*0N("'@1,-A53(+W,^);2/Y4!YH$"R"A=$&!^^4"
M]R!E$/*-_TV:GRT#<1W/Z@]QM][]F5NX1_DJ*M=ZLPDE%=2\E^X9AT>8MK`+
M@B5*&[^D[*U#-5,H4?Q]7(6.ZS#^N4LFVG5".A'2;P0V-HHV?W/'B]S@0&S'
MP^PV>P\W0<0K$QO5O$,;B\=0O12;VS1GER`T8=(5YC1A%@3SZE=;I/0:/8WT
M]&?Z=J9OUPZWD\/MSP+9+)"M!;))(/NZQ37F-&-VWYJPU9DJ,$V\.I:4V&LW
M'NE276[G,8TS^807><<;^,M-([0E9W1^LG$,-:(#WSZYV5'2^O>S)!)J%\);
M'YOQ2HV)PVY^(,LK+3X`4$L#!!0````(`%>"54=;YV<[GP$``+$#```9````
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;(53RT[#,!#\%<L?@-.T4%2ED5H0
M@@,2X@!G-]DD%K8WV$X#?X_M/(A0)2[Q[F9F=NRULQ[-AVT`'/E24ML];9QK
M=XS9H@'%[16VH/V?"HWBSJ>F9K8UP,M(4I*E27+#%!>:YEFLO9@\P\Y)H>'%
M$-LIQ<WW$23V>[JB4^%5U(T+!99G;.:50H&V`C4Q4.WI8;4[;@(B`MX$]'81
MD^#]A/@1DJ=R3Y-@`204+BAPOYSA#J0,0K[QYZCYVS(0E_&D_A!WZ]V?N(4[
ME.^B=(TWFU!20L4[Z5ZQ?X1Q"]=!L$!IXY<4G76H)@HEBG\-J]!Q[8<_ZV2D
M72:D(R&=";>1P(9&T>8]=SS/#/;$MCS,;K7S<!-$O#*Q4<T[M+%X"-5SOMK>
M9.P<A$9,NL`<1\R,8%[]8HN47J*GD9[^3U]/]/72X7ITN/U?8#,);)8"F\M;
M7&*.$^;V3Q.V.%,%IHY7QY(".^V&(YVK\^T\I'$FO_`\:WD-S]S40EMR0N<G
M&\=0(3KP[9.K:TH:_W[F1$+E0KCUL1FNU)`X;*<',K_2_`=02P,$%`````@`
M5X)51VV-O:>C`0``L0,``!D```!X;"]W;W)K<VAE971S+W-H965T,C$N>&UL
MA5/;;J,P$/T5RQ]0$T(WV8@@)5VMVH>5JCYTGQT8P*KM86T3NG]?VUR*JDA]
MP3/#.6?.^)(/:-YL"^#(NY+:'FGK7'=@S)8M*&[OL`/M_]1H%'<^-0VSG0%>
M19*2+$V2'TQQH6F1Q]JS*7+LG10:G@VQO5+<_#^#Q.%(-W0NO(BF=:'`BIPM
MO$HHT%:@)@;J(SUM#N<L("+@5<!@5S$)WB^(;R%YJHXT"19`0NF"`O?+%1Y`
MRB#D&_^;-#];!N(ZGM5_QVF]^PNW\(#RKZA<Z\TFE%10\UZZ%QP>81KA/@B6
M*&W\DK*W#M5,H43Q]W$5.J[#^&>73;3;A'0BI`MAGT3C8Z-H\Q=WO,@-#L1V
M/)S=YN#A)HAX96*CFG=H8_$4JM=BL_N9LVL0FC#I"G.>,`N">?6;+5)ZBYY&
M>OH]?3O3MVN'V['[/OE>()L%LK5`=GO$->8\8?9?AV2K/55@FGAU+"FQUV[<
MTJ6ZW,Y3&L_D$U[D'6_@#S>-T)9<T/F3C<=0(SKP[9.[>TI:_WZ61$+M0KCS
ML1FOU)@X[.8'LKS2X@-02P,$%`````@`5X)51T7G*H^A`0``L0,``!D```!X
M;"]W;W)K<VAE971S+W-H965T,C(N>&ULA5/+;N0@$/P5Q`<$C^UDHY''TDRB
M*#FL%.6P>V;LMHT"M`-XG/W[!?R(%8V4B^EN5U47-!0CFG?;`3CRJ:2V!]HY
MU^\9LU4'BML;[$'[/PT:Q9U/3<ML;X#7D:0D2Y/DCBDN-"V+6'LU98&#DT+#
MJR%V4(J;?R>0.![HCBZ%-]%V+A186;"55PL%V@K4Q$!SH,?=_I0'1`3\$3#:
M34R"]S/B>TA>Z@--@@604+F@P/UR@0>0,@CYQA^SYE?+0-S&B_I3W*UW?^86
M'E#^%;7KO-F$DAH:/DCWAN,SS%NX#8(52AN_I!JL0[50*%'\<UJ%CNLX_<FR
MF7:=D,Z$="7<)]'XU"C:?.2.EX7!D=B>A]GM]AYN@HA7)C:J>8<V%H^A>BEW
M]VG!+D%HQJ0;S&G&K`CFU:^V2.DU>AKIZ<_T;*%G6X?9[##[62!?!/*M0'Y]
MBUO,:<'DWYJPS9DJ,&V\.I94.&@W'>E:76_G,8TS^8*71<];^,U-*[0E9W1^
MLG$,#:(#WSZYN:6D\^]G320T+H2_?&RF*S4E#OOE@:ROM/P/4$L#!!0````(
M`%>"54<_&*5NG0$``+$#```9````>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM
M;(53RT[#,!#\%<L?@-.T!52ED5H0@@,2X@!G-]DD%K8WV$X#?X_M/(A0)2[Q
M[F9F=NRULQ[-AVT`'/E24ML];9QK=XS9H@'%[16VH/V?"HWBSJ>F9K8UP,M(
M4I*E27+-%!>:YEFLO9@\P\Y)H>'%$-LIQ<WW$23V>[JB4^%5U(T+!99G;.:5
M0H&V`C4Q4.WI8;4[;@(B`MX$]'81D^#]A/@1DJ=R3Y-@`204+BAPOYSA#J0,
M0K[QYZCYVS(0E_&D_A!WZ]V?N(4[E.^B=(TWFU!20L4[Z5ZQ?X1Q"]L@6*"T
M\4N*SCI4$X42Q;^&5>BX]L.?VV2D72:D(R']0V!#HVCSGCN>9P9[8EL>9K?:
M>;@)(EZ9V*CF'=I8/(3J.5_=;C-V#D(C)EU@CB-F1C"O?K%%2B_1TTA/_Z>O
M)_IZZ7`].KS^7V`S"6R6`IO+6UQBCA/FYD\3MCA3!::.5\>2`COMAB.=J_/M
M/*1Q)K_P/&MY#<_<U$);<D+G)QO'4"$Z\.V3JRTEC7\_<R*A<B&\\;$9KM20
M.&RG!S*_TOP'4$L#!!0````(`%>"54?G[VO5HP$``+$#```9````>&PO=V]R
M:W-H965T<R]S:&5E=#(T+GAM;(53VV[C(!#]%<0'%,=)MFGD6$JR6NT^5*KZ
MT#X3>VRC`N,%'&?_?@%?:E61^F)FQN><.3"0]6@^;`/@R$U);0^T<:[=,V:+
M!A2W#]B"]G\J-(H[GYJ:V=8`+R-)298FR0^FN-`TSV+MQ>09=DX*#2^&V$XI
M;OZ=0&)_H"LZ%5Y%W;A08'G&9EXI%&@K4!,#U8$>5_O3)B`BX$U`;Q<Q"=XO
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M5(@.?/OD84M)X]_/G$BH7`@??6R&*S4D#MOI@<RO-/\/4$L#!!0````(`%>"
M54<MUCM&GP$``+$#```9````>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;(53
MVV[C(!#]%<0'%-M)+QLYEI)65?NP4M6'[C.QQS8J,"[@N/OW!7RI547JBYD9
MGW/FP$`^H'FW+8`CGTIJNZ>M<]V.,5NVH+B]P@ZT_U.C4=SYU#3,=@9X%4E*
MLBQ);ICB0M,BC[474^38.RDTO!AB>Z6X^7\$B<.>IG0NO(JF=:'`BIPMO$HH
MT%:@)@;J/3VDN^,V("+@3<!@5S$)WD^([R%YKO8T"19`0NF"`O?+&>Y!RB#D
M&W],FM\M`W$=S^J/<;?>_8E;N$?Y3U2N]6832BJH>2_=*PY/,&WA.@B6*&W\
MDK*W#M5,H43QSW$5.J[#^.<NF6B7"=E$R'X0V-@HVGS@CA>YP8'8CH?9I3L/
M-T'$*Q,;U;Q#&XN'4#T7Z9\T9^<@-&&R%>8X818$\^H76V3T$CV+].QW^F:F
M;]8.-V/WNYO?!;:SP'8ML+V\Q37F.&-^NF2K,U5@FGAU+"FQUVX\TJ6ZW,Y#
M%F?R#2_RCC?PEYM&:$M.Z/QDXQAJ1`>^?7)U34GKW\^22*A="&]];,8K-28.
MN_F!+*^T^`)02P,$%`````@`5X)51XELUOVB`0``L0,``!D```!X;"]W;W)K
M<VAE971S+W-H965T,C8N>&ULA5/;;N,@$/T5Q`<4QW&RNY%C*>FJ:A]6JOJP
M^TSLL8T*C`LX;O^^@"^U5I'Z8F;&YYPY,)`/:%YM"^#(NY+:'FGK7'=@S)8M
M*&[OL`/M_]1H%'<^-0VSG0%>19*2+$V2/5-<:%KDL?9LBAQ[)X6&9T-LKQ0W
M'V>0.!SIALZ%%]&T+A18D;.%5PD%V@K4Q$!]I*?-X9P%1`3\%3#854R"]POB
M:TB>JB--@@604+J@P/URA7N0,@CYQF^3YE?+0%S'L_I#W*UW?^$6[E'^$Y5K
MO=F$D@IJWDOW@L,C3%O8!<$2I8U?4O;6H9HIE"C^/JY"QW48_^SW$^TV(9T(
MZ4+XF43C8Z-H\S=WO,@-#L1V/,QN<_!P$T2\,K%1S3NTL7@*U6NQ^;7-V34(
M39ATA3E/F`7!O/K-%BF]14\C/?V>OIWIV[7#[>0P^UX@FP6RM4!V>XMKS'G&
M[/YKPE9GJL`T\>I84F*OW7BD2W6YG:<TSN0+7N0=;^`/-XW0EES0^<G&,=2(
M#GS[Y&Y'2>O?SY)(J%T(?_C8C%=J3!QV\P-97FGQ"5!+`P04````"`!7@E5'
M>0K3RJ4!``"Q`P``&0```'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6R%4]MN
MXR`0_17$!Q3'N;2-'$M)JJK[L%+5A]UG8H]M5&!<P''W[Q?PI=Y5I+Z8F?$Y
M9PX,9#V:=]L`./*II+8'VCC7[AFS10.*VSML0?L_%1K%G4]-S6QK@)>1I"1+
MDV3'%!>:YEFLO9H\P\Y)H>'5$-LIQ<V?$TCL#W1%I\*;J!L7"BS/V,PKA0)M
M!6IBH#K0XVI_V@1$!/P2T-M%3(+W"^)[2'Z4!YH$"R"A<$&!^^4*9Y`R"/G&
M'Z/F5\M`7,:3^G/<K7=_X1;.*'^+TC7>;$))"17OI'O#_@7&+6R#8('2QB\I
M.NM0311*%/\<5J'CV@]_MNE(NTU(1T(Z$QZ2:'QH%&T^<<?SS&!/;,O#[%9[
M#S=!Q"L3&]6\0QN+QU"]YJO'7<:N06C$I`O,:<3,".;5;[9(Z2UZ&NGI]_3U
M1%\O':Y'A_??"VPF@<U28#,*//R[Q27F-&$>_VO"%F>JP-3QZEA28*?=<*1S
M=;Z=QSA$]@7/LY;7\).;6FA++NC\9.,8*D0'OGURMZ6D\>]G3B14+H3W/C;#
ME1H2A^WT0.97FO\%4$L#!!0````(`%>"54<)$M:DI`$``+$#```9````>&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;(U3VV[C(!#]%<0'%,=.VU7D6$I:K78?
M5JKZT#X3>VRC`.,"CMN_7\"7NE6DW1<S,S[GS(&!?$!SMBV`(^]*:KNGK7/=
MCC%;MJ"XO<$.M/]3HU'<^=0TS'8&>!5)2K(T2>Z8XD+3(H^U)U/DV#LI-#P9
M8GNEN/DX@L1A3S=T+CR+IG6AP(J<+;Q**-!6H"8&ZCT];';';4!$P(N`P:YB
M$KR?$,\A^5WM:1(L@(32!07NEPL\@)1!R#=^FS0_6P;B.I[5?\;=>O<G;N$!
MY:NH7.O-)I144/->NF<<?L&TA=L@6**T\4O*WCI4,X42Q=_'5>BX#N.?[&ZB
M72>D$R%="#^2:'QL%&T^<L>+W.!`;,?#[#8[#S=!Q"L3&]6\0QN+AU"]%'Y>
M.;L$H0F3KC#'$;-9$,RK7VV1TFOT=&SQ;WHVT[.UPVQR^!_]M[/`=BVPG032
MKUM<8XXS)OO6A*W.5(%IXM6QI,1>N_%(E^IR.P]IG,DGO,@[WL`?;AJA+3FA
M\Y.-8Z@1'?CVR<TM):U_/TLBH78AO/>Q&:_4F#CLY@>RO-+B+U!+`P04````
M"`!7@E5'(J3<]^@!``"J!0``&0```'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6R-E-MNG#`0AE_%X@%BCGL2B[2;*DHO*D6Y:*^],+N@V)C:9DG?OK8QA$0(
M<H/MX9__&\N:23LNWF0)H-`[H[4\>J52S0%CF9?`B'S@#=3ZSY4+1I0^BAN6
MC0!2V"1&<>C[&\Q(57M9:F,O(DMYJVA5PXM`LF6,B']GH+P[>H$W!%ZK6ZE,
M`&<I'O.*BD$M*UXC`=>C=PH.Y[U16,'O"CHYV2-3^X7S-W/X61P]WY0`%')E
M'(A>[O`(E!HC#?[K/#^0)G&Z']R?[&UU]1<BX9'3/U6A2EVL[Z$"KJ2EZI5W
MS^"ND!C#G%-IORAOI>)L2/$0(^_]6M5V[?H_.]^ES2>$+B'\DH![D"WS!U$D
M2P7OD&R(>;O@H.7"F&AG)*V;KE#:X,E$[UGHQRF^&R.G"2>:<Z\)1@76[K.(
MT)M+#WO$>GHTI$?3"J.>'FW6#>+!()X:Q.Z*R><K3C7G0?,-2#(+29S!=@$R
M:';KD,TL9.,,]@L0IPG\=<AV%K)U!L$"9-!\XU%WLY!=_ZA!M`#9.4BT#MG/
M0O;.(%Z`#)KD"P1/FHF!N-F9(5'.VUKUO31&Q[%T"FTS?LBSM"$W^$7$K:HE
MNG"E6]KVWY5S!1KO/R0>*O7@'`\4KLILMWHO^EG2'Q1OALDXCN?L/U!+`P04
M````"`!7@E5'Z[DAG+`!```6!```&0```'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6R%5%MOFS`4_BN6?T`-3M)V$4%*.DW;PZ2J#]NS`P>PZ@NS3>C^_7P!
M2JMH><$^Q]_E'!V;8M3FU78`#KU)H>P!=\[U>T)LU8%D]D[WH/Q)HXUDSH>F
M);8WP.I(DH+0++LGDG&%RR+FGDU9Z,$)KN#9(#M(R<S?$P@]'G".Y\0+;SL7
M$J0LR,*KN01EN5;(0'/`QWQ_V@5$!/SB,-K5'H7:SUJ_AN!'?<!9*`$$5"XH
M,+]<X`F$"$+>^,^D^6X9B.O]K/XM=NNK/S,+3UK\YK7K?+$91C4T;!#N18_?
M86HA5EAI8>,758-U6LX4C"1[2RM7<1W3R6,VT:X3Z$2@GP@D&<4ROS+'RL+H
M$=F>A=GE>P\W0<0K(QO5?(4V)H\A>REI?E^02Q":,'2%.25,OB"(5[]J0?$U
M.DT6M^F;F;Y95[A)[MOLML!V%MBN!;93BP\?6UQC3C/F\;;)[JK);A+X\A^3
M"4,_=T)6@Y-@VG@_+:KTH%R:VY)=GL"1QL&_P\NB9RW\9*;ERJ*S=O[ZQ%DW
M6COP]MG=#J/./](E$-"XL'WP>Y/N;0J<[N=7N/P*RG]02P,$%`````@`5X)5
M1W(]CVFO`0``%@0``!D```!X;"]W;W)K<VAE971S+W-H965T,S$N>&ULA53+
M;N,@%/T5Q`<4A]B=4>182EJ-IHM*51<S:V)?/U0P+N"X\_?#PSAN%34;`Y?S
M0A><3U*]Z1;`H`_!>[W'K3'#CA!=MB"8OI,#]':GEDHP8Y>J(7I0P"I/$IS0
M)+DG@G4]+G)?>U%%+D?#NQY>%-*C$$S].P*7TQYO<"R\=DUK7($4.5EX52>@
MUYWLD8)ZCP^;W3%S"`_XT\&D5W/DLI^D?'.+IVJ/$Q<!.)3&*3`[G.$!.'="
MUOA]UKQ8.N)Z'M5_^=/:]">FX4'ROUUE6ALVP:B"FHW<O,KI-\Q'\`E+R;7_
MHG+41HI(P4BPCS!VO1^GL',?:=<)=";0A?`S\<&#D8_YR`PK<B4GI`?F>K?9
M6;AR(E89::]F$VI?/+CJN:!TDY.S$YHQ=(4Y!LP%0:SZ50N*K]%IL+A-WT;Z
M=IUP&]S3]+9`&@72M4`Z'Y%^/N(:<XR8[6V3[*I)-@NDWYA$3/;%A*P:)T`U
M_GYJ5,JQ-Z%O2W5Y`@?J&W^!%_G`&GAFJNEZC4[2V.OC>UU+:<#:)W<91JU]
MI,N"0VW<](>=JW!OP\+((;["Y5=0_`=02P,$%`````@`5X)51PCR[62D`0``
ML0,``!D```!X;"]W;W)K<VAE971S+W-H965T,S(N>&ULA5/;;J,P$/T5RQ]0
M$X<V5420DE95^U"IZL/NLP,#6/6%VB9T_WY]`<JN(O4%SPSG,N-+,6KS83L`
MA[ZD4/:`.^?Z/2&VZD`R>Z-[4/Y/HXUDSJ>F);8WP.I(DH+0++LCDG&%RR+6
MWDQ9Z,$)KN#-(#M(R<R?$P@]'O`&SX5WWG8N%$A9D(57<PG*<JV0@>:`CYO]
M*0^("/C%8;2K&(7>SUI_A.2E/N`LM``"*A<4F%\N\`!"!"%O_#EI?EL&XCJ>
MU9_BM+[[,[/PH,5O7KO.-YMA5$/#!N'>]?@,TPBW0;#2PL8OJ@;KM)PI&$GV
ME5:NXCJF/ULZT:X3Z$2@"^$^BXTGH]CF(W.L+(P>D>U9.+O-WL--$/'*R$8U
MWZ&-Q6.H7DI*[PIR"4(3AJXPIX39+`CBU:]:4'R-3I/%S_3M3-^N.]PF]WSW
MLT`^"^1K@7P:<??OB&O,:<;<_V="5GLJP;3QZEA4Z4&YM*5+=;F=QWB(Y!M>
M%CUKX969EBN+SMKYDXW'T&CMP-MG-[<8=?[]+(F`QH5PYV.3KE1*G.[G![*\
MTO(O4$L#!!0````(`%>"54=`'M<8P0$``'L$```9````>&PO=V]R:W-H965T
M<R]S:&5E=#,S+GAM;(U4VXZ;,!#]%<L?L`83:!L1I&2KJGVHM-J']MF!X:*U
M,;5-V/Y]?0&65FC3%^P9G\N,&#N?I'K1+8!!KX+W^H1;8X8C(;IL03#](`?H
M[4DME6#&AJHA>E#`*D\2G-`HRHA@78^+W.>>5)'+T?"NAR>%]"@$4[\OP.5T
MPC%>$L]=TQJ7($5.5E[5">AU)WNDH#[A<WR\9`[A`3\ZF/1FCUSM5RE?7/"M
M.N'(E0`<2N,4F%UN\`B<.R%K_&O6?+-TQ.U^4?_BN[757YF&1\E_=I5I;;$1
M1A74;.3F64Y?86XA=8*EY-I_43EJ(\5"P4BPU[!VO5^G<)+%,VV?0&<"70D?
M(U]X,/)E?F:&%;F2$](#<_\N/EJX<B)6&6FO9BO4/GEVV5M!Z:><W)S0C*$;
MS"5@XA5!K/JN!<5[=!HL[M.3A9YL*TR">QK=%S@L`H>MP"'X)]'?+6XQEP7S
M'TVFNR;I+$#?,5DPR7V3;-<DFP4.[Y@LF/0?$[*9#@&J\9=`HU*.O0G#L6;7
M>W:F?KK>X$4^L`:^,]5TO497:>R,^H&JI31@[:.'%*/6O@1KP*$V;OO![E6X
M'"$P<EBN^OK>%'\`4$L#!!0````(`%>"54<?VI:-P@$``'L$```9````>&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;(54VVZC,!#]%<L?4',)I!L1I*2K5?NP
M4M6'[K,#`UBU,6N;T/W[VN92ND+-"_8,YS(#8V>#5&^Z`3#H7?!6'W%C3'<@
M1!<-"*KO9`>M?5-)):BQH:J)[A30TI,$)U$0I$10UN(\\[EGE6>R-YRU\*R0
M[H6@ZM\9N!R..,1SXH75C7$)DF=DX95,0*N9;)&"ZHA/X>&<.H0'O#(8]&J/
M7.T7*=]<\%0><>!*``Z%<0K4+E=X`,Z=D#7^.VE^6CKB>C^K__+=VNHO5,.#
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MEH!#9=QV;_=J/!QC8&0W'_7EOLD_`%!+`P04````"`!7@E5'UIY$],P!``#@
M!```&0```'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6R%5-MNG#`0_17+'Q"S
M+)=TQ2+MIHK:ATI1'MIG+PP7Q<;$-DOZ][4-)C1"NR_8,SZ7&3%V-@KYIAH`
MC3XXZ]01-UKW!T)4T0"GZD'TT)F32DA.M0EE350O@9:.Q!D)@R`AG+8=SC.7
M>Y%Y)@;-V@Y>)%(#YU3^/0,3XQ'OL$^\MG6C;8+D&5EX9<NA4ZWHD(3JB$^[
MPSFU"`?XW<*H5GMD:[\(\6:#G^41![8$8%!HJT#-<H4G8,P*&>/W6?/3TA+7
M>Z_^[+HUU5^H@B?!_K2E;DRQ`48E5'1@^E6,/V!N(;:"A6#*?5$Q*"VXIV#$
MZ<>TMIU;Q^GD,9AIVX1P)H1?"&0R<F5^IYKFF10C4CVU_VYW,'!I18PR4D[-
M5*A<\F2SUSR,]AFY6J$9$ZXPYPFS6Q#$J&]:A'B+'DX6]^E[3]^O*]Q/[G%R
M7R#R`M%:()I;C/YO<8TY>TQ\WR3>-(EG@>2&B<>D]TV239-D%GB\8>(QW^Z;
MI)LFZ200!S=,/.;K3)#5"'*0M;MI"A5BZ/0T@4MVN<RGT(WP)SS/>EK#+RKK
MME/H(K2Y"&YJ*R$T&/O@(<:H,<_-$C"HM-VF9B^G&S@%6O3^/5D>M?P?4$L#
M!!0````(`%>"54>A$*Q,O@$``'L$```9````>&PO=V]R:W-H965T<R]S:&5E
M=#,V+GAM;(54S6[C(!!^%<0#%(?$;C=R+"5=5>UAI:J'[IG88QL5C`LX[KY]
M`?_46UG-Q3##]S,C#Z2]TF^F!K#H0XK&''!M;;LGQ.0U2&9N5`N-.RF5ELRZ
M4%?$M!I8$4A2$!I%"9&,-SA+0^Y99ZGJK.`-/&MD.BF9_G<"H?H#WN`I\<*K
MVOH$R5(R\PHNH3%<-4A#><#'S?Z4>$0`O'+HS6*/?.UGI=Y\\%0<<.1+``&Y
M]0K,+1>X!R&\D#-^'S6_+#UQN9_4'T*WKOHS,W"OQ%]>V-H5&V%40,DZ85]4
M_PAC"[$7S)4PX8ORSE@E)PI&DGT,*V_"V@\G=]%(6R?0D4"_$<A@%,K\S2S+
M4JUZ9%KF_]UF[^#:BSAE9(*:J]"$Y-%G+QF-:4HN7FC$T`7F-&`V,X(X]54+
MBM?H=+"X3M].].VRPNW@'O^Z+K";!'9+@=W8XO;_%I>8TX3973>)5TWB42#^
MP63")-=-DE639!2X_<%DPMQ],R&+Z9"@JW`)#,I5U]AA..;L?,^.-$S7%SQ+
M6U;!'Z8KWAAT5M;-:!BH4BD+SCZZB3&JW4LP!P)*Z[>W;J^'RS$$5K7359_?
MF^P34$L#!!0````(`%>"54=7,_AHI0$``+$#```9````>&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;(U3VVZ<,!#]%<L?$+,LNVE7+-)NJBA]J!3EH7WVP@!6
M;(;:9DG^/KX`H=5*[0N>&<YEQI=\1/UJ6@!+WI3LS)&VUO8'QDS9@N+F#GOH
MW)\:M>+6I;IAIM?`JT!2DJ5)LF>*BXX6>:@]ZR+'P4K1P;,F9E"*Z_<S2!R/
M=$/GPHMH6NL+K,C9PJN$@LX([(B&^DA/F\,Y\X@`^"E@-*N8^-XOB*\^^5X=
M:>);``FE]0K<+5=X`"F]D#/^/6E^6GKB.I[5'\.TKOL+-_"`\I>H;.N:32BI
MH.:#M"\X/L$TPLX+EBA-^))R,!;53*%$\;>XBBZL8_QSGTVTVX1T(J0+X4L2
M&H]&H<UOW/(BUS@2TW-_=IN#@VLOXI2)"6JN0Q.*)U^]%NGN:\ZN7FC"I"O,
M.6(V"X(Y]9L6*;U%3Z/%O^G;F;Y==[B-[OO_$,AF@6PMD$7_??+GB&O,><;\
M/21;[:D"W82K8TB)0V?CEB[5Y7:>TG`FG_`B[WD#/[AN1&?(!:T[V7`,-:(%
M9Y_<[2AIW?M9$@FU]>&]BW6\4C&QV,\/9'FEQ0=02P,$%`````@`5X)51W($
MS.6D`0``L0,``!D```!X;"]W;W)K<VAE971S+W-H965T,S@N>&ULA5/;;J,P
M$/T5RQ]0$X>FJX@@):VJ]F&EJ@^[SPX,8-47:IO0_?OU!2BM(O4%SPSG,N-+
M,6KS9CL`ASZD4/:`.^?Z/2&VZD`R>Z-[4/Y/HXUDSJ>F);8WP.I(DH+0+-L1
MR;C"91%K+Z8L].`$5_!BD!VD9.;?"80>#WB#Y\(K;SL7"J0LR,*KN01EN5;(
M0'/`Q\W^E`=$!/SA,-I5C$+O9ZW?0O)<'W`66@`!E0L*S"\7N`<A@I`W?I\T
M/RT#<1W/ZH]Q6M_]F5FXU^(OKUWGF\TPJJ%A@W"O>GR":83;(%AI8>,758-U
M6LX4C"3[2"M7<1W3G]UNHETGT(E`%\*O+#:>C&*;#\RQLC!Z1+9GX>PV>P\W
M0<0K(QO5?(<V%H^A>BGICA;D$H0F#%UA3@FS61#$JU^UH/@:G2:+G^G;F;Y=
M=[A-[G?9SP+Y+)"O!?)IQ.W7$=>8TXS)OYF0U9Y*,&V\.A95>E`N;>E276[G
MD<8S^8271<]:^,U,RY5%9^W\R<9C:+1VX.VSFUN,.O]^ED1`XT)XYV.3KE1*
MG.[G![*\TO(_4$L#!!0````(`%>"54?&UA26L`$``!8$```9````>&PO=V]R
M:W-H965T<R]S:&5E=#,Y+GAM;(54VVZC,!#]%<L?4!,2DFY$D)*N5NW#2E4?
MNL\.#&#5%]8VH?OW]04HK:+-"_:,SV5&8Y,/2K^9%L"B=\&E.>#6VFY/B"E;
M$-3<J0ZD.ZF5%M2Z4#?$=!IH%4B"DS1)MD10)G&1A]RS+G+56\XD/&MD>B&H
M_G<"KH8#7N$I\<*:UOH$*7(R\RHF0!JF)-)0'_!QM3]E'A$`KPP&L]@C7_M9
MJ3<?/%4'G/@2@$-IO0)URP4>@',OY(S_CIJ?EIZXW$_JOT*WKOHS-?"@^!]6
MV=85FV!404U[;E_4\`AC"Z'"4G$3OJCLC55BHF`DZ'M<F0SK$$_NDY%VG9".
MA/0;@42C4.9/:FF1:S4@TU$_N]7>P;47<<K(!#57H0G)H\]>BG2;Y>3BA49,
MNL"<(F8U(XA3OVJ1XFOT-%K<IJ\G^GI9X3JZ[]:W!3:3P&8IL!E;W'YM<8DY
M39C=;9/LJDDV"MS_QV3"_/AF0A:#$Z";<#\-*E4O;9S;G)V?P#$-@_^$%WE'
M&_A-=<.D06=EW?4)LZZ5LN#LD[L,H]8]TCG@4%N_W;F]CO<V!E9UTRN<?P7%
M!U!+`P04````"`!7@E5'RY<;,*4!``"Q`P``&0```'AL+W=O<FMS:&5E=',O
M<VAE970T,"YX;6R%4]MNG#`0_17+'Q`#NPG1BD7:354U#Y6B/+3/7AC`BNVA
MMEG2OX]M+J'52GG!,\,Y9\[X4HQHWFP'X,B[DMH>:>=<?V#,5ATH;N^P!^W_
M-&@4=SXU+;.]`5Y'DI(L2Y('IKC0M"QB[<64!0Y."@TOAMA!*6[^GD'B>*0I
M70JOHNU<*+"R8"NO%@JT%:B)@>9(3^GAO`^("/@E8+2;F`3O%\2WD#S71YH$
M"R"A<D&!^^4*3R!E$/*-_\R:GRT#<1LOZM_CM-[]A5MX0OE;U*[S9A-*:FCX
M(-TKCC]@'N$^"%8H;?R2:K`.U4*A1/'W:14ZKN/T9Y?/M-N$;"9D*^$QB<:G
M1M'F-^YX61@<B>UY.+OTX.$FB'AE8J.:=VAC\12JUS++DX)=@]",R3:8\X1)
M5P3SZC=;9/06/9M:?$W?+?3=UN%NZI[G7POL%X']5F`_CYC^.^(6<UXP_[MD
MFSU58-IX=2RI<-!NVM*UNM[.4Q;/Y!->%CUOX2<WK="67-#YDXW'T"`Z\.V3
MNWM*.O]^UD1"XT*8^]A,5VI*'/;+`UE?:?D!4$L#!!0````(`%>"54<E/)$&
MOP$``'L$```9````>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;(54VVZC,!#]
M%<L?4!,22#8B2$E7U>[#2E4?=I\=&"ZJC:EM0O?OUQ=,V0HU+]@S/I<9,78V
M"OFJ&@"-WCGKU`DW6O='0E31`*?J0?30F9-*2$ZU"65-5"^!EH[$&8FC*"6<
MMAW.,Y=[EGDF!LW:#IXE4@/G5/Z]`!/C"6]P2+RT=:-M@N09F7EERZ%3K>B0
MA.J$SYOC);4(!_C=PJ@6>V1KOPKQ:H.?Y0E'M@1@4&BK0,UR@T=@S`H9X[=)
M\\/2$I?[H/[DNC757ZF"1\'^M*5N3+$11B54=&#Z18P_8&HAL8*%8,I]43$H
M+7B@8,3INU_;SJVC/SE$$VV=$$^$^!.!>"-7YG>J:9Y),2+54_OO-D<#EU;$
M*"/EU$R%RB7/-GO+X_TV(S<K-&'B!>;B,9L908SZJD6,U^BQM[A/WP;Z=EGA
MUKL?HOL"NR"P6PKLIA9W_[>XQ%P")KEODJR:))-`^H5)P.SOFZ2K)NDD</C"
M)&"^?3(AB^G@(&MW"10JQ-!I/QQS=KYGY]A-UP<\SWI:PR\JZ[93Z"JTF5$W
M4)40&HQ]])!@U)B78`X85-IN]V8O_>7P@19]N.KS>Y/_`U!+`P04````"`!7
M@E5'.2L.OJ(!``"Q`P``&0```'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6R%
M4]MNHS`0_17+'U`#2;M11)"25E7[L%+5A]UG!P:P:C/4-J'[]^L+4%I%Z@N>
M&<XY<\:7?$3]9EH`2SZ4[,R!MM;V>\9,V8+BY@9[Z-R?&K7BUJ6Z8:;7P*M`
M4I)E27+'%!<=+?)0>]%%CH.5HH,73<R@%-?_3B!Q/-"4SH57T;36%UB1LX57
M"06=$=@1#?6!'M/]:>L1`?!'P&A6,?'>SXAO/GFN#C3Q%D!":;T"=\L%[D%*
M+^0:OT^:GRT]<1W/ZH]A6N?^S`W<H_PK*MLZLPDE%=1\D/85QR>81KCU@B5*
M$[ZD'(Q%-5,H4?PCKJ(+ZQC_[)*)=IV0383L&X'%1L'F`[>\R#6.Q/3<GUVZ
M=W#M19PR,4'-.32A>/352Y'MDIQ=O-"$R5:84\2D"X(Y]:LM,GJ-GL46/],W
M,WVS=KB)W7>;GP6VL\!V+;"=1DR_CKC&G&;,=Y=LM:<*=!.NCB$E#IV-6[I4
ME]MYS,*9?,*+O.<-_.:Z$9TA9[3N9,,QU(@67/ODYI:2UKV?)9%06Q_^<K&.
M5RHF%OOY@2ROM/@/4$L#!!0````(`%>"54?O7*E8PP$``'@$```9````>&PO
M=V]R:W-H965T<R]S:&5E=#0S+GAM;(546V^;,!3^*Y9_0$VX-8L(4M*IVAXF
M57W8GATX7%0;4]N$[M_/%Z`T0LL+]CG^+L?FV-DHY)MJ`#3ZX*Q31]QHW1\(
M444#G*H'T4-G5BHA.=4FE#51O01:.A)G)`R"E'#:=CC/7.Y%YID8-&L[>)%(
M#9Q3^?<,3(Q'O,-SXK6M&VT3),_(PBM;#IUJ18<D5$=\VAW.J44XP.\61K6:
M(UO[18@W&_PLCSBP)0"#0EL%:H8K/`%C5L@8OT^:GY:6N)[/ZL]NMZ;Z"U7P
M)-B?MM2-*3;`J(2*#DR_BO$'3%M(K&`AF')?5`Q*"SY3,.+TPX]MY\;1K^R#
MB;9-""=">$,@WLB5^9UJFF=2C$CUU/Z[W<'`I14QRD@Y-5.A<LF3S5[S<!]E
MY&J%)DRXPIP]9K<@B%'?M`CQ%CWT%O?IT4R/UA5&WGV?WA>(9X%X+1`[@>C;
MUQVN(>=X.H7XOD>RZ9$X@=M3_.*13![)?8]TTR/U'H__\4@GC]NS(JO6X"!K
M=P,4*L30:=\92W:Y9*?0M=8G/,]Z6L,O*NNV4^@BM&E0UTV5$!J,??"08-28
M9V`)&%3:3A_-7/J;X0,M^OF>+X]-_@]02P,$%`````@`5X)51Y'I_\?B`0``
M104``!D```!X;"]W;W)K<VAE971S+W-H965T-#0N>&ULC93;;IPP$(9?Q>(!
MPFDY9,4B[2:JVHM*42[::R\,!\7&Q#9+^O:UC2&D0DMOL#W^Y__&P#@;&7\3
M#8!$'Y1TXN0T4O9'UQ5%`Q2+!]9#IW8JQBF6:LEK5_0<<&F2*'$#SXM=BMO.
MR3,3>^%YQ@9)V@Y>.!(#I9C_N0!AX\GQG3GPVM:-U`$WS]PEKVPI=*)E'>)0
MG9RS?[RD6F$$OUH8Q6J.=.U7QM[TXD=Y<CQ=`A`HI';`:KC!$Q"BC13XW7I^
M(G7B>CZ[?S.G5=5?L8`G1GZWI6Q4L9Z#2JCP0.0K&[^#/4*D#0M&A'FB8A"2
MT3G%011_3&/;F7&<=E+/IFTG!#8A6!*"J?`)9,I\QA+G&6<C$CW6W\X_*CG7
M)LH9">.F*A0F>-;16QZD2>;>M)'5!"O-9=+XB\)5[IN(P-E*#RPBW3<(9X-P
M76,X\<-XW^`P&QS6!@=;P>/70ZXU%ZMY]/8AT28DL@;^5TAD--T$B?[W3<:;
MB-@B@COGF#7A/B39A"36X'`',FNB?4BZ"4FM07P',FN2?R#NZC^GP&O3S@(5
M;.CD])LOT>7&.`>F3S[E>=;C&GYB7K>=0%<F5;>9UJ@8DZ#PWH/Z<HVZTY8%
M@4KJ::+F?&KS:2%9/U]:R\V9_P502P,$%`````@`5X)51V_;T#A"`@``FP<`
M`!D```!X;"]W;W)K<VAE971S+W-H965T-#4N>&ULC57)CJ,P$/T5BP\(.UE$
MD+)JYC!2JP\S9R=Q`FH;,[83>OY^O$%0VJ1S"7;QEJH*JLI;RCYXB9``GP37
M?.F50C0+W^?'$A'()[1!M7QSIHQ`(:_LXO.&(7C2)(+]*`@RG\"J]HI<Q]Y8
MD=.KP%6-WAC@5T(@^[=&F+9++_2ZP'MU*84*^$7N][Q315#-*UH#ALY+;Q4N
M]G.%T(#?%6KYX`Q4[@=*/]3EYVGI!2H%A-%1*`4H'S>T01@K(6G\UVK>+15Q
M>.[4][I:F?T!<K2A^$]U$J5,-O#`"9WA%8MWVOY`MH14"1XIYOH7'*]<4-)1
M/$#@IWE6M7ZVYDT66IJ;$%E"U!-Z'S<AMH3X54)B"<F=D#PEI):0ONJ064+V
MX.";9NE6;Z&`1<YH"W@#U?<7+B2<*1&I#+A6DUWF.KA2T5L1S6>Y?U-"%A,-
M,.L.,Q_';"PF'H?L#"3L$;Y,TIEIY+FRB#0]#H(G61A,-([86D3R),]O1?9?
M1$9+B;M2XF'38UO*"[U(.H%D*)!8@8<DIQI3FUX83#".V#H183B`[`PDFB:3
M=%QH_R@T6DWJK":UU<3?"V3.?F:O]W/JS&!J!9(GO5@;D!S/DQ=\9DZ?F?M_
M"Z.AS\S1\U&?N=-G;GW29_484")]L@<??S!)"&(7/?0Y.-)K+<PWW4?[O;**
MU"1ZB&_"Q39TQ'=R#YFU<9<O\@9>T"_(+E7-P8$*.?_TL#I3*I!,.)C(05G*
M3=E?,#H+=9S*,S/+PUP$;;I5V._CXC]02P,$%`````@`5X)51[WSW[L?`@``
M``<``!D```!X;"]W;W)K<VAE971S+W-H965T-#8N>&ULC57+;J,P%/T5Q+[%
M!O-(1)#:1%5G,5+5Q<S:29R`:C!C.Z'S]^,7&5HY"9O8OIS7-<0N!\8_1$V(
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M5<G9$(@>Z\\#+A6<:Q&E'`BCIO9`F.*3KIZK!&1E=-9"#A-/,,\6$U]'K$>5
M_#IF8S%9>H%$*J0W:3PF3:9)8^<![PLDHP":"B1&(/_6:6X@G>W40F($BB)%
MUW$;BX-Y!F*TN)\'>?,@UU!R7R#U[D@Z?T<R;X+,"1376UU;#(I1!L!]G]SK
MDSN?Q5>?=.J3N[<SQZ7PNA3>]_O%Q$)@7"1S;!9>FX5M!H(;/A;S4*#%'!\(
MO$:FK)W@#2<'>H!@EA/T.XW_W_3&A^!`*/=\"='DZ.GQD?S$_-AT(M@RJ4XQ
M<^0<&)-$Z8!'E;]6U]%E0<E!ZFFNYMP>T'8A63_>-Y=+K_H'4$L#!!0````(
M`%>"54?;N_^]"P,``&`-```9````>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM
M;(U777.B,!3]*PP_0$@((`XRT]I:]V%G.GW8?:8:E2D0E\3:_?>;D$#1O6!>
MA,1SSOW(O2%)+ZSYX$=*A?-5E35?ND<A3@O/X]LCK7(^8R=:RW_VK*ER(8?-
MP>.GAN:[EE25'O;]R*ORHG:SM)U[;;*4G459U/2U<?BYJO+F[R,MV67I(K>;
M>"L.1Z$FO"SU>MZNJ&C-"U8[#=TOW0>TV.!`05K$KX)>^.#=4<Z_,_:A!C]V
M2]=7/M"2;H62R.7CDZYH62HE:?F/$?VVJ8C#]TY]W88KW7_/.5VQ\G>Q$T?I
MK>\Z.[K/SZ5X8Y<--3&$2G#+2M[^.MLS%ZSJ**Y3Y5_Z6=3M\Z+_B>:&!A.P
M(>">T-N!"8$A!+8$8@CDFT`F":$AA+:$R!`B6Y=B0XAM+<P-87Y#\/1RM(OY
ME(L\2QMV<?@I5R6.%A+>*!&I[/!63:XC;R<?U.QG%B"<>I]*R&#P`/.H,3A)
MQC$K@PG&(6L-03W"DTZ"GF(7\@)K3WU_P@N-F8CER:B@"4>?C0J9B.6NH9?[
M(ILNHOA^2H(N)<%P\0(C8)%3T@F0H0`Q`C>!Q"VFUCG5&'\<\0PB$!I`UAJ"
M8S(+QX5>;H5&HPG!:$(337!?(`+S&=GG,P8]B(T`F<C%HP;)+\G,PLX<M#,W
M54S&D[G1&!):I#,!C21P<5P'DP`+.VH'^:"A=EJ%,U$;3QTHLC"#8#/=7A=-
MF4'V9C!LIMMBXFLSY&I+[4!S"SL!;*?K_OG-^N!A%1@4P61F$Q*\32"S3Z#$
M0B($6PN%]KV%(MB+"*[Z\"I>`[(I>P0W,8IM%M"`L(T=N(F1Z6*,IN+1($1L
MV@ON8Y3`A7)M)^EV)8OO,]S&V'0HQA82"*P2C.RK!,/MA[%%5@V(((NL8KC]
M\$C[7>W!!H3_JQ)O<%:K:'-H#^[<V;)S+?37OI_M+P</6)WU;N97:/&,@/DU
M6KSHH_^W?):>\@/]F3>'HN;..Q/RA-D>!_>,"2K]]6<R2T=YW>D')=T+]1K+
M]T9?`/1`L%-WG^DO5=D_4$L#!!0````(`%>"54<4&H\:)0,``,X.```9````
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M#@'7LE'CK[<^*BW;:8KOM=6K/=;=>#S9?S)PT_`)X";`>0+8Q*W1F.:72E>K
M12]/GCI4P\-C-T;>#T%,9$^-T4R&:AR\'49?5ASX(GH9`CD-S#1W5L/.BLA$
M1RW`QZ:#LTBN!^!3`#[/D;L`Z?4`R10@F0=(7(#L<I',WHG.IFE%2<'#XKI/
MBOJDSB=_YP-S'RMB&<]"PAW)4*/,&1671NG<QVH"GE\WR5&3W)F4GZW&B@+&
M4A;RZTX%ZE18)QY_YE2X]0`+X;I1B1J5SHA]9F1%&8M#PJUC,6HT#@].A%09
M0ZN>,7K9,\"S@`\*_V*]3I7D849PXK@3QTO_HB(G$>FFX"2S!*_\=RM*7%52
M2I+A++.44OY.%4">AR7!"\>9910`G"I(:(6)0\UR"@).E98D)QQJ-E%->08E
MCD!)1P!P$"&F(#"IBCRD;',,MV($!IR(04[890#'&H`"@5,%$%,J$W"N@5,H
M<*J@R!EE\P2<;4@H%#B5(8Y1WE>`TPTI!0.G2N.8M"P<;IC@)NSVD*,<0/X?
M'.`T0D'BP*J2DH0!OL="B6/PSLFJ@/01Q'&V>4SAP*D"EE`>(L?9YHS"@5,%
MI,KD.-P<*!0X55!0V.8XVYQ_P,#%9[%3I?$_7UW1K-]H1;\;VRKEK>6QT[;=
M.(^>6[?;L<&)WN2KQ:':B1]5OZL[Y3U);;J>L4792JF%22`.S?MS;YK+\T4C
MMGHXS<UY;]LM>Z'E8>H>SRWLZB]02P,$%`````@`5X)51\<8$]+N`0``U`4`
M`!D```!X;"]W;W)K<VAE971S+W-H965T-#DN>&ULC93-CILP%(5?!?$`&,Q/
M2$209AA5[:+2:!;MV@DFH+$Q8SMA^O;U'QD:T80-V.:<PW<OV,7(^+MH,9;>
M)R6]V/NME,,.`'%L,44B8`/NU9.&<8JDFO(3$`/'J#8F2@`,PPQ0U/5^69BU
M5UX6["Q)U^-7[HDSI8C_><:$C7L_\J>%M^[42KT`R@)<?75'<2\ZUGL<-WO_
M*=I56ZTP@E\='L5L[&GV`V/O>O*CWONA1L`$'Z5.0.IVP14F1`>I%W^XS*]7
M:N-\/*5_,]4J^@,2N&+D=U?+5L&&OE?C!IV)?&/C=^Q*2'7@D1%AKM[Q+"2C
MD\7W*/JT]ZXW]]$^R4-G6S9`9X!70Y3<-<3.$-\8@"4S=;T@B<J"L]$3`](?
M.]HI.=<A*MD3)DV5),SBDUZ]E'&<%N"B@YP&SC3/5@/_KZBL(OL*`0I@D0).
M%/&<`CJ*['%`/`4D\X#8!6S^A8QLK;VMPXJR*`SNR2HK2_(XR!_C)(LXB<-9
M$9`N-B1=WY!LD2!;;D@Z[X?51$E^TPTX[X83P218P;)99-DXENWC@'RQ&_GZ
M;FP7";9K?@\K2C)X__=P6>DV@#<X8+8!!W3"/Q$_=;WP#DRJO6PV7L.8Q"HE
M#-27:-41>YT0W$@]W*@QMZ>.G4@V3&?H]2`O_P)02P,$%`````@`5X)51^K"
M<@;K`0``8@4``!D```!X;"]W;W)K<VAE971S+W-H965T-3`N>&ULC93+;IPP
M&(5?!?$`,3:7N8A!2JBB=E$IRJ)=>P8SH-B8V)XA??OZ!B4CAG2#[9]SCK]?
MEIT/7+S)AA`5?##:R4/8*-7O`9"GAC`L'WA/.OVGYH)AI9?B#&0O"*ZLB5&`
MHB@##+==6.2V]B**G%\4;3OR(@)Y80R+/T^$\N$0PG`LO+;G1ID"*'(P^:J6
MD4ZVO`L$J0_A(]R7F5%8P:^6#'(V#PS[D?,WL_A1'<+((!!*3LHD8#U<24DH
M-4%ZXW>?^6]+8YS/Q_1GVZVF/V))2DY_MY5J-&P4!A6I\86J5SY\)[Z%U`2>
M.)7V&YPN4G$V6L*`X0\WMIT=!_<G&6W+!N0-:#+`9-40>T-\8P".S/;U#2M<
MY((/@>RQ.6RXUW)A0G1R(&V:;DG:XJ.I7HLXB7)P-4%>@V::)Z=!]Q6E4V3I
M)`$:8)$"C13QG`)Y"OAU0#P&)/.`V`?<0&ZLIG-M.`U",(VB^[+2R2#:QC/9
M79QD$2?Q./'G?=(YCM.D\69SBS.7E5X&/U'?Q4D7<5*/DZS@.`U,=^LX7I8E
MZ']PLD6<S..D*X?E-#NXW2&X<EA.MHV2"*$;'#"[#CT^DY]8G-M.!D>N],VR
MUZ#F7!$=$SWH'AO]X$T+2FIEIAL]%^X-<`O%^_%%FY[5XB]02P,$%`````@`
M5X)51Z+BVT^?`0``L@,``!D```!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL
MA5/+;MLP$/P5@A]@ZF49,&0!B8*@/10(<FC/M+6RB/"ADK25_GWYD!0E<)*+
MN+N<&<Z2VFI4^L7T`!:]"B[-`??6#GM"S*D'0<U&#2#=3J>TH-:E^DS,H(&V
M@20XR9*D)((RB>LJU)YT7:F+Y4S"DT;F(@35_^Z!J_&`4SP7GMFYM[Y`ZHHL
MO)8)D(8IB31T!WR7[IO<(P+@-X/1K&+DO1^5>O')S_:`$V\!.)RL5Z!NN4(#
MG'LA=_#?2?/M2$]<Q[/Z8^C6N3]2`XWB?UAK>V<VP:B%CEZX?5;C#YA:V'K!
MD^(F?-'I8JP2,P4C05_CRF18Q[A39A/M-B&;"-E"2(LO"?E$R#\02'06^GJ@
MEM:55B,R`_6/G>X=7'L1IXQ,4',MF5"\\]5KG1=E1:Y>:,)D*\Q]Q&2?(YJ(
M*+<+A#@#-UUDLXM\[2(+_+38?2^0SP+%6B"?VMB]-YG&7F7L(X*VQ2;_`M5$
M5+D"12]D=;T#/<,OJL],&G14UKU4N-9.*0M.(]EL,>K=`"T)A\[Z<.=B'?^I
MF%@US!.RC&G]'U!+`P04````"`!7@E5'>/[_*`L&``#Y)```&0```'AL+W=O
M<FMS:&5E=',O<VAE970U,BYX;6R5FDU3XS@0AO]**G<F^I9,A50!@>P>MFIJ
M#KMG`P92D\2L;8;9?[^VU3)QTA+M"TG,(^EMQ_UV6_'RHZQ^UJ]%T<Q^[W>'
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M&#Y`P``Q#!C6P0=(&"`_!ZCD``4#U#!`IE?0,$!35S`PP%`'6!A@3P8L_-GM
MOYMUWN2K955^S.JWO+MB^66+5]TD[<RSNI^M_5KJ_N!U=_372BJW7/SJ)@)&
M'#$WGA$RCJP]P@=BT0I`58@YMH+P*\07N`5")31\.<G=UY/<>T0R&V<VGC'Z
MZVAEB%8>GW,)YY-]/8$*$ZCC"11\:=E8I.V9@S^EGK%&:<=8G%L3N0UP@EG.
M",(U*EQ[X?ID(7TLW#,74AEE3A4=@VLJN`D@M\Y0M!M4N_$G0">D>T1QQX5*
M<&LBMP&.":>/+LBH;HM>;1;..2$Y'1JX@ZLM$;A',L>,CE]"MY[B0BC)$V?'
M8VW,F17QV>Y`EA.:$S(Q0T/+X-R(1&R>25V(IT14!&>HBOYP)T,F9`"4*9E,
M"A2+"^*X(*@*.O6=\Z%TG!G'6!'*Q24)7!(8LT[E7X"X2SL'SL4E25R2!$DF
M)0G,/FM=,RD)Y>*2\,+`H3)HFY+D(6$U3TM"N;@DW/)Y\'R7DN0A8;(O)*%<
M7!+NY-R`I"PER4-<9R9+:\+!N"B+BP*?-I0I!J,>.3UW],:"XX;(P1%-PJ!O
M`-)*?N%%-&Z#<_$6$G=1$5PTU5P`=*&R+/VM4L'-`#IN2>IQRQ7@DB95B@!2
M4B5;NC@V5NXQPTDF*'!?%F"E1A*FP-MA,:$?%KCO"?`]<U*PCJ'U`!':!8&;
MF0`S,X8PA<&C-1.BQ:U"6$JT`2(TC@)O_`2T6,81ILCP:#-ZM!+/:\D(EA0@
MQO29UXQR(P6.LB,"QM7C>2U#*Y5R)8`NA!8RW4R1R<U`RLR0&B^))[@,"9XR
M)H!:#]3ILQ_GQN+A%ILY39*.-V@2&C23$:90Z/4KU83K%_<,J0G9&B!+60?O
M:B1T-99PHR?Q6T5I)T2+>X9TE&@#1/`FB3<J$AJ5HUO$^"8*0Z-5;,(^#)[=
MBE*U`5)6G'42XYT8E(M+PO-50;Y:0D%6>$%64S:H(CM4H=:F3#M`(K/I^S4J
MN!E`QQ3I'.(IJRC[5`!=*,72K205W`2PK3>DVQN%&X$RE(O2A%T68]-790(<
MJP<P<XQ4,!7>W"CH6ZPB3('?!ZD)]T$*MQ<5[H-2-A8@2V@H-=[<:.@R+*&A
MU!R-5G-ZM!KW#"T(T0;($DQ;XP590T&VA(92XP593RC(.K()'6IMEHH6($=9
M!\]##7GH4AX(D)7ZS-E&:9C@QGO=L"A7M&UZ/`EUV#1.;M1[**D:1<:"3Y&X
M5KSCT,-&<&+K&2!N!.FLX*:@(=\=H;0:O.<P$WH.@_<<!GH.I^+QW@&D&:F5
M,+@M&,AX1_`W@[<29D(K8?!6PBA"N@;($7S4X+9@-"%=`3+J;#=W=-W'L?'O
M.Q@6UQWY7<H0<A6@5)N"(Z/?`,^0N%;<5PSX"J-D$%[<S83B;O`\-I#'S,5C
MO0=("47:'K-X?;=0WQWEYSN\OML)]=WBB6P%(6"`R`'C)=Y"B7>$$F_Q$F\G
ME'B+Y[(-]]R)FG`#D+"93>]:1$`O:G'TU,6^J%[Z)VKJV6/Y?FC\`P##T>&I
MG6O1/;5Q<OR&7]YRY/B:7][Y9W(^IU\MW_*7XJ^\>MD>ZME#V33EOG^PX[DL
MFZ+5S+ZUN?U:Y$_#AUWQW'1OVV!FE7\RQW]HRK?PH-'PM-/J?U!+`P04````
M"`!7@E5'TWRF_X@"``#;"```&0```'AL+W=O<FMS:&5E=',O<VAE970U,RYX
M;6R-5LMRFS`4_16&?8.$!`(/9L:O3KOH3":+9JW8LLT$D(OD./W[ZF5"7.'@
MA4&7<\X]]TI"%!?>O8HC8S)X;^I6S,.CE*=9%(GMD354//`3:]63/>\:*M6P
M.T3BU#&Z,Z2FCF(`TJBA51N6A8D]=F7!S[*N6O;8!>+<-+3[NV0UO\Q#&%X#
M3]7A*'4@*HNHY^VJAK6BXFW0L?T\7,#9!B(-,8C?%;N(P7V@S;]P_JH'/W?S
M$&@/K&9;J26HNKRQ%:MKK:0R_W&B'SDU<7A_5?]NRE7V7ZA@*UX_5SMY5&Y!
M&.S8GIYK^<0O/YBK(=&"6UX+\Q]LST+RYDH)@X:^VVO5FNO%/DDS1_,38D>(
M>T*?QT]`CH`^"/@N`3L"GIHA<83D)D-D:S>=6U-)RZ+CET"<J%Y/<*;@G191
MRH$P:JIIP@07.OI6HBPOHC<MY##Q`+.TF!B-0]86`GM$I`QX7<2A+T-L,XPG
M6#D$ON/A2Y'-?R*C-M'5)AHV"]EFY>!K`7P5P$,![`3@9Y/$8%K;"X=!`.1H
M'+:RL)A@0O`X;&UA.<"8)..PC861&!*0?UU<XBTN<<7=S$`RM&,Q*<XQF-#$
MU#L+J5N.$Z:1>(T29Q3=,6HQD*0@QA,ZDGD39=9I=B>/A7PC4]J1>Y/DKIH[
MJV"9NX4/LBS!=]SX<:.&(/`Z,F%M*9D@`;US#.'TK09COXO8O]D^%>Q`),NG
M3`!$_DS(O_(_;40'2H'^W:2*!F_NAG4'<V:*8,O/K;3OHC[:G\N+6+_Y;^)+
M.%M!3WRMSW%S4GS(E\6)'M@OVAVJ5@0O7*KSQAP.>\XE4Y;!@ZKZJ+XT^D'-
M]E+?$MT.>_;:@>2GZZ=$_SU3_@-02P,$%`````@`5X)51^Q@,:#A!0``:"<`
M`!D```!X;"]W;W)K<VAE971S+W-H965T-30N>&ULE9K;<N(X$(9?A>(!C'6V
MIX"J29AD]V*KIN9B]]H)3J`&,(N=,/OV:V.)\:';:MT$<'XU/RVI_;GMY;6X
M_"QW>5[-?AT/IW(UWU75^<MB4;[N\F-61L4Y/]7_>2LNQZRJ/U[>%^7YDF?;
MVZ#C8<'C6"^.V?XT7R]OQ[Y?ULOBHSKL3_GWRZS\.!ZSRW\/^:&XKN9L[@[\
MV+_OJN;`8KU<W,=M]\?\5.Z+T^R2OZWF7]F7YT0TDIOB[WU^+3OO9XWYEZ+X
MV7SX<[N:QXV'_)"_5DV(K'[YS!_SPZ&)5'_SOS;H[^]L!G;?N^A/MY];VW_)
MRORQ./RSWU:[VFT\GVWSM^SC4/THKG_D]C>H)N!K<2AO?V>O'V55'-V0^>R8
M_6I?]Z?;Z[7]3Q+;8?``;@?P^P`F)P<(.T!0!T@[0%('*#M`40=H.T!3!Q@[
MP`P&+-KLWN9FDU79>GDIKK/RG#4KEGVIY9<F2!UY5MZBU=-2W@Y^;8Y^KD6J
MEXO/)I#5\([FH=5P7/%HHS"!:S:M1BM<\LU^D<0E3\ZOP37/3I/<-8LZ'V!2
MN$N*Z":%VP"I/X!P`60W@+@%D''<=\G:U)_:M+8B8>(X2B=TFU;'&6,1\QN2
MH"%I#1$"*#`EBIX2#3K0UL%@&3'>34DK$DDLHRG=IM49IB/A]V-`/\;Z$5-^
M6A%7D9ERTZIT1,A-`GI)K!<YY:45:19-J3:MRO".8]1,"II)K1DU92:U$Q7I
M*3-61<H,BT$WM\-U##7<(CT[5F6TB*-DRI$5\E0*DBD&;@;&;(XT(02'?Q>G
MS+E5"19-+=.-E:G.TL#]P!6+N9(UM=(?G"H9K\)NR7ITNM2S<YBK;2H:+K=N
MO&]WG1C5A:[NR>E,VBF58]VSTR4Q:17`-95)TM)L58IQ3RI:'><T2PJVI.PL
M$DY]3,-K6],K/8-+*W.U=7CZZR>F5;%8I,/SG^HEQNDTH=8SN,`R5V$I/RJ%
M\Y+2\\+A6L9C2EZLBLO>^1Y8,5:8R#2BD`Z#/=E2QF)""(26`G")P]6'8\#4
MSXS=M7*T8`:):74L32AXP.'=S2TR,0(R<9B9>``T<9B:.()-JI>75A1/;**1
M!#<"[VE.XB5.`R8>0$P<WM$<8:9^8A)_8H82W`B,2QSAI;Z1U&]D*,$O.>#J
M(DBD9%6^&;(RT@P)&))$`"0)&)($`DF]W%K15&Y'$MP(<CV'T%'?B/`;&4IP
M(W!5$@AS](U(OY&A!#<"DX:PI,$X(01,&B*`-`1<E01"&OUT&'\ZAA+<"%R.
MA"U'C'#"$3!@B`#`D'`)D`A@]-)A15/I&$EP(S!52$<5A`L2"5.%#*`*">]:
MB5!%/QW^73N2X$:0[HMC"44(`;.$#&`)";.$)+5@)+4'(X.:,!+>P!+!BOX4
M^3?P2((;@3>P)/5@)*T)(T.Z,!+F"DGJPTA:(T:&=&(47%P4B2^4Z\3$:GCU
MTILPY1HQ@I`B!1.&"B`,!1.&(K5A%*T-HP+:,`HN68H"&LI?LD82W`A<LA2I
MN>%4OL3(@,3`O*$<;U#F&N8-%<`;"BY7BM394,3.A@KI;"BX;BD''I1M!(.'
M"@`/#=<&3>IL:&IG0P=U-C3,(-HQ""4$S"`Z@$$TO*$UJ;.AB9T-'=39T/#6
MUHY&*+\*IA$=<CL(N1]$Z6QH?V=C),&-P'M:4Q!$^Q%D),&-P%M94UH:VM_2
M&$EP(S!Z:$I+0_M;&B,)?HL.+BL&08Z>$>._GAE)<",P:9@`TC`P:1A*+\/X
M>QDC"6X$KDB&=*?'X'=Z^O<^H3LXN"6X(AD2;%B5WY(,L@3SAK&\P2F)AGG#
M!/"&06Y24_H;QE^;1A+<"%R;C*U-G-`--S!FF`#,2.!ZD%#Z&XF_'HPDN!&8
M+1);#SBA^Y7`;)$$L$4"[^0$80O32P=XL6!ZZ8`O%A:=YXG.V7O^5W9YWY_*
MV4M15<5QU3Q']%8455Z'B*,ZO[L\V]X_'/*WJGE;[Z/9I7T0K/U0%>>5?:[M
M_G#=^G]02P,$%`````@`5X)51P_\=DL'`P``$0X``!D```!X;"]W;W)K<VAE
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M'!(&3?EIKU7;7T_V&Y9`F#L`0P"^!"`Z&4`@@%P%Q):LG]>74I6+62=.@3R4
MQFWTI.6=2:(S![+/IJ<D^\%G,_JQH)C,X@^3"#1XH'FQ&GQ;L;0*EEXDL09P
M4N`S!1E28*"@]Q.0<P(Z3$`@03J&1':NK9T'`4I$(S*A6UI=FI/(@X<Z>2CP
ML/%[TB&.U3"6)U<P>`@#*II%^#Y,ZH1)`2:[GX`Y[6'^]F1.@@P2Y!,S?;&B
M(KKV<+0<5H1PQ.ZSY$Z6_,9/9<22`PN:8K$BA"*/A2V<+`6P%/<3H,1I33_L
MZ0U"3@B$W.Z,?JP@8HA.K<A91:B//PB[>;"/0Z!*&8N*223095XV(7=Y05!?
M2.*1@KJ-H@\8Y=['*/791J!"ILRAVXXN0><S(^;&85X^616B!;ZNNF,<YHWC
MKC$(B@Q!'BERMT?Y`QZY=S0JO#RR*I0D>42G%J7P712<.'%PXN,1J(H"7>^E
M$0W(?&C<E09#I2$>?V7X1J?P0*N`W9L9$Q^+0(4REDUN(]#Y+(J[5<#4RR(*
M.(1,XU!O''>1P5!D"/%(X6X7\`/]`G9O9NS5,8!*>_3?G\!X43+O17'W#/A&
MTY"-:*`?R#"ZK5J"ZIHE'C3OAW+'?Y3=KFIEL!)*GP/ZIGTKA.(Z11+IR>WU
M^>SR4/.M,K>9ON_LB<4^*'$X'\`NI\#%7U!+`P04````"`!7@E5'O483W9("
M``!@"0``&0```'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6R-EDV3HC`0AO\*
MQ7T&`N'+0JH4W-H];-74'';.4:-2`\0E46?__>8+1`>B%X'VZ;?[;8E)>B'M
M)SU@S*RONFKHW#XP=IPY#MT<<(WH*SGBAG^S(VV-&']L]PX]MAAM95)=.9[K
MADZ-RL;.4AE[:[.4G%A5-OBMM>BIKE'[;XDK<IG;P.X"[^7^P$3`R5*GS]N6
M-6YH21JKQ;NYO0"S%7`%(HD_);[0P;TEFE\3\BD>?FWGMBMZP!7>,"&!^.6,
M<UQ50HE7_JM%KS5%XO"^4_\A[?+VUXCBG%0?Y98=>+>N;6WQ#ITJ]DXN/['V
M$`C!#:FH_+0V)\I(W:785HV^U+5LY/6BO@F!3AM/\'2"UR?T=<83?)W@7Q.@
M,0'J!/ALA4`G!'<5'.5=3JY`#&5I2RX6/2+Q/H$9QULAPI4M*M7XT*@,+D3T
MG$$?ILY9"&G&&S!+Q7C^-%(H!/2$PQL8[<*SQRIXJL)T@5P3AC:+AR*K;R*3
M;?I=F_YP6+X>5O!8`'8"<"@`M4!XVV0DF4;-0C'N-)$_)`I%>!$,7`.VNA>:
M=!.,N@FTF^BV1#!T$^B1PVDF5\P+3*#O3V.%PH(X-M1;=5JA!_S'OL)17Z'V
M%1M\*>8%?)_PC;4."XU8\9S:2F,>&&*3YJ)1<Y$RYSZQ5N/111`_OPB2T0X2
M+9`8QJN9)(B,XTWT>YX`XW@U!@+S>#46N\DSXP7NJ#L9YJU#P\);=E`,H&F!
MYIKC[[)GXHHG]5;C>LJB,]@^:MSNY<9-K0TY-4S](?;1_G"P\,3V<Q=?@ED.
M1N*%.$S([>HJGZ5'M,>_4;LO&VJM">.;GMRA=H0PS%MV7_FT#_RXTS]4>,?$
M;21^!G4`4`^,'+OS3'^HROX#4$L#!!0````(`%>"54<N6,O0M0,``"X2```9
M````>&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;)58VY*B,!#]%8H/$'+AHN58
M->,XXSYLU=0^[#XS&I4:("[@./OW"Z1!Q`X37Q3BZ>Z3T]TQR?PL\X_B($1I
M?:5)5CS8A[(\SARGV!Q$&A43>119]<M.YFE45J_YWBF.N8BVC5&:.-1U?2>-
MXLQ>S)NQMWPQEZ<RB3/QEEO%*4VC_-^32.3YP29V._`KWA_*>L!9S)W.;ANG
M(BMBF5FYV#W8CV2V9KR&-(C?L3@7O6>K)O\NY4?]\F/[8+LU!Y&(35F[B*JO
M3[$425)[JB+_!:>7F+5A_[GU_M),MZ+_'A5B*9,_\;8\5&Q=V]J*771*RE_R
MO!8P!Z]VN)%)T7Q:FU-1RK0UL:TT^E+?<=9\G]4OH0MFN`$%`]H9='%P`P8&
MS-2`@P&_&/!1`P\,/-,(/ACXIA$",`A,#4(P"`<&CDI'D\SGJ(P6\UR>K>(8
MU25.9A4\KYU4GJVB\5;EL6@&'^O1SP7G9.Y\UHX`0WN8)X6ATZD>LP0,TT-6
M"G()Y%0D4:;4QEC0QIRY[@@+A:%ZQ#,@^`C/;YV\?._DM64;Z#%KA?&][Q5A
MK2*LGSNF<L<,'/#6`>\[X)#\P5R#!I,I-13&_3Z$AX;P(,2@,+Q^",\TA(^&
M\"'$(!V$]&(L`11,#,0*T#"!\C#,**'],`&DG4RF(VQ66EA?^K5"4==`F1"E
M'$(8JA=_&0[$OZ'QC"*NIKU2$!KPGKPWCEZ&CK2SF:*SF4*>O;$$`"B8#IE<
M$];#^GE:*QCU/9.R(2Y*NQFNL\`,7!"TT0DQ[W1"<184KX6K^3X!ZCJ1^E`,
M#Z76)4:XOA9>`<0]@W(@^.I%.,09=&0?]-2!0H,X^!)&/$WA72TP@"*!/QE;
MB%8H3D\)7_*(#]D,1T*]`HI3/O$-0N'+'H%UCTX-7(1X^89WE"_>^Z1M?E^?
MZV4'&BF(%0+2;T3PCJ8NS,>@=BG>T?2.CJ9X1U-J($D'"D<D04!Z,GC/TW8O
M8K*]X[@D_`Y)\$ZEGHDD+6@Z)LDM2$\&[U$*W<>H@8L`ER2X0Q)\"T!#$TG"
MF\48D>06I">#=S&%WF,&?X7,125AKKDDC*`L&#&0I`5Y9$02!*0G@W<Q@][S
M#*J$:8X!=YP#&/Y7RMJ3P.@>&E!D,EPGG-[),Q7YOKF&**R-/&6E.KQTH]U5
MQR.M3ZZ#\269/1-D?$5F+^HBX^)^,3]&>_$SRO=Q5ECOLJS.R\WA=B=E*2J^
M[J3:Z!Y$M.U>$K$KZ\>@>L[5=89Z*>6QO9WIKH@6_P%02P,$%`````@`5X)5
M1ZS*5#95!```NA@``!D```!X;"]W;W)K<VAE971S+W-H965T-3@N>&ULE9E;
M<Z,X$(7_"N7W&-02`E*.JV:\-37[L%53\[#[3&(YIH:+%T@\^^^72V.#:>3V
M2PSDDWR0#@>UO#D7Y:_J:$SM_,[2O'I9'>OZ].RZU=O19'&U+DXF;_YS*,HL
MKIO3\MVM3J6)]UVC+'7!\[2;Q4F^VFZZ:S_*[:;XJ-,D-S]*I_K(LKC\[ZM)
MB_/+2JR&"S^3]V/=7G"W&_?2;I]D)J^2(G=*<WA9?1'/.Q6V2$?\G9AS-3IV
M6O&O1?&K/?ES_[+R6@TF-6]UVT7<?'R:G4G3MJ?FF__%3J_?V38<'P^]?^MN
MMY'_&E=F5Z3_)/OZV*CU5L[>'.*/M/Y9G+\;O`>_[?"M2*ONK_/V4=5%-C19
M.5G\N_],\N[SW/_'U]B,;@#8`"X-A+(VD-A`WC1P>V7=??T1U_%V4Q9GISK%
M[6R+YP8OVTZ:GIVJZZVYI:J[^*6]^KE5OMRXGVU'R,"(^=HSL$SL>D+[%\1M
M!)`J8%`AQRH`5:C['<BA`S7N0&('_E2DZ.\U[^^CAV3@>>O(PNUZ#H00:W%?
MD"(%*12D;[X(QH)Z"-;2`NUZR%L']Z7XI!0?I00V*3WT!&NP:;E0C(G2I!B-
M8D*;&'V=*!NWT\-$P8A;%!20@@(4%-WO("2]&_*]&Y$*H@7O3H:DAR"`D26)
M$8F&D>/,D/!(/=UEPKO^6`]"WC*RFR'+0@0M1'"<B]239Q^9*P8,04`+`HY[
MD6KGROHP(==.EF9(HH-/8/)ISC`KTL!"\1TLZ(@1/L?#2`4ZL#_6R.D(6`-#
M!XW0M(MO).E9NE*"!HIC'3IF1,#R<D\]"?LKX8HQWK@BI`6%+"^'.&7A*%`H
M12%.F5PS@E3002@P"37CK0L>Z67P^%X&.G5`<+R,E%"AL(\,@J`CSL@`'3P`
M'#,C-8Z3>2H/$$,+G3@@:2=/7@\(>=:1D?/@7A9#+[-`<5R,5#-9LP7%=&QP
M019P1H=.0L`DU(RH`$U[6#_@83IM(&!YN*<BB.SQAYP?\"Q,YPV$+`N':&'K
M"^)"288<.FL@HEU\(R<:+&K-XRO&*6#H59?T.$Y&JITRL!@9,3]D&%G2,2@Q
M!C5CC"5=U<E'RKJ%NFZAL)N$C62$S<!P7N&2SAJY4---M:B[Z^(9LBR$SABY
M4-%-A?CWA=PBRT+H-99<J.:F0C1C=AY88$DZ\B1&GN:8C:[DY`.EG*1C1;**
M.:1`1;.-B.FP])R(0M9&!!TL:J&<N]F*\&8S0.U%S*EE.72N*%91IR[5FFT@
M=^J1HD[1:RO%*NJ0`O_>",%#4T:GGAJ*.L;R7M%%G7J@J%-TS"A648<4^/8U
M!&*:LX)0=-HH5D6GABBQ/EE("99OZ,!1K(H.J2=IKQ(&C&=D>H6EEBJZR28H
M4A#.?#S9`T7,G\V7.]IE/L7OYJ^X?$_RRGDMZKK(NMWE0U'4INFD>7A7SM'$
M^\M):@YU>Q@TQV6_M=Z?U,5I^*7@\G/%]G]02P,$%`````@`5X)51U!>W\T_
M`@``!@@``!D```!X;"]W;W)K<VAE971S+W-H965T-3DN>&ULE57;CILP%/P5
MQ`=@FWLB@K1+M6H?*JWVH7UV$B>@!<S:3MC^?7TCI:F3T!=L'^8,<X9CNQ@I
M>^<U(<+[[-J>;_Q:B&$-`-_5I,,\H`/IY9L#91T6<LF.@`^,X+U.ZEH00IB"
M#C>]7Q8Z]LK*@IY$V_3DE7G\U'68_7HF+1TW/O*GP%MSK(4*@+(`E[Q]TY&>
M-[3W&#EL_">TKE"B(!KQHR$CG\T])7Y+Z;M:?-MO?*@TD);LA*+`<CB3BK2M
M8I)?_K"D?[ZI$N?SB?U%EROE;S$G%6U_-GM12[70]_;D@$^M>*/C5V)KT`IW
MM.7ZZ>U.7-!N2O&]#G^:L>GU.)HW.;1I[H30)H27!!3?38AL0G25`(PR7=<7
M+'!9,#IZ?,#J;Z.UA#-%(ID]KMED25P'GU3T7,9I6H"S(K*8<(9Y-ICP-J(R
MB#2Y0(`4X%013BJBN8K0JL@>$T0303PGB`P!O!*)3*V]J<.`HAS&P3U<97`9
M2H/HL9[8J2>V!>6/"1*G(\ER1U*G@O2&(^'<$0,*41#?054&E<Q=NRDF<XK)
M;#6KQP2YTXY\N1TKIX+5$CL,".7Y[,=K6#*WPZ`BN*#;$72*T6&I)H,+*)#3
M$(26.X)"MXIPB2<6%2&T"M"]+IF`LIL6]`ER[V-D-W*&%E#$;F?B_W`F<:M(
MEAPG$RI+_MD^?QTG%A<EP77[@]F)/>`C^8[9L>FYMZ5"'O[ZI#Y0*HAD@8'L
MP5I>RI=%2PY"33,Y9^::,@M!A^G6O5S]Y6]02P,$%`````@`5X)51XUFL75&
M`@``J@<``!D```!X;"]W;W)K<VAE971S+W-H965T-C`N>&ULC97+CILP%(9?
M!?$`@,TU$4&:,*K:1:71+-JUDS@!#6#&=L+T[>L;#*'4F0VV#__Y_1WP)1\(
M?6,5QMSY:)N.[=R*\W[K^^Q8X18QC_2X$V_.A+:(BR&]^*RG&)U44MOX,`@2
MOT5UYQ:YBKW0(B=7WM0=?J$.N[8MHG_VN"'#S@7N&'BM+Q67`;_(_2GO5+>X
M8S7I'(K/._<);$L02(E2_*KQP&9]1\(?"'F3@Q^GG1M(!MS@(Y<62#0W7.*F
MD4YBYG=C^CFG3)SW1_=OJER!?T`,EZ3Y79]X)6@#USGA,[HV_)4,W[&I(9:&
M1](P]72.5\9).Z:X3HL^=%MWJAWTFV1,6T^`)@%."2"R)H0F(5PD^)I,U?6,
M."IR2@:']4C^;;`5<BI-A+/#E)LHB:G@DXS>BBB%N7^31D8#9YJ]UE@4I58D
M\23Q!<`J!1PIPCD%-!3A8X-P-(CF!J$QB.XA@:ZUTW5H$4CCT(LMNE+KDBCP
MOE!0M,H3&9[%//$<)YIP%C!P#A--,-ECF'@5)C8PB66>O1:!#`8>L/$871B%
M7OH8*%D%2@Q0:@-*/H&L'R@9@6(//@9*5X%2`Y39@+0(P-3.,\H2;_,8)UO%
MR0S.QH:333C+Q7R'DTTX7U@_FU6<C<;)`AN.%H5I$'@V[%+K(`!@ML[^"P2"
M52(5EDC+I7JWWXU*,2W_[-V&-T(!!?_Y2O[L5.W1!?]$]%)WS#D0+@YH=9J>
M">%8^(CSPG4J<7%.@P:?N>RFHD_U5:('G/3CS3A=S\5?4$L#!!0````(`%>"
M54='#-$Q1`(``"$'```9````>&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;(U5
M36^C,!#]*XC[E@\;2"*"E)"LMH>5JAYVST[B!%2#6=L)[;]??T%0"K07C(?W
MWKP9HW':4O;&"XR%\UZ1FJ_=0HAFY7G\6.`*\2?:X%I^.5-6(2&W[.+QAF%T
MTJ2*>*'OQUZ%RMK-4AU[85E*KX*4-7YA#K]6%6(?6TQHNW8#MPN\EI="J("7
MI5[/.Y45KGE):X?A\]K=!*M]K!`:\*?$+1^\.\K[@=(WM7D^K5U?6<`$'X52
M0'*YX1P3HH1DXG]6\YY2$8?OG?I/7:UT?T`<YY3\+4^BD&9]USGA,[H2\4K;
M7]B6$"G!(R5</YWCE0M:=137J="[6<M:KZWY$BTM;9P06D+8$_H\XP1@">!.
M@+,$:`GPNQDB2X@>,GBF=MVY'1(H2QEM'=X@]3L%*PEG2D0J.URKR:9Q'=RH
MZ"V#BS#U;DK(8L(!9FLP(9B&[`PDZ!&>-##J(G3',H0FPW2"W"+@C(<O1?:?
M1"9M@LXF&#8+F"JC^&L!V`G`H0"TW7YH9:(QM>D%M-U>)$O?G\;E!A>'$9R#
M[0P,@!B`!$[C]@87+&&X2+YQCM%H?9&M[R%1-*S/8))'TT-,;C`SB)U!!&!.
M9F_M##"3]<2C]<2VGFCFO`SFAYS"<Z=E4<'L6752LP>_MRCPJ2QO,``JS"YZ
M]'+G2*^U,+]T'^VG^R94`^0AO@U6>3`2W\G;P`SONWR6-NB"?R-V*6ON'*B0
M8TO/F#.E`DN__I/L<"'OJWY#\%FHUT2UWHQPLQ&TZ2ZD_E;,_@-02P,$%```
M``@`5X)51_RYD)G@`0``.P4``!D```!X;"]W;W)K<VAE971S+W-H965T-C(N
M>&ULA53;;ILP&'X5BP>H.2>-"%)"-6T7DZI>;-<.^1-0;4QM)W1O/Q\P81--
M;K#]\YU^L%T,7+S+!D"A3T8[N0T:I?H-QK)N@!'YQ'OH])L3%XPHO11G+'L!
MY&A)C.(X#'/,2-L%96%KKZ(L^$71MH-7@>2%,2+^[('R81M$@2^\M>=&F0(N
M"SSQCBV#3K:\0P).VV`7;:K<("S@5PN#G,V1R7[@_-TL?ARW06@B`(5:&06B
MARM40*D1TL8?H^;-TA#G<Z_^S7:KTQ^(A(K3W^U1-3IL&*`CG,B%JC<^?(>Q
MA<P(UIQ*^T3U12K./"5`C'RZL>WL.+@WJVBD+1/BD1!/A&A]EY",A.1&L)\.
MNV2VKQ>B2%D(/B#9$_.SHXV&"R.BE9&T:KHE:8L[4[V6Z3HO\-4(C9AXAMD[
M3/0UHO(JJPF#=8+%&'&P9!%;@?B.A4/DV6.'Q#LD\T83UT26/Q9(O4`Z%TC'
M'M?_AIQC]A[S_-@D6S3)G,!S>,?$8Z*O,97'Q(^#Y(M!\E$@N1/$8]([03SF
M__^&9YN5@3C;0RQ1S2^=<GMUJD[WQ"ZVF_T&+XN>G.$G$>>VD^C`E3XR=G^?
M.%>@[<.G+$"-OLFF!863,M.5G@MWN-U"\=Y?5=-]6?X%4$L#!!0````(`%>"
M54=C27EKK0$```$$```9````>&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;(53
MR6[;,!#]%8(?8&KS$D,6D*@HVD.!((?T3%LC2P@7E:2MY._#3:H:N(D.XLSH
MO<<W'+$<I7K1'8!!KYP)?<"=,<.>$'WJ@%.]D@,(^Z65BE-C4W4F>E!`&T_B
MC&1)LB&<]@)7I:\]JJJ4%\-Z`8\*Z0OG5+T]`)/C`:=X*CSUY\ZX`JE*,O.:
MGH/0O11(07O`]^F^+AS"`YY[&/4B1L[[4<H7E_QL#CAQ%H#!R3@%:I<KU,"8
M$[(;_XF:?[=TQ&4\J7_WW5KW1ZJAENQWWYC.FDTP:J"E%V:>Y/@#8@MK)WB2
M3/LW.EVTD7RB8,3I:UA[X=<Q?-DED7:;D$5"-A/2XE-"'@GY!P()SGQ?WZBA
M5:GDB/1`W;#3O84K)V*5D?9JMB7MB_>N>JV*NTU)KDXH8K(%YB%@LO\CZH#8
MK&<(L09NNL@F%\72119=;+\6R">!?"F0>X$\2;\6*&XZ***#W;]=IN&P1#B(
M`-KL5D6R>-)/*'74W:YV'YR1Q;0&>H9?5)U[H=%1&CMX/Z562@-6)%FM,>KL
M?9P3!JUQX=;&*ORB(3%RF"[<?.NK=U!+`P04````"`!7@E5';VF_9%0&``"(
M)P``&0```'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6R56LMRXD@0_!6"NX7Z
MW7)@(@9C8O>P$1-SV#UK;-DF!I`7R?;LWZ^$2IA'=E/B8$#.KLXN.JM2C^EG
MN?M5O19%/?J]66^KN_%K7;_=3B;5XVNQR:ND?"NVS7^>R]TFKYNONY=)];8K
M\J?]H,UZ(M/43C;Y:CN>3??'ON]FT_*]7J^VQ??=J'K?;/+=?_-B77[>C<6X
M/_!C]?):MP<FL^GD,.YIM2FVU:K<CG;%\]WXF[A=9JJ%[!%_KXK/ZNCSJ"7_
MLRQ_M5_^?+H;IRV'8ET\UFV(O'G[*.Z+];J-U,S\+P7]FK,=>/RYC[[<+[>A
M_S.OBOMR_<_JJ7YMV*;CT5/QG+^OZQ_EYQ\%K<&T`1_+=;7_.WI\K^IRTP\9
MCS;Y[^Y]M=V_?W;_\2D-PP,D#9"'`8=Y\`!%`]37`!T=H&F`YLY@:(#ASF!I
M@/T:8/?)[Y*U3_4BK_/9=%=^CJJWO-V`XK:![]H@3>11M8_69+G:'_S6'OV8
MZ2R;3C[:0(211YAYAY$J#%ET$!%&+&DB[PZ824,2,I5CQ$)V+,)3W!-"1WA>
M#?)P/<BR@UAS?26J7XDZSKG:CS=I>CV`[@/HXP":`ISE^QBSZ#$RC%E>8H)$
M#"1B*("*$#&TPTR$R"4F2,1"(I:(G/ULHMOKVVX'6=K'B8J@%BS4LD,YF:39
M\>LZ?P?Y.^(?2=+"\9/DX22>)K&QY7<@D27N%.6.0`\=Z$:(ZU0R2"4C*F>3
M"'G\>W4@GX@(W_L.Y,[IGD1:=""=R`CHH0,)D3`2+%*XK/WA=EV>$4+`XB`$
MOSH(B5E("I%%EKLDE%"I/-KJX;D4GHN*F>#0U7C%>L"*<1T2AK'B.:&<=]&-
ML&#BEH13UB2,"BIPY1)4NCA:$@XGD*J'X+#`I4%0;1#G1>\T@832%Y(\S1\+
MMB28S5B"PW5$4"$1^GH(F<+LR92?/2D@"RDXV>M1R7G]/4D>"[4DE$@8'4?B
M*B&I2@A&]B4V,E(-2!VV,I+$+V++G1-*N"NY`[`P(5Q*))42P3&J%J?%#D@+
M]@/2L=+BJ$.::%8N46$ZN#S(OCPP^IK,<%+ZEL^H\@IW5]5WUVB5)Y0061HO
M\Q@8)H6UKWKM,Y2H)$R-DOS]HG`;5KT2HQ6(4")NEEBHY0'%\`X*:U^1]B5G
M2QB<.C,@=;@!*\N16H^ZLJ4XJ.4!Q6A:"M<'1?5!,ER#\CAU?H`@<?=5&1:D
M.<E<![+.A$$+``J?$^/JH*DZ2,96T-A[:\'?31IW52TY0NQ1\78&4&$ZN"YH
MJ@N2H5*-[;D>8,\U[JF:5'I^5>4L*7050"6Q^GY/,!E%+0C5%/>+\_B3DS["
MW;B$H22-*X@F/4O.YL467KL!2<8]6I.>I8V(D4#GY>GDC)HP-VG<5O3S);$?
M]:$/)EB;&)<9365&,BR9P2;?I/S\&MSH37]B'CVK)I003G-6;'`5,:1\R?!;
M!GMS,^`JH\']V6C&BN>$$D+;^&DA!H9)!2XY]K6$X;<,]N?&#D@-[K_&L38#
MH6S"V;E8UH9DICADL?4V`ZRWQ<W5LJPWH9KSKUA-6"!8F!!6HR4U*L9.LMAV
M6SD@+;B]6L79!H12FG,&9K$6+6E1,:R)Q5[9F@'K#5QFMWB])SV&0$*&,8M+
M3)@*5J`E;2F&L['8`=L!#MCBUF0##OAL`]"E9<MI"0XKT)$"%4,S#MM;-^#2
MLL.-R7$N+<\)U5BO]/@5[0Y7QX2I8FTZTJ9BB,YAZ^L&6%^'VY4+79D^N9M$
MJ,:L<NX@86TZTJ;B[#'L0MT`%^IPNW*>L=ZY"WG'DUM1`!6F@_7IZ,X/IVQZ
M;!W]`.OH<;/R=/-;GUGS8]"\!YDT#%H`4)@,EK"7E!)&X?386_H!WM+C?N8U
M)R4$,K$;W0`4)H-%ZOLS3\YZL*?T`SREQQW-.TY*>I"/I>02%"83N%?<VTZ&
M<_78=OH!MC/#32_KM1>]94THYQ.#;\9?CGGH(SN.)\NPK+/>@S+2G&$/F@WP
MH!GN<YEBY:A#7=X$F!P]-;0I=B_[![RJT6/YOJV[!U@.1P\/D7V3[5-'9\?G
MXO9>@.,+<?O0/2+V%7XV?<M?BK_RW<MJ6XU^EG5=;N[:!Y.>R[(N&KYITMC%
MUR)_.GQ9%\]U^[%IE:-=]Z!8]Z4NW^[HN;?#PW>S_P%02P,$%`````@`5X)5
M1[E/8C@*`@``?08``!D```!X;"]W;W)K<VAE971S+W-H965T-C4N>&ULE57+
MCILP%/T5BP\`;"`O$:1D1E6[J#2:1;MV$B>@L3%C.V'Z]_4+AE:NH)O8OIQ[
M'@$N9<_%FZP)4>"#T5;NHUJI;I<D\EP3AF7,.]+J*U<N&%;Z*&Z)[`3!%]O$
M:(+2=)4PW+115=K:BZA*?E>T:<F+`/+.&!:_CH3R?A_!:"B\-K=:F4)2E<G8
M=VD8:67#6R#(=1\=X.X(,P.QB!\-Z>5D#XSY$^=OYO#MLH]2XX%0<E:&`NOE
M09X(I89)*[][TD]-TSC=#^Q?;%QM_X0E>>+T9W-1M7:;1N!"KOA.U2OOOQ*?
MH3"$9TZE_07GNU2<#2T18/C#K4UKU]Y=V:2^+=R`?`,:&Y`S[H2LS6>L<%4*
MW@/987/SX$[#A2'1S$!:-NU0VN+!5!]5D6W+Y&&(/`9-,$>'0=D(231]4`-%
MH7YD^S.4SQ-D`T$V-9DYDWDZ3Y`/!/F4(/<$\,^4T/T5K;/I0##-X\V\3A'4
M*;P.FB=8!9.NEB==!QVL_Y$439-ZT"9>S<ML@C(;+[/@F=@&@VZ7!X5IT((M
MST;U*%3$VP5*,*SD7Y)\P0,,43`N1/^1-PN[R)8\Q!Z%TOCO6Y-,Q@,CXF:G
MH`1G?F^5FPYC=9RT!V3'RR>\*CM\(]^QN#6M!">N])"R$^7*N2+:0!H7$:CU
MMV`\4')59KO6>^&FHSLHW@W#?OSB5+\!4$L#!!0````(`%>"54<CWP[E%0(`
M`%$&```9````>&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;(U5RXZ;,!3]%8L/
M".9-(H*4I*K:1:71+-JU0YR`QL;4-F'Z]_4+PE0TS`;;E_.XU]B78F#\3=08
M2_!.22OV7BUEM_-]4=68(K%A'6[5FROC%$FUY#=?=!RCBR%1XH<0ICY%3>N5
MA8F]\+)@O21-BU\X$#VEB/\Y8L*&O1=X8^"UN=52!_RR\"?>I:&X%0UK`<?7
MO7<(=J<`:HA!_&SP(&9SH),_,_:F%]\O>P_J'##!E=022`UW?,*$:"7E_-N)
M/CPU<3X?U;^:<E7Z9R3PB9%?S476*EOH@0N^HI[(5S9\PZZ&1`M6C`CS!%4O
M)*,CQ0,4O=NQ:<TXV#<Y=+1E0N@(X428?)8)D2-$#T)L*K69F;J^((G*@K,!
MB`[IKQWL%)QK$:4,A%%3)0D3/.CHO4SBI/#O6LAAPAGF:#%A-$%\);_H$7I+
M_-#R_^]PLH@T67>(1H=H7D7DJH#K`O$H$,\%8B>0?DPRL'O5VCHL*(A"N$F>
MX$X.%^3I)EY/*%E,*'$)9>L"Z>*6I)_?DFPQ@\P)!,^VQ(("&&_R=9]\T2=W
M/OE'GSGF.&*VZR;;19.M%4C@$Q.+B;)/G,(`+KJ8L+9YNF<.I4[1OS?*G]U@
MBOG-=#8!*M:WTE[@*3IUST-H.L`#7A8=NN$?B-^:5H`SDZJ/F$M_94QBE8`Z
MO1ZH57^?%@1?I9YF:LYMQ[,+R;JQ@4]_D?(O4$L#!!0````(`%>"54<#S>%O
M=P,``+(2```9````>&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;)68WVZ;,!3&
M7P7Q``7;&)(JB=023=O%I*H7VS5)G`05<(:=IGO[X3]0NAP3IQ<%G-\YY\,<
M/L"+"V_?Q)$Q&7S452.6X5'*TV,4B>V1U85XX"?6=+_L>5L7LCML#Y$XM:S8
MZ:"ZBG`<IU%=E$VX6NBQEW:UX&=9E0U[:0-QKNNB_?O,*GY9ABCL!U[+PU&J
M@6BUB(:X75FS1I2\"5JV7X9/Z'%-4H5HXE?)+F*T'RCQ&\[?U,&/W3*,E096
ML:U4*8IN\\YR5E4J4U?YCTWZ65,%CO?[[-_TZ7;R-X5@.:]^ESMY[-3&8;!C
M^^)<R5=^^<[L.5"5<,LKH?\'V[.0O.Y#PJ`N/LRV;/3V8GZ9Q38,#L`V``\!
M0QTX@-@`XAN0V(#D,R#14V-.14_$NI#%:M'R2R!.A6H/]-CAK4K290Z$SM;-
M@="#3VKT?44I7D3O*I%E\(AY-@PF;B0W"!J(J!,`JL`A5`&;"A,%;A)K0Z3T
MM@;2:R#CF2`Z/L')[01)GR`9)TCL5/XW3YEF&G.BADGC_L^-YD[4*8N"LJB5
ME7RM-69RP^"Y1Y$4+)+:(G2B2,^DMXMD8)',)LB^%J'C"39,DE'/.9N!E6:V
MTFSB4AH&^5Q*)^J4-0=ES:VLN7N6GRV3>A1!,5A%#ZL4:.+L+12[+T5^A;B%
M(%B(<96$^*3`X$V-L/]=C0BL@GC<UQ9"U*,;W*Q;&NPXR'A$DJ03#3%`LXE[
M$X#<8F"?0=9H4CPEIH?(E)AKR"T&]B.4VM;Q>"2A#&Z=[([6@6T$S7Q:YPXC
M<;-N:;"5H+E/Z_30A.'D`.1^^L..@V./UAF@J0<9`+G%P*Z#>]?!'BE@U\%W
MN`Z&70?[N(Z%4$9OMXZ;=4N#70?[N$X/T7CJ:EU#;C&PZV`?UQF@J=<3`'*+
M@5T']Z[C85P8=AU\A^M@V'6PC^M8R*]UG*Q;&NPZV,=U>HBBJ:MU#;G?]V'7
M(3ZN,T`3BG,`<HN!78?8#S'D<=T)[#KD#M<AL.L0ZSIHJG5Z*+W5-[[@VH)H
M[ME=!#8F8K_`L(=S$PK/(;UC#F$3(*G/'*:^<PB#1E0T^N*O67O02R<BV/)S
M(\T'_S`Z+,\\8;UB\(FO%J?BP'X6[:%L1+#A4O):+Q+L.9>LTQ`_=*_U1U;L
MAH.*[:7:S;K]UBRIF`/)3_T*T;!,M?H'4$L#!!0````(`%>"54>T>CLYE0(`
M`(X)```9````>&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;(V6VY*B,!"&7X7B
MWN$0CA92Y8&MW8NMFIJ+G>NH4:D!XI(XSK[])G1`="!R(Z3Y^N_^8RI)<J7U
M!SL1PHVOLJC8PCQQ?IY;%MN=2(G9"SV32GPYT+K$7`SKH\7.-<'[)JDL+->V
M`ZO$>66F21-[K=.$7GB15^2U-MBE+''];T4*>EV8CMD&WO+CB<N`E296E[?/
M2U*QG%9&30X+<^G,LU@2#?`G)U?6>S=D[UM*/^3@UWYAVK(%4I`=EPI8/#[)
MFA2%%!*%_RK-6TF9V']OU7\T;D7W6\S(FA;O^9Z?1+.V:>S)`5\*_D:O/XFR
MX$O!'2U8\VOL+HS3LDTQC1)_P3.OFN<5OH2V2AM.<%6"VR5T=883D$I`MP1/
MF^"I!&]J!5\E^`\5+/#>S-P&<YPF-;T:[(SE<G+F`J^EB%`V6*,F)HTUP:6,
M?J9^$";6IQ12C-MC5L"X:!S9`.)TA"4:&.S"-8<JN%!AO,!:$9ZFAZ<BV3>1
MT391VR;J3Q92DQ4]%_!:`:\OX"F!^+[)L&$JF`M@/-L>9];`H%@';50Q&VF@
M#*"@)S1JR1^TY$.5\*&(W[>D&!2%SCBU!FH6HF@<V@#DQ;:/QJD,J#`()M@*
M!FT%RI:FX14P[N.?<&<*&`VQ`<+1J61!NR8F^`D'_83*CZOQ`\Q,+`:MI?"I
MI6E"F<)B9XJM:-!6I&QI%L,*F!G2FHJ>FGI*9(_$J)=XT$NLO'B:S0&8F1]&
M2+,]`(6^K<R[[6&25#8@!;:LWFE3DOK8G//,V-%+Q6'_[*+=56+IRM/J(;YR
MYFMG(+X15P^X*=SDT^2,C^0WKH]YQ8PMY>*,;`ZT`Z6<B'[M%S'#)W$YZ@8%
M.7#Y&LJIA_L"##@]M[>?[@J6_@=02P,$%`````@`5X)51V@PQ/DC`P``E`P`
M`!D```!X;"]W;W)K<VAE971S+W-H965T-CDN>&ULC9?+CILP%(9?!;%O\!V(
MDDB3RZA=5!IUT:Z9Q$G0`$ZQ,YF^?3$V3#(R!A8!G._\YX)],(N;J-_DF7,5
M?)1%)9?A6:G+/(KD_LS+3,[$A5?-/T=1EYEJ;NM3)"\USPZM45E$"``6E5E>
MA:M%._92KQ;BJHJ\XB]U(*]EF=7_UKP0MV4(PV[@5WXZ*ST0K191;W?(2U[)
M7%1!S8_+\`G.GV&LD9;XG?.;O+L.=/"O0KSIFQ^'90AT#+S@>Z4ELN;TSC>\
M*+12X_FO%?WTJ0WOKSOUYS;=)OS73/*-*/[D!W5NH@5A<.#'[%JH7^+VG=L<
MJ!;<BT*VO\'^*I4H.Y,P*+,/<\ZK]GPS_R3`FKD-D#5`O4'OQVV`K0'^-"!>
M`V(-R%0/U!K0J1Z8-6!?#")3K+;4VTQEJT4M;H&\9'H"PGF#UUJD40YDJ]94
M6;:#3WKT?45CNHC>M9!ET!VS-@S"P\C6(+`GHB8`9Q0H='E`QL.P@XTEB">&
M49'=N,BS01@=SP1WF>#[>F);3S8N0#H!<B]`K`!X##)NF<J4RS(XB>$PM3'4
MMQ@GP]#60"0%%`]3.T/%C('QM*@S+6K3BA^]0'0?C('2&4L?#H_)SIC`&1H/
MC#D#8T8`44^1#(/2-(&IY[GL#(>I!L?CB9T3*+:%2L8%$F="B17X4C9ZGU!B
M%T(,P80GFCK]I,9/`CQ^#`,)(5/\0.!TU`YK3W#8T[J#&$X]V,9B$&+@JX_%
MTCA%R3"VZ]0`(A/F'X3N]$SO)-27G6%21AE"GB5ON82RA'H"WUH.Q9`2G'IF
M=`<""C&:\@B1.T=D'Z$G^'4'@?;P+,<!<#@H[`[*]NH$>QK,VE)PYJ.V#FHX
M''?CAZ;)IL17(L-`3!"./0U[.Q5\MB"!*8-TPDL+NML[M/T](1,D^D;\T/@@
MF_[JA+$[BJYY>F>/@9AC[D1W.ZB2UZ=VLRN#O;A6RKSP^]%^0_V$]`[LR_@:
MSC?0,;Z%\YW9+G_*KQ:7[,1_9O4IKV3P*E2S[VLW:4<A%&\B!K-F[9Z;3X3^
MIN!'I2_CYKHVFV9SH\2E^P;H/T16_P%02P,$%`````@`5X)51U",77XF!```
M]14``!D```!X;"]W;W)K<VAE971S+W-H965T-S`N>&ULE5C+DILZ$/T5RGL'
M)`%"+H^K9FSL9'&K4EDD:\:6'Q4>#N!Q\O<74,MC/$+T;`S(IX^.6IR6T/Q:
ME+^KHY2U\S=+\^II<JSK\\QUJ^U19DGUI3C+O/EG7Y194C>/Y<&MSJ5,=EU0
MEKK4\T(W2T[Y9#'OVKZ7BWEQJ=-3+K^73G7)LJ3\]R+3XOHT(1/=\.-T.-9M
M@[N8N[>XW2F3>74J<J>4^Z?),YEM6`?I$#]/\EK=W3NM^->B^-T^?-L]3;Q6
M@TSEMFXIDN;R)I<R35NFIN<_0/K>9QMX?Z_9U]UP&_FO22671?KKM*N/C5IO
MXNSD/KFD]8_B^E7"&(*6<%ND5??K;"]5760Z9.)DR5]U/>7=]:K^B3P(,P=0
M"*"W@%L_Y@`&`>P]P+<&^!#@8WL(("#`]A!"0(@-X!#`'P)<E=UN;E9)G2SF
M97%UJG/2OK%DUL#+EJ1A=JJ.K9F6JFM\;EO?%D$4S-VWE@@P]`[SHC"4#4-6
M"D)N"+<18%1!)Z8>J.IAN(,E('R+AE&2>)QDK2"A)1T;!6$B&A\MTZ-E]SEG
MD/-PG,#7!/X]@0\$O*^2=YA<I51AIB3@/@F'<4O`L<CSO&'8"DD7X^C6``N$
M'T7#L`W`*.=W;(/)"HS)"B!9#_T$]Z-3&"+XH^A[5!Q`#HB'41,:U82@1EC4
MA+H?;M>C<!%&##>*X2"&#'?RPF&F0B8LL"77FIEG&QK`!!?4,A^Q9O.H3\<'
M%QD'%ZG!"41VA-&F`F]3XADE=,T&H_82#*`I"6V3O=1<-M`*QQ5CN-::R[>A
M-IHJQ+R%A)C31!`6!="44OO08"7R47JH60]%F!1`Y$.=Z\M1J&D8H/0PLQXV
M[M,5@*9D)#\`"PA*D'G](;``,8Z@"(SF(L$GW&4NI23$N$N!V)B[%,PGQ.XO
M%%N,8UL#C!-KF=\`;$H9:A4DYEI/.,9D"L2CD?$!%\>]U>;Z3"*,RR*]KD3V
MM1"`G*$4";,B@?&9T&71.KDQX$(?M3Y3\P)"H;H*S,Z:&(U&"=YHU%P/*448
M#4#-7LU:$9<:1R)FM1J2+T;RK35NQ+N;&Y]`+6G47+(I0[@-0+[=;(`BJ#>;
MF@LV]1%>`Y!5RR-D6(AY,TX#A,4`-):7X#-Y,2\A%)80@=AE4F[V%_^$O\R5
MD$9F?_6^YZBNA*'W8=_6^Z#3P-"^$UC9"/N)'B;L?=-IG!!6W`9P[<X),W/F
M6DT%QF!"*[?6AECC>&^$PU_UYF+-/(3)`&13\P$R+,2\GV;$;++>!SV`3+GI
M?=!KG"DW[MV)4R;+0W>:6#G;XI+7ZO#CUGH[L7RF[8G50_L+F2V)H7U%9K$Z
MCWRG7\S/R4'^EY2'4UXYKT5=%UEWJ+4OBEHVDKTO33J/,MG='E*YK]M;WMR7
MZE12/=3%61^RWDYZ%_\#4$L#!!0````(`%>"54?>01>I8`,``+<.```9````
M>&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;)6777.B,!2&_PK#?4L^2`*..M.*
M.[L7.]/9B]UKJE&9`G$!:_??;T*"10V!W@C$YWR\AQ.2S,^B>JL/G#?>1Y&7
M]<(_-,UQ%@3UYL"+M'X41U[*?W:B*M)&/E;[H#Y6/-VV1D4>(`!H4*19Z2_G
M[=A+M9R+4Y-G)7^IO/I4%&GU[YGGXKSPH=\-_,KVAT8-!,MY<+';9@4OZTR4
M7L5W"_\)SM8P5DA+_,[XN>[=>RKY5R'>U,./[<('*@>>\TVC7*3R\LY7/,^5
M)QGYKW'Z&5,9]N\[[]]:N3+]U[3F*Y'_R;;-068+?&_+=^DI;WZ)\W=N-!#E
M<"/RNOWU-J>Z$45GXGM%^J&O6=E>S_J?"!@SNP$R!NAB<(EC-\#&`'\:A$Z#
MT!B$4R,08T!N(@1:>UNY)&W2Y;P29Z\^IJJ?X$SBE7(B/7MUZTT6K6X'G]3H
M^Y+$>!Z\*T>&03WF63/(@20:@1<BD`E8LT"^+0+2$88#K`P1.G(8=;*^<S*8
M)N[2Q/UB85.L"0["SD'8=Q"V#G!\G2-KD5*70B,/D(00#V.K#J,H!L-88K`0
MHB@:QM:=-P8P&-=&K-J(T0:OXY"^.,-@`&X;KH^M-(98R%@XC"4:BT$8,C*,
MK37&D%07CXNC5G%49T0=V@PB"\`@<X@S'(0,4X>_1'.4442!2QXU30EIV)NB
M@_J851]KG82..,\:B2FA"#GD:2PB-"*10QTSKUCV^>UTN%)G.$`@1A-:,[*J
MBTR)R+B#V#KQX^D3'P)K"NWP2(4[1DYIX*BPP1!S48FA9)LYN;7A'B(PH;P0
MVL5UJPB=X`)9*PS1%TJ,[5E@Z]?UNL38?.FPN\0=YBYQ1U%WA34&`9Q48OO*
M`;NEP_5Y-1!Q:].04YA&1F2910/32;+LBP8DYK6S"2ZHO7/H%SK'_O6#;$+G
ML+&RK<:19!Q9WR'#:NQ?.QA-:14-/2!WKT23YH&A1OK%$G%86FR7%EO7X:L-
ME&'DLG*;SM4&JG/EI!)#01C??3"N-E"&8_=3/.CMR@M>[=OS4.UMQ*EL]#[S
M,GHY<STAM:N_&7^&LQ6TC"?JC-:>`C[=+^?'=,]_IM4^*VOO533R+-%N_'="
M-%PF#!YEG0_R%'EYR/FN4;=,O0!]KM(/C3AVQ\3+677Y'U!+`P04````"`!7
M@E5'S[)"7O<"``"=#```&0```'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6R5
ME]MNHS`0AE\%\0`+-C:'B"`U(:O=BY6J7NQ>NXF3H`+.8J?IOOWB`S1IC4-O
M`IAO?L_\&5E#?F'="S]2*KRWIF[YTC\*<5H$`=\>:4/X-W:B;?]FS[J&B/ZQ
M.P3\U%&R4T%-'<`PC(.&5*U?Y&KML2MR=A9UU=+'SN/GIB'=OQ6MV67I`W]8
M>*H.1R$7@B(/QKA=U="65ZSU.KI?^@]@L0&I1!3QNZ(7?G7OR>2?&7N1#S]W
M2S^4.=":;H64(/WEE:YI74NE?N>_1O1]3QEX?3^H?U?E]ND_$T[7K/Y3[<2Q
MSS;TO1W=DW,MGMCE!S4U8"FX9357O][VS`5KAA#?:\B;OE:MNE[TFV0(LP=`
M$P#'`.`.B$Q`]!Z`G`'(!*"Y.V`3@#_L$.C:E7,E$:3(.W;Q^(G(?@*+'N^D
M2*_L<:76F\;5XH-<?2UPEN;!JQ0R#+QB5IJ!T312:@2,1-`G8,T"^K8=H-YA
M>H.U(9`CA[LBFT\BDVE&0YK1M5F1,2N[+X`&`70M@)1`'(:W22:*:;47FLEB
M'$,XC:TUEN(XQ>DT5FH,)@"C*)OF-H8+,8A@>+\\;/4'*Q$TPY[8:D]L[`&W
MB>)K>V+3C!!D#FP]8#$$R316#A@"$9K&-J-:C&;T>&(U)S'%P?L"J=6=U`A$
M#G<T@SXVV(TUFDE=3)G:&_7&E,\ZDP5EUH(RLXG#^54V_-TQ@(Z:!BS.$@=6
M#AB*<>:H;,`2-*>706BM3BW+\O`,"6!M&0#F]PR`]BR@D8@=)AL(.-MF#E3.
M@386:+JLR%Y69,I*9D@@N[GH"^9B>Q9XCKG8'*U.<S6$W>9J*'*;^UEINBS[
M,0R&<SB=(6$_[,`73CM@/^Y`.L?<=$[GIO?_@7(.M+%`NJS@:O9J:'=04R_W
MMNS<"CU-C*OC9/T`Y>SV87T%%FM@62_E)*YFO7?Y(C^1`_U%ND/5<N^9B7YB
M5./=GC%!^WS#;WWVQ_Y;87RHZ5[(VT1:KZ=G_2#8:?@8&+](BO]02P,$%```
M``@`5X)51]JGNZ01`P``.0P``!D```!X;"]W;W)K<VAE971S+W-H965T-S,N
M>&ULE9==DYHP%(;_"L/]`DD('PXRLX*=]J(S.[UHKUF-RBP02^*Z_?<E)+"H
M,;)>",3GG)SWA9!C<J;M&SL0PJV/NFK8TCYP?ERX+ML<2%TPAQY)T_VRHVU=
M\.ZRW;OLV))BVP?5E0L]+W#KHFSL-.G'7MHTH2=>E0UY:2UVJNNB_;<B%3TO
M;6`/`[_*_8&+`3=-W#%N6]:D825MK);LEO8S6*Q!()">^%V2,YN<6Z+X5TK?
MQ,6/[=+V1`VD(ALN4A3=X9UDI*I$IF[FORKIYYPB<'H^9/_6R^W*?RT8R6CU
MI]SR0U>M9UM;LBM.%?]%S]^)TH!%P@VM6/]M;4Z,TWH(L:VZ^)#'LNF/9_E+
M&*LP?0!4`7`,&.?1!R`5@#X#?&.`KP+\N3-@%8"O9G"E]MZYO.!%FK3T;+%C
M(9XGL.CP5B3I,ENLS]:9QOK!9S'ZG@9>G+CO(I%BX(1920:B^T@N$3`2;E>`
MM@IHZV:`<H;[$V2*\`TU/$RRODERMTPTE(FF9B%I%O`>)_"'!/XT@:\2@,LB
M@;PEC31#0C!RD('*)(4C)S90N:1`$#J!`5LK+$83[*XTK)6&E;0K_P&<2I/0
M$W0B`Y6-U+4!4RI75.3X!FJMJ-#!CX4%6F&!$F8J9B4AB"?3:(1)"@<W-^-"
MF*0`CAV3EVN%18$S8]F%6FFADF9R<"6AI\#H<Z8H<*,-3Z4IRC?I7RL(8V?&
M0HVTPJ(^!8*/XV/M0H_G+W3@:2OHAT4*TP.Q4A3PS`M"8=`W/A'Y,.?MF^/"
M7X6%D>/%T\\,K4"O5;[]$9J1`6K]!O`+AB-]$6B6X9("H7FA*@SY3F@T7&)Q
M_,!P-2G`<]Y"0+]U@&'OF/&&!ECO,OZ"R_J7(0CNN'RQ@RD*Q,[51A=>F"PI
MWS.DRH=4`-T\^Q<[V,`A;W++I#IWTA?5I-WW'2FS-O34<+G3CZ-CU_L,15]U
M-;X"BPQHQG/1)?=]V&?Z-#D6>_*S:/=EPZQ7RKMNKF^]=I1RTE7L.9W1AZZ/
M'R\JLN/B-!1W0':V\H+3X]"HC_\6TO]02P,$%`````@`5X)51_>/4G$_`P``
M*`X``!D```!X;"]W;W)K<VAE971S+W-H965T-S0N>&ULE9==<Z(P%(;_"L/]
M`@F$#\<Z4]&=W8N=Z?1B]YIJ5*9`7(BU^^\W(0>*-L:T%P7B<]Z<\QJ.R?S,
MVM?N0"EWWNNJZ1[<`^?'F>]WFP.MB\YC1]J(3W:LK0LN'MN]WQU;6FS[H+KR
M<1#$?EV4C;N8]V-/[6+.3KPJ&_K4.MVIKHOVWY)6[/S@(G<8>"[W!RX'_,7<
M'^.V94V;KF2-T]+=@_N(9FO<(SWQNZ3G;G+OR.1?&'N5#S^W#VX@<Z`5W7`I
M48C+&\UI54DE,?-?$/V84P9.[P?U[WVY(OV7HJ,YJ_Z46WX0V0:NLZ6[XE3Q
M9W;^0:$&(@4WK.KZ_\[FU'%6#R&N4Q?OZEHV_?6L/DDR"-,'8`C`8\`XCSX@
MA(#P(R`R!D00$-G.0""`7,W@J]I[YU8%+Q;SEIV=[EC(]81F`F^EB%!VNEY-
MF-;U@X]R]&T1HV3NOTDA8/"$62H&A[>1E4+02/@B`6T6V-7-@-4,MR?(@8@,
M.=P567\2N9EF.*093LT*P:STOD`T"$13@0@$T&622'TEC3)#03CU0@.5*XJD
M7F:@5HI"<>+%!FP-6!9.L)NE$6UI!$J[\A_A:6D*^H:]U$#E(W5MP)1:`95Z
MD8%:`Y5XY'YAL;:P&`HS);-4$":3:32%*8K$G[Z,B\(4A4CFF;Q<`Y;&GL5K
MEVA+2U1I@<5Z3K4O1&K_0F3:##(0,-FV5%!B7`[Y`%V_6A?6*B@,S6L&J&#B
M_\VR4*"MJQ^6UB86$DCK+4+VYB*LSP+;V`N4J-?D2@Z8Z$NF9;D"+(N\()O^
MF0R'&+&4B3[F=N&AOO"A4]M(1'K[HR_8KV^)B%C9#RTJ,_<.P!"Y8S]@B5%M
M#1@);!H^TC=&!)T1!Q82B=[DY`LFI_HL4BN34ZM?'L"(EQ@]5A1"UWV<7%@,
ME(W!^N:(H#MBFWU5H#48!_8&8Z3-`J,;!E]L6H#"QNU(/E)7_B93>P$R;I+6
M`_2Y2?N3;7!-VWU_`.F<#3LU7&WLQM'QD/.(Y3;Z:GR)9CG2C*_$H4@=83[D
M%_-CL:>_BG9?-IWSPKC8O/<[[1UCG(J$`T^8?!#'MO&AHCLN;Q/IOCK(J`?.
MCL.Y;#P<+OX#4$L#!!0````(`%>"54?N61T./@(``,@'```9````>&PO=V]R
M:W-H965T<R]S:&5E=#<U+GAM;)55VXZ;,!#]%<0'K+$-A$0$*<FJ:A\JK?:A
M?782)Z`%S-I.V/Y]?8.PE3>A+[$]G#ESYD2:R7O&WT1)J0P^FKH5Z["4LEL!
M(`XE;8AX8AUMU9<3XPV1ZLG/0'2<DJ-):FJ`HB@%#:G:L,A-[(47.;O(NFKI
M"P_$I6D(_[.E->O7(0R'P&MU+J4.@"('8]ZQ:F@K*M8&G)[6X0:N=C#6$(/X
M5=%>3.Z!%K]G[$T_?AS78:0UT)H>I*8@ZKC2':UKS:0JOSO26TV=.+T/[-],
MNTK^G@BZ8_7OZBA+I38*@R,]D4LM7UG_G;H>$DUX8+4PO\'A(B1KAI0P:,B'
M/:O6G+W]$B.7YD]`+@&-"6,=?P)V"?B68*P#5IGIZYE(4N2<]8'HB/ZWX4K!
MN291S($P;*HE88(;';T6*4(YN&HBAT$3S-9BX(@`BMU;`H6^=&32[Q38.43\
MN`(>*L33)K!M(LH>$\0#`9X2Q,X%_)@@\2I(G(+T<Y>)P;36!XN!&8RBZ&O8
MSL(03J>P+^6D7CFIE0.7CPD67D,6\PW)O`JR&898#(3)?4,<+$.S#%EZY2Q=
M/S,(8.1UQ(1G6@*A5P2$,TQQH&QYWQ0'2Q:S3('(+P@Y08L9%-AO"_X/6V*_
MBGB.+1:$E_B!+Q878X\Q8#(@&\K/9G&(X,`NK;3#:XR.RVEC1O@_\:U>6F;P
MWFB*O"-G^I/P<]6*8,^D&M]FUIX8DU1)BYZ4T%*MU?%1TY/4UX6Z<[MH[$.R
M;MB;X_(N_@)02P,$%`````@`5X)51R2&T.$%`@``'@8``!D```!X;"]W;W)K
M<VAE971S+W-H965T-S8N>&ULC57;CILP%/P5BP]8[N0B@I1D5;4/E5;[T#X[
M<!+0VIBUG;#]^]K&$-IU2_(0[,/,G!E'/LE[QM]$#2#1!R6MV'FUE-W6]T59
M`\7BB770JC=GQBF6:LLOON@XX,J0*/&C(,A\BIO6*W)3>^%%SJZ2-"V\<"2N
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M$+$-D2X+)*-`,A=(K$#VI\G48-HAQH@)]&>Y4>ILE%J1U;)`YHR:/1YUY72P
ML@+K_T0=,)OU/.@GU'%`A>ECY[%VNEE;-YME@8WS/#:/GT<8."V8\M*)6%`2
M?\[JSZX=!7XQXTB@DEU;.5R)J3J-O+T9#'_5#WH4FNM\ERGR#E_@.^:7IA7H
MQ*0:"N8&GQF3H)P%3\IGK8;UM"%PEGJY4FL^C*]A(UDW3N/I+Z'X#5!+`P04
M````"`!7@E5'>&BC<L("```%#```&0```'AL+W=O<FMS:&5E=',O<VAE970W
M-RYX;6R-EMMRFS`0AE^%X0'"&1\&,Q,.G?:B,YE<M->*+=M,`+E(CM.WKR0D
MA<9BPXT!^=M_]Y?6>+,;&5[I&6/FO'=M3W?NF;'+UO/H_HP[1!_(!??\FR,9
M.L3XXW#RZ&7`Z""#NM8+?3_U.M3T;I[)M:<AS\B5M4V/GP:'7KL.#7\+W)+;
MS@U<O?#<G,Y,+'AYYIFX0]/AGC:D=P9\W+F/P;8.0H%(XE>#;W1R[XCB7PAY
M%0\_#CO7%S7@%N^9D$#\\H9+W+9"B6?^HT0_<HK`Z;U6_R;M\O)?$,4E:7\W
M!W;FU?JN<\!'=&W9,[E]Q\I#(@3WI*7RT]E?*2.=#G&=#KV/UZ:7U]OXS=I7
M8?:`4`6$)L#DL0=$*B#Z"(C!@%@%Q$LS)"H@^93!&[W+G:L00WDVD)M#+TCT
M4[#E^"!$N+)#I1K?-"H7'\7J6YY&?N:]"2'%A!.F&)DPFD>J$0D,X?$"K%6$
MKBU#.&:83U`J(@9J^%*DOA.9+3/294;3S8K&^/4"G[$6B*<"L=KMX/\BITRA
MF7">*1<PU0*FOF=F#2560XD2B`!#FHD!0PN82C,)8.A>9]90:C64*H$4,*29
M%6!(,VO`D&8V@"'%Q/[7AE960RLE`+6<9J"6TPQPTM7(Q!L@5ZUU%IS0VFIH
MK02`-B@T`YQBJ1G@%*OUUVU9K^\V;];0QFIHHP2`5BDT`[1*J9C$!PPM8&K-
M+'C+!;[5D5P6$D!#%1J"?L^E48+:3D-0;]86I7E;@=V6^B.$#DHQ:0*][0P$
M6*\,!#1Q;:#5`E>AW56H)$!;&H(:4$,IU($&@EX2!OK\H_(F,TZ'AY.<+JFS
M)]>>C?_:9M5,L(]R@/VT7@3;,K"L5V+BE3/5AWR>7=`)_T3#J>FI\T(8G\SD
M&'4DA&%>K__`=_C,9W+ST.(C$[<KL?7CE#H^,'+10[>9_/-_4$L#!!0````(
M`%>"54=:F%G\-0(``(4'```9````>&PO=V]R:W-H965T<R]S:&5E=#<X+GAM
M;)55VXZ;,!#]%<0'!&P<2"*"E(NJ]J'2:A_:9X<X`2U@:CMA^_?U#<)NG4)?
M@CV<R\P0>]*.LC=>$"*\][IJ^-8OA&@W0<#S@M28+VA+&OGF0EF-A=RR:\!;
M1O!9D^HJ@&$8!S4N&S]+=>R%92F]B:ILR`OS^*VN,?N])Q7MMC[P^\!K>2V$
M"@19&@R\<UF3AI>T\1BY;/T=V!P!4A"-^%&2CH_6GDK^1.F;VGP[;_U0Y4`J
MD@LE@>7C3@ZDJI22=/YE11^>BCA>]^I?=+DR_1/FY$"KG^59%#+;T/?.Y()O
ME7BEW5=B:U@JP9Q67/]Z^8T+6O<4WZOQNWF6C7YVYLTJM#0W`5H"'`B#CYL0
M64+T(*!_$I`EH$^$P)2B&W'$`F<IHYW'6ZS^'F`CX4R)2&6/:S79`ZZ#.Q6]
M9W$<I<%="5D,'&'V!@/7ZP$32'VG"?1=`M":H.<F!X.!SQ''7F4YG4;4IQ&-
M:XVL0#PM@'H!-!9`5B#YF"4P'6U,F@:$UHMHVF;IM%E:F]5'FV3D<C`8B*8]
M8J=';#UF?-/$V<QD?C-7S@Q61B`)GU>Y-Q@0A=,F:Z?)VIJ`:0$0.NO4X9F%
M`N!,`@!WJ<MQJ18TJU8`W3[VA"1PAH3[B(#_."/`?4@`FO%A+>CO:H/1)583
M=M73@'LYO37"W&%#=)@X.Z@OP0<\2UM\)=\QNY8-]TY4R*M4WWL72@61_N%"
M]KZ0,W'85.0BU#*1:V:FA-D(VO9#;YB\V1]02P,$%`````@`5X)51Q>MX"G^
M`P``W!,``!D```!X;"]W;W)K<VAE971S+W-H965T-SDN>&ULC9A-<Z,X$(;_
M"L4]@[X`X7)<E9A0NX>MFIK#[IG8LDT-("_@>/;?+Z"&X(S<UL6`_'3K;7VU
MI/55-S_;DU*=]ZLJZ_;9/W7=>14$[>ZDJKS]IL^J[O\YZ*;*N_ZS.0;MN5'Y
M?C2JRH`1$@557M3^9CV6?6\V:WWIRJ)6WQNOO515WOSWJDI]??:I/Q7\*(ZG
M;B@(-NM@MML7E:K;0M=>HP[/_@M=92P<D)'XNU#7=O'N#>+?M?XY?/RY?_;)
MH$&5:M<-+O+^\:&VJBP'3WW-_X+3SSH'P^7[Y#T;P^WEO^>MVNKRGV+?G7JU
MQ/?VZI!?RNZ'OOZA((91X4Z7[?CK[2YMIZO)Q/>J_)=Y%O7XO)I_)`$SNP$#
M`S8;S/78#3@8\$\#@1H(,!"N-81@$+K6$(%!],4@,(TU-G6:=_EFW>BKUY[S
M80#258\W@Y/>L]>.WOI6;L?"EZ'T8Q/%?!U\#(Z`80OFU3`,05*#T)D(>@%6
M%<RWU<!,#?<KV`(A$`T/G;P]=I(9)`H?1\*G2/BR/3FTIWCL0$P.Q-*!&!T(
M$=Z*C$>F-LT%3)R$A-S'4C<L,QB+PB5V5W5H51U"V%]4ATO5P%`2?Y6SQ%(W
M+#.8D%RZJ(ZLJB-0'2&J#<.H8*AJ-RPS&$_<5,=6U3&HCA'5AJ&A2%#5;E@&
M6,R$BVII52U!M414&R:4`A7M1&6&HHPD+IH3J^;$="HFV2!]`^+#PPW+`".Q
MTU2DQ*IZ+!Z:.D%T`T03*F6"C*34%<PF4-*$<X?EC\X)Z68!I9"1I$L#,'L#
MP"(N*=8`#+H$6QNW0/$([5V@*">8LS?`9.S4N=P>&R08R;#8#/1$0U3W=N)B
M?,)-&),4X]YFCE&G".T)D`J(D&,1&HBB@K9`/7$42V<,CPZJY&YSTYXG*60W
M*;#@#/0D4$';&9-X=(#U\Q>/#[C$+3Y[1J60X"@Z]2(8)[]-E]OX`!,/)A]@
M\8/!.6&14WCVU$MCR-]8=/$T^03EV-(R<1%+T/B`$Y1)B:TND[^8<)<(YS1]
MN_Q"GI8..V!JSYK49#%!L`T*0)Q0?(?BR&7`#4/*I7^9/74R2)T2VQ$"Q.B#
M?8HCETT<(4Z)@5&[=/IXLP(,%_BZF3IRV52G2)PVALR>KMF4KK'Q`I",^ATV
MLK:DCEPV5=HO=DGD(-V>C9G)>'RQ(-QW(:P3C@GW$R.S)Q5VY_1U<V8$2$3L
MMW/5S:'1D<N`X^'-EM9(#Q8W$95JCN.E4>OM]*7NS,%Y+ITOIE[8<)/QI?R5
MKK;44I[2U9NY=OITOUF?\Z/Z*V^.1=UZ[[KK=#5>=ART[E0OF7SK1\!)Y?OY
MHU2';GB-^_?&7#Z9CTZ?I[NT^4)O\S]02P,$%`````@`5X)51[:M]Y)(`@``
M=P<``!D```!X;"]W;W)K<VAE971S+W-H965T.#`N>&ULC57+CJ,P$/P5Q`<,
MV(!)(H*4]^YAI=$<=LY.X@0T@%G;&6;_?OV"82-(N,1V4U5=;COMI*'L@V>$
M".>K+"J^=#,AZH7G\5-&2LQ?:$TJ^>5"68F%7+*KQVM&\%F3RL*#OH^\$N>5
MFR8Z]LK2A-Y$D5?DE3G\5I:8_5V3@C9+%[AMX"V_9D(%O#3Q.MXY+TG%<UHY
MC%R6[@HL#C.%T(#?.6EX;^XH[T=*/]3BYWGI^LH"*<A)*`4LAT^R(46AA&3B
M/U;S.Z4B]N>M^E[O5KH_8DXVM'C/SR*39GW7.9,+OA7BC38_B-U"I`1/M.#Z
MUSG=N*!E2W&=$G^9,:_TV)@O,]_2A@G0$F!'@.`A(;"$8"HAM(1P*B&RA&@J
M`5D"FDJ(+2&^(WBFNOILMEC@-&&T<7B-U84%"PEG2D0J.URKR6/A.KA2T<\4
MS6:)]ZF$+`;V,&N#@<$X9&<@H$-XTL"@"^@.98":'L!P/,4&6J?S<<S68N;^
M`ZL3<NTGY#JTN29L.F@W'?1+'U@!^%P@;`7"OD!HS@7];S+6D,H4UD*".8A!
M/([;6!P`<8`>Z.T,#L4((C\:Q^T-+IH#%/;NS>C^HL']1;9`$P308(71]`K'
M@P[BIQ7>&D@41+[_/,ML,,O,VKR[D2#HY3D84!S=)?%Z?_J2L*MNZ-PYT5LE
MS,7KHMV;L8*J:=S%UV"Q!0/Q'5CL39/YED^3&E_)+\RN><6=(Q6R5>F^<J%4
M$.G6?Y%-,).O8+<HR$6H:2SGS#P,9B%HW3YSW5N;_@-02P,$%`````@`5X)5
M1]I\9<.X`@``#`H``!D```!X;"]W;W)K<VAE971S+W-H965T.#$N>&ULC9;+
M<ILP%(9?A6'?("%`X+&92<">=M&93!?MFMBRS020B^0X??OJ!B&.N&R,=/R=
M_UP0DM8WVKZR,R'<>:^KAFW<,^>7E>>Q_9G4!7N@%]*(?XZTK0LNINW)8Y>6
M%`?E5%>>#T#DU479N.E:V9[;=$VOO"H;\MPZ[%K71?OOB53TMG&AVQE^E:<S
MEP8O77N]WZ&L2<-*VC@M.6[<1[C:02011?PNR8T-QHY,_H725SGY<=BX0.9`
M*K+G4J(0CS>2D:J22B+R7R/Z$5,Z#L>=^DZ5*])_*1C):/6G//"SR!:XSH$<
MBVO%?]';=V)J"*7@GE9,_3K[*^.T[EQ<IR[>];-LU/.F_XF!<;,[^,;![QWZ
M.'8'9!S0AT,PZ1`8AV!IA-`XA$LC1,8ANG/P=+-4J_."%^FZI3>'70JY`.%*
MX*T4$<H.4VJBRTP9'Z7U+8V2<.V]22'#^`/F23,^&D=RC<">\$0"UBQ\UQ;!
MUQ'&`V2&""9RF!79SHOL-!*%\Y6@KA(T["<R_8SF!8).(!@*!$H@N,L1*Z31
MW=)(B&(,QZE,4]\PBL>AW$1+0(C&J:VF<!2!^:I":UM"TQ8\+Q!9VQ(I`73W
M=L-A6S02PB2.T#B6:2R`&.)@',LU!@,,80#&N:WA4((06K#^L;4Z;-H33Y2G
M&0@PF$@G'Z6&+W2G*9R`!2\TMF8<ZV;'P;Q`8ET1R?(/!0)K"LK\]5/YU`[#
M1``L*15":ZH0+E^]T+?G:O:5))E*UNQ/.%R6+;*'0M9/Y=,.TC')Y#+)#(:#
M*2HW5"S3GMA$#.8G\$MQWN#DJDE[4I<,YNSIM>%ZH^VM_47FT9<GWYW]":XR
M:+'G<+75UY0/^71]*4[D9]&>RH8Y+Y2+\U8=CD=*.1$9@P?Q=L[B:M9/*G+D
M<HC%N-67%3WA]-+=O?H+8/H?4$L#!!0````(`%>"54?6D4I).@,``,4.```9
M````>&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;)57VW*;,!#]%88/*%HA+O;8
MGDGL=-J'SF3RT#X36[:9`'*1'*=_7X0$(<Z"E1>#Y+-[C@YHT2XNHGZ11\Z5
M]U86E5SZ1Z5.\R"0VR,O,_E-G'C5_+,7=9FI9E@?`GFJ>;9K@\HBH(3$09GE
ME;]:M'./]6HASJK(*_Y8>_)<EEG][YX7XK+TP>\FGO+#4>F)8+4(^KA=7O)*
MYJ+R:KY?^G<P?Z"IAK2(WSF_R,&]I\4_"_&B!S]W2Y]H#;S@6Z539,WEE:]Y
M4>A,#?-?F_2=4P<.[[OLW]OE-O*?,\G7HOB3[]2Q44M\;\?WV;E03^+R@]LU
M1#KA5A2R_?6V9ZE$V87X7IF]F6M>M=>+^2<E-@P/H#:`]@$]#QX0VH#P/8!-
M!C`;P%P9(AL073$$9NVM<YM,9:M%+2Z>/&7Z?8)Y`Z]UDB:S)]MLC6FRG;S3
MLZ^KA)!%\*H360P=8.X-AH;CD(V!0(\(&@&H"NIC#-0PC!.L+8)-:+B9Y.%3
MDE&982<S')H56K,<ULFZ!&R8@+4)PBN-20NIC!4&$L$LC<-QV-K`&"20L''8
MQL"`)0",C.,>+"Z<A6'HL+H(75UD[:&W$\2HO[&[OPFJ($']C8;^&DA,R."5
M'V5)49;4L`";H#$8EC)RO;6&L`T*&Y4S0^7,K&OA[01`4-_;:4?C`5`1`+>M
MMY@H3ET6"Q0GH@[N6Q`00J;]'P&.BPIQ45UEF!1E0$#='C;@)028I8JFJ&RA
M<5P4OIVAV\_Q%),!1?H-GO(9@XT+BG%!77U(I@094!C%3DQX'8'$,J533`:4
M)DY$>"F!U!+-IH@L*'(BPHL$V"H!#BDH7B7H%ZH$Q:L$M<<-@(GE6A#<V+HH
M;%P07DTHM8(<OED4/Q30+YP**+ZG*7XN^.B*/1BXK1;?T31RJ)T6Q!(:3?N/
MXL8EX7N:VCT-#E\OFN`/(/G"`\"W(1WYI'\XF5E0-/MLS(<S%XXSDH+!&;WD
M]:'MCJ2W%>=*F5-G/]MW8'=4G_&OYN]AO@9D?M-T;*:_>D^_6IRR`_^5U8>\
MDMZS4$UGT;8!>R$4;R23;XT[QZ:G[`<%WRM]FVC;3)=E!DJ<NJ:Q[UQ7_P%0
M2P,$%`````@`5X)51Y03@%WA`P``]Q$``!D```!X;"]W;W)K<VAE971S+W-H
M965T.#,N>&ULE9C;<J,X$(9?A>)^`XTD#B['58DSCIW$55-SL7M-;-FFAH,7
M<#S[]HM0BQ"/T&IS$4!\?Q_40FV87ZOZ9W/BO'5^%7G9W+NGMCW//*_9G7B1
M-G?5F9?=G4-5%VG;7=9'KSG7/-WWHB+W`M\/O2+-2G<Q[\>^UXMY=6GSK.3?
M:Z>Y%$5:__/(\^IZ[X*K!GYDQU,K!KS%W!MT^ZS@99-5I5/SP[W[`+,M)`+I
MB3\S?FU&YXX(_KVJ?HJ+S?[>]44,/.>[5IA(N\,'7_(\%Y8ZSW^CT4^?0C@^
M5]97?;I=^.]IPY=5_E>V;T]=M+[K[/DAO>3MC^JZYI@#$P9W5=[T_YW=I6FK
M0DE<ITA_R6-6]L>KO!/[*-,+`A0$@R``HX"@@-@**`JHK8"A@-D*0A2$MH((
M!9&M($9!;"M(4)#8"D3-9>5\:\E0;+"6J'*#=;U!%1QN*^[)M=BOY*>T31?S
MNKHZS3D5SS?,!%\+.YUQI^D-=JNXZ0<?Q.C'(@(Z]SZ$)62"$?,HF2!)IIDE
M,F0:64L$1D1WK^SOO8I[8LSK(M>''[BZT`(,GQE"DPP)#"D^*3OA-/--,=$T
MLY),&!NFZEG9B0US91'SQL+7B_)E8%Z1"?QIYDTQ,,UL%1,,S'0UB:HF&2]&
M@A:(A06J+-"Q!8H6;N8M<C_7VE(R?X0Q(=/4"BE&$H.M-5(0,!I/8QN%T838
MS`[3YL9P37SUP\:I281!$H=D&EM)C$*WENDTMI88T`B`^M/<!CF2$$+`(KU0
MFUZ(I6.&_"1#XR0$0WJ2`I]0WS!9:\18R%ADR$YB`6,DC"R2B[3)19A<:&$A
MUCX;\?]X-A)M#`E:B*87ZF."R?K=WU<,Z(C;(A?[=\PB'O"U`?7#(J*;1V<,
M/0Y08N,(](ZPRQ'?D#I"E/V6^I?=`S$#LM8C,%Y5+_]MYA61.#26X@VQY`Y,
M!5/9)78%"_3SB%L\`5/!%!1,0\L!(M/0V@9ZL8&VFI@,R1-]\MB=B*$?/"'$
M(F/-OB$6WMD\S:!O=8"]CC!3,11DL_&`ON\`LVBJ"'5=]3;S+UNSPA@U/61K
MA8'8B0Q[\\#19,09,M2W'@BUK74<TC,R-/3M/.G[`&`C`#"Y0HA9NHKUKK!C
MD&AZ?3P/4&SC2-]70#469EH?"3;EQ%3X%6(!$//ZD!B-C'OU!C$6Q;]-I#=Z
M6RIX?>R_&S3.KKJ4K?QQ.8P.WR8>`O&V=3.^A-DS:,;7,-OHQE]A]B;?VC[=
M+N;G],BW:7W,RL9YK]KN[:]_3SM45<N[3+HVZSHGGNZ'BYP?6G$:=>>U_"XA
M+]KJK#ZS#-]Z%O\"4$L#!!0````(`%>"54<6=&&$L0$``/4#```9````>&PO
M=V]R:W-H965T<R]S:&5E=#@T+GAM;(U3VVZC,!#]%<L?4!,@C1(1I*2KJGVH
M5/5A]]F!`:SZPMHF=/]^?0%*5Y&Z+WAF?,Z98\8N1J7?30=@T8?@TAQQ9VU_
M(,14'0AJ[E0/TNTT2@MJ7:I;8GH-M`XDP4F:)/=$4"9Q683:JRX+-5C.)+QJ
M9`8AJ/YS!J[&(][@N?#&VL[Z`BD+LO!J)D`:IB32T!SQ:7,X;STB`'XR&,TJ
M1M[[1:EWGSS71YQX"\"ALEZ!NN4*#\"Y%W*-?T^:GRT]<1W/ZH_AM,[]A1IX
M4/P7JVWGS"88U=#0@=LW-3[!=(3@L%+<A"^J!F.5F"D8"?H15R;#.L:=?*;=
M)J03(5T(L0^)C8+-']32LM!J1*:G?G:;@X-K+^*4D0EJSJ$)Q9.O7LM=MB_(
MU0M-F'2%.4=,FBT0XN1O]DCQ+7X:^-E^][U`-@OD:Y-9$+C?_X>#?!;(U@)Y
M/&6>?"^PO>E@.PELOOZF->8\8])_FI#57`3H-EP_@RHU2!O'LE27&WY*PUP_
MX671TQ9>J&Z9-.BBK+L=892-4A9<^^1NBU'GWN"2<&BL#W<NUO%:QL2J?GYD
MRTLO_P)02P,$%`````@`5X)51P<)GV2R`@``S0L``!D```!X;"]W;W)K<VAE
M971S+W-H965T.#4N>&ULE59=;^(P$/PK47Y`8V\2`E6(U!:=[AY.JOIP]VS`
M0-0DIK$IO7]__DJ`:EO,"TG,[,S.PD1;'D7_*G><J^BC;3HYCW=*[>^31*YV
MO&7R3NQYI[_9B+YE2C_VVT3N>\[6MJAM$B!DDK2L[N*JM&?/?56*@VKJCC_W
MD3RT+>O_/?)&'.<QC8>#EWJ[4^8@J<IDK%O7+>]D+;JHYYMY_$#O%U`8B$7\
MJ?E1GMU'IOFE$*_FX==Z'A/3`V_X2AD*IB_O_(DWC6'2RF^>]*1I"L_O!_8?
MUJYN?\DD?Q+-WWJM=KI;$D=KOF&'1KV(XT_N/>2&<"4::3^CU4$JT0XE<=2R
M#W>M.WL]NF^FQ)?A!>`+8"P8=?""U!>DIX+)MP69+\A.!9D=C;-B![%@BE5E
M+XZ1W#/S]Z#W&MX;$LT<2<NF9R#MX8,Y?:^*+"V3=T/D,7"&>708^C7BR2&R
M:3%B$MT!V@;$F`18`OA&`GRCV=>8Q8#)K[>1#FVDY]-(G8\T@"`;"+)S@LP2
MI.13EX7%=,Z)PP"0ZR(Y*I)[FY/K!!/4YB3<9H%V4/@.BJ]M+AR&!FA,48VI
MUYA>)YBA+F?A+BE!6[#'5W[.1P_*\X#?DU)<9TCA[%(GO]#Q(2,D1`AP(9^0
MH%[QB-`;,D+QD-`LQ*X#Y6%V\:!0GY2<!E#@4:$W9(7B8:$%_B^ZM#N`0MSB
M@:'3D+$ZT"1LK#-<:.;'"@&O>X*.%4CX6`$/#82$QH/TRA/B%_#4P)":-(`"
M3PW<D!K`4P,AJ?$@&F873PT,J<D"*/#4P`VI`3PU4.!V+]Z],*;FL]WD;!EJ
M>;^U6Z6,5N+0*;<+C:?CYOH`=IDZP:MRS[;\-^NW=2>CI5!Z);/[TT8(Q74#
MY$Y/?Z=WZ_&AX1ME;@M]W[MMTSTHL1^6YW&#K_X#4$L#!!0````(`%>"54?U
M-UE+F0$``(D#```9````>&PO=V]R:W-H965T<R]S:&5E=#@V+GAM;(63VT[C
M,!"&7\7R`]1IFK1LE4:B(`072(B+Y=IM)HV%[0FVV\#;8SL'LJM*Y"*>&?_S
MS?A4=&C>;0/@R*>2VNYHXUR[9<P>&U#<+K`%[6=J-(H[[YH3LZT!7L4D)5F:
M)&NFN-"T+&+LQ90%GIT4&EX,L6>EN/G:@\1N1Y=T#+R*4^-"@)4%F_(JH4!;
M@9H8J'?T=KG=9T$1!7\%='9FD]#[`?$].$_5CB:A!9!P=('`_7"!.Y`R@'SA
MCX'Y4S(DSNV1_A!7Z[L_<`MW*-]$Y1K?;$))!34_2_>*W2,,2\@#\(C2QC\Y
MGJU#-:90HOAG/PH=QZZ?N4F&M.L)Z9"03@GI*C;>%XIMWG/'R\)@1VS+P]DM
MMUYN`L23B8TTWZ&-P=L0O92;/"_8)8`&33K3[$?->M(PS[]:)!V+9/,BZ0#8
M_`Y8C8#5'+`:`#>_`[*K'601D&?9O\M<KJ-(]^OL1>M\D?R9?__59+-M;OD)
MGKDY"6W)`9T_L;B]-:(#3TP6.26-?Q>3(Z%VP=QXV_17I7<<MN/%GUY?^0U0
M2P,$%`````@`5X)51XW:3I_F`0``U@4``!D```!X;"]W;W)K<VAE971S+W-H
M965T.#<N>&ULC51=;YLP%/TK%C^@8`@0(H+4=*JVATE5'[9G)YB`:F-J.Z'[
M]_,7##1+X07[7I][SKDV=CDR_B%:C"7XHJ07QZ"5<CB$H;BTF"+QQ`;<JY6&
M<8JD"ODU%`/'J#9%E(1Q%&4A15T?5*7)O?&J9#=)NAZ_<2!NE"+^YX0)&X\!
M#*;$>W=MI4Z$51G.=75'<2\ZU@..FV/P#`\G:"`&\:O#HUC,@39_9NQ#!S_J
M8Q!I#YC@B]042`UW_(()T4Q*^=.1_M/4A<OYQ/YJVE7VSTC@%T9^=[5LE=LH
M`#5NT(W(=S9^QZZ'5!->&!'F"RXW(1F=2@)`T9<=N]Z,HUW)"U?F+XA=03P7
MQ-:X%3(VOR&)JI*S$8@!Z<.#!P7GFD0Q`V'8E$-ADL\Z>Z_RM"C#NR9RF'B!
M.3E,%LV84/%[1>)))%F*Q(X`/B9()H+=DB!Q!/':Y1)SLI@DWN!RYQ79.9'D
M,4'J;3/=WF;F=9`Y@MVZS=Q@>MNFQ>S3QQJY5R-W&NE:(UUJ6`R$&T3V7I&]
M$\D>$Q3>K2RV;R6,O!9,VK.9JT8=J-C0*(1^&>C?S]69.1#\[]\,%U=V0%?\
M$_%KUPMP9E+=?G-5&\8D5B31DW+>JD=V#@ANI)[F:L[MLV,#R8;I%9V?\NHO
M4$L#!!0````(`%>"54<N@$-D#)(``*9-`@`4````>&PO<VAA<F5D4W1R:6YG
M<RYX;6SDO<ER(TF6('CN^0J3%,8D*`(BL(.,JDH1.)WNR4Q?6"0](K)&YF``
MC*2%`V8H6YR!/,5']*5$JB]]F5^8\\R?Y)?,VU3UJ2T@2(]<:OK@3A(PT^7I
MT[<O_YSG15`F\;^7T7E:)L6__&8VG?TF^'FS3O)_^<U#46R_^_;;?/D0;<*\
MEVZC!+ZY2[--6,"?V?VW^3:+PE7^$$7%9OWML-^??KL)X^0WO_OG//[=/Q>_
M>YTNRTV4%$&8K(*+I(B+77"9\`AQF@0G0?X09E'^S]\6O_OG;_$=?N\L>)\F
MQ4,.[ZRB5?7;FVC;"T;];C#L#R;5+S\NBUXPF#9_^=1Z_H_Y(B^R<%G\G]4W
MY>'KZ#[&)V"(#^$FJC[UZO+CVXL/P>6'\U[+`.<P>Q:N8=95]'/PQVA7?>Z\
MS#)<X9LX7\)S?XK"#*$0O`Z+VG0G)X/AR6C0,M6;>!UEP3F\=Y]FM7G>A=E]
M%,R7RPB>@F=6_'PKQ&YWV]K\@_[)O[:^<!5E<;IJ7;LYQ/_MO_VWO2>EX?`&
M/JSA2O5)F;?QV7\=53^9PZLK?GT=WE>_O0O7>6WEYB33S090YJ9(EY^[P0WA
M<?"Q+/("D"M.:F.=IW#D20Z`AM_R=!VO".HW!?S`!>1!>@=HL4PW4=#YE(3E
M*H;OC^&.?+IY'72.CN6N!'$2W#ZD90[3Y-W@R/N[.NGHX(LTKGYY'7V)DC+*
MOZM^<96EJW)9=(,D*JK??8+UJ\W]E,8`V469QTF4UQ;WL7BH(]QM6L`A9C)Y
M'8@Y7][HYRT"L[XZ>@(@F8?K",`3_;Q<EW@<0;A)LR+^,U]T>"!<_GL99[!(
M6&*8W,>+=12$>1X5M4FOHQRP;_E`$Z]@9>MTBR=6!^=Z#3-U@_LHB?"2X_/A
M:A,G1#.*^$L-E^8O7E3G+1#:XV"=YH`X27`7QEGP)5R7$<!N$X5YF1%6X:!P
M)`6L"__"TXE7>.%APF;0+ZL@KCZ&$^.4"&$</HOO'^KK$TR^R])-`)R#9VQ&
M`=@L8[W,>-R(6C+@(@)R'9E7BO!GLTY>,X`/[B8LD`%S![]^B?(BBFA,_`!>
M:1E:#5:[\R\:]P-\PPMM_R;HX(C'05@46;PHBQ"/O$B#),6K5&0IX13B0P27
MO\@/FZ\VW*LX!01`^E+C3.HM.">F,K5K]2K,XV4`UR"!U>3NP>=,]#I>ET@5
MOFZ4'R+$MVAU$GX!K`(>)F2QS.G:!,`#EN4Z1(QO(`X'T&`@["#6/,!S<&'W
M4^3]Q-<.VSIJN[S!%V/IO<2'5-O4IP2$L'7\9]C(/5S-G#$J`IS"2QHMRRPN
M8@!0^"6,UP1@N$%T>S4NX8^CSJ`[&O:/Z2H==:;']"2L!/YE411LF)=$R$L"
M8!ZPNP6LTHAB]!JRDB[0H'P;+9'BK7?_9(8[.S,CC[K]X<"-#MCPTL&?!8QE
MF#\$=^OT,7B(5O=1WK#_TYFL<=0?_JJ['P[/[,BSO_G.D:@ABUD`9[J+8<^+
M=7S?R`18_ESN`I1R\S5SIG#U4YD733R/>4;:BJU"WO91K?.FUYY!$!K?_Q6I
M:M/X?QW"TKD*4?9_B(H8J-CAA.86&=?='6`&GC7NI&Q%ABQ:IO<)??,4>=@W
MS=VSIJE>O`/!]RI<A\DR`N$:%,S\133X=;0$$7?0+.(:78LEK#JWP%7CY:/E
MHV@!`A8>9O7!]V'V.6(<<P"MB7K+):K8.8(F@I$60G]K*RY%:BKWR=(M(A)(
MS46#LB?<Q-MNB_2W]QD0_8%G%[MNL%V'HD8C7$@<;EE218YM?.IMFJX>X_6Z
M:4-,=W*:B^G,OO4W?V<.>AV'BWA-QU,_;7EFBQ(Y2^-)6L#%V(8[.EJW@+LX
M`;PDI2(#*GG/5[SANKBW6[&A_?NLC)P0[F;??VYJAS4Y[ZMV\RY-[D^`6FY`
M`[J+,M11D&N:^5I0;FW?VK,PWL&>!U#5CA4:6(5F67\8C5??Y=MP&?W+;X#:
MYE'V)?K-[X*:/"O\9!4MB:FP%/F0KD$YRG\K>D0=_<W6<];ZMZ%1NH[ZO7Y_
MX"3:IBT@O6U\KS]I?W&^`HH'^`@0VH;QZH0DW&T,$&M`F7*#DF^T:F3(2)KK
MJFT!=%O)Y+6SR4B7W)F5AP4IB,U'J)BT!\^__/(?+1#]T,*/F\=O'J.&/DH3
M_'I&4^?)1\&W+69+3^!_P]<*+5)I'C]A7FS'K`,1Z64""?*U-\"67\9;SPU7
MSSTU'PD)RJC-9'9N1<D<!3*4$P!*0)`2IX:BH`9_+5\R_NL(4![`SG(K&F"4
MB:5V8'B,)XL0X827!2#6^-QK<SK.[-!`I1Z0>))]3JV4^!$M1&$H,<$Z:.H2
MPN%LX1`.(&+`,]?99"]01[/-TB\Q:BZ+7>,)/84U;$AYXE1!\%A&T4I>(=L>
MK743%D9^!7S>'"*'79490"!_QAMS-,KQ%::7/!F,#&PD*(KI;N]\VWT"5,,=
M;K3;`7XPE8=[\J;<A%O`XDTP?\M+X(4^<6C&6-($_*<.3,D+>PY,=DTZE<=#
M]A]MG.<ED6(TX>+CK(VTW-.]$HL_\"+-LO2QB<5=1R`3&:K=_MC%STLX<Q)Z
MC!;-R$BK3+>-]LT]=Z4C9W#<"-`6(QU",F(KUX&ZR855V**?^>8'Z.ZQ5"!]
MQEBM"E$70'(?)RA!T($_D"DQ3FN78<\($5*R?>_>E!NXKCM\Z"8&W?(.&#(<
MFE!-G/H*^%R#2/B[AD?V\&(U3Z[F"=T@VY9Y#E]A\$IH2/#Q"TBH<?1HA*<8
M"%MPOTX7(#@LXI3N-@BS)8D?A/QALH-+L23T@=-;Q?DRA4'(\R#>"?I]$R;E
M'6RPS`BUR'>QCOE)!',&8B2L!.]7$I4@@J7W.`?(>&61QIM-F;"6@-[?@K_%
MR=(,1;I>\+',A'S".K;L$T*F@OZ6*+B].']S^?KB>MX-YM]__'#Q8S>X>G?Q
M]OKR]9^ZP>V?;N:OKB^[-/R;^?NK/UW/G;$-<+PPUQ'DV2+>(G5>KJ,,Y"B0
M5-[?',.@[ZZN/[Z[_+'Y-5@R0`Z86!B\Z@87[SZ>W\YO+YY\=LX+^O1^#BM_
MW_QX#A#.(B3?_P[B^Q;`$8>PK%[P`T!KG:?B_"DBX\,2V:5$<7R]#H'`,.EZ
MC(N'X"T\##+O\J'+4G/'?@![#(-'$*#7NY/T$47T#9L%Y8Y<ITOX_VV6EMLN
MCR7&0>0*UY>WGWZ<?VC>09(F)[]/5_>?XP0$\SQ8[S;;AW03=H$F9&D"I\R?
M+'<%_AZ5GZ,-`*=S_N[=L98W0,)DGLCGR(9\0`2@C")(D"VHLE%:T]OYO_WI
M>T"-QX<8/D&4WR)IA$TVKAAF[@7H@2`>>H5:75(P%"\3>AQ17I1V0/N0.4*7
MOL)[2Y<&T;XT4BXMGP5DS\IR9Z7VW(G*!JG#]5J90F'?Q):9?Q)@X:JB[Q)%
M,2;G(*T!4J"@@,P#:0-N,&1WW59O!-Y''&F<']\AU2C>"&TDZ0UWEJV(6Q*,
M-86"^9=X<7+CC%SO\'LT+A/C1\A\2F*K$Z`&T+OIP<G,KXY[(/,CEW&!$0(!
M>17.X=_+,(,%P:A9A!83I$1OX/$`8P(`%])R#5P.+T'(7IDT^:E,E@[S^4(\
M!7E$H]HALEE&+PD'FR<)P#JXKBWGCQ:I=AA$P&;VUW`@;&47VV#0X1_VK6,F
M<0UD/T!$7T7Y,HL7#II_^>4_`S:QP`7TE"ZG"2KUZR^__`^S<G]>VG.YI5?A
M9N4.=[H6^A;2?%*XKY,H:47JA:BW%*@3P&>AP3VY<01<]E`'VS+;IG1O86X@
M]3%=2T/#S/5I.BV0`DH8/H5WX8B\6X-,"LA!B8ZZ+!(?-PA!%N=X(_`U$'RZ
MY<YG7''#('@.<IMTZ9QP)0:"\1I=N"O@<K13H:1.:3'3FPGO2E@Z(0U\0!<7
M6"]3O[Q<Y+`/)%#^S>RILT=D_\AX?C"MR:*[-0EL+<0`B5K*<C4^XG$(7%2\
MBF&CD;DZ\N@2E`YTVW^![TC;,986`%_!^M/C`_*UQXB@1E(8;`HI%DN[L(QL
MUT/,\S=1?Q_6@O#"84!-37-65-8D/(/0"7C;_\;`'K7_=!,O85N/$1D#LI6V
M!#S3C6-N5`O`<\_Z(5/`*0*`85"1/)=(DN^CZ@IQ2PCE+'^(MPY\F3&@P<QY
M"<S,P@.PNV"4%I====5PX_#!'O`P&,Q(=G)7Y?S0!Q<N^1H00-?Q!I!"B/A2
M8QJ.`_<5C:TQ">)P((2J^X^4HDX27O:.3@%X,3(+)/'KN."K0OPYA.W!"19V
M%CYU,\E#"`\NX'H$G<$Q3Y<^PE<`VA7<=Y1,%#R)(_GRM=%]+.@YT`H!T1GR
MB,YOB<.&"Q"_%D;.2.^Z@5Q<"DD1\U*$ZQ>-C77!KAZ=-K0D=K4%Z@T?TLJ`
M=>G%$7J$<EMV1*S@8GE:.2`?G*#L\C'<$2B9>1#M0+R,?A9I08F"7R+6YW$(
M0"W/T:&T6Q(PV?!=IF6.)X2[SI]SS&W7'\>R"B%LU2[37Q@2P1+4B<C'RTVX
M$\J).%GF&BU1,,H`7RH?`?6&CS<8R"-TS`$DS6@FO!T)*1H_&!*-+B1^UU+L
M/+IG2<]*DO\`FM$GIKD7`,,-B5:W="81LU@GZSV/+1#31,L-GM`F_`P8;";H
M!C^5JWMA#V3SS/-RPQ8)QEL\HY`M`4R44$B*R#A:"CDT[CG/_,=6]*Z-Q_,"
MPW@N8XQR++X2<]9L6@3I"NVS<$XG]RG"?4'R/6!QA`9M/&VZ,0U[9,L?8'VZ
M(N!'C"0+,C?I=Q`)0%P"E"+E&=<-K!$E(;ICS`[A,CF_H@\UO$\+P(SH"_,P
MEF?S-&'G;>%++(R"*#/3-[P?Q"$X+-R@6O\B+?D@EG#%2:8E(W[;.>C0-BL1
MT\E1_%W3V?2".>`W:2.\0,2`50PHD+$P5Q`%<Z`J`1<S>4).S0(CU=I>+[!V
MZFMKI]:BLK9?"RE"P0O^ST49%FN!V'&--H*B(,5EEV@D%?-NG+"*P>*JQ=>5
MUJM1!HHH&G&%@98H*``1Z8(D"]QB&8`,1/XR35GOD2XDI%\:ADV"VY+"LZVE
M=PEB:@Q,/LX_UW3LM'G'AA01+=YMA=&5"9F72:*'+Y"+TYTI(R-Y/`(C(7R,
M"B+60,4*$$\R8^=&0PO>?J*?968M+J0B/$:HF2+61C$>(BPRHWB?<)EAO.(&
M)0MWMO=1>@\T#M:)JPES%KXWX4]P47CVELT9,A08BRD"!<YOU,=MG/5!M]CE
M`=U&D,[CPLC1EJ+!NDBI-'=0`/P(U.B![6&&-MKMY\)Z'_&V)&)!=^R/25"^
M31.ZHLJYP<"0&<@NL8YH:6*%#<0[#&-0\$J!;(T^-MOEZVONB#5H6(HJ7(\0
M,;1+)J,*[)C]XK@H@!;<&H.Z1G@R)`7C/-8H\W.41$:VV>P>>1C@-IP(2"4G
MZ=V=6^:#73N<7(H*':`=0DT1.[<Y``R.$N$83&$:#I:$-]25%E&4:-&'Q$IZ
M/O.D?'K!451@);!-6&I&[$WP`[2SGV'U%'^]B'9X1L+XR/1:DE.;,8F"!&BM
M/"Q?,H&,=R;W:!I"N?*!V(>H]>$=?P87*MY$)@*<!%J2`XA8PMQZ),8=N$:1
MY6*6F"*!4,9HDDEQ8(.+!BM$QS*$":-8\%#15R^WE>@\`7!'J,%W6;P9UM_`
M5GER=J`:891)UHK-VM32$4W6<`?@F!#X16WK9#H`[NI']+"=<@FWHE!2H*A"
M:2)L0<VD1"L5TQ6BE1I5EC01&UW:'LE]J%;FE+)VM#9GF3/G<P#9@\`?HD?/
M!I^!!@*73B2K-\0-8W8[XT]<\Z-O3/->0-"CFXHM&`AV9^!1T]Q@'DB8K?+@
M50H_@LZ;^<VK8U(CV8(@WX,,6]`+BW05&^J"POPJW18D\;(VA(R'#YMC\%!Q
M0!"!O)F0<DW#/B*312"5<-PK1O]4X$*"#(^/`XJZ(G!,"C2.\+9RNW0K!N$(
M.SA*-S=A.D$]1#<LX"OLWXR95.P76Q,"D68M1IYR2W&F[$<CHO,>*"R'O1*,
M`7IF??.;3\&'M$??GO3/NL&U-K6?"W41R_.YY22=6Y#_E\&T/STV6)V7R"FC
M%=ZH]5HK/CR@H+QX78GWB9C-UBU\=I/2#5K!/-GN1(YI&=R7,=EF^0XC2MD3
MM\)\:!TZ$@I!U\O.#L0V">*"U:T[W,)]BK9?)!+H-5JRNN9X94PBM8B&='9B
M3LJ%"FDOLD4$LP8FN[G6F]D2A@2N-C.=T;R\A\G)WK;WF"8G>([//J;O`HZ\
MP!!CO@47%O]>$WG@8P3U+=Q%+!C[M\.\Y\&?YO\#*(&H&+/]=X:[]C\ZY9.C
M'9%G)P3.PUP;<"5]=*8>DCM2A!)^1_>6;JR9SUUBH&+W,<9R5>_P#\+YF5C#
M510MR#`05G>(>\L=L9J`-5LX`P0<K`4B22IT3]MOI0A1]6M)A_P'U'</N(D#
M@-NM154<\X9P!?<@AWHZ[<.A7D=;"0\X*=*3]QS#L>-WQ:K050\9^IK<B\KY
MVJJ:#9<+L#@DD[!(W(K%*IH.!V7LTYFWFHU9C6][(P#9!5F//7\#%!QO"F`Q
MKD0IPIIDT%U28Q`V"3%18=AK$9<*#QC^_.WKM/1:MBKV?4#`&C1$%$!LHIL#
M#-["$%!B#IK;6F["Q*B6#%A$(FW0=[X$H#_H`@EF7<43+T%FS4H;\548T]FA
MM@\^8XOV=)/T8E<@:2%[8EZ4O)P',46C?1]`T/JC+EMN48`Z"2XWV]*Y\NP7
MG9MR43#JCR8G(\3^&UC@.K[;F:M]57$#OHX617!IXF`PGS'?QT/$(@OOV-@9
MC-#,=910J&4W>M;&[9*PJ@^0;1?:843"GIAP5R@NTTJ-%<'9,)Q)PJW)SF.=
MI49MY.^M//=<=C)Y(?0]:!.-<IZ<]W[>9,-!!/,\3S&Z$-9#FW@'BAPH5B?G
MK&;.E<76,"<0TS,6W`XYJK4,*'JK-@&3_GO8<24L[NL`2+RX1J<A94M84ON$
M%0*!U]9)ALS3&MQN8B<IT%]@?`=K<KFA7%>_ROZP_F7V;/!?<:_1:Q6Z0&KE
MV<9`/(JI(D<U$:\I$"]TSW]/`=H*)UY*OIY%51BO)6<B!]0VN1%TEAS!><(8
M#ELY05OS37I7/"+1=^@^FO1/QHCN1JSZ;:YU$^0);R(8_@K55)0:@_-U6JXH
M1:FD1^8:#SZ1<=`CNR`!HT=A2:\M[6L*?0R#1>J1FR4")B#<&`K53X-H;2\?
MV3C58"ZDP&=M5:K"T0(V#M*IIM7)\&">VD'=E]VRDT-62F14I&=K`FF@[,:$
MX$1$?+LD:[8OH4Z?8HTQKYX%>Z8OOPZ7%-WL26R>M=TE*Q`.$4M?*VD"-ZOS
M?@`[S\5[?6$$[ELDI.>2Z!L%&!PY)WK'\V`R!85V!QT<#`:YL)&&QXV\=)-^
MB7(QK%F1C>1Z+I^!6IG8.LF@Z;+M'V(`#(AE.U(@8[5PW(CX!-SC<"*2G:_-
M0TDD]AEYRB5&;Q%)K/=B%=-U_#J4N0C)?.JH,BYJBS;)`G"$C;<AUA^P\<'V
M(&P8`7R`\JUDH@1W9;+*9;/.XL\ODV=\`\#IXE=?`)XF7J%KQCE9A,O/*)O&
M*8:()>C5V8E:2I9YW#!#1LS#E74Q46Y>%6S.67#;02XD!]]AWQY<5S(E^:%/
M+6>O9'ZZYN_0VQB,`E6)P3B-JZO46S&6%FM/$3_#LZYGJU3/+)NT.2^WN`&@
MS:#DY5%2%]OZO``L/\:'S`Y*)?AK<-4_E.N#R!`JIC8WTE">4:,P7A$![5L-
MEXYN$#D9USO6)\T,[N93,8W8,_HO=J+,&[<CV;'785Z<Q"".W,49_(;^0:/?
M4XC)6@W/KUO#K.&R[@&2,^N4AH?V)T&^)'44<*T]!2=%[T!&WT:-[,4&<[$O
MP\XHIJ4U18"0/UBJBN"]XZ1A\CO01>H1!:]^BL.30<?>WCR2R)F,3%^RN#0#
MA1DI'##;C%WO+D.#+*/6:;M#V7D5+SF0B&5O6AP@0<3B(#K/TIR<_28`!WWE
M2GQ](>6=_=V8M1/2#[DK<%%M<#J(@PL,-R+;@N'8_4G#O:D(E^H:G4A!)I7X
M]:0ZB_H+I]-DRBP:^JECY,;+6:(W[A=K_XA7:!,CK6M59LZ*YFZW^'4$B3@B
M@I#+?L[WB\0[.[.=B6-`[:T6,U!^@!U(*7O^V$UP^4<7!O?F2ND_:@FXC3C6
MGI6Q;RQOTO,4*%AV3V$>5U[V1(XA)V^B1<90&W;E/CQ&A@*(<:NB/Z!@9^RW
MKKZ72?RYVSMC1WU)(?U+H&#XU4E.48;M*1X<TLWQ3!3-9`.8;/S$$E>RHO`-
M&ZNT#0OTZV]!3.OIE7&H/RJY]BW$"(R)NR)[Y-`N33UQ'?X<%F2S!EGZ_,/W
M@_Y@?-H?6O_)`\4(;]*$"EPAXS9C2#@?U4R"]:9W9&/`"(LMJ$A%N3(15CA\
MM"&C.&X@7-]CLL'MVP\,+DE)2+,MLDFX4ZBM]P*7%KW>=;UEXI*<25S$7+%U
MH2B*^1NV9$D59"QAR$6TIEKB-U;39"M\<#3L]WN#8`,7-#9)5,:9C2&%</4I
MV&R[YI"XYE0^(U2F;)!1U<78=D-Y$;!<F`;X8(HAE^6637J;\.=X4])K1^-)
MO]>W:^FZ<*2CD?<-IEI4+%@X?>NT,(Z&;6-V!AR5D!YU;3!X'(5&'3ONHA\1
M5AB;%5:%[9K&W*#.AY:]$W<S=AV2E1>HGAAJSX7)*!]&[8&+LKFD^OI=(HR-
M+"8KX$B4LH3\DF1D_'"PL,_1+HB`CJ2[*,HKA$'"*)(DJN1`5#:G7E$AT11>
MX4RV>.+#V;@WL>=J(Z3,WI66(J2K#07Q[!`MV'B+Y^8$K@)N7WG_0)&CY(V"
MJ3;I"E0;%C$36-P6@S8):N(!Y<`&@.O"K)=97.3')7)L*;MB^)0?T#^M[#]P
M\Q3:LSA<YF*T_!RMXX>476(28%?9I8E!D0TJB&@Q`+[A!9,#VK,W)EN@]L0S
MTP6>LT3.LB1!01Q&1L^X*)T]A7TJ8(6L4/R6`5#7)S),&=#7B,7,@@Z@D!QX
M?LS)^ZI8B4]7C@(F3ZTYQ(P_7#NA0NB.@C%\.=66<3^LZAG8I2.VC2Q3B2/Q
MI;K6@=@%IM3*9P;Z[[,"5V6RZOXP\<SNXV]A,G[M9-8<@Z=7)N$*UV.E%GNO
M."!0D@-`MK'!20:):N=E@G)-O4FOK$H-]-9_;5SJFFI1N,"=A&F!1(X1*C:L
M5`P8,<90H&310%0I%3[OBH`I\LW"!;]B/%.Y7)I@/XESDIP[8Y&RA,*[]BX4
MGN7GW%&6^E)Y?L:M,/&RK8NJ_<F1R+WX>F]L]Z#T'XVF'HO6M=PXU<PLJ7(=
M,=C`&>J\*T`W#\1'BNY)'WF8O:]CBA`(L)+E8,1>AI4E-8%41*!T9KBG53W<
MH9.+3N+H]@C-?J)ZA:[HDX]G7F0S<H3(V*8:A'-%':L4\#(YV6*./VGXS25:
MD98-D9:90J.5:E3!#+ZS'I;!\+0W"EXWUC<*.J?CWEEPS"-Q7%MG`"=ZO)^(
M?E38TGX=XP.VTKF\NO[?P\WVGUX?XPVYS\*-`BQGZ[G04LNY&QFQ<;M&*U6;
M+02JN,.@==!$UO&?R1GB@B<SV<!@\$T@+-4)!3B[,_RN,&DP,=%QO-$FL=-7
M1SPQ7H4=QHD'AC89E."%QEZEWRZT9I>D6.5H'1N3V[`_[%-!(_2.;T1N7$KY
M8)*`?Z93@PT=#<83=7GENKA3K&[N$)F98$9*A![X!XFL=7*?8UCV_`WR5KA6
MR<8O/3G2B,=4#U+3>$Q"),69B-)9<+DE>^$MKAX-A_T:(.K0:S@O#(YZ3/5L
M-N_;@7D\F'@TDI>3N#-UECK+BAJ.=6!L[<TR'\;+9Y&(?2\6^LI<Y2488:]E
M0G>N)I-1U`?+()1,)*>IK0J/:?89X+B,?LOX#4*?E`$1]9A.TJ,<C9PVY"!Y
M.%C85IP_R!5O)G@&<2V)<?A7IZ/&'$!!N%PDA<LBW.I=B@D*OY9`D@7&Y%]E
M*6G`84MLZ",Y5#F(U?I&UCLO6R4P+UL)IU6QJDCMQNEBPRIZ6O*UVHD;S04F
M-R_7.(L+/S](/5'1#9L*CE/L/A[!:QOQC,N>(XNF!-%:\1%*IK%/8P!=469)
M];4NL;M]EC9O]I4W>]@Z^T%+#N:)8S)&<>":-(*^3\[+,HS()20VL-225X4#
MMX9SE6V@JX\9^$CM.HZAZ8HD4J\/@`P=^/E1,#J=@6(%?Y[QC]-1[S2PU2.-
M4=I7<&VFDXG&IYR%T6@(Y&[0'<Y.X>=PVAO#'],1_M0+U0,!DP7HX-LYBA\C
M$#\Z0))1,.D,QK`0^#F:D5AR)8+PMQS9<\B".L/9C,<ZG0UXL`'L&7]T!Q.>
M[K!AO76.^[T9+70FHYWR)".@U$/XI0+[AJ"BHV!R!F/`#^"7I_03WCP*I@,<
M&FE,(7T#3-;+(OT2F2CM)_5%+X`JYQRM@[!L3@OF_Z]M:%Q+CLU1,!CC0<-/
MDDG/=?Y$V%[9;3P=PB9'`(%A<.MOTT!`T+"U(*R*L-AS\]WCMQ(63LNS]>[Y
MNY<!)WRTE!N7/82CGQ`D4.3^`?B;&(I)!IX`"L^"R0"?>8/M$QZBE42@#P@1
M!M.Q!89;V5%P-D#4.@I.^V,`]+P-G;K6Y\TO6C0YFHQA.48`J8IU^-*_77YX
M=?VGVSEH_.\N?YR_NJ2#>G7QX>)J_N[2"N9=S1')M"FN=((9:IBK+Z;.61;=
M8QP+P58,KSU9>YT,M2]]>N#*S1K=$E<O6>&>2K]SE_';5MG7BVJKOWH@NNZ;
ML6'4YF+$<OML[51=,+)+KK$XVX@1++N7F^F5`=IS(UI1L.U\_2MT847P=_$=
MQZ`&NLZKUS\$G>A//_&Q+$XD=FV%*7MTP0>CD^%(R#40U_$(<.D("/?9&5%J
M("^CWMC[YG1`-!T)$)"RURQDH@SI`G@&$S?HJ-OO3^#5SK`[&8Z(M>`0$_W%
MZ&Q*7TS[I_#%(=H]=E&Z0]L29E&"THHT:Q-E:$XS6YZ-)K"^O_SRW^6W$7#)
M`?W-O]UBSB<*]K;B!C"(<!/E>O`I4A-\AW[Q_YIKTP;H\1:VXG[`CPV81R>#
MF07(\`SEB<YXS.Q[V#V=3)'.=X>G?0!V9T0&7/SB##X866I7%;V/@EEW"OHI
MLL7.J#N>CHG)PIEU!Z<#8I.S[K#/0@L\,`!IPSS0'R*HW[RXP,[![6N8/R.9
M.CM57C.<ZVAXVFX9(YF`RQ.Q:G0T&`X!.MX`H].A\H54!Q#ES4DD?KDCKJ?5
MJP#AZ;WK19$%+-Q$*GA`B#5[UYPE\1D0:[.I/`!>19G3B==`&2A_T>6NWMFB
M>U1DAI0ES/Z%ZP\#<%#._O>E1%\O.+Q#D0ZT.`2(8\>[0CC6*6"J=5,ZHDO]
M=I2A@^I_L!%VCS[JCO-`3/Z[G6;H#<C'YDY"@;01:5]V.@?`1!T.2]8-?!#M
M01,D7LX+V71,:1/#X0(<AQVE8RZWCKDT<AP'8%Z*]3\(7+>F=1E+/G@FUM`6
MU_VS'#*4W;/;A0MT2J%&$EM>7YS7`C[.Q2,JSOUAOS\R83UP^=+T<\6O)'D:
MK=D4:"0<SX8*RCT%+?>;\CT6->-D?"_E!EHYJ:'2)OF8\8C_MJG5@*;+!PUQ
M,C#=`?+&QL!<M+F)>L$G=+#6&#0YLDA>L];KBK>AS*.[<DUDZ@5>=#P$ZU9P
MGK.Z3<N:U*W1L<'?P<$6I+UI&ZCRGXN/TUK:[[AT7`1'4*G`>[<NT2BA4U2X
M)-**`C[12D\U!OUP+I7NU^"('':]H*L7>A\]D>92B3373J2YDHO\'/&G>CU=
M&17O]/#XA?^842B&Y`*4=.]^;=?+H(.?'O?X2[PM]FB!N%Y%&0R0DJ:-,57T
M@GQXC)AAY6_`C*^_I\/N#&2ZB4(-)[^_X<I958)=5U*HDHY^RO2WLY$*7*;!
M5:;#$Y6P"M;4:Q24:O6B9N";NJLL(LPBCX8[PHFG:([$5)[I2<E-E+&$N>`;
MU/*#LF'(L<M^@=U2:G%(`1B*\%260/1(+N-M^(0\H]=A[IT9!7_'+&TIG4G)
M\QCK%>`H!1<Q<E$,RS@#'0E=H6A49`.S`L[:*Y?UY.JBF`PU`AD%;ZZL0#`)
MFF!">&-6+((JH%M6\_=3_5L3I5+HC7?9E$TC(9'VD^:<>94CL$3F,\X\#]$H
MY*I=@##.=T47&:>]0>H>N*<,1'1_.LZ)I&5'U%+.T"2#`:[!:'P*6@YEZX\&
MJ,1@EGXP/$,W+/QZ%@QG$U`NT+$7#*=HGF6=Z2@8=">@7)XYXT"3OUOJ`I$K
M`;Y">#Q2-K2V5-L:D\ZWS\;#ZN8.,"@/NK,IVC$O3:@!`,P..QV?@9[#?NL.
M&U`/L9,.N^,^VL!NR:OL)$L[[O/DP(D(298H'$T]CR5+3=60*Q/,M<)*,"!&
MYE)N%>3\V:D2950Q_6,<'$F#27V2WC$4%J";'`"2JJ\**O*D>,U^::!G`P$D
M:<(<JMKAP=SZR5`BN1]-`#*!1E^UX28!`(ZMVB[I7+=+>J%(<-B&GPIH_&O)
M*^UV7JI41;Y_;>*KZ)?^^9N;4K-PMH1X[7E,YS6VVS';0L?(K<'5C2B\QW@H
M/>AS+4$"?&.=19<2P49<S/US63K4B0'$H8@R=K320-(<^>HCB=5`#_=3.9!"
M*EU@"*D*V%^>2CMR8`F#V8G[5/#*#;?':.I36";N_UJF>'!7-B=HSGD2[Z5D
M7H=]\X-CKR<#DX&/SL5_R8Y_>7KH/_TI2=N>'!V+X/8=1V2JGA;H*^RB)P)-
M<&@OK/ZM^@9250!7!N0[*^?6O@*NT1^A619'T+^_=34-U=/`#P8#L7CJW]\#
MS[['#`15;I9$7,G%U$.,S13N-[5T*4RI7Y@`NZ+_\%'\]SJBU$\\EZ6M^S,=
M`(,C.ZKYY6IM*A>(%]A$)GA-7T:G8M&UOQ@V/^M.1^P?I-GI@_Z$#)_XV#O5
M_J]Y27!"`S)PRW&Y/UH#:5U@:$XF[;'=-/]EUC89#&E)WLC\R&&^@/\"Z#X;
M3!7T]%\O1O7I2(SM^O=F5#\%[#RE[]UOST#SP1FZ(FDJ^]M>-$>!<BKWH17)
M9T.Y!O:7`Y'<C&Q_,8@T[)Z-1^3EG-+_\#=Y_`_'\0GY<OB0W.\'8?@05)&)
MW3'_91=&@0C^P/($:2C.%YJD?LDXYL6V^*<`YP`V53,Y'^R\\')'K`X5<8:S
M$O4;61GUXZ!K83D:93*9VE>+J'C$?;;D'!`O;;"7/V/QE0!$`)S<Y"!6Y99T
MA<B\UG-)599MNIAM(:6LGZ)C@0RN2Z[#;8K"L1VK8KG"0X5)34\$\NNM)%'<
MREV2U:M[9.V;"MT\=UQ>GD1)()J']U_ZKC5>OVODV(/;PMC@$K^/QW-DYE6T
MI*`A[FU@$NQU*XB#\O.?D,Z^$F+[RVAV7YKI0$66%,Y:S#:WOE(?F^&%-93<
M2[KHLKD'7AWSOYZ'7N'1N5DL_]G^C=^)E[OX85IZB-8."HOAT#*0&##@;("N
M]FGO=#;Y!M:9H!N31\#RT>_)G"\5"T&20I?T9$JL:81FZLD,WQ[VSK#K1NUM
MMVTTC)/A9-"=D&-\T!V?#84-$A_J38=-"Z@-,416W3\%\G]V-E#L$58V.6@-
M$S*,S&@-L]%(!%;\-^D-#]K&F(=`*,#/X4#$!LU%I]WI:9^XYI0VC(+*=#PC
MV7QRBM$.=1*+J)>TGIV?.L<E%R1BV`LE1KZAZX>:"#Q;C1<1WQ@A^,OESK=&
MY%4&P%9(;-`AR\RC3')G/&`1@VN@Z;S.KEIH5U*"LBREM@PH*\'`IO!GM?=4
MK33>,YW!HJMCVJ5E64<8@FA,1=[-;ZV>AH\TW12I=,`.N5.IV&V*I$F!/!.]
M)Z:9QK)V4=/HSZ'T[>ACC%<-$S083C!!!@-4%C`VI='_';A6$X33I'89\?_Z
M^ON5];^4?RBI]=R36C\JJ?4%UM[*W3)ERY\4D"M%61JR0%'XD."$6[H9[_EF
MF`\_H`0HG_F\ANX)G9?[[8U=9Z4)IP0O8)PRZ\+#&7,5%LGAYRF*ZR:1/G="
M/66&DD;@Q&!%"-%BW2'C]#$0Y#/X?4I1O"8PF`*1)Q0T/)6?\C?%?!Y[2Y:N
MGVZQI!#C(D=$BOV_6WDU585MB)6LY)>,^@-E?>;@HWY_3_#1<TZ>=F0(?].Y
M,_5U"7P2V>1B;%D_)0<:56C49KSG!#"[Z`7G5;%]I;SY*T7<VX.0_\KYZ]U?
M(8/=ST:SKE*=__88H=T\6KGVXFE9W+%I-?TI6MKLC%I!!94PQP<<6A_:\)M`
M9:OY'C*7$`5LR_7YY:XP)!I0@!8Z%UVFN@.45[V[FK'J*K`V9>6:EE-_E\S;
M?ZA@AG;G0#7);S95D87=*KL[B`A@EQLZ8=LP<<_]B%]Z&Y]%#50\APH<>M%M
MYC+HG%",`IH?"2/7M&A*AT49J[8*'8>E@\^Y@FW5`RU%1E@:<XMH'-DG`5^?
MX$<$;'^2GUQ>>SLI%H7@94.!#$XTINK_UTVRSUV0HT0_P:),[)-RM842+M(6
MJ]V5)BY2=XN[K43Z4$UPE5_1&).06L+%_H$(4<WKUU0@O2DCQZ89D*F$.F2Q
M*?K&F>KV.!<;Z[`KN[8:I4%,5MEVA&-5<V'H.I,YRV&W8G@,OP#D\9T3P(@3
MS!$[V,>GC"AOJ975IX3K!,+(;[$=4OWC=^S1G5LDH9R(=B>#2=U#"7EH?45'
M&'0QH#!Y_'@(F.!ZZ:!UXC3`H`S)P9M-T=[1[)8PXP^Z+,SVQ6F%?Z.S2@]\
M-L3L)ORTTZ>!\8/A<[P89C8CS9M_>A9VXY$<WR>)?$CI=&P:V6,01O_EK,]&
M_B'G@0Q)]#=?G.YUF'2]?D361\?C=4:D4*!:8@7]9]C>_OK(,9KUE=NDTS<;
MG^%Y:NA.S]!L1]!E?6=Z-J+0HWW(@>%*;"H3M!O.4`#5XTYF?&HC?(24+S)@
MO0`W<&T&+_H5U!Y0?H;@!FZ1/S@`-X;=`7F7CP+.2.P,S8G"%\-GX@:[MCA[
MQ<)Z(G%->PJ5^/4++5LJT,15F+4":KEVQ*9K74V:MA*,MIB0TL"6Z8HS1:(R
MO4[EA\AG^[(FSRV+!(Z+1:%1$99$+(#)1\0H:G6+P8A9KGN9J/XBP>`4_9FC
M_H30)8EV1M!AM\$(S@=-`YR.>_,`",7Z9_6,QS-TZHWH&,2,Z@(:V-M[JRUG
M5?.)OQEM`S6BKK&!=HFS'["W+MH5JQLRIK2\?2M*]/?]B:8A8RRO<Z\$ASP<
MW'G@ZKBG#[:V+;#H(!$<#B]'F7IW<E^&('@4V%5H8ZZQ7B1W?3&]+SUM!:CF
M-_0`L"QNITTG8H*`GFLH\:L1*;>0SIY_;Z$`_-OCZ5A\H"I)-,;/^PTIC'K<
M)%DH.#PE3:"K4/<4M+UQ_A:)F8H)5;C*(<^\+CDXU[0Q!'F52!,%ATY&G"--
MOY&K8MRG3_#G*;W+$K-]W=CS[]#ESXF&@^[IL$^^%/PY@I^C\0A3J.'G!&ZN
M&T6_-)SAHT.,9A\,R8\RQ.1,OO8-)]`B)1BQ0','PPY(FY/:T_;$GD:&ALF?
MB>VDF7F7:3`R[@E\`UZ4OZKWX@H=U]%*F(7B9R2:5_!_ZSVLV`_5"J9"">G=
MWIW:KES<DDX("'4!Y3`_%F;V8/FO:&B^>GH[>+98'8-B4X8<`#+JCJ:<.SSH
MGHTQC^G:WX@1%UBNXK`HE&_L8[)+$BCZ)`=8R;PSE/1DD99OJ`HMMN/6'22>
M;34FWF&'<JYW*K<(L(U3-ED`H\](%9?Z"*Z,(5HRX,R.2"WP[,WCF7)J5<W-
MSHNM90ZO0X`OY%F[\+/%#F%D3VS3*RZOX@_JP5#*3-#2QD%B2@^)8Z!@'"II
MA8UGUK2I:I^$ME6T-9&H*L8J-FJ/`M[\%&WE]]'JGCKE<*7C.#JP;$'+D&_$
MXWMN/+YOQ"'E&B6>V#GUBZ]=$^G[=;K`&E]A(6W8*?_2UAWJFGJA5B9SO</A
M>:#\B4BYO`:":&%[%.`,U*5[A1)-5FG+88>R85LPD'H\%^NX5%W*R\5/ILFO
M<C,]Y?:^Q%KD*PYBV0#0[R4^.7?Y&8]<":TVE''PN4@X;+>%-;SC2K!_O4AR
MJ"NMDHX!HX,*4!B9E0N84VD6!D//'NB>!>#$G&;T3!:&,>VK4I63&N!F'.,R
M=CDWE0N^@^L,RPJ-!\J6_WL`W#+5+<B[#XB&1$EPBSHYJP:P&""`IKP*7T(!
MA@EV:OJR''`2')^.,&:\T<'ZC(%$;*,'(&MX<4R?89SJ&).'3`6S%/<T_WA^
M:;.I5`#]<:_*?!07->7.7*5]=>04HEY=KJW81L6K5,M63B!?LQ8I]:5-M4X#
M@T6$]YA@OO*;*U/S8P5QX-(.YO2"-E<VBP,:EGLZ,TO&8RJX:^_R(7>',X61
M;)#.1O<@I:8"M$1U02QE:*_=]<$L@;NDUXCA/B7YHLQ2$B\&XRF'374'5'KS
M/$S"58Q5XXD`!8,9,&.JL?$*V0653\9V/[#(C-CU``6,$?HE_Q`"UT#<W<%Q
MGJ$H/(4!YUC@&O#'#8DRSN#,ZL,'P(V6=\;5JT`$[P]%:5;(UNC]/)"BT:F$
M?I3'\RX3(BJ7?V3NZCQ4<L'1>3O2M890K"'+J:L^]%7:YP^V`SQV7O#(]2*B
M=MGK2#4S3.">*-+'->5WME''LP'`T]@;).T470<0<L401M-2C2^0Z[C:GMHD
ME-E^]^@YSLC5&^5_^>4_`FFV"-+C9V,X:O9W"[U!KH;%DJ0@OO.C4\P7!\AB
M8<>?013"Q@Y%[BG$RD.YQR':=CIZL:8_HW#+^L(-<]R/J(<5'&;6>!@]\KG:
M@\A).A@Z?7;)\!;]Z:(AA`TK*Y')^=L.FYB/@=4HNP4I3<*7X*`^LDQ&DASC
MGFML?<64X+AE3,=T,(XW*NP(EXY/N#'>F=K/3I%K^,@TYJ8Z3VS=/W.9DA[?
MH"_[K')1,$^#,OG_9P"AJ90\'S/205N!Q-JOE$^T#6FO45Q]2J"G!GP[YJN\
M"QL:2CX*DED=YE,R@OX^?PRW^GO7M\^UPO:[1F,Z1H)V&$D29Q6F-K&1L*6,
M+(5,\CLI-5596X.>G:A7V?L[7+L#P.L718GZ$D=&^L;.P48+)T\(NU9<"8FY
MU1H=#/HG9%?#'8_D=])I[*P>A&3F)943((F;&4(D><FJC@`9>U*L7RM0:JP^
M8R-=A;)B##6;?3$4NAHE2OD:Z-Q>1*[Q7D.DY:/CHH54IJY"D&U/)AXC"8Y.
M5;36/347FC.5-J26RX`".CW$6XZ%=E(KZ::(@-6*.W3A<:Z&WA#[15?'_]'3
M;UCF/OA44?$&KXE#Q0-/`"/IOP+N'NK6KZVK/A/>WV<1:;=6/'>!R$?36:50
M-AF.`$!8M*<A!G?8[TE%@#V$(JS=%[DE=9FT<DWJ0+&%KDV<LWK#OS*]X"9&
M^)+2!%(?!NJ0TX61L&'W]"0!:Q,62]/!:%%X.E47A"!I=T0-!J06!55/6^^4
MEB?WGZL,/]WHA"<V"B"'-M8BMUI@0F>;I(2^(BGJRV#ZE,Q!>J5'#)QLU8!-
MN(JX%QL6E8UL*9@GC[72<L5?K7W;5IIY67.5I\U7S"V=`8QX'05)*6;'E_YI
MD:\;E#G'$W'XFLF;<X:1;M5*5!^5A%H5Z&<YI==2W?3!4X7<J96>*$:"0GX+
M1-;9-)^5`+9]%YM?TEWF:BMV!TLUAV:G,U4XC\LA3B?ZHZ]3QE"`,@:=.V0#
ME>*-8S65WX_`,S])Z/,>+-Q#Z[L"T&=6I]Q;1S+Q]X7UAKU]4>WAKRPIJ=RH
M'LX_Q-A]5##-)K:X!T+?/@I+K78FSUW(IJ]<$I-9I1S?R!4?W<AM)2*>%TUZ
M@.96<?B*!]L6Q3L\D#VU)03MA="`<@$$Q4.:-W&OBA+84J0GN*%K;@5_[:]M
MNSX-DOMWTH5<+Y%)G@ELL25;)YAB=[G/L8,JQ-2F<^^\0>?MD<%':.8R_6Z:
M4PF.`A3F:K3X&:O'E,(7K`S)TLO@7Z=37P?^Z1E5&-X+_H'5@5\*I-'+@#2N
M>HRN,O3A%$!XL':`BP'ER-Z]WSYOJ':GU:\XB?MV:[^-[+>^9%601ME8IGN%
M@3'HHZ$,D'G+-Y(!LF="XJ*#[FC85P2?64!W<*HS`KZ2DUZ;VINW60QT'*CF
M59A]!EQ?,H9<F?BACZ`7E?=ECH&:JD>MB2\26\E%G(>Q5"/MT!_'9/=;9:7K
M$`MJ?7F'1D!2L^_,5.2R+[>FY7&<W&4A7J,E^0V!0K>LM7-]>P4L^0/U.#X/
M,R#;24C,^6C0'RO']M,-5`O-16IDN8S72-:)"F*1E_=84"R)LEWE\(88B_:.
MPJ!<B>Q:)RY>6PM8.49_PW*$UZ9TT&?>;L+!K7!#T/XM6EXPQ!MY%[!<FH\K
M([:!'0%[>U6#WZ/4GE"O1=9^_-1<I(?+\KM2J8GW+NF-5-4O&$E\4$2U%\4<
M8>+4J/J"`1KS;UDQE1LDM3+4W@F>P@YFUJBZ,ZEP@-#ZQ^F:.L>B3@\CL[9(
M)U0M4=RNF(`,MR@58=AF4*FVDOOMNKX@3ZA*J.)$NT**?IHX.T_=DQ)NFSBA
M7KL"6Z_%H`DRC?;KA`N+TUQVHQ&AM?.#FF%R\S*6-LT)R=(41CR%>%*65Y(M
M*R>XI^SD:4.7!V71T'_4HQQ`(3\P'F)1XR#>-$1C/47Z8W.6\6-DTI!S?KI,
M*#8D6DG>-=T%;5L!"I&@1<XWKO3ZP<*BAU`M286ID*V__/(_,4U]8I]'N-45
M_^92"UV3,@K'<W;6FYT-*9`3)/E_,@/W]<"'5V"HC'R&IK#*R#-OS6PW.Z`T
M0W7-T[$;&3&Y<?2Z+:ZE:D-E].&9'=T$-/`YDH)4/6(O#8^NV(XMBBND<C0F
MA\-PW3R^$O?8E8_QO3,X!I+/D!+MSL<-ZN1M(I5QAC+9AK$+6D;+3&=XS&8B
M;LS-XRBZ8HUI+C,WQYK:)1ICK9U'&V58@3)+47FH$I=APM5QGZ8(<()58*--
M?,(I5]R+S6S9-_?RIJ3=*<[.8?X@6W/K<E)VI;[M$FA&=Q\$;#Q!)+EO:``@
M'F`<AND=&P72M6N5Q49S/*XLXK+C95YC23)H01TMD:W#H[!4C'KI#[[BS"I0
MM'-2Y)GE85ZYX)ZT1\J+IF[J5-"8S?HDLE8Z'.KZT"XFQ^<;A]:B8!_"X>S/
M107E*EG/A6-3KU55^:%B%N3$9S]&QK<\;B+0PY5K7M+Z25ZUAG17<X1C?AF<
MKN';L]?UO.D.WH;R%XB9-9%*%[9^AQ3?80U`DS/KFD>IJV>++'"Q[,9.`PIM
M#G(4]!I2+?:8GFT@9P4?)RI_5YM!GS*#-ZZHO71(0U+E:3=HCH1\<240#E.P
M^M2ED_>-=.`!-?09;(V?9-&7=/V%XFEY9"-.=84X2/(R=Y#<8DF=0L"WRL)'
MB65%D0/;=](X$N6*V'(?)>@R10%74L^`]&Q3$XDVX4!\/F7VAEC&T;(L<\:P
M,0>@)5R.!)5>HK%"7W,DL-2($T-&,*H;DV3#GTG$]2"-E>HH0)_D__;8$5UH
M5QOKK!^863+)R(3^(-?&KGH0NXYYI;E`EZZ$V5M-#N44V.9/]\B:\L"M#G!J
M5>M-8Q:L$C*>*<.WMB/7]?Z>5TK-1:5F?BETE)0<70B$*UD<84\I.MBI$AY5
MB%9)1A*'U3T[.U4&^(HKDH(>NQ+124K83H#+V5$PY`DGR7NE)ST[LXME'XS'
MRAC"@N3'AF@J954_FZER*TY`_$#.+3+T5]V$W&2%K1J\P]E@HJ8%X!(DKA4D
MX**_#TUS#]S9JU0*^;P&9%\6:0;85P))E[A#T^J#8Q@<Q]]2??.)+W2;S#6D
M$`4&+W18':FL`JU:..:Q:4L@\S%$5VG$%XY[`'LJ-5ZTGAIIQ0>3*Y=X@<4-
MF!3LG5RZ91L2;'O7^KDN2OF5F9PLZK!#]TP9M,_8V?OUL>LQF+.@4U(3(".E
MK2EJ3?P4'I0-^\X/05BJ;=#3P20'>H@>]95:2=!#P>U,/*"=*?>0`(TD6;5B
M$DU-_$OM9KI=[#U!W9/1#X$C6D`B8#O-H'92>0QSAIF(BF10,$%[.D<QV;5M
MQ%MJ^]D^%][CH&+%K*+E\'D0'DUUA9Z#%[VO'$P[9$WWNFK%F.YH//2HTX<T
M$?UFS=X)%I.:2Y"AU`\7`>/3#2^JD,/$'RZVPW4^G%\>_ZKY73!@6P4Q3GSG
MR,`)!?]1SKNCXA(Y6UT]#2FF>VSU,,$AI)<%=4]&K^L;3[9,HJ+-2QGJ3D.Z
MJ15,8U/:,3,,2V"^CG->B]!!?*9#&'/,6?;R>^>,POANT4V_%O;G0GV=7T82
MS+R*"KB[:OVRSH1:6"*TAM4_7]QF,7DNI+O5KATA]NU0UZ56R85#2RA@$F[U
M9E/"5S?EXB/\F+]]IF0_F'4]WQK<H^_#+)9JXJ(W7"0%'^L+Q?VJ9*<=0"R5
MG'M2B0D"?4?P>];37S451[["L=S"!6@73/]V"SK$?Z_4OV?%SGNW?;%S!O"J
M@Z=6J,,&\%+PFLWGLUGFI!11EOG>5ZDF_1L,\/P]AZY]2E`-PXL%J%,2[;\"
M#L)<GA#_%?>?(5=E[A$"W8/]X";Q4IL#ZR%P%8S10+JM=M"BR;]-SBAVNDEZ
M]N_Y@I/E7%G4I1@XI?`*M7+%7)?.E`O1#%!2F6]L[_%*@/7S,B%0/>X,!J=$
ML`W9@P]F]`'BM7%Z"_T[(%6+.[YC2WBDNWKIG3/N/7](EZ..`2I!%Q.!9R8W
M>##EP'3\=3*CP_A?`?=&$C""L!A):^8.8`.#:<"ECA%,LZ]#/"P_,J&R`%B(
M9B;'.1@0^'\MQ.MPX="9*C]-E9)>A'$3PK0INH#]-7-9F:?0;4SB#B+=F.L7
M=`:GA*]'A+ERHT>G!(`#:&OXE3"JDE(A[C>&-;HH&G,:#7D6AS&,@Z7+)GE2
M+LC:79"F(@YTMRA7LC630DILZ;3_@4/K@5FLZB6F7N]+*5L46#LC>JV^L%I:
MP+7)6*1T&$R&X;2/_4D?U9);>Q<F18UD3YT^+4T^Y`M?NWL>=P5T'$JJSHS2
M4F;,;O">U`2$BS!+R`B'-81(-VI]XLH\L<^*5AL.NQ/&2Y)I5_&Z1+R*]$-L
MOJ)J..%Z*9CW5RI4\:'<8.Y0FGUWJ*'I*#B;,NW$%NS<4X7-3OA;?X((^#K"
M9IL)C_N#J2-KZI<D)9$,I;&*"JMLH<,1\NSA:$K_8_P?_CX-+JR.3Z##^Z>[
MX]R0[LM>2U:*HLUVG>X`3*P6NW`7;"S3I^I=[M]MO(E.OD22B(M*T9*#N%G5
MQX@A1#J\)ZCBX$^N:U)Y9""/\;_79J7;%'.4V=*L-]ZG0G>G=._PYPU_3.8?
MTJL9"RB@LQUA$&13^!^9.X)L1K^/+66CYH(K0]784R8#L_5.:4XXJIF*1U]$
MR[!D]R*HH&QJ,89:V-.)/0YI"^.U3ZTI(#?*.F5*8=="'5P\!%?W<C:L:U'6
ML"H0W/2FT?;<R,;']8?>7!?B.'N"6[7:VUR>@%]*_NM3*U]VXZ_;NEH3AZ#J
M0URC;'I*N7LSC&*_B<BFTK6>&#(KK##2AXJBX,$/4-`AO#NC)'"JG`YJ,2=(
M#W&T"?:S'$PQYG9P-J*L<U?(MA6"[('M#,DZT!FR_'O*PNJ,9)^;YP"?UT.F
M,2(0)JYTB.N=()$93%#YP'A&CV&*?;$SY:DIR_V8*KJ3<60RH<^?M9;D4)H[
MX'+T8Q9-!U+P?3!"^]#78F;5+>^UQF@U(TL'\%\5-QN(Z1$)MO@_[G^$U9%&
M5'_S:5(]0KI*%3+/D(&<3@GA0'HQ^7S27YE<:_Q*AW7-`09?$SY/D"9?U9]C
M9,2:G`.4KP:(`Q?[6,V09"-ZO!^0-/U?Z&H<\>4XXNMQ)!?D2*[(#ZY\74N.
MNQ=M5,$VJO&L`&SK1;:?DA^A1^C*%0BH5#/K.B:2P?97YN$X;O"<!7K*\E"Z
MH[6M^47*5:0BS67"_E29Z4H(@"``A=X0(&UQ.Y!QZ+:;$!RWMQ-C@43&8!*H
MWF;DY/U$!OM6%B4:\=/%/L5P?L^CHD-;4#;'[@W`J[$?&\NEQA?H?`5&F93-
MX9S?/:'@--SGP2DV/$()94H_6R^DR$;`1NBYP>F0?M;OXND9?3&9T8]#Z,+9
MB!X=C_@5>V]9>K2AY=1[L'-Q<W6%BF/P!S3S.K\IC6AZ#9.KXXN$YFK*3;`X
M8`)V6.*OQJN%`M=&A]VDN`1T_I@H`L#Y=;BL3+J*ECSSX.QL0@.B94-^/?:3
M7U<\)FS+6(MX&2:Z067?69'=N9MJSEX;F;;0GBL3H,"[0Z_KM#OL]PGR/8L_
M!QKW*X[&4QH%$7;,1VJ\P10ZP=&M#H$=1#@&?C`1@/OY:CI@H>)VF_3U+'LF
M."3GK2%<F$C#;?ASU%#;W'QW6)RP'BN86^>9Y'F8EHN%*5)V%ZU(K$/ILX1[
MOR.!AR)M3`"\0T3[57N)HJ\RAMS81=`L(_2B?=/\@PPYN""D%,BS13O#G[SW
MU-5)LSH36K-F[,\:B7%KP(P33:H<&B4)U6A#L-4UT`HB32P9CIU!Q2!QQC^0
M&U_9&U#MS8!+G5`A1U[R`.BDCD1?V8C&SI#'YUJ.YL>`IF&["D92A10U'\-M
MR44U'8LJ.9:GV!1-YA(IB8W[OJB?Z!![NWW#&@#]F.(/],M]\W*/G+Y0Q!W#
MC<W[#*C+F"TDV8!D8@TR>BO@5^07ARC:SIF+-C8,::J7Z3OI]F*71D&YMJM,
M:%;2K0<-N<*C5K=&H[5K8HKD,K'B$#:"Y%!97)+*EY[[6=&?S'.<#N/=Z1_<
MS<S+11ZOXI":V)&X`E(&;`<S]W\.N7?=8@<2&6P+@X6!NF-H!`?=<*H)C'87
MKZTUF"`5`3HF5J3QR,1/@*CY*I86$&9@>H3TU[SK]>73C^-D*/;=18\43K<5
M:YW.3J6$'`SO0T$DQ^XECQS^QI&O99X;P$L\H6L#JC*!O163_D;`"&W''Z[>
M*\9[\@J@>177W\7"'N&ZBQ]@J74:2L%&C90W#=4?]SC0"O5L&_)G"Q%PS"'7
MG\YS0A"+-Z_#!(NM(:&?RPGM@L[-'^>WQS33'0``=89^_PSQ[CZD#"$2I5$8
M8='O9U-W1B+8"X.$!N\H-D**H/KE;>+$1$PB:LEJ0I`-D7=(Z8>$#>ZF<)?Y
MTJ3XE$0^Y5L$%WZ/=!?7#]#H6^&<@!Z*O<CD[P"REH4*]]Z"G!-*B4R,O$R2
M*+/I<9B3B.C$G%8FZO)G)KA'[\\(0!Q`C[>6ADV\LR#RD.:1%U;*Q9REH0X]
M'*UD1_TS9(5'XS,O5<IAM(OXI]"`]=J2&&L17)M@0T#P;5EP!R%`\CA"PH6"
ME243`-+/D4T-U_!%2%+G8(D?E8KJ"7:8,3=+[?-+?)_".>28;_E&[HDE.82!
M5W;.YX>+F4PQ%Y554;7V4$*N.DVO&V=`/3M@.%8Q&G#^*(>L=Y6Z"GR?5:FY
MT)($?VYDGW!I"RXO&>9I`@K4#I>4$^>6*DD<:,@[H?$]/;=M.Y7F6&7BF?Q^
M2@%!`.GS.#$MA>PPTB7;-G0FF5-JW!F"TM:!DFA*.]77&)I%E&)WK[1DU1C/
M8Q753N`<I8)SF[I?-]QT.NA<7M\<J[`@6_85@:/&K/,KZ=!4I5$:$+0X$=Q-
M\:TU<FI,=#%)S`[PFL11:64Z:/]T89$[(@S(=##=T]5*P19T2-H5ADII$[Z,
MU=50"53;8X^A]A$4:KPC&'-G\AI^`E3PFXHIUB+@O;YQ[##T&6+]4J!%T-V*
M.''"I!1M!=`SLP*R->MRAU=6AX"*Z0;CQC!./D=I(^[U&\?5/@+/@6G31Y0Q
MA%E8<607F+9CL([?PY*B[/_]OU>8R9!@(7>2.CP2Q\87%F1=*P>F:+(//"Q[
M4[R2`$3\+$6#Y^\B=B61@4G.S96DX?Y?W*ML4Q+6N!1?VW/=TY3P)"AW!9BQ
ME2$M,`>*JR%O%K92%)AHQK8B-!ZY24PY(KS1E6MED`L.=QT+FPDQT)I;8\"3
M7_#\5_8VN%&KZ_*Y[9@7`K0''6?"'X6FF#?Q_*)_+W$PYG]5W=(XP14)<XVS
MG&O]-?40J[V<W0.:F!YF;A!32.!*ES\!_&X8>9]OYUEK$^W(%DVT9730%7K>
MT&VTI>#.WZ:G@(T&E%68LHDC-LERTPL,/[JLYGQU!A-64"7"9W@J:B6KE^CC
M-P$@J5=!GYWHJ*%V1D;3I<`I[+5ABEC9:N#W7JP`O]L9LXH]9@OUX)1_JI`N
M>4YTV[%9Z(!_3*V'?U]Y.PI?DE"R#K76H=_&-AABP!%/II;(A28<C`1[RHR(
MK.E*N[558O"Z$9G0&U>J^*">F$?!>,9M[8=3M+D+4[76X2Q:4.W$\12]"2,R
MQ%O[HI^9DJR,]`2$8(`J_>AL!/"_3G?AVG:C6`-A3[@-9X16E,D8'1$SC-1^
M;2J%FX+=$W0M#(9]6^QE,L;Y)WWT-4B[D[W5=KIG@U-N5M4]I2`1'N8=EMZY
MQ?SZ=RJ&>5]9'CF3YQW)8?#GOL='`3<[/@BV"!9\?"9K'E'TTY#Z/FOL;2TQ
M-.5&5=,)6J*NA*AC'.R?;N:OKJD^^R4,LPM.@OGEFSER"]YVB<4Q_#H$(%P8
M8S#ZC\+@YOI=T$&Q$+M#^(9B^\`QVU_X@T3Q\*Y36[$$VU)UTC4/?S!RW7ML
MSHZL.9A3RZ:@@S__##/(HR"^1.O@30@2ZC)%H0HW<\S,WS9Y,7OF/CN;>'6B
MTFM`2.$D/&+<0(`VBS++F:ACF]`"?2T@N8,@@NP1OBO#1+K67Y$_!D@_9A\F
M)I(`&`4'OI-7A$4;@C'`W,8-PL13XM'J$P3T(]M-J.HG,.N(I`@NCFK&J'C)
MEWAD5-P$Z%A73C6/HL_2)[E<LYXE/JZF'<;HE8E0T%]&Z.5!!34LS/PHUK+D
MT]->BW&75R3-5`MQ&S2-3P>L4YI&P7TJ-BFL*LA55$1])D%'3?+H5:X[HJY,
MJN>M.5Q;YKZBKAG%V.56^`MQQ6JWV-K5R7H997W1%O%RUF\`4U]N_V&L2*'3
M`#*'"$80$D^B$0%]+,1)_A`F=F5.LO0E\HM/U\%LHM*&5>YZ$ZE<56FNZ/F_
M0J-SWE=,E4`+[%+>GJ@@!6H1$]-*^1O25`C.^IG:[344JR'E`5%QN;3AED!<
M3,R#[&5_-D,MDH:D(]C+!BL0_['!K7)@=L6+7]SKASET#$]FW?/<Q_;SW@<M
MYA?V`;Z\=&)?S%RN5H"9"XL0Z[QM\6E1G49F?TOD$;W&1!BD/JQDUI/)J<W?
M(A7^6T&NQL$Z[E/@5:'6,F$/ZI7YVZZ]P3J\B<PJU2[*I$'#;A?I*E8JD&<S
MG:___`!4,LK^\LM_Y$@Z$)V]+>-Q4$6AS,16H4%BA6"\VZFH/Y0!PFT$5&:I
M9U7&.B[?Q!2I81/=2LVB]CVMUZKHU4<IIWT2;G;K-":2%IH58+5/>`[&W82+
MH//J\O)5?S0[[CX#&()-+K0PSOT3)D[DK(2NG%B2I&7"+FQA>'=Q1D5\`?^2
M@E([R0@<)9C69XS`5^0^!VZ0Q=Q(1&W!6'CAN_M[PKFG\[FDDZ4[4F)QCY&^
M7NT7R+U697\$"3,)5[EZ"+/[?=F*^RI,37H8.HPNYZTI9"):1D/S\D<NC`^S
M:U25O.VA5Q*;6O*8K.:FON529)\<8CA@9C4(62T(WR=%>H+"6@''1>XXRQ+0
M?N<\9+JSJ2O+)C&JA`;2TJTD-KCPEG]']9Q;`A@M'XT34[#/Z`<^O3&V7"O\
MR-TSO5L('OLG>5G99U,?K0IA$*((3%V5QZX6\\R)#L2T2@XD]F(BLZ5='CL4
MT#`,^U_U7NX`KI^`/5Y[9JYTPNBL6E[X=+:GO##?]M@7"UP@6^Y'LCT?FK5B
MR$>S:IO"X9FJ=_'"\L>WJJ9?)9?7YV]A/;S:B$Z..AE[)]<_MY3*=;?#34G-
M]W9<3Y6MSLFWU@:<I*K&H)\-JQKAJ=8Z:UNT:F4R>WKH<3I0\C$+T,T33&UG
MFF^/)&.NO%1[UG2=?2GKD"*8T,3_R+%]'`/'#A#7M9!U50=[V),XER@D$09.
M-\#>X28MT41MRY2;E9BR4OXFC)!6Z?AX2)-(>WHM,M5+FA@5UN%9KYG$KAEO
MF6W+,X4`CBC>QF^!I6J=5&N_?J2>MAR"IONK2*V46N'T?0)LSCJM4S"?W)!#
M=$]F?1+,C(CFQ/:LR58P9:8C]P&FP`1(.X`GNJJBH(P]S=_6FJ'^%;A85_IJ
M[3PV?0!U>/*L%,U0NOU3Y.,I'=9Y7:O=5%M7TI2E?_:<+/V_EB9[[E#O2Z1L
MU]>:EKSHI>!]7(!&%<,?P6V8A""!@(P-@`2UE$MN(4"]2J)GW28Y/JQI<P>-
MW'E_>W5^+"6VUF5.E$!,TU'P_O9D,.J/4.U;4P6U`M/($(>!WT@51C$]2C2(
M5;D`L!L4/+=K<F.GPI_B9&42!7MF>&*&"5>*I5S\,C%Z"4I2!6>DYEOTDZ?H
M@0P&)]N'%#[`-75N!E?'9"O=%FG6DY#MHEJ0S`*G:X,)C!?_,<W6JT>X.T&&
M"7.$1G;GG+Q%'73S.*3KYD1%7V>4OK9UO;!*!%@\XB`L>I,_J%CD<+X$-Y'%
ML#'NFF`[+[,)4>:W??;P,"5J1O7>I&A1U\>V!!F3#`D8S&H:,<>-T6#UFLKD
M&%W2]7L,8QWW[\*-?P^JT\G-,BV*DVM0M($>S?&"9ABY<;FA>&UI><V1(8.S
MV=1&NR7$,VY4,%N<NUP"7/\Z9?K9:H<';>T3ZFFR/W?@J$$AB!#;RBVHS(GM
M6L,E=;6RRGV@>191'T2K8U6N6C+S=.PK=G5E@X[:7@IU$SAD3!^TKBYM:MM5
M53^C\U%[,$!<_@-.8XDW\]ZH@%1:%14.4@L=`K-!E$;R-UZ%3)C_-=B9ZT'K
MR!8=+=$%.*,':2-)=Y(#(S(3>VKF,S<.])<8@_/(+.%=)$-B<.$/W"132NM2
MX>H3.,--2EUNDI/W-]ZAZ/C+N<0#O(T`DB!EWAJIBPV('J6F7(%A,Y&N"C'6
M#1CY=<X%QI3U)XDG;,,RQC*+1NGV`4CE&D5?,0J)0'3PDCOSM[?GQZ9<K%X>
MX<E=NBQ-FV1?2;F3AM/<A!UM5#`0F:>TO<WDJVG:LDBY;+HY-^8K2TQ!7IDX
MX1]/X-O/L(%K6'Z2YJ`-8WG@SH_O3'`3ELB+3NP@_NLU`]J/)^_4>-A9-[B*
M[_';-`]I6),,XDZ"["ZV**G);L;AX3J@^XC6345AOV"5=+-7PIW'M/%PR"V;
M,,:I[RT1[NH^JJ%M'Z\:WV-'.H!TS^]+V&"U:C(`U+);Q`A*E95:Z.+`B_BS
MFK^1H<+@R`M^:EUQET-*X]43!`4`44JNRQ%YOC5-9O7(.<^=FYO<Z%1T3=>+
MY3/UQ\%:6,]:B5\V/_9B->I=69[E'-)]!86<KDP+71O^1;5;1<#OO;`?I5W^
MT62JFF`<0MZKJ8-XF"]287SQPC^H_0?;Q:Y>,]]RVK)J`S446X^T!0O.?!-C
MR?-$)^4I/&6J<J1-M):\Z!F4I4[Q&J1,/8%-COY>3CTA'98ES0:9P*1ZL8&0
MA$*V7GAE?RMW+C?FY/%LJ/:'-]UH\XX(`AU:HSYEB1,5&*?W33'1,SU*N,PP
MW8;(?8VRN?UQ0[R&338**GBB:QSP/BZXW]WJ&?(*WCX3)>"D];J@+?*[V3H>
M".T6B7MU"S5I@,LMU.5T+FV?4L0)AT90]""%,59E#ZR3&K+UUM2.D<JV+7('
MWW*\0\YB9?MD2#=(D^+H"22X!2(;=+9$YYLPU1XZ<D`$AXE)-+UW>'0I+,`/
M7=F'3*Z.:Y="7J*3.#EY*#>HG9#`Y81*8_UO7<^2"T=H?<04KU=:B,JF-9XI
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M%U4,?WV(UG2-,(TL?33A.L%%[U,/4WHP-1VS'\V=(+QVXI/8.!`$N%G*'J`@
M&);5JSN-L,@[C!=\?WG)[8/E;]CS0[0!V0^S=^QMU\SQXMW'\]OY[06]90#%
M)C>*AM?&-EA;632%BN`Z&RQJV-'E,-/4KV5-"VZ``)6P+4"E:`NLXP^4=_$]
MO(MJ]=PN^]*+]1D,FP(8.&?CB[Q;W;*;Z!TH.DM4='K!NP)DIH[Z;DW?'7==
MR!K+&VR(W'6K"^XJE:SK];_B#BZ4:[^(4Q/7O24[VY+T'R*/M;G9NHI51V!G
MP].^ZLUS`\?Y$/P1CAD6](CZ637]9J)1_-BT"SJ=?(-G\IEH1Q7B(N3K6?U1
MQV?/6<)X4EN!I%Z*+WL`B\'<A(SZ;+LT+$>)6\[1T6*LT>_:9Z'^S_(O>;65
MX1F-]U9<Q)(7M6E-:KRIJR1!!]9([H?;B*-*61OVEF-NF3*N]K`8]+^QY,BF
MMM*M=5NQQR,D$N.I#SZ3B9*.CZWEBH(Z*FJAS5#4&6)V$2(5MT%'BG1[X*$H
MA5AZZ&A!QQ7R=N-+Y?0ZCK*GD)K24Z*-]->AEC_44,R#M),;A9\"!I]](]J>
MX4\L4\661<5L&W&:"[7X$2,CFUE030AW)A&8!Q7;)RLH2ET@G7FQ:[C>1*RJ
M&_3$^T?QBW+DXAKI\\Z[G\Z>JM)CJ$\0YU(SN-B29S)V"JH1Q@G$7#*02MF\
MT!'YE,>N\1#%\]A7R@O.@8[Z@U&Y:H8].E5JXG%K'(*J']G4/OQ74MA-*)`H
MD=A[9,T3W`&4*#D,._W46,BC[;WMXD$5+-UQRP4T78KN=,MNH>,VTLF5BG*-
M5YJ"#EH]<DUGB/JI(1DQ-=J@E"9KL%53T'J)::)AB4)@G-YC#\;%U(2YT[JY
MJH,]FBCR*D>^),RG9A=Y1JB,'S\6RN*2*KC(3:"M)XB>@^&>,)EJ$,ND&L0R
M&+>ZY`\.8GF!1<C#'/'PVPC_0ZZ_UOIR%*4M`"L-('CP'B9VF0`T)_-]5*']
M@QD7">YZ^0,XJRCVY5/B0TT,9'K<($C6W*5U2E:1YBF0LR@W6)H@0AL)=_Y!
MB;YS^^'-L2<!BG9M;=*Y4W/PU.W!+J55)MXYF@!&T@/9`;K!'\)MF+3X-U'<
MJ(M0I!0=49F\JD9D6YU4>[K]^HX>L65:2P3%,#!!(M<5"WN%C7=KUL1JS+39
MPA8F&O..JM&6ZKMF&U[#W+9D6.U,C9^QJMX2^\R<HS@,)B#]L0U)[EP3RO5$
M"[LQ5M^;&-T\81)A'KE-"G>J'[+T)C9#ECE?;:IYF=`X2D:+FHG&&9V='R3A
MWEM>"/3>Z_,508N51)9!7Y%'(ICCF8?0-8+)K-TFNL0FJ2(UO8;R2-N(*_1Y
MJ%L/T7R3F2+X+R30AT?+\.IUD&'%9ZCZ7OU#J/?5N)=WL$G6VFK?($^UR8#+
M'8;V5`T9[NW@/67+[$OR4`__Y9?_F$TFP55(I4G4%Q^E[]8I(5C?YNB]GTM7
M\L8$/?GVV&29L1D4E1S/#,L-7):8M(S99481MA]3!.EC\`?8!MJSUFO,KN)6
MYK$<(BH0K\(=',_OHW!=/"R1/%SY%@19*3UV''24!2+KBOTAXD;<.=9B($WO
MU<7M_.;B^N,',5*X5_#;BQ]OY]]?SD&8OGC_&BE.FJ2F3?M!PU]?O+I\`Z]?
MW<$US>3-97IB'U?/X)L?@)1FY'2M;`U=T31IXS1FG4;\(*C+(7](>\&L.SD]
M[>+)=SP,L`7W0"F(F>F0\3:5GK5WN&-.Q\!#H^BD=`,$WE1ESMA[S,F!7V*.
M3;(N6OY`?+I=9`E4P1'?0@'!-E\U.(-YACG2/K86K\(-.CRTR6^-M3^MF\&W
MWS)Z/)`/Q\;GU1'3)$"6KAPFNGHI\;$;I'(/9N8>N-S'%=9PSYCK_52N[CD*
M`?5+X%>V*YQ!6AK9OVYAHA))MOP9JS=80J(K9\K362!D6('BSD7R9-2+&.Y\
MFB71+O^MN/WJL>0&N'CC'L+<IV#6Y14^YJ!H2`P1\90[#B\V3]BJ)+GLZ#^]
M3#!_AW.IH?677_X''X?!_*[#;)S(W2:CV:_EI+@A<B;X*+M^>D8+MZ9#(C'+
MP)N!3?VYD-FFR8DF,\\Z!`?SVG%4-DDIGX*>&+F+E38<9KH='X1M=<2J9MPZ
M(PW14N))I%#2EY(.YBZ,>"GA%I"X@5?+71?TP<"B./?"+8M"[C^DSI\7.6$Y
MQ^[$3V=?/SM)_'^53.\.?^\^.3X@^5MKB,-1MST!7)#X&G@LP6KN)X#?HF4M
M87G^7?CG.`TZEVO[:13,-^KQU`[#-?GC-;]#EM6OR"#G)5;!`$H!VSVWVS6U
M>GW,L$LOR:MI`A\!<7+FW.%8I&@D1NHTZ7AMH=E$)+;:Z4J0DTU:SPN*C=R3
MNFX]T*'.UL;R<WC*;LM4^Q4-]ZW)[412".F\[/*]^>/DE>>\<0;T`:GC-%D=
MKXU?V\\??XL&NX26:D1.$U2_QI*6)DN2*YI1?46I9'9OWT0'NBJLQ2Y<M)3$
M$MM!YA:Z?Q)/L$GE2F]1M&6%BX(4M1_:Z`9YN=BF41*J)`DIDFDK&YI''/&H
MKY+`M$J7W,*ZEFNN4V/\K`KQ:.UL53B0$4&"R7@]7.W.E6NUJJJ:F3$_CR0'
M'E[\UQ(#TS<569V<T=87C204"&@<%.'&,FRY]T[:68@]`1WLP/01VBC;/83K
M.Z.\>W'%GF.9ZV9RC`FVU2;S-8SX'!G_?9CGP/E*+.)F4LK\LH>NJJ)?EH(3
M+:P,T!6^UH(J*N,$$RGBU/40T0?^!G`#9`N6-##(FE@_82^(188OHPLG=V)!
M("$Z),ME$=XO*Z8N858B$2R1=@.7RF@%!&#<'(''?O#<`,*'_`.U?L;0$-9X
M:2!0U",;,GEG$[],9#2^@P*H"5$T[]#68;`X%^L.OBC)+$Z^<S<&QQ`VGGTQ
MH6SH3;2YJB(:5-XA!5%">.#H3!XK!DLF=^$7T+,16*;`//G`=M5]H+DJ+K@D
M\'_"D2[P':+?]$D68300_FTJJI6)J<W@E?B'`P%X8L8:)AA2&(@D^KK4"[2W
MDL4!:X:8I`__EGW`&'PRN9YVK3ZO'Y]_>Q-T_,^,+HQB=8.N8=DN7Q-8U6N@
MV-%ZE69WW>`ME4M6*C"!\/;B_,WEZXOKN54N<GDR^%1P5L/[%.69UQ>P2J3A
MDZ`_'`:#P3#X-+#1':$M"8YA,]LL7O.>1&F@7O*Q5P=P4H./*[Y&U1`+)S'2
MDL6/PC$N45:TK]\?][>Y6'UA2TIM'79/^X/N:#)IWH-I%-Z^@V'##DC'5&*L
M&&&5J8&LNGRI@>4&#\#=\"R<?+L$D:[$0W8QSK".Z5?=A[\YYJONB#[6S\M[
MS$$1G`?8?XB7*4QU&SW`@+$2*"5QYGF6'H\+V!O"`@W[6\X?4-FZ^!D62"+I
M1V[]@-<CQ9SQ.2Q^&6*64]?&,_`[KI:>?><J+-?!'WI(Y\F69J^6K2GOX(!D
MW[(+XT<!_,*MG?>"_^?_FIW^U%EP6#W^471"_F,P"\Y[;WK7^,P0VV'V%R?2
MK(!I97QW5\<\G_J)-Q:]L_))E[BO[1EG+>QV1'%&;&U-PB_6P2GC(%^@$G'(
MLRE6GK^0#VS494A7Q!0Y<A,D*S4:#*U,,I:UU?7?_UH700@."[6>M&>#[QK*
M@XA%SY8^M1G<4KNI"$7A47&12">KIKG3[K0_ZLYF,RKP""#-Y:A=6!P';_Y(
MM@XGU[P/-QM6>\^C]3H_E@`_7?U"5[EP\7'_I<Y&O$FF[MY.V>G?`;]9XQ.H
MA5,(C@C9DH^"A<*941B?U-J.(O8E%^*PIL&V:C!I)88)]$!25JR]B`J0H#E^
MK6HBJPSH'Q[B-6]3-=-QL@Y'+MM9EICV5)#[:PETB$,[MMCB84F"K@NU<J5H
M`:YK@:;2[:JS1#_'7%9;5`D)&F*M"#^,R'03KKZ@V=U&.;'SPNXLU64;K&FW
M(?5W`]JKBQMQ[HN&PE5['SZL?\BA0SSOO3?E)B0=SI6'FDI(BN1UZR<H7@C5
M`^=<QL>DLH7WUJ?W<Y!_WM.43AKJ%,#S"JHQZL85C,^/Z:*R;WHX]#,/)<W,
M9*::P"N5S$H7$%V/IEARU>4[\%R^F*-66P)7.3=&#63EE/KGF#U\0C'!8LB3
M`'W?D#<B^-$V"$3^Q*KDJ,JC=!#R5J"GEM5H!?1-FG)A^==9>>]9M="D]N;U
M_+CG$0A=VH`"T"LAAOZZ2*AE'QC[IDUK):34&FU@8>HK"37CN`QKE26F7Z!>
M;:)E;'B_Z_S%E)L"IRJS&!2Q[-E&5W'LG4T+:7G-<\86CQ$66]:M1<C;NXKN
M2/N4AS5J6Y]V[P5U]PTV'$TFE5+@34`WA>1#%+EIFJ-Q)6:.\I#,!VWPJR2-
MMP.ET1H]%O6_`;\GM4`FO'E2.?%HU*]=7%O*_FBJUNUJ`E4WL/<(6ZIPF8BC
M]+$6ZN&OJ.'^D4I#R4P>N?#7V@SFEK6:TXOO%-J!:BJX8K?9<C!L98>5>XE>
M&.FW9J<$L$(;/M.R,%X"4)]AWQL%13:NQH9C8$D0/'VNJ5S#1;CV'*BR*B-3
MZ,1^:8-8.`I1""8G3]G87,"^>Z!2W*.!(@:H.@D78U]BA!'WD;&-#5Q((W4>
M1AE=E1;`Q"?#IT'06-B6+Q2#V,BV@&>1E)5Y"H4<O8U$Q,A"5=#>57+P@Z!,
M&RBUK9[K6$L&Z3(RH<33/B@/N[R2M!39C"X=2REG\N`54F@Y6A6B16@&NF&Z
M!IFNS!),THD+D-+7DE;"LM_'2E,YHDD825*M#Z)#L]=2Z*!E<#SLZ425V8(O
MX53>`$M>6D\L5XJII$L;RA\E7^(L-59R[,NTBE4332X[5`GU-XLC'B#QV0?6
ML)!@)?L!R_U)6A<,5>](+1EVQ2.8LU.0K8M2N]:4LN7`?5N\46+;NBR#IDNI
ML;9R/*2E\]R-*_E_\860J_;)TZ_L:;C\_,&NL75C:8*\/BJ;TZ"UI`'7$B"9
MW;U;2UDU(8O&+TCU`UQ_PVV\C=`L[.>I`MH.!M^H*XF7*,T^DT>8^`'7!I%,
M`3P64X"O5J[*6U[%EDX..Z.O'9VZ<%X,"3MS?[*D99N@H7Q%Z(?--"W)K(TW
M&/@##H:MZ?2YJ;"DUZ_"/@P'AL=1G_SBUT?O$?X4H6EMA'3=ZDUF8$/U;"U`
MFT`G4J?0+F*Y=8S9;*3VZXV*45,-U*Y2(&P(UF<\VC&_'=?Z2GS!2+WHL?JY
M^`FICIZ4`5G$J9]Y%9@F-E3#@B54D]),&"IAC_1[O<#K"O"1GR3GIBN^D41E
MQI'%V*I,53=BJQ00&OX6)T.^DN6FMAK%.*U<AJ\I/V<5@VXP__[CAXL?N\'5
MNXNWUY>O_]0U_EV6P-[,WU_]"12(QAH7MBH(:(D11RAWWM\<=YV]I_$UE8WX
MJNN2#Y]ZEAVV5@5L?#Q'B8L,;T!E@BV`(P[S6-R&R"[8&$'$@\MND_N2`Q/]
M6B0@.F`MDP2C5DVHFOV`2A-S4YP3;HJSB0QE(>]$"BPT>)NEY;9;:QIT?7G[
MZ<?YA^8=8"#-[]/5/=QSRL9=[S;;!V`^7:`SP-;@E/F3Y0ZKG:RC\G.T`>!T
MSM^]TSV8='HSR=P/4M/!!GQ)#+Z_45K3V_F__>G[N4JH\'37VHIAYMJU?850
ME[H7MLU+Y:'@Y\WZNWP+U^=??D./95^BW_Q.=&!C14,L(]\O!Q4988[N&=Z4
M,J$V=!P9_NQ:V:'M\27QK=)N0HP!8IW*T+`M1!RH(>`1IHY@9A62&^[90[VP
M]69-!&'C_!0#B(;?>*,;9%9%5R6V@K`/HVQ17'/V-/@>-4.GT7N^SPYI\V_G
M<U-H1D<!>T54T9X@4B/5WN.*NHD-NOU7$S"RD-#?N*6IU=.0-YJV=XA)RAD+
M?MSOG&LS7->6\T>O^9'HR/6LLDXE<OA8"F0KH!I^P)483+-/@>9??OE/BG$F
MB\53G8;R`,VUC1'+`1?`,`[WW.%.UT+?0II/"O=U$B6M2.VEB'$1",$]N:1>
M4'B9H66=F^T!=Z``#DOVS/5I.JTN=6A4$9GNUJRL93!W!B#@YQ;G>"/-Z6&6
MC#PW5M_4Q#40C,FHS#6TG,O&18:8Z<V$=R4LG9`&S;&4R+PS$?!.-/5O9B^H
MVSY5,ZN:`/',LOVFLWP;K4":E^8V'\KC.7Y#6+I9\NASRY.*/:%>\/]-6KG5
M]?=A+0A.'(:JN+(,N8ZHJ`L*U/V^S6DU=7-S52*(S&RFWQ-WIPH+SDLUVGE+
M9>N7E'G&A$#V/XB>9-)Z*RO$+34D6F?84$S,>:2W67B(,.N,6-554PXS=U94
M#0_E*LOY>>T+$:"NBPO37(=X9"Y>2>@CA4$]D`W\B2-E]X8M/?`8F2A`Y`"@
MUDL2!W+\D&P'86%GX5,WDW",$996ZPR.>;J&DLH&GL2P=)J)4HC\S$X$1&?(
M(_IZ>K@`@6YA))?TCOKV$M!-T3Z3EV5[-B&=Z^K1:4-+XF:Z*>LBJA;:I@?Y
M)6.D\KI)Y;H>]&.XJV;<<I-'$2:67HJ,7Q-:I0>K7!LI!D(&`%'%J*/K<XZY
M[?I3S*<Q1U`M5EFFOS"DD5R*TL-+OZ5NJ0/B26[*T(SA?Z0Z:PH=<P!).9$!
M;T=B(OR8@I,QDMZU!#V/[B7GT,BF?W]=J\H!/C$)-H[:FA&$@AFHU[$G*#Z/
M:1#'S:5F`7E=['Q=%Z\O5G0LDR/%!`FKJ<<#NRF99*&$%=EBRX0[E*G>U?7I
MNY)+W76Y;CI-@N<R5@0G'W"`O[4"-]>^I[!K=)XG)]R":D$*!*;1<G=5MH$U
M[9'SC2A[7<I-<L-14\/!OH,H`K(6UCQ%99W+"E,&/=W`Q+;0M;GZ/M3"S+8Q
M74FM+-M`..H:XF_$'490+LST$,E^J)0FFW#4^BD1K:BE0+>=`T.=T]JM.,W]
MJN&%QK/!CO/4^M0LD+O?WF&*BHG?S14*V1[5^(2<F@5&JK7+>M-0)V+G0HZ)
M`KG&S?!_+GJWB2=@.[3V2U+>A\U?IGH?K)I(Z0F#JBNMPJ-P%.%8B'XL00!U
MP?1N8"/+`&LX8WT*37)5R+#AY)@Y3M8N%=:VQ$`"X/YQ_KFFSJ?-._;*)^^V
MP@$Q6@BT2=($LL@6K9<:,<1*L.@,HF+$19;9^(QN4%?]!R^^B?)V!9U4(4]V
MEV*/<7B1''Q<98^"(MVQWD=H^]P^8)\BQ&46VC?A3]R.7BA3TW$*!7(N#W9.
MC/JXC3-Q47"IEC3!.L,L?[O&%5%&RJBY?@+@1R!$#Q(P(631;C]/;6S0DFK'
M(UMP?)&I#Y:HYKK-SMK.P)`9R`2R9ENN*?$CQ@<71`='OXK4=J4(JUP/:SNQ
MQ%38(><<V"63_09V+*$R'#_@>N!8J<I0$VP7SA45$<(4Y4ZFY15>.4G1.$DQ
MFLPL\\&N'4XN#3AQ'Z&FZ)S;'":FP2@1CI&K2A_>P59"EYU,1/(F/9]YXC\G
M8EEB2G5R*5"&ZYX:(S7'N!)ICW:I!!NJHO\6DZCWG231.6.[0,8[DWNT0IE6
M`B@GD&;G:B:2+Q*-@N&:B^Z1@$!TDK(/W$B,.W"-G!G?TE$JK^)\*B2LXL`&
M%U5`5MI@]99*<<8QPP#<$6KP799ZRR`+9>S.RTQ-8=(OC!+*VK19FUIZ%GF5
M:(K:ULGD`(S5])!BEL(FT256^E/BH>A(J<F>4#-Y!59<Y9):Y9M]_7L/5-=T
MD94VM#9GF3/3<P!I1^`JJ\)4:<_$EK*7:=/DNGI#;)(./J6?N*,][W-.#H=8
MBVKHS$;*)W$C_N@\>)6B6[KS9G[SZIBT3[9+&'\UAOER,>N5;G03KM(M!?N(
M$H5LB5'!U5Q>4=FL3PGIY#3L([)@B;!LBXX35!(M1Z#,C7!X6[E=NI6/<(0=
M'+2;F^Y!-5;.C)D\NYT1A7[0GHT*+,'K8Y;`$'IF??.;3QS]#M^>8*OV:VWS
M/Q?:(R;P<\MG.K>@-BR#:7]JL[KS$OEH1.ZR]5KK2SR@7`BIKT"<4>1OEW&]
M2>E^K6">;'<BQ[0,[LN8++Y\PQ&E[(E;*3^TGB56<:48DYF=HA3B@K6T.]P"
M1A&0H&:+:U@O-G[-==-$9J2SLR7BF$;IILD6$<P:F"CG6MUF^QJ2O]K,=$82
M">^*A+<<T^0$S_'9Q_2==+!VQ5,N+/Z])N+!QPA:7[B+=#$Z<SO,>Q[\:7Z3
MN\=6Y1GNVO_HE$^.=L3IOS9<D.O*60L1225IRO$K?&_IQMJ(%'N)@<;=QU0=
MKW*'3?8;DW),'6'UR+`75<5+[HA5$52O%&.WP)02`T228SB>H/56BHA5OY;5
M-,Z]-Q'3:6\MJN*87($&]R"'>CKMPZ%>1R8P`WL.O@]1?P<YZE89([KJ(4-?
MDWO115WT:L/E`BP.R=`L\KABP(JF%S;`!'4/M9J-68UOLB,`V06IHH8<]T:6
M(<!B7(G2D#7)D-:'KI2A;3S5]3(L1)@J/&#X\[>OT]+K6I15#1HB*"`V11)Z
M:F&8FO2G0=?+'V+`(A)I-X'S4,0)%X^9=15/O$PP7,*&B!;&XG:H443R(`W:
MFU!BNUA32I)Y4?)R'L04S:1]/470L*F/[1QU@@UI2N<@M%]T;LI%P:@_FIR,
M$/MO8('K^&YGKO95Q;GX.EH4P66.V?!+K.Q@,R";>8@8<A<%K9+>J;4!"K5D
M1\^Z0/]%Y!\@&S6T&XHCF-CRN[(!-#8]V!HWG*W"K<G.8UVP1JGD[ZVT]UQV
M,GDA]#UH$XUR_J'WH"F7F954&PXBF%<Z&+P#-0_4KI-S5D+G7E$E6SDF8\'M
MD*-:RX"BU6K+,6G'AQU7PLH`6PDW&,R()V\U'E+%A"6U3U@A$%3NRDJ&85LE
M4+&B%.AF,"Z'M21H-5UE?UC_,GNF^Z^XU^U5LQHJ7TV!>*'3_WLJ5ZAPXJ7D
MZUE4A?$:CB`FI><D>&OC86U>SPEC.&SE!&W2-^E=\8A$WZ'[:-(_&2.Z&['J
MM[G639`GO,$<ZRM48E%J#,[7:8G9'GB1\)&YQ@-3*U"17>YXBW&3)94KE]<4
M^JA(M"`W2[2E\DE`JGP:1&M[^<CXJ09S@0H^:ZM2E:(2BF\5U^ID>#!/[:#N
M(6_9R2$K)3(JTK,UD#10=MO$Q8J(5.R?S-R^A#I]BC7&O'K=]NS7X9(FL?@I
M;)ZUW24K$`X12U\K:0(W6^G4>"Y.[PLC<-\B(3T/U\N2JC]^`$HW)WK'\V"A
ME1N*B^K@8##(!2`$"-0PX'$C+]VD7R2R5(EL)-?#^/<@M?_9AFF3N1/WQ.5,
M'V(`#(AE'".IJP/C1L19X!Z'$]DP%+3Q*(G$>B-/;4T.C2GJ(6Z-54S7\>M0
MYH+2L155QD5MT6)9%-((U%;A;FEG:^JE2EUHJIV>RV:=/X!?)H?Z!H"#79O@
M$#!_C\,<NF:<DT6XQ(Y:+6UH></[^M<R46Y>%:9D6OMN.\A-Z8LR6=EB$61H
M\@.J6LY>R?QTS=]1Y/W(G/7&'%O#*KV"TF)IL?:4Y_>%WB/5,\OV(OMM=GBU
MMVHC*'EY`?849$N@%];E1PZI[N=_-:[*'?(.$!8'W/PUH5IA0GE&C<)X102T
M;S5<.KI!Y'U<[UB?-#.XF[],N8:_<@DL3$ENKV'N.J36-%UI4H..0Z/?4V3*
M6@W/K]?BO=T#7'*O1FE,_QL]"?(E:0R):^TI."EZ!S+Z-FID+SI'<!&Y&<6T
MM*;`$:D$QP%A$1JEJ,0M>B7H(O6(@E<_I3R;ATC=7BSG*#&32^=63#-0F"F'
M(\5243B;2\$@RZCUYMK$82GSEO/M<:V)NN1:2_-0$O])N48GNA)?7TAY9W\W
M9EU-S-]_5^"BOC(Y4^<Z9\IP[/ZDX=Y4A$MUC4ZNV+TR=^&X3ZJS5#J#/LB4
M650%]-H^'KD4-!+GC+5_4#HZ:UTJ>T:18^/U,3D6%"H1NS:T?I*5G=G.Q)&E
M]E:+&2@_P`Y4R;0,]\+E'UT8K'I3YD[T1HU#_=&Y)3=.+3'CRAC$Z%;;TC&-
MP37>H^079^BA+&$4`9LN9_/HO@LZEXG)D\F/07#$)!N7X>>;Q8\PJ;TW<(GO
M1>6!X6S<FP2WE(SJKPC>'<.7T^K:+RP%<\*#\^MPP!!6-3!(2]3)Q-.8#,5*
M8(WTR%HUP4EE$-)0.270P!6J$M1??SDB9-AR>0/;P%8=5O5`+I,3JOB0[VDA
M":`=`FA%`XZMBFP6-H/OK*H\&)[V1N([0$P/?U8&K\XI-DHXYI'8?=G![-WC
M9YWIM?&^XWU\;7V6N.PY0I]C/]N0?@Y$:R>9%&1#<T$-QJU??P4&;WI+O\2%
M^;S5A&XUE/PHJ$`GQ8B25\_#;>=<^?$5`<?>MV4&EYHA]HKM3UTY_'K$/L(0
MSN<H&)W.X&H=83\<^G$ZZIT&Y^*_M@3=KRAH8XB,GYNB`4:C(9S9H#N<G<+/
MX;0WAC^F(_RI%ZH'<K75<SSQ$9QX9]@G7.@,QK`0^#F:$2:8'-UOV2IVR((Z
MP]F,QSJ=#7BP`>P9?W0'$Y[NL&&]=8[[O1DM=":CG?(DH^&@-X1?*K!O,,@=
M!9,S&`-^`%T[I9_PYE$P'<#0-?*1%CJT1,OX!W6U:2)'A3]FN`!ENUM3'PX:
MGH.K#D)B;E7$_U];JW5+<,Q1,!@C'L%/HC+G.O#!I$J:H#L593:>#@&T(P#P
M,*B`3@!LL+P*&*V/--,(NP;;W(:>;X+PLOG1%P(K?+0**&YC")@V(<@@4?TA
MS3Y+Q2`BV!.X,;-@,L!GWF!!$2QDP,[B`>'=8#JVP'$K.PK.!HC)1R!/CGO]
M.G0L?9^[N%)+W]M`=EEE"T\^8'L%87$A2I^/K,5<#,0H',49,2$.VQ*ZJM/+
M]@"ZM676O(58^B?C9(=W\1U[(5#8MFN=J[62&O7T$Q_+XD2LERNI^@V'-3H9
MCH3H`(D8C^"LCX#\G)T1O0$L'O7&WC>G`Z),B.=P8UXSKT9NZTPXH$_804?=
M?G\"KW:&W<EP1`02AYCH+T9G4_IBVC^%+PX1"RX3*L,2%Y$4O*CW")U1=^B_
M_/+?Y;<1T/H!_<V_W6),((9LV50-H$/A)LKUX%,LJH+OT"_^7W,M$\6)@ZU4
MM>&T:`;SZ&0PLP`9GB%7[/Q_Y5W;;AM)>GZ5OM`$-$![V-T\.D``V=+,:F-;
M6LDSF\%<45)+)E8BM:1H6PM?Y4ERNT">(H^2)TE]_U^G[CIT-44CV.3")M7L
MKJ[#7__Y_VHX9"%4]*>C,=A)'R<Y"D(H21'%#S-QH=2;J*G['&23_G@X(N;>
M*_O#\9!$A5BS?C[-B=E/^L6`1:^X(9],]0T#L:M'$865ZP3L'<'.;#5FIS>>
MBE%X(!B2B=#M68G1A]M(5-9ZL,>H-EQN(6V6M4SIZ-`?[4>IHH."F]"RC"ZK
M5FY)F[AGSJJT#\S"W,Z&8LE@F&6ED"U3SC(I<TP]LDNR8@:M4WR="9,"R!C%
M`-BD8ZA&O-*"Y_9'8DO,(L7S*$+"#!`\H:M-*MB1%#-!9LT2=$F\5:R)QFF1
M$KHY20E*8=Z?C*&+G/C@7\9"1QQ*=;_'2E"*KE/TAX)Y.#,6\CV&)(DUP_["
M!@OKY=&RH[SZ#^<O7E9(&E)Y[H&C=_WOTFX-/E8*_GOC:4.2]7R]7C2[(MD1
M%5%*!!3R2K?%,>1RR_PC;%LZWNFO6T*WSK8`U/T;[Q+M`.&45M-<1.S5J80)
M_4_;%?;=F?;K';*OX[U,BN^Q/SU_40.`8-HXO83"101\LGS8FKN+^MV_+%>A
M.\L74LMXS;Z!2D>+P%O+/E04,%%P_.;?W$5JE"+[)I7G-1U)PX@FC9\$Y0]*
M"%:T8'^W(.2MNP5-"_V*99;]_;W@7[=PW5J59A32D/$4NXFA>H7Y9G5=5IW8
M#^`<6/H/M^+?447A&X8*4;E[0O8/61*J+V=W*OM`6J/*"K?Q180A*&6R_J)8
MGA!E)=LI]':Z,!B1Z,)M[\RV>.WODEBAG%04N5SFCZ!+QU0C;D@I&>I!\U^J
M;Z.\H"[56N9;TK2Y?P!RG^1C:_;LOW8F]7$IU27[NY_4IX(ZI_2[^=:!S/,9
M;!1ZE?X6)7,A7.E?E,@GA=P&^DLBD:N6]1=%2$*C$WHTS)\Q_2_^)L]#.HV/
M2!OG13+?DRB\R$="NU8CYK]TQ\@A4F^8[H@(2&+[2@S53_KD9">3`.A50_R/
MZT*A9AMV_94D_7HUX_<SQBPMXJWJ+/\9_H61)A[F3ZKF_2?X2<4FA8I(AC7[
MP@1K@8<LAU4EK*#)Z`?1SR4\0=P"*LG>DPTDTY,%RX7U,1H3#9?0^4<3/%V\
MFJ$RWWG:#!O^6-(VA7Y)-E#>'\X*N5^(8%^-"U\'G"8*[&FA<`VSF5!GS3X2
M/1LE]6%$6N"$^C`I2RG9\&_TJD@:QI";P"R(SR*7_,7>;N/^>#J@[36F`8.C
MC8<3$N*CJ3!LO>JBIN*KA%VU!P6[X8U7=52M^[D1!_;D'@C*5\=H?B0KY3TC
M<JB+'Z#"R6MUBJ?-03O!?#.3TQ=*[>UBN92P.C)T!O<NB^YBPK3-/$9\3L%=
M#J\5Q)[F0112(09FC`Q+.861T"-[X(4@BYGX/B;GIX92A/]V1+[6L?R4?Y/O
MZD6MRQ*5S'26Y#<Z61)!U/YV",.;UARR(IH2TRKP-3(H@7(LOSV1Q7U*N_WF
M0>;J1.V7@NY>PMN<K*5;W.UG*C?]9<G1>M'RSRA9="^_XTK*0YU\2GZIL)J@
M@@`@FD)K>P<P_7)R5>!R(=B`J7<#VYAF,`VE-W\R!B/R*Q:J?<'I:'T'4NW$
MWU`W[89G!1R7N-H;4,.X4'310]3;%(&K?_9;6!$GTAX0D1;DF&>>U5QAJVU8
M(),!B^F"?7$%[0;UPS2J\O1K-8-:R^;V>B7M,>Q4T61GH?C]B:.<#"S%IS=0
M`Y]@/>W9'<\@3VEVF06,9U"XXL0!YPO+,$EVQ01BPVYW-.%5*W$+\2.2+#O0
M!OJFZ&+0(&UHK[FB#0R1+R301M'/R3X\R#CX(&A#KJCXH>A(&ZR<L@=1S_4H
MZH\RR0-2/::L7%FM(C%A#(20*BC7P2#IG"`<3-8)ZP9*QW!W/9VA2X]T>8.J
M(M-AX5I,+-1/#6)NPZ&EA+ABD1GKX/N'.7)$(:2D5UXL#B`NEP28@P+"]<8N
M;;+*C;)\"M.H'(R(;I?5DZ0HF>57"D*!V.8(X\4G0=DOJ6"@26S#">R#$@)9
M*5K&-T*&8X1.[`IQLQ:O/5*J153ZLAD:=0^4?"8UJLCF:1.72-WS=#L:9MM;
M],?BL@VVF7+/T99]Z:J6?K5FDB<?[*CD^!Y](R5Y.*`K^)S2LUQ[KQ]7YQ_>
MP"KE:$;>GQ8#TN+Q68K/4EBX$_H4FKS5BOU0,<&MXG^APQ>DP1>(`#$Y14FA
M)@:5W+/9G^1W3KH1'RTB-WB8&OS@/O5G-0>A["^%TAZA,%-GR47&4AP2ZH.-
MW1DAJ#WJ\<VI\`P'TXB<#?)4%.P.*/OEF&.!>7\V%,9F=EX?B!(]+*/92099
MJ6^3HR3A-""9HK6\7B'#C:QY-5?!<H:DZ-]B7JK%K4K4N'K2%I?QI,AR^S7A
MB%4R@K2BY+CJ^I;2[2K!W"WD"!]E+-7)BMIFO/D>KXZE\'Q076`8DDR-_:WL
M0$RP`)"'UC,7AE7.WR:4!S%?SJ]Q@M(U8+V$Q3T1ZTA!RC>@%<JC0\;\!@BC
MH.D<*UK"^/KC7(@]9'4_54*J8IN/18.'J)+G0YEDDR"J?*9E2,*\4?=FG,0B
MV,N@B`H:4Q/.#BE%0$C*1L21(_X;FG/&(#1TI8Z124<AW"4=3W<N8>Q)?>Z(
MG!A@*L<>N$ZD#Y!._V./=?@78E=;<I,XR>'IVQ,FY5.-[W8B84-,_?X9)V"^
M"+2IJE6I'=RB6CA95FX;[U:RE,5P-\\EA3]`R0QL/LUT0F$=UH1^'#`?(@>"
MA\/^7YX@J(!D6DZ(,0<GB44"9[JUN8B-:M;$4[9VY0X;*-9XE^0RI2*NMH^4
M-(T7VOS"0'XP)$;K7@R$Q(5.C3I=/?^VVA92%_\@6S^Q6^>:-[N+O$YU0"`V
M#_):45W#2N6`PM@Z1,YN]#"<_W8`B:"2<E$7Q):"';L^R)#+PW<8\=VE]_!I
M[]`S:)V[S;^KE3]O^L<SRF:*3G^N6=&NDU3N-DF.[_N,\-=0L8\H%SL743_)
M"5?Q7X-)_O(I`/@OC;^2'VHD7"-A6:[,[]1<]K'Z^IB]$5?_XIQ,XI8%="@$
M>+-=W/$A@P@#"#I^3R=/T=%.M1X6L''?X5IA\K"<//%<F+Z.O7',/I;0Q("1
M+W'LCN:%"@`R$2DYA5^NY4O$VG=L/>M]>'OR8J]6AV@P%#9@UQZ+YA%)7_+J
MM:)(4Y,RCQ.Y_B,T(7.&*-,<*:KUD(XN_W23;6HE#A#<MQ+)3[Q&.^U@KR#Z
M=J3P*"62,>[IC0=DUI`?47[OS4B.$L2-/&S=+BK2.U(ZG&L^8XRN&;3HC2A1
M$K-5-/YT2W),+B@S#V06KZM/@ANP(<5S^X[FMMO=P?0I6<73S*Q59UC8+=;6
M=@?Q;^6E=7I5C60NGTP2=9--./YLK8;A&"MCW1\J?P6E!%S`7Q%]E)(O?D)2
M&,1+!0\Y/'`5'_2P)5%TMA+T53VJBO0W#']-O'=3HR:[Z"&Y*D.ZL.&M8V=Q
MF<O$T-YL)MV]O=&,-.#3MOD4FQH&#+B-U'>O5.4@QR<HZQ1696_,\9H<899#
M?4Q14TWNM)H9XKZ]/)_2KE=[1UR8T`4P$24S%=YC:Y,]+K%`#08VK]WUWHR+
M/5)2$GMJ4FEVX>.8*+='/F;S`E]'$UJ,_P^T5TI]$W-1RBSRGJ`&GJ:<0_68
MILGS"`_.\1$Y%Q&OF<CES+G::U^$U^.0\\1*GZ"`XDX4-R)*&Z,:J=[G05*U
MSY!D)HANR%[07CXE>CT@RI4[ND2IBT\5J4U?1DFIJ?Q[!\8]?^8"N&6$-)7Z
MZ!:CX:NE]ICB:>(N6?_Q:3QR]]V9W6>[A&L;EYS<06-;AKEM=VEN]DRN.DOR
M3&Y6\_A`9EA`I>J5])C;,0ICW8`M?&*V<*X<C^0Q@;^$/0-QOT`S[!WMF`PL
MRC'U!ESFQA=5355C8]=$-RI#I3=G0IZ+"<LR;$*'R(_GZR5I_!9&3$"'P5%7
M5UQPLKC;TA$I]L.$S[++,PSTJ,!KOIMW_X,P4^D4AM>V!MU4G>7Q=W0*VD$V
M&S-71AT*IR5.<ID#V!]0#>-1A4,_EMSNGRM$&S$$"2%A3F%$&0X('0/>U#PJ
M10EMH"C']#\<$_@^ELB>Y`W"U-$IIE:"Z<6C,/^RU8/!8ZSN'^Y63Q70P_"3
M,<>0FSF@\+GY]W%Q7[V$`4[.=.CL5^P.Q:/;)6HQ07'8)-#`\<F!\L8MN;R-
M_QVIGAH,SOK`!Y1I,J5-A\\+ODP'6U#XF*F`/$UA@L&4C<7_4!LP91/Z[ACN
MU/A+KK<QF5$A#9UN9HCJ6M*JW)<II9][<(!ONG1C/W[MW;;3>;@P/9>A1PY\
MCZ?D.)T@7^."`4OZZF@W63AH#EX7I)-#/Z%%G5&4A%+E",@-K(]J+D>HE,S'
M\+3ELY+",@3+0[I=<`89WJ17<"URP6KKE'7,":DLG6A`GKZM<%RT-ZE`?T?8
MP3F5P>;3<5T4R?A&;\ROIC#0"TKA(\-X-*+KG?JR3&5HN:PS9XTREQE^>>FI
M?+:\U:U$.6^@0.)@9>4]]C_,,.)T'NV^=TCWSJR6NC-[W2,>CGE`>C'^QSJ4
MB!N7E.76SH]+,$_*0YM!2DS'1/A"/P%@^AU*5ZVC)OB1'INJ.5R_M*]&8+QG
M[GV\*9#YED.#RD&+QS%Y4I#V0[</,E+&_X&VZ`%OT@/>I@=RHQ[P5HWL`^DL
M%(0B(7>4R!4*V.I&:&,*YYG!87'@$Y\OP^=[L.TC9Q-&XP[)6_ONPNL6K=U#
MPOD4*>Z0O&/Z#-*@E/F"@]-]^;2@3Y?\IC/Z832ACY2M,"OIUF%)C[A5[<0*
M/\Z_1B!'&I[FR^KQ"^#M,!5T,,]-=4TB"I)TRS!B@GGS:5U+^]`!==GQ,VH_
M\XZOH/5V7A-)>7B657:A.T%O*>%P_L'_018E.H35!6N1FB(^>=*Y"IF"]UI_
MZ^42NF/&^SJ7!@X#>+R5""`*$\T<A09S3%99\CSV\H9E-.,/,`V%GN0K?,Y)
MF9W(+N>"MNW3T@R2<Z_@]CD91WWD!B2'T"'G!(>Q$%K61JK)0ZG6JBI==KB1
MW2;S8S'N8W=%"U1@_,`*$WV,\0$7]@_.J5/2)H\?TBK,$L+(2X/2B!QD$BT>
MVJ.D/&F<RZ("Z27S9T[#@RM3WZCX?2\?,1E(;V$QE8O'BPB37CF35C7\3K:9
M00>]4M$3.6&1_:>2A:JOLO#^MN8:D"A)0R9D"9633_G3<@_+^R0%#55'<_X8
M:X,^=I0,N4*E6[I'U8?T;:A]'_G$Y[V*1#EE0'#3&@^LY=HJUUT-)ZR]&`=0
M1US658PA=*4#Y:4YXN>2#F*SD6.TYE&3\!B`/NZRR+%9A!P0<WZ^>IK?Z40]
M1IL@X#T@.N<CH%OE$Z1]:P`L=:#("+I%3B5^O+%&0[Q_-)CH$L`(V`TE_$G4
MEKP_A1_(OUW]B0!R&;JM0MJ4EX.<_16#@:W(Q:83,X';)W(F2G*8%E1D9!-I
M,*EAS)G78Z%BQG0HNR;7`DD\4R=4=[BUQUS.8\M7#Z]TP$&>I.E!OE$<QQPO
M_"1VN,Y\OQ4\>FD=G.N\)L?L#AP6_4$[?1A$D=4X[H6C\IU9AX$%CRK#08)$
MT,Y1@LWF:L?2.=57PLR^W]XSVCV#A#CO\C3H;6K^M7-3@5[50!$;$(EJ@;.7
MV2\71UGO``Q/+-A[N3F<%:FEHCG9K]7E*V&=,%DXGDJ%\6GU(/L=QQED)Y#Q
M3J9%:"MZ[OM<K6_I_,TSH1'?SZ^J+4%8.]V/`C'ZD<GJ21<=T"?EU**HOC&Y
M'S^MMAO!'=R3P3!_"L#0W4_MX$2&=;:BY`1@#=W\9Q^DH;<QDJ8[3!"2;;;S
MNV0:_.-V:9B/L]VU7U1B[MPC"^41A03J`$&/,<-@,!*CI(;[;8H]0L(XUEP(
M#$?A'7K-FL+'\R)$GGW+SN=?YX]TTI/3&OP';G/G&D2(C'<Z%I$@B:OL[8=?
M<Z$Q3@=.7D>\#Q]PWO'#_!%'@#XPE/NU"I_LB&6IN5.4'FK"2%)0&_RE/CF&
M49<U^%,_B(:I4OD"N0W.7.T`,>ETNAU6,B#M.L!([M9"I`OUB7+S$T)[P676
M?BA0EY8(&?1Y).;ATD%RLS+]64)(?<$<X>?'LDQ&L*S!.KKCBB-+!BW1.+!D
M!"TRI",$Q9@?1])3XE0#?FS^V,!]]-3%6]"/_CD,0EB:T;GC["R/=!/][%=Y
M[O>9=';WN1*Y*]ADYQD/X/3ULUO?ZT-8C9TQ,=5$_7YXN:&MZNAP]JLL6$M9
MCV4!DX<DY;&"R/-!Z$DR5@@"`62\G9MT8;53GW1B/<E/NNF\J4\Z-=*I3Q:.
M>Y?(R='Q/"">[L[?.!K@!U<I].*!?LND^>2,PQR6O;@1/>Z)G4"2Q[472[](
M"KV/;2Q'_PJTX@,<3;DG/#)!M,EO"O<W</?AKZ<?CO_-JX^G08<^X]'PD`-S
MV[%M_T0HH-,=+"?W$0W$>K?X['5V;S?5S?:.:#+R=``CUK=QJ$^>W7)B^"8.
MB#D[_Z?Y_<,_'SE=VL5@_.;%Y@V(%P>6V+G/`VR;$;)M>(:Z&1D[+.7'WRX.
MWYR?:#7M6Q?XW!TE=Q>C7S\<\X7$\MF"!FA$K*J7>@LCPC?7B@*<B3Y^^]/)
MT?'YH9CBG[;W\P>L7G;XLZ.YA9!1NSJC;$>`8X`)"^V5SOYUV`VC$;I.M]3B
M?#.&?FT0.$48UI683Z_O*0(L8I5KN6-Q$?D<NRT%(+#YD(W[E^I^BV&0)4R+
M((X@[,YNS7D1=G9K*AU4I]E^"\)F7X*DY=@;W6EGOZUW68*]OSEIM?;^UMT7
MMAL@ZDZK^QU>T66)O\_KD];Y^[QZ/XL=Q[-]]D+OH?E=%WD_K^Z\P/MY[>Z+
MVZ9W=/`!\D'=NC0[JKK5X%C[#<Q9;\,UZ-DPTCLW?.;BO+;T(-QB"`76YY<(
M8;[Z_`DA<%?`N3;O#>&X`KFU>6\(L!40K9U7OTA7V7VAS+Z=.O"VIC#%J$-#
MDSKJEP^7-.2L]PXV#)@:NSVJXK=.8E??*:,-M%N6UFSXC@EPG>3-RC*%#+W9
M;,GU3HFPP:!-MQ0<-R!ET:.J;/>&^GC#^;:6<Y'WD&^W.!>Q+9R+)H)"Y@'.
M?)R;E(\'P5VO%@]@#Q6?UJQ.=?P6Q(;V<84`6FU7R\XRQ(X4W*S$-;A(X.^.
M`>M%"6V]BZM7G8FL`=VY5E,+I&CZ`Q8\IVN11T!%TVZ.M-X=6O09+<3Z$0$.
M[49XNX7W_#B>*XJSUT`D]PPQVD3==-S9:;";[J(TD3>=L0>A-SM.MRM+$Z;;
MCO>^MP`Z#VNHC%1I'F8"`=S)OA>U,_GA.K*G[[%6O,J^%S9SQZ;B/,B'?)D^
M`>Z3\=$G0&?V(R-.>CP^WA9B+-,5NW:`2E?3L)$H@[_>>45)2\>5,N7$.8IH
M%MZIGT%=-;%\:4S).][F;__U'[X\PT2VU%<9GR:#PI]Z-O"I0<6KW*/;R&I@
MC8];!T6U*8ECPLZ,EJ$?1H$?_$N7MJ!=V".*-H4"?Y5%W,/F)I-]3SKLS4HT
M&G$F/TM'"R*CMF<%O%M]P3GKE',%S7PK#_=.@Z1TUHB7J'GY#X(4]_@6J(P_
M0B.DTIL:M%/WQG1HGJNZ.$%Y<<^0#/HI'%D;(#^JNL#-CVNRPV1-$1#+K#8=
M1X`0_/4ZBW!UBIV<T7V`1RU(A<X.OA7\X19#T,"VG*+G\66TPB`ZC,D'8/<M
MZ]I'2U4Y"H*Z>G#[(AN'^F)[9+PYM%$@O^[CB!2N=&_,&HS.#FX=4*QHHWL7
MG%(B195[;BM`1KM09.PUT>79Y64GM@<BVWR9/^PP,=Y&]DR8"@SVFUL=IN8G
M@:-QRF`M(_-&ELQ9W!8*4;5^!!LU%:`-,)K8.6(!')IG=UT7<XH.)H")PP^C
MX;L7!H=WZ<F8),SM[JLB']OG+M,@WT>,R+V/%O;9/P4U?D90XQ<*:GR/#>VS
MMQKW_+=J^?S']]DS"WM]YY7VM;'7/EH9J@KW6H%-DA5H-2C8R)^$:KNXH0!.
M$]'N^[5,K-;FO]#S?,;K[C"ZEO9_O-C,%W'=/]Y8+-ZA46T^KL62W@KK[$P8
M:D)AN&(<864PNB$71LYU?80V@*[N@V-QB%^_QWQU#WA81'%=/:RKJX4W,X<6
MP?&50%DB7Z-GAO*!/_M1/307'8<WTONP!`_A'ZW8AJL&P$U075/TZ\3Z[C$?
MHV$1'7`(Z/GGU75USQ$(4R"J#T&WFTI[D@PK?<2[A!XVU3GJX(76UO.!MY[J
MJ#VXI"HZ-]SZ=DEN":Z57MU]IEHL*KG1F\%9I/K/5!OJQ'Z"&=`:#ZWQENQR
MM5Y37;2[S<W\/<PM@S<V0;/9J\FL<"9(7/9?G8R'OLO%S+VLD*T[ET=TP;Q^
MF01Z'<*4]BEYG:"DO4&MYX)(.]3:P)`.@'$[G*0%2]H[2=%X<F-%@]Q4KVQ?
M8=Y$6.R'^FBTY(S7&C.('D'@R%<8[V6PWPF^+GGK0B7E7C,8"IB-?T[LJC^Q
M-G.9($!NVX4$\2-FW0_#/#$8$[R]&Z*;C8UEZ*/1=-S8.T]!46WVY+D8V\=/
M*T8T`>LU<YDR\];#IJ8GV@J*3Q?W]UNW_O6[@I%WYD2':4"_T8R172''`VZQ
MT"('08Z=#CT7UMA'4DWEV0K+&Z^#K5+'&CA"K8'XK`-*FXT6>]8/._V_065=
MB@J<!!@K_4.B+"=V(J[,^P&<TYI^]I*C\/V[]N!9%MM^N^:#$?9P'R,=+9$9
M)Q4#VQM17L*@E\V'=H'H=08;1>9UM9DX)JYCA^P"B>O&W+J@`_N?)J@]1\EJ
M!>=S#8LF@J!WQ`Y.;]>`GXT,^=;6-H[]`+[=8'L5NF7`,DV`M8SUMP.2Y:8&
M9>D:P`V8V:YO==:;7MR&N1J3X]'5W2WSB5&@.T#`7B_$9"C`"R_H;`N(I<?T
MK&-8.CRBRW:+SA!%XP.LPCI5QM:A)3QHM_=8QHW_;7I(S!Y.ORRK]>;3XH'T
ME:QW?'%Z]H*@+(3"M`4+B\GF*+CLO?)%>/N1SV:C[/CB["S`.>'G$"-DV%/?
M?>1%\?U0QPT-HHO5@#*;OP(BTW7`6(B9SG!\Z;"#5R/W8A!:LWDC(6T.?G!Z
M#N1-WV4@<?JN3Y'BXH)')B-UND/U9,<,7HU]%Z?NQ0BVI_LFS_S1I+CBR0L"
MZLQ%X9\B0D/RS*AWYL[JL*%N_X:^3GO(J4=$X[0_P/(Z]PZ\B^["D#K;9.AK
M#B"EWJN>502$J7O5N\LZ>ZI/KQYU`:V#-RAT#OVC!ZE,O=_41%P]M17)X$@[
MN*D1"MWH&*W.CH:8^;2ZX],P1<OF;$PAD2QTRI#S"LJL*ITF/#T<V_D9:"UW
M3X*5K<WYI@\KKNCP<(?L-V1D%H.!`_"!<,%J0TY]A<]SO=C,%=(0COM"KZ5G
MPWO>M]6\DU=O_^@`?72$K-W%:4$9"<=V1L*IS^,7P!X-RJ8@7J;3<`2!U/7%
MUT%(_1I7.A023Z\^+E=CQ_J@&NHHN\&?`[I@`TM7'_#>!-5UG,0)8+K-9ZS2
M[SZ2\`,Y^'JIU)+:/N=E\+%60-/GT7#BW2[O:WJ3__O?_S,56FX8"&O54`B"
MH2\+HN[XE_.L)U[L.[.4TE;,J:JI[/-$S+83+I+'LDL@L6N9!;/8($WVD;*)
M1"=<$C4I/6)B`&@EZS4EZ1Z+'CW6P&&3^4B@L9:A&==/2W\2G/'UQBX7*PLQ
M![QHOES046'S1X+EOJY`M@L92+F$)5*S:S^KWN@BKTKVQF6,RHUMG!0V#HN+
M4DG\:*W9'AFY.H&;.0,KX(@D:'#;*Z1(7*YDC9I.NG:=[OJVSY5AY]EYQ9Y.
M6!V;+.VNE_9]45#9"&"<_:+#->7LFEF@$J'0+>R@G5_QNV.4]%[(E>WE0O1:
MJ";+^:7"E]%%U!Z9?_CSQ[?-:[\\W*Q7OC4+J=.V[PO&F+OO*PKM)"/:$',U
M0A"W^P1A\`0A,`0@*W@Z<K\09B$,?16V4AO&86E?A)$B3/K3]0.*`MXL5I\7
M2+%Q9M#$KUHG[%TUO]8.!*1">F:?H!P_(^&CY<;]TK@,X[VOA/YV74M\;*"4
MUH3+WW'E34"X,%KRC(1"$1`<-3T[Y9Y_/?\SA,O?G;MJ>#@I8BJII9#`J]T3
M;*DV`\&[;"=,>!E:XA1*N??%FLXU<*?.>.?2XJL&ER90*R,Q'L%Y;N`A#NRG
M"T&=6[%!Q>;8+`3U"_W]4+'D[/?WA(OJA;W6P7F*.JAF1+]D;_I"ABNKFJE6
MEO5=FC<]Q*&P?_7+KJ=^]E>$-1YY0PB50?R)'_COQ9*\<ESPOM(.*I-HTWS-
MU.NM<<<H`PI['>)9+7%H\SC_"R7_\#BS^Q`FGZ_#N==+8/&V*WM$]\`]$T.Q
MUK]Z6'3MGQ_D;CCSE47I@A+!%&'AL@.77+,MG1AY1_9.C.M6'@83<M-1,8S1
M4!<M#LGS:G%_N5UOF/KOQ!(^<F#@6@%O"RI<W6U]8K@8!NI@D#VPL#+037<:
M&JH-2)9>X:29V,#!`K75?@=?3$.AN;R:':]!6`$Y%=AE#%I0YS[S!Z2LV;+4
M%2N`+;_D(3G3Q9%'"JB1"GF']IT6\'N@A8O%U]!/QS@&SDI7@:"7MV;;!^*J
M7\0XGD+/GRZ#;^4#<$*#"M(`5:A'?[7#)!<_K5/1YD9O__!3UA,/N,)*[+F_
M5>L[3[[I.VT':\70="ZZ=2ZVEQNAD.&VX\\T$O>*3>S-7Q,<?45<QW!:C'47
MR,V"@*^PHY4S+"PA0JBOBJ-1$'2K_,<!?!!]-Y5PA)#^'=S0'S>;QW_Y'U!+
M`0(4`Q0````(`%>"54<=SB.R60(``.@R```3``````````````"``0````!;
M0V]N=&5N=%]4>7!E<UTN>&UL4$L!`A0#%`````@`5X)51TAU!>[%````*P(`
M``L``````````````(`!B@(``%]R96QS+RYR96QS4$L!`A0#%`````@`5X)5
M1PA=9UBD`@``\C,``!H``````````````(`!>`,``'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L!`A0#%`````@`5X)51X\KD)?_`P``"!0``!``````
M`````````(`!5`8``&1O8U!R;W!S+V%P<"YX;6Q02P$"%`,4````"`!7@E5'
M4SJPUCX!``!I`P``$0``````````````@`&!"@``9&]C4')O<',O8V]R92YX
M;6Q02P$"%`,4````"`!7@E5'F5R<(Q`&``"<)P``$P``````````````@`'N
M"P``>&PO=&AE;64O=&AE;64Q+GAM;%!+`0(4`Q0````(`%>"54=09#B[K@(`
M`'L0```-``````````````"``2\2``!X;"]S='EL97,N>&UL4$L!`A0#%```
M``@`5X)51V6#Q</I!0``X1H```\``````````````(`!"!4``'AL+W=O<FMB
M;V]K+GAM;%!+`0(4`Q0````(`%>"54<H3D]U/P(``(X'```8````````````
M``"``1X;``!X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"%`,4````"`!7
M@E5'"!#"#6`%``")&0``&```````````````@`&3'0``>&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L!`A0#%`````@`5X)51V%CT[%"`P``F@P``!@`````
M`````````(`!*2,``'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+`0(4`Q0`
M```(`%>"54?Y:<HE%`(``#X&```8``````````````"``:$F``!X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q02P$"%`,4````"`!7@E5'HZ5Y5J($``!R%@``
M&```````````````@`'K*```>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!
M`A0#%`````@`5X)51WJ&!5BS`0``1`0``!@``````````````(`!PRT``'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;%!+`0(4`Q0````(`%>"54>`H6-_@@0`
M`,\4```8``````````````"``:PO``!X;"]W;W)K<VAE971S+W-H965T-RYX
M;6Q02P$"%`,4````"`!7@E5'LM"4T*4!``"Q`P``&```````````````@`%D
M-```>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!`A0#%`````@`5X)51XZ8
MVD&C`0``L0,``!@``````````````(`!/S8``'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+`0(4`Q0````(`%>"54<L;64,I`$``+$#```9````````````
M``"``1@X``!X;"]W;W)K<VAE971S+W-H965T,3`N>&UL4$L!`A0#%`````@`
M5X)51X82C;>B`0``KP,``!D``````````````(`!\SD``'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"%`,4````"`!7@E5'&4K7(J(!``"Q`P``&0``
M````````````@`',.P``>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+`0(4
M`Q0````(`%>"54>P5V+,H0$``+$#```9``````````````"``:4]``!X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L!`A0#%`````@`5X)51R$O9!:B`0``
ML0,``!D``````````````(`!?3\``'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6Q02P$"%`,4````"`!7@E5'OLU[,J(!``"Q`P``&0``````````````@`%6
M00``>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+`0(4`Q0````(`%>"54?4
M;U]PI`$``+$#```9``````````````"``2]#``!X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L!`A0#%`````@`5X)51T@(KDVD`0``L0,``!D`````````
M`````(`!"D4``'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"%`,4````
M"`!7@E5'NV:<K:(!``"Q`P``&0``````````````@`'E1@``>&PO=V]R:W-H
M965T<R]S:&5E=#$X+GAM;%!+`0(4`Q0````(`%>"54<7#TQ9H@$``+$#```9
M``````````````"``;Y(``!X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L!
M`A0#%`````@`5X)51UOG9SN?`0``L0,``!D``````````````(`!ETH``'AL
M+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"%`,4````"`!7@E5';8V]IZ,!
M``"Q`P``&0``````````````@`%M3```>&PO=V]R:W-H965T<R]S:&5E=#(Q
M+GAM;%!+`0(4`Q0````(`%>"54=%YRJ/H0$``+$#```9``````````````"`
M`4=.``!X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L!`A0#%`````@`5X)5
M1S\8I6Z=`0``L0,``!D``````````````(`!'U```'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6Q02P$"%`,4````"`!7@E5'Y^]KU:,!``"Q`P``&0``````
M````````@`'S40``>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+`0(4`Q0`
M```(`%>"54<MUCM&GP$``+$#```9``````````````"``<U3``!X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L!`A0#%`````@`5X)51XELUOVB`0``L0,`
M`!D``````````````(`!HU4``'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"%`,4````"`!7@E5'>0K3RJ4!``"Q`P``&0``````````````@`%\5P``
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+`0(4`Q0````(`%>"54<)$M:D
MI`$``+$#```9``````````````"``5A9``!X;"]W;W)K<VAE971S+W-H965T
M,C@N>&UL4$L!`A0#%`````@`5X)51R*DW/?H`0``J@4``!D`````````````
M`(`!,UL``'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"%`,4````"`!7
M@E5'Z[DAG+`!```6!```&0``````````````@`%270``>&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;%!+`0(4`Q0````(`%>"54=R/8]IKP$``!8$```9````
M``````````"``3E?``!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L!`A0#
M%`````@`5X)51PCR[62D`0``L0,``!D``````````````(`!'V$``'AL+W=O
M<FMS:&5E=',O<VAE970S,BYX;6Q02P$"%`,4````"`!7@E5'0![7&,$!``![
M!```&0``````````````@`'Z8@``>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM
M;%!+`0(4`Q0````(`%>"54<?VI:-P@$``'L$```9``````````````"``?)D
M``!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L!`A0#%`````@`5X)51]:>
M1/3,`0``X`0``!D``````````````(`!ZV8``'AL+W=O<FMS:&5E=',O<VAE
M970S-2YX;6Q02P$"%`,4````"`!7@E5'H1"L3+X!``![!```&0``````````
M````@`'N:```>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+`0(4`Q0````(
M`%>"54=7,_AHI0$``+$#```9``````````````"``>-J``!X;"]W;W)K<VAE
M971S+W-H965T,S<N>&UL4$L!`A0#%`````@`5X)51W($S.6D`0``L0,``!D`
M`````````````(`!OVP``'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"
M%`,4````"`!7@E5'QM84EK`!```6!```&0``````````````@`&:;@``>&PO
M=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+`0(4`Q0````(`%>"54?+EQLPI0$`
M`+$#```9``````````````"``8%P``!X;"]W;W)K<VAE971S+W-H965T-#`N
M>&UL4$L!`A0#%`````@`5X)51R4\D0:_`0``>P0``!D``````````````(`!
M77(``'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"%`,4````"`!7@E5'
M.2L.OJ(!``"Q`P``&0``````````````@`%3=```>&PO=V]R:W-H965T<R]S
M:&5E=#0R+GAM;%!+`0(4`Q0````(`%>"54?O7*E8PP$``'@$```9````````
M``````"``2QV``!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L!`A0#%```
M``@`5X)51Y'I_\?B`0``104``!D``````````````(`!)G@``'AL+W=O<FMS
M:&5E=',O<VAE970T-"YX;6Q02P$"%`,4````"`!7@E5';]O0.$("``";!P``
M&0``````````````@`$_>@``>&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+
M`0(4`Q0````(`%>"54>]\]^['P(````'```9``````````````"``;A\``!X
M;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L!`A0#%`````@`5X)51]N[_[T+
M`P``8`T``!D``````````````(`!#G\``'AL+W=O<FMS:&5E=',O<VAE970T
M-RYX;6Q02P$"%`,4````"`!7@E5'%!J/&B4#``#.#@``&0``````````````
M@`%0@@``>&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+`0(4`Q0````(`%>"
M54?'&!/2[@$``-0%```9``````````````"``:R%``!X;"]W;W)K<VAE971S
M+W-H965T-#DN>&UL4$L!`A0#%`````@`5X)51^K"<@;K`0``8@4``!D`````
M`````````(`!T8<``'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"%`,4
M````"`!7@E5'HN+;3Y\!``"R`P``&0``````````````@`'SB0``>&PO=V]R
M:W-H965T<R]S:&5E=#4Q+GAM;%!+`0(4`Q0````(`%>"54=X_O\H"P8``/DD
M```9``````````````"``<F+``!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL
M4$L!`A0#%`````@`5X)51]-\IO^(`@``VP@``!D``````````````(`!"Y(`
M`'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"%`,4````"`!7@E5'[&`Q
MH.$%``!H)P``&0``````````````@`'*E```>&PO=V]R:W-H965T<R]S:&5E
M=#4T+GAM;%!+`0(4`Q0````(`%>"54</_'9+!P,``!$.```9````````````
M``"``>*:``!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L!`A0#%`````@`
M5X)51[U&$]V2`@``8`D``!D``````````````(`!()X``'AL+W=O<FMS:&5E
M=',O<VAE970U-BYX;6Q02P$"%`,4````"`!7@E5'+EC+T+4#```N$@``&0``
M````````````@`'IH```>&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+`0(4
M`Q0````(`%>"54>LRE0V500``+H8```9``````````````"``=6D``!X;"]W
M;W)K<VAE971S+W-H965T-3@N>&UL4$L!`A0#%`````@`5X)51U!>W\T_`@``
M!@@``!D``````````````(`!8:D``'AL+W=O<FMS:&5E=',O<VAE970U.2YX
M;6Q02P$"%`,4````"`!7@E5'C6:Q=48"``"J!P``&0``````````````@`'7
MJP``>&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+`0(4`Q0````(`%>"54='
M#-$Q1`(``"$'```9``````````````"``52N``!X;"]W;W)K<VAE971S+W-H
M965T-C$N>&UL4$L!`A0#%`````@`5X)51_RYD)G@`0``.P4``!D`````````
M`````(`!S[```'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"%`,4````
M"`!7@E5'8TEY:ZT!```!!```&0``````````````@`'FL@``>&PO=V]R:W-H
M965T<R]S:&5E=#8S+GAM;%!+`0(4`Q0````(`%>"54=O:;]D5`8``(@G```9
M``````````````"``<JT``!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L!
M`A0#%`````@`5X)51[E/8C@*`@``?08``!D``````````````(`!5;L``'AL
M+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"%`,4````"`!7@E5'(]\.Y14"
M``!1!@``&0``````````````@`&6O0``>&PO=V]R:W-H965T<R]S:&5E=#8V
M+GAM;%!+`0(4`Q0````(`%>"54<#S>%O=P,``+(2```9``````````````"`
M`>*_``!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L!`A0#%`````@`5X)5
M1[1Z.SF5`@``C@D``!D``````````````(`!D,,``'AL+W=O<FMS:&5E=',O
M<VAE970V."YX;6Q02P$"%`,4````"`!7@E5':##$^2,#``"4#```&0``````
M````````@`%<Q@``>&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+`0(4`Q0`
M```(`%>"54=0C%U^)@0``/45```9``````````````"``;;)``!X;"]W;W)K
M<VAE971S+W-H965T-S`N>&UL4$L!`A0#%`````@`5X)51]Y!%ZE@`P``MPX`
M`!D``````````````(`!$\X``'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q0
M2P$"%`,4````"`!7@E5'S[)"7O<"``"=#```&0``````````````@`&JT0``
M>&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+`0(4`Q0````(`%>"54?:I[ND
M$0,``#D,```9``````````````"``=C4``!X;"]W;W)K<VAE971S+W-H965T
M-S,N>&UL4$L!`A0#%`````@`5X)51_>/4G$_`P``*`X``!D`````````````
M`(`!(-@``'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q02P$"%`,4````"`!7
M@E5'[ED=#CX"``#(!P``&0``````````````@`&6VP``>&PO=V]R:W-H965T
M<R]S:&5E=#<U+GAM;%!+`0(4`Q0````(`%>"54<DAM#A!0(``!X&```9````
M``````````"``0O>``!X;"]W;W)K<VAE971S+W-H965T-S8N>&UL4$L!`A0#
M%`````@`5X)51WAHHW+"`@``!0P``!D``````````````(`!1^```'AL+W=O
M<FMS:&5E=',O<VAE970W-RYX;6Q02P$"%`,4````"`!7@E5'6IA9_#4"``"%
M!P``&0``````````````@`%`XP``>&PO=V]R:W-H965T<R]S:&5E=#<X+GAM
M;%!+`0(4`Q0````(`%>"54<7K>`I_@,``-P3```9``````````````"``:SE
M``!X;"]W;W)K<VAE971S+W-H965T-SDN>&UL4$L!`A0#%`````@`5X)51[:M
M]Y)(`@``=P<``!D``````````````(`!X>D``'AL+W=O<FMS:&5E=',O<VAE
M970X,"YX;6Q02P$"%`,4````"`!7@E5'VGQEP[@"```,"@``&0``````````
M````@`%@[```>&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+`0(4`Q0````(
M`%>"54?6D4I).@,``,4.```9``````````````"``4_O``!X;"]W;W)K<VAE
M971S+W-H965T.#(N>&UL4$L!`A0#%`````@`5X)51Y03@%WA`P``]Q$``!D`
M`````````````(`!P/(``'AL+W=O<FMS:&5E=',O<VAE970X,RYX;6Q02P$"
M%`,4````"`!7@E5'%G1AA+$!``#U`P``&0``````````````@`'8]@``>&PO
M=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+`0(4`Q0````(`%>"54<'"9]DL@(`
M`,T+```9``````````````"``<#X``!X;"]W;W)K<VAE971S+W-H965T.#4N
M>&UL4$L!`A0#%`````@`5X)51_4W64N9`0``B0,``!D``````````````(`!
MJ?L``'AL+W=O<FMS:&5E=',O<VAE970X-BYX;6Q02P$"%`,4````"`!7@E5'
MC=I.G^8!``#6!0``&0``````````````@`%Y_0``>&PO=V]R:W-H965T<R]S
M:&5E=#@W+GAM;%!+`0(4`Q0````(`%>"54<N@$-D#)(``*9-`@`4````````
M``````"``9;_``!X;"]S:&%R9613=')I;F=S+GAM;%!+!08`````8`!@`%(:
(``#4D0$`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129117889232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated other comprehensive income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax</a></td>
<td class="num">$ (157,416)<span></span>
</td>
<td class="num">$ (38,000)<span></span>
</td>
<td class="num">$ (157,416)<span></span>
</td>
<td class="num">$ (38,000)<span></span>
</td>
<td class="num">$ (59,488)<span></span>
</td>
<td class="num">$ (27,700)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income loss before reclassifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,700<span></span>
</td>
<td class="num">(11,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(117,700)<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income loss</a></td>
<td class="num">(56,391)<span></span>
</td>
<td class="num">(11,309)<span></span>
</td>
<td class="num">(97,928)<span></span>
</td>
<td class="num">(10,242)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Accumulated Net Unrealized Investment Gain (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated other comprehensive income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax</a></td>
<td class="num">(1,600)<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="num">(1,600)<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="num">(400)<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income loss before reclassifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,200)<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="num">(6,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,200)<span></span>
</td>
<td class="num">(5,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember', window );">Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated other comprehensive income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax</a></td>
<td class="nump">31,600<span></span>
</td>
<td class="nump">41,100<span></span>
</td>
<td class="nump">31,600<span></span>
</td>
<td class="nump">41,100<span></span>
</td>
<td class="nump">71,700<span></span>
</td>
<td class="num">(23,700)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income loss before reclassifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,600<span></span>
</td>
<td class="nump">57,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(118,700)<span></span>
</td>
<td class="nump">7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,100)<span></span>
</td>
<td class="nump">64,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Accumulated Defined Benefit Plans Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated other comprehensive income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax</a></td>
<td class="num">(27,000)<span></span>
</td>
<td class="num">(18,300)<span></span>
</td>
<td class="num">(27,000)<span></span>
</td>
<td class="num">(18,300)<span></span>
</td>
<td class="num">(31,600)<span></span>
</td>
<td class="num">(19,600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income loss before reclassifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Accumulated Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated other comprehensive income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax</a></td>
<td class="num">$ (160,500)<span></span>
</td>
<td class="num">$ (61,200)<span></span>
</td>
<td class="num">(160,500)<span></span>
</td>
<td class="num">(61,200)<span></span>
</td>
<td class="num">$ (99,200)<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income loss before reclassifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61,300)<span></span>
</td>
<td class="num">(71,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (61,300)<span></span>
</td>
<td class="num">$ (71,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e681-108580<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51821188&amp;loc=d3e1436-108581<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669619-108580<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1B<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669625-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51821188&amp;loc=d3e1436-108581<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51821188&amp;loc=d3e1436-108581<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129120070880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 6,514.3<span></span>
</td>
<td class="nump">$ 583.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt instruments, fair value</a></td>
<td class="nump">6,680.0<span></span>
</td>
<td class="nump">647.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_NotesPayableToFumedicaMember', window );">Notes Payable to Fumedica</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">9.5<span></span>
</td>
<td class="nump">12.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">9.1<span></span>
</td>
<td class="nump">11.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember', window );">6.875% Senior Notes due 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">614.0<span></span>
</td>
<td class="nump">634.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">566.9<span></span>
</td>
<td class="nump">571.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,514.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">1,492.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,008.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">991.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,767.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">1,733.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,766.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 1,721.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13476-108611<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.16)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.16)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 13, 16<br><br><br><br> -Article 9<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19, 20, 22<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_NotesPayableToFumedicaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_NotesPayableToFumedicaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129191724144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2011</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Notice of assessment of corporate withholding tax including penalties and interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Net benefit for a previously unrecognized position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2007Member', window );">Tax Year 2007</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices', window );">Proposed deduction disallowance by tax authorities</a></td>
<td class="nump">$ 130.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2008Member', window );">Tax Year 2008</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices', window );">Proposed deduction disallowance by tax authorities</a></td>
<td class="nump">130.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2009Member', window );">Tax Year 2009</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices', window );">Proposed deduction disallowance by tax authorities</a></td>
<td class="nump">$ 130.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proposed disallowance by tax authorities for payment for services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15A<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Unrecognized Tax Benefit<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6527854<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2007Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2007Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2008Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2008Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2009Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2009Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129194176816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions Acquisitions (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Feb. 12, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 2,408,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,760,249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember', window );">Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development and other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 424,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets', window );">Other, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 474,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 37<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744172&amp;loc=d3e2207-128464<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 37<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744172&amp;loc=d3e2207-128464<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129204760944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock', window );">Intangible assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26" rowspan="1"></td></tr><tr><td width="21%" rowspan="1" colspan="1"></td><td width="17%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">543.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(499.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">43.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">543.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(481.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-23&#160;years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,005.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,523.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">481.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,005.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,396.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">608.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">735.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">735.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">314.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">314.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks&#160;and&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">tradenames</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed&#160;rights&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and&#160;patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3-17 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,297.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(440.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,856.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,280.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(300.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,980.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,645.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3,464.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,181.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,207.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,178.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,028.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated future amortization for acquired intangible assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based upon this analysis, there was not a significant change in our expected rate of amortization for acquired intangible assets and the estimated future amortization is expected to be as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="87%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>September 30, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015 (remaining three months)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">94.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">348.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">318.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">291.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">275.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">269.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,596.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of roll forward of the changes in goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="87%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,760.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase to goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">649.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,408.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetsExcludingGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129189408560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration obligations</a></td>
<td class="nump">$ 479,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 479,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related rebates</a></td>
<td class="nump">610,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">610,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">483,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">214,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties and licensing fees</a></td>
<td class="nump">154,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">58,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">549,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">549,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">507,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total accrued expenses and other</a></td>
<td class="nump">1,918,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,918,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,819,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNetAbstract', window );"><strong>Other Income (Expense), Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">5,400<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="nump">$ 8,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(15,600)<span></span>
</td>
<td class="num">(7,400)<span></span>
</td>
<td class="num">(28,100)<span></span>
</td>
<td class="num">(22,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain (loss) on sales of investments, net</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="num">(3,100)<span></span>
</td>
<td class="num">(300)<span></span>
</td>
<td class="nump">13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains (losses), net</a></td>
<td class="num">(4,300)<span></span>
</td>
<td class="num">(4,800)<span></span>
</td>
<td class="num">(18,800)<span></span>
</td>
<td class="num">(9,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="num">(2,000)<span></span>
</td>
<td class="num">(4,600)<span></span>
</td>
<td class="num">(7,100)<span></span>
</td>
<td class="num">(7,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(15,413)<span></span>
</td>
<td class="num">$ (16,290)<span></span>
</td>
<td class="num">(41,288)<span></span>
</td>
<td class="num">$ (17,030)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Liabilities, Noncurrent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">301,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Employeerelatedliabilitiesnoncurrent', window );">Employee related liabilities noncurrent</a></td>
<td class="nump">218,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesNoncurrent', window );">Other</a></td>
<td class="nump">341,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">341,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249,400<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Total other long-term liabilities</a></td>
<td class="nump">861,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">861,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,096<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related rebates</a></td>
<td class="nump">$ 462,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 462,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 359,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Employeerelatedliabilitiesnoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee related liabilities noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Employeerelatedliabilitiesnoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph b<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph b<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30700-110894<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30690-110894<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-04.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.7(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.7)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion (due beyond one year or one operating cycle) of other accrued expenses (expenses incurred at the end of the reporting period but not yet paid) not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 09<br><br><br><br> -Article 12<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129117758080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">$ 28.3<span></span>
</td>
<td class="nump">$ 58.9<span></span>
</td>
<td class="nump">$ 167.6<span></span>
</td>
<td class="nump">$ 193.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(2.8)<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="num">(8.4)<span></span>
</td>
<td class="num">(7.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">25.5<span></span>
</td>
<td class="nump">56.6<span></span>
</td>
<td class="nump">159.2<span></span>
</td>
<td class="nump">186.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax effect</a></td>
<td class="num">(6.4)<span></span>
</td>
<td class="num">(16.6)<span></span>
</td>
<td class="num">(46.0)<span></span>
</td>
<td class="num">(55.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">10.8<span></span>
</td>
<td class="nump">24.2<span></span>
</td>
<td class="nump">68.3<span></span>
</td>
<td class="nump">78.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">17.5<span></span>
</td>
<td class="nump">34.7<span></span>
</td>
<td class="nump">99.3<span></span>
</td>
<td class="nump">115.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember', window );">Total share-based compensation expense, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 19.1<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="nump">$ 113.2<span></span>
</td>
<td class="nump">$ 130.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.F)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section F<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense, net of income tax, recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the compensation cost capitalized during the period arising from equity-based compensation arrangements (for example, shares of stock, units, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)(ii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total recognized tax benefit related to compensation cost for equity-based payment arrangements recognized in income during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129118170448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Feb. 12, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementsChangesInValuationTechniques', window );">Changes in valuation techniques</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCosts', window );">Reclassification of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 301.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">274.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">479.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">479.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember', window );">Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Contingent consideration</a></td>
<td class="nump">$ 274.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development and other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 424.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember', window );">6.875% Senior Notes due 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember', window );">Adjustment for new accounting principle, early adoption | 6.875% Senior Notes due 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCosts', window );">Reclassification of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51824106&amp;loc=d3e2420-110228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph b<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph b<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt issuance costs (for example, but not limited to, legal, accounting, broker, and regulatory fees).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value.  For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (bbb)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementsChangesInValuationTechniques">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the changes in valuation technique(s) and related inputs used to measure fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (bbb)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementsChangesInValuationTechniques</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129119402560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details Textual) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Employeestockpurchaseplanmaximumshares', window );">Employee stock purchase plan maximum shares</a></td>
<td class="nump">6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_A1995ESPPMember', window );">1995 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under ESPP</a></td>
<td class="nump">98,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_A2015ESPPMember', window );">2015 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under ESPP</a></td>
<td class="nump">43,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Employeestockpurchaseplanmaximumshares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee stock purchase plan maximum shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Employeestockpurchaseplanmaximumshares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_A1995ESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_A1995ESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_A2015ESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_A2015ESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129197712640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies Commitments and Contingencies (Details 1)<br> SFr in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>CHF (SFr)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_CH', window );">Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Land', window );">Land</a></td>
<td class="nump">SFr 65.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6812-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_CH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_CH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129118150288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">$ 53,871<span></span>
</td>
<td class="num">$ (738)<span></span>
</td>
<td class="nump">$ 49,053<span></span>
</td>
<td class="nump">$ 7,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInVariableInterestEntitiesTextualAbstract', window );"><strong>Investment in Variable Interest Entities (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">519,863<span></span>
</td>
<td class="nump">417,174<span></span>
</td>
<td class="nump">1,471,140<span></span>
</td>
<td class="nump">1,393,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities', window );">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</a></td>
<td class="nump">10,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember', window );">Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInVariableInterestEntitiesTextualAbstract', window );"><strong>Investment in Variable Interest Entities (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement', window );">Remaining potential development milestone payments and royalties on commercial sales under the terms of collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 39,700<span></span>
</td>
<td class="nump">$ 7,400<span></span>
</td>
<td class="nump">$ 87,500<span></span>
</td>
<td class="nump">$ 29,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInVariableInterestEntitiesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInVariableInterestEntitiesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected total payments including upfront and milestone payments as well as the greater of an annual maintenance fee or usage-based royalty payments under the terms of collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 4J<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Research and Development<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129323634736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events Subsequent Events (Details) - Subsequent Event<br> $ in Millions</strong></div></th>
<th class="th">
<div>Oct. 21, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Workforcereductionpercentage', window );">Workforce reduction percentage</a></td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected restructuring charges</a></td>
<td class="nump">$ 85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RestructuringandRelatedCostExpectedCashPayments', window );">Expected cash payments</a></td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected restructuring charges</a></td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RestructuringandRelatedCostExpectedCashPayments', window );">Expected cash payments</a></td>
<td class="nump">$ 120<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RestructuringandRelatedCostExpectedCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring and Related Cost, Expected Cash Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RestructuringandRelatedCostExpectedCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Workforcereductionpercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Workforce reduction percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Workforcereductionpercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 420<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 420<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB Topic 5.P.4(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 5<br><br><br><br> -Section P<br><br><br><br> -Subsection 3, 4<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129191554768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation between the U.S. federal statutory tax rate and effective tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Taxes on foreign earnings</a></td>
<td class="num">(10.70%)<span></span>
</td>
<td class="num">(9.30%)<span></span>
</td>
<td class="num">(10.10%)<span></span>
</td>
<td class="num">(8.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits and net operating loss utilization</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization', window );">Purchased intangible assets</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction', window );">Manufacturing deduction</a></td>
<td class="num">(2.10%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
<td class="num">(1.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Permanent items</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">24.30%<span></span>
</td>
<td class="nump">24.20%<span></span>
</td>
<td class="nump">24.60%<span></span>
</td>
<td class="nump">25.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation manufacturing deduction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h)(2))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 6.I)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 6.I)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 6.I)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 6.I)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 6.I)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 6.I)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 6.I)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129120487120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">$ (15,413)<span></span>
</td>
<td class="num">$ (16,290)<span></span>
</td>
<td class="num">$ (41,288)<span></span>
</td>
<td class="num">$ (17,030)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">330,093<span></span>
</td>
<td class="nump">274,774<span></span>
</td>
<td class="nump">904,475<span></span>
</td>
<td class="nump">721,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">2,391,717<span></span>
</td>
<td class="nump">2,117,366<span></span>
</td>
<td class="nump">6,762,605<span></span>
</td>
<td class="nump">5,916,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">965,622<span></span>
</td>
<td class="nump">856,858<span></span>
</td>
<td class="nump">2,715,439<span></span>
</td>
<td class="nump">2,051,320<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">42,900<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">117,700<span></span>
</td>
<td class="num">(800)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Accumulated Net Unrealized Investment Gain (Loss) | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(1,300)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="num">(1,600)<span></span>
</td>
<td class="nump">10,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="num">(3,600)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember', window );">Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="num">(200)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="num">(600)<span></span>
</td>
<td class="num">(200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">$ 43,900<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="nump">$ 119,300<span></span>
</td>
<td class="nump">$ 7,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -Subparagraph (a),(b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Income Tax Expense (or Benefit)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.7)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>54
<FILENAME>0000875045-15-000034-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000875045-15-000034-xbrl.zip
M4$L#!!0````(`$:"54=I6T%N6O0!`-+0)``1`!P`8FEI8BTR,#$U,#DS,"YX
M;6Q55`D``P/S)U8#\R=6=7@+``$$)0X```0Y`0``[%U9=Z-(LGZ>.>?^!U\_
M7[>U(&^GNN;(6JIUQXO*4O4R+W52D)*R"H$Z`=NZO_YF`A((H0494";$/-2X
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M`JAAV<A05Y![WX#H6]WM7;V]O;UT6U==+2VN([MM]?+/QX>!.L4S%'0F^SM?
MK-Z&^:A_?.(/N[/<EA<\/G,??C=U@<?=U<72)_W"WN3<;^8#\>NY169SG<ET
MZ=['<W:J:=CXW3XC[*V[;7[MU_I?P[;[J&4?YHV)O7!_6?[$/"#[<4PP/7-?
M!:^)L<1FJ_?O\\\5]K^;ZT9%:7RZC%[L/>5RXS'^4^;,M$QM[<%,$]1NL\#P
M>0FK2G5Y@Z`M?`4VM%#_VXMZ)7B@MNJ]_"UXY/(77T-;=-;S5#:8(HJM9\?F
M(\7#F[`*],!D>^JH5BZJ5ZN[^BT?48<+(>5K_:LL$&(1\CH)A)3T(;34F31F
MIR0TNZQTUI`(9XV$.,O`575]7R6LPM9<TYKXJ;BFGFMFB@SB*Q?5&N-+J8M?
MET/\>D;B*W*`7TD?_)Z[K'[WV?_W>\<B!K:LIOJW0RQBL_R\^4ZL[YQ!?F^9
M++6C+,]5<9_QFAE2L6,3%>G6(YZ-,,U3ARMGBB>\*N#]YOVHL8>_SW6B$MM[
MKS.-L#Y>K<$7]&Z+H.>?N:1W^R3]=!G[(/_-+C=?[4,!HI8P0-0N:C?I<]GJ
MAE(`-2*A9CU*UIBK3--19(N!U5WZU-0<U7ZF`TQ?B8J#6[R@=V13,F$/`=R$
M<)/@+>*4Z[_"AG8!JQ_`ZA-VJ#E']I2H<T0,PC)_%?&G@,M+'[K[E"TSDOUT
MML;260BV(@7;*$53$E*TJY1S^%1Y/$3C<D5CT?*-94$J0#/2^3S'8(JQ_6!Z
MWMW%XK)#4W4G4:T7K&+RBD:ZC*C<(N3YYV6/;5+F&>&RJKX=/M;/]A33ECOW
M;3\0-"(ZLV`L8WS;.^`[1<UMU+,J.B8:=;!PJ<<ZD3<'"R^`7P_6#*S&]7>D
M.YX.=-U\XYJQFH;V@BU&@+`U7,SQ&@S\AJY)6\B:MHGEVH9\*#A,[``3N^3.
MEPB>>A'%!T"T3'1LBE3;07I3^^%8-E>+A'[D4`0M\Y>M0I<,/E&6D=`!#9".
M62BV'6KP?L%%Q470LO\>T:7F(Q^/3`",TP"C*`X&@E/^P2GG)`>XKN!<-X>R
MUA%X`,]P4L^01X$3/(,\GD'`2`'<\^1)21[QHDL,8N,'\HJUGL%N/R$C'3<M
M"]O6_>(1_6!FH2/+"H+&LV,_$)6I&&M]QFNE#!@)A/:CQC:II<=".&(DQD+/
M*"$4M@A=J%@!2)`!":+YA.4U;?R*=7..M2%6IX:IFY/%"YE,"P^*Y45[Y)?>
M4X3QT3,T/#X"(SVC3TU&J2Q.PQ!5IXQH^7KC<LN'E(2*"-!RD"8*A1G@G')P
M3I']QY`B#<\0_<DS-/<_GM!,QN3T:+^Q4P/28R3,1@$C<F-$M#H&\%2Q>&H>
M^`">6BR>F@=F=FYN&2XL-*+$WUT1V=!2QOK)[MTN<>K:"1:HW!Q]BD_ZB1:X
MT1.E<R5Q[*(=[Y33SFZP)J%V2LIL01GO#\\AW3I@-W#S]^>GSI_RP3OW["S!
MN^W8'AQ6=Q&H4?AT`W"]!7!Z0IZD&5GROY,I=)T9FO.0UIP<[`29.Q@S#%`D
M']9VA_D-9>3@XB+*S!&N(FPKB(%K6I6+8%TIN\?ZRL)']HB9,Y,/OOG4&1*\
MT$JW@5=>4R[`.4N>6E9DYTQ0`>0B^&ST7@)DG\IGAY4+<(;4K&BI6<&`!NM*
M3KBN1`9@I3_O5NJ(G/7,&81D(0!=BN3I9("&E.F$=8%2^&H!Z@(E]MK>#&TM
M0#@BE&]\QFR@,+(<BKF@78K_=OC'/-?PN>H;ZLG/AG0H)<9$0MCNEST`S2'"
MYSG[>97Y4FE`AIS(R&BS)R!#;F1D\+FNY<?:`!E2(R.[[]@!,N1&1G9;.X&!
MRHZ,;!CH%I_A)I.;N;;[\SU2?V)MP!41.JT\[BZK/W]C`\@G/!8//`F-AUC/
MF#NVY7:H;;]EF2&[/BBASP9L'Y6TLOK#!C7&=C9'-8-7DLZ6<XW_QUIA%:PP
M5?Q7`?]2X;\.^$\5_W7`_TGP?UHN!U941"X'MBR4+;=,.C<ILG$;C^PLK1DX
M82)KWCDN(MDS<%.Y[1F,[_3&!TC/(@N#6B!4X8J`_U,S-\C#A`X>D(D5PYX3
M5E7`]$Y=`@&4'X'R;X,A=96Q:!K:%_,54X-+!C/!)S:=G>,B4M0"%EI.>X;Z
M83'M&>J'0MES;EDEQ.=B9I40GX6RY]SB,U2)BAF?H4HDE#WGM/8&V+;`A2?@
MVL6PY<2Q&4SO]($4D+YK_SG$&S'FZL'3Y_FI.JB&B(9_J$*<!O^P*K$X)4!`
M^A%(AU4<DB73@/(C4`ZK.,0T'6FJRL#/Y+9G,+[3&Q\@/8M,'.8Q8?ZP"/B'
M]3U"VI$HR3TPMV+8,YRK)J(U2[(>`&Q9*%N&LSC$M&9I8C/,^@IES[#V5DQ[
MEJ9*"KFS4/8,)RZ(:<_2Q&>P9Z'L&?:NBFG/TL1GX-M"V3/LC1'1FB6IA8$M
ME]&6@6D7T9:!9^=HRSSIZK$;4X>_KFLA[A>C!]@@)GTR;6QU38?V36+8_\'4
M[))7W,=499W;#AZ^L?]?>/_R%OG,9E-^_Z/0'U&`]`@)[X0\`"'#*<78U="`
MO`_?=NB(-183(T>H(#>4Y+%?]A`_PE7"-<0T$%5-UZ2%]B"'BRX]*A)&%_`=
M0ON.4T885SE]M$`C'0_-+FO5B(H*A(%=`DKO!Y)R".89N0D\$6,+^`LT\$?(
M+3T>DL8%P(,8>!`DQV"AT=5+ATRF]@"_8B,N3+JM&!O%Q,8Q.I#>;R3-,J!:
M(6JU0I#(`IY$<$]RRKHGY!Q%'V&H2(E:D<H"%6T/%5^'[6!R4OOA6+8[L\,D
M?<)O354U'?:NQJ1/38/]J7KS/NM3FKNN(H9*YCKN(*HOFIHYM]EX1.8F(3#=
M)5)\:-KR.,VG-7\H9SAEID/M-K*Q;UC7%Y45\0K:PE=@0POU#QOBLB55]WSO
M6"S#M:RF^K=#+,+'+3"*EFF\8CK!#!#]*:(SI&+'9F%*M^1#_19!?1#MDU1J
MYQL=\T?TPZ3#Q1Q;SV-N5DU#ZS"EV(M@.4*`@6#I8-#:<BC%R[6$,H'@0,E]
M4.P5O;RHV+):_,DT2H*-`Q507H3$&4]YX'&(].7%QB/+;"9H@EFG9WN*:>R*
MN)(@);DN2HF;9?]H8X'AL;P@7N12HN!P[U&>4'.4.LJ+GBW$K21@.41ZJ;'1
M]J8J_QJV\QS$XVM"RD6EFJ0F%)F\2ZTF%)[>361/`YO#:4+4GO&*_?I@T:UH
MN\R%FL0%'(B/@SR6!0$[*RH[RV.Q$&1XHF=X(J$`:H=BU0Z%PP;D;\+D;[)@
MHSRN0[19*>$0`C,/4LP\"(<;6`4AP"J(/&H>02;/%;26F,0=C"?3L&^*%F0@
MB0_]DZ&&<>"X/IH&7CPB^A/;7<?0"C:R\=))/[9A3[YC;%_PW*'J%%FX.:$8
M2UJ5W#6^VR64WB\?.,9@OQ*.[8&^N67.9IBJ!.E]Q)Y3K*&-%4YZSWS@R()G
MEGB,#_3,8+W2^>4#1Q9R(8G&-6;S79O=XQ79Y!4'>ZI>B/5S_6Q.DV(R,3KO
MS(D9$]QB]Z1(M2,[ZGJ&:L[PP$:VZ^(>3!6M=A$M^[CUI2?3,-F[([YCS+NH
M\SYG`R/EUL[MZ@N=8KE+?SL1E0C)6]4?O,DA^L\6XL)MA#N]40R0+J/KE`W[
M(367$.(*0!P@G@W$E8005PH)<:`V0&T$,XK-(U@.L(@>NP%E.=$+>_S@#<TC
MIO`;UB9,N6ULL6'?M(+E[UAK6G[7X%E%-8)XE:6%_GB-A]/4O2J7NL[D$_2_
M#G7M[CS]<DCX&AC=5']&OW:Q<B;>A'?+G,U-`V\<,J.JSLS1N6Z?L/T%$>/!
MM*PN-6>!TI_I5P?I9+Q@>F\A:]K5S3<^#,7C.^XJ@"V*30OL.\<E=`9-"@.3
M;Q*0:'-/5@>^A(MZ>QPYBZ3:2I7R(7F?TXP13^K27C34P^B>:G3SF$Z[1SHR
M5#R88KPC&?$79[G+^:+QKUPT;IN^(ME#C,*`Q&4SI00(!@3+'6$_CN`4"U3%
M#O>G![]`Q;`R<I]T(P?8'=A=L>Q.B'C75%7J8.V!H!'1X[XP"W:7FMUMTS78
M7?GB'=@=V%W)[$Z(>.=RGXT#?Z`^L8LJ)CL?J:#5"7$JQ,R&58^\;X\>@./X
M=2;;%`>(/F7>#_X8_+&4;&(OBP?\YDO%94)P/M]ORRN++!B4)<KIRH#I!&N@
M"@9$F48_CVVMWKR%NG#'7/7_XWOS6[ND^`CKX_SS4B%W3"%E]#]YL,)X!+::
MF6QB`3`S,#/=EK!6*Y)=Y<%5X^WJRWT?["HCNV*Z!;LJJ5V%&1/8E;#D"^Q*
M,KOJ?'L!N\K(KIANP:X*:5?[,_QP?@7&D&Y2)!,"3U=C"F<B@,!TTP=`X"'<
MXG_[?P&WR`C,3+?`+4K*+<*<'8PA7:(M$P)/QRW"GAT0F*X[+CL"DQ[%DXP\
MP"EK<,J:A`?KG-XHX'3-`I^N*0K$%8`X0#RSLS(303S#`V2!VI06^X)1&U&,
M(G(V?I]R_=B+OLZR"?^#D7,N[OUBX^,@]PYANC(F$6/@_9['34KY@/-+W8O<
M8SL[Q$)$/J@?H)0`9^M:20OBL4KUS^P,:35?XB+$R?<?`/`C4J?$P'01[@=H
M7OLLW785`;1SAG;QH`A#GX%7>T"&!DXL[,0"C8#/ROH,ZO#<=/%@)\2X"WG6
MQ/:=^?!9BJ0H._7N?O@LABA66,L3MA\0_RJ;Y1A2B*]D('[,I-/OB!(TTO'2
M[#K\-0FV[A<M'5D6D\-S%,]CMV41Q-HG[%`RFSF&A%7&8Z3VXW%4[!).ZD0@
M=,Q7<;X9%".=_!_6@G"S_""+?'`ZZOLS^U4`T$H,K2&CT);N!7;MA^-IM0R`
MVB$XP"@QC-IX3`RLW6.#_6'S:H!5+C@=H`"`%7P.#C[&=LI"&!`O*8E7SH4V
MX%#"<ZB<-Z%`W"ITW,IY0PGX%YG\2QZ;1R'=DB[=$IV30`22-`*)RF<@#Q(I
M#Q*2IT!4$B@J9;4Q58&YK`*X$N'V0'C.!XHPLB9)V9"6.A1A2DB!ZYF1&Y@*
MD#QN9>QSTB`X$(A.NJ)"%#+ST=`%SD8D9Y-%2$K#V4#*?>J46TCG\R&F`Y@Z
M-:9RR*P^RH4ALY(QLQ*5,P.@9`*4D"'O0WP;0IY`(2^K\L^'$`)9_0G+RUEE
M7Y'EZ2]87=_,YMC/XY`JW-V^7&443[EB^;Y<?G;5&F:.O4EDIS64##XR&@&2
M/S8<.Q%>]/*'<,OY8Y@FF"R8+)BLN,P\Y@PEV4VV^(EJZ<U8^*1;A%.F_&@,
MI@VF#::=:M1.9-H91NTB$6TP;3#M4YNV0#FT8%$;["Q%.RML/!(,M%#XD<<F
M2E7X$2@[%(Q"@DV)'&>$J%:*!UK(>^2VD]+G/:*8MG@4$NQ,V'@D"HD2KPX'
MH!49M%!A@F1=<ILH5;(N:'VMR031B.[PKX\,L.I0][C_SKNJ.QK6.-7DNG;L
MY:G_B!J,:%I]3`=31/'](OX&P=<0'A']B>V!;:H_OQG$EM".,E21_^F$>!T!
M"<H<G$,VVK\SSX"U%_8O)2K["Z"Z"ZJ':`R($'A5`:!Z<J\J2LC/&YRNRI_G
M_'*+?RMR-M?-!<;NSWV'JE-D8;[U"$"["=IDNBLGF($B"`UAP2B"H%5I`"X`
M5YJD#.B#)!`6ECZ(`N:\Z0,D:G(D:D)0A+S!"9ZV@)Y6(#`#WQ4:PH+Q75$J
M#'E/0H`7+J`7%F5B(F\P`]^5@.^*`LX(W^6&^H3\Y4`NFIK5V]M&9]#ORP>C
ML##^N$>D*2$G;.P=<-ZI.`.^+DT)+7S_@(.%%VK`(R[=6PNX6KWW8'J+"-?6
M8/99U)3QC,4=L@4K$L/"E=#A1XH``(>3P4&(U/H(.+Q@"R.6R+'LKHU?L6[.
MW67`[W.F?PDW*AR$D@-D!O`<`IX!UG66G'W!!J9(9^IL:C-B$,NFB&=GOD8E
M3%(/@E$BZ<L)J*1<!0`E**"$8#L-8#LBL!U1UAHTP+\4P[^(DEP?X5\`4(("
M2@@/=00#@GQ,@'Q,5K8#X#DU>$3Q/$=P(P"/`.`1A0?!)(,0>980<-B[C$#^
M12DQ<XTG7T4B$`_9.ORK'S$=FW2&#!6[JW2DA\#JUWC!2N@%]BXUX*?C#;!M
MZU@K'!Q<C[!?P!+"8F]P*-JZ\1A@B+?06XC`L1<:X#'*"(N]@03H9%D#!M!)
M\`+`&\!#[(%&@;9PQ:!"G$U6HOB*R,HT8`RE6T>V>_@ACP!8`)$$&`!;@!,,
M-]9-0+@X>:%:E!41$"X`!GN]`^02I1Y^*#N5&!I0=A*!2`I4AP1?(9:OD";'
M`%]1FN#!\5#]JCRK]@H/0_3>=^^REEVP7__"B-8JE5OY4+`F4I!8;,B4X]A7
M+ZJ5)&/O]J]74W4&/=<95/,<R40*(P93"].T!_UZ2/QE2\[0ORX@]*_+"/TC
MQOZF@&-_4\:Q]^EQ+<R!5GLHOF!S0M%\2E2DNT!03<>PZ>)[;RC3R&^5Y_RS
M+]!=;Y@O]5424M^KM*FO%^WJ,.;9C?EZP`YSU30"=MSZFM\1)6BDXQ[K1EF2
MU^&O2;!UOVBM?YEV[+8L@B3G"3N4S&:.(>'VP&.D]K.?J-CY.@$15^0`A*2"
MD(@E%("0/!`2I.A2^UKMXE%`1MA@:HZ.F:[<CY@_8GMJACY-OODKQNM%NP&:
M68XQN2>F169$1[0YH=CE`_(AZR/:6![^OT<=.2*N=E&I)4&<V[]VFR;B>A[B
M!NT:(*Z8B`M1[PA^4J/>]:_*6LX,`"H2@-9<5CUAF8;UKV53G0[R]>%BSK3;
MI!09$U<K(2"]88U8TV<ZGR*#Z>^5V-29R0>B6!&7Z-@A8]&R>G`MQ74MHE0!
MHK/@U-0<U7ZF`TQ?B1J"T@-&VISRDMK,7S-PB$MJ?AFVY(-:G!9\"&VJ82=H
M4O)Z@1K+E2)N5JO!)1;))68<4WMN3%4`/85'C[+.O--D9)#L%19`HA;5(0DH
M!^1$624=20(*Q^>!6A]`K2'U*W7JEP,5/[",*2=P2C"&R4+%([$M9T2L*1DB
M`XUP?XKH#+5,.C>I.R%>K#$^4-R2!1D/,E7(H8#0;H%</8MUS0U(VTL$N9-[
MN9ZW+`#P5DR\A6A5/8,Z8P)J#)PJ?TZ5<V*T/0UO$TLU7S%=0"Y^MT47D)`G
MQIUWG)8S<W3W>W\#I&/K@7]'*4#/LX'OB:ZO[&V%N'O'(@:VK*;*7+A%5E\4
M<J_J.C,TYP;;G,@#/>_LK2W:\`$054=:H-NB3?^I&^HL"_H&Y'T$Z`NH4$0=
M@+Y,T=<U'0KP"P$AJ@_`7Z;XZR!UVM0T5Q](#T+/M_G0'+XQ8180FD.'VB33
M%F#WF$U;E:NO2GB%0O&@)N2XAJM>E:MDA5;6/YN="?6OM2-Q<$#".\3JF(TH
M1>5&3CH9<T29.5;,ULZPR)V_L=^!OX6@%]4'Q,`/+=.#!!826!F6^7DN,[3O
M>>^Q/ZW?9$!<@F-_6K_EZ71.&?2&4XJA9!LF/QL**:37$2KL0>6LC)4ST0*?
M[S7=DZ]99N108DQ60'SATWMK!UT^HG<R6^XG#X*E,[+PWPY?J_#*_N&S@VM7
M1=KEP>T20BM%!,=CKFDB+:AN463PU%A-YN@TJY6+6JJK.W;BK_"X@O'>YV^(
M`?[&\S=A38"_28(_QR`>^`QG`P@SC"R'XL_^W=B?R_LL6T*WYC>*NZ\O:^R-
M79+A=SCFUNZGK':\LM?AB#L[%O]RFONIK+7;:^25H7EM2/@U3\X,4V2;:R`+
M'D@L4ZE5K^^^#=HQ[_*/M;>)W"KTD#8VS!DQMC]FC\SKSXG>;=D62'B`CF)5
MOUO:?7?M?'O9>5?6?L1=__WRQ\Z[LO8C[JI.QSOOVOJM>\A=O95AJYG'1\(2
M`-LT<!\MN&&<^4;[@L>G62Y\IF&5S)!N_7I^T3CWTCFDVA>=1JMS?UN[K73;
MG7J[UFVT&Y5FY[K>OKFIMZK*[?D9%]%];1<K+"BX__MTN4?BX[22QD%7VT15
MZI5:Y[;3Z-9;2E?IW"C5YDV=_=&XOKJZKW>Z45&KE2-$_>%X0V8-37\NYH6E
M@8:#&2'`E`W="^8IHC$9FFZ2V#/ZS+]3?A"]M:Z.(-G>*M%5MUMK7#64FYO[
M^LU5YTIIMJO>X'5J3:72BDI4OXY(])&WS5KJT*FRNN,N]FWJNOG&/W]H-0UM
M>><5-_(J$NQ>E*G&07KHK?8`HWY3O>YT6PP7U_=7-TJ]WJS[:JPU.0>*JK%6
MN2VN&E=4U6OHFI1_B=1=;NOL]2;-1N/^^J;95&J5_R?OVIK;-I;T7TGY/=FY
M7TYMN6JN9[7K6(JC[*FS;S`)VMA0A`JD<JS]]=L##DA0X$T2:<FV*^78,@ET
M?S/3]^YQEG'%K`HMDIHH$[<<,?K]`]F^X$,)GL`L?6[]I0-8$@F'V;-(@0:0
MRM8;N\126>4)&V+)U%G`_*L`??)QFG9"^MCOY0A\FC3?V)<?%[\6B_PW,UF4
M34HNMM\W-W6SJ/ZO'+MZOD7,L]_83KZE(D(;K`7'.+J```6;3V/$UN$!WT1L
M,OY\@L_,/>RGG=QCKX.*3E*0ZPZ#=F;"++FGB@JOAMQGC?QZN(]%U:0S4CYR
MW2DA*C"+I6HM$0T+GSFWSD>S9=WU\SE?$7M&KO>MM[:*2&>5$8A'':4/(G2[
M7>(P4.&PWO1,7(/+\JG,W[B_G"ROFTV/7C]S*!M96PK6-R@C)9X+*@+QSL".
M#4HN50"F'`7UYNT5YK^NJ#_BI<^FL;.B5C0JRK4FE&,+B@H9HK'R2QJ10BJR
M1"-](HW;D@#;[=S74_S9WYRJAQ,/UA"&I($]B:.P!!N:CZ0D5-JA8;3ZE<';
MQMZ9L#I9H<\N-`(FL&%4P$AZR5BT7AL:%7?1,.8Y>8@&?TDP3I5[VP6&MQ(T
M%8M1Q<BQ5I:PY3%7+'*"!GJ*O2`8IVI?VH6%\H!!1`1$GE3@D5&!L_\`?S0*
M[7(L7P*+4]4B[1091ACGF&6@V#1A.GE4>5\(0T-XB(5X02Q.5R6Q"PV-N-62
M*U"#401FI#,LHZ&"5V+@H#\6C:8!)0#6_5]5BGL?;^GG;R9CX-%1!^;`S:/*
M((8E+"E(/I$-=!Z$E(,EQF`,L$VF3D#V5T+AZT4A#),NQ>)89"2`[Z<TRY$X
M`9X?&TH1$#;H1X'U65$)I9"A7AK-8.-ZV*2!9)D4@D)Z>`HI^>&`?6J40BEM
M-?;>6[#U@Z"(VHRMBU&HH8EX5E&0?)Z+6<J\MJ'OXL_R'Y_K:;EZ_(=R7-[<
M)E2NFFI47I7-"#X'UOTQ0O#B?>P[ZM@20C@25AB$"0?7(0E#0\'/B6:#\2XK
MAW])I3#/([3'ZUT9F_KFCQF0/J^GU;A8E./_K*O9HE->A_UOVM?<*>/+)#(<
M3@KH*2<)R9YH"C(/,@%$42IZ2WF8GN?1_M"+[M..N"8"L,?2VQBT`5ZRHQ)0
M9&R@DBC64JFGT1XFDW*4-/(%?/JFO"Z^?(!/?RCAJZ-J6BW'4A2SNTF1L_^^
M3/L9?KK->TYCBOIL];GR%&,?8#F<EQ%[Q^&$Y6BJCIZ1+5OL9_0+(AU73Z?T
M;-S^<S>WW"A!78C>"J<-"A+DR'(-<4P_V,$MUJ^46[YW;:4@#F%IF;-6`==,
M\6P9.LQL$+O6%K]>;O>L;0#YD6*Z4B`:)=6@,7#>R0X'MVMM3[N3;VZG]7U9
M-DF3E&/X%CA";?!F!D]9:I/'12PU@Q-IH\*21,<#"Z`".HL-C/U!0"#=,MY7
M?L=0]%SZ]\8>!48.$T8-!U:HMB!4<NX7,;I%=V/%GD__?%&/_KR]:T:?BWEY
M.RUF-\M"PV7-PT$.4)\!+X(US,*O`&J7<,>SRN)21M\_1%V9B2#;.-A/4X^'
MK>GYRW_-RF;^N;I=J^E</+G!S<M<=[C3@*&4JX`]E5ZK:+D`U\TMP=,Q@L+?
M<B;1+TROQ.TCH3@$XCQ\N84S7H[!!II4B[9L9RAFOO[=:SOQ8Z"=C!5:>:FE
MX<;;D*,^8$=)LAT_OA>];1BL<8L5/*^<@A0<@V%2S#Y5'Z=E,9^7B_GD#L1>
M62RS.,500A^2!$;%Y-0;*Y%"@B-F9+:?!%.4#[,07&\F7QY%VYJEOQ?5['*6
M+/K+R8?JT^?%U@S#0SVZ8?H!YAI'1;P/'B,MD_V0\PV66#%PFQF5>DWWD(!'
M$_<P5-(G3F,'<M1APP7()T54:]6TB08F4J)AX-/#ITY'W=`$V:".(K"YG%)6
M22^B`]>-Z+SJWC,VD/\G)&L?:((1,'RC<DP@KW7`G,=LS//@E7\*61>S<3EI
M]^B[M$<O5GO4M'OTCWDYN9N^JR8['<&5R#GP)'O_:_&_==/>_+OA8*?L>@W^
M]#QYM`5H&O"R?0KGU;=]:;-V:2BEFMOHA+!2>14#Z8+*$7'%WKQ=4P*`+*H4
M![VY`;%;%=-\T#(P1S/_FO"Z;@IP@8OFSQ2.:/^2!/=\B!.(JTBI8A89B\'S
MED'DW8*)8;Z/TW/P6-[M?#%+!</5N"J:^\?'#"2AQ`?P;Q2!A34Z&I_%K#/@
M#>#M,0.T(GM(0Y_"5+]<-_?I.NKZ;GZ5Y^+]O:F/B01L9.*#P1R!"1@D^"61
M&R>R72BLLF90#R4V,M)["7DRO?NTE[0&Y)9/RDI;'2U".A\5B5)$8Y"88T\E
M>*FF+U+)X:(<?9[5T_K3O:MO;HL96+W7GXN%:4I?PCK=5+-R?%W;<C.FL.NN
M\,<M4$#&V115!\D(1KD',=$5;2+"]$!=2_V0W[,Q\F)X[=T@3B;WC$5CM`1G
M@1.5@Y2*@%\Z5,.;?MI7!PRDXO7GJAE?%<WB_F+6!J+^&WX.=I29@V6]LE$W
M8'B9RZUWI;X0`[LG@%-F;<3,(QE0Z#!G)/:-B[:PFRBT2I@/<#\:D.\)S<TP
MNW6@UZQUG#ID!9B3G34`IU\-3CSA)X2R_YG6P?M]P\'K/_`U.[PD!L:Q!OL@
M!4\U5=YG<Y<[+93:ZK"ISF-[!`AKY++O>PU2(=:-&;79*K``1V7U5Q(&1]0J
M"1JM51$L81#RTJ*H72ZT"&`>HOCF[95&/A-YZ'T]RI;=5L^A3"DMM?>@;[6Q
M'K8EY9DR#@Y%6T5%UY0=>-^:LO=UDIN+IIY.*S#+LKBL9B-P(N<E+&[[_WKQ
MN=R2!-OB+/:/4?0<D60=8&-)P)%[E`-&$FN!!\>H.SZ/H.ETC.S+P2N7@G:>
M2THCE=$%PG-J`,D8PR"E^7*,;/%!-VKO*=."VA3T3X<0,\7Y<D6B0)8/JGTW
M++<7X69O0P;QB*&V$L@*8X0VNC/,0+WI00[M68Q<_E4VL^3G-N!&-G/X2A?!
M+#J1.+]="JAZLJ@7Q709D#EH:VZ$5[RE%%%A4[$DAVWG0E<J&3V-<JO07*<I
MGDKC.;A\8"'VN0270>H@A$=@5T>D'(DN!Y&XY6Z[:@`WXV1<YDZB)![GEY,G
MB6.3^G4=,SI(*5DP-*A<EN/:-&@Z.S\MZI\T^FE<W,\SZ8=>/"!Q521P>SNM
MRK'Y5*2NU4-)^^?4&UD?M<;4(VZ))"Y&Z;+09H8[,DBS8,PW^TI.1?G7P^+K
M51T1S*E/;3M>&4F#H[BK4!/P8S\`%Q2E^K&P?5;ID;,Z1,G!\40N:FJ9[VPD
M*[W8DB*4F[[ZCP/O4PN0P/SD/""F.;-"1V%$U[SGC$!;VD;$*\9WU8#U>"$9
M!?51:`?[S5!/+=9=C1NCU@U;00DF)P-B1?;7@N'KR4?!-+:61A0=X`FJU.EL
MGX)6(F2PO8@\X09[];@^2S9:`1YXI)%A*Q5+/5^KTD&AC!]L6;89E?LQD'UR
M]RAL0VL1U0%19SD!'92-)B60MX,8OCJ=VMF&[2I.<E4L&\\N)[^7,_C<^WJQ
M(YJ[@F"S5K(7"5H_(/7^7*4`S?6_ZOPN?U<N.Z1@4\)O\(%#\2%,J`0UC0/B
MSAOX(Y6,!&<8D<X)0;<Z`5H3S3K4]G/Y%>&H[YH6CO\IF[K%Y@$F&9DC0#$,
M#!8DN<!@OQB&M+0^@4(Y_*ZHWP&*%*\.E+;;HT7E]^H+[)/=N,`_'H*%&X*(
M)<*+`/Y(("8Z!(!H^+$DTF]W&#5L%O3J8($3DT!Y7\UVP'$(BXBTMSXPY233
MS%`0Y#)M#@\NA65Z6W%?NT4T>306TV*VS-'"H?;EI`3[:YR2,.5LWLK455]K
M4D'3.DUKV1KM6`&T^H*]7_WQ/ZJR20GZ^W6[T.#C%[/;N\6R'0<_:!WJ/?+7
MY<"8A'ULVBE3H_OMS^M],CG?8%B"*#UD^5)E`R5<$,FDQ$$PV<6S4QQ@D-5:
M;;TGH/C*UX"\U!I835TD-%BJ/'?6!N1S$5VT@<C!D`:Z63;U'2X%?:FED%QB
M$A76G#K/E.!>^JZ>$5R@;_$XG!<P*@$7`]J*.RIDC-R+[-HXZP'*;V#O]G7=
MMRS*D9#(P8YU`EOAC>8V)_DT,HH,*UB^XS5X,5$.QFSTGA!,@PPJ*L9UCI^G
M421^4`U)E?C.C\.+B7*&"1)!:.:=UE%$)E6N`(W1:2F_P>-P9C,D$*N5$$%Y
MD^H""(E9]T7XCPSDQVGW+ACILT553&-;Z?UP.MX<'G13M<&VZWI=)&%N;YOZ
M"S"S**?W^V$\]XW(.V<Q$>%0]$A@\&G`!R;,>!J95I)3\(L',RZX)ANSF$X`
MS*M`^5U9C,\"L$LI5TE@WR)+`;PTRBL!S&,(`HGA$!'Y+0/\>*SZ]70I":^)
M,PX+JTE@C@8.6"EA!.-L.'UF,&3DNP'KR$OA=X=&`\4";"SOE$T=8S[B=*PQ
M`LF99HT-=EWN>OLF@%SBB%T]`['X";1,AN>XR2:#KXW*NT6Z2.=@N#D%\;63
M4D<7,?<8A.92`1G8H\,&;,:_H<UY7DR/$,`?BB_%HJD^P4L.C?-UF(.80!YY
M&R)""KM<=6L"0\.<"CWK.H`54]W=P-?;JLYJ5>6YJTKL1&H%3,9@K!%<2,%H
M--8S!IZNX-%K:]W`&MJ<H+B3ZCYC]6T]+\=@?A1=0L;>7Q=?S-WB<[V<"`>6
M5`8M3>9;KNAFM#;QC7]CEZ/%FN_BRU4[[WVS%:;XDM(IJ7WXT`P9@B3R!LP3
M33FQ2*Z3X1I6?UCH3A\L_U,9>P78J(.97!!,5C`O*:>,ND!)+L5PDD4YR(A]
M3]CH0^*;,M"($2O0C,Q)"YYOK@*RC%@R<+C.@4VNF*LGJ8VMGK4MV><6%#2P
MX+AUL#<D>)O)M`=+@!D9M13#^88/N=Y&\IJC#V5U\_&NF;=TO:M`;K9WU(TO
M9A_*>3V]VS4D@VQT.!^\IN_B>F.<NTVN'1$X,$(UHHKEG`!+_;'AS=LKPKK)
MEL<0V&?GIJAFX(NN=$2_??&AHD@Y[?J^F*:5OYRY56=BF\_^8S8NFUQRZ.KI
MM/B8+;?MK1C;T^C;VVGL?=M*6$T`I_3$RTG[+_?K??&^O&NJFYN[P[J4VB")
M3.-7.%.:"NJZ!N]4B3"(CY('L_&_*F#]=5KVEQ:S\7C]OODV27+Z$^6\QJ!R
MF3$Q"N,M0]HQ!O)**O#LR*"<6\E-Q/:1OL'B^G*=(E5/M`,HTO#BKH,^U:%T
MT&XQYE[D/K`^:*(_Y\=@;Y*%@@`H9)&.#"FI,9AQRB%)!]*7H`<;[5%PO`R.
M)[SG:!>.X'Y$HD@*TV`<`O91.R456'V1.CJ<MHCQPP/[1!S;00TV5>KW@V;I
M.[-Y&EDSO1LGJ9H>E,YY_H?C9AULG"ZB!`NH%>M$::]9U^LLN2=B8-USL1'F
M>R*9Y^%S7S&C<]@2L,JH$Q2L5DP4RN%,%@(5`[V,E<"OD]$#W2\D2$=$E))P
MQ:F5PO&LKDGP7@YGKG'^:OG<NZ!!(MBOA(.U1<`E$=%UO0G))!\6Z7)-3LOH
M`O1E^:D:K5L-K^IF,:FG5;T_'=N.)TB""51O*J=)CV\=P_7P[UY=S?`UAR(G
M&'$G-)QK8S4'[R1B3;K4'X]B(/R9W*B_W\?84]GOQ^'.S3[75A,6C*.>,!I4
MM-[FSAM&HAG(;+$Y@NHX]I/E=#EYEWJHGF/_!/!NJL$`"I!'`3QMC80FEH(<
MEEPJ*04'-X(YE@;>TW]F<GN$K*D[>@KB$=-P1!H3R"+70@CKC6<.=]VBPIFA
M(T>`;-F;.'/4!,3'$KQOV(OC"E%F/0:T0#2@R/)U`2KB:.F`8*61XOJ<!!\8
MF@/(,C#1F&+61*.#]2A7+8,@1WX08J%48H7/3/`^A!67'ER80#E6!`?A'>GN
MU4BSB89Q#X0X1>31%#=EFCM3CM,8GG?U?)[<&/#TR^I3GM4ZNO=E4_W53K.>
MOR\7MIS`/U\77QXW_`+$)4[7@P38ND0+\-"Z6(5AX',,^)%DPS9X#J'G8G??
M[`K%+8^41VU]C%I004)FUW/'W'!('Z5G8/=VT@#1-YW3>KOM_K:3.Y.8RW3E
M$0L4_/#4VD)L2GE1+*5#\)>A7[29J-E!]9JM?]3-G\#KJ&RZ<9&WVR<"G^$2
MW]U#@A0&"2>I`QLP*`,BQL`F)VD8+[)1]\,.ZW):W#7<[F.I97Q<5G\S`,.X
MC<1-BT]'M)9ZD!HZC?4'U\KQY*2&;*/@0!$6;]Y.@)'RW_]M\/#5*W.O5*SF
MHV*:HI)A>;?W$6^7WF'``8&N4B+-2@VN:\Z5G%%X^\\_8_(SQ<OW[WK3BA1?
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M<1U23BC9-UBZ(:D@;#2B./6W'T?B`VXB2-S&)<.\WC<F;5V^!$O)I)'61F6P
MLBR2;II%Y`+A-V_?%0V(9#,:E=-TLVXY_JE]1Y^^C9<^(.@#N`@@NHO9_Y-W
M=<UMY3CVKVS->Z9(@"2(>=@J?O;TUG22G>Z>JGG:\K25'F\[=DIVSVS^_8+R
MO?('%4F6+5W9SD,J<62'!$G@`#@`KELSF6V*Z8T1-5,6592M<T,0+#J@O$89
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MJF\_H=W![LL^=VUU%``C\`%(_)K6.QJ78Z'"BM&NXH_CD>S[_:4@F''KFX)[
MBG0"D-],<#9[E]32=\VF[UHGV!KVN<V[@<W-AO7VY]X>[%_/KGZ[3]N^\:3+
M_[6LY:^SL<?`@SS7'N^2\G*7T,0VS1+;Q%#QU0;-XD6Q=.$0:Z:5\%T3_3(D
M7*LVVH2*N<7%`J/GT=IKT+E+THA1FU;$=ZW]RQ`Q@DHA5F4%_6M76S?DL94@
M6+<B1BGX0D\KY+O`X64(&4C,2VY3V0W6HA<`;=`4V972V]KE%+2)1'P7@[P,
M$;=X6*.01V]$31AT/"ICDU*T7<22]VK5[W<">`GR<\D%)V@GJT#>-E+>V`TR
M!#:\0@^P.AABV$J$(Q^MS2?Z\=\G7PYX][S+1>E"0:>6\!&3I:#XS"F`]GTY
MK[NEJ^U==,^(*95OT+$-A[<$Q1F!T0-VSJX5O77I'T^/N2'#DOXT=D+\>/*U
MT0S3MO.A[O7.Q.HRDZ$LGK!ARE8M`]>"_;O;#"#_<).,7;^,G5:Z;GY>@"C(
M/(`-5>R""C[ZD8<2C%^1-K8:8.>5WG:7?#^[WDFR*I)#!N-;Y5A@Y<2W'B`9
ML\&.9JA!/KQPJ?L%KUK-$Y:]3LRV8@K*@<&6S"#/9JS.B`FQ]X<T`MW0/79;
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M`5=P"E((%K#ED6^>,(?<>SCV]=S#G^;R9,]OT/^V#Y<+UJ**P+T:T"1'$(8!
M>KHVG?ZMJO<CD9=98\+$]7=48A404E$%2*Q'`H6+N@>#[]`?V]XF4N:0!)6R
MV$%*#*BCX)_A"2GQ!;L[\4Y[?#6">WYE+D#96?8F-VX510@I#?Q00=&@.VZ^
MT?HU2?,)NCRB:E,S!95AP-HREC2:0<<)^[ESKT9NNZARV_A'1?P8>;\9;,*2
M!@P&L9;<I<#?N66'\B,1V+?C$5Y\3''ER6`6E]Y4`>;+^(EV_9S7=Y:-[^(G
MD^YM&ET>G4.(P#6K")C8<AY'-^H$I?=H4!\5('J2X)Y?E\LE9-_&(<=,43&P
M0*2A!V9R"CM@3OJH</E3I?D$7<Z&LBT1(RT&:(%7,"3'V")BC\;6!%=>F.!V
M4N:ZYBR8%3"V,B=C853F[)L[V(F+^:B4^;HHK2AM<<O$WY!]$*'U3@W%BEFE
MS"OPI26S4$O'L[EIM+G<!QTB16Y%C;JRTWE(WW%0IN^8\`[HJ%R:)PGN^;6Y
M*:DHGRABJ&A+4&'L2,J./?2DP>.RC4^5YA.TN4[:F<:`4CX'0U`4#HD6`1BQ
M)Z*^>T62VT6=UV0XVAQ(`YK,)H0QGV8CN-I10YJ\GM6;.3T]NTG%?CPY:X7<
M)U_.KD_.'P?"!?HH6[*FPL;X;)TN@R-K*667>T=6%)1]H+=7+V2WQ:XS,M"F
ME*OB74,=2A8<<&CE@*3=JE2@`23<8;'+24<_77[C&Q;E'/]X6%V_J*-O/6BN
MVCB&5O;QX4O[^N.K_R$;PXT/4PQ9RQ54Z]7>NBZQ0\Y]];\Q';IZ_FW<%]/Y
M^>4O[>JN[33PK7+L.^R/=LV73_8OE[_T9(>/)_,M\%6B]NY"@:Q-DJ./XTA[
M;C-?^[O<QSVWVM%40A@[_<CIW&F*-/P/FU!&U,F:!)%,CK$:PIB69M&NH%68
M#GH>M6Q^G"VFP'XG"&Q^<MZRD*>?SRX6546-M#(VM]AT@T0R)A8LA75VE#3H
M$3R`R[I#Z&@Z5W`R*374>7_J=\--/\ZNK\]GIQ]G\T^7\\^MQ=Q-'=JFN1">
M,0<ENK:T5Z7:R[J)TH$5C-"3[>WQ7)=>$.7SE_/+K[/90I.-#>C:QS;YMPFL
M\A14R;*WR&1QE`*P[J=CP#'?AA].YK_-KA<B^%E6O=&WIV(%]`5RV>ABK8]U
M*"^$C)!71$6.>.\_G7V>_4W0\.QT48U^UKI2;2V)HA.+#2[1L(G9U9"Y#A%K
M[1SWS03\D;Z%Y1<?J0Q:.^(43&/B-6*5S38/`@"3@^NTHIWV&?Q]']A"*S`:
MK!QM#!5*MAIAC-U0**L:H;XL*3P%7""IK+/)*4?067[!B,NI$6P[:T%^6F7Q
M6-D\#[A(\FX*QHQB4X"#C@PCN,!@8]^Q4-O.79Q,3,^*+E")VL1"8E*M@'4#
M10_M`,"C[WLW6M5%&HY($+NB"X@8J,1$EG6A1@RR`TVC_4L?J=)J6KNR7@J/
MA!>B`JQ/2KQ;>0Z%;:IUO`*B6;FO<CSJS3\)7PB2;+P,=H*T23F?PS"'AB$Y
MVYL6[X[T->R*+P*$-D7-56YM^(MM]6LCOM`N]2U(W81^N]U3\$)4G(U)I1@S
M^VPK01P`!E57?,]5Y@EMZ`Y">`J^4,ID,(%\PQDV<62S;!\7\@I"O?(O2C;/
M@R^X5<I`S!!="KZ-7M<C"@LQ]!0O31/""[O'X(6"8"`G=#YF>4[(+HVNJQ;3
MVCVE)KGC%<2N\()*=A1RU&C981!?WHR%5(+7;1=`AJZNXXB$\$AT$:T.['(.
M[(M/N2*-'JL.,?K.8Z6.ZWA$>W\:N/`*0!<=LZ*BLM>A#*UB@8+#;EH8JBZ+
M<!RBV#EX8:A"+:X%L[1.EGW(RS9\I9]@\@ZFM1U[B5Z(<Y&,+Y3%\TKBG!OB
M@6,`B5)940B%$\+M':3P%'012^.DRJNPY2;2:>R0]W;.84^G<STS^JAE\SSH
M0ND`*K92<XBVYB169&#)44JU9\DQ'X^4GA5=A)Q$CXCC[AV*IUK0FA%=*$ZE
M]U8FAEG["5[4F)/8#TNVM70LV;HXMB!OU/@^%:^G]=F>-W@1BR@)T#57$XQ6
MH:817@#[GL...*U1W6/PPA2M,!LB$ZO<_L9A&VN-E-?<%<&SF=9M??;@A2D)
MM3@5C3>5V+KJ<AASA)'JBH=PL.C-:J[4%B-3V(L=A-)HJ>([LA?`-)""V(@%
MZ)A-UN_F.ZRF-3U];^MX-=D7ZTQ5UA4CF-!GPR-G.5.*?4,?QMT.;"^;VS`:
M)5K12%1::4"DH((JN&SQ$+F?#0P[0IE][6W=P0G>0-W(*BAZQ1@%*HSAC99P
M[8-`CI[SX.X4M7_X]/W%]<G%KV?_.)_=3`!_],B)0+5:I$95RKI`T#H.@#S%
M2/WH5PU@4-_?S-H5/77QZX8CJ%J-URX5@M9-VI(K8SFNI0C=$T(/5MM#+7[#
M*`H1KJK!,^76*#YCJ6,BMZ#8]8[3(0ZT.^3:UPE>@THIM:G!4=YVLI9'-RY7
M9.X(;M!ZXL/.BV]?^O[SEY.S>?,MTC];.^GM%GUOP!@7I9SR"GT0QRH9-_3^
M]I5:)]N'B[Z[V)4KZ!?Y8%&;.*^0G9R[_`H%?::(&(=P<O0VK*)6HC;D'SR_
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M:=!;,8Z;+,H!9+I?`?B$2NN,#`%UTM'4.!#=JW@P?:X8V.#>G^[=^IN7K!2Y
MD1P%'#AQ?<'&G.+(3%&YJ-31<J"G.QZY:"?3BI1,0@[@W6+22QNFPH-HC3@(
M7:1='#C;A8N.7+B3:<6*KH8JMU9\!(J&E+7C3$QBYLZEG$"F^Q6`DLU:;(.,
MY2I59W/.0X"@5@$X/0O58<\3V4X2_SHY.V]=).OEO(T:;S,^[XSVO'&Q;F8@
MQY.KLRW<DWL111+H(/Y<31:TSSIRQG'V8,VFKSK0NL]9/G*%S[R]=5T(&Q.!
MO/6I>=S.B9LSMBT7"%1Z?[`!H[UN[_8;'W=.W!S8$L6GU=DW\EXL@SN"5AR4
M#CW+.?5=@+ZYEJ<L>=7;6]SL='YR]:`&MGTYGOSRV^ST]H=^6X6].&NN(UCO
MQ*TWQJG%@)0T`'%Q;Q5W3)`W>#:3P0&TE)E-:P>5G;CPRM!(ZS.12]^/E/MP
M]1LYH\E0A7<F>:C)&:O8&IWS6.2.P5(_;/T%G\U^!>G(9Y&BJ6QL+9F`U<`R
M,=&UX7@OX+*GR_F7RS9)\+Z]?47F`F(4O]IR#5`+&55-'J\[VUP[S_I-GLYT
M436;,8)+C2"?M"_!>3_&/93*?:Y=.>RB:F_FF":S&=H438Z"BQG$P@<+0XM'
M;W3TW#&D7O3I[-G\<HG>4U:XF%.22?'H"U8LO4][E#?^YQ]_FB_V_C5<G'YW
M^:_9_.*VO<ZK,!M!)P74PEHIL.7@=1XS4\F:/C'[)D]G,K-A6"L(<5%6&1`<
M`0W0*['*L8->WO"F@,/K/:7I/`WD:F/Q8CM*U6+1DQM.2>R\ZEN.O.C3V7,H
M.%1G2DL&L09;:LIZS`_%3*$3Y>$O_`\G_WLY;Z/EKSY\:I9V&`UR_?5.%.^6
MK+W:)@])_$V(GG5E;^5663(NE`I.CXTIM4U=6!RIKX`Y?EF\O[S83AP!J"J%
M13ME;"!7N8ZZ$`WV<SD=0\>B.R)QW+ZUQ]Z+6C.)0Z="P1A",:)L]$!<CE&0
M:A>]==RE4(]<$%M?BLS,4<DC,;D(S+3L!Q*W=ZKJ'K!;.FI9_'`YO_[UY->9
M?&C15'%E'&@[R9AD%AD*]"&S$;2`0VT0JP16][?DI8MEZSM3:RLJM$S1%K*^
M@L>QX2]2S"OJU?NF+\<AG/'S#_]Q$T\@:]("6CQJCI3%[UI6P%A&OP5YZOFW
MOR[OIL7Z9Q5::BKFV%J6YH'LY:S/_2-O>;?#+/GXPNV3.9*N(*18+(KB+<I'
MU&[H.*>`3=\9YPV>S61NI/=4Q0+4-B@V5H<"I(8YQ=4KV\^*!7,(*WF49S29
M$ZF"=RDF='(VRI1"9F#(LXH*TX&=R+V>S9Y=2,[B0<82&!UQK,:-S42JV#W;
M$UB/\+*__G054T%Q:J'D3)0%D"8>S05BH`Z#O,G3F8[?$%1KEFNS#T9;:Z&X
M.!KS%L'O@_?XAA_19#:#`S32M$O0N$$:JX&AA%FY8/N"_A=].GLVOP)<"0AK
M"%Z+5BI+;E\MG/JQ>$=YXU]_NBHJ'\14Z)BT*[I$G8U=F@W;^^YO\G0F,QM1
MGHJIROB0*$&,CG`LF%0N]>V6P1R$5WJDQS0=RT%I#-:6&,DVBRXG-"99,F4Z
M:E?CR/)58F9K\Z;99?`,V2US-/)E-L=PXP^7L/+)DO*^M,:?B$[;K`8N@4N!
M^S:.0/`"9;%UG+G=!5=+K!J=\41BKX::=U<=Z*[8CQP=()>YLSAV3UBY-HS"
M9M/Z%L22C3(PQF_14^P[T!NO#Y#)?%9)/.961$'GC,8F;A(`&'B:;M$GMB\%
MYZY*[XAD\8P9J\K5^*+0*6.L-T457<?W(HIEP@CRA,DJXN"*EP?!X&PT67D[
MO!U"AWV'Z<-'L_:<K,JA;3O%H&73NDWQ61J50,A][+HO:GWJ_N^,NOMN?GEU
M=3NIL,TGC+-/E_/95C.D[QUL#N*K"V`&9U)D#G[,E^@JO_=3:K;>U9;+/<#F
M)\`@1EF(P6948!%%D^@X*)'BN6+GQ[]EB6ZMA)+#XI3GP#4DZQU#5(/776I,
M/<I],W=U=U`$:'V"0`(`F$OKI0/C&`DDZ"=TO5EQ;F\J19"53.:8C&6$K.U0
M,`E6D^DLQ?9%2B]=K,\(TF+RIH(/J5*H)B;(XW@]E7Q0N_'%WX1\M[['[`77
MJ>12Z_^O8C'1ZW&"(3C7M_%X"_=X1_2H_Y^]J^MM*T>R?V4P[[W#(HLL<H%]
MX.<@0'<GTPFPF$>UK23".%)6EH/N?[]%^U['%F7I2I8LR>F73HR.9%:Q6#SU
MP5.Y*"`=0O(4'8<5^GL7G&/OT+(5GILRUS5.V51C!XD&K<HY2<OA58>="10V
ML:8\.Y=XG$07)BO`NAB5K\U-&'14?:0*8CTQX(^FT<%N#Q@-U1M<>XW1I1H0
MW6>)M&UGGYQ=0'2$S!OJ2NM,X`(:*;..J7_=95P,+5GK\(;YUZC3X?$0I(A>
M9V>B"L)HAIQ=USD)+=JWC</3NN>NUCTB32]EX=@=0"LB(1EH]F/%3(S&_IA.
M=K](,VD'FO&!TPSIBX5LZ=X]Z!);?/`CV/&N><IL+-]85I:"J(VOF9%.EU;8
MEMEP>);VI73Y,_^T8S*S'D@OG)58,%MII.ZZ^6RV2LNV\C>\O#-PO2\@_1&`
M)L?4MK:P(A`JPV<45<^,ES.)@R3>SEJM@UU?#M'&3-F:%!-J0BNZ/'&*7K54
MT=",PGFUJGT&W*02)2'XVTR%BDEU--<.$CK?%GI_:)T.3VP6*3%)I]D!2"]*
MB=C7-*1QV-0T?ASGND>X*>L$M1)--%+()$!"-\K7.E6H'>O\EWZWMF.D6/GN
MO14F(+%_<#W/*^1D8SL$XD>PXQWA9K%:%*5$K1LY"TK6B/3N-7RN4TW.7I?K
M\IJHD[#(-D0*+*$'-%VSMI'2A/:)SSE*?XR\IG,D4U:^OO\@&X/5_:`B$5=P
M_Y_=_7VTY*:SD;2M572T"-8'3_<\!2FU&6/81R;^/%3[C!*Z3([--?@HA$95
M5(&>",-""KLUC+U&=0YO3@R!7-8BV\AN5(+.I6_!P^1HQ<SE'\5*]X@T<R7#
MTVRW*2GP=WUM?56..'[Z(<UVSR5TR"YI[94"JKU*(E'?9%L3]TW$=';!_0LF
M-D.M<J(7+I3D2W%*]YR8)`6J)@?53HQ]*64^),_?+G]9C!.94K(*01J/0$!=
MGJW4S,\N@PN>6-C>A#D"/JSI'`^UYAW`.JV*U-WU$!AWM\V5BL06%<73U]+P
M>Y1CLVP]ZCI=CHTIH^V`=((,[<AQX]HI1V>AJ-W!FV:,%J/BPZ:M5580V2Z&
MDY"C:FM/W92Q5Z&BX:1WGA+[7AE#Q5^!O$ZIYZIRIM62MF>JI7V^(U&QY`"*
M[Z<4BBX<)?1#7E/)T#0];)$<.#>%#0=,A"$G05FB-`!4!\UVQ-?*6MTXK*TX
MT4Y$;3OB'W;<S@/R;9<C(CJ.V+LB.3EM36-.^JB>?%W:3+LBI59@^40X8@F"
MZ!\D:@-M'6'(_*)#"W,$E!,H:),BY&)=9+#+R+?OFLR>PXH5SUB/ZD*.EM0B
M$)JU9+2T-5D`1JA>41I9=>T#5[M%;'!"BMH=Y22H%27AV)U*R?[54S^$ABAG
MO>KIZYD>N6?!'(&5PH8O;E%""9$517U"WZ-OJQE.NO,\<GN$.6Q0)&.&H@DI
M9!LKYUG7+YMU&Y>_3EUM01_-EQR[;X\D+)+D.[U/"14C2]M*H\79F=B."(=A
MC&.5%,?`63@E`_9$!>SA76FI@NUA-1-WF?V>HXY!!)VR$0(+<*`4[T-N+]J0
M&P6:H5+$55/7MU__NA'Q0H!B$*82ZLCK#VBPZQ^,($5+G@&DU=U;[_T+4&WL
ME]&BW\*/B_'\[73\X?-\=O/I<YE\&_][/)H_)]]F4B5P`BRYHFIK<P;=3])T
MIN5R!X5ZN,WML/R75,Q:B"Y3S:\16#9?#3(6U\7[,GDCFJ/(6%X,+\(<6S'W
M5#O;68M*2MM*Z\DPB@T^@K"J5TJ.J>D;86M1PU^';+GTEU+(.BL)Q69IO7(R
M!^TQJ`C]2]>B@VFR0M5*AH?K+Z&0_YTL/D^F_+7UNY[A2%)@!8B85`FVA."D
MAMXT2IVGO,+K#X?70Y=\<`VLLP7GP#K#6!`KQU)]Z7<_9^LVC;/JWAB>(GPY
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MUNV7YL.EBT..ZVLFDJ&`[:W0L9S/X`$YL%P;3A="3.`2!X?D^7`)]H;](ZLH
MI&J[7H=?\X<7;-V&&1"\+2XJ0SHX_N>$/14.QX(R-((-K[#L+MBOL^G%+GD(
M'2/QW<1XI!(^5AH/TT\7"C&U+72`),QM<#M$GN^KVH,8Z](1+@;#<($"V=MW
MN`RSNE8/Q:'[BIBKSGC1^#PQPLWU9#J^OHZS+[]/IJ/%9#:-L^GUY'(\O_WA
MPWPTO?XXY@]>PB-Q[HP,[A-@_1?YB_^[F5Q/ZF<?ECVFW\;S3^/IQ?C=Y]'\
MR^AB?+.87+`.-K6_B!@KZ(JI*+[>=(+495R#3:8=T8&$R^TOVT@X0#6+R93E
M6#SZ"C_G[_AT1V,;/]>_OIDR5K^9+MY^?.(C/T]&OT^N)HL_8=79E>R4#JS9
M.L&M>';6KM)?Z5`8#?6O&4*P[:A#L^S;7D@_>]B3W^K?WGY\>[.XF'T97W?,
MT9\^M^=3_4L.TWNY^3+Z6A7N/RT1(;^;SRYO+A9OY^_'\V^3B_'WSWP87WR\
M7=\FH\]6:IT<@I-6*8.R;PE&U+&]3;N'DL_>FJ?4]%([<.<@H3'I_9R$`1OT
MZ_AF/OLZXL#KXBLCP\GTDC]??\NFP^2+!_0QQ%KJ$&BSU[V;$@9"^USPKRW;
MTY;]-OICM)A//O$OV>3PA)4Q&UVTE])IDKET>5Y?,*]X?HRGN4?WGG&5]UHY
MA_C``[.]TUH5QW&9<2:H2G_55?F2$JVWDK:9%+B#\/M7'CYP_2\W.2M!3:0E
M"I(#VR*UMSV%!6$Q+0XGMQP3GHCR5DX4./3D:@%&:J%$?=51-,<!?9L8EH@M
M:Q^HY8K6B2AOY;$]NTDQ7ANA$`IIP0&,0N5\%RU++*Y-C[[R?3C>[,D(+L:4
ML5:HO!0A]6EJ!*`?;A^.-O0EY5"2(0`/09`1J?0O4`N']RNR1Z"7JP6GO!^'
M55[,S@$ZXZ4W%%B1MI\]3R"M::85GJKR]#%@14"'2A87@X\FJPP@NOPY&2?;
M!FIT#87_B2AO):PXNYM19JJSSTD84J4`)-/3<`A78?.I>^0][\/1;D8PQKE8
M0@ZI4G-R'%AZ;F*`TI:N7_D^'.UF]"`8F;@HI,8<ZK.JO@XFC$W4UF+;Z42G
MO!\''H`FDTS>6A]9+1SZE)33?<`=57,SGH;R!G>8/CJOTB:7<K1@O5=9)NK)
M=!G;>M'DU:39!PA8U;FY3XG7]YF)0"%A9$<50&62JH,]Z`*VM(Y([CPD/G`Y
MP]:97GR_.EV[(0+:8`SF`CZ0C+B"1X?,'@[%GO2V3>'SD1N-H;B,:)+G,(^"
M"!WYGZWOYFR;/1)B]Y3FBM4>4NYUAR1B,;S-6@0CBA0V$O7L?/P7U]:N!.PA
MY3A<;O;DLT_36O]^<\G_?/)Q4DNRMX\I[LQ^/K[TT\O^FVO+Y_7US9?Q91K?
M%2(_C/YX\#^?4--A<^]K9KX4D5THE%T"%U'GGNC#>JM:@G-V7)MU?S"-'6RK
MWDPOQQ\G+.GXY\FW^N-B-/TTN?_L*>R4S8F=(`JT)8487,RFWRF,I:UXU+$5
M!]RJ#1K[`7;J_ELV+(D19'U^U([B?3-]-Y]=C&M_S?6X`GT6.%4D/_OZ?23O
MT_GRP!8`AL!X8@-0=#\'LY+X40L<_[*'H]<W=RY)!QFTSY:L(1V=BIK0]^5.
MX(#A"<+&OS;[+(K9%HK7,CJ-4)`*D`]=#!B4LKEE3QJ$_,YP=_M?=!(7;BA>
MA42F2%EB,K<]HQVAL?3%K1@_?=`]N=?-P?3_Z_@D(*GS4C$>A:B#3\2^#OMX
M@`,A:MNJAW4)/D<KA]/X/;(]'9SIBS11.W"DLXHB8^Y)3FP`D9J(X"<XI"]:
MUM"CK8BCKY/%Z.KG\>AZ_/;WJ\FGN[MT?<:B/@-_^_%!2\]WG>7)]6BR23V.
MHI,@32HZ>2!)E&7V49E2J>]:<I/F>>D3JUZ2[+JBP?I'?8O^;715<XI^$4?S
M^9\<UC[QW$FMZ:MFG!@Q1^5+]NS3C%&Y;Q&-4>LFO6"$U$8NK7S`JO8A!ZYI
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M-&],-J020E1LWG48KJ'4O3H5F@_!NDGVIZ+S`_>)L57JS(B8/,B4B@F4NG?4
MOMC8TH4>V#K?C>>3V>6;Z<6\AIYI?/?GH.?ACXBV,N18*F^>%B5Y:6U//)V$
MR+)IU#<"W&V&9I-4J]>W1\%6/*-6CRHJ)IA$'-IS*"-"JEF^+B#S=>O:9]2`
M=T1)>Y+L.9'EH\=1DDU-V<16E[T@C>3Z:D$$:$FPGH`!6P1B6Z[\00GLV_AZ
M44]53<L\.GIQ]N7+>'XQ&5V]&WT=SS?V9$:^?H/,CJP#4Q)'1%VR-E5&YH9D
M>.5).Z[$CUED-PY!<3X)!/0R:S"019\&2:5RH#7.I:%5/K[`O\RFXS]_&<W_
M,UZ4F^GEQL1P,/5))H4D*-J$@47J$\,@6RYW)>'T-OFW\=<;OMSY^/M/\_'=
MA;)Q:D1$P;<J7[0F**R]0-U6.TRI[3=6HGGK>$"YU[7V"%>,DVR;QM5>+D6E
MFX?F`)PM[8X]<0,>;NG[]T1(1EO%MHK9E2!XB_I1SA1)B<83R::?\_@2;^6)
MM`A`&5T2UALMM?74LZ(+%_2*>HT^/8FW=$4Q15.9IJV*)CGV0U+UC*]6\[XW
MALWVOOS4\_A"[^"+L&(+8]GW\E7+VRV*Z:"%$^1#.^>`5?0,N?GD36[7?EU!
M5=_2=S%9)LFY1T3?=Z@$I:J;@:@+XS@AH.>U0Z]IV?7\[8_KR7]/)U?_\_?%
M_&;\][_]8_=UW#K$[\[;:Y$8,:<4H!"BR5'>EUUB7G8'F]<QF[Y?S"[^\VXT
M?SM_OZBCGV[UQA#S_>?1$YFHA]OYYM?R,(A#D[2%.K+.@`D<KWP?*9LI+NUG
M_TLXF/LOWE/]8%,WK^SYDBQ=-4N22).QWI!D)5DCB_=]M$4,E-0+2+)#$2AF
MR8!<&X`2.,XH3LKN/"G%5V;+(28?,Q8O__8ME[:NK,-62XE-PP<.\AE%9ZV[
MZH*D$$13,(3EVM2&I7V=CS^/I]>3;V,.C&9?QK^.%V\_-L/:GN!A>U1_TI@T
MLG_E0`<$,2S$?L9/*BXT%4&+_(E&C4\MYUG+7A=N,F8'/GT`RF",$+T+LA]-
MA-`.>Y>,]@79PZ][!8W:([M@CUI#+5+U/:<E*7N6@_I?:NS""2<5O,BRUZD[
M).7JJJ6,)E.28/LQ?%D@NI:_W@!IV/NZ_6(QG_Q^LZC]#Q]FM;V!Y9C/KJ[X
M1GG#$LW'RP2V`TX`.1%ET#$C^_$"AIUXY_ND5R8V*1E2@\UHR'H/+ONZ?75:
M4?3:NXR6`R**]U3HLL;(C3G^1&:)MOZDI=]P&&W4WC.LB*"B]Q)<REULZ`/$
MEKWX)ZVT-6<E_MK-K]1_-<-:Q^C8%%SH?)&35D9J@JV?L":GCR$^_W1U<\D?
M?%=9GV?3@_@!5<AE[V*@E$PT'*50EP4+65-;@[*(=KB+VT6$%U?/V@0OLO,O
M*7OELM!%R=B1!G-,$%)[6/C&M5NXRM/7SP9G(HS#HA@\>QV-"+&(G@O<5Z-J
MKDA7&ZOH5:EG+8(POM0X-RJ^6!QRV!]%YVPB9=^26!ACM&E`\0'U<\W?],_9
M[/+Z_>SJ<FOOP2$(6N-4")4"#$/(T,4BQ4<#34%/"6G4,HY^M(2ME[?V]$;!
M=SMFXRBPH1I2JEM>+KPCC?KYZ!(M.[=G+&_#X9%!)J&S4Z(`_]6F>PK.^L*[
MY8>ID%@N^Y;G+6^=]CC$-XIA0D!A?1%U6&4?)$&=D=*B=JMIN\VMN9'\QU>V
M[8%DVH^".)=2C)'AJE;.I^`Q=:EBJ8V!EHU?&25QV?D\7L3V*URG0:M%+>,F
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M1&;$%YN)\%Q;=`\T>@H476^&T:=BT:'/!#Z7R[33`-I52WV2/%S<K2N,NT_=
MY?A_+*;E;/[[;%DL<BN>][-RNOST=?:^F(_QN;`J/GW%O[\GW(._YP<ZSL/5
MYB0E:0E0CR%W[A"4A$"S%!UP%TS@'9V$E#PU%&:K>87"_Q3S607)#A0U(/NQ
M$"J"YR)8A(#K*@\Q9BQ8=IBB[F!M.#4L/EW-B[5*?"R_H5;TPX%O=J"QN3Z`
M@05<M@$]*LL#1$%$1B-;%99$6S-.;GWD99&Q^+V<]J"P!P(BA!0@@E)&H'DG
M"ATUA``-!,892K=VS(9'^=$0/*@3DO4.MR`@GAD#(:#U#4T[#QY8NQLO"+5[
M5]TCQ\-D'226D2E()U)N728-D3:!K&7U%MJ7S`#MOO:'"]M$'1]&RV)]+5*K
MQ>ARSR7D\:SQ]B60Q(4&GE$=390VH`4*BD<K:=#@I=B,$::KZJOR_8]D?:@,
MC?C%@'J,P=Z&BW'B%;5*)T]9!$<]<QDN$@']L:W\V0VXQ.9UV>GCA::\@BN6
MEU?+C\678MH%6O5N44SW068(AZI5FF>6>BTIAL8(&7@T=APT=$,&6IT59H_<
M"+<A\X01EGANIL>EEMHP9Q`R@4%)0A]`=4/&@9T79`_8+;=Q`JUSQF8P*5\+
MHK>0@"-.#->G#,J1;IR8>6*4ZJYUWT/5V'XQGI<W^3BJ/]:[VT%CX.CG,<Y%
M0GO"0*;Z-)XDYDWXZ9=)L5C\97DUFO[%D'__-PKD/RY&WQ=]`^B19$#V#\5%
M<5T]]'Y>CHN^Z>V.5+=G([?KD$H)HS"R24RCTN)"#TP$CY-DNF:#]@VD5ZSV
M4!:+U6@Z+JH@]^`.5]HIR,V%T-N.N+R\LQBB18__!Y7K)#I2L;J<@DT9'B;A
M[<*Q%_]8K;./<-^:_UY\M>-Q=M_R,>=\-L5_CM=Y1UN)28.?*J?C\F92Q-%\
M\MU>S"I8=VH@GF%7V$Z!$PY7J\KT?3JB5HO<F#`*:P7E`DC;T=WMH;H/]C4M
MEL<_977V4?5SWZB6OQ=77V4#,B!_+6:7\]'-5:8#J,"IP)U__]]?/VT-$3;/
M1[QUAC)M`L&M3C,"K+Y:DKD<8//\,/[QX:=?5"L']=ZCZ!S[^JS\T^A;?>SC
MBFGQN3S\#D@*I913T0MB>*;V<#XVY>.*MMGFWC!FF.*=(^F1Z7'R[SE!4Y"H
MU2+Y2(W#S0)7>DT&[5.FPVW3,^".2]BCY?^0E\BJ>!#QIY#)NZ!3#G\%J@T1
M=9F6SDW`5+L%$FLU%>D6XT&2#L55B@9O7.+6<*=RACF534]81ZUM!>U2[Z:R
M'B#HO7@!]QY<:A>3L=J3(#1Z\"E7(-8B@\6W6B(3D+LGEP>P[ATN_-`9)^>>
M!\\3[EMJG4=,ZAM9IE6"MF9PW,AV3SD/DOYFCI)4C!OX[TE17;1-+^I>S*-N
M1V>/2>'24,&4)A+ESY=38&K3Z"T3[9XY,B?HZYU![)?K"0:RQ[80G5M^9G9^
M)E4*Z/MHN+LC:F?\"2%VDYH?,)!Y^05?_E+<GD"\^WSW8L7Z,EQLX4:3O&U^
MO"J*Y=O9FD]MRYNHMAF_R2+3<A>:G]MPV<K%_VV7`L[F17DYC=_&5<^[G`0\
M1]!VONH_BXM+]%+06\5GVZ*@6E[4;Q47^\H^K':@%"%4)P#G\V57O;"]3;:=
M&KJ;:'T?:$]N+O8`&&[1LXOZT8UX81]?O/1`4T4[3;RG6C6]K9@1#EI;)[3(
MF$\6T;LD_V?$4QH2+#ATH:2-GGB1J5_6KE0TM&-;;V_JSP+G%E_U*S463IID
MP42M2#!HQ97238\03GQ'7<9NAY"SG(LC*K?*E_PI8)ACK$K2Y=O>6KE!4=:Z
M#9`=6^&)(MIO+.ZEVUO'2E]'-\\W)U8IAOXAM<JBQ0'#6"`L^LBBQ+]%RS^1
MN[R`9S@EQ]P/J2:!2H?!F`[)>_3`#8O:6<*25KYU7WMT.._9M6HOI'8\GJ^*
M33;!L[#A@DJM%01B%6="XWS0.N'#&,,[YJ,=>]X/WB>:DX/4_$SGA&$PIY5T
MRK*(3J..E#2QG:.AG=,@VU?"9SPGQ[3EVC)(N6563$R&Y'+F^AI8QO1NX6'5
MXN.,D*V,^MT9Q(L@S+SU6D5&A5?>!0QW9,V6QH!!FY91'QCM[`,X=T4NYA^*
MZXKI_+*YS*D:*-.N0Q:Q<YODE3`>@8<(Q,E\,E0?;&4F9BU^^N4]E;]UB3OX
MRT\C;>ON2\D`QFET&8/UX"0(J`U%\+FM[=-*>Z<$B[_BQ][.<A.!<>XP4'XN
MBXLTGUWCXEY=KR99=][Y7]%IFZV/>^/GS\5X625;5&GFNZS/&\FZQ[#-:R%N
MKR(Z5\_'T60OZT!NB4,Y:K)#DTR"`E/?-6H>J6^S<[/^X/-IP7RY&?OSM&<,
MU[),D-GP$MHAD\M+:GND%'#1KM52_1'5JY@R>?*+3#,-+@E.`4V:`RI%:`JF
M0D0+USH0YJ]\E<F37V6<)6ZM)E%1'QQ&$2AVPTPB8D?5/C7]Y\8O.&<-7?QT
M_76_3HN=+UQ?*JRF2P1VLKI82W/[JYE__A.&U+BAGN`&U[B'LYNJ+5EVZBK,
MUM>P>[EGF,N4$2EG6Q.,V27HIB&X-[(5DKSI]^N>`?H3F_077+V/FG2;6ST;
M[BA$DS/HA+K;/%V([2IWVA\N_6"S_K+;[*-FW82$D3$W/L:8.$84*357@"GP
M%GE0TQCH_R?]A3?J1TTZ:&9#YM.UFG.E/;6QV<%MH+%5YSIP#/ARD_YV]O4Q
ML7_5V`!,I)9*H@07RC<<,[CI69VCZ<Y@>NAWGT34=M(KP=GBR@B7N!00@38,
M3M*J0/WC18VC>7YBT=!/N=&B'-^GP)9M=1OA2GH;N-/.T!11M/KR.SF3R,YI
MT!T]%O\9^)WTG:(\4-@_^X4E.>DN:92U.B"TQ*>F]-%K85.?L/IG4$<0MIUU
MNRDL1K(<H"H=%5)(3;5NB(70"=\EH+D35OQ,X3C"#B`K<B.`B/,?*2<J2C#D
M%MGHI.T3EM*?@3Q&VE!.5A@C'*JVGA"0RG%G.15"1^M#S6_#E;6&#J@MZQ>W
M%N;!`@^IKI-5OJAVT3/(W8QO.48(=;N\O%NJ*XXD\+#Z$H@48T.7^9-IR"WH
MF:Y+R8)DIM<PH/K*XPD\@+"D@63JR62$8<"(BYHTE(6X9X8!%98#UJ%3XFK/
M>_>Y<0GRE?>[:3?']\%I@T($-,E:^.!1RSG+R70U68^3B;?.Y]]0S7:*]0^1
M[PD'MB]%&<V@T51ZZKA529M,4K7>O$V,IAV@<L*E?LJ!W7*K?!I]RQ]=,W:N
M<+K?W=2-P._%4+$U71`<UR1(XBD$DUEL&X(*RR%M9H_=5><PP78'=1_9GG)(
M?_8/B5,%J%1Y2+G;=V#.U_F>5N%(1?>0I'[1(;6MV18+B^21\&0Y<=3A7J&M
M;Q95KD.7/;/$7WI(`[.$TDET?\`ID=#U%;K)GD?KQX4V/4."(PTI!Q#3<3E9
MY_C:92HN\-.3'!"MEK/Y]ZV'[[/(MLNNG/+4,ZFX-SD%66O:)&DZR1-TZR27
M^P9[D-3/@L+`C+L@+!4Q"8M18,!_)-$H<<BUZ#T8M.SGB8/07LD[I;;H?T2,
M?PT8+S7#^6_V$1>B[ZS`.T-5&%[\R9),YJ,3]^BO2^=HT_C;02(03E,5ZI.4
MK2="B1_,R1#E:'+HWILR75#2C`)HQS#.HOIVH\K\*QTHO"$_$[/7K!\F]O/@
M,*`-,6#D9JO^03PE(DDFREHGS2A&H^W!09NSPV%XEW?<X^3F\S",MIWPG#5<
M:PZ=&-%548XX4*+.$8<!?1"&&H[[HQ#)!H_ZH%B=]>T2AG&T#P?ZPCA4&7@7
M*WSL[Y/F5'2S<N@^%5F#YD);D0,0Q2E7'/>*IE;59;_==1I-<JAV'#B(%P%I
M0'=()$&9X*36J"K>2MY4;]"D:.K2'02)'J@Z)P_2GG`B4-QT\ED.".9H<KJ)
MT7&A21U[0#K0!SD'D`8TR>?N)Q@%5R?)*;._F:8DF1@;>UADZ-[(^.5!JNYQ
M#K4^P'-V$Q@"N8R2<"7KFE;#'(#O@8.(Q\-1B7OD@0_H`66<:S!,F:HL';QH
M6IW0)"+M#MW.8^![K(2*,AG&?0*F=21:-0TH7+(F]'`"D2>P$L\Q\,&5;X4,
M/(7@5(I2I`!-WX%`9.]&N_=HXE@#KSZU02YR\-)FA'GMT=M*&)J"BA!I,]ZD
M6-<9X)L'F+I=,8\SSH%Y#2X2HS0.3B0C#2C<^&J+CKOA%H_\YCC)@?'6,XQS
M>.%:GH]QC7/>H>)2"U;510@VD"2[H^N.@^I3&.:08>8JA6A\BCPW!^$@P3=G
M:L&G/L/\W+-9Y53@-IY3*B:WS]V/2WKK_H&C(V*X`1H-SYY;,KJ)#H4+7=K[
M@$7:)^UQASTPRRIJXAD#:G'W9=08TG!IN%Q+UGWT?0[#'E[#1JIH9$@2J!(D
M<16;#B@.-Z4^#L/S&/;0W4T,:*T23SY`T@[R17G3^81+UK>F#_0YGFS8^&+-
M^W3H:C;@&02GG6<T1,$S#7MS[Z85].Y%!SH9=P(^]=@&)E&C&Z&C(3$EG0*Q
M5-AZR>H@9>H=V]X;N&<9V_"Z]%'GFPL,>+R147HB:]\0HP'G:=<EQIL''#`<
M;VQ#IA9,RI?Q*:#G+ZPVZ=;F@#6RZV:BFK<#SV'[QG9],YE]+_#A*NW^/C1P
M0^Q<+A<&JL`8"Y'0:"$U#6LYFA?;9KXW?)>^;J]$CY5_B+/+2AF9SWW8\XU\
M;J5'FDHP7$*A1;[':*O'\,/D_UC,OY2Y"G2=`%5<Y.8N&)RLCR,FDSHS]-WG
MNYS+=2/XBN'/CV[*Y6B27^WBZ^YIF;'3A)8*@KX=^C0V\R!$79.5:<<I:3<0
MW"WT.-)`7@RLW:24K:Q:=`E!^DSRIX0()()HFF@SC-=;I4PM9LQ7!=8>'M$`
MP@$0)A,&#2QXYVQ]@(Y^).&M3D"LSR"\%K`&-2OWY=!!@Q(\=U/AI$E6#2P2
MU>Y+M)NO?3)@X7Y34T#FA._-=^I3EX--E`(6A,(@FW$')A(=S&WK>LK;5;H4
M=LM6GD;PY\)B2$\\59KD:Y9(<^*.HB0T)3P1/;^6!9*MQ/XSPF*/@8$(,G*3
M*_F%Y3$[4/6:R4F1[34#YPW%D%IP(A5/FD"@.:DE%VW62T3[)-KNBX#=(I]C
M8/'/59D)RY=7LXL[;J)W7Z?%?'%5WMR7-OWC^*JX6$V*=Y^[O[#]:E'\/KHN
M-AB;1]>+U?32E;-%>5U.1O/;3O5[B?H%=493D;PD*5*33+Q=;I[X;M9YN@GK
M?3%X`N0R<.R_Z<?`3@([+G'+UVBA*<;>#E*0JJ;>D!XWN:X\$[*=#OZ$V"TZ
MPYD7PFFKOTU"1]M@W,XC3X1#3KZH+[PTXWXK<OJO#W_[Z1=SV^-G'U*+L\-E
MRWT43$M#3.Z'87#7,Q@NKW$!)G6[@DVW-OVG!.7E#-*VG1<D..5S8P2O#<8@
MD3=G/;F6H<73_`KAV%P[.A!M,FFB85$&D9M[UJ<.P(W?ZD=9K9TCP/'B1G>[
MGU[201%J':,L)6T5Y0TQ?828^"X@PG1TRWH]T&Q%$1A>F9@H1J-!<FXU98V+
M!%'%5D&):/4>N!<NW\:YLG7+3^KVI5(Y'4W'Y?32YA.\ZISHX.H?0HUCE@<A
M$J<AR<!2;0Z"R+E&[7ZL@FUW(7B4O,<<^3Z6<<ZDBUI)H@B#I&,43:=-B8%B
M:W=01"E]I)'?$IO].KU9+1>A7%2M,%J9VNMAT3L"N-6BS'70=HR*M2AO"\`K
M/?<SU+#Y93$=%^]1JNO1N%@M<Z^-#NZ6;;\+W0<+F>A!*1J(HE+%IH%KIOCO
M23?;N,H:&,_+C_OV6][/9SF=X]V\CECNON+#Z-MH.2\O\4?:6&W5L7J2#_)P
MV0BN28Q*A2;SE7E\I=M#I8]`ZK=BM%C-*W/UMW)Y]<=T]O<%BI^[<Z^_8OOL
M'O^WFL]1\W)I[.*6*Z\IPU\W^\Y%^$T=XL$=D[UV"5>2`.9PB40KS&T_8J(9
M:3?[,8)O6Y!G&]L)(3K8X=D21KECQ$1.HQ),N+H#)*'HL[7H-D1N\/QC([JG
M([50P7*9#WF(,A@/>%`-5Y'!X*!EZ]\P(7YX0`=[C5!EG5-"<]3-JCR.UFZS
MMCSZ-@]0IA1^?8B^7\W'5Z/=#N1'VZ5W2/&4,LDK1W.M/]H+T22-.>\%:]5M
M,R5V[Y*.A<;S0WZ?2P#'N*<YXI4>S8'0%!J'#V(0H>6^OVJ@AHZ"+08X)#`%
M0#'H(X2GIHD#:`&NU9OL]0*UY_H@1>.EHL*;9),7'%%K#IB\Q@CQAP)J2*."
MI#)R9Y03UN3&?;'A"H00>$>*P.NP51^+Y7)2W#O%>Z<%'#551HG&N#1Y;1VK
MTTG`&*5;+@N%(R.V,9B7Q&Q0S5P`C,,B^F[)4)GS#^L#&@74VK::T1\`LSTV
MC-E$).#*3"8Q(H/4LL8,,FUK6\^.O3)/!+,A/3,\&2(E`B2T,CRBLC6'QB9Z
M:/=9/27,%KZBLD%/.;^SOI0MQE?3\I^K(<N^D?$;O<HU9192=!;765U\HA-'
M[?%[M[E!`;;%+Q'&XFWY)?OS2_Q0KKRIVKG\L2@^KR9OR\^]%]UW=(J]7[)P
MWW\;_6,V]YE)^,XC_W7ZMASGJ^B+]Z-ET6Z%4U'C;?$L_C;Z5EZOKAN'?:.3
MBH40T4&W"J1.28HZ.5I+SY.MR/C5GQMHW6.\YPD0_D070&BFB;!*T,",YL1P
M)T/CDE.5)`+$SP^?=ZOE4VD0U\%'A"0!.DW2AH"!7L/JF*@,"!#[01#J42'T
MCM#^2BLE\YR1S'97K[&*VM_E-79>"#6?"<678C*[*2XJZSB;S"Z_?\A]P!^N
M3;BARPC>:R/`!B`\-,=@QJ)%XN>G34^`58]><42&FQ1,4(Z+$"DTQ6K2J>C6
M;5^.@]5B@\R^OR!^7SX],>%?[%U;=]LWCO]$/H<`+R`?>=WI.=.FTV9FMH\:
M6YGHU+&SLMU.]M,O*/UI6Z*LBR59MC=]:)-4D4&`N!+XH<9P,:!"@5H6PL&V
M9D5%=75Y"=0U0.Q.XS&.>'!/]?3J,RE2UI(46B4"Q(C-W'K^$]DU1T@AEI>#
MO'66/66:GVXH"0K0"1)>HJ]`,,8/"40&&T*W?E79;NGG&^;9E@;HZ6Y<M,)8
M3\3&QF!"4FV_9T%PL8=6YX\M=[F_,O;]<'4Q_O0,%OYP]?/TNKZH_S*^&8^F
MYQ5C<V#K%LT92D2CM818G.$\Q,>B!WN=V0+J[D7B_?'OXW1T,?XRFOY^PXR;
M_:;VO6Q67V3G[SA\RDD2>PIV%,,%)#+FE?-MW4!6#CD09UH19>9;@<HT".12
M)[*[!Y*ZV.`5.L#'C7)'=X""0!1$2RX3<RE)V28*L^),I*N@*2665RV]=9;M
M[`"3R3822?+6ZL2_,Z9ID%*A=/=,.?>.>+:O`ZQ5(^>#-(5#;!6U`=%@Z[5U
MI:_9:NSF/E\9^T[C`%EO`4T2$#1'6*Y"B)AV#1,'9Z_>D)_(`?J0BS<Q%!E]
MB,FFI!OXBE8AK&N(/B+?'OV=83#F)^;7QS_'EW^,?V3F?5[=4OVTFX_>@D4'
M6&1VV22E!F=H%"UB0PW.T.ZB99O)W>/D\^4D%^/IAT]E<G,^NOR-M6.WXV,T
MR1<5G,."I-&GUM5L0%K9#9<[M3RD?`"2]V!!_>N%/[O;J742@91!%[/)=7[F
M'J?5D('0"1V-VR6=?9K,?4]Z?;>C?*5,1BE'UBD'!.Q2@FZC'JS'713+=^``
M)V4R]SSIQ\_3\8Y"%2*;$`TX#%*22DZU?<1&*(S=5<8V[K//46=T[GO6/Z]W
MO+X:]`RYP^JZFC48UW9(&HZSH`_@8:<"UI-4;GO._YI>WVR8?CIZP!X@Z1",
MRJ0K'IQ1H<U^<?HC?<\CM&)YB'73$4_)C]W+47SZB'78D@-+&656(;6574Z%
M+I[4\V[D-\"/?2-M=ND$.F3C77U_S$Y#R^VD(]$#K`BA7Y@U+YKKEB2UL;)8
M[V1=G`;!Y:8ZAG07,$MTM(-].3D_=E:=VER>.`&K-6]GI:[PPH/J0,FN@]MX
M>=4Y59)J$FD=,)!V)J24[?TFC"S92_57Y8BJT^V9?'&?DR*`D"ZAXE#$9W22
M[E^6.)CN85F<%3MP8WF;XXOR8F>E<3(F*"65X@L5,EBB:O4+HZ&SJJ;;B/L*
M6;&OOE084V]D*9DC$@&@HVN61`&X+O$PPG8=4L?CRF,KLK8W_^.WF]&_II-A
M3FSI*?D%:K%901(IV!A,CJZHAF=N$2)TH#5(KD.+>B$N'C_,#5$'(JM1020K
M7&[YG0<)?2T?K38[O#*>E!<[FQQ/UI?:>:>2B)8C&(S4M"M1["?NY`X1_ZE8
ML:_)22BLD5`7^QG!5J?(^VC.9,3.Y-3%'.^&*UN,M/I_?/@I__>FU^@BG-*1
MHU^3O591Z#QX=M:GW-<6%.$.3QD=$^?[7.;8AN??XO5\T?7LP_>-HW4B]O*Z
M]HYN<&_M+X1O][_\RV0\K77T;W^M[%M<LKTX=SO[`"Q;^(>O?-2^6J;C_[FK
M]*[^OL>-KO?=NAO8GE.,T6)2R4<C*7C=ZG0YJM`7.AZS>S<>OFK^XZGXKX/#
MZ$2-:"U+0-<M*\/3B6:7TPT\$7:^Y1V)09Y*#*#KSE]1+$>#G(2BJEC$0T)>
M8O9O3`V.RRS.+125HD-1"C/D@,U4J[HMJ+,9K^S.+CC$-VRZ@RDJQ@!1:NE!
M>%^4;K/ZA7#M4.D[XO_)3'?QY'7)28AL,:H28!A?8G/N''9)DH$N%GY'8CB9
MZ=;6ZPR:XQ7A933,Y0:P6J+,<6WSP2OD_W&9A2A-)%<!8HHP4'04P[HBH9AW
M7<?!B]S9AV&R_U>AMY28<ZK`P"+*&),J;?5!T2R;[KEHLQ#6,O+U2^)DEMR"
M$"$JG4H@<%1RI"$)*MXXW>6>'2SQ^Y3'R4RZ22Z'G#!X1(3:1.;;/@.#HG3R
M>#.2./(USE(X9E:4(&(&DDB^P;"3UCV\]BN]QN\E0"?/OM58*8J0*`1;=3_4
M!4N6)#IYO'M)G,S`RYB5K(//@,F2"XY59`A[1('<]Q]`]VCX+@5RNGI++&1]
MW6!%%&260`E;[@39O@$+?Y+PW2LMG2]>5%C,Z*4!YQLZIL*^E_3X]_CC='1U
MPU\PN;YJ.&AA_(D_\W'TGYV!9U))[+.JJ61CF35@]@W]"9+VW>O^F>H:A;>G
M[J"G6KOU@DV.%XE*W1U3P&6A[L=Y;>[[Y,Y<]SITBE-M`&^)&HR3P<3H@O+$
MME6U!3DVQ=A5/\[ZMN83G6KM)ILHV/IDE9S4*4=;WS6'4Z4D1%<'/H.^5_V9
MQVK_]\/5TC>D\73RQVB^*.WF=GHWLQ@_7=^F\0U_:M;F?_.7\<6_V7P\^L#.
MRN>L+1*-+*+.F"?*MLT2):U][JNZRT7=`Q_@Q9FS%M[)@]`I6$4ZJ``D7&BA
MM0.CNUHK="^\;YH[FY9E1</66M8I1Y6A+LP:*M',G:3Z26*[W`#_UIFS[NI`
M*:Q(B?/9',E9'R@,+WP5,2SWW0'+J_E>ACF_CBJP_9-[$[8P((4D&T^9*=B@
M#(4<=&M'@Q3Z-3YG\NEKT%&S%]7KQ)-]B-(HU%H2FS1KLVT/X!B!NHX6D$]K
M]@&IWJ!Q.F!%QT3G4Y$F8<IF0,*B4%+HAD[@15B]01/(E\A^-7AVI&Q.5<Q4
M&M%)VSX06HX8MB;Z^OKBS\GEY6;4DH75]H9M>BQ)>9<-&BHD[E>:<N3663$@
M(U"Y10J'G[PE.<LC*`O@YB46%ROZ?=)!"N^IC5?49<`]SC$JOKQ:/9.<.370
M00(?&4DX0\S60H7G#-$JE>+]_B!PI3>.@+:[%.O..*-V.KY(=S6[FN\*W#TH
M1/['1"\*)++*%L`VZ&)+]MW%,,HM5];6T;,WX=O)J-Q]&7VMPO'_WKISZ^/X
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MB:];2^2!&Y>5&]L)Z/&-/0T[4V&+"6"@L$IC1:1`A5F2<B5RRK`"<WDY3=B'
M*8O<G:UCK_9JOB?SZG9R=<<?_O"5'4%5X*&`<;^V?7SSX^3J>CJY_<8_=SSE
MD(R/OO@M6^UFVV+C"]92A"P>B3^<+62C2]MTCFP*^[A7&K2+NY->\'ROBJ]K
M-U(E3ZI:4D*?M`.OY`#/Z&=<7C'PH0W"=[YNV/YB4RG%6A,IIIS(.;P'-?))
M49^G26T4N.]\W;`$)EI#V;H$6AOK0_$16DW=LC?JZK326-"SFMQKX^NA+*,D
MXS1:S(Y=LM(51,NW#N8*+=FOQ9%.K>''T4_R&M8JBKHZ+$6;2ZRN%CB0;.FG
MY01@Q2ZAY<3N)9FV3B%R00ILM@L!:8["BFDS2-*Z$/I$@-.%VI1PNJ.\!OE#
M]@'89$CR2J1"RE-#<,Y1R%[^H+HH]J6XML'3"-9SI866'`4Y$31B*S.KDEW?
ME']F[-(NO!<^R6N0O\Q0'`6AC41TJLYZ4'N:+:&?H#[K`%!?DFGK]#\9&815
MRIH22B%CE6^K$!4A=C6J,T"MUL7%1S_*:Y`_!P2^1`A>9.%%$BFV33=L"$H/
M35:Y=J`+P/%$_L_HR^1J%FK\/+X:7=;=K+.(8@@NSL^G=^.+564L>/I9/A:+
MWI<4(@('Z;H%\G7,#/L:.WN!E0?:FKRGCC9#-1JVT^X<S`0A$)67.;`W8[EX
M&H"='9JLY(IT1!&MBF8Z4O8A]P'*?7Q>T__)I\GYC#T?[CCG?E3UFQ?3KK]\
MG8X_\_?.'NCJ3UJH%SSW2Y:J/[_>\H<?U*3^A>NK>N<6?MBC[_UI?-O>4>J-
M?7@L_##]V]WH<O+I&\?`<73SN5Q>_UF?#S?"&*9<U8:31Q-B37:R;\DC:?"A
M;P59?HSZ+JNG9?7WJ^F8I?*_XT?VI,EO$SX(*1M3?:T`&Y!#');1T$YEC.MM
MP1$ELLYU803!9A52C%)4'^PLM!'DB+J[/H2U_^*H%^BW=W2!#JSL6$2T"2BI
MV0HF$K;UZ%6`2]$G&EV=\KNLCJ'LT2N':%*%H2@<Q'!6TQ9"UG;S/@"4RV!`
M!Q7,IJW(69,PQ;GB-40PY.1](ZL'VV^[X"C%K4I7#DKNN[E'!]9Y(Z1P%@UZ
MK<&EVNC3UM<:3RN*"T?5^7<FJSUTOFZ<@HC>Q!A]+.A,>W8W2JSHNUN=NQQ.
M+.N\O&.W+C@ZE)[3+*#L*-Z_KT.ACE8GE*)5!=N#DGOZU@EFAPD"4W$Y2`WH
MM&PER"B+Z?A"=G4%ZCAL>>O*=6!#Z'.*F07EDU;)*V5R0W@USJ32O=*>'=O'
MOB=9[6$(9:U^<EX@8A84J"Y<:74<Y!2BJ^,^4RP+/2(_7#'YUW?SZ9WQ9+8W
M=>?<1SL!UJ(M11(4MN:D!T1MI4007?<I<L"M:9GVC70=X"`;S#LX9G7.1@7+
M44+63KJADJY(ZMP#"W#XV94?#W".6I)JLTR3+1?0+[RC&-)%AQ#!`R8,^KX)
M-'D159<S@YMW)&XXQQ)9!SC'!GF4G*.#VHZ7020;M/9#8UB@X$0WL'`&I'3_
M(+3O2:HF7]U>3Y\C"A$T&)](R>@D!*NA=>0I2]KV_;A\!UVGUT\3M`_I&[BO
M@BE62"5\\,*(2)SI#*3K##TT#V@A[2:UWI[TF9$>GK&KA_LZN1U==N"`6XB`
ML!9GDG-"5DTHI31TLA2][ILBSQ"=Z.JP6U)WL$-M$`[G,B([;2`1U99OCDJ;
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M'_65\N(7_O=T<LZ_VEI?9`P8DZ,Z'*:CU$ZU@-"G4A9@4)M(5F3U;T`DO[UB
MHQ5(L+EB=U"[RWU%XHQM+U=((-R[,5HO*H0#&:U@@V1E4/4=HH!$AWG(-'11
M:F'GX=LV6B\JG+V,EO-6Y*RPA"!5@>R=&(R6BRDO3$>_8:.E7W>DQ6H`0?BB
MI*C@-II2VQKO0'-J]#[TXJ6%<""C!0XIDPM*9O`!I(0&L^VCE0MS"]^%\S)&
MRTBKLB5B9U*4D4GIT"*MX./"MJXW[.3UZXZTI#6<7M?\0QL15$1LBT:B*T*5
M[T(XH=&*-L44(!$*ZP19H1]@/5P(Z=T8K;<3:7DG331"Y22<`5$*2V,HI^2*
M3+-")"OZ.P\KDK7CDAOF+Y>Q,D\S?)E+*.A=,A:*1J.<,&W%C[1\[7M8-=5?
M]-W8\`IY^+P=UCF5'$U)!3C2YU];*LV-5E"@;A++J.51[!.S[O3KTY.3=6S+
M<*XD8TH&V!<V?(DD?=\`*77_@/GF>?B\ZU?#!VUCQ?6,'B*;Q/O%'4@Q],@3
MA[Y^*]8I;J>O3Q<X5/(NB*(46W6?A`6IVW4(`;MN*W;/U)NC;>@ZR%'6K5$V
M(7"@`,STHE)Q$-*`NVK97(B^<8R,TOV$S=Y'^6E\^PR9/'XS\MXH+QU'I!@L
MDZ@#^/:\S4K:/80IP1&M6'[1VTS5`8ZQ#E,H9^OK9)BRF2VUEM%3;N&V+Z:3
MAP(+J):[L'8_QFQ@9.BMV!U73#L11!W22<HDT/G^"8EMI=,=*BCU,YH+!.Q,
MW#H`%JEBQ8LDL`X+%8Z5V]R504D]-A#B"E5]/G4;8,*$(HK`&LBYKI,256I]
M,62833U<P@K'LA]UZWBGF*H8DTY!*\BY</`U!+-46S`ZI<(.-W`]=?/G\F\5
M<>7F\_BB7LYZ6S]\JEYZ^L?RN_XFNZQ]0,"`"8UU5K+DS?WN60L]U@Z;O3Y7
MW4C3_F=89Y!=]A:LT:&0SEBR,FXH$D8^3H]%6S&1#G6&I];$/MW#(@6*&-C`
MB@IX1IH@MU$#8&O0P4H*-KO++2P//WP'JM;94`[6*+&R0Q929U%3@2'@E9R<
MJ:YERU73L(R4L8FJ7T9__CCBNSWAG[_'E94>K2>LB%P5>C@H61HDHPFBQY!;
M`:^VF:2]3[#NPH*/*F24WI7ZE"`HM-0LNSJ_NL*^]D\+SSO!/Z^GO]\']OO8
MC<"49L>6PV;OG9(B#T(H%;.ARY!T#QZ[!4W[GV&=&#*$BMOH.-SQF#R'0^U%
ME/\E=7?I*YCF`<XP;P*==V<V6[]S_`"<6/DL58D:4_%4C+AO8BJQ-R,K!F-6
M4_)\<M?"A5LA$WKK(N;(QL4"R09!K=(*,-U5C#X@N9NP?X6I4$"%\U1=./6W
MJ<2&^NICZ6<0^NCLT.2NQ2!-0BB,!H0!3AJUU__'WK7UQG4CZ?^R[P)(5K&*
M?%F`UYD%)K%WXEE@]V6AL=NQ=FQUT+*3^-]OL76.+#5;I]4W=<M)8"0!6E97
M%<FZUU=CRPOGR-3C;$$?+VY%[\T?:J<5Q0I6`N]`$F,P9Z?'E?0FB^_>B9?Z
M888IP9V3C$^VS$3"M^*KA$0JJ>1MJ6YL$4HQ8^GTV8N4[LDVDW`AR\ERA@J,
MS@3QW<;=4S9@EXP[J72/O&W$$6KG+"M0+,&:OD,@;J+I-P(\YV/^7G9$):/(
M$@6;Q?ZT^3T?85B$$ZGF'N79/F[NSUW()].8*5D?$6V*,:1,MMA2!B$;9UUG
ME5ZD=$^F,5.+`'0.W/KP`A/X<+=3U$(/QGM2Z1Y7%`61@$@G>;WH8LY%Q4$4
M$GYSER+:ZS7_[?)Z+3B0Z:?P_C*;_[RX_.5#PU9><KL<K%I\_=_TUXFEF-J)
M(31D',2&KUS'?3#HHWY@"-]^>"_:WZYFYQJ!#RF6@&\V^YL(5D1YOZ)\-SC1
M/IO=O)DM/KUZ/^ZFVMAG].;K+[-7[^_]OF_%]G)U<WDU'MHW&Q^K,A#`*1:>
MN&*U0;Q5\L*62<7^V[^_UNJ_[S&R$]T/67]LEFM3$DQL;?$,.B<LK+0$+WY(
M@%@NJ=\RW=93,#[,-STVKS5)U%0.C+!5$HKWL6HABR".L*;):>KK"%IITFCL
MME2%Z]O6B`_SC^]FBYO;8=+MY,<-)]@;K*JU2@2?&S[6+:E0=;\44R/(+7"/
M"G`M27O2/R5J3>)Y*DK:M8DKZT(=O7T`D`\[E:)8'BRY@]!_NVEFR[1MJ_D%
M6Q4Q6I5SRS@.,6`LD/L;:XSVK.@Q@@<:MB9Q4JCR=,2YTBGI7"3$AYS'5+XX
M_ZX?NR4`_[A,-Y#XA\H`<(@HDBTA5:5-&Q,<?"V'6`"GMEI/B^R<I'LR3[96
MI3*V/2D%5?6E\+A+,&4#II-NEVU[.3(^F3]K&HY*+$:4K1&3&S0Y&K>!>RZ]
M<M!V-5___%(^LDB"@ABT\DJ<#Z=TMFE`E52BNWM\!6.Z;0]'%,GWD@M@PE0@
MN8PUN.`0U-!+(-&#!*Y3>'TO1[JG2YMBC-HZ7RJ)W\>J.GN7!!#WNBM4]+MS
M7XZ03Z8[;8PF17&M15'J5,G7-`;`,9O0V2=T^ADMU(EV-D?5L#C$>Q05Z@-:
M]H-(W+KV):O-:E)@*Y$L5P6E^<T3!G0F`N?PES=ITTP3LU;!*R27366PX`$J
M,@9E@ZI=$-AWK=XG=H6+:R$L+6;OKC[+=RT74Y???[E:#&C$CVY#6U8JO[4_
MR!N7X(-=\*[Y]3Y&!2772!7$Y2\2Y]O[8?X3OG4CF7<')(+]U+(LK^11?KZ\
M;NUQ&X,4=3_&=B8FZ\322H!MG/51BS^2.2<$HT+7NZ6F&9FB:R-3/US^?O7I
MRZ<X7RSFO]WB6\@G3PEEW?UN-%+BKP94-GO23)`D5BU9Y9@IL:U]UF#\9YJU
MQZA[R-;\^N>6G\FS?VX9SWI?<C%%*T8GEABT32-"6TMT=FUJUJE53*#[7[X%
M5=/K(16V3K140A6OK*5BZK@>4IRT?BFA-=ZL`.H]2M8@T;_//EU>M?&6'RX_
MMSF6KZ_>/[J"]D8_7HN_MV+3$9D$BG(K8'HQO7J<*"*(KB7>[`_?"-R)CH><
MK&QLZ84,$ZT[N<5/7*GUR4D0H'-20^NI%QNWI@*V<EM7OWU+TO`_S>.I9F[M
M(=$8JJE:DVKAH9'!M_5KW6."58=\;]H>[Q;*##IR"<H;JW*)8L^&#)!3(<>^
MXV:U3W)OVAY_S?*660R739"!%%GM\I!/E8`ZE:X69!4<E#8[<::.BP0`.GEV
M(K`*KJH1%5<9D[I*RJKKM#=ICZN;&H(UE3BB2`],RG%$@K*:4J\$+RROZ,"M
MB!N!E9:XC5<WMZ-I;9SQS?S'^76C?#'_^'&YV/KV+_SU-IVY=7-8I&@]$556
ME(QX"@&&8)]J-:9KSIM@:%>:GT\04XU1#AU!+;X8UWPZE8,;,DNWZYK[MM8-
ME^_,Q;&AK4W;3!HCV;9MD$1%:+GQ8K-28,^J[TVGSE-Y>?*8[$HD%[T+E8)-
M<C4P`4*#8%$N5@5]F]\SR>/'V><&X/IZ,?_UZMWL7?SZCYLVPE6OKB^OW[9B
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MNN-PEISMGLXW`K8G[9P@K">"FF(0M(C'.,,<2A@Q77W4H=\5V67Q]A'2)-2O
M!*C91AM=(I^3T.G'$>B,)G=1@U%6WT9<!Z/M11R@Q:C%=),JJN9(#7]TN.=6
MSK0?K+A8G43>64@;EJ'XEF)@+VY5U+$H\3IH'%`!N44=6K`G2Z93A_N0]B+.
M#]D46XP8B)(<MU8>.P*<14A]J(9F->6QCY0F#9I8,)]S+(%3!6W9I+$#$A3U
MB[8,:XO@#TG;RSA!50"SB;$X;UN[`K@XGB!RWX>K=3=%]D0Q/42S61]/;&TH
MQ>N"2E7,G\<06/S].*2U@KB=JM]SQS!A)I]"XA$8G(0MSYR1+%</5?11&[D?
MFM$-.\#.DC#1Q.F<@L$-FC85;SF53#6VI@V;-`RF4@X3^SA!+FCO39^<PTDO
MM"TD@9`2B5MG6F_&\,2\%B9==T>Q533.D<,[7?1?EXNK]@ON9OVO/R\]X/@U
M/=11[Y>??/U6P_QQ]F5Q]>G3E^M->JG8"E;NO0V$'$C)G^%:<$"ONU"_3V[L
M*;2U/S*"S+<$R;B>2'3N/X>=K%NG.H-+B9.3:U_DAW/4:L2]]QERFIILVHG`
M([$XE:4*B<``DK#JJKA1XE(-13&6!U&Z@^S`@,Z&T0WIR=I.#=AECJRB&".R
M0Z7`&2!<TQ5\OGQ.'F@MU:B,B8U.@3,XC2.`B1)SO+YD?&`^YV/X??O$M\&Q
M>9#-429S%3/*HI\!@,4"C0U(K?[=)ZG(^(Z=]<3L1_(Y.8_GM.ZKF(;`%GTP
MU3-5K"XI**4J5H9SZ4+^/T_J.99]16*PMEJ+QDD,$=NT[EBIRBIT_;G=NNEC
MG,VD6VV]5Z@]0):`)INJXM!YV,923%>JO]"\6G0^$LG?S74Z\,-/4"@6[8+S
M$H%:E,NFV\/G!(%LCRKXYTD]RY:_&K-I>1.=BG4*$N.(!\6^]M.56AW]Y6^(
M-Y5*!APNDT.NH2B7;`:3W[)]?=>$MJCA.4C^;N[3@5^^3@UF3(N^-AHQ5L;0
M\/F3*J#1]W7N/T_J69:;UP`F41"[G\3J>XAIZ-+Q)2KN4K\77>_^,0YGLL[N
M.5H,;9-3\-$%,GI\^8E=#])R@=HX]QPD?S?WZ=`OOV%B>EV+N)`<EB`&H=E\
MJXS<L#0%J_/G21UOQ3F#1/T%#16EH3HGSV1P]EUAVWEB$C3O^/(_SVY>7W[M
ME]]N@O<SA%`IUABK*A6<Q"#CIE5DW:?5K(/5OLW[7[X=57<";RW<_W%]\WGQ
MY>$<Q_W?\&9>Y=-W<OZ;]CF97(H(,GADI"J1[Q!A>:-+@KY17W=EFN-Q]-/L
M^FJ^6/Z>*I?T]?SJ^O.;W^:O9XNW\G/YR^S-;_+?KW6^D'_)#VR*)H/2;`"M
M%GL?*"DC%J8@*P9M<\_K\S,Y_[)8,OD_L\5\R?$*IP._FUE-[*U+%&,IXME@
M-&R<L$K%HRJ4.O_YV5G]Z>KW):?EZN</GW^:_3J[7L?O\M/9;-/VDMI6]U$I
M4&K&"('%B[M[ERKW<U=\HEO\YL-B=GN-A7^YR8^?L7RXZ3:;T!:VU%)+TAX2
M:0KMB%.MG.T9''%[J8W5'Z^N'V%RTSA=DMC)96%3B7)"=A*=-PXC`H7:CW'N
MS^$DGK+.S3)5':TC#5`]#)I2`@;+74&1K,;>-=V5K.-H_ZS).I]L$`XPBF!C
M&`86Y0.K.IZZ3O`C,G1@Y0\L#P81"I%P@1'%P9#+9*,B&Y'Z5=`\P+<_/[<'
MLP(ZY6`RBU?%I?4Q$'![0-97"Z;T8YN:`4YSP@<U!Z@2)I]3$G4ABL-;',=P
M=52Z;[*RU,$9/@_7AS0'551B-&T/1?89F3TEOSQK!6W]>9=_\EZ?B.E]S0)S
M##J$T/8N$`K;+C0WKF%DN=:OT\,\>;.3(MX:I..@NAG%+W>Z(+I23'4EPCB4
MX)K:ZM&L3!\.3?)R?+X/[;^WL,NQR]`:`Z/US%H.'HL#$L]^.FP_(U$<3+\[
MRADSFMAF5+&2SVW*&C&5%-NT[0L1R$&5O\1U$0NZ:E,KWXJ.&!L/BX;:-[81
MX#F_FT.:"'`.=:"0$[F48TA44[LNT1A;81)TYJQ$LJ\!,2D%;Y2H41T;P*5U
MIKE%Z$&)L^">F@<XN!R.YN:+$R!!E+:&Q&ZFE+PXPH-#E,A#[QNL@ER=G.T#
M6Q*FAA921#%03M5X-B0.,>26>)3HLNO/T3SM(IY<)@<S*=$[ZY(*"A)R9-/0
MJ9ID4B`"YWNO@ZG;2'=.DCFH;0&6^V%\8I<\HD&*,0WOB'7,_<H#O:;K\'QD
M<TC;XEW-9#E+D)U85S8-L$+N372D1;UV9E?NC)O*C9]<-OL:&6TC!B,NJ_$V
MLHN16[(9<K"U.%)]E&+[3;-;">1+(Z<MV/E%E&#[&S_-?I[<@_P8&A$@5J"8
M`4VU;&(P,,+H.H@/]C#=W'Z%4'^/Z$<)>4#OJX>%FIW&&<7G!]O6N:?8%H51
MRD.WE9,GR=3OO!(3:/EAZ74-'3O1.3FS'#B5BL'**U%06-Q0-P+[>HR=PV&<
M!'-6'Y[.#3TL!1*'MHR(%4C(;$,<0$F\8:/[YG@-K!V8H]`Y67$G:FV:(DR.
MV68CAFG`J#20<S]<!&S,ZF3[1CI;C32\?;OX,GNW"TSR@SBM:JVJ>%4$T'[4
M61B!G1,6VT.Y*E[UP*;)V8ORR:2W-\31D[96+'W02L<AFD*BP-V-L.A7^\_W
MI[QU=N\B=F,5EEAR]JDJ8WU@-RZ=S!JQA^A'OVJ2-E*T+_U3P@_&BY-1;4U0
M#1FJ-,+R.^WDH7;7'/6J!=F%_N6JUYW@P%T$Y:*&(,09%FU+(R"T)4<]AA8B
M>80U!-\G86L*)]'`@ZA<*_XM595;\C#B.!7FN-1^`%Z\%V=VI'";>_M`O;G6
M`X6ZB<QD6WP(-&[!]2'U,TJ:+=!C1&X^ZVWNY\-FY\@M=YZ*:\T"!<NX8EAD
M5ON4L_/&K*S'?"*=:WI5EM-7OUY>?5PZ1_/%3Y?-T7C;,.,:]/V[__MRVWRR
MW#KXYO+WK9T+L86U$COQRL";E+5-P]Q-&RI/?6?$FFMR`+J?3QA3%I<-U`K6
M16S-(MZ+_AG1_,3+[2WNQ0!M^F+EL<%3RN+/J:2H8$PNEN33Z".#X]AWC5\8
MLS($_O+D,0E?4Y"3KR$H$/=&/$<:54'(UM>^!U*,`YZK/';1%@DL14!O*R/:
M$@*:<85.9M4O][I8HZ]W(?2([$Z==X,5P8;-D`I5'RD;,WBT6`NIODL7U#K-
M?TX<;WCQ-2YQLP`469\4>SLN"[2VFMX<7'3`*^?(\=09^^)M,^^LE8?H)02(
M/.)`>KGC_97VAU!QVS`<9^_GB]EJN^O-5F;N80MJ$'_0*+M<[)524G5,E$/+
MBZY18ZL)OCW(/3;;NS?VYMG[J^O9NSB[EO_Y_/KCY?4]S;NQV@(-=!,,UR)A
MKVHYT^$:.<BZSRBOUNJ_2XD>88(U88R9/3K`D%7R-&+FE!)3[O=VK\\Q?(>"
MWF<:)<0JXA3=!R%*K`HI#!#"1C[H[5RWXN"[E.F;A2B`C\MO>;(:@)8/#QQ,
M30V5PGD)H0;5JISN5X5=L%Z;23HW66X"4X42E:W*02(KSQ-R'A)H(H2@^KJ(
M7^U,/F.N[Q541DSV;V65OU_=_.M;:67$8UC(_?DX?_NOF_.;"E+@P!8NOB&:
M!]"$SDJ42T9#70<!X%Z$_K0G-/TB3PT)O4ZLR6)#51QG^13Y'AR^Z\3Y+B5Z
MA!GVX,F1JQ!\L*)F.*81[C`:4SM/G=T?1=![F'XQ2N(X$12LQL:`A<*X$*(:
M-FM`H5^0O7IFVY_!F9*LA%9);&#RG,="1DJV7V5X02<)`NYM%OGV$,/-[1/<
M.8_,CK$ZB1_)6%6#A#]^W)&*;7ETOR?+X--3R4^B^1DD,)5($,7$235C*EHI
MZ^02C-C6#;^[BTP(V:^I"IVS!#8DCP#%V\5::YLADC_R$H8[D&U;/="GR[3F
MI^?+SD4$4Y<@<(1J0S1.-4A]ZQ6/4_)!FQZ-_@*'#J&S$\%.Z6%AV@27=:C&
M5<VDQWRI55[W=710!U(!1^=ZZLQ3`JL,J=**J$7;UBPR<&W:.J:>ZZ?7C$[(
M]8;''I9;1"QG;6P.#<TNC55P=M&L`:UR+X7MR::<K##H$K`2B,>?3=3C]GK,
M:PZ[+=]]?K97EHDMO1FAOGDSU^M]FYT-OT$O5\&Y:"NZ8G5"SB.&L*Y]]'-!
MRFQ1%-N=DU,):U)5%,]%G`1QCE*)@"K7-*Z+8Z*^H,3:X--K:"],6)NJS__/
MWI4UMW$DZ5^DB;J/QSH5BK4LVM+,/&[`1$M$#`EP&J#7_/>;V>BFB*XF&B</
M2P]6.$B0S,RJRCN_=-Q0BL,M226PH.!;TK;_#>+``7>"@1[^V]ZL$;U$>*2&
M<*W!UXS,"!ZZQ"-SF-0="C[8[M;W&81UL`82TA'+;8#KHL'EY(ASU6H@G4DN
M<ZX4XJ[=E?)I&=FZ]R($3:0/5'*MI)#@0;9@OZ$!/!C`@=PGB#HY(R^3;L.I
MC01NIDZ<0<`9B(RBVTT0"2EN^EY!]BN2T1D2:%E;+9QT2@6"_6S<M7B]U.;`
MBX>B1']AR-L1W3$IL1!8(G"I0)TPR;BCN<TS\I3!:`]T@;U-,1V2Y`(G+\?D
ML2M$4B]XE*I;.N\#L\<6N$XHG1'O0B&(G0M&I)P]U2:+W#)"J0CEF.@[B0[_
M"S&R=4%"LS$YX9X=JX/64M)N/(2QQ`H<B'=6XP*V%V/D9:P&W,VD?)0)ZUVX
M^E@_K'L-FKKCBC2O2$:GMQI:"E"'G()C(HQQ7#H1NBU3FKFR*584*+5O1W9'
MF`V6A<*Z5,P*PA89C6GQ6(P&!WRH.?3E%..SFPV3O:/6@?4$%271WS!=MB@F
M\$B.K(WL+9T+_$(3O#2?NE@L5W6UFM6-((85S.'Q"56)NAPUQ*PRQ"!L>`CZ
MN3.E@E9[V)DC&'DQ86UML?8:HK;D`T&@F^C`+^5=%25F.=2`RG<W9F].6F/M
MNH)F%UE2DBDN)"8!9!?U@X,VX*JRW4M.;U%86Z\64=((=.^<P<87ZKO-Z%RI
M+$O75:C^U.=S2>N044S>LT6*)&&\5`ZGU4Q7B(E:\G+/+C6XS&$@=[;+*.,A
MTY<;J:OH(BC&9#)3Q$?M`NN>/,6M7V7S&#7&#A03]B3VT,&US"0AV"NE+5PH
M)P48MC9-PTD8P$>`C]N!).Z.DXH'CEANYN@%+AQ6%'0KF!RM;.KFFC!E7_9\
M*2J&!AEVI!B_!Q[F3FL@GK::A%DF$+%:)0M^I]*F;4R)!'SXPA!81+DO21ZB
MY5"*1_0+!(TDDA1HMH:Y++UG7?G;P>,:F!:A4@V\N9U)/F*-TX:#GQAQ..MG
ME,?%R>"@=9+.F8LRSSX<&^T&2WT`[=L:3V5RH,<-DS0;S'AKKW(7UGE3SN*^
MT\](^\C*,Z#=)`:*C&9/@N&6=+O=X$!\*@,K-CB%<3;:M\E=.,%P2M=P@@WC
M.+Z='X)";\H[4\#G[$L[CL\L?T=HF[L*#.?>7G@&"R<RA3?I<V+@`SS,^+/D
M=2Z\<$K`'@Z8_QX=!Q/Z/?ZZO*JF=]?5IZ_K`.QCM;I:/`H_RZ]6U:^3%@M_
M#>@RN5G>S;_YV6(YNYE=3VKWK:ZJ73K6J#`!S).`LR/P=%QPW=(]2\!1*J`#
MAH.RDXADFV;E-M@@0(E*',6CP8>8NXPLV*_B[)B47`TX"*<B]#6<78:P.<0(
M=SKBQ($*KMO\:H2292EYC0AS!I&,A2C<@V/G5!:><$)I(*+U[H)/L=P_(XQ5
M`W;\5'2^AJ,320>6@\+U>T(D8FB[7=L8HYDN'5[21V4[G4BV`OI@AXLV,2B>
M6(3(29(NNB2&E;C9X,Y(>99GUT]9O=S9I4@1WPI.A&4EHU:,MJXT>*@Q%I,N
M0@\:[6TBN9C<-T!2>5%?U(O+JIHVJ=SFY];<8%?0Y6KV9^.)[X]R8`P+"&A`
MN,TD*ZVZCIW0P":6!53*-U_DGA2>EKN12PO!#:5>@H_J71;:4M*-(D4(U7(1
MZW"N>A/,)^+N]^KVKKZ\FBSAFH;%S<UB_GFUN/S/_GW%`EB@CI+LDPS&^,S:
M&Q?@^O&2(6FM>?*\GJ#J:";&3L51;J-G`>?!./B]-';MX9:#JUY8<.3!/GDN
M^W#Q9>$N01_4U=/#V/MW:E"CP1D)6ONL32#4=4;-PU'I(N_&-`Y6BT%V=J#O
M='R-'!-NB#+$4TV-8-*)Y%CK:,5`="Q&&(2!Z*77@G(ROKI%QM7R?=W'3P->
MB/I-/#8*W<>;GU[.FO+$@[[/=S>3VZM)?>.^C4$\DB@A')"9@K,91<I)M,\-
M3+5W19:PG8?9*H$>)T>Q#4=(=^,Y+$!9U=^J^65U@:Q/+JN[U>P26!ZS<3[C
M,)`2$(5&2R,WJNUQ!4T*]F)@%W<_NCN?"![[`VLVUW6IV9]58U1_`:-Z_>C@
M%W?U'[/K:Y!,;Q;S1/=%AQR58IR'[(C*#IQ=T:&!06Q9Y*FD?,;[LJ>P/L_^
M.JNL%,B&6D.HSO"?X%'9!ZP-YTFA7C@YFZR:W#O6P=OO3/<'AS$>-S$H8Z-B
MG@CENDI5T(3[P@;LQD1!UPD9&K/1,>A`+?79QY2!&1U5UW[H*"T*V'"2VII=
M3V=/QH8=^\';35])6*>R==1'B+/!W,L<;7)=C3L)7F939'\&?E<A_"TD9QX'
MQ)$8YR*6@+R,`H*K+IMH>;#NL5[XG]__C=L,=E`,!PEO7;NK%],[].^K-6;?
MWJK!.>."\C$'IDQ.$(_0#@Q&6>++\EL+4K*-G4'*3L+,B%H0E@0**LUI2ZQ7
M-IHNT12`.7V0@3N`&?CT;56O[K&&NG+S*1[O[4U1"MOA=)BPW!.KO(A)XHY4
MW)G5!E06S'=9'"5&COCN3U)W,J9&8:S0^7!"9JET]H&ZAR83HF*94Q)2F0;:
MX7BFZNIK58-";T*PBTG]J6Y:BJ8-CO=%57\&WV!\!>F'7_,&S`^).K!D*2+1
M>$](%_1:"+EL[P5U?P2,[#_`%WW$TDZTG82=7OUUDQT.[\;%2*EQE"&J8A2Q
MVT`'7H1^+G::S^U7[=;,6XFK$10/3CAP>0CKL&2]H=O6B`S\[?UIV]HY``I6
MLJA%X";"99:X,FN=H+1:E"UW^]%V.YE-VW)4U]4QI$+[L/M?[F_!AKJZGLR_
M59O(^^[]ES#F1,@$IE"FB%L^::#"`S]9R(A(I$P4ID,6^P6V4=YC\7MRZ\-R
M>3>!0/'3U^8*+?\YGV*R"Q<"H'Z>3YLO^\FRFF+_"_SFIO^O:6B!CUW?36?S
M;XTH/]TVL`1[:^4HK..>R=`T,6N(-4WG3F>(NTL``='T5&PP?D9^7E)R8TF;
M#$Z2X=EFK(!'FQ_"=1$LA*:EZI>]\:>7D=S3^_9V<;&RM![\:VTU2[@K+H3$
MX(&DR#Q&+5N?_C`-!Q(Z<CI*<J*`6II58-E&%/Z:4`[.1JD_I>7$]G"N]Z;X
M4:JT>?UY-H<S/:YLD!$+%/WSK))/#*L(LANSTRH4X<T[*OD6/G8@\;3LC9V3
MP,TDPF=J.->><(C:NCJE5G9@@))1H<_"'J9FX*%]G*PP3WH/QF2_S/6VIA,K
MP/,3&DX2W$/$_S1M([9EG$M:HI2LA[6?8G,/4L_&[E8U@5LD@_=.1:>L2(ZF
M!U`6'<JZ`[6"F1XFR:OB=Z2G2&>(:33$THR$J`E<7-XYFMD3479*<*/[Q>77
MQN_6XIB25,<,T1S'[:&@7U4;]@3"?3G2"!H)7K<X![]?9ZO#UOL$G9A"5%.#
M=L'`#[17-#O#16$@C%2T7[%\^.O[$+4UG(PY1B&UEI&K'"S\1.OUNV2S+9>*
M$&F:7.!Q5(T!#%F\SX:!X>&)<4=(V\$-MYLG7;YF`N^Y![)T&%5;!_`$"2X0
MJICGA/$`EJ1-D"3#M2NRVDPKL5X@LPM5PQ&XFTYG3WN+C]-Z3_X*?X^1RL:0
MC[^;7:/[ULO^;XEHTFPYF8V%-$$$C0M+:21,!T^45@PTL6]*9VP@I.GW:(Z+
MX26E]LL$%,9))498)I0RJKT'&TTH#REHD%<`XV2)*AIO&.GWY;UNB7V<7%[-
MYE5]__ASIQ4AYP',G3$D>D^<Y`DW%R;'G7(T"%M`43$Y8`:?681'LLPHXEV$
M))4'LVA`3T=P93P7X*PG%0M;"-YNOR7P5#P735RC629KJ"%P0$(G,'R$QFZG
MDM?2VS(GJY54IM#L3U)S!-G;$E#@>'C!::`T9*T%Q34IW0XC1(0M'RK$3:QP
M+W<CNP_]B/[*H[',IX:3VE&8BZJ>+::'[PQ@`FX6=RQH(R'NL:K=_&%I!#M<
M<-J_6:<D_MFE\C(CZ]9E2C47\)PUE08"&-/N*21*D#(C]E/:9T#+)IHX2S0X
M>%J;(`WMP!7@0+@INJQUWQ#_N"=QQ"@]RAR<1@-.?10T!!*Z91I@S&R9I'BG
M^B#E/ZC8#QG-%XKDD`5#D%JXZK@PPW5`*('T:U-_!S4S,MLDG0*]FY0-7&M-
MN'V8%++)V7+%R#OX=+^5XTU+YH5@]#&/'[.60DHEL?<PM\UACB/PR-_U'KXJ
M<Y>L!3,7$SAU,LA`H^C0X)6TY6IDN/KFY]4_@<53(&YJ(Z>8%J&91-H%$L$8
M5N;;BH5</ZC4#S%X-@N%,_R)1(9=WMEU-0$IL:/@913-;5LP^O3UJ+HHX1&B
M-&.9($(J3#]JRA)3F2B;:2HC4M7+AC]%R8'DCN1.N18Q1!>EDY(*SHV-K"57
MA5RB2#/2"_IW)'=93>K+*XBN(W8\+YKXNNV02'^U1>NN,?7#O*D(+)=AL1QH
MQ.*_B5?2<.J\S39Q%J0#%9&(L%WKN8&C3H6V;N?V-Z1WL&#.)^"1>@DX9.`=
MA`3/UYNLN%</R\I(#&7?M:":%G?\U;+]<*_^-:EG>)&[E5)IOFK*3OX^;*@@
MN'?XG?OO]^G7ZJZ>W=S<S:O1^T-\D%E(;Y*W4C-'NO%O'&(H2MZZ7PE^K7+<
MVL[J26)8<[,A!L:<=;';T(!HG\6CH=QRWIM_?,5\/^?]20&"1;0J`A%92`!)
MM@,#AN)*@'*HKS\F]"H%.5*$3(H9&XPS,E)L3#4T=-`7'H=JBW(6M4;UC=:K
M9?MQ/0>[LS_5GZOZS]GE(WOU2S69WM:+;S78K=V+-COT/CKEN,>N<F)%S-AF
M%++@-FL?L/152O9-F+/=BSP[B`AL/:Z3U9HP!T90*_!<043P5:.R+VO-4I6)
M^#<MHX^SU?+NC]GR:O9E,I_\T4XVAD5]NZ@;?3:6[8*`RD5MA+9PJ\!S`%^9
M9Q[!%F"2L>BV4,4PPUL0X#,H?TM93L8AI`ZQG/%@4P=WFJFR!1`"+U9^OE9!
M;L405(DGJ9A.`?MB@/T.B28'-03=(31=;\M]$WP_J_=)'=?4:TDXA.)&>-.N
MR@)5%E,)R&2*3<XG%.2J!EL'A,/'Y]/?JR::Q\_A+[ML_Y]N2*TM#6_\[(/X
M?D?%U6MY^&MV<W?3WP=[]\>R^N\=4OTG_%,T2O2^/R!1M3&Z#B\O.F:D$Q*>
M&_BTWCBOF&<VN+)#UPX9T)TD\?SBF\W/+CYP\P6&TH*#\P%>B$])HOA,E,'P
M,APRIQ+?:H))\S2IY_!CRUXZ_7*V9RM%D)8GSQ`E!+0R]@UU\)0\B(&%3)89
M;JGM,3)&T]$L;&NK2,Y)X3W//B1,9P7_,,PF+%'%1:;46LNE.8Z'!HSG@/Y-
M0:222<00B#9&1R_;P97L5>1EQDV"1>@M=>K^^.X4;1WD]C)$K@/$*2Q*%<#C
MZ2(4R6@L%^42Q93HWX"]*!J)F0)AE)JH\%RU0ASPV&U-LW*@C,ZTUD8>2]'V
M73O,"H$5/15L3!J\Z+9I4W+O?"DCR^#0^FFD`8H>(SN]7RRFRR=PY-AO0WGO
M]Q7&5;=7"-/1J+++Q=U\5=__[X<O3U?+C1:@HS*E.)GGJ/&J+9PQ9KPH]!8"
M`&_JK2&:#V)J9&-@8((DE5)F$:=)(A<=G%A6HO`8&7:_*'4^2K_;FUY:_]/=
M"L*/\;S^AK$Y])>\OA7Q+C&;F-0Y\"2L#1ZA/M>56"I2.5#&^JV3ISNEK?!T
M.0C"N3'69R$=:(QV@POB1DM2-"Y(2Y7HX9^?E-*?]^F)^^2$94Q"F"TS(R$C
M</;ZH!1HK53$W`56[(E.:0RI$FQ`$EXFPBQ8`:=,;AVGS*SFI9$"MTE3?3Y*
M?]ZG)Z!/LU8^1FH4E6#SHG]8^*=<MK$HE@M^)@4UMBO6"\&42HXXF:B.4=IN
M=!XT5PD(@W,1BLCS4?KS0@U?*,K`__!6$:$B`1?96MTYS#;H<GDFQ!O]/L_Q
M<ZJNKX&N]]6\JL&WFT_=]`:"6@@8&SBN?<#;-X:_B4H:KAB-X%(QS+V95K?F
M;)(OLBA2$]&;RMV-LE,QL_7!4$,H-S83G7647DC639UIT,YE;4Y)HWL[.IZ1
MFQ%[(JGT4;/@$3:7.Q?!_K6!N(1_BG*&``^&Z1=D9NL@;8)#,")3+06%L,F2
MT/J$V#P3"^-();R07J_&(=P,@@WLC]6F1+;66Z&XA1=B->V6E3N3;2@\$'C@
MDFRF$X8I.8C8L9X8XI,5%*$W';<\)WBNK5\K;2R7^E"."V-/0^RCFHN___Z1
M=IK=_=^DGJ[5](<YIKK6C3>HY[]<3>8MX,-[^!6KY8?YNMUIU%G&+M'-AAC4
MW9^KU>JZ0BB<KXOZ!@$IUG`4I28G&[MAA19$!VT('+GUG(<6-DACBOEQ2+!L
M?AVB.[$=1'=ZN;R5P_@XJ?]3K1I`CW^"[$8.P!FI>7#!$-!\+C+MNV%FD9ED
M8>``6-\<_3R`C0/X,KNI_H5M8],FO3S#+/*NQT%=Q`RV5>!:&B\9][Y-I&HX
M#R$&CD/LI$I^R.-X^.)^2@D\LP`1)$D0649GG$V=Z03K0_C0(<@?^@SD^0Q$
MSME)*9.U20<*1Q([['OAL]W8Q?A@(*C\>1BG,Q`Z**FR"W#%$VYKDB1T*V<8
MY6G00M.?!W`F`V$1=14<2/`Q,_A+6B)0X7KN@$J1^,!Q\!Z@QL_C.-9`$$6=
MYPX<5)X(31;A@CNEI,5&3U)W",:^@C/`.X9P<=4T-A7O]6?6'*>;V^O%?56M
MD2K;90W-0-@!+I"C%H3R^>*BE.,FSJ9QTB;G!8B2@CR)-;'5+BYJ00?5N^PE
M<@[CZCR2&7W[.TO&6>VC)AFB7Q\]!\5+NZ%&\`SIT!WK87N_,<'@AW:Z,J#G
M!`'3$VF*G*I(N>8IX[82[B)U@R[R>03S?:O)Q;J]UMVMKA8U#I2Y&ZP#T_$V
MBL>PVEGB<BF1DO796]QCP4([V?O_[%UM<^)(DOY\&W'_0>&YV?!$8+?>2[*G
M)T*O?8[H;O>Z/;LS]TT6A=&VD!A)M-O[ZR]+$F!`!@,""<CY,`VV)%>E\GDR
M*RLK4V&-@E_)IUV<W.J!O6$R=W3@!2P3X_.(O9%Q?<GIH^YCDT[OZJZ>Z\RA
M71U4VB*"Z@)AR@K1-&U<<EM7R4RL?8+\A1AN+>->%$4_#KLT20NN72^91X<7
M100P!+JJ.(0GBF'RXV0>S5WL;RDPTBNZ<<S-:V80:X]Q:1$4B0B6K.FN*(C@
MU&FPRBR#+@ZOFA5]`WB%=3E3MQOCI-;HESC)C5T&KL_#*&-9B_<QZZ$*<TCB
M/.(XSF)<,Y$*/']3-(FN*8:MVX8BV65>A6FJIETE>T'FY56RWV3@>Y'%LG>L
M.AIQ%5BZ2KQC\"9Q+7OLHJB*4OF.556O(LI=RZ(@7WAP0@&--BW^7;L(@.NH
M8`+`';9%6P6E)J9;*C5;L!B+F\'RXJ[U&\<V,Z%[[\?D#.-&K;^)P4X/&Z+#
M$]MU==5UA''K;XD89%%K58V?RYRK&,/Z8URF398N6*:I:+9L"*P5(F^KY3Z/
M+%HP^L6*Q9I*Q/7&R$0[2I[SEU`R]CJ=7F;R%XA*3,W0-5DCNJ48/#'*4_&J
M;HI6Y9I5G%.&)>/9?-RK"EGH1'==V59E1[5LVV#E+$H=MD7=5:I\OODD_8W&
MO4&9>4,3-(FXFF:*X)G:CNQ,2[Z`Z5ML$,=J=/#JZV-=+.G^EB$NTUK9`5_*
M`DZ0)%`(47#).'0AFF)%5X]\B(*TSA!9!0$_?HQRM\+[4=;1J"XX_^IKMV7P
MW$6#UXG#&["FEPFOC1=!IB,MGJF6YYV^5X8Q,U0V^&*5&8;Q$UOJIGG&<TJ3
M[S0UO9#]:+4.S!XIX567")H*S@VQ7-:=LLSKD,"E(!7=YZ3YTTUO&E5-\YB6
MS2PN^MJG-/L8%\D0\\D+S$M.[ZA/@^^,LE;60I$DS=%57@.^47B#%]2Q)`1V
M4F*!Q,6%GNSME$21$U+P]<?`>PC"_%C)"G&8)C"M"G]*`TF8+JS,W+$X>%M9
MS'"5%'V>?QL1Q_)'3(XKC+OU90E,=N2%TTH6JP0CNXZK2BIXJKKAB@`:@XR]
M%/"^%ZL]2-J"E])FP4PSC?)?N''"(O]VD.9P6B$;RR6BZ+@F.`Z&`;ZY)8V=
M#,<&N[W@P<FD%1!:4S1EWE$V2B)VW?2F50QC61I(2%%8_0^1%?<95_I1599\
MOR"=A;/;>Y/.,EOG.*;$3@LKIF82VW!UTRS=!M%5P8(LI-@)_+R'L\]Y[-!D
M2,3F75VQ;`'T6'=M,([JF"-U7ERL_EH6?VV])#8S&40@FJ80494E2U`%178E
M=Y)\I1B+.:*JV`K%V+G)$'C;4713<T5)8X6"V!',$C$ZT=RJH&!C3M8&@MG.
M9!B:):K$LF7B"+`^=>QQQI[.VF!5]&HY))W9UF2X0"VZ(8FPVG$=2Q)<9=RA
MB?6<L!=B0`J_O1/V+QH\]C/:-;[3Q'ND10C6#L(1V^/,5Z.WHRS-O"@_Z3L!
MP=IM44PBZ?EI=M$DFB)HED#*N3F&`<NFJBVXN<EM.-2=37=99$!7%2)KBN-8
MJF:`#V`[=NDWVJ+ADJI-CU9/=T57%%A"@6_GL+1[#=QB0Y3&61\F.^M;M2TX
M7^JH;=-=]G;!'5)TWB`2T1T+=-DAPG@75!==HRKA:-[UW=ET;WNO/67]0F#@
MREF6JK!-7QT6/[I3YLGJO&4[,QV;7N0:ZG.!Q#5'6?L,E^;#YX5=B"N(KBQJ
MAF9(9NG$Y&7]^,H9$GGN*&^C,UR1(R_*BJR:L(Q592(I-NOB4D:KV>%OHRIA
M5Y3$H@%.>V:XM-Z8:$BL3ZZAL];&ALLK?/D.@8"5F6J3TQG*JK+S=[APD^FE
M@;\V"E7>,556!D7B%=&55-4<6TZ#\*KU2L:O.'=N;JTQUCR[I;GXCFQ+O$U<
M5]<L6Q,$MTPH!XY1;5(5^H?9L0Y`K9C="O3I(DQ.,$W!%6"M*.BZ,3YO(YJ.
M+%?/3A3T]LQN^?E@6`[+#JLFIA%94%7#U,='HP3%K/+I`'F")&\Y.[8VNS(B
M+WQ.@_2V5V1(P+]1U^JS?*R\$`VKK58>%YLXZOFN)\S0#&/_V^O3G<9P;--1
M>%F56!,_73(L99S30VS!D=VSW_X>9M?=X#N79L\A?7_6@T=>]+Q!$#Y?L:S!
ME/M,G[B[>.!%U_GOTN`_]$K@A]GUV=\?L^NYV\,@HA?]7!Y7P,`_7P^]+IOZ
M118/K]3ACVLVWHL@ZH(G<"6)\(/7'LI^7C4H-_&B;_!GN`]QUH=7;L;QMT[J
M1>D%B"CH53[/B#BO%#87][BL#ZNE7,X</"<I9<OUXH3KEJO`%&[H<MYD#<+!
MG>EH,/#R=`[.8U>S7Z97;*SOV!\=#_P=B.,MDGF#-,?""VDON^+GI,>^OWQH
MQ-()PQF!"^R:R8.SHOPN#</RFCS%D'U/AYX__KZ^'CP%W:Q_I>N7&A@N51-S
MVZLI/U\_Q$F7)A<^2,H;IO1J_*&8AA<&C]$5F]J+(2:33VPODPTL>G\FJ&=<
M`K(NODPN?I=UIQ^3RD?D0WM_)BL_SSSAQ:.KGC:]4=CTOHUO/)3[#F:@.,%&
M)_@:,DN:`8N9L4(V)1L\Q%D6#\;$47R[$H8_N#0.@R[W4Q&.OI[A169$7I+>
MR^_E$U[^*,G)DOUDY31>,/$\8TTI4*O7:+''Y=^>"E9_B,-N\?SSFXB#AX4L
MY?J7I59G]K5-)B:=M4[JRR7-&HK3I`E9CX/!Z1IR7BK;_6ML#`/I@8=RU0^Z
MX"^L[6<%41_$E57?YPV&US\)*G^->KA3/7RQ??-6/[,5XWZQUX0(0@0UJ(GE
M)A9J(6IA@UIX'V<K&'Q;E[E-+O'N`CGE_F^'!6#B'F=3/]^/YB2AP[%(;9,P
M?_#\;X\)>(U=%O&(DZN?NOE_8QSD`9D%$+18XN4L1(5X_D/Q]/^I2\"O"NLM
M@MZ!/',(-"!0F5RJ.Y=I:Q1PJ2V"^QX2S@^IE[P_B^*(GKV;"&$?&G?")GU_
M7(ATMS;='1BC21JY%'8N-V0M9"UD+62MVOPP'4D+20M)"TGKD$A+DRXU9*V=
MA-5`2V;A*!QM4&U<GV&8Q-^#E&TO<PGK2L526;.82]E9$)8HY9?7/<,+V"1>
M+*Z*%]=I-M8("S>V4I+$2Q[ABT['_K9L$(*S$!0Z(M$0A`A"!&%S(!35R]HV
M[A"!B$!$X/IF4)40A+B4W/Z@S33O;V8-.4R".,D7CNMD8B%>7\'KN7`I[<U@
M3+5O=Q&TAH*.ZZ31H]5%JULSBD7^4D<8(XP1Q@<-8T'>PRX,PAAAC##>)8PE
MLH=`,,(85]$K5]%E]Z7TG9_0;I#A=NR>W'%"T!]'0XZ&_,!QK!$!'7+$,>+X
MP'$L[.%H'*(848PHWBF*.X*"VU6XLFY:GFNLK'>]6[VB+L;)483,7Y+:^&%;
MX2)_H">P'T\`:6`^_E:GQX\\@#R`/'"(/*#5&(5'%D`60!8X1!:01.%21!YH
M$0]L&54XVJ#"7%'"KW28E54)^;PJH;(;+99`B[OQB/5TV*:B9BL.:[2I?L0J
M(9]0@0E%WU5@9AVY'LNI(?2C-O>CD!>1%UO$BSQ?8X8)$B,2(Q(C$N-1$..N
MUNS(B\B+R(O(BX?)BZJPLQ2'4R3&%Y'(=WE7T\KK*S[_^JZ>SKO3)K[F*`TB
MFJ:W\*Z^!_3I2QP&_O,Z+7IUS7!4VS9=UU4,C2BNI3M%BU[+4E35/HT6O680
M/]*(M=GUN,<P?O!"[B&(AWTO&7@^'>4P`&$.0&&?N5[LCU+:Y>*H:-@+LH<)
M=+@NO+,P'N:?01JC'FN=QGZ5=_/MTC`HKF0=@!-O&)1-?R,Z2@`GC^QO=#AO
ME,7!8#"*:'Y7GPZ\K/@M^V,Y]M)+[G:4P)](OM$,QC$L5(8EC_GAJ$NY>\=R
M;VSGSNAPQC]O/SM_=+@O'YT/=S?VGQWN_L^OAGEWT\D?[QJ?OOQY9^3C8'V)
MLX1Z>0$5%DH>C,(L&`*R4X!*$K/VQ>>?OOX"#_WXY>[VX\T?U;?!D$%R01AX
MG-GAG(^WUKUQ[ZR\UB@&]/LG`T;^J?KR%"2<4&X8>G^-X!\01^#!L"ZY?X&T
MPC3FX"6":#/*)05^N%X2#[@8I.6S[K_`75X6P'M["K(^]P$N!GCX_0YW$_F7
MW/GD!S!'CWOJPRW/%_%3!#(>%#'ULGWS7>S#_S\`R0T[Q;,2F@ZIG[%$OKN;
M^]__,#Y7SP#8YN)_X^[CMR`J'`M-%,AURH7/@V$?,-3A_'X21_"VBY_XSQG[
M3$??Z`"$=&Y]_/A++JB8*1'#=S=@,TJ+]YFW"6<*T0O*)M)AG*:@:+,3SL?V
MP?B_/_\)*O($(.GGJC]D-5AALI4CA[]\N9PA9UEN!35-.>PFRH#Z`B`X`X::
MI<X/IL6`DP]QW'T*PG#MMN,F[_"6H1/--`3'$7C!$MV"TS394`E_&IPVE2OG
MY8+M`-7DK]+S_1&`VV/DX0UBL/+_R6'1X0)@N"#)7[D/JO1(RT[DT\)*H&>@
M8=B,?%DS<H'GZVL_+F[;?ES<N-4R.9!FTH<RSDWOTPYDG/C^3G-^J)^-]:IO
M4X[+#OJ9[B@"AU([#*FU+JX[':YPH!F5^^A"/!N"S'^WV*-]Q]EJJ*PU*NL1
MZ.0R+=RXD?-&)KN!QN1M,D[5+^+\)N+@82$+9=5W-*#-DFY.Z9TT"P8L^//6
M>$TK1OTQZ%$T#O4;!ZD!V[!"EFU502M.,U1!5,$F'99IZ/Z@V-MXL<V`$$((
M-:B*GRF2.&H@^A&H@B>L@NA'((000OOR(_#L>G6*TNTHNP@#>(4LG7((9!1E
MZ]2\:QFJ]YWIG3]/D"Y$:>UJ@2V37.OXL';YO+K=5Q)JGJ*VP*8MQN].SVYL
M<31C%_)L[#R;+.VA=&UK-!`/LYTZ&2+?'?M1M'-9U['-#1;00^I#ZCLQZ@-G
M#GO<XQJUO=S48@JJEW0.G%OJ7QLB:R!K(&N<`&N<RYI07RF08UMEU;NN0K)!
MLCEILE%K;*AR+![*(>P$[T,W[*)6#NV^D5?V/#Q6)"5B97>>#]<:-+,=K5R(
MTO2=XKXT-OK<2W!-ZO"\LH?-TF.Q0[@I@""L?W-/["BB5&-M<MS>0R0CDIO8
MJ]*$R_H:!YVZ,46DO1UIQP"H77BDB!7$RM%B!1Q'25?K<QR/S3_$C0F$V+;!
M>%ZKSZ,[%F-T"-'X)JCF)KH8)K%/TY05-@?A^OVRAGT>M6>%H+=6I<:EN3_L
MW41=V@NB(*/<*,J"O)/`@"9^``/!HZRXIM_/FIY(2GW[L2>_IL>P&D)P;0A.
M6GZ(N]=#!"("$8&(MA!C=JU"VC$`JHAO"_*E@`$%1`HB9052=N#U(5X0+T>+
M%[0L!QJJWH=RW"=>E[+6I^D435[4UC1R-MC(&]`#SH%N.&)^N(([7$MR:M$`
M5;[D,1B`\3A$(`;&$8@(Q!,&(II"C%Y@]&*K1+L:$81`0:`<+5`P+(YX0;R@
M8<&H^/:Z8?A_C8*$=O,L[2":--680BL?>]K.,/E,_![;@&RT9W8A$.P"@E&"
M?55;$76""708JD,0-ME*0>:QE0+66D$<'S:.Q8ZFJ/45Y3UY8XI8.\'@"'BD
M&E]??PW$"F+E:+%R+O%\?0FVQ^8?UNL1(L!.$&!B1P=CA*6_YN:Y9;!>V'?T
M=F]L<Q]G7L@%4>9%C\%#2#DO3>DAA\!;QT$HGVU6E$6#X'+VTO`'UXU'3$W'
M38(W$6#[VQ&WJ4OBJC>`';/+<_T=559J+$"]L=Q;H\6XK8&,BXR+C+NS72BI
M(ZMRC7O!6PM^K4#$$>D^[F(A;1^HZB)M[UOB<D?0A$NQ>;FW1HMQ&^;4B+4M
MFM=HH]$WB_88B;&,&8@\J6\_;#45MD7OD/&0\9#Q3I#Q8,TN$&V/:_:36IIC
M`@$2)1+E41"EW.'%&MOFH&M8?$RF'SV8?N7U%9]_??<0!`]7-Y,\"2-/DW!^
M^.&(Z=V'..X^!6%XSQYZ#Q(PP]C_]MM__^V_?LUO_)+$0W@OS\/08X_HTK]&
M0=[+9CA*_+Z7TF$2^-0+X:Z\*<OL<T#B$1/K'>V]/W-MD1>4?TA_WMMG7-"%
M'WA^=B'PIBNHDN@HQ+$EB==%B1#!<"57T"W!$,]^FWM-+T5^'PQHRGVF3]Q=
M//!>I]T7MX,VTXL^S5E>$/F?9P"I`OKFU2#_'L#,H^Q*8O#<!XCN^Y0;2YC+
M1<Q$F09I1KM<W.,R^'TO!JD_P="OEFK1LKF_F.N_1VD6])[?(L(9Z\"/15:*
MB'U_^7>B.!EXX8R4!7;-Y,&Y.G,^#</RFO=G_%G^';#JC[^O__*?@F[6AX\P
MS9(B`/ZA-TSIU?C#PKN>#NIEKM6$-N3*S+DW9&OE8WE_II&?5Q+2+#66-PJ;
MWK?QC6O=MUZ26B6Q+U)WHX>0YPR`5B_.V>/R;T\%1A[BL%NN,FXB#AX6`I.F
MZ[C#DXE)JPX*[5_JK7>7#Z$@0A-.L3D*0C;D1I,JV[\)TJ:M/-RIRY^NU!FH
M:;T"MCC__&BY\9/G]\'+39[SZC&35=$F)AO/]LZ=[57V<$(?\7G<^/S(ZB/M
M`HPK_.>3`VN-9[8VEBV"^20.>\T&Q/868,95"R8@MH-L!5[&<SH'LN.RW<;)
M=`/FCOIQY`=AD%]UVW/@.=FSD65)\##*!W8??X8K8$9)'()Z/=Y$&4UHFJ5K
M[\68FJ3HJDY,P5%YHEJB*2J&0R1;4Q35T?5F]F*:V'N9[*UPQ?9$4KX%F"'-
M7P#GO7@#7!9ST<P[8`>3BY?`G7^V;G[9?(L&]V,6W*$IJ:A;;LC(RG%NR#1X
MW\$,%"=X>'N&;8I=[&!/</-TK\DD2`/[?VN$*7S*[&(3.ZMNG.19$_?]A%+N
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M3<+`>#APSL.H<^UT[.>)T(NH#VC'@*<B586OKV_NHC*L*Y46\CJ6(6P`7J=F
MQV2]QNK):,<0:"=GQTA]9NQ8<()+M5=TQ?6"A/ONA2/*EF)L159T"\V+MX2!
M]Q"$0190^.[_-0H2VLU_`=?`*.%+L91#LU?'[GQ][5/0ZJ'5.SFK5XA)$P6Q
M-CU"O"!>T"[A:@QQAG9I\ZK_]>W\'PM.<#7VBJ[805KLDP5QA&NK^KH*J_P>
MTF^.+>1?(4C<`$!+B"LT]!Q;C1>T;FC=T+H="EJ/`90%#&O<MSXVL*T'+UP>
MOE9_$^Y)P[S<*>=U65\R5C8UWY&#A]!D)]84R[K/6MLVE'4_-GY`8]P.8]QP
M6;F#7HJNDATN51%O:%R7DWX#L,1-2<0KVD>TCVW9W#S:Q6M^Y(]&W?HK:&&?
MHL:K/&"?HC=&#Y0VM"G:*'QP1'J/L87Z?*<&F/E`%7'/E'O,S)H_3ZKQQ,1*
M*FV+SN%*\=38#OU0]$/1#SU\\X]^Z+$Q\X$J(OJAZ(>VV@_=ML%P;8V!I[V&
MO_I]VAV%]+9W1]D1#3^CW:\97/)[%&0?0&DVZ"EL\*+%ZZ[H6#:1>,,U+=$L
M>@KK+E%4<KH]A=/18.`E<%W*Q:-DW%?X,1<S.Q9#!\,P?J8T[7!QKQ?X-"GJ
M%72#A/I9#-_`UZ!)?K,_2A*:#Y>]%=9S.L66PV7+85V_U'B%5S515&%^FE)?
M`^)M^P\3:=->J^*A=)/=ST`/I)MLZ_S)R7"5=N\)8RO.=BCPH;5#;E5JT@K1
M-X^`V<5[-1ZPW]OQ).6T7B%?54'L][;E@N23EWRCX_7"")9W:6VK^SHI\V!C
M)A5Q4$$3.C#LG<OY)*(G:%KV+Y^#!6-A-22U5OB=`LK0>E;KDN6E?2ZE61;"
M>F\(N&<1KLBG7-KW$MI.4]IF@%992T'9B[4\%JBB0=R_?-H,J=+E%.L$T;%@
M!<U:M;I\>6')VKLF;#/J*@R9IJ,=0SN&=FP;8E((FC$T8V].M@@&].([33-8
MG"631);6QSK;C,(*NR;I$AHV-&QHV+8JFRVA95MNV?Z?O2OM;=Q(VI]W@?T/
M#;\(X`%D1:1N;R:`QK(&WIU<MB<O\K%%MFUF*%+#8QSGUV\UJ=.6;!U-LD4]
M`9+8,D5V5]?SU,'JZIUJ([<N9%RH@4RJ\IY^N?LU\.W8BJ[%-^'%@NXC`K(I
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MC4+R=RWA?$OBG`)90O^",IWVX&.+??J&N=')X5@&;300"<)R)0BU4:Q"=[>7
MF;-2EC(;U98REM)%9_!NL8#*3W\T)F'2#5,'+HB%S<1?8YF.#'%&19ZN1Z-E
M5MN*0;V]<,L">'@?^2&U#(!,:P":W:S:PL"TKC.MG;+:UMNEEW_9J%76_0HU
MEO'!MB34.;Q8(=264<O*+]E&L&6A2S@F&O*?QC27,[$=.'^ED52GGF.CU+(0
MT]Y%:HHKS9(:MC@\N^=\?-XC+93OF;@[<#SZAL/=*R_9W",_[3NAY?IA'&Q5
MI]9H#5K]YF7/O&@T+MOFH->I7:1U:HW+BTZ_D6^=6F>Y+,U4#`YS;MR;[8[1
M;:UYL?J+3/>PQ25B,XFSFX@^2$XO[8N(.^ZKJK5SA9[1RKY";^[GU(=\\D=Y
MTW.'?';'>E4XI,G^2+#3RS1-]JY":A`I$45A_1QG:<#DM7J2\I-5BLDTQ6R:
MGHA0A9AS%:*Q;T_&1K.<57JE+T/$!`]]@@?2!%&[^&\VW+;>B>GBNWC>/@0B
MRS:>4%8H:ZE;SJ)L'V7[1:,&;6J+(VV4W&?2IA8J6!JRW+P\L'C%!9,>KAJ#
M25&XND7&>GKXTR1-722BM2A9T*EXYGAJ8YI592Z1%EJ$PA=]"U]0U[+?EA^=
MJ26M/E:WIP><`<Z`.P-W9MO=S_4<-C^#F\!-\&>.P)_IJ-LV4!;.0#;GC6S.
MI-APEP3DF[L8CVP_\:G15-@DX"WAS77ML&E\A2"W>04.CT`16LL`RA2&;74Y
MPK*!#?`J;$O_L1E#LU,U8`QA#`\2K64`Y02&ICH8E@UMV^$+H>1J`7[D=/VI
MZX?A.^9[S/'DR3ERSV*8;&"#,560)L[!E)8EXP,S"#/XT@S68041$^H&KV,S
M8Z>U:ATA(4+"@P1K&3`YK3E05H]?%J<1L=UJ71GX@:`',O&7]<"]>\'N*=@+
MTVA/A.\0X*FRC`U81EA&6,:"H\2&NBYV90,;X(4H,:\RFH["9I(PAD`KC.$N
MQK"K+DPL&]CPXE"%`)/FGMF%D#CMYEE!CL*M)OO*MBQ$`*NKA]4]F@-S3M6?
M0_>FT,H"5L!35W@>G2UN*RSH@2V&+3XDL)<!TU,4PQ8?1`1=\A/O7CD^(AO]
MS/H0/&U.2-:I*T:6)^0=[.G<:[;AJFL2MK?4MV+L$BD^?"]UOE<!U'R@BI@S
MYY:96B=DVE)8F;2I.(^",\&2A\^2<&#AP&90#&KDR+EP8.'`EI&:#U01X<"J
M=F#;6=4]P('=,8>[_K3KG0C)W6'OSX+4RG)6<L^R@EC8;')*<LBX9[.DQDJ)
M)`H[*GDZ+[$XKS3E;?E>Z(3I&<KRP+OT8&0:,8Y&GAR-W.U6.[5FK=4QS1;-
MK]-4=U!R9\]SDMOU<AY"BU-V-3F-".<^%GV4F6:'0RT'>6NL:&),UOD42^>D
MKKT*)Y[AQ+/<E'H7->X+:Z+%QJM:C$/3]O1=+^(@(!U@8Y\$X'MR3<AGC6@2
M\M/$?26-Y>G?AC2VY,>P2/+0HD&83FGKXSF-I-%6N.=+"SU"HSE]T[Y[UX'J
MQ4%J6>?`R26YG]EJHM,0/*7-E.5:?!->+,X"X?)(V"P00_K_-IX0&BJL,^LM
M4]W!0##K,.O'UPRAWNQ639@RF+)-E.5R-';])R%H:"/YRBH-[^5;JZ'PQ)T3
MP:HIL&JFT5`'25@U6+4CM&K=NKI.6V5!"JS:F@#-?^)NY$SJ+US'(LM&,V!W
M`E&:DC,^FHUJ%_8,]@SV;.?.YFU3W<[/LB`%]FRULO3%G0B")-.89!YAP_:W
M8<V.PIW7,&$P8<=GPLR:.B^P+$B!"7NE@6HF=@O]VI;M6D-A^G]GX98%SC!\
M^2&U#(!,(5AK*ZQ->T-J94$:^J:]VC>-K]U9EHVBH>L$ND[H0:FK\L^5KM%1
MF('>6>[::#%\('V+A]$S`CTCLDO"5#I&-\\6/+KH74Z^*/H_9-'_(<D&L4\^
MC?Q6!"/VR>%#QW7D*WLEHBBL`40Z,5=.+)(3<^<3FW:`4-@`8@%#?\9AY-P]
MK9WD@?:$,&HU=($X@&X.>D\072#0!>(@-\RC"\1!AH/H`E&R+A"%J78AC2!\
M='TXJ+3Q\71]J-<,%!XC<9M3XA9='S80SH&2RTGJ,-34-=PM"VN@@@U;98O<
M*HNZ;%AXU&7O:=64]5`I"U(0[Q=0FGUDMJO>,!2>E0W;!=MU?+:KT<6VV`QL
M5\FKH_WU91?*^!CET47GN5$>O9G$.RU#AU.EM=%A>#'ZYMA1'(WBZ,Q$V6K6
M%`9D*(U>]D51&IU%:?2O@2.K9F4QS.T?-[T/UU>,GGA%7WEB9ZQW->@ID<BL
M0GI!SY8JIFLY54Q?>9-JZ#B('MC7F`?DP<O9FS7#J+`/CG\OTOD[G-U<?V*G
M=WXP$@&)8_HW6U@+%[RK,+K7Y`./A?$P=&R'!T^5N?4*A"6<;\)FGD](IZ<'
M_B@9QO1;/R=O=RBR^$G8<CU$R'KT+.N)G<K__TV/FES*F2U<-N#!B%L^\X-D
MB=[1S3B)B+LB7%Q)?B<G-W+LLX$8!C37)YIFK<O$7Y80-HV'LT`XHV$<A&(D
M"W!<9^1$3(02:D[X0%>,Z6\QIS]%/ETMM46POI!1C^.EKZ2N!5%/G/QX3PLB
M.Y0/GY)A24V:55+1@UM5=K7TB93X(XG#<>58/,;'8R$WG]YSQPNCV3VX30]S
MPDC6!7V3+\1H[>3GU_Y(5":Z&@KQ1>HQS2AVY0^)1*2,5\W0"5GL"8^6UA*2
M5:KL5EX^>3[]=2P\J;M5II@/-%#__]#,I>P;E53`0HK$2SK+KQ-7HJ\+*F34
MV;TOA4P"?.2!766],-&E,':CBER:A8<\RGM:_KU'([%?RE.I+].L5YO3@N%,
MG[2(LDF7K)!-&_035*0DQ_1MWP[94-P[GB?%M2S"1$,?14!7TBT</PY)C^U)
M[ZUJNCCR?>]+3DH/2HJ%?)+MA%8<2O&/_3!TI(<0S!%)"[0P%AI*]"CH7LMT
M(!_R'^[-1E9E_R_8`R>H$2`"_R]G1-.BL5U^OLY4J.V<UDZJ8Y#07[AZH[O]
MK`&:U&A)\JLWVDS^2(MBRUO821FC],8291AREWM$FL2F(@HG"T(,0S*E.U6S
M\3=RVX`TH.G(@4S,ER,I=93:A00-"1/[B7SX?2!24GETR/0FZKUXS0OK-?5#
M*FQ,7EHH]9K;[&<_$JQ1R8Q(7CI.:;VP16;'HP6\3FQYXHIFJJ03J2WITAWQ
MM&<Y)&BRT%$B3*E^EAM+;9[H8:;#6EGSK'3>I%$C9M3._OLZ-*8___!]')[=
M<SX^[\W4<#`5T]5<'?M$DZX?QH&X)9Q\<'WKRX__^N<_?IA]^QMW7+FJ]/P;
MTL0;8<5!@N_9]0GMTB_7XN[]R:`O-S'\5O_CMG_"')L^X%9TUKAH=_O]9J_;
M[PSZK7ZCWNH9O<MVO=\E-[#7:)W\^`S6B^)Z8X?:JM!M/Y\[+Y*X7=Q^R)(P
M+B1'>33B`5V8*"W]^$6D>_ML,8P2%A9?8R>2GMUT)2H4KG&R<7?.A+NG:W9&
MRWPF^0.'6R\>;MUH==H*3[4V6GMN:&SDOM_//)2-B9@@)H@MJ8>P)37=.+:\
MSU&Z`JSPO:I'M'MOP)W72\AT&_#OW-VJCS9>\@$TJG7P8^"'&_<[T6+$GST*
M^5V9-SRH87^4Z6N`'6`'V,L/]D\D9W5E?T`[T+Y+4#+R24*'!IT+/XPV50QL
M$UW7/2,8^P&/)GG3>;(T$\05VPU).ZK21ECEY7AH'#0.&@>-@\8=A\;MZ><9
MY77TXB`@3[W(0%.+/<(Z[1`[GDYH9MO$7G.8S:+]#;`66&L+F:4*V#$-,WOH
M@KO`7>`N<)<JF9VJW$OZEMCF^,M.D`7IWC:E6"`^$!^(3X-04]V)TCKHD3[-
MFHXH7_:S[YU96^?,T&QP#2K;K7:U`U3"E\COO0D@N`Q!A6UV`4``$`#<.B0W
M%)Y\BY`<*`:*"_%D<>1#;O%E:</+CQ+P7M+.!#6WVJ0:81"@<=`X700'C8/&
M0>/T%QS>(2BKN474M2;J,BJ-CLIC`LH>=\$*(/61P1N$%@`(``*`*$@&$`'$
M(P:B=$=K*&A!B+AOB(@R,Z6X[)I=5+G`-,(T%ADDPBP"@`!@D3N_4&:&,C.@
M^*!1+#U9;&/**;XL;7CYDQ]$]_Q>)`?BI,?.\S`4$9,:(6S4GN5*=MH(ZV"M
M!#0.&@>-TUEPV@@+&G<,&H<7"Z@]RSH4PUMW9#:1$P$0`40`$4`$$`%$`!%`
M/%@@(F0LJ!;MC?/6C@V[9J-;[2I#[:["+0NJ85[S,*^`\+-:-W6OZ`%@`!@`
MSK]6KEDX@E%+!Q8`"Q3IB3=AR+6)K\U.6>/K6S_B+AOQX(N(^-#=Y\CE+32P
M3AIH^[%\WCXGFVNAMCJ=J/"6D(_HR(5ZI5VK997+V$:T9:%0>$%9%:#E2HV3
MI\FOOO0#P)OJ>3,+@1?FE"K<Q;6SS+718+`MV!:.*!S1-])Y*H_^VENNR.>!
M6\&MX-9R<&L:Y*OK[7'T03[V+*_9LSQ/D(JOL1,]+:1(*\S;J4A)(RI="*E6
M/$KCQ3E8HLU$XL6]JU+8X$Q%7J!@)49B`,XKG%<XKV\5ZN'M%&@1M`A:!"TN
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M*`)6-RK,K!D-=GKE,7J(Z_A>N(UK/YOPFSW^-EP--?MN+#)J(BA"P`/N!*_*
M3[<!_\[=6*ARZQ"SJ4=$MLTOM=#!CX$?OKY92+<1?_8"06/X6]@'->R/W/&4
M[<H"V`%V@%W?87\B.:O;@PFTP]E]$4V,?)K^H>'BP@\WKK1#2>.:9MQ^,/8#
M'NVSY7MC..5C'+6C&]`Q]`?Z`_V!_N@I'^A/=HY3>7O2;G^,B7+=TEU$RJHW
M#KP&([E?O5U35])6EN()6">P!ECC%6%DT$8?W`'N`'<<`7><*NP=6K9*>+6U
M[Z`:4,U14XT,;EIP4)`ZT>$XG[W91A=4M;HF4`5;G%V[_=(@1:&G"YP`)Z7%
MR:FA[E09A(2`%^#US&&KJVOG4A9#A-*[U<KR40+6&PD/97>'D9$J*SU#?Z`_
MT!_H#_1''_D@=ZRL[.[XPA"SI?#\]K*$(6!D(`7E5<`+\+)?29&!_#'RQX!7
M-HY;NU:MP1`A%$(9C4(Y-=L(AV!_8'\V*:-1=K(O<`*<E!8GIPJW<B(,`KP`
MKV6'K8,P2'485-HHZ"<_B.[YO6#<LQE]302,AZ&(F#QY0-BHK<&[;;S;UDT^
MT!_H#_0'^H/:&IU<*=368*<94F2(X5%9`[P`+\`+\`*\Z(H7^&&(:S0IE,GB
M3"`M,6=T.^K*/]^26EE0">L%I!5IW8`SX`PXRZ%%ZJ9"0Z$/X`EXPN'4-`PT
M.V4-`V_]B+MLQ(,O(N)#=Y\C[[90M#HIFNW'\GG*\*FA<)6U0]Y8>H?<+]FL
M&(:1%;6MD%E9N`U>!*@)U)1QZJ$-6@(M@99`2SK1TJFI;LO5Q@)#J@9L!C8#
MFV42_YG5#APM;()3HD\_S9-:XFOL1$\+::T*\W:J?P#'@>/V:H:OKNG*T?`;
M7"_0$F@IVW>*6;WQ!RV!ED!+H"7=*I&0WP*;@<W`9KEV<$+LMT]NZ_LDE;/R
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M-2"0G]&C@YB[,ATH+!&&/'AB=W[`.+OC3L#&@0CI/CR:C-R/@]7/E]]Q2!\"
M9\3&]%_?EF-*9A;8=+E@CT[TD/R>ZA3=FL;LC%U:Y'OAB8!&_B3_+L9RDDXJ
MM,]>(HD;^:"0G7ZNWE3GENMCK_?KNRJ[I>L<[T[.+!GF1!23>S@A^QKS@$9&
MMP_$V`\B1A<1%$;S.QFUL]]8^.#'KLV&@B[CR;=)=G_&GI7<-1F^G/[;:R%;
MCKU85L^7,U@<F[Q9S_-(^NQZ_;C^FXA6WNZ)&(0)3W[[!7FHU-<^*<)H*(+Y
M,.I&A1&^7[YI5?E8=IKI[;,?_\NE(^7\A19Y4>DEAQ+Q,A[(0M/0"ISA7-NG
MN[W-%5Z9HJ&FO\K;G#L1F3QKNA=2:F?DLXM%[1[,M/MFIMV9RG`F`./?4X24
M3BD2>HC'B80KC(=SXJW,&.LE.Z4T)RG@C"A@G6D8<C?AVO!!B(C19WS*X)*K
M?$E>1$@!\>0WP<9Q,/9#6O9'&@0Y4_09713XHT3N4R.TBN$J;!C3[7WZ+M':
MDNVQG=!R_3"FIQ*-?HV=0`[KB;UD[G1&=%WL$F=*VT)V(V'P<$9YF:Y-]!"(
MM#^D1WY#MFHPH@\?PCS8^T;:SV?T74OH^^41WRJ?6TDH3:K#5)_I3J0:-OGN
MB;K1"J=N4++*Q(73I9\N]EU,^I,8.?H@\4&\ITGKSC`>AJ1,\E#<92>C^E*8
MK_O"F_FV2^[P!0\?Y+^7I,W?R'TF`/0\>_YN=84[O8%O?%GKM)NMRXO+YL6@
M<]&][!IF(_&-NT;--'KU7'UCH[/L"YN*?6%Y/PK!_.#\_YKMCM%MI7]\3(<S
M]%T[?=S<X%QY813$JRW.X@IO/$/SF?MOM+)W_R=3-IOM^I"O,+VKA;#PUOYF
MLUTH6X=`"[%N(2&19/X[WW7]1TD$R5Q#`OEH1*SQMTCLS_,-.9*G5Q0Q6"X/
M0^?.(5HE*\:GD>X9\<=92&`]WUEP&V!J*:-5>Z9@\O?%FZ:AU[)2RFMF-TXG
M:PG7G5SS_J1VDOP>CKDU_7U[-GAT[.CAO-NM=FJ-%I'.=]/D":FGR\>A.)_^
M\$(YYF-;+*N9)U-:*_<';E"9DXSI_4G#^.[-/,UR4FCRQ9V_9^;]0$P0$]1Q
M@MO5S&6XQ3BKLKJ.6N/5F0;/+^QU+XE>9GXWF[K;[/3*8_045X8TV[R&VKA-
M;P'+\?H26#+2#(I8A`%W@DU-O18#_IV[\<N@$^\F9UF@K'I;`S0S'?P8^.'&
MD846(_[L!8+&\+>P#VK8'[GC*6LD`+`#[`"[OL/^1')6US8$:`?:=PE*1CY)
MZ-"@<^&'&^]%PJ:O-<=U^,'8#WBT3R.CS1''K2_W@1][]MDDV6TG_^0$->VH
M2AMAE9?CH7'0.&@<-`X:=QP:A_,+E)W+ICS07*NH&LMN7I3!K:'J71QO`?=`
M=V^LD)G9-A5VJM1!CXK<*@NS"=8":V4OLVF!N<+SU+30)G`7N`O<56[N.JWE
MX'"5K0?`"CDJZP@`X@/Q@?CR"375=4'108\T;H99WGQ9UN=]JK0&NIV[M`*5
M[59;8:O:LJ,2OH2"]R:`X#($51[*`0`"@`#@MB&Y4:TC)$=(#A0?,HK;K8["
M4V3*;DA1=[LZO/PH`>_)CA6HN=4GU0B#`(V#QNDB.&@<-`X:I[_@\`Y!6<TM
MHJXU49=1:70,Q%VP`DA]%/D&H04``H``(`J2`40`\8B!*-W1&@I:$"+N&R*B
MS$PI+KMF%U4N,(TPC44&B3"+`"``6.3.+Y29H<P,*#YH%$M/%MN8<HHO2QM>
M_N0'T3V_3P\N2T_'XF$H(B8U0MBH/<N5[+01UL%:"6@<-`X:I[/@M!$6-.X8
M-`XO%E![EG4HAK?NR&PB)P(@`H@`(H`((`*(`"*`>+!`1,A84"W:&^>M'1MV
MS4:WVE6&VEV%6Q94P[SF85X!X6>U;NI>T0/``#``G'^M7+-P!*.6#BP`%BC2
M$V_"D&L37YN=LL;7MW[$73;BP1<1\:&[SY'+6VA@G330]F/YO'U.-M=";74Z
M4>$M(1_1D0OU2KM6RRJ7L8UHRT*A\(*R*D#+E1HG3Y-??>D'@#?5\V86`B_,
M*56XBVMGF6NCP6!;L"T<43BB;Z3S5![]M;=<D<\#MX);P:WEX-8TR%?7V^/H
M@WSL65ZS9WF>(!5?8R=Z6DB15IBW4Y&21E2Z$%*M>)3&BW.P1)N)Q(M[5Z6P
MP9F*O$#!2HS$`)Q7.*]P7M\JU,/;*=`B:!&T"%I<S)?6%1ZI@GPI\J7@5G`K
MN#4-U#LZO(LJB\^YD"S]/LD-KKQ^X>>%>=$RBK,'D9"<8?Z/O6M];AM'\I_O
MJNY_0.4F54Z5K-7#>CBSLU4>)YG+;#+)Q9['?81(2.*&)#0@:8WWK[]N@$\]
M;-DA:8KNJ4J-98L@T.C^]0/=C=[+O1/,/5-`@QYPGR:.XP/0F<_Y07VI/.X6
M>+B/WTD'-M%,2[AN_)T?7O1>Z,^P'5;R>0=)KQU/!.P7L69?I,>W,';MV.'R
M]?EY=]H[&T\GHY<)I\!&NWP5B-?)#]]O;FXVMWSL.6.0\<Z\[0/"UWI./[PX
MZ[^\E_>*$A`_^.CG!G6_D!9("VSB`A]VL'1@V4*3SIZFY6IP'$Y_6ALXGTG7
M-N-?!$S.V1MA"6\F%!OV.VS0ZY^QD_<^@Y>XCO2#AYCVZ8+O[?%WX&Z44W=C
M@5(3ZBD(_(X[ZD[Z-6W"OW$W$F69=>2SE2\1U3:_;`0/_J1D<'>Q4--F_*NO
M!,SAW\(^JFG_Q!V_M*HL$G82=A+VYD[[`]"YO!I,DG8R=K>\"4_"\H]-+BYE
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M$$)DDA1*KR)Y(7GYMI2B/L6/*7Y,XE6-X3;I=7NDB,@5HC2:$NDTFI`[1/J'
M],\A:32EW>Q+<D)RTEHY.2FQE)/<(!(O$J^BP38E-ZAL-ZBU7M!'J<(%7PC&
M?9O!8T(Q'@0B9'CS@+`IMX;.MNELNVGT(?XA_B'^(?ZAW)HFF5*46T.59A0B
M(Q^>,FM(7DA>2%Y(7DA>FBHO9(>17].01)DJ[@1JI,SUSZ?EI7_>1[6V2"5I
M+Y*TI]1N)&<D9R1G-;1(/91HE.A#XDGB209G0]W`P;2M;N"U#+G+/*Z^BI#/
MW&^Y\NX!C#8$1K-EA.\K33X;2-S2VB$?3+UC[I<\Z/3[_:J@;0?-VH)M9$40
M-!$T51QZF!`L$2P1+!$L-0F63@;EE5P=3#`*U1":$9H1FE7B_PVZ4S*TJ`BN
M%'[ZF`6UQ)^1$][FPEH=YC\J_X$PCC#NFYKAE]=TY=G@&YE>!$L$2]6>*59U
MXD^P1+!$L$2PU+1,)(IO$9H1FA&:U=K!B7R_;XEM_4V'<G9]O[:)Y8@&>R].
MET(C6W_0>UG@4%TUI,GJ^`!=X>LA_J(.'KM>"C:7+L`FS(69X%<0>1Y7\+V`
MR4BQN>-SWW*X:UI"!6SMA$OF\3`.C3$Y9UM4*'..K@@"%BZYS\Y[&1#;_'8[
MV:S,U[*YDAZ\5S";AP)7N8J4M>2!8(YON9$M;/B!63Q8ZK99^@<,'-YP%_80
MZ.+KI[EE20^DZ18I;$G<X$!@HJJO4R=A;)O-N`LT!M(OA0A?/YJG]G%,[IF"
M6NEML!U^S@_J2^5QM\BJ^)UT8,,PEG#=^#L_O.B]T)\!/ZSD\XX-N78\X)Q?
MQ)I]D1[?4M9KQPZ7\".L*88N@"27KP+Q.OGA^TT8RB:5#VJG4#;=F9Q[0%A<
MS^6'%Y/ARWM!LHC(\8/]QS[WZ`>/Y;EZ7OBPXXX*L\.K.A&9EJL<<#C]:6U`
M8"9=.W:OWOL,!G,=@*Z'.`H'-U*ZC^K8C7"A9.3;B`=2O?YO6_]7Q7;<O046
MP*50U6Y"O,3!:,*MV9XMN4C5[R[CY$JL0N'-A&+#7F?OMP:]?NGW63]CMZ\T
M;F\E4S^&C=\(*^;B_IU<?'!N$YV`[^E=)CU/*&WKK_A*J*=$A;U8WV`B%A&[
MY)#'?;KO2$,=.V@VZ)>8IM@$-J)CI>8&8BG.>@!QCA1;3!CUC+H<D0%T&*]\
M@I7[.%NF!/P8"/A_&O7C"R6$AZ&]QW@#]]:CE^G;-JT0?8>2[T^GY5V41%J>
MM/SS:]\W[(WHBA=2;8=>\>*+V[AQ`YL#4I(6*T&+#3O]_GF)/0A(CY$>>WYZ
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M#@*6^=H.R%>P$E;HW(!0=4L&XQA\^^/JP3=S6H8S'O\1!WWM`(<ZUIYT^"M=
M@7F+?'L)7U#<"B-@Z(\IVKUF%S?<<5$1GLZE.KWBH/.O#HN$'TJO<9-T%^@>
MC;!V7BL@]W,$:`W@E@S"1*?MOY\`-#W@@C-WX`E`!EX@8X!DG-UB;69*]%C%
MW&J=D9;&ZH=-X6Q`]9I5U&OVQ]]8L'DV:F<]8^L+-FF!Q[[`1Y7<-NGXNH+"
MMQ*.P"9'>EC=K&+98E$L%;]6<US[K;S:`I:\BPD+):W5E:Y2-X,&=S-X1O7=
M;Q/W[5!7J1&S?H>NYF_H:I*&*%]#D/@<KC.2(,=1B<^E#$IKE4^"0X)#>H?$
MA\2']$Z9>H>J+/:<^T78Y9))7[!;P163BF$;SJ?$HT8DWS4I$?3YY'GV.Y/1
ML%M:G*X1G/24:9QU]E$\-CN!<(MPJUS<*JU%0R,XB=+/VP5/#4:A<G'GR.%%
MCS<^ZY5G!A%J$&H0:CP3U"CMFN2VH`9%?O9'?O@\%"H+_H1+,#H72S9W;LQO
MJ'54*<[!=-"CUE$4U*CS\(.$<)<04A]2LK7KE[4VB%0L1,.S87="%B;)"LG*
M`;(RHFZ'Y(T]U!NKV/EJ:.G(D]F%@TE573JHSR&Y;B3"]8AP>2DC),)DS-8E
MJ6T0R%@$Q]2KE"2-)*T622OMB.^Y2!IU!;ZK*_"NWCB/:K;_`%ZCGL'4,[AB
MH@X[DUZO*JN$>@:3<U\>X6J%QOAMNF?8DVK\YX*;51#\:4&U(@/T(71O#!>3
MA_C,@+7!$%DS*!ZYS:C'&W3Z_7Z)R7G/I4\[01-!$T%3Y=`TJ-'6:@LT'?L5
M$D_1=IL#S^#E!VD3[/O[:^^(&E('_N/KP,_6/*CS:HO^$&\,"9?;@>7CVJ[^
MJ(YU;-R/L+VDEE^0\%E)2P@[8',E/?8Q0Z,WB$9MO@AA55AY=O^-YFQ$6XVU
M=^&SOKPFB-P0U@<_<7/]S8([OOFC*X-`!'3=`5UW<,]S1]/TGA9("ZSRA73=
M02.O.Z@XN><)^X-*K,D6['JIA&`?M;G)]GFA;T%WVL5+#RB85UHPCYCU4&;]
M!0RW"GF5[D5HS;T(%2>,''Y$_/0B53QJW[U?=(--F_M$'Q.W[N7/@V^W(?XD
MF"68)38FF*T49JG:?G>`_?.]P?6G1(#F)STV*767,G/C;)'A=%)BN4/C>9"R
MVYJ;W?8HU&L*8S6]#>W1HI8>;SP8=4MS$QO#,P1&+0.CQJL_,L$:9X(-.\/Q
ML$1P:SP/$NJU#/6:PEAD@E7;FO+\;%!Z9?S3<TV36XBT-9+VI9!7VDB3K<$D
M;*I5UF0(VT&S7GD]J1O!1617M<NN:C`"U6XZ-1E:<BPS'?0'I?$,80=A!YDU
M9-8\M+$QW5=#T-1@:&HP`I%9LSE>K[S`=%LP@V(Z]\1T3(4P63]D_3P!S4X&
MW5YM9,N$\[CUW@XZ/J2TATPH,J'(A-I'C),2;_%M&_`0U#0=:LB4>LZF5/6)
MX6U#-#*EC@O?&LQ*9$KM,*5*BVVW#7@>!C4MZ7;:W!:$5Z'BH5C`\._]&Q&$
M'DRWY'Z#=?<7O*`^K4?7I[6C^_$&*3,Z*3.RE53A7+J.U+U<+>FME!,(&_<X
M^U;`0KSL"WBO6O)\-YYVSY*^,D>^U=^=3;K36M92[//:86MX<*E;<SJ^Y4;8
M+0D&S.\F+A[&%XKQ(!#P"_@[<@BWD`&X?XL[;4E$%N0%^$DGY@+WV&S&7>Y;
M@@5+`4]VV:?[.2N>1E"8`[Q2_!EAN^A<WU'@.@OT-(<_SAP9"FOI`^XN;IF9
M5U)EO3'.#?P0P7(MOD(T9G-P,`(@@X#?85<I^"B4JQ=5H(*FT.Y9['E[]V[-
M&O_\][]%P>F"\]7K2QXL\=];>,<-=_&U%[Z=M:+-FM!>`Y;_Z$KKZS_^ZS__
MX^_I\]@H=":!NK"W%PJ88R%P\F^<P')E`(M.G\-=0H7P1<Q_>/'N#8+E_P[_
M[_K-"^;8\`MNA:?GX^'Y\/S-Y9O1^=OQY;O1X.UX>O%V,GPSG4XN)V>C%__8
MT$!YSKRGV^DNV^=N+3XM*JQ!R0IKD"GMT63:/Q_O4=$%$FON^J0EXXMPX5?`
M^4MG58[*SNR6/3V"-TG2'#OFHQ,&T<P!6K!K[O.98)^77'F<74JUTK3;@7%'
MW4;YDY]K,7=NC`^`5N007T8`@#;\Q/A""2V0;.V$2W8(F=C)Q^O/EZ]`HS+Q
M%^!BH%&;`>T1;-G'Z]/^L#?L,,Z`_P!F0VRM+_Y:P4SQ10!OGK`="QOEZ7>N
M`*C\T('?PP(][-B\PF[Z42@=SXM\A#CXNF'E;C(\<Q!(&4S)U>"&(1F`2AZR
MD*L%:@3$S6"UA'V1`;ZK?[I:2O@%SNGDJO_Y%2@="P@D59?]BOBJGPB%\C1^
MXH>4.)IN:]"$^AD4L[54KKUV;,&TXX7V1;9R31;D"'81.+S+?H\?!G*BHH-U
M.-BQ>2X56[AR9I;@"64Y>/1LB(QR;`N@K%SI[;%D`&^!D6'*^DGS"X5"#EL)
MK\<9X_M\7`1@LE2`RGEEBE](W^^X\44'N)E=ADVW00?Z`<`LOA[("XSP+]#)
M.+05!>`Z<@6*Q$5J&MWJZ"WIQ-H1?XMO@)UV8D9)R+A:`7/H)M5K[NB&W,@,
MTC9Z37_G?[@*3Z\L<%%/OT@82[(+X(E0P8O9>S#IY(TP.N\"9@3C]L\G8^07
M?/97WT$27(5`"9B.UJ^!YC@K)@W.6B1?GX.A`&SW9P2OA+?#8"@:=RO&TA"R
M-O'_%;8YV:V,?5?\5F\XRDZTFBM\(?Q.<UC53M%WXUZW5Y]MG.QVI"TK#Q:.
MBX]6R`\UWOCPW=GTK*YE.[JE)9B'$O`NWM9`@T4*JSDLU50J0`5W)<BF!N7D
M2A0E;[FK;<J8GIYCGX9"^$C&)0B!^0#RC#VAX`D-GJ!B(D`U7X2FGU`&@8"?
M4MEZI+8PVZ8<<43E0'"%L+N!X@A*OH$B=%?V>"@!(IG9/.W%@G80Z`WX1:UD
M8$WK1)#H)3<Z3^LCW)T5QWBALT*%%[\OT3:P1(PD`N*#QBDHD42]XL1Q1-2Q
M*PWF"*/R%.3&`WW-?.F??KPJL%."QMVKTF_J.#IS\P)5'E#T)P$R`"^Y3EPQ
ME*0VFYP_1P"H@]W6)K,R3R6V<!*C,>-I8+-88-@"B'<ZXR@>Z-"`;RPVT$RN
MEF#SN1[,SW9`Y/!&#PU?A]*?G5S\='WYRM@_Q>EIN)I+,'V8-)R=%V0$N5R`
M`#[B0&GUS.3[()ZSB/#](#8+Q;V"L323B+.9,!I#V0*R:!C0*_WC%/[Z%1;R
M!9;AR\!:.@'8-B=_?/AR]4I3$&:AQ&DZ2/%Q;=$JP<-DSG^<?LB-![98P#X[
M"_RK#+@>]G-,C&Q'`"%R$1"#!F8?`.-@M\V\@?X6'K/=IFO5@+"6.S=)QV]\
M`R.YOZ=690=1="U@!PP&Q2&.7'`&!D>*M\UL>Q.IQ)"&9T!3;IBI'?VG(J?.
MA,5!08CYW(30-'77://8XDD,O?Z@+I,G<6_2."&O>&G#VLR*O2S?08E?<<>^
MQ\P`20++M_K#CN]&M<:\=2`_5APH*EDH>"[J6.UPU!W7LEJ#PVW9.MB7A['M
M&H/?QETX//Y_4,C?X&,<D(DM<GWUEPX9"74#O&6"ZQAW<.#U79;#Y4KI%.)E
M)]7NA+FXCPE]"T4KCT&UX9FR3L42-*[ID.P@OQ*D05J.YGEC!X.^>(2SN1G3
M:PFBWJ,[.A6O<]J=U!8'VLLI";YU*C>5)MU1/<L%O>(YD8=N&O+YMN%D_*2*
M<:`NNS!U]?*[FH;]"L$<]!+KBL74E[ZC(0WT%\Q#'Z/`0I-3F1W13[X`1W;!
M0W-VK@]0@AJLQ#ZPPZQ^!RB(`]Q5)X8,ZI)M]'23Q)`LI+&6S!7<SD(-*.%F
MY76L?W1>V_JYI61@+-/M"$N7)<*@8S2[)&)G_!YU']Z9"U_7`;<TIG]O&+]E
M6(*G$NAF`#5];3.EI[K;![+Q.6_"@XBMFNTP9K:Y(UN1\V")[L3V>2X.`,_.
M'?QY'L:'H3HRMQ6G9V"O<>V6I)?/F\/.?3%ZX\Z@V1>?Q`;:H[$CRYQ7SX0Y
M"+L1=B%XKY>@_2,M9#K@M$OII-*'@44D!S@O,EHLDY?$H\-3W$Q!DRKYDHEC
M>2M7)&?%<T<%R`.GR\C#4VQ].)$='071"@.N^^>C2=HIG%O'J5CYTVISOW-B
MV6Z\,P@CV^!,NK_O?WES*GR@-CZ"?T^BT+B:?.H`/!_-N14:3S&.;&M79,EO
M1"*1>KO2O(DT`([(!?_;"B(#`5?*$2&>O>?RN5:@XV$.GI9>_A4>O/B-W<"J
MI3*3,S`8.'_I*'J`84.\11.HG$^NVWX?@HP2)@1KU.424[;TF+GX8<[>T#=M
M)RA34SBVN0<_5VL!)%RR3VH%A&,_.O(&LQ@\=O%C.\]Z^N/DL.>.I;.3*SES
M7@$[(::B"XJ`EX$6N*V15\1'9*MM$,9SE@^?OWSZ\/X/9,^W$8@'R-B7*`@<
MWF'7D?HJ;LVSL>B;.^)3]??1L6U0?6]Y8%ZA`U)14+4U6%?4.#$'D^C64K@:
MVP5(M5PS'5X#<'K;_;4+@+2(`$8D($L"U&T[3?D]?U02IYLA)R+/_4LZ?@@,
MG)PV;C*<8)AR"K#WV_OW[_5?X\_`>DOAR=72<1V>*M1\R.3MAT^7UQ?7;_53
M";]V&=X1ZTD-O(C=\2GH3$:AR5TNIN+A/#L`]'A@!GL%BO@75.J#7G5ABFV0
M^X8$TY(#-TD(*PM<S1V?^[A7^1!6/F$<GZAT6I67/2#+>*S?._UGV9+9_,(C
M,"PCD"50(V+E5%-R5*,9,9Z<IY<N;DO8SXA%[+>X"N`B`8)*%ET;^+[WV3LQ
M4Q&:KB`I`VT*ZXL#M7BBVC<@G)8_;")@Q@(?Y,*Q,'.CRSZ$=A?LB>QOKO[;
MJPXH.2Q)P.1E'=K%=SGA;8=ML%(GEV/2R5GM!MJ,O8#E$X$#2^=@]NH,:$LG
M<J!#DAUF;$U"ES`H9Q:%59\[#*:][JB6"!,HH@@VXY^@N("F:\R9J3-]<C"J
MRW9ZI9T<6&.E;YF.7E:[72`$7[5OM\'V259(GD5KW,BS\^?!KV=U'02\2D-1
M2GC@Z51>V]BOFG/EVA<*C4G4#J`E@C"'M5F<98_.R"(M/AB+H`<6/'$OXV-\
MD`!P=6P3"8JK[-)30+`5M]^OT\9G&"EUM;S8D8[4Q):GO]!N9>QQP;<DO#K,
MY]UV68N+C3O[B(984Y_$]7O5LF7B4BLQQY.(P/AJ&1>E>!K')RJ=S+@[?`X@
M.JKII/Q56B6"8>#-7$N3;K9,,BOUB4BV[_$Q\SXL<.QM,/@=@\0@)AB7*@3M
M5Y&RENCGY\8/0JR)W:''=97;6D8NZ&\,96/X*M09NDK'"HI2F1WIU'$T!EK^
MO%IQS*F$:UUM9B**YH3#28.*CDD$SU)?0B7=I#3,Y)3#MU9<UU2C(CURLB2U
M=B;#)9?[H).`9[=LVU?1+M@F<Q6.R->:TV*MRET,0MT6[,>L?B]SW58N\"-G
M.N!F6-74_:PP)<77QS>.@L^@O7W<@[CFO:(`!W45.896$T_6542?)7*E-`S<
M<#?20(*04<R[WL)@%+.J??Q>33DDU>_O>;?_',R66NM;JUW*M*:4S%>[>[^`
MB%DN#P)G[IC4;&ZJ_/WX_+FT7/`N^S$Q!O`9%\."Y@5S``/\'J;<;(<0L;+-
MLF3DA[$;[N2;P^048VPF>B)<2IT$$3^6.)YQIO+"QQ,GW>1(IXK$ZAQH$[DF
M,U>")1=76N92_.Z'*LR&2PQ;M#L5R(8*LG+2W"OT?'70%&N*L.@TEVF2;DSL
M")E]29,M=;O\;&L$/(%Y0S@J_^L1*<@UI]SKO?#!M*A6<)]1[KWF:,R[-8SA
M;[)J]>T&:DO,KQR-^W7E&VZB<=Q1C2N#-E5[_:UIG=8_ZYX_R8;%\8R5<D`K
MW0+2Q_MGSNY-VY6`RIF.#%(+=H&YET:[Z<(6]D$^3#Z+,L`LH!2BM1V219W,
MX%5E&S3EO/TRS?.IZK#]J3.?/ODL<:I9?Z*9=-C!.&,0<3],+,<XISFZ[VQE
MZSS>A)!VG.AO=13;]IPWLJQ@.LYI&'F`5[[`;'?XTMQD6IU<__+N5>$H/DXL
M3KL<!%D6(*)ZBG\6-R%!-'[U"V"D_$#I`!WV,U]Q?^=!4ZX7&!YI;!\TZ>3!
MBH\3QS5G#F+J^@QK`=+Z2>U]5='1)JZX3=/(X<-M[-OH[D+F+"\$CVGI",R<
MWI6QN!W!W%T:A)R9P5RUFS:IK1C,*:QJ=Q78#JHESMZV/'69:1RVF7FK0V4J
MZV-7<3G=J.)#O;CH(E:JNX"J[2K0I'!>Q=6@Y2J_NI7=E8,=@;@O9!3W_S%]
M_I(<6^#VG0$<73153$C;:DB$=;*Z\&*KW"3K%)"URM&%IL5"D+OUH<D*IAC'
MD1GDQ1A'Q;YDKR9?LIZ6XG69,UM^L8D1*Y!@/S*&HXH3V./NJ8'(5\?7&?D8
M]+O#MFSQZ*FZQA\8^CCR<V94%SF3+U]*LG$L8/@]`#_4F8/RT@62A?Y[63?V
M@`I-J-#DD$*3'1<$'-[@?^-B`,]SS`G>A6]?_C][[][<N''L#?^=5.4[3.G)
MUI&K*!H`[XK75=3-1^>Q=S>[<LZ3][\A,!1A@P"-BV3ET[_=,P`)2J1$4@`X
M!#N59$D*&&!ZNG]]F9[N0.Z("2"SB';K#7`Y[)A&[_JJW[%:YM5-?WC=LE1O
M@-95]ZIE'6EO@#F5I3PMT;DD#T?;(T4WR93+PQQL^%.]HGVW/L"UT4VWI?](
M7+1:\M.5B<B8B[@(9^%ED:M*G>;O^O67X=7UUU\DN]Q=7][<PK<A.XV#>X%@
MW,B-^R4]^_B=#"]7$`VSK`JK.J=57[.*]UF"'0R6%<F7[AZZ=XZJM_Q4:93)
MK"[*A,5N7RR[[+<T+R"!61"R(/2\CL3"*8,_R1/'MWZ^)L5RMFU+,J_D(<F?
M=:&=G2'N4H'PA6`M$3%'O8R@HZ?%3S=!X$BFNPJ3>S9TIJ[ORLY%LI+QS=50
M":(L$8*QC5"D0IU5B7B6MK[\7C(VC]:D2#>;)H"<(I01VSR6,'BQW)_2?$ZU
MDS#/K)4YH3%F.F>;_?-:',D4PY%HX<FB,BKGYME3,F29IV#/$W-4@NN\),V:
MVY9\@?A1>%@<"N,2J1\@_3M'@&6WH'H>$>=!F]J5O*EJYY?B3`7%F2I0JYW*
MSEBBK*U"'EGM&YU/>R*JZ`[1KDUJK2P\6,E4U@'WLQ9$Z]%X9>.=MB312I.@
M\R(;">TMVPZ3TF.N+:-:0U-R?@7=*:OB%5QQJ:A?,,VK^CI>5?*^AD5IY"YJ
M\%CMKG2%/+W"Z)7](F3UPNH<I`JY?34XKN'V3,^YXYR5:EJ913,7E#5PJC*_
MRN:6R@J88C(\YJ79$Q:[B[20-115M"O;/[2J.GL#2BU.,V_DY'UPP5!+BG"E
MG01^F<J_<!(A^P-$N5*W\]P,=<(@=<I5*<KYZ5#0TO?@1LIKN0QC)R&XB'+[
M!&\,'7DZ8KZ+GCNN$,6@@'GHY!OZ81G)!/LK1G*_;.3ZZ1D%>;Y@93BJR8;^
MD^R=D^L1F,'$_)0!GAH`PQX87F;R+/HG+F<ER0O4#EXVK2;[,C<K0TFI["AH
MUU@8\`Y_BI[5@A3S0IGY`Q/IXBSW,5S#G+GD*2GA9>TVZ1MC_09WQ9,D]+$>
MH!O_1X1>6CI--IRL5]A5UD#T!<N<0>FOX8;;\]ZJ^2/>7MJ<<`VE2C^+W.TT
MS6JL`)@6H`+>:D=9ART_#KG]O*=4%AH2_H,;!G[:)384V"=6!;=D:5?5JOM9
M:8^,K#)(E)[OWK!S:9JN,_]!'5?V,58&LH_[?=P!BP4&5T50YR?+,L1K**TE
MH<@1MANE+R4K-2-F)B*M%I'8W`?\&V7)C@V5W1C8"GT!I.91&16@VGX;;IOM
MM.<[<;-03+`EPH.XE:F9N`&\S=[;]<V@WVU=W'0O+HV;SN5UW[@8JKVWBXO>
MY?7%4>Z]#>U42XAL'WN)TDR1FIW^'$31=]4`HU$1,-Y);W^N6Z7*C)(IR"%<
MEYIW"Y'B.4(%J>F3)U2:+GR*9Q.^6SI6.'I:'`L]WYF$.9+9,AUP$Q;,Z(Y$
M/C>>Z6?\GG^,CSD:WC*7XC7S@16);.%YZ34?3XP3^3V:<3O[OKWP`,7O75^]
M)';4SGZ0X7KURZ/KQ!.X&@@Q0M,J/)-I(K-(G&<?7C#5XKW#^2?,^,:W]3^>
M6/"N8?"HOICSB[^/G<7'<.40\F4^GK3,#TLC+(9>.=KBQIWOJ_R!-$&:($UP
M#Q-<!STIN(+!)^M\IG`W"F*P'S-D5-_.S=F?3*:'L?]CR/_\8TD;H/N1A_K\
M]W2$_$\*B_&7-Z>1TS_/(7D!_/UBM7H_R]=[8>"<WOJ9(_&&`;.\;/.)M4ZT
MH_KKE'YA'E1&ZU_]4,CS<@[["5RE2)F-(OH.-]N_"7`C7-GE99@5;)".Y#?N
MO=R$7;\PKRY&]2R.E3?&8$.>3UP'S*JM+5?7!UO2C5??-P\$$>/NCW$O>31A
M-UC#[K^%<_]&1B+Q*O%JV;R*)6&!4[_%/$[D%LR7((JQ'TZH`GD7PA=X;O"+
M!R,3MQ*W[I%;[S`3-3W`-'1^2])Z6,25Q)7[Y$I,^]B4QCOY8L40,UTR&8I[
ML5[%.&+EQ5<O5`T[F<4*2FI>Z6-MU<P*,6#$[=_OPP`4Z5D:)7?D?PZ6XHN-
M4#Q.K_(#BB+P6F)M0N@2Z"GE8P\$/36:A3'MFS1=@,">J+PGKMTF1O,^"A^Q
MS4!X2GBZ?SSMF<U>Z335A@%?%6*X;Q0RVQ,\_'CB![XX^7Y.!,)"PD+"PIIC
MX6G+;';)N"3CD@"5`)4`M0!`'0R:%@$J`2H!*@$J`6H!@-H9-%]6$B!`W1.@
M%K`K9>PW!;#$(T]OY>>SD1@'H3RHES9PLM6)P"WX>Y%(_M:^:Y&J;8OMU;T!
MA:6KX:4QWY)MM>?L"9+B9\'Y?@7Q*(J_DP22!*Z1P#8)(`D@">`>#=FNV6R1
M)4N6+(GQ(8NQ.:@@S:0NBI3"2NO#2L,I%IF*<E$CK%X5!M/MBD.4(M-OY/8?
MG<PWC<)$?E?2U@422"E7H91)@)=M;]/L%ZBVWTM=,LX)!P@']L"=BMI]R[2*
MTU>DT$F029!)D$F029!)D'>PS'MDF6MEF;\_:&=6`@+["-I]$C&3]8NQ0KVL
M6KRG"-W1P01E@9%[7CMCX-BDN&TT31)C$F,2XT,68THE(Z>:!)!2R4B/DA@?
M;&QL\U-^FF+`H-<<'&;<C`Y8OK4L0)H]((<&93WG;<?9VF[CA;!X"_C."1)L
M&O">@K5T]+W(%:"S\?-@9W$.UKN)3M!.MN%^BI$09!-D'PAD%UIO;V>B:\/"
M%%$CN"6X);@MKRA,KZPC.60BDXE,F$V839A=>%2C:Q18\H]`FT";0)M`FT"[
M7-#N]`IL4T6@7>$^X_<Q-L5>=7UE89L<#6'ZXFRB6B>:EO'A'Z^U;EQ^;&Z4
M)63$TB!R%-<'T%??\X_Q@W#*O25.,?&:^<"20,P6GI=>\_'$.)'?@1GL[/L*
M0MVY4Q&Q3^*1?0VF_(6^F?+PWO752_(D#K(?%/?*7QY=)Y[`U4"(E$UAU3T^
MB\1Y]N$?S]EN\=[Y'>1%>H6Q,FUA@TUH^3(?3UKFAS>E8EG:TQMWOJ_R!]($
M:8(TP3U,<*=#97OH,;RS)5!9M^'36Y_!8!X6&-_I;!EU=MZ8UK_ZH8!W^(]P
MV$_<]2-V^G,012+ZC@4^^R;L!*PE%RR!X0-W/6E,C(.0?>-@=A5D,I,O38Q;
M-.->\FC";F")V7\+YUYLTZ:`>)5XM7A>'8/##YSZ+>9Q(M-`OP11'(K8#<44
M3UI?"%^,W9A]\?A6336(6XE;B^;6.Q@C\F1_%S9T?DNB&%F4N)*X<J]<&<3<
MVR%&N&M5WEV)>:@AV55G%:Z$G1Y5,.51A<).Y)5[G$E#PA:VKU/GW1DY7J?P
M--/]<\P^DT5)W1(4$13M1*E3JU5<X;:CVM\M-@V'((P@C"!L-P@S!\794P1A
M!&$$801AU4*8:11^$&;_+$,>(6$18='!81&>RB./L'QSBKKJK2?BY[>J<;.1
M&`>AR+7=L^5FWC8[>!M7--L%+'6K/:;,C.(.`9`A<32&Q/')2:=7W!%'$A02
ME-H*2H$%;$E.2$YJ*R>GO0([G^SD4^EN\5,4FN3K/5M`!3;W/F[YHK#$>B(.
MIT'BQU$NZB`<-@Z#*>.VG4P3C\=B7ZW$2LBBU5/4NV65GUE/M.-$`M*T))Y;
M<U>OP)8F;]",/$:2LZ.5LSVTSB9Y(WDC>2-Y(WDC>2M=WHQFG^1L.SFCCN_Z
M=WROC7R>=HKK`4UA%E*/)%Y+XW7;Q>F_NN@W$A02%,I`(3DA.:$,%#+8ZB%?
M9<0S#JHG>)J^8A0GG*5L:M.1G)?TIO;>67OOZEI+E(L'&I*^NF8I>Z)DE2'E
M"OM6Z<)SY&CH>PB;T([0KC12MLWB`O0$=P1W!'<$=QK#W:G9+ROS]!5RD@]-
M*$DH22AY,"C9+7`7@%"24))04A?6(Y0L#B5;_<++,1)*OF\_1O,VR/DEDUFT
MS^F:[W#<P@/251#Z;H*M##U`=7@WIOHD1\ETRD.X+F(Q_)F_\TCS^<XDRU$(
M^R^YXZ>U-,D-LX3KVK:.+J$OM-E[9U]HJ[UCBUBKILUL:]^MER9XZ!-<)]+S
M$71IKE;;?LM$Z6TI?:O.T&`;4-7W\^=`U6;=@NJ+27;T/A"WOUZ!62V:KR\,
MMV'.<%.%="^7##>U0#O8X*L-D]X!I_CM;_EN@E#:WW>34`CV"UPSB=@ZM^1:
M-=;-IUWI%6@JS!W5+@I%;%X(FW\"KZQ$+G\3I-ZKO4?<_OT^!,1UT),+PO/_
MX\C_5"X_^U_H=/Y6I\?MT9IEMPRSL%P["H53+^4=D*?(M&1B04)20E)BX\*1
M])"X]?TP2QWK=]O&^8F[?J2*DHCH.Q;X+!)V`G+ABHCQ!^YZ<AMC#+9VQ+V-
M/7NB_(9]B+*J,.+/F?`CL=<DC[7J\U#IO*P$"TYE>,O6J&,*PPJ"GA98)>%-
MFAY%'L,*(E/N5T6Y7Y3:1;TKUV5N&7NN2G;0?$8(IC."D>%'AM\.AE^7##\R
M_(X8-@^4S\CPVZX,8(&&GS8LHW>Q:`(H#>BS#U1*$_QB_B<;"5^,W7BGT.CF
M->**W#'4K?[;"GNBR#I%ZTA7%QC33R*U0ZSCJW5:0J\6DA>2%])+Y<<22,Y(
MSFJKETY;Q4G03D$WW3V+*IM4[T/FTF/)UB[GO^ONR6I-J\W3!LO-;GT+UK0F
M(C%<"0Q'?$5\14!&#*<KK0C(ZF72ZI'_;O-HPG`=V40X]R(Z7.'=!SV_B@?A
M)UM1C8)B:X)B[59S0%&Q@Q4_BHKM/2IF%2=`)"<D)\>ND$QS4,%A'Y(TDK3:
M:J33'O6V/^I]FKW+G&;T.<BCUV0AK+$02DB/(CN!,.OX[`3*,R1Y(0^6]!/)
M6ZWDK0YB1?J)'%-R3$N1*CK^5J[Z/S4*;%%8:,T"C3F3RA*0[5!L#'S?E90T
M%C82+W*%*].%FM;OT5@\21?J(:QUD,G"+=*Z"=M1[`?KDR5.M*+C+L1P^M**
MCKL07Q&0:4I$8C@",CJW5YU;<!?$W&/AO$&M:@,<-9@O8A:,<0NE/M*[=XE]
M72TLM;-JS?YD3I!@TZ!WM2>EDN0%K@#5+$]/5!9X(&QWHFO#PI0U=&RHJ@OG
M[;5B^<:DK2,JRO&L9J\Z&-2%YPCMC@WMM%?`9$-JCI8K#T'WJD1/[7F88/78
M8%47SB,C<M^I"_W*J7D4C<!V3GSX/L9NW2NO7_'YA^^3Z.R>\]GY93"=A6(B
M_,A]$"H)_5,0BSN8]H47V+__^+>__N6'Q<6^I*2,N'Z!3_;3_$*@HX_$^BK&
M'T]NKBS#[/RS]>^[JQ/F.O`#M^,SJ]WO#'N6:;0OKZ^OV^WVM7DQO.ZUKOH7
MU^VKSL7)C\^(GR?DG3L5$?LD'MG78,K7PV_N=B"[.$MC^J9E?%ABG"YPB5Q<
MUP<TC\];U@Y!_YV.H"<ATLK!U'[<$<E("E_&KL]]V^4>/`M^F,)[12P48T_8
M,0O@OE47-%@\"2*!H6^\Y'$2>-[36?#HPX!1,HI<Q^6A[.GN.XM+;1!&#B_^
M`'^3?=Y=6+U01#&#,54/^$?05X(]"L;AGW@BV"QTISQ\2@\HP&N$3TUV$X3+
MDWAY/[P+@ZMP&/'G+,!IQP'S1!3!L-QG+]B]2'*;AO&AU`?(/0>@C@`J!%/7
MA@6!.8?P-73DGD16;0`K#7['>!R'[BB1XHID`-,()2>$50/6G"]#!)_D>JYA
ME1R#P//31X@_$F`-&%2NE@AM^#N_%\_?$!<#^2.,)NYLL?"A0(Z`L>')46)/
M%BLY>I+WPU4SX$0`BN=O/>,A7MADMS@8O`L`*O`)]X!;,\X#TD:``KA7HUC!
M<Z?`SK%ZH)V'EN9+ELBCV*8B;EJ9C.<`?"\R?^LS1P!E8,)(+I`,68?B==G"
M90/ID*OP))F*SV;>$^,,E]D%!L"5@-_"@,-J@2C%\Z<H\<L>,N%P(6C'"3LU
MOU./"Q[A3\`ICALBN.39@P-^L`@()C?7@`BX:@^*$S).DN\DU_744B,&(Z"Q
M7#T<EH^B(!PQ55P3[FH@STD>PJ7"*^"Q`M\_/>T4L7$83!OYT>6$["#Q''C=
M&'^4;S822R\GN9VGL`5X=#<1@'#(3BY8`&IOD+G`D.DL'_F3)*4-(\/M8Y0%
M$#/QIQO%N#9@#G@<S`=%W5!X:@B0%,7'@20J#X$+[I4`-MG_R@?"[4F01+A"
M..MHFV5>A\,X%K,G^*P(ISI_S>47@TF,DSC!A^3%;`ISA;$2#T&()5%>RF`,
MN,L1SW[R!?X\#<*Y0ED0)`CEDU#8$3R:!0MIU4()JQ;,D$4$$KE4'0%D+5D'
MR8G@"D;B'KD2\`)NGC`7!"NP$]0?()F.&]GHQ\*%#5C[!^$%,_D9+*ID#&R3
MX)\DGSN`S^I*9-R0SU#\45I\D0#L!_<(%`W&DSAPI],$^`;OFH@I\(G\*SY,
M6N%O,,HJFW2]F;EDCUZ)47P%4P*8`=[?QA0=MHS!=?^R;UU?=:Q!:S`<W'2L
MZXO+WJ`_N+GL]BHU1<W^,L=;!7.\M0AG=7I]<]!5?WQ4KS,*/"?34@X05#B@
M/5ZOXEN8`GX^\W(#>:T13_^(@YZ#!@766D,+9!KV3?@N<#PZ1,40I/N60;)+
MYM%.3H@/DYN!!3D"_61V&@SG*VT,-XH2M"_5U!.P/&V0+;!DD0@2`,`FX??W
MH;A'Y`2%!@[)#,Q./I4*%;1&J5#W]V[38",7[,[`+_5!#65$*'6;VCUCT(7!
M(_QP_BH[*./>%IZ7+O['$^-$?H_`#LF^I^_Y0F!>@QJVCCE698D]NDX\43SU
M9LAC.6*S^<7;):K!'+<)OKR0I6>S7XIAHFR5(BM9P0NK^_[H+!!@J_#3"PJ4
M$8]:+6=FLU.)G+T;,=;L<P_*]OOSVH$YB7B!J);1`+O>0S@%!Z7X.0X&S=[`
M*C^Z`0;_QIR_-B1)F$B86`-,K,;V*`<36\VNU=D[*%JE@^+`JB#D2Z!(H$B@
MJ$"Q=\B68KMI[!\4.^5;BMUV-:"(<4`"1@)&`L8#!\9.LW0[ZG5@7&3%64:[
M?(2T!M4@Y!O;(1N@X^%M@*M=615#QKW0%^'EQ?:QVF;%K<L1[K\Z0DS5HN-F
M9#"3.\Q<[>7>AX+'P"M`5]S8+G7Q*LLC>1%1GWE)A/O5H61^H$WBS[CK+':*
M@9#9+GR43!?C`,GA=BDU\YW[4$RY2D*([(EP$@_&G/&G7"9).B@^:/$J<N,0
M7D:E[N!`F(:"-^`*3=6JX,+`RD[=,^[[F(DRXI$;98L5PV)%2?C$Y(ZKFI2/
MF2NAW$:'RZ<\O'?]AOQ;`W>LA2OWSVT>B<9K%)"[_AEW>5$@-P`QNXFG>^<R
MXRF0^2HPJ>#!C62>`N8-J#WR/Q(7N#*1>^RS)(2[(K5AGPX*]$!JV+D<FY*Y
MS=25VYZM_YQ:"4!*.,\KL]W03J91+!.`:I?/@^QF!YBEQ:,HL%V9Q?0(W`JD
M<5&.QFKG'%,[,#_G3W<*EWA/)6^-M7O-#IM687"HC"(A_#31#7D%B(%HD-A9
M$A"RB<W#\$GF%,RW!R7WB%&,>/%*AEN:/<:BB1#Q(J\'B?X(4T3M`&.";?B?
M].'`*/AD8.5%#HVJH`R"G>8Q,`%+HU+8%GEOR,E3$4\"4$,/(LRRYUSXCDE)
M<DM4ODH\"8/D?@*8@8D2:;;1'!MW>*_M'K?Q--(\/*D;_!R,`6L"UDO7ZA<.
M8@M&EA3QO-6%*R0PG^Q)@*E2-\$=SA?#>VJD>8>^4!S[4G[EAKB0I)0`&#RC
M=O3(9Y%B@CF?2W6;L7FI0ECU%A<H"B]Q4!M6"&F=9K<:1),)=<J\R?+M7"4[
M8^Z&R\NZD@LP$7I)UL=!.)46+5HT`E4D6$".)";K-TJCF_J:SW"1$[R":Q]4
M4N.M'\5ADB:/ETI5I014/N:F">]%IQ4>7.K1):"-&[,;;KL>H'XAY'@S\:C"
M3.AA<I^`[,PSCI8`EI>,)Y7MX+WP<$/Q$'@/,L58+?`X7>!&:CJKA,TT67B&
M:=QQ"DA.R!_9&*Y2"5B/0?B['(?/D)&D"K\7O@CA,QACLT!Y6$F(9RW4+:7.
MM5,N)=$02;4L)K?G7-DU!,TT%3#3`F`P[]67">/H]:4>7X0N']A&*K7:%FBQ
M@;D%N@W\Z"6D\@28:GB60J:4-]E0OL;"<&H9N1RZ"<!\J33Q@Y*=PR1&UPWA
M@XV",)0Y;RHP\XB'>J3A-)UYKK13I>$$%M6<QE'*T=*8RE9EVRS@-<F]SQ*`
M,Z66TVE#W_EOX=S#&P_G!Q=VRQ+N7W0NV\;-5:_3O;X8]+KMX6"@#JQ=M2RS
MTS_*+.'5AD3!2CM3TEU=E318>_"3SRZ3,!2^_83FWR,/'7:)829@GHB=L90-
M"Z>3-MK\*A&9HW_O!>"Q,Y_+8RCIV9'T6((LSS=#GQC#N^G?`+Z%GZ3Q8(#X
M].29K0@J#QO)Z)\\(HA/^+7YK;G8$G#P6$JHU,+<.)^/.96Q1C7BJOND+XS#
MBS$>=8F2T6_R&-22\3].U]C.UAA4A`HGHH*5I]V8/.&`]X&V=F5&=&KPIL,\
M8O!!O!QJG+*+/6<7/!*)L(1QSZ7GO(@Q\8R6&2EQ=)M'ZB@=Z$B?ITY(1H]#
M/ZIS\S;YD&PR*((QE[*3T.=Z?\%7F0%0KF)&#5SJ$ZZ$_7QBIIQ8N^R`HL.<
M)#NO5_;ZO6Q"5.AD2M\=Z+`I_#QYJ4V*?$KN+&4J8XNHKR/P#*:$)#R@R*,)
MP]HH;`(:+SWPBR<L0\0.C+2E2@*P`[>DYM'+!L-SPHD?"M!D&"^]YZXO#QEF
M)T?]%$\W`%#4(Z%`:%2X#R^03!,5U5&JQ,X7.WAV+OL45($(0^5PP9R&GR]O
MLPB0W'R-8.8PQ>^:[.ORV^)DT]<=IZ=<%^'9'%++,]7/7]<.[GTYENMG:(WG
M1M5S(^ZI/98PP+!Z]CIS&HP$6A>2Y@XJM,5PL'9+%`=87]!<WI`_*?IR(L]I
MJ>B742QK3"AK[E84KZET;P=<0J5`YY;%)@H<'4OI'BU%-."_BN`Y+3VW4V#1
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M$Z[4"M3O*#"M<['4536D&V:[6UP3="TXB>I`[U41%TX?C5&H6-PY<'C)`*77
M+JZ?>UUP@TR?U>QRR7WNN-QG:A]\%WO_K0[MA;JVNK5N7Z72>\V-+7+2YZ3/
M"Q.T.LB32B#M%M=7I2Z"0@IL-:]<`,'=:,)F")(PJ`BQ`CGIL0+TF-4T2(^1
M'B,]MBLVM=K-PG88ZB(HI,=6\\K_<'@?S&Q[$B]/(I'VVEI[#9HM4EZDO$AY
M[1Q([%(4D937AF44DB@.N5=R'+'*%!K=1'*%ANL4&&;<E;1U$6S2@-7):1W$
M46G(07-0E0361=#>J4'-VJK0NP!+-[Q]K*0<ABNJ(;0.>D*G1*:=F[H?>"K"
MZDRG@=&T]D_:ND`IV2P:(J#&0%<QM!TX@J68U3*L`@.);]&L+M"T42/ZREY,
M_WH6=Y.ED^$KJPQN6#5$'CKF\^J,.YQ\QU/ETAC%FECQ4]9P?G$:O^R.CE:K
MV:JFR&/IY3/^WK.:9D5SH3(G!U?FI('MN&>J#H/W)!N'8RT%+%HCRZ?E:@%A
MFW,1QUB??5XEV`>L*KNR2+D+J\J6J/H@_E-:%#K:'K,4@>85*KBL)<^=WY(H
MQC);JL&\K+&0=6>7[>!5]5;5##ZMG21[NLLJU%C>/L3FYJZ(LHXE9N\?677!
MT(U^S\HIORP)FZOK@46?8#6Y+##%^$C5),S**N,#GE2]06$G,;Q.',WOQM+R
MN4X(69E!$O+#$O(\QSBN[)V<-2)XR3U9`:_7%7T=JZS,NRFK`CN+2BA1KHC.
MAL57E@L23=+">^ZB\-X;U>87]8=5%PP$F]V+L.1(C)#DCI_6$O5`Z[)@.Y3"
M*K&8@W>68@&:'TB%$^M07K3V$ZR\>D_M*:KW!-=!R!(*5;[1>:"%#&[20G=W
MDU`(]HNRZJ]]C#\L%>/8(8"T>G%H;38O-R1B]A-&;KX__5E6\WN]P(UNK_]5
MV!Z/(G?LBK0A3EJ*$7RFSZJ>L"RIC!;:H4Q,_1F'7>K)<7H]KQ/Y144#MZE%
M1)M!K].'L.,8L6-13Q7P`J=3#Z2X711PW1HKJ)!<4?SU<V#+R!RA=/$HK7E%
M/<W@>Y.B>53P3D].K25#KF7!PI+6B06U8SO2V$?(A*2Q26,?&:?6DB'?K[$/
MOI!^>?O;7U7V"0ES-;9/H8=7-B^>KA?CZ5JBMPQZ[NM42[M5X!E`[1F0CK/4
M#/)T82S=R_X>+&0I&Z[P<\K[YQB"HGI!T>&9])]7]D`\7!K6G\?T-[#(PM?.
MPJ^B"JHV_$=:M6:(IPMCD8%?)J5.C>(*S;X4J;KSV2Z)4YH?:W]MZ^#`SQM-
M>7CO^NHE>1('V0^*7^4O\U;1?:-C=/N6U06B]#MT0$G;PQ@T03J@1"RS&830
M`:5W'%#Z!"J,SB=IM32'?\:`SB>1\T_GDP@[Z'P2G4^B;.<C06G-LYTWC\CM
M'U4.,Q6ZL)AG?7G\^%AY+?/2L:>*MLG($"!#X*!`D@P!,@3JSN/'Q\KO-P3H
M-!6=IM+#I*)<2\JUK*9'D%E%VUYM.)"R+6N&>;HP%F5;EIIMV6N:11.+LBT)
MP31`L,-S!>@4UJ'QF/YV&7D&VGD&138[UY[_R"^H&>+IPECD%Y3J%YC-+OD%
M=`IKL^:B9G=6>FNMA2)MC?B*7+W5FQ2WN#LBHIA]Y;%@ET'64^N,_7?:1^MV
MT4>K$.)T9YJT(?M?P:;\B<G](962Z6;$")$87F#_GNLR%H3/_AX]\EG^[SZS
M0;PYO`3(9I@V-X/WBN#/V-$/&_]-N<_OA6Q&!NY+$"6A8"\>K-K%J4Z)LIFA
MD]CJ'E2?JEMD))NCS1_4?-E-KY0><6:_,D;N]@;SC>&72:?+?/LS+M6<>>O%
MIE=)*#EI(LKMF!AC.Y]2GY!U`!7R+$ZIC]I78\L&>Q0*4;(T[S@4',3\:8$I
M6>-FN.99ZT*;1Q.&YK%L8B@D8LA/C,MVS/$<&ES5B]0TSIY`@4FD:*6??VU^
M:RZ>NH0LZ9/M(/$<-N$/63]4X:3M4,$X<6?R;1PQ0H09BU"BRZV/2.<+B63L
MT8TGJIUJ%"7<M^>]+$NE;;MI=#Z4RZ"EMR7M-`%GRIW#-^&[H*L^!;#>#>0J
MX#$[=$>J/3C^#&S3*&V::_$:.4HXOHA>XG/A$IAU3T8>726`N,[PLR=/8W"_
MY+[@_6:GFK;@"!*R;S#..^N#&@I/=12>N#/9+7Y^6*,AK\.;Y.^AL-&GD&PB
MC[4AE1[AO56[Y=SIE;1)\_-`;(/Y(EYTK/;<\;Q%,@&#7L!044MA3<W%;VBY
MU]1<U$%36\U!M5KN2-7<DJ'YTCF-U/*#?N/W]Z&XQ]_]`/F">XQ/L>E]Z1WF
M_][M=9I&)>H/2`*73M"Q=L&T!NY?'/<W.VC\6T:38?/Q5_UX_L(L3XWQ5)7E
M.K@_L\;K)%.,QS%(4Z(J^P![Y>:Z[%,TV3<7@04I$,V$[8[A>7#!5)E9*QA.
M7BGY<\IC6^&3]#=&`@T626ZGP=P84`OH'R53(0,A8(9P-@'\]9X61DSF(,&C
M9&1D>4ERB[7T8%SDN;T#2\R!`::SP!>+-ZS5:DH@\`-IH"F?;\G<4Y8<F([^
MD[HD6^$9?Y*1/U@I1V`(#.X20'4'Q2O>1)1RAN-+.L_O3DU(:5N"=H(A'/R.
M6>F^#&U+68QB^$>]C[Q9OO2Q16QO@A!^\MEE$H;"MY\8_/#(0V<I>*LR):[@
MJ0\<I:1F1L[_@L![49"/W2J79)P2Q\Z(,TZ),V?*!DO`$O(`0J1,`"NJL!1S
MDE#Y20T9J'5C5RI,B2+/1PW=Z'?E6"EDF@=^N2>-K&@B0(IF0>3*$9L,7EC&
M6P`-F?"$#+FDP&7;B(L(?&-5MR822V'CDAB\LK5"A?NJ_:&F'"0QB+?OI(18
MIO<"4M!1+==@Z?5[3:L:?[UTK_+OK6ZGLLE$I1N3^XKJEK]05Z!6GTW,E!-[
MF0E3K,D,VG>F#"GOJ2EKDGBRMDKYCD&_:=9%RMI5R5A.Y2C4S`&C>,O8>B5H
MUY"ZI_SM)>41@)ZB?:8B!5>&^7&M>:B8PZ]0CGO-7EWDV#0KBM0_7[[46YV%
MZ+')73RUFM)V9S,8)W#*,@3U]72^)=,I#Y^0A>OKR4Q<63E9^0]I<-99S%;Z
MT%$R^@V8)95LZ2OP,,1`AW*&E2<C_>8$/2+@G-C%N.BC8$X@G8Y@/(X`%!8C
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M):H???8!^;<^:,E8Q58QRJ=VS@CZ"?KW6!.CL./F6G"1/LA_1)[`S^D^SQ-Y
M`SL[4[8=)L+)$E9S^H$4`RF&/=#,[)%F()^`?()JPD!>@/,2X32?,T'(3\B_
M!YKUFX7UQM""B_0!_F/>VWMQ<HAV]FAGCW;V=)->VMFCG3T="$FV7#%>?+-'
MMARI`PKO[ENC4GB7%(-.BJ'3M$@QU#NZFQZ;L8P=3CG5/=*K-:TV]N;WX[3K
M0RLZ]$.'?@Z-TOH<^JGEV9[51']QFB>KB\+6ED.A@#\=YM$V<JV_D7!(AL$1
MA7(HLE^KR+[N]*JR[Y?.`1@Y7G=07&(%A5:.6_MK1A\Z3$.8?)"8;#8'!,GD
MX5)*FW8:COQ;\F_)OR7_5FMZD2VU9$NUR)8BG*:4LF-.*=.=:H38N?$ZS8WW
M/8\0L;^7]8177K_B\P_?)]'9/>>S\X5#F-OZ'/I.NB$ZQ.KL\GSGE1O9GNS5
M?@<4N<`6LC_^[:]_^6$^T/SOG\>7P13%7"8+?%7=&BZ#*(Z^37@H+G@DG"]I
M2ZWY6+*)`WSY*L8?3VZNL&3E/UO_OKLZ8:X#/W`[/AO>7!E7_9N;RW[_TFQ?
M7+2&%[WA=:]UU;<Z'<LT3WY\MG3Y97BC:O*JE7^]7O>SIIY6P6QO+3(A.[V^
M.>BN21:0)#T;(4U91M17V6?C"2(H'$B)_!P-\JS'KI6V*80>W=D>6T>]4H\]
MRDW>SD]^T4T.BZBG+8NW:RM'Y=3+**=N=M];3[U3=5GTG6\\E/L.YD5I@GN=
M(&T!OS-`WMM#'NAA9'VJOI?L3K8(^R60S;O6.0C7LJG74I7WPXU'$+,>++-^
M`A.M1%ZE(Q/[/C)16/X^->UXOB3;=.4@T*Z.4VO)D&M9L+"8*K'@P8!E^G@9
M1'GQ;,T8EY#T<-F8D)1R%K<(='\5$;@.]D3N#3OB07C!#`/2+_L=ZU!U9',0
MU8O4NI8D*8.>>RMD933[I=-4&P8L<X>;U/4>($\7QM(]9>9@(4N9+.T"JRKI
MPC*$137#(NVU'YE?VIE?W7YQR=WZ,R!!7LT@3Q?&(O.K3$KU^@6V,=6%930^
MGE+;L-DWX<$=]PUV+WP1<D^&S[@S=7TWBD.9VKU+\-?2:0]CBQCP'EN0%=>)
M9E?:UD76R>XH3E#K(&]RO%:[N/X`)"@D**317M=H@T&!;C1I-!+4J@2U#O*H
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MI\`.I*2-2_2E:5M3;FOZ(D[[.#(>QZ$[2E23Q#A@%VYP+WP&OGFS'(YN`4<[
M08*/>P\0:!%?U:G"XUM$?D\)2)U+IJT*Y`\*+Z"V`UWK$KXDDTA#^-,8Y2K&
MM0.'+SE>VRC+#5Q!,,(EPB4RR\@LJ]XL,UN%]Q4@NXSP3R?\TQCFR"[;/IVE
M91176/1H#+-<C.Y[&5=:=7UE+Y8C&JR^.)NH!GVF97Q8XE$9&GQ.5OG=]0',
MXO,67E`%U]U-!!L''@`IO!M3D;DHF4YY"-=%ZPL#9)$^'D6![?(8_O[HQA,F
MN#UAP9@%2;C^YED8W(=\&IWO3,QUI,G=LX2H1D;OE+[X/3^H'X13[BVO$5XS
M'UA1QA:>EU[S\<0XD=]!<.SL^XI%N7.G0,=/XI%]#:;\A9YZ=)UX`A]A3JG,
M@BQZ?!:)\^S#"T99O%0^*KV0X>[*C8L-`MOR93Z>M#L?WH2'92Q*;S1WO6_G
M&P_EOH-Y49K@7B>XW983&=\OP*^G]S[Q_EH#WP0ABT'9WTU"(=@O<,U$%?99
M9>1<^[AY]TW,8C$=B9"UC`9YBL2LE3/K)S#12N35G=!V#^W&=_;/*ENPTUN?
MP6`>6/?1-OE/\XF]M\E[H=E\;RS'_J5F.>"Y>DDLPRSLS#.!=G&<6DN&7,N"
MA:6J$0L>#%@65>B;D)38F)!T:R2E(Z"K0]V_\/!W@:,%]N\L\=UXF](ZA0NU
M%EO&.B4O'$]N0H^:MFRC+TB?5DP?C1&H6,PY<&A)P81J8!!F[!TSM%!$9,[L
M@V:M5H$'$G5@(\(F/>(#1U/)JF44EZM<%T&A*,::A#UW*LX>1(09=R'\$[HV
M?MPMJD'E&=?I-(-T&NDTTFF[XY35)YU&@D(%@XO22(-V@74&2".1H!V=1NI3
M"7ORLC9NCAI-6"3BV`/?:@:BB^>#?%N0AU58.<)!!2U97C+>86]_4;5!THF%
MXIS9(2^-!(6\M,+*CA39<Y"\-!*TH]-('8.\-/+2-N.5+^28E>"86<T^.6;D
MF)$:W*L:+*X65%VT(,D)*;7=RT$6V,*(_#(2M*-32&:!W8/J(BCDEZWFE>OI
MS`N>A$BS$F=):$]X)-C,XWXIVHQ:?2UI.ZLY*$S9[4K:NL@X*</JY+0.XI@*
M8$F5?-^HIT%R1G)&^G"5][?_SI<DJ"2H1ZL0S0)/N!V+1J3VD^O:3R:C.(BY
M1X'1`ES%/A6C(=5'@=%W[-3UBXNVD*"0H!R[1C*[/=JK(TDCE?0.;VO0HB3*
M@MVIVGI3EWSF@C,%/SKK.W;90512=B6%*LO+OGPO;2D[DQ0LA3MWP%20XN*B
M*AL2K2["2N*IJW@>G2[N%U@$C'0QZ>)#$O8ZR+22XB*/Y)(N+L_#KO&&Y5M=
MM%W?]A)L8PCCRJU-Z7`S[CO9)87U*GFS,_PN@J]%F%6GZM]O$?F(RH-;G;+P
M=QNZUB6*22:0AO"G,<I5C&L'#E]J0[_`.H%O$HQPB7")S#(RRRHGJMD9E)62
M2W89X9\6^*<QS)%=MGU62[];8`GT8S',<D&Y[V,.,UQU?64OEB,:K+XXFZA&
MQZ9E?%CB41D+E&1U?0"O^+R%/U3!9?\KF(AB=\ICP>*)8&/NANR!>XE@P9@%
M2<B"$:RTC-]%C$=18+L<._`\NO%$_CU?+AHC>/:KM:09C^5S!%P)#Q#<GK!0
MS`)@6O\>+W<#!RX`W7D_D<%`U>Y'#C<%RC076'R93!,/7NP!GNO\ED0Q_CUB
M<8`/B,3RBX<"'F.C%#CJH7\D/(Q%B)>'8NS!<Y@]X?Z]B&14<C(_S1^ZZ<0R
M.L&+)[$=3"6%\,+<),]"X<E+[,!W7/GLYH;:8V=>,;OE\\K"HFJ->/I''/1<
MYE+9ZI<7;;Q_@H?`BOP*[QFR?%3X,A\5_N+!8PLA37=?4G2'DA-X8'X@%TO<
M85$RG?(0KHNDF(@_$C=^8O>*),!U(JT:$36`C\;`9&$DV<QQ@5'C`+XEDFYX
MLYV$H?"S9MY85R(ZWYEBZPB2NV?)^C">416_YP?UD?>]91[%:^8#*WK8PO/2
M:SZ>&"?R.R@9._N^8BFP^5?$/HE']C4`\7K^YH^N$T_.!X-FW^@8W;YE=6%^
M_<Z'3-L!TWI\%HGS[,,_GFNNQ2OF-W#FVJ^[<H=O@RT@^68?3WJM#V_JU64E
MGMYH6KO>6/5]U;SH=EMMY(.\X.2.WMOC-N"*"'/S[A>+U#C<:A5U$X12AW\"
M0&._P"63B*TS]:Y]M!Z^B5DLIB-`YI;1V,$LU9F!UUOV)2R(!ED?A:9XO4'Z
M_4O`<EALM3Q8AEG8]B4!\'[SD[1GR+4LN'$>(IUR6>V0_,+#WT7F+VQ;*WRW
M(X8[[=@HKI<N0U&%+?:VP]`W&_#:I=.Y#)II%\8CU5(]?0Y6&)76:'4+%;]C
MD#+2GENV0Y0'1O54I3H+Z,H:=9U*M&5=1)448O7TT5FD4I/3*E*(ZB(KI-:*
M[Q]%BFR-(NL/2(^1'B,]]JX4]!ZI,5)C&R=;N%-Q]B`B3+,!;RP.794CI'FL
M4V<I7*'76H,6*392;*38W@-5[19IMM<UVR$GZ>J;>#GO2/5-*L4O64<J3+5D
MI]??OGQYO<J!]@F7MS[[G\07#-,5&C)%4JK_"5!`YE'.9B'`GR-3>R[<X%[X
M[-:WF_)ZM@%UF@Q3.O%C@SW"2TW82-A\*I@8CX4M<XX#?`7OB9F-]"U",?.X
M_>RACK#5D\W!H",'9*?SC]]E@XL_9VZ(B<5J6@MT;1EJ=/4^4_ZG.TVFC-_?
MA^(>4[;]1&8B!>,T-)TE;=O!=`J#*9LHGO`8[GV".<R;DSEI=FF<3I.Y*N]I
MB26*7+%NPS*,E6!8Y%.:+R=Q6/GX63Y:J53R8>ZE/H`!\V$FG9`9<Z4^:IZ.
M]U)H2GUN0X',G_)(`,!`J0\;]$N7')E[7NH3VJL=BD(GD:+@HP@%(%J4S'$.
M07$!P3A7I0HDPL,M,X7JWE-#EJSAB,9Q4.4:FYWRX7$A(RFA7J%1>@IF%KH`
M24]@4*6$42=NU$F=YNL67_KYA^^3Z.R>\]GYE1O97A`EH?@\SI\!^:I.S5QB
MV5UY3N0"5=07_B2/]-P!$%]XH,E^_-M?__)#-M8U#P''[J,O(I2WS*_"LS>(
MW5_%^./)S16N\S];_[Z[.F&N`S]P.S[K#LS>S7!HM"UK,.A?7[9OVM;PNM>Z
MZK<&UE6O?_+C,VV1)_P;IQ)6&>.O*YO^LFZQ"M8MUL*,[/3ZYJ"[SFA,";I@
MDEEV;.>PC45@)KA2G:WQDEB>`%-31396F"%/B('#92?J_!:/T@,]=-`F.VAC
M&D9Q1VO,]YZM:7>J/NI2^=D:FB!-4,<)'LAA%NWBG_/7[=%IK-4F2.;]WDU"
M4>9Q+&)68M9:'QW<PW$BG8X6KEZPTUN?P6`>5F78I@CW?&(M.FY(QPT/`K3?
MRZFU9,BU+%A8VP-BP8,!R\T/^.R?<0E)#Y>-"4DIN7&S6+7ZFD_ND$_XE$Q%
MR&,`@%+8=[\FJ79R3[A8$&,1_Q#_$#`18VG'6,?(/V1MK<X,^"1B;$:%M5QY
M'(?N*%%;Z'&0SQHM2DJIZ<'ZXR;4]*`$H@ZZG0I[NVC!B73$1U\KA9H>5$*]
M`\4O.5Z_TVT.*J,8`1,!$QEF9)A53E2KT3,[975;)].,$%`+!-08Z,@TV[[`
M9L/HF,T6&6=4QJ6DG<XKX0=3UZ>]3ATT`FE,VE(@_J&]3F(L_>A#P$3VU@Z=
M/O%5\6@SD(#?YVO'9-5BTA(R21S%W,?I[<*3;W:Z*:VHG@:>TJI83\LJL/,X
M!7((_3>5M#H(5"I"W>)$B"2%)(5T4KO`WO*DDTC2CE(G%99;51=)(=]K-;-<
MRZJAZ&K)"E180"T2=@++X(HW"DQ12(E"2A12VCM]B'\(F(BQ=&:L8^2?=]I;
M9FT-+E79/9AA<=E(EOX46=%W51,]JX/.9A[W*:3P_I""00$%@GT**.P.604*
M$,D)R0GI(])')&>DCT@?:1/>KJ^[56A+3E)I:U4:Y1&12B.5]@Z55EB)3)(3
MDA/21\6=!B1]1')&^HCT$;E8:WCE%Q[^+N+27:HJB[+K)I,E1Q%W)6U=1)M4
M8'5R6@=Q+#SF\0;-2,Y(SD@?5A>")'U(<DKZD/0AN91[<BFOLK,HLR`6?NQR
M;[D2`"G4*A1J254@2:&20B6%NHE"[9-")3G35<Z.3Q^6U+""]"')*>E#TH?Z
M.9BU]2^_J7IR220<!G<"">S$XS%,0I5!@)^!XCY\C]A,A,KK+%]X=VD]L%7C
MAX(Z2^^S8)T&7:,V)^,!0P>IZ`JEO/;"G(IOKVE4)[XDI22EI(O++-37(UU,
M4EXW*:^],,]U<85=OHY!2G/.]O>R6?.JZRM[L1S1@#7$V40663\W+>/#$D?+
M361)5M<'28[/6_A#%2PXG`*>QQ$3?]I>XH#+/0Z#*8LG8N&/!SY6)O07O;#1
M&<\\=.F4LY&P.?CQ>)\;,B'+&4;L4<"?N!^[9_.RAO(G/X#7!^YQQ\#%?OQ&
M`^WT\P_?)]'9/>>S\^LT*/!%A#*$<`=TN_`"^_<?__;7O_R0777#W?!?W$O$
ME1O97A`EH8CF5P*#^TCNKV+\\>3FRC+,SC];_[Z[.F&N`S]P.SZ[:EN7_79G
MT+&&%[VNU;YJ#8?#ZU[KJG\SN+DV+T]^?+;`^97``Z\1^R0>V==@RM<C\\;\
MT5]F!ZM@=K`6YD6GUS<'7?7'1_4ZH\!SU..0J$Q2E?TB.-)T"MSZ>B;`]C*0
M@Y:]R,0=<+_$C@@8&_0KFP'OP!L`_X^#<*I$@H^")&9!$C(>12)65:0\EX]<
M3Y;M!%G@,4/A",4]R%'H/;&IHIDCK[5Y&+KX.69C).N#)"O^!>8+@A%+<6*>
M>!`>>W3A[7WY0^[BB2M"'MJ3)Q10_!O^K%XO%O;$=_](!(HA`^'S8(X.=JYW
M1"S"*:P$BQ)[DAON]4*CFRYC^Y5%RHVQI."-9^B'W_,/\9'JWC*WX#7S@>5J
M,5MX7GK-QQ/C1'X'-69GW[<7U$?7B2?G@T&S;W2,;M^RNC#??N=#IDM!9CP^
MB\1Y]N$%`R]>,1_Z7>C7[DK#9(/HL7RUCR=M\\.;JGO9B$AOW/D^J^H'T@1I
M@CI.<+M]G1(W"LO:^ND7JV!QN-5FQ3!"!?9-S&(A>PZUC`9#FXR=WOH,GN)A
MF<;O=G%$WRPW6_URO+X$-N@_$>YC$>Z"F'L4#"D^&$(\N#$/_C,)P*E<D/M+
MZ-IO)!KK-@6X>VBCKWM0;ZV.#Q\6I4]_EJZ1N8UB(-`BT"J:#[\M0ED+FG\&
M=SP\*''Z/()K'V3(=#Z+6W^6'"8J6(0*A`JZH,(AR<^O?K``@D-Z\</%JM;&
M6$6II"\B]NHK#G/N@@/KVEE(`8/RU#NK`NV@#;'JJU:)XXCCB..(XXCCCH/C
MJ";%FM2,2QY-F/@C<1^X]V;F2<E.OA8'1-^?0_SWRF!PT[..FY-L7WG7K4;?
M:%.Y?=*@^S8]"+<(M[:@F6+`OF5:Y8LN81=A%V$781?97(1;A%LZ<!OA%ME<
MAX%=%/]ZM<V'/.WBB!$,*^PDE.>-:*MSWWJ!%"IQ''&<+H0CCB..(X[3GW#O
M36GKU]74NPS"61#B,?!GEMXN+$F]29>=,K-AM`;-`3EDI!>JTPLDA!09(4$D
M0=1.$$D;DA"2$)(V/#A!).=QC?/X$\J]C\79R'$L5$JM1MLT"^SZ77<))55)
MJI)4)0DB"6(=!9&T(0DA"2%IPX,31'(<UR68!6%\S^]5(>H`BUBI^M8,60+K
MO9,W6:3^;%/8E;0G:4_2GB2()(C'+8BD"TD$201)%QZ8(-)1I;>/*F'!GOB)
M?,=B]66GP-:?=9=24I>D+DD"20))`FLE@62PDB"2()(@'J0@DN>XQG.\@K\\
M<-DO&OLTA]S>JM`K">D:(>V:!7:;K[MTDIHD-4EJD@21!+&.@DBJD"20))!4
MX6$)(GF,:SS&+Q[W59YJQ,9!R!PQ%F$H4/RF,^%'X$P&?BE2^T;#RV.3ZE:_
MV2U,G'>E;5W$G?1N%7J7)+ATO4R"3(),@DRJF"28))@DF%3QX;K0[79=7>B[
M(.9>.6S6`C9S@@0S@3,^VT5BM>!-G7JHO$7D(VJRTFMT6T:SOW_2U@4GR>#9
MW>#1"!K3I^&M+Y4]X6;QN%D&P6N1W[XST;5A88);@ENR1,D2?=,2-3H%ED0C
M2Y2@D:"1H+$&T%AZ//,8X?&]E>QJ&,]47W&8<S>&Q]KJ"3^[?.1ZU"Q5#^5#
M6ILXCCA.$\(1QQ''$<?I3SA*`"_GR/"K'$AN<`506!\OMV4V6Z63K2[>*ZG0
MDFP/`BT"+3J-1]A%V$7857/L(H.+0(M`BT#KH$"+#"XJ?U!8].L2?H,WQF[/
M=N!'KB-"6?&`!2-X$?FQG`)Z=&!K2:C;_2++"AW[42TR50K87B$1WK]>)D$F
M029!)D$F029!)D$FH_J`?6BJ?[`#F]'1"CI:43)1.Z:EPUG=NJ`D&3IEI<02
M,!(PULH-)'@D>"1X)'@\3'@L-'>&<)%PD7"1<+$&N%ABT/$8@3$7=?P^YC#U
M5==7]F(YH@&3B+.)D!!J6L:'M0_)W;.$-0;PMJ2\ZP.,JN_Y0?T@G')O24),
MO&8^L"0'LX7GI==\/#%.Y'=8:SO[OH(L=^Y41.R3>&1?@RE_@>"/KA-/S@>#
M9M_H&-V^975A?OW.AXP;@9D\/HO$>?;A'\\9:/&*^4#Q@@F[*S</-H@URU?[
M>-(V/[S)W\M2EMZX\WU6U0^D"=($=9S@=KM`&^Z=56_$KE=Y_6+-A'Y65>91
MH?HH\!PU_C!BP9A="5M,1R)D+;/!+,-LL]-;G\%#/$R]_&X+0V+S<_'5K\;K
M*V"#^A/A/M:@T*T[<L6(!W?@P7\F02R<!;F_A*XM7D^ZUFT*</?0QA(*!_76
MO_#P=_%&L0?=WOGT9_$@/&9NHQ@(M`BTBN;#;_!X=PPD`@+/:?XYAI4Y*''Z
M/()K'V1883Z+6W^6'"8J6(0*A`JZH,(AR<^O?K``@D-Z\</%JM;&6$5E:C<M
M4SN4;:Q+J5!;#8AIIP1(21+_$/\0_Q#_Z$D?XI_R#*<:%[W@T82)/Q+W@7M@
M!^^UW*ONM"HL1^C`,WWD>#VS6US28UTR=$A-$6H0:KQ"C!(.DA!V$'80=AP!
M=I#%0:A!J$&H01:''E5,ZAL44=E0\DB!(T8PK+"3L+R6A\<8D".]1?Q#_$/\
M0_RC+7V(?\JSG:Q^76VGRR"<!2&/7YA.NW#>6U4>W^V]Z>*EF`VCVVH:Y*$0
M2I=5$;4VLD(>/<D+R0OI%I(5DA72+8<2+:ZOQ_,3RJT_Q;Y1Y.UL1+%^>]#L
MDWR1/B)]1/J(Y(7DA30+20I)"FD6/>2%/)UU>3%!&-_S>\&X[[``*YPPCN>L
M&99>%0ZY/QL&Y`9]2F0E)45*BI04R0O)"VD6DA22%-(LNL@+'0MX^U@`5DR(
MG\CAV8QPW>:`A(R4$BDEDA.2$Y(3,MY(7DA>2%YTD!=R=M;PS!7\Y8%C(PMX
M.3\.N;U5<;CC$[*>U>R1=)$V(FU$VHCDA>2%%`L)"@D**18MY(7<G#4\\\7C
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M6WS[,;PQ-KRS`S]R'1'*8[(L&,&+R(^EE`HZF@,/EMEI=HH2QV,YZD"JGB1-
M!_5'\D;R1O)&\D;R1O*V=WDC2Y(.S=*A67TH2`G16Z&79="163(4Z*0&`9->
MP$0G-0B>")X(GC2%IP(3`0B6")8(E@B6-`]&U1B8<M&H[V7ST5775_9B.:+!
MZHNSB9#89EK&AR4>E=D/DJRN#^`5G[?PATJ"5#!CP2;\0;"1$#Y[,9TB'^8'
MI0[/ICR&/W*/N=,9=\,I4#)BP9@%29A5+9\*'B58L9S[#K-Y&+KX.69CN)X]
M<"\1S$E"6!<63T2YU(@GH1#R/7S@C9(I`S].(B:`NYQR9_5-S&(Q'8EPH31;
M1H-9AOD2S(I\;I/=^@Q%"A-J&KAZP->/^'\'S=+VA/OW(F)P&W*GRAR*A3WQ
MW3\2^#T(X4^S!#@[B5T/;G;PIQ@>%8U%&(%0QX\HUSG^3D4`I8-YXD%X$;'\
M@;(\H'=^90'J?L8%918P112'B4)`VP/P<\<2Z>`;CR:R(S?<(_^,RS%=-.MV
MQ"C.M>IFCW"/(P!8I[!D#O!(&"3W$_C7#1TVXV'\Q&:A:R/_P*L^N+:(FNP&
MF)##;9$=NC.5[:9@&![J.HJ+9V%@"^`\>$8H/(!N&#R08\$O\,<'%U=N]/3J
MHQIP+S`ZWODIB`4S&Z6MM?J*PRQ5B/B63(%Z3SC!;V`2`9UM#L\;VG:0R,P_
M]B6`B[&`!+O!M?J77*M?%E+X,OVO2"YI(&V0])A]&$CJ`UG'KL]]&W5E%,,/
MBE%<W_82)#H\`>\H];U`/%[ZW84B`##AE)G&V?]-^3%5#F@?^&/XFV+#'._A
MG!UANY$$V8#Y`?,"@-\0F<P3=BRO</T'$<49Q=@#?("%!+F:(5NP<>([(#4N
MO*<O$34GH!-7A#RT)T^'Q;:?Q./2'\+`A\]V5<P+1(SDB6(PC2/9;.8-1FZ6
M8Y2;W?*-<O"\@O#\_UB=7FO$5ZR=_.51O?$H\)SLX#5@]NT"\@N9?W>//HD2
MFLQ&?T*NDQ(T-^>EELHIN09[A.$GC(,D2AVXT,46\Q9%?!KRBD@RO[26.'8R
M\CQP?E^O[_,:U=81)7?/4CS'>$99_)X?U$=P\I:9$:^9#ZPTM2T\+[WFXXEQ
M(K^#VVYGWU<LQYT[!1JB/'\-IOQ%E.S1=>+)^6#0-*Q.JVV:+:-KM*W!ARQ^
M`-SI\5DDSK,/_W@>"UB\8CX79!%/Z*Y,_-D@G42^VL>3=N?#FZ&*Y;A(>J.Y
MZWT[WW@H]QW,B]($]SK![1*]]K81L#XZV2]682V&>U?V9>^=V9<C;O]^#SZ9
M[YREQH,C_U-V6J8-FDN$Y9)W80UQ>[3&]AE*FV#N@[.UKC=M9>V=5VO`DJ\Q
MX96P4QXT)0]NO*^\$[260>P#@M[5"W%ZZS,8S,-3E=_MPN)O%3S;`]5U97J,
M9FWJ,VGQPC+R1GJA>+U`0K,Q#UZF\0P2'!(<$AS2-B0T)#2D;787'&IEL'H3
M!;<5(S;C3W*K(`[833(5#I!BGXBT-E:E3;^RG;?K,$!5<);K6X&].G;*6T'0
M08%IL-KSWSZ3]@N-)-?,^"`H)"C4`0I-@L(JH)`0KWCZ:(Q=Q:)5'4X?F5:S
M6Q0]"#0(-`@TC@$TS&:/0(/B4YOP2K?9[W4^L&_"=X.0J6B5@^<B,#]^@3TJ
MD:*_2YCXS;)V>TJ<VI?ST#7;!7;R7D>\NL@M!4L*V*DA$5P6P4ZW6V")MF,7
M09*TS26M#@*EM%BK39XI20I)RMMUK7KDCI$[MNEI[.;`,%:X8XMS%68'73%K
M&P^"[,`U=J#9Z(`S5OY>3EVDEIPQ<L9*$,+VP&JV2`C)R"0C4Z/:SB0O)"\D
M+\<G+^2:K6:95K-KK=HI>^&:6605%F$5&D:_P(K@QVX5DFM&0KA]GNO`I'TR
M,C3)T"1#D^2%Y(7DA1PS#1VS=M/H;+1GMLWY1;()USIFO6Z/]LS(,=-)_1VA
M$+9:)(1D:I*I2:8FR0O)"\D+N68:NF:=IK51.F.['-=,TY+=^W3=BCSXLBMY
MZR+UY-I5X=J1$#\78LLL\``I"3&9NE7):AU$LBQ3^"W:D;R1O)&\D;Q5[)J:
MM?5-[X*8>^5P4PNXR0D2K/C['E'4PO;2J?SD6T1^3WU*G:LZK:HBT^CVC;+<
M@&U(6Q><)&=^=X.%H)&@42=HQ%/=Q1TH)6@DETT_!-08Z"J&M@-',(59[5YS
MFW-C[Z,8`1,!$P$3`=,F._C]5H&G,(\%F')!M^]C[/RTZOK*7BQ'-%A]<391
MG;Y,R_BPQ*,RUO><K/*[ZP.8Q><MO*"2V-Q$L#%W0_:`/<BPIW.0A,Q?UTN+
M/?*(B2AVISP6#DLBF!&;\O!W$;-@!(]YD'>X_BR)HP;\:WL)SIK921C"Q."7
M6(0P`..^P\9!"`3RTS_:3TS\:4^X?R]8",-'3;;\=K+EM.#V)'M-G)9(NZ'G
M\EX>X0G,$?"@*2R"P^()^`SWD_0]&[D7;<C7L(,P#$!BY)0B&-C&9]_ZC-OP
M)X?[MF"/;CQAPV^_PB.:LMOZF=%J,"<)<7(QO.8+OBARE6`&XF6#N"*?P*;P
MXP36%OC/*7<R\Y2DA9I=V\*^R.<V@#%8*&R/1Y$[=LN>YM_-9C_KS%WNTJ72
MX(@1R%<4)9)A[2"*(YBN)[D:1!@O*?4]5('S<J>Z).<X5Y@;#&$91I^-PV`*
M\LQ@>0&-8,8<IN\D=@P+@%]12NVT/23CTR"!]P+2E2Z\5=.ER6[@(VH;G#GW
M@$``M`#82(=G#+$>Z!$8:\<R#38#?1XA#'!'_L1,JU':'-57'.;<C4'3V^J5
M;GT45>'X(HK*G7NZRG;@RRU7N?)CUP>`<($OHAA^F()6CE)%K82I]%4'I']I
MZ!8Z;Q"`*3.-L_^[C2RLPA:XZGD&+?[_2RXRZLM%C10\(U0J:)Y&PGF;I9HO
MZ?$^2SFUC,UN^9;Q(M3=&O$5])>_O&P]#+_":Z.5"Q\C%QPPQ6>?1V#DRX\O
M%VH7FG2U<AX"SPL>I14L=<@L#!Y@ZA%J7_@3VOB//'0R3?O,FD_1*:.;O42W
M8$$W]@CO-,E@*F(_BP?AL1:;@APFH>*X\YV)NXY6N7N6XC/&,Y[$[_E!?808
M;YF/\9KYP(I4MO"\])J/)\:)_`YNN)U]7[%*=^X49O])/+*OP92_B'H]NDX\
M@8\PIS0"`*SL\5DDSK,/+SAG\5+YI)5%1*"[,D]I@[P7^3(?3]J=#V\&&Y8C
M&^F-YJ[W[7SCH=QW,"]*$]SK!+?+2-M;*']]?+%?K.9:#/>N9-&>WLFBML`8
M6[E47&T!H:V-2OX.PU7L%Q516A=(O9:1IH5UW3(:146_:3>*F'5C9OT$AEN)
MO+H3!I>Q*`>$T:L7[/36S^*IT7>[B$)+IP-P;RS'_J5F.=]K]9*LC-D3:+\;
MM-_+J;5DR+4L6-BN.;'@P8!E^G@96GG]1-'^&9>0]'#9F)"4RK!L$1&_F8>W
M&VPD[EW?Q\AX,&8SN"5P]BGA:P%Y<RC5B^"EGO)XQR&.,NBYKQ,>[4&GN)::
M^G,@I5#KFT*]$^;IPEA[39^N,V8IRZ4W*+!$JRX\0V!4,S#27OV1`::=`6:9
MG69A@0'].9`PKV:8IPMCD0%6J@'6-PJO=KI_GJ%B47L0NF&:J_UZJBQUK]C(
M>BBCFAO5X#AZ,X$J\A?`1R0O)"_'KI^L7KL"[Y8DC22---/Q:2;RL=;PS*4L
MLH&G?G/G\4B?O5^?&066%B-M1MKLZ+39:7M07!&LE]RP+5DTQ.YM3CZ0?)$>
MVTF/=0J,YI,>(SD[0CW6+<X4/&X]1E[<&@I^X4^R[DDI"H]Z`2XIQ%.SR$#E
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MK!OQJM9@JB5P*,8>/`"NY!&,-IT!*.$?\5$Q(!GS`L07$4Z9Y_*1Z[FQJTY)
MI6^RJO?=B'NRWVHT$0(?A'V"L:T$/)F[LOIK>D6T_'R^>`-\`6[;(<Y!_#G#
MAT2J_R:^55F-]"J#S%L?*>8+U8A5$@CIR>T_$C=RU6*.L64>J&)8:%MDC7I1
M!P.MYHOQ5#KT_ET>2*Z,WV?`\D+R][/>>%FWO'7<CYVQ7<7W2AJP+?>(1ZIC
M)6#=**.8JO(,O_L"QN`1TCY&NQ^O^DVM2?DJ[>_M3G4XXKB1C<U]YXC`93OQ
MTB=IE=O(MI'U0(PD:RR:L&.G9YR<[/^<MN*$68^#,.O,/N-HX[I@H<91RCH+
MF4I1*4I1Z\%%+LI&5TV5\2].2L*\V.(C4)0!YV+L_FG#E-"6AE<!#`YFB+UL
M!N@7271//,GJ"_9,F[='B0WPJ"`/'P6/=E75;!N,<T!19!QX(P!+;%6<MA>5
MC5W9-%"]WCE<X<"'R`[=688I,<XT!EI'7#+ZBL:MU7?_'2X(6'[WWQW:MM;8
MPJW6$#1[W6:[,EVRU,IX(ZN)AZZ$1RGB;VED=U?S92OSJ5F.J:-OSV`)!B'0
MX?;+5RD,^+^K0JC0/2Q[CWM1`/_G!;;DBY+-$:O=[%;CHZ667!P`&[!9$MH3
M5$"ST+7Q1T65%PR0Z7HTZVP^DRSTGU3P?)"HF/OW+H:C>!2)&%4Z?)RBT9,C
MX=K1EZW%R+WWW3&H;;C9]6<)6`)^`$(]@DD]R#[%,&.<0FI,*"V=1`O[51KI
MF=N5,V)S'EAJ=<S-"GP#M>+.;TDDE5&&0C"HAP8`#Y\6U_,H(^0J.P1FFH+3
M"P,FRB!Q+S;*G52_<I'0-?0\-H);A9HPV"_N=`;DDJ_`?3^!M7MBL(BNA^@Z
M%2$J9_<_7-DN?`RN:<H8\'@AW^/9PJ:/`%X`BP\Y!L/\S(VCG+V81&*<>&`!
MC@5942594:^'7]///WR?1&?WG,_.,0WQ7R@S5^"[>`%*370'V'T!LOS[CW_[
MZU]^>''ESXL(Q2]*SIS/_E=A)V$(C'G!(S?ZU5\(\2U*-OPY@%<%VQ_I-G^`
M-!?@RU<Q_GAR<X5FV#];_[Z[.F&N`S_`JI]=&OU.IS.\MFZZ@ZM6MW75'_2'
MUSWX]_JZUVZ;)S\^4TUYLK_1M'Q5R'PSS9:+J>]%TR'LC@,`W$?IPDNP!.1X
M<+%%/7B=\"<4\T<>.AE\+>`QVBK$E?I^ONTE./BJ(-?YSF;#!@NRM+]F/#,M
M\'M^4#\(I]Q;MLGPFOG`BE38[SZ]1O:[Q^_1C-O9]^U927;)AH\PIW0'QT[;
MWI]G'UYPSN*E\HG1BQV=[LK<^0URJ].6W>U./9N+U[Y[.DWPT">X4^]EG0X^
ME-#[KX`#3-12?(TWG[44OYN$HLR>XOJQL';91,2LFS+K)S#<2N35G3!X#UU9
M=<+HU0MV>NMG(:MHFX.Y\XEIWM)9,ZE9SIA=O234M9FZ-N\9QK?IVDPL6!NP
MW#QK?O^,2TAZN&Q,2$KU%':LIS`2]Z[OI[MDQ595H$-T91^BHS-RZHS<H-/L
ME4Y4;3B0CL#I>P1N)\S3A;&H_6JI1]]Z@Z99&$KIPC,$1C4#(^W5'QE@VAE@
MEMFIH$.@-AQ(F%<SS-.%L<@`*]4`ZQL%=LS1A6>H-^,>A&X(+[PZJYGZ6&UM
M/930')7Z69&9<'S]K$H0))(7DI=CUT^RW`1I)I(TTDRDF<C'JLK'NIQP_UY5
M=EJ<QR-]]GY]9A18@9&T&6FSH]-FI^U!<3697W+#MF31$+NI)1GY9:7KL4Z!
MT7S28R1G1ZC'NL69@L>MQ\B+6T/!+VF9I5(4'G7<I8Z[^R`TF;?[,&^/IN.N
MV:6.N^1^UDT^21N3-B9M?"S27@>A5F)LF:2-#\*)KJT/G3^O+7RG^)/:U`]U
M[R>)J!\J]4.E38.#LY>JAU6-`;)B2"R/6-0/E8")@(GL/;+WR-[3C(<)5H\,
M5C4&2++WR-ZK^HS$][(KS<KK5WQ>T;RIP)9,2SV??@H"!SM[#7WG=M[Z;2B;
MBBWZ16W3S6EX<].^Z%Y==;J#[K5Y8]U874-U<^I?F-9EM])N3F9_MM2MR2I8
M0*R%]N_T^N:@J_[XHOSG@K1,T5;V>LMH_RH_;3Q5!)+#:$SY@AJ%$&"//2F7
M6R9&#=D06W4N3::)ZIZ:MLU+^^WEFO/9$Q[>IUU-5<="F7G68#P4+$JF4QZZ
M:7]&U0^,FG&5THS+>F\S+FOGQD.]`VFM="CON>M]_0-Y3UJ_XYP?\2=U;ON/
M9IW;B&HUH)IV`:O%ZYH'FK^I2_.3H>P%O-1>C5%#%$V9M08\^1H77@D[94)3
M,F%)+5%*)/8!*:?5"[%KH[_#I?3^F/XZBMTI!G\VC==H\=8_N^-MZM60<MA0
M.5"WK(U9\#*(8F)!8L%]&BR+T/U!H?<PM\U`(D0BM$=6_"0(Q(D#R8X@%CQB
M%B0[@D2(1*@J.X*.XJY.4?J<Q&>>"TL8"8?-`(RV*VVEF53O)076;)U9+?8D
M>'C`E-,.#PNGC_Y'(70ZSD.G=>3HG7:KV2J=J-IPX#X/XQ2Z'4]@N",8$MYM
MC7<'!FFG[<&@@D+3+R7PL,^&E5FGBZ"/H(^@KWR:@3%7W-%K'=B(#D_7"YLT
MAJ!B0>?`L:5XWY!0@U"#4.,(4.,4"\#TBJ9(7;RL8OTJ`AL"FZ,&FZ[9[)*%
MLCS/0]@)KH(WKL2#\(*9<#;$E8I?+Q;VQ`?'^O[I<+7!?K:C.V=6:[&FM"]-
MW2LK":ZU&H;1J6"SM"YZB#8%2`B+W]RS&AVKU>Q7QH1U<3QI>X\D62M)QC!1
M<6UZCEV9DJ0=83OH@BU2DA62E=K*"AB.K4&W.,.Q;O8A;4R0B+TW&&_TB[/H
MZJ*,#B$:OP^HN?7/9F%@BRABH8B`N/9$UH%V5-0>"T&_FY7V3LWJ9._6=\38
M]=U8L,2/70_><3H5H>W"B]!15O+IJ_'I>ZU.<?NQ1^_34UB-1'!K$534[%NF
M53X?DB"2()(@DBZDF)U6DE8'@5+Q;;/=-"F@0))"DO*&I)1@]9&\D+S45EY(
MLQQHJ+H*YK@+N2.F//P]6D@3]W5-(\>7]?E4''`.])XCYH=+N,/5),<6#>BV
MFP8%`R@>1Q)(@7$21!+$(Q9$4H44O:#HQ;L2[0J4(!(4$I3:"@J%Q4E>2%Y(
ML5!4_/V\,;3_2-Q0.#)+V_7G3346HB7?/=(S3+X4OZ<V(#OMF9V9/>H"0E&"
MJJJM6(,>)=!1J(Z$<)^M%-H&M5*@6BLDQX<MQU:CW^D65Y3WZ)4IR=H1!D?`
M(NT;Q?77(%DA6:FMK)RV#*.X!-NZV8?%6H0D8$<H8%9C`,J(2G\]F^<[@_5F
MU=';RM#F+HBYQUP_YOZ]._($XU$D#CD$KAT&$7W>XU&J!L'I[%NS/YD3),BF
M69/@70BH?SMBG;HDOK4"U#$[/=??Z+8[!1:@WIGNVG`Q;6L0XA+B$N*6M@O5
M:K2[[0+W@M]-^*T"$37B?=K%(M@^4-8EV*Z:XNV&V3>;UO[IK@T7TS;,L0&K
M+IRWUT:C&Y.VCL"8Q@PLHU?<?MC;4*@+WQ'B$>(1XATAXH'/;O;Z%?KL1^6:
M4P(!`24!92V`LMTPK`+;YI!IJ#Z&BX\<IK_J^LI>+$<T8`YQ-A$2-$W+^+#$
MWS+[1)+5]0$5X_,6_E`%$]X$(8LG@KV81I$/B2>A$/+TJ`]4*/51;`H_3B(F
M@(Y.N;/Z)F:QF(Y$N-`[+:/!+,-\*=-%/K?!^#0`!%#-?5@P9CP[H/LBRX?%
MF/U3-B7^/N@W30:W>ZNZ#16ZO,A$Y<[%ZG>;1B63:6#_JYFP8_=!>$^PK!'V
M;IIQ7,DX*'F:IF4UVW59LU;?:G;VLF9P-\+G+'0!2/&(=+J$'"]@,Q@G<*+F
MR^F3EEBM)4@YO)<_\Q"":Q;Q:<:(R*VE/AVF]_*43+'3PRDYP@X%CP3.9PM=
M^`@`"X(ZY2$\GCDA2*C/1D]L`N(F0B;^1+F&.SUW+&(7J!8*N"(1$8X[_-?G
M3]?_K\&`MK'+/1@@&(]A6!P`_-DW[[_[][?AQ=?;)AMN_L).$H+LD^05)'GE
MLB:LG^TE.#U>MNKN-JUJ-+<+4.*&V)$3>%SVZ_1XK*`%'"#DWB`)V>V7KY+6
M^+^KEVS<9*3^-G@(N4:D_?:A_?C2@$K-+3173@6M-&PUU&;'(4A5*;-8'1]:
M*`)[PL-[9=.4J^8Z1G-0C9I;K=:"))Z7.F-IX3#IRVZA^LI1?&:_?,67)E)U
M>P-,ZU)_Q$'/7>`'UU;/NU(MNX$^=\*>^'#+_5,A4^YF,\Z%F9=4OU&1ZE_,
M,)[/,`>CBG,BR3G`#BEZSL+`2>RXP1[A,1.)O*&P,?PNE9`=^#Y&$``Q']UX
M(A%Q*D"H0F2K"S>X%WZ#W?IV4[+;[=7U)?L"4C?EMDADY#]BET$X"T(%NS"D
M91BM)KN#@7QT26!B[(%[B>13F&ND^!$C3&6+[;Y4OZ1RN8#4[ED5(5)9`2-M
M@&,)-^N%&,LJ(12S4$12=:"8CT&+II()$@DOJK0.7L)#@`J4=T=!CE2V611_
MPF/V*#+K2GV?<##$_""&N[D]R2,40@0;@TGGCES/C<'&BY7E"%@U-](B%\&C
MR7Z=!0A)4T`@VP7B*5NN@8][!%:'UXE%.`72RR%$%`/VH;),(C%./!GL:`)8
MO4`UQ,/<@_"YEX'_@#CGV]+6O!&C,.'ADP2'1FY^SC.]"GAZ'_)II`;F?NXM
M<@0MW2!I6^UFMR+YOY.@/0T2&%0NPPBHX_R61'+2X(_"_T`2@!1_@D'FWPL6
MXN*./=`[B5Q!,,[1;^5@K8;H-,3<Q8T@1T1VZ,ZR)9'*(897C+BMUGWF25\`
MF,IAGP(8TVJ41M<UZ#!<L,W+<^J%*@WE)4;HW"!,H*4'G^36N&(OU^<^B@4\
M$7Y`F:R]4;=4[O=V4>Z7?955?N7/7S:HHUL8<E<5YEE7YYB%BXEG?L!S$S"S
M`)\A'D)F&OG-1AF'P91=>X!B>1MNYMGL%'_]KJG^B.;,'`[!3?\B0A@@@)O`
M%?.?U`WIC]\AFEX)6]I=B*9D"Y9M"UJ-WJ!7T9YC[:W!Z[DZOTGB!+35\ZC2
M[<*Q'BJ+J%[(\QF1(S]GW$OR,2(7L1%'"`K4/C-XD7XPA5%12R73N1I?$73'
M,:=!!.\(<W/'8!/"^[Z,RO%0+,4_%EXLPEV&7:E'BP$_WT]P^ZN1Q?/P#B_`
MA%!IALP`O'S\W7ZR/2&MNID(P5J9HN'&?>X]1:Z$'G@?UW9G_(TMM_Q[9'91
M-@I^]J*`)3.EKA\GPH<!0H:CP.3`_E'6423];C>TDRDH<K`_P98,$L_)$P>P
MG(_'8,)*2K_Y=@)L47A22IFBC0(=.%)R3PAJ16[_P)*N6F&)M1G]TVP(>$KH
ML#_`MH]53`,1O\DN)"<G,\G+N6648>U0C83^#%]BV=2\A:&1T^:;K&'FR^3%
M!@WC5R+0R$G+3LQ8X<W2(/!F\Z>`1*#A#5H[\+S@,3K?>9ESJXI6O#M^6KN.
MN6&6\HN-9_B-W_//\4'(N+?,4'C-?&"9$,ELX7GI-1]/C!/Y/9IQ._N^@H/N
M@/DC]DD\LJ_!E+_(VGYTG7@"'V&::9(IP+['9Y$XSSZ\X.K%2^6K=<T33]LK
M:Z]M4.]+OLO'DW[OPYLIK<O)M>F-YJ[W[7SC5O=M5^9L96KPR^3?ZH\!K$\A
M[A>+:/W,RWQ4,C(*/"<]IW+K9]9;M,V!BOG$6F^5FGZ#ZE560GA]"1#A15CN
M(BP?$U^]),.Y2[(JTWKN33!T(M9=M=*Y**1FH`X]7RH[YX%D9*>AF'+75[NV
MF,*M-C[W>OQ(BPKD.A6E>$?-"9V/R*R@V:!=7-E3+=A(GWJHQX9MVYQ.I=X2
M:^2QU>X76`V1!/*8!7*;#B4DD.L$TBSRW#T)Y#$+Y#;`3@*Y1B"M@5E<6UT2
MR*,6R&V:\9%`KA/(7J?`8EPDD$<LD-8VP+ZY0%89-#X$@>T.RJJ>MP5Q2:#]
MX^B34PZGE5VL66/2'FP]Y@.+C9N-SJ!;8,/FG4E;0Z@\Y$)29K>R'#]@Q]:(
MK\CQ6[W9^U,0.)C97LB\N[,]'0W'-%N5&R1W266"S2P,'EQ'1(R#+'@>9B4]
M\M#)\H%S&6F8T72?TH&-N(>9:;NG&*V;+^4343X1Y1,5(_F43W08E5W?V0YT
M9RII4V1S%V5VH310(ST;,C]1TC+7E!S0(>_G4"FN:U+0P1;57>D5];I&@8UH
MM.=!?8)'1]1A^=9/Z^?$P=R:+R4V?&2QWVY[T"Q,YQQ3P(+$<^DH$YXN*D4>
M::]FN5NGT=PFC:M<VF[5#41C%GY/+\Y].4$:DW.5G[-\L&2;`R1Z;0-I8X7J
MY`E1S\X--]H;;:.OPP:2-EQ,NTOZ5.#%;1;77Y0IG6^:4%'1`RO+DJLU4>K#
M_MXUC(KZ>*0U'6-@1"R5,.-/4U4KU)ZXX@'F>BK^M+TDPL*Y6+&@Y(GW^E75
M38WYGVPD?#%VX^]P0;'*!UA1T82'8A)X`./2OKI)IGR&]2O9\"<LR9'[$\BM
M&^;K*[U>-:[)I#.75:>-YGNI.:[:N#`:X!I^Q>JV/KZYJOZ0'TD5AUBUM&EU
MZ?=->%6M-:/R8FN7P73JQM-Y==O+;+JV*W2LOK;AXKW.2%3F;E]E[JJKYE;?
M^F:RJM*$EVPF^$&Y3,EM.YDF2F"?-9I81O3,V'N=([///WR?1&?WG,_.LPRC
MH>\L"HBI^F%7;F3#@P#>[X`W+[S`_OW'O_WU+S]DM][Z=C`5=_S/%1=*A0!?
MOHKQQY.;*USM?[;^?7=UPEP'?N!V?#:X[/4&G99UV;UH#6[:%P.CTQI>]UI7
M_0O+O&P-3WY\)D-Y8KZ1'+/*U7E=!)^5>;,*ECAKX5!V>GUST%V3(*%HRH"H
M*_3*025]#64Y;P!,SU5Z9R3B1R%4\:M?F]^:"SP8"]#\*:XF<1`^2:-)FB29
MN2-DT3$T#N=_<B,6)5,L,/D?+$=)Y:>J3A<SK7?FB[4[NZ9O654GFM&+'M>+
M'LBI+KWRR?+@T'GGOF#)VW]55/-:K>&S/EEWLEC4+RJ@M2XB>2T#74M[+T4%
MGXE9B5DW9M9/V-J@/%X]$+2M-(&Z`+;6*C=C^V1I#8LO%KGO30!<'*?6DB'7
MLN!><\R)!?<"EIOO^.^?<0E)#Y>-"4DI2W";W9UYR!9CLD4)='E)P?KGF+4Z
M%51#.X($X`6,?B`]4YB>*9P^.DMGX?)8-[$C0=N/H)%^)/U(^O'@Q':G@RR'
M>GQ"#^6IS4&)BC0K^:GK_529._1&6A4IX<UJ1E10+Z(NQYA(:Y)7^6*\`@6(
MY(3DY-CUD=$L[C@ZZ2.2,])'I(_(E5ISS!R=**8:B:M#I#S$]J?D6!51'L@L
MLC[0$8<W]]I_E]3AX0JE$L-!<5UTZR9L)%[DU56G#,MO1%8W^21E2,JP6&58
M8,FSN@G;=N)%+N5J`EZ&PG'3TCJ^B%DP$R''`CNRT`5+8M=S_R.K")!:+4*M
MDE8EK4I:=<]:U2BN#7W=A(W$BUS,BG2A46`Y7]*%)*RD"W?3A7W2A>1AED?`
M+TEH3SC6]'3G50X9EV4.28T6D0]*^3>D`4D#[HQ/!>[ZDYR0G)`^HO,))&>D
MC]Z1#UK8%D%=Y(1<J]6L\@OWDS&W8]5DR!%.8M-.74'128MVZB@Z2;IPS]%)
MBRK`T$Z=#N)UY+J0ZKZ0+CP<8:V;3&:Y8Y0+2CMU)1)0-:^<B7#*?6QUYL9B
M2GMT=$:>8J*D^_:]1U=8X7V2$Y(3TD>%Y3^3/B(Y(WU$^HB<JM><JL+0MLI.
M.#I+X=JJRGW+M(JS$78E=UV$FI1?N0Q4-[',`I7%I8!M2,#C#&22>)(Z+<]'
M+*P,$ZE1DE-2HSN<S*M,`H];C;[7=>W7U7>]'H^%';L/LGU#L6T&EQBR!0SI
M!`D>#"Q%]1YL)Y<5>MEJEP4+NZS"472$61MLH!9.>S,"5C#K42%#A@4E>=JO
MD/<H1)Z$7%,A)[M@O5U0W*8NV05D%]0&,HX*&106=(HKZD-V01%V02[$\'W,
M@7RKKJ\L-)FC'TQ=G$V$7#O3,CXL+9Z)2_6<PO*[ZP,PQ.<MO*`*DM\$(8LG
M@KV85I$/B2>A$*H2+E"EU$>Q*?PXB9@`.CKESNJ;F,5B.A+A@FU;1H-9AODR
M*;G(YS9`<J<S'L+\XD`N7L2G`M/+W<")&`Q6ZN-A?B]S=(J=7Y"$3+P(D;&1
M\,78C6'>XS"8,E"D(@2N`FQU9QQ_CM>U\6FRSZN''*?LKRC*Y1]+G5Q%`C#G
M!NY%`0O%V(.9P[>,A@WFB,@.W1%0;22`D@VX*$H\6:!:4A>I$HJIX%&"_\`+
M!F,@K9#_`#$3WP:UQN'ED)BS('+QA'S4+!@?4SPTN^7CX<+J;(UX^D<<]-R-
M`:5M]<NC>N-1X#GJ!8:V#>:ZHALPTZ\96>(GE,1;'SA+L+LWF_1N2IFN+HKC
M?Q6@(RM$R2AR'9>'+D@?X!)8&0D01'A/3/P)3_"1R9[8`UP0)!'R"U*+)_$D
M`.T+-S49C#9VP?9Q%;VD?(HX"7V)9\B+OS:_-1=`.Q9@Y7"/_9:$;N2XLCI#
M8_X$O!;F"0(>->1;9GB0OQR?ZH*DC,4CO*8-8(X_-O`5O`3I+1\["P/@;9B`
MXT;<`T'AL,#L4>!W.XFB3'K@%YRY'P`L^?="$N4WD#F$Z-6OCG-4Y)%5X"7W
M/`%@X9#XOJA(6@Q^E!-IP+A@0C;P!S!&SI;'S)$M-V2T:DRCW7R)<(=MP]SZ
M[!<>VA.I>N52A,(6`.4.`-X8B.')LHA1)&%LCFY7W'>C"<HF&Z:\^,1.O_W?
MX=UWDG!C6&&X%4@V0'2\YZ'DBD=@F@F(O^00J7"0PW#`.!0\SJ`R0T=``A%*
M]>(_P14P$Z[8#_[R$'@/.`P*4?HV?`QRX*)JPE&Y'\BC8RGFSO\8Y=;^#I[,
M$]EK(+T,V0`O!,4G)P)D,>`%02KO)XJK%*O&4NUY`E7G*(G9A#^@DA4^<+U0
M!@9,@+,I]WUX"1M>VHUBG!_2`"YR)97D@QKJM\B%5>3ATD3A3["2$QCF*54R
M<EA_:5&D'@9!4^SZ;'IQ$.,:3A%HT[N$DT[-&#`W*E=G_[T]:+88W.ZMJ@%3
MK.FS0!_)."**<[1`8QU`:*[<9P&NA@L_/8$^!EA!5)HEB!:/N)*>*]#8F?!X
MH:"!.WX7R)8O6`69XH&COXBLEP(:+#JP6YS!86[)'MS[`%@J\IZ:K&A$R;1^
MOS*MW^T-,-;T4NLK+RG%[+EVEZCQ):-IL9J]:OB\4E6.2O<"R?<K`B!PF;"?
MC')F$/*Y\UL22;T3H;7QBG'.'CGZ`'A[Z@?(^V=@Y/SI3D&O`(Z4BZ16NVE4
M@J2HG:9@#GJH<SSE':;.,II3S`6%G)*/91;9,M7PD':3W<:H7D"Q1X'/1S`:
M$#.2E98EK`)*/L)LTC60XP.$)F]Y2?EW2B^#7S%6)W_]+0#P!Y4<@<1$RKZ8
M#X.*=8RGR4-P>U%-1%&"-DB4LWL8P@H^"";E^J`GIZF)B:;/>C,\KWU@QO8$
M/T0BCCVAN$NJ>*D&\K8[F%_9\Q1[WJ+FPF=_!?7C`S&^B?#!!;/Y]/;KM^^4
MVR#-&F6FIK9P;LR7#H2DTDM3*D\(^7*@,&>IU8U7>^CV)O``-..!@CEFR%MB
M^$:N7.CEU867?))F"QK_]QC#D@^17G`(:`/Z,2=;0AE02K\^?YLH`0L(68.7
MZ297:7)_MN,``!`QST3.05/A-V!DR6F*3AAS6;@C*7-\_;9PJOBR6U4Q&)DM
MHRHT@LOG502548XLKUPSL&%[J#J,OF1$:=+F\&'&GY3TX5V1DJ0(2?C@.LJQ
M1CH_@DL"!`L>T=E.?8FY7_XDG<=8V?/_#?/-]);5[O_#:;`KX0-6_B[=\"6K
M$18,3')9K@)>";R"2%I^TDA,YX/",D<J\>=,^%'J$DE[<FXDPO5C4,R9NY/)
MC7RFE!O7AQ_D2X+'D4BIE3(GC4V8K@W/"_']XD=T43)>PB>ASS8/Y<V):N9\
M'G3A4J<CAMG,I$Q*C,L])%"C2D1]!FN9<`-[`GF4[\'9R,550M7!G0?D8&>.
M1HM1G[_7LB_65B\"V`^C9]Y3BNG9G;B.XH\$!TN]HU<W1]+//WR?1&?WG,_.
M51`*+-8K\&B]``-Z=P`:%\`4O__XM[_^Y8?%A8#7<1`^K;A0>0)_QE_%^./)
MS15:.O]L_?ONZH2Y#OP`4'HV''9;YDW_XN+ZIM6ZNK[IW0RZP^M>ZZK?O>A?
MWI@G/SX#M[Q8W;E3F/(G\<B^!N!PKD6QC;'QF>]@%0R%UL)WZ/3ZYJ"[)CXX
MI^EA.PEW:9`\\"46`5*[V<2DH$?)%,VM_Z#X(N<BID?G.\]Y@]5?VGTVGM$%
MO^<']=$&\I89!*^9#RSW#L'*\KSTFH\GQHG\'H&AF'W?GF\?72>>G`\&S;[1
M,;I]R^K"_/J=#]E&+;"0QV>1.,\^O`BI+5XQGT(]W[SM+VWJOKY#NC2"?+./
M)[W6AS>WA9=WM=,;S5WOV_G&0[FOF@=NEUQ?XH&/LM+O^\5B&0ZW&J)/0=6G
M5F"TS1'!^<1:)^^C>J&Y=V\LQ^M+8`OTL<I=A.7LKC6[:E+%K,O!F$=?&`9=
MUEVU,AA#N6)+>3;[X/9:,O4N;'PE[)2+S5>Y>..2*%0J9+7Q^I4_,HPHA"[W
M"JN[N%/VHPX'<M^?C/OWHFCXIN([T'.FJ]+(+6HH]T;V).GCO=)'8PPJ%G4.
M'%SD>*;5+^ZX:EU0@^R?-;EZ0?@[AK]E%#W:Q@*:S\5ZR^@OK:*+!A*W0IUW
M6KWBVEN2.B=UOK&DU4&@E`B9!5K$=9$44F%KSBFYN*4M''8?!$XY&FQO-<LT
M$,A5_68[@P(U'%4J(PU8E:3602"5"'9+JT.RW\/!.FO0VA8=NY.G*-R-\E'V
M7B9@G3XXU//MI4;1WUU5I(X%&U90?&#VBVOUMCO5M>%A,GCTC>`?3/65PXO_
M;TS:.L*B'*]OM`OL//LF$.K"=169G0=9B"9+*#8J2BA>I,;4\)">.JV4Y4>K
M4U5E'TG\>Z==T2EE/`4<V.JLQOR@S_]W^^GBZ[_OA@UV\_/M_QM>W,J3&1?7
MGZZ_#'^^Q:VG^Y!/YX?!%V?-;3Z31VW_DQXW5R<ID#E"<9]X7*68X[&@!^XU
M605\D^5EY=C&E&Q31=V;RMFFJP/79/RQ8`]G%^YX':Q7'(Q9?][EQ<&8](CM
MI0?S<,>N<"Z>+N%)(9<G#'_A<8(%)*Y@?G<(_]L<G.E8?;-_U;L>]OJMWM7E
MY>"B>R,/S@R,:_/2NJGTX(PV%6;PR`F6'IA*EAES-TS/ULK#9=,`;!'D"CN(
MXNRX+9YB$^HHAR-&\";"3M(CI?9\W?"`"G_@KH?7G8V#\"SB>(CM2:Y4NIZ8
M+R@7E$ZWO'FZQ32,XLZSF-UW'FAI=^IYWJ/V!UIH@H<^P9V.).FT?UW"P8`"
M]L-Z![ISK==AHN5#0W0XJ)R]V_?R:@U8\C4F7#KR4][1'CKMJ?%ISR,Z_W:=
MN6^;NDI:O/4-NIK_0E>3-$3Q&H+$9W.=D04Y#DI\+H,H)L$AP2&]0WJ'Q.<0
MQ:?^>H>.6:RK!2QD:6A?U:O#,I?>=B<&"\<C+8X&Z)3M>3PU$\Q&K].BJ@G;
MJ+OWL<X1VPF$6X1;Q>)6<0F6.G`2Y8K7"YXT1J%B<>?`X46.UVT;=%2>4(-0
M@U!C2]0HK%UQ75"#(C_K(S]\'&.SN2SXD[4I&&-+&=EY8)>X*U6.>NX<]"VC
M:9)S0$&-ZC8_2`A7"6%A!12/7@A)UHZP@)O9:+5;Q=6((EDA6:FUK'2**^94
M%UDA;^PM;ZQDYTO3HR-[LPNM7H%6(14])->M?->-1/B%"!>7,D(B3,9L59):
M!X%,1;!;5IV]^A:0(DDC2=M)T@K;XCL62:,*P:]6"%Y1&V=11Z<<7BN[:K#&
MA#_8PL`ZIS^L(&JKT3,,':K_U@5%R;DO*2^+"JK7&C</MG+P6E`MR0"EDNKD
M(>H/K!I#9,6@>.`VHQS/:IBF66!RWELT(V@B:")H(FC:$)JL"FVMND#31HT9
MWJX3OFOY[Z4ZXC^+>WEM+,)HZ#LX`+"A\&U71-L4#+^^-ML7[>'-\,H8F.U^
MN]VZ'LJ"X?W^3?_*Z%9:,-S$>&AN$*M@";`6OD>GUS<'7?7'%_4_?G9C]Y['
MJ^K8%](:P^S.2B]\OO"Q6B.>_A$'/9=%\.TU,V=*(?4ML_>/7J?#O@`7PNL4
M3)!5A>&7U%)GMJ=>(I]]]@M_6FAEJR^+:QH-=N$&(%[LER&[]>TF.QT'X52$
MWE/VAUM'V-E?OV-CU\,*[R"`TYG'77A!>(]X(MBOS6_-Q?!7;A2'KAVSRR`)
M8P9CRHOF/P=C*5W_`T(NGACW/'$/-(*QQB%*.^((5IN_X$\B9/\MN!=/;*PR
M_V7"PRFW12+A.DI?65[V'3L%44W&B#:A"!MII7NX'XOA1P*>$>)S+Z[OAM^N
MOW[^)'_/WX)_O?Y_=\-_W0Z_:[#K7Z[8-Q$&?M!('[/1\%^O+VYOX/8O8UB`
M,+W3#L[FE^>NP3L_!0\<E$_T8FJ703B3#UWYF.P]L[+^2/Z,J3\%3=9K=/K]
M!G+ZZ4K._RYK(V'#*DXCN3I))+M&N%B=:(PS9R,1<[EX[G2:^,$T<+"?!$@+
M5KV)0\$1FX$;'MR0>PC*CHM_;:0_.&XD>"0:S,:.%&$D[TJF01@U&;8N6#!1
M),3O$9N"YHIY^,0</N7W(FJD#3[P(1[V,)B%P=B-(TF+,'@"M@"MT$S9!!MB
MS$+QX`9)!.S[DE/Y/?P#HR11QK01G^);`(LV6"`EA%F]3##PG=3T0`(\'JI&
M&K\ESKUDSWC"@?ECL`E`5?A!/&=>.?)JN,'WEO?A)3/UFXMO\P"`X332-5:/
MG1,C%)XKQMDKHWCB*H&&#$)?/$7_Q<8"285-'A1EQ)\SX4=B3F24P`F/<'UD
MU$<VB\"QXL>`>?PQ2H"FZN&/`AX':\_B8'X%<#P6@L6V#OF96<8_+O,#KI[Q
M4-W<G-]EOFZ5;*]ZUD'M2^74JPAK)3MF"-!82#@2>($JJK\/0%_*J;!.*'BI
M/*:KO3F%YWRSBEEE8>6,WQ2SR;X=\$)@+9[E87<K)ESPW`MV?#99V>DH%5.8
MMN#V)">ABYEO)'7K!0RHG/C"A_>SA6SH,0+\<5"VI8Z1'7+$'\#OJML'`%9B
MQPL`@;EX$;PL/`J["B'4+.`#1`)?CD4)O/OB]8#X35AC@$,7(0_>0PXD6_-$
M(GZ]X4X-+:U;_"/WV2=)&B#)+\)Q;9A<Q(9HQ[_>5??P+:W;3$0`=B?LCP1D
M7ZELT"KFW-Q25&+?OOZ\,)I"80OW0:!,@@T`0X3!5([U)DG9*?[['Q@PO139
MTV,WTJ((4.T.;V_`6)#2@^D*$A#N_OUM>/'U-LVBG[K.V8T8A0F*NV48`]`C
MMA".%-%0N--1`L::%$+/G8+B`W\/I,B-)G#%#/Z6<"4DG'T)\?6OT&R9NKXR
M&+X*`+)$?CQ5?U_\\AV[!T(CQ('-AV^*.#.O`P_OTFVRSXM?<E9LJY&2%117
M"B<^]KH2LHVS)-Y7,"TET88.O`P:H/!"`$%WH3M*\'>@Q,_\/V[`3F^]^:^"
M#:>YRX/Y,*"WX9U<3]WS'3X%?$2P<9#R3SGX"A,//\P!:Q4)TU=\3@\638+$
M<W`B,"2`R2,XSH!O2-W`AY]R.ECRFAN"6?-"K@H-K93;V`T533R)<E9"GD$E
MQV8&:PK-_DN&5?9.MOJ@$6,7M"O80H@*33#%V?^`<I`]!1J*S517M)3#Y]3G
M8R#H-+]XX'FX:.2M7$0IIE('2CG*O9+9:J;/0>WW7/!EVRPPD>TDBA3+S`+X
MA(HI]S*9ZP1<YP:.>MA+4<WJ$/P/N"CS9Q^;YOD)`]J^7)DT@%1S5?._0EE3
M&/?S1>I:`"K'J@'<&,`;W;#[.5TP=2V))T':\`T9T)6!.QD$`1Y$5U+I!QP`
MA&,:I"IGAF$\@"GU%_G8N;X"XU`:J%$RF@7"Y^!Y9*\F[:GYA7Q^R4*YO7Q+
MR?-.8"?*=)6C2VD,Y/NI[V#R3MR9:I,(OF4,)AJ;*1?Z"8PO7X"CB-X]^)&A
M>A^<K1T$($AJ.'DKOD'NR0J0P0^>*@8Z.AGZ9^*R.SX]JL#8_R2@4KNJX5%#
M&FY@MKDL!C)DOF]J6RP""*,GQ8=!"'HFD:*#X9()]\:HN61$S'=1*+ZA/"JI
MR?@T4C\]HEY)P%/GGC)]LC@:VR!\]@N/(G"B$G`QXM333U_V9?]8OF3Y>$]+
MD8!&ZAJMD7L<]$'!!;SY@QMD`:#QDO3>@*"#NZJ<5W!)E1<IH<CCCYF+-P-C
M.%IXF`SUGJ?`*@Z%[$F917YL>*I4WBK(TU!A*8"JQL+7S/F`TNM41$:?5!%D
M>070*T.GS950&:@!'P`II-0_!MF4YO$.B7,JMC/E#K[F_!Y)`AC,C?!#:L8%
M:"GD0R8+&,0Q4H\P?,BZNW+_*7OFW,M\=H\,QDJC-IC!$@:^PGCXGOAC_A"$
MTH\-DA@&D//(C9G-`RP7X<I7RYF-L,0CN=.3M[B6K@@%\,#2WZ6-(UE6/A5(
MF/4>E<^#A0-Z)T`H&`@D\5Y&$_&%9@$ZY^@>>V#A'!VFW@3A(P^=-,)[5-#Z
M"52K=.),M=_09L^(,?S^&SM=_BW;9,"PY(J8[=R?4]B('</`@!:>$X3C!OL)
M7$YDN?F6@I27N^O+F]NKZZ_#>9`V2J]DOX*3@+&P7P+TF*^N<\ZE@;9UAQF6
MQ4S36OSA5S.#V$>.XA4ERB$9SD*`+#G+-`SKA@HV/]MQH%Q9L]-\3@(PB2+Q
M1P)+X^4V:&#!%D$H.1ME]"RN0%<;)A[&Z^>X_*3_BMAU$H(!!-/.;158C;YA
M-EJ=SNI9R:`XO/?Z.5DKYB3C^;D06:1V%G+;.SA<BO;@);$)V+"X7HO8F3T1
M3H*,@.H/_NK)]^CF=IG>@92$B?O%Q&^+MM/'A(?#Y#X!-$O1$"3NDPOT$^Q.
M3&!`-Q?#DLH[O[FZM5$XQTX5>6A(Y^ER@F'\ZS^!_#(*]GD\!J<N1.`,0N#.
M89-]LX%/@]1,6]QSX_K<MY%AY_=\X8G'_J>)9I]O/S46H)M9A;GFXF@%SJU'
MC-([J!4Z<FJ7398)=>\?O?YOIZ/OY,/S/\:G7/UH]MAE\Z;Y-7^/U3::IC$Z
MZRB[3YE2[GC\$H>6C2/9YUSU/4]_:4@CW84)+EV^&%'>$8H9H"`ZU)*(F1&G
MQD&S$>:&)B^H);Q!_2']0=$5EU@"9KK1EGN`[^1&@Z%SFZ%S"_CECLN[[$9"
MP_VB8:J-5=1J*>`Q_/G+U\\_W_Z_FD/CK9]K/JR0,4V@`#:<!5$6W'J<1TS!
M/4\#[4!6W.Z6+AV@WO-,B'ZC:[0:O5YO83><7O^)\ANE`H[Y8L"0_[J]E0Q\
M^__DGNK"Z?V%3Z=J`^92>%ZD8&B6SZ:9YR)@%&"^OY*M'8GF(8MF&.`>,5@I
M?*0\!:3D9[DD,E>1P16X3P9S.X)X,[*0C.FZ_D/@/2@789;2R)O3*,UBD!:$
M))4G235;D(J!28(V`ECU+I@5CHI.IR%>'V0$OHV2"#<YHUP0"F1IXGJ*9S,9
M21E5:6$`@OQ3P)91L1<8`VP18'=X(`B_`Q83QKX04((T/..YXD&-G'BI:.0V
M8IX_1?P)AI?,D5"A8O8H]^Q4U!M_%#(A@#L/F.3&Q'@LT$CSY03G,PNP?%EF
M6,T3J%Z7LI?9MQLES2ZEV?XB0@R,#^T_$C>2S\0;P98$L%5?X;,-$I^$V^7=
M7EVVAY>M5FMP;9E7UZW^Q57K1N7=7EB=B_;%4>;=YLE\;``*S/B`S.;;+](W
M2X/+)72TJG/OYINRII4Y>(]I<%=@)!I%GR]X06**YV7^`^!9%'.Y6PWOA.(&
M?WB%?.PT]T=,)V48W);G&&`<T.`C-Y@MW2)?!5%,Q9_!%@%3BLE0]H/PT!ZY
MGX.YC6_BR,@YNIJ^P-`1E]28@:_2S+]9+A`?X6ZDL[A;YC?&,KT54-":OV+N
MBJ_\3PXN+'B.`J;TZ5^F8;;[AO7=8B,#7;@IR`[N8&"J7#9&JA>>4B44C,_@
MOX!1-MB20,+$<=.WQ^$%YJ)X<B+<NW<Y.[W[Z9,BVR0,8$``8R"7GZ6M-MG0
M47",6JJQ])KX2@O#"/,TX'U2W8<;/$!.]'^5[GM.NG3_I_DR8Z.P3,B]"(!T
MO9/0EBL]DSDMN-$$:A)9'UB]W!25OUN&T309W.^MBB45FJYB\VB"+H"*9(*P
M@*:$!6F`'Y_(1%NE?V-%`$>DP8=GZ9.IU,W#H2H=!?@&7@RL\P`3O)*9RJF:
M\C_=:2)O*Y>*[8[1-"JA8@,GHT2\W"FU*IL2HAV/H@#,N3C;YL,57[O2>!H@
MARM94$_FULNK,0WJIT_9!N]"=6"0?IS('0*92H&J96Z22O:$BR8JU.0LHNI@
M!<NM6!553U.ZGZNDN7DJDZ9XBH+2.!_A!K;:5P'K&!$IPM_S<Y#/G"/G*GTB
MT5K,43Q'G(;*0,>'I#GJN&$JTT[@Q7X73TR`+@V>A/HAIX**=DSW#:9`>,`.
M7Z@XI62D%=9#C@`IZ6P\M.C(L$BFD$J'#*O7;G:JD:]YY#7CP3%VA'_`CO"+
MO?35Z)O;.+J;H)Q.41*D(&6A$&>>2,?EF`JUIW)K4)WW\(&^LR!,V=A)P"1Y
M.E-)YBHJD\8(G-\2J?8`#)+I3,6\\W$])783]#@S,4\3CQ;0KR+!B9)1S_T=
M'-1)$$A5.E7!KV?33162S'Z`">9(,P6#!CRY:9HCKUXXF6&T"MA<AKME]M,,
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MO5I=92]V>#L+W^;G31B`MCPGDNU+;AQ+9\'(2Y/VV2.>LA^IO8=['Y[E+"*B
MZ@1O'*P?2)9R$F-/8#X6O@CN<F`B%.9T.LLUB^2^^;R>#<;BIT(>/<GO-[E8
M_66J!L\.)J<!]^?S<Z/</'#O%K?]X2:.9;EBP;J-5Z(4!2V)^II/HU%GQO!5
M_R5?]9=%./UEQDR1C+%TM$CM1JQ9B$7*VF))JMJ`JRK2?Y6$V19+))`.SVJY
MJ-R>^48/LNT,JR1AEDGXM,BNS;8!7L@6'M["?1/<T0N%DQY>72<F47:;DPZ:
MWPF,@TR&&!9`P_7*GA]E.96N[\IDE57;KGC\``\.AR+"U$>5!91N9KEJJS5*
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M?OD\[;<+;.7]%O$6''?83?=6$'+C6`S)^"M&<8/Y8IN0`<GU.KDVFP:)]>&(
M-:7^4>K?048-*?6/4O\T=J-JE?I7607:7-[,^L0D]^W-'W9Z^^6KW&[#_UU]
MA_E"]R&?YO(;'F75'M4":NE@_<IS\EC5,2U,(8M7X!8A/)1[3Q'V=,,BW?]Q
M55NX]$H6II-XL49%4LPT/Y0Z?GI4?U%L`,FF,J9@2.:$[H/PL]X0:I56U1=9
MKKFT5*LHJZ(D^TPNK>&Z8B-RL;'PY)\SE2T4!YC?N2ACY0>R'K>+W0ZP8))E
M6`:V99"5<:=I@1#LPR#SU+#4R9^2Y;RR4[#,=J>B'"R5VI:3G>>KLDE5%[G8
MY5($#^)519&LRNFB",DB*W<)+K)<J&?IN6G_V3SETLX<N8%>%-,"#$V+-6/G
M$U77+):FZ2)-:PYO)1/;JH[8=[*EW'-A6R'>D>KBFB.3+%)4H52VS:JD,F,`
M?X%=*6K)?BVIPE@!7Z8D:"36U$Q)>_7,FXGN5C0EB1;U4N;%4M8\L&Y9E?-^
M8'&,'1:S#L3S[-S<X8$4#?*%#Q^#\'?9T_6_E%;"=KJ2QEGE/HD$2\;*RC1G
MN0[!HG-E:E&L#$+/47MNT2QCV(M=WGS;)6`Q'`P8QDVSH.<S=16OX)\!(Q,[
MQB'JMMQ?PD!6N>-I2K?,:4U;KR$"J5JY:67>K%8NVCON&-9"+I6JLX\W+VKV
MKZM]]:PJ$18IQK%361-.D^4.O<RK+RU&4T:3:BZWZG55&W*1]O%<=<4VQ<A>
MUN_=K1KO4D'?3^)QJ&J[`3=\P9[+";R(Q)(OX`O:3^K_MRGE:_6[U^W+BX'1
MO1FV>I?=B\'@4I7RO6P9/6-8:2E?;<J\WLC&A3`[R4@NMG[U899\3GQT<'+4
M5UT653N=U(Y?M-)8+!EV*?,='CH1O`4VACB]&7Z[^`X+1*LJHE'Z=VPJ+6\8
M!;*\:587GSO!+,Z=$\$3`J"C\'R%/'B!C2J0SYOL5]^3I:=QV$<$TK2D_KIZ
MV&D#6W<ZXZK-"/9SQ&Y%V;2B^:NK4O:I^#V!YEL\6X+?\^K8V9CJV-?B6%'&
M][(:_4J!D\7+Y)S?K)=]>$?T;N=ME]H-Q3'`"QFUA]]^57V;X*]GQ@"</5@F
M/TG[16/-!&S5&2E3Z!+<ZV"*Y<E/[X(9/+YK=.>%=:-DAK7)'2$[3"W*1X;I
M@*E23H_222TH6;J1`J(K.\1'\:(27LIT-KM/P!-%))3*#P5DSK_I2++S2EJ.
M6)Y?2@V`^=,?)^#YNL![0,!HC%-`'2I+IL^+0N+)POD,U:&AM*R?Y,3TP$N4
MG67,G0V:LW7V#LIBC-)WP7ZEJ0401.+EDV5ES+2;CSJ5\<HR=<YP';=>IG.F
MML?YO$+T]5R:KJ3&4LOH@!OUE!I4R[*>W;=$?_G\K%&P*0^5]'#6RS_UU<K)
M&<F"__P^%,HZPU-!CPR/MLB#*[@&DR!0'3@4"DG\R9ZW@*1`>G7HF3U#I*P[
M:Q*&"EA$&A!)#^!-!2R#JB&<2OS\'-JB"G.*):H96D9$@)HGA3KK,48=05T!
M,C6$E5P'[%=Q!7NJW\T%#RGT37(^KDC*HOVN`2SZ560[0##9LU]XC`V?GM2]
M\X:DBXLRW>??IPVF%H;-"J@`F>2RQ*UL)(4*-`A#=3`KIV]E+T]EH(5+;S/-
MWB;.O4VZW/,7&L]?*.U+*CUGD$E\$V?^=DL`*)$A-X:4C10:\SVO5.OQI<<W
MGCU__7O.=>F+FKTOJ)$V.$;9D#@@FY^G-`RRQH1*KN=]_!1A4206DXP6)C.B
MJ3P$W6N4%AY07U^>?9Z+Z"V6?$_*/_G,=CKPK&HR9X"4G2B?$]YQE8>C;!Y_
M=UNGAC`T;Y7YEN(T6@W@`M7WC)VQV^DLB>>=V>9_.`7W+E:@U.J<M1"7O@&Y
M/7?\E*F0+_.&;>K>*S&*V2T\$:T44,?SIL&K;14IC`[>XV;WR$;#^1@FST<Q
MY+6+8,)(+(L6OM*(>W*@:")$ZO`Z\#`[S@(#\*;S-NDV#T,YF=2^D>R6O=/\
M.8OZLUC9&"T+^?=LSV1KLZ6S(_67J"VUQ\+_SM4S6+,0;/@LF/XS,G8P/KO$
MQCTQ&X:R0U4*N,H(P@Y_RMW99*F\=$!;#<AS`^(VRH;+Y:O(CZIX/L4*C+CR
M>,)-A?N%*O.ORC>O>^`SZ$806OA3RG9:M$9K&2F(2[*$(@X#K@RIM`>%](96
M`-/RL,O0M!S.W!FE7BG$L;*V1N5J90\E-793+,>,]PIQTLAJ!*"3)>WG^JZ=
M*>P!)CO[%4C[+1C'CV@H+8"HU3'.V@A$F6/U7U$^UH)VU`WV$/C"755L@EUZ
M0>(`_"#$X27#O(3^*KN5+JEW\(''LN,.WF;/;\L)=F:4(JY'V2NFS0H5%9[_
MRH27KP:_-%@TD2'3T7-S\#G>KPB4IO&C9P]#7?#6#)Q`J&AU9E^OF\DF;RH5
M7.H_R^@C^K\K=&Y63VCA).+=JD_1LH_:?<L$2V/M^8ULLL;6QIK>E$UP!5:#
MZ-PEM%#F<K%JN72W_H/(2D&YV$13U8NYS@((=ZBP+[EG)ZB?V2?0J$.I5]5S
M@/+LVT3*-PX&@UP#>S]P\*[B[U;:;%-0P5$:K)\[;3).`>/?!UC(0PK+R[)7
M$Q>6&1PSV4`>>QS.7QPGHBR-W.7`7^FFG<.P9<I]&FV)4\/@83Z!2$Y@ABPO
M=Z60)1U7@LO[!.!:-D;/:7]\J1EFW<1RX^-_<7\%]ZKD5OG20F2%>Q[@!_1P
M;3Y#?2G;RF2[68M4%'6S[&XU!>(T\$\/<OOX+'CT,7:<CG.&.6KHG;J@Y^V)
M'WC!_5,:9I,='.^>E_)Y]EY*8:Y^*S??K&,]R;/<IN1Y_YL4R.9&W<JUSWG]
M?&UCB[N5;YF?2A8'GT>[TTI,6QE5:_UZ91K*>,[<*LPZ=C\CZ&I2JM=C7@#`
M'2X1YGE08*EN$%EO1V>]_4_B;:0@,&B(8._'`4!4JA-:*]WQ9T[@_*X5<"BQ
M3;96]IY4K"][P@*39?Z+NY1P.'I*P\;I3I?*]?!XA"1LP-*%\"E(YAUM5-LI
M+S>\NGV>/Y=9<XL+5$N@%SI`#;W\$+1_L"?@O7)&FSDZY301>.DSL=*,2159
MEHLW?V*ZB>$%CZHPG20$S@@1$;PMS_V/S$>1$->4NO7YKSC\<E6K2'B>VLB4
MFRSIRP6AHTK;@5$7JE2MK$]8@WDJ6Y1'`?:7GK?8506>I/<M7R[+Q6D@O@#Z
M<4_%0V7@$WL8Y!S8'75BCXS"4OJQOR[YH!`NLI[&X$2-@'0JBIU9AD9G!0H\
M<\ERH'#V!=XM@*<LRHB^&9[#>(S*U0ESVXG/"I%BWSTW4A$*%4K+1=JS@FT8
MOUN4?\PWSYJIUTI%(A2R[P:*ROQWA1;2*9H_>?XD?$@.H](-AVB#'8=GN9+\
M5;H<M`OU,CUFV]R6I<08&3+X%/CIYN+/BY)[=XA.VR3$&)W>5==HMP:]UL7-
MI65V+RQ#)<2TN^;-T-I/0DSE?8ZE-D6S\4Q&./-%#--H!/4^VU>=POX[ZQ3V
M6O6L4[C'^Z@0(Q5BW(KJA1YIW[Y"8VX),,U/A.4NPO*1RM5+,HRRPQNK#NDM
M;X^MNPH5^A:K67C-PO?)A5YE,P^O[&C%3+T+&U\).^5B\U4N;F^Z2CNI!)T@
MOSP;=EUGL5P_B&VJ]E57X%1CPNI:P_3`Z@FT#+."PDUUJ0B@'YQIIZD+IX_&
M&%0LZAPXN)PH@\$HKF!475"#2K6M9I;KZ<P+GH0Z%"/\:)&_.1*^&+M4RKB0
MUJMFO[FQ$4\:GC1\89)6!X&::[4>:37R][?9LR+=58!WVC:;)NDNTEVDNW;6
M7>U!<>9?722E`-W5KZOR4H5V@_5I%X7A,57=W7><FZKN;D;Q?M<LT(>FJKMD
MQ9078R\'5G7AO+U&Z#<F;1UA48[7[1@%.F1O`J$N7+?W*N.O9RQOFG2\E*G\
M)<04Z?CIB\?]>.@[>,Q1UJU<'*C<)ENYVS&'0_.JU[HQ>KW>3<NZ'O:LZ\'%
MC=F];%N];J79RF9_.3O9*E@>K(69T.GUS4%W30I.1N,&DU26>QMS.K_*(`=7
MJ'`QU=E\JB*;JCR)L"C4',M#.K))CZRR9=O)-%$'#APL68O%..3!G.&:O^`I
M@-FK#RR_UK79:%E&LU-)I6$YN;*G8_:[S79%TYFGII7VC'F:YL+"R@ZN'OA2
M99E[N8FITS4O/90B']O`TS4S=<#'>ZKH"-IS("_7WVN->/K'_('@U=#^-2O_
M?!>ZW+\'J^4+#W]GH`M5":8O:<6U>J'\YT4]IW8C/:KW*.9MF=)RC]=NQ%T\
MG&LWV:G\\AUSXX@Y82+KU6*Y*09Z/AF#Y:!.OHTSNLE#:LDL.^GF^N.08UDV
M6YXIA[==0_C3KW=?OFNP3_)HVR4/P5;TN3R(5C)N&NUFO\(J_,L=L.8%61PZ
M!+6O0U#M=QZ"ZO?HC!"=$=+ZC%`UIR;TBK-1UMYJ-721N!Z^LIXG%K0)&>FT
MS4.[.'+T3K_`UHG:,Z`^^^?'@XV_<'L"5F[XM!R-VD5E4RK8LS3F#IU3(OE\
MIWS^#&)9BC!6><;^$(35:+8*$]9=:4O"3"WA-<NBT-YHU,EKH>2TS2@N(]#[
MI[HV/+SW9(W*7NSP*CVNV3]2+;_`5<J:!,V;P[V8?Y%O8[X\JESD\.P)%I-E
MK2CF!17EAMA_87\WK.0KQ<0)I/Z2&V/1NITQW/NZ^_)BB^L1&Y$B$1>W"4E#
MF6SRQK.:;!AEA&]DO=W5WQ]<)ZVHSLM=A9>68O&+('/8LWK5\_Y9LD)G9CZH
M^MPIK66_1_'GS`UYKJM)2ISY8!EU<UV?L>YL6NA<MDJ165@RD446M+WWGB3#
MSW-A9'5-U="78[9]UE,<_HS;[8%JZ37O&I:K&)-5PEQ3+'JY?TSY^Z!H\E?4
M=3LKP9XUMWY6A%T*P-3UW6DRS=B9/^6;:*4-E,524E+6(1*@5U6)'F6!;KG6
MT]6A'5DR794KE27_%2<H;IJSUKPAX5P(WY+UM-"R\)T5K)>6@P6*A0[[(^%A
MK*HQRSZ*KVNR%ZF#VV0!+J4/?I5UG87S$[#ZST$4??9SC1>VKG5J&H.KUL5U
M=V`90ZO?,P<7YE#6.AT8-]VK&_,XF__*_?XPL(5P(I59D?;NP^*G,E&"8]<:
M6'K5^5WNF<M>5+FV@(M^DZYLMJJ6C=W#NJD_PBI'0A4+CI(I]E_XCY('E4H0
M[9Y(0%D#+YSVA>G;?6?:0+M3S[2!VM=.I0D>^@0/OO1!"9DKNY]FFD^BMX<L
ME8.HY'D3J!:/=Q-P7-@O<,TD6ENS\UHZT4M5:HL*#M'1.V+6C9GU$QAN)?(J
M91?6)KNPY`KDFP>F]R]2FY0GI]+B=2XM?DC<NI8_"ZN50/Q),$LP2VQ,,/LN
MF*5\P+6'UM\(KN\3`?1/M=`I78BR@10L-%K]7@6ITMKP(-6BTK<6%96:*K$9
MQ,&BEARO:W4*+ZFW?YXA,*H9&&FO_L@$T\X$:S5:W58%/3>TX4%"O9JAGBZ,
M1298F90R&X.V5:"KJ`O7:'P8K[:1M*]+>:5:FFP:DU!7JTQG"%M!LP*[-&G!
M1617U<NNTAB!*C>==(:6',OT+=,JC&<(.P@[R*PALV;;`_X%%E/1@8L(FNH%
M31HC$)DUS\<SJ!L@Q72VC.FH$\)D_9#ULP>:G5K-EV5:RB+;0C@/6^^MH.,V
M1WO(A"(3BDRH=<0X+;`'7MV`AZ!&=Z@A4^J83:GR$\/KAFAD2AT6OFG,2F1*
MK3"E"HMMUPUXMH.:`MH(;U'2[UDI0%NX#_CWZ$O@N?;3-I7_.H-NQVAWK]N7
ME\/KRTY[T+J^D)7_^O#ELC/<3^6_RNOB8EE2VP9U&D=8DS*E)]8TQX)\WA.#
M_X^$.J>8=5!4U?_2:I"_-K\U%P`LJY,F6-LQ+5[I^C!&*+*2F7RJ'N4DZ9A8
M2?1Q$L"`'&L(NE$<NJ,D#L*HP6;)"%:538)HABTQU>G(`'M.LWO4)[ZLI0K_
M2XN=7@8^'HM5I5-E>4([%(X;,YC"[ZK`:=I*%$MF!JNGWH#7<>V)+$L8/\U0
MW&$&B2\K&V*Q6OR#YTY=V1L8I@%#(1T>74>P!Z"6B)_DHY,(9%V$615/K),8
ML21RL9@J/#JKQ-G`BH>/PO/P7QC(#9$*,[@1:ZUR.P2!P&J=3_#S>"RPSS:[
M%\%]R&>XR/`V/"TO.N6_!:&KGKYF<O#QC\0-YX5))5%@(5\(>Y$\UC*01@.#
M.?SI93"WR"?)HJC3P'?CM!906K\6J_6#^8%5'+$T+2Y(RAF/6-,8)#.*,JHM
MUBW"A>4QELVU>=;W&24"@]+S^I98*E=68)UP_WXN%K"*Z1/@MK'K"?EJ:75C
MO$V$#WC<5V8M`CN&7/X\QS-9.!<@$*0PG@?"U>M,^5-:5U-)$)^_\CQSI/</
M?`_5C/U)%AOF3TTVS&1/8#57F+1\[Y$`YL9BDMAA%UD$^1LF$]YC26P03F"I
M6/AGP7B\>-W)?`[`>@'#RK\-2;T)"#`P(0A-;I)`(!Q%X!A1VGC[!6=.^(-@
M?A##"PF?1:#LW#&,X\=%=_RM&F)O?29G&^+Y[GG1;#E=K-\+/P-/.K",,PZ$
M#F4IYZQN,%P!M,=)`%F>@K2.-"JW$&OW(E^G@CRO#?VX7!98KNL29]T#8F#A
M7F`FK.4L5*%J/E:_`9Z!;L-W0$"6-:,!CN0$Y+/S(RD)`!1;E!D/Q8/P$ZP-
M^Y`.AS,,5#5A'#B3J(RWX0>L"Y[IA4<7@'"$^.0Z*5CB((J`3TL,KB#U;"3;
M_XZ",)3=9UF(@Z+T1`F@N'JZPL?%.^:F@,SN@40#LZD.\<])@+#L!_X9H+_$
M7E7$68HSL'&(-9==+,4`$X(/=H!W2@B(E@0Z4RNN9/H`N/L_*XL_*_66#G2*
M*PF:YSO5LMY]M?!V%,,_TW08-<!ZX<S65(ICGB`[BN$JHVZ=<?;<ADO);TNU
M_3F)/X^'MIU,$[E:GY$>ET"A4$Q@TNZ#N)53V[K2\_#2ZO<NK)O^1=LT;OHW
MG<Z-J>R]BXN+=G]0J;WW=F,$HR)TNLNW;F:JCO&\&G.DRL1/YV"]D!2E>A;K
ME#*NG5^IE`NI(715I9U[[RSM;+5W+&-KU;3@;NTK"M,$#WV"ZT1Z/H(>=:]J
M7(^4*+TMI94)Q[[-+=:?`V7];4'UQ20[5!%Y-9DSA__K"\,M9V`S:6&S)1.;
MJ07:(02\VC#91\WJPR^T5Z_JZX6=TM9N)Y'8_)#KME.96RIS6X-T!LW*W&K&
MD&M9D`J&:\B"A*2$I#5@X^/CUO?#[!X[G&E31FJ7;9R?9%?-4Y4G\!WN0.8[
M<3YPUY/;&')?E'L;>_9$^;<SJ%9NV.Z3P/K7;:Q)%O[!5N%;E:)?1;&'G3)E
M:\2UE+^O<?[^H?)9Y<G]!PM[>ARB/&@^(P33&<'(\"/#;P?#KTN&'QE^1PR;
M!\IG9/AM5W6^0,-/&Y;1ISP9`92F]-D'*J4)?C'_DXV$+\9NO%-H=#XQZZVM
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M=1`KTD_DF))C6HI4T?&W<M7_J=&T2M?[=0O+45D"LAV*C8'ONY*2QL)&XD6N
M<&6Z4-/Z/1J+)^E"/82U#C)9N$5:-V$[BOU@?;+$B59TW(483E]:T7$7XBL"
M,DV)2`Q'0$;G]JIS"^Z"F'LLG#>H56V`HP;S1<R",6ZAU$=Z]RZQKZN%I796
MK=F?S`D2;!KTKO:D5)*\P!6@FN7IB<H"#X3M3G1M6)BRAHX-577AO+U6+-^8
MM'5$13F>U>Q5!X.Z\!RAW;&AG?8*F&Q(S=%RY2'H7I7HJ3T/$ZP>&ZSJPGED
M1.X[=:%?.36/HA'8SHD/W\?8K7OE]2L^__!]$IW=<SX[__HLCOHYB3^/A[:=
M3!./Q\*1!Z8O@^DL%!/A1^Z#4)GJ=_BX.R#.A1?8O__XM[_^Y8=LR&_V1#B)
M)^0X82*<GUT^<CW96'SY-J"]CP3^*L8?3VZN+,/L_+/U[[NK$^8Z\`.WX[-.
MZ[K?OQB8P_9@8+8NN@/KICV\[K6N^A>MB\N;[LF/SQ8L3_P[=RHB]DD\LJ_!
ME*^'[-SML%3B+-T',"WCPQ*S=8&S)$.X/FB`^+QE[;!1L`M'I(1DZ8F`B''?
M88$\RPXDC-PHCF3H>X+]VCU04O#&YZ]RT6M3WH!,2]K#>$86_)X?U`_"*?>6
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M\`";!2$Z&+@F:/;#)/!7:;X"QW+UMQ&\F\KGV"=X:%'80:<(\3L"P#H',U;E
M"?0&U"B3HK0:IX=JC$'%HLZ!@XO:;N]VBH.3NJ`&64JO=E`X"X4,O;)0C.!?
M:JA0A%KO%IGX0FK]Z-7Z\9U7;G4&Q1U8KHNDD"I;S2S7TYD7/`D!KS;%+2OE
MWN.N55K=BK1:`5K-,ML55+6JBZR25B.M]E*K#5K%Y;+415)(JZUQT((G[F$:
MB]1DGFMC1HQ_S\:"O+1"$FP[;>I[1_J,]-GN$&7VK.;&6Y:DSXY;GUV)L0A#
M&6F4D4?28>_789U^<?)'*HQ4V!&J,,N@YJVDPK9HZ%:*WJHR;50W.5REU]H%
MAO]W)FY=Q)D47W626@>!5")H]`K,37N#:G61M/<JSGY=-:>JH\;7GBPKA]&H
MP`,5>-`#4E?%GQL#LT]UPL@&TL4&V@.PZL)Y5.)AOT&81M\<-%O50:$N?%>1
M+;IKO8;-BRNLK\GP5FV'GX-H^T(-@Z$UZ+>O^UVKV^ZT>M<7G<M>6JAAT&X-
MK?T4:L@QPE+AAETJ/.]D9.<K,C!5YR!*IE,>PG61+-A@3[A_#Y]A8+Y8FWEU
MA]SJP"6R2>2I!POT7;[@,1L]R4N!(V%VK[+C:R1\[=CF@9>"`(K?N[YZ29[$
M0?:#,A3D+ZI:A&D8Q=6'L(QW%HAHU;1^0NT+1-`$:8*:3Y!JF-2FALD1577X
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MA3ICX6G+;';)N"3CD@"5`)4`M0!`'11Y)I(`E0"5`/60.),`M6A`[531?8$`
MM;I=*:.NQV<_OY6?ST9B'(2"A<\Z;%*EP"*`PM+5\-*8;\FVTKV2Q9%)<:]?
M03R*XN\D@22!:R2P30)(`D@"N$=#MFL6>,J>+%D28Q+C/7"?.:#V8ALS$H65
MUH>5AE-8^#C*18V$P\9A,-VN.$0I,DT549=EOFD4)O)4#Y64<OE*F01XV?8V
MS7Z!:ON]U"7CG'"`<&`/W*FHW;=,JSA]10J=!)D$F029!)D$F01Y!\N\1Y:Y
M5I;Y^X-V9B4@L(^@W2<1,SL)0RR,,X.K@GU%Z(X.)B@+C-SSVAD#QR;%;:-I
MDAB3&),8'[(84RH9.=4D@)1*1GJ4Q/A@8V.;G_+3%`,&O;+ZUY4=-Z,#EF\M
MR_%T]7Y6UO.;F,5I74]#UO4LJ0LN-2>EYJ3Z0GN1Q9O>372"=K(-Z]3VE"";
M(+MPBA=:;X^:21/<$MP2W!+<KB\*TROK2`Z9R&0B$V839A-F%Q[5Z!H%EOPC
MT";0)M`FT";0+A>T.[T"VU01:%>XS_A]C$VQ5UU?6=@F1T.8OCB;J-:)IF5\
M^,=KK1N7'YL;90D9L32(',7U`?35]_QC_""<<F^)4TR\9CZP)!"SA>>EUWP\
M,4[D=V`&._N^@E!W[E1$[)-X9%^#*7^A;Z8\O'=]]9(\B8/L!\6]\I='UXDG
M<#40(F536'6/SR)QGGWXQW.V6[QW?@=YD5YAK$Q;V&`36K[,QY.6^>%-J5B6
M]O3&G>^K_($T09H@37`/$]SI4-D>>@SO;`E4UFWX]-9G,)B'!<9W.EM&G9TW
MIO6O?BC@'?XC'/83=_V(G?X<1)&(OF.!S[X).P%KR05+8/C`74\:$^,@9-\X
MF%T%F<SD2Q/C%LVXESR:L!M88O;?PKD7V[0I(%XE7BV>5\?@\`.G?HMYG,@T
MT"]!%(<B=D,QQ9/6%\(78S=F7SR^55,-XE;BUJ*Y]0[&B#S9WX4-G=^2*$86
M):XDKMPK5P8Q]W:($>Y:E7=78AYJ2';5684K8:='%4QY5*&P$WGE'F?2D+"%
M[>O4>7=&CM<I/,UT_QRSSV114K<$101%.U'JU&H55[CMJ/9WBTW#(0@C"",(
MVPW"S$%Q]A1!&$$801A!6+409AJ%'X39/\N01TA81%AT<%B$I_+((RS?G**N
M>NN)^/FM:MQL),9!*')M]VRYF;?-#M[&%<UV`4O=:H\I,Z.X0P!D2!R-(7%\
M<M+I%7?$D02%!*6V@E)@`5N2$Y*3VLK)::_`SB<[^52Z6_P4A2;Y>L\64('-
MO8];OB@LL9Z(PVF0^'&4BSH(AXW#8,JX;2?3Q..QV%<KL1*R:/44]6Y9Y6?6
M$^TXD8`T+8GGUMS5*["ER1LT(X^1Y.QHY6P/K;-)WDC>2-Y(WDC>2-Y*ES>C
MV2<YVT[.J..[_AW?:R.?IYWB>D!3F(74(XG7TGC==G'ZKR[ZC02%!(4R4$A.
M2$XH`X4,MGK(5QGQC(/J"9ZFKQC%"6<IF]IT).<EO:F]=];>N[K6$N7B@8:D
MKZY9RIXH665(N<*^5;KP'#D:^A[")K0CM"N-E&VSN``]P1W!'<$=P9W&<'=J
M]LO*/'V%G.1#$TH22A)*'@Q*=@O<!2"4))0DE-2%]0@EBT/)5K_P<HR$DN_;
MCUG?!GG5YQ^^3Z*S>\YGY]_LB7`23WP>#Q='=&5YL<M\YN>M3/S$[FIW^)P[
MH,J%%]B___BWO_[EAY=C7221ZXLH&MI_)&[DRLIC%T^Y;_,!@/P^TOBK&'\\
MN;FR#+/SS]:_[ZY.F.O`#]R.SRZNVA>7G?:-<=%K#8>7_<'PRAQ>]UI7_>'-
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M71L>K@B+WQ]_W3QFNB;H>LG#\`DX^U_<2T0T])WK*':G&,^]X6ZH?OT\OA*C
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MEJT63(^>[Z8^DQ8O+-UTT@O%ZP42FHUY,`LDD>"0X)#@D+8AH2&A(6VSN^!0
M4LV:HM-!+"(VXT]RJR`.V$TR%0Z08I^(I/^.IDZ[\K3I+D<?5)#`I`W_[;.&
M2*&1Y)H9'P2%!(4Z0&'YV=;:\!^54ZH7XFF,7<6BU8&?\Y#CF59QB8X$&@0:
M!!K'`!IFLT>@0?&IC9H,-?N]S@?V3?AN$#(5K7(2P7[AH3U98(]*I-BF'1$=
M!5OC/'3-=H&59>I^%(R")07LU)`(+HM@I]MM#D@$R=ZN7-+J(%!*B[4*/()'
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M364WS]68M*66GRRS/Z[.59U659%I=/M&66[`-J2M"TZ2,[^[P4+02-"H$S3B
MJ>[B#I02-)++IA\":@QT%4/;@2.8PJQVK[G-N;'W48R`B8")@(F`:9,=_'ZK
MP%.8QP),N:#;]S%V?EIY_8K//WR?1&?WG,_.O]D3X22>^#S.FH?)?ES1T'>N
MH]B=\E@XV(M/_?IY?"5&\:T?Q6$R%7X<W>%3[X!$%UY@__[CW_[ZEQ]6C1Q-
M8#S\Y_J/Q'W@WLM;815\)/57,?YX<G.%+;W_V?KWW=4)<QWX@=OQ6;M_==TR
MVKW+OFFU;FYZO6['&E[W6E<#X[IUU6J=_/ALZ?++<.=.1<0^B4?V-9CR]8B9
MNQU86)Q-5+LRTS(^+`F:#%A*WG!]0.#XO(4_5!)0G`@V#CQ`?W@7)I>=1<ET
MRD.X+F)!$K*QZW/?=KG'>!2).&*/;CQAL)8)<*(K9/?J%SQ6Y#MZ(HI8/.$^
M&Q@+?>+PIZC4Q[)Q&$SAN8(YP+<XRUD2VA,>">;ZMI<XPH$/S`9&9-QWU`>Q
M8$D6^/)N;MO!%"`!Q0$9$Q8X$KAAXLO@/<H$&W$/:`RDGP@1G[\JL:_QU`9\
MN*0=C6=LA]_S@_I!..7>,JOB-?.!%</8PO/2:SZ>&"?R.X"@G7W?7H(>72>>
MP$>84XJ_@*L>GT7B//OPC^=8NGBI_);!'(_[*S>)-MATD._R\:37^O`FTB^K
ME?1&<]?[=K[Q4.ZKYH';;2:5N$M9UG939<TU3V]]!H-Y+D#7=UO85_.)O;?[
M:I7Q[->7H(H.I\MAPM5+,IRKWU6FWR)EM64TUEZ%YA%YK\5G0E"OX8V1Y74V
MOA)VRL7FJUR\L<]'J>^K3=[+8#H5H;3U9WPF7N^9OJ\FEQH3L=3=LN/9#+-,
M*J)%\>2*XLD4+MZ`.`>*+2H:W"YNEZHNH$$&T&I>^0PS]_%M62C@8R3@WWG4
MC]^'0LA`]2[>`)6#>'8FJ-^G`NJDY?=P`J$.`B7':QF=XK)IZR(II-I6,\LO
M0,DG-N7A[R)F8T!*TF(%:+%6PS0'5-2(]!CIL7?H,<LD%XWTV&;,\FT2A/%9
M+,(I<\0(AA5VFHA2BCZC2@Y+^J[=ZY256D=U'$@;EBBI=1!(I2T[U95#JHN@
MO5>9]NNJ3>E`^<'M`].IR9SWW3<*W-VA4Y-DD&B(@!H#7<70=N`()L?KF=T*
MSWG7!9@*/IST]A&B=:>/@NE,^!&/W<"_#*+X)@B_37@H+G@DG"_\";>'AR&P
MQ;W:*1YZ,)B\^O-X<>'S4:*+IR\>][<^Q&1>68,+\V;0,X:#2W-X85VV._(0
M4W]PU6E?&7LZQ)3C(1T/-46X#F<CKD[A+%:"B3_QL\!S3H'MRH,Y\JR3X/8$
M\U/Q--3:FV=A<!_R:42G=\HXO6-VWWE\I]VIY^F6VA_?H0D>^@1W.H!%GL;B
M=7MZAS[W=VP$K"]YQ/9N$@K!?H%K)M':`R+7/I[873H216XQ,6OES/H)3+02
M>96.N])QUX,\&;C)<5<ZJDI'5?<,X]N<,R46K`U8IH^70937M\GWS[B$I(?+
MQH2DE`VY35:_RN>/8MPP2'QWJ[-IA0NU%OOC.N5J'$\J1H\.\VVC+TB?5DP?
MC1&H6,PY<&A)P:2P$U6$&8099,Z0.;-M9FF1%:1U8"/")CWB`\=SJ-.@,YT4
MQ=@P8<^=BK,'$6'&70C_A*Z-'W>+:E"M@G4ZS2"=1CJ-=-KN.&7U2:>1H)1X
MAOG(--*@3:5S2-!((^VND?K=9I<T$GE9&U5WQP9%D8AC#WRK&8@NG@_"KD/D
M816DSTX'S<*2:MZDW8+Q#GO[:P4=M\FV)9U(.G%Y/+-#7AH)"GEIA57J[E6@
MU4C02-!JJY$Z!GEIY*5MQBM?R#$KP3&SFGURS,@Q(S6X5S78[)$6)#DAOZP@
MO\PLSJHDOXP$[?@4DMFE_DGDEVW&*]?3F1<\"9%F)<Z[`LX\[I>BS:CSQ')3
MX.JJWI,R)&58F)S601Q3`2S,>SN6MA,D9Z0/2_3^"K-=22&2H))"W-I[+/"$
MV[%HQ'=ZEV9MW<MOR2C>LA<3!4;7N8K469Y4'P5&W[-3UR\NVD*"0H)R[!K)
M[/9HKXXDC532.[RM08N2*`MVIVKK35WRF0O.%/SHK._896/G-0I5EJ_]"LV^
M?"]M*3N3%"R%.W?`5)#BDOJ6KB=:7825Q%-7\3PZ7=POL`@8Z6+2Q8<D['60
M:27%11[))5U<GH==XPW+M[IHN[[M)=C&$,:56YO2X6;<=[)+"NM5LLS"+6!A
M)TBPM_5[!%^+,*M.U;_?(O(1E0>W.F7A[S9TK4L4DTP@#>%/8Y2K&-<.'+[4
MAGZ!=0+?)!CA$N$2F65DEE5.5+,S*"LEE^PRPC\M\$]CF".[;/NLEGZWP!+H
MQV*8Y8)RW\<<9KCR^A6??_@^B<[N.9^=?[,GPDD\\7E\F0M>7091?!.$,K9U
M@:&M+_QI*OQX&,+:W@O\&`T]+[#EU9_'BPN?CQ)=/'WQN'^';W<'I+R`FW[_
M\6]__<L/+]_@"@CU`'<^B%L_BL-$/N8G[OH_!U%TZW^+>2P?_7E\X_K<MUWN
MY:J$S4>'!?5QU;Z*\<>3FROL\/W/UK_OKDZ8Z\`/W([/+B^,CGEYV6L;IM%O
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MZ1Y=)Y[`1YAFBGZ`:AZ?1>(\^_""Q18OE0_H+]!PL'++9X,]`?DR'T^`YF\"
M[3*JIS>:5=]G'<J+UGZ"@T-YT8.AJ-X37`<A2RA4^5[W&\[9ZU:B#8I!A#F`
M[A>KKG$X^>U1Z9Q1X#EJ?+#8I(Z^FX1"L%_@FDG$KGW<>_PF9J!)1R)D+:.Q
M@WFY>G%H;39>FT\B9FC*1M^?HC4KHM=WWG5[_:_"]G@4N6,7F&D<!E,V_'QY
M"R99'+#/,Q&"U0Z6W:VTT`YE8NK/..RY3)*WTYR2:VGB@A?"O@0A^C&4PU1"
M#A-AQQ%A1W#ORS,H$B]P.O5`BEM?[(P5VR54[4\H=@Z/5<9?/Z=A*$+IXE&Z
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M+^I(TF#0[!L=H]NWK"X0I=^A`TK:'L:@"=(!)6*9S2"$#BB]XX#2)U!A=#Y)
MJZ4Y_#,&=#Z)G'\ZGT380>>3Z'P293L?"4IKGNV\>41N_ZARF*G0A<4\Z\OC
MQ\?*:YF7CCU5M$U&A@`9`@<%DF0(D"%0=QX_/E9^OR%`IZGH-)4>)A7E6E*N
M937=`\Q!@1UNM>=`RK:L&>;IPEB4;5ERZ\_"&@90MB4AF$8(=GBN`)W".C0>
MT]\N(\]`.\^@TRQL`T5__B._H&:(IPMCD5]0JE]@%M?AE?R"3>+B[V\]5E#C
MKVW:BJT9-8A<W*&]X6[X+^XE6S85Z_:-RU[/N+X8#"Y:_0OKTE)-Q:ZZEMGJ
M45.Q=4W%QD!N]H#T9MQWV"P4$;RBW"L'I^*U#F$C[B$+L&@BA.H2AA<'21S%
M,!(^T)FO?H0.BI?(7^-)$(FW^Y/MWFQL@_4[C)-^)706Z[SSW%Y[UZ,_.]^X
M\R&E]EX/*6FP6WQ@*3JGMSZ#P3Q`GC>RV"D9ZGV4ODB1^QLB-]LA->I04G\T
M2XG8)+L'S1\F[1\VE$IUZ7@>VR;Y9SMH`L)J)0VE6$7JZXO3&O^=FA^WFYH?
M%$_8)IZP.5SL%P[T(MP[Q=>LH_S*\891!&HKYUP<KJCN;\-(M8Z.P?D"8NZ5
M@FN%7F-"ZKKCH7.(<-6F1KNX1`(MV*C,C8L#28?52XGJ1Y]]0/ZM#UHREG:M
MC/(%4@40]!/T[W$_N["M(BVX2!_D/R)/X&>7CUS/C9_(&]C9F;+M,!$.2Q/'
M<OJ!%`,IAGT<@>B19B"?@'R":L)`7H#S$N&4>:DN=?>K0;4064+^?="L7UP-
M;RVX2!_@/^:]/85SBT0TVMFCG3W:V=-.>FEGCW;V="`DV7+%>/'-'MERI`XH
MO+MOC4KA75(,.BF&3M,BQ5#OZ&YZ;,8R=CCE5/=(K]:TVMB;WX_3K@^MZ-`/
M'?HY-$KK<^BGEF=[5A/]Q6F>*V&GAWE,>9BGI&*HQQSPI\,\QVPD'))A<$2A
M'(KLURJRKSN]JJS9HW,`1H[7'1276$&AE>/6_IK1AP[3$"8?)":;S0%!,GFX
ME-*FG88C_Y;\6_)OR;_5FEYD2RW94H6US"%;JN8X32EE-4TITYUJA-BY\0IL
M9E!#Q"ZIJ/>V9;?7E/2^YJ$/_!9]$>&W"0_%!8]<>^@[5ZZ7Q,*YPW??IG1W
M[^*Z=S'L&,:PV[^XN1Q<=<P;5;J[TVT;EV:EI;N[LS_W4ZE;4E$BJ:/HR$1*
M9S8#RSA"2C/\'PB`G7A9W6Q5W)MJ99=2*]OLOK=8=J?JFM<[WW@H]QW,B]($
M]SI!VM][9_2SMX<DO\-(Z0M"V3CC;A(*P7Z!:R816V?]78.6=)9+>!^NLTG,
M>K#,^@E,M!)YE?+A]YT/3QT92NO(L$W+!0+MZCBUE@RYE@4+"Y@1"QX,6&[>
MSG#_C$M(>KAL3$A*"6GO2DC[E$Q%R&,`@%+8EVJ'$2Z6P5C$/\0_!$S$6-HQ
MUC'R#UE;JS,#/HD8FV<'4\%X'(?N*%%;Z''`+MS@7OCLUK>;14GILJO0`E?!
M"1)\W'M\!2T*->E4[NLM(A]1/;!!M\A.0#L3MBYI9*2%-<0_C6&N8F`[</R2
MX_4[W>(.;[Y),0(F`B8RS,@PJYRH5J-G%IBG3Z89(:"&"*@QT)%IMC6UK(;1
M*?`TZ-$89Q1[VW2G\TKXP=3U::]3!XU`&I.V%(A_:*^3&$L_^A`PD;VUM?W^
MOS)=#X\V`PGXO6!^(H^B!&-XV>DT\-5!Z(@%21S%W,?I[<*35I5@MT5>Y-YB
M/2V+VO(0^I>`_F])6AT$*A6A;G$B1))"DD(ZJ=TT22>1I)%.>H].*BRWJBZ2
M0K[7:F:Y'H^%':.K)2M0N0^"1<).8!G<[0I,4TB)0DH44B+^T8X^!$S$6`1,
M!Q;KKF\IZF\Q%D@-9EA]5151%M.9%SP),+SDGV9):$]X)-C,XSLU:J60PG)(
MP:"``L$^!11VAZP"!8CDA.2$]!'I(Y(STD>DC[0);]?7W<+^`6?8N54X+(1_
M0M?&C\K52GQWJX9CI-+6JC3*(R*51BKM'2J->K63G)"+59@^*NXT(.DCDC/2
M1Z2/R,5:PRN_\/!W$9?N4E59E%TWF2PYBK@K:>LBVJ0"JY/3.HACX3&/-VA&
M<D9R1OJPNA`DZ4.24]*'I`_)I=R32WF5G469!;'P8Y=[RY4`2*%6H5!+J@))
M"I44*BG4311JGQ0JR9FN<G9\^K"DAA6D#TE.21^2/M3/P:RM?_E-U9-+(N$P
MN!-(8"<>CV$2J@P"_`P4]^%[Q&8B5%YG^<*[2^N!K1H_%-19>I\%ZS3H&K4Y
M&0\8.DA%5RCEM1?F5'Q[3:,Z\24I)2DE75QFH;X>Z6*2\KI)>>V%>:Z+*^SR
M=0Q2FG.VOY?-FE=>O^+S#]\GT=D]Y[/S;_9$.(DG/H^O4_?SBPBELWK!(]<>
M^LZ5<D_O</P[(,:%%]B___BWO_[EAQ5CR-I^[H.XE8VD[_B?7WDLO@H[\&W7
M<SF6H%D>"*CO(XF_BO''DYLKRS`[_VS]^^[JA+D._,#M^&PXO.A==LU^_[)K
M#:Z[-]WK7G]XW6M=]:^&@\M!_^3'9TN6)S^>QHS8)_'(O@93OAXV<K<#7XNS
MB:P0?VY:QH<E<>R"[$F6<'U`H?B\A<)8A?@,6;A$1C82\:,0/HLG@OW:_-9<
M@-A8`.MS#Y[,XR0.PB<6\S]9""LAJ_\$2<A$ME"+/[D1BY+IE(?P7(?QB(T#
M#_#VC9*,K]$M)SJ_)5'LCI\V(?\2&AK/R(W?\\_Q@W#*O:45,O&:^<"JA[DM
M/"^]YN.)<2*_@\S;V??M&>?1=>()?(1IIE`#,.+Q623.LP__>`X=BY<*5^D1
MTUJ)VQL$U^3+?#QI=SZ\B6S+&)O>:%J[WECU??2BA_FBVX6%R<A\`0X=O?=D
M;`!G$>;FW2]6#^)P\MNCPOU1X#EJ_)L@E"KP;A(*P7Z!:R816V=878,6<=@W
M,8N%[/?2,AKD$1&S5LZLG\"$*9%7#P1MU[M6)2R(!OOB>R[W6[$$+$?P5LL#
MNGL$P/L.214#P-HSY%H6+"PJ12QX,&!95/R4D)38F)!T:R2E-+%UM=JSD"W&
M9(L2Z/(2IS<GX;YVC5N=`C-`WJ+C@M'*(V05O+B"C@L8_4!ZIC`]4SA]=);.
MPN6Q;F)'@K8?02/]2/J1]./!B6VY>5.:B:X>RE.;M*J*-"OYJ>O]5)D[M%5E
M#%+":Y2'2=7L]ZH52&L>KC@5+4`D)R0GQZZ/"BS&3?J(Y(ST$>DC<J76]0M#
M)XH%/AL'H8`GS^M`D")[OR([-8T"SXP><7CS.U*'I`YWQKC307'MD>HF;"1>
MY-55IPS+;P1=-_DD94C*L%AEV&\.2!D6H0S)I5Q-P,M0.&X<R=/^OHA9,!.A
MJC7H!5'$DMCUW/_(*@*D5HM0JZ152:N25MVS5BVP6G;=A(W$BUS,BG2A49QM
M2[J0A)5TX8ZZL+#"]743-O(PBR#@ER2T)UP5LX^Y?^]BE34>16*K5MRD1M?F
M@U+^#6E`TH#OZ-Q2V*X_R0G)">DC.I]`<D;ZZ!WYH(5M$=1%3LBU6LTJOW`_
M&7,[3D+<L'.$D]BT4U=0=-*BG3J*3I(NW'-TTJ(*,+13IX-X';DNI+HOI`L/
M1UCK)I-9[ACE@M).78D$_!R#D&)+Z2GW!0SKQF)*>W1T1IYBHJ3[]KU'5UCA
M?9(3DA/21X7E/Y,^(CDC?43ZB)RJUYRJPM"VRDXX.DOAVJK*?<NTBK,1=B5W
M782:E%^Y#%0WL<P"E<6E@&U(P.,,9))XDCHMST<LK`P3J5&24U*C.YS,JTP"
MCUN-OM=U[=?5=[T>CX4=NP^R?4.Q;0:7&+(%#.D$"1X,+$7U'FPGEQ5ZV6J7
M!0N[K,)1=(19&VR@%DY[,P)6,.M1(4.&!25YVJ^0]RA$GH1<4R$GNV"]75#<
MIB[9!607U`8RC@H9%!9TBBOJ0W9!$79!+L3P?<R!?"NO7_'YA^^3Z.R>\]GY
M-WLBG,03G\=SM_S6MX.IN.-_?@77_*NP`]]V/5=6:[W#A]P!<2Z\P/[]Q[_]
M]2\_K!AH.O.")R&^B?#!M<6W"0_%!9;JN0RF,^%'<J2A!R/(3Y_'^(Q['ZCA
M?`'J!'!=%$?SI\!2^;@>7\7XX\G-E668G7^V_GUW=<)<!W[@=GS6&?9;P[[9
MMBX&W;9U==-N7PV'U[W657_8&K1:[9,?GZUO?JWNW*F(V"?QR+X&4[X>EW*W
MP\J*LXF0K&E:QH<EWNP"(TK^<7V`N?B\A9Q9!0/=300;!T#71W@5)OF!1<ET
MRD.X+F(1KL/92-9,LG,KP<2?^%DPU[>]Q)$5E5B0A$AW!_^`E_M2EH`?4*[A
MGRG,+&+!&&\"9CE_E6-?H]P&U%Y"6N,9=?%[?E`_"*?<6UH0$Z^9#ZSH8@O/
M2Z_Y>&*<R.^`!W;V?7L^>72=>`(?84XI#`'$>'P6B?/LPS^>P\KBI?(!P@4T
M=9<P:XL8HWR9CR?MSH<W46\9M-,;S5WOV_G&0[GO8%Z4)KC7"6X7_2>C_`7X
M]4ZVL2!+V+U[W2RT0?F(,#?O?K%J'8>3WQZ57AL%GJ/&OPE"%H.JOYN$0K!?
MX)I)Q/"AJ_:2KWU4Z-_$#%3V2(2L933(@R1FK9Q9/X&)5B*O[H2V92Q*6;NQ
ME2W8Z:W/8#`/'(-HFXRQ^<1:[Q2%0D.Q;RS'_J5F.=BW>DG0XR70+AZTW\NI
MM63(M2Q8V-$48L&#`<O-XZG[9UQ"TL-E8T)2.ORV1:#[JXC`=;`GLKV<(QZ$
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M"I66!ZH@Q50`G_K(U$P\CTX7]XOKE4BZF'3Q00E['61:27&%J7!U$];MQ)/V
M.M?M=6Y3%57NBDJ/6^;.II=$%%LN8)^TR`0&"BV3LCVZT'*G2Y%E$A3:[2QL
MM[,S*/#<.ZDDDK2C4TEFOUO<V<6Z2`KM=JYF%M5V1/8$%;(5"<51*XBC=BF.
M2G'4FNK1XXFCF@7Z?A1()?G40SZ/3AFWNTV#M#%IXZ.4]CH(M1+C3J<ZH[IN
MTDK;FM5O:_HB3OLX,A['H3M*5)/$.&`7;G`O?`:^>;,<CBZJLZX.\56=*CR^
MN]=V\?"QMT#^H/`":CO0M2[A2S*)-(0_C5&N8EP[</B2X[6-LMS`%00C7")<
M(K.,S++JS3*S57A?`;++"/]TPC^-88[LLNW365I&<85%C\8PR\7HOI=QI977
MK_C\P_=)=';/^>S\FST13N*)S^/KZ<P+GH3X)L('UQ8RS'6!4:[+7)!KZ'F!
M+3]]'G\5=G#OXQ'Z+S##`*Z+XN@.R'4!U_S^X]_^^I<?7C[EAKOAO[B7B&$4
MB3@:^L[/+A^YGAN[(OI%\"@)A?/9A[&3,`0NAC=PHSN<VWQD6#`?5^6K&'\\
MN;G"SI/_;/W[[NJ$N0[\P.WX[&(PM"ZZYK`];'4ONUWKJM?M#*][K:O^3:O7
MZ;=.?GRVROD5NW.G(F*?Q"/[&DSY>G#-W0[<+LXFJB&A:1D?EF12AD*?LY'\
M[OH`WO%Y"R^H0LKN)I@$!+2,V$B`^F"S4$38W<_UQT$X56%,/@J2F`5)R+A<
M(GD>PULL$HLG/&;`'"P4]XG'0^^)3=.%D]?:'%8./\=L#*O-'G"YY5]@OB"M
ML9!]RSWL+L@>77A[7_Z0NWCBBA#;$#ZQ8"S_AC^KUXN%/?'=/Q)XD4?!DMA5
M11SB@#DB%N$4NZ%'B3W)#7?^JCQMNHSM5Q8I-\:2+C.RE4]7&K_G'^(CU;UE
M;L%KY@.K:+$M/"^]YN.)<2*_`V39V??MF?C1=>+)^6#0[!L=H]NWK"[,M]_Y
MD&$G8*+'9Y$XSSZ\8.#%*^9W!Q98VEVY@;3!!H-\M8\G;?/#FS"]K!/2&W>^
MSZKZ@31!FJ".$]QNZZ_$/>BR-@<K:TD\C%"!?1.S6$Q'(F0MH\'07F&GMSZ#
MIWB@T:)M4B;F,Z:^T!LOPMV6!7?)UR<>+)H'_YD$L7`6Y/X2@HOU^NEFW:8`
M=P_M-SL9Z?;6O_#P=W!B#NJ=3W^6KI%)N70$6OODPV_P>'<,)`("SVG^&=SQ
M\*#$Z?,(KGV0X;'Y+&[]67*8J&`1*A`JZ((*AR0_O_K!`@@.Z<4/%ZM:564;
MUS'96'W%8<YEJ6(["RE@4/[UD/:N(%?DH:#MT4T[[:`-L>JK5HGCB..(XXCC
MB...@^/H5-G:AA31A(D_$O>!>V"V;U/XLG`G7XN$3IU2BX\G<[C5Z!MMJLU&
M&G3?I@?A%N'6%C13#-BW3*M\T27L(NPB["+L(IN+<(MP2P=N(]PBF^LPL(OB
M7VOB7RI/3YYV<<0(AL4#8/*\$6UU[ELOD$(ECB..TX5PQ''$<<1Q^A/NO2EM
M_;J:>I=!.`M"/`;^S-+;A26IM=*STC\-HS5H#L@A([U0G5X@(:3("`DB":)V
M@DC:D(20A)"TX<$)(CF/:YS'GU#N_2D6+2/'L4@IM1IMTRRPFG_=)914):E*
M4I4DB"2(=11$TH8DA"2$I`T/3A#)<5R78!:$\3V_5X6H`RQBI>I;,V0)X9`W
M6:S^;%/8E;0G:4_2GB2()(C'+8BD"TD$201)%QZ8(-)1I;>/*F'!GOB)?,=B
M]66GP%9P=9=24I>D+DD"20))`FLE@62PDB"2()(@'J0@DN>XQG.\@K\\<.RA
M)7L8A]S>JM`K">D:(>V:S39))ZE)4I.D)DD021"/6!!)%9($D@22*CPL022/
M<8W'^,7COLI3C=@X")DCQB(,!8K?=";\")S)P"]%:M]H>'EL4MWJ-[N%B?.N
MM*V+N)/>K4+OD@27KI=)D$F029!)%9,$DP23!),J/EP7NMVNJPM]%\3<*X?-
M6L!F3I!@)G#&9[M(K!:\J5,/E;>(?$1-5GJ-;LMH]O=/VKK@)!D\NQL\&D%C
M^C2\]:6R)]PL'C?+('@M\MMW)KHV+$QP2W!+EBA9HF]:HD:GP))H9(D2-!(T
M$C36`!I+CV<>(SR^MY)=#>.9ZBL.<^[&\%A;/>%GEX]<CYJEZJ%\2&L3QQ''
M:4(XXCCB..(X_0E'">#E'!E^E0/)#:X`"NOCY;;,9JMTLM7%>R456I+M0:!%
MH$6G\0B["+L(NVJ.761P$6@1:!%H'11HD<%%Y0\*BWY=PF_PQMCMV0[\R'5$
M*"L>L&`$+R(_EE-`CPYL+0EUNU]D6:%C/ZI%IDH!VRLDPOO7RR3(),@DR"3(
M),@DR"3(9%0?L`]-]0]V8#,Z6D%'*THF:L>T=#BK6Q>4)$.GK)18`D8"QEJY
M@02/!(\$CP2/APF/A>;.$"X2+A(N$B[6`!=+##H>(S#FHH[?QQRFONKZREXL
M1S1@$G$V$1)"3<OXL/8AN7N6L,8`WI:4=WV`4?4]/Z@?A%/N+4F(B=?,!Y;D
M8+;PO/2:CR?&B?P.:VUGWU>0Y<Z=BHA]$H_L:S#E+Q#\T77BR?E@T.P;':/;
MMZPNS*_?^9!Q(S"3QV>1.,\^_.,Y`RU>,1\H7C!A=^7FP0:Q9OEJ'T_:YH<W
M^7M9RM(;=[[/JOJ!-$&:H(X3W&X7:,.]L^J-V/4JKU^LF=#/JLH\*E0?!9ZC
MQA]&+!BS*V&+Z4B$K&4VF&68;79ZZS-XB(>IE]]M84AL?BZ^^M5X?05L4'\B
MW,<:%+IU1ZX8\>`.//C/)(B%LR#WE]"UQ>M)U[I-`>X>VEA"X:#>^A<>_B[>
M*/:@VSN?_BP>A,?,;10#@1:!5M%\^`T>[XZ!1$#@.<T_Q[`R!R5.GT=P[8,,
M*\QG<>O/DL-$!8M0@5!!%U0X)/GYU0\60'!(+WZX6-7:&*NH3.VF96J'LHUU
M*15JJP$Q[90`*4GB'^(?XA_B'SWI0_Q3GN%4XZ(7/)HP\4?B/G`/[."]EGO5
MG5:%Y0@=>*:/'*]G=HM+>JQ+A@ZI*4(-0HU7B%'"01+"#L(.PHXCP`ZR.`@U
M"#4(-<CBT*.*27V#(BH;2AXI<,0(AA5V$I;7\O`8`W*DMXA_B'^(?XA_M*4/
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M>2-Y(\5&@D:"1HKM`.7MG7Y?NUU7O^\NB+E7#C>U@)N<(,$TP<)$44,*%E9E
M?&/J'7(9<JLQ:+?*LA=6T*PN`$8&@X;0E`Z*5^Q7=1X\;I5!R8/,5WV3F-KP
M'*'=D:$=`5K-#+%6K[AJF&2($301-!$T'42<J\;P]-Z:/36,<ZFO.,RY&\-C
M;?6$GUT^<CWJ9D7=9"JE#_$/\0_Q#_$/\8^&]*'TT').P96;=ZTAO:CU<&Z\
M3K-=%#GJXJ:1HB+,(,R@,RR$'80=A!UD;Q!F$&809I"]H2-V4%!D;8MO/X8W
MQH9W=N!'KB-">4R6!2-X$?FQE%)!1W/@P3([S4Y1XG@L1QU(U9.DZ:#^2-Y(
MWDC>2-Y(WDC>]BYO9$G2H5DZ-*L/!2DA>BOTL@PZ,DN&`IW4(&#2"YCHI`;!
M$\$3P9.F\%1@(@#!$L$2P1+!DN;!J!H#4RX:];UL/KKR^A6??_@^B<[N.9^=
M?[,GPDD\\7E\P]WP7]Q+Q%"6O![Z3NXXZ"^"1TDHG,_^5^QK&@)_7?#(C>[P
MJ7=`H@LOL'__\6]__<L/+T?^*0B<1]?SYM?)`Q/PY:L8?SRYN;(,L_//UK_O
MKDZ8Z\`/W([/+@97YF7;L#I7QK5Y,>RVKBX'P^M>ZZH_:%G==OODQV?KE*?Y
MG3L5$?LD'MG78,K7PV/N=N!7<381$HU-R_BP)%5=$"')!ZX/:!N?MU"F*HFJ
M300;!QX@/;P*4_UE9V'PX#HP/PY<['E8FOR1APX+QBR&R^T)]^_AK_"@(`G9
M?4I[-N(>]VWQ^KG>UPBR`1&7<-QX1C3\GA_4#\(I]Y;H;.(U\X'5=&WA>>DU
M'T^,$_D=Q-7.OF^__(^N$T_@(\PI10I``(_/(G&>??C'<ZE?O%0^ZCM'CO;*
M"/\&<6/Y+A]/^KT/;V+2,@"F-YJ[WK?SC5O=MUVXO,0=F+("ZOUB);^?G<U_
M5#(R"CQ'C7]ZZS,8S,,$JN^V4)0;GVU\B^HC;O]^'P:)[Z"X!.'Y_W'D?^A0
MY)M\75Q)"6TJG>VBS"Z4!FHP'J&RNA*VF(Y$R%IF@X$)4)A?N@NIUW+WH5(\
MG875Z7%[5+1'\A84U+&JX0J"FHU>UVA:I9-5&Q[4>&>]OBG5M[X=@O<E6!S,
MK?E=#(`W$U^*5/"Z9;RLD-YN>U!@+'0=\4@\:RZ>G\'I#DN1QRH-\@.0UU.C
MN%Z7[Z;M@C\/.U2]@LX;>Y=45V\C/^>;F,6IHV-(1Z>Z.#=Y0F5[0F^6)B=7
M2>WO--I&O\J2\-IS\<'L"[W8O5FSRW/K/P@_#L*GRR0,X=/RUM`&6S[7K<'E
MY75G<'%M=*W>Q45_T+E06S[=RU[[NG4\6S[88!86W8^E`G$SPC(>"A8ETRD/
MX1X']8O:''JC6NL1[>H,!LV^T3&Z?<OJPOSZG>+V>/KOW./IM>JYQ[/'^V@3
MBS:Q#FD3*[<$-H"G",M=A&4[;/62#*6*66=P+/LNZZXJTJ>A7+KBN+V63+T+
M&R]M-;["Q1N'@RGTL=IX_<H?V90##[C<VVLQ7"WB\3H%*MX1ASBT4(-E%IA*
MJ@,?46Z[OKGME+J^`7$.%%Q4DH?5;[:*(DA=4(/LG]7,\K]!^#MF7L_"P!91
M.97NCFS;M]/J%;CO2^K\Z-7YQI)6!X%2(F06:!'715)(A:UFEAO7=Z.)<&2N
MX5YJM1Z;AC,[`PTRF^HBUZ0!JY/4.@BD$L%NN\`\?JJ%MY$&[==5A<I:>(NT
MC7+XBM+]*-U/#P1=0?&!2<E^9/!H8_#L`59UX;R#+UUSL+`HQ^L;[:91'1#J
MPG4'D]S\>M+RFDSG3P'VL>'><`HZ)XX^CS\G<11S'UEWT17X2Q"YLM_-UHG0
M9K_?O^E<F>:@WVO?&#<7UYV^2H2^NKCHM_J5)D++DWO/^6%OF=%^2GKV@)6*
M,.=G'(3PYCZSY0+:3_-Z./.FS"R>\)@]BE`PF9\D'+#-XP#/T\**W@LYA,VC
M&/X0"N"'!,OG1)1I_5:FM6%U6FW3;!E=HVT-],FT[@ZJ3D2N/+6[GA/<*=-:
MI[!\"?F.!83Y>GJ'^?:7-9HI<J8T>3F!+SH0L'X!;E+E?9DJ[W-6]R,"FYOH
M^Q<:.C]PD-$..C]`YP<.=.?D.@F#?2*!%KOC.FUX',^Q`;-AMKM-LW3*U24,
M1XJX>OIHC$)T<.!%3DG#[+6;W:)(4A?<(--G-;M<<I\[+O>9@U'3<BK*'5MB
M98\*/)(^IY,#[S@YT"TN,[DN@D(*;$W90R"X&TW8#$$2!A4A#'!/>JP`/685
MF$-">HSTV-'IL5:;#L"1'MN,5_Z'P_N(2+`GX9/V*B`7O+CR":2\2'D=G_(R
MNQ1%).6U&:\,DR@.X9GEQA'I`/=RB9*R>FK3\6W2@"7*:1W$46G(05FG#8_B
M&`TU='IY>OOM8R7E,%S9Q[HUIO[!GMS6.15A=:;3H,BVE3N3MBY02C:+A@BH
M,=!5#&T'CF`I9K4,J\!`XELTJPLT%7I8^EWGGM><I9;M,S\%?C`3(=SNW]_Z
M=C`5UW_.A!^)K8].#X=]L]6YOK[LM2];+6,X-&],=72Z?6T-KMO'T4/J<JE_
M5(`D9JZD*SL5BK+?-9@OX@:UE'KSH+-I&,4=;3:[[SS;W.[4L\E2[;M(T00/
M?8('<CI=.]N?SJ%O<`R:@9)F=Y-0"/8+7#.)UIXSO`8MZ2QW%29'E9BU<F;]
M!"9:B;Q*11:HZ^)!'C#?I&H"53R@B@=[AO%MRA40"]8&+.M6?X:05$\V)B2E
MO,4M(M:WLC!G%*=AZGU*M!;;U3JE3AQ/9D21B9PZ<!$E/>B;]$`Y#1L0YT"A
M18[7HE,;A!G[QPPM%!&9,WM)]&Q1W0#")HVQ26,((GOF^7A]*@5$T9PMHSEI
MLN$N`4@JH["LS$_-3G$.Q9O$6_#:8</X"D)NLP5.%D%!TEH'H51B6&!-R;H)
M&XG7WDYZ'YLRM/H5E&JOFWR2,M1#6NL@E*D86L6)8=VD;3OY(E=R-0'___:N
M];EM',E_OJNZ_P&5VJMSJF1%+^LQ.[M5\FO.NYDDDS@S._<-(B&)$XKD@*0=
M[5]_W0WP94FV9)-Z&?MAQY$H$&AT__J)QD\<GC]Q_3!\RWR/.=X=^)4S/-I&
M!]B,,BTA3&QN/3%18J,&7Z`&VT8+&I]PW\3KM:FQD\86&LT>FW@:EW`_A/48
M9#*I.3"=UHUOMQ:O)+<_B^_6E'L3P2;@[(7*VQ/A6^/@E:49.T8S&LUH-...
MO<1.O6^\1.,E[I=XO3I=V.R7)X9&&1II-<KP6<IP4)Z;>&S"9A*'91"0&HM6
MYT*:*U`>%.24>-3DI;0]%B`P6G<_M.ZKN4<%7-3R2LS7)-JQ"*L1SWT5SU>G
MBWLE%O0876QT\2$)^S'(="+%1A<?A`?=/U876MV$]LCU$=7P9]57H*W?`G&_
M]J32KAA5WH]6!<%W>0RWHMM>GT/UC1#[B!C?V%[EV5X[@.8#9<0M8^XQ0ZL&
MT^X6[W1[59AI4/+P4=(8L,:`K:`8M+E%S#4&K#%@CQ&:#Y01C0%;M@';JZKN
MP1BPSXSAOOR>XTWN)%YQK?%G8?D3#Q9CW^"=ML[8$?8P#$44#JT_8T?"OSS[
MO<-'CNM$C@CANW@F[(WO.VZ?75QV^MW6=:O1OF@,AX.K05O==WS>:+?/!EN]
M[[B)_/:030H7(..UO5N)7$^%OL<8YL;4_<#I+<<A75\GPLB9\4C8;,P=R>ZX
M&PNZ+AF_#$7`8>N%.P=2J_VC,3AM(>-Z#QGW;.9FNXC?XS;B-<HPTK48R9C+
M>:;4FJT:PVVLX1/<_B,.80+/OVDY1VL<RAG/U]G#@L)[39<O=UYX]W*_9RZV
M-5<M[O55BQ50?>\]`%,!O:H+[VD@?4N$(9,B%%Q:4U)8MK@3KA]@$Z5=.J$F
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M/T_7S^"7:0D+59BH`I?P^>4C1U8K,AC4^XVS1K??:G5A??VS\BI'FMT7EHYT
MSHZS=&2'OSN8B9H%FNHF4]UT.-5-.4I;`F^RW@6M4S.H+*_$G!,Q?/@,/KR`
M3R5X+N#_K&MG[L6\AU1<31<%&@DR$K1#3OPLHEAZA@L-%^Z2"RG0_XP0W?HF
M\SZ9Q-4%<LZYB^&8FC[B<RDL,1L)R=I-.ME36FL@DQLQ%=5;2GV8@NIR$ALO
MYKA7K-*WAX4&[C:&NP-#M':_S`;(^\!'!K4,:AG4.F[4Z@P,:!G0,J!E0.N0
M0*O?WL)MBL>"6J8*>450[2*64L!P@?3OG!#3RTP*EUHOL<AG(7>Q_LECEGYN
M#AOPG'BQ.8?PP%-JEWEMV[&+KS$Z2DC9&!%\<`2WUNKUC1`:(31"N#LA;'5+
MO-/#2*"10".!&ZO!;ML(H7$E7W[0)JO[*_B0@71\28ZCZ>14S@GVZAO'F!/L
M1NL:K5NE%+<:IK^,$6,CQ@<NQLW.%K(P1HR-&!LQKE*,VV5>)F/$V'C1S_:B
M/_$YN=#O+"EL)S+IV"V9X[V>L<>-(C>*_,#EN-]K&H/<R+&1XP.7X^86CL89
M*392;*2X4BFN-<],NLIXUKNFYP:>==79ZB?Z8KPZB.@TZKW2\.&EQ#7X82R!
M[5@"!@8>QM_*M/@-#A@<,#APB#C0+S$*;U#`H(!!@4-$@7:K66\9'-@C'#"W
MLZW5E/"+""+=E;!!70G/JN'BJJ]TVF.R+^'BP[BUZ<`:3)P-J@K,;$+78SDU
M9.RHY]M1!A<-+NX1+C8:)5:8&&`TP&B`T0#C40!C53Z[P46#BP87#2X>)BYV
MFY65.+Q&8%SK$N.M32Q'M,<O_$7&W<G]M[=3P2*Z:SZ][):/`+)KS/$L-[:%
MC65/?BSQ#F686B@P<^%1C)Q'\(^1"G&R<"I$%-88E\)<A_OH=;C-1J.\"W#[
M+[S_MM<^SLM%S>VI>W+OEKD]=;L)W">VX_$MV,8U:$4;:/F6#"E=MDKE%M-H
MJYXJ,[UFO"9SM]]S[CI]E(T+5]0]PL5K-]\S6?CE-NYG8<=6!/".N\$M=7TS
MV+N6<.[(1=@A2NS_S6S[%#<P5P/2Z,W.-CI3[PT'[C*0:C1_!9BW+XSU'&52
M&I@=,V8IE&IU2C^TL7N>V>/FP4=KP%WXLP"("0,J`T[&PF;B>X#AR)!QSV8P
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M,RJ)&].>%P>!F:5OB7PV$J54QN5V`&_7`OXUQ7*+/EZ*=IT7%LOU>Z:6S-22
MF5JRO2F[V<=:LF<)TSX)2W6Z&LG(3J28<3"8L+/F5`K!9O#D="-IV5X5SAY3
M=%\+;?;9\5I"LT%G"QV(C]#[,MBV@&V;%#NLG]9Z90GF=J>_A2LZC$"^!H'<
M)"%@!'*50#;[6[AMPPCD:Q#(38#=".0*@6P-FENH_C8"^1H$<I-VRD8@5PED
M[ZS>-`)I!/+E`MG:!-A-$?-S!;8[*%%@7WL1\\L%^GAOE:+JRFHXS115FJ+*
MBHG:K)T-NE5=N?$:RRI+K%XJH^JH6,Z4E<?H"BA@WD^@RBQ'A)L4*ETU+GOM
MLXNK[E7O^O+\:MCIG`]4H=)%?]!N7FZ_4"DW2*MDR6EEDG/6ZS<'W159Z"_4
M$FM.MP#DZI`R2K.$U(_RTK,;BC6[U==C90C2'G'])0[Z@P-*T+%64.8\#F$E
M8<@^`FK<.>*^%`)T@QTU5#MW_(F@>B_.)JX_XBX;.7XPY7+&+1$3+((0S0#`
MYFSL6S&6K_D>LYW0PAIG6$"-V>).N'Y`?X,4Q&.0JQB_HFHS6[B.>I)JW'@`
M7$-5:IZ()>S!!-]18SR.?&<VBSU!OYJ*&8_4M_@RPN*PSC[&$EXAOPFL3`ND
MCZTRPJ3Y&[N]NKB^N;SZ/*RQX:\?/US]J\8^O;_ZZ?/-Y>\U=OO[E^'YYYL:
M#7\]_/G3[Y^'-`\LAXNDX-%,G]F<Q6[D!(#T(4"G]$.@SLG/7]["H.\_??[X
M_N9?RW\&4P;*.:[#V7F-7;W_>'$[O+UZ\MFAFM#7GX<P\Y^7/QX"A:5@@<O_
MC.$_0`Z'P[3J[#>@EAOZ##914#F@A"<]>&8L_9ENA.>Z''29*NR[=Z(I^TG@
MZ51A36OLQK/J["3]`-;(V?T4?C(_]>\]H/%,E9O`''!2GWW`<_83*+V@IL:2
M(L0Z0:P2_'QS^_5?PP_+5P#:Y_1_?7ORS?%4_7J_U>S]-63N?!9,`3MKS)I*
MWX/=5I]8\PC_%O$W,0,BG5R\?_\V.SM+[?T<7%&H]C.<8B<_8(BQHXL<73_$
MX[;%!=/<?AK^W^^_`HO<@Y!,B?4#^.$=ED(NFSF\N?[J4`ZY"Q?_"8]:@;I&
M4A\VTMUXM+4(4[JW#D`5GPC<9JJ^I5X[!'0(5;''8^`PU3]R62?)L>-QSW(`
M'D,@#PV3`1%W7<9M+'*ESVOT4R<DS4G"@%6JV-,GE@HG\90X"'(-0-$"[8*Z
MEPIYV9@[$O@ZVP7\/<KUTO?C;QPL9'-F+(#_]VVZ!QA7)FUJ?$GRP#,]'L#[
M+02[4&,(B#Y^CX5FU$P3*?/5(TI\P1<!%GZM?ZEGAU!^&@X_O:TS;,WI>&-<
MF2HASC7DI%+G/V,N868PO!0!F'JH1J[A\6RD9N/T%Y!D/W9M+#D&(:1?`^W^
MB#TKPR_=W_.)O4@JG0O;ZOF1"!>:A0X]#ZC//J^>US]3;,#;E)GP\-<+`E$F
MOR;]MK)I8..MI0VVRGPM.ZET^.KGO[AU;Y79D&=Z;;Q2^U=;A)9T1AFW)_JI
MM>2`54E37<1AFOP'XDY0I1=Y[KY.N?M+RMV5TC`E0/.OB80<'5,0/,0!49@N
M/$N!MY8BUB(Z*9A#"#@%"%BKR3"#SWB"X-K&($!"B^P.;)98!CY9*C`),'(=
M,D02ZRU10LL0KL9&,0SO"W5D)*][[/0P$':.TX=!1G.VB-QJ1?`<V+RD\?U`
M*%LQ3"&OTKU15;6X&Q[8#=6R@:K=W09ZIX7:.?A>=8E>F>]5':V1'1)^AI&`
M-6QPLHC=M"&O=QFP,-GZ9+/',?`/*3GX@&P0\/R4T1W&HQ"8">WBHI%17R3F
MD1O(&4`?O&'\<76W]*5VE11C%SV^548H&M,`:(F=6O`FD8,<VP&N%(F!IA^U
MA(PX3/P.OJ,C6L1A(HQ`6B/P]!`@U0DY02R.K`JV*T6I1F"XCD&AP]]U!.WB
M(A9_#W-!YL9AQ'<$7SKDYF)4)YIRKUIDP"-BU:*<%G$!5/!GC@4;<H\(CRX`
MH`(I"G\FV`EZR.!31Q%8/[$Z%P=D`$<=@Z82=@WA(=F&\(G&^CD&@??K5P!8
M`&O`H+1;0N(A&W"Y'LX0-P/Y0X93)\@V7@KD"&67A3&XZNE.@B:+E-;"V`/"
MVH-9@W;%!^OL!@=+XE=:+VO.`]*&W%*:CEC!=6;`SMKML?("7CJ^[?H8*CC#
MM@#*S-3)%I`,`OC'98N.FGIJ%^;$5#P(T%M$U\YU(J5@*)C"8;=`E*+T+4K\
MDI=,.3PX@NFRD^9;]3K_'KX"3K'!5,%P4HX]R"7-'X?%7;M3G)!P$LV)]O6D
MI4;T1T!CY8K"L'P4^G*4!(7\<8UI=4?)*GQ"-=@5>L&H$,$&J^5'IP59Y)T&
M8*C#AS0S\%3SDR-NYQJVYF1>`<*1_V^GEI4##*E7><_G1$KEG9#&58=\=;@@
M%[^[0Y9WU1`@*;E><K!M$H\(DP!25!"EP?%B/PYQAW#5X2;;O`J'<2Q]')D<
ME72:Q8FAZ:".%1?$;,;GVMY`$8O#O)1A9$0"OSSXR!/X\<R7J4+)".)+>A,*
M.X)'15&ZK0GE;XE91J>M*]41?M66=F9?AF*B0FQIN'4/T@A[9*XN)G#[13]\
M::.7G1J_7Y7)=J5;")23`]R9_7M+,"B40Y[%5S<SB<G%#A'2`!1G_%O68`',
MKS]B>Z)-8^1)0.-X%BA$)%6!L,C'XT3OJ?`HWD8T4[W?$9`I45YC+H"RXY+N
MJZ%Y19I8YWR4/D@:C:IW$2S#4%E`@(QM4@X3=.1R;2%R8]?91P]UO>^=3GP4
MN1$E!$!QB#OJ0B*4DEJR1AIJ!HK&MTGNA-)',,"#WZ#\3T%[^)*2C#AO<`LP
M;D)J3;D"H+\2#?>0:JC"1@`*XBYM4B$%#WT/U58M,1"3L(9"'PQ/TS=J/0@?
ML%FXP-S\1WZL-L("K4I18URS6+4/BNJT%5G,F78.?[!T;^IL"-"F&MG1!)$#
M;`=80*K03T1&0T:J&'A1ZB?TKJ7$\//9L%>7J4K:W[#/ZUV0L/=PE`M5YV]]
MT)8:1G/@_T.=X-49<!9RE](:*EM3"/(AWUV!A@R47.%A=I6"41')%&3L?-(8
MG7:!@R)P*/\0C*T:"V*PJBT&3GN`NY*W0">HQSU*FB9^6AWCV.CS)68O0H\4
MP*I@=H??%A+(_O*E)Z8#V:SS0#L$,0B2!7AFJY`7.F\$=+%(',Y[,+@)1$1$
M1BU8'1%XI5)#%%41(&23G1G+M)R`PL'W`E-X"#7"0<F#2<H0U0.W)#@1:*#,
M<P(Y$?X$;!+<9(XHI,*J,_X'H)MZ^XK%);H#K-@Y$0^)XE0<@V@WD$:#!K/Y
MO-I4`F'_S/><*`DOIOH3"$K9P@3Q-6?<@^Z;JA*;1!.G^Q9JW^H>L=G##0LH
MH:C]&Z7PPL#W2"$D;HH2"]A%_0:J$G`%30T3_\@FV76"$Q`0\':`9^GC9)^4
MLLBZ)FE/,M7?VJTA">+IE`NE#K!RTAESG!QL-VB!1/82+SE19+&'7@[&-JAU
M$[`'+$9.T&@&X026`O?SU!^/L^E.TS4`Z_F8=`"Y0>KE5&RV2"`0CB)PC'#%
M/3/*2\=0\D@(+^_C'KJC=8/A'5BM+$0%:;F9%0+F%VP2$%J22:C%$_MB`>UM
MLHG$'#E-&XO`,$JG)X*,6ZHH+70S+6)*M:\%SII@N0F&/Z9D<ND<,Q^KSP#/
MG!F9;0C(%'<AMXD,#'AW?B0E`8!B(K7\4@,$\3D)Q#F^3:$3'#B1J(2W=4PV
MT0OW#@#A"/')L358DFU$!)P7&%Q!ZNF(>IR!AR[]>PH-X*`H/13$2S(&*NV4
MS#&W!&1V%R0:F`TW(5H@`67KP#+%XHG,A%6U4!;(>)0+6NA`)+5;0Y,J]Z:<
M1XK!4>!N?0,HI_Q<VL%?J;<D:*I-N+<U'4I=*R::A417"V>RIZ&R&C.";%L,
M]]?6PSK;?`FJ]#WXVUJ1$7^1U;?K`.TU>0$DGC[]%_GMOEBXDU\]B8T#7H'*
M\Z+(9&4#.9I]B0`BN+1#F`7\AYU<#[^<OZ4`O$KQZ>\9B!3]8.3;3J+G,&YH
M^P%*7!)X1=M-":H@!Q9CE,C>=?;5HX0*#7N/!BLR>`RB:BL(\S5/DP.GQL<!
M=614RX`78?92+2M,IYZZ?SC"',0P>S>A%4D,9PAF$M>?C.D]R%D%?N@HEU^N
MR(!3HT9:,V8!CB\)\#-8+EA]H=QEY(6$VL,O7]D'OT[?GC8&-?"O<H6E%UK?
MZ?K*B]1".[GUP4!GW4;W;8*O88RFL[`1VUTW'S%6`VKPI8W0QK`.EJB*!GQV
MYA.6V_`>.3_53&>Q2>Q059O2)B@@*?^F(1F>EB^K(+\"^O3MH/X]YD0J3CW&
M)4Q\K)I#=84%WI:*<V<VJ$.!$>W@$R?JA&BH]6(NT)^Q=3('90B$^82#2KRC
MREUX,^:OV#">P,NI=.#1;3H[Q7W<>)M^8)<"UBU!'K1,7Z72=$F*2FVC#;IZ
M+G3ST(*L)[\KT)_>_P_NQ9A14(5K/5QU\:.^VCE:$=4Q<["%E!7,L=EHEO(C
M>]Y'*N%WA$*$/\G[,D@"?3H!$7<7$.DW;4DKLP&`1<>R$I-&!:W(&M82G\9S
MTGQ/EKF!C4V)2!X`H<YJC-'.R2+('"&L_`/#[VO@2A.XX#85/*30%^)\W!'-
MHOUN`UCTLPAB"2Y0*&"QIS]SS`N`'W6;2R[5<@\ENL^;Z#!HUAQY"52`3'*J
M"-(!A9SIFM.WP'9)A94LS&:6S*:84:;M3B<T3B>DRM4%9?I`)G$FN>!L'@`)
M&7)CD&QH:*2I*LEPM3L2%8A1?/_J>::Z5"]55ZB!."U00YO8*!N$`V`XIS0$
M!A\&TG&U7)\EX4Y%6!2)?$E:5@T'K(5%CZQ7JRSBL6A=*@LK%=$;<*!E7'U9
MI8Y+J6SPNKD%Q:\I(!'&Y0EO@U>&9I"R>;SGVSI'"$.*(]=0G(UV356*H,MX
MRFYF09P5VZ=?G'R)1Y$"I?;9:1MQZ0N06_=AIS=\>E"H?RE&$;N!-U*4ZP*L
MF/`Q6T673,!OG.0W%OXF=911]^6]57HVR450*4)!M%2F(U^,2NZMKK&PTXN&
MDYQ#EO'($AC9G-+WI,<9DGBE^C[U8#<U6\Z>2?T"M4E[9`6*/PN.6)-XWTLV
M@@W#T`?90%K1(MXC8_OCTPL5)ASF2BH2(\ARN53NSCI;Y>H!==PQ7Z-!\<OU
MMLM3`0Z5.E1G9!%2DV@.A9FTZ;/ZA0^@&T$H\Z>4[53L+4P@K@/T$1;T),4]
M+E628DW4(C`5ARU"4Z%(YODH1?5]"#CX3[3'LB,G-1:X@H?ZX`BIE>[VU0J>
MU\&;&D2>!?=1L;QFO%>(HP^AAP`Z/X'K1;$#E+*/%`HY5=@#3':*!0]?_'%T
MCX92!D3ML\9I!X$H<:S^)\S'6M".NA8P_"<,G:+?R"Y</[897A`:TR/#O(1^
MI21O0;V##XS%6!;]S$I_EA/LQ"A%7`^3*0(W(A<H*CS\E`DWA47*5><&RPY?
M%<W!AWBOSE6!UDK$-0F3/GP9ZH*G5K!X@F'%2M:9*2DX[3^G8?DE.C<):V=.
M(OXZIJJ$HH_:?<H$<]3L\Q=F&&ML9:SI2=D$5V`YB*8N80ME[C+G3^#6W7AW
M0A^W1%F[T/7D5TD`X185]@5WK1CU,_L`&I6Z3^CW`.79%SI$?(*#P2!7P-YW
M'+RKZ.U2FVWFWXE0)]Y2IXWB%##^Q)<89=+)7$I\XIJHD(1-'=AF<,SF%!!S
M<A/'A>A*E>QQX*^9HD(^`>,)G?G03^$"DE/0J*V3FAK;(7!YF0!<<4JS9MH?
M)Q5@SC("CE=)7HZ7S3A>83U82)T4]L,'Z.%:G$H'V#CV[%`O-JMM4#^FBN\9
M$*>&7]T!/9,3!+5DG%/LOH+>J>/CP6X/:XWF.LQ&I0>X8$49G49^,"^E,)?/
M"J^_23.]JTFN`11_HXH-`7PH25,\^[IB[W->/X'6>RQ_9.UDKV?)MBV997XI
M21P\C7;K0HJ-C*J5?KTR#2F>DUJ%7"<]'Q!T.2G5])CK`W#+A8.WQ7-J%$;-
M!06,]?::K+=_Q.Y:"@*#A@CV7N0#1&F=T%[JCC]P`M-?+8%#PC8J2G3G*M:7
MO"'#9(NR$(5RC=%<AXV3,D7*X;L\1!+68.LD_(7UA$DDF0ZUN+GAU<_39'1B
MS64/D*>YJ`/4T,67H/T#?B$>L<&YUG-TRFDB\-(#L=2,28^*JBJ4](TZB>'2
M(0VJ'PW5BA`1P=MRG7]3Q0A!7)UTZ\-/<?BH<.]8*/19'4E)%CTY7P)WHNX!
MHTZJ.N.1;KE34T>TTB+/.7K/MF/I*[W(^Z;)`1,(Y1!BW98?4EUX<N0':VMS
M#NPS=6+/&(6E"'T6=%A'\D$AI/V7P(D:X7$MBF(GEF'C;`D*/'#)<J!P^DF5
MP@RS5AU/AN<P'J.NUY.Y=&*NV0=5=V%96:@B%$DA31II=Y#**HIDQS++/F58
MI2MTM$BH>G`2E?1SA1;D%*5O3M^DNAJD&*43#N$:&8=<\*HX]C*Z'+0+M:15
MW5H=Y8I-Z"+X9.J[>*CDBBK`T6Y9<A/G&GWHKB_ZE]U!NW%UU>GTNM?-?K>I
M+\QL=<]ZYUON0]??CSYTBJB'7="MKJQ/#@BDU[L=7>L!/+N'NKGJU@I_:75Z
M]69R;V&U2U*-.A0@5?JF'77[J1?:.R8%T_="KG_AZT87JB[O=;D"Q-@JZ5S6
MMUG=O]KIK].VMM@$MJJ+1V&-FS2"70"O!ZLO=DONY.^T+9,CTMX_W;7;Q#Y&
M@8UZX3YV8?#6>F`/L]Q2H./V240#._2HZFIR_%2T+2NR>#FTK\"[VF#0K[>V
M@GAT]B7KB#42``#ZU*(Z=#_79]'0&","Z')O1$KAA3H7F\]T1JC_T'JM@#3-
M3J?>V0IAUI:&E4V3#5`:H#PFH%194I1[*:8@^N@`IOTUJA#V0:\^V(ZL$^`9
M@3<";P0^-]Z'K'?4PZ91NHTX=9.NR@CJ-<^VI.N?Z`^RCNP?X>DKE1W/BJP/
MO.U'H2(!K5EU(`IK!:D\$IL+\3B:4B*?#H-*/.(]4T<WTJ+L.*@\-O"7LWJ#
MC;81[DA;G\QF8,6'&-UD)Y3S?;CY>/@.J4&E$4Y&*67_IQ4]21!7?`\<?21&
MG<7(1M*]V[.#IE)$F(-2(>-'7XYA8RRKTAY;&K7&#F3?*<ODSBMNYE=O;R<0
MI6DD!999J/[DB1=V+4:28NU`J^9J6IT\^G5Z6BNM8:`63;H[.#5<P+J"\1BK
M'PK\D92_ANLXAH'+*^M1LC7DN,R2-I5NNNF'6T8\XSX?HK'UN1A"F&T"Q:#>
MVRI0J#QX)J68>E1I^ZK3#UL-5^4PYU%-D:%;_@"C.F5LQW3>C*^.^XWF5+X.
ML\2V#)1DS378^4VDE>[YPUK>?-5>%.:\&I+KS`!-F4!3;2:%@"8',]NT0;8D
M:[N'EG:W`:;P]H'E,2$='F]&M_88*%)8?[N<_I=FK=UI;2L(4(V5NK_^_8=B
M"^WDX-V!N_GH1*H\-JE2W7(-%FHY>/(G*<M8MPGZR8>+F[>/)\0WB%PN"_45
MHIF-!V3#?^<'51=)%3FND0^`;A2#SM/ZB8HB%53&7O;)/:G4ECD(Q0_)'PLQ
MRN51ZBSPV5UZ%_<:46::S-_>=,[^>\,`M_YA\[F_>_8/#^5W!S-1L\"=+O#E
MEZKO^$[U?KGZ9YT6WJMS1NDB>F\>IV#QBNIF\)W1J9$7W;"^%(27TQ#[<PE9
M+167VRK7NIOH+5T>];/R+O&ERZZ[OB*OLW"\?8/-V#,6QG/_8[!F?I@Z-I@$
M&]M0C]X7;IBU2F;]`(9;A;SZ+`RN8E,."*.7;]C)C9>XF.';YXA"^X6B@&=;
M)]*//?M4^W(V_:^D[="O)V]AX=U[)E*9+\NMT8K]6AH(,8C^8D1_*1M70,O=
M,^1*%ER,+QL6W#D+&B0U2'H$;&R0M`23%XLN]\F>K;!2\^*FQD9BXGA4*X37
M%]#)X5V*]DHD7A]#]XO213Q5":JR"/RDVGJ,T!70DUA_!P1MU$NSJO:?_QY5
M/ROB!499EZ:LRT>\?6&L9^7:RZ;<,2(6C=>N#TK#J'WA&`-%1P9%>Z_\C/&U
M=\;76;UAC"^#>`>*>/O"6,;XJI)2C7K7&%\;0-$+(V;-XPV998>;3["+P=N%
MFE`*JF'#2^Q>Q[\_)PS<>BH,7&:V8H-H[\XLC#)]IU6T.Q;1-59$>8)V#/*D
M2E4:]5[9#)0QPZ94V4-<WZ1^QXB7T6//TF.=0;UI])@1-*/'G@O3O?+4V+'(
MB7'55MV-GMVF`JY8>BF+NEDUN:00[W+0?=I5TP=X!F:I6OF"*V?47AG9^9;1
M>D;K&:WWTI:"S59I?&3DQ<B+T4O&&S-R9O32L_52I[S,_['(B?'&5G5#=$*5
M)],=.(UO58H..\%65Y5KL6,+^2\AI$D`&$UH/#1C.>ZUO!CM9K2;T6Z'(JW'
M()1*#$O,6Q^;L&TF7L8]7-5_$^_<=O6U<+FKBCU;79A>B3;=9E.(?1/L9=JV
M46^7IFQ?2MMCP0>CC/=#&>^XK=Q!NZ)/T<ZXJD;>C')]'/1W()8F*6GDU>A'
MHQ_W);EYM,XK'?D3GEU^!ZTB9[6!LVP_QH.&+Q'+_3]EOT]='I[:`=,&0D</
MSNK]_2'Z1N&#(^)[$ULHSW;:`3(?*"-N&7*/&5EIO':))R:>A-)]X3GC*;XV
MM#-VJ+%#C1UZ^.K?V*''ALP'RHC&#C5VZ%[;H;D(ZCOJ&+;L^:U-+$>TS6XG
M;N/EL=M@0)9<BK:PCC+?$M'U@%AK]#JNN*_Z.G!OTR9Y-7;/0R:%RR/5>8%7
M?$/X]BZ(G^']T1'((POXG&K:9MQ6-!"Q=&:S&+[Z$H\^PG^&/]6)X5'T]'7J
MCC?&NYOQ7S46@'2'>"\UM]D'/Q*LV:M51BCU3QPFN0^<%G3CW0E5G!?B->^_
M<NG0IB;W@+,K+Z*V&A7S&!`0<`&H8?F(2:'`7*='6H.8:.QXW+,<(&$8P0<T
MX<?O:D_^_O%=')Y..`]^^!+YUK>I[X)>"J_H!G"D^J436L#5L12W`(GG+CSS
M]__ZS__X,?U5/`K%GS&\\.H.WYH^A1-$%/TLQG][<WV)@OA+^_?;RS?,L>$#
M;D6GO7YWV+CHM2^N&KU&\_K\XF+0ZK6:EQ?]7N.J,^R]^?L#W,X3\HF[N)?I
MRL=AOU]$^5;)*-_*7(>S7K\YZ*HO%Z[ZR0C*%$6K46K-;O5*+?.4VB.^1,26
M$^`SR)6,K0CPPIN4LOANLO:<G;03!?_18Q^MR,<[3%M-I9Q`&:`R]L"KMK`I
M#XB-#'P)0LQDGA#P'+QEBIK&C6W@?+03`(1F(/E41PRZA3,OI@M2,3/K!`*)
MP@+I3R2?J49`W*M6U32;_UVM@I'"!HK@>N&'][[\!@K#$O7%51V6Y?>;8.)[
M(*P(D1ZV.);("5,N)R)O*"@=4.`+!D#JW*G63O!.Y`IX_X2Z0%5K5?3/MF-3
MP+JK7<A@.PNIL]]0TL%;=`(4[QG_AOMG\7":6$O;WL)F\UCV$&1Y*RM9@&$^
M`^2."N9\(,6=X\>A.P?AM&0,G\+CL+W.'1IPLP`,.,+L.IK"8+#!-]S%IUV7
M7`22\F3@>U@5&PF%"DG?MH`[-AO-B5=T*0XJDXU-OE7&6\'$^QJ*C^.K,'+`
M,H<5/VW7778OSMN]WGFG<]9M7URT!NU.?WC5:U_V+P:79]=76[7KN@\QO;4E
M3+^=HO(5`9>I@O8!US>PX(&IJ%=?R.(0&0L0`[8[V8@:^R.V)_1@+6GF%\\"
M?!=:!QQ]+^"I\9C4"H**`,,"WY6P%IH,U"2PEN\06&."K/\:_`"X(A;*=$#]
M!-/6[TK8W4[=`QP-60/H3F>9EG8?K#,P@<`(\;W3B8_H-^*A$Z())+!W(<(B
MTFC9&FFHF8BFO@UFY80&`T`=H8]8^`T,SJ8.>*$2XW(T;^D($$!UOLIC=^#%
M@7BJHU:+5..PEA'83K!X$N<1^:`A.*C@^=4T)</85014<(!N*WVCU@/_3.`]
M-_^1'ZN-L+B4<_R2^C6NV@=%==H*^A-_J78.?[!T;^IL"&8!+#J9('*`[0`+
M2#:6_DQ#2T:J&'A1ZB?TKJ7$\!6ODF^^L3-9Q(P"G"1.=.)#DPL]7^)GKN-!
M]OK75]?=0??\JG-V=M;N=RXZ"FD&C>OKSO6K]""?'[0X<L_R(@^X%9-E9VKG
MXX8Z1ELR!"_9`SF$NTL(Y22$$II0Y(,1_J$/*]48@029EW.`34^,P=:%OQ\'
MC^<S6G]KC-;M#=+[P1>CA,MBFX?-1#<>V).-'@4GZ-)KLF$I5`T4<4&5::.&
M3Z0@1@([-9HNC?*RD^S3MV`]L!"L3L=&QD#VROUD^%.-5">RD0WZS?6#]%PT
MV,TS(9$WG7]G`0]@Q)%O(RLFOXM`5ZO3U/#]T/TWD':6)`7ZK6;OKR':+!A9
MKN=?C1(#+C6:7/"E!)9&1QR)[HSG+/`C048ZOD+R0,3@Q>7?CC/4,@`#!"!T
M#DK,DL740"=[\9BG[OO*M8'9'TB?9@5F$T8$X'VG?#9W?33^1<23&8"IQN$Y
M&'?&1^SD_.;FO-'NO:T]@RA:\!$LE+W@A,4=KP->LC39LBR$14:40A,)8`&^
MKH-OGG*<M/"`GR0,2`P%S/!IBF]MPQ21O&/*!R1+29PM^&XR(1X\YDR)'3](
ME(`U1Z9Q#L-7HW3V,]H.*2Q_XL$[;;6'R4MXF`66X&6>[Z&1A1N"S)@BO`Y#
MP$^ES?Z,.;@-,G4RV3E'U1('R*BH;=`OQ07D1#9P8?TT$S1!X>UY88N#Z@,"
MK=[9MK82'I=BQAVZ5GYA7Y6;0JZ8&_I$"NG/N9N/V+G^/>#]Z<RQ3R,0$7)A
M0NYJU\";ZXVF<%&*%1DZ5!3\W):R&6IW-/6^TE#'J,`V"`XI/"-NYADN<8&0
MI&$<H*>K8RD/-!:]A23$F8UB&2:H/7;!3U:H]-1+\)E'7/F<<04S4*GA.KN.
M(_22%_FCQAS:Y%H:ZBE,9L,7K2GA#_+14X%4@Q6GTPN)+-R:DA]\Z"QF"BL.
ML+!B47938$BE/?+1#@?&KE:;M`?UWG:4";)/Q7F;7GT[4?\:V<("\U/"G:>1
M\]3E)'BC#81M#J-B*.L9T%=#[,/X.I<J<E<M'7OUSK&P1&M0;^Z$);3]$T@'
M`'H.2E?O'Z=<B3I='):>W5U5!K#-S,"*VWF*#C&J8,^']\)\G;$#;A$EB%$N
M,B<@\$-'.8TR[Q#X0#VN(KD@%DZ$@L=7FS:^G'!/NY]DL4[Y'14/W#DHJ9Z?
MO!&PMEC.I<+H8%9Y%+"5G$+0[CS)7J3YAJK"0'L;;_SJ6;N(..Z:O1/FH1P1
M,N#4"4(5'U*\\DA$,;'.;9\8/^_Z<G*&76Y]4YCAWR/;^<P&'M,9KEPM!`V4
MDQO@1P>013\(WK'GSV`]8/1:(@RSM&LRDSJ[U<46^44DP5*G&&*WA(S`_V,C
MQX^$-?4P03574.8EX:%4\E8$T,J'N:W[<6'E%0N[,D:KU\&7PGJX,%4AUMF"
ME:V-L$):,LE7/V#U52Q.0U3MB_REV3@>.[Q7'^S`YE*AY!G_[LSB&5K;*GD/
M.(JUZZ)0R*(0\;'\3PC&R\S)'G^:A\HQ`OK[INL*29(GH5XIPT1K/$+@>U"7
M(LLL:'L*7C&.,6^@!RCD2E(5F&BPY=\F@;;4$:L@Z$4.&7#%O!#56\.Z?)+Q
M<C9GKMKJ"?/SV-R(U8<G\D*\!,-7$W;9J8O!*SUUD1!O[11Z&JZM=%J5FP1X
M*&?&FHW3?VY:]+-V90_5`\&TOOTP]OT(#'WQ'O[!OM-'TL=53*,H^.'=N_O[
M^_KWD73KX)^^:S4:[7?X]3M\\(U^/IH'\#P,3<'0-S3VNX7!X>,?W^%(S@_X
M__#/_P=02P,$%`````@`1H)51T(.B;YQ)P``IK4!`!4`'`!B:6EB+3(P,34P
M.3,P7V-A;"YX;6Q55`D``P/S)U8#\R=6=7@+``$$)0X```0Y`0``[%U9<QLY
MDG[?B/T/6L\S6KB/CO9.^)S0A+OM\#$];Q4XK8JF6.HJTI;FUR]`R;)D42RP
M6`72[GVQ*1*9^/`A`60F4*A?_GYQ-COZY-NN;N:/'Z&?X*,C/[>-J^<?'S_Z
M\`X\>??LY.31W__WO__KE_\!X-]/W[XZ>M[8Y9F?+XZ>M5XOO#OZ7"].CWYW
MOOOC*+3-V='O3?M'_4D#<"UU=/5I5L__,+KS1Q==_7-G3_V9?M58O5C5?+I8
MG/]\?/SY\^>?+DP[^ZEI/QYC",GQC=2#)=)?X$LQD+X""`."?KKHW*.CV+YY
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MGW?LISR5A9ITWR$?L7$9RO??S-T-=:>:RA`P=M=.V9O/?5M_6BWV)_-NT:Y2
M<+VKU4:AZ6!E+OHYLM.!S(LB,D3'@7B=58UK[HNXY"XN3^:A:<]6WEPOQ@S9
M44"^T.T\>@/=&]^^.XW#M@_80^4G`9-I=#UBDT#+,[7-4N,`6X4$O4#NE!JQ
MXMPN6E=X?!B9B8]-,B."RK21-65'`?%2U^V_]&SI?_6Z6[8^:WG9*#0=K$PS
MRI&='&1O*)8E/#E,O`M,7`QFYI#=0L5TD/,&=(;H.!#K>0P;:SW;PGO<)#,9
MJ-S!W2\Z-<3^H9TA.S7(_H&=(3LU2+(#2%(*9.[<DZUA,L#]$`99Q19J)VM:
MYJ3:*SD*P*MP_[V^Z$>TINC8$#(GSH<E)@*4.6YZ!<>&EV=*#PJ,!,=YL_!N
M[KONY.O'[*[,D1X?Z*W/6T%<(S<2N(6>?ZQC[SSI.K_:M_A'T[C/]2S#ZGI%
MIX:8W=FY&@H![G5_ME`Q->3<L9ZI8"2XG^*ZU+2]Z9A[!<>M/MO^UI<?%\RW
MM60O'GGRXX+-M:JUQ4>#<KVM?S+_EV[K5$4T8]_&KU>YX(PM[:V4E(.]A5UN
MJVN41KR*FC]FY>?OEQP90"95#PJ,`N?Z*./7G;$;+_QFB^RJVCZ86RLJ"S^3
M[*'ZRC8FNV#N3#Q]S64)RIOC!ZH;I2EOVN;<MXO+-S-]M07XY[(^3S4^^$-?
M:X9KW%.#,H?DSHKWV[S,$3B6_CTU-F_`[:IWE,:]]9UOH_?QLFF?UYUMEE=G
MYI[,9LWG=$:KMQ79"LK`S1Q&V^HI"KXW*MU:45GXS_3,]F9GAVDKTY"\\;NE
MFE&@KPY5/-5=.G)VF;4!]K#$1(`R1V"OX+3P>L=8O^2T`'L'4+_DM``SE_)<
M^8G`Y@WE/KEQP"U-Y_]<1NTO4C:E^_;O7I"9\D7`YH[R[=2,!/WL3+>7K\.[
M^N.\#K5-7I1=S<_U_..;&-[D/"2QG9:"P/-*9??/9%4>'"7C]ORP.M>28J.'
ML[QZZ.E5+'1=-+5_3X_67Z&,\[.?NW0$_-!PKK6T@X>+OA>\Z]:^<='F/(E=
MHL;-AK2J-E8\:^R=*>.ZLM4E'$%W9G5EQK(#'[4^/TY3R;&?+;HOWZPF%P#1
M]74>?[O^NGJZ[.JTC1P[P=3S5;-2]BT"OWHJ]'VKYUWP;>O=C>7,M/&SQX\B
MH&J(FDI0B0/E$FB'+5!:<J"0L4!P`AU3!GL1[I(Q2]>;-.V73IB,C1N_JUGU
M3_3&KMOENW^TMZ:F-0STB58(*HZ8PP!)DBY681H@$RRP!@KLF?24PKY6WS*^
M)ZT]:MK([^-'L6,^^_KCZ6+U\4J#;NT]F[Q[7\MUB>,N+2%)(Z@7_NR+?+I_
MIE07-Y,S&=LZN>VL.W_Z>[TX_3!O3`K1KW;3SI>+[JVWS=S6LWK%6_QKV;9Q
MM8Z>?]V]JK6)ORPNWRQ;>QIC@4TV-U65%8?<JT`\P!Q[$)`10$E.`1%&:6V8
ME7"@K>(?RU8/J`=NV?@OQ]^L4E,O70\Y%<77KL1R=(3_X]V)BUT1/6+]]1#*
MU6SBGLS=%\*C3QQ_6YYY]YM?;+>\[5)3);W$.G`,F(,62$TIB&;N@*.,"4.5
M]X+O9P4<LZ7IF%JHYW&HOHJ>G?OV4%`AOGM05$0S*8*GD7P<1S[F`@B!%0A>
M!JA<'(BVUQLYL'6YG&TVWU._E?`"OCWSN,:XOQ2I#((RXJ0`$2H!]9P!(I$`
M6%%J!*&6,_V=K;)[L[P=2"UA%F-2]=Q?>2[O]<6M'W^+WD5T*6X=(9AX7NV#
M41E(D8(*`4BB"V.)I,!Z2(#51$K'$!%JH'F3K^8-_B+V?>`]][V-H:^-+>J+
M?%MM9!I:8GT`A@H5/7P<@%8Z`!+7-LDXYLZ186.$_N66@`/KJ.]M2'QUL,IY
MYC<U5D0:%1=N"(AS`6`=XUT&!0=.<(.MD59I,6P@L/\?"'OKHWWF)-;N[)=(
MYT^]<;'M#9=EZQ[EULE#@[S-!9#C8M_J,L<25=_;1BY4Z8:?IM_9''P?8J%,
M:*\3>^W%^!`LHG'R#DY@X+V5P#NO`*<>0H%,RGOO)^]X!?!9;P1[IUQ%E-?>
MQ%52>$\`8S%&H3)$_=)B%P)DGAWTGMJ0;FG&):2$FWKSX-[F+/OM8E5LAU#4
MQI80;X%U,1KUP1"@E,8AH(#I8:=E=^B79E1:2G1PNF8TS<KQO[14?M*SU3R]
M>*;;]C+.TZLML@T]GR5?64=HG)8-8,1PX*%6`$L7\6@E*++4P"`/.5\ZGDE,
MQ5<)6WGR*2[6R45^V;3O(O!W:2MT%7)DS/Y]LA7&V#`M*%`,<R`HE<!IRD&P
M-B`AF!-VX(I`OC,;F8*K(O9Q=7PQ;9C[>K6!'N>]#-/8(%91AZEG/`#-XG"`
MPF@`&90@L(`8(=K'GP\YS3:B58Q+TV:#N'^J-7U3/5_ZE[&)'^;VEC?]SZ:>
M+[YD+M;T<Z9D90,3Q,2I#E(M@=#1EV)0:."HM]8ZQCDYZ$32[ET]'5,EAO\J
M^,Z-!NX7K@C!0GH:@!/(`H6I!@%)!HQC6FLLI8-F6/_S[Z3_1R5GOQY!UJ9F
MCG@D$L>ES8<XH04'N`PQQ*)2`,*\9%K&^4VCP_<==XL4I^&IA(4\^"SRYH!R
MDU@EK$=":@HP99%/+20@7*,XR#"'2G/!&#U\3W$GBQB9GS*IA+O'@"+2%Q=V
MMDSOV<PX>Y,C7DE%-<(R1`P\NL3I9!'RQ$=*K2(.>L?LP(,+);W%G2QC(I[^
M.B>P2CJ+._7T@1^<NN7$9#D#:\M7RBCIN53`<V<`\<P`SRP!T1^B(01#O1N8
M3"SI%.[4SV,14Z+3;V]#S]V[16/_.&UFD>_N[@L5UO1_GVA%-4$T0`<L#QHP
M&S"`QB.@G1-4T&CDH??$S32MO@_V9'X]Y;YIVI7=+19M;9:+Y,2];U(W-O-%
M-*0(Y>.7B]HV<#-.!972S$:60C1`3H"FD4$FD(XN(F*&Q65`DX$15IG,_+@F
MTAP(QR7&Y58C<0VQ#@9"E=8`R1C-<H()D%S',(.S((4@%O*!+G<9R]E'Y_;:
MUP!6RX1LUZ=,5XC[-H#6E*X(4P9J2X&$U@.-%0)!$`-L"`@2(Y'7`Y.V^[*6
M[;KJ7K`V!D5%=@.;L[-FGM7OWQ:MK*=0DZA3&6Z`"M$7,<%PX((Q,E@7L!JX
MN)3)TXS<Z2/P4R2#Y]SJ[)N>O=&U.YD_T^?U0F\*P1Z0J!1BTLK(#D+1*\64
M4Z`L35D'XKG&V`7>>T)EGUF9D?M_/)H*;=WEW.SPFU^\#N_UQ>;=O&TT5<YQ
M(S#DP"(5`'4N!J]$F1C+<F69L,'#@0%>F93-V&8S.7TES.EM.M<W]^[+Z_QN
MM>JY#[6M-P4[_<(5<HPSZR!PP@3@?!Q)U)FXCE))8SQM4/`#SY.4R?Z,;#23
M,%;"3MZWJX?O+[,\CON%*VBP)@H[$)WOJ-\2"*B&%ABKM9'<2<0'GAGA91Y4
M&]D01J&H1,?_6L^;=A6%]>8^OBU:&<^PP3'^<DXS@)&'`+/4(H&L]$$SJ08^
M>;4O1[-X+#H"IX6SB7F)PXIZ`2G'%G@6./#8J6CR@0$1$"'8.6,A.V3;F#3#
MM1M1A3N\_PC)_<)QE?,,1NQ1M59IQA0@2!+7.^1%2HB[@`;Z!<43G-OUT,,]
M/9R:DD<&W^C+--GE'Q:\*U!A;.,("`H025>+9FRB)PHX2YF,2ZAA`G\G'3^H
MPQXX*[@S2T6<P/1BN6P#6%.Z$I1@'[@$'&H/@K8:!$8H0,H;CD1@7`S,3A>?
M]<?H_7$H*K9'O-6D_X!$!9V$4&D$5"`Z^KK8`ZY#I(_$@(<8Z@+LO9=IG]FG
MD4U@/)I*F,%S;S+.B=\J57FL8&`.`6Z3!XR=`0X+"930!'IIK1,#%_HR6:.1
MNWLW:HIX=LW\XWO?GB6DFWRZ6\4JA1%$4GA@8U0",$$84,H#@!!B(IQ!%`W,
M*!>?UG?SYG8CI<P('GRS4>^=-HXH"(V`<::*2Y>TB@*FH]="->1!(LL<'^C;
M%9_:=S*#"8C:QQJ??QAL?2NCKV*%#0[$8#>V#2L+"-,&8,X=%XHCB@>>!R\^
M]>]D#J-25&ISN>=>@@?VF1^0JAAQ%"$6@"5IO?.IG0$3$!RBU&`!.1IXSJ#X
MS#!^MF=<XB:]#V:+2QK>Z&3AIWY1VREOB%F+Z.8]AMWKD![@?3EK/N_Y^HCU
MCQ._\6V=KCNQ:3O`/_=7_V\:9%NHJ4+T+@V2'@BC4%QAF`->(0H@P\)`K"5$
MO>OQ-&RD!R)C$]ZTS:?8G>[IY8<NW8/T^GQU>?3\XQ.[J#_UI9/SE50*<8^\
M$0"C.#SC'`Z!3J,*&LB\XX2(_LN`]YEUFJ[;FX*<EGEXY2X;$7M:?F\:<'VZ
MH^^6C%PEE0G:2`,EH(RBM!.8+@`P##`)<?"!8JP'[G&A,AN;4_7XO:==)J1T
M/X9U_SGOK4SJOG@DV$EH6,KX<@FBV\`CP<@!B"&!CA#GV>YQ]`]I3*.06>@Q
MRU`O7O6\Z.2F4,6"5#+=0^."I@!!!U,Z./J9D*>7)T"-^,!35V4\YT(6L1-C
M9?(NYZVW5V^FB)]G?M4;<_?D+)TD^,_J^XVYEW[Q2DAB%+4,<$XUH,:FQ"0B
M0%K,I+6*4#/P7H8R`7<A6YF(RR)/A]R\OC(=-XQQ3Y_=K!>H'+5*&::`I;%U
MENH85D*5Z',NN-APJ@>>OBAS+*^0I8S&7LG,[M79T_?ZXL5%@NR?^KD/&\]Q
M]DA6TE`B'':`&Q,`"@(!3:)KQAW1%AO"!1SHXY9YM+/8O#(VC<6ROBDE&1FZ
M0GX-NR_INTZFDEH%$Y0`Q,:(DQ*6FL?-ZM`\(EPK%P;F?,4/Y<&.R>!^HI\O
M5R9NSM%LE*N84E0@P@"FB@&BD`?*QS\C>SX$;XQ4`X^#R!_*6L9F<6_Q<KOT
M+N^L:(YXA;S&2E@+)(]QGD`LNFM!JSBMZB!<H$H-O9M6_4@+TT1<EK"B!QBZ
MNB!\QT3Q&B45DYH9AWEBF*:G+P+@"$D0%VLB"$%4FH.^_W3?B>)Q."V2B+E^
M!>K+IHV-L-Z[+MWFMUJ8MS.O+355,`0N?7K%B>,"2.<(@''L`62P1YBH^--W
MF3+>N>\?>$GM=+R6M+.;5^T^?$=<AHUE:*D0,MH@'P#CQ`!EH01.QNF<84Q"
MP)8SM?L]?#^0?4W#::%D\LVP2(#CS/^K7B3,EZ_#,#L;IK%"2BHI'08XP.B#
M!BJ`H]%',=9+%)3T.ASTG="E3*X8O7N9VAZ\['";F>U!)161'"L<`HC.:3H)
M#16@C&F`TZU<1#%#W.Z7!OZ($]N8E.[%L+Z^GG[U//W*R[U^I=8VIK5!344E
MPX[X]"Y&XJ//``402EI`D><,$2X('>B5L1_;N,8E=2_FM7(I(W%N:5?OI^I[
MU4^>@LIP[P02`6"?K@[2$@$.&8JMMP%I*;AF:N>\^8]H4F/1N<<,Q<MZKN=V
MQPS%&B65YD):#%VZ$"*]F(9K("%,6Y3I.GDHF),#O?LRGM:^,Q3C<%K:N[\5
M"Z\&QW;FM:6F"A(#8]2,@"*$`&9T=#>-=L!*`;'%F(7#OA9NJJ[?X,U/0VMI
M,SOINF4ZR_TZK+:^NP]SEW(M-KW/=/7>QO4[XLFO[&[NQE@=CW]]GG[(-<K1
MZZV"\X%8@X&W"`(N+`466@OB(H*Y#%K3,/`L3)E$[AY,^!`ZH83!O[BPT5U]
MKR^N-^97P?C:IFTWR^ZDMU+.>`,AC33IE+-$*CK-3`!IF#4!0A3=Z$->UPL9
M;&F2"V]%O/7GR]:>QK;$2.KKQ91YNP\/"%?48B^%9]%3=A`8P@S@+D17BFC#
M#&9$P(%QR'[S)J-/AE-067H)_ZU9W-PID;GZWA:IM">2,.J`$($!Z8P`4!L'
M`@J68ZF1T@,SN7L]&CCEPKDC?R4L)-KSM7&_#ID6\I!(Y3D.DO``I*(\1OF2
M`LP=`B).GRP&;(Y(-\Q"]IO6&-M$1B2P_$.==QZAO'^UZ9X?IKP/Z,L]JR._
MSV'DFF((*`/E$`.EC04H<`@@TQCP_ROORIK=N)7S+^H*]J4J+[)E.4K9EF++
MUY6G*:P2$XIT2![YZM^G,>316<1U.`!'UWZ0#\D9+!\^`-U`+UE93I33^K1F
MW1S38?AT2A`I=;!@#4&:^Y3!$E.B*`=MF14FZX$J6".GRUN._=<^XB/BW,RN
M>'ATZK-B*B=-E0O>@(VZ7&$I`:ZDR`I$6!J]8&2H&\/-&7;9J.ZS+AX?O%O3
MYO`%^8OX/W?KS2ZMWC74NJ2*S@AAL^(&$K$"DLD!]4JFP.)G)S.C86AZPS;T
M&Y\F%_"P,M*WYNK+M)I]<N7@;/U?=VX^RR5G_(OU?Z3X/EV[_IU5=J>%X-X$
M4B+*&-QNI`*=BB,!CJB//B3<=*9\`GI3=M:"^-:T?%N^Z+T=MW>LR_5FE3:S
M52_J[X[4^@/=T5;4*VKLG,E.A9(L7<4(A%`&N=BI),-R8(XHQ@;:9/`VFN9-
M.=P6^5LS&[<1'-#%-KAB^/QNA1US8>?:VW_:D6`L8@^OL,N^Y&V-*/_;X!!B
MDR#;*,N146;>*>K20,&AC:/V36G=%/=&%B0/O3MN)/+P7#E$"LD@O$)@D0PG
M)!AI#?"DA-!")BL'WA<U\E2II/M<BU*C`'N'^E[OO.JL,PJI2,S!4R`EXYG,
MV97`XQX,DSI%R[@;ZI'9R'?@&SFTJ308TSTGGDHXP"D<7]]NP:]V_3B1F$;-
MS,N&CLNW%K;HD=B%,&QCD][A&K5S4<9)]EW**)!]B7F1UL]3%J%4]K24;<C4
MG]/F0['X+*;$_=P\PIV&K>@R28[Z$BS,9@U9L`#*&`8B!%<,]#+^/&5R#J74
MUS[C$X:\B;)Y[X5_UEJ]Y^FN=$M*FH`JP4$F1K%+*@%^HCD:[5`#F3*5)LN!
MY]KB*-BW,</XE!9W1ZT([Q_IO).6*>(@<6$`=6@#DFL).:;BC9JU#9->B*X>
ME:_,*08#TR0TFYNG]:Z-/RZ7<7T\Q.R^Q[O@E%#.(S)46M`ZHBA!7(:L24H^
MD,ST0,N:-D,^;(B>!UT;!YGC8^YG,]^/)$$MKA_'\DWW>]'#ON@-_[F<+3;W
M[FU[QO+4*YV-FE&>.,*`VZ[,(6Y]6*)(`?\32@T=SS9G-%>-9P5TFITQ/^;@
M\7F\[_&.$N$T,:EPE$%.P8+A*((1GWW2(B83!AK<MK'E'F4>CX1,F_.X=9][
M81>#[7B6BZ>/=H89BE3U8%30@!T*$'0.P#7CFDA$D`T,+=_HQ&SL?7H$A%J-
M^9O<;S"_+>?'W,B?/=D)[3-5Y320XKIEN'$@5<1EC$J1<2="Z"9M]G'=`.T9
M[>O`:2-WKQ/64QQ/7^)B-%_VT0]V`/SPS]VY\+W;^NM%;]V]7I?.'175!Y?:
MI<`1"T+`XO^!"HG_E)3?1MK`0[8AV>N7C6^%1&V!;*(-I/XH_\>TP,5U7H)+
MQX^SQ6R]6?5&):=#K)Y70%<"RG+*BF&4+U[2QD-404'FD;I`17#3EC1&I5$U
MS%HPYG'T\7)-L7&+]S,_/QV,XOB+G3(LH90=08N$^I+5"C?U[!!0JS+UP5@S
M\+"]C:W!J`P9':L6S'CE9JM_N/E=^CFY]=W6?.>/V>;#[XNE7Z=5G^WB]>+/
MNS[[Q7(19O-M;/M?BT7E"B?$=VX]6]_'^OS\HYLMBI"WO0XMR^D/;K7`QXZ1
MK%D;.A,M,SX6FSHI`27/``)U?TB^%R%\C'*@SMPH#L^HA)TR[H-.6$H+WBR*
M6O@F_UH&X^#!RM=/=H&C"JJ2QAU>1/#2:%`66[L],<B4.#*0&VUVN[%4K?'P
M:6+?M%PLGW;\M/AS\)W.4HG+=-;@;0C`$NH6RD@&5)O86TL0.G`_:R,X?RN7
M*F..0+N;ZDO27AS*T^!-Q+EB*1!35%AF8@D_U&?H9E99;VR>M@W4J%?`8^#3
MWE+A6AN#0S/*:^J-R@9<]*08@5$(W%G<RQ--2GL1AU[IMMF!JE@'C`=6<W/;
M*\TM+RZK4ZA@,!LC6$LI.,DU6*E*$G!G@S(H#J9I'Q>/9_S4`KRJ!I$/3D*O
M%^O-ZN[)$C.^;>/>ZEZFC9O-6]?ZK@Q3S4J7H:^HJ%$H(!71!V6B+3_KU7JO
M"[U-JSZD4+N:CH]BW?7PCW[12/'%)Y3VWJ=?[C[ZM'J37\[F=\5VM@\%]@85
MS(U;E%/8(ZOAA25U.&L]JI<"!-$<O$;51WLM@3I"C)*61WER,VV*R5==*-IU
MN!R1_>5TQI7,3[@C"Y(9N$`$Q)@LJH+9JASQ1SWIBZ6JX[]LBVP+261O'PZA
M]>#.="G?3I=8HO=2W*TC1,\\\)PM"H0B@O`<`5(B\C!I9Z*;,Z\*QHW4INVI
MHIOOXISU77@JCCT$V-N%2'NQ6KG%^W2&3G5EX1T1PJ(D&8$)'!\ODP9C68*0
MHHJ$,6O$0"_V&ZZ)8[-E7[ZOUK!7E;2?RTNUY<^M1EN[_.JR^Y-JWF')=S5]
MK[:UU1Z:?3<BK:N[I;C^*&??E[:]G*W#?%F:=V0Q/OYB1RW).DL4D;P)X#/+
MH$4@$)R7F<;D"3MYKEZGQ_<&H[B6^=FB'\7ML3D.UJ;X^>&(K7:#N[OG.@+#
M@-(ZDI/D5'OP,2`LCFF@C&:0,B?")</E>-*1S,8<^N4MX&QRS?XTKD#IQ<J%
MS</EZ673;4AQG68Q!VL5,(0&G`P,!"\VLD9ZQ3G)TOLIR^$5B=8(SZIBS+'-
MA-YF#V.WJ;:Z,+*W\NJRR3:"K)LW.0_>5]LM)9,C$=VV9E?%*__H=<J9)70Y
MT*"$8>`#41"$C9!Q[P#N;5*):V_#R;A0K3$8U.W.J:25XP*R$PRB*A&9F!,@
MC9(A62:$&K@AM)$\JHSH<Z.^,>%K8NIY&)00[CZ6L4KQQ]5RO?Y]L4IN7E`J
MUCY;PY#C$:NN+KN+,O@4/4>X6(!<NN!$N=[/7.LDN#%TH$EQHQO*VW*N'LQ3
MI6:YOJU%S2=E=TR:(*@KZ2F)!<NXAYBMAN"-2EF8;/G`>+]MK"^FRLQK4:XK
M-!\6<VK*S(=K/20RMYV9+Y/?'.!/;_-[P40\551GN:*1$%]4-@/$IF+L)Q.P
M;((,)G+KPM3DK=*I76YE_%1LIHNY;/KOY%;7BZ/G%MZ18$0*B0-%J'!"X7JO
MHHB0M&-4)A$F'L2A+E7.7KHJXGW;7?5IQU[D35IAO]Y]6"WOWG]X-?O4=W$$
M_6E`/1W!L<P)A6>/NQ'(+!+0E!+*TIR;%(V?>`#I27*W%O2#G#$N:O39;!RK
MZ,Y1P3RU#HRV'$3)UI8M2?<!(I)`J>1;$O>J$/"&:-]VZ;S=@4K5V?7EX'+<
MF?6EV,YGRK5A$:G%!)`@4/'DDMT["<GDR3=ZI'39X%X_?Z[!]%L0.XY1<?0Z
M.LT]82PZL$3BD"7JP?;!YT7BW'+*G1CH6G$;<>-*7DX!X"F1](G0/R8S]Q?<
M"24]CENY.N2X'?;'+TES")+A-BUX#GS2GCXWIN-HJ-[J;.G9!5*CLZ7Z]Z)[
MZC[=GIJWQ'LJKWU/^\BWMDDEM[R5_2'G%#9?`K)C>WYUF[3/[_C(6GI^(1WA
M6MH2/B-8&4%398%D%H!$Z[,-2AI]HS#E^SOQ-&["+R5^?+S#QY"!.[_7E^G/
M50K;WTM0F4<Q1"Z&[*K:.ANDS(P1L,Q+B)PQ\$P),%+)J+(US`S,A]1&=*]%
MH^<YXB<!?0OA:6A/^]B,%<C;E]OA,IAQ5_=@!"&@N=-@J3+`HHK"$.&9&'AN
MTT:2GSA-AX(\%4*^V+Q*Q2AT7O)RW.&P?W[R\)6T/%%ZYU`=CR4VH:)1H\@;
M$+R,,#H92-;!:Z(&.F"WD>LG1,[QH9X*1?N,,;@%_(1#/]\C+0[DYJ%B.^&Y
M3T)DD,IH2-IP<`$5M"!YD(%G2M+`JY8V0=HF1,H1,9X*&W>FST^>>#G#%TM*
MI=F#MCB0E:>*[[3UD@G+(47A(7O%0$:7(5$4>YB6)9;',';*OQL[*V`]%9;B
ME]^O4IP=]0B]K*#.ZQBD+E9Q6N(@:..Q90HGKL/M`V>LD$.#`:J_&_.N0G4J
M'.M%WP<OV6N9]KRX3DNBN8ZB!$Q3$&/PH!DWX'TRR<6HN1VX#^N_&]]&P':0
M3<,Y;?O9+>ZR"^6L>O'^Y5:_VGN8<V6)G6':$(G=58DY,!1G6J`Q;.\%(W>6
MRH$'-N9?@4_MX:UZF_#UB6_UX_Q'5=8_-(_);U(LWIZO'_ZL[L3^I-Y'?]>L
M\6E<:-0F2H*#OV;SJB-YL-);7A\\;]8O:?,E(/]S4/9&`#G]>F>L<)29C&U0
M!F))$DX3+R%P@^61I)*T^S97!J]F"UP@?\+%*7XU/@_6]&?>"%Q>6">SB]H8
M!YQ[`\J%!($'`3I:&B+NHWQHHGC:QA=G_/%_[A;<`M0V@7B>MKYWT;AFJNTO
MH/..IR1-`$<C`^*IAVB\`Y>2DXE2%L2D0SU59U0U')L$,3@\'8[G,3O^8A=I
M5IH)`\EZ"5F$`-J3#(I(G:GCD>H;+=%%),B'&W_9#+JLJ(XC)"PZ`<;'$E1`
M2!"9"!"1(SDXZM-JH*MDF_O8,0?]JUE4'<NG\^FF+J<5@?R7V>".=*1?8H<M
M3OVK'?%*.6LI*(,`"XXK,@^>@T@.O_&.^=-&)[>\U+L-?X9B-^A<9MN.>6G'
M[$L[7-^.?(>*?7+'I>C+"^ET-E0)IW`>$`V9,0Y9J_L$HSE(0T]*S^WUBD<]
MV%WX_YH^NAFNIZLW^=5LC3PM-I4#%8TS2^\B<XE3;'G6PD+.48*W18+*1!.F
M">5NX(RJN[75ILD%JW,]J&^\7._IV2_IGYMW?Z7YI_3S<K'Y,'`Q/Z/@CC%A
M4X@1*#$1>+'!2C1[,"P&EHW7V0X\4JVKOTR:F".@/#U.ELGU[J_E:%3<E=<1
M;J6SU`"W6D+,#+<[ES,$94ER-F?E)FE!-&D&#@=WHL3#ZH^&!QQ68B<9"UE:
M!L+&#$9P`E3@Q$0AGWFB(S%#R5?74FCZY!L([S3I]VIY-YZ$>%]@EZWDRHL$
MLIRHJ512^Z"8#SH80HRA),N!\7?J&@)-GGP#T9TH]_#9<;F'SW94<,F(]"`=
MS>"R#T`\MZ"BXD8S*S0;J)#4-06:/O>&H5OY)OW496C%T$]'*J]_Q_XI+8HA
M=8,J;GNKO&O$\4N)QX]UR25M16"@2]*Z$"V%E#T':QW+F68FPHT"E']I9IE\
MZP^IITLYN'N32V;[U:>CAN-GO(UB22(N^02.\`S$^@B>.&P+$S'8$)0/`S?>
M-A<-PP?RJVN%&F"UN=_=M?R/Y>I_7R_>KI8AK2\GR>&W.]PT6"8!MPU;JA>4
M%%P-""<4R=X::TY&:;OMS>[8)!D5K*8D^=7]];/;I-7,S2_GR,&7.Z6I-$YH
ML"5+M"UW"$%%`28A&&5JH-8SQ:.+>A09$ZO*(M&NQ<\W\`8VAKL*6T@_.VOA
MUXM_.!R3/KO]-OEGGP=R=O/JJYL[_H35O']R"5:SCNK=Z<W`2QZ0Y7P6RTWU
MEW@/O:-607O;A@DTX982\<%TZT<6_#%3M+>4E;>3;-OB,Y(L'WJERX+F'#2#
MY%T$J:V&1"56:2RW,7)M]*33\HPT?GNVMI'@:F3WN%U@3]+]V9.=B=PYX4J*
MO.3`8J]`2&U`1NX-]X[[,/%4VI7&_UJ86@Q["89?PHZ_690H4F_RH\WW"`6.
MO-4Y%-&(802T4A%$MAR(21Z(<LHGFT@:FBJCC6Q;APWC(M;DP/EIHJ=W*[=8
MN][?Y[XOYR0;N*"43D<K"5$!7"(.%4(?P'O#P*(&P`5+U@T-J]/&^[X.<^HB
MV())O>`W1+`Z_F(GJ3#*!0X\Y)(;(8N25<P!B=P:HK5T=*!7<AM_^#I\&1VT
M9A1YE+4.VQ]ZPA\32`^_U)7L=CID7$V5M""8#<"E\\!PA57:*BK8R7C_YSJZ
M?OQSOOR<<*_O+8#G#^U9'.O$V>]VV>+$M3A$E!5;8I-+1A!-=]=0T41%)IUZ
M>:QA6M8'K@75!V3J/&LV7%5N9Q4N"C%Q%#^XAF"3`,9=!BZ\U%'1:$ZGG;WE
MH?7()+L5J,W6VA<AK.Y2'+3D'GNW"S3$D(('Q:4I7E@,Y1#*P1,;N6'6<3?I
M>+V5B%0#N*KGW&>?UIW]8/T3\K.;4OL$_>VJ2%^;SV_G;K%YL8@E)?N?I?J#
M/TRI+=4/HP<WJ3J#+F]9;2K=WX.A&E@2*B_O%KTES(OY?/D7<ONF55<GRKDM
MJ&B%='83OL<Z*L;G/MF.VD3\[8-;I>_<.L6W[G/EE,I?UW73A,KS7D1)\:%9
M*`\6=?JI[\;F33Z1>?.B@KH4I71<:^`)&Z4HS1"BSD"R3TPX3]-I4:H.(O?J
MUV](R5E(^[NSZRW^56[SP_+]HN0X>IM6LV6?Z6C]O?MSMMEFOGSQL1#Z"'25
M:NRT4H8RZ<$DJL`IGT$RHL`K&H05+,@TZ5#>-2GU/-K89(9@D./K48!>+XH?
M?+'5[1M9-OCM#_MN0:XIKN,\)L\0<NF#A*Q+>B]F_2Y6%C.,DH$FA(W2Z]0G
M7&-\JZI1!W>RBB++P3HKBB<'ZZPNLG]=<W5)Z,ZOT__=854_%(NL]?//MZNY
MND#^6UDE5I_?Y-]FN++G62C:4.BET=GB_5O4NT-5V[#SZC_OJ8F`==Y3YT#[
M[_]6?O(X%?##_P-02P,$%`````@`1H)51P"X=&<W:```EP\%`!4`'`!B:6EB
M+3(P,34P.3,P7V1E9BYX;6Q55`D``P/S)U8#\R=6=7@+``$$)0X```0Y`0``
M[%U=<]LXEGW?JOT/WLRSVP`!$D179Z=`?/2X*FEGG61ZWEBT!%O<ED@W23GV
M_OH%)5&Q'4F$*)*BW%-=E98E`#PX]P"X`"[`7_[^.)N>/>@LC]/D_3OX$WAW
MII-1.HZ3N_?OOGX^9Y_YY>6[O__W?_['+_]U?OZOX/K#F4A'\YE.BC.>Z:C0
MX[-O<3$Y^WVL\S_.;K-T=O9[FOT1/T3GYZM<9\M/TSCYXR;*]=EC'O^<CR9Z
M%GU(1U&Q>/*D*.Y_OKCX]NW;3X\WV?2G-+N[<`!`%^M<6U.4?YU7R<[+K\ZA
M<X[@3X_Y^-V9J5^26Y2_2OES^>NX6&=XGMB]6/ZX3EKF?5'T-[1("RFE%XM?
MUTGS>%-"4RB\^-?'#Y\7;)S'25Y$R4B_,W2=G?V2I5-]K6_/RO]_O;Y\4<!-
MG-[I)![KT4^C='91)KE@(V.8^;2TR54QT1E/9_>9GN@DCQ_TI;'J3'](\]PR
MF8%>UN#G2:9OW[^[B>,;PRUT`46@9/9OW3RM>+K7[]_E\>Q^:DQR,00BA"ZB
M>-HS'Z\>.EQ:X%%X@0,FYDMT,]4]R^7E,ULBY<]YG,=E]YP__UQ?L=WY.@5G
MW5:MLO<!U:+]V.7O`^P7_5C,H^F!D%^5TBEPV\9HD[L5H#R=3J.;-#-^SX-F
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M8"Q%5Y.M$VAV4MN=JQU@BRE!+9`7J5I\L*V)-B5N'X;EPL>N/"V"LM3(AK2M
M@%!1G/TSFL[U1QWE\TQ;#2\[,W4'RU)&-GD[!UD[%;/*W#E,YQ"83F\P+9OL
M'D5T!]FN05MD;0=BG)AI8QQ-]_`>=^7I#)1MXZ[/VC7$^J9MD;=KD/4-VR)O
MUR#1`2!17R!M^Q[K$CH#7`^AD2KV*+:SJEEVJK4Y6P&XG.Y_B1[K$6U(VC8$
MRXYS>XZ.`%FVF]J,;<.SD]+6#"W!&>N;0H\3G>>7WS]:F](F=_M`GWW>"^*&
M?"V!*Z+D+C;687FN%_L6OZ;I^%L\M5!=;=:N(5H;V[:$G@#7NC][%-$U9-NV
M;EE`2W`?S+B49K7+,3\D;/?QUOK;G+Y=,*^?8CUXV.5O%ZRMJC8F;PW*:EO_
M,OEGE,7E(XR,=6:^7JP%6VQI[U5(?[#WT.6^9;52B0^FY#NK]?D?4[8,P)*J
MK1E:@;,*9?R^,[;VPM=;9,O'UL'<NZ!^X5N2W;2\?BMCG="V)^[^R?T29-?'
M-RRNE:I\RM)[G15/GZ;1<@OPSWE\7SYQZP]UM6E>XI$J9-DD#R[XN-6S;(%M
ME7^DRMHUN$/+;:5RUSK7F?$^5)J).!^E\V7,')M.TV]EC%9M+:P+Z`>N93/:
MMYQ>P=?.2O<NJ!_X=K+?LYA6H"]B$8(H+R.UGJSVC;;GZ`B0I7!K,W8+KU::
M]3F[!5B[*U"?LUN`EB.@;?Z.P-HUY;I\[8";W^3ZS[DI79:+$/GKOVM!6N;O
M!:QM*]^OF):@SV91]G1U^SF^2^+;>%0Z'Z-%_QPG=Y_,K,#F;,%^I?0(W"Z5
MM7TZ>^3@*&G7\LV>N9&4*!M5O*P^/J=F?4`^3HJ+<3R[6*6YB%[OJ&PY@E^=
MJB]/[KN+&D8U&RH-`9G/95!YFIR/]6TTGQ8-X6TMIR.PZ2R*D\.QOBBF5:B+
MDL]G>G:CLZ8X-Y71)LB)*2L;S6_T^9J2AE!WE+01L!%)G"R.DWXP:58I2TQ'
MNL]A"=)X-SH9E^<.!@9S8S>]1KO`:M!.T]$FZRTL=QOE-POSS?/SNRBZORB[
MSPL]+?+JFT6'>@[@ZI*0OZV^#BTA&H+T9:%G:Y#3Z$9/W[\SH,*F186,0`&H
M4*[`@DF((,:,28($X[XOX2NO>5I>G))FE?4Z8V2])+EP.'?4]V7",``&>4"!
M\H@,/*48XOZJ-L0%A-;5YKL:638Z2[.QSMZ_6T]M5HUZKS&HO)FF+Q.E+7)C
MJF*^6/1!/X^FJ9D#O']79'/]_<LT*4S[D-/%(TSWH^^6RZQ]26,99UZRER:E
MT\P>XUTM8V>^$"HE$)>"J\"C@D.B7%B1`Y'O]22<'9W\CT)J:M]M,FF!F(5J
M.A;`*YCBA8.QP?`;TX<<,*5\#A`'Q-0.**IP52\,B!]N=+(Z,_Q6YVZ'V0^S
M5]H=2V]'!?U;_T4]AFW\_HW^;.C\31=?DTQ'T_C_]+.K(WXUP,O1\^,+CWZW
MHV155!@@Y3M,2H&55!0+!*E;C<)>@&H=I;:DLFG&\J-.#K1HVBM9_4NG@JL,
M<4+G\5VR<,>R_YF;BMT^Q<E==;[_'WI\I_>54[/B0Q<BZ@<`$P]!CH7#`Z@J
MUB@7S7HCYQ0EU@N!/<M.E-;1XT`GYD-1;O[F;/R_\V7[V4=@%@6%`<.F"4)(
M,6#008I3N6Z`R'6:20F=G)3:IZIGT7S)#.3EA4G-Q+*C@##PF`])@'PJ@>1F
M5HG7[H+II66S(0V?G$C:HZAG<>Q:/C"=Z-7ME^CQ\+6BJJ20J8!ZT'&@,B,X
M%PP%S*NX"#`$P_*`>EMFZ9;&/B2U"W:@;]-,7^O1-,KSQ8;.XO(V"WD=4&H8
M.([C$8F(:672<YP`N[3BR"&2#<L3ZDUJ_5':A^Q>8RV=/0LJ^3PK;V/ZI+,X
M'5OHL,W'A`Q!$5"L8&DOWP?(\=<LFKD.&I9?U9LPC\CQL3O(`WO"=:T!`,SQ
M7.8C908&5C9.OG9#84"&Y8P-HLMKR-TSQ?QR\7+_<9![DJ]"ZWK:E'S=I+^[
MQE=S0[M-%2SV*UM\2NAS"LP(9Z8#2@8>E\1U"%)(.@YG@<^#T]K*E!`H`I#`
M*E`,`.0AXE2U(0+TM32]<ROS*-;;O<NY'VU_L5U.-P"42P?Z7`0ND,S%!%?D
M*![P$]CEM+;O7KN<^Q%S0OM;KBM5`#DE@8_-^.N99K6NER#\5'<YK>UEM]'5
MB*6WHX(3V^7LU_C'WJKJ=Y=3.(`J287/'4.*%%(Q4;$A,'&'M<9WH$4/W>7<
MCZQ_[W(N6:,((DH<CSL`NU`1CL&:-8!)K9L^B%W.5B36"X''6,FS]?YKG-E#
MBC6.HN-A7R$@I'!@X*N`\(HE[!+8D\R.X>OVR-N0U57K+1U6<$BH2ZC"KA>8
M]N@21GR\GK%BZL'A.M?]"*0E51[$]K_UN9VQP;G];U&6IR/'6N_OL()#17T7
M&\M(A(D0@2]](BNFO$`,;&K1ERQ:4F,CCOM0XV]I4MYV$I7'/Y=0Y>-]^8::
M'4+;FB=4&/F!`UV7^@03B#U'K1NYQ[V!:^@8R^-M<=F'5M87V:X@KL+V=BAE
M2XY02`Y<0!AC'@4DX%!R5-6-,V=@\2-#T$D[3/:ADL_15.?7^D$G<UW>?5IN
M`^_:$=F0/.2"``=QX?J.[U/A0NS[5:T@:QC,WUD8QQ#TT0*-O0PWNOCQZ/&F
M(>9YNE`@CAP7N3P`"#D8NL+WUBLJ2#2+;.PL]F((<CB$OY.)O]ATVTVK!]AM
MWEC>PP./>?8]F.=Q>=OZ,SPV<2.[LH6*"$ZHH"Y%6/@N4U@NCX%07\$`JB,%
M@HPF>CR?ZJO;#>#SX.G97[6A(GL6%7HNH@(J2AWI2(PH\019,2*!QP813-*.
M25\/6]TR-=CXD0VUK5ELWY(C=,T$P7AZ/I72<.`K3_$U(<8GQ#U)9[]U],ZL
MGG9!6A^.T2:DY<=,UZ]#UN8-*:.*>0($``KC!@H72UK5U^?<'>Y2^,$6M%!$
M&UR]?8T,;CEZ>-+81Q(_WN!6?A/R-'G0F7$-1_K3),IFT4C/%Z^UWK[[;Y4O
M1)XC``>>#Y!4$@O/7QVC-".T(.[`3H>U:(NT.Y;Z:/3KJSW3%0$5-3K_-=L]
MB:[+&OI*<?,?0`QR,R?T(>)>55OCP/7E.S37Q.$.:,L<]:&(3>_[_#TN)E^3
M]*:\VWGY]I+[>9%?:^/?CN)IO%B','_-LRQ.[H(HC_,/<71C?BF>/LVST23*
M]2XE=?7($/A.()WR'^H0RC%V1%"QZU'4[%1-9PO!G2AP(-SVZ<#P='83)XM:
ME&^\B,>+#1#C[)<GO6]UENDQM/!E;(H).2$(^])SRV`=Y4(DV=HLO@>:!==V
MMI3<B<(ZY*O3M<*=JV''.775Q7*8!SG@PK!,J$,)IS``2W^5"1_Y]9%P;V\Y
M##*NA,^0\>0]Y@AF:,$5(T"AOJ8BS9?#K$UZZ'+8?DS]!9;#!/<0]@@+.%:(
M,3?PA%<1@A47;V(YS-KJELMA^Y%V^DL=D`!D!E$B`XP(<Q@%U6%GX4-,P>DM
MAUE;<.\UCV9<O7V-G,QRV/&D,>3E,,4=%R`%)9*F(_4"5X!U%^IPM[>;1=M:
M#K.VQ5[+8?NQ=*0I9#DMODL6)\'&QEF);Q?O;UV]?WG)TI@EXVJ&'.O<_#:?
ME0?'5E;4'^*'\L^7[V[>;P;:%8J0NE@Q,[]#PA@7F@F@JU;WWPE*%#RE1;JF
M;O%PZ3X]R5?5[4_>ZR>&V.>.+US.L?`H<Q7S@*BXI=0=V-'"$Y!R4VK[D&WU
MWOL=.JN2A$HY`B&,*6<NXL"76-`*/:)T8/&>G0BC(1>GU@$)O5QH_!(]/OOQ
MMS09+>\:ZZE7JH,1>DP!8"P'N"L!!53YJ[76<A@(<+,WE706<CKXKJIEOD]-
M]=\KVJMK^?JQ(3;C@\(^8P0"Y7%$D0<KEH7TFFVWN7]951_([\FI>.=!CI:?
M%`:NZTI.<7E6U"VGG=B7%9<^!,W."'E_7:WN3>GQ]O8VOF3WA'?X%"$^=UV!
M/<X9A<B'Q"70]Y&$4@9^[7[6V]OA`Z8%".SZ&%'&S3P[\`!:,2*04'+P.WS6
M)CUTAV\_IOX".WR.H!P[V`F`PZ4/!'`%KP@!+NE+.MWN\%E;W7*';S_23G_W
M)B#<#<RHZT%`'.YB2&10U9<XQ#N]'3YK"^Z]C=.,J[>OD9/9X3N>-(:\PX<)
MX9XGRT//PH$>@(Z4%787![6G#(^^;]+4%GOM\.W'4B\![UDZGH^*J^RSSA[B
M4=TE=)N2AY`&KD\=GQ(6!$KZ`>9T7:N`]156/$P?H07&>M1!;F:S*Z!Y;:>_
M-4_(F0`<HL`GR/-<HWA23KQ79"'`ANL0'&:NS;9OC:"W)X3!C?H#L7\+0_UU
M]!@567QG.K?=8_L/"4,H?%<I*!@#I+QDT\/8J:;;@K+>?#6[P;P%EM,6Z6AD
MK-_T/$OOHV(2C^X-\C@95Z^LVFV[NGPA$Q[V&09(,.`P)I54WAJ[:OCJR\Z"
M`%HV9<OLG/H!1$X\`H0'!16NP,`Q#B=?KZ)QIZ^UG'8.YS1;$&R9HT9M_5-:
ME'L)T53-BWFF/\93G1=IHBML/)W-XL4-1E_2+Y,X&W^*LN*)W=]GZ6,\BPH]
M?=K6';10=.A(Q@51'`:*!)0(0M;S6\E%T"P"[EB'!/=3R9$X_/<QUOV.6@I6
MOBF4\<!QL`-\7W&P-BOV4+-@\6,=,FS6CPV$V^,=8RUO\#1U?G&RDF599+Y=
MMM))^?$R8;-TGA17MUNRK!G8_P1LZPB,C^.4TPL,7$PQ=*COR&J)P7@F[L!>
M>MB)KH=)=9\!G,O7?UXFH\RT;"WT\O\689V;,X8^,(Z,--ZLZQ"L*&,NA55-
M':_A13/'"4)J*JI6&>IUL%YVX2+.1Z6PKXUS83/>_I@K5#Z&QK,5AD`?(\.>
M"]83'6*Z^A,*[SEXR#R8GN&.>M?EIZO;JWE1WMJ9+ZK[C_ANTOK@MNU!(0Q$
M$$#@B3(FWH4(^<&Z,4F%FRT=D9,2VE$9/;4HQ],X%8:]@$N(65#N!"*!"9?5
MZI,$N.&-H?ZIJWH@=!\A<K+CNY!Y.C6"3\M.XD$;!A?7,E_KZ7+M<A+?'_/1
M>Z4X\GW*+[$^ZVT-[C*<?,O/BRMZHM$"_KKE[.B*VGQ,&*C`Y>4M4I*(TAOE
M4"B,E&1`.LH-:D]G=1V^VD)E[0-<VWI8"#D15#!7*0`(I`PQLF;5$:JO+:V=
M(;#'D='6D-DC<3_8H-HV0F4H<LLC*@$TPQODU',5`A45S,P_AQU.V[\B;()I
M]N/T]&(HJ*D#X`HB)MT``\`<P:OZN=(A)Q9,8VTNZV"*9@2]/2&<1C!-__9O
M8<_V@X[&]UEZET6SFHB,'U.&R.>2E*^NA10R"+C'J:SPF<&XV44,1PBGL>8Y
M;9./1O9:K.X]Z.S)SFA;DH=,J("7"R_2A<:98H""H$)JO*IF]]L=(7JFD>7:
M(:6/;O:+>=+5[3./H\8UVY@^)`Q[/L"0"%;>P!1(K-!:EI`TNQ:CMS#FH_MF
M;9#:AUA^Y";:3$?M*V#W+"DD2`@.:.#YC#H"HX"@=<,A@2>&Z\@=:-OT&+S]
MM;4T.%]PV!)JP>7X&!?Y_";.)_&7*#$&7IX`XFEVOUH)W>V"6&8/)06$@O+-
M"%*Y*(`0.W@]^@H'#<N9[,Q.:>?4-1(!^_4+WVWG[RE"AGV,<>F)`1Q(Y#*#
MK,+CXX:W)W?F7?9BRL;L-++6YV]Z;&1SE=U/HB2(TX>XR.:SW?;;E2>$BT`2
MXV%S&3@*`TSE>FYK?F@68=U99&(O%FV1KSY&]&N=:_.<B>%#Z`<]3>]+,E:O
M@9:/H^E\'"=WU>[F96+F7*/%KFB^Z[:>`TH-`Y=C((&2KB\(<3$L&\:*(^KX
M`SN,,X@]C/[H?HL'`+@#J''+*!<4D\",E5A4RS/(E\'`7A=_5,$=B?-&JOMZ
M;\A+BED%[WX);YN2MB0/N3#]/^0(>PQ#Z99QL]52$E(<-'-:.AOBCJ^.=GAL
MUL^LHOK3VY&1H*E*D8[^V-IS;$H<8D60YV*EJ"^D!P!RB%.A+./2AA62?GQK
MM\%B/QM31HCQ>#4D5E$\M3%WN[*%P''\\EZ4P`U\AWB8(<&J6L*@_LU*_4::
M#\)1:9'//E3S(1Z5.$L_:9=*GB<+N4$M'6`X`8PHSU/(5&55"Y?)9A?#=!9Y
M/@A5',!?LYL"5NYRE(S'W]WE?+6%M&W`V)TKI`!BUW6(\#WE(:=\G:>9S@,(
MB?&M37<XK$#PXX\<K=+9S%W(]"R>FT%+FWE1\10G#\9CV>4B;LT0*A<:5`YW
ME2.Y$_P_>=>VW3:N9#]I<+\\XMHG9R5Q)D[.K)D7+$6B;4W;4D:73CQ?/X!D
MTFY9$BD*I&C/0_=R1`($=FT`54"A2D)F>35U0=INT'?F+WUYX>="LMV>Y62R
M@7ITOVNZ'-S#/%@B,".<X1Y;@ZSW2'.L9-E>)$6[[6GY?B6?#<H.O>!S^(2[
M#;$_%:N[=`.OI/=%G<.?S\X/-.YC`]?OYI4$3%/0(*F1-H[`J-PI*[:Y7BG'
M\9>ZH7$A%)H[:Q^K('CMHB9+/05.XOB'Y$^9?F+O!53MK(/,#MA="/.@>W5&
MM`;K,EW7V]>_%L7GT4.=:_4YU082M6ENF8R3*H*0<:Z?<K=%:#47[7*-].:"
MG8<U)Y(R(YY]F*F'FEOK>GN\8-!""*`HY!8ARZPF%MFRIRE&Z'#]=_H1\+P'
M--\S?P;GL_,6:9/#+6#TL%S/;O5TOIP^3.]'"W6[*#8K9XUK0$VYP%U4W3E@
MDC-NK/9",EPI#9(/S!$\ER#FW4'42KPOEDW]^'P@]V'VSWE$ZE_Q]_6B4,LO
MQ7/C#DF\156!0.6Y89((PBGWWD#BRQYZ('N[Q=&,!!VJQ#TAV(HC+[]^]6M6
M+*ZC$1L;,8X_C6Z+ETT]Q(T3J@B4:&0XTHQJ8C`7.()7]HAQ9X9UY-XU)[I#
M[C+:PP:3D]2&38D@C2;>*ZD)E0X:RC0G%7AX:-YD/1C/>8"Z'`DV9%[^C<PG
MTV)/'2&NQ,X0CYAG3CH)H.6P[+^!:&#I,R]&E/.AZ^5H?C=$[>D32M,J@E,:
M0J6TCC.G%U@3A"MMBR/9[IRFLR/['HC3$7*M=)#&)/XT^CU]6#\<4D1.K2=H
MCJF`5L1I54:%RDA%604>,>VTD<Z.[+O61CJ&KX\IY<,LQ13[.%\N?83O]/FD
M4?F03$$LA((I_R9UWGM:&H1"(-S.;[2S$_\>)I,N8/O_Z0,/&8*>>L33S7&!
M((O_*#&RO*4346?^!#U0JS\P+^]2H#V)K43<.:2D`]A+Z\KV*N<'YE+0]7*4
M#:B,.LDR$6^\*B:19C?3U?7=:+'/L#FQAN`QH=A0I9V+RZDU&$A3S8RT99QW
M"-ZJY#M#KH\U9>,1<CV*C/T:YZO9NCB>WGS?ZX$R:YR3!C"`&;>"\N>5,MEN
M[?CP%K=.,\+4J=]0>?$E^5-5,7!36)(+NOWLB8YZ,%Y\JTSD=;4%8@1EG$,O
M'`7`>R#29(U=\O?67M1&D^W:5Z,V(^*!'F;,6W[L"P%:KH'@WBKL((WZ2S3`
MG_"#B-F^<HV>FLX\'R_:9SG/B&L'3D>'DM:N'];W&]?"S53W,2F\!SR$CKX?
M`4Z!C[&*,*=TJSBJP%4'M69]7:7M*E%I'N'.\R/92M7<]^V#'A@U)<(F=9^/
MJU^ZN!YU8>"L+=O+XLHX/->=3/C72?,L?(8OU\&XU`Q+G!G$Z.?KQ8_I_7UM
M8)M7+P9(K)$VA?U1T'$(A<.F;)TCKK>DL,?5^&P8SS."T4Y4L?G-1+7[8E#4
M00:33:*1XAXAQG6U:EC<;GQE=TSH1E1G@M'.]6SZNY&D=M\+SFK)(G<XQX`Z
M[*71$'O!'!(6>#807X%.!'4F%NWVP4;CN^>=N*M9H;<M^/[SV_S;KZB!/>HF
M8CRQF@`H4U9"*I#53GD,F%$E/I"(=B$JLQ_T=R+E;J%J18+G1AR7\NY[@<:)
MWB$?V^&8)5!HJRL`HH+>;@',?NS>B1C/Q**5G+[%I\TD]?K-0(@P@"'CD42$
M.T6$J-JGF6GGKIG],+P369V-1A\;RWNLXIK;0P=*!"R0\@A#);#T0@/-H:ZV
M7QSJ*QS?F]@=R(OEI7BR/1ZMO]=16S80:&6ZF1W!PP+3"!DM\4.>4C:\_85L
M$FS`B!Q8O7^.#&:O8KC4R&$,KQ]&/U.`6'5;8PSOOA@@,,I2I92'G&%#1(KK
M]-0Z*ET[&ZNSX\>,:,\SPM*+"VV&3$V$,"05H2*%8""*0V59V2L);;N\R:<;
MU&]*&\@`9(_TR)25QZ6#>\D\9%1B[YF$H!I%4=E^:^F9&HNK<7J>=@"]/R(,
M;GT?B/QS6/C%^&8SA]68]W]_+4!G64JJC!AW3%NDM:D.W`VR`XNEGP'A>38P
M+G(3IES5BN4?B_GRI!LP.T4#L\1[C6Q47HTSL8O"5#1W49T=ENC[]";)#%V?
M=EN>C.L-C+Q,J=V)(UIH(XS&0!GG'-65B*C1`SE=NP0)+PIT-K>&4QP:`E46
M4(IBNX0BWF)KG\TH)O#``FOW089<6%W`Q77::7;X@]\\\NC)Y18>:%;'@8/G
ML]MOQ>*A#(_]W,Z*'4=FW0:E0UR,J(!28B-U2AZBI-_>QU0R:B^B5OGNN]]U
MOK(U)>-8`M!K[VGR'+).)X6O[&\TUP>1SSRKW'9C)&?%IP-?UDQ.V:O1:O/)
M/XJ4@_/GW70\.N3[6ELFF!0?(2Z!`CLK!(E_Z0H4V9^%>M*>5C9![SI-9T*I
M#_WV>LNVERVMW:<X6"9`(Z/!J)Q7"@#C!"*T&G)"0CS<#:L,,MME06:4WA\;
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M*O)S@Y9^-%UL]BN;;(@<+1=4M((D9%!QX*6G`@`@.!0"6\FU)[4:73=]K1JZ
M?-'ZES/9Q]20*%7]^/Q"VL%:C,:KE#Q</_ZCF-Q.9[>V6$YO9XUN''?WT4`9
M@UKZE*-#"<@QT=H_H0RPM[67N/O8@,G$D_E`01W^KLTV\$.:\.>SS:9LPYV;
M?>6"C\HO=Q!)0Z(BY..?CI;@("_ZNO9^TN[-$+AR:.,G`\A]F!`[S6P8A'[G
M_>`8!HX#FRZ8QO^($$B7_:*.@3>PZ7.>O/9&",V#TOMAP7`W>P8@_/Z%KL;C
M[>EG,?E<K/Z(C2R#"9:S83&Y6OS[>G0_O7F,<V1I>Z4ILU@>](7*67U@!'-O
MM708>^+27*Q(B1K@M%VPT(YS&K26_/SB`/9!.UO\6#U;2#4ZR^N7`T/*,T8H
MQ8IY3Y3#M.H1I2U3A'=\D6J`BLK9R/;/E499<@X5"51*Z2-`D&`*"!5>.E/V
MSE'BAZNCG".JHU(_&YWWQH'!:2A#$'T&][7K8C:=+S[/5\4RQ2CYDE)P_%>Q
MF*<H&$\AKNVZV%ZTW_X_/:D)4G%&G8$2R;FV',7U$4/*-0.\[#-Q:&!ZQ?FB
MFU\&N+/)DIJ4VO?MUWRW:7Z^.)4FS6L+@G"K!+4$6F6$CD.+5\@RH=IY0'7F
M/-L=03J#[%QJI`:EAGV>S@ZPMC$OFE85K$+>*:9IRI&N-!=*V+*'G,AVA^"=
M.=%V1HJ.\.I#F3#KQ:*8C1]KS(Z7KP4OA'((,L,%EX@ZHG2UX"J#VB56[/BN
MY@`-CC,P;>'Z\O2QQ`Q2_2NQ@KQT?GGZ/:C[^Z?F38]<TCOV>L"&6.\(4];X
M.+P0BEI9-?MI0(=K7K03S+PS3-Z#M`=G2%Q.R#T+UWW_>DR8\7'06@KN#,+0
M8VT4%P2BLL60V8'DR,P#^JX$3^]_YQ(SRAZ36'P<)()13XG-Q4(X!$SLL*MV
M,3UOYT::71OO1F*G][]SB?VAOQR36'P<[43&L64T*I@6QDD%$%9I"2D4VS!4
MY6XD=GK_.Y?8/[_\YS&)Q<>!*2&!T9!*A:-J9Q4&Y:P`N6IY0S![],=N)'9Z
M_[M74KX?G17CXP"CH>TLU(Y1SR+7%#6X;#$1+0,,9`_TV(W$3N]_'^;EUK.Q
M.E8NC:P::_-(J<"!H=8`JS$2%AJ-/2D/#Z&5J)TCV.FC\JT;G_D@OB"-:L\]
MCI8+1MHXK0'EA!2">X25+<<:5,B3X5JH6:37C!%G8?5^N3$X>W9XE.B?"IN0
M!;5^."_>"EX:1:.UIY!DBA/HXL)9Z3A.]^:AU6P#.Y,\=CTT6^/1ATPW.=<^
MSV?SGYL`%[/;+0A/N3=KA=VD>+!:Q<Z"M'I2)(0V!I;;/Y!A,!!KNEL6=`!4
M/\X0KR^9?)TN_ZQUHSI<+'!*4T@VAZ(BC;@QP%2>^E#8EK$H3S<CWKJ*F1'C
M?IGT$I8&KC6'BP5(%3'>I&"M!E)LD0/5=(H]&K2+50[A'61$-JS>*S,&IU\.
MCQ#]$\'/%T6<&]WO\5T*?5:VN58).5HN4`D=@$P;A)'1*"63EM6B:CT<E@Z:
M1V2[=]PR`M3*C^;#;%4LBLCKJ%3%(G\>MB*.O1ZP!I9`I6UL*(S+I6.@,K18
M[,:P%,FLHLR(2S^[!MN6?HTMO?XU^ED[AO<7",F01C`EE`,2$8(XT-7,9Y%N
M-X]WZ`'5P>#-@DP?,M^G#M<EKSE0)%B$H202`6^=-29.3AH\FUE$MY+[Z7F*
MWKJ-D`G?2[&G/DW)P4)!<,$UT]PJXY+?(2#>5>.#0C1<V^!\H35@P5DHO4<^
M#,XB&!(-+K0ON3V^7:GELEC5;SP?*A(45((*[AT@G&I,B4>E6S`$BO9F##:,
M19Q!3/LV'\]'IC>Y?YC%E7,;^+>9U%\5"#[J6IQCR"DB%'K)O*V,&JQ`NP.F
M[H*1=R3S<W'IZ5KX8EU,/DY'/Z;W$?%F5[WW%HF&$),^*M:*`HYTG!QYQ6=D
MP=`N3'0@]4S(]'GRM'6Q69TB_[JB@1ME&8S3&:.8XFAGX<K-!VF#VVT49/<M
MZWKTYT.H#SZ\MGUJC,?]!8+UQ@.CH&`$"B>A<ZR\;80<;GF\Q$^6_5LW';.@
M>QG>U)H)AXH$#1TPDFL!HC+$`446E2%8D"=`#-=H/%=<M=(_"Z'WQH/!&8M#
M$?\E3@_+V#1J^=3LYQ.T6DVB0>D@*736.^\M45X":JTM';515)D'YL1TONA>
M'2+FAJ@/6GQ.06'+AM?28,_;`1$,O?5*TZ@8(4Z,,F6?N.>HG=@[LR"SB_U\
M2/KU'=CL:U1ZU.=BI7XL-^I1(Q>"@Z4#XAHCP!2E2`F&@9*V-)P,P+!=5K,>
MCH]SQDC-CU._W*@:?'6STY5&Y#A</-B-]Q\6#@@I%%)2V?+DU2#1<L.A!W9D
MD.-!CF2#:P`D*0WGQ_9$J:H(G#HDK)#>,PZ8]`Y7Q_2&<3<P/]@+DJ4M9*U\
M4_;&4?]6_%ZM1_='UI#&90/2DGI(K=%46R&B:J15V0="Z,#R8N9=0;I"J=^I
MX>/\5['X6B3\HH[U:;1:+R(Y-_DY8:.)X5@%(:IA7A(@H0;0"J,M9:5692C#
M`\F8TH$D#TX*&>'JER@I/>MY3#E:0\#8L+0E+#"T6%,/J"Q]B$R<A-N%D<L^
ME?1)E9QXG7['>KHY7]LFO-K^O9OO:OOKBP9_GB?X(P8/*=/3'D[4E`@0.D4P
MX81!R(5%#O-RY]X(;]JY1F4_X^J.`WGQ::4R?)\MBM']]'^+21DEN5A>S9Z\
M;,O(-R\6TJ@RZ>(F/OXV^GU(E3BGSL"U<9YSRIEUE%FMB"AY;C4U[3P<LI]W
M=<>)OA'L8U7Y-/H]?5@_O)K:KFX.=^G8&M.JOA#5>1]!B5.G]QI!H6&UVD95
MOZ7O3/:8#]VO.'V@=ZD+?<MRO'PMQO>CY7)Z,RTF*>[[BXCP5^;#A]EJ_G1K
M\>:F&*\VH3H72;2?&VZDY/UDD,("S3A"5'K!630,:6E]6@-Y.Y>^TYV$+\[-
M@0`\!/K.;V=I`?@PVW;JPZS8Z9::3;9Z@OL]OE]/MIA4?9\5RRB59;J?>QZG
ML[8C)$88Q+WV0`(#(66^FD8XP.V"`Y_NTC!XHE\2]7[8_S+"[M\NAJ3KZI.G
MX+BCVV-9Y)I7$J)M312B"@"N3-2EM7Y6BA(&K7@GWB+O.H*L/T_JUUDZTYC9
MZK_/2\36R2AIQE<W^VV5#+4&X9E20B.')+78*$UH-;`8:IG;6;X]6O6'81\\
M*^?A(R;7"PRCT7[4L>"8XU_F+P6)L!6,:H>A-A8*):OX/3;^XMIMP(*W1\C+
M`ON"I+F37^]'+?E'=IB?=S[>)E&93=QL%4W%#[,XI!\VX[BSC[K1(EFGR[@B
M7=^-%D5O'[IDXF$5X9U,[]=)OM?%.-GETV+Y4L5+D^QZM8'^ZF:WZ1\;Y"C.
M]8F`HPX0-4IBC.7<0JBH@-M\\,H2J&MW;[M!\'I\5TS6]\75S9D=K4MAG/=#
M`6/DN$P!5!D1"`+AK'A"TY"VU\,SIRWNGSJ[`<@NB?EHJ%F-S\1"/^ZOH.;.
M0H=?#0QQ"0'5WE%B13KN4KP4#)"]A9D_Z>+#I;BY>VUJ,&+IY<;=WL8VRG17
M5S1@1QA7GO)HD&@.2#2%4=E;"[T<[@V*07"@$2_/AON]DVQPUS/>);<R'*1?
MK^;C/Z]^;K8VDIWT\/-^_E@4FY^_K!?CN]&R^'(_FM6D5CNIEN`@)43;E#4N
M:D[&805]V2^-_<#"`>03T[POR%I1X5L<3/\JEJMB\C5%N)J.XU^;YGR/6-?$
M"VM2-B#FE*&"0V"X9H082FVI/CN#VOG-=.:&V8W8.P"JE;`_C19_%JNFXMW_
M=O!2V+3]R90WL75`,D++=DI'VNF[G5WV[T:@6:!I)4(]6D['<>JPJ4_%9'?)
MJO.<;E@\""\DX0@((IGV<?YA")0]T1&LMS!9]V#K=XAI+[?UBM7ST4>#BUM[
MWP_`II@(6,0!XSQEE%OJRGY90UKNXW>RC9]=5+NW]S(`U+O@FPH\>"N04MQH
M#[FVBCA`5-4/Y0=V(_=,61R3[(E(]"'1_RBFMW?I0.BO8C&Z+3ZO$SA7-QM:
M+Z_6J^5J-)M$KC<8Y:=6%;RF4FHB.=."*PVDE]5H\8-)--#+!-`Q=D-BT@;*
M##3:U!-0["MGBB)":(J9PJ,258THA]MQJ+.YI3LQM^13&Q![<9UZO7G2X'[X
MP4(!4*6]0W%,>@>UXD1X6?8PXMI.+^W,FNR-)MD0ZX,3<1U=;$Z=1O=1+7^8
MS[9XJ%6TC']$)?W'??%MOMV`&RV+R9?1X^8\?[%(EXOJG%3.KSP(B"!"V+$(
M$6%.*TDK(P`YU2Y#9G>7RS.(_G6"K'XQO-BR]J0&O!Z0D_]>;P,XGKK`U=<8
M@)&:80@<]RA*`6GGJT$N+6X7Y:B[B\GY^=4/<!?4E0[UY71MZ5!-@0GK+150
M4A.[+PU%AI180,S:D:BS7;A+ZTN98.S056[OP7IW7G+N?]8OHFMT5/UQY[3,
M7WERQKR()]RGZ6R^V+@:;EW4/S9P;3M8)A@"/(,$@?]C[UJ;V[;5]%_"_?(1
MUZYGVB33I+LS^P6CVDRB4T?,D6RW/K]^`5FD8\<6*8B`J&2G,[92"R#PO`^!
M%^\-UE$"K+9<6\&IPA9S9>#@JUUGCD,A9R]^/Q`==W\NN>+`"0(8@;:?FV.9
MMX]/'#DV@62>9S%.@,5L([K^>[%>IOETD]M&W48U0=^;)T'T;S\^Q.,.A&KE
M=!<@Q$)PA+AP"@I$-;"^@S*NX[5,T`?%8!U)BK8Z;#44JN>#?7%:]X.A+(=T
M$YPCA#@&N4."RJAW2`3[MQIC/M_8J;)";ZMC^K,R;':!4^=+K`E<[&^:>-#]
M\N5V]?H]S"]^+TAD&488FMA=/%<``4`/@-:\VNWJX\YD96!OIP.HO@?\B8$K
ME?%/I=[;Z^MM?M4#*J.]XR/Z"HYRD2ZABZ=.3C2#!I(>5:_$S)P>T^O%I1&K
MP:`/ZV:QN5W?;X.!=H;2RW@P7:<C[JM<V=,J,&:QDL)JPS22WE-(=#='R>3,
M"A=.SXKIL*DA_YWU>^/;]>_-UUT,Y]N/.\-YFL(>&@PW#A"EDA\>&Z>U0T1I
M)TU_(%`LKPA%,4/?]&R8'**21KRM0:JPZ:XO#_K;]C5YZA&K\[139IWV`WJX
M44VMGMZZM!WDU=O5[\E=L4XFY=55W$O6W3^3HWPSQCXWZ7."XCH5I8!42.0Y
M)8;L[,Q2&L?58+'1^6(Y9`><[!G!&P@MDYB@E&\1`742[S!443>ME7ZRUW9X
M(M8\OWC\1)C/UD;9`Z+O^X__M6S6<<"?[W]M[IKK`:ODN`Z"HD@[8!'SRA+.
MC!:Z@TLCJO(*Q1:V0YZ`+*_1=4IP:^A^+VZ.WT]AT)AT4#]!"H`UB_/'U$IL
M$"3"=SAPZO5\[953"_HU'A6$\>>EU>R,E&?%IA.RZ&+U]?9FLP4$#E[)M*=5
MD$9A:!SCF+-XSL)$,]K-T5DVLZ2@0O)[C25'XW4J3J`L3J#^*FN!.?<60(X-
MH<"G[+<.-P'R;E$H9JPZ'2?R\#H5)W`6)W"7R>H`X-Q1[^+4J.,NXMC-43LZ
ML]BTTW$B#Z^JG-#WWZ#BU\V_;U-=NO&'I==:!R8B]Y50CC!I-9=4X/X]$`#6
MNE+C?$]*$R%[*GVV'W.6%ONL=1#.60F99\XCYZ2*[V+_5EJ!W%D<B8Z7Z`@-
M=AKD?@[6S/G$,TNRS(,DFWX!'J_%[&D>C$XIO98SZUW4YA5"$G6S)F!N^4"3
MRG',D?@XN"IK,]N=>QOY,EZ'>=HF(&@$UR"5@R"<"T.8@[VVIFW>B>=P[?9\
M-9>C\*S*EP>T7L!G"\@?J_;/3;.^>PB:BEI]N@IA=1E1W494?3O1\=O5Q(\,
M<2L@"E(IL"1*6`/2[VX[@(J=A6:4RYC];K%3@_S_5)X6Y3FK:^?.X!/$:;?K
MK^UZ<=.D6T`>DT\'5;J][8(TG"FNJ=<>66TAAZ2?)[)^KB;LDXG[>:CVA.#6
M(-$?[[M@PJC1_-+>->M5TED'2;2W78A@62*4]%IY&A5GCWKT#(MSGZG->RXD
MFA+<&B3:3EPO+O]JK@Y8A_:T"D1+B:7EG&H8Y^2T`MT9W2C%\PP/Y0WD<R'0
M=-">0`4;/'MMP1Q1)>>H?H-TRAO$J`0><N*E)0@_X@1F5LOM/,/JCD&\VL+V
MZ.JRRTT*VKO=6T5T=-M@.":2,4(=0-(@HIE\?!--/76]#,,R9?O22C8ABE44
M\\7F<X0G_4KQ[G>+ZR<.T\<Y[%/2Q_81K(T+.J#28FR@!`01#OIW5>`\7:M<
M(=KIY/E<\RZ$6)5UYFZQO$YJ@6_7[^/`'S?M?0O,JXT"P30NVTY!!63:[RTB
M\'']YC,KH%2.$Y-!5(,$%ZN[YJ&.TX%KQ?Z&@7$IXVI+@(.2.$&1A#W=`11S
M*T=>C`R3PE1%+WYZUZ%)V9X1@"U"AS'DP)Z"QY`[(+3Q0+)T+R+2ML-"4)FG
MF9#SHTQ9W+)R[]/E%[L)MVO;?&SBT*Y2\?9FM=D>(\<Q([NOX"1W!$-EF1&(
M(L_8X^[)`819W*#GPXU:R)WT?)-SK@G"@L15RDV<I50.$^?[%93"O/AX=C[,
MF!JA&@SXY@R7=\P=UT$PBB@D/+20QHT6&V'MX\QU9HA(+8MPI;-N$2A/J*AL
MN@G=3Z*M[.TN&,H,L_%MQ9P`KY077'6H$&-F9JZ;6M3C])8I$:S!*WV[6:Z:
MS29NK'\N5]M]-4TEOG!1B8^?-LLHI<5#TOYN8GMHE=%;@!Q:3`VUEDM'I9"4
M=Z=$2T7F+3_%EJW"K"H/X.EWO.R=+D2]WS&`F`+Q76%,&-Q'+%@O25Z\?K%C
M=F&J3(K5-ZR8NA[)ON(=S_3Q2M4[4MS`Q2K"?YO&\NN(.AROM`A*8"$1X<PY
MA:712BF!'*(8,$$A&SRHU9C?4&V,%[X=.:DT3G=W>`H0\DXZ1';SXEKY6D'I
M>ZM<'"V3Y]=7'(W#8JZ5)YY.;2#H^/LO!T4`@4PC8K`FE%'B#>Y@L$;G11L7
MKBAQE#CW4B,#DAJ;[M-!CKIL^;4FP2D8=R$FO(6>$H:<AJJ;G5(8SC=@]QA1
M[97ZT>C\:!R87:3K'$0_@?7Y37O3;-XM[A]*4/HX@JOEY6*@"NR>-H$!"`$6
M$%.'@="8""N[,6.3F2M2[BJAHZ%ORP"3)<SW41MNU]M1O%_^\ZZ-H+AT.<C[
MYJY9^>5=\R[N:'&>]K;Y\'?\?;_]:],,W7I^7+?!.T$0A,9+H(6!\3/M=20M
M,R_1+'?[SZ24J(O=L:SY\'>['>*;J-\^']C#S]%,&=M58%$_PHBPY#+Q'A+B
M=5PUL>>(T50N8E['[&+L*(37T8R(7VRV`XOTC6-\B;+=SW8\.0[O-6C!D&#0
M$$0TXD!8`./Z22#!T$F(\C:68B[L<CPI#MVQE/'M[7H[P/]MUGN&E_XRFC`'
M]QE$/(M30$1<):%'1D9P>9PSTAHZA#,KLA3S:A>C2VG@CB9+&E(:7UK_G@W-
MM^M#:3*^MQ!W3P0=3T72*#264"-<G&=<2*V)D\V[NJ"8<[L<08I!5N,(^JW&
M?9CQ?Z!E0$)K"H!`2GHCB!;Q<-<I7E:(:@?2''H<;YZ<%IW:3!@I]D"HEH[$
MI0W'_R3RQC+YJ%R[O/B62@>3:65\(!3UK4L]"4<;E_H6@7++#.>1IMPASR!F
M!'1SXS#3OU#IA#&UIR$7E1.Y[)Z%[E=RV75^\>T=')OE7K_XL#LOH[<0Q<N8
MYH)IQJBRV!KX$'&D9`HW&[PFIPPN[R\_-U>WU\W;CR_,::/OAV<XY!Z<Z`F!
M19PDEI0E4ZQPRBDF=O@)I&FMRKY[78I%>='.`=?9NBC+%WLDADKGO.8VRD4Q
M`+SM@2+2UKJYX2`G9G629)1Z/`S7JLG.Q8KV$8Z=A!A&M4P!8A6!D'4OO692
MSM<_.JE$,ZKWY2'W<[!F=A[5N9-E'B29NM0C$D9C$R?J./,&$05EAZ@T5,_L
M0L9)Y9A3ZO$PN'Z.F&H+K;!6*\E`?#DM)1Z1#A-.B)H7A6JJW>71/-4R]#_+
MF\_?E;_9/*U_\_NS8B2[&;[;W6@X2L6>^)$!8NDE(#H"*2#T$5R-.G2%('G+
M73&37TVNS@3R,R3T+U&4Z3K?B]7E]>U5<W6Q<HOU*GZM(L-?'T,04BNOA(^(
M.R`LY3#^CV[+4G9FUZF>,>4GD\$9O@/OFYN;ZZ<7LY8G_3</#9(P+!2D+"7R
M$@T@Y+UB%G?2/'=NL?"0,V9Y/N@G\B%\:/ZYN5U</QW+3^-)D!8Y`[G"@B*D
MB=0`"Q*/T)8;Q^5P-:F?W9-`B1410TXIAD)1:B3%._RL@[!6-:[)/0FC>5'(
MDW`8KK/U)*BK?]UV-8C:]9OF;W5YV=YNY_UNW:[BQ\N'Q6C`IW!0/U%XS"NG
M3,JS%((SR3'MP*-<U\J8.XEW831QGA?Q*(AP#87M0WS2VX_JJOV:L!@T_KWT
M]:"=(]Q+B%$\=TE+E(NGLMVL(-%JOIZ$0M)KBX'VHU!B=FZ"&3.A/@/V@K&,
MNOS7ZR8>0J_O1Y,DL\=@)3?0"`1I'*EUBFC,.VRT!#/S(QPGWD-VELD@JQ]S
M=WCJ-D`42J>$$]Q23PBR3O9OF\\D0>$K+D^MEQP-X[FE^C(`'&%,0<RL(X0:
M#7PW.T_L>:5[CQ;5V)S?/'1^-`[,3NN8@^@/$?EY90@KBG#R"\4)6V*]0XQT
MQ@C+$:P6JW)D+LYH`4Z9(7P8=N>8(2R`8(!X+"SR#$"$''/=#`$5>=:.^OGC
MQ[*C$%X_3H:P31?@0",-LP(I["07_;RM$WE'V?J9Y$?SI#AT/T:&L,:"0F(M
M08PB1(0@MCON.4E)WJ93/Z'\6+J4!NY\,X0%C&I=W$,)DT1A@@#`MILGMCZO
MQ'']%/*C"5(,LIKAD=\<XP?L&J^T"$9Y@]-_1"F$!$`"FWYN7N6=60K?@GUJ
MX\8T6)Z*)^ECW$L'C[F#;8-2BG-,09RB(@99PR7LO:W,\_G:/(Z6X`A&3('5
MC\^1V=E$YD>-"32/N/C=->NX#%XV[SXOUE\6E\WMS?)R<?WZ_:>CV@7GE+06
M"HPUU)HC*GR/"M&9VT?-*/E<6;3E4*KB8DLW1EQ\^;I8KI-B9>*P/^V_QNW%
M!H%PBY33TADA/=3IJ-5Y(AUE<[-QU0PIF@2PD^5CQ>%&4#87J_27!Y6IN?R\
M6O[[]N`,A[U]!0BQI5Y9*8``EEBC'O%@U.5%N,XJ=2&70*6QK.9=V6QN%W%I
M-.UF;QCU=]\-&$)OF51&`J\M(W'1[,]='JN9W550DQO'8E7?LW:QNFG6S>;F
M]\5-\_XF_KC:G;H7G\97O]G72?#&VS@4XA4R<:.-8$#4KZS:S>PVP.IL*0'B
M3#-!W[2KR^V=0OMN!#NJWZ"M8YQ":J1@`*JT<[,.)X1]7BF68E:TFF2KB>L9
MIA2=-$\4.8TY@L`!R2WV3"#7HZL%R_,E%:L.>6IEZP209QWNW[4W<;3+Q;6_
MO8E#_VUY'5?W=M6\6]P_Z(SMER_+;23?A_;#Y^7ZZMUB?7.OOGY=M_\LO\0-
MX/JEW/FIN@XL'GNE$]9I)Y5.J52XL[(Z0$A>K@D_9]*="-JJJ^7#RY**:Z:@
MT:1KC%GPOF\5K"`0>0Z$H33JM8P2T#EQG5(^S\(@SID^TZ,V4SW.E%#B=IT&
MA[U@G$-`:50TX@<+%'$>4:,8Q#BOE+;\$7A5#=03T2[MX)]6R_\T5Q=7:0G^
MN$R[^^X.W0=S\-73NW3CW]*U)Q>KG=";7Y=WZ9\WB]6G9=_V,)Z6&D6@"DD%
M$,5&:$N%CV\_Z`,94&;]7PA^4&;/1`RUL\BW#O#-TS'TV>/=0(YX9D0W*LF+
MZT>S0]V'[;+D7WEFK31P=1<'L:TVWJ[?+ZZ;]^FTL"51S^4]B\9!_01*O-5(
M2TN$A\IK[W?%.*2B-F[Y0Z_]Z;`8G_0^T$=P5AHE:`K8\I@Y(O"N*(]41"">
MMZ=/G-9>2*JO)K1/B]EL4]9_6_RK7:<$N,W;C\G>&==L%U?O5-FCF^]`A-3(
M'H+`*1B=.TB%0!@IFFJ7[P!S&N4%T%5+4Y^,#FT-]&IHB"-&/A@',[J/D)(9
MJ#<IFEUCK07@RG;S-QK2^<9,32[APQET%(8_'Y=F%UMU/A2:).9J_;6-)Y<F
MC>1Q`+NC\E#<U7#;D/*JB4,&""*!(1!PIKHYR(C?O&)O"LBF+8O8E%)_$T^U
M1PC^>?.`N./4(P.Q,Y+2./Q=/=4X$PM-GK.[6-C,:61_)&A9XO^EO6O6JZ3Q
M'OC&#S8,&C).+"8"6H32)03:X&[T*/=P4RP:IK#(IX9K,F&/?=''M`V2"H:@
M\50KP9QAT'/U2%@PL]M!3R#R(Q'+DOIO[?KFT^)3$Z?W]N9SL][:^_3B\J_F
MZL!W_O">`J#&`$RHQD@RSR6'HE_"G!!YWK!B<2>%&5$<OW+\&+M,9'46N-,J
MI4E+Q#217ACZ.$LD=)Z)HEB<QQQ8<B2$-<Z6SS$9+'KU<H,`@#$2<6\,!X+:
MI`GI_A4@*"_BNE@\1CER3`I3E9R-5TUWZL_-S7IQN<]3/MPX8*<E)(IK#HA6
M0'`E.XV)8@'SB%'L/%G'CCXY;*<E2A9!`N-<"X\<`IY*JAPAO)\AA:I6M>"1
MQ)A29*/9<"!&)UXN+B]OO]Q>I]#O7];M9O/':MTLKI,//!7[U\W'=MU\6/R3
MMYJ,ZSL([UE4T852FECCI;6[*X<B7I*!07=E70/&23A5!LJY4B_=,5&*>D_Z
M#IAS)KU67AJHG+7:NUY2'*J\,U0Q0\K,J'<,E">FWI=X$$A32`E3>03[MH=@
ML'/&0:R=MG'%-QQRTK]VE.?%614SSIR&1D<`5C(BZO6`H6>IV)4BALQB\SD>
M;-*O=!JYBR#&(8V)$1IH&11.97(@=5!$87)NN-O=NV8LEWIPK2L=%?3R^,='
M!.UI'R2V&!+K-#1*0HFE$7XW=V-@9J6CB:.!)I/?J_$_TR$TV]B?B]5=\U"J
M.AD*!L)\OO]RL,A%I5UJ1XTD5`MD,.Q@($S5JA:?&=$SB8#;B4&JL=4_':2)
MRLJG=KW\SV)41?CAQH%SY(%'&!F&%$?*>2BZ=R\YD.<;JG.,^/8R84*<?@:&
MS"X`9U[$J$^(E%07U]BH^KU;Q,5VD`,O?C\@3Z&/RBQEDFF%'`-<=_-2MI[8
MQVG^4PJJG1Z>&F+_O?FZ2\A5G];-0P;$H.Q?;Q0$5=3'(Q$@A"I++=2RQRNY
M"N9EO"I(@,DPJA*<V:Z:^]\6Z[^:&W^[NAIFP,L-`E?(4N.4=0Q9A50\NO8S
M`\KG^4F*V8\*2G\2?&J5HCG`<?K2UX.V2@C@`=``29""R*#M05(P+_RJF+FG
MH-0G0*?*5O_T/*1NS&*]OE^N/FUSX49X3,=U$*`#!FE#@.1QYA18+%0W<\]8
M+2O#2%Z4LC<4`>OT-,FF1Q`8.^B8YRPJ0](9Y/#C]J=HK<LL#Z#%E.([B!T'
M8G4:P_`S!VZ=]%5\BH?NOUFZS*.'A_,:_M5K(X^QRN]K%I*'##)(#%.`.!S?
M(?"PQ.I4\4H.K@RE3?*#-=4GO*3ZP4J)J=8,PZB`.$ZY(BK"TR$"),F+!2A_
M&W6&2/.OG<Y!:K8&^WK)NHA;P*5"VDG+B?7Q)^TE@W2M\N.EKC<XD!69.;N'
M@?CCY5DZC346UA",F35`*&U,-W\*O)RO(V!R"6<G7.9A^/-Q:78N@_.AT"'4
M>>V&IO]C[\J:V\:5]4^ZV)='K'-3Y4E<B>?<Y06EV(S#&DM,:4GB\^L/((NT
M8UND1)$0G7/R,./$!(C^N@ET-WI9IS3"V_+ZT7_2T2%A_X@@B!=:`ZN)P<YX
MRR'C]7J9Z1EH/X'\W(/Y4(V!TU!\O:R6ZR_575D=P=EF3"",4:<UYIAB%M?-
MK;3UFCT&V=J:]*ZQU5]Y'1J<S/;\R)6OWBWBCRDV,L\[VNM<C?&J=O?`V/?Y
MN]4T%>*N[P^QQUO'A123:!%4$$(@E:82."#BX8537U'O.SW[^6CMLKSWC@F4
M4`$HL99YB3@$1#!<T^@=GX2)/1"77L0I#(/)9(WI2-IEL2RKFPZ3^9?G`K7>
M`XB9BD>E2ZT3*:,U\1#A?@4D1C:,!V!E-1PF.6R39GV=%LBS)X,!'FKJ&%.>
M2B6)T<#5M`!.\71MUIX\V<?9D_!XVSR>G"UY'M:>A:7_5\R6"`#>&6SPXME@
M%<960D:L8!0CPJW6-3UQ@\L5CGR@;=&;&R^Y>A(.>?DJCN#K[MG@D8(62$@)
MD492([Q&#3U"]DNC'2UJ;'B^]L,A+U_E$7S=/1OW,8RD5I$6+RBG0AOB&WJL
M[*=;CQ8/-CQ?^^&0)_Y[IS"ZG[/YKN#W9;&8W6V]EHN;NA66NKZ.FOS-(9;5
M83,%H[V4B7BFC((N0F/D#@NF/9B8[V]DRVL4S'+(3TI[K<O#1SITL8AL:2WT
MOV=$D,`*[B&2W'."`4J%X6O:%/+]*GF-&#$\ACP,@TTO_^_ELOJ63'9;KF9W
M=]6/U#=11]OQI]JLOU8/WFU?+7>]=U(>:['\7EZ_6C#CM`F#!1"A%`8+%88@
M:C<4FIK:*.3]`L-&C!X>4A*R0C>B7_F)5W1T=_)-\7E=W"3O_;O''\_9WN#7
M;I*'N%_WC`@>1-ZIJ#,@+Z!5AEEAL5/(42&U[BYOF(.^+I?K*T\'`:Q)K7B%
M5,(`@+VW>$>7D$#GLLM;G:TG\Z2UQV@?'";K8+517?X>M9?OQ2.!'\O5WQW^
MUK9A@6J"F&",>4V,4"A"U4##+,X5!G"4^_4D%K\0E\'`R9-`4B\WG8,I%CK=
ME'<Z[-J&!8<0T=IPX.,)"B)M0,F:2@?LA-.+AV'>7HD8#*O?53(FY]>=GD"<
MP]?PI*WVC]FW`_++7QL0,*+>>XDC-EQI22T4M-E1/9E8/M$P3'KA.!@`F1P\
MU[.[9+U\^EH4ZXO$B81ZNU:P;TB02$)@5:0*.9G2L+SC-76:PEP%\<ZF$0P$
MS+G8WKGC[Q\4@'?`&"*Q$2E\VT!D'BF4QDY7$SB=:0=(P4DH_8[R,+GS?TIB
MD)_]VZKBAP0,MP\(3D!'M&"(>P(485"`AC(J?+;K_`-C2@=@434"+CDX_M_%
MS6VYN+7%JKQ=''+JOSX@2,4L9=QX":GA%G)O?$V9<,)D\@6?[<P?!);S,+QS
M?]\W)(#X<7CEK'08$YRZ%V-=4T><0=,][4]E5R?W3T+H=Y.#R9WR4V'_.9P\
M#VLL;M1JM^S'+?"`<C*=HP-CP!D#B/5&2Z)3.;;&M@6>3"R?Y'36O?#U#`U1
MKK)"C\OLO`YX_G`@WD3]11H.*``)*^5=@U;?O/?C2PJ=\1+@1$CR,_G];'Z(
M<_?U(<%@#IR(NZ5V#"5AA@;4EVN4$#+=H_\45K5R_61T?C<9F-RQ/P76#Q`"
M]*E8E-7R?;4N5E<_JLLJ`O*^7!27<>N+:[&;XNI'_/_]PW\[<GZ/GRHX!(@2
MDDN"@,-QNQ2Z/ADEACV[=X[HUC^54556O$Z6B/A@L5W8I_)G7*,OO^]97OSE
MX<)Q_*S!$D.=D!Y;+HC7VF/4``RQFUAIT?'D9'3H3A497VV6VP7^?[%L65[Z
MS<$"<_2<P6(+A)$*"D^HQ,@#K&J:C?&Y/$CG%I>Q@3M96-*2TOK2_O=L:;Y:
M'BLFA\\6'(U6.2&*2L281LA&J&LZ/2;]8@E&*ULZGH",!EE^_=//K@LUKS:+
MMNJE^X8$91&C"II4P0-281@C38`?5VIBMPSCABGVAB4_TW^)B5@G3\E.C&>W
MAX>GMDT2$$N!.9I0)B6DT'(&:O^*)-#TRPC/I'D,+1@#`M4O7Z%YV^5LN2V2
M^N'+D]ULWQG1,2Q@2*5R.IYPW"+GC!)"U"M'3$ZL<OE0+!X!FOS?_\?BIIA_
MVZ90+<OKHL?'OW>&P+41+(HS<UYH@!P$(MI:%A'CF>2@WTU$)AUAZ"]_*)1Z
M??:_+N7/V=_%_WR-R%PNJ^]E\M4<(P2G31B(D4)+[(4B$5C/(LDD4JNP<$([
MT2\)G4Y=)K*"EFT36:TV*50C-6'LO*%X^FS@4`%++/120\"YC'3`&C[)4;\+
M"C9U(1@*C[SAYWY6UN?:XS^JU:IHMQ*ZAP>%-+90.\.Y(5(K2I5K\!.\WU;`
MWXX4#`Y1#L%(A'_X8I;%39G,G/*N7-__.?M9SC=S72V7U8]R<6MFW^)OUO<M
M`G+,-"&>A01(@B$26C,J,->R\=G:GG&+XJT(RHA0G4M@W,]OY7*7MY]*1API
M*,^'!Z$\9)BG,,!4U`6*:$7%\]%K9C$WL)^W4KYE`3D1HG,)QI.M\,%_\F&S
M7JUGBYLHXT<*2=M4@5NL@`0>&@>`-U9*1FJHG2,]8Z3`6Y:8`?$:-4/^2=[Z
MDY]_7<"@B?(1@]OR\]W#B9SJB_Q153<_RKOQ.IFTO/.<"?H^D5-<1.7DYOD*
M+P[(UC]D>'!1Q&C<ECCQ.OGFJ52<0R&P]1Y"W>E)&H?RQ\X)+40<WKZD:Y)@
ME/:.2*.9TPB[5/]:[5"P#IM^55T&3O0?EIU[&Y@,C-5DBP&\4DJ[*^/O]1$!
M:<B!M@IYH)S!3!&.:D"B.:DS"4_/UB3#\?MYZL\@<&5)^WIEI>G'9=$='M8Y
M-B`>B4+6"LTDM-IH#^".7H>)GG!Y@),Y>(!$#('5[R\CDXLEG)YH#."U-]7B
M>[%,I;&*RZ^SY7QV76S6Y?7LKJ-U2->X0`3D3FD"-):$0$40T_7:F5(3*P0[
M("^J\5#JQ>&K^]7L\[*\7%8WF^O]"1][GPU1BS+0:\0,1$()@8R3]1H==?V*
MOHUVMSX2)P=`)D\ACQW:KVLW^G[;*<?<S59=3>J.G"E`+CU1$D(:_V!-#33U
M+N@LQ[F*1$Y-(QP7Q@F(U./Z#THMZ#%;H-X9`A"PG#/#:?QZ9?/!QJUSPB4F
M1N/^<5(V(*K_D;B$S>1TT[<L:.<0L'B.7T<EX6.Q*N(+4U=Y6WPO[JIO!R7%
M'C0^&,^<B$H!@<0S8Z*N86U--_7=O9)SE]$>D;,OI&AX_'+(S=5R=E/,9\N_
MD[=\^Y<$1G?-E-9Q@7FMC;6(,66=ET(:WVB1A-!^%XLCEM?.)R=#XI9#/EJT
MR",T[R-F"1AJJ:DCSF(I(IC./6+`*.UWQSAR$98,6O=X$)Y9C([4?8Z<*0"K
MA8`P;K9&8I7\$IC66`A#V'0U[5$X?KA4#8CFO[>$34ZS?HN"-8#7\,-F?5%>
M1XR*F\O9NKN5]+[G0SSL<4I[HQ`C("B(?\'U6H&U$]."1^-$-3Q6>4)TMUIY
M<7-57']=5'?5[?W'\O;K`74".T:&U!*-.49LE#L(F+0"-Q:HIVQB367&EHMQ
M4.OUY;];'/7A[WD\(*[B'X\!%D1;DI)0FYN-",[$6L5D^>Z'@2K'9[^[YOA0
MMZ_IL%A>>SQX3QV"R$I#&8GD<`E,(ZK0]SOI1RX0E<$T&0"KC!*0#.^ZA5&G
M+KAW3+"`6&XDQ0`@J6WR-[+FRDUA-5V[XC1VO<[[P0#Z_01A<NK_1/@_P+FN
M_O'AO?O?]L/\Z3,!*VL5D5`2(JFEU`O0:*/,3:V9PP#85L,@D>.K_!A/I*Y3
MN7DF`$<TX\I&ZID3W"JJ&[L4<=<O%?+X?-BI'<5]`<K&X$XCZ\E3`0F'L0=.
M.D,](E'@F6^<[![#Z9ZQ/?CP&B=/PN%M\G1RQV5>5N9GX9\1SOEFWLG$7YX+
MR&I/`$4TGCN.$B"`=,T))*96/[$7!ZKAZ,_"QX?<UFX^/GTN((*AADY'T@VQ
M6G,.&C1@WY("H_FL!N'C"?3GB>3X52%X7ZS=S^N[34HHK-/9U.?5MKE7:T#'
MX=-$:?;:4HX=E@0X9@T"M>_'0\TF]C6/FD(U(F[GO0;[:U5\V=Q=E%_:DNT.
M&1Z8)\8Y"J4W,F5&.VA)3;66<F)Q\.,P].#KKMZX]?1TMX:RM,K`<1,$A1TG
MSB*MC6':2Z]X0XW'?'(Q/B-*P:C(G?GR_(]EM>H9VK,=&A!F-C4@8)(3A"$0
MEM4Q;QY@VD_#&.W6Y,R[12_,)A#`_`*C5LWDN*F"=`YBC*D11#NEO>7-';(7
M7/?33D:KAY=%@D;&\!QZ[E;RCY.C0R8(%G,4*;::X*@2,NHU:KXEBG"_5CZC
M5<[+)#TC('?F<TI=7V_FF[MMSZ)YM5R7_]R6\>EW<NV9+%@)-8("FGA,1X2Q
M8Z[YBBRU_0JVCE:`[]QGV3`HGEFNWK<6[&L?&"!VT?B,Q&(GK#(&2^N;7=?"
MB97J.[>\'(_85/PQ)_IA`F`"*2TH!)8[QCAW!-14,V?[:3BC5>H[RQDU`&Y9
MI&7^;58N4\K/AR_/27A4VNZ2^!\E12=,&SA02CD@I9>$08:<]@U*\:=^&M!H
M9?[R2%<^/,\M=4.)V4L<D`<"6J$(1,1S9R%AC1\#,]WS*F^T:H!G%ZQ3$<PA
M276M"5/-/Y</O40_%M?5[:+\9SRP;R)=Y9=R]D3%V]:AN%&+FXOXSZDB8EFL
MXN\V\W2^MQJI+7*8<14!*,XM@U@KSS2`$#_FW'D'4+\.7_!MN[.GB_^3;V#X
M&IE=Y2.??8^9ZD?6B[@XH%CDBV>#\(AS"@5"D'O@.2:**,>Q54Y`WMU?:!R:
M'D.AZA4?7@;REQ&!8F*9!Q)3IXB'Q&B.=O1QKWLVZ!NXYN,)7-E;X/$4%&93
MK>8X1)`^T\0ZR8$U#E'.(C#0U5!8;7()1,_(P)YL/20B_SA@WEX@-F0<$6!D
M\BL13;7CA#7T*3'A3-_3V'5P1'8_@'X_09A<B.%$^#]`_,%5<?TE:E7+64=1
MOE\?"U0"AR2G2&GO!=/<JV:?<\[E*MQ\<ES^P0A7@X&1TR@\O<BR!0(@ABC2
M-$HT901BT0`D0:YPP[,>SL-@<RZ^#U<MESF"K4PH6N`IINE^NJ:7&SOA\_ID
M#AY=-K<?5K^_C$SN*)^>:`QPJOO-?/8M%?M5M^WG^HL'`\&*>1E7X@355$@+
M@:X-765[1G^=L6;RP6A7`\*2YYKSNIH75[.?[N>WE-"OBT6$OCW"_-4147^Q
MPA/&`(8@7>\+*1K:B+83ZV@]G&]F&#QR\+KQ$^_\MG:S+!>WG3W%VH8%XSU&
MC@(N*;)&8*A1K0T)K%V_4(?1PH&'X_J`H)S'M[U59L=L!/6]6$16WX__AO8F
M3P.^Z/D;K^)+-K,Q&UOMWI>!5ZMU\O2NWBW^,5MNKWC>[7JON\5Z>ZUSWK>?
MLY'7JVNZ/^1:IF-D2#E*B'(AX]'`@=+&`$JPP5;'/8G`SIJ78U_2[./&X9<V
MK3,$H(V/.R+#BEHI%3(,@II^;46NQBFMESB#\7#OE<Z0&$WVBF<?D?I^6Y"J
M_%)>;^^;/WQY`+C#T=1GNA"ML(B9)$`1XA$D`MH&2HKUQ*^(!A*3*CN0.53;
MYXM]_:OM]$P<,TWPV#/G)?'6&^0$(EZ0&@7KF)ZN(VM<IE?9,?UWE;#)N<'>
MKF`-X"Y[7T0;<#[?+/971GGUN1!IE](3HCP"SKBH2B!;KRWNX_U2:D?SG(P#
M>S4<0#EV@_?%^L'O<U&M5FJ]7I:?-^N$PE7UOEHD)2M"&M]Z6Z/2LB4</5>0
M7D>J+2,X995[`#7%-1Z.XXFYVL;2H,?&K6<F?FW-[C=F=WZ#EFH>?:<*S`K$
MG))&&R*L=8HY75.(C>VGXH[FCAM:,C+!UDLP/A8)DN0CK%+%W')V][1/3'D7
M5U<MBLO9_=83HA8W'ZO[V5U:[(>%J>;S:#+$,9]F\<&_%I$M5\5ROOKPQ401
MGWVNEMO-6-TNB^+!G'M=I+(N(D!A*`0X56.!WG@3+1)>HTJ<R5;SJUT8QQ>:
MZHUP(,?!^7J?I-W521/17GO5F_9*IFH]0D^8-3AO.1;"8DB9P@)Y@4R-$<.F
MGY(]^):934KS0WKR.:O+^"W51>;C1_)MMDA`?)VMU;*P1<1G'H^4FZM*%W\E
MO6!5W94W*3VYR]?==B(/_M+`N.+*$ZJ@=$9%S*BN/U:!#>BGU0U>,27O=CDE
MQ$>\I[N(HVY_*5PP^#7+XRO.>9>25'43-?.X=12+Z\B#0ZY1]@\*$`($E*+<
M2V\4U58:L+UIE=@8J3L#A3)1V75A\OJ`@*`TRFG!H\4")9/Q\&ZH$\SGBH]M
MO1\9@CG5"&A,]B;DTSKN2>E-?Q35[7+V[6OJHMYQW;%W3*!44ZA3*3$8-R^/
M$;`-*-K)7")RU)W&J?Q]?I,V$#@YU-]/#T+V=*6=+N.]8X)0*-K&5"-)&?06
M84-(31^G%DWW!F(`GCV7@H%1^OVD87*W!5,2@K[,7T4=Z[;Z_E_7U6:Q7MXG
MWN/Z+XGM^`G;=_\<WEV]PM_'7P:+A4446@8@,R)JH^AQK4Z9B;6K&`#SZD0(
M>CKDROGGS7*UE<"+<EZNM_(83=EH^E9WFSUEQ`X>&Z3R"&M`%8EO=I$4CV@C
MQ$#WJQHV&AL'U./&@FA$`^S#^FNQ-$]L1E\N9HNMJZW>I![,IM'LLX-7<$[S
MK5G*(6;;RX<COQUDS!CD+>6*,N:XX0@01BS%493.%/!6+[0SKNV7!P-T"GF?
M/*R`0R45@,KOJ"$&NESWMJWFV2E,V*=G]Z%^LN:8GMW%SZSX]+4HUA?5PZ5V
M5Y;CGB'!4&J)5=RSN$=2B1F)1LP.62%4KH/[N`"SGEQ]GK`T#"994M=>66IW
MSMK>00%XJ0G5CE`LL+11YX&RII!Y3J=KA9W.M`.DX"24?D=YF)P=-B4QR,_^
M!\5KLUQN#\FFC%5G0YW6<4$@C^*6Z:#E6#,J'-:\IM,+.+'6*D,PK!H/GBDH
M_@<_V)$6E*6B2@WX_:-%]QA6TR+3APP/7#$%*$$20J-M:NTNW0/OC#>,=O;#
MSDYYEUK?-32DJ%3.B4+_:N]*F]NXD?9/>G$?5?L%YY:K-I'7]KY;^VF*D486
M-Q2I\'"B_?4+4!Q*ED7.$)S!@,I6)16''LR@GVX`?:$;<$-`V`N](PW%3KM<
MU]&/*OK]LN[MXC)](52L,=!O;`8@[I2''`:-6G@5#"U/&U"(-KG$YB1SH#].
M=X[2G`;3Y?GEL28B_",=@SP<HA`)"AOZK#,%%SSI@6>='?1I*+T_:2C..BA)
M"$J*TF!*A'7,>P,8QM!;8V4S5X!8KMN$9T=I.F/^8Y3F-`BRK-68&/NI_E;/
M-W6L=-#2Q^.MQRN%K%&Q*$3,3T/&4D>>3SA%"XO;#*KW]8!/#J[;^K8.AN:-
M"?].MUG36VOMA=FY,T2/B$+G=\0B/I8SXQQD`@:SV(AG,+DBA75`'%0^A@*M
M!(-_X*(;@2]!+5\_?IQ-YNL`G/MM,]VF6!_\BX*F,F8,\N"D.CHX6@97DB(I
ML!7:6NX]4PIHPZ&&V&IO(6C=_@<ZV/9U``Z2T+TJQ_%75":L2X6QCE?BB*/>
M2P9V"#@K;*XP5IN[HS=&'JS,T2M.Q3H]OH3I7=VJY3)V68]?;'%XO/E\I3T4
MU'J(E'80&$F\MCP6O@JV`6`^UV6OQ.(:?7%ZT3]4.12H%S.,A_C/B_GD^9<O
MX4^KR75D37M4Y,0W5=8PC9E"00M`Q'I$F,`1"PP`51Z9<ITC9_)V,09N?VY9
M*LZU4K8(]9!CZ::KR?1X-8P7CU1:&^L$`!QPKX%'`FCR-".DI,*%U8,?#.]%
M+_#D6.L'CTW]&&6[O8]+V^@*:*B-5]@H1Y34G"O*FY,W_"E7?=&RU(K^@1M5
M6.*<N_3]:!M=*4`=X=P2B[4/RC]'0#4T0P]QN<I$KQSM*BUG(_?GD)KBU(;2
MA66$%+[-=!;+$;2JE-\_6'D23F,OG`=0Q(8[3&+]=*)BKK`OK)!2K[SYH>'`
M&<#D8/%/D^N[Z;Q>/KXDO)7?1T95!#I''*8$4T$IH1(@%VED4#"H>6L>4W8_
M_F#,[P^E')+PM\G\II7QSP\%>XH)KBR00:62T##&?52;,6!<&.;3[D7V7E<C
M!Y^301GUH%<W-UOTDTR)_>#*QQQ3XVF\;88M\\+[:'Y!@B160!=VJW)`_W;O
M6`T8K4L.38V<A#MHA$I;!04--C\30!H#E0G6(J<*6R*%0*/W]AT^0J6`%-(3
MC9T))$LD)-`-`I"[2XE0=69D:H3J-)S>>82*.2$X!T23<-P!"16!M`$C_)CK
M2L8PKJ3.G.X4H3H-JO<=58@5[)36BCF$+"#*8R,:++BEHERGTIF\/3.\D(;;
MGUN6BG,UE2U"^2-4#@2MVP1C2>.@;V,!PS[;S,@365C2[V!X'XI0G09/EK5^
M?;VYW\QBHI^M'Y;U]717`_%A5F_9,+]1]XOE>OJ?[>^MR7=O;0(]?:)2$&,-
M,`<2$<0"(PA'._04UCI7.Z3^+-14_78D1-^#ET-"S*#%$'*BG-4J+&/64`QM
MHI*;WZEYO@SUCE46UV:]6M7UW^K)*M96?K%[7P5:)C%O._Y=K*V[O(]%O^>'
M&@B<]\)*<V`H88IJZ!#%(":C-,AHBOF%N$S/EZ(L^"4I+D]?W'[]D.+RXI&*
M>NV@`HIP`96`3+O]R:R@TFD<)1?$T3,1R;'ZS>1ANI[,MM.[^F6V*]=\[$`X
M,**"&`HK;9`]RR17WA"+&]HD\&FA+7I!W.X7H*(<W`/?2XEU_Y??ZI5?+.UT
MM;WL%VT'-9LM?H\U0D;\\KA-8&>;R4[W_/MF,IO>/F[;'SQ-,\YWMEAMEG47
M%__)[ZHPX`H:J1#B&D%H/`,*;4\6B:F1K<GUXV+2YO8_Z3V58X!@J"6.3>,4
M$<))VV`A=;8B:RU-8P?C\`_].X?#KMAXP#/1^[TA=LK9[1\=,D^[O:"2A`?K
M@&&NE<!!<V-"PP8N*&2NA/*3(@8#"<1!L>L1P!PZUO&)M^83=AE>"0"A!0)X
MAITDL<\<Y@W5P3(`Y48,^F;K25)S%GI_%MDI+D)P"2*37U1V$PRJK)FL[AIU
MMC6>=&Q8!22%0%%F%*%6$ZDQD@V5G.:K'-.UMV.?C'NC.5E/."4Y7QI'3^QO
M=?/OS5.'JL/APM8QE?/,40&A)LHA@[@!#.SG+%UAN:B#\+9OD#*6FUEOEO/O
M3=76E=XRLN)42$8,"$H8A%@A@\%>,1,B,5MQ,`_LH(N]7ZB2UKN:3V:/J^GJ
MZE;=QYTF_'=^8^ZB-WC;^3!66-F5R6F(;NON>\8K*RVHT2@0ASP31F&#L6LH
MMC31F9OA)!C*&,X,Z/BZYJY>;[*RN1M?Q3(_QCGAK);:`*IX."QW="N=F!H_
M3(?>+.P]2?E,`S%-WWBJHA3(_#:-6OGJR^)MDC_5LVU4ZLMBNVM^F.]&_JN>
M'%9,^GAY98'Q6%DAG/<P`F[D'F/M8=J>-$P;W9RB-!K":>?<L\[5>8H?E]/%
M,D[P8-O<\]Y:">J\X8A"2*PS4-GOSG>5YH4;IB]N=LG*"FV22#6MS!L%[N%A
M-JUOU->`Y6K=-N,.NU=?[Z^4"#:C)8QZ8P'W'%ON]_A+FE9\HO<(^3AB-A+(
M^05NOS8&$;?]VRMF(;<":<>%-PXIP`S;ZPR8I`E;[P'Z"Q2V5(@'#/%WC6N_
MBN)>2$LW*PG%%"&CB:>26:.UV+;PTU1#0,8JEYC8THT'`66$82N"[%BCD.:H
MH488441P^1PF'&_I=AKUQ8:'^VSIAGP$%6H.@0-(4\O`'EFM7)F7QA*YVK6E
MVVF89*G_T7,++QU.+&<4%Q!@+A4CCJJ&0J#L);9TZ\RT[KV\TE!ZC_)07%2V
M)#'(S_[&M_RIOJZGW^(FV'Z3[\"0"CK@B:)>(4$YA#*HE*:ASDF=K:CDV8W<
M.K/IQ\LX?2"3@^_#M/+S$FLMK87!:/`>"O?R_)30E^'9'%`"^H0GR:3_O+F_
MGRP?MY?@W[#^/LRO9YN;V%K\95W_ET"T1N/Z^T(%D`&QQ!H7`0KL,%3*-WA@
MK@I+T^C!F!@7P/<3C).:.>:-0=!@#0T+BY3OZ#8<B$*JWX[&[:38W&F8CND$
M&OA:Q^>[R;+6DV"D-^ZUC)\:\^*&NW^8+1[K^G.`?QJEKYF<6=P_!&UZ+T-/
M1^75;=!S%E_GT_^$Z=?+Z2(\MUJONCC'>OY2!2VE%FH@%2)`:RP$;HYK!DG[
M5=Z!/&O[BC3]T-N])E2/WZL0L]23`".0#@"E.-J?<2QH'[FT^J-^OM'DZ6"U
MJ?$X4*RO,1QUB_OZ68OJYFX\,BJPB0&CE>0.(\R$53)P;`>,PCA7B9'$,E6C
MB,AB*'1S*)<'9MOJKCHZKH(>4$2#<:X<T]88*Z5KZ#36Z7(]F+UPKYM$G(75
M^Y6-XKR9Y8E$?E&(!D3XSETP&FRPMF:+[65P]T?<5-O=FQU&5PABX:VVB`@<
M+'_,H6L<.8QH6)CCHB?^O7&QI%^<LEQ#J&?AG5__6L_KY606S<J;^\"*:&&O
MI]_JW?0[7$HXY3V5=AQ!+UTL.FTAH])1L#^>)4U+'A[,+SJ,O`R)6)9R5)-E
MES+Z+Q\+:AF4@-H`E=+`0"`Y:GPJ3&N7Y@\?[&K*,'P_`Y`L&T*+VATSN&:3
MU6IZ.WWZX</\QS:XQYSFPWRH0M)0K`63RF`"F)/6T`9)K$!A_3B*,=#'9$*6
M>.X3*?7-VY3N=MECT=U.+ZB4D(`#BJ6T,FP'(("PWY^!PX5U?A^+[:_CPT-@
M6XY4_5ROKVZ_3/XX6[J:%U4&4>^1X\3I<-K$L+G<+_/8@Z,LO>FBI"P1XQS2
MUL]AL:MG%G]]RL8>/![QPQ<KI:!W4BK,+6,*"J-!@RU7!!2F_Q4BOV4P(RW[
MXMB*>QGJ76U#FHW-<S#5(NUUE6!,8"DD8YRC0+-VKDDWXIR@M$S<P2I8CBQV
M&9$N9O,,^[X.=OCM=.T#.TY3$/OY0(6PU]P;JC5#!@8+4N\-?!YT^C0%<K"Z
MFY>T-?:-_8"I'@?S'\:YX'.Y"1!!:KQ&@9W`"*0!PSJF*$>.8LN-:^W]_+\$
MB,.Q50*!(HH98XF0A`)L&-QA&U:Q?Y<)$)WE*4L"Q&D<*#8!(M8G_GERW]KK
M_<5C%616&BZX448P)9263<HP-A#X7)&F`E(<.@O!:_]S.IQ9P@J[Z;7WY_[N
MP8IQ[0DF`CGM'7",$.*:%2H\*SAK(8TA![AZ%AJ7S-_B,@_&8&L/)OM/D^6O
M]?KS>G']ZS\"7BV5"=]^NC*>:N08)QY`1Z!E@?9FG@K[TAKF)H*\Z!N()(9]
M"1+Y__5J7<<,]O5R>AT]G1W9UV5LA9UE/ACTECF'G8(*@^:@L<`F1M:&ZPO4
M`S,'@"6M=M=D=?>Y7J]GV^/_=K&\?[H%$;2&MHJAK2.KH#QPY(47R`#+)!+F
M>?Z,NK0[(\,UZNF!K;V#DN6\[,SXEA$5U,0%=3'6SK&&:.8AVM/FI4YSO@_7
MQ^<\AO<+1M+JW2O[<>?XN%E>WP5-/Y+5TC/R^+#*448YH]9JXY72&GGI]Z:H
M9&G;\7`->GI8M_TB<MXUTJ..<;5:+6+#P?KFG]/UG9W>WM:[XGU?EY/[[C=)
M^_A(!867%@B*K:-A+T.(FCTJ#+!6%]AE)\2<ZK`9G0'EI"V<GPS#XX5)83WP
M6FK-8BE3VU".:2FM;L=D>5HBS&FXEB-1_2?"(..#>N8IT-Y+1H&2F#5(6"O2
M>ET,4S+VDB0L$=]BXK@7D03#PTKE04^1&@-.1(!3TST+46+\9)BBM&7(;AF,
MN.0$&.DUIT9A(KT(A'*CZ5X;,L:E^>.&*5`[KLAE1'F,-()7UT1RU0E]>\$^
MMT36CS_,6/T^6=YTR1PX_^65"[QB1##M#'/><TCU4]*2LMYYUKHA#YTLT$KB
MZA"-W1,$SOQ&%>NP0"TM9,!ZP0P%?(^A)BA7>.9X]=.,HG(P#R`OT.\J]N^)
M5XQ9!8C!EA!D[,[\":0+*](<F-EB_]D8?RS>?QJ$)<>#)=<!#X/#&O3<``2H
M$`TEF"AQ(?'^S@PY'AA.0^.2^5MVO#\36TN)]P?-VH03D7D:YBF4P,K39I[A
MP"RLJU@JR!WB_:<!46!0F#''@+184P,PQ,(RW,R?8%5(*Z8^&=D[*)<5%,8,
M*H&P]DA3CE%,5G$-;0HENNIS90&<RO!^P2@S6X<9[`S%&&H-C6+"0,@:&EC0
M&LMP]?2Y@@>`)<W7]ZSJQZ]?/400_QK4^PXUA-N'5D@S(!Q"$&NK#1*&0ME0
M8"0I[(P=P=8>",D1BVZTH^5^VTS7CQ_F@;+-UH;<%MS^<C>9/U&^>B+]P_S)
M$3Z$'^W$*52<<$&%MA@R*5A0CHDB#?H0F&R*?1=?=)_"U*WRQMAXC^&5_E+_
M$;MVC^*;_BZWZ.KW>;U<W4T?XK'D/E]]?.XP?-HMMLXOJY!5VGC``BNP%!1+
M@#AV7DFJ@?2J-9MK:-]S9Y(2[J)U>F6%((6.2@>"W@T\EMH%37R+D))AR>5J
M--SMNMD`C&^_438$CN_*<8RH0MH02Y2B09MP0;^'D72#M`)>Y+JQ>.ZEL9[Y
M?,Q/?!IB)?L1B4#0,PP%1THZ9CVG#26>4$<NQ$_<F2'''8II:%PR?\OV$V=B
M:P_6K8)24O?YX\?C/HI7CU78J/B3EQIPBH406/HP,TVXLQRPPBK#IL*ZZ`V!
M--[$GSKPYOO'*F,%I40Z8;CBP'-'),4>Q&0_"XQ,.Q9S.7O3>',6`F?=`EG%
MT_MA=WGA(=!R/_EC>K^Y7VT=D(=8UFUTQ3P@G'D.G21`,&2AU=@IY`)U7IM2
MBU\.IRT/!UX6=U"<\(?5:E/?V,UR.O_Z9,H_^:H/WH8YWGTYZ8T5M0PR`[$E
M"-"@3C+$18.-P**P>%!.,RP+H%F],4.WD=K\LJI_V\2:Z-_BYU[__V@?'K/%
MU*NY='$R'1I2.0ZXL`3J8/RYF'3*,!%*<\X0QHRV)OEFH;#53?3&XY4/ZK%"
MC..@*?.P0QL;@^M;RI#FP)7@`CJ?+:]WF/.1*-:)\RDZN5L\./MGJK`K&V:D
M)E9)&8YI(BAK$&1!VRK2?7,6]UZWEDB$(H>NLIU;>Q.1YZ?"$4B"=0N%T,$>
M,@9[Z6!#`V$E>V02^/`6)\_"X3)Y6IP7)B\K\[/PIP!G,'%:F?C=<Y7TC%#C
M`&+&Q((F6!'9T*&0+<R.3.+`HC_ZL_#QR51MY^/+YRIJE.#1I"'(*RHQ`*(Y
M:+"U+"W&/IC9U@L?SZ`_BTG_2A\('V[1?PZ,J!""A@C#=5`K*0Z;%P9[VH`V
M:1[5TWD[GC;4#S`C,;TUO'%P3*4\(%0*P(`'S@"!N*0-?9X`7Z[>=#;'VB7@
M+(S>GRP4IV^5(P*CL[Z]E]Y;SU<2(4(<E+&BC8;>6*;W?@1D7:X\F*[YG^?S
MYSC'DU!)BN#\<['\]7:QO*Z7]<WF.@(83[XPA<G7MSQ9K6,JY;!A5""AJ882
M$$Z=VLL\IH64Q^G=L=4W,%DLX9A1'N:Y=?&K^<VG>A:+#L2K__':__7NS_#(
M:N[ZB@HSK@A309PIE9`@I:W>XPEP+L4NMU@,C%/2DO]N+I.WYS)9W361DT.[
MP(FOJ8A$W!#$-`46`2DMUWOY=P`45I*SWXUA6*R&#*3M"Y9,O\ZW_4[F:W5]
M'2O,Q+#@8C:]G@X:5NOR^6Y/'8^$E377+L#^Y?_B7_TR6=7A?_X+4$L#!!0`
M```(`$:"54?Q;?4R-`4!`+!##0`5`!P`8FEI8BTR,#$U,#DS,%]L86(N>&UL
M550)``,#\R=6`_,G5G5X"P`!!"4.```$.0$``-Q=:W/<-I;]OE7['[">+Y,J
M*>+[D4IF"B2(C+846V/)2;:FMKJH;DCBI$5J2+8LS:]?@*]N/9H"2(!-[Q=;
MEKMYSST`S@7N!<`?__IXMP8/)"^2+/WI@_Z]]@&0=)FMDO3FIP]?+H[A17AZ
M^N&O?_G/__CQOXZ/?P\^GP&4+3=W)"U!F).X)"OP-2EOP6\K4OP!KO/L#OR6
MY7\D#_'Q<?,M4/^T3M(_?F!_7,4%`8]%\D.QO"5W\5FVC,O*_&U9WO]P<O+U
MZ]?O'Z_R]?=9?G-B:)IYTGUK[R?8OX[;CQVS7QWKQK&I?_]8K#X`ZF1:5+8Y
MC+0??WSU^:]F]6G=]_V3ZG^[CQ;)6Q^DC]5/?O_E[*+R\SA)BS).E^0#90.`
MFH\\6Y//Y!JPO[]\/MT+SS]AGSA)R0VC_)SD2;:Z*..\/(NOR)KBJ)YVFY/K
MMQ^QSO-G3V`4^8PBW6$4_>F=!Y=/]^2G#T5R=[^F_)R,<6``XO(U6F7P*AH^
M#D'9Q^O+!\H&?$E',)$+^?4C98.N.UN4KE3TX9>/E0U>+F:UG2,KX[7DSO'J
MD?M!K]G'SNA/S2?9XWMDN++>B.O.D\EC2=(56=7B^>S9(%G]]('^M-@4QS=Q
M?+^`RV6V24L:P\ZS=;),2`&OBC*/E^7"C73--K!OF)IO^I;K:)$!(]=$T#,<
M#=F+ZHD+DAY_N6@!5+^29N&#"`VO&<Y)D6WR91VE*#06IVNT?]F"`BTJ\(\6
MU__^>+)UYCF'V?*M;E'!N8Z+JPI3XSC%IMLG9%T6[6^.V6^.-;V)M7]ZGZ&7
MM&9+F;36+*W9G"++VX[XK+O`?`FR?$5R.M]IOQ7GRW?:H_G$R3*C$?R^/'[6
M-&S:(]^33'J?J\FAKKQ)S*MQ=)'<I,EULHS3\K7Q2SHB`^KR'PN((BNP#2<*
M-4]SO""(`J>U'OF!N2B[4/+NP))D4F20E7L"7<](N]C<W<7Y$\BN0;$%#.+M
M`+QO(.\?=4H9YU.Q`Y`MIF@[`,&;ZL9`@@KEU/K&QUV/UDDF?R:Z)]NK3&F/
M%=1#:G)SMUFS"="G\I;D879WGY-;DA;)`SFER^8[<I85!9WL?[J^C!\[>?:-
M$"+7M9V0*C-T#,U'CHG-R#!"7W.1SC_I4&)>Z8RD10PJR.`99E"#!G]FL+\[
M`A0YDU2*_:#SEB$D]T]JE#;;3$:^<C=?3X<FH)5_KE12)"PM=AE?K<F"3LBP
MJYG(P@&&E$W'=(W&"G21Y@G-B<0>K7KNTZ*AT9?AZ1F@4HCBG,JHXTAPRL)/
MCYIYR3,B^N8?PQB;B=H,1?]R/C&&!'%MB/ZU2<HGIE192O]9P,>D6-B!YH>1
MH7LA"FPM@K;E6JU1'`;A(*D89$FQ<M28P!84C?(4UF`!&<:FH)XH)U),7L0Y
M5*LR;]'#(SJC:)V;!HUS9I\D2:"(6Z%>V$+979RDB]"V(QSHH>\&GH4TWXE<
MNS.&7"%E&F9A8D4"_ZAQB4K20/KXI$@]<^,DB(,T)1KT)B\]VC..QYEHSD@G
M,IE=:WCVA"[*OJ0YB=?)O\GJ-'T@1<D4[V=JG:W9?B%W5R1?(+HVPY&/O-"@
M<"(488A:',AR;1'YD6Y<L3+M9DY86F2+&&PA`X:YR9X(*I;\QA#.84W?#L.3
M5ZP)WN8=P++,DZM-R180H,S`>9Q7HECC/V#ZBHM?OKR5W*::B92J\V]_IDH%
MD0,%N+6)*3&(L#)6E4K+_[ZAZ*Z?DO0FC(M;O,Z^_HVL;DB+S3=UTW<-)S0T
MR]:Q&UI:ATVSW&"X*"L"-+%0[TI#M1MNZPKMTF#K#&#>`.8.J/T9I>"J6G.(
MJL^@(<<I_:LV?-E4LQ;]8?1S!P+%K3O+X*#:Y]Z`,0GAW$'D,UFNXZ*HBK!L
MU^ZG3?GIFJ,64V4O(MUP+`^;&HJ0H0<>#MRPQ639KBX2/)0"41PT7F('V::J
M?'+62P>E3=4V'%^<F$V;B<4'Q<VE)":,H;HG%DS2@C.)`=/XFAU@B$RD^4T^
MR?5MU\>6[00T(MDN=#W+[5#YSB2JSPEEYKH_+#NMNOG4:K^"EIM6_0^3'1]'
MMX(((-B.WW@,$/564A081++R.-"L2+#OV18-2Y%IN0@%7N2Y48O*"9!0/E\Q
ME%G'@8GDG[?5U,J_@@:;5OX/DQ(:1[<"^1=LQV]<_D6]E23_@T@>+/]P]<]-
M7;_@Q7>6I.2T)'?%P@M]S7$CC#T<!4X8N;;11:C`"X7*"%/BFCHP;'T1U1WF
M$ZB<&KM>4-K.PZ+'7)IX9"A1W+J31)8132$09J9H\)G&G$E<?R<`34<_=S3Z
MF*79/<EC=@*L-AD]WE,$9($MTPL,W;9]S[5<W7(,W&7!G-`16F<,MZ(X4M3B
MD#0'J$@-ZKLCD))24.Y'$,DGWM-P*";%NYBZ8V@-K)Z]5$H4=2\_/?HXGM.9
MJ)T$1S+9W4U0B6HCE_%C8R<@*;E.R@6*0LW67`BAXVMN$.I1:+;F0FA`$1T:
M:D.Q"C4CIXP?P56-:*M%@C(TF$4^$9J"0#$):KACIUT;3.#/#:JI%6@/.3WZ
M,Y;.F:C/:#<RN;U,]&!9O";%9_)`T@WY.<M6[+3K(D2N9I@ALCW#\WQDZY;G
MM;9T:!I"Y\F&&%"L.>=YMMHLRR%3G6%\\0F,<JK$U*6"`QH\1Z!"5)VPG_JD
MV!NT].C**!9G(BKC?'AY'&P\(?Q+*E)N#\XOD!F:AFW:8:"9IF'I-O+:@_)0
M,Y$FM(P2>K)B`6%;/)N%4_QB'V>09#<D90N"[T5746+<<:Z<E-$FN%JJCC\L
MMW=U[-D`._7":9>>OL72(!IGHB8#P;]<%(V@@%L_/N4W<9K\N\H8A5E:9.MD
M5:>/TM4Y[5ZTA]3EC&N<I'&Z3.)U=]IU>YF9Y?JV@33;0U8`'8K&"8/J\A[?
M,K40(\ZQ,PT8=6-N%_\1>.8!B-,5V/6!98X[+\#6C<-=HR.%_9XA/6WKSD0*
M)G8Z.^2`$CW;M%HES'B\[HR?IM=9?E=!0DFQ7&?%)B?;.\)L-W3]2/-L%V%H
M(E/7Z$JL`:)#/5@\D/PJXS[*)-V^B++L0A7,(&];DJS>TA"`2!DG:]'#2?*;
M@T_U#]L.8@J_Q;I#_`Y:L(5[R)L.A2GMD6UUS3,3B5;HX,M#0HJI%$A_T\4I
M)?UI:[-3>^Q`VS$\U]1,EYHU/-OSZHL8L0>QY7`G;X>;4)G`;5`]&ZB'FG'U
M<-2;QQW/[$R&GA177N5S9='S[G"Z2I*KK;U?XSS)-L5YGMWD\5WQ<\Z6;;[K
M>W2@.J'A(-^V?.Q18ZU%W7%X,C(2S"BO*37@CD`##[3XCD"%D',R(H/1?GV:
MF,R!\C0''E?-2V.JX#07/I^!XN:UP@&23OSIVONAX?>^@0J^WB;+6W`;/Q!P
M14@*EO%]4C;WMR1T_;YZ8"^"85_-R0W;2,,>%-_3[S_$ZY[4XXO(P?BJXH'F
MFUH5#=YG\(U@()'V`\<"F9YDTONDZ*5L<9XFZ4UQ3O*+VW@G\B`-6SX,_4BW
M#!A!3/\P:WLPI`MJWHK5X.>KTZP6$J"80`7J<!.J??3TS*9&,SJ3J=1X/UY>
M-":'&/["^/*6K#9K\ND:IF6R2M:;,GD@%V2YR>FBB131XW*]69$5NU.!;5[<
MM*FKET#K>V%-TXA<WX=FY%B>H6M>A+P6I64$6*BD/BTTQ9.UUIMJ[_*./V#K
M$&@]:NY2V?K$OO36B!]VK_3$3<ZY*V"^K2VXG^`0#:UF1X+4)NG;RW"8MI])
M##F4]R_W3QRR$?C+%^.P!4]O/Z"Z%,(Q7%_7[`!'MH4\,[`Q=%O(FH]<H1O;
M#HA3<223)&I'X.IIKT`.NKCGH'V#L^KRC70+P?K,P%944X511W%?O68&#3N3
M>#8+*E[6@.:`24:D^QAW=U>8D>6X$-MN8-F!JUF&#8UN1:AC?WRX$C!VF)AS
M!!C$H=?]C&=XC.@K(E>*<G/S.J&";_D2EN$!5,]:2X?XPR6(@XGB*]I=E-GR
MCT_W3&,+F*ZBN_MU]D1(]>MSVD-OXX*<T_[9W,X0Z;9E!4A',(00A9$)==Q"
M"$R,^38>J;"L?,M1!0QD->!J%R-I((.B^J_[!C2XI]\3*4_);@..NM\!R1=,
MW0BQSG%CC7KZ!<J%!VR&8?5#L>8870P4XV=?=5`1RW,H%ZIR+5/?246BU&5R
M1WXE14E6G^F?>;*D/U7VOZ1)V5X:;3@1#&W/U;70#1S+"FV[J61"%(4&YZ98
M>?:41R2&\OBA@@GR#F<S$#<,J8@,RN&8(_9,3JY8Q&'P0(T/;`&"6ODJB(.B
MC!QZ!6++Y#0/BR@5W;V=>'04X6%B7^R0RN(<(H9<AS)5'4XD.OP2YW^0\I4I
M['LH,GS;@3BD!C3?L>S6E!]9KD`\&&A!>02H<0U5_*&\<6C\!(2)J7K#U%@5
M'TJ9@&Y/0-TPI7[=V48K\]N^[M/BD<S,07W'NI#)ZRC35GG/NBO53.1J.,!6
M&"+71;H.;4]O\5EZ(/82KJE`?1OUVS$79T[7OI.49=4TK9P:K)I6G6/E]HSC
MMLS)&WK6=025?LLMP`XEGF].'\1%LH3I"C&`9+5W#ZZ'/=]R#<VS?"?`"(:.
MH;6V`VR+3/)EF50^ZZ^`5LG750T5D%8T[JEH%`RMR*16&M<<"X-#D"RFVC6[
M%")H,+XIR1P;^Q42+;"<.`3AP]87/-UZ](J#DXY]2Q#9;,YA32+=ITQA]QMS
M*UAG3$,ZLG73@S",L.W8+K*CUA@*K4CL^HQA-I1'B8]T".:L6_TPYC8P?L[X
MIO7JR1)3>][;P0YWE.M-QGKFT^,8GLGD>*03?1>(#:1DX$6$&'D&A&X88-T-
M$+0BS8*=$8BU$5+S[K/52PS/983?Q+UZO%3.<7CP@^^]5T^,`N[A\!M);FYI
MY(>TA\4WA$:E*Y)_NJZB?_%I4Q8EG?'1*<'V:HK`]OW`\ETG\%P8:#[VNYD`
M-C53;,1(-Z]\4+6(C^,:<CWQ+<"FJ,_?+^/UDIVZIZ!%([O\MN`+^@=M!+'Y
M0`L5-%A!#99EYFJX8`?O4;=$/-CL0)3:'D54UDHS$4UU_F43=7=%TENMT18&
MNPO(@;9A6;87A="UG:W^1Z8I4I>1:UEQ\:4;\JW@IMV0I\'Q+DM;!<ZVP!4)
M+V=+R%5=^8V@5'(KN#-5V0J;!(D5:Y)O3%\%G1LHKD,HY%96]/K86;>JM&&`
M(\,),([T`+J6A_W6(M5VSH*$!$/*)ZK1]3595B_^ZXJ<10=3=&HZAE$^.9R(
M2C'M0Z_+PT>@)3:MM6YH_4&)$NYGL4?V)%`_$XV3X4DFO5^*O_,KK^Y'CM=A
M-<&IQ7,W\7F9U8=L8[KH/(^?V(=AGM.>6]^(O?!T0S<,,W(H%,N)`NC;7<G7
MB"`24[D)`"E7PPOA/9A3-@>?1,ZL'<2D=`<\J-&WT\>7&?U.=+<1K/KD\17S
M"C1N@5V_IG^GV<B&Z%'C"5MY)JH]I<>O7ZHV+=GCL@--/NMUJJ)[A^Y""_W`
M,74M<K%!8Y`11+A+5OC(]!9E1IT=D2>0@$$H8]#!%9^UW6<EA<.NOG^6*9"1
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M=@[LW,C#7`!;'YHKK`'7V]FF;[I^09U;JPV3VO]7#29P*&5&#3?LK,JH!N2/
MH'L.L8RC[XUX.66CS.'(RU2N9M/W>=&7C;3O2MUY\^UY5E1O9^PB?QAXH:&[
MEFT&D6T$$701,B+#L"QLNA0`[_LD9-A2)\K;U\8^>R-UB_!P,V`>WGHFP5)I
MG\D\6*Y/+U^[()\P_FLVBH+LO'$:18Z%D8,]S3,""WF!8[BM%?;&1L$7/8L]
M7'G-'%Y<1)<7HA=5"#+$ITT*J1%3H1K(X<3F.1$]LC*0L9D(R%#T+^]0&$."
MH"B$FSS?78^;H>M##2(OLCW'T.E/=M`:@R82?0G\(!O*):(!!.(*GNBNPH'$
MB4B&2L:&*,<1:"D[L(2\(.9=)1E*Y*P$9;`3;^K*.$JXY26,BUN8KMA?+.OW
M$*_9OA-8AG&>/R7IS:_Q>D,6C@NIJGF.K</0@S:,C*`S;NJ:+B8W<FRJEQ^*
MKUK=+]D/9(M44(@D4<PG3--S*R94':G5#SL0CT!<@A8EJ&!.+%U<U/5(F5SJ
M9R)MDIW*5/96T9G50YRL6:(%9_D%M;S=A-UH[R)P,#5B>8'E8^A!%%FAUQDV
M1&5OO#WEDE=?*UDEFK?'.43G7>-IY9R#3<JGX'RLQ79\G>7'!47W[)1'`W#J
MN=E[A/7-TZ21/1-AD^C0R_F;9*KX!6VYS#94/S^3):%:2A%\)&5KTW1<SS8,
MWT6NYX6FIFM!V-KTL1$*:MD84^IS2PTZD'?PCD!*>L:;`CXY16PJ(@7UJV7P
M\PZ#%-G!I*N'IC[5DL'N7`1+BB\OM4H>07R;/M"&L-M%OZ34ZR);)ZNX)*O_
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M#D8ULYW\E.^6@YX)[""J9C)A'8;]U1G:P01PB\`G&H+R9U67!4*NC7`86I@^
MUC6A;T*[M82Q+7C'P0`#R@6AP@26STJL@MHPA#<^A5!,F)A.U$R]J+!.+!>O
M">D1C1'LS40ZQGB02>M*8W9J+/S`0Z%K.H%CT39%+L*1U4U8#$OH3*;8DT5&
MPH`3EY?L*^.$0Y`ISDR:,I($4V<'%0I>C1C&UDSD82#XOGT6@A1(*#)^I+XV
MMD-J--(CQX6N;VFZ9D)#[^8U`1;=Z2G#Y#=>:A0A=VRU41&K4@N.6XRSJ3EN
M(0TJ.PY@?2[J)=4G[N+C8,+&GZ1F:S<3A[YF(+9SWC`TUX6>BUN;6H`$]U*,
M,J5<V[:GJ=\X(C:D$CF.63Z!FXQ2,6'K/9E^B,Q-'T\]2B:%WIDHF!Q?>`^A
MBQ,DD/XM:5]+J%S6DT%JJGX'8I+>_)QEJZ_)>KTPO2!"MA&$`39<W<=V:)JM
M;2LPH6A:6(+)"=+%+<IFA3=$M>2PRYM3GIA6T5QSQV>[/F0OT/ESAQ&T(+^;
M/!']/G&]"6J)O,]$WN3Z]"JA+9TP;KGKGN\8,$3(TCT-P2"@<T$G[#)@?FCX
M8I+&_5CELM4B$10J?E[XQ$@)(6*"\SX32M2$0S&$R9F)*HCCSD;VBN%EK)VU
M'C*1HP6!9D8FUES3<-@,JITYN=`:7,D2L#%)=;N^DK&H%@A95;(96]0285&X
MKJ6(OC&EK8,EB=ZDA:_`-8#&F>C)2"?VE[D&4R)8Z5JP"CQVO0A:-HX\^D`3
M=3KFV`82+W&]^\A):ELC:EKO<R)2S))*QY`JUD&*5^]6K;AIF<E(%T7]9IU*
MT&GNL7R6Q%?)NG[W2+JJWF1QFZTI(P5+P)1/.P>00]</,-0#Y$%L>E&$._L!
MTCRQB80TL\KG%F>G,#@].[T\C2X`_(A`]/<OIY?_(Z@.\ECFTX^#T"NF,#L0
MNZ1N^7_4G5N3V[:2Q[\*J_:65$T<WL!+[1,($#D^Q[%=MK-59_.@HB7.F'4T
MY)2HL<?[Z1>\2M9('#0N%),')\[8[.X_B1^`!M#X?KW*!:*23>!)N^H+`9C^
MN"K#GZL\!$_K+K`0!:Z#PB!-D!<FV*5Q,D[64`B\Q%O!D''0#;5#M@<?H357
M5'0$@\VD@-(H6T`)ELL2B:%+5M?EP4HZDLMX4A-'_)+)_/-X#"_"J4_2*(W#
M&#LT((3%]CB)LREP_0GRY-F0\U#MVJ,\U:U55GL^('C(OK=;@P[)G-NN&E]Y
M=WS>!SI)`\DJ!B13>L((U'AQK2V'1PI,`$9&IX401<KUTYL>I<,79L:G["FO
MWW<-9ZPT@'V/SQ3]A-EI@J,D#%W<FT(X"A",'3(6C#.D=6H`!I`'4I*)<<&T
M5C`^="+U[EP+%&<DF0"&BH`+`8=2")6^[TFRCLB)-9+$C`389=A#29"F$1[+
M`:`8QX%<!1&@$>,X&2M?R!%%5CO!M+!YT8!IXD&M*Z/EO#!3F60U)1<"&-4H
M+E0#41(%ME[]?&JU"I`?)D$0)!&)`H]YB"7#[F24\%F5Q(JUA)4Y0+-[;*ZG
M>WK(RSH_6KB66;&6T1&P9FU80)E5ZW-)EVNL6S^7YJ65:P4Q%\(=Y3#.K5XK
MRZ*0[EUYMD_\(,6V[>+8)MAW2#I8BO@_D+5LB<?/LJX]G-D\2O`JYW=?%DXV
MKZM5,_5\[M63N*#DK;!X"P&*2@0O)FN!8HACI"KO/N6[^R:WLPH("IR`.H@Z
MH8<H0\@=[@1!7N0!ZRN"'FU\J/+69$X6IJ(@34S)!^0(=^.7/??#:AR9FR!'
M&DRQ0T:JI5!#RO=37L@+`%C.N<TYBC:?LJ<C/!UMU(O=YFJO%)$T#4+;9ZEM
M!X/=,$Z`FVN4S9G?5#.VC$WOJ]74?QM&)M`J5>KZBB[VS"@L=`6HUY'[]N/<
MJ"W;>K6]O2])-KEDI$GMA>!*7SS/%I>T"B6=P3FR:'N8V`G!.(D\QT>(#[Z&
M=7'$?PL$FH(AXRCKLA';$6CRLRL5.>5R.89T5$[G7/<D`I13&E1="*%T1/)"
M:D=:')GLSLI/`A?SY](@9@%)PY2K,IAP4CN43.N\^-Q9\CE:\C@O2P1.X&A5
M1SIS<[V$C5BF1EBEA;!!RO7+N1E@^.(7FE7W]T5W%+"Y6:@J]T5YEY?KQB3F
M_R0D8H$38>QY-':2X5@U0BP!KF"K6#(^*CERKKO#[-@]Z`5F*I**T6,N+6$T
M.161B(EHYG:RRPI-\$:'K@OACY903N\?TR8/X-+UT\,-K\N^_,/[;A<LWN]W
MQ>?'MC;>IZH9+W&_N%+\H7>O2S['R.NC:R&9ZY`HX@,IVV&4D#!E8\(J\!S@
M8OG,SAFG8!<#]!3#W*](#)$+?C<PJAX'\E_]L:\;:PS&ZJ.QCL.Q]I7U8T#6
M$-'U#EKH?2,3%+_2JU\(^*\5?;6(]J?<O8P6G3#TDL"/HB3U@]1.<#A>4(ZH
MDP(K,"H8,H[]I*AX+VZ]WN3KABNONLMF1N3DK;O*G8*XL+*`-Z*H.JR?D?E]
M=MT3;U*'=37(O5A`PB-Y$7:2X@"*Q_:+&*WI[N+?B+B(Q2'V&?-C%H5QX(XI
M@C1P/6C-6+@%XZ@:G;+JQJL;ZR';65\;WZQ_MU_QOL%ZR/O+LL`U8R4$%2.5
M:25AB#I(^+&3L'6(CRCK^C'?S%X=]IDT$PQ2$7(A\%$*X5D)6%4Y0&G"JCRR
M0TD8,<]W`I2&(8I1Y-/1#L81<,$2_/A9$H)\4G6>,C:2Q@Q<2/&,H#$%X6E`
M+MT"Z'(JR@N9/RG]%L(5>?_/Y/@4A!`_-;?9%,TL,-N^SXK-ZY)D#\4^VZY2
M)[8C%+,DB=.88)]RTR/`^&^!Q^8DK1CGR\$Q#I=B\TM16NO.-^@).ED=Q;@R
MAX`PO!PIU[AD<>7(2\J9.41W7IH)R*B*N1#6*(=Q>HY.BRR0\[J/]X_;YM+4
M=K<%)][#+O^2EW7Q-7]=KJO[_$U5-Y6FW]U^RIY6#DIM$I/0)S[SB>U$43JF
MGI+$!6Y5UVW=/*D.#O?[V-?'+EO;2OA.:&-O0)!E5Y0>R+@CS;O]7C_X:G7.
M6C\U[O[<U<:O;INMK/.?(X8H.H5&0^]F*<@T%=[S(\D&911&[(=\GQ5EODFS
M75F4=_616S2_+=;%?L6M)"&+_##"GDL#Q%QG7"]V'9S`J*K!H'&0#CY:>>\D
MD)HZ1!4#Y<QJPM@XRCAX9_UTC,O>P;GO!7E9L@GX:=1[(;S3&5%E[..$5HS:
MY5G]N/M^-#F.4=K>,<(B#SNN%\0Q&TK*!"CVTE69WS6>B5%,PH!0.XN[=G;L
MB_C>V=ZG(166[?GXKX;>;20CG1BK3&DF5S=J$.LX^35WV:AG@DR01T&]A9!&
M)8+3FE&J8BAL.UAY##&/.#:-?.K'GI<P?SAS%*38"R!;[R4>#VD3TCOPAXT&
MIWL,_O/?(M<)_UO73H.7M93=8:!51F,["ZZ^G0"TC4!8TX4`1R6"%[<-`,40
M!L[O15GMVCU8W;ZJ51J'S(V#E*5I[&*?_VJ3T0YAP(VPX,<;GVR=['XL>L>@
M<RZX;F)H,2J8`;!<V$PZ,VE.59O@C+3`"Z&,O/^5IB_M*AOU5X1%E#//2R+7
M(VD8Q'0\1A#XW%6U89`1EV89.FD:&IEY)[+#J:N_#G52*NS$O_HP349^T-#.
MZ/M="*CGCMK(-GN@Z-INRUK9MD]"CQ#JN9'#DB0DP7"F/0CX_Y4\<"YG;!:0
M'YU";P])2H%=75<Q9,\J*0S&Y^_#6M@E6!.TU";M0CBH+Q[@95=`H0!%R';%
MUVS?KIO6^]WC<.SU;_GFCJ,3K_F/6J]H4:^W5?VXR\=-_Y0F@1NE+F,NLYTX
M)"CR0B>*/!HQEE+16:))%\RUS(/7UI';;2/M';<.GEL'UZ]W($9!YXD6/L?;
M6TCCGR749U6\YI)7&!DL*W;MND%]<*Y.,MXZUOG'+WF^?].\*#XF2[X?_D!S
MC+YQZA.WE7SOO:=Y7=R5[9_]U`S<5B@(G*:N?)02'#G-)18)ZSR.;8_1:,4'
M<J+9NBNZ"1IBC1$)HZ>)K%MTXV`YQ'9C]=%9;7C6$-^-]?G[T9^SAABM)DCK
MSS:D"18M[AL0ZU7^(J\?UNG,^^:-]$+FWLM$)[6`CV$A?=@2E*@6UU(E+F(\
M=,?XJ:A7@8OY.-Q'R,,!8SY./>0/EA"R*:3GDGB\X1ZG\>AHF,O'L-PI:)\A
MHYKH#,*H8-")`4PK8]<O_JC(Y!!>6KZ%4$TE@C-W,BJ)(4F1M]E]3JO[K"A7
M*(YCQFGE^!ZR?12Q."6#O13Y3)XE`"/S$N7&:ERS_NR<4R,+1$D9OA@248DR
MPOK-0)N#/L+,D9!TD>21B6.2/]+"O$BAST7Q>?4Q+XMJU][DP?B7]KXJROW_
MYKN*\1'6^YQ_>>6>/N:?OO%_?^]^;7[R>W[_.=^MD!^'84)#-_`]ST%A$MCA
MX)"?ND0$4^:],,PQ_Y6-[/^PNA"L[DZ4S6-NN;:+!"DVPYN8QMRR7@)PM?I8
M^,9QJ_7<:ERW&@^MWGF+>V]UC@__:G_\9Q>":)<SP\O:5.NV[;?SF+_(2_O!
MYR6]O)/^KE&M[<7LV+/;/DQ9QS.=W'SOYLJ]X(R!5G-_]K+]:.-#X]"G;]6I
M+ZS:_>!*Y(<41XCZ#L4D2OAL(AR[]"#"@50/JM&^X;X3O>)__6S?Z4OWG3K5
M!_::5Q)>I;]L$=LBESM]#K:MXWHZ2IUO1K*+O-(;TM$YZGU3\%Y17#J1_M#`
MBUA:3V@BQ$M]H#$YP;U?XT'CR=NBO-`3]WY0[+(4!PD*O.:L:ACAB`Y^A'Z,
M9;H^;<8-]WONJ_A"O^?:DG35ISNLT[N*Y`H]7@O/%J.-QQ/3"\7>3M_[D.OJ
MKO)>-/1S&M\/N(\3U4R@@],N_\)Z-_WQ7>C:#`DI7A&TO95L_;U=!V)1A%/7
M"4@8A;&+4A\GXSH0)JX/69<!/=AP?S3X(K>L"Y-(;,'%F#JPKD-8&#-U/8]$
MF%A)D=)J(:LG<KZ?UO*4%^!%#JS[9Z_P=MO;:?9:=BLR'O$I2_T`4\+BF+DN
M\L=,4I#82(0'2@8,<X&[9!U\@B[.JDDWS8G95(/Q`BS8!#?J?/WJKOKZZQ!J
MPPU__%W##/^(&5."G&&'%OVNS!`],50:/R@H4](_/JR2)(["E+B>P[R$X##R
M'7=XMA/04*Q"`>B1D.]?[H*MQUT%A820%H)0T"T"#`)-]%8W*K5(]5CN=^WM
MQ=.BZ`<!%V&JX4,T6DI#!_E\VK#A`8LW9(+I*G8='T7\P5X4I:Y-.";2X=DV
M"P6O)0$]TGA#)EF9;8JLM&BUW68[:)L6DD6P3>O6`S@1:(3(;GH=Y&[YE&S'
M//"I=@S192GM&.3S:3N&!RS>CG]+WJ^0'X0>#1"R?>KP*8/M!^.6\32@0I-\
MT`,-#^*37;$OZB_6>]X5-9?AY#O^]^Z@35E(&<&FK%L46%/^HRR:`JK_X")L
MJON;3I=96S2/?ZI%0^192HL&^7S:HN$!B[?HO[__YRK`46R3Q$$Q]E*.#^S9
M0Z_OA-@3.IH!>J#A%OWW["$K\SJW_IF7T'8LI(=@.]8M!:P=MRK<3&N@O^WR
MF*?:+D22I;1=D,^G;1<>,"#E]@==.0[%*762-$`LX'S`B'C#L_VHJ9P"2;$)
M/-!T2NVQ.9N]E1]3"XDBFCS3K`<P639(<95A-8]],B\&D&8I#1GD\[.\%SA@
MX36T[D*&C_MLGS>KP\-ISC9=']H$46(W=9@BZI#$8WXRF*2Q"SKPKV+'<+/O
M;S(9?1M/:,LMN2DI*K8"-Y>8,&;(ZVADA6Y"I(D%.QW2+F3]3DLHE?XO3P^A
M^O0_B2D?U=@XC>(H"IGK83JD_QWL,M"ROYJEZU%*[ERFHJY*I#(@J3967>>4
MYJ10<%X!!5XVL:#!B#%+2B+Q6L39-J_[[4\L)ACYCHO=.,"A[Z1\!#?.P=+$
MAC`*\ES#1/J0?\W+J;M%U(41@XPI36!(:;V`;WW45%GW(,$$+&2$6@@:I%P_
M+50K';YPLV]OO'M;E=5#ON.4:<K;-O!)GQ[RLAZV^=,$<Y-V4_$&N5&4$.(,
MVZ"<P+.%\B9:#1H&17=]9-%?&)EWKDW<CF9063&@S"XJC#2=GL?^C;=Q]B[^
M?"T.B2@W`2BMPB^$7'ICJ@Q^J1JJTWXHZG]UDT&$8NRCU$W2P`T)L8D=#38C
M2H6V7VHQ9)AM9RO-RI;@4M%3C&RS20DCFIR*LQ7B'12:()<681="+#VQ"-3*
ME11(@E#'%0G[B9^#L$\8P1@SXB"/NJD]C@`]Y@(+>2D8FH]08XE1Z5)>*GI"
M"6582FE"`50T3*CG"@D12D'8Q1%*)9:+A%(62+Q<=[7+B[LR?5I_X5_;:'BH
MAA([J>T$"7$]ER2NB^,T'@=NE#FP&_+4;$&:EM1^UMX]*^_]L]:]@]#JUVJ2
MBE%J/BUAF!I$'!P[@M5U)H230DW02H_`"\&5IF!.2S-KE$BLEL1P5Q.?:N8\
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M-',E#LGEZU7DE&>1`27UT.@ZZ?K+$@&)!-1UP4R"1B)`)2EQ8-NZNM(S>US7
M^7Z8\F$'1R@*66K[(4H\Y#-WJ&SGV!B!)F'21F;9OM4=1MI;6>N9S.8M*?W$
M,#2+=#`(=:KU/EF=4U?=E75&GI=V8JDHNA#\J,=Q;L>5NC`P]+PNO_)Y8'N]
M\+!_U2<L##TG1*Z/'!8'C([I?0_;H',ODB:,9W]&A]J+NZNV0<GC1T)#`'S,
MRB>#GF/]KLF=9\J\1!UY*9?$'(4HSA%'511AWN#U>O>8;]X4V>=BVUY>/F:W
M@YBY*4>9';H)G_2%(]]<:HL5A5<V8I@YO5]6OT?]"#Q`XLBK*,:<602$46?0
M[LBG:W'GDCH3Y%$6="'L48^CTORE29Z@Z><;S^V&!-/`X<.K`'G(LX/0&PM^
MN@GQA#8;:#,VR]1K6Y5WO_"_?6]M#PY*'I^1EQ4P&)I+49EAT<&W)9#J);E>
M&BOI4'HAY-(7SX4S,IJ$$B;9\WOON]0Y(\PFV(D"WXG2V$G38+CDQTT]V,D8
M21.&J=5[91VY);>2)JN@&*IF$`\&*!G=C%#IO#(3+%*4<B$$4HVBTOI]*=.F
M3XDG3FJ3.$PB._%0:".7NFBPQWP;5,5)VL@UB".W9B:OHRQU#$BH@3O762R[
MI`Z(/4!!%TL?:!PO\D=*&,!IN\Y0OL%U;_MPU*\?:L7(22E+&:,^9K&-**5#
M.4K7P[8-.]&BPR*D64F=:SDX:66U]:5O:\7H)_@,G@:5Q5`UM[PP:OVHZ\"P
MX^/#UYG2":@V03.=FB\$;%I#>G9F3[=<PKCC,\K-:+TWY?J>PRC#">(32#?T
M"2:#J9"%+JC2D\SS#0^SWE9[:Z,79U(JBN'+M(`P7#7:+1599Y2:0)2*K@M!
MDE((E;[/3+J>0<VR8O<_V?8Q?U.4^>M]?E^O,$V3V`D<'-HL9BBR[;&(0I@P
M'U162LV280P=.7=C->Y9K7_6GXV'5NNB?&4#*65%QU-SB0H=2:GH:;C&P1FI
M)H=/.B1>"*4T!7.QS(&Z1!+D:O=,C8;?YGO\N6[/+:_<,/%<.\`(N3@*/!O'
M=%A0)+;GQ-"YH;I%XW/#CX_W]]GNNU7=6D>OY62,]7R<`%W\TZ(^E''SR"Y+
MNFY'YC'N;BQ\W]P(V%QV;KV[O>4_MO!=UHQL+=+<@<![JFQK_3F$<3TD7E16
M"(SJ[V5Q>-00TD5(ZI)+`I6CU7>W)_ZL:%NDV(M2.XHC[.(8T^&H,7$CV&8L
M+09G&_)U.T!OK-NFX7[M&FZ9P[-H.D2&(G$F?74R\;==5=?=#Z[&N\NR"0%/
M@^J+(YZ.F"XB3YM@NI@W;-GXO@I1ZD8TBAD+0CN(6>J-)19($*:2<UQ%H_.Q
M;]C_]=TP_P"":V&@&:VE.?CF(/-S%HX_7!8/1[?DF0A_"W\-+DK$!6.CK'!B
M5;?.54ZM/^5/^\=L>QB,)C%B#J(D00F-(DK=!`^&?1\)3I[UV9MA6?5,R>#:
M^JEW]&>AB9HIL:>A>!V5I6FX/'D!%;YFEUFNW-=YN5^I5OH2B?Y,?Z%?N274
M`-,;4&7J(Y,>.K^ION6[#WFSQ:<H[W[/]H\[WB5]:&I#.BN7^2SV[=A);(=&
M)*$H&%:D"`H\))M<53)JO)-HO;-V;274ZM;:/.[:9EDWO[GM2Z4.MVPV_^-;
MMMN,=6?ELZQJ;P(ZHI[M%<CV(#=6]QY&'ZW!2:OU\FH#Z2GEA(;16J1?W"!:
M3U07A]`:19.@Y-^*NR^7S7L>"9H:(I'G4"]!S$;Q4.:;8(2(+";5K!KG9.?>
M_*!4?!E04L[W%N11V;^*Q;%R4CLA6.I1?W&TU!3615SJE.U%7A9MF8$CZV^K
MA@-\&-NNC:X<)\6^YX=^X#AA1-W4"X>C<B1B1*@6I*H-P^E6?'>WR^^:"JIE
M[Y>5M8X)4DY9PFFJS:F>/,4&I_HU=2EJU?GZU5WU]=<NXH997O_?#:V\(UJ]
MH,D9.NE2\<HTTA9&I??C@J0W_RAW>;8M_B_?_,8)]Z:JZ[Q^5_:7&Y!^S'&T
M.^9MOD_R9DSR*7M:A0E)61BB,*`I"FB"_6C`'TT088"TIU$_C(_@&I]_;9RV
MJO)H;4CK^&V&UR60.%W,>X+1\>"VU?AM_=1Y_G/SOH9;6P;OCS>#<98V:_*?
MVQ`L'L-R7A8@#;N8ER:7GNUWAO'&5.9[Z_'P*N_:5[GE\?QL[?)MNV5O7UG[
M+[G57\!3O-@<QPN/VC+WFXO[`-=9_<6ZW5;?SIRZJ%_Q&<.ZZ6<VC<5LS:-\
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MU'P8<KRO=O]/W=4T1VXCV;^"RT;,1&@=!+]Y!`C0VQ$]5J];LQ<?%*42U.).
MJ:@ILN36_OH%R&(5I595(T&`I"^V6FXS7[X$'A)``E#9FQQ9;K.4>31.?#_*
MBC2):8*CO@:;Y3@!O0HP&TC'"UH20INGUEVBJN8<4LV?=]7]?MW(K/5%;/>=
MWJOD;S`.2,U9BUVC4MQCNO=C<FCA5,K4C0*Z;[#@]F"CJN=J,"/].QIZAI2*
MH8%O2#HG0R[G`)U[5^CH(#IXV$Y8%_!HNXU0:>UKS-0Z%C*JS<^#QD/S,P3&
MVMA8?=NJV=:G;8?LTU:\PT:V]]WZ!/^^WNSO.\>.#FQ%7=^(NI$I@')"E1_E
M?E+0PLN\'.,H+HX#?.(%L>D&]Q*P.Y\L?3R2BM5.)5CU,$<_O]:*[O?MPDL_
M>HJALY9'T(F;CIUA=;EMQLE8>W!7-:1^2!VXW`^J[47DAU7(WNUN<'[C.#IX
MOL0QV&I<1PS,\[2OO\AH/1,YP"%\SA`"QO6[Y@3_S5N>C<HWO@BI&]MF]4W<
M4A:%Q(^(YR4D3U)&Z6E95&&`S6*MF74\+_TJMF6E+N1N1*WF%*>W?L'#H#VF
M=<>P64B&#D!WS6#H4>/*X'W@*]1!12>LDP\8NB1>5'OKD5B,5-OW[`>==40>
M\&&]X=YD)^E*Z+MMH].,K7OH3VTH73^HS:2TB`E)J<_]+&)!3F@8'74[]G,"
MF\JX1#))]4>W@K<3JWJ_>^WVDM7C](,%/:-'^QS%1D]GEQ(4F/`>GOY[L^/>
MX3[D_<=RCA_0MXF[FDA>+/1P^$B@$=<7]'F*""Y$L"=Q]</7"*>@5UO2^SS]
M0E'`(*N7V=_%.USKV\P/6!I'E`>8Y@RG)`O[(]5,_H;#9'YJ='.L24GYZ(I^
M#F4^?SL\9_:F1,GZJ8[)XZXWA"PYX+!A9;AP=+EH\,V1;9V+9Z>N'[`<E`OC
MSUSA7\B8-)O[U3)Z(7#L^KI^%/?[C;A^^+*KGL6N>?TBNV!#MO?\W_OR6=F^
M6=UMQ"WQLC0K0AKP/)0_^6GFT32)2,#"#"><059LK!EUO%[3H[M"+;YV2?J(
M$/W18H3>NVN/<+W18!:N83(_DF8G>JU+VP4AML[\0A36OE^5XR8+U,0;^=>O
M'\BN/1RLK+6O6,4\39/$"VF8Q[&781+BJ#<F?PEZ5<K,@F.U4Z!4)CV`U7;%
MWZKM?ZX&O[N1/]8R76Y/2QN]<F=(L)[@N><6IFY.:'6B>1\R=T'@QC&]$#4;
MZ41EL_%!'RX_F:FE.,H&-6A/P^9T>*,A)D%**"4Q]WWFA:0(\K2'D;`(I&"V
M;3O6MB%<C=YG]I">]7CH"=Z<H8!)H>THN'E*'4;G!7UT%9B%**<S]]Z_Q^Z4
M1KTCV[RL5^7A^]S+(C^/DX(&A'A!BF7:V7^_"+-,1T;!'W6LCRT4R#E;$"&7
M=<PI%S"!:E%HO$DUD@_`,6)7O)B="M;E1^\<[,"W#U34V/TEG%(UPEV-C#LP
M?3P[N?Y\?!N',H+3R"=9G'I9GF.2<]9;3E,?=/FX!7/S+O=]-GYKRP;3>KG@
MQ"1;7>?3XM=)RO=SUBYD>18I7TAB9].CREG[A$Z63^=>F'C>B779#GWRYXTX
M%=#NFO+_VM^?!7I+<!!0+TB\S`_]6"::8>(?\)&`4E#IZF2@7$^O!^?E[@>.
M0"?0D\5(<V:]Q/``I]R#R`Q]N$)'+_J3%D<_I#Z_5>JKMU(]]83<4A0NS=2G
M#O1"E'YZO]_/[><A?GR.3.[ORW;1X3;#08Q9@'$2$LXH85X8]Y8Q@^T+63#G
M6.E_%[60[#VBFUTI?[\1Z,MJ]R_TL%JWSX&@9_G_/:YJZ($&&SR/S)#=4&PQ
M0[Y"1XA+R8^/@$SR8SCA"U%-FQ[IYL>F9&DKW6=1UT)\%JNZW'X;+KE>2T`K
M=7),_3=1WXC=T_5#?BB9O*6)ET=A3"**N1\%7H%]TJ.A49!`U,\1!-?;YA*-
MVM_="+CLN2)=3PH7P#=,'CO`Z(!XN*->7Z$C:-2AOD)]9'KD$ZNF&;T7E-1Q
MO!:BKJZ]K";M!)!-ILY$:^XV*BC'Q"-ADF*2XICRXYHOP81JZ2KXHQ,IY4KR
MJT[S0Q033I#&II,K;F"JUM)R_=#)EC,Z`'M.KF@QVW-Z0\_HNU<'OIW;<S)Q
M?PE[3D:XJY%Q!V:9^>JY;%:;UL;UW:;\UIW0NL4!3EG&I)2R.$M(D8<LZ,UE
M7L$A::2I#<?J=X#5J1ZJCL"`*:,Q@WHYX13DP>2QYZV%A`:8)D[GSC!S(5\;
MR^5"$K+1;E1VFYBM)3SZJJHUVP)-CV*:%R3("9>V:)*0*$DPQ0&C7/Y$K*SA
M`>S-N=$MYTVJ8MFHL-L*UR/7\1S1;'4A3XOA:9?R3K29K.49D+X0=;/JDNYJ
MGC%=XU5/&>X*:V^)%_$P29C465KX69KX'NE-XP+;J>X!V%N"ZIE5?EMA>Z3N
M.2+:@>[-4]>M09R)\AG0OG3E,W%)5_F,Z=)6/KHO-_?J^O>N>+((_;PH4EYX
M,KO,N1]G`956_,`+$A(4()$#?MJQGO5H@%H%Y4=/EAQ2`U.@'@B\2MF.S+PE
MXH*B&#*V$/$P15]9:3;@UW+6C^56[%Z'2G0P&6+.0QY$81"E411&F>=S93+&
M:8QI`EIY&F/'L5@<H>F6<MDG4D](IN(0IBIGZ)M+9"Z0=$%Q;%"[$/FQXLH/
M[\?8HD>_Z$*VIH,%6L1I0IB7L91E.(_CI`BEA<"+DS2/"]"[+H#/.I8=A01:
M$P'@1$]2'-$!4Q`%8BZY.!%PJ;H`SM)"Q,`$^?LJ`%/G]7>^JJ>GLND/L:HZ
M`IGVB.VZ%#4KZ_6FJO<[0>[JKKP@HV&0)3BB6,Z)TM3+B@S+_(?[?HI]2G6S
M<KM&'>[QG'"V`^P;I.@$%?W1@YVZ"X&8O+0GY"0B"^F(CIQ[OW_DD$*#>]/H
MOB[5_?ID+7.&NBO2I*^#/QT1-O*GNKQORXJJ;7>%$68)]=*D8"3@.,*QG/T$
M1W@Q*\RN57.+R7'.T+NA2H5Z1]#0$W3W.OSSU4DN&O3&G=%7M#F.K9Z(+S&L
M,'F?,J*.;X,;%8(+X\+405[(B#&YVV>OFIN2=KURT+P[&56^B*^KC:@_BQ<9
M%+5E&.91Q,*`I%',HI`&?G(R1FD<:]>&&EMP72IUQ(5J!0QM%#)82<)("B]+
M\W3L`?/H^8D#U)E.0J!9T:DAD7HUJ.?\/E>0.IJG)52GCG>BLMETQ@IQOX=)
MO"0I,IYE/@L)+SS.6&\N#IC^75`C;,PDQK!*B=%$&@JR`P[M2/+$](V490<T
MF@ESSUO[]L_D*GVV3,06<4M5:J@;/]-J(UKTU+J03>>NW&QDJSJLZ.*0Y1E+
MO1`3S!.,4Q[DO14><JWJ7L-/.]9F!0@=$$&4Q(`C#?UU2P],=H?,&%WH9T`1
M0&/=4F4FK4#*]%3T!T?/B:<Y(TO0S!'H*RO-`J204HK?6B$1Q['\'O:I3Y+"
M]^.$'I<O6*"?QL(_[5HA57)@HI!PCG04TBD]0(4<,&.FD'"*(`KIE"I#A811
MIJF0[QT]JY#&C"Q"(<W15U::!40AOY;?WQKAC&:QU-XD";R(!T664QP4:<S]
ME'E%K%4E:/9EUYMMY7<3>803I*&.3KD![EB=:#'21C@_`&ETRI.9,L+XTA/&
M]VZ>TT5C.I8@B^;@*QLM`G0'_FK]V%]#M=I<;P7M3/[S^::Z^5,VF5?Z!H,7
MQ81E.$I]1CDI`B_.22_,.$RU*AJ=&'8LJ0HN6AWQHFI[2AKVS^HETJ8%;:*[
MUF.@(<MST@]3;2CS9C?]VPX!Y#6`&4-A^&*`_9!H/BX`H^K<X.**\26,/<Y\
MJR9HLI"1ZV3U8"3B">9^(3_(8Q;BE#)Z7'<N&-%?$09_V?'8<[TU6NV`$Z0Q
M;CCE!C8P#&@QTGPX/P!1=\J3F6K#^-(3Y/=NGE-<8SJ6(*GFX"L;+0)TVZ",
MUCLS89CF7NSGA9_Y8<))F*9',S3.`9<.PK_M6!A;1";2:$*3AC@Z9@@FCV_(
M,1)($Y8@-Q*Z9<OP8D(@:YH7%/[@ZCFA'$'*$J1R#/S*3ML`WRSQ0XEP6W,6
MI#XI_`"3-,B*E'KJR/K!G$^YSV!73)C9<"R?'U7MFUT19DSB95&=DC^8N!I1
MY^AJB@^Y^4!?;+&YD%,&H]WXX=8*&[2,TAWUH]2]0QU5B%D6LR3D.`K2(/)C
M%O55KWX115HG`NQ9FT&+KE"/T?0*+PLDFRN4.W[':Q6(VLETZPUC0`4S8WO!
M6F;HD(:JC:%*LQAI_[1Z?ESMGDA_"1#V<L(B0DB!DSC(PS0LDMY*E'']O7;X
MIUT7(_6`$/D55&D#YTAC"NJ6'ICP#)DQ*T:"4P0I1G)*E6$Q$HPRS6*D]XZ>
M+48R9F0)<\\1Z"LKS0)^F^O]?MU<[[Z*W4NY[FZ.#</8ST@8I7E2!"%),&%Q
M;RO#+`)>WPHWX%@M#YBZ&T$.N&KC>ZD-^-/+YYQ3!U-2,]9<W;CZ`S,74K51
M1"XD.QOGPX^7J(XE!*HPZD:5OM$<DCZ.TXQF<8'C*`N*(LZP=TSZ?!:"7G@S
MMS*/UAC?!FW*)4AR'--H17=FN^OY8X)^+C\C2%V6!HUQY&,A&DV-[C-HZX?V
M>HT^I^(L)K$GIYL)CRGS*<V]WD;N,ZT;G(T^['I+DN?%)\9_)[`WOX#DZ.Q%
M.N0%N!'94V*V"0GE!O0FFCN.#+<?`5SIOHWVQL>S^XZ&5"QAXF>,O;+0%L8O
M^Y^Y@^BS_'N?&O&DKK](HSA)<)'RR/.*PDOY$0HM4M!CY"[LS[(U</XR,04<
MM<@M;!>,#X[Q!L*D<;&QI3`R)%-M,_R,5]C&@[4H+231=.KBSS<G+-.I/U5>
MO;:7C]Y4A^V1'INH?]U5=7T;L[`HJ,\\FN0\E\;2_#A%YYC"WE4::\RQXN:K
M^A$]5[NV\U8/:#T,!73>/)I8S>GSE)P"9]$':.I@Q`$<.J&[0BV^J2?3/Z'K
MTIS:%M,+43Q[_KR?8=LE"IQCYM737;E=79#5X=/HOZN?KA^N]\VZ>A+U_ZPV
M>_%?Y;?'VY"'-*5YFM/`(SGG/*)'Q8URFMV^B-U=!4U`)P('Z=5#/[0[]S]6
MW\NG_9/2R#[Y>2.7J-RBYE&HJZW:=]+OU4U)5??0B%I56ST_[ZJ7U08]E1M1
M-Y7DQC!KG2K<L(1V@7$VS'4'GES(=8?>7*'6'Q7VWJ,KU/ITA917,^7"=D*B
MD29/'/N%C"=S>7\FN9XE".9W<-Y&A'E1Y,N/IR0L6,#8:;<]3@.MPFOSK[O.
MK#^\W'#L?9$_YTQCP=@Y73#9G8NID7=J6F7,YC7'+F[./+>8/(J8):PHCW/@
M9_=D`JG0?[YD?U>+?^]E@^$O[4,J_7,I`8L)C;,XB(J8!`6C<>&E242"G&&/
M1]IO5IA^WYU*G""A#M-\CPF=8^="GC2:T(5D/./]>/^"@QUBC'O.C?C>4.GA
MOVZ9_'A$@Y3E49@&/$NC]&0PR#'H*1]C*XZSDA]Z$?1M'7/ZS)3'#7.CI4?!
M0BVNN<7G2!!`?>"D+E1^#!SYB?Z84J,M0&2][A(%<<_$@YRWW5.QE3\TZJWU
MFMS_[[YN!B^74A+*W`'C+/0(]H,BSWA$>!(PDJLC'*`=8<NF'4O5`"TZP$4'
MO*@%C$Z(@2IF.P9ZTC8C_3"]@S"/2-/LRKM]H]Y14ML>7U8[,=_+RC".+TBF
MHV`M1$==>5=-TN+-%?=F)^UNNJ6P'ZS'),6)%/R,>SP/0Q)&N+<>4PYZP=F2
MR0D5=@#3BJZ.8AJLIU.1;*ZC1;43Y;<MRO<[J8_KU[^$A%Z@54\Z;<1E>9)I
MQ:OS4FF/-!.)O&X>Q2ZOGIYWXE%LZ_)%?-JJ#8+/55U_/M;FD`2K)[:+B(6,
M<!Q@":7'D7)L*I9VC$\HFY4"C-9#Q*AL(8^I3K0?#K"B3A\)<VUML:(W8%&'
M%OU-X?W[G&6)4$[UA-5N>)8GL9;].R^V+HBT+;N_B>;ZX6;U_984-(NQ[^."
M!G[.2$!)W,.@(?8<J*ZV[66([M\VJK]?H:UH5"U&L_J^S.[>TSJ^MX,#]-?J
M['#WS/JZ(8W:7?V2;2H>Y.S@=['>K.JZ?"C7;>YW@D1]]2H*#Q*9X_'8]VD8
M93TD/]%[`&\*'(XEX/I\MU>]'MVU\-'N/?Z)%6`$PQ?48(JX+409)G&UFKY;
M`!7CO<%"$J4A9MT"0_-%[,KJ_J1J`68T"PNLTI8T]0(_/6(,"PXZTS`I,-=I
MQ5.U5QMZ)]&0^85JDFBEEW!L+A;T+R"P>C._Q<84-BM\[T872KVYXM5A;:Y!
MG3M7Z+<NB;R9/(FT&8T+8\HL05_((#./[]4">IW%Q/5HV_,\XL<128-"ILU$
MC7_Y<><&4]`E,U8,.AXVE#*L#VKQW(;!\AAAAW4][9^<<)BF_W1U;T:A'CG%
MM\K\0H35KD^`--V0,&TA["Q)`ZRLU[)+[W?B5*R8!I2GL1^$(9=6(S_KMV6*
M#(?:9;=C3+CK@(?.)F&A$Z[YJF\OD'2AJ]F@=B$]S(HKE?V6!ZW$73^*^_U&
M7#_PAP>Q;HZ=6:+X7:8_,CF2?)2;LDV-;M3F^*DXCWH)SH.`%UZ.<4!B'.>T
MQQ30V(>=5'4*!=(QC<ZEOD6'[D3SIQ#=4=1__O+U%_0@U/&O#:J;5;.7+?=5
M+8NCG?2K/98J>I>/OX;6!#L-I)YR+B:",&GM8:OLY0@<#01784?O`OQ'"Q_-
M6((\@NQ+5<I3Q'`A&CZ-K^]KG:<C6'\44&>EU*#3KL/]+IK];JLN*B2;3?7G
M2G)9_UI5]Z=C(46>8$8"QJ.P\,,LHD'8#T:QY^>ZM_[:-NM0(MJ#?4>H5^@`
MMM7N$]PKU`*>\5`4C-%+.N`H-DOI^J[<>]_;G=)HD.:I$^9=5=OV_K_WJTWY
M\%INOY%U!_"4>)XTA],\YSB5<[;<IRDGC"9Q#RE(>&&:Y=E',D&25XO=BU2"
MAVJ'[ONH=O>*'`-JG+@Y"`TT;YLW)N9IVQ%W&XL3<M1#?S-I7D+2!F9:*V=S
M%[^EZ/84KI[-V%S3JZWGQ:K<M7>%G&R>QA`Y<GAY+A-$G'L>I3Q(/!9R7K`D
M9RQENJ\`CK+AKMLK6-VE/H,^/6/*=8FF"WW6"KL+Z91V?*D<-#]H*>BQTK\N
MJMUOXL]#UY:=_,NNVLH?U]VU/>TK$AF+"\))GN8!3],DSI(@ZD%$"=5Z8\N-
M9=?U&B>P;28DX:(37O06L-EC,Y8CH:=X\P4!)H%V^7=3@0NA\E+]K9.0+$0W
M'3GWOO;6(87:RGHC__KU`[FOGIO3$].4\S`I,ASX:1AD+"2<AKTM'%)02:V1
M`<<ZJ3"IV4F/RO0M'#/R]#3/.6\P:3.@S(E^?43+!9D:Q>)"U&B<#Y7%9F4S
M:RNWZ_)Y(_AJMWE]!X=E28[SU,>1;`.,DY`&20^'9AZH'-<5ALDRN3:1V,I$
M8G5*))Y[Y%=(*.QH=0!O,YD;$R`+:=U$L;&<X!WCTN(>J.5,I]7-&#;-^RS$
M;"&:Z]Q-2"YHC5:]VVB_BFTI,52-J+^6W[]4Y;;AY;?'YJMX$=NB?!%?A.P=
MVX;MQ<V?\M^O[7\5HL=$(C\("Y]2KV`A*[@?AVF/*?%QIGUQK6L@CC4\_B5-
MHO]`G1>H=0/=[P62?36%W-_J/!Z7U7IQH0#N1@SIE]A1"QZU^%`+'RG\Z.``
MDAZ@S@74^V#T7IOSJ`$NZ%U2],SN\K40Q5_&WOP[DL4/!M5)@[.$^X0G\[6:
MH?4;CK$WLM&)%I5$=_-G]1&B_I]5/^Q'%,<XS_*8I3X)>):D_+C,SE.M!9HI
M<#@>88-?8O_C$=;W#;7:231@`^S<@1@QOK;0#]JL5%H"/*O+QW]58\=7)S$S
M&U[GCIV%T=59#,&CK`&9&H.LRQ`M;(QUZNJ9(=8]O9IOJE3;%['[)B1A7QY7
MNZ?56NR;<KW:U`>CG).,,9P&`<64)GZ4%OG!*`\IT;K1W(XEQZ/D`!]Z!Q#T
MC,AH0C6&P4FYA`UT%V@T&L#&\PEYHF5*7@V?:QG%K^;C+3^AX=SP88V^)0P0
M]IRI7+0PZ"9378OFT]/SJMRI-I=+V]]$?1LFS"><9CQ/LP)3-;3TV^4\BO46
M(4>:<+U%I%"A\@@+K3M<T#T@0_XTMWC<4P?<P6E9.R%"^<]8<[,Q\R$OE_9=
MQA&YE&V5D5Z\WS6Q00J\MO<?8J6J'MO=&FES*VU^VAY+D&_$^G%;_GLO@6`<
ML*@@+$N]U&,AR\D)2!SQ$")"]JV[3CL[;.K=UY?C*8#F"`\H4P[(UU.P>7F'
MB=N@!'N(]@H-8G$ZD7&C$0NWE=FZE.J4:UL/ST(DTZ&#YPJ['5&I+;1,W#6?
MZGJO3FWE5=W4M\'_<W=US6WC6/:OX&FKN\H]Q6\2.T\``71Y*YVD$F=FNN9!
MI=BTS5E9]$IR$L^O7X`2*=FR95P0()'IIU9L"^>>"QQ<`!<782A8ADF)`T%9
MELC(L4LKYR(F)41(X=_N6"B/RK*UKV-_E;'=#B6Z5#"!@FE`HIX@NN4/)G@*
M"^K`((5F9"D[(N.$5)D3YXD4#3"@L=6'@%*B__CSNWK^M5[4F\?WDHQM\;(9
M93S+TS`M<9$%(5&Q8]:!BF)!83=LW6*!##*C.[8'+[U?/GGIO?FZJ&_>*B8\
MA7?T],P?M\"TK\.-#H#+2&_OI2?8SU"/_@SM\8\LEX.X/B&MX_C0$QD>R=AF
MBF%B84G^]WIS^V79?%45`521EO/E_8.J\'!8O45^DL`D=CI?U^L>\$<YU&[G
M:QG91IS&>10&/,`YBT561+S'2XL,=`-F,I#NSY5>G!`LK.S'\:'Y!H!W[C/=
M)S@[W"A`WZ59Z-`NM#7L68TM565G9QMJC7LRN?0&>K"K8,-/P,V'4;N&)S/2
M]#QH;&5,X!B]3(6/S4;"J^<+\;"16/^H%]5ZTRRKC_/'[19,<W=7MW<#+IJ+
MVWIU]7&^VCR2^_M5\Z.^FV^JQ>,L*^(8\X)QRC&A>4%X''>X@B31>G%N-#".
MYZ7>!'3=VH#N.B/0_<X*R#G]*.[12(WPS3.P*6?OE"U\U.-'G0%H;P&Z:%!K
M`VJ-0$^L\,YY@#P,WYQHEJJA,<)4K??.F9L&;5IGWK?.G!]:,S@KWP*CKV5]
MC.DL'Q)#1K6WF6A4F*XPM^%"5S%0%02=L2()(Y$'19FF+$NR-`FZM$5.B`#E
MF`QIQ_%\VF$QJ7X\B#[@^LPQ<\9'L5M<9WV5TK9L\52+HV.2=-8W`ZCU;8DR
MQ)375AF#Z7%YGK%[#V?&8U%D>1X&:1J$)%=OMI*$BR@M21;&<0%1*X<P7&]:
M=>_2-*ONK/72BX,-;3<Y.]5PX:'1CC3*G^4\HW1QF`%UG2>B/(:EPX\QS,@=
M(NEJ4^IF6?^[NCJ_4H'Q=:TVK-ILQS6Y_+^'>E5=D>55A["NUO)G<AUW=;Z\
MJJ[K9;VIWM7?U,>-'%YU_[>SE$28!%$:EP5E:2'DQ!1TLQ*..!TX!TR&V_&D
M<;[\32XU+I4RR=^JI&MOVWK&5]6W:M'<MXM<]7G[REG=HT?S%O[PR6.Z#F$\
MV_P4?<'&]+0W%!U:BK9P46=KVT$.K$4[<\_0WN#?6HO1WN3=ETP_J[GR)FP:
MG+Q/^3MO3D_-VQ/M]!@'S\S[2L=15)(<9SEC)*9YG*2%_+^V@#@KTCS7+?$_
MJ(UQI6["6MZG6())")Q<?\>\@2UO#U)3@@R>/.E:;\?^NFY;IX\'G]I'EF8A
M*04K2)RF:48B)L=ZGG0X`A&GD*#5>N..(\_#MS3Z,7D(^0Q]?3S\A]W[9]!*
MMO:=HB=_D_H#)HD.7.'X*1,]2D_HIS/O>**I[NQ[]:42)T2"(YJ#]M[)?SC?
M5'?K61:60<F(D*(OFRMQ2(.\:S,N<JV"&%8:<JRI+PU>]$\%#[7XH-HYC%18
MF.B<3\,P$4ZETSCQ)9HTXL1!['JB:79L>25.M$#01/NBW8IQ/4N*,BI86I:)
MNF^4"I(%75B+,4XGW`/5Q^A8(3]XN(\)<.`4>Y9N?.?%_J1X>6_RY]Z5[*T8
M;0<2WD,\FU$FH\'ISJ*I6[3G,?6.[/=ZL9@)$;$X3A)<DC0N@X(G#'??'V.L
ME:,-_E+',T6'8V0MZ)H],7C!#'DRVN"XFX%=8\*XC%77U4K^\&+^X^"'!_<&
M,R*"0(:309GR``=8%%QT-N0TP;-E=3/?R"^8)F8;C%]K>.+M\#PR53^#<P<3
M;>8_T*++:Y@PG!ON]_%CO'%\[5/@UW<;:?*3W_#I_K@S?XX4&%KK5I[,7WYR
MXS"$M.S`2>;A/=K=B7HBHV"1%(3D82"R,L9Q%G:8U57^J39)P$#'V"DY0\OJ
MA!)ZZ+WQ9T^GCO-BMMQ;^/-G;3WWUDASH7$G^0^<^\RY<#C7#730-'-;M9G1
M-$UYB9.0%B(-$L*3@G<PBS`@LTVSF2\FF,XTL(%FL-X,;36\4'^"[G<5#M33
MHI?02WZC>VN"Z<NRH_R8L4Y%+?[/4=582S2(\_\39R*(^2XG'[`;P'OTLMWG
MR<7J5N>B445D^L1(IA['9ED2LR@K:1KBD.=Y6!0Q$RQ/B.X!I-U&W:E/A[,5
MDJ.["6B/=;K\8!"5&H<&=EWBB28X,NZ5XP<7%!KD&(O7KPUL,^U*0@5/<$DS
M3J.8TRQ(28>`QZ5A=O'@9D?,*W[E?+\;WT,3BH=[0$].)R(?IJ4V>7></?P6
MBUIYP]9<X8F&NK#LU5QAR^3I5:.[>%S/OZ[JCZOFZN%RLWN[28BP#`65&AU&
M!2F*J.1XUQ#G*>?:Y>6,OMVQ%E[\^9G03^=RZ=N"@I07,R/KM)Z-PQ-,MIY1
M9/3>G1E7@-IJSCDS*Y8&YTZO\-E+YKZ@R<.I\:$TV3`#&EN]!!B&OG%OE3[^
M,?]7LRK5ZQ_D1[V>A3D6"<%A*%>Y:4S3,BRC#@;+83?=;+?M6(0/+L$O7@F(
MOCZB%C-J0<O%IH0-#4NM>T0O-IW2&3"EU_##6\0[B4N!#)X(3EWYPI,(U9EY
MS3A=VJ[$[D&\G]]5K+F;U\M9*GB9!%'`\CPK\Q1CBL,."DT"9E%FC=J?7&K/
MG@BM0H[^N<5N66_-W&-%<YU[QK;N&CEE"BU^B5ES/1[DIY]#DX>9"--E"W0"
MM/GCMFK6IUW1++*\8ON26;O8NQ09+V3(G82)R,H2AXRQKO%48`Y[9,M.FY!Q
M;O28ED9%,;#26B%;5UO'9AFJIF@'$'TZI/<`(WP=;DL\-:@[*9<VJ?=&(*T:
M=22)]BG3%L&+U?RJNINO_G<M6VT_*.%=[QK-!*4E8U&6$<8%+G`I^HV')$E+
MF/@-:\NYZ.WAM8-QHSZBI4((U+J!G.IIW'AD`O=BG[+8?FS#P?54DG:2J1-2
M9H=A3R3,DC&-BTX(??,`L*R/0XIIRA/.8ES(:)'S/80L34&76FVVZW@-_<;9
MK8VM2JM>T).\J1P`$T"[W+MY;L'*3J4+=WBBEDY,>_X\@S/Z;"CIBPOQ@-&B
M"$,9?98X)D2NO>.T@U&4269)38W:GE11[>U(6G?)8&EU[@V;\NK/+B2043.=
M'>0;_[5VF'GZ>FN!1KWLI0\/FW?U9;5<5U<?Y^I1L2Y4QIC&/(MX&L914*2!
M_!!WC06,Z6<P&;?@6#\EKM\6.V#H?HL,DIYCSMQI`1R/-)C,24BHPX1VH(SR
MFLR)`^0VC4*@67[32QUO\*N.K]G[6H+38'Y\2'(:;D1CL\L`8]W=CJHJ4'-Y
MNVP6S<WCI_KFMF\V2G*6\2QATM-AD&%6Q'T"@$@S4'+3T+8<:W$/#VUZ?,`P
M=3";>F'IF$3"]'G/X1X:VF*;:I_S#;).1)BV:/8DHK1F3N.F-T(BQO/ERRH9
MY43^)^(@+A+*DCSFA/;Y2K30#QA-&W"L44^N!]?+_12^VHXQ]<\&8:0QG1I1
MY!A,@L^9K<20QJP!0L@QV#.+(,^7]@/(5ZQ]+7X<2HX/X>-@&QJ+O04BP>1O
M'][S?^P:B`EC),$A3A*<LC051=!'IQE/M)(SX=_J6FQ;+!!%@'&B(9[.Z(`I
MYA:&D4C"*`$HHS-JS.3PK<ZB)X"'1KVF>D:&^R!U9L";H3X'KH@_2:]6[?%2
MP!.:Y81A*N/7(F<DI?WQ4I1S`5G[ZG^K8U%K@9B=;0.8T5O'NB$%)FUZ?#A9
MF?;FGUB#PBGR9+5I`+P9VCM,1GH7(14\CD7`,2]3$24E3C/1)U.+&/2,$N1[
MQQGM9H>N('X`(]X!-49C?IH3T`,*WAKW0*)\&OE0Z"^-?2/SM4?_'_6ROGNX
MZQIA5"1!&J59'O(T"8H`\ZZ1N,@+6$HO[+LA'=THA7<'!SC\@03I"8`[9F`2
ML,,QU:;T$QI.R(`979X(@2'XQD:/@8K!_,=A(TD<TI!3*2]EPBC-\Z!7G#"/
M!%`,0-_M7@RV<*!B`"-(4PR<,0,4@RV.R<3@D(938F!$ER]B8`;^N1@,H,!&
M_N>[_OU$+L(RY4SDB:!EG`<I)ET-/!&&-+&4]*G?H..5Q%MUS]X9O\1JAVX]
MQ1F=:9@062%Y[+S-GK@3TF65=T\4S:Y-^FF9IH0!;H`_;?!]M>$_+A</5_7R
MIB\4VM4"C9B@+,UC'N,DX!DKHR#M,=`,N'"RVK3S4.I@A,Y-WEJU2[2>`D[&
M,$P)7TAAETC1+SU6U(']=;H"QA`N3XBC$Y=X(I)N;#NZ*NZ,0`M!XY=U=?VP
M>%=?5[-,)"7G:8A%B?.T*'C(DJYMBC&!B:65)IV+)%]OZCOU!"):2#QGZ)=Z
MB1ZK^6K]J[4X$<+PT#C1$;46X\0SM,6(%$AOPL0];T9AH@'MGBB@79NTPT1C
MPG03,$\6+#IHG<0\3SB+*"W+C`HL2-ZW+N*\!*1DVFK2\5)Y#Q1MJX+5S^-$
M]+`=H8N3(]0IZZ=U<$+"H7%BS_5KJV8M-73*-2C?<PK.33-`(?W<0G*H)C6O
M)4[9Y]:'K"H'5C5..Z2]W=C?5\UZ/8OBC`D6QQG.DR@.@X)E70DH$<0I\+1F
M<'/.`^JR64/+S`WG</#VJGWR;&ZMGJ$6GS?1\I8NLPU5&-/>1\E0>_0W4DV(
MLE7B^&A_8H8Y#^,X3LLBH9Q0P?+^@J<H<@K>2+7<_"BRUMY?.OG`X4A<Z^ZE
M3DBR:9S\ZNG22WNK?M4H/B+TY*:J(]]X(ICN[(.5)AY*I/&I5*O>QZVS.(]D
MJXPFL0C++!4TZN4\C>(<5B;>2I..MQNV;P$?K;W.T,WID,8IRV:'42,0//@8
MJL7HAUCJD`<X=QK(OC?":->J-\Z:K)!F8S%,+B\?[AX6ZJ2%W#6K3?WO[783
MPR&-PB(LY1I<A*J("._EF*4LF2VK&_5'@Y?'I@"T1B_>CMY#K-J#^``8.D1F
M;Q%MS/W@9;53TITLM.'>&'OM_0JG9JOQH0[R1%5=6JB_8K=#I@VU5<^:AS&G
M92P;CGG!2%G&F(D^T&4AF6U49#985W6:`H68/2KM,0U?D@^E;K`PVF;-K@B>
M)'1LO9-@S+0-PK'_.@:R1E^SX"193=2<!5D1$5JD8<!RGF5YSI.@:SOCK("H
ME)4&'6O545+F&5J./MITB!J8$:C-LR<CSZY-!AF`0,+T1^'=_;Q>J>/S#]?/
M<>PWS]H3\F-,>4`(X0'&`B=9F$6<BAZ3_#_8=I5+(*YS9GKLJ+E&YQ\__=?\
M[OZO[&A;"[J=Y=0WFIM<OK@%N/7UU"/',<S1XX<^[(D-X/J4'H_A0E]T>A1;
MG^OW>`1;T?5C$)$(BI`5)`FC1.2<A4G69[_$&045$+';\CC'#WNUN+R=KV[`
MKX-99GNX-+LEVJH6^ZZ\MJ36W"4_@;8.,`X@ID,I'+(V/5^^=B<'1Z2@'!<X
MR),4RQ5RT!=X$HF(HL&7",V;=I[W<CR:51),AQ/]<E']V#S,-:^YC>`*LY/=
MT7PP^'RWO6;88_7TFN&K7,(V%8:[Q!=A=6+;VYL,M@C4EM7#8X]C=9\)@<.8
MQ#@MN!!1DJJ7P;M6250"7Z8=V)ASZ3S$IP*C>5<=_2@9!JB80UG6T\@1Z86I
MXG->CU1R9`$\3=0)R;/$L"<B9\N:QDDW!`I9)YC;8+6Z.CC:W<>O[U2"=IZF
M),O"`.>BS*E<Z[.\3Z41.,Y@FF:O7??R=I`I<;"^7DAPU1JMJNU/-@VZV=D$
M5#F++M`3O&FXAVE?A_$,=2B?IJP<+,7?C7]C1)O!$Z)HWPN>Z*,#PQK7'=AB
M_M^!C/,?]^H5B$^5*G`K6?]P+>KUY7SQ9S5?S5(6YC0F')=%*?'$9;'?+LT9
MPY8JEUG#XWC_4F&[5"/[^F'SL)(!XV'P4VV!GR$U'M$OJ]8`M2S<R%%=H;MF
MN;FU6,C"HA,')]!,XC^[639/XEC>N;*W0H6V6SN0,L2?A!Q=Z@TS$FT[UA/Y
M']5D0,ZB&[H=31GOJQ^;B^_5XEOU1ZMMLZC`1,0)Q3P461IB.8]U3P<).<6!
M'H!T#,67B2)S.A_`/>1B*G#JG#%F`64`VEJ`MB9XK?_/^;8F_<:._"E5W]S:
M08(_D&1'6J]FG8OOS4S.+FF>9"$1E!=9$H5R[FG!\"`H:0$\?7.#P?EFB[:Z
MYT[57=LG+D3=A3/&T'*%6VIYX[6"[\BU)MQ09_V4>@TV<I!,FU'J4IW5+L,L
MCC*>A5$>T[@H19H%Q2YO6<(A::)50<\U!E]B[\*].NOYQ)D^6W?'>`JMH/NO
MT0JE794&N>SGU6F8F<.5VH!6AUHMY(B9<2)27DH<(L%,(B$E3CLT`>/`_`M'
M(/R)I;%SM=;SBBNQMNZ.T;1:(?=>JA5(JTH-\M=/*]0P*P?KM`&I+F5:_NXL
MR-.\P)2Q,DE+5G!>%*)#(V<3AT>@VA`\":BCP+U$:WG$F43;=L9X$BW_QG^)
MEK]K5Z(A_OIY)1IDY7")AI.J]TR`V-_;V^?D;E-RM\)SJ#NS@$2"AD%*4AK(
M^8%D81IV"%A*8YU2!0Z:!4DQO&!!>X$.4IG>,JFGE75B/DW4],6>+UJ<!N6_
M7%`.>!!@.NK-'@6PY`*])P%`Y+PP#3EDV(>G`1Q9UCCOGN"[AI?-7?59]M1*
M==C^#DY*6"["(B1A+&*<RY5&F!&>QXP&L<@BW?)[IE_O3N>VB%`/:<J[:2]R
M<R+D&\JF)S'=8#..+I?9H$5[R'RJOE7+AVK=MQ/@,!>$E32.8QYG*18EZ=J)
ML@S#=B[!7^]\3[)#]-_`]2R<*#U1<<H03$TZ*-.IR',R3LB',6^>Z(8Y_L92
M!X*LW[Y(55JNFT5]I>XX_$\CYWCZL*Z7U7H]BY.0TH+E2<HBILY<U(R^:R\I
MDU!/,08WXUPYGH)#_U+HT-<=/,@B8A"9&JNTL5B$J<LS^EI8B(Y-'V#%-1:-
M9NNK7JR5M*"'4WT3J9_5Z\U:7720WX?6M_-5I3[<KZK?-O,?\A=^NY=?T[2[
MB_+_KFOYR_42;6XK].4OG__R5[2JZKNO#ZMUU16?65>+A;H`HXI47$DLB^:^
M_=%NS_CI7ZM?6FT!(]G">KZH6C"?SB^^_(.\EZ`VZ_JJZO_B#'V_K2]O.^!@
MW.5\.;^:#WYI[D0/>&T1::/3^+!DM&)'8WDT`6/;#[([K3ZKOK8;+*H$:Q9F
M(HAIF,9!QCB/2T[R75N)R%@`BV^-FG`^4[6H@/&M&5EZ,:YSEF`S40L'[:!,
M48/Y)3Y.A+J#Z/,DW!UF0V.Q/QDND&<J(S\C89+CG&>A(&64]]\?,A)!ZB=K
M?^D81P[=S`PMCJ+/#&PE;)44LQ7P1,M>C>6N-CF>C'LX[E>6MT##M<>W>FYP
M3997NU/0_3*:XB@D61"EH0CSC&#,2;?AEN"8`E/XC)MQ'BST[RWN(G?PSI@Y
M@WJZ,`IU,)UH(;6D=:"FVS-[C9X38C*844_$9;@=C>6N9B`^'ZY5-9'UYV9Q
M-:,L3FF,14&SN&1)*;*BZ&.8D.=PS8%\^SA2H_8.5.AV)@6G*Z[X).O,9@$W
M,,'ZDN2*6;@2*<9:+$B!F4!^#JAX0W5,2/-(;(S@OZ`QYC0`UBWK2O[RK50S
MMM^>VPE;7_V7[`;:^?+CJKFLUFN%;A:%$DB,4U+@-,II$A5EKW:"4O`9H#LD
M(QP7;L$_W^<$KY4<>D-W>>6'&Z`KL@/^#W!W@==AR7.RGS70#CU2\,<N@3Z`
MZ9,K0/?^\T1J1S'U:)TY%KW:$OYY>\3R>[6L5O.%!$:N[NIEK4+23?VMVF&;
MR=DCP%$6R`5Q1$I&4Q[2KG4)`ZC6EAIU+LP[G&?H9HNT%8CY$ZQ`C;9%MYX<
M3\`S3'E[@G\_(/@IR$Z$1]97/>I.2*EE[CU13=M6-4X[+/2"U[Q>_6V^>*C^
MJ.;KAU5[#/WW>G/[9=E\75>K;W.Y1#Q?WC]LUI\JQ5>]J-O5I/STL%I)W'2^
MKM?OZOE7^9/-X^_S>JGJ<V[KMBL]Y_.5*NBXGK$H%#0I.8FR/&)YE+"0=0;D
M64J`[V1[@UM+*88\K_V+`O=K6Y98'?)?2\O1-V4Z4F;WUJO5JK1T(T&WKP2I
M(WXY,HQ>XO:&7-UK:=X`=C=O*!M1:^09.C`3?9=VHD-#T=92]-1459=S9RQJ
MK3U#O;UR+I(6HU^4S;^BSFH5[G=VCWT/;BQ_GIC,_.M3GLR''A+S_(*>?PB'
M'9[-:)3%-!=E&H9!&L:AG/S[V3]-6``Y)`=_^2B'Y9?/C\L&GI:]39G9*9E5
MMH:>CDU\)`8X"M.FS1.1,\?_QM$7D`B]-'*E4!^6*G/GP_6G^N9VLYZ1)(U%
M3,H0%P1CFB1)B+MF:)$F.B483+\;)!CPV@IML+)+=U51[ZI%!4EU-N'KM%R,
M015,+:9A"9`'[I@ML_3OYZRI].A5\SA?;!Y;Y6W:',<MEX=/Q.S*?/09V)2_
M?_?GYPLB?^>RN5G^/W=7UQLWKF3_"A_V80)X%OJ@*'+WB2(EW`"3Q'N3N_<A
M#PVY6[:UTY8\+=D3SZ]?4E_=MMMMD2+5R@`!$L=VUZE#U:DB11;SO]IZ6G[<
MLQWEU7#$4/Q2WIQ1F[R]^C6Q1X1ZZA`L83/U%/BEF2=1=>OT?3,C+V[:XXC-
M52:1CYC+?.H0%$#'3;B#^EW:$"=(J;;3^7S+Y5UWEK8Y3E'>=PL2JM6=%F_C
M"CS;E*FI]H`&=+RUD_*Y-U*_YN1$K3>%P864>Y-<>+F+>C(=H^7D<UF4SZWU
MR\4$(H;")`X)9AA#BOGPZBR(F</57E[IV['^OJH]=)!WP=)-'C]<@&+VTP=O
MDG0B=*83NY``,N!(:?J9T^IR(<,U$>ZQ9BG]01C_,B2M*+LN=UG[<]_2'UGU
M*2_*75X_?2S$-":K:C'/>_XI\1\/XMN?LOJV%-]Y%#\B:[UJ)4]1T)A%V`\"
MAD..>=+K01!$;J*2\Y>$>YY:XJKQIP]Z>6"Q/QW9+"`UV&6UW;XRD76U]"#+
M&E60_R%^1?F.[^60K-1691F0[15,S\JDMLK<NPKVOO8/3>L!:%T`!SY<]!57
MP\0%B'_4NU3H9EZDNR?P4<S2Y.7EI3QN60N<V[9&:WDZ2U.864;V1.Y:XO.U
MD&RX2&J.-L19&$:=C"V@=95!E!79=5ZO')_ZD`<<$HAYY'L)QG%O3IXK4"M^
M=:U8+WT_OLI_9]&A5\R\JQGZ7"XJOB>X<306I]*B6>F^%;2$Q$Y,')HXW$=0
MWK!+!^,1HK[:AATS-JUOMHGM%X_:?.N4?5:)-E6PO5F3G;6NFEH13:5^45IG
MS*F358@9RD;KX&73V:99H$/$#:$K:I,P#AA!KDMCM[>0P#!2F9`K?*SE^?)G
MH5CM+%E1L528&2=+EDA1TQ[)QS/]N>AVN\G)W*4\*UD6@-;U+K]ZJ)N]='6Y
MD#G?GK\3`J1!\D)41@=Y.?D)4UUNS^J]7AT^)M_*YP])_XRL./(9Y*Z+6.@A
MCWDDP.$P\7&]2.4B#//6+>_3V*L/^&7;9/OT16@5ST,K[X!7$VHM"V,T3N#.
M.SP3=7"AHJ?,Z:E7+=;&9R$2:M'!EZ]F+%.I)\@KZ*($^U$8(^(E(8O<&`ZK
M3!`25Z6&4_ODV<JX5PH:Y>5-5LA@'K]MR$)LCHV[T4PN,:;&@S\5+XH4C(Z%
M?D_Z9;;[*OMY#CU6_(CXF+ER8[H34<@2[`VQAR&":JNAVF:L+X<>1,E]UC4U
M/=%SR4I0O,7.B?B83.A"0F6Z'Z7A)VUB`,E#(.N52SCV72*O/@TQY1%'/.F-
MH1#2:=$SSH;UT&E@@*P#MP\?O71CDMUQM;=]6M7JZQX/$(!`@^BB.72W/K,<
M-1@4M$B-QX4*D:(3[ZB0#B7:$L3S[4.=;5:A%R+DQXS1`*&`0)XX@SG?PQ-3
M^%@KUF6H`S*O$(WF6$^*;)`[78PZ5&>6HPZ%@B"ILKE025)VXQU1TJ-EM"S]
M.Y.'(K(-%5&=WF2?'^ZNLMV7Z\9T]>6AKNJTV'3'9M<KQ@(GAF[,F9_P""+J
MN+`#@0C"BIW@S=K^R2HI*U&HQ.B)V+0S,@N)6$O.E7,\W&:BN].45UA6#L()
MBGWY+C9."`^<(')Z&/+.<95W&J9M6WZC8;I`F3.^W^)4/<(GC\ZR8WRZ>^.B
MW!"-X]O>K6^SS8,\XRBW5A2"^B?VL-N)?WUKUNZS'W4DZ/E]Y3`?<^;$-,8>
M)S[B''=O3U'@N1Y2;'QGRJSUW,W*N_NRD!M.^GU?#5K5=G?&:!XWX3@+OVHS
MD!ZBI'4`>0$ZF.![`Q1(I*"!.G>K][$4GI!*XZ.P$(TT[]?+]G=VB%-O@!<]
M'70+2G;9'P]9L7ZB/_)J!5E`XCB)0F'7H<AQ$MZVDJ8$0\*)2L5CPI[E*N>P
MN]@`#'R7T$Y$ICUVQ^G@W,2J2:`>IW:;J[U-U`FA,TGS0C3.J$MOM2(S1M>D
MUIZ#85[>I7FQ@J$?$]=WB9=0!W(*W>[V:]GT`A$]99M@S[*RO=5#\2`B6Z#:
M.C>%:T6=FXEF-9TSP?!L+25?T#9&]0R0OC35,^'2B`:,T^B:I'K5T-CQ4R;G
MWBL/L\B730/B$"7,@U2V^>ELLR!2/"!HQ*3UV>T;D5D=-(8U('KJ5.NKGE6.
MC<C>(;G@>XMR"<+WDCE%Y=,F?L'2I^_3".V;2-AH\>MO?F;EW55>-*>XV=`2
MG!UV!!^:VZZXRS'G$27($54H#V#BP1Y*""%=W6>[O-Q\K=-=/4X/;:!0"=V7
M@-6B^+&-XJOL)B_D(G]S+WKSB8KR:&4PQJGEN4=`33Q[M.``[@78`P;/$!_T
M+9]92358/2&L-L=H(3IKU<5ROD?^O'=J7(JPN4UEZV#7)PEQ8"2@8==-!-S(
MZ_%B#`V4K;/`M%[JTLTF?Z?+Y,]P;<'`J&)Y-NL@+D1JSL^#W3L(=`=F@1<!
M81+1A.)$0(X=S(/0)=%0^U*.^KXBWZ8M/9X'_"AM>]Z@Y)OZ.B:[%5]EE6Q3
MLK\.Z.<6NX7?T3)VW/^><FB"F+/=T:(V=.<2S*]976^SKMT)1#ZF;H`HHPA&
MCNN&P^J`*%7A6:]*4P&JH89J0GB9/KW3*&AQ8Z>_WKFD05O>%68'+O[<F?#`
MD?E2G\X#\O?,=5I,V$UN^H-C=>58Y%+D(`<'?A+BT$\"PMT>"G?B?N4X+D8F
M*AL8U->->[A:J\:9O"+F_?7BO^GRY-C!6(AP6'71P/*D&IVC0YUG5S7/J_6V
ME-*T/U5/PIA#%I/`QP@GD>?'S(^I%P<8,\3'MD'2_'1[18<$!/:(P/<>T]PO
M8H\S<R($)U*YD"B;ZD5I]/G2B)6/A;#17"76[$A>88<SU^<!)A0S04B2<+\W
M19S(5]DSI_/YEO?('6[6_ZTL;GX5GW$'FBC:(ZVZ3?NJ^^2T^!PO/#:I5%,=
M4RQ:4Z(75+TC0[K$+DB#M%TX(D#3Z%!0GRJ_*>2J"*W^D6UNFHYJO>5N)PE"
M3LR8`WG"(@(C$L5!T)MV$ABJJ=%T>Y;5:0\1I!6X;4&"?$`Y>R2]R]C)R#+'
M]V(BS:!+KR+/-%V:=<!OHI1O+H19)4Y`?>J1R$NPRZFH-##OS)$H<@+]6F"\
M#>L1]RQG@>\267L?SK3LK\"B3@5@AT"-N8<R=S/D_(&<T7E?G<[%*-)$-T[F
M?UU:-)4G2=<9O2L?BGI%N8<"ZC:G(MU`3'(0'.R%E$Z8AB@8L3T7R8J\W('/
M99U5X'Z7%^O\7M34:0-NDOBH$*FC/I8XG"0_%T"B`O0=]F:0GST[H_5'@]!%
M"I".'R<52)N8=R6HN1O[,A//5E&G-]EEVK[3^'+=AF43E2O?#0B-(TQ8R+TX
M9A1CW-OT$(%C9,B((<M2M(<'[M-NO5].[@\E:J0BF>'UM"K-3JF:,AVP*:"U
M[X3!ES.RN2G7330U2_#+8?49K)G8?:'_TN=&U1WB.XVFCV'AB*X;)>_,VF[6
ME]+"TS6IS/QGMLGN[N4S=[G+U]D>TRJ,&$8P0"A.<.1XL>O@R(^Y!UF"2.AX
M^E6GODW+RK\')M_K]H$EI%\&A8YB&>=<IT"=A^Z)]>H!]0W*"[#'>=8"]DWV
M1M>ST_E?9'EKP*V3U:XIVL85O\]M?TI_S_Y]*ZBYW)6/>=7LUWD+#60$1\1/
M,(6)$R1(0(("#?5QC*,8T]%EL3T(9Y'-:Z&5ZV;WNMR\WET5(Z;VG3=`_*EO
M,VUIM3UJ(XKN90S81.&5L$&#&PS`-=5XUO%1*..7,4YZ!;[-\1I7_FNS]];$
MP/YP+&'*,(.7Y:S/N,XTHZH>4D$5*ZNZ6H4N=3CD;D(BUPE#(@RX_7R&A%ZB
M=J95_?-5@E7O4@,9JWF'262\:O;]Z:](>:](U2)P2>6HG@/'"L\)5(P."OD.
MZ<LUVV6;7*[F-IL_/Z4_\KN'NZC<[<H_\^*&I??B._+,N@>A0Z#O>CB*4(#]
M4(1IA\'GC*M,P(T:MEQ.=KA`U1:%#T4E]\IG&[#+'LOMH]P%LFX<`=>=)XJS
M<;.C,&Y*?K8!4"L/F[?6Y35H@8(>J2P[VD$9P((>[<P2IT+D"?6S,AX+$48[
MOI4S/-`&Y#3^<9^WV^LOFZ,9*TP3%_EA@'$$.48N]B-9WR01XG[(7#951I4-
M6I9/]EP;@=R.:D`@U7G5%T:KE!H2Q#U&<'F.,T!C>%/4/VW:%ZQ[^CZ-T+N)
MA$W2N>'@X9?K=D_`X;T2(?>I0YS$9;'C)(P3@F"OMW$,E=[=&#=N6?\.H+RL
M$\%5GYE47^"8'P%]=9R-?$-*N3\++K_=0@8'F!<@G*<H5111(Z.S8$$UX]\(
M<35(Y/A%J^&XF4!3WMUG1=6=UM[*S>C-VD!SB\]56F6;OB7%<#2-NR'T0]?W
M(@P]Y`8^<MKK?"CWG#@:V]/1,@J++Q?V9R^E$!Q`!QUVT("_:"^G_+7!#WH'
MSGA><Q+AI];8YAG)A<C%7-Z^7+V;DV3S4A(=HMI?@@-#H6YBGIP$,7088U$2
M#[#\(`D55\LMH[&^MGY,,%0WX=@>$</J/L-0S"OOY[OV:R+G)A1^XFC^;!(_
MU5U=C3="\_B+%FMA79J2=YJMR[N,%AL);Y?="H3Y8];];Y]K&.>>&_*`HB2.
M@\@/8`A#5V[KA,QUH[%K9J;-VI.,`6FO&`-$T&(\7]&G2.()#;`U'`N)>6ON
MO;P?T"J-HV/Z2WV;[8[8E3TG/V<"W+?TQV6YD^I##VX"_E9>IO(NPP$>XIPR
M[D$,W8!ZC"<!CSIXW$4,JA5P<Z&R7L@UCH#U,RG(&U?^2[&>FVV@QHGR$D=(
M3:S;H3FJTK](+SY<`.&(5'+AR@7HG`'TQ7W8K3_G$W9#`W%"\.<>ZH4D@MG=
M+L\;8083!WU,\ZT$DY2[K^DV^RJWM.1UGE5T\W\/52W37N_""O(`0<HBY/N0
M(!;0,'9[?"1R%6_EG@V6]=3QKV*7I=O\+S&IO$GSH@*_B"E!E54?Y%[R:H`.
MTMZK9@]Z)?RZ`$4K7'7Z0_[U'[^X%[[G?`!IL1%?H`_-3\KMZ+50H@S<E45]
M6\D>C\+65Q$:3<L1X#L7[7YU^6OB'_`""+CWV;H6K&Z?_KO_.$+Z3_8O',_=
M?WHAWY'H?;C!Y&CV89R>'<_V%!I/CX,GOXH1_U4^>6#O#-A[<YA(%Y0=509"
M,SU:&>N?(#_:\5LA05HDWDB&Y-DN?TREUE7_\R!4_OHI+V[:[D_9D-U7R*>,
MN*'O<!YYD#!&\0#,BR+'7&HT@^>\.7&=5K?@>EO^V;1/RZHC:1"'7:KR'<]H
M$O0\,GQRN+`$:.A9FY[YYG_(C*>\`Q?`W@?9LN\?W3.WR%0WBGG-'&=V5'^"
MY&;8886L9H-J(^GL4OZ'F(<6F^:G+DLQ]\SJO+T@(,J*[#JO+T6L'<N^+'1X
MX'D\3ASH8!1Y.`IZN#!)/+5+8<Z%<I0J3;D1YF3JNV\]`U>M$Z"\VN8WS2LC
M@WG$ZB!/SRYG'UUC.>>7UJD/0+HE#[>V@RL+A?;'G_L&.N=`X]W%\B=>$T9*
M,T?-\6S\!)EK%AH4\ME\PV(DRXFY9);?%.QAM\N*]=.WG4"6KNO6@^:K;:.Y
M1]"B.'8CQ'P8.@01'P9Q[`PYF7.#,SF+(*U/[WK0H-[C!.D`U&`NLSF4TU/9
M0L;0^.RI\PL,XWS@69/>#GQ;?AK3'R7-+#;#8_$3)+$Y6%#(8;,-BM$M'2O?
MHS3Q>1#!"+HP=J%+:6\;Q9&WJLLZW9K;K?&N0:5S4@.VT>KT3?X**-_<CM%.
MISX<KADN2&HF"H?R(/P$,J#ND\;[=47"1H?H$;.#23?Q8E'9)BPFQ/&8@Z)]
M8<M\%*I$YA0[E@.2'0O"],7FFB@O;[)"EA'_J5C\36)X7`4W%[EJ9=CH#4W'
M-S+-+'HG.#RA=2:87XC$&7&E-/]@FA.TYYN3/@M:VN:(V^::FSH3SW*]XKY'
MY#V0$?:A!VGBX&3069]"Q9O!;:.QOMA[5!S;"N651A;/?!`_W#I1C2MESC.:
MDP5VOF&<5X2?>P)Z5Y:CRF.(UU-NHT.Z?'4WZ^[X#&"!9A-90GRU?9"'W8]N
M:7T+9N(Y21+Z)`P1PH[K!'38VAJB`!HJE:U@.T-Y;2X+V!FMR5GA[`-E*4L,
M?KUY"F'Q>4-G:/3RB-6'8/EYQ:[[X_/,#,,PKM=]?T/]E\=L]YAG?UZ6VWS]
MM#\LRSP4^\R'T/6(F[@HPIQ[L1?X#HT#QW?'O9HS8LK^<;0.F$I7\\G\G9;U
MV8E3T^@>&>BA@>\M.##J?+\%.A5:P<])JV[#]VHM9$$>8RE`V5,L)ZVW6;-.
MGQ9/S9O!O*Y`>9^U_>>J$ZN!X]J\O\/,D<QCE-`EM&PWYDMIX8E3G%A$:957
M7Z[I>BU;9S5)1]I]:5U8$-8A20@)8>+&-.&TM^X2HGA(V9!1ZZ+?X)0Q)5)U
MU4>HXES`%,'C2OPS,*N8%7I*]Q#E">$F+RCE!RME^#CZ3E37AOE?2-%LVJO2
MZD.KO+125,+2INW/^L*FYT&.,<,H\41]'>`P#L+>IN^'OIKN33)E?P_9(3KE
M%8\I)(Y=OIB)/=6UB`-8"]*R4W2=7!\PP/)"=,N,+Z]F[L8(&JU1_ZJR+]=Q
M5>=WJ;SQ,T(8>4D<!@&ACI/@F#&_LY*$/E/L^:?XX=9U2."1!4+6(U*4(E6N
MQHF/19+4Y*9C9X"R(,5YSM$)C=$D<R&JHHN^-/)$*2K'/[-UEC_*I</JI5:%
M$8H<81$'B/(`!Y2'O58ECN>'*LW?)YA1>IVCWN:]JRHKL!L@*@K*%`K'B<M,
M[*D)S0&H!6G,VU2=T!L#_"Y$>TQX4AI_^!0UZ7/VY\%<;U<6XI_KYN12=7SF
MAZ"PSV,?4I\X$28H1+C'$6$>J2B5<>.6]4O@!>D`6-Z+>X!84<G,$S].W\[*
MN9KJ2;KW6,%SL`O2055*3ZBCM=%9B&;:\Z^<Z3%7U->/Q6/6'IBIY(V5M-C$
M?SSD]=-!*Y^A-VKH<AI#/_$@XBP.&'?\MM\Q8\2EP<@`-VC17F@?@)3M2*[J
MYO58"_2P_=;9&E*.9_%$-%L8BH7$L0W/2NO/L6JG\/5MMGG8RO;E:74K.QN+
MOR2(QW3;M"J7A=J*^-QW(8\CEU'B$I\PG/3&F9LH7?EJQJ+E*J@'V;0'E]VJ
M9.@V_SA`"KXW6,=N*C!,^3BEG)]M-9$T1+2=3NQCN#LAC6:Y7X@J&G;J9:]U
M"Y1IU#'?Q"_2'WFUXEZ<!(1$0F\)#"+L,=_M+8EBBJH(G\;'6U:Y/2(@(8E*
M1(!2E3,=UE2K/"N$Z59SX[BR7+'UC(RJS)3I6XC63/'@S4I+DPQ-%6%IG=V4
MN_ROYO7=IZ:CY"H,O<1)/-]CR*.A1^/$Q9UECB%Q]%5%R]S,*O,<(_C.R[LT
M+Z;)CA[-.C)DG6'M2>8()F<0I6/\C!:I2>0N4K2F>712Q`R0I7(>["[;K?-T
M>YG>9[O.F)<$;N+'<8`(BJ@7(R>,>F.4$\5>67HV9MBFU,,"]Q*7^MDL'>;&
M29-]RM34Z("K!A#XWD*:?R_2$5Y.;D*:PN-"A&>B$Z\/#$VF1&'7P+UXHF[3
M*J,WNZQ=PNXLXH`&B8]=!\*`\H"[$1D$+>",J&G,!$/6A4;NQ"_RF]L:[+)'
M66:)OWNT(!W@*N\FT*=V[&Z"63A5W4TP4+='=2XY>INADYL()M.Z$&$RX<FK
M302&R!DM49_*(GOZE.Y^S^KDH=CTUD+J\8#%E,?(X]2C01@-UAR:0)6IG*8)
MR].W!A6X:V"!:XE+48%TF1NG/C.0IJ8\+5\M(M!`.I?L'*?FA.1,Y'(A<C/5
MB]+H`Z9Z/7MV5>_?_G6V(DXQ=A+'B1Q/]H)R??DNL)O441<KWKFN8\)Z]?/U
MMMS5OPI]N@,;^:Y\?V^:ZG7J6@R.$QOKU*E)3;.IX'`GP7ETYA@K)U1F$HD+
MT9AI/KR\1'PZ(>,7<HZ^5OLM+[*/=797K:COQ!"Y0>QBXM,P9&$,>[,AB8A*
M/3/5EN7"YL3K9HD1-"!5EZ4G\SMRX6=&:A67@":R:F<]Z#1=IU:&#!&]$-TR
MYL[+U2*C-"FIV8$]6K-TMY-7+?UONGW8W\CNQ@[S(@8=$@HM#1SN8]I;3Q#B
MBNO49HS:KZ@>[L2L[4GNK+G.B[1HEF73JLI$+/Z9U[?B:<MOQ#>V8G)7]R6$
M^.&M;*)2WZ8%(`[8I$^5;$JV_7_NSK8Y3ES+XU^%EY,JSUT$"-!+"=!<5V62
M;)*]5;?F11?NQC:U;?`VW9EX/_U*/#5^:"P)"<A6S4QBC]WGG+_@)^E(.CKQ
M2_'XK^7M_7W\':__DIVU4("ECN839^;,[::`SH&'5U9ZM#HGK=K+Y3:+BJGW
M#DDURK\BH.J,Z@VN:A=-$UXWH>LF(/%IX$-`41(YB7O.M&&8Z,3JN\;,KP.:
M9-W[6NI@G%81M;-M54!3!IFPQK\$P,2CD0*7I$@2>Z]X8</OZ<\XK[;[LCH=
MLO/I%Y=$CNMXS$"`'>@!+[*3UJ9-$E]R)7&2*>.P:DN4,O>D\V?3-!3#U&SB
MR4'JK)IU=LSZ:[E3=V,ZC6ZJTB#O2OBD)Y97&ZFT"21YV5-]^=3Q8Y[>Y/MA
MNB]TJ./%7@+BP"4^#!.7!(%C>[X70QJ"4";O-LV2Z:Q;^?!8%GPS*)MJIMOM
MX<3FE=E/?B]N75MRUUS]I'2#H+*X8M2:3U<Y;+7W^36.60//EEH0&!5JA%MZ
M!%X)N#0%\^9=6'HD$C\D>$R/]1Z+<T(/X03X?A0YE&,2^GX21)TE-T)2)1(4
M/MXPI'J/IBP%J*@F!B+#@LG11U8K,T?U7BDR@ID)\JV$+5,B>'GB;JH8PA3!
M36<_H%;+L3Z-Q6CE^[9'`+8Q20`DH6=WAATG]N5F:-/M&9^FM2Y:R7#\\UEA
M_*-!6S'TS"NJ'(DZ-0?.7?7#HL42Y^\J-D(J?6JO!%P:`RI-/9BR%<W;0NIL
M8G.3%_59G*BL2[(PX[QX9[YKB^%WOCVUGFV@EX01P8'M0YL$+B8^1KU'`93D
MG4%'S"?7V[?TL;TUA\T-M[WO_*]GYZWR9I_?-;<+S%VN6UGAD7=\AF9;R<L_
M1Z0O2WW/):XP+GC^N[EF?+\O_TZ9<!4N=E^S*CO\R"J2[OFW-B2A3I*X=NP!
M!U(VYJ)!V!G'/H!R9-!CTS@$OF8_LN*4_7[(]OPB3NN0W2C4X]4DL-AP:'YE
MY89$O7_6V<%ZD-FY>&6U3LZ,4B'A1JBI5_B5`%)S4*7)9U42>\G#X[Y\RK*O
MS;O]>IBV0="CB1O3@#JQ2QP<>F&?NPJ<0"H#/MV:X013YV!]<Q*;^C7O*'\Q
M;[(BN\VEMQ=HT%>,>/-**T>[SK>^!WEK)C@SZ-[5:P1R^K1>">`T!E2:>BS5
MLEI?RZ=T/S3G!;8-`CL)*8I=9MMG_W3F0$0DS^RH6C$_9NL\JN&US[?\ALGB
MSKK-I`=NRDI*9:Z,2JB6K^I=6HI1%Z1Y/S&E+.9*>#0YC+>34!-ED3@L>)LQ
M`[MVXM19BRD%KH,)"'P8,,SY).H37;8/!.])G6C$.'DZO^IJ"<78]D&MVHG!
M9@;1Y%C3J]5ZM!1JWA9FA#03E5P):*9&\>K$H`91Y'8N7<RO;PA,>"GQP/9"
MZ@7(C9*PM\JFCY+;P"<:,XX=E=6YJ0**,6=&Y>38T^Q/&EN=6V)_TD6EWMN@
M-%WBE4!)5S1O;5'2)9(<I-XP!T+,(>C:S"#!"0AMXO3FL.U+;ZQ4L&$XF?2]
M//*3?0I[*<V]7?*OU01=U_0^30GCK1=ILBP2AR?8LY=5QV9S=+LEY5-V7D!/
MW`0B%,0.86\LBH@;^%YOUX>.[`&*B>;FZ>JM]E#`;ZV''ZXLYJ3TF8JITHH-
M`6;55&X0T+GVMIY+7H(R+MD(MK2IO1)^Z8OGU7$+K4(IE.)N+'=^;&P0>C#Q
M`M>)`IX(3GQ,^EQP[$@F9Y7-&"=8_]+EM6/*);9EY1.EU0RZR5*JKU7>^'1E
M=5XM5E7[N3BC/)JHYVHX-#6.BW6S)PDC/9)J2;<)7.!&-"8`PBB,,'0H[<TX
M)/`V1797KUI)=?*BGR[TMJ#F;1DZ(D^9=NJA.#@25DMN+*15IFE#G^0]?8R.
M<%KK`@,:6<E6PPU%]R\,5]1D$*;$'VE>?"RKZG/Q+>4W'@VN<M@DMA<&;NP#
MCS@)H)ABW"]6`S^2K*P_Q9+Q,0IWSOIMS]S[8)6%53$/ZS)$^?#ZQ$)ZRC5)
M73'"S"6K'&T:/3]V>G+7N)P#YV;FSXA,(RS2(>Y*N*0EE%+_LR?)*UH>LORN
M:+)0VZ?OA[2HV.0M+XO.&9+=LI_YGO[<$&8M!+Y'V"C*=;W`<WID,@?B2(Y?
M.BT;YUGK+!L,;>_9]S/KCOE8-83+J@\J+-.JO!C;EI)<CG6=UIV;UL!/:P#"
M*^NF]I:7]IB9?A)"CM#01'.LA(Y&0BO-/\TJZU.?RJ)\K`^<%'?/DF$;+P'(
MBR*;A$F28$(\A+L,F(^AZT@O4ZF;,KQ:57NG0L&I"DJLHL\CGLHJ^M"S5ZGT
M)1;Z+DKUWGK?=(U7`C!=T;RU^J=+)&%,C1BT200`XG>H1"ZD3AR1GHLT`(Q0
M?!E:C%#J5J3@U#LD^9+E[7N5]4M4H[0R\G*IO%?395W)*Z4AD%+W$R?Y(@W6
M[9GM[8NSZ$GB40`CBBAT,?1P$B'0&8V)'<ET]],L&>[MG^WV.KLGV?5/%%.L
MYY]/1[F._X*$RRV9CPHU@B<]`J\$49J"*4T\@^8K6)R=VP08DHB9CX$3HBAT
M@R@(^OD2<U$&968],8RZZ/]%P8JSGB-O\CSMM)(W?:9@IU>N4);X75+<Y/E-
M?\2R/5R[/Z.J.!N.2(!("*,@MB&`Q`\\F/2(PM@5H8$^:X;?^/X4=W?>>."E
M5<@.=C2*/#[@649?N4'/:J7=E=L37V:I7[V52?S,M_FD?M%U\=CK#LE&KEUW
M1\)JO-'EZ%=RX6[%0$"EJ8=.ST&Q0;^$B>O"`/FV[P5\NQ4-89^UBH@OU#WH
MLS9'IEO/43$9"27RW+.IIY+J?O/`F$@*8<XS8T+#97U:KV1(K#$@L<-CRE(I
MGQ\;6(Q\UPT@&S?[)($>H2Z-NWJX/F1_R&2^)Y@QG/IN3I'5!\:L?5G<-7?Q
M#OJ/A8^1B;]IT^1=TRLV,9)WSI,IBR->.'Y[G^U.?'_2^&K6]_1F/[B!(^`O
M<N"$E%('Q=B&#J3U#1PHQ$&"`KG=0X:<,+Z12&DM:M9F$!MIK$!_N>%'YS#?
M-BFPZF[]57MN+7=-D)K"(Q@UW&0K0:SI*%]6VI]#5`4TOQYMO?"`C;(2UC40
M%(,D\3Q"(N1T'B`22UZ?J]&P<01CA3/UQM66I>ZL,JN3]HWIWIK(^IZ*0C35
MUA2K(ZB^R"Y24[-XTCLWMZ]N77IA'S@$A%%@!S1A0VD/D<"&G?W$=1.5/9R3
MC<Z1XY*=+QJ662(!-K?"*GFPP9:/5;%15$"!C:#:VF`E7-0?UX7-H9J%$]_=
M5O*5Z78Y>OMT7=R6AX>FN/A->6+^'-L=#W^F1TZ5?@L+`2X;R'IA@``(H>W'
MF#87_R(WPC`6K;MOS+[!;5S,96O@,Z\LT'MMI=QMZ^RWU3J^X"XO18G'-H"9
M;K65O/[FXWRY;6P>817QT%%IXP`4X82$@>^Y`/G("SR[LQ;Z%$KM>E4S87J[
MZ_.7_-Q/RUX>J:J@"CZ-B#<)CD*ZS4"]3AEAIDE+N4IBR4<QRB-%4>2OI_TC
M*^\.Z>-]ODWW^&=>;2`D$!"*`P]`$E#7L>/>($F0%'#4K1AFSM`?-EQ@'BG?
M5"LOH&`R:A;MY)`C)9O92VM?JC*62YJLY$J(HR&02S?93I1&G#O9W4MS<?F0
MYL4FQ$Z($"0.@CZ@L>-&GM<9#&`L=9I7W<JLW&E\DB:/NH2"Y)E%O2GD>5<X
M,^RYI,L8>R9KN1;V3`_D)7LT2?,N>[;EJ3@>GC;7WS>Q&\8.!+%O`S\*W9@X
MYT].<!2+0$;BXPS3Y/J8[I\$Z2$CPC@F#,4OQX/K[_CCOY7>_RK;_N.N_/$?
M;1C\]7>[+_B;[P[>_'.H;[SB"CHL_"ZK>%PJ-_K4_,?'O,BNV>BDV@!@.S;&
M,*"(1AB2&$7]6"1"1/0>]@D6YIW%<[^LVK'%I_*]1#+3>7E=5]+)Z8CDO6F]
MJCAB!\Z^9OG#S8GU)`_U$L=#?JR'^+OKXBM[!O>G^@0.PM1QB0VQ!VV4L!>9
M.K`?V]O$$SYPIL6:X4[RF8_6GCMI5;675EY8QWM^AJ?S5>9HE!ZEQ\FUC,AR
M`'NN;^V?U3AH71?6UP6UE3AV-KO&:L?.9)[E?TP]?":BR1N]@GX]UW#X3&]`
MI:E'3ZJK2'^FQT-^Q_JC/[.'F^RP`7$(*04QQG80."[U/<\)0!BZ"4ABA(7N
M_5'\:-.=P-DA*0[)2R0"=*/J2-+[[(OU5^.-:#Y*52$9+!M52I'!4HH)HO9E
MG!>YJBS(*B"J[GVIY:F0P>.G['0H']/C?;Y]3/,B+W;YMBE(TAK%L>^%V+/=
M&-L.Q@E-J-\;I4XH3,O)E@S#<^"?Q1VT!A[*L&*ZH@)PG55,.=:.Z:@$W^F"
M2K!X5F'5T#Q18#%6OZ?#)71KTV\-)-<73&GB$3-6S`L?#KP^>5TS/JI+E5\7
M^('G1C_?OE=J"&PB[!!"$\^&'O*`@T(G<3OW:0(#,V6_S/IL>HFCV!ZRM,JZ
M^>V/='^JC[ZP7["RZI@_U+/?[84Z8I)+JVL153"AO19WS7697836(,2K<[K\
M:#USV1J&R7ZLN4N`/3E-J/RQN?2K5_TY@9$%M87KS4UJQ)'\_=H>HY4L!JQ.
M%N5J=W,VF_A53F6Y^SO?[[]DA[S<=9R/L^;/36C',$Y8KPZ=P*,(8XA`9]7Q
M(ZEMB!--S=C%W;6>RE[<-%%+L>YF1AGE>HG.L2NK<<WJ)?VM\V[N.O_C6HW`
M6)/(*V&HKFA>WN2D4R3#TX2O_&^?;S^?CKQ>0?4O/H#]9WYWOP$D)@38?DRQ
M;T/@NB'IO4RH)Y1M7\@UXTNV#_7T[XX-YJNC=2S9GP^/^^R86=&G?P$;>*'M
M_!+#M$L*:Q^-36[*E0!CJ>BUC*TT-8)"/9+.7[S]GU->Y77.A#P-OCJ?;G4C
M!P:N2U`2QM#'=N3RZL:!&Q/?<Q)$I?99FW#`,%R^L._?\['!XR'?9E;5AJ!<
MG$2G]&+CL,55EQN=#0N6]//YH<=7ULW3\!O+']-747@$Z48;;"7@-AOCQ0(G
MQ@15@/#7;%O>%?G_9KOK'>L.\ML\V^&JRHZ-=P?V53$LQ<+^W^DAV[VH/N!"
MA!//\X,0`)\&,`C=H',SM@%2X_,\OAE&=]+G>V_3_-#D@NM[CWEFN,H>4]8E
M9_LGUD1-B#5%TCI**VW#K,M1#:MUITVDROR?J=5ENX;U-;AZKW&.Q3H'8S71
M6'C8L,-B+VU$:^I-M#2*4$<S;_.OK@^:.?R+W=,2S2#<<T5I=<__39@GC*5\
M!L.\^3,]_'=VY`Y\R[:G0U,@IW<E)#ARF7D[!J`N'FU#7+N"0]^F,96K:VC"
M`QDDJ5U6S2:$Q39/]]9U41T/IW?NAY]/>K$N8FG-Y;H![NF5Q?]K#1R^JF%_
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MV]TU/J'8I;878"]VD]`%)*9.W/ED!W:H#_J379F5^[=2W-_R,>3MOOS;NJ_#
MT8CZZ2TXG?:S-IUVX`^\M\[N6VEE-0&LC?GOJ:V(?6V-^`N07U^L$O#7++#"
M(D%WU^"W[/`CWV;?[M-#1M(JVW&/F;O-HO*^;CKVMV$*J=GM$I75L:L-Z,>0
M>C[P;)38-L:!0YI*I`3Z`-I2UT@OXZ'A!8-A$KF_LK.-RZH#^_V&1V8-0V/#
MSSZX%]GG=GM9':!BD=*%G@39Y8.U/@3JBPCSM[_AQ02-322TI+#$([&2?FQA
M$2XN+RS7),(]W]>LRM@/W^-B%V<_LGWYR//E[;5-[;$N![@AC4GL>*'K4>@&
M('$ZTQX!OMP$1X=%X_.8SLDZD;T[NRG9FVA15ZQOF%M6.=(_TW/@G]4Z*'_\
M4P^N!50;@:].S5>"4JTAE>8>4>FZMGOV?^_^R(KLD.Z9`WCWD!<YOS*`SS9:
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M@N((=EZZV'8ELPOS.F<^_7`):EVF,"^V^].N*:G,BTF5^WQ7'SJJ^FAXAY;7
MB\JRF8J96UHPE;'>)M;383T;C/#\Q_-P>$N?=_6?(UKN(EF]+3*6,5FFZ5?2
M3RT5_<N<RY*-(-Q+M?YDN[?=;?&YP2&R`QNZ",7()['-'.E30G;B>G*]CR:C
ML_8J;Z5P)/L)75J+\7\!D>6XWCMX<;K9]=XS<UI,N1'^:I9^)5S5'55I]'DU
MPL%/V?'S+=]1&#F04B<)O(0@Q%@<.JB?,W@!()LCSP'KI*&P::E<4>^E.!-/
M-_5O&6&?N+XZ&6A$6E,LO+(^-<L&\^^=EE-S,A^EF^67XJ1\=$J\5!1QYBQ]
ME#[FQ^:\1U/"=(,QH`E"V`UBW\<@C(C=N1M@SZ:;(KOCP7^?.VDO[ZH0-5!#
MC5=1"1-DX-?EI4=>>4_VC,QB+3QG8MY0JRKU!;I78_A)^_.ST83W2^;H7S62
M\5R]^F.QDKYH<1F,Y.ZG-HO874&C_>IUFT^^+FJ/<+'K-M%L0M\/710BWP\"
MAWE%DB3J?`D\B2N$3#E@^GS..UF39[GX>B[1]$MU#K?]&:DKB(PUU'@/M)HV
M4DBG6^3R4DGG-;_ILUG.9X[WNPE7T3`2-QRMH8'4+CYJ&DKP/7K]!DV^*E11
MN3<ZY5D:8@TW*!F/L9SQR38Q$V0S49(5V6U^I$RYM_)[CDM)0"-(B.]$P(^8
M5UU^+W`\V^LF?AKG?-.=4ICBR?6I[<GZ8U\HP<0D3D/C:)RSS=0JIJ=HO+9%
M&X?%:;&&!0X]^D^=?>EKX%]ILJ4Q:I6YE6[1A;N'AF#,?%]R?_O4G%&%'@QM
MZ,6Q3Y$3`-L+?3<,('9C&](DD*I=KV[%\*2H!3BGP<`UQ7(#$[04`_0\,LHQ
M5U5!(P2]*-`(%*>+NA+.:0BDU/V\2=*(F6KR2?AG7FU@3*D-7!^S*5!B4R^!
M/NR,`,>5NK1'[I,-4X>_+&TJ^"_NCRQH)&42@XLYA>2`(B&.$88\TV&$&VIZ
MK805BLZ7.AX952;$);^I:A/9%!"8^#ZF$&'D1<1..C-V`%TE*@A^]HQ<:#Q2
M)H.H6))L,*"3.AW>E<@L'QKS(H205&UMC)!U_Q(EE&20X<2_L_3`(@W:$Y`Q
M=MT8`=^+0Q^ZCA?$A'2&V,`%2Y)"\M-G8`7WR.(NR5-"5BIA3AA429X4O4!+
MG5Q^)<@X+A3%6P\P5`-XC8Q)4BA`(VP-40>#V$8`>AZ*$(Q"2IS>4(@<-6B(
M?OJ,T`B5H2$LE2PT3*BD#HUP>6B$$M"0%6]UT)`.X"(TU*10@`9J#<'8=1#!
MS`@-80!#$GFT-Q3+W?,I_^DS0@,I0T-8*EEHF%!)'1IH>6@@"6C(BK<Z:$@'
M<!$::E),6FCYV!]VCQ+@Q@[````;80*1G=B=T9!2J2HHTRPMM.#R4;DRR41A
MU5=>S&BJ9_5%2,[9EF`^"E3QT*/P2OBD*1B!Y1A5B>2YE?Q,']KKV;]D1;JO
MKU`L=M<%HT!6'?%V>SAENTU$*$+<KH\C#!)&TPBU;OB$VIX2R339-LRV3^61
M;SHI;^M[<*NJKLW#OMJ6A\>27Y=K_9T?[^_+_8[?M\$W#35;!?E7CUU8]6;!
MO`U,%86ZVDH2C@LTDS(N![Y>65^>J=_Y:[4.+T50,3E%F*JY8=9&6=WA7>*N
M$1F%2?Q?Q?F2I?-^H6J#[#@,*'!00`//M1W;@=U:O(\="F6(JVK#-%FSHW73
M[=8K#U9J/1ZR'WEYJOZ/O2O;C1Q7LK_"QWN!ZAGMRR-%B8W"5+<+M5Q@T`\)
M.9.VA<F4W)+2U;Y?/Z2VE%U6FJ1$B3V8ERIO*9XX09X@J6#P^-Q<2C6<L'HL
MVJOH!953FEL^A5R#5C$E'",:)T->.4B@1.PFF+DB:G.YU$2\9IM1+-O%1(Y@
M?2X+.L[((<ZJ]'@L?J34XNB9M@K/]4/17O"'B[(K3\CN_FMS'ZM=;)B694#L
MF-`V#=-S7!/U:*@R)GP%:Q2#$!EU4@5L>NC@0`[G?9-Q?!A9P<H\LMEA>C%$
MY'B/0N]<5SN-W"(FAH,_QJ!!]-P(XP@WH'"'HIOLZQZ[)NX1.'^EAYOD3F!=
MAL_U0=-,%1X[=S6W#G<VS#Z#)<W>&W%M)7?H<`YK!2N+5?NX],V$J#C27Q1M
MG?]1A5^VG/B=,CGQZV_TJRIM(D9WDY2)_#B,H8NQ8?AF"&WH8\?&"302RXJQ
M4([L!O`4KQO&=]*]L&E<5;E=]%.S?ME/_0D86S;[,L+UG,^W.M'<[V*Q?".7
M*[Y_<"G'7%E7;=@+-%F2;<G`Y+6#&SF#;R'XB:2'Q[*X+]-3?TN-':#$]PT[
M-D,3F@;R4)CTS206CKC+;$@\6W$T88A`#TEDRB]#$\=22S%#8KK[@AR.)(AE
M6!)8\2AF2VXI(\H:W_+D9U.GUATS2-%A03$'?K%,WQ"12[H0V1=/I'Q^U1:,
M<81B#+V$KC,BVD1H1'U;,0YC;LV4;4"Q<`ZPI-13FC4."5V#,#$=_9DK*3&5
M)DU`4=<@3TY6I4CDT]8)HZ<$=BY'.JCL;!N*!3N-B-[^EM75^3:K'K)O:4Y_
M_?DA+4\IZM(Q:(?JVDY"PP^-(##M!+MV9)J.Y0QMQQ;7D<)%&U2LQQ>8H,4)
M6J!@A%1$;!;CF4.QMZ!83,%YV)72],5H%M#X+>B6T_PIVO?D7&?[]"A(/U\T
MX*1G*CHLS:X.T6)QFPJ%W5$DFL!?OZ$^6#F!XS@Q<FS#B1+;A;2A_O&!@_@G
M[`+/5!P3&!(1,1)A@T/6%1$AIMP,A)0RBY`A(+Z*2)'35TYR^'3S8MF4-$K8
MKH/ZR<`NYKE<J'CR#W*@ZGE3/CZD>9053UE=GD]=@Z8;)TD<.09*(@L[AA,F
MQK#ED<0)?X7D.:VH?B788@,M.#"@$RJ@.XM%#C5<C4#!=VL3W$EIYCP214H-
MKT6F9#WACM2B)?6V!SB_4/`5NZ=4=Q&N=-#A90PIENY&@@DC"[S\^S0<$(IP
MY*(H":W$CW$((3+CX04@=B.AR@:K`E,<$1;,$O@D?8IQ74]?#T':.UDL:JWM
M7R6I($OZXDH2R"8NUR3]8QO;"PW&G&!4^D(J0O_X@4**R1,Y%H\,0E>H./FK
M.]((]W^>LY*5NO]<%GM25:SB_8X"<EAUP,0-8M]W'9.M<CI(H14(Y2NJQ*$X
MYO30&P4Z7,"OK"HS&+PB(FOX11/-6,748OUN+[*G\/V1\I+7I^Q(JKK(29=Q
MOT-QY`4FLAT/.F;B6HGMHZXM&R.#?Y-4M@'%8[B#!09<_5D#D56P-'D<NPAK
M\"8V%=N6,H$]@S6HD]LND*"0;[M@PN2IG8*Y#.FP23#;AF+!+B-T`)-VCH>T
M(L7=OCB=Z)RO+O;_LW.P;WNN@W$8Q(E'R;!\JV\IBB/^U%NYQRN6VQY46U&#
MP0(-+J&S=W*\<6BM>LK$E'9#MD1.(2IG3?*$H3![G.<&W[)W2F'GD:.#OLZT
MH%BLIP@N<#^75+VS_FHV.L^^J1](":N*U-7.L*S`<JPH<J/`\CT'VC'LVS0C
MWQ19P<YJ2+7>MMA`*;Q45<`IWX;E:G0*:G''9'^3)R.R009::"LO^J^Q=&55
MOPBYFBS;E[&E4-#[!)7J4[9GC3672>X0?69B&1`B`_K8\[!-&^K:<&$B5(56
MZ,&*E>A;<QGQL4'$:J6Q\7-'N*LNR''%ISC*:!)3F`Y&>R_PRG(RIN"*?$@Q
MI8E<R&$O%N@J(HO"?E^0#H]1F.YK7NQ"PW1<U_+CP,.>;9G(C1W',4S3-W#B
M\]VFM40[&^VL#\4_1%9`<RGE6#BNR*:8IFA%I,":<D5"Y1:7,XCE6V5>9V!J
MN;D0;SJL.Y<RI5B^6XF562.G[$P7N^3/<U8_9_D3J>IF3Q&[)GVJA5QL)<B*
M0M.+_6$V:;I<,[V93:A??3)@H,A!"PU<L(E5VY+FD&?7;Q7ZA%>;6S,G5(=L
M#09EZXS),,E;06S"[LG=P-E$Z:#,"UA1+-I[A`X`'0Y-;=GT^%O_DJ>K';;S
M4)`@']LQLF*,K<BW8=@W9X4!_PG2&6TH5N0+LGFO;^>PR"')*Q$HILDC[@94
M?2')M;@3.7>T#H>2YY"N],/9.?/3ED_I\@)<Z2#,2YA1+-N%1*3Y(^U%^7UV
M>R3M?NN0!O5K41Q^9,=C4P/K&_FKCH[LQ5&`DM"-P\`U@A!A9$&4N)#.TV.8
M1)X7AP)UB)=N6F0$254?O@!N[JFXMF&X`M$<DKXEPV(Z/Z*VA0H&K*`'V]42
M!`PO:``+'9M:W`$"<6%+1\@%BY_Z.B"#0^X[T+.#AB`M4Y%$%;LZA!=EMA4K
M=$_)*K_%'<[RK":?LB>6AOL2&S[7YY+`4U'6V;^;/MV]-WR%,4*)X[DH@;$1
M!@Y&-$Y&/<8`A;Y,?=]5@"E>C215G9W2FAS`70,8I"/$[1TA70(TNTQ)*MYM
MXT^^]X[:NE(L7HZ+];:&_-)8`GX*I!]`:PT8FS-D5(B$5*65>I?PQY67J)NX
M79.7L-O8/E&7=P,'2%29'^+>T*1E.R[R$\M(3,/R'=N%AMDW:>/8X5OW+-&2
M\F7.U_/IE);/3%KH0XXL)OQ(RP/[OGX@@+W)N2<5C0[#1%"ZH+L$SV(RKYI@
M>=666M4H+I;^$U<<BCJ'8<T$<I8IDW7(Y]+#62&W6^7!_)#D=58_?\SIN#TU
M(@IOJ[I,]_4N@!8R$=5,V_)@X$.K:9/^$YF)8P=\A5^7:$C=$.OA-3D"+4`P
M0@C^Z#&*%85=A%V1"K%KLRQ9+O8ZV[,W"'AHF-H56)1"';8"EC6H4-7;.%7K
M0+)=V]@7<I^Q-O+Z]_1$=J$?6E;H)TE$FX$88M>SNW:PZUOP'9&2?JXZ3>H&
MQ@4/8("DHGQ%]O]Q7SS])[62!7B'?<'&C3.*ZU,,O#%09I.U\;B8C[]8J-<(
M]WI$QUN9'C_F!_+7?Y'GG0-#'QEV[/F>;]A6$AE!/[RP:>'W7N'*/UAYO^\`
M@081H)!6Z/FO2+C:]64)TZ;O2QOP4^>?1P57[T?GLJ2MX*S:I\?_)FF9Y(<X
MK<DN@A#!V+/-,/%C/Z*1!@]MV29\+ZULUK/5C8$.$F@Q`0:*3I0.@,%2.@ZF
MN)@8"K.ITV`TS+>A6+`O"4<$G!U)B6@3]T7YO#-,TT)AY%N)[SN6XWHLVG3-
MQ&'RWLD^V<<JCP8-'-#C62$4O+#_:B"08TJ#CC\+_D]!8`X-7-V]7VY\HQ_9
M&79@16YLVK%A.;$5T5D5'"98AAMP]'.AYZVP]<!P*.W88X,G>K04)QIT93G<
MQ<S.(-%Y/Y,R*PY]4+"Q!T//B4,Z8S+B$!J1,8P2+W;?JUTL_^`5NG,+:)U9
MRYLDO-/%Y0C3J*]+&O!&IY]#A5#OOTR+,/U)M7-"`UJTH01:H1%@[+K1,"D*
M_8!GMB+[Z!5&P'CRWH!:90R\(N*=42!+FT;C0-J$-T;"/#HDQD([]-K&H!6%
MMD,7SG3NY-%IDFO;1M\8]FTD/!I$'K[>>.@"P]HC8D0&UYB0(4^[42%EQ.2X
MD*>$:V1`VM*A:>V8WN\,(V*;J+YI&MAR+1S&-NH;2"+XWEM'\0>J&P$##L"`
M*.WS+TR>Z.=RM&C0MR6!%W-[A/@N?5,SZRNKF?7U(:4]X^9<5W6:L^38G>$B
M;%JA9WK("%U(F[*C(:9$_GNY*@NUHG[_OJWCUL#[`%J`8(1PC>W\*P1=W]M?
M@ED-!LR2UOR\Z[\<2;R'COKCIM7'_%]IF;$,J(]Y36C;=8,I(]7PXAG9MF.Z
MH>'9L>\X;NPG)G1L1!'X?A+$7(<;EVU1W9`;X60)=CU2T$,%/5;)1):%F1<Z
M`K.5!V0/P%P\\?&:)Q8X!2/`S%2VBQIZ=4A[4619H;QO2F<?3R%H$D5W1H1P
M$MB>#=TX#*&%/-/HFX_BP)`YV#*W39'A*'/UW"AO]IHD-F!%+Q!:C/?K86A+
MRL5BT%)L*TY6ODK?&S*IR@':)3$O9-9D0O.2M'&KXU2CT3,ZIE65W67[)K[?
MW+5S6OA75NU<BS4:.@9T'&R93F#&`Q;7CD(1J50"0+%N7IT^4GRB4JG&"7RZ
MN3G_8B(Z@WHENBE#WQ415>H-3115K8W%BMU;]/+,5RV^B>TY+DYIEN^PC;T$
MAPZ.,;*2P')PX/08XL3CNCM#2</;:.OS!_#2"O!'BU?X7LM%G<"GL9OQOXBV
MRE"OYLI)`1JO:*P2;VBBK6IL>WTEI#H"^?8Y?R?G,CN=SCGI;CNF6AV&V'$@
MMHP$)4$86G'?")TH(X'J2<+/%AF/4N>&+XA$=B3%.>+8[E5*CIA87:!(7?8N
M3H_`GJQ2FN2V72^09N^KOK9N:NM4F@4==D?EP1=+=(0E5O'/GX9[=QT<(<OU
M:7-!Y!LP0LAPAPFM8PK=M#ZWK8WFCW/N0I]-[XREN")FEYD9;GD!^3MLB2ZR
M)7C69,ZWF#D\2V=IFD3?8$^_,&(%'\[I<7AOY,6!Y24P1!%R@CA.H)=$/0X;
M"9;.7+YYY?/#"^AW7FW_HX/^S]DON1=TCE"2P39>D4TU^#NZ0RKS8!NWS,T_
MN.Z>!=,/N.EY/PEA>:9UF&PKM>_MA`151/+>C,7V1K+\_G-14S!9>HPO5[B\
MKD]=P?SPI7A.CPS=3<ZRRDBYIY_YFM(__)Y3SWPCY:FZN4/%D391E&V!D?N2
MD*:^M1D@US3L),:^B1%&IN'XO05.@DR!`*D7<.6A=3`7//;VOK@@Z:=Z[U53
ML:?LC68W=>P'LT'%[`9G9GA3\JUFUK=7^H[L!VE/@-B%5CIYAN^B,9T0JYL0
M7#K18"@86?KS!0P5H,:"P5IPDX.+O:`Q&#06@\9D<','7A@-X/^!#B1TP9I.
MR-5/85CQSCVK-%PW]Y`.TI/E?27Q\R.-L%WYL+<TJ@(_R/'(_F<R1$U+J10Q
M(4JI^N3YF5UE02FE;*8T>K.[3>D,`)RK])[\<IM6I)>XY\LS^55M]LQJ57]/
MS<GT['0ZS.8T9:;07C%D-TJBC%JQ?\B+8W'/#AT\ICF;QSZD-2Q)3-AXS')R
M^%9$Y'M./5@5Q^S`2I5/38%WG@]]B!T7FF&"(`XL-^H1!S8R;,DME?6!KKSY
M<CLVD,W\6@NI+*94C$M")X^]D52\P2VALCFV$SSUZ]&L7X^2SE39G8$-.H?@
MEH[>O6+.YL__=P?6'22WE/3N%DML/BGL'HON7BWN"9Y]KNW<K\,<2A,FIO;.
MMG8.?\KE94;V1&!9LA+[S(0XJ_;'HCJ7H]L/G"1PZ?S,]7P3^78$XQ#BYD1F
MZ":6%T5B5Q$LV;+R6<P+L,VJ\8:NY$KPA1P;@:L>LD?16VH6I9[O!?I6G(O-
M$5Z2/8()+CC!']O=6R#`XK4L2P6^T.2%NQ+37N=8*J-O9E+16P`\'+B1$2<P
M-GV8F$EHFTY[\0(T#=.#8LJY7+LKKO[>.5:^2,*1%/5S4H]4<[Y0$I(>LLE-
MH7!FTAPW:"*9"@SCRE::3YW$.?/D]'@LG@GY2LJG;$^:VA\1VS5G,V625^WV
MX+%Q2I-`_X7LB_L\^S<YM`6D4%'5U06P$24^9L4VX]ATZ/]18G25I%P3F;8E
M>T?6VCB5RW%C0?>"8C^R`9#N6K[V#4ES!2/]@_S`?LC^=+2FKNB2GK2*7MRQ
M#Q37KI30K2?PJ?W?HPN(18?QZ?K>*M"9!<8=8VS9!W"QC7WP8EU?A*^Q3Z>[
MQ!;VV)5@M'TOT21X:4#$9-&`;5TC$1S'N%C;N"@OH+LW;J/U3C7&_K9UC071
M\V<J!Z_NLW1##(/$-2!&`?4[#'"0],8X&+JR@5,G&]0'U<NUE=5[\36MJF*?
M-7'T1U8_`)+N']@'Z;,G/LQ2J\KBODQ/LK<@Z^4.X0BL$_AUHO,8:Q-?F]NQ
MQR&Z,WN\-U:]#M53(;V+V+?/@!&@4^1>T=-<45W'GJ==Q->2I,G9@)9H!;):
M+I9\H4OX,F-9;DW]S.]Y5O_*+H^K7J%`OA&[/G9LRX^Q9?E.:`TH(N@8`IDJ
MRS>^9FPF?Y[97MA]@Y.]+B;=S)`J9W%W1^>&99N<?,A*LJ>CJT_98[%YW]VF
M53%SP2-M0RC!0(';.')(MO679/R[88O,'FU;^Q<PO*`%+!2O5G&$0/;&M@Z1
MR\@83TS*BV/:@7!FCFE'U.R$"F%RII(DU+&L0^*#0NN*5;JJ],)XN,^\*??G
MVD[L8=J%W`0ZV'10U%T/1O_!42)48D^V#9'1-[/Z:`]L=JU1019%5VOJ")1?
M3_%SIWB!\X(<KB6(')W:+1(DS9B<QL^AA5MY^D8^#0?Z`VSYOFL&EF7ZV,"^
M[<#NQ5@2F#ZT131'_.F*U>8R2CY)UP&1H(Q/8-2R)28M@D0IT92?^+BB)O+<
M::(C,PPHENI&DMH!]W3569)#?"[989KFA<(.86Q;B6OXH6O%*+#-R.KU*K"C
M!,K(B%1#BA7E8[XO25H1MMB^[W!*"HH<CV+:HIQ".9GY`'I@H$76O7G=2''>
M8HE#?&:1JYD.S;-E0I(6($A8G;X4QR,NRA]I>=B9+@H2!R(G#AR#;5KZAMDW
M!3TO$'L5*-/"FIN!]"%']E:%`6/?LV.Y^P>V[=OD*<Y4*R%>Q41*%:&R4R"&
M!W2`MIH$C3CA4"(9!C43("D3)G1'G@YAN=D9=A1X!HY<A#U$)UZ1X87]\QW3
M,7>/C>Q]K=.R%M.9=Q\M,A9>HY`(V;?D/LN;DA947!ZWC-<<(X*;/,V&`3_N
MB;XO:+APAV_."*$VK.SB@-V$;1C(-`TC-&",HB&6A\@4JE<OU8#BV7Z#13)@
MBA$E%C&5<20[G6]/CG6(-E*%,2D<"B'%H69J(6?#A'+,($0\;"+/MR)H>*X=
MF:&7!#@.O?[Y5+K<+FPF^4$P:+[W8/&@V6.0&!8D/_PM@B4O:9IU?W[<4\%2
MS'#N;AZ=JRPG586*TVV6=SDU>9517IIOOI5I7MV1DJZ-S1WR?=L)$L\U#>QC
MU[23_B1?@&DD1[NFXA/?,%BT8:'@.F#D'B;?VD)6]+</;$/ML<SVHH<NEN69
M+P9O1K%8;.YA@A'.#^`%4C""NK(XB9!X1<"4^$(3D5-C6[%"9Y;.AL!I5OXK
M/9X)K"K2E.#ZE*6WV;$Y3?L;2=F1OL--_H6PU#6Z$(W2*GN=LH%CY$78\=PH
M@C:F"Y[VG2G])TS<)(YET__7P+;F;F':F-$D!QXOAH"2[%G//H"T!G?49/#$
M;);.S%C%HWRZK:\KQ81]G`7"+`&-*1\`O#AT9`[H[6%5:0>+0&.23GGR"_B$
M*_ED3=]K$D@V,GXRT65]%\B<6$O+\IDVW@!E&).JSD[LD-,`O[JYB\EM_3&O
MZK))0GT-$KHHBHW$#!(S\4TC,DW'Z$':&#K2)]%6P+9F*&KB#-.M?6=8&W38
MKP[4")!=K)`_+K:&/T4#D6Z.E`]$O25M,&JCT&#,*$PUY^N906!DD4YQ:`&7
M<,6A-5VO71Q:U?CI<U.KNX`[#@T`."+C][RXK4CYU-9!>3S7[+!WOJ>?:E=P
M`U;+-Q,C"6C`]*/8MLPXC`:LD65SUO?=%*+RJ(2')4];RSQGAY79(:G]BXV3
MXO:8W;=%\@0CTC:>Y0M,VKM4+#Z-%T><*Z(/8&P7:`P#+RW;/EBI<-.5F+5I
MK]`D=&W+0:'1,)5>4/U>L`;3(SP59QI';^YNSG55TWDBA1J3,GMJBAY^+JJL
MD=77ZST/.8%K(1QZ7F@&;N0DJ(,7)8F!99=2:E&I#U=%2;+[O#O*NW\>TO]8
MY&(7675UI7^0DK`RT:1LRF#5!4M?IAS<$_8)LD\K-DTOR1/)9VSV*7:QZ.I*
M']_*KZMZ&T!G!/O9R`QPL0,,AFP?H1;R`==":ATO:Q*'5C=[<O&T)NT2T>8"
M8;1V^S7-\D]%57W,O_;U_F[N<,:N.\K2XV=24BT\L;N/+D!#TPUB"T>Q:_JA
M:<1^%'1I,"&R4"P==];"M^8V'LLW)W=W9%^W.W>]A17]NJ)1JMD*2JLF[C#M
M&FWKL:EXDZZ^0GG&U;J&:+S2L4^(1:Y1-!J9\`$P(\`_F!G_U"DX+40X5YA:
MV[G:!:S5"9@,7=NX8JD@-@&P"[3#VG"T18DP=GT$/3-,W,C\7^JNKDEN%-G^
M%;W<N)X(SX8^D`3[!@)V';%C.\:]]V4?*M15:EN[U:6^]>&QY]<OH(^J+E=7
M@P"5_#+C&;?-R9/BD$"2F:8%2WN8C&>:C6!OA6[R>ZCV\$_>7SR)/]67ECE;
MT=PN/NY=ZF3IN:DOQV^9+B]"\@7<8(Y*G>@-&C9.;T_NJ6:_3)DZ9_PBY>TS
M^#F6*'_FFRU0GMV@O3Q=!(<WJ[^W43U>BM]21Y(7FY9@`&%"`$B3G+$X`YCU
MZ=9B#46&1>V]0O&^\%S6*<.5Q:\W]):1V;C!Q69%K?P=\N`(?2;M1FRHOK("
M3.+!F<C]-+8V-Y@BAD+.5.U0?+]3%P4+\1=C%A8Q2,,\QAFA>=Z-0N(,TEQ3
M#`S_5G_3NP42_*N',O54?4[$E<DWDK&93*>QZ!LGGXWIUEH6>_S2K`4GNW;$
M]\V^NC3G<H9`Q`'D/&11E$<DY&D/($E-VT*Z&]=[5-+",]W?NN-5<^=Z$T(-
M]Z0G&/\WZ.1(PIQ)+*'-X;6MHW,_S$36/!AVOMWS1)VV&)ZT,<3=X^_3_]5+
M,:(XB1C".0IA+O:.69RWF?8D"\.4ZVX2'(WF;[J>H%%=)[J2!J?-'F\62^B1
M=V6>.F9_)I/4M56-UT_6<'K^5OZ[V=Z)/]/E(,O\9"43GV2"E]HLX&_U;B%&
M"W.$8\(0S0'EXI]I/WP4D]RD!(NK,4UFZ8BJ+`IFH'`.SPG4@X-VC3V"%3-6
MP#4M^.J,>3UEO`7I9M+HCF\OZJA)X!5Y=.V"F>BC<[,:OU^N>X6DS6-9;Q:,
M)"2!M`!)DM$BA)@410\@#;E177UWH\Y')5O`'G12EW]G2NF!>F]:^2KKMU++
M%IB=7AHZXN=13%/#S#5S%'6:K;9$R+JO/M?+DT#VM^KQOMHN(."0D)`24"2L
MX#2/LKP?+BMBH*.1MF-X5L0!V>FNSJC3D@5]UR5N2N9,C[$ND!;\J\5EUJ?*
M@CV3AE33L#BR\]3`9GU$9]]FZD63+XBX*Y)FT3C*@1F-VV_'4HX_-MO]0[.N
MFP7(LI01DN1)FF1BT)RBX5R!)V%NTN309AS_&7@7YD3PU..S5!@#/L<IM!\B
M[34Z^#@]@W8J[8=)=SI]_"9]"/9@O8%DFS,V4]$>8<@KLCV6&OWT"?72165T
MR.<H=^6WWP6&0E4,.-2;SQ^>NF(!N^ZWGK^\'8Z/(4X8*J(TXQCG((HY(]VZ
M`B`'4%/FIT;E?5$X>W1_7^W_J*KVD=`___+I+\%#)8LQK-73H(/XEK\'^_);
M(#\#M=VN>AZ&_VUXN#&9>_6./N;H5[,U:K`@:$T(!-!`(CVKK_!6M@):2KF]
M7>J.&[*OY?Q,[,Z9'*],;O9YEM%-:+=<4LXP['FK?)]ZX7OVPPN,<$%C%B4P
M)'D2HS0L!FB(9H;E3Z=`-,'^HE\BG*T#CGUBLP;<SAF^]+_<!YT1P=%U9W]H
M6"5FL308^<!X6?#CX5DO"9Y,UEH.?-+M="E0[X%D]53AP_7P<]5NP:(X)(B!
M$."8\B(#I`A[3"Q-#%]\>H4RB?BK38#QHTV_+G`G^9-P[TOK6_>HFM42_LG/
M5[LY:_Q+I%N*N[4O?R)5M[=UA)P[(MBICG=%O)[]!*W%']R*;[\NUPL"<YS'
M-(.,D"B-0(J*I,>6$H#<Z[DU).^ZKKPFR\8\="70JG(K>Q/Z4'E[![E3^TD]
MXTOU^[)UYS]W:LB<U?\U)UBN`LY\_!.M!NYL'K$J.";<Z>H@_F>QK5;U?K?`
M'.4@SW.4@0RF45+@L,L(`F*KP>+%IOHLZV6Y6P<,!M?2%=3JRBE.;7GI@*A@
M<5/M@Z8]K-M\#M;-;A<<]@+TGPJUAR7`Q`ONQ-XU_9YE7?Y&BW?.XGTDU5*F
M1WCG)Q+D,=:-D-[1)#H5V?>R[N#J('[L?EVQ;T^R!B&MGK;5LCL%VJSP8[/=
M=P*S(#%'"6$`PCCDI$@ACWD/%3**W4?DKA%Z#]`_=GT=5;UA\1L2=]=TS(,^
M.W>@.Q&_I>=\*?TSFX+.J+?!J5EJG3XU;,YK@J&/+!<.7U_$3[2Z>*-@Q!+D
MUQUZF:`Z.'\K-X>'<KD_;%6-9858P,E3%.5)D0.2)KR($Y;P`4Z<AT0[<=\C
M!L^)_<]0!:L>EDGBHT\'7%]+YL3]V/6B+<E\3,':/L_>>IRW?PS25F?BIW%)
MK?[\I9?U.IZ\EW)B)W#''#)FIS"SF?8KGV@3IZHV+!*"LKQ(<%IPQEF44)['
MP\Z2``])4>.Q^-^85;*0M4RPK/?5XU2;,4U'^-UVN??`Q!LL9<#/MI%2H#UL
MF<R\^9-OC@R-=;0-&D.Q4TU7`/#JWX?N,=XBAB!-8P036#!$<9R0$/=8,AX:
M-K'T`L&[@BM$'G3;G&QW<NV595\JW98(.T$]9VD^9]A2D4<[["<2XO$VCM!?
M2T(]/%Q;D(QBCD*6@A0!D@!,NA+R`@'B.5[LFWVYMI':4<,:G28-"$?,_[WO
MMV.O,VRCL-[)]:6K<Q+12R0:2Z>5)V8MF':6C7Z?94B>WB'\F1X_=$6I]_MM
M?7_8JPZ&C8B2)1Y!G/A;/K]3+55W)]4@L[2@408C$(*49SQ'(`&`,4XSC`I:
M:-X,3P;'>ZQZ]HZW>0BJMA)6>6*'[$:[:3:_+H^FR%OCUA:34^))/*AQG#\W
MUYD)]9G//CSTU<M.#0CN&GE*$9S8$`Q&:+W=O9'[#$[[Y^;&<<?^]E/0NMZ%
M`R)?N@*8TD=SN`N8U-[F1I/!M!)HO6FV`DP_X(+%((\*5E!.B@32/(G$0-TX
M-`1T(0*)NEE]VI?;O=[VQ7@(DWE]CD9[:K\OWKT-[JO/]4:^?9!3N_VKIJXI
M>4;.E?AX-(\SB8+'XS\O!&E'A/;<>%_MVVA:=C?]8;8N?YRM"R*&8R'$/$_$
MO],(L9CT0`C/#'N?N!_?>\PJ(/<WY&_6JFGQ^4JIYIU*0G^0AP033S=C2J_,
M1W_NF<F$]6A@,]67;CKE+XXFL&VK<E=Q01$Y[.I-M=L5S>-]O>G2VD*2`T!1
M$26%[#'&<8P&,(R$)D6R_2#PG$7&C^U_Q;26L[M-5U:9K"+LN1>QCZK<7"Y%
MZ+.5S>PWLJ&][&TO_J.5!<.C0D^NTCLUO+V7S/:ES_$.N\VW00\YD-,_Z$$'
M)ZBG5N@QS%Y3::^>FHM2^S7R7*TGH'3T!H961QBTWK5+B3SW?&DI^7O;2&J!
MBB(-LS0BJ=A;@0QG.<M[?"CFJ'\B>&?0\&`J;%K"\?P%X9VYRI]"[@X]+IUY
MF/9"F,R!>M(^+Z>Y5?O>EE;MGUFC%N'+?R[H++KQUGBL(PRVU-Y]/9/U8GJ[
M7]G"3T2\WF76\Q%[6:N[]6W506U4@A>A.(U8`B&B-.9Q'`DX_?@,IL1@U7`^
M]C2KPMVVW.S6W<.U(0=#!?B-0;:5>^8U+ILF9]N%G->#G/=`@S<]U%]NS+G!
M#=&MN!]W$^32!WH7/P;\O'3!XX/B.5SD>+&K\?QMVE[,X#CFD)&8%Y3E-,%)
MBFDW#H[BC'47,VRC6<3$>`#S:YD>B]FE3"57CI_P.D:7OYG&@/KX7[N.,2-"
M-R;;5[N/Y??V4)@+!5_5R[)K,).%410F,$I2EH20)`!2%+,X3<(L3PJ:&F0.
M68WC_WI%H@LZ>'+'U@,T6_!MJ-2*JB;BT#2,.B7O[DC>J)9<=BP:Q4D3L3DV
M,)*L/K7XK+-=KAG[<I3C@*!YA#4N#&E<?SM&;;FJ3=ULU;"?ZF\?&Q$ZL?KS
ME_VGZFNUX?77JLM/IH?J[@_Q[^_J=ZMJTV'B#((XB@J.0@*+2/PZA1TF2!`/
M33IW>8;B7>RSO\`\_9^@M2-HY]GJ4`5BUD#K+DIVY+PT%:?B?`ZS=3);FQM\
MU,;7YD>=D7?!_R>O@FF]6ZZ;W6%;+6)(2!J&,,:(%Q`0"$+0#TLA-"RK;CO:
M1&%:MR:^#1Z&VW'C*VY+6G4OLZ?CTR)D>QNH-`.%+CC"F_Q^^BI95V^BW=`\
MD_VC,W-^N%UV2=,H"5N`5!8T!['L(TV0W,AFZ"B3S#2/S^2OGEJ<EN5V^UT>
M:=H*U.NDF:N14[8LI.>&&J,I*-I,S5`]]+%?D0I#`K1U07::?[?9[;=J;SP(
MTB+-:5;DN1"@G,4\BY(,A/UP><29F42,'<6[6DA@03T@VUE$,Z.9U-.-*2@T
MDQ#%W1'2/.*7%VBZ(C.VQ,Y$<:S-:-Q^;R;'*L<<NT^'^UV]JLOM]T6.,:&`
M1`G(LA#1D%**(8%A`HJ0T,+DK&34W^]=>X;\HWH3[`9<P9NUS%#=?RDWP6>Q
MX]W(FR*YYRT_5[^8G.".(U7C_-L[FV8R--#X;A,<`?EGRN",VSMCX\ZV+W^`
MUH?<EZQ]Z43-BIDY')/9&="X^DA,=X,'>5SVX>'W2G:NE_'EI^IS6UL&(AAE
M(4,D0R@F$6`$Y?V(M(#,Z+''^&%,OOX1+SI:9/(>?CM@"W8=.--=H@69FGO&
M:7@TW$$.%!YA!9]>I=#/CO)%@J[M+^U9G4GLY\*2\[VG*W+T(D"QRY5_^5VU
M?=Q]>,#+97,00_U>+:OZJ]K^,I*D+*1Q"EB>HS1)43$(81[')M&@]5C>(\,.
M8;"7$.4,*SN0LAQSAS(HM_5.'FRI7/>G;2,+-`:[<JW=SM01\1H1XZ2,FZE8
M3[7")@N:].B"([QI^32(*R?E=5R,V?-[]5NV#CE?(^*E\-,9@7,(1=T9T_CX
MQDR6@]_J3?UX>)2#\F9[85"*0<Q2PO(L@S$"-`T)Z0=-@&ZQ5S=C>5\..H1J
M"LFNII>FD(E&V;.KH?F3TFJF^3V?$IOL.&JK^?9\&FC^I+R.TWR=[]5:\E_C
MX27)=\;?'"3?G3&-CT_,2/++;]<'A;Q@15PD'.9%)L9DG"3]H!CDFKVNW8SE
M7_);A.XDWYI='<F?DE9#R>_X=";YUGR:2/Z4O(Z4?(WOU5[R7^'A1<EWQ=\L
M)-^9,8V/3\SP(!I_+>NU2H5JMI]*><BT/&Q5+9V[ZMN>"*O_LP@Q!Y2G&>8%
M*EB29@A`5=`7TS`'R+!'CXL1)Y#_[7^J]D1U)6_9Y6OCKC3G;L!K>$SMA&J]
M\^JI.39;"P9TOPJA^E6>F`5'@,&_[MKW,P)HH)!>>3;CY2Q;@[PKA]HNJ9_)
MZ;93DQI_7ZJA]'U:?JE6AW7UX:$H=U_P9B7_)4NG?A4XA/BJ[_"(HBA@*(_<
M"8THP'&4Q2#K420(<S,5=#RX=T'\='A\E,D1S4/P4&_*S;(NUWT1MC_J_9?@
ML=SW,UC\S#&%`H7!JOR^D^_8UX=5M5(_76^"I;!7R:KZ176TW%!577M13V!O
MZ#XSK>V!2J<4/>7J%R=H;Z^Y9GQ>D5]/CIF)$ONRKIGDZS;4YW>;KU77<*=8
MRUJ.#W6U(M]5%6O9W;)<_]9JSG=:[JLS3``S4J1BL4`)"B%,PR+G/28$46&F
MUEZA3*G=RR/B$\7^:U#^&)*-CG/]^DU/GV?C,#.U/H$=''$']]^#$^1!#SV0
MV&^OW39<7U'R25PX$UV?QM;F!G/$4/-_K\IU_6>U^EM9;V2MY@^;$Y1G$"*$
M4E!$61Z+!2>-`.-XV!9$&05F$N]R9/_Y*=MF656K79M[\GAV6#%:N9VRKR?4
MMZ+=3)=[E(&$&;SYAZH\WVR"4[V^N0X;4'E%=GTX9"8JZ\6TQO_W;'JNL1=R
M+<=KPW>^;OXXMGG)HR@!8<'B)(\I3D*:A3B/($Q8`HN(Q+K[7YLQ/.YV>UC#
M=E<AT^IYY6=?>X6G:[M8%_3.9-:YL>5\A^J.()-V+7(LL?9^K5<R4OKGKEJ]
MVW2=#S>?L>R/J);=`0G,<`%ACI(\!'D>%CS.TAX)`M3PS-`#`.^1BIJ$#VH2
MJEBEZ<$&Y8#VKZ;Y_AX<H2=[-_:`F1C*7CF*_AZNW$>^D8B#>O-+,(`.CJAO
M)Y3FS%Z13X]NFHFH^K3PQ]XY?LG4%F`!X:'>RZAJ460)!"A-<(PS%N.4AAGO
M1Z!YJ-G+=<1?[%TPCQVN)IZ!1Q*NS*P13,UDQHQ!WEA_)J;9&,<>\W=-W]6Q
M>M:]ZJXQG8U$Q$`IRF.$0D+#&(:\`#U6G&6&1^$W@>A]UIU8)<N>;GN[5*^I
MKN&<[$@B_FOI(:*YC=\U<TGF[G##Y)/GGAX,"J3PONM:"[8'/.*W?YKXR8>7
MKF6YW/*CF,F*<EL.SO-H;N\0@Y)'3T)@VV;%XM?K2OX";U;XL=GNZS_;A-PT
MXS`*,2.,)WF:A6E&4#]VF'-H6O_(P9#>5Z%3E&T'PQ-XQM607)"LMT1,SJZ9
MY)_"DSVJ.H"*8:S%L*=*2:^S=D6"G9(^$TEU:],/!96<$Z9_)O^EW%9$]O8H
MFL>G:K-K1PLI!$F,XSPILCPN>,*RO!\-PMCP"G/D(/[S3R2N7^\EL&!Y@LPT
MTV\DAYHW&O[),[S+.&&MT&+-SPW&15ZNW5W8$3D3);*UXOR^P@4I!@'60[7=
MRNA.QGYWY3?V38Y9D6I3/=3[!0U!3E@&8<HIC9,($CJ<SR6<&I;+MAUM@K"J
M!3ALY,MOQJD1UI3J1E+3<6D:1'4D=GMD@2WHP`5O.GA7RN-YBJ"NLG4U>'+#
M\TS4RIDY/X1,+FG2UJ\/LO&9[)$F]JOMT-VXBT*VX(QQ$5%&(YQC2H5X=@/&
M613U[3#UE&O\.%KS['GK2S/-^F#09M$!;7KJY)FO4;JD,`4=J.$`K\,UM2"]
M2-`5*;(G=28BY,"0QO7W9OSDH.V\V+<+/CD>*\JG>E^NCW><)`<P3"`!F,8`
M88!#V",@XE^F#PR<#>P_I>.+^*]*ON@ZO?MHGX+)(Y5U7=[7:W62^%;>F)A>
MAKAT@IZNW8A],Z%[-S2"I4,C6.&"XS5$!_5V=Q#Z-%Z10P^^F(D^^K#LAY1^
M3^19*.B%6@89B#/&"$ARSJ.(9DA>FG=C`Y8SLRC.R9#>`SH\NGZ,6VK'*J(O
M3EUJH5%-F8DD4*M*BA?:9RM[-C:]*GC6A%E(G4SUWPBR1>2S`%F6LBBC"/(\
M1AC)KI?#10+!O->X._UJWG8#CE"X._.ZWCTBW?K_CL@<JVK."70I9R?@;BYC
M)UB,]&L,P;,5KE'&O*I8XRFRB\JV!Q'#'/=JBYA3C'`:YSB,<,2BI"#]V"(\
M9(E)XP$G`YI,N!$M"#I$0=6>*;2;UT8=)RT/VZU\172RE741K!DS;A&L^23;
M5;"FZ/^'#L?3!6MGO)D&:V-IGZWFV=BD$ZS9$69SLB=G^OGV^'VU7V2RIP)G
M*0AA!%D8\@)%/8(4A8GM[G3TP--<.@1+P_,]^^.]T9X8?;SGU05.C_>42TYR
MC8]^^,>I']Y?\\-4IWTOL&IVVF?KFMDJJ;UEKY_VN2'/PY/8!<H`I4+<PQ2F
M".,BQG&?6(<2PHO%OA%8]335X;!&,>:`4'M6OW_^8.3IY"7!I7<CWA["ODZ_
MGI3>B'DS*1WQ\'6VKUVO:*<'7\Q$.WU8-OI5JR%YMMK9E@NY_!X#PYRB@A:8
MYAQC5I`"I`.2)#-,%_8`P/_=\]GCN[H'Z[Z<@)4CK-1T*@\X5=4!]"R>PYDS
M:RZT+MPT;\%U8J&>\+HCTZ2<@"JBQ@4=LO0TWJSZ@G<?'EZN2[V(8T(`1S&7
M;6%YE,2(T`%.%!MF3_M"X5V*G]>@4WT/U;;T>2'HD]ITH\O2>7.4GDK/P4-F
M4OW<-1*6\LQ0-U3XY6H-_NDK3XPA^(IB^W;93&3;NYD_%L"8@%9]`6\[(^[N
M&KS\_T.]K:Y`B!AD!0595F0D*J!8-7!?L`,1%L5FA[HN1_9^JOM1_/\OY<ZA
M'KOD75.#IR;<II>M*BS1X9R7T.JS>$U</?AB+H+JP[1S$?5&WWCA)(==O:EV
M0B-$>-Y5_6]_9[7@!,.4<9"A),Y8GD0)93T&%F,Z(I')Z?C3Y#4I.+M:OMI4
M.GK?(58W8*JROFJNT8&V%50K?XQ45.\^<":I1Z3JWFNH]8I?97\:5;W"I(FL
MNG#(7'75B6VO":L[`L<KJPB9GZKM_OM'\57O1;PLNZ@\R1]9%%F6Y.KE9`)A
MS/*4TK!'`).CKHZ4U/$#3QN0/G4XWP9/$NG0:4]AM=51"_9'JJAGVIUIZ,>!
M=H7TK>*=O<[[-`KZ(HLF^FGOBKFJIP/+7M-.5^2-5TZ5RR!@K`[R1+AJ$U\6
M-,UIEJ(BBT)(4X93Q(;+N#2$F4F2JJ,A/:>IRGXL]>:S3$<5W\NN7JD;RF83
M;*NUU%XYJ_GAL7SZ4FX?`_RW-@AM0U5;_1SI@Y':Z9]^>]UL\[&.(+N$K%L+
MYD7J3,32CONY"J6E5:^)I`O2C`62-]O3<UB%X<+MV2(.":`HRT.2%B#AE*%H
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M"T`D)3N6#(``R<Q3G$DF_?77Q->X-!I31<"HJ@Z@EURI>H%9=:$U$:9E"ZX1
M#^6$UQR9.DO_+\5S=WIR<X^KIZ>JO&W%>\R$S9B#V',3DE+J)#YTADH!Z$5P
MQ"G]"*O3G,WWYTG\.*GE-^'V]0MH.$#]];\VS\I+?JO<CE_E'^&)<W8!$-Q>
M)M?VJOX,97(+^;%\+T0(37IT?KENABRMDOSKIMDSH66&1?/TYI_EAN\6K!DR
MOM=:;M[OJ<X/K!KVUW;[#=-H@?;F693MK'R8L:EQ&L(@X7NS<<9\Z$%[0:!Z
MXCXK5ON']*]JR+>=@UP#A+(*;6C./.P`\KKF/03$5S2BV'^&3T!2OI<?>P,7
M!ZY/@G[P#>RY<V#P3E0-G'NH0E06-%=@</*0-D#GYHR7#(R'3/(JPGR?RE*2
MUC+(N'"M8>X0::7*WZJV:%C6%MT.$4EBEQ+?)?R\,8XQ6WCT]@("H5*%A*X1
MRS41KW7JKJKKZB_&^YA<H\:A>IJP1M\8A1>@0(=J1D$^)4=22[7X7*`,ZOEQ
M0<%&$",M/FQ9T*T1;NY?V?,2"%T8D)!F,78=G/F^/XA=&"*-;0AM6]-L/@SP
MQ*T`7272)U1.B>R2J*5$1TB<N3F5Z!PY%Y1H-)\+4:+Q?E2&/S1%):+?UT73
M?,V_=T\2B:NI[T[1WMFW76$:DI1XB9\F:81AG";'9H,.#3.5N9)=))8G5`?P
M_&4T<'>`WUWK%RNVZJ,5VQRAD1.^Y41%31V[@/!7UM!I0,XMMJ_>/=::6$A'
MD7U!;:<)XD(D>2)GJSG&R8@U[LFFM*@;>P]&BJ,X3'#(,DR0.6$0D1`.,.+(
MT^_,8L*Z]9(#K9)7TQ2KKXRGYG;,@OD?IV=C?<GK`I17D4_)-;;)R"Q$7:VY
M=V%%;IY&"Z5;JR3-7"=(,I=ZCN_2R*59?Z\+AG&2&"AYU3$[;<GK:8/6?^S[
MBJ'W:K>LE6Y]'`C3)5M&8V"]5&NQ]5E&ZK*D8[$0/;7AF78=EB)YTBHJ.@>4
M&_X+OP?[9[[C<OY[46^KS=LFW*L$>C#Q,IS@.$20F??2J,>`W%A)1XT:GD!)
MMWT3^VW9-40I-X<?BB-\1>4T2[Z<=L[&NYIZXIYB\<,)TBMPP`K>>55@8OU4
MH?*"@EJ)R$(TU(YOU02?M.IF[?U]L6YO[NGWPQLC7_*VN"G?1[;RF"&?P(3Z
MU".N1[W`ZTO,H.]XB@\L&S5M?25_0,O/18H.+Z@9X.%IELJ<O)J-B>2F[%S!
M4-R#':+0`P4<*6?_K/).O>.JP.2E#58;`5F(NMKQ[>WVJ3T"1\Y2(9L\U_4+
MFR?_=[[;%RLG0%Z8P(19AZ[OQHC$@[33,*:K9Y$2;MN\;L=,4E7MJ@SCMQ#5
M)TQO1?,*W!4/V[+D2TU^B^"Q``<CBY@MO>%2>9JD&XN%C&##3DE-C,919GK,
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M4:_\.*`!];"3!*F#`]>)(]@;3J-`LA.-.7O6]XX'E&##YR3'5UY`!U12%PU2
M?%D/Y^%6\:1M(%5,]&Y_(!7\<<`HFW4,LKNIUGM>7R2J,Q?&\BMLYC[A_Y!.
M,]QMD3R<U'=$ZI`FXIV489[$F5.%!8<J6]^;@=3P6U6^MNW%-`XS#[L^Q6D8
M,H->T-LF+H[&9P=EDS,F"(;UE[6Q)*%.MGZ>L,JRJ53Q&S\X-)\NU'D>GS&L
M\CTV:5S@W5;B>,N'8N[0IG/!Z4/?)XD,,I(PN23R:\7TM>1?XKG4A=PH#H@?
M)"[Q/.RC`&&_M^KQG0#Y]#'>F/7$<80X<E5A@%B)5#$MHVI)XH1*0VL)`YPJ
MI(5IN=5+"!<_U]&)X$,&SJ4`<]0M0?P->E-9^;[&"OX/F28-D\AS<18BF$04
M1VX6PV.F<<*1FJ]L;R;9UUPKF*%84_VM<FLB`9R0:BP)J+,[,@]897ET*K"T
M+I`A0B4C:).XU*2@[]!'>6$D57*IX7-5MP_Y`^\`)^YPBK>>4+[^5FS.92@G
MQ)@WXT>^ET99S)N^#4L2FB2I0J*P8-UZVN@QB_JM2ER4SCEL<"=PCUQ"V(B'
M1%:9.1!J.6:(`$/;7547>,$!L*F5AXU0**2@F4.BEY#4!\?H#*7.T[E\99'Q
M)60OF^Y5TWRXQC/;#SDVI@@2+XM2+T)!FB4X/"+Q$D1,)S=E`$O*;YIK)4N1
M,97FK(;$6J8;>PAC*2BF$Y[5X(S,>4I!FB;OR2[5['+_TV0_?0^5$^!(,N7O
M)O][OVU?CG;[C.M@G'IQAG'L)"'A9TMHR+B!%RC>0M8S8C^7Y?6WHN6%>N*2
M3?MRDKU4[Q-K\G@Y*TU(H%KF.0!Z50C[85*Q<Q/X768NE+V.I'(A-:YCO7A[
MC]<$*48K_C]MR^*Z+9Z:51AD!'DH);S!#<Q0EJ4]B)!`J-2LUJQEE>%EM_*?
M8P8"M(WR?X58R,G9?&%04SG3$9CM+L!`Y@5AM!.4A>BE)><T[@7H4BBMKN=-
M']]KI"AU`QBCV`D0=)(8IOTA<N@GKN+LSH#!*6=ZHDR.;U[\,(=1E$X31,OI
MY<0,JXGD!\(XUP.S'W-V00L-$KX0`33I467MZS0F=:LHCE&2>=1SLC`-(0V"
M>+`8NE"Q)_8(0]:E+<NW-1`]`(SIU\?LC=4MH[09U*O%B)26.$FSNGA1DO=$
M6HP4R3$QWUJO]T_['7]AZ=>Z:II_EG61[[;_QWZ;;TM4L.^O^)I_7R59%L$D
M2B!$`<%92DB:],#2R%%:X=I'8WG5*["!(SC`T1F<FIF*R>B9VPSA,"B45^#$
M`?!NT'AS,>X%?\UE,;HJ2;O>W-!P2!>OTL8=EI]96J':JN9_8K\[`N,=4](,
MP2S%+J2$H(P.R2AV8:KV*+=]/%(R,^;A[1\DA.,SN28W%1A[PF\A(I,+/_?A
M)Q/^5[0;%GZ]D/[$PJ_IL`'A'T.U">%_JNJ6X\!5TZZP3RFFKH\H(FRM@6,W
M#H:\$\9(Y34$4S:5)N[J#R$,8`!'8TZWU7@=K<[6*#6KP:_(!BAOMLO9NWC%
MH9Z@:D5A^;*IYY:\.(Z@3>5UPN>B;E]^9]]K"\L-/T9YYF5Q[_4,#"F$;N:E
M3A*A('1H0C+/HRG*W`"C@`8J6QM&#5O>Q>BQ7@&!=CAO$GC5WRHT2+B<0,[&
MM9I*7J1Y(7U)5:B\()96(K(0Q;3CVX]/$]HB4%H[^3&-J!YF]O]KS^:M]R_B
M):]UM2_;Y@3(H7E@Y`2^BU(VET6\7V!"4^)1+_2=U$\1)"KB:=:R9?4<P(H!
M?80+>KROA[9.VU/#D9!3U?F"H":K9OFWHJI*5%Z053LA68BN6G*NFN*KUE;6
MW:[Z*V?T-`S.EZ(IZC^+YBO[Q^#W;;-*@]AWW<B/$4S\`*(H06YOW4U2K">I
MHTQ.IJ5'F&)8]T`!1PK^X%CU170<Z:KJ.1G?NK(YBFK+>GF)/"FA-,+^XA32
MC%=GI=$@:88TD51/^;9<)8[K$B=QLLBG:9!ECNO'O6T4.XXY190T.+L>_G$`
M:E8,9=DV(846B#8MA!]S/(,*'C!I:Z`B[3^%`JKZI*1_6H1)JU]G):MJ_G(2
MGX;R^6A_LRD-70>&$89!2%"0\LX"O<TXE&V`;,24]0+1'H_J6?HX`N6$;#+F
MU`2L@P7NJ_KPU&F/;*YKCI=XNB!81NA=B%"9\:6R\/VI=6@O14D\6R?#S?_N
MFY;O0/;W+6D6T3!Q711`ZF$OQD[D#`932I7:LH^P8UV23M"!$WAJ7<''$'E9
MG:9E4$V:SE"GV5E]#(=*[=0GXE*WA_J1T_R(ST#7]/-NOZ/:YJA:0D<-,XY4
MIK\BU;OJ^:YHOA3MOB[YU/4XC^W;<H1)&@7821%T71]ZV'>&[<Q$NB&4*6O6
MA;O#IGK)?"R)<I/)*=E3$VV!#'30Q$KX9&$\TY3R`[8NS"I-\;R0B:4Q=][>
M!C=*D_$SYD_#173?B:&+4^AY,?)<%V>1`WL@(4Y=&^?,\M87==;\2;O1AH6P
MF#UTMA,1FP?/4L&8]?3YDT3?#7OQ68B^6G10\R1:ETJY)3XL\]U+LVUN[N$3
M-\Q^+3?XD7WGQ77Y>UUM]NOV2_%G4>Z+?B=TN"B/DA`CC\F_ET4)AC[V?=KC
M(2&*%78`;,*P/L_LP?/..^UC`7+A`OO=E5"&M7`#\#N&=8==9=UK-4(26PM+
M"8V:.`\QN;D'!]SB)Q:.`W1P78(./.C0GQSX2/0!F3A0"OL72PF8WO:&[&`"
MSUWTZBYZ_=@:O1$R@K]S^R13A&0)VRB3^%E-_*T;+61`^8[_IU64TAA3FE""
M4H2=$,;([XU#E'FKYZ+>5IO;-J];$_4,LG95!OA;B-)CO`,#<C'*2;$6:TS@
MNU>`#<=@4>?L'5;M@W95XA<W#S;BE-)1NQYEDD=:AS[%3!K^W#8,0/.U>E\F
MOA0[AK!\^%J)K9'KOL/QOXJ\7A$'9SXD24*SS.4Z@M-!.E#FJLQ\IP%D_Y"L
M:]?^//C!$O(!,&@KT(@]19:UNQ;[X(6A5CK]F29N,D=MBPN8XIE<%X&C`^!K
M=7XNW'O!_])A9_CZV)S_7\N,HLIAW^*BJ7DJ^./X8\/NW!SYX[$Y_CC1!+%G
MSQTGC=H29M83>US--D24-J^.!ZO2F'YG<]::(VI624@S''NAZP:$8A>25V<:
M$,NUM9D"B91^C&EH<UJ<<:H-SQRC$`2U/2O+@9'9MEI`1/1VKDY"H9R8A0<B
M+2\J7BJ[5\N)F^8&UDG\E%/PR7@;OX\UBLFS6UG3Q&<).7<J5ZOI/W^5+/M[
M_B+P]-4!S\^[;;&!#[S59?L1Q-,I`$Q@&)$@"C-,G#B+?1)GPX9;&H8*^78R
M3-8S;^_)?Z[K8K-M#2^;IXN=1$I>5M#T>GAT+@SE49T3H/-"+EWK+I^GBZ9"
MPEYD5/52]S`6V2#LJM^Z\.9=>*6RN=%UM"EZS^7SR<.WA,P^O=/5G"-FLFP_
MS$16$7%CDGB(QDF&J0>="$?#WKT?3);KY1$M)--KKKBG"IOM-&\X7C,F^>-2
M?(EQG"K!VXGGK.G].$+G3>X#M592NWK@?OK$KN&RL;2N2[?ALI0X<9!/'-\)
M(P=Y)`QHV%],"D(O=KNR%%I*]GHW8U6]**4'J%F2<LN^LZXFQ1$U*>'?LB9%
MEO>?JB9%VBFMFA0URJ1'YW7)=(&1^_);T0X%:H3Z)($^"0AV2>SX"4Q3T1,7
M(N0@HO@LF)8)^W4CU=-S58K9%AMWVPZC^ON&>@1>GLU.QIS:]'2`<P48H/D>
M+7R/E@N2-(K%A2C0.!\J@Y^5KKY\R?_ZS):N]3;?-<SNS7TO<"L<9#$*,0Q#
M[+G4#5,(L]XRC3/)FC:#!JUK#X,&GGILNGHS@E!%]9F&26TMXFP.^`[2Q!2]
MQSB7-ITE34:IQC.^--TRX-$Y%3-%EKJF_4]5?Q/5_FS*]L9T&I(PCC!UV%J*
MQ'&6.3[M30=NG&B*V@B+UE6-8^ONQW!TNKHVAE1%89N(36UEZQGM$"Y&V\[S
M)B-N!EA?FKJ9<.F<O!FC2UW?LFVY;1Z+S:]5M7EC&GG0#:(DC*@3Q12%*/+<
MWG1,,-;4MQ$6K>M;CPT\<'"Z\C:&4T5YFXA,;7D;"!4`%Z-NYVF343<#I"]-
MW4RX=$[=C-&EM>.UPNQC\),0^RA*O2A,TX3XO0WDHU3E!3JE?UAE@&D\,_>5
M_R_#KM;+C!LTDALSTH0M;7`H8;^P$:-(@'QKMC4;7?M=<7-_^YC7!<H;_O#9
MTW-1-H=-Y[KFEY;%`1)Z.?Z=[E`)_I77F^Y-BC".7902-W)(ED0X=&)\`$@R
M%'A(I0'2=*B4!IIZ8Z3>$7%XPV'^<L=Q@E-GP*DWX.[EU5_L/`+")<UG>B:,
ML=P49)GA59NH3!U9.^WK3`7B@HQ/'^R%Y(`9''_;/&\FZN6?P61#ZK?\Z?"`
M1Q9D,(H(=`+LDR#P,,E(;R,A2:;TS*7*/VPY!W`L@(/1>Q](C2,Y`;9&CYJ&
MRC-CYU')$Q8N")@660O1(#WL;Q]]U"=`60FZYRS2&#'!P7X6NUF,'<\)DZ2W
MX@<PT=$"R7]Z.C70>R)'E2DU1;!`DK8FS/.\S6LF)'1!D;*%*8,J^C/:H$6"
M9&N<O'F\+=IVQR8F17U?U4^\XDG,5OHNP$R1:.2DQ$<A=GRV3B:1WYL-?!C+
MR(4I6Y;U0[RDTAP@@N<C1M`(D$I=3PP0>UE=YN!436X^H%/O10@#O*JTBIF6
M7\T^,*-YEFSO\B$9[RBZ:1J74'%NTIW*SM>F.D4\8\Z/7)AX/LH\%,:^ASP:
MT=X<]-)4::ZH:</VI/%DP.S+K?(K9-K424X>)V!-<19Y0MBMIL(8FDY*JY`I
M-I<RP1SKQMN9IA%:Y`]&/MHQ.[=A]FGHBTX3$D=!$B&*(YJQ*7&(ADTSFD5*
M[V1/`,?V48C$)OD'>^2?M!^.F"*:DF<?RPJDXJ''1#&T<]@QFOE+IQS3A74A
M^CZEQV_/-:8F6VZCXN2XI:W6WVZ>.:I?&:CVV-S;0Y&34,]S?400]A(<NFEO
M%Z>!2H=>$^:L5\6='I,V'":H!$[P(("J+*N-T"NQ7S$UKYKGSC?W0.`#!X#@
M@%#SC0@CW"KL64S-L=ZFQ0<?[^AK]A(LG-NM,$G@$K8KC/I36?K2IEI"T'_O
MM^W+=<G@B:^VN6D?B_KK8UX>X#<'_-?E[^)2^2H.XB1,$/'=*$TB$@0!#'K\
MKH.53LL6`]KV<D2,9YW-E,4P9'O%,6=$)UZ77(&#L^#$6R#<!2WSM\NQS56?
M9?FM&^'TS[*&48REC96.K<_I9U\/6>/%U*K);N`T2I5I7I?;\J%A]GK$VS4L
M-V2[V[?%H63M:_&]12P^WU8!@J'KN)F;9BY.?-]WX>$X(@U3BC*H^+JT)136
M5V("GGBK;',`"(K.`7X>=SB'TRXL-AP1R<2V@%!H+M[8@J+'S!/)(3%=@6.,
M.N1=73#@X(%`/U^)L!+)4@7!=L*VE'Q@V\VSQ;XV:956:U+<M<>4\3EO]S5+
M(B1O"U(TZWHK,L<*$D+=*(0H2C(G)IB@?AL.>UGDA6K:;,:F=26^J;</VS+?
M\28?'.&V$$V&UM734U&OM^P/GG,NR5P'FL>J;G]AZYLGL&'>@:98=_^+HE8;
MBH><,D\?"#4=YOA.IOI7H(<(.,8K<()R8KF58NZ"N)IE?B%2:MBIRN;'JG)@
M<,/DH]P^/+:\KV?=%'7QS#[81S;_SA_JXG`O@PG!FM\"O!?7//.F*=IFY=.4
MNCC$*5-JDD4PI33NP6"2$NEZ1VL(+._>#+A!!QP<D8,C]"O0@1>O]HI+KP?\
M*GOC]J(D<1BQB`"IB>O?(S8*AQF+B)'>"8>]6,F=@.A2=^Y8Q'HHEG!68M_)
M:LJO6^EE/08A?RCZ)'US_SFOOQ4M7]'<#C/C%:6N&U''@;%'20)I%E':6T8P
ME=SQ,6C0^I*B@]FO*%[X.'T:D)ZL&J[`4U6VCVJOL)DA72+;3<^V6FKK:1Z6
M"S?WX`@1W*HNSDS2J_*6W>0T:SY9U]%=%_QRD6ASOWTJ>*_[,]_YFR7R%<C_
MS+<[_D>_W%?U+_PQBY,_'O^2G0R/YU*5V2`L(2\9]JBR]L4J;F5E^;;F7;@+
MLFW6NZK9LT_VN'^&/#^,HR2*/1)G69`BIRL>2$-"PDQQ"VN<+>MYAL,#`A_X
M7.0<G<C_BGM1(PF5VX.:CDFU'')"X0DR\,=\6_P7F;JPUV2&X87L,1ERIK+Q
M$2K-D,M\]])LFYM[^%3MRY;]6F[P(S_C%6TBWWGMX\V!0.AX*8PH#.,8NB&$
M&4W0046A@YW,49D]6P=C?V;=N2!6OH\%6`OTH@*D_K`3X2SAD9EG+RHNBG/P
M/B!L[GU`+WXJ-^#@P.&YZ3,/8:D<I\X2/)59_**"J#G#/QE=^2&8_"<6S,,X
MZQI&O_OXU?CI^U@"ST[M)XO,(J;]TWE;S?+Y*]T!V3^Q]2A;H+R/X+I<[_:;
M8G-=XJILJMUVP]]K[![QN7TLBO8M2`)]2@@-@CCS$,%A&'II#]*+@DCEPLC4
MV*PGYT,?T^$UO&WG@7B9NBHW1<D+/=<GWH"[[CVM1OBC=$5B\LA*)/)%AU2Q
M-NK@"D_F9]/W_[-W;<N1VTCV5_BV=H1ZEU>`V#>`!#R.4'=KNN5P[/JA@JJB
M).Z4BCVLJK8U7[\$;U6Z40`(@.R-G8D8NSV6\N1)XF3BENC]X3G^W".G?R:M
M]6EBFK<?:9F;,TN.N.(UFR[RP][2F\]=/AO@;PWKZ1=S-)/\YBV>N8*YA+IA
M/N?+)8PGR47(C\6NK)ICV(>\'@^'MB]G2'R*(8(8NC0.71!Z:1K#"`=I`"D(
MA`Z"3+-@^*#'I_I#*G>'^L>W?/V_QZ;8"5F11+$%1_/\R2549>J,+#*^RL[(
MXN(T-A>RJ#C1B5+G!R8SB_F4'ZOBX>&XR[LF*\A/0>`'7E*GR3AE;NRZK#="
M"`R%#YQ)_V;3^C+@F5HS//?LK9ROS,`2<K8Z^%+'1S`Q9UX.[1^2T&7`"WTW
MI5'HIB2%9!@T./&D;LRJ6YDK=UXJ]]&9P*A:$C5#IJ9$*L2CE6QZ*="B9CJU
M"\VJ"HZ\DUE5J1%6INNJV3U_;&ZAM^W,\/J?QZ+*-RL`T@"C."4)(#YB+/)"
MTIM$0*Z?X10[AM4I*1\>REW75Z/K`GHZ6SARL5H_H6+29(M+.7'J4;7-8"ZZ
M;H<73@_-LC"-D#0B33JH78@X:7&EU/_ER39;;>]_[UE9?1D&Y>?;=M`V.%:>
MGWC09T%"":%^B`E%R3#QP`!(]5V=;LZP7%WUI^+Y*F4_YAKQLMU0]%VJ1@::
M1IX7,MYT>O2\XZANLL0FWVV[!;Z@>,RV0X\B0CV0@"@A/O'JV5+B$D0[2W&2
M1#)GVM4,&-_,ZSJP_-0!^UFQE9DB?0*;;>9YDTO]\Q(FL6=EGCBUC:<6U^3=
MHE?=>VOY9QH72U@#FNA!J>W#D.T?PQ7[OMS6W.Q;PVV_FE]W:Y[/\S1O_[K"
M%$:!SQ>B0IA0-TD2A'K[OA=)/EZMS:PM`2XZ8,[F6#5W+NYS?OUOM-F58<+%
M)FBS,"UYR.$,XK]U/<<NNE9B3H_3^:E'^K/M9B^"#(Y4F-J#L)`Z4[]?S_NW
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M77['#X%=B^<N+7:%Y`BU<O0"HL2!B(.S/E85;_;15OU.V?3!79_#YY.$&K^S
MK1VPK#4B7(Z(A]90+$0-]/I4&OQV5:;LI[77JZJ\J[('?#S<EU7QKWS3WOSP
M5HB1.$4H81"[?LJP%\?!(!<,1%(-T#79M+E]^KVY3IP-&)W;LCK;3%69M^M@
M76+:;IEPA5F[<X+H=!@OG!/*[B[B'!/V][E[;[ZND?V%2*)VMUZ;K6NG;:(P
M?NG[I'PZ\F-U=4W5[A4/J*Y+DI]^:K/R:`1C4.-*TM!'H1_`<%AIQ3%E"BN=
MYD$97P=][63*F;:>NM'H%UG]$9RBP;.&3I=$#TXXK1?-7+D-ZIEZU[/PF_SL
MYZT_[*`E`-(Z;RS"BTX#YKP6RA*&29=8\7UUKKY"`8V3!+LIQFF$4QJ$N#_S
M&'N48+E56S4;QE=>GRRU?C@MM5I?.7N5G]'5KVF,+F1D3G;CQ2J4#EJ$Q\XK
M$^)/Y>'L&B!&+`Y0`OS$);$?P02PL.OMXR&6,)E!--F8Z=&T7A\?CMOF)F[[
M:-(3Q$X+V?F)+QF,;&D:(EJL`K+*L5QM,T*FPS'.V3OL/=I&A$P;XPM1-'W^
ME(8^3=GK4WEU5XM!<]1XWXCKOGE%9/^M[/[X>E<S0#"E/O:I'Q*8)@BG7H.&
M`!@")G>WR@P$XWIX@BM[P<H0YV(BN`"ZY:2Q`]Q==^@P=@\HG4`OI=&B&KTC
M$FHX7@L15M->/K\,9H-4P:/@#]^VY6.>-_/(_@;"53T"NGNS-`(1!%&:DH1A
M3(C/$&MM!BE$()`Y%#[1E/G3B1W`;EUN6.CY5O];4L>=IW(Z+J76R903S('%
M=L%LN-7"P3E_M/#D3H]/I5/F'+E%6A5/E(]\I-//F8^[_^:)<TVL+>+LN2Y?
M2@.?E5*?P-=?9:5_\;_-\7Y?K@L^K_Z].-RGQ>UMS@]F=.N(IP?,O9BAU(VC
M(*61FP+?CY(!(7"!S.4@N\",9XVSWF+-3H[SRA'*O/6)/VG3.>7\67OE;'JW
M>$.RQB^E+G)V(BR0E98;6LF]'JTQ5;PU93F\*AT"%Q?FR>T!WSP%+1YN?;T!
M==#[5LZ>)X9+R/`S>?YJ2\`9R!??O-LV<<HWHR"'`WI^PE*`6.02QA"(7(P"
MT*-(TUBPJ;\AXQ:J@)NFLZCMS3TIFL;V_,SPO9#U'5/>/=\A-$FB\+A]_CCW
M6>-02KV0IAX$!'D@"+R$=`M('@FQ[\D-474[YE=R.FC\?'E[%$=RD7P"AV+K
MX';(DURYZ5F[ZEF;<RG[389&5&PZJPL1+`V.E+H_.-GRH7\8CY75U^S\%37^
M'/;'X6'Z4QE3ZV'D1@C"('23@(0N#MH]1A"X421Y5%2[>9L+"0EO!EB#.F9;
MYP3U/QW\Y+%![I;\BY#FXB.F?+,&1DX0\<NW';^>/?W(\9Z%1VB:;Z8*E*1T
MK`XT%9V%"*LY_Y[7@F:)U"[#?(I9[#[O\O_*LVIX5&X%&'*9F[@$>LQEO`L`
MC7M4#&#)3B6&P1B7Z/38O!=5[G+GL4;&C^=O\WTM!?G^4#PTBT*W_/'%YK:4
M(3U6#91>=;80(9-:?>%\XH7M]9_Y]GON?&P>K+YP3@]G+E3`7V==@YQ/#.</
M)NY3O564>BTDFQ5^_%!6!WY!("GWAQ5B*8`N35$$(001"P,X('.AZ#N=%@'-
MEP"R'J>SKH':D'[)4!F4?W,QLI\"!E\<[HQ#LGUAO=7)Y!CH3@AJ`?Z1DX*B
MQSH2PQ2R]2_.W![RJ@9V?5^5Q[M[5GQO,.Y/V0N#F*`()8020-P0>SY)>X`X
MC`U-$*;CLI(J,@[SE"T.+5KGEM^RX/^D%APZS!Q$JL^Y@ZEYB<=J%,TF$PZ\
M3B:ETSGC<&]^@"G%NS'0L5BD+<X_6$[1Z+CJ\I)FZJUEF*=I,,8D]!")?0!C
M5O_'8S'L0(:4)M1NEI'#MI1,\[2TM9QC),-I)\^8B^,LN>8'FKL(1<1@YE&+
M_/^1[*/HO.8,-"4$8B?@I1"^DAG#((H0]>JYEXM\WBH>4]1C8E$`)<Z\FX9B
M,<><IY0)VQYV(C2>1Q87&L6TX=30G6>G`5[L3C?XFTS1Y(^]_'S33L@DSJ$O
M*71J)\^O[XN]4QSR!][FBS]"W_1KOL_/QA,_#[+AL=R?E01_WA?K>X>?T.+G
MTM>'MK_4`_?XY3AU>`II?NN31^P=_M!X<Y/Y]-OXZ<6[KF'5+B^:3AO9WKG/
MMYL/A_+#0TOIH[.K/[A#E6UXTZL3KLDGWR<&]*VS[K:^DR6<;K?F:SG#0#2?
M_9]6)1Y)O9A"ET+/8VF4^`Q'/:ZZ6C%?`<C!F:D*4-K[LA<C8S6`N>!8K0.4
MU@7LA<]X/6`NC!IK@A<50'9H1MM%G:8/O$3(SAY\>,@V>=.@.5NOJYP;'P9I
MUOZI:;C^X7"?[3[4AKZ5%3]X6CQ\JQ6Y^14735UPGV_NZ@Q_X13U[]\]_G_9
M\?9WH[?T4/LD?]SR0]'?Z27(%*(U+(6OPMC%7@P8\`!E""38!UYOT2=AL&HN
ME4U=U7[7C(RHG1")*QK_$2=[N<IY+F@+W"E36H`4)GOQJXGBG@@O#4J2HSS$
M^)@_67TRRIME\54:>%$2X]2%"$"W1I`&N,<1><"=,O`F&U_"<-2Z6S0]'&H;
M0E8C,7G/IZG4O[X9@T5LZ+S'J(1D:@O.0H54GW_OR*MF(L6?B%C7$X3C-O]\
M>]:>=^PQGVL.^G3Q$,01"@")?4;#F-``>,QO884L]B.IMQM-8Y&29/E^GCW\
M9B9WUNMXY&&LG[8*O8Z-ATQ,IY<4+3G9/@^45%-JYX_&!V>^"]4321]1=EOA
M7(C06W/W^5L/5FD63@-?\O4VV^^+VV+=K"Y]/AZ$$#Y#%P4@2OT8>2D-_0AY
M%/I)CR[PF2^3#2Q!,IP4GGOAE,>#>(*0S`RVHBB6(!880+D\\5;L!'/&[,E"
M3P!&<H;E""\D==CVNIQU6$DFDLMR=W>=5P]]@U3^2EK1;&DT]E=AXGJ,,!8E
M492FE+A!T/8YP\AG+`8R&6*J+</2S^%]J'_NX=0_^82P4P?19I+:Z!63;IO,
MRFGR1%*-Z.P[;(T(J"Z>%Z*,VMPIS7R.@EJVYH]R5H^KY&^K"%+$"(Q`ZL,H
MH32!-.A_,Z2)T"-G$K_.]`K%G\7A7WE5_[.1APN5J1B7%D,L2,[\?__U^K_I
METO\*572B'V^_O>[\OM_=,YPB0CZ/W!U",[4X>3P*P*@P,;,8UP%<:D<>FU5
MQV6QRW\]Y`_[E5N;C3V$@@01E_H4(S:83OP8ZJD\Q.W-6WUPG$X#5%\)(L'U
MU#+$#,U:2Q$AABW7(P-M2C6)/.F+KTL47!*N353I$E>].H^O<(!<-XDHH2Q-
M$^#[,1AJGQA%D92LB?Q"T[HE7IS(\2`H.;HID-244>_-J$5M<DP.9`A9RGB7
MPOQ\0,L[+#YB\[ML^S$[\'&!=QO>(K38W>6[=7'^1I@/(8$H<GT0,^9!%J<)
MZ99FTB1$D=Q%:3TVC1]+ORP.Q5VSH"4[^O5P*B@/ULF4U`^.S^D`-@=TGT"<
MLQ>T$'5C0J25^J4HE5ZGGDN9`<J$M>[7W?>Z""JKQ],[B&?/(*(T3,+`PT'`
M0!I3XH/6)H[#"&')KG233!E7M@&=I+!-(U!,SZPQ)R=C`ZRS-UGGU*XQFD8D
M2PN["U$J/;Z4!CX_25WZI2PW?Q;;;2V(O^X.]5=7W&SY,SWY8?\:"C_V4P*Q
M!PFC00R3&/B@4T>/!$SPT3Q#QBUH5P_2:5$V-47OA:2@Z69>3.)FI%Q.]'J@
M#<4OB5^&$LJQ.:*-AL*R$+4TY5UIY=N65-2KJESG^6;/:AKX6>8:37=7Z_'S
M[<@]$I1"ZH((>SB&T`V\*$K<!@X!/B:!U-EA4Q@,KW;UL-M[E@^G&[Y<`_B%
M`MMW!11Y'!GHIB.SD!%OW,W2[@>O[7[D+U6YWW_)LRV_S_!+5NSV*X]@+XA!
M;3A($/9"C$.OQT`)%GR0WHAIXQ55#\>YXWBT=?!385FL?IJ-7KGJZ9W^>PU6
M9R#_EW'R+=]1?4GDB)X:B<="1-2,;\(W6R<3J%LN^06`6K.AC]+$HZ$7^Y1!
M'R2>&_4@`';CU2Z_XT<_M>JEH&VA$8W:$7T.4UXPMPT@,XHI2K16R=3)L`7-
MO'R'_SE%L\4V734E0_)CR::L<VJZJ42AQ%PSO\VK*M]\/=0SVJNL^EQ]/7!1
M:;I.]`]CK@!.,4DB%,,4^%Z"$"9A.],-*(U\R54[34:-UY8#3F?/@5XXWS*U
M=\QTL2PFES/0*Z>3)UZ_MKQ>M<\&M2C;AB>G!W>MS]A%V!N=H&NE?R&:J-NK
M%]-O`Z0)JR`_9%;NQDW',<(1]#WJ$^Q2!OB;P)UIE@)/L.^A3HO&]:\%.57\
MM)`KIGRV6963O8[.!6J>`&\C@J>3]86HG5:72G,?J6QWDN/-/O_G,=\=Z/?A
MM@^K)^'8!S!(PA3&P$]2!F-,(`2^3Z!+I5J.J!@PO"=PPN0TH!2O"JIQ)Z9;
MQFF3$RIYQLPTYWB%E1$9FD3B0G1GF@_/>V-,)T1863X6N^+A^/`Q?[C)JQ5B
M((P2ZM;3U,3#@1O@$'5&`NRG@8RDR/UFPUK2@;$\$)Y0,#("U*A:R*>O"+[4
M\;7(?NS97V=&H@3'D'EN$/+>J"APW;@?44&:@ECJ8Y?ZS:8_]A:,[8_]G(*Q
MCUV)JJ5\[&K@GW_L$RA0KAGKG\9_%?N57\^_PSB!Q(5Q%`0H"=S!G$L2J<X3
MJC9L5XX<F/,'AS:U>A1F4:V`-$'@Q!I2B#LK=61'CD0I*4OG0E1FLAOO%)1J
MM$Q1GK1\R(K="C,WC%#L`I>Y-'%C'Z*H-\A"ETW4'D$K\ZA/"TZ#_HARJ:Q`
M!FC4HD'O,FA+A5H@<CHD2>IRE4C6D?>U2(D:537J9QB^'X;40[Z;Q,1C20I(
MV!OS4RK5H5'-@F45FJ8[HJPI:8X!PJ:NF[609I::=Z=2TWA<IL3(.C$N+TJ4
MJ$K+Y=#H@L*ZD$I#CT2(TB`E`0@&>[S?X`1U$3=B?7G^4KF7CCJ12H)CAL.I
MFB-$GPW=N13HCC.9T66JCX(?XP*D2HS8NY"_E]4_;LOZ`ZORS7'-FT9\R^L_
M[0[97;["-$A`%/LQB8B'W!!&%`^SNR!"(B(TW8IA%1JP.0,XYX1.Y@'`:5R.
MZY!=&N6$:"D,2KR-:(U)M4</51D5>^!OS/E7!%L?84MXDD^/(Z7N;TGZE8']
MH:J-':MB=X=WFR]YT[&:/W)#N[<H^=][JP!`'`)<UZY1A+S0QR0E0\YP`ZFU
M>FU&#2MZ#Z8>/&>`G?5]5MU)7WO0Q[18H3D+R7)Z_P1B<[^V`]D\S'7A#/R/
MOY5FJ%._&'TCA:GV""RD4-7OUXM^^D:($RMDGQC/7C>>[>^OLL?F2=]5B'R8
MA#X@D9OZ+D(I)(,P4]<5ZO9HQ+`M<5S7H)QO'2J9(DT[TP*5[YPDFQ)'SO_5
M$OB7J)OGC(-:*:T['F(EMB1/;U7=INA>0B%NS+?2PO>J<,ND;67\HGO@:]UE
MO!@A+V*NBTB2^CZA7M3>=:FG$"!Q/9FB7;-IP]GI#.TK/3=/@!4NHNCD7ZR4
MGY%ZN9PEROJ<[;+DR!PI[PU%92%%OBGO7KG)8HQ$85EE65$UMV?:1ETUDLLB
MNRFVS57JCWG&06P^[[[PZ]7=G.13N:OZ/S;/`7=GXQ//2P$*0C^-`P))3%';
M5QXA'%(@M-)M'Y5A,>:.M-?3+LY[%IYYX_3N..7.&1QJ_JUSE]JWNA5OWU@,
MLIBL+S.^<HI_"FT?PF8L7XP%<9ZK0-K8'DD)]B.ZD&PQ@^/EW(-)-<>0Q^%O
M_U;D5?T+[A\O\^]UI/A!6!S56:V>,P"&TQ""A,2DMT[\"$MU8-1DTF)V&-"I
M'9'7Q;&D?MNC5U6<99@UJ[ZC7(E(JQZREZ:;FKQZ2Q1UDB:O>.>5P4L<W9E;
M%+L!`;7Q($I1D/A>&+,>!(P841(^+98MZM_3&NJLN#H;OFJG]S4'0U(AK<=!
MN8J5(=JL4HIP)B*86KE?FF[J=>XM^31`H;R*_KK[=CSL&]7V^L/$"0Z\A`(8
M0$#],`@)B'J3-`62#86F6)(9FTJ-A/Y^+/GFRE55K/.]4^P<O#X4W^M99U;]
M(^=BV<!U/%595&%74@0-TZI>&[;`!@KGNG,P0I2(SDV@=VFJ-L65MS1L,CV3
M%,OO3&(O#B!DJ>OQ]B&1RU`$!I&,7<F']*98,JY87XN[77%;K+/=P?E\N,\K
MY_/-/J^^\T6&;L@Y/[5#SO]9@VP)4ZPN6R:XU25;_I)DRU>2+5EZ%RQ;TJX(
MR)8:/9-D*^A,^M1U(:01H[6EB$):UWJ]24*C>+ILB5JR*EN_[<JW)"O0(5G"
M]*I+E@E>=4E6L"3)"I0D2Y;>!4N6M"L"DJ5&C\J>0K/MD6RS_;[MI^$E,21N
MZ!$20A@G(:#>8)"D4F^0JULQO'+6H'$:.)/W"V3YD]XB,$B=G![)L&9Z+^`I
M*6++_XI$+DUYU!UY>Y%_$C6JIV5>V5QM=E//BX=&$NO_N^:HV!;-P=MSM-T*
M&L-QB+T(Q0$*<9PF+O]KAS?VL-0=H]E`6MLM<&X>G2=C>>+&@/5H*IV2668@
M)RCPS+L,FED5/QQC/Y!+RP"S\3!^=&:NP$@<@J^^E55VR-/\YG!Z\F98U(0`
M0Q(QPOR4I![TPL&HGS+I1Q:FV#(^61_@.9L:G[,?`$J?:Y]$J9B2V^-23HY/
M)')@9^]MS34]'R5J]$2Z#H(7(I.:G'EQWEP?1<*"]=O7ZZH1U4>\V_Q2UB-]
M]W#J"%6+8AK&&#&"6<0P9?Z@D@FH@<@)UC1;Q@7KA$A=K";2*296]GB4$ZO?
MOCH]L.9D]1FA,ZG5*%,C:J6'X86HE29G2A,?H>Q#J+R,(]GZ'_GFA4"&!*$`
MI1!&Q*M-4(+=?NLEP1A2R6>B)U@RKE0?R^IPE]WES2@KF_W;K)FWW32`U>5K
M$K]BXF6+6(5I[X>.OOFKK!&21E1+![4+T2PMKCQ_D50;/58O[UT.O?'J\B].
M"?&B&/D,1F%2_[<'22%6VSBQ@LSB,64ME_@NE7MT6HZXTCKE@H*MOEUM+\Z+
MO?)W*="!=)[0+R2+S.2\@>M_JB$PEJD:5/AF?ZBR]6&%*&:)#Z+_K>YJFANW
MD>A?P6UWJ[Q;X">(O9$@6#6I2<8UGLHE!Q4MP38WDN@5J<EX?_T"I$C1CB4#
M!$`RAV1LC<?H?@T\-+H;#0PS!_D93GW7.V^?$(ZL0;(BB_TJI>-NE_,C</G0
M>N4M26T'),5M*^;^!N0U>!"<-N;A6<L6L[.SV#.5[DYR\VH;$19KWC!]*K><
MI*J_`?K?8U&_7-A?3MM)I]C2-Y-75C"X>8RS[E]TLQBIK.;FH`.Q6ICE?)OH
MW.VD'Y@@S\=AZ`<4NIBX?A+B\WF)Q.&(8(O6>-9)O17QWV/B*7I`*D15)D-P
M1&SE]9718;NEN4CS0\@^BK08@7LAY&=0H?>B+@:ADD_%Y]63Z-O$_Q![-W>Q
M7EV1/`NR2M,$8QC@U/.(Z%_M^@CV+G7D*6:YS(UK/T4OVD&RLY"JF7ES"$MF
MZ6>!5C%C+S!M&LR)+P9B7B#`J?/WLA!>R^4;-\-"6-""8F]S_):@DW?MON?%
M5I1)9>7ACH]^CH2O?"_(1.M^)X98Q,-3UW?.D06D]-*SQC"68\7MI>SFUI!T
M79(=_^,B1-<<#WU<%[+63&CRUM4P!8[T:OJT_\ZJ>G=I#8<(8WXB\R%UL$^C
MP,5.OX:A$R&5%:4YE.55-9!.T8G0A5#.<Y@0/35W82#8,AR$ZTA=H29#$"^$
MGDQI4UJ9AZK!_?+`BL<].1X.;+]^$:ULQ<FK.9J])T;F.8C"*"$9Q*$3<6\C
M23LQH@`K1G=,CV[]6)2R`_?,FA8NZY.PJJQF''')</R,4"L&X%M)02<JZ&0]
MQ>.708:*>%X+I5NRS$+HTIIZ;\/E5F&4>X7GED_D4U2K/*3L@7%9-J3</;-]
MU5PW>4\0BA'U/2=.0Q*Y@9N%X?DXAZ#CR%&JO?&MDZJ0NLN'/I0'?OAJ!><4
M>Y9<Y8D8.V:XSK/+P%^-:1O@3]4R7&#020R&(JNR[53F4'BV9W:SC'N[)^OS
M_Q5?'J)HH'YBX#[G/[1FH'IBK`8;<0%(E!-LM]T2XM^]NX+`,_^'U;]TW_89
M`^8[NY]]PRSAE1^["I93S7%32>)5E$(QFP)$^+`XIIY/L_X4$SB)H>3PA^-8
MW].^E76^-942_A@VS52P4;P,IH"7DO<=D^^5QG0A?KH!163SNXK02//.H#[F
M:E8Y]F,WRIS4"4*$/1*EZ7GT)$[52,C0H-89:2"G:JV**5SE6&H&0-4H:R#@
MXDI7Y,"[PF>&T5\(N9G6JK0Z9<W$<*M.JI?W*)@$(0G3,/0]Y,,LCK,(Q9TL
M/B&J==DV1/@+1W,UL=<*Z4X'NJ&X[J#`^F49CN`89-4CO&8,M1"&M:NC7*S7
M)*#2[)L<JV+/JHJ?M>^+?7/4[A^$K/E75<&1;S[NI5LYR$F]@`1IBC`-<(0#
MU-4<I$$4*&7_;8QON23@+)_@W;.`H+S?%H_-EU.7W(Q`\<J"MVF3A:QWJRJ6
MTTUQHT?,%841#:$;QI`32AA&Q.M[5Z89]LFJ%G$A$P?+#X=26L.]5%8#7+K@
MF3@_&L5-T0'B<W>_+O)M=^GXH?_@XR/EHLZ1H\^/TN@OA.5,::-T7E0$23XL
MOUZ7QWU=?65K5C0-$4\M+AP*,S\.,GXXY2SIX#1R23->$B04)TJO=XX>Q++/
M\95MCNO6R7@`^4E(<=WV)*5JK'XTEI*A^BE@5(S4=Z"=99JM"<X%=*[%Z74!
M70@CZ>OQ-DIO!ABY`IG3!?@O#[>'4JS'K^P[VQ_95R9:M++JTWZ]/6[8YI/P
M[ZIR6XCT]B9I,]YW(N%]ON`*70)I@!"*(IIXU'/XB:X3ST.R]TRGELIZ3&O0
M8J#QZL!SJQ.GND8I_F>K%2A.:HEGZ=8#Q5Y7&,@&Q"8WKT0YSD+MJD:[G4&_
M/("3&N"D!^@4`9TF_`LPU`6<E`&M-E)IB7FMJE#5LU#KCJOU&2Q;W06K7>%C
M#MA+=3\SF&X)U4!SJ%W.NV(4CRCB)-0LG'B[+?\0XXJ^%YV`)U%6.`EIF!'B
M.L1+'!)"#Z'3X`3!2*G;G9D1+1]>FF!+3P03.]M2"%WQO,TBO!`WW+!2I<U)
MJ;@&FU<_!Q&*<_H:9F[@.KX;!,2#?@IQB)$+_=`G%%&221YM1_]^>SY6^]#I
ML,O3;`4<E]"YLL"T`5W(FM+7HS0\TQ17SFE;[9,0?9)B_?)-'*Q7&1\3(3]V
M(2(^3%*<4?\T;D83JO14E/9@EO>L[K#2"P@&$H+?&AE56ZCJ`RQ'49-BJT95
MFK!:X:R/X+K"7<:07@B'F=.GM#0ES7':Y[[S*'?X8QCX+G8<DJ30HR&FW=@D
M#*@A7I,?<%YN^SRZ1[09M+5)S@[01HE."N.IV>ZS1-MEH[`OG_5&Z"3/?&,!
MDV:__B(5_Z]H>G"^]2G;&K1ZY7MQBD)"J1-&CA]X)#H+@&)?*8=J;E3+/!CO
M1.JH"TQLFMN[]5-1@5U>\U^G2'X&P99CP'EP5J/!\YW<5LBF=N1/Y]6;4U5M
M/3$72B-XA1#-6V$AK&A!L=+V!%;DQ[OU$]L<M^S+`]T];\L7QIK6V%_^V',R
M>2J>Q:U4>O?E]ES<4K7>JNL$#@TPA5Z4PLS#"<6I1[,8!S%.TL15H4MK0EAF
MSTYND?3I)&];BX->=M#<T?^[$/\?@VJP:N0!VIZ]Y!AW$:92S+]:M9(55AZ+
M\A62MFZXA7"V?3W+B5>$2GE.[&`<T+O;V^ZM/A*+CS*<0!1X411Y..-C)#ZB
M*8*A5+QRU"^VS+Q"&B#$42F#4`9'HD+%)BYJ--=#(E'39P`;A3H/FQB-*]90
MP4JNY.*-CI?J)L9"L83BA]&REP;F@A()"O,,QB!I%`0^IA%!,8(9HCX.O`S"
M&'LI)%CJ9#_J%ULF02&-.@FJ@B-#@A9Q42/!'I)Q)*B*C0H)6L1H'`FJ8"5)
M@J]UO$B"(Z%8!`F.E;TT,!<4S_;2_N@Y"NNFL>BG&&8.]'`4>!BZJ/5)$XBS
MV%,YU5L8WC*AJI\.QR>*;!A'[@@_LUW4"-V22:R<VM6!O7)>MVBEA9S4;6I8
M3C;E51S33HQ*B/',9_Q37C'1U'&7_RAVQUWUE',95F$&?11FR*'8AU'HIDZ:
M>#1V*=\DLH1(D;#)\:9BW49,T,G9=+L$)TE!*ZJ*,V<*;`G_=P:<1[+H,B%6
M<*-G@'J<=VT$<CFW6PZ32]ZX8427X*2;5JFT-P%5TW5BU$]5=62;]"C>#+UE
MAZ+<W#6#OMKE;D^BB4VN6@5IZ(3$\5+?A4$*L]!%42=.Y*F]5F-+!MO)ND8^
M4#2"@^.>3T"5X(EU"TCFWQ8`OF+ZK>&_5F30R@Q:H6]`*_;-V[1<)WKCY$]]
M6V8DPM=2;Y9MMA!_WKJ:;Q-OD\`ZII*B>4[\9U8_E9O!HT"G*M^$)DD09`&D
MV.-?8)0%;6N0`$5.[(RLF]`9<LHJB>ZE=2$H&$BJ7PZA!;IR\<-4>&N4.HR'
MVG9-PQ7PY"H83*"_%-8TK-7EZ@1SH!GCQ#]_RM@O^8[%/XIJY5,7HC3$;IJY
MCA,BE/AQ)U."(FR2*;4$L1T?>6<A,W8#A'S@-R&A:=;4,XL9+IW,(FH,>Q90
MT@"S<.DU\#08UHA-_B*\:T97138V"+!\EO#"F&FYRXO]*HFB",:!@U+73<,T
M\5,W[49U2>`K903UAIJ59UL9E;-\FN!*9O2FPU67+3^$T4YF[BI`U[)P9I!=
M".>9TN9M=LTD2))MZ/)===P_)D59%;MBFQ_BQP-C8J*=2BH0A=1#,,0H1"1-
ML@B'7C>HAU$BG4/3'LGVZ;J5#YP%!+V$HXJ@]*&5R)A-BJKB&7IY@*KT5)L2
MV)&=TDX`WQ?E/SN$\TY*_=YG'P!P*0UF#+@E),#,*5/:F%NF(ZOGJ@TOP,B)
M<.(FA/J.ZT9Q&O42\$^,1E?EAUU&A/7SZ&(UDQ8P%&JU`[Z5<*L4[O/$7#]+
M5*)9,,5"_&$;FJG&7\>")^<G#P9*7KX]%8?-;7ZH7S[M?RJ+??TK_UP\;U;=
MLC.7KWPGSA`)L1_Y*$!91AP_Z^3(($8*?9EM#*^RG$<U8&X>(RKNCTVO>3%I
M0.>QU"78L.]L6S[?@%V^/S[D:Z%`<Z-_EQ]^9[5P:CJ?YODI/^SR->._:)UO
ME0JKK)A-PBV?VUYCHPL52%Y`(R]H!!9ME!N1P4EF$%>BZ.#LR5_Q,R<RAX)3
M/[=9QOGY0_/<OXBV(MP\SXUYBCWX3V.>[R?SY!5X9H-C@.XI8`1BEPX&-L%?
MPEG!JG[E1+-894\<#M?4@M^)6G#&)S&?X8]L*-LJ\!.7(#<)@\0G'HH\OBMW
MXX>($H6]T.2PUO?`7_-#T;P/PF5F_.=JP*5L7G?\[S'?%G7[YF9Y$-^*OVB_
M+_8/)=_R!$O<@+*_JO'<*ZE"ND;-)+'WS64?M3WO]:[6R`GNFOLPO:1O]D*E
MG<XHZ`H[W%S@C]O9?GJU=S43';R9Z6]V/.VPE@)`ES8R&Q@O80.SHE=I>7)J
M)VF;?72%2>)G68P3/\#4(4&8(+\_,WHI57L$>NPH,QS)DJ)\9/M)3F3:-AB;
MQ#4/OMI><S&D-7OVMI%"*6VKAN5"XE/::GR8J!T#BR9IG:]?]@RZBJ*($C]S
MPRRDF&+HI-U;KP$BCHM-T-B8<:T3V\!K*Q]`5>>_"R_ZY&R#7;$75XJ,\-0H
MV'68RS;>9KCL9GBE7.*<,B'!O0.@,N7I&&'1)*BEF!0MZD,GWZ(]?VEKL<MX
MS64YL$M$3>/$<>(X2;AGF45>XKM>GV!%+LZ4VK2;&M1R<C/>;`KA]^5;\6;:
MV0W<Y1LF_+]!O09[+E2=.G/0RW'E+*BK464GH@#W).3E[.;4K=LEX;M"E,8M
ML!">-*_7VS;N=H"3;)TAR]$_M]>P5PGR@LA)(^[;8I1!@N,@['U:GZA$;HV/
M/;=;V8JIU.G!./P2$=E9<3?C7K[K78*?EV``E:8;<QIB9/N-UB"[UB#%V2#O
MI26Z%:$=I54%ZE*HUAK@2XC7VE.NG&+.*OKVG_;K<L<^EU65<1@N;9FB.MZ+
MHMAQ""0!S;(LZ&KDH\CU8A7'WLR(EKWZKVQ=/NZ+_[$-V')))W8CI2"ZXD.:
MA7@A#J1AI4J;LU+?=:SHCV>VKMGF]E`^%'73-6*5>>)EC2!.*.5,D!(/8M(/
M'WA0OO.:N3$M+\1.)/%J.9>I;4D%_BCJIY$G:^.8C_84K<-M*)UR`WHCM)*V
M?7'FPEO;,;2.NY9+:`!_'6?P/7#4W$`M>)?K`.JI];'K9P`VM1>X[_(MJ[ZR
M[VQ_9+^P>A6$*:$4$QA"+T1I%*#SWB:"R2H^WJ@!K+MTC23@P+:Y6$MU"6JV
M?MJ+7'N7I6^.8"(YW_Q-N2T?7T!]R/?5@RBA88?OQ5JA'Z+!![O?8'G%]]."
M?B&NGIX.[SW2K0>(G",GS@S[=;$M&M[O;E3$=9L3$.6*W\I?^$^(+$&YY;_E
M\=.I>K'M<O.-_:@3#L/O*XR=*(T=DK@N]G'D9@YLESTG`@<YH4)P<#JAK$<-
M7ZLB(H>LW3+S@39B6>]?Z=/7B"IYB!,:4\*!7*85U?S+-^;[TM])&ZH!OI7@
MM2*@U^34&`P(94"CC=(]YPDMJN"B+M.RXSQ8[06J'>`TAN8EEW=Z<RW!(YY!
MZW+6-?*G;7\X,3_SK_B'W4?\?_=YQ?@G_P=02P,$%`````@`1H)51P#W3BZA
MHP``,@\(`!4`'`!B:6EB+3(P,34P.3,P7W!R92YX;6Q55`D``P/S)U8#\R=6
M=7@+``$$)0X```0Y`0``[%U;<]LXEG[?JOT/WLQSVK@21%?W3H&XS*0JZ623
M],R\L6@)MKDMDVY2<IS]]0M*HN+X(H(425TRU55I60(.S_G.!YR#*W_YZ_W-
M[.S.%F6:9[^^@C^!5V<VF^33-+OZ]=7OGUZ+3_+-FU=__>___(]?_NOUZW]%
M']^>J7RRN+'9_$P6-IG;Z=F7='Y]]L^I+?\XNRSRF[-_YL4?Z5WR^O6ZUMGJ
MTRS-_KA(2GMV7Z8_EY-K>Y.\S2?)?/GDZ_G\]N?S\R]?OOQT?U',?LJ+JW,$
M`#[?U'JQ1/77Z[K8Z^JKUQ"]QO"G^W+ZZLS9EY4>\M<E?[ZOOOBN_!>\+`TY
MY^?+7S=%R_2Y@DXL//_7N[>?EB:^3K-RGF03^\IA<';V2Y'/[$=[>5;]__>/
M;[X3<)'F5S9+IW;RTR2_.:^*G(N)0WLQJX!^/[^VA<QO;@M[;;,RO;-OG*MN
M[-N\+#V+.=4K"WZ^+NSEKZ\NTO3"`08IX!A4</UEF*?-O][:7U^5Z<WMS.%\
M?@A`*#M/TMG(>#QZZ.'"`O>""SQ@8#XG%S,[,EV^?V9/H/RY2,NTZG/+AY^;
M#=M>;U#EO-NJ5_4Q5/5H/W[UQU#VL[V?+Y+9CBH_DC*HXKZ-T:=V+XK*?#9+
M+O+")3-W5F2K5OW1SI;)37F=WC8JZR]A)(5;E?!OI(,_^&#@T8YQ\Z_O[/PZ
MG[[)[FPYKY+F,7'RTZ`GP&YNTI5XIXK,L[D;0+B!A/6WUU/`H.JFS;V*1]6A
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MO`OZ]L3#/WE<@/SZ^([B>C'E0Y'?VF+^]<,L62T!_KE(;ZLGOOA#DS7=)>[)
M(,\FN;/@_9KGV0+[DK\G8_T:W*YR>S'NHRUMX;(/DQ<J+2?Y8K5G3LQF^9=J
MCU:C%=X"QE'7LQFUE3.J\HVCTM:"QE'?C_8MQ?2B^G(O0I24U4ZMKU[K1B_7
M&$@A3^(V5AQ6O49J-M<<5L'&58'FFL,JZ!D!?>L/I*Q?4VZJUX]RBXO2_KEP
MTG4U"5$^_KM12<_ZHRCKV\K;B>E)]9N;I/CZ_O)3>I6EE^FD2CXFR_XYS:X^
MN%&!S]F"=E)&5-ROE+=_!GODP4'2K^>[/;,U*`\/R/,5)IF]JD:U;Y,+^ZCW
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MKQQ2[I=+6Q3KR+CETIHEC>=/^IRDF#QI`-]77)<XOUV>N7H]N4YGFU-*U=T]
M(W,B'Q1Z9^RFOSA_W&$<6C?R;";[P_4F1".LD4*:4TDT"PC':NE@(1D5".^G
M-]FLX2Q'Z%O,_KY@'`&G><2!"9B.`F,$EN'&&L#XOWL*;W_G/0+]H%\8GC*K
M`SL5'GE6S3Z(^[3T8=!S]6)H7%\JM9(F"KB2D!D*:SLA#H/3(517![_$DQ[@
M'(,VC]14^4V29EOH\FSY6+J8:T()L`3,60<,7X=)9Q<!+#Q!FNSFW[Q_5,=@
MRX->U_6LOV>%36;I_]D'E[W\S2E>=;SO[,V%+?P"MI>H.,(F1$)K18PVG+@4
MC],U&F$0870Z'-N1#?FH0(]/NUI=XX!3MDROLF464/S/PAEV^37-KNK;//YN
MIU>V+16[B8\IQ-R-/0@+,)1$(1FMAR`.-2Y5URX0_5CT'`7\D2FK[&6:V6ED
M,_=A7FT3*<7T?Q>KMM>&G!Z"XD@0UWPAY`0(B+"17&\:+Z:H*PWQ#T3#_F$>
MF7"?"Z?RZEJV;D3;(B".`A%"%N&0:Z`E(8)L4AP7'737,$Q^((+U!^_(Q-HV
MTG[KVLP;EQIO&VNV%14+!A7@RE!%W"@=8N@`J=$(->Q*M@,,JCT-/P=&^(#X
M5L_L]#<G&`L3\0`B!(W+<J42.!)!C45$(#B=$<9P-.G&QXXN&(..V]2.[&5>
MV(]V,DO*<KD]8GD5J@<U=Y`:1P@AURU@YB*"#A"*".4U1HAI<3J=XF@T'<\=
M8U#VL:[58,H#2KDH*J>L]D-X<+C/Q\0"0Q?OB(&5O\(08!1N4"1&-Z[#',^X
M9312[]$_^^Z8=^R!-U8#``0*J`BQ<0%)5`U;;H9Y,&*G,]@YB*ZV(^['N.S^
M:)O*#[?NSI$4BC$:2!8`$2!'I0`;K!&2'#"UIUT\7=?=-02&`:R(B8QPC2_`
M#*VM$4R!$UK_&MS?V]?=VP%]O.ON-`)<:@1#J2(*M*"$D=I.(R-Y.H3JZN!6
MZ^[MX#RB=7=*M8F@Y"P*B0O'@69T8Y=BITB3W?SKM^[>"M537W=7KJ\VFJM0
M(@>*5MH(5:.A"*.GP[$=V;#KNGL[H/^][KY"C6.(.4.!1(!0:)@D8(,:("PZ
MG=FP(>DY"OC[F/MZOW")J$?2VI"M[2+6Y30H(*'!0&F%8!2:B,D:)4)9XUCG
M>"C:4S(W(MJ'S,G&I'`WP3'CE'%#:!"Y5DR98"%A&Z1XT)67!QC9QR%43RSN
MY)U#YG%C(K";X-CPD!+G&8T)4RH*=<ATC500J1/*4,>B5$],[N2??3#YVS8<
M7]-\MKOT^)0XE!P$3!L3&AT%TB5Y:..Z*)1=T]P#7!\;*(<8#_PQ"/Q;GE6W
MCB75-0PK;?7];?6FN"UT?+%.;`@.(P0IY2$C#)(`F4V$"V1PPAWH**S(A_'#
M&#S;7$:_5G&]*78+RUZH$2LM`05,"!%PP"()M<2U;5*@$]JU<@@<Z\<+HZR?
M)#-;?K1W-EO8ZN[S:NEHV[+),\5CJ1A`6"H:HC#DBD(2AK554'0^&G2`P?$0
MN-6#"T8)D7;^],Z,Y\+BPW*QPA(CBJF,`,:(0*K"8#.CA577/:`'N./C$*BT
M"_9'M>OCN9OV?K@]'RRD`0&*5&<F,'+C31ZM+],@A@.\KST?DVL[7<RL'^5K
M7_I<[+*CY#@(*<=!%"*C2>A&SP$TJ,8K1/2$5G<'9]3C$#:J9PYY;LZ;S/T\
M(*8XH`J%'"I-$.50,R1KY#`R)W2B9VQ.[\5!@P?A/Q=IF2XWW#_\O)=`&BW*
MM'J3F,/P(LU6IP`\HN6V:K%TO8@T41C`4$J("*9J==XE"AC`K+$Y#&/I.UM<
MN?;Q'?K95*7E;;[^L[H+?)97KX\M?3J/;@+C*(B$UD@@C4C$E.1"P1H=$I@3
MVE;9#TGR/:"^IQY@G[>7#=$1*&VXD%P#)"F(!#+5',VRVPVUD<&^[B';Y$FU
M\@]]$'U]\%?CCNF6HN*`8JZ@X=SQ4!/,6:!8C0@(Q(_2^+V)\6**.PC>8^2T
MSRC>L$WGA1HQI=2!*$*NM3,G-(&1&]M$P,GI<&DXM^=#0+TO&E4?"]N\PZ:Q
M;LP%-R)0(`)0*0H5)9K7]KIP?4)K9SM[W(-!NV"[G4M/K\"OOHEEGMU5:5(V
ML1^ND^(FF=C%W(V@9B]O7_6J%^,`*2!!$`*LC28J"-<WQ/#0*$9/Z#*!'OV8
M#X?PGGH:GWTBVZK%QF7@C"M..28JI,(0;6HK802[7OY\@!,F^PQ=7?$>@U6;
MM_7DZV95ZV_+OQ7;U[::JL:A,=+]!["`DJHPA%@&M;7.\!-*C/IQ>CXHOF.P
MR21I\8]DMK#O;%(-_"O]_YG.KW_/\HOJ56^KEQG?+N;E1SO)LTDZ2Y?>=7\M
MBB+-KJ*D3,NW:7+A?IE__;`H)M=):;>Q<*A'QB!$D4;5/QPQ+@E!*JK1#3CN
M>CS_`/O&0=A[('X9,S(_&&)7+\]-I\M]6"Z@5%>RK3P./2*UCYA8,H9)J`-:
M[6`T%&(M-FX)`]!U^:[]KI0GKUXY"G8.B/5^YRSW<_7#$).6RSVX/&"JNJC+
M.8"&:GV9OG,T8XVYZ>E-6D(AC0H%=F/B0"`E$&>D1@08?(*S`;L18]=)RW9X
M']>DI9(!)@$3D20&"T&C8+WLXVPC1JK3X=)P;O><M&P']?%/6D(&L(O'3$<$
M,X$$!_7E32J$A)_XY%0KC[>>M&R'[6%-6AJ)*,`&:JQ=ZPHBJL"F72%)3W#-
MK0<_MIJT;(?PL4Y:!E`"J5P*SKCKFB6'$6"UE3@\J1/O>PQ=7?'>TX"[FD2X
MRI97H$P=LNEE6@$BRM+.RW7;FXIL6L\GI+9TORUNJAM3IM65_.G<ODWOJC_G
M27:5;NJV&[T,I47,*3'"C6BQ<ET&=$->:M:O!%"<&?BC3*5Z4[%YN'\@KCJ^
MYE*;.U[3V#PQ)J%$H:)2$A5P08T(0#WTXYS3$[J/YPB:05>WC$'YZNC8EW0V
MV\+1NDAL#%(8$\*EH%B"4!/%:^TQYR=TP&\04G7$\=@Z/K5VY>?D_L&/O^79
M9'6E]4B]89,:<2`,`,YS0%(-..`F7,^(5^$G(EW?TNI_QK#I[?1'0>H#=MFQ
M-9QOAHZ:43]^;$Q<>#(D%()!8`*).0Y@C;+20=?U7/J#=/,'Y)NC:P%;+QWH
M^4EQY`;_6G)2729&J_D?$NH:RQ""KG=A!$>V,GP0/&_MCOTN'E?'=!;)['N5
MCG@)V4!,W'A$!$0J'@FN0@,9#$.LH8J"YLS^]):0@6L%BM"08"ZDCF`4`%PC
M@I71IS>/M!LQ=EU";H?W<2TA(\4E001%`$D=`@6HDK5M@+(3XM)P;O=<0FX'
M]?$O(4=,TL@%\``"AB0ED.FHMI<A%IP.M7;V>.LEY';8'M82,F%,!H&N+H!2
M"`8`(JUKW2F)NIY7.!)>=/1CJR7D=@B/<D*AR*>+R?Q]\<D6=^FDZ3+UYXK'
MD$<TY"CD3$21T6%$)-]8%8D3VLL]6JCJ`><1V5/=3;!6M&R,3R_6B:500$(<
MA0P'`77MA%5#R358N//8^@#[G]W<^SQ7=@:T4S#ZF-PG\R*]<HUA>_1Y4C"&
M*J3&0"4$8-7%P`$A:*V=5ER<4!K2@X?R'J'LY.C?[*+(;Y/Y=3JY=9JGV;1^
MG>YVOS?5BX4*2"@(P$H`)(0VV@0;W0WJNG'M`*-'SS3H&=ECW;!F&`LEI8H$
M4@H.<0@9K:W44=AUW_X!+C#O<Z#<%>]C/V4K6<"`"J#BRID,D$O2Y<9:B4YH
M&J8?I[<]9=L.WTZ1ZT,^K]85DIE9S!>%?9?.;#G/,UOK)O.;FW1Y>^[G_/-U
M6DP_),7\J[B]+?+[]":9V]G7EX);#Z)CI(54S$@8&19QIAC;S$5HJ:*NFP\/
M,/[URK`]X?_O<][MSA,K@:1+2V6$$$$@#(T$&[>2`'<]KG*`T7F0_O-`_+*_
M<][5FS:<S=\='Q9%D;AO5RW\NOKX)A,W^2*;O[]\H<H&@?9'Q'O7P&7[J!K@
M$T`))Q#Q$.DZ+7,Y.NTZ7W:`%]4/TB8.TTUC[KO]8(LTG[[))H7K%:RRJ_][
M[,9]OF(<`I=\:3<FI(@1PX6@O%ZPU2CH?!':L6W>ZDK(7M$=-<%8A8[J*MFJ
M47QT"9%/CO"T5FQ"`ETFKQR`;K3IT*-@,]7`7(@9;5O4<3*H/V@/-U)_K#Z]
MOWR_F%=7EY=+<_^>7EWW'I!?>E`,(Q5%$`2J.D)!(<9AM&F(VI"N$\[L!R'I
M7KUQ;+M2C^/@(PDBJ2$14;7"C15A4M?SSAJ0SA<UAS]NBS@05^UII^L>WY4T
MR"L>&*$!4`I4)[VC"%,-Z/HZ?>+"<&-6L_\=KJU>=>0O+L82489QQ'6H:""`
MQ(&LD4&:G^!6H=T(LL-.UXZ8CQ$POYGQM-MSW5QSI]?A?5R]/"G&E`M-2,!"
M"`/C>OL0LQI+!6#7<WP'/.D^$'_WX8Z!@YO,9XZ!>97*WEFG_?+M2Q_M;(7=
M=7J[GP#WOKA*'-";VQ3S63I=\2^;?GA@[OM+X_R<3=)DMGD?MT\D[$5^#(7@
M#%%L!)01D<P(M#J0PZD.--[3O8+?N_3;Z.3;2W1\.J$64F*B0PJ-I&ZH+AF.
MA.+UK994HR#J>I="ZP!Y9XN+?.`N9F3FY&-Y9>_]3*L2>WZSTG%T3]*$*%2"
M$,@B@KDF&E."C19`HRA$C1?[#IU'O43F:L]8=:[WA9^7%^HZ^S9C,*]4JJ^'
MQ:XQ*:X$-08`!KG`@ID:5:3,">WD')F%+Z9=>W+=L9Q(X)A6)]PCJ"&!D@?4
M8%!;)2CJNL)Z@(3<)R5\SBRT\\3QG5G@S@8@#<1"TX@`()"2M7TNIS@AINWF
M7N\S"^T`[;0A\*U-IK=%?E4D-PV;UY^6C'$H-6,`*\BA@$`&TO7?:_TT,J,E
M]OO<KO[_[%U9=]NXDOY)@WUYQ-HW<]*=G([[ON(H-F-KQI9\M*23^?53E$W:
ML2V)@DB(5M]^Z-@R0`%??02J@%HZRVC>)Y99LMY<I8(1]+.;P+<T3\9'Z^J;
MJL#!.H$!:F2;D?JH<Q-ZC_"\J&>I]P-HB7WA`K[IT[=G.^,>Q>/-]DD:)A0"
MQ<Z;.D^P#2S2EM)X?U7H]T.4$6D>?8BB!,5>8S-Y&XZMBU3FDY*DWCNDK5!&
M$\_JR@[MZR:M.*."!$=R85X2YZP=[??I:KG^.EW>3"\F,T#R(=+<S1?WC\=`
MNW>XCMU3T$AJ5)<]"Y%3BS$CK%V@/=E;U?K],&8P&<\'ASV+0.:W"[>;(T\M
MDF&*,59O](C90+F!D37C42R[DLD(][,B-,A&-DO27_ZNKH!RGQ;W-Y.9G<Z_
M3U>+]=UNV>_JD_#&D164/Q<LB0PQ'5IS#_Z0&PTWPFB.(FSH$>L2ZDL/>E[K
M<Y5QS9;S-<E&RUU=S#!(7_M>.^Q;E3)R>T;IIT>DCY]0@B7>@S^!$O`]-S`;
M7WVO;N?W]>C#C_MJMJS"C\O;]=5T=MWX/WR8@4E]N?'`6.ZZX#KBJ0D08BB@
M&+CR4G*&Z\WE$2--U!E=P)R&6O-3B>H<`YX=01K,,>V\9M*"GLM\<^I'5;"Y
M:7Y&J%*>E*PGDE<68_^Z!_!FJ[MF>/</P]O&PBW-D_.@?V%'F3`,!U['ZS4G
ME#0ZE&NLC'"S/SVS^I%!WOKV&,4\_W8)](6IK-[VV]K>.+$HJ>`L1JU\$(`_
MD:0991V7DLF4$8;@GIXI?4B@S,4PD'AZ];B--^Y6>^-U=G5+B!!5YQFUW"HB
M!3/4FV:6V&97TQMA9.TH%+,>95&"<1^GE_4X:[UP%\.>-TL.1AT(`DP06&-"
M1`I3>9P%-R$W\F*$D;:C8-01V.?E4WPT+2:SJZLGTV+Y>!.[;9/;W2MIA!GG
M1'HEHJ`$.^X98PAC"78(+,.9G!EAX.OI=[M>19&G'BVJN^D:-MH*[,_5S^GL
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MF+.FV?'`%_&">5FQY_#%K.LC4C`68V.LA54[*FH9H:UM(TEV%LD1>L<4(-U`
MJ&=I7IU?@-\G/Z9WZ[MMZM>ASTE64JZP5["@@U6$G#9<M.`QEZN#'>P=\\X7
MLA+@EUC,/LSJI.,?Y\ME!/@.7\DZ]4_UD0]5RF#LD.,AQLB;@Q^E",UU:!^A
M>TV!96P(R/^904%8$!QY)++.LJ((%O!+@Y&7V9Z"(W3>*4#+<H(XO?^.C0Q&
M260(Q.B`:-2^R<0)6,4S\M\9>@OM#>0>M;!E3=K+574%%/TV77VY`:0.T[_>
M>D**E''JN+$A@`K@'47:M2LRSR[TA]$_CS6#H5YB']RX;7V9`-O_A'5RMJ[^
MJ'8Z.+W1/''A70C:(8&HD%YQ^;2[UU9R+I=&>*=88.OJ`>+!G0.;*,3:<;(M
M*E2G'CNA;]^V44VKY5-NZ0X^?`<])^DZ(ZS$W&)DI%)(1XUII`'DC0G8[*?V
MU=M;L&)+3:CNSGQ'?4/"7EJD9/2&!LQ!UXJ*MO@)?T:520;B57ZIDA[EDJ7O
MN/7=^G;C/KQ9[3[6>OH6'[V=[1/;%(.B1L$JR9FEH+FW8[56G%$ZA>+2G?>/
M?V]<V>I#MZ=',@9)&6';K%/_@/*.@O?->`5LJ>^?+SW):Y_TL_#,DG^<KQ=?
MI[>W>_/EO6J8,/-.^SJ;H,%!8JP"=<WH`@NYQWWO0=J'RF?>(Y!Y8H;A=Q/S
MRX;)\(`%KC5M2XR,A`AIVR7-TS,H$36,F(\$,L^Y=?JCDY1?MDO!6RV`=U)2
MQ`.-VEG0BI0(1'D4Q1DDM!M$R$?BF'>:-;F\>3I/^S2K[,,(_KJ_F%_\#0C\
MM%TH<.!C$N+">(VY(MX&$RD2SC3X8*9R$\B-*%/((`P9%N8L`CT-8C=#7K9+
M'#:G0"*,(PC/L++>M@"`QIN[X8_(36$0"AR)8Y:,+^"OW:3\NF5B3#DDB(M$
M$R:#84JUX[/"Y;H$CRBUQB!R/AK)$L?2;YBW>\+WMO1(5!$3"<5&41V515;B
M1ITA-I`SRHA\JL.!?B5P*G8]7`7O#\S;VS<Q['6=\@'`HXIR@(PW^)'(^1D=
M1QTM\0X,.@;;/!MT?3>YK].]F^L]-NC+A@DC9SPWQD0L!75,U5G3'D?'=<@U
M3]Z)Y#,E->\1TB(>MST4O&-,$&T85W7"#V8D-EXTL]+8\_=OQXYE4^H!_H*D
MZJG*7:COG;6(6'!-8Q0:H_;=`TWQW*O<=19OYRIWAP&:9PI5E]\VG-]C!_W:
M+.'@A1$(UE<9A/7$6H>:D3GBSZCN2P_2F?<&Y(FTU"U+Y,<.$=P93TO,*2ZD
MQ%$%CE",2(46$QN5>O^':6/9IH:7SDF"D9II5<O?%O/E04%(+[HFX5F,EG@P
M)EQP,$7EVD4]X/V.-N]GH1N4"_NBD(Z#O>2RZ.9W7Z>SR0YXGF?X^[/^Z=.W
M3^M5':^P_/?D=EW]:WI]TV'%[.>+$@O,*NN4LQ09%T+@MA41=[;8!66)6*>2
M%#ZIF'IS9CG$C25QXQ'G!,:E#(N>>O]D%`M%SZAP0@DB]87SB;QNI]4_R=^6
MF!B4-)B+*(1!(8HH-X[0%FO%[=[$9R?$X@($8V_?KGV1]Z`$AH_&/"*DK?.$
M6-`Y68.&<.B,<F4.Q))7E=`&A/]TZ\.N:3UX[.-_T!+"$-68:6:Q$QII@C8U
MTD%J1I-(R-[3L6&P^#B?75]4B[NF_,JS4D][7/'W](3]$.%H8^2UVZ</MCX<
M:><;SZO:W"`\>%ECHE>\2YA,;=;@WZKY]6)R?S.]G&QSM=_;)[DZZPYHQXH&
MKQ2#GVP[/WU6I\N]2?IED$9/V!;A3G7]<J1[;R:V]DG8Z8#K@%EC$')!$<;;
M=TYI?$:G.#W(^"5K>D*U.VN6H%]<S[__U^5\/5LM?M:DH<TO-5_H,[X\?IS<
MO]X@QM,?$Y=!1RNY\$1RL*^=#.U897!GX([?H[SF1\)78H'8ODAVN9;HT#LA
MF*_"6E.G;5U-V^C8SMD1E;OAC-"%:Z@-IW^4BS!K,KO:11WX<S)4HSJEC`W1
M>R<(42(^O4H\UY-BA,M)KS)\R8_#H1S<F@7[<[:LKIX*8U17=G([F5U67VZJ
M:K7\:S997TWATY.8KNWV_JPXQ^?YHR?4?HNU2_?DK'($2]@<;.#$!B.])X$0
MQB*5-.[-JS#,S!_*,W:8XZ\-DP^"12^B0HI8YI451#:S4;`9EGI3B^1ZZU6\
M\QYQ+;%N/PS0K1<U5)V)\J)]HDYJ@XQ7@2M!,/S$;3,O0WVQ0@4E^)(KTC>9
M<1R0)0CB)LLZ,U?]3YU&Y?OD=G-DLW*3Q>+G=':]N8W;==[7I7\2T@!^2G!L
MG#+<!&+;>5-<[G"\'(&R)?_R&'P`?(LL/-\GT]M:48[S30:=+]7E>@&+;M4@
MLVL1VM<W61%A;DQ9IJ-1Q@?F5#M?DLVG45[@]\NGOK$MPJ7+C=6]_+.ZK.`-
M@,'_4:TZT&A'MT2%5)P0+;U4RE&$D77-+'4DN>EN1YD>OF<&]0=KELN&7U=U
M?M._9I?/S)%-U8/&0V&;`\?^GDG":#WUA"JK,>8Z"M6,G]6NK:7<+-\/+89!
MML2R4J>*FX'X?N[.L_>\6>(41<4$X9$)Q>LRU%@WLR#1%LN[_G[XT0.,)<BP
M2?7WRXQW4.)UX^2]Y#XZ5[MHQKI>,#6\F5&=8CF3&*-,G]XO,8X&L[@=W=5^
M3MHJ[R055C!2%ZCP,;!VS2,LUVG_\/3F\]7D]AU1XA@43VO<U*7+C[!OGKHG
M!],-.(!E)S4#/8H:@MLETL;<,[H1FSC'G[GTCVNA@,/[:K'Z^?EV`N_.[*JV
M\S<YTG?K);NZ)1J=1L37QYJ$("F-DK&9);(^UT`>L7ES-'MZQ+.,]KJ:S*ZG
MP/:'^<,HVV3ZO\WG5W]/;]_R9#^D>P)=/7A.K+.12*PC=Y0VLV8VNSS'B*VA
MHUDT`*XEV-2!,>WH!3'.UUF(D#?6PF(J7*N=:9==\FS$-M#1K,C$KK#ATTEY
M>;-]`LM>(&L1#30B28FHU\EF?90FMPCZB,V?HSG1!Y#E3)^]-D^JS?@H53",
MQZ!@L-2WU!8\.[O3:(V=GJX(#\2MB+//=/)U>KM1G.L(_]7\\G]OYK<@C>5#
MI84.]\A='P$F(MB(-AILO3*`5PBQG;WU*-=$'J69,Z@KPD"(%^9;=T^%[9U2
ME%P0S*4(EE-I#?':MILLE]E%4,;(J?[%OIU7Q^%<@DF^^MKA8O!9JP3K,W-!
M!2VUP5XX%\'.:_9;4-+.E"O9HISW!64).EQ,?E3+SY.?]9G0?EJ\T3I9PRCL
MR,Q&%*Q15DIB'N?$C1*Y/JVCW)X&H,?QD);T+^C,E+<[P-:MHQ.&1$.Y%2$H
MTUY^<VUT;G3?*`_=!B!++Z@6,YE?`[#/:'[=(PG.I!5"@,ZGZEPN/-KF,)I;
M0.N<#M@&8$P_L)Y&Q3U(M4T4,<=$,`@1HY$S#+O0S$BI[/1?AR=2']RX'H`F
M1^-9,G:KUJAV<>-9LR0<%UAXS#V6E/O(.6ELQ3K3:ZX3V]BUDX$,G7QDRY@V
M#P(!E>H9%)V.;/=U39J(P&VH@QB%1"P&A$0S6\`R=W49N^(R#(]Z1OL4"DWW
MBX"W9XBH<<@Z8ZRBF'$.ZVRS4'/XM5BRRK/@4V\X%]9SNBDXB5E!#`S<"QV%
M"S*`#)HYX(!R(XK'K=D,?E1W(*Q%(HWV)TT[+)]0,O"?=2H*K(RAU&MLFVMT
M#BI_KKT]RDO'P<G3']!ETNB\!.##[-'+XO-\L1'H:K68?EVOZJ.$BWF]:,*4
M`'`8RO6'V:H"V7>Y9NCWBQ*-!#NE8-E&.'H058BM7BDHSC7X#[XD/0O*GE0V
MIV%Y%F/;&6(IJ15,*1O`^$76R/:F&@R=<%9AF*<BQUZ.9DJCC"?JHQ0WH]X7
M^OM&ZZ0<X5%+PV)D.BJI!6G5CB!(L:12IV'8X:)]Y8-Z+*2E-+GYK!-'7C9-
MWDD5*<."!RFYYHKY=C;&9!]DCO+(:@""'(EGD=NTMG;IY\GTZL/,3>ZG8%KM
MNDY[NT<*6"/%=;16!^T,\S#/EOGPZSD=2PW`E7Y@+70!^Y#SN[K:G'8`RT%"
M-]5L.?U>P;8]OZL^SI>U+_6G;Q>3'[MO9@]Y4L(\(*>=9`YT38>P4J'=UJW-
M#@,?Y4G5$!0;%.X2U/NS3KH\JZ["9#$#O6_Y;$:^^C:]G.Y2M?=W3C`[*Z-B
M4AE*O."@1K:F,\$F-Z!\E,[R`Q"L=X2+N!TMJLERO?C924-ZW3AI'C:!(%%1
M@PD56L?&0Z8NJY4;^M?]7$L_<&967==`OS?.'(WH:4S[@TQZL$=YI`XC#PH?
MTY3:R)I+)!$,S3W['*&W_0`,.1K/$@SY?3J;+S;'%@]'$3OX\;)I"EI&HD6(
M(6AB&/P?N78V+IY5@:.1'/0<*8/W<V@^^&%Y<E%Y>/^H582Z((7V[76#8`!C
M*;OO%&O;2`XI"\AM#)%,W>ZHW^R:$&).4N<\)0J#,2V=:"[?A7#9Y5[5^%A:
M\N*Z#ZR?,>O$^9`_;_"]J59UQOE?!WE&R9&U!4$H%8F!9<:`.*0PFVS5H%E+
M'D]4Q>?7LW20Q*?%9C97&Y/@<[7X<@/2Z7R_L>T!21AOK.-:22]@^=7:6-;,
M/G!R5A%$_=)AY^5'3W@7O@_)H%F'WDDI;;@D.!"[*:%&L;./<XY>X&)E%]X]
MQ_H'^Q2;30O1\M.W.C-PO)W_/9XD_.V(#MM?7G5+$F/*D`N$2N(-15X@([%2
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M*9*;<FV4*^.H>->+/$J&C#Z`=#'Y$7[4PZUL-:N^[71LV=,S>=AM;!!*\>@]
MH5A9WVX[8"2?5WK9,7&O7\$4BRVM+XP`H8=1/PYY!_VV]DF."5/GT,0^>&RD
M\1Y>N,?Y$8%SB=?=7Z^@:\RHB->72$I0#L97NP!5OGKX]QDBCSZP':R9[@])
MRDJF$%66&4^8-LP@U2!@X9]S\O$;%2D'D]%I6/JZLM)!_'S=/0E&1`B641DC
MQE[H^BCB<=8LR.$+?19<+H<@PUZ^'8WY:9C6%./9'7N]LU]B0O"`A=<JPIMK
M-$5/^BZR)O<<NKO]\2NW+@:O^GP2@N4C?K(U;+$&R?T_>]?6W#:NI/_1+NZ7
M1USGS*E)G,TD=6KW!:78=*(:1YK5928YOWX!2:0=6Q(IB(1H91^2.!8!`5]_
M!+H;C>Y.>2"Z-`_(6R4515P!J*"#V.AZUA%8E[N[GAX-=IT$.QOQ"VET21]]
M#D];(;>NG02&-"3>40($%`Y$?43"&@$J02[G1FEF7(1U/2%?@GO=O?*]G/,&
MR4@TW;T%5%"IE$$*U1Y+B;7//?$X.:M)@3SZ8[(E!I/0!3F:E(=E7S$)1SH+
M2G`KC37*<J^4,]H0VB""V57YHDO&)/2'>:&8A-NJNENF4K"I_IJ:W;V9K%()
MMN\W]X>+LQT/8,CI,2"D-?$2>:(A]A`CJ6V##417E>AD2.J\C'8H((XB5)U\
MW^T[ZO9_U]-%E4?/[KT$Z(0S-IIPAFEH1$19U>$A4CO8&LS6L[E\-90<3`07
MH6%=+KO:WIE/*.X^N3N%AT>Z"5XK09TG3&+$',<06U>CX)`:/JM&:;_-)=G8
MGR`N0L>#-3%/(>/!3H)A#//-6246`CE.K04U`@)G4W&49O8E6=B7!"["P8VK
M(,[@;IT0JEK+T77K(%C*+:/2,`B$I4Y1Z1HCC@*1>X'^]+RS5[W^]8%]2=9%
MI>&IDKL9_AZ@.M"O8T\!`4VL9!QH:@CVUDG8.%NE<+E7>T:9[.,"3!Q&#./R
MZ?3BRPG.D>1@C?`B:S'F#)O&\RJMS#W/&V%&D8(T'`S_"S)P=RNO'Z_BD<X"
MMH!X82'"P`ML%>"4-/::0%=5EJ*D5[$_S`MOS>^K/]>+VR^39151>KS)V6TW
M/M`X$!L7?L(1%%8Z!Z+6"QJO@$)L^)M1([&'>V'%X5VX'_A+N[%_72[7*:_#
MS?TFZGOY<7:7](?;.*FDSL[N]@>#)T-KV>10V4STYL_T05=G=^_?&[#R<6N1
M5!&1U&[N(^PUSHAD)U-]3?['01@^(J&5?CG>SE=-=<^.O'[:)&@K.'060YOL
M/LY-!+J>';$J=^4=863/A0AY!MHEN!2WA-W^<'/?D4N'F@0DE(**6.H\-Q`8
MCZ,*7;\IE.;F6<UU)5[5+MX3Z"4HY;[=5LOEA\FWW868S4GEWE5W#U!'>'=6
MO\$X:J5%`DLAF5%<BL>`.N!HKFG]>GR-0["RI$A*[ZQ/].:-Q^HTLI[84Y"&
M<2H,C2\Q\8`29JEJL.`L]VAZE'6T+K03]R^&<3F`>G'\!"$]!$1XZ!#`T#'H
M?'T:I2C/+@[R>ER00]!P,/R+I%9+!^:SN_1/.K3\:_*0WJ)WU6(ZOWL>57R$
M@Z=T$X1"2B!OA.%41Y@ADJQ&04->K'IIB?2S`S@=!\2ZB`9Y?U_=1D"B>O%E
M,OM<O8\0W<SV3^J8PGA"-P'%J<8W6CCLD$VU6`BJ?6`1^.RJ6:.\0#H(YP9$
M^W*KG(KK]F+Q/2[1K56VNK0/@&A$A1)QX@IBR+7ES;OF:/9ET)/5O#\W2T'D
MP6+U^I@V!-171#%G,08IW8Z46GFE*:]U%(58=D[LDQ6X+<7<;.C:)9<CV$E`
M/R'897*4OBP+-9ILI=OA;$H>OQCD:0E,N_04C+4(\FC9,>\<U3CJ\#O!$0.A
M;KW=-9BA]WCGZK@M]_A<(!)HPYBGV'DEL&*6ZWHN<6*Y?H.3;UD,[]8:3,HO
M;;5L?(LE\VDI\K:W8L0V$7Z']ZFG;PC,6F4L(H)`JI"QGMH:.PN9N=8;:8.R
M\S*RN32O#U\H>;R_VJ$R95]?$8BEC"BC&<9$,D,5=[!&3VJ8&[@\RKMMQ1EW
M`N,'%-JE*6^C^OS7)`4M+/]K/7F8WB?%4RW_4=U]KKI483V[[\"P2A?_H]IL
M-2+2&"4:O)#6N26@1KE\CYGD0TCKTNQ^EWZQR12[O9TPC_A5J^EBLX7N#A,W
M,3F]K>]G?&,P'%B*D'4>$""81D+3&EOB?:Z2G7M=[Z=]$\K)\-+O1]S/JNGG
MF5E';LQNOW]8Q$E%5+>3W_SO8<NFOEZ/_"\,S#FHF<&$`\DD)M0YT*P\UN;N
M$Z.LWSWFMZ.8""_]<IQ)]6;6&"GEL:6::`*)@P0J5<^:N?;:-KV%!`U^R#AF
MVF:*HXC#_N6(.W#O2*L`/7)Q&_+&20F0`4P_[D(&L^%O&OXTE.M/"A=FVIGU
M@,_L.5B,I*?2:H$)(LH#X9NW$BN2Z\3K?IST$^F^965U85[W7/>ZYV\*UB/@
M/<>2<\8$@("J1H:<T5S>C["T\(A97T!R8SZ7'57IXL*'M(0PXI5$%@"DI5$T
MFB?82>.U1U8K>IE#VCQG]!"G$DF/X3`E1J"">$<4]89!96J,C!2YVN0HCR$&
MXT\OQPVG2^/21O11K_)`1PL))6FQ!X2KJ)$X@:&.J[6M40(<Y$;VCO)480R<
M[5D@E]XNQQ"YM!U#,ZINA6SVM0@TY3*!`BJ(?=17``"0;<I<:X`]:Z\?-]2=
MT+^JV;I31I'GCP8@(??*&HTC<S&CTAM5SP@Q)J]I2SI;JB_N>)X%9HD=)>UZ
MR]TX?YG/[Y;'T_WO>SQ8IIE35$@%/(0<..-A/2MN[?`%<8J%K.4+]'FYP_-Q
M/,Z.3]/IIXW,@<1@(_'TF_`Q&5C-.OS/^72VJK-I[I%Z6Y.`"=1:6$ZH19L<
MAT;2>L3$D-R4T*/<^\^6?<]H%M,WGW+U^.JP[_'`(/,`:T@Q8-8Y;)SBNUD1
MS[)/$T>9<*JW]:$'),LDF]C.MX-"$:SWE"E(N.2.0:\,XLWHH56YAW,CO`'8
M&PLRL2OC!UZNEBGK[;9@91?5\E"3H"6"B@%$H8><*2F=JM4K(G%[^/YKVD7Z
M5C%[`K4496[N-]K.[_-'C`XPY<F305M,-99>:(:-)<8S(9J%#V:G<QVE#7*^
M0/<P)!_,,KO(LHK?DVYHV;CB/<PW:;1W`+AONQ.#.L7[K[--#HCE,DWLZ,:3
MW6M`,"*#H_8E)$5<$R1,@[77.M?H'>6*U#OAR@%?Q$"N-H=1OU2S:C%YB'-2
M=U^GLVG"*/G@VNMN=^L@Q'<22,1`W-J1,E93!W4]\PA!+N5&J2;W3KE!,"[!
M+O4UG8/^>R.UY`M=36:?IY\>VA/R'V\8B%/.<HHMBV\0T`XXUBB,\<?ABT"\
M9C;UBFT)%OG)=+&YPORFFBS7V^CI?TU77S[.YI^6U6)30OG7V9_K34GE34'`
MZ69R[]-QUR*^.'JRG"[K:J7??YE,9^FD87M8GY9H-UG,XF/'"%EL#,$BZ#6)
MQB]B'%F.B(TFT`Y_SFANALON49X%`YAZY_98Q70)F_4$6S5HQ+#FWE`(`848
MQIVCV3HHR?9BC3#.<Q`#Y`PLL_S<B9<WL^1`N[E_/_W\9>]>>N#)H`B-1K@R
M4(HX2TT(@;(>GQ;9D6(C3*';ES>B'R2+>+3KTK.=4C/L>3IHS`PT6`')*`'0
M6\!J+ST1GA6['3/\2M"WK^I\-(OD9YS/YC\.M-W&.]@F2,(,X]YQ*8P01`G;
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MY3#D]>]XV2`64?B?YH<[\]+:R7T%R[`A%D)F.&+(($D%;S9HB'))!<'U>AM*
M@5V<?%V)%0AD7F#-'9/(<Z.A(XU61XC,C;N$IX?<OKJEZ!P@2Q"B]I^_JQ:;
MPBL=`JL.-0E8RY07-_G=@5;$>($:N@O"<AV9<)1Q#'T3I2=4+\&9=$9S>P)A
M-L\'**W`4!I/&1?*:LNLK^?%.!F^9F=!LIPOW!:VY$!Z":K8Z</ZR;6K#F39
MM0@<<<:P,^E6&Z.26`^:N6$DKBH9[.!TR0.U!&'^5:6CG.I.19PGGZNWZZ^?
MJD5=C/-FO5JN)K--/%?[/G5J5X$+Q%+R0^*L$!Y"*I%H3$9$<XUR.,J@J+[W
MKX'1'A/WVO:[D_H)QE#@"'368&\U80I`LL.!229R#_A&N0\.1Y),-N:(X()4
MW*W;+Z9Q.AD/]10`$YXYG-QFSDM+(\Z@QB(EN2JUSP[O'[@T&7L2P<`WZA_O
M__\ZBSBL?_!_%[TVOW<D:G:74A'\4`//3I>W#_,4;M9!2SBCUZ2.4:!E5,:H
MA>GT@OIMS)ERT$C>FL9]-#A]B"+4<31_]`M4TVT@B@B!-2$4<^<0B\LKJY'B
M4A8K,U)BDRO"J/G%A'.)]<96J\GTX?^7G2U)K-4,"8>\1QY`R0T5VY+=5GCO
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MMUGAWE3)P#U"KCZZ#XQ@[JV6#F-/7'I]%:E1`YSFIG$8(1?/9,WSZX;EP2]!
M65M]6CVJ+RT;Z\N'`T/*,T8HQ8IY'TV@5%*OAI-F1\Z/T.\UPMWT;'F49]C;
MR=>J=1<]U"10*:6/`$&"*2!4>.E,/3M'R17I;N>(]BA+LM',NN'W>S6;SA=O
MYZMJZ>?KQ;N42>U_JL7<QW?C7;6X3>ORNOKP=_SW^_;O],G!G?#L/@,EDJ>:
MY"@NQ1A2KAG@]9R)0U>T_9TO]OEE0#^;:&E(:7P?_IX_'YJ?+TZE6/?>@B#<
M*D%MRO9EA(ZO)6^094+EUB<=X68X'+D&@_M<6J4!I8&]G<X.,+XSI[IV%:Q"
MWBFF*<,(*LV%$K:>(2<R-]AKA'><!R/40%@7R82P*RG7HI4_?2SXE"8,I=!I
MP26BCBC=*`G*M*>V?CV,&:$^?H8DNO-I6=W^Q^?Y7_]YN_NRQ"?2_"]QB3SA
M4OW[H!X>=L-+'NE#&OBQQT.*RO>.,&6-CR\E0E'_;-9;#5IK@[P>W2E/D//>
M,1R<%>[C^V,LB!\'K:7@SB`,/=9&<4$@JD<,F;V*M([]B.RY_$]';W!Y&V6/
MR3M^'"2"<9N-P\5".`1,G+!K?%2>YX9SCBIB>!AYGX[>X/+^1;\[)N_X<33.
M&,>6T:A=61@7-$!8L]DY9J]`8QA&VJ=C-[BT__GNOX]).WX<F!(2&`VI5#AJ
M-U9A4*]'D"M<+.7@:Y/VZ=@-K]%]/+J6QX_#YLJ#A=HQZEGDJ:(&UR,FPN:N
MY:>76GYETCX=NW(Y%IHCUMJ^:3$/C[0*'!AJ#4@I)(2%1F-/ZL,P:"7*#=89
MT6HP8FNQ/\%<D'RM9SE'VP4C;5Q(@7)""L$]PLK6;RA4R&???1T?`7N1=C<&
M96%;)*`KE4II#7-X\E3PJ1Q?-)D4DDQQ`EU<BYLMU^DKBISI29;[*EAE85F"
M#YOZ.0?SQ[42I4OS8+6*DP5I6:9("&T,K+TWD&%0S)Q]K0P:`.0R40<O@W/?
M3Y=_M$:X'&X6.(V:/Z$.19T0<6.``:*>I;`VU_\Y(FUZQ-I2CY(IR[^GL'2(
M?#G<+$":[JX;I90WD&*+'&@6<.S1546_]"'L@PPZ&]L2#/+S115?'??M]LMD
M]KD9<^NN>+1=H!(Z`)DV"".C$5+2R6:EMCX[)]&8O+O]"OSY#8P>X<T*2:C3
M9,7=N(I-_CBL4!][/&`-+(%*VSA0&-=BQT!C<S":G9QJA'I1KS3H$=,R5OMV
MI._C2'__>_)GZ^JQOT%(]BB"5@`")"($<:";-=<BG;OUC.B08-!%HQ=42_!E
MGX[7HC(?:A(LPE`2B8"WSAH3%T4-'BT.DILS\?34TS^CNMR35"[%N59%^7"C
M(+C@FFENE7$I:`P0[YJWBL)BE^:'Y]WY0N[`FBQ4BWF/MF<^JVW1KVX>HSU-
M@H)*4,&]`X13C2GQJ`[^@T#1*S*M^A#Q/A?1^:@6X\R3?-?=&/.B0?!1#>`<
M0TX1H=!+YFVCYV,%BJ75>[U\.1?30O<Y%^LHB5T=M6FW.YI[FT3;@$D?]45%
M`4<Z+LJ\>1>0!=<4RCT`8WI"M>29QC:68'4*=]J:!FZ493`NHXQBBJ/I@9MX
M!J0-SK791WA</]2JTQ^Z);CTTBAHL<7V-PC6&P^,@H(1*)R$SK'Z#@5R./O@
MXN02+#^E)=:+3"[#ME8K[%"3H*$#1G(M0%3[.*#(HCK3`_($7%$6H'/%V\J6
M+$3+'''5>0_4<C?LQ].:ULVN0^L@*736.^\M45X":JVM`RY1U`BO*L?K^8)_
M<=S5-\`E2!4WZ+MFX*TDVO-T0`1#;[W2-.[>B!.C3#TG[CG*)<T(3;/>*7,^
MG&6/UI?-=O_;=%;]NJJ^=HOMV-,N*.NTA`PJ#KST5`#0G"IS[<GPI<5^9AVI
M3]&4I>#&W]6,^6VU.BF)Y<'6`7&-$6"*4J0$PT!)6QNV!F#8FJSR-6U]/4G_
M(*?Z0KDLLYH!W]P_FTHG:AUN'NPF\@\+!X04"BFI;'U,;9#(=D6-4#GOE0,'
M^=4;U",@6.T6^9Y/LJ:+P*E#P@KI/>.`2>]P$P]A&'=7%'M[0:+EPIT5?+0W
MYVU*B;V>/!S9^3JW#4A+ZB&U1E-MA8CVB%;U'`BAN?O>J&X?#[/O#85QV47I
MM_G?U>)]E<R8J&"^F:S6J:#V^Q1J!SLM2<<Z"-'Z\9(`"36`5AAM*:N-&4,9
M+I;!8DAV#<"#@PM2CV"7I=D_II^_G,>SHST$C`U+!Q4"0XLU]8#*.E#,Q`T@
M-\W<J):QDD3K$^W3+V9/-V?5B6=X]W-B&'["L.UOGPSX[3R)+F+P=;Z>[=L2
M6UH$")TBF'#"(.3"(H=Y?1IEA#>YT7,C.B\>CC_]8INE*'V<+:K)P_3?U5V=
M*KA:WLQVP>-U>J$G"D!4%'5U'S_^,/EV2($ZI\_`M7&><\J9=919K8BHWQ&K
MJ<F-<#KY[/AUKDBE\2^Q&[Z9?)M^77]]L:C>W!^>TK&],:N_$$T@'T&)B[;W
M&D&A8:,E1/,H._+NY$MUKY.7);&_U+7-9?VVO:]N'R;_Q]ZU;;>-*]E?POWR
MB.N<K.F.O3KIGC7S@J58M,UI6<R1Y)SV?/T`DBC9CB51$$E1ZO,2.PD)HG9M
M`%5`56$^+^_+8IP*K[\JR7YC/GV:+JIU;NK]?9$N7RENJUFBQ>>&6V;M?C)(
M88%F'"$JO>`LNN*T]O>M@3PW#GE`\>]]6H!G5<X0J%\]3-/2\VFZ$NK3M'@G
MEIJ.5_:-^^MN\CQ>8;*1?5K,HU;F*8/[M/'0:C]"8H1!W&L/)#`04N8W4Q`'
M.+=D\M&A29<]_0]99_V,G=?5@]]D6Z5R".-UX=_1P[Y+T9HW$K2E1"&J`.#*
M1`]"ZZTQES"X_,/B/CC;$=S]Y9Y43U%=C\5TOD0HC:PTWE8V_W9Q6AVF)V_@
MYOYC[ZZ%5H/P3"FAD4.26FR4)G0S*!DRN8=Z\N\UD?:G@3Y86J\`>YS45QA^
MKA9[8\;VQ=:T_*4@$;:"4>TPU,9"H>2F(I:-_^)R-^K!WXO.YU7+*XKW=N7M
M,@[IWS?>KFBC'!7`2J:`%5;%68A#M[JA6.K(J(.CJ!N<OMP]%N/G27%S_W9;
M=GYS_^HZ]ZW<M]6\7,ZT2]TVN7.[I2\$SPP1%!DO&9-04$U248<5?LZ!WK)"
MAW[]=F.>O:].=Q8]];'R;B7;ZYI]FF[*M=W<^W(ZFMZ5HTFT?*.E\93B,8]C
M>TO?"A)289&/9C?D$@++M4!K/`TR-I?W@SJ]'`;OSZ.Q`8R`';*M!_@F'*8%
M_A_[I:",]Y0;Q:!T5$-*C:,UELZSW"S+HT]>_Z;L[UA?71NEU=WJQL;IV$T7
MY>+ETW0Y6E-;1UJENT+P]GSA8`A>@W>#4,A``Z3`B"G!%4I0)CPU=`2+@U<$
M-(FH&!?EJLI]_.5]@?OX3V'5N]^*AS)U:G4AV`="[7HT2"X1DMPY'4507GG*
M\%J&R!5T0HAS%RY@JUJI6H7F^&"99JHU1<HGF7R*(^"O_RP^BC;>^6P@2G(#
M<)QP&`<8.0U$#86'R)\05GQYRCT-F_:UNRX#X^-R,9K\=S&:N>G8QNE\AX)W
M/1ZT4BD='\<YG4=K)F+C-W)@J$XH.'=).FX)GJX&L2\GQ<S$_CQ4L_U#^,V3
M`4"(C-0<.<X)(I2E>6?=>RO="74L+DFYIR/3OEYK85.:WPZ%OGXD`"R0IA9B
M"Q!))0LI5YO%!-#</']Z69H\`9+N5!C]Q+(:[Y]^/WPV8,^49,3*N)A$`U\!
M#38D9/;PMN'NP)5+5.HIV'2GW>V2X.._?'0TL^?I0"10*,K@%))`1/>)ZLWR
M(;G(G8#Y96KX-'2ZUO&*?\VU_.KYH)"6F*3L,HA87$$HQJ"6Q'.<FX8@+EG/
M^?BTKVD5NS5>=FTR>MBAW3?/!`!T\M\XA,`CBKQ,)\WK'CNM#CKGNX_Y+TFC
MIV#2F4=;/3U5TR^+ZN[/+X\1F_FK(XS][NV>%P.@)OIMDD$6(:(J"H3U9B[2
M//N"+'!9"F\=J8ZW`=UHEL*PYW&R6?;T+`?2[SO1X+1YURO1,3$:QAF120(\
M]T9[)-;H:BCTF8Z2WW>WR7'!SG>"=0X29R%G*?$6XR1R+2-1Z*KNQCA=T54W
ML/8\,&VQ&)63\P2,M#D^+?!$*B,CU-$?43[^L=K55<I8P`XF&W1]"*CB!#XN
M)\_IL.=+<9>24\IB_CK:.$7=/:^4>G/_$YO2@7^C,\`V/A0P1H[+=,TO(P)!
M()P5-9HD_[J+`59(.9U0.T_WSJ")/@ZV3Q1+OWS<P('*KAU^-3"48@:H]HX2
M*U("M>(UQD!:?CUL/Q<YWY>S'HPRSS=@TEGDP?JRAUX-V!'&E:=<$ZHY((@J
MM)FEHMU_/=0=!&<:\3A;/5F)]DMO\.;[,BPPN9U/WR?52U$L__GV>7;W.)H7
MMY/1=/\M:<>U$ARDA&@+K3)*61-71NAKN33V5Q48VIZ2J[X`SR+2U_*I^*.8
M+XKQ;^EJM_(N_K;LSN_3<L]%(8W?#8@Y9:C@$!BN&2&&4KN6P3J#<BMZ##*J
MLAO2=`!S%E5^'<W^+!9-R?'QT\%+85.J$%/>Q-X!R0BM^RD=R;6Z!AEFV`T=
M6@'V`ER&7QH4-V[K$P%;#KSVQ!C+N85040%K]`C4O<U2_W8&NM5<UL2G1_/R
M+B[7-O6W&!^Q@77,ZT%X(0E'0!#)M(]K/D.@EB3%4UR_>=6E^JO.-=+'G/JY
M6&Q3<QOLG'[X?``VW1F$11RCSJ=H*TM=+9<U)#O/=$A,ZT;1[Z\.:`'>WFG3
ME"[!6X&4XD9[R+55Q`&B-G(H?U47D9RHR7V\.!+'/OCP7T7Y\)C2G2.THX?B
M\W,R(6_N?SI>;C##'-M4\)I*J8GD3`NN-)!>;L::QZ"W\M@7/_ETC/R0>+B$
ML@42+ML)*,K*F:*($)KN[.#1:=J,1X=S&3C`[=/N*)+)Q1P%]%)*Z><MX@9%
M"G:^%`!5VCL4Q[-W4"M.A)>UA!'77%M^4)-<[R1K#>\^&!77_]DRG7,T60=P
M+?%0B\6L_!8=FY3*7ZT.*4;S8GP[>EF&D,UFJ;CSH<(SIS<>!$00H>BV1X@(
M<UI)NG&<D,L.J1RD<=<&<:HS:^!LR_':?/EY.(__]WEUE?6Q"_/A%@,P4C,,
M@>,>12T@[?QFBI`6YV;8'+\?5T4%7QHW^P']C/;A+EF.MQ!WM128L-Y2`24U
M47QI*#*DQ@)BEDO`XPO1=T[`<]N(+:F@YPC*,U;<:C.`D@/`.7+>1XRY(]1!
MOPH?EU''7!W<XNDZ@/*G@(ZW/G5&;:RC6@Q$*PH!]%!Z:`3&&"I<X^.T[^W2
MN+,&1S<FR<Z@R"Y![WK@__/YU;UP_0[TY:>;#.\W#X9H,B@'#"(4<*28MCPZ
MV\N)4Z,XJ1YT/CL:U.G$^K&:Q`$P7W7X<[4HMA5V&@WCIFT$[B2!/EI,'C@(
M.=3`TQH#3+,/=(<Y<#/5_WZX=@1N+P/TK!D-F>.4.^4(]HA+C@RR3@EGB'/>
M,B4]I0?W(1L>7Z=*Z-.[<E+6AZFK7KSQ5#]7T^5=Q]5DLBQ^NBI+O6\3K*VF
M`XNK"F0"$D"H9YY+@DF-@K'9)9PO8:0V)D!U5LS[\/1^+:?5;)DZN>KKGE'T
M_M$XX1$.C3/6:X/C!(=A%&<MC06DMZVL[\L<ZR^+T6S1W:E2K^I_?]_.:<CW
M'R#Q'I6[GU%I'#S1H*V@H]0.".4YCC\IE`[I&@_MV54$NYZ=A5VKI1>:?MC1
MY:;R:%ZD^"?]/"_3#22F>OI63M]44OR(JCGM!0TT)\1*`[%A1#FOD-S@XG1N
M@,?0;EL\*UE[4,PYUF=;;"6PJ=!B@G)9I'K'(/S'RK$X8EW/_420QE#`*-0T
MJHDPQ;CC-7H29:='-;_T4:YH/2T>TIT"7Z^7W6=26584[]L.E.L.E.N1.%[W
MO$I7H>QR=XYH(FBK*'18"&DM\@C!*&`MD1,TUQ1H?L/CU9.P8Y4,W>M1"'GA
M-/+&.FZQPE39M30*(G9"O;H<K\=-Q]?%KI9P[W/S:WU_SF7M@2&OA;$4">0,
MP`8A!@2G"EO,,78'SUG[&9>'"G%\^'P@&CG%)5<<.$$`(]#:6C;'<&_[$CW4
MT\A4ZH&QE@-C']/V'Z-9F;I6]W-9IZLLYOK%O+DE+<Y4RPI>!ZI<Y#07((P+
M&4>("Z>@0%0#ZVM4+,2]Y7!T3ZX365'U#G8?%'S?V0_%>CE8:N*89H)S)"Z9
M#'*'!$UGOQ+!&@6%\1553.F6)%5O.LASE(KG6?GT]#PM]F=XOW\N2&091AB:
MV)RP'@@`-@#H$ZHV#H\?W:BL:@_<<S@OOS1(V-[Y3C`$>`8)`M91`JRV7&_F
M<V5@?Q&?%[:>M87H]1_..,H%Q*E6KN%$,V@@V8Q#KT1O:3]]'#2WP(J33UV.
MP[L/_GU-FT'/LY=7M735771=HN;V,&W/6X$QBY445ANFD?2>0J)K&263N5O-
M%S!KG<ZH]G#M@SOK#(ZYKV:_%=_7M9IN[E\59]Y#H<,O!X@,C'XS-DYKAXC2
M3IK-_*\8RV32@,[BNF-2Z_!FV<VK39!WEUCO,IX_?#AH!YEAU&BD8;3W#-#2
MK7LIC*&YL5"#BA]H:<^H-13[F#Q^#JU<W<=0GP/7YV9'A;Y^W$10CE.,DH]`
MN''`&"-E+3V"-/?VBT&9.6TH_V#T:ROX]E)H:Y/"-?]:J?&X7-TJ?3LJ8^_-
MZ'NY&$V6Z^NW="26"NL4T_E*O].Q^ZN8W95INGQ=G'`/$3OX6M!00>2A,5C$
M/PDFF,*-TI3/Y>R`S*@.&'M^1?1![IMT=)LZ/RL>8_^7M^;6;DCT26[NOX[^
MVL/6)J\'']T1H!2`G`J#A$_A-[74A-C<@YKFME>O9_7MLK`#@(=;$8E9)`P%
M$,!H0A(>,1*HEL,9F4N4YI%%ESA/G0)A;\;9UF^XG54/L]&3>EX\1C?E_XJQ
M>JJ>IPMXR#8[W$*0T<2U4AK/%4#6*R@$WB#H&<VD3_.8H$ND3S?@GH]8OQ7I
M5*"</KS-M-X*]+72Q?:M?3M3[7P@P+13QR)FQA(D"<*<;#2CA,NMZWUT)-$E
M>@Q]H]^//_&A+;G7)_CPC2"CXVZ,`BEEGRKK,%'UAHZ`3N?N9_"KGO#:`;.7
MP+-S5D'(##BC5@K/@$J%'1%PS'%89\<Z[]%!$Z[=I,L/SDWF!XL:M/N!("44
M5L'(TSC]1&O,0V!J1&!$YQHVC$XE0T8"9NO(=SRB_:B<_3&:/!>_+H]EWM8@
MZW5H;WJRS3UO4HYOWVL!"*.Y]Q9$F`&/?\-4KFM*6&3!P=B4_B1M4@=A[WLA
M)>%S)AA'-HI,I`9P(ZNE/M?-&.2`;D?I57?PGF/4GK,80A>#UU*)E4+0"J(!
MU1H+L"X((Q6FAPNV=BRIFL^+1;K/YY=R]"VN"RE2<*V.\<WTMU38;98*:$W'
M<5F8U7]--7#FAP++6_M&\`9"RR0F*-UUQ;5P<H,A<>R*[@QKATJ[IH2>%=&'
MO[>13;]L?OU'6<SBMQ]??BE^%),#`>S-&@B*(NV`1<PK2S@S6NA:<HVHZNUD
MLD<*]L>677QM4R6]DO'U@O:S"`<CVX]J)\@X#6@6Y<?1)<`&02)\C0.GOK=R
M43U2LR5B[.)=![#W2K]/T^_/B_D2$+@S#K[!6T$:A:%QC&/.'"*8:$9K&9UE
M5W6M3T?:W\6QD]$^%Z-0%J/6;P4%!>8\NC7IQGI"@4^WOM6X"9#KWPTR2NQ\
MC,I#^UR,PEF,PO7MD2Z5^'34NR@:==QMK6*M'>VMVO%U,RH/[9X]@%>H^%GQ
MS^=B>G<H?[7!VX&).'*44(XP:3675.#-*!(`7D&$UR!M_Y;T<2[#?]/G+'/_
MW=M!.&<E9)XYCYR3*H[@S5BV`EU1RG2K#&A@X9^&]-G<RLT8;+YX[GD]&)UN
M<[.<6>^B":H0DJB6FH#KNE*E518T\2%/`[OG170Y]2^3A)LOG6_?"0@:P35(
M=Y@2SH4AS,&-D:!MKI$_P'R@02V8)VFA5Y:MT/H`GR4@OT^K;_-B]F.5E1Y-
MT+>GUJ\%;;ZVMOS)$)<?HB"5`DNBA#4@_:R7(*AZBSSH=4'.9=C^`XES*:67
M6B?5['LU&RT*6WQ;;.]).KAH[WTO2,.9XCKZ<!Y9;2&'9",GLOXZ]^7.1I;W
M-4]:5$T?%/S]2YVM'%>?_ZBBSJ;)*CE(P;WOA0B6)4))KY6GT33R:(.>85'V
MJ]S(&PH%VU1-+U&Y27`]NONS&!\Q!^YY*Q`M)9:6<ZIAE,EI!6H/T"C%<_WA
M8>_Z#85^[2GF#%9GEHW^2X/Z0*U^)\0U1%BM(142>4Z)(68SB!U7N3[4@-*U
M!NA#G4%S0QP!2X&."7S+:3=(I[Q!C$K@(2=>6H+P=J8`N17\+\&([8MA)_+\
M%'WU9E9LS[^V,7,-N'OPW6`X)I(Q0AU`TB"BF=RN9*8_#W^(_,QDQD=V1(LZ
MZ,6A'\T?(SSI1TJ>^#&:O#F#W<JPS[EOVD:P-II3@$J+L8$2$$0XV(QT@7.]
MK$%RL$4VO/?8.\*[ESGNQZB<).O&5[,OL>-;@WO?Y+;SI4`PC4N&4U`!F6QU
MBPC<KAW\BFI5=L>GUN#M@T"?IC^*=:F5XV:I_2\&QF7*^"7`04F<H$C"S5`!
M4.3N00[PD*<[(K4*<2^>1#4KRH>IB59`.BQ=WEH1`5@B=!R[CFPI>`RY`T(;
M#R1+]1&0MC46@LI<:^QH?_BR5\)N4=_/P!W9QK>3T70M<#6S:U6\KOC4C%?9
M;04GN2,8*LN,0!1YQK9K/@<09C+KZ,HFE\FLOG`_JS^9XT<&84%B.N4F2BF5
MP\3YS>Q-86Y>QJ!*D_1@:[6$;Q_\>>4SYVU*-&L@&$44$AY:2*.)@(VP=BNY
MS@[6NH2SMYYV)CI1Q!D-M'DMT$LK5MK>YH*AS#`;QSKF!'BEO."J1H48<U4;
MNVT3I9F]UB;^?;#R@WMBDRAQN$:(XV_S,FIX74-@+=@>4F:T%B"'%E-#K>72
M42DDY;5?;JF@N=[J`+<].F9D]^"??Z7.7J%#])4<`X@I$,<98\+@342<]9+D
MIHH<ORE2+4:32Z99JSB?L8[).R_F@@N9$(&P,-!#SP@!4D&M*'*(8L"X!>B@
M.].-I"D&[],T=O$YH7ZH),D'3T>&*HV=4=Q3@)!WTB%2RZ65O\;,FI/46[4-
M:1_S_=M>'DAL^/GAH`@@D&E$#-:$,DJ\P1MTC.ZM+%7W)#E)GWNYD0%D_]3X
M/'HJ#B85['HE.`7C^L:$M]!3PI#34-72*85SMQ('3Y/C5+N7)=EH9FT^?ZX6
MQ?QV]+*J?.AC#\;EW>C`W9%[W@D,0`BP@)@Z#(3&1%A9]QF;[-2G0?J^IRNN
MZ@;6+"I\B69=-5OVXDOYUVU53A>N?'A<?"E^%%-?_BANB]E=E-,^%U__%7^^
M+/^W**;[V7)BL\$[01"$QDN@X_H<?Z=B+;G0TN=NI@QRKZ]=0O6+_*F<^_JO
M:MG%S]&[?M^QU9^->=:TJ<#B@HX18>F\Q7M(B-=QQL:>(T93N9#K.<+OC%D=
M87TRF^*#Q;)CD?JQCQ_1O?ZS:DZLXUL-6C`D&#0$$8TX$!;`.',32#!T$J(K
MBF/OCF.=PWXJW7SU/%MV\'^*V9[NI?]I3+:CVPS"1)\5$!%G9^B1D1%<'F5&
M6D.'<'8EH`%=4=(YU;H&_62BI2ZE_J5Y]UW7?#4[EF+-6PMQQ4?0\514D$)C
M"37"13GC!&[-_[-WI<UMXUKV+V%?/F+M2E722269FII/+(U,VWJMB'Z2G.F\
M7S^`+-)+9)."2)"2NU/=[20B1)Q[`-Q[<9<PV=0&\4??YI\SN0:#.[^?X&.'
MA+!7GBB4P$(BPIES"LNP?I1J%$L*6:J78()W4<,YDU+1S,&4IY;L<;=++4\6
M2&A-`1!(26\$T8*`&CMAA<CF7\IO#";(^V4KMUZQS<VCCJ0I"-72D7#\XO!+
M(F\LDX]&JTL-.CL#=T&_##D2R/P'4$/AS@=0\T1!N66&\T!R[I!G$#,"ZKEQ
MF'SE-<GD^;Y)T@^F(]Y(O\AA.N,;:1H])RSHB,YX#(0#04E\:$$DA>:JU7TU
MS$R_S6_+J_ME^?FZ#I51\W_?+S:[OF@;_>O)[UX)G&F[Q>[I&PJF9*S50%F\
ML!%..<4:_)"FEU@X_B0:O>RA.(H8,E<#'*BD+C%4.N<UM\'25PP`;YLY$VDO
MJ*-+=I8D%-0]3AI9&3A805W"L9,0PZ#:*4"L(K!NGR>E9O*"&-@K`Q(*ZAZ'
M]%CLZKN@+A)&8Q,FZCCS!A$%98VH-%2W]OTZ)U.]5Q:D%-0]#NR<$>_MVWL7
M3V+":$4P:1C37##-&%466P-QC0D&-)6`$_0RCGW$#B^=]Y&C8:$5UFHE&0B'
MD:7$(U)CP@E)[;A]])9Y5ZX7U=6W[6R]'92W@_*FA[2-X^0QUL']WXOM[6^E
M#S?/:Q]^?5%(:S_#+_M&]IVLF9Z_LH!8>@F(#D`*"'T`5Z,:72%(MOTYAX*0
MD^D3$=@9+H<_@I[VL=IL/JSFR_NK\NK#RLW6J_"QC.OC]7<HA-3**^$#X@X(
M2SD,?U`K><JF5@#I[K66#PMF5=[,MN75]\'UFC->-;V)\0R7T;=RNUT^;T$_
M_+IY\J6%)`P+!2F+=16(!A#RQAH*1WEJJ$KWD+OG"^6?-=*WR-Z'.1#V!@88
M$!1[+CCV5%I88V*!2S4'C@[G>S`'W.IRB#R\-$:\W_Q>_KV]GRV?O\\9WW(&
M/1,88R"$!@"M'>;`$N>\Y<9&^^R?6\ZWO3J46"$MXI1B*!2E1E)<X^<@S%9"
M=>S\WJXT&NB6\S@Q9*GV=?6O^[KX8K7^L_P_-9]7][LI?%E7J_#C_&%C:;GO
M/&J<0EKFE5,FEBP0@C/),:UQH%Q?4+IY=N:\K!PVH%QR\/-[^*;/U^JJNHM8
MM-Y*'?IXH9TCW$N(D2!86J*<)O6L(-'97*H9BK0.(^VJ=Y!'W]H6P3*Y6Y;!
M(%_^ZLRNQ!$+*[F!1B!(PYM:IXC&O,9&2Y#M&G1X`IY&C6/VKM[@/H?*&P!1
M*)T23G!+/2'(.MFL5)],H`N^QDP]+T\&_]RJ=3``'&%,0<RL(X0:#7P].T_L
M95?KZ"S:KM4ZCD/SDDHT*(IPO`T*$[;$>H<8$?7,.8(7%$IVNO#[+-!P'.[G
M6*!!`,$`\5A8Y!F`"#GFZAD"*E*-Q0D>?H,Q:R"L+Z=`@XV-&J&1AEF!%':2
MBV;>UHE4$_&<BH"<S+'!8;^,`@T:"PJ)M00QBA`1@MC:&G*2DM2#\IQJ@9Q*
MM:%!/]\"#0(&-3:<^X1)HC")0JL=W`Y;GUH4_YRJ?YQ,KL'@'BGDNL7=\,H3
MA5'>X/B+*(60`$A@T\S-JU3#<()'XM@^AWXD,!:[XH_AY&_U0+0^6RBE.,<4
MA"DJ8I`U7,)ZOISYU/+T$S0A3Y9X!P:=@FW2`1A6Q,]R'=;&O/QR.UO_F,W+
M^^UB/EN^WN2^TW.%<TI:"P7&&FK-$16^087HY)WH3'B1*,=J.(3?1^I0V,F=
M@5P%S1$A3:0&6#1(R^2NL^0=G6(]8YSETC`V6/KPXVZV6$>]TH3E<O-VE]F#
M#Q2$6Z2<ELX(Z:&.%FY]M^HHNR1WZ*!R/]0'[52P1TNN#:\;0-E\6,6_>5AQ
MY?QVM?CW_=')-V^.54"(+?7*2@$$L,0:]8@'HRXU]GF"'M.<Y!M:#MEN#C>;
M^UE0!4RU>3,X_[?/%AA";YE41@*O+2-!26C,78]5OL8^%\6K4W'.?^/\814D
M4&ZV7V?;\MLVIC?L'26SF^Z5N-X:I/#&V_`JQ"MD@E(:P("HV=&UR];H^`*9
M-H0`)IJ+\6>UFN^:!KX5=W[2N(6VCG$*@Y8L&(`J:ANLQ@EAGUH^:I)]DW-2
M-:=4SC"];M2D;>0TY@@"!R2WV#.!7(.N%BSULG2"5:#'5B]'$%>2Z^]+M0UO
MNY@M_?TVO/JGQ3*<*]6J_#+[]:`E5S]^+':1G-^K[[>+]=67V7K[2]W=K:N_
M%S_"T;,\E#?7U]`%$QA+)ZS33BH=DPIQ[=)P@)!45PY_GX0=22Q9=^F'A193
MB&+`<=20NFRTOS]56$$@\AP(0VG0Y!DEH(YP<$KY5#^0>)_4ZQ_QB6JN9@BU
M=3]HX;`7C',(*`W*4?C!`D6<1]0H!C%.;1$BWS<GLPED),I&K>-FM?A/>?7A
M*F[]UXNHD>P\LIO])=656ET]Z5D<_BXVL/NPNBJO%ZO%MORX^!E_NYVM;A;-
ML\=Q?*BW**A"4@%$L1':4N'#S@&:""&47#,>@G]6Q31%.$9V_NZ&;?/\/<XX
M*]]Z8T5L:PH!EYJ9V)YF7P[!!<.[M:W9T%GYS<OOR?6,5'NY7'U^84'M9!3K
M)^CP>G^]`4VOWU-X:YCV05W16F%/((DP[K&DKKW"P5F62CV)5*_FZ.<71XXC
M^7%^9K9>_PKOO9MCG)[;;'<VU54S\\WGZ^?.WA1:]_`]A:)&6^"@<-`%!4=#
M2$"-(_8JVU7D!=`ZOSBRFMP=UNAOKK#GGK`N[![BZPK$H0-.A)V":XL1M$$]
MJE'5"*>FYTZRE<P@))^`5(96!X/R&UYRMGRR-D?1`S^L?I;[I/JX5<1M)*C<
ML1!;`/E!VV[7"KL/4@0"(`-`L&85X`@:BZE_D()@3/'6[+UA4#"SS6W\-[[V
MS]DR3B1,XM-L_5>YC<1ZG$B7325AM"+PTF`1"Q"%/=@RHP%5-2[`6W])^MX0
M=*ERBV"$#6)?S.U=[!,&::"959A8B<+&#8%[J(@J%?%2MCHEAU:ZU<\@BEW;
MQ&K];?:,4)UKN+6,43@KC1(TIJ1YS!P1>%]<.6`@$$]US$XP:'0(8KRJ./<+
M>PZE^-/L7]4ZUM+9*_2'\'D[JZOC"(7`L6``=Y`*@3!2-+8"W,\]:$G9W`XY
ML[QZXT.5`_.)\*TUOZOS&$4L4T&]B;4&--9:`*YL/?]@.K2Z#<^'<[TSXGC&
M)6&>F/^UOJO6LVT9W^3Q!?:77&TY8.W/%K&*%W%!/11$`D."C<E4/0<9\+LD
ME7D`R5;#XMTG9_ZL5J?0YN7C!>*.4X\,Q,Y(2L/K[YNXA)E8:%+#B2?IA1R'
M.2="GD2>/ZJ`YRHJD4?N-JT/%AHR3BPF`EJ$8B<L;7#]]BA=$Y^D1V]@PO0-
M=F]4Z;K)='FVD%0P!(VG6@GF#(.>JT>ZMU^%]I6P<*&$.1'O),Y\JM;;F]E-
M&:;W>7M;KG>WB7HV_ZN\.G*_.7ZD`E!C`"948R29YY)#T6R?3HC4N,%)YA4,
MS*?!T1^.75VWJ*3!"NZTBG7>)&*:2"\,?9PE$CK5]C\ZCO^]<.Q$`>1P!+S$
MI+4D]N$'"@",D8A[8S@0U$8-L'':.8)2K_V/CK@_;VKU"G+>&)77?6Q-3.&)
M+O/'V$1*O-5(2TN$A\IK[V6-`[5*I5ZE33#=?7@?YI#(9ZG?\>I;=[BN:G^X
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M'9"2A&J!#(;UC`A3%]2LLF<)5SU#FY\L)BA5-]5Z\9]9IVZ4[0\7G",//,+(
M,*0X4LY#L9^QC4$]ET.F4\3])G-ZP#4'DV*]G7(=-8\OL[MRW4J>@Y\OD*?0
M!WV*,LFT0HX!KNMY*9N/+WF34DX7\\MDE![`S4&:K^7=ODJ8NEF7#R4*6IGS
M^D.%H(KZH-,#0JBRU$(M&[SB_=0EA=D-2)_>$,X2.EZMRE\/>5;^?G75SI_#
M#Q1<(4N-4]8Q9!52P7)K9@:43[U8F6!MX0&9TPNV.5CS/'BTE3.'/EYHJX0`
M'@`-D`0QTA3:!B0%4V,T)QER-R!G>L`VBX)ST$;H$DS0\F2A<&P8!JF#0F+%
MN>&.U'/E4F<[M<[=XNH7YUR<>IHPO'U68J.#8ZS;``5TP"!M")`\K"8*+!:J
MGKEG[*)J^_3&@@/LZAWJ\4F63*Y"8.R@8YZS8%9(9Y##CZJ@HJEMD2=+JCZ%
M?Q2WCD1ZO!N&%S$,%WK#H!U`C'#)A29$,(!`?2/.,&*V];C.?;D8Y_-IMNTC
M"NWP4`5$QE-`)>>8@)@_`Q2N$0&4OM=2(IV)TOGBL1?\Q[WJ?CZ%6%]^L?J\
M*O^GG*V;(DP]<//PP`7S,A@5!F@.@ZTB!:>N$8EGR0V$)LG4X6B4R-=>9#)9
M]IX>P]%U\$)ZRSAP5E+.@T[@">8-8H#[5"_Y)-V<TV;Q*7*9$I/5=3#^PYR^
MWZZK^YO;V&$\3F_3YY;<^AV%8D)+*HUVFFE`%$3:UO@I(K*U=WN7O.Y;/.=`
M[[[W[$[?4PBE"91:(,:%#_]`+_@>1Q)#R2[);WPV-#]%1$GYMT>]<*<-N8]A
M"X(IE0Z&,PQ(I)&&RLEZYIYBGDC.2>9]#T[.$222D8MMNV=?0Q=06RA<T*QX
M[$M*#?**U@B$59K*R4GFB4^9DZ=(Y1R3XH@`"@KF&63.2V848K">(=(DM:SV
M\6W;1@RCSW9,'XGV&'QZ?E/];#7L*H,?P;*VH0J+(35"6<!EL"D##A:K&@T*
M6:J-?WS?MLOE7L\R&._>Y<72N-![%V(X@-XK18,R+BV65#_L#YK%&A2M`5K#
MH/!E7<W+\FKC`Z\CJ79%OW>4_?56VOH;D"2.6$C+'6!4024X!X&ZU(`:'Z5Q
M-M_VI+(_.I.F&D,(XRI%N_3)KT^R?M/4I-^'":JA@EBP,'5LI()$*=*@[K1*
M59PFZ:#.0,8!L9\0`V/Z;J*F?F"<@B-I#70$"N0\1\Q`0&L<F`+#5]#,F(@]
M'0XF@3^>YA1[<=S/EN]"?](<ZQB@BY!V0G$%[+[&MS)(<C"2_O2\75A]QMI=
M?=_-?+VXBQ)OB<QN?;Y0UCH8CF7-A`?<&JNUJ>?N&<I6\7UB!U)G2AP(V>X;
M]"3'Y>=8J75Q<[M=ES^CVKEN,E=F3>;*7;F>A_]7USM3=O9:S]^3QBNPDPX:
M:F)I`>N9DL[Q>J[&RM0(VPG&<`](KYPB2/23E^O93?EH"1SJ[_2Z)[S#PX5S
M$#('@.+(6:&<9X^8:253TZ\G>0<^-)6&0'P$7:5=?QD]\%8ME[NRLT__Z"CE
MY8T!@DVM,'12<0D$MTH&1=7NE4D`J&^M33?,[!]S60ZT,]_H7T]^U[VZ1[>A
M"DRU9@$3#QVG7!$%&6P0D21;P&W6TZ87BKQ:Y&,0Y+/DOV9KU14P!5RJL`-+
MRXGUX;^U40<@2KZ&G2#KAJ-%8L>NXZ"?".UZ[-CE--986$,P9M8`H;0Q]?PI
M\*DIDA.D7N^,2.[8=1SF2?KTMVULY'.SF#_9T]]N-/#Z$X4@7F@-K"8&.^,M
MAXS7[\M,<LGW\^3(L3*LAL`XQSYT8(/^V"$G^ZW'BE@H,FS@Q#`%B,,6"T":
MM17LRLLQYK,==#WBW==.\Z5:;Z^KY:(Z8J]IGBD(8]1IC3FFF(75P*UL-$Z/
M039E*(>=WH_P6K:85&A',,AW2^%]=,7FDG/*B.1>22`UT,K7-<R\AQ"VT3SW
MC6+37#WI'O&Q-7NL2F,]9<H;:1RF3))]RG50NTBR/W>2RWL(.G2^/4R%/(=N
MT:E<21?&'3=088P(X#*I+;1$(<@083426.;K)W,AY!L4_;Q5.C<FWG8LKA?E
ME?YEJM4.F/O9\ND57&=6GC)L$<YX;6A8IA)+(`0%AOL:)2GD1>7J9>!H1EGD
M*>SX&)(40T(^KYY,L#-!CQBE@%)28H(YBL)ZI9`XKYK3`S*;:OU/,JDN`Q^'
M@WY@??W#*OP8&T",IJ#OO]\N-O-EM;E?=ZGC]<93!26.(N*(YT))K93A^SP;
M98!W[1V_LLVSVYGS^F,%U@9A1(RE7"%*@DT)ZIM8H!W+YN7-LX9[D/AOATAO
MX.9;I?N;[`M9K-Q``RFSG%'K'2":HWW\=S!F)&+C+%9W?5W.MXN?9?/J7X,6
M$96+Q>I^L;KY?%>N=W+<[/_J:SFO5O/%<O&PEMHQZ>D;"J&PDQ%!KQ0G$'FG
M>8V?)^*BW&J]\.AEI]91Y)!#I3P\LQ>OO_5ED/=L^2TPX#XPX]>S#Q_-WZ-&
M+Y14QB('L0":8R2C'EYC)NUE5=G,SK-./!]27E/A>)Q,3$?Z&/BS/*#M)I+[
MM6$+!Q'0TA%`%++>,*)-LQ,YBEL]P.?DC#H'5O<DJ*G0V5?K<G&S>O8)NP@/
M1GDM'E,S$FG=-GRA!5<<62:<UC`8KU0:7*-&-1F^7^,_]!Y28%.A>?A#$ZBP
M.)AZD#90H;SDA',N&6&"0FP4V`=WD'!\N=2>S=U=7ADSW,Z!NLFBF0I)_ZRB
MS7T?/O:_R]+]?5>N-J4M`QGF>Q175_LJ";.6K*P!OJW0R$NL'1$"`:\-%1[Y
M&E/A;&IFQ"0K4YT#W8>57U*43Y?7_C1;W5_'*Y5UP-$^3.`@ET\<L>!40HX-
M)YIB;Q!VV#?S11RD-N$]NFK5\%%D8[$UKX2FO$OO$B,&V(]WXQ982\:#ED6-
M=S[8R];_/WM7MMTXCF1_"?ORB+6GSLG%)RN[9WI><%06[627+>9HR:6_?D#9
MI.VT)9$0"5&JKH>L7`@8<>,B$``B`O7S/H^KF2:I!QN]ZV#]Q_(.JZFI,'H[
M=C7_U^;Q?O%((O_:74""4(JDP,(X:17"&J@&%>9!:CF2WK6T_L/?011T.MJ^
M!>,@ER)!,QOW#,#1N)\E&A.E'6T0D)ZG.K=R>N7>IDG0`922_<KTM,5+AKXY
M)00X0R1'0"MFG(9>:\&IPA90#LR);D[;$3\0)&KE^N>A=-Z=;4(DD@"46,M\
M=#`A((+A1D;O^$7E[0Z@Z5WA#4?BFF/]B*.\*I9E-3^0>_OBNT"M]P!BIN+&
MU@%/'&6TD0,B?'`.G"$_TG59#8=D5D8<3(O]Y<M@@(>:.L:4IU))8C1PC2R`
MTU3W=8*L2-3A+B8DX9>)"W5![8@0/_CT\*MO@U486PD9L8)1C`BW3_8SSII4
M7W'*?.BKR=>,.`K#O)P0/3CQ^&WP2$$+)*2$2".I$5ZC5AXA4^^")IBR.CPG
MTC#,RPG9@Q./WT;[B9'4*LKB!>54:$-\*X^5J=[F!%^T'YX3:1CF209Z[3F]
MZY#QOK==,/5A(8(*0@BDTC3N>D$CI_`^M5KJ!.W'\)[GD,AF99#[,;LO%UN=
M716+V=TV<V0Q_VT1M5"LUNKZ>KDIYETXU:VG8+27]0./BBFCH(N3R\A'+)CV
MATN0GH_G,A`G=C%M%+QS<._OBV5Q7=TNZMRB*(<N%L7-_J"8'2V"!%9P#Y'D
MGA,,$$"TF:U,(9]:TO5,+-;Q7!H&UZ1K^JME];5:%7-;KF9W=]7WV>*ZT-$(
M_U";]9?J(8/-5\NKV<_Z>J!.&2^6W\KKW:4UDSL,%D"$ZLQSJ#`$L'[7PS32
MQ@F26NIEDN%_P_(H*_#YSM9/6MMCZ#-U++!V@B%,2!W;0)&DC]F?7D)R^&'V
M<>1\RL?O%E77N\A"_VZ#!AP:C)T'!D*L&&1&-TAAS5+WSY/,W1B$,3MK+(P.
M_NBV8%[\L2[F=<&CWYY^>\HTQ3K)NY=->+M!P)([2XR3<45G]>D&=@8[A1P5
MPC![,")M/.F>BBL=NEQ[X^L@@#5Q\:)"*F'B?/#>XD8N"?0%'9`?J]B]=?Q3
MP,RQ9[#%LOPV>S`IS5@_E:L_#URM[6L6J":("<:8U\0(A:+4K93,X@LJ*'J4
MCE_Q93!(\Q*GJ:-2%\T\>/^VKUEP"!&M#0<^^LH@R@:4;*1TP*:^RSA)X@RA
M[)T,.AK;/$=E#P<JM0OS^_?9UX.G\&\W"!A1[Z,S$['A2DMJH:#MA//)$;23
M9LTQ"GYU[C4`JEFJT<[NZBWP[U^*8ETG:&[UM7^9VM4D2"0AL"I*A9Q4&#@?
M7>)'Z32%V:K`G=<2-1"<IR++P<5I=Z,`O`/&$(F-J$OS&HC,DX327)"1.5[)
M'5B3A&H.WOSZ"L;!1>GM!L$)Z(@6];M_!"C"H`"M9%3X"]HV#:'>:@1,<[#E
MOXKY[3;K:57>+KHL2&\W"%(Q2QDW7D)JN(7<&]]()IS(5O#QO):C0<`\#4T.
M+D6[F@00IY17SDJ',<&:R/H5@D?IB#/9#E/'I\JQZCW(EB1$\^RM'\98S-7J
M<=C/7H0\M")U:!T8`\X80*PW6A(MM:.M=P\\N:#GAHY7^ZM=]M#PYJ'4<[M[
M\'3OUX\#\752N8S;2PI`C97RKD4K_56TWB5@SVN%.AK(_-3X,+OO<HKW=I-@
M,`=.1/NL'4/U%(`&/$HG*2$7%(1TC&KWLB09S:1PD=^+15DM/U3K8O7Y>W55
ME7$`Y:*X>G@$UFZ*S]_C_W\^_'K@^:C^706'`%%"<DD0<#C.,:$;(RPQY*FA
MD9/G2XJ2JZQ8'\VF^&&Q'=COY8\X1E]^VS&\^(_=B=6_UV")H4Y(CRT7Q&OM
M,6H!AMBE7D=-_JQO2(Z-#ONQ=//59KD=X/\6RSW#J_^E,]EZ]QDLMD`8J:#P
MA$J,/,"JD=D8?['[^`&I-C;H1Q.M'E(]OMKN_C(T7RW[4JQ[;\'1N.$E1%&)
M&-,(V0AU(Z?')/5V=/(N^)#D&@WN_([ZNPYY*3M:!`^HP@I)C;R`5AEFA6UD
MTQJDQG?W+O=VSKNY5#3S,\7/K@MU7VT6A\+:WFH2E$6,*FCJITXA%88QTDK'
ME;J@FXRC];N7+\F0YB?,BY"`NB3R_-%8SFZ[AP_NZR0@5L>T:$*9E)!"RQEH
M#L@D@8<+DIRK3SXTJ08$.2W;I/UI5[/E/V9WF^+CS;/U=I<'=*!9P)!*Y73T
MW[A%SADEA&A&CIA,/4::O!^=3H\18,UO=SX5\^+^ZS;Q;EE>%PE&9V</@6LC
M6)P*S'FA`7(0"(V=1<1X)CD8OZ#SV5%J7(23S,W+H;R?_5G\]Y<(S-6R^E:N
MXI#Z$.BX#@,Q4FB)O5`D`NM9%)E$:1463F@GLE5,/A\^904\F_%:K39U^(NI
M5GLS;5]]&SA4P!(+O=00<"ZC'+"!3W*4>J/6NX1QCJRH44S2$6CF#9#WL[)9
MC9_^4JU6Q?[]V.'F02&-+=3.<&Z(U(I2Y5K\1')ER][%@\_'"(T(;PY2U8)_
MO'EX"2%N*,N[<OWS_>Q'>;^YU]5R67TO%[=F]C7^R_KG'G+UZ2;$%9P`23!$
M0FM&!>9:MO=&-CGTM7>%W_,CV8@PGXIL[L?7<OE8&Z,N"M239+\V#T)YR#"O
M`T+K<F%0Q/UJ7-6]9A;7[_0EDJM_;=Z+(->1\)Z*5,],\,,)V<?->K6>+>9Q
M?O0DV+ZN`K=8`0D\-`X`;ZR4C#10.T>28R?!7Y-M`V*=,^_\V>]?#N+,,LZY
MH5@;`"5C`,;=$6$6(:>5CCMPC?!!TYE#NBZU)7:T"(A2'9F"$;#<"`(T@C+*
M9[BDF'-V8;%!QRCXC=W1\8"./B6CI;BM']G8^MIUA:V_5=7\>WEWFJ+KS0]_
MJ/3U8FB])FNO?H+B7`"IK?=<">N<]NCAX7!)(+.'B[:=$(LN4[M?1P$)9#57
MD&OOL(@<98@U:&B<K_ANCB.1D7A2953`Z2S$*0O&G,906$*<L]&%LH@93:&$
MCG,H!+;><J).5%[FJ3*1+Q?ENGA7?BM>27.HZDSW3H)1D9A$&KU=`)UFT9MM
M4'#8I,:M3-`E&(D=.RM+#0Q]EA3OS:JLG7AU_7^;<E5V*0?P=HN`-.1`6X4\
M4,Y@I@A'C6Q"RM37!"=(JS$4_FNZ]R`@GXI`]6^7Q>$,F(-M`^)1*&2MT$Q"
MJXWV`#[*ZS#1%U3,YFB-=V#0,=@F736;:A'=P+J.9W'U9;:\GUT7FW5Y/;O;
M71*@4[M`!.1.Z;C]PI(0J`ABNAD[4^J"7I@84(_5>`@GL>/SS]7LCV5YM:SJ
MIR+W,^*M;X/WT$"OXW(-D5!"(.-D,T9'76IMW`D&P(W$@@%0S5/D:E[<[%YJ
M]<_WLW]52W,WBP#M=UYZ]A0@EYXH"2&-_V%-#32-]766XPNJX9W!J1D7_`D0
M\6G\G1*`$WH+U#M#0'WXR)GA-,YYV4[S:*POJ(32:&SIQ\H!M)"'F=&(7\<5
MXE/4;_R!7^*>UQ;?BKOJ:Z=Z%YW:!^.9$W%%()!X9DQ<:*QMY*9>IBZXDSQ;
M')47KS@X//HY6/=Y.9L7][/EG_6YXO8/-1B'ZWWM;1>8U]I8BQA3UGDII/&M
M`T((30UGZ+WH7AK+AD0]![OV."(]7+X>O00,M=34$6>Q%!%,YYXP8)2FQC9,
M,&4B@[LW'O`G)E]/-Z]G3P%8+02$T<`;B56]!<>TP4(8<D%O[(["D.XL'`#]
MI'./CYOUN_*Z6*R*^=5L7>PKD+GW^Q`M/ZYSN"G$"`@*XA]P,U9@;39W[*1,
M.4Z+U?`XYXF+WSJ'Q?QS<?UE4=U5MS\_E;=?.I1:/=`RU"_-,L>(C9R%@$DK
M<+N-\I1=T(G'V)P:!_$DB_/;HI?!V?%Y0%S%_SP&6!!M25W)H3T3CN!D>XOL
M_+DQ(,PYS,WC`?''YG6T`R[W6Y\'[ZE#$%EI*"-1'"Z!:6D.?:I;,\'<T0R^
M]0`(9^1-O=]LWM4[Z"[O;!,L()8;23$`2&I;'_&Q]HI#X0NZ]#M.O6]SY6A`
MDU8>]8^/']S_[%]NGG\3L+)6$0DE(9):2KT`K:_%W"4]1#*`7JIA4,QA"CY%
MZW=HW6B_"<`1S;BR47KF!+>*ZG:WA[A+S>N=8&)XAL4B%=9LM#BX:7GV54#"
M8>R!D\Y0CTB<)LRWIY\>P\LQ$`EZ>TOS2;CET/W[2/C[S?U![;_X+B"K/0$4
MT6@2'25``.E:XRCR5;O-<3N0I+]J./2RL.`AE_<P"YY_%S?-&&KH=!3=$*LU
MYZ!%`Z87?ICD'=$@+#@"O1,?M[_K4*.Q2_,0O61#G?6<>%T7P:12-0'>'D*=
M6A"K=[&0BW`J1D`\3YS$R[%^*-;NQ_7=IDZW;=,%NKQIWKV;:'.]MI1CAR4!
MCEF#`&U1T/ER,'/8JF%I\?J5Q;%0/ZV-^_NJN-G<O2MO]J7X=&D>F"?&.0JE
M-[*N6."@)8W46LJ+ROX;APZ=[5PRZHE'^'L#1?8RJ%\'06''B;-(:V.8]M(K
MWDKC,<\6?Y,CQG!$!HV*^HE]LK\MJU6B/[9M&A!FMJX8S20G"$,@+&MBV3S`
M--5_[WV5]!>P4TF(3R":^A5&Z:'4K[H*TCF(,:9&$.VB"VQY>Z7O!=>I/EGO
MVZB+X=_(&CC%WF`[;_JQL$L'P6*.HL16$QP=84:]1NU,I`BGOALXP</M3,P;
M`?43KZ_J^GISO[G;/I!X7RW7Y;^WVDY;<7=T%JR$&D$!370O(L+8,=?.0$OM
M^.<A\H&'B^*V'MOY,W%T'9R8E1_V%EO=WS!`[.)F/PJ+G;#*&"RM;^V]A?G*
MK%;KV=U%<ZT_VE,Y>3ORQ"T`)I#2@D)@N6.,<T=`(S5S-M6KZU]E]3(X-@+F
M69AV_W56+NO$J8\WOXKPY*;>U5.G%P./Z#9PH)1R0$HO"8,,.>U;E.+O4GV^
M"99HS</,?+HX-6.'HNAK')`'`EJA"$3$<V<A8>V)$V8Z.9)B@I5<3T[*8]'/
M6<K'5/=_E`_/O'\JKJO;1?GOZ&3,HUSE33E[YM)N"U#,U6+^+OYU7<VV+%;Q
MWS;WM4^R]SA@#X<SCB(`Q;EE$&OEF080XJ><1^\`2GW5%DXPF"C+#)BN[D[D
MX?ZV&.1N>6<W02(EM)-"`DZHC)X^:"/#//$H-6-UDG$P><KYC0A_#A(^/UUX
MO0SMH=W^AL%[";'"D@KG/2*T3CUO)%7(I%X*GLO%\@`4J$;$.P>S&LD?W)QH
MM9^.M)X\GW?[[P4[]Q$XI8HQ""3WANOHL5O>'M=ZB;,];GDQ?!L+^E.?E#^;
M1N['USJ=[E-19U%$==?A;ZOKV=T_B]F^R-(!>@_40JZQ<M(($X'"1CSM*;FU
MJ9[D!%,C\ZS"^74R/1Y_*'ZL/W\O[KX5[ZO%^DMBO$6'C@,24GE,M'30LZBD
M..%U>S>FDI.^)YB;.47V'JF.Z1&WGGV?OU>#\?6QOQ!G+>6$0>6U$XP@&.?T
M%A<'@-$B=;/3^^+\<C8[.?0P47[&'Y\6;;NWQX`1<PPBCC46QE,&Q.-U2,1&
M49*Z3YI@DL%D&9J@AVERU%>;X?S6IL/@E*?.1$P\D3:BHHRD#3+`NE2&]KZ(
M_RM;T01%3)2B\=MA*1J_#8!3+J2VUA!JK'!."-\@$V=UZFYJ@J^E3I:@_=60
ME-;@GRYJRW9DL^W(;C;K*/ML?_A;_TX"4,AK"*BB&L09IQBDL)'*4HVS7<6/
M'B0R+KE&A_X9H4[S--8O=[`7_3:6@`8K"+20A@@)+=+NX7&T^`OP[F#=E7&P
M>$ID;:3I_A#6BQ:!8F*9C\:'.D4\)$9SU,@7MS')5[WGOJ1TUOO.5Z^.P?E<
MBI<Q3:R3'%CC$.4LR@A;E*PV%\2>H_7:I5)9/SC/KU(99!R1N,+58=U$4^TX
M8:U\2EQ0"=_CU-NY4ED_0),\T<_%]4UT$):S`P\1O?PL4`D<DIPBI;T73'.O
MVGGAG+N@UQ0'T$XU&)`YX^&.?QO1`@$00Q1I&F<#901BT0(D0;9J->>W?`R#
MZ*G8,MQ#B,S%?9FL4;3`4TSKU,E&7F[L!:TH1VN\]T.(_;!-.^;8W,^^UN_L
MJ=O]R\NK#P/!BGD91^($U51(&YWUQ]$)99,SY<]$\XF:J@:$-&=LU;L.M:Y>
M?1N$1YQ3*!""W`//,5&DD0=RE7JB-<'@DZ&7EV.QS!-6?%W=%Y]G/QZ/9W6Q
M*&[*_1'$;[:(+I85GC`&,`1ULJF0HN4]T3:5)Q,T)4?H]54X\!!8YK0A352]
MW2S+Q>U5L2RK>0=S\E:S8+S'R%'`)476"`PU:N:5P-JE)NU.T'$=CC$#`IJ3
M-I^JNSM?+;_/EEW8\NSK`*D1CBA#ZDM,"I3G`+;+*4NN;S?)4-T\AZO'HYR3
M.1WH$@#6@@&OJ?',Q(FE`9.MN80D6]7FK]MI^/MZMEQGX4F2!G>PH2>(.2GP
M<?VE6)HO=:':+J[K\\^#%58J`("!$``)E#6Z-8G20'UY:\R0I#@"RJG9",,X
MT@HPBC64S`EO97.,*"+G4X]2>V]C'FR$6XQ;D684"]$/PM-=L&]W;:N7H[GH
MZW7+A(B;A6BN)3)422]0HUF%-3WH(W4\9SJ8=KX%_G.$6L<>_]QU"M6SFR",
MD]1*04'];*Q!RCCZ*)UF+#G[99+)@2/IO<H&?PZSWYS35/L*D/MM@-`;`6@'
M23K&CPG:.,*H<<H"*8@WV+MF1Z^%D:DE6B;LAXQ#X0DH)R?%GQU%]F#L&ZT"
MPH0:[A!P$"!.,%7MZJ^Q3Z['-\F:N'DI>#S:H[M*WV+3:OGS)"Y1^]-[.4![
M6@4'/?)`1UPM\G$+(C%_W*D*PK@Z>%V93<XN<W9?LZ"E)89@J##VS`JG$=.-
MI#1NQB[)]1E$XZ_.UP<#-]<<?8P.OI"IJKTBQ&CJ.!+8(:2L\`\8Z_IL^D2!
MO__/WK4VMXTKV9^T>#\^XCF5JDR2S>3>K?V$8FS&T:XL>O68N_[W"T@B[=B6
M2-$D1"E;E9G)V`*$/CAH=`/H[F;$G\KU*0(^^WBP#ENAL"760,L!%DK*6C*@
M;=]PT8M;FIUG^-#2[`]JGOO1_3"_%O_ZLXC6\ZR8IQ0:GW]\C?.W_/OHB61[
MXV"(YYH:1:E!T,&H=U0#G^.^KU\P;1KUFO)#_!D*VZQL^H]J^=\?%E^6U4VY
M.IU.AUN'5)"5,^.`\,9RGJHON%IF`GL7,)SD==DX?!H,W*R$2E[P*OHCR14Y
MG5"'6P>-%"1,4.8`XTY3S6KO2&MN>Z?FFJ3?.`ZA!@,W*Z&.IV-__K%@8E]8
M4(,UDXA1*87%M10:Z[X'M*<G>,F0&'L,@IR.82YGY*57DIRG33'_=3`7ZYQX
MIBA#@F.`.>46"2KVCWZ]4)Z<?(YP\-ID/X1_%LM9M5G%K>5N6=P?+'/5WBA(
M+@54D!G$K*1$>K%]];$;.617]&![D/FK1@(VUS(\XX7F\*LN:CGD')8484<X
MUD2;W9ZG&76RW>,9^\"]&;O9+!-#3[XO:NLB`(.%-2":C@)9B9FUHD$`091M
M]9[[Z*`S$PX>O`\*=(;5O%JG/)BK#XND?-)8/RRB"HT_=HOU-CWUB6O\R([3
M^E5'EO'IG00-C0?1;A$\NMJ8"1$MGYWB3!:N:WUG-<ZJ?G/8)Q[0=^XC,"^H
M!M8I"[ERT$D,28T!@.PJRN..28TJ#_!36.?]3OFGL]P-Q@12"1BVG!!JN8.*
M8!,U:XI[:@_V&'L3/R1`]P0?1WL(0!OO!&9841N]/608!+7\VHIL%W/C&>!C
MDN+@?CXDZ#E.2PZ-5S^:>;%:S7[,;O8IV'?*JR7"NT]W@:(DOB1`$>(1)`+:
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M\G[U^8>)"Z3X7BUW\WVW+,O4_A`ALPXB0&$H!-BE:N#>>!.W(5ZC2IS)%H>=
M\0!T!,I5%S)_.3;\]%(F?L_/*-DSP?=1/$WD6IT,HWFV9:JC6_\[>@W.6XZ%
ML!A2IK!`7B!38\2PN8*`\FP,SS\=[[8/]"RNPYN?BVI>W3W&!?90+!(0/XNU
M6I:VC/C<Q\WL]ENERW\D>V95S6>WJ0I>VX7?,4MB\"\-C"NN/*$*2F=4Q(SJ
M>J$+;$"VG%[7HZBG-%\C7W!]C&.Z^Z5D0M87*<EU,-%3B"JA7-P\?EC\J);W
M.R9^KS;KI]']6:R3DNSP7*5OET$Y*+1BT?M66A"A?.3,]N)1$DLL/E-XR\?R
MKIC70UW</DFV)WO;C7>G]@%QKKFD`#'A/>1>6*-KV0V1V7(3Y_!;QB=(-?X4
M9%,+YPQAFY)VT!![[XG@$D)!`=L^(MQ.#S:*VM85D@.A#G?B;S<("$J3XN,Y
M(QA*)J.K`&KI!/-7E)M\?`*\7/U#()XE34&<OJWK^$>97M$^_)S=1$/J^"7W
MP3:!4DVA]HH3&.T;CQ&PC7S:Y=M1<C/J]`E^^8!B($BS4*:\>SG2UJOH@VV"
M4$A(2362E$%O$3:$U/)QFB\*-\-ET/OG^"5K!D*U.VM6T5ZXJ_[^MYMJLU@O
M'Q-I</T_B2_X&5_V/PX?OKU!C*=?!HN%111:!B!+A;@U>AJK4Z;5!+\@!KQ_
MOJIWPI=#0;S2C5TNC0\W"A`"!)2BW$L?=UUMI6F6AY&Z[VM[="%[PV#(]+P$
MF=U_W\25D9C[<78_6V_UV.V'Q==R5<TWQPHO=FD;I/((:T`5B=_L(HT]HHWR
M`[IO6J,)+O\A)K(:%]Z1/<Q=-M)GYV5^MB@6VPN.>G/<N9YG\3P_+^^*Q3[-
MV-,@$ZT6MU^>2?WYQ^MA=W%#!^D_D&UN<$"%)5HQ;`%KC@PP,/Y,)U;J]G9;
MD:.8-V-_YF6=%J]Q<E^!<L.E`X)RZQ6V&`)5'])@J'KG")[D259F%E5YYV8J
M"NB<)V"7H8<@AECH]%!1$TTDT$)PC@!AQ!+&4&NLU,CG&:UQ(K]\,$"GD/?I
M\AQPJ&1*]N=K:0SL7?5^@E9(YMD_=-#1!_8<SHLNYE'H\J^?9;G^6.U>`+>5
M]3O0)!A*+;&*>Q8-.BHQ(]'HWTF7`MVOR;/M.:TOB[$-@^2Y>-)>R.]@HP"\
MU(1J1R@66%HD))2UA,SS*SHZ??\D=V!-+U1S\&9G@>R"W3_.BN^S^?:!P,%H
MC$[M@D`>Q;7EH.58,RH<UK4ZIE[`ODG#+H0]ITYV-1ZT6>]LNIRKO?YPD,I!
MQHQ!WE*N*&,NFNA[B;"15_``;N!MZ=T8YF"%NKE9;B+R3P3>4[J#1]#:-D32
M,P:(A@HH[2#5@H!:7H1Z%YB=Y!OW\UK(0\]%%F-H7YK55/??(R1[X'8'G>L$
MX;:2]\YAWXE5YWLY9BSU[C10XH31B@-&@>98::::G0!Q>E7Y>0;DRX'2R*-/
M0)YPQOEF-Y_S>?6O9$)L']OO\SCNK8HC;.S4/FCG4T(D8`E$U,=]P'-1RZT8
M[&O%3U)-CD>\,;#.P3%W_S"O'LOR:SE/9XNOD3G"K]:V05+B';:>>V2Q1DJ0
M9D.A'/5.##S!,L[C,6MHE#,:=DU<4#N7#K0(A`,`.7#"2XNCH"S^J66#1O=E
MT,EI7B];.PV#;@[FV/VD?"W_+A>;LITX;S<(UGN(D=*0,\KC@F#:-$@!!OM&
M!=+?BS>#@)OMB.H@#FUG5`<;!DV=D(QS0(0G/#U/$HVD<?=V/6G$?B\:#0IR
M-CJ=SJ,W9(-"I;6!091.I\",5%"HEDV!OFX=_YTLH&&PS<&;.H9NEV]B'TS:
MM=[/\:;!84>EY!;IN#JDT9BSYJI!,MKWU?&DPB>G<9PU\%3D(=Y3)&@:=(=4
M-(>:!``%H2DW,C(\^1*.*=VX$Q9ENYC)DREZJ*E^H\["`.CF5%I[Z3OHJ/TG
M`X\+S'BK(:5&&$61]XTL2/.^[V"['QW)'5,6Y=W6-;Y0IKP'U!P$^:.8+=)#
MX,^+E--CEP!]GZ#U"%F.M`HNFGH<6P:)1@YZY95J3BP@,WTSV4YR+QN-.,,!
MG(-$OEJ6L[O%SG:[>?RV+!:K*'V<P%H.7?Z(G_E6_.\14IW02]!17`$9T1%:
MC`DGJ%E($0';]WW<)(^.1B/9>(!G\^,^58OJ87OKDU*\/<.GS9T[V#`0!R4Q
M)EJ4SKE4ATVJ&DVF*.YKBY]\NI2C%,Y(Q!H4X1Q<ZD.C(_(!;2"4EEIC,/7(
M&MVL%<][)Q0]^6`I1_FRD1@T%+A9X@N?3B]2SLG.KUR.M@O.$0^I\=)3K"A1
MSDA8RVDUR+;#7?L+\"%G8:)O6Y[D&O9YRU._@2NJ343$0B2D$9@;SAOS0%U3
MO,)`?'G_VY;>Z/>*NZUOJI>[F^KY$PJ+8^SJW#88S:46U'`+**2:<9(J@.^1
M4ZIO!KD)O@(=ED%C(7S&F[U.^JJU;5`:8\HE`]'D2&=Q7M#&S#2:9<M)>&F,
M&@OA<USN=:?2VQ(:AC&G48DR[2C1'GM;OZMF%+17=+V<2L0C<F@(:*<2B-OY
M@V<M;?P2]BY1N`>:!)-2-"!($*4&`V*!9/NWL\9Q9WS;$AA'PB_+ZG9ST\3'
M/#Y+I]86:MO6-*2".IP3A0`WT=VTTKN]6C/>:7=%Q9#?/^G5J-A>7LHY@+A3
M'G*(O!=>,>8\K>4CT4B_'NX,-]6=D\^=!N[E)9_#FHCX1SH&.<4B>G,4UO)9
M=TWD&6"..R>?.PW5\R:?PY0(&PUI;T`TCV`TB6RM=SU`[)IJ+[Y_OEXGGSL-
MOAP*XHB6_-@A7+9+\\`54X`2)"$TV@+LF'2UU(;1O@]9)WAT,MJ>,P+.6;:?
M5(=E_X#[CZJZ77TJC]GX;WT\*&2-XIS"5)0`&4L=>8(L^GK7HW*&G>27^\_[
ML<T9@V'B/[-M@9_3WT-W[B,0K"QGQCG(!"04&_$$)E>D[[7`96FF]W-K+,"G
M<JBRU=W_G]SL\.6FCEN95@`#C9@EGE,CW"YIG5#2\U:S<*3=IRDG>OS!QW9Z
MNV1:[-=AX.FPF2/AO4?2QA6&J*_1X4[R:WK4G)E/+S>Y'!.4Q7!J!'E]P=&#
MKFV=!"*<8T9I::&+-H#61J(&<&W[IEZ;9"#^5"@Z\*3D?--X\RK[4V=2=NTB
M0*2A,!QP[R@S1&H.:"V]P[BOUSC!Z]'S$G*D"1G9=HOV;-3LZ\<O\V*QCCBY
M_]G,ME44#_[B+.;;P=%T,,U:VP8,+5+$.^F0@\9;&\UJY*1.C\R`;T]0D%GF
MT]):G])-H$XI&#=O()@F%#AA/4I(>$B,)NZZ#@F&8L7K,Z:Q`)^<,CAGONIQ
M=8+%EAN7%+XVPE#CA08<:H@Y443+UN038]NS!R5HS4#=L8M@$"`*8QVW)DP<
M]5ZR'0)6.RMZV[(7J0LZL^&@E3HHV#ELU&_QFZ)QO5P6B[NMB=1R5_[FYT-4
M9():#U'*%@",)%[;*!=*MWZ`^6R5W3-<=`T^U=7P`&=)'/4TPG2$&4WBXNDG
MSX+/VI,/G]A3L(9IS!0RGB,2-U+"!$Y88!`M;(^NZ'7Z.[GP,K74J#CW>X<^
M6Q6S@P1Y^9$0?7KK!`#)JXK&&1)`D]V(D)(*7U$:\]'FJAH$VDQW[6_K5_V8
MUD7+/M6A=0`::N,5-LH1%1UTKBBO573\6VN1D<NYSQI]UQH>[K-2+(VY]>57
MA]9!@91!A*=BWCKZ?RF%J*IEAA[VC5J8H,8:E`%=V=4;Z3RQ?1&PV>*NU0#Z
M]8/!DZC&O7`>0&&-0TQBO5/%F"OL?P?.])G75S%X[P`U!SW^+"(ZBW+Y^%SP
M5JX<:15(NOAPF!),!:6$2H!<DI%!P:#FU_5R;#3B#(=PEG#U8G';2IJG#T7G
M@0FN+)!Q-Y?0,,9]LO,P8%P8YK/EIKMLCO0&]*Q6S<=N3U1;&@=)(U+8"FTM
M]YXI!;39@^8M!'UO#R9(H?.9S7W1/BN_ZO*=O?C5-`X^%4$RGJ:RPM@R+[Q/
MOBPD2.(H_>]P(MUC^KLRJR_.4[V4.F=@YKAW4XQ%96(A%0*)^&^DA,2"4X4M
MD1RTYVR\_+LI!:20GFCL#(E_0R(E@MDC`+G['33!Z6SH>S=U&MB7<S?%7,H=
M!(@FT3@#$BH2X=O+%7]X1=4+AY_J3G=3IP%\W7=33&&AM%;,(62C3>BQ$<TJ
MM?2*R/9.+KSS;NHTG'/<33D03343O3^-HY&&!8R+JAZ1)_**8CU'FZM#=U.G
M07L-+K:V"@J*E&0"2&.@,M&-W$L<#8`K2I\U^IXU.-I9-K";F\W]9IO]RY9Q
MRFYFNU+$Y<.\W#]U5O?5<KU_!MWZBO>MG6V@KP@*8JP!YD`B@EA*`,O1'CV%
MM>Z;(7R"BF](*KTN^W6.V;B&XR(),8,60\B)<E8KFW);[R6&MK=]/T%=.2+_
M!L<YR]U'N5J5Y<>R6,T6=\^MDL]U&%OZ7;GZ5B[O/_](,;QM.7Q[=1@T!X82
MIJB&#E$,TM.L&AE-<=^(Q0D>B(_(P"S8]W($=M^X_?9#CL"SCP3JM4MULP@7
M4`G(M&NL5065[LN&":9Z'H$-[T0SA]8QQ<,LI6],P_O\?3Z[*]HVL0,M4I)K
M8:6-O+5,<N4-L?61GI*@=\G""=8F&%%O#`/NY&XWSIA$8=Q;#0^%T@X`CFGT
MW87!2B(>9QO0:$58U9H5K:/2K@?RD`921-3J@3QLEC<_(U<>EK.;LIAOOR#.
M:&M$[@"]!J&EU)X(Q=RVI&(TIW"4W6,/I'/MT497X"J=SH/J7/B/K!/JBO.^
M6J:0P93V+!VG/56E/\OBWR8^:L;SM5QOEHM?A[5-A]1!%9S84_"&0QO5LZ/$
M(R*IQ@1N`Z:59P"9UL?]8U]W_K.8;^HX\W_?%//9C\=DJ=[LY#LM6O<=O0:G
MC7%00,T-TL(IJSFK<<+<M6;PO:3\**-QZ.`EZ=CS<6ZE<LY0WO/I%LR$-,Y[
M#>+\0`6!`0YM_46)I9>MY^GCX-&9:RWO*4[J)S@&"(9:8LZU5$0()VV#A597
M]*AB-)94^?#/X=$^C;\!)DI2JY(.P5;=.@B2<`QA5(I:"4R49D+#6G(8H;\>
MYHW$B(.\&Q#V\Q.N-?"J2_,@`(06"!`W82>)]P!B7DNM.;BB:ZFA:7`2RWJA
MG8-C^P%&0\@4JY_U+M#ZX.=8LP`DA4"E*B>$6DVDQDC64G*:+Z-[#M-[V&FO
M1D.YUY%^?7T05;.Z_:_-OA;S\<<^Q]H$YYFC`D)-E$,&<0.BOU&/6;ILH5<7
MRXRA(<Z2=G*7)/JU6=FJ95I:!DZ%9,2`N/M#B!4R&#06@1"]0R`F675]5$4S
M+-!Y;:/CIF.7EV8G]Q4PX`H:J1#B&D%H/`.JQH.:WB?4$WQ,D=M$'V<&>NU^
M:E','U>SU><?ZCZ-(_YW<6M^IAOW#XM]ZO-][OMZ&1XYDWEOER%5L=0H+C?D
MF3`*&XP;M]O2WA?F$[>J!N=#=9;I.+^[J(MY^E%O?W'?/J3L_<8YX:R6.EU#
M\6AX[N56NG=D],DT?"B7L^KVKW6Q7(]"Q7P$.<F1[#<-_:S_7>[>*.;?LU5Z
M+/"M>EODKZD`;UR?WZJM'?%AL6_YGV5QV$T8HO-@@?%8V;C/>`\3X$8V&&L/
M^^K$2?D3V8EXMOGIMTL_>4"=A_@EJHYE&N!;5N$`O09!G3<<40B)=08J^XN]
MK/H>X79W3.2.EXOR+KV5OB)>9IV87H3\4CQNAU>[4P\/\UEYJ^ZB?[9:MXVX
M@^8<JO^@A*+,$D:]L8![CBWW#?Z2]DT3V/T%YM62]$Q3E)^NS<H:A:Q-[X%9
MR*U`_]?>E36WD1OAGQ3<1U5>T#A2KMI=NU9.\HAB)-IFK40ZI.1=Y]<'(#FT
M)(N<(3B7QGZQ)=5@!MW]`>@+W>"E"M83@X05!VV'LE*H-D\!_0G5-@4T'6M(
M*@34(8JX0$`<9YY7WE;&B2QU!(DR:\@O)P+-+H4PDM2B9[.:?&Z18EAAG"Q6
MJ;!BRB5[=9=S!ARP$K6AGX[X4;6\J2W&\N3!*!.`!1/4J;3M.6L(2%)1HZSZ
M@;.#&LOY6`/T$@;W4J=TM]M<?9K/[W_9)T[7)/P<&Q))(!88!HF11P2X$TA5
MU('Q$ZI_42K6YV5*V^'D4#BIS=4Y/BB=G8IX:])R0E1J(]+I9BH*D7$3JN9^
MN9`;H*:(JST5,]AOL=?SQ9>\6NK+[AP9$K%'@1D>#%%<8JR3:FXKZKR&":40
MMB'B[XL,M,'5/C"S:S;\78^]6N"<'!>#I@#:.9P,MQ"P\H\W:8U+KTZ,,+K=
M`7K:9&TOV3G5`=TD4^+[AZ-+-A;E)&_0@6OA+,!A;\:(E9:Y'2%86E)E+N9A
MD9OOZN'N;K;^NJT?](*E_F9Y??N0S,\WR\>MRQ\OC]K<AO:^$!&Q*'<ZD"HM
M$.J3`6%"Q0\JZR^_OJ94ATO@L!H#^Z?CS-,@O`C6$FPI8"O2QB_W=%N)U`0T
M[<&04N37.T\>0_OU!BQ%,)Q7#QN*P7"EJ0DZ&*HE8[M;G09Q:L^^,=A>*EZS
M2@47OSAR1))VZ'.+'H.3BAB\@HH#%H7>+M",\9YQ8W1<F)1WD4@&4J>:X;/M
M[T1GJ'?.,R8#`6<YYXE7>]Z0I,Y.(6.J5[@.+*&.3[VK3XG3,-O,;ZI`\2`'
MW+>,WUS3[.[S?+G9DK,-1<]O[&ISO]E.]3^/I]K@O+OLQ=%AR:C$E(!B1&!.
M!4([63F"/-2V1AR86T\$VZ0@QX5OCDRB@*F$P#U#UEH(_L`ORL.D<MC[@M9J
M2!'UOOT,69ACK+M04,JZ`(AJI267&DE?^:4%1KK67]N147(H%N/O/M^NOL[G
M5^E$7.13KQ+J8UK-H1K5VP^_SZ]7'Y>+_R5:MWDM6P8T;Y?2XO<B$8X')C!#
MVJ<%:"0Y^&+2HD03BJ3T!<*C-86&$UL?+JRD"*[NYM^\?<TR"$Z,BM@)9,%H
MZ2FA0CFCD:YH-)1.J)7"P!A9=263`7%7FY%P<ES$`7'">3#&BV2D6*>UK^BT
MSL-TL->*M)LAJ(BW?14)2=_YE&QGE\S;V]6VF*3_*Z^X^BR%!J,CP50%!XXP
M15G@2?'U53!-,,"3BOBT)/T7:H6TR^5>HL_SV_3.C_^8+^?KV6WVS=S<+9:+
MK%/<+[[,]]-O4"GBG/=$\)+@H'UN7^NPX-IS=-CY-2^]PSI*)U@W:.N2WWW@
M[MV6=[6P>OQ8TA>P1MPE5AE`-NFTDE3A*`%07%%TE-5&ND'-!>SL`Q3M*)=-
M\FA:_E)21#AW&)+V01@"H$I1<UA@;$K-7<9E"@PKQUX.Z!J2<FSN=K;9+#XL
M=G]XLPR+Y6QYO9C='K:/1I'G5C\4B;:<@A+:6,J0\-I97G&2&E3:&FZ4"N5@
M*'RN%`PIPEY2M'>DS&]>IG2O]9Q*V&[T@FB41A)QJK73Z8!%B0D'?0EY6II3
M.4KP#@6:YTG?74AF/)C\;7[_]L/[V5\78[-Z4;2$AT"\9!Z2]I=SX?5ADV`2
MEWJ`SE<Y5KFMS4^$7B:?UZ->[QL9Y;_N\H,Z5[._^V(T!@>OM:'2"6&PLH`J
MWDK#4/>6X--R!.^[U[K'L03&(<^RA+%3B_9QDM!FFU9:.5".YH65O2XJ(52.
MT`DA)4DT@S]$Z:1DI-10'&'7O8$AVZ.41K-WIV,'YLOYA\5]2.(X3S-NYP.1
MT``R6`X@B,7")HY5^IE,QDRIYCRJ0C$C0?B@DALJ[VB8JAUC33SB4DLI!'-@
MC:">)>#L>CH!M=S55\'XF7ATW"7),#+,"&L=4YIQ1*W`!][2\#/QZ&P0]I)X
M=)[8>@EUW<Z6O\WNZIH3/7XL8N&TE4I:8Y4PRH"N[K92BU'H+1S_6N,)C5'P
M/$!6+H0^H52;//3TP2@D!$:9(CYG$WO!&-O'"ZE304PH6ZA,@$=04,2](NOT
MU]GZC_G]U?WJ^H]_+A=U+5Y>?CK:P(%X(5E`V#/L1**]FJ>AH;>:6'UXK4M%
MM&J;C47B?K^XF_]KODF'Z^_IW_7B.GL5&PJ_R=A(O1,A6:].>$^]P8:B:O]S
MR!5'WT:98-,&%#I@:A$P<INIJ_G]_>WV3/NP6M_MKJDE1M2U?:H=&=.)*$E0
M01&+G-!$V6_S%]R77J\_.W^FOU/@$DBTSM!>%(3&H*D9$3$PG_2G7/38608B
M8'*@+6@H=;&/T%%Y(5C:9631KG'0G/..]6[?8CZ3=7K+J!D6/1=<"NZ281>,
M`2#Y4NY^YE*+TD.DN2_OE1TB[?)S-%[E42;<"6H"$!`$644`"0H`!UY:7WOQ
M]T=/N"LUD(>5XV6E(DY&@\QFL[I>9'_7OQ?WG]SB0P+!?-M_Y>-Z=M>\^%8;
M'XE8!>V0XM1YGC0+0K@][!0"B5)TC]*2&PQ1+Q:1&$!\XTE2NCQQ3N8Z4<H%
M%$`#B-P)RU644ZY[NQ+9>3^H@0!3EC1WGE3&@\?VD^:(#<E0"QQ!"%IP9#2M
M8A7..55:+&I4?I%7A\]"Z;P>!7D,*7,RK7.9K`X-%$FF$CN!'T1(BL.9XTN9
M&Q'\QR'+UYPNIP-(;@UE.FQ[65C@!V7.6E\:TAB1%VH$<.U10D.E#3V[X?J#
MIPTQ;G`NGY_D@ZT!8;&D^Q)3`5RH;9K5==K0D8URO<XU*+>DP-?O1&W^G*UO
MFJ<*7?B-F*ON8M`."^2"$I8C:0\\9&1"(?6^P'8T/:A?48TU)2BP8(1P!C%+
M'6/$NKT1EZA03I4&9$8(N`$D?RH-Z#S&CSD-2$M(_+`T2!RD101QI2I**#,3
MZGI5)L#3:4#G<6^X-*"D\5EOA0@\S5,914W@U3R=%).J\5DJH@9I0.>Q<839
M'D)X@;2CP"VBF"HG#N<NHZ84!B.,D+4!@M89^KJR/:C`1A$*@0"7E.3\-U_1
M9DBQWW[\J4'G@J5=1HXS>5!8ZBVG%`,DC5THB[&H:!!)B>K+Z?):#I`.F#I@
M99EORO4QW;I)OL?E+X]>I6.6*0'I%/8A283#07GW091ZK$=X@`UO\/0NKC*G
M]#<^Y>7U]G.>Y#_2'!LT1ZL?&@D(I#PAF((#2Y3E6%<46,TFI3CW*?!5IW(8
M]5;I__NPN/_Z9IDH>]@NWVUWRO>?9LL=Y9L=Z6^6NWA/%QOJF5.(DDG%%3B*
MA58BV<O,L(K[&-D).`G:!V);NVFWLAHJ^))[6SS,;I].Y@</P1CO'`W&,BMT
MT`HIPS#UAGC.&<+A[+YMG=W<WBZ./Y=I,7Y:?,[:LK]Z^^X;\267LQN],A+,
ML>?:HV1HHT`U^&1Z^V`T-SHMQ](:P2/:A_J&4OW]ZRXD,]9X"N&&@&6.&<.3
M"N.3Q8XS%9:`04%-Z'Y_]X(^%3XYC\]C#I\P17`0%"M)C/;"!<DK2@+COK>J
MD#V'3QH+\'3XY#SN%=F'!FO-_=6[=Z>=8,\>B]2:_*>@`4E.E5)4AS0S8-([
MB<2$BBV4BF35&O?*Y)K_U$"N3Q^+UJET!&JOK#02!>F9YC2@G%;JD-43<B"U
M(M>+N-=K,F[=Z=7$07G^RR)Q!FQ`(IE65"M.-2)R=QP"RNU*IX.GWC6&SJ5Q
MT;W:39[5Y_V%SL]I4G>SOQ9W#W>;;>3GV';4;'04`3$I@L1>,Z0$<=A!I;X'
MJ._@_7I.GRZ%_-(]W%89WXN;,4_XS6;S,+]Q#^O%\N/.S;,+,!Z]77PR#%/V
MQLB=P,)BZAA!/*UD0:2J>*.HFE#R0`^@[%<8O7OYMCO_SX:PCUTR5"*BJ9$8
MI'0,9]=,53\6JV0SC<:[=]E-\@8-JSO[9D3@97`XWPS#+/T/'E7U2G%:++WY
M!U]!*^O&<.RZ0F.A\'HY>P^T/B8I3SNLUM]':QY%Y!^3_3)CML3#U[R;;S?+
M\Q9.C_.)/)U?*C>'"U8EF!H55-58#+-@2E-_1G4_=C2+:KR"O3`[XX4TJ%W@
MLA;]92^*5B+'96"42!<(D4R3`W5@6.FU[E%V!NP9MKU(I&N=]>$_F_E_'])P
M_R4SX_GO@^BNSR?1I$7;D2&1.F%`:$%Y$+E$)23;5DENJ'48>5Y[-Z@?"AL=
M>\?&1)?HX4"5L]GJ\<GP4M]HI+;VTN+K\9-<+N;G1TY+3!UXF>[325[]:L5>
M2!Q$D)0JBG7`GG%ETGXL""*6#Y7[\72ZM7D=+SP>`S/&$"&I94XJD6]:R3UE
M!"3R/\`:;2S<TVNTA)]]F$F_9VVT)LWB\$SD5"?U0@-S1FN96*&XV,^?BJ0]
M3A8/9XKO>2OY0@;V!H#:>T:/GHK<,0(&*P624VMIT!Y7-#`QI;2)`KF])/DB
MOO4A^U\7RQP_J97^D^>B#H)QZQ$1UN::V=0P7=%AB)O0)E`DO55[O.L%`[L8
M6CT&'C\7N35*YG@)(\%P35'2,BLZG!,3ZH_>"@8NX%TOOM)GAUWZ<(U*<&1$
M)`1;IJP$)!6G:=.DZ$`;`EN:>C5"7+2J(+3#SH&@4IMV>71,-`$QKA42*"!O
MD2)25\HU#>5]7T=XE%PLX7K$%/%T`,S4'C4O/A\U(8QYK',=8,#!.@&LHHLX
M/Z'[`RW(]C1:BC@Z`%)^:7(Q^<B0Z&5:28YAX-K[7+Y.T`-U5/#24H,C+('0
MY5%4RL^BB-._5^L_/JS6U_/$VX?KS/C/\_1;$L+'EUQ7M6.B\=0*KH@"#E@C
M)KDWA]V5\M[*5_>.@0*QK;IA:B\^C!S$2O/<)F&9Y<VCT%FN:WF]_QF?V$::
MOB)2(0T3)FV<G&O,B`$'!WXB.ET-MQQ2'?.X:*MY,I?9RW.9;3Y5X=9CN\^9
MKXE,$VD9$<"1(TAK)^&P=CQ"$VK9U>Z&U"V?.X^#5=6`%Q^7V^;ARWMS?9U+
M/^>DT=7MXGHQ4,+E]]-H$`@[/BA*CQ$G0:>30%/-I$!^UZ'3*"*0J\5W1VKE
M*;XWBF(W>D$TSC/@1&35'`D%X$%4U'L-$_*,M@&!YXIG%SP>Q<IN]M20T?"V
MMP$L93)0!;(X!.Y$^@6!`H4HLVD_9K5Z=\-#_,TR(3V=#&^6^;19W"P2EX^=
MU"\]&W/1?<<`4R9R)4#D7(+1?I[@;&F>V2ASCML0UZI=AO9A&_SVD'T=.='M
M\VI]GTWCJ_G'8SI=_:"HM,)I2],@M":`F0<M#[RRJC0E8H3Z?XN`:9VO13K_
M7CM\/U_?;=Y^V).W^7U^/5]\.9(=TVA<]$"Y3X1SYJ74/-G`]H!Z2<BDTE7;
MWD9:9FX1,/8QVCR'L%HW!T;=N.@,(YZ#ET(HHIGC"`X<H:RX;?<H*V^V#8R6
MF5L&C%W@]GQ@U(R+*EAOB:5!22O2U'T`6LW=,%GJF!QE*][6@=$N<U^1B3`I
M5X%AWCIC',=`N%+<*V>))YPBXPD]/\?]R!*&A\UB.=]LWG[)5]WF?V[G\;7V
MSDK-L&B3!4HM90P3C0,6H)RK9L\1[2U[?>`%W%B(J\YXVX<1`;/-XIMV4C'B
M:SV6SGM!3-0ERID.6DL6L#?!F8IRK'5I:N4HK^NUB*I.N=P'ONQJN4F3O-D*
MKCFJ3@V+A#"GE%4B)"4Y<"4]EQ65E,I2W?.U&26E6&J1MWT@Z)^;?*M[<[^X
MF]V_6,+FY0<C""5(\))S;1`*REM+]Y0$26UI89#79J&4HN0B;O83&J_4XDWS
M?>7XH"A!`$H4*BX2MQ0W3E;(#XC04KR<;;@,ZOXJ14MK?.W%<3K_\Q$+UJME
M^O%Z=W']7.WGW%=%P1(7G*?,4)TL0BUD,O'WW$C:8&DS1O%#H*QC;M?9RW__
M6WXX7U9/O_P?4$L#!!0````(`$:"54=2TMA)*A8``"<2`0`1`!P`8FEI8BTR
M,#$U,#DS,"YX<V155`D``P/S)U8#\R=6=7@+``$$)0X```0Y`0``[5W;<]LX
M=W_O3/\'UD_;F2J6[&1WG5GO-_(MXXX=>VQE=]N7;R`2DM"0@!8@;:M_?0_`
MJT20("@E8DJ])#*)\^.Y$><<W/C;/]X"WWG!7!!&SX]&[X9'#J8N\PB=GQ]]
M>1Z,GR]O;X_^\?N__LMO_S88_'7Q=.=<,3<*,`V=2XY1B#WGE80+YT\/BZ_.
MC+/`^9/QK^0%#08)E1/_>A/>1^$N<(`<%(:<3*,0WS`>7.$9BOSP_"BB?T?(
M)S."/>#"Q_(A:PT*MT/$YSC\C`(LELC%YT>+,%Q^/#Y^?7U]-R5LCBGQL/O.
M9<'QR7#T87AV"I*!K%1\G!(RM6GO$_IUK?W;E/OO&)]#R^'IL;P]10*GS2FC
M-`KT!%[(C\/5$A]#HP&TPIRX&9V9:)T@$@-Y6614,R2FBB*]HT09#$>#TU%*
M)%&],",IBO+A.+Y9;$IJ!"=4A(BZF>!O)46]GJK6H[.SLV-U-VLJ/%U#@!T=
M_W5_]ZR\Y`B<QG&4VY!@R7CHT)*YBR+/$5JN21P[VQUS4:B\NRBSEO`8^Z%(
MKPQRJ'?`PY%S;,D/9_Z&"=HSI+"VYJCL%.TY4EBM.*KSI`I^RB3RKT%*-Y"7
M!J.3+=G(WV0[-E*ZG;!Q=HRX*\T-EG/#`7Y;^HBBD/'5#?S=C#6?\S64ZQQ$
M\G@F>1S]O`V/"IKBN>S_F_-4I-HM(Q:*22FV9T#?FS?AHTCY.2;<)3OM6-F"
M#WT8:?@6I03RR1\LGRD@9L_9R['+(AKRE>RB3IOT;3JZ](]!#M*6FXASR*(4
M['LK=HJ$V5^#'*8E0QXFUKRD-/+']AS@-W?1./*4B-2O5L%F#8_0%RQ":R<I
MD"6_MW<1BHBK0O'(AI.<*OXYR`%:\B&(:\U%2B-_[("#<,GM64B)U*\Z)A"E
M+%1(ZEIZ=;DD=,:22W!1QO"/:2!_PC-'Y:L?DRA:G]4>+SE;8AX22*X*U8`"
M6'`\.S^2)<<@K2O^Z2+_'>3!:9/2`]93#!6O@,2-?"7&7<YDBB#[[_,C`?KV
M<2K\=Y?*PS-;J8"$4-)EH7PTM14*2+#?57F6'-O*`R0""O%VOB<1)M#"(5#P
MC5TW"J078^\A7&!^R0(`7V`JR`N^I5![XSLF1,-F1XX$__)T6U?+*PEV_-Q,
MQ%3(W(U_/QF-?AT-A\[`N2+"]9F(.(8_"M".PG;6P)T8W?E)XO^[7>O?CC=Y
MV&0O$B`0_5W]WC1F0ITTJ:/<Z(&:$ZZ_Y'JZY&KJ+=_/B:YPB(B_-U]*'U_K
M4N]'O[X?GGQ'EW)^2O@Z.-<NK#O:LW>-&KC7Z3[<RQD='&PK`T_0U,=[Z[R2
MI]<ZU^GHU]/AZ+LZ5\Q6#SWK[X@(A2>*OVV\HP*A/N$9OM<F/#G]VA\'L\2_
M6R0>]4#U??SPO3:%*!AI_:\>9P"U:K:*Y08DL\4T4;GBM>IW3*U5]`2_A1'R
M=V:X%,]LOO<MS)>@'XR8_+9/<6IQZI.5X7MMLE)IM)ZF&I?,]]&4<>#D!8]I
MG"0^X9@SL2!+"WLUP*I//TYTZ<<:JH-HFCBN`1_,MJEJJQ9MDIAOQT)];WP"
MO7'IQ6[D)`U;K:'U.H':A8FOH9,-5_<X7##O5DVXR:5@^W$W`R]FORNEW;OU
MNY@_)V;0*7#89Q<,`A(K`4QZR6A(*/B&B]MXD`G*X``_:SN>#%09M@A[L-JF
MJHE-^E<'8L@C?M;F$566`L"#@3)5U-RR+YRW?([YA=3TR#5F-MSM<>$-BO`P
M!7+X(9A//#E$>X%\N23S>8%Q*+Y0%'E$K1%L;OWFH'6FAK?Y=*C>Z&?0L5I+
MKBR=H#M%>"?!=^('.#]ECSC8M%K]CXB#K`L<$M=F>*7U$TS6_J`B[5;6=GY:
M>^3!^E)?F4;%P^P2B<6-SUYW]F8;P`TV?]_X#<^?X["9(Y_DJ$<=WO4Z@Y0G
M_KZ)W>L>8_"`D[8>H)U"//A"*R/M,A*T>Z;)2QK'!CLO.<0+@P6_7:=AV4^,
M6O83AY[A"G/RHD:A;JD(N=KZ:5&1Z\D-:RA/-+5X#N04D`[6:#,P6HMB6"UV
MHBF@];;I[UB65K^V4YEU((9%5R>:><PJ&_5T$C/=Q3ZFWC4-2;BZI3/&`\68
MA8WJ4.J,-,Q"4K:=OO!3#C/%>$X!L&\FND:<$CH7CY@_+R#/:FZ6$J4AWIQI
MXDV*X2PQ=Q1*W_5O'6:J``P1YDP38<K6Z&]TV52K;6"IH#?$E#--3-%9I:?Q
M))Z'M3!"W-[0,?VBZY@493_U:]\%K9$9.IY?=!U//+_>W\ZFJ$#KM91::K,5
M2@M?-ZS0VV62L1ZL._PBE:&;_T77S2?:[VG7?H,(_P/Y$;['2&K$<@1$3U[?
M\0]U&:D$<A224X0ZF*/-$$@M2GT/-=0EJ!7&Z6_@J%.PQ6J0>ABSH4JAQ&2H
M'B[DJ-/QR6Y,==+`5*7]$D93G1Q,5="Q=7;6!,QLM@_69NMK]J;5MVTR5P=2
MG]L-=25\I;'ZFNP1BJA+D-]JMDM+;:CQA[I4+\7I\UR73IGV>5X-B*$0'>K2
M/)UA>ISD56O7)L>K0S$;J9SBU1JICPE>M8)M\KLZ%+.9RNE=O9EZF-Q5*_AT
M)V8Z;6"F<CI7;Z;3@YFV2<'-6&:3_6QILM[FWQIEFPVP90_9Y`%F$__2S,3-
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MX?89GPG*,#VK.RK99+G>YH0O(`#C%@NN<Q)#L-*MN<Z(>ZOH%E%H@]+0;^D6
M7V<8?0XOB0HV]=EBG,"`9#:0)K"D!BJ;JL>C!HDJ["/(.J$A7NB6:A?,T./0
MD!R!>$O_0)Q(-4`8Q2!9J#956ITHUPS.,/I\6A%2TJ,:"752:"?%=E+P@P$U
M&F\5CAJC&@9.3[5C00W-V=]0=@=0<\L-U@4:PSOV0?..Y=3]U;7UFU(F-;P.
M'S2O0P[27W]//IZ3GRV33?EF9\S$JFENF^:0AK=%=\)*^G&=PF$X^21U?G).
M_("#,2LT;_V^62,;7D?=`2U6ICV\L493-&YH7Z9]0Q[,CE,J\.P<IV'KWE>(
MC4UG6T':`AOFI'7G"%EV)3VM0A_C[_*N'GT4GP[T=T264C&5-YH;N06V8?)4
M]PV5%.P_'`47GTF4`M;?/1C;9!#K)*'](PSK&G1?J-C"]/W-'5I;R#I#V/I)
M9I<HY0&[<(G>AGM[@]G&_=9/J$\`1KH/HFWE"CU-!YY``/Z"Q0WC4I<LBK]@
M,?9]]BK/HK<PM1G*,+^I6RF5@CHSQIT,5ADO!SX8;4/3UE&\,:)A*D[W$9-&
M)NQO>&ZJ>HO%.LTAS>8L!5P[<_9PY4YC[5\"PQ9[N"QQ#Z;=@VEMTZ.F@(8)
M]Y\UV5!#8_8T[U%G@EX@(;_7L+(\2T-#:YC4T)VDH5`&4PGCI#@'*UAG+M40
MAD%EW2$:L4TNUFS2W\RD4K46J4@-AMD^I0!5:Y\>QJ-*[5JD%3489@N5CLZH
MMU#_MG=7:M=Z<,V(9+96Z02->FOU=52LK&G;M*X2P3"MI=N.K[=17].V:"KP
MWQ$(<2V7DXK-ORU,9$(RI'2ZQ?@YAA.#E*\<#+;^MWV^UQ#0T!O^HED:UL!\
M/4X&HR!`?/4P>R9S2F;$E</VKBHJ"9T_,I_8?1"[(9YAR%AW>D:"+#^25L!V
M<G`G13_84*?S9JU:O+B[?[AAC$MWND=S[[!I>N@6=F#5;]6)6#Z]UJE.AG(T
MYSLY5?KK_[-7_7;\)KR/:+DD=,;4M>0*I2P6(;XHKV$_7L*%IB+DR`W/CT(>
MX2/EB%-"IO\<C\[./EP_/S[>XV"*^9%#48#/C\J7B>_+!#H%$!#G0Q)&\G&?
M.(N6YT=O4^Z3CR3$P9$3`KOG1Y11&@4?/18@0F_AAI3BR(D;+C$GS)NHAE[$
MD\T$QS:\@U_I>"]=[B+OGR:7&VP7KW21XS\>/E__M<'S^K7]<9USZ7GJI4+^
M/8%R+V04)R5@QG-=BS82Q%<"P`FAF]H481I_H?[\R.48'JR3C%`1(OGX>L'^
M)THV)4W8(V=>Y(9/&%+L"*?S%D]8=D1T/F'/""2[I8_P#/Y?&'&1"[\ERC=4
MD(>G>OVT]%>P\$H0\3`;!S)0P/_4NUP@.L=2)IWHXP0KT]96$.U5!1!@@!V\
M#/;\JU$2.8QUX3/WZQ:**`%MT3F$*<P.5/("2:?DXX9QZ=_/V(UXLF%P&MZC
M,/EK/`LQOR$O6#D^2,U#\K_R$]8B]XZ=0.WCA6K6X;02+_NDP79:*L)T6$.8
MHSE.9(!L^1[QK_#`:5'*7`_-&K>7-GT!=A_Z+Y`@+KSQ5\2/0NQM?G1RL]ML
MWGS_7>1%)(@\1NP!S/-"\*LJ(%:E#M#<;*_=6Z7E+I%8/.,P]+$'ZE>?'P;'
M5V80ZZE<HY8=3$LO&54W(N07DIL-V>K;=%,J\#2HWEW\""8(D(N!'R@VRY*9
MVG52.KYD0(AE",A[O\N(<Z#;E+!1VQ]'RL^,V@BJ:=Z!,NLR"M2HQPM61<(=
MY'Y^)HC^7N=*JVK#:008OQ%1)V!ROYF07OC1(\"#2*+U3D.;E5A7RA_J!,M:
M=,+KU(L`!<<+D;IK7L,FE#*WS(7=#=A>_+J9OF1/DI](?X^^XC\7S,>9R$_8
MP\%2XD"-#Q$$<U>.@LZSY'T;@%;^`LZRC$%V[_]7@/"BO+MXZ'^\8F,SA6W8
M=F_Y:[60<MDJI`2K)6=SCH*-?*'Z=@<#Z!5SE>+E7B=YXL[JEJJ\5"*5#-:L
M[?X+CJL(WW`6?*%N8=OU?S)"P[3&R$1JTK)KQ7&E,:^1N\B'7A\HO@#6X?>7
MY81-7H%TE5Q8=UA[L@[$J>O9#+MQYY&<'/\$MGO"8$B7^$0AW",:S61-(MWJ
M"LNXHW`3L;=!Z%S/>TT$(AMV7;O4P<[G.ECZ;(7Q<PB%^6/$W0426.Z#W)##
MV*P+_I@PR64F@SWPGRDXD:PNX$%NG,UL"F1HV[ELOB2LD!99)A99`G:`WD@0
M!4(-:6R*:VR]1>10$'56;";7WQ&$M7L<+IB7GU#W\$HQ%PNRS'.O^YCS3$)[
MNGUU(`99Q?7;$GI%[$'^.2.A&INJE[*"HGL=I.*^(A>MNKG_7.9&KF#`/H0I
MCV2'6R-UMO4L@KB$43S9@8JAS9;HA\EPY.3%5)?#Z&YT,.+=L(CK^=?<Z"+_
M48"6<A!T/-_@7W.C`U'Y$Z`\4#FF\#![(O-%F`4E[9WNC3-46N*3+#&I;&,8
MW&W2L(.>IF.[:EBW8=L.2GE+[PB$.[4E(RQ/JE3?[L"[);\0I-;7X3L9:#:_
MY_!%X%GDWY$9SJ5I3M!&OD@,Y`^1S=(^[R@&;W)Z_>;Z$436^=H'*TH3FO9D
MW5B_D9[!?$OE3@/B$20_')')I+O7N6POY5-.]DBME%ZLJMN=>+&20^GEJ=@L
M$H_)."(\/Q^Y,C7J6DJW)EU<.=S2"\)"["XH\]E\=<F"):+0=4\6*!QS?(7!
M1@&AV)NP"[P^1%=]4'VNG6_YD*YIM^8]R!51)4]%3=2.=/\54Z$TO5A-%H1#
M\.1RL%J-Z_X!UZ$`&LNE,N,YQ[BX;K4=Z0_H##6'^E>[03.B_3M`T5AJ#.9Y
M;0RF:-E42#N2SD6[.XP\_624]DX'$^%XI9X:X?T"&>*&%)5W.Q"MDR&]"821
M&\:3'3/B";N8O$C><AF,[?:X+C$7!Q+T1N*8VW5QF>4]>$\T)6)!)HBB:;*B
M*UT75!J6:=Z\B^\4X^$<>J\Q]=0IU*H*N4#N5^P9Q@Q:4?ZH&J@:56A+W$$]
M?,;`;A!$%*^+J+G>4>[9$H4+XB[A`81ZQ%4PHBR-H5T'X@5XC"O7RC+?AVR'
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MC5KJL+D#78!H`5$#6A.6#^N`>W,&%;J<$,B&A78#U=UU7(\<!R223U'K7T@V
MU)<IH*9!AU_KY*,*<HT9*,'#Z0<5LL5G<B4]\GT6UP?ZZ;NM4;HQFR?%8)"L
MP<N+TA.6+U83]#:.P@6+JUAX\1.7ECN(Y?9+M]#[;0'081])C,AF+KS$4".&
M1=-7W/R!2JLG](8@%X-J<:/FU]WH8!FRO@[[81:OT!N'P/HT"N-B4`Z^Y'5Q
M.B=1FL'8#=3^<^*&<K@:.?0]W"X!N]'9/6$23".HV^3E.P+!67UBS[NED*(R
M/RHNDFS8M@N#\D\X4`-:\RPAN9+[!ID*1Z6L9$R])[9"ONR8'ZC,42#+E-\T
ME%OKOD`@XTGM=\FD;,E(=FDR]'L_M'N=:T'_4/_+D$`]+]>!V`B4QE;=C89/
M<BU,E.QS`?Z?XIT)\OR4='FW/+P@_RI!)K$E6>=RX<H`](P"$='Y!6$"^@8?
MY5/^Z_&T0;L.C(L]NPOL16JQJ[09D:;)YE,_<42K8D0;PFZ>TY%+HOA_6,;\
M2`DV,X9F3;NW,[4P*"$7Q#_*50V35Y:,7UQ%.-[.!SDZ_`,--CRY+74'T\>B
M+"SB2I;_QIPIP38$2L2JU4<+C&YKY9F\*8&NY6#WLQS&TXFE[F),*Q73$J;;
MNIDLH`=78H%X\`94&QQN5JJF'4K'-0/=@93H,U2/>EFJU=&<M`OQ,OM60G$D
M5"8U5,@-PW[DR4I!9CHR]4UN9(E1>_+.Y8C5;D'>M%N9-->[Z-1Y8%<6:+85
MV9JJ"ZZL5KG/B9NOY'R$$#YC8*)<KMHV71OKK[%J20ZQ:<&:%EWTT_28</V,
M6[$OR5>N7\3:?5Y@K$EN=XFX_U&Q[<6I*'QVC]O1NB@[B+XN:(V%8"Z1,OY)
MPL45F<UP<K236EM<Z60[`NU@K?6*/2(6#WRY0'*/R0N19QAM=#;U;3K8W4RP
M.R,>YAN+L,J7.Q#8Y(#BP^Q.KGW+^2Q>ZN("9%45:)>':>]TT45(@/^`T(D]
MS8C01K1MV+:+4JX$FG*2=/X;4NGO=>"5:'#DU=[.NMIV$/X+Y1CY\EAON7?_
MC@DA9QIN&,=DGBS"=E?YH7+B,PXO\`QN3]!;+OQ6&)T;O<Z5LYQQ1L,@G999
MKG^0H?IVY^K-3*0_&?\*JG<A)4C.W5J6#D\TM/E>R[+BC\,(=X$#!'_^'U!+
M`0(>`Q0````(`$:"54=I6T%N6O0!`-+0)``1`!@```````$```"D@0````!B
M:6EB+3(P,34P.3,P+GAM;%54!0`#`_,G5G5X"P`!!"4.```$.0$``%!+`0(>
M`Q0````(`$:"54="#HF^<2<``*:U`0`5`!@```````$```"D@:7T`0!B:6EB
M+3(P,34P.3,P7V-A;"YX;6Q55`4``P/S)U9U>`L``00E#@``!#D!``!02P$"
M'@,4````"`!&@E5'`+AT9S=H``"7#P4`%0`8```````!````I(%E'`(`8FEI
M8BTR,#$U,#DS,%]D968N>&UL550%``,#\R=6=7@+``$$)0X```0Y`0``4$L!
M`AX#%`````@`1H)51_%M]3(T!0$`L$,-`!4`&````````0```*2!ZX0"`&)I
M:6(M,C`Q-3`Y,S!?;&%B+GAM;%54!0`#`_,G5G5X"P`!!"4.```$.0$``%!+
M`0(>`Q0````(`$:"54<`]TXNH:,``#(/"``5`!@```````$```"D@6Z*`P!B
M:6EB+3(P,34P.3,P7W!R92YX;6Q55`4``P/S)U9U>`L``00E#@``!#D!``!0
M2P$"'@,4````"`!&@E5'4M+822H6```G$@$`$0`8```````!````I(%>+@0`
M8FEI8BTR,#$U,#DS,"YX<V155`4``P/S)U9U>`L``00E#@``!#D!``!02P4&
2``````8`!@`:`@``TT0$````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129325179504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative and Other Relationships</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Mitsubishi Tanabe Pharma Corporation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On September 9, 2015, we announced an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) to exclusively license MT-1303, a late stage experimental medicine with potential in multiple autoimmune indications. MT-1303 is an oral compound that targets the sphingosine 1-phosphate (S1P) receptor. Under the terms of the agreement, we will receive worldwide rights to MT-1303, excluding Asia. We will be responsible for global commercialization and development costs except for costs related to the Asian territories, which are the responsibility of MTPC. The transaction is subject to customary closing conditions, including the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the United States, and is expected to close in the fourth quarter of 2015.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon closing, we will pay MTPC an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and in the future may pay up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$484.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in milestone payments for multiple indications and territories, along with average royalties in the mid-teen to high-teen percentages of annual net sales. We will record the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment as research and development expense in our condensed consolidated statements of income when the agreement closes. MTPC has the right to participate in our global clinical trials related to MT-1303 and has an option to co-promote non-MS indications in the U.S. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Applied Genetic Technologies Corporation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On July 2, 2015, we announced a collaboration and license agreement to develop gene-based therapies for multiple ophthalmic diseases with Applied Genetic Technologies Corporation (AGTC). The collaboration will focus on the development of a portfolio of AGTC&#8217;s therapeutic programs, including both a clinical stage candidate for X-linked Retinoschisis (XLRS) and a pre-clinical candidate for the treatment of X-Linked Retinitis Pigmentosa (XLRP). The agreement also includes options for early stage discovery programs in two ophthalmic diseases and one non-ophthalmic condition, as well as an equity investment in AGTC.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2015, the collaboration became effective and we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$124.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which included a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> equity investment in AGTC, prepaid research and development expenditures of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and total licensing and other fees of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of prepaid research and development expenditures were recorded in investments and other assets in our condensed consolidated balance sheets and will be expensed as the services are provided. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$56.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as research and development expense associated with AGTC in our condensed consolidated statements of income, including the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> total licensing and other fees, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in research and development services, a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> premium on our equity investment and a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> clinical development milestones related to XLRS. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">AGTC is eligible to receive milestone payments aggregating in excess of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which includes up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$472.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> collectively for the two lead programs and up to up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$592.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> across the discovery programs. AGTC is also eligible to receive royalties in the mid-single digit to mid-teen percentages of annual net sales. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We were granted worldwide commercialization rights for the XLRS and XLRP programs. AGTC has an option to share development costs and profits after the initial clinical trial data are available, and an option to co-promote the second of these products to be approved in the U.S. AGTC will lead the clinical development programs of XLRS through product approval and of XLRP through the completion of first-in-human trials. We will support the clinical development costs, subject to certain conditions, following the first-in-human study for XLRS and IND-enabling studies for XLRP. Under the manufacturing license, we have received an exclusive license to use AGTC&#8217;s proprietary technology platform to make AAV vectors for up to six genes, three of which are in AGTC&#8217;s discretion, in exchange for payment of milestones and royalties.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Swedish Orphan Biovitrum AB</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On July 16, 2015, Swedish Orphan Biovitrum AB (Sobi) exercised its option to assume development and commercialization of ALPROLIX in Europe, Russia, Turkey and certain markets in the Middle East and paid us </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which will be held in escrow pending E.U. regulatory approval.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We collaborate with Sobi to jointly develop and commercialize Factor VIII and Factor IX hemophilia products, including ELOCTATE and ALPROLIX. For more information about our agreement with Sobi, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Joint Venture Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012, we entered into a joint venture agreement with Samsung BioLogics Co. Ltd. (Samsung Biologics), establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals.&#160;Samsung Biologics contributed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">280.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$250.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) for an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> stake in Samsung Bioepis and we contributed approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) for the remaining </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> ownership interest.&#160;Under the joint venture agreement, we have no obligation to provide any additional funding and our ownership interest may be diluted due to financings in which we do not participate. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership interest is approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which reflects our additional contribution of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.3 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) in the first quarter of 2015 and the effect of additional equity financings in which we did not participate. We maintain an option to purchase additional stock in Samsung Bioepis that would allow us to increase our ownership percentage up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;The exercise of this option is within our control and is based on paying for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the total investment made by Samsung Biologics into Samsung Bioepis in excess of what we have already contributed under the agreement plus a rate that will represent their return on capital.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investment in Samsung Bioepis totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.1 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets. Based on our level of influence over Samsung Bioepis, we account for this investment under the equity method of accounting and we recognize our share of the results of operations related to our investment in Samsung Bioepis one quarter in arrears when the results of the entity become available, which is reflected as equity in loss of investee, net of tax in our condensed consolidated statements of income. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a loss on our investment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$14.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our share of losses exceeded the carrying value of our investment. We will suspend recognizing additional losses.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Commercial Agreement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On December 17, 2013, pursuant to our rights under the joint venture agreement with Samsung Biologics, we entered into an agreement with Samsung Bioepis to commercialize anti-tumor necrosis factor (TNF) biosimilar product candidates in Europe and, in the case of one anti-TNF biosimilar candidate, Japan.&#160;Under the terms of this agreement, we have paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$46.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which has been recorded as a research and development expense in our condensed consolidated statements of income as the programs they relate to have not achieved regulatory approval. Samsung Bioepis is eligible to receive an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional milestones related to regulatory approval of the product candidates. Upon commercialization, there will be a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> profit share with Samsung Bioepis.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Other Services</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement, a technical development services agreement and a manufacturing agreement with Samsung Bioepis. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$47.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in other revenues in relation to these services, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$21.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$57.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our other significant collaboration arrangements, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 808<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129120253584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Components of inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 221,500<span></span>
</td>
<td class="nump">$ 128,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">537,700<span></span>
</td>
<td class="nump">511,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">159,700<span></span>
</td>
<td class="nump">164,200<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 918,921<span></span>
</td>
<td class="nump">$ 804,022<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 5<br><br><br><br> -Section BB<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655945&amp;loc=d3e3927-108312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a)(4))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 5<br><br><br><br> -Section BB<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 5<br><br><br><br> -Section BB<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129204769664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(10.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(10.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Manufacturing deduction</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129189983504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 2) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfStockOptionGrantsAbstract', window );"><strong>Schedule of stock option grants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Stock units</a></td>
<td class="nump">181,000<span></span>
</td>
<td class="nump">236,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_CashSettledPerformanceSharesMember', window );">Cash settled performance shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfStockOptionGrantsAbstract', window );"><strong>Schedule of stock option grants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Stock units</a></td>
<td class="nump">115,000<span></span>
</td>
<td class="nump">182,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=us-gaap_PerformanceSharesMember', window );">Performance units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfStockOptionGrantsAbstract', window );"><strong>Schedule of stock option grants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Stock units</a></td>
<td class="nump">89,000<span></span>
</td>
<td class="nump">57,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfStockOptionGrantsAbstract', window );"><strong>Schedule of stock option grants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Stock units</a></td>
<td class="nump">393,000<span></span>
</td>
<td class="nump">437,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ScheduleOfStockOptionGrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of stock option grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ScheduleOfStockOptionGrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(2)(iii)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129319108048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock', window );">Property plant and equipment purchase price allocation [Table Text Block]</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The purchase price consisted of the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="87%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Buildings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">58.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Machinery and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">25.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Land</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">104.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property plant and equipment purchase price allocation [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129117796736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Feb. 12, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total intangible assets, gross</a></td>
<td class="nump">$ 7,645,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,645,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,207,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(3,464,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,464,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,178,600)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">4,181,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,181,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,028,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets and Goodwill (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">98,065<span></span>
</td>
<td class="nump">$ 122,431<span></span>
</td>
<td class="nump">285,972<span></span>
</td>
<td class="nump">$ 382,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses related to goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Expected future amortization expense, 2015 (remaining three months)</a></td>
<td class="nump">94,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Expected future amortization expense, 2016</a></td>
<td class="nump">348,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">348,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Expected future amortization expense, 2017</a></td>
<td class="nump">318,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">318,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Expected future amortization expense, 2018</a></td>
<td class="nump">291,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">291,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Expected future amortization expense, 2019</a></td>
<td class="nump">275,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Expected future amortization expense, 2020</a></td>
<td class="nump">269,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Finitelivedintangibleassetsfutureamortization', window );">Total</a></td>
<td class="nump">1,596,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,596,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">543,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(499,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(499,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(481,700)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">43,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">23 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">3,005,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,005,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,005,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(2,523,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,523,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,396,800)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">481,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 481,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">608,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">23 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | AVONEX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">472,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 472,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">3,297,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,297,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,280,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(440,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(440,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300,100)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">2,856,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,856,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,980,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Indefinite until commercialization<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">735,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 735,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of IPR&amp;D intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development | Out-licensed patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Total impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Indefinite<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember', window );">Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development and other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 424,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember', window );">Convergence Pharmaceuticals | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development and other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 424,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember', window );">TYSABRI product | Acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 2,797,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,797,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Finitelivedintangibleassetsfutureamortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>FiniteLivedIntangibleAssetsFutureAmortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Finitelivedintangibleassetsfutureamortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite lived intangible assets useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IndefiniteLivedIntangibleAssetsUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:durationStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a,h)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph ((a)(1),(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_AVONEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_AVONEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129180277280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness Idebtedness (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Senior Notes principle amount</a></td>
<td class="nump">$ 6,000,000,000<span></span>
</td>
<td class="nump">$ 6,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption percentage of 2015 Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage', window );">Redemption percentage for change in control provision on the 2015 Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="nump">47,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum senior unsecured revolving credit facility</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Credit facility term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding', window );">Outstanding credit facility borrowings</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Senior Notes principle amount</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Percentage par value of Senior Notes</a></td>
<td class="nump">99.792%<span></span>
</td>
<td class="nump">99.792%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Senior Notes principle amount</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Percentage par value of Senior Notes</a></td>
<td class="nump">99.92%<span></span>
</td>
<td class="nump">99.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Senior Notes principle amount</a></td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Percentage par value of Senior Notes</a></td>
<td class="nump">99.764%<span></span>
</td>
<td class="nump">99.764%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Senior Notes principle amount</a></td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Percentage par value of Senior Notes</a></td>
<td class="nump">99.294%<span></span>
</td>
<td class="nump">99.294%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherInvestmentsMember', window );">Investments and other assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value, net</a></td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap | Investments and other assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value, net</a></td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Make Whole Provision Redemption Price, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageParValueOfSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Par Value Of Senior Notes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageParValueOfSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 470<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph e<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt issuance costs (for example, but not limited to, legal, accounting, broker, and regulatory fees).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4B<br><br><br><br> -Subparagraph (a),(c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624163-113959<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 7<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51825145&amp;loc=SL20226000-175313<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 860<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4D<br><br><br><br> -Subparagraph (c)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51814546&amp;loc=SL51823488-111719<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the amount outstanding under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13476-108611<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(b),22(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129185153872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details 3) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sales</a></td>
<td class="nump">$ 2,387,900<span></span>
</td>
<td class="nump">$ 625,400<span></span>
</td>
<td class="nump">$ 3,363,374<span></span>
</td>
<td class="nump">$ 1,942,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains', window );">Realized gains</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses', window );">Realized losses</a></td>
<td class="num">$ (2,000)<span></span>
</td>
<td class="num">$ (100)<span></span>
</td>
<td class="num">$ (2,900)<span></span>
</td>
<td class="num">$ (300)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the gross profit realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the gross loss realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 12<br><br><br><br> -Subparagraph (a),(b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3179-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26853-111562<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129120182096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions Acquisitions (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Feb. 12, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 274.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember', window );">Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash portion of consideration</a></td>
<td class="nump">$ 200.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Contingent consideration</a></td>
<td class="nump">$ 274.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Increase in the value of our estimated contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Increase in goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development and other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">424.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember', window );">Convergence Pharmaceuticals | Raxatrigine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Remaining cost to complete CNV1014802</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development and other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember', window );">Convergence Pharmaceuticals | Neuropathic pain indications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Remaining cost to complete CNV1014802</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development and other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value.  For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (bbb)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_RaxatrigineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_RaxatrigineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_NeuropathicpainindicationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_NeuropathicpainindicationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129389783216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions Acquisitions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Acquisitions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Acquisitions</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Convergence Pharmaceuticals</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 12, 2015, we completed our acquisition of all of the outstanding stock of Convergence Pharmaceuticals (Convergence), a clinical-stage biopharmaceutical company with a focus on developing product candidates for neuropathic pain. Convergence&#8217;s lead candidate is its Phase 2 clinical candidate Raxatrigine (CNV1014802), which has demonstrated clinical activity in proof-of-concept studies for trigeminal neuralgia (TGN), a chronic orphan disease. Additionally, Raxatrigine has potential applicability in several other neuropathic pain states. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The purchase price consisted of a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$200.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> cash payment at closing, plus contingent consideration in the form of development and approval milestones up to a maximum of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$450.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$350.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> is associated with the development and approval of Raxatrigine for the treatment of TGN. The acquisition was funded from our existing cash on hand and has been accounted for as the acquisition of a business. In addition to obtaining the rights to Raxatrigine and additional product candidates in preclinical development, we retained the services of key employees of Convergence.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Convergence, we recorded a liability of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$274.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> representing the fair value of the contingent consideration.&#160;This amount was estimated through a valuation model that incorporates industry-based probability adjusted assumptions relating to the achievement of these milestones and thus the likelihood of making the contingent payments. This fair value measurement is based upon significant inputs not observable in the market and therefore represents a Level 3 measurement. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The purchase price, as adjusted, consisted of the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="87%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash portion of consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">200.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">274.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">474.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subsequent changes in the fair value of the contingent consideration obligation will be recognized as adjustments to contingent consideration and reflected in our condensed consolidated statements of income. For additional information related to the fair value of this obligation, please read Note 6,&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the second quarter of 2015, we adjusted our preliminary estimate of the fair value of the assets acquired and contingent consideration as of the date of acquisition to reflect revised estimates to our initial clinical development plans, resulting probabilities of success and the timing of certain milestone payments. The primary effects of these revised estimates resulted in an increase in the value of our estimated contingent consideration and goodwill by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$36.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our revised purchase price allocation is reflected in the chart below. Our purchase price allocation is substantially complete.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the estimated fair values of the separately identifiable assets acquired and liabilities assumed as of February&#160;12, 2015, as adjusted:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="87%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">424.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">128.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(84.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">474.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our estimate of the fair value of the in-process research and development (IPR&amp;D) programs acquired was determined through a probability adjusted discounted cash flow analysis utilizing a discount rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This valuation was primarily driven by the value associated with the lead candidate, Raxatrigine, which is in development for the treatment of TGN and is expected to be completed no earlier than 2020, at a remaining cost of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$145.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair value associated with Raxatrigine for the treatment of TGN was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$200.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have recorded additional IPR&amp;D assets related to the use of Raxatrigine in two additional neuropathic pain indications, with a total estimated value of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$220.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The remaining cost of development for these two indications is approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$415.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, with an expected completion date of no earlier than 2021. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have attributed the goodwill recognized to the Convergence workforce's expertise in chronic pain research and clinical development and to establishing a deferred tax liability for the acquired IPR&amp;D intangible assets which have no tax basis. The goodwill is not tax deductible.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pro forma results of operations would not be materially different as a result of the acquisition of Convergence and therefore are not presented. Subsequent to the acquisition date, our results of operations include the results of operations of Convergence.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures.  This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129323244000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Original maturities of commercial paper and short-term debt securities</a></td>
<td class="text">less than 90&#160;days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Overnightreverserepurchaseagreementspercentoftotalassets', window );">Overnight reverse repurchase agreements, percent of total assets</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageMaturityOfMarketableSecurities', window );">Average maturity of marketable securities, months</a></td>
<td class="text">13 months<span></span>
</td>
<td class="text">15 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average remaining time to maturity of marketable debt securities, available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Overnightreverserepurchaseagreementspercentoftotalassets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Overnight reverse repurchase agreements, percent of total assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Overnightreverserepurchaseagreementspercentoftotalassets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22(a)(2))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129205577856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Other income (expense), net</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">13.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(15.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(28.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(22.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(18.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(7.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(15.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(41.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(17.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued expenses and other</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="73%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>September 30, <br clear="none"/>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">479.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">265.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related rebates</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">462.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">359.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">214.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">393.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">154.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">172.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">58.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">120.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">549.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">507.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,918.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,819.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock', window );">Other long-term liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities consist of the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="73%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>September 30, <br clear="none"/>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">301.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">218.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">341.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">249.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other long-term liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">861.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">650.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129191733696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BusinessOverviewPolicyTextBlock', window );">Overview</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS), ALPROLIX for the treatment of hemophilia B, ELOCTATE for the treatment of hemophilia A and FUMADERM for the treatment of severe plaque psoriasis. We also generate revenue from our collaboration with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin&#8217;s lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, and share profits and losses with Genentech for GAZYVA, which is approved for the treatment of CLL.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our consolidated financial statements and the accompanying notes included in our Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K). Our accounting policies are described in the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Notes to Consolidated Financial Statements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K and updated, as necessary, in this Form&#160;10-Q. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> operating segment, which is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts receivable</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our accounts receivable primarily arise from product sales in the U.S.&#160;and Europe and mainly represent amounts due from our wholesale distributors, public hospitals and other government entities. Concentrations of credit risk with respect to our accounts receivable, which are typically unsecured, are limited due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. The majority of our accounts receivable require payment within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30 to 90 days</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We monitor the financial performance and credit worthiness of our customers so that we can properly assess and respond to changes in their credit profile. We provide reserves against trade receivables for estimated losses that may result from a customer&#8217;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve. To date, our historical reserves and write-offs of accounts receivable have not been significant.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year after the time of sale, we discount our receivables and reduce related revenues over the period of time that we estimate those amounts will be paid using the country&#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recognized as a component of other income (expense), net in our condensed consolidated statement of income. To date, our historical discounts of receivables have not been significant.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. We are currently evaluating the method of adoption and the potential impact that Topic 606 may have on our financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2014, the FASB issued ASU No. 2014-11, Transfers and Servicing (Topic 860): Repurchase-to-Maturity Transactions, Repurchase Financings, and Disclosure. The new standard expanded secured borrowing accounting to include repurchase-to-maturity transactions and repurchase financings and set forth new disclosure requirements for repurchase agreements, securities lending transactions, and repurchase-to-maturity transactions that are accounted for as secured borrowings. We adopted this standard on April 1, 2015 and expanded our disclosures presented in Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements. The adoption of this standard did not have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2015, the FASB issued ASU No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. The new standard requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. In August 2015, the FASB issued ASU No. 2015-15, Interest - Imputation of Interest (Subtopic 835-30): Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements, which clarified that debt issuance costs related to line-of-credit arrangements can be presented in the balance sheet as an asset and amortized over the term of the line-of-credit arrangement. We adopted these standards as of September 30, 2015 with retroactive application. The adoption of these standards did not have a significant impact on our financial position or results of operations. For additional information, please read Note 6, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2015, the FASB issued ASU No. 2015-05, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer's Accounting for Fees Paid in a Cloud Computing Arrangement. Under this standard, if a cloud computing arrangement includes a software license, the software license element of the arrangement should be accounted for consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the arrangement should be accounted for as a service contract. The new standard will be effective for us on January 1, 2016. The adoption of this standard is not expected to have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2015, the FASB issued ASU No. 2015-07, Fair Value Measurement (Topic 820): Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent). The new standard removes the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient. The new standard will be effective for us on January 1, 2016. Early application is permitted. We maintain investments in certain venture capital funds which primarily invest in small, privately-owned, venture-backed biotechnology companies. The value of our investments in these venture capital funds is estimated using the net asset value of the fund and has been included in the fair value hierarchy disclosure as a Level 3 measurement. These venture capital investments are not material to our financial position or results of operations. We adopted this standard as of June 30, 2015 and our investments in venture capital funds are no longer included in our disclosures reflected in Note 6, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. The new standard applies only to inventory for which cost is determined by methods other than last-in, first-out and the retail inventory method, which includes inventory that is measured using first-in, first-out or average cost. Inventory within the scope of this standard is required to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. The new standard requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined and sets forth new disclosure requirements related to the adjustments. The new standard will be effective for us on January 1, 2016. The adoption of this standard is not expected to have an impact on our financial position or results of operations.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessOverviewPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes an overview of the company and its operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessOverviewPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.3A-02)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph k<br><br><br><br> -Article 1<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02, 03<br><br><br><br> -Article 3A<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6378556&amp;loc=d3e10133-111534<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49124121&amp;loc=d3e4975-111524<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3-5<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6061-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6143-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6132-108592<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129187998496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Subsequent Events</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Restructuring</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On October 21, 2015, we announced a corporate restructuring, which includes the termination of a number of pipeline programs and an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reduction in workforce. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect to incur a charge related to these restructuring activities in the range of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$85 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$95 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We anticipate making cash payments in the range of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$115 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which includes amounts related to previously accrued incentive compensation. Substantially all of these amounts will be incurred and paid by the end of 2015.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129190754864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 2) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 274,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value</a></td>
<td class="nump">244<span></span>
</td>
<td class="num">(49,433)<span></span>
</td>
<td class="nump">5,887<span></span>
</td>
<td class="num">(46,213)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="num">(14,500)<span></span>
</td>
<td class="num">(16,500)<span></span>
</td>
<td class="num">(14,500)<span></span>
</td>
<td class="num">(21,500)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, beginning of period</a></td>
<td class="nump">495,700<span></span>
</td>
<td class="nump">279,100<span></span>
</td>
<td class="nump">215,500<span></span>
</td>
<td class="nump">280,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, end of period</a></td>
<td class="nump">$ 481,400<span></span>
</td>
<td class="nump">$ 213,200<span></span>
</td>
<td class="nump">$ 481,400<span></span>
</td>
<td class="nump">$ 213,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph b<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129191761200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2015 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InterestInSubsidiary', window );">Interest in subsidiary (less than given percentage)</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentTermsOfAccountsReceivable', window );">Payment terms of accounts receivable arising from product sales</a></td>
<td class="text">30 to 90 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumTermForAccountsReceivable', window );">Minimum term for accounts receivable</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MaximumTermForAccountsReceivable', window );">Maximum term for accounts receivable</a></td>
<td class="text">90 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest in subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MaximumTermForAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum term for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MaximumTermForAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MinimumTermForAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum term for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MinimumTermForAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentTermsOfAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment  terms of accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentTermsOfAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129194180944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Purchase price schedule</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The purchase price, as adjusted, consisted of the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="87%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash portion of consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">200.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">274.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">474.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Estimated fair values of the separately identifiable assets acquired and liabilities assumed</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the estimated fair values of the separately identifiable assets acquired and liabilities assumed as of February&#160;12, 2015, as adjusted:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="87%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">424.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">128.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(84.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">474.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1486-128463<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1392-128463<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129204680400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Discounts and Allowances (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract', window );"><strong>Sales Discounts, Returns and Allowances, Goods [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock', window );">Analysis of the changes in reserves</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">47.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">387.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">49.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">483.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">332.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,278.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">26.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,636.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(20.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(14.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(37.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(277.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(871.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1,151.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(40.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(271.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(321.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">59.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">500.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">50.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">610.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock', window );">Total reserves included in condensed consolidated balance sheets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, included in our condensed consolidated balance sheets, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="73%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>September 30, <br clear="none"/>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">148.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">124.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">462.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">359.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reserves</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">610.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">483.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Analysis of amount of and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of total product revenue reserves included in consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129204734144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Overview</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS), ALPROLIX for the treatment of hemophilia B, ELOCTATE for the treatment of hemophilia A and FUMADERM for the treatment of severe plaque psoriasis. We also generate revenue from our collaboration with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin&#8217;s lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, and share profits and losses with Genentech for GAZYVA, which is approved for the treatment of CLL.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our consolidated financial statements and the accompanying notes included in our Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K). Our accounting policies are described in the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Notes to Consolidated Financial Statements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K and updated, as necessary, in this Form&#160;10-Q. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> operating segment, which is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounts Receivable</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our accounts receivable primarily arise from product sales in the U.S.&#160;and Europe and mainly represent amounts due from our wholesale distributors, public hospitals and other government entities. Concentrations of credit risk with respect to our accounts receivable, which are typically unsecured, are limited due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. The majority of our accounts receivable require payment within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30 to 90 days</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We monitor the financial performance and credit worthiness of our customers so that we can properly assess and respond to changes in their credit profile. We provide reserves against trade receivables for estimated losses that may result from a customer&#8217;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve. To date, our historical reserves and write-offs of accounts receivable have not been significant.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year after the time of sale, we discount our receivables and reduce related revenues over the period of time that we estimate those amounts will be paid using the country&#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recognized as a component of other income (expense), net in our condensed consolidated statement of income. To date, our historical discounts of receivables have not been significant.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">New Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. We are currently evaluating the method of adoption and the potential impact that Topic 606 may have on our financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2014, the FASB issued ASU No. 2014-11, Transfers and Servicing (Topic 860): Repurchase-to-Maturity Transactions, Repurchase Financings, and Disclosure. The new standard expanded secured borrowing accounting to include repurchase-to-maturity transactions and repurchase financings and set forth new disclosure requirements for repurchase agreements, securities lending transactions, and repurchase-to-maturity transactions that are accounted for as secured borrowings. We adopted this standard on April 1, 2015 and expanded our disclosures presented in Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements. The adoption of this standard did not have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2015, the FASB issued ASU No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. The new standard requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. In August 2015, the FASB issued ASU No. 2015-15, Interest - Imputation of Interest (Subtopic 835-30): Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements, which clarified that debt issuance costs related to line-of-credit arrangements can be presented in the balance sheet as an asset and amortized over the term of the line-of-credit arrangement. We adopted these standards as of September 30, 2015 with retroactive application. The adoption of these standards did not have a significant impact on our financial position or results of operations. For additional information, please read Note 6, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2015, the FASB issued ASU No. 2015-05, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer's Accounting for Fees Paid in a Cloud Computing Arrangement. Under this standard, if a cloud computing arrangement includes a software license, the software license element of the arrangement should be accounted for consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the arrangement should be accounted for as a service contract. The new standard will be effective for us on January 1, 2016. The adoption of this standard is not expected to have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2015, the FASB issued ASU No. 2015-07, Fair Value Measurement (Topic 820): Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent). The new standard removes the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient. The new standard will be effective for us on January 1, 2016. Early application is permitted. We maintain investments in certain venture capital funds which primarily invest in small, privately-owned, venture-backed biotechnology companies. The value of our investments in these venture capital funds is estimated using the net asset value of the fund and has been included in the fair value hierarchy disclosure as a Level 3 measurement. These venture capital investments are not material to our financial position or results of operations. We adopted this standard as of June 30, 2015 and our investments in venture capital funds are no longer included in our disclosures reflected in Note 6, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. The new standard applies only to inventory for which cost is determined by methods other than last-in, first-out and the retail inventory method, which includes inventory that is measured using first-in, first-out or average cost. Inventory within the scope of this standard is required to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. The new standard requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined and sets forth new disclosure requirements related to the adjustments. The new standard will be effective for us on January 1, 2016. The adoption of this standard is not expected to have an impact on our financial position or results of operations.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18861-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18743-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18854-107790<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129120283920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="73%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>September 30, <br clear="none"/>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">221.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">128.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">537.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">511.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">159.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">164.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">918.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">804.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 2<br><br><br><br> -Paragraph 6<br><br><br><br> -Subparagraph a,b,c<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129191523520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships Collaborative and Other Relationships - Equity Method Investments (Details)<br> $ in Thousands, &#8361; in Billions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 29, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Feb. 29, 2012 </div>
<div>KRW (&#8361;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Recognized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,833)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,394)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12,548)<span></span>
</td>
<td class="num">$ (14,932)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">519,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">417,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,471,140<span></span>
</td>
<td class="nump">1,393,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Revenue related to technical development and technology transfer services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,557<span></span>
</td>
<td class="nump">255,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Biosimilar Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement', window );">Contribution from Samsung to develop, manufacture and market biosimilar pharmaceuticals</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 280.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_JointVentureOwnerShipPercentageByThirdParty', window );">Variable interest entity, qualitative or quantitative information, ownership percentage</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Contribution from Biogen to develop, manufacture and market biosimilar pharmaceuticals</a></td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 0.0<span></span>
</td>
<td class="nump">$ 8,600<span></span>
</td>
<td class="nump">&#8361; 9.1<span></span>
</td>
<td class="nump">&#8361; 49.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of stake in entity minimum</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Additional contribution made to Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="nump">&#8361; 6.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageMaximum', window );">Percentage of stake in entity maximum</a></td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Recognized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12,500)<span></span>
</td>
<td class="num">(14,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentsExpectedProfitShare', window );">Expected profit share with Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Revenue related to technical development and technology transfer services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,000<span></span>
</td>
<td class="nump">$ 57,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment ownership percentage maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentsExpectedProfitShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Expected Profit Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentsExpectedProfitShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments by third party in joint venture as per agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_JointVentureOwnerShipPercentageByThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint venture owner ship percentage by third party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_JointVentureOwnerShipPercentageByThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 323<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6382943&amp;loc=d3e33918-111571<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 323<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35755396&amp;loc=d3e33749-111570<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.12)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 323<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35755396&amp;loc=d3e33749-111570<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.12)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 11<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from the sale of other goods or rendering of other services, not elsewhere specified in the taxonomy; net of (reduced by) sales adjustments, returns, allowances, and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1(a),(d))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Research and Development<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129194457120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted earnings per share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">965.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">856.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,715.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,051.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">232.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">234.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">232.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">234.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129188127248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">$ 330,093<span></span>
</td>
<td class="nump">$ 274,774<span></span>
</td>
<td class="nump">$ 904,475<span></span>
</td>
<td class="nump">$ 721,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">649,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,760,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherChanges', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, end of period</a></td>
<td class="nump">$ 2,408,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,408,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other (increase) decrease of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (g)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -Subparagraph (a),(b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Income Tax Expense (or Benefit)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129198900256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Details) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc</a></td>
<td class="nump">$ 965,622<span></span>
</td>
<td class="nump">$ 856,858<span></span>
</td>
<td class="nump">$ 2,715,439<span></span>
</td>
<td class="nump">$ 2,051,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">232,191<span></span>
</td>
<td class="nump">236,217<span></span>
</td>
<td class="nump">234,134<span></span>
</td>
<td class="nump">236,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive potential common shares</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in calculating diluted earnings per share</a></td>
<td class="nump">232,612<span></span>
</td>
<td class="nump">236,972<span></span>
</td>
<td class="nump">234,659<span></span>
</td>
<td class="nump">237,449<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember', window );">Stock options and employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1500-109256<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 16<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Weighted-Average Number of Common Shares Outstanding<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129120395552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">$ 2,391,717<span></span>
</td>
<td class="nump">$ 2,117,366<span></span>
</td>
<td class="nump">$ 6,762,605<span></span>
</td>
<td class="nump">$ 5,916,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnconsolidatedJointBusiness', window );">Unconsolidated joint business</a></td>
<td class="nump">337,181<span></span>
</td>
<td class="nump">290,678<span></span>
</td>
<td class="nump">1,005,302<span></span>
</td>
<td class="nump">890,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other</a></td>
<td class="nump">48,961<span></span>
</td>
<td class="nump">103,402<span></span>
</td>
<td class="nump">156,557<span></span>
</td>
<td class="nump">255,367<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">2,777,859<span></span>
</td>
<td class="nump">2,511,446<span></span>
</td>
<td class="nump">7,924,464<span></span>
</td>
<td class="nump">7,062,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of sales, excluding amortization of acquired intangible assets</a></td>
<td class="nump">310,028<span></span>
</td>
<td class="nump">302,639<span></span>
</td>
<td class="nump">908,579<span></span>
</td>
<td class="nump">873,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">519,863<span></span>
</td>
<td class="nump">417,174<span></span>
</td>
<td class="nump">1,471,140<span></span>
</td>
<td class="nump">1,393,331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">477,827<span></span>
</td>
<td class="nump">570,436<span></span>
</td>
<td class="nump">1,530,083<span></span>
</td>
<td class="nump">1,658,732<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">98,065<span></span>
</td>
<td class="nump">122,431<span></span>
</td>
<td class="nump">285,972<span></span>
</td>
<td class="nump">382,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">(Gain) loss on fair value remeasurement of contingent consideration</a></td>
<td class="nump">244<span></span>
</td>
<td class="num">(49,433)<span></span>
</td>
<td class="nump">5,887<span></span>
</td>
<td class="num">(46,213)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total cost and expenses</a></td>
<td class="nump">1,406,027<span></span>
</td>
<td class="nump">1,363,247<span></span>
</td>
<td class="nump">4,201,661<span></span>
</td>
<td class="nump">4,262,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GainOnSaleOfRights', window );">Gain on sale of rights</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,379<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,138<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">1,371,832<span></span>
</td>
<td class="nump">1,152,578<span></span>
</td>
<td class="nump">3,722,803<span></span>
</td>
<td class="nump">2,812,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(15,413)<span></span>
</td>
<td class="num">(16,290)<span></span>
</td>
<td class="num">(41,288)<span></span>
</td>
<td class="num">(17,030)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense and equity in loss of investee, net of tax</a></td>
<td class="nump">1,356,419<span></span>
</td>
<td class="nump">1,136,288<span></span>
</td>
<td class="nump">3,681,515<span></span>
</td>
<td class="nump">2,795,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">330,093<span></span>
</td>
<td class="nump">274,774<span></span>
</td>
<td class="nump">904,475<span></span>
</td>
<td class="nump">721,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in loss of investee, net of tax</a></td>
<td class="nump">6,833<span></span>
</td>
<td class="nump">5,394<span></span>
</td>
<td class="nump">12,548<span></span>
</td>
<td class="nump">14,932<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,019,493<span></span>
</td>
<td class="nump">856,120<span></span>
</td>
<td class="nump">2,764,492<span></span>
</td>
<td class="nump">2,058,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">53,871<span></span>
</td>
<td class="num">(738)<span></span>
</td>
<td class="nump">49,053<span></span>
</td>
<td class="nump">7,660<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 965,622<span></span>
</td>
<td class="nump">$ 856,858<span></span>
</td>
<td class="nump">$ 2,715,439<span></span>
</td>
<td class="nump">$ 2,051,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 4.16<span></span>
</td>
<td class="nump">$ 3.63<span></span>
</td>
<td class="nump">$ 11.60<span></span>
</td>
<td class="nump">$ 8.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 4.15<span></span>
</td>
<td class="nump">$ 3.62<span></span>
</td>
<td class="nump">$ 11.57<span></span>
</td>
<td class="nump">$ 8.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">232,191<span></span>
</td>
<td class="nump">236,217<span></span>
</td>
<td class="nump">234,134<span></span>
</td>
<td class="nump">236,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">232,612<span></span>
</td>
<td class="nump">236,972<span></span>
</td>
<td class="nump">234,659<span></span>
</td>
<td class="nump">237,449<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GainOnSaleOfRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain on sale of our royalty and other rights related to future sales of BENLYSTA recognized in our consolidated statement of income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GainOnSaleOfRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnconsolidatedJointBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from unconsolidated joint business consists of our share of pre-tax co-promotion profits in the U.S.; reimbursement of selling and development expense in the U.S.; and revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnconsolidatedJointBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.2(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 52<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-04.23)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 7<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 323<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35755396&amp;loc=d3e33749-111570<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.12)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 11<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -Subparagraph (a),(b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Income Tax Expense (or Benefit)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 4J<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.7)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from the sale of other goods or rendering of other services, not elsewhere specified in the taxonomy; net of (reduced by) sales adjustments, returns, allowances, and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1(a),(d))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 19<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569616-111683<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 4K<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591552-111686<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1A<br><br><br><br> -Subparagraph (a),(c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 4J<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Research and Development<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 30<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51677171&amp;loc=d3e3636-108311<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 16<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Weighted-Average Number of Common Shares Outstanding<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129194167600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions  Acquisitions (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 274.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember', window );">Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash portion of consideration</a></td>
<td class="nump">$ 200.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Contingent consideration</a></td>
<td class="nump">274.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase price</a></td>
<td class="nump">$ 474.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 30<br><br><br><br> -Paragraph 7<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 30<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129194439920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0005<span></span>
</td>
<td class="nump">$ 0.0005<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129197761696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 3,804.2<span></span>
</td>
<td class="nump">$ 716.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">21.4<span></span>
</td>
<td class="nump">54.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember', window );">Overnight reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">188.3<span></span>
</td>
<td class="nump">305.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">3,119.1<span></span>
</td>
<td class="nump">321.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Short-term debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 475.4<span></span>
</td>
<td class="nump">$ 35.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129197214432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Marketable debt and equity securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize our marketable debt and equity securities, classified as available-for-sale:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of September 30, 2015 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">272.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">272.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">767.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">768.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,481.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,480.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">929.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">929.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">249.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">250.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,700.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,700.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">25.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">28.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2014 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">370.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">370.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">692.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">693.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">269.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">270.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">579.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">580.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">198.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">198.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,111.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,112.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">less than 90&#160;days</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from the date of purchase included in cash and cash equivalents on the accompanying condensed consolidated balance sheet:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="73%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>September 30, <br clear="none"/>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">21.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">188.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">305.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,119.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">321.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">475.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,804.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">716.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of contractual maturities: available-for-sale securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities classified as available-for-sale by contractual maturity are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,753.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,753.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">640.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">640.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,820.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,820.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,343.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,345.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">127.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">127.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">126.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">126.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,700.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,700.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,111.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,112.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock', window );">Proceeds from marketable debt securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,387.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">625.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,363.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,942.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 320<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 7<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27337-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27198-111563<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 320<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27290-111563<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized gains and losses on investments reported in the statement of income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129204777216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment Property, Plant and Equipment (Details) - Eisai<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Research Triangle Park facility purchase</a></td>
<td class="nump">$ 104.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Research Triangle Park facility purchase</a></td>
<td class="nump">58.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Machinery and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Research Triangle Park facility purchase</a></td>
<td class="nump">25.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Research Triangle Park facility purchase</a></td>
<td class="nump">$ 20.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129205588016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(10.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(10.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Manufacturing deduction</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our effective tax rate benefited from lower anticipated taxes on foreign earnings. Our effective tax rate for the comparative </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> month periods also reflects a benefit, described below, resulting from the remeasurement of one of our uncertain tax positions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in the U.S.&#160;federal jurisdiction, various U.S. states, and foreign jurisdictions. With few exceptions, including the proposed disallowance we discuss below, we are no longer subject to U.S.&#160;federal tax examination for years before 2013 or state, local, or non-U.S.&#160;income tax examinations for years before 2004. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2015, we received a final assessment from the Danish Tax Authority (SKAT) for fiscal 2009, regarding withholding taxes and the treatment of certain intercompany transactions involving our Danish affiliate and another of our affiliates.&#160;The audits of our tax filings for 2010 through 2013 are not completed but have been prepared in a manner consistent with prior filings, with similar transactions, which may result in an assessment for those years.&#160;The total amount assessed for 2009 is </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$49.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, including interest.&#160;For all periods potentially under dispute, we believe that positions taken in our tax filings are valid and we are contesting the assessment vigorously.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Federal Uncertain Tax Positions</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net effect of adjustments to our uncertain tax positions was a net benefit of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$24.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> primarily related to the state impact of a federal uncertain tax item. It is reasonably possible that we will adjust the value of our uncertain tax positions related to our unconsolidated joint business and certain transfer pricing issues as we receive additional information from various taxing authorities, including reaching settlements with the authorities. In addition, the Internal Revenue Service (IRS) and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2011, in conjunction with our examination, the IRS proposed a disallowance of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$130.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in deductions for tax years 2007, 2008 and 2009 related to payments for services provided by our wholly owned Danish subsidiary located in Hiller&#248;d, Denmark. We believe that these items represent valid deductible business expenses and are vigorously defending our position. We have initiated a mutual agreement procedure between the IRS and SKAT for the years 2001 through 2009, in an attempt to reach agreement on the issue. In addition, we have applied for a bilateral advanced pricing agreement for the years 2010 through 2014 to resolve similar issues for the subsequent years.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129188218768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock', window );">Foreign currency forward contracts that were entered into to hedge forecasted revenue</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="69%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Foreign Currency: (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>September 30, <br clear="none"/>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,146.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,174.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">17.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound sterling</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">12.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japanese yen</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Australian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,190.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,302.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of the effect of derivatives designated as hedging instruments on the condensed consolidated statements of income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments on our condensed consolidated statements of income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td width="20%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="19%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended September 30,</font></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Effective Portion)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized into Net Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Ineffective Portion)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">43.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td width="20%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="19%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months Ended September 30,</font></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Effective Portion)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized into Net Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Ineffective Portion)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">119.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of fair value and presentation of derivatives</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivatives including those designated as hedging instruments:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td width="42%" rowspan="1" colspan="1"></td><td width="42%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">Fair Value As of September 30, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">54.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">17.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4C<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624171-113959<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4A<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5618551-113959<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4B<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624163-113959<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the notional amounts of outstanding derivative positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1A<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5579245-113959<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129184954832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsInVariableInterestEntitiesAbstract', window );"><strong>Investments in Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Investments in Variable Interest Entities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Investments in Variable Interest Entities</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Neurimmune SubOne AG</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2007, we entered into a collaboration agreement with Neurimmune SubOne AG (Neurimmune), a subsidiary of Neurimmune AG, for the development and commercialization of antibodies for the treatment of Alzheimer&#8217;s disease. Neurimmune conducts research to identify potential therapeutic antibodies and we are responsible for the development, manufacturing and commercialization of all products. Our anti-amyloid beta antibody, aducanumab (BIIB037), for the treatment of Alzheimer&#8217;s disease resulted from this collaboration. In September 2015, we announced that the first patient had been enrolled in a Phase 3 trial for aducanumab, which triggered a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone payment due to Neurimmune. As we consolidate the financial results of Neurimmune, we recognized this payment as a charge to noncontrolling interest in the third quarter of 2015. Based upon our current development plans, we may pay Neurimmune up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$275.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in remaining milestone payments. We may also pay royalties in the low-to-mid-teens on sales of any resulting commercial products.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts that are incurred by Neurimmune for research and development expenses in support of the collaboration that we reimburse are reflected in research and development expense in our condensed consolidated statements of income. Future milestone payments, if any, will be reflected in our condensed consolidated statements of income as a charge to noncontrolling interest, net of tax, when such milestones are achieved.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the collaboration incurred expenses totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$39.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$87.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which is included in total costs and expenses in our condensed consolidated statements of income, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$29.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Neurimmune are not significant to our financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Unconsolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have relationships with other variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the total carrying value of our investments in biotechnology companies totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our maximum exposure to losses related to these variable interest entities is limited to the carrying value of our investments.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income, as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our investments in variable interest entities, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsInVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments In Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsInVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=52262685&amp;loc=SL6759159-111685<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=52262685&amp;loc=d3e5728-111685<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=52262685&amp;loc=d3e5710-111685<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129205493632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract', window );"><strong>Reconciliation of equity attributable to non-controlling interests</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">NCI, beginning of period</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="nump">$ 5,030<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to NCI, net of tax</a></td>
<td class="nump">53,871<span></span>
</td>
<td class="num">(738)<span></span>
</td>
<td class="nump">49,053<span></span>
</td>
<td class="nump">7,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination', window );">Fair value of net assets and liabilities acquired and assigned to NCI</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distribution to noncontrolling interest</a></td>
<td class="num">(60,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(60,000)<span></span>
</td>
<td class="num">(9,100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Translation adjustment and other</a></td>
<td class="num">(300)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">NCI, end of period</a></td>
<td class="num">$ (5,783)<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="num">$ (5,783)<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Noncontrollinginterestincreasedecreaseother">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling interest, increase (decrease) other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Noncontrollinginterestincreasedecreaseother</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation of equity attributable to non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 27<br><br><br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 4J<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in noncontrolling interest balance because of a business combination that occurred during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1A<br><br><br><br> -Subparagraph (c)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (e)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129120694448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 2,764,492<span></span>
</td>
<td class="nump">$ 2,058,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">444,100<span></span>
</td>
<td class="nump">530,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">131,537<span></span>
</td>
<td class="nump">119,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(185,802)<span></span>
</td>
<td class="num">(229,273)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">31,564<span></span>
</td>
<td class="num">(95,711)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(63,608)<span></span>
</td>
<td class="num">(297,057)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(150,387)<span></span>
</td>
<td class="num">(119,890)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(174,532)<span></span>
</td>
<td class="nump">19,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other changes in operating assets and liabilities, net</a></td>
<td class="num">(121,659)<span></span>
</td>
<td class="nump">22,904<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows provided by operating activities</a></td>
<td class="nump">2,675,705<span></span>
</td>
<td class="nump">2,009,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">3,363,374<span></span>
</td>
<td class="nump">1,942,871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(4,870,142)<span></span>
</td>
<td class="num">(2,738,584)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions of business, net of cash acquired</a></td>
<td class="num">(198,798)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(456,885)<span></span>
</td>
<td class="num">(180,854)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Contingent consideration related to Fumapharm AG acquisition</a></td>
<td class="nump">550,000<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="num">(33,620)<span></span>
</td>
<td class="num">(13,131)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows used in investing activities</a></td>
<td class="num">(2,746,071)<span></span>
</td>
<td class="num">(1,164,698)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury stock</a></td>
<td class="num">(2,998,190)<span></span>
</td>
<td class="num">(359,981)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of stock for share-based compensation arrangements</a></td>
<td class="num">(45,509)<span></span>
</td>
<td class="num">(44,960)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from borrowings</a></td>
<td class="nump">5,930,936<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of borrowings</a></td>
<td class="num">(2,083)<span></span>
</td>
<td class="num">(2,674)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities', window );">Excess tax benefit from stock options</a></td>
<td class="nump">70,778<span></span>
</td>
<td class="nump">90,423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(62,147)<span></span>
</td>
<td class="num">(15,336)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows provided by (used in) financing activities</a></td>
<td class="nump">2,984,803<span></span>
</td>
<td class="num">(242,608)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">2,914,437<span></span>
</td>
<td class="nump">601,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(30,358)<span></span>
</td>
<td class="num">(18,227)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of the period</a></td>
<td class="nump">1,204,924<span></span>
</td>
<td class="nump">602,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of the period</a></td>
<td class="nump">$ 4,089,003<span></span>
</td>
<td class="nump">$ 1,186,281<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 230<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 6<br><br><br><br> -Section I<br><br><br><br> -Subsection 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 230<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11374-113907<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other assets used in operating activities less other operating liabilities used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets and liabilities, other noncurrent assets and liabilities, or a combination of other current and noncurrent assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other income (expense) included in net income that results in no cash inflows or outflows in the period. Includes noncash adjustments to reconcile net income (loss) to cash provided by (used in) operating activities that are not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash outflow or inflow from other investing activities. This element is used when there is not a more specific and appropriate element in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3098-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3095-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (a),(b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26853-111562<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of or capital improvements on other tangible or intangible assets not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total cash inflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards, including stock option exercises. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow from other financing activities. This element is used when there is not a more specific and appropriate element in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3095-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3098-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 12<br><br><br><br> -Subparagraph (a),(b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3179-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26853-111562<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 19<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569616-111683<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 4K<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591552-111686<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1A<br><br><br><br> -Subparagraph (a),(c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 4J<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129188046512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 965,622<span></span>
</td>
<td class="nump">$ 856,858<span></span>
</td>
<td class="nump">$ 2,715,439<span></span>
</td>
<td class="nump">$ 2,051,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on securities available for sale, net of tax of $(1,320) and $(6) for the three months ended September 30, 2015 and 2014, respectively; and $(699) and $(3,021) for the nine months ended September 30, 2015 and 2014, respectively</a></td>
<td class="num">(2,239)<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="num">(1,154)<span></span>
</td>
<td class="num">(5,127)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax', window );">Unrealized gains (losses) on cash flow hedges, net of tax of $(187) and $302 for the three months ended September 30, 2015 and 2014, respectively; and $(229) and $307 for the nine months ended September 30, 2015 and 2014, respectively</a></td>
<td class="num">(31,171)<span></span>
</td>
<td class="nump">48,242<span></span>
</td>
<td class="num">(40,084)<span></span>
</td>
<td class="nump">64,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Unrealized gains (losses) on pension benefit obligation</a></td>
<td class="nump">523<span></span>
</td>
<td class="nump">691<span></span>
</td>
<td class="nump">4,632<span></span>
</td>
<td class="nump">1,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="num">(23,504)<span></span>
</td>
<td class="num">(60,254)<span></span>
</td>
<td class="num">(61,322)<span></span>
</td>
<td class="num">(71,246)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="num">(56,391)<span></span>
</td>
<td class="num">(11,309)<span></span>
</td>
<td class="num">(97,928)<span></span>
</td>
<td class="num">(10,242)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Biogen Inc.</a></td>
<td class="nump">909,231<span></span>
</td>
<td class="nump">845,549<span></span>
</td>
<td class="nump">2,617,511<span></span>
</td>
<td class="nump">2,041,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">53,586<span></span>
</td>
<td class="num">(738)<span></span>
</td>
<td class="nump">49,053<span></span>
</td>
<td class="nump">7,660<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">$ 962,817<span></span>
</td>
<td class="nump">$ 844,811<span></span>
</td>
<td class="nump">$ 2,666,564<span></span>
</td>
<td class="nump">$ 2,048,738<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e557-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 21<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4613674-111683<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 20<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569643-111683<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 4K<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591552-111686<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 19<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569616-111683<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 4K<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591552-111686<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 10A<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 10A<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 20<br><br><br><br> -Subparagraph (b,c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32211-110900<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 10A<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669619-108580<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1B<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669625-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51821188&amp;loc=d3e1436-108581<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of (increase) decrease in accumulated other comprehensive (income) loss related to pension and other postretirement defined benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 10A<br><br><br><br> -Subparagraph (i-k)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129204684768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness Indebtedness<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Indebtedness</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2015 Senior Notes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On September 15, 2015, we issued senior unsecured notes for an aggregate principal amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, consisting of the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15, 2020, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.792%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">3.625%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15, 2022, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.920%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">4.05%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15, 2025, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.764%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">5.20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15,&#160;2045, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.294%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These notes are senior unsecured obligations and may be redeemed at our option at the greater of (1) </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the principal amount plus accrued and unpaid interest or (2) the sum of the present values of the remaining scheduled payments of interest and principal discounted to the date of redemption on a semi-annual basis at the treasury rate plus an incremental margin, plus, in either case, accrued and unpaid interest. The notes also contain a change of control provision that may require us to purchase the notes at a price equal to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the principal amount plus accrued and unpaid interest to the date of purchase under certain circumstances. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The costs associated with this offering of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$47.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> have been recorded as a reduction to the carrying amount of the debt on our condensed consolidated balance sheet. These costs will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. The discounts will be amortized as additional interest expense over the period from issuance through maturity using the effective interest rate method. Interest on the notes is payable March 15 and September 15 of each year. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additionally, in connection with this offering, we entered into interest rate swaps. The carrying value of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes includes approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to changes in the fair value of the interest rate swaps. For additional information, please read Note 8, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Credit Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2015, we entered into a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> senior unsecured revolving credit facility, under which we are permitted to draw funds for working capital and general corporate purposes for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of September 30, 2015, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> outstanding borrowings and were in compliance with all covenants under this facility.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129185150544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Oct. 16, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000875045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,903,109<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation 12B<br><br><br><br> -Number 240<br><br><br><br> -Section 12b<br><br><br><br> -Subsection 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation 12B<br><br><br><br> -Number 240<br><br><br><br> -Section 12b<br><br><br><br> -Subsection 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129197732608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Equity</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total equity as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> decreased </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$247.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Significant changes were as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additional paid in capital was reduced by share repurchases of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$2,998.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as described below, and activity under our share-based compensation arrangements totaling </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$144.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive losses of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$97.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc. of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$2,715.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchases</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2015, our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2015 Share Repurchase Program). This authorization does not have an expiration date. Repurchased shares will be retired. The 2015 Share Repurchase Program is in addition to the approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares remaining under our February 2011 Share Repurchase Program (2011 Share Repurchase Program), which has been used principally to offset common stock issuances under our share-based compensation plans.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2,998.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under our 2015 Share Repurchase Program, which had the effect of reducing additional paid in capital by a similar amount.&#160;We did not repurchase any shares of common stock under our 2011 Share Repurchase Program. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we purchased approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$360.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under our 2011 Share Repurchase Program. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, additional paid in capital totaled approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,342.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Noncontrolling Interests</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table reconciles equity attributable to noncontrolling interests (NCI):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NCI, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income (loss) attributable to NCI, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">53.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">49.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value of net assets and liabilities acquired and assigned to NCI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Distribution to NCI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(60.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(60.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Translation adjustment and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NCI, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(5.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(5.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, net income (loss) attributable to NCI, net of tax, was related to a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone payment made to Neurimmune SubOne AG. For additional information, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (SAB TOPIC 4.C)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Preferred Stock<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section C<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129118104080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail Other Consolidated Financial Statement (Details Textual)<br> $ in Thousands, &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">$ 2,391,717<span></span>
</td>
<td class="nump">$ 2,117,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,762,605<span></span>
</td>
<td class="nump">$ 5,916,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_IT', window );">Italy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent', window );">Amount reserved for this matter | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income during the current period and current obligations not separately disclosed in the balance sheet (other liabilities, current).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductLiabilityContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductLiabilityContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_IT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_IT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129120763936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Unaudited) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax', window );">Tax effect on net unrealized gains (losses) recognized on securities available for sale</a></td>
<td class="num">$ (1,320)<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
<td class="num">$ (699)<span></span>
</td>
<td class="num">$ (3,021)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax', window );">Tax effect of net unrealized gains (losses) recognized on cash flow hedges</a></td>
<td class="num">$ (187)<span></span>
</td>
<td class="nump">$ 302<span></span>
</td>
<td class="num">$ (229)<span></span>
</td>
<td class="nump">$ 307<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 10A<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e640-108580<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 10A<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e640-108580<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129187947488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Intangible Assets and Goodwill</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26" rowspan="1"></td></tr><tr><td width="21%" rowspan="1" colspan="1"></td><td width="17%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">543.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(499.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">43.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">543.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(481.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-23&#160;years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,005.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,523.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">481.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,005.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,396.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">608.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">735.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">735.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">314.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">314.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks&#160;and&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">tradenames</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed&#160;rights&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and&#160;patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3-17 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,297.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(440.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,856.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,280.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(300.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,980.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,645.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3,464.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,181.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,207.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,178.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,028.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amortization of acquired intangible assets totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$98.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$286.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$122.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$382.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in amortization of acquired intangible assets was primarily driven by higher expected lifetime revenues of AVONEX, partially offset by lower expected lifetime revenues of TYSABRI. Amortization of acquired intangible assets during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> included a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> impairment loss related to one of our IPR&amp;D intangible assets.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in amortization of acquired intangible assets was primarily driven by a decrease in AVONEX revenues during the comparative periods. Amortization of acquired intangible assets during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> included total impairment charges of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to one of our out-licensed patents and one of our IPR&amp;D intangible assets.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Developed Technology</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$472.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">IPR&amp;D</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IPR&amp;D represents the fair value assigned to research and development assets that we acquire that have not reached technological feasibility at the date of acquisition. Upon commercialization, we will determine the estimated useful life. In connection with our acquisition of Convergence in February 2015, we acquired IPR&amp;D programs with an estimated fair value of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$424.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This amount will be adjusted for foreign exchange rate fluctuations. For a more detailed description of this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Acquired and In-licensed Rights and Patents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of the TYSABRI rights from Elan Corporation plc (Elan). Elan was acquired by Perrigo Company plc (Perrigo) in December 2013. The net book value of this asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2,797.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Estimated Future Amortization of Intangible Assets </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption of intangible assets. Our most significant intangible assets are related to our AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of AVONEX and TYSABRI. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of either product.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long range planning cycle was updated in the third quarter of 2015. Based upon this analysis, there was not a significant change in our expected rate of amortization for acquired intangible assets and the estimated future amortization is expected to be as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="87%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>September 30, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015 (remaining three months)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">94.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">348.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">318.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">291.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">275.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">269.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,596.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="87%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,760.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase to goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">649.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,408.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in goodwill during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was related to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$600.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in contingent payments achieved (exclusive of a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$78.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> tax benefit) to former shareholders of Fumapharm AG or holders of their rights and our acquisition of Convergence. Other includes changes related to foreign exchange rate fluctuations. For additional information related to future contingent payments to the former shareholders of Fumapharm AG or holders of their rights, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements. For additional information related to our acquisition of Convergence, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> accumulated impairment losses related to goodwill.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final.  May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129323407392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Inventory</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="73%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>September 30, <br clear="none"/>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">221.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">128.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">537.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">511.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">159.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">164.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">918.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">804.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our inventory included </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$54.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with our ZINBRYTA, FLIXABI and BENEPALI programs, which have been capitalized in advance of regulatory approval. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our inventory included </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with our ZINBRYTA program, which had been capitalized in advance of regulatory approval.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 6<br><br><br><br> -Subparagraph a, b, c<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129197744208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Consolidated Financial Statement Detail</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Consolidated Financial Statement Detail</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Income (Expense), Net</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">13.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(15.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(28.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(22.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(18.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(7.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(15.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(41.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(17.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accrued Expenses and Other</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="73%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>September 30, <br clear="none"/>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">479.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">265.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related rebates</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">462.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">359.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">214.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">393.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">154.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">172.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">58.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">120.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">549.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">507.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,918.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,819.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Long-Term Liabilities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities consist of the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="73%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>September 30, <br clear="none"/>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">301.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">218.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">341.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">249.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other long-term liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">861.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">650.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Pricing of TYSABRI in Italy - AIFA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2011, Biogen Italia SRL (formerly Biogen Idec Italia SRL), our Italian subsidiary,&#160;received notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) that sales of TYSABRI after mid-February 2009 exceeded a reimbursement limit established pursuant to a Price Determination Resolution granted by AIFA in December 2006. In December 2011, we filed an appeal against AIFA in administrative court in Rome, Italy seeking a ruling that the reimbursement limit is unenforceable. That appeal is pending. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2014, AIFA eliminated the reimbursement limit from February 2013 going forward. As a result, in June 2014, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$53.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of TYSABRI revenues related to the periods beginning February 2013 that were previously deferred. AIFA and Biogen Italia SRL continue to discuss a possible resolution for the period between February 2009 and January 2013. We have approximately EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">75 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> recorded as accrued expenses and deferred revenue in our long-term liabilities in our condensed consolidated balance sheets for this matter.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information relating to our agreement with AIFA relating to sales of TYSABRI in Italy, please read Note 4, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Accounts Receivable</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129120384128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Accumulated Other Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td width="31%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">71.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(31.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(99.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(59.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">78.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(61.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">19.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(118.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(117.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(40.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(61.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(97.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">31.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(27.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(160.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(157.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td width="31%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(23.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(19.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(27.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(71.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(71.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of September 30, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(18.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(61.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(38.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td width="24%" rowspan="1" colspan="1"></td><td width="21%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from Accumulated Other Comprehensive Income</font></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">43.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">119.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">42.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">117.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e689-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669619-108580<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e640-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 17<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e716-108580<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 16<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e709-108580<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e681-108580<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Reclassification Adjustments<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6522872<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129197703520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2014</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_IT', window );">Italy</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementLimitStatedInResolution', window );">Reimbursement limit stated in the resolution</a></td>
<td class="text">24 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReimbursementLimitStatedInResolution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement limit stated in the resolution.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReimbursementLimitStatedInResolution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_IT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_IT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129120550368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Derivative Instruments</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the global nature of our operations, portions of our revenues are earned in currencies other than the U.S.&#160;dollar. The value of revenues measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign currency forward contracts in effect as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> had durations of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These contracts have been designated as cash flow hedges and accordingly, to the extent effective, any unrealized gains or losses on these foreign currency forward contracts are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses for the effective portion of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized. To the extent ineffective, hedge transaction gains and losses are reported in other income (expense), net.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="69%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Foreign Currency: (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>September 30, <br clear="none"/>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,146.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,174.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">17.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound sterling</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">12.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japanese yen</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Australian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,190.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,302.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The portion of the fair value of these foreign currency forward contracts that was included in accumulated other comprehensive income (loss) in total equity reflected gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$23.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$72.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We expect all contracts to be settled over the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months and any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, credit risk did not change the fair value of our foreign currency forward contracts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments on our condensed consolidated statements of income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td width="20%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="19%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended September 30,</font></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Effective Portion)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized into Net Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Ineffective Portion)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">43.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td width="20%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="19%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months Ended September 30,</font></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Effective Portion)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized into Net Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Ineffective Portion)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">119.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may enter into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Interest Rate Lock Contracts</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we entered into treasury rate locks that were designated as cash flow hedges to hedge against changes in the 10-year and 30-year U.S. treasury interest rates that could have impacted our anticipated debt offering. In connection with the issuance of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.05%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes, as described in Note 10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we settled the treasury rate locks and realized an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> gain. As the hedging relationship was effective, the gain was recorded in AOCI and will be recognized in other income (expense), net over the life of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.05%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">Interest Rate Swap Contracts</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the issuance of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes,  as described in Note 10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we entered into interest rate swaps with an aggregate notional amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$675.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes attributable to changes in interest rates. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recognized as a component of interest expense in our condensed consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Other Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also enter into other foreign currency forward contracts, usually with one month durations, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate notional amount of these outstanding foreign currency contracts was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$787.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$365.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to these contracts were recognized as a component of other income (expense), net, for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, as compared to net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While certain of our derivatives are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivatives including those designated as hedging instruments:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td width="42%" rowspan="1" colspan="1"></td><td width="42%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">Fair Value As of September 30, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">54.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">17.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6441202&amp;loc=d3e80720-113993<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4C<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624171-113959<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=d3e41620-113959<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4B<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624163-113959<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5579240-113959<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4D<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624177-113959<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736893&amp;loc=d3e80784-113994<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=d3e41641-113959<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5579245-113959<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4H<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624258-113959<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736893&amp;loc=d3e80748-113994<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4K<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5708775-113959<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4J<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5708773-113959<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5618551-113959<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1B<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5580258-113959<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4E<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624181-113959<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 25<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6886632&amp;loc=d3e76258-113986<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=d3e41638-113959<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(n))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129191593344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Summary of Contractual Maturities: Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less, estimated fair value</a></td>
<td class="nump">$ 1,753.5<span></span>
</td>
<td class="nump">$ 640.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less, amortized cost</a></td>
<td class="nump">1,753.0<span></span>
</td>
<td class="nump">640.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years, Estimated Fair Value</a></td>
<td class="nump">1,820.1<span></span>
</td>
<td class="nump">1,343.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years, Amortized Cost</a></td>
<td class="nump">1,820.3<span></span>
</td>
<td class="nump">1,345.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue', window );">Due after five years, estimated fair value</a></td>
<td class="nump">127.3<span></span>
</td>
<td class="nump">126.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost', window );">Due after five years, amortized cost</a></td>
<td class="nump">127.5<span></span>
</td>
<td class="nump">126.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Total available-for-sale securities, Fair Value</a></td>
<td class="nump">3,700.9<span></span>
</td>
<td class="nump">2,111.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total available-for-sale securities, Amortized Cost</a></td>
<td class="nump">$ 3,700.8<span></span>
</td>
<td class="nump">$ 2,112.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (aa)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph (aa)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26610-111562<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after adjustments of available-for-sale debt securities at cost, maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27198-111563<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 320<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27198-111563<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after adjustments of available-for-sale debt securities at cost, maturing in the next fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27198-111563<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27198-111563<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 320<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129120285168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</font></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of September 30, 2015 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,804.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,804.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,039.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,039.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,411.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,411.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">249.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">249.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">25.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">25.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">61.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">61.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">38.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">38.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,630.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">25.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,605.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">31.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">31.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">481.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">481.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">512.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">31.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">481.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2014 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">716.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">716.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,063.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,063.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">849.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">849.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">198.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">198.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">72.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">72.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,943.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,937.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">220.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> material impairments of our assets measured and carried at fair value during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In addition, there were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> changes in valuation techniques or inputs utilized or transfers between fair value measurement levels during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities was determined through third party pricing services. For a description of our validation procedures related to prices provided by third party pricing services, refer to Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies: Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K. For additional information related to our decision to no longer reflect our investments in venture capital funds within the fair value hierarchy, refer to Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies: New Accounting Pronouncements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Instruments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875% Senior Notes due March&#160;1, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">614.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">566.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">634.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">571.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,514.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,492.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,008.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">991.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,767.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,733.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,766.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,721.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,680.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,514.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">647.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">583.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of our notes payable to Fumedica was estimated using market observable inputs, including current interest and foreign currency exchange rates. The fair values of each of our series of Senior Notes were determined through market, observable, and corroborated sources. In accordance with ASU No. 2015-03, during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we reclassified </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our debt issuance costs related to our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes issued in 2008 from an asset to a reduction to the carrying amount of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes. For additional information related to our notes payable to Fumedica and our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes, please read Note 12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K. For additional information related to our Senior Notes issued on September 15, 2015, please read Note 10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the fair values of our contingent consideration obligations which includes Level 3 measurements:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">495.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">279.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">215.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">280.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">274.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(49.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(46.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(14.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(14.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(21.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">481.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">213.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">481.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">213.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$301.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$200.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of our contingent consideration obligations valued using Level 3 measurements were reflected as components of other long-term liabilities in our condensed consolidated balance sheets with the remaining balances reflected as a component of accrued expenses and other. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Convergence, we recorded a liability of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$274.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing the fair value of the contingent consideration. This valuation was based on probability weighted net cash outflow projections of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$450.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is the estimated cost of debt financing for market participants. This liability reflects the revised estimate from the date of acquisition for our initial clinical development plans, resulting probabilities of success and the timing of certain milestone payments. For a more detailed description of this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$176.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, related to our contingent consideration obligations arising from our acquisition of Convergence, is reflected as a component of accrued expenses and other in our condensed consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquired IPR&amp;D</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Convergence, we also allocated </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$424.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the total purchase price to acquired IPR&amp;D, which was capitalized as an intangible asset. The amount allocated to acquired IPR&amp;D was based on significant inputs not observable in the market and thus represented a Level 3 fair value measurement. This estimate was also adjusted from our preliminary estimate as of the date of acquisition to reflect revised estimates to our initial clinical development plans, resulting probabilities of success and the timing of certain milestone payments. These assets will be tested for impairment annually until commercialization, after which time the IPR&amp;D will be amortized over its estimated useful life. For a more detailed description of this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 30<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 21<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 16<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13504-108611<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129197778048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Financial Instruments</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Marketable Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize our marketable debt and equity securities, classified as available-for-sale:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of September 30, 2015 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">272.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">272.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">767.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">768.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,481.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,480.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">929.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">929.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">249.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">250.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,700.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,700.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">25.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">28.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2014 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">370.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">370.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">692.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">693.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">269.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">270.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">579.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">580.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">198.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">198.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,111.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,112.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">less than 90&#160;days</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from the date of purchase included in cash and cash equivalents on the accompanying condensed consolidated balance sheet:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="73%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>September 30, <br clear="none"/>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">21.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">188.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">305.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,119.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">321.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">475.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,804.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">716.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and our short-term debt securities approximate fair value due to their short term maturities. Our overnight reverse repurchase agreements are collateralized with agency-guaranteed mortgage securities and represent approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of total assets as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Contractual Maturities: Available-for-Sale Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities classified as available-for-sale by contractual maturity are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,753.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,753.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">640.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">640.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,820.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,820.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,343.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,345.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">127.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">127.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">126.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">126.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,700.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,700.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,111.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,112.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The average maturity of our marketable debt securities available-for-sale as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proceeds from Marketable Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,387.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">625.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,363.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,942.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Strategic Investments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$68.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$47.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which are included in investments and other assets in our accompanying condensed consolidated balance sheets. Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies and investments in venture capital funds where the underlying investments are in equity securities of biotechnology companies.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129187968048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Property, Plant and Equipment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are recorded at cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,320.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,186.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Research Triangle Park Facility Purchase</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On August 24, 2015, we purchased from Eisai, Inc. (Eisai) its drug product manufacturing facility and supporting infrastructure in Research Triangle Park (RTP), North Carolina for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$104.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The purchase price consisted of the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="87%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Buildings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">58.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Machinery and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">25.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Land</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">104.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On August 24, 2015, we also amended our existing </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> year lease related to Eisai's oral solid dose products manufacturing facility in RTP, North Carolina where we manufacture our and Eisai's oral solid dose products. As amended, the lease provides for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> year term and our agreement to purchase the facility upon expiration of the lease term and Eisai's completion of certain activities. Accordingly, we recorded the assets along with a corresponding financing obligation on our condensed consolidated balance sheet for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net present value of the future minimum lease payments. The assets were recorded as a component of buildings and machinery and equipment. We expect to complete the purchase of the oral solid products manufacturing facility at the end of the lease term in the third quarter of 2018.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13-14)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=d3e1361-107760<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51719941&amp;loc=d3e2921-110230<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129119588576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLowerRemainingMaturityRange1', window );">Lower range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeHigherRemainingMaturityRange1', window );">Higher range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax', window );">Gain/Loss on fair value of foreign currency forward contracts</a></td>
<td class="nump">$ 23.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1', window );">Expected settlement time for contracts, in months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Gain for treasury rate lock settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.7<span></span>
</td>
<td class="num">$ (11.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Net gains (losses) of other income (expense) related to foreign currency forward contracts</a></td>
<td class="nump">8.1<span></span>
</td>
<td class="nump">$ 7.7<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="nump">11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,302.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">787.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">787.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of Derivatives designated as Hedging Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value, net</a></td>
<td class="nump">54.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherInvestmentsMember', window );">Investments and other assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of Derivatives designated as Hedging Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value, net</a></td>
<td class="nump">5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of Derivatives designated as Hedging Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value, net</a></td>
<td class="nump">17.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other long-term liabilities | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of Derivatives designated as Hedging Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value, net</a></td>
<td class="nump">8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">1,190.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,190.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contract | Other current assets | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of Derivatives designated as Hedging Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value, net</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contract | Accrued expenses and other | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of Derivatives designated as Hedging Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value, net</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">675.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">675.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap | Investments and other assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of Derivatives designated as Hedging Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value, net</a></td>
<td class="nump">5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Net gains (losses) in product revenue for the settlement of certain effective cash flow hedge instruments</a></td>
<td class="nump">43.9<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">119.3<span></span>
</td>
<td class="num">(7.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense) | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Net gains (losses) in earnings of Foreign currency forward contracts due to hedge ineffectiveness</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="num">$ (0.5)<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_EUR', window );">Euro | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,174.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_EUR', window );">Euro | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">1,146.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,146.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_CAD', window );">Canadian Dollar | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_CAD', window );">Canadian Dollar | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">17.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_GBP', window );">British Pound Sterling | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_GBP', window );">British Pound Sterling | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_JPY', window );">Japanese Yen | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_JPY', window );">Japanese Yen | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">9.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_AUD', window );">Australian Dollar | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_AUD', window );">Australian Dollar | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember', window );">Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Gain for treasury rate lock settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78.6<span></span>
</td>
<td class="nump">$ 57.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember', window );">Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges | Interest rate locks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Gain for treasury rate lock settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DerivativeInstrumentsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative Instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DerivativeInstrumentsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 12<br><br><br><br> -Section 13<br><br><br><br> -Sentence Column B<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4B<br><br><br><br> -Subparagraph (a),(c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624163-113959<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 7<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51825145&amp;loc=SL20226000-175313<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 860<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4D<br><br><br><br> -Subparagraph (c)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51814546&amp;loc=SL51823488-111719<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 860<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4D<br><br><br><br> -Subparagraph (c)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51814546&amp;loc=SL51823488-111719<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4B<br><br><br><br> -Subparagraph (a),(c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624163-113959<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 7<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51825145&amp;loc=SL20226000-175313<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeHigherRemainingMaturityRange1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>High end period remaining until maturity for the derivative contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeHigherRemainingMaturityRange1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4C<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624171-113959<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4D<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624177-113959<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4C<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624171-113959<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 25<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)(1),(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6886632&amp;loc=d3e76258-113986<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLowerRemainingMaturityRange1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Low end period remaining until maturity of derivative contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLowerRemainingMaturityRange1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4C<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624171-113959<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4A<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5618551-113959<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of time remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51821188&amp;loc=d3e1436-108581<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_JPY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_JPY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_AUD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_AUD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=biib_InterestratelocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=biib_InterestratelocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129120054560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingences (Details) - Fumapharm AG - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2006</div></th>
<th class="th"><div>Jun. 30, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash portion of consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_FourbillionMember', window );">Four billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash portion of consideration</a></td>
<td class="nump">$ 550.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">4,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_FivebillionMember', window );">Five billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_SixbillionMember', window );">Six billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash portion of consideration</a></td>
<td class="nump">300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">6,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember', window );">Each additional one billion up to twenty billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">20,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_OneBillionMember', window );">One billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_ThreeBillionMember', window );">Three billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">$ 3,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevel">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative sales level</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevel</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_FourbillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_FourbillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_FivebillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_FivebillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_SixbillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_SixbillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_OneBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_OneBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_ThreeBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_ThreeBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129198890224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment Property, Plant and Equipment (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 1,320.5<span></span>
</td>
<td class="nump">$ 1,186.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Research Triangle Park facility purchase</a></td>
<td class="nump">$ 104.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Term of lease</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TermOfLease', window );">Term of amended lease</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligations', window );">Capital lease obligation</a></td>
<td class="nump">$ 20.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TermOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Of Lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TermOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.14)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal through the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 16<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the lessee's leasing arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129194109312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments Financial Instruments (Details Textual 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_StrategicInvestmentsMember', window );">Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="nump">$ 68.4<span></span>
</td>
<td class="nump">$ 47.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_StrategicInvestmentPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Strategic investment portfolio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_StrategicInvestmentPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_StrategicInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_StrategicInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129185035728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of assets and liabilities recorded at fair value</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</font></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of September 30, 2015 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,804.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,804.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,039.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,039.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,411.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,411.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">249.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">249.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">25.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">25.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">61.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">61.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">38.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">38.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,630.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">25.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,605.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">31.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">31.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">481.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">481.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">512.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">31.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">481.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2014 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">716.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">716.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,063.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,063.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">849.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">849.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">198.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">198.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">72.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">72.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,943.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,937.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">220.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Summary of fair and carrying value of debt instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875% Senior Notes due March&#160;1, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">614.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">566.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">634.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">571.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,514.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,492.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,008.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">991.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,767.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,733.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,766.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,721.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,680.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,514.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">647.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">583.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair value of contingent consideration obligations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the fair values of our contingent consideration obligations which includes Level 3 measurements:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">495.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">279.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">215.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">280.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">274.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(49.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(46.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(14.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(14.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(21.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">481.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">213.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">481.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">213.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19279-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19190-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129191569184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory Inventory (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InventoryVariousProgramsGross', window );">Inventory, Various Programs, Gross</a></td>
<td class="nump">$ 54.3<span></span>
</td>
<td class="nump">$ 6.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InventoryVariousProgramsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross inventory of various programs which have been capitalized in advance of regulatory approval.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InventoryVariousProgramsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129197760848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Share-based Payments</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-based Compensation Expense</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">68.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">78.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">17.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">99.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">115.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">28.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">167.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">193.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">25.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">159.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">186.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(6.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(46.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(55.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">19.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">113.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">130.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">33.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">30.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">94.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">86.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(9.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">17.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">28.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">167.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">193.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">25.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">159.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">186.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We estimate the fair value of our obligations associated with our performance and cash settled performance units at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Grants Under Share-based Compensation Plans</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our equity grants to employees, officers and directors under our current stock plans:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td width="73%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">181,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance shares</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">115,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">182,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">89,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">393,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">437,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Employee Stock Purchase Plan (ESPP)</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2015, our stockholders approved the Biogen Inc. 2015 Employee Stock Purchase Plan (ESPP). The ESPP, which became effective on July 1, 2015, replaced the Biogen Idec Inc. 1995 ESPP (1995 ESPP), which expired on June&#160;30, 2015. The maximum aggregate number of shares of our common stock that may be purchased under the ESPP is </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,200,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">98,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares were issued under our 1995 ESPP and 2015 ESPP, respectively, compared to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">150,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;shares issued under our 1995 ESPP in the prior year comparative period.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 40<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 50<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51659978&amp;loc=d3e25284-112666<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129389783216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Litigation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Litigation</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"> &#8217;755 Patent Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On May&#160;28, 2010, Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (manufacturer, marketer and seller of REBIF), Pfizer Inc. (co-marketer of REBIF), and Novartis Pharmaceuticals Corp. (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 (&#8217;755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the &#8217;755 Patent and that the patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. The court has consolidated the two lawsuits, and we refer to the two actions as the &#8220;Consolidated &#8217;755 Patent Actions.&#8221;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:12px;text-indent:17px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bayer, Pfizer, Novartis and EMD Serono have all filed counterclaims in the Consolidated &#8217;755 Patent Actions seeking declaratory judgments of patent invalidity and non-infringement, and seeking monetary relief in the form of costs and attorneys' fees, and EMD Serono and Bayer have each filed a counterclaim seeking a declaratory judgment that the &#8217;755 Patent is unenforceable based on alleged inequitable conduct. Bayer has also amended its complaint to seek such a declaration. No trial date has been set.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Italian National Medicines Agency</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2011, Biogen Italia SRL&#160;received notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) that sales of TYSABRI after mid-February 2009 exceeded a reimbursement limit established pursuant to a Price Determination Resolution (Price Resolution) granted by AIFA in December 2006. On December&#160;23, 2011, we filed an appeal in the Regional Administrative Tribunal of Lazio (Il Tribunale Amministrativo Regionale per il Lazio) in Rome, Italy seeking a ruling that the reimbursement limit in the Price Resolution should apply as written to only &#8220;the first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months&#8221; of TYSABRI sales, which ended in mid-February 2009. The appeal is still pending. In June 2014, AIFA approved a resolution affirming that there is no reimbursement limit from and after February 2013. AIFA and Biogen Italia SRL are discussing a possible resolution for the period from mid-February 2009 through January 2013.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Government Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We have also received a subpoena from the federal government for documents relating to our relationship with certain pharmacy benefit managers. We are cooperating with the government in these matters.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Qui Tam Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On July 6, 2015, four qui tam actions filed against us by relators suing on behalf of the United States and certain states were unsealed by the U.S. District Court for the District of Massachusetts. The actions, which have been administratively consolidated, allege sales and promotional activities in violation of the federal False Claims Act and state law counterparts, and seek single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. The United States has declined to intervene in two of the actions and has not made an intervention decision in the other two actions. We have not been served with any of the complaints. We have not formed an opinion that an unfavorable outcome in any of the actions is either &#8220;probable&#8221; or &#8220;remote&#8221; and are unable to estimate the magnitude or range of any potential loss.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Forward Pharma Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On November 18, 2014 Forward Pharma A/S (Forward Pharma) filed suit against us in the Regional Court of Dusseldorf, Germany alleging that TECFIDERA infringes German Utility Model DE&#160;20 2005 022 112&#160;U1, which was issued in April 2014 and expires in October 2015. Forward Pharma subsequently&#160;extended its allegations&#160;to assert that TECFIDERA infringes Forward Pharma's European Patent No. 2,801,355, which was issued in May 2015 and expires in October 2025. Forward Pharma seeks declarations of infringement and damages. A hearing has been scheduled for early 2016.&#160;We have not formed an opinion that an unfavorable outcome is either &#8220;probable&#8221; or &#8220;remote&#8221; and are unable to estimate the magnitude or range of any potential loss.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Securities Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On August 18, 2015, Nicole Tehrani filed an action in the U.S. District Court for the District of Massachusetts against Biogen, our Chief Executive Officer, George A. Scangos, and our Chief Financial Officer, Paul J. Clancy, alleging federal securities law violations under 15 U.S.C. &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5. The plaintiff seeks declaration of the action as a class action, certification of the plaintiff as a representative of the class and her counsel as class counsel, and an award to the plaintiff and the class of damages, interest, and attorneys' fees. We have not formed an opinion that an unfavorable outcome is either &#8220;probable&#8221; or &#8220;remote&#8221; and are unable to estimate the magnitude or range of any potential loss.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Patent Matter relating to ALPROLIX</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2015, Pfizer proposed that we discuss taking a license to its U.S. Patent No. 8,603,777&#160;(Expression of Factor VII and IX Activities in Mammalian Cells) and pay&#160;royalties on sales of ALPROLIX. We have not formed an opinion that an unfavorable outcome is either &#8220;probable&#8221; or &#8220;remote&#8221; and are unable to estimate the magnitude or range of any potential loss.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Product Liability and Other Legal Proceedings</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129120790672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Reserves for Discounts and Allowances (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract', window );"><strong>Summary of total product revenue reserves included in consolidated balance sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total reserves</a></td>
<td class="nump">$ 610.7<span></span>
</td>
<td class="nump">$ 483.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Reduction of accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract', window );"><strong>Summary of total product revenue reserves included in consolidated balance sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total reserves</a></td>
<td class="nump">148.0<span></span>
</td>
<td class="nump">124.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract', window );"><strong>Summary of total product revenue reserves included in consolidated balance sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total reserves</a></td>
<td class="nump">$ 462.7<span></span>
</td>
<td class="nump">$ 359.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of product revenue reserves included in consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 09<br><br><br><br> -Article 12<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129188101680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based compensation expense included in condensed consolidated statements of income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">68.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">78.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">17.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">99.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">115.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">28.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">167.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">193.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">25.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">159.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">186.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(6.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(46.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(55.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">19.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">113.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">130.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of share-based compensation expense associated with each of our share-based compensating programs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">33.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">30.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">94.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">86.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(9.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">17.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">28.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">167.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">193.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">25.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">159.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">186.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock', window );">Summary of equity grants to employees, officers and directors under our current stock plans</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our equity grants to employees, officers and directors under our current stock plans:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td width="73%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">181,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance shares</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">115,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">182,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">89,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">393,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">437,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of restricted stock unit grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.F)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section F<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129120535616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,089,003<span></span>
</td>
<td class="nump">$ 1,204,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">1,753,499<span></span>
</td>
<td class="nump">640,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">1,327,780<span></span>
</td>
<td class="nump">1,292,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DueFromUnconsolidatedJointBusiness', window );">Due from unconsolidated joint business, net</a></td>
<td class="nump">319,788<span></span>
</td>
<td class="nump">283,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">918,921<span></span>
</td>
<td class="nump">804,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">861,882<span></span>
</td>
<td class="nump">446,943<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">9,270,873<span></span>
</td>
<td class="nump">4,672,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">1,947,354<span></span>
</td>
<td class="nump">1,470,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">2,027,821<span></span>
</td>
<td class="nump">1,765,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">4,181,245<span></span>
</td>
<td class="nump">4,028,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">2,408,854<span></span>
</td>
<td class="nump">1,760,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Investments and other assets</a></td>
<td class="nump">892,221<span></span>
</td>
<td class="nump">617,536<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">20,728,368<span></span>
</td>
<td class="nump">14,314,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current portion of notes payable and other financing arrangements</a></td>
<td class="nump">5,171<span></span>
</td>
<td class="nump">3,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">458,672<span></span>
</td>
<td class="nump">168,058<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">251,228<span></span>
</td>
<td class="nump">229,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expenses and other</a></td>
<td class="nump">1,918,897<span></span>
</td>
<td class="nump">1,819,334<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,633,968<span></span>
</td>
<td class="nump">2,219,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable and other financing arrangements</a></td>
<td class="nump">6,529,275<span></span>
</td>
<td class="nump">580,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Long-term deferred tax liability</a></td>
<td class="nump">136,761<span></span>
</td>
<td class="nump">50,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">861,421<span></span>
</td>
<td class="nump">650,096<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">$ 10,161,425<span></span>
</td>
<td class="nump">$ 3,500,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Biogen Idec Inc. shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0005 per share</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,342,373<span></span>
</td>
<td class="nump">4,196,156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(157,416)<span></span>
</td>
<td class="num">(59,488)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">11,999,358<span></span>
</td>
<td class="nump">9,283,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost</a></td>
<td class="num">(2,611,713)<span></span>
</td>
<td class="num">(2,611,706)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Biogen Inc. shareholders&#8217; equity</a></td>
<td class="nump">10,572,726<span></span>
</td>
<td class="nump">10,809,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(5,783)<span></span>
</td>
<td class="nump">5,030<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">10,566,943<span></span>
</td>
<td class="nump">10,814,040<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 20,728,368<span></span>
</td>
<td class="nump">$ 14,314,781<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DueFromUnconsolidatedJointBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable from unconsolidated joint business for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DueFromUnconsolidatedJointBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e681-108580<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26626-111562<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments in debt and equity securities which are categorized neither as held-to-maturity nor trading and which are intended to be sold or mature more than one year from the balance sheet date or operating cycle, if longer. Such securities are reported at fair value; unrealized gains (losses) related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain (loss) of an Available-for-sale security that is designated as being hedged in a fair value hedge is recognized in earnings during the period of the hedge, as are other than temporary declines in fair value below the cost basis for investments in equity securities and debt securities that an entity intends to sell or it is more likely than not that it will be required to sell before the recovery of its amortized cost basis. Other than temporary declines in fair value below the cost basis for debt securities categorized as Available-for-sale that an entity does not intend to sell and for which it is not more likely than not that the entity will be required to sell before the recovery of its amortized cost basis are bifurcated into credit losses and losses related to all other factors. Other than temporary declines in fair value below cost basis related to credit losses are recognized in earnings, and losses related to all other factors are recognized in other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Available-for-Sale Securities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505594<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26626-111562<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, netted by jurisdiction and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31958-109318<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph ((a)(1),(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655945&amp;loc=d3e3927-108312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term debt, net of unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.16)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.16)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20, 22<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 27<br><br><br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 4I<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4590271-111686<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 16<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4568740-111683<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4568447-111683<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129197713008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Discounts and Allowances<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract', window );"><strong>Sales Discounts, Returns and Allowances, Goods [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Reserves for discounts and allowances</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">47.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">387.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">49.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">483.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">332.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,278.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">26.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,636.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(20.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(14.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(37.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(277.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(871.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1,151.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(40.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(271.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(321.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">59.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">500.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">50.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">610.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, included in our condensed consolidated balance sheets, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="73%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>September 30, <br clear="none"/>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">148.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">124.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">462.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">359.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reserves</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">610.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">483.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any allowance and reserve accounts (their beginning and ending balances, as well as a reconciliation by type of activity during the period). Alternatively, disclosure of the required information may be within the footnotes to the financial statements or a supplemental schedule to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 09<br><br><br><br> -Article 12<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129118142704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">$ 3,700.9<span></span>
</td>
<td class="nump">$ 2,111.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2.2)<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">3,700.8<span></span>
</td>
<td class="nump">2,112.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesCurrentMember', window );">Corporate debt securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">272.1<span></span>
</td>
<td class="nump">370.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">272.2<span></span>
</td>
<td class="nump">370.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesNonCurrentMember', window );">Corporate debt securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">767.8<span></span>
</td>
<td class="nump">692.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1.3)<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">768.4<span></span>
</td>
<td class="nump">693.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesCurrentMember', window );">Government securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">1,481.4<span></span>
</td>
<td class="nump">269.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">1,480.8<span></span>
</td>
<td class="nump">270.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesNonCurrentMember', window );">Government securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">929.7<span></span>
</td>
<td class="nump">579.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">929.2<span></span>
</td>
<td class="nump">580.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember', window );">Mortgage and other asset backed securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember', window );">Mortgage and other asset backed securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">249.9<span></span>
</td>
<td class="nump">198.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">250.2<span></span>
</td>
<td class="nump">198.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_EquitySecuritiesMember', window );">Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">25.7<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3.4)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">$ 28.2<span></span>
</td>
<td class="nump">$ 5.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph (aa)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26610-111562<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129189648336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships Collaborative and Other Relationships - Collaborations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 519,863<span></span>
</td>
<td class="nump">$ 417,174<span></span>
</td>
<td class="nump">$ 1,471,140<span></span>
</td>
<td class="nump">$ 1,393,331<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_MitsubishiTanabePharmaCorporationMember', window );">Mitsubishi Tanabe Pharma Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments</a></td>
<td class="nump">484,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">484,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AGTCMember', window );">AGTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">56,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Upfrontmilestonepayment', window );">Upfront milestone payment</a></td>
<td class="nump">124,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Purchaseofcommonstock', window );">Purchase of common stock</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and development</a></td>
<td class="nump">58,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseCosts', window );">Total licensing and fees</a></td>
<td class="nump">35,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Researchanddevelopmentservices', window );">Research and development services</a></td>
<td class="nump">8,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Premiumonequityinvestment', window );">Premium on equity investment</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SwedishOrphanBiovitrumMember', window );">Swedish Orphan Biovitrum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_LeadprogramsMember', window );">Lead programs | AGTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments</a></td>
<td class="nump">472,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">472,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_DiscoveryprogramsMember', window );">Discovery programs | AGTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments</a></td>
<td class="nump">$ 592,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 592,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Premiumonequityinvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Premium on equity investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Premiumonequityinvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Purchaseofcommonstock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Purchaseofcommonstock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Researchanddevelopmentservices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Researchanddevelopmentservices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Upfrontmilestonepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront milestone payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Upfrontmilestonepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.2(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicenseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Research and Development<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_MitsubishiTanabePharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_MitsubishiTanabePharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AGTCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AGTCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SwedishOrphanBiovitrumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SwedishOrphanBiovitrumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_LeadprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_LeadprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_DiscoveryprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_DiscoveryprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129197731600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details Textual) - USD ($)<br> $ in Thousands, shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to NCI, net of tax</a></td>
<td class="nump">$ 53,871<span></span>
</td>
<td class="num">$ (738)<span></span>
</td>
<td class="nump">$ 49,053<span></span>
</td>
<td class="nump">$ 7,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Common stock shares repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.7<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,998,190<span></span>
</td>
<td class="nump">$ 359,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityTextualAbstract', window );"><strong>Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityPeriodIncreaseDecrease', window );">Equity increase during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Adjustments to additional paid in capital, share-based compensation and exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income loss</a></td>
<td class="nump">56,391<span></span>
</td>
<td class="nump">11,309<span></span>
</td>
<td class="nump">97,928<span></span>
</td>
<td class="nump">10,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">965,622<span></span>
</td>
<td class="nump">$ 856,858<span></span>
</td>
<td class="nump">2,715,439<span></span>
</td>
<td class="nump">$ 2,051,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Common stock value authorized for repurchase</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased', window );">Common stock shares authorized remaining or repurchase</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">$ 1,342,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,342,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,196,156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember', window );">Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to NCI, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes in additional paid in capital related to exercise of share-based payments awards (such as stock options) and the amount of recognized equity-based compensation during the period (such as nonvested shares).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 4J<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669619-108580<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1B<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669625-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51821188&amp;loc=d3e1436-108581<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in stockholders' equity during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129341328720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Fumapharm AG</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2006, we acquired Fumapharm AG. As part of this acquisition we acquired FUMADERM and TECFIDERA (together, Fumapharm Products). We paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$220.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon the closing of the transaction and agreed to pay an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> if a Fumapharm Product was approved for MS in the U.S.&#160;or E.U. In the second quarter of 2013, we paid this </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> contingent payment as TECFIDERA was approved in the U.S. for MS by the U.S. Food and Drug Administration (FDA). We are also required to make additional contingent payments to former shareholders of Fumapharm AG or holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior twelve month period, as defined in the acquisition agreement. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$550.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in contingent payments as we reached the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> cumulative sales levels related to the Fumapharm Products in the fourth quarter of 2014 and second quarter of 2015, respectively, and accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon reaching </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in total cumulative sales of Fumapharm Products in the third quarter of 2015.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We will owe an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> contingent payment for every additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cumulative sales level of Fumapharm Products reached if the prior 12 months sales of the Fumapharm Products exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, until such time as the cumulative sales level reaches </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, at which time no further contingent payments shall be due. These payments will be accounted for as an increase to goodwill as incurred, in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm. Any portion of the payment which is tax deductible will be recorded as a reduction to goodwill. Payments are due within 60&#160;days following the end of the quarter in which the applicable cumulative sales level has been reached. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On June 30, 2015, we signed an agreement to purchase land in Solothurn, Switzerland for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Swiss Francs. The contract also includes certain environmental remediation costs. Our obligation to purchase the land is subject to customary closing conditions and a condition that no material adverse changes in our business, such as a decision to discontinue our aducanumab program, have occurred during the period.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 460<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51674963&amp;loc=d3e12565-110249<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 440<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.3.0.814</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>295</ContextCount>
  <ElementCount>330</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>102</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Condensed Consolidated Statements of Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002501 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1003501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Acquisitions Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsAcquisitions</Role>
      <ShortName>Acquisitions Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Reserves for Discounts and Allowances</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances</Role>
      <ShortName>Reserves for Discounts and Allowances</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Derivative Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstruments</Role>
      <ShortName>Derivative Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment</Role>
      <ShortName>Property, Plant and Equipment Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - Indebtedness Indebtedness</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessIndebtedness</Role>
      <ShortName>Indebtedness Indebtedness</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2117100 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2118100 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2119100 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2120100 - Disclosure - Share-based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPayments</Role>
      <ShortName>Share-based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2121100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2122100 - Disclosure - Other Consolidated Financial Statement Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</Role>
      <ShortName>Other Consolidated Financial Statement Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2123100 - Disclosure - Investments in Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities</Role>
      <ShortName>Investments in Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2124100 - Disclosure - Collaborative and Other Relationships</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationships</Role>
      <ShortName>Collaborative and Other Relationships</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2125100 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2126100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2127100 - Disclosure - Subsequent Events Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents</Role>
      <ShortName>Subsequent Events Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Acquisitions Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsAcquisitionsTables</Role>
      <ShortName>Acquisitions Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AcquisitionsAcquisitions</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Reserves for Discounts and Allowances (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables</Role>
      <ShortName>Reserves for Discounts and Allowances (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Inventory</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurements</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstruments</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Derivative Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsTables</Role>
      <ShortName>Derivative Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstruments</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2314301 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2317301 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Equity</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2318301 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2319301 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsPerShare</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2320301 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2321301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxes</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2322301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2401402 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Acquisitions  Acquisitions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails</Role>
      <ShortName>Acquisitions  Acquisitions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - Acquisitions Acquisitions (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails1</Role>
      <ShortName>Acquisitions Acquisitions (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AcquisitionsAcquisitionsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2404404 - Disclosure - Acquisitions Acquisitions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetailsTextual</Role>
      <ShortName>Acquisitions Acquisitions (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AcquisitionsAcquisitionsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Reserves for Discounts and Allowances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails</Role>
      <ShortName>Reserves for Discounts and Allowances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Reserves for Discounts and Allowances (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1</Role>
      <ShortName>Reserves for Discounts and Allowances (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InventoryTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Inventory Inventory (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryInventoryDetailsTextual</Role>
      <ShortName>Inventory Inventory (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Intangible Assets and Goodwill (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1</Role>
      <ShortName>Intangible Assets and Goodwill (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Fair Value Measurements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails2</Role>
      <ShortName>Fair Value Measurements (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Fair Value Measurements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual</Role>
      <ShortName>Fair Value Measurements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Financial Instruments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails1</Role>
      <ShortName>Financial Instruments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Financial Instruments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails2</Role>
      <ShortName>Financial Instruments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Financial Instruments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails3</Role>
      <ShortName>Financial Instruments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Financial Instruments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual</Role>
      <ShortName>Financial Instruments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2410407 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2</Role>
      <ShortName>Financial Instruments Financial Instruments (Details Textual 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDetails</Role>
      <ShortName>Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstrumentsTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2414402 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2414403 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetailsTextual</Role>
      <ShortName>Property, Plant and Equipment Property, Plant and Equipment (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2416401 - Disclosure - Indebtedness Idebtedness (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessIdebtednessDetails</Role>
      <ShortName>Indebtedness Idebtedness (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2417402 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EquityTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2417403 - Disclosure - Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityDetailsTextual</Role>
      <ShortName>Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EquityTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2418402 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2418403 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2419402 - Disclosure - Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsPerShareTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2420402 - Disclosure - Share-Based Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails</Role>
      <ShortName>Share-Based Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2420403 - Disclosure - Share-Based Payments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails1</Role>
      <ShortName>Share-Based Payments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2420404 - Disclosure - Share-Based Payments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails2</Role>
      <ShortName>Share-Based Payments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2420405 - Disclosure - Share-Based Payments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual</Role>
      <ShortName>Share-Based Payments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2421402 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2421403 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2422402 - Disclosure - Other Consolidated Financial Statement Detail (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2422403 - Disclosure - Other Consolidated Financial Statement Detail Other Consolidated Financial Statement (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual</Role>
      <ShortName>Other Consolidated Financial Statement Detail Other Consolidated Financial Statement (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2423401 - Disclosure - Investments in Variable Interest Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails</Role>
      <ShortName>Investments in Variable Interest Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2424401 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships - Collaborations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails</Role>
      <ShortName>Collaborative and Other Relationships Collaborative and Other Relationships - Collaborations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2424402 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships - Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails</Role>
      <ShortName>Collaborative and Other Relationships Collaborative and Other Relationships - Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2425401 - Disclosure - Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LitigationDetails</Role>
      <ShortName>Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Litigation</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2426401 - Disclosure - Commitments and Contingences (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CommitmentsAndContingencesDetails</Role>
      <ShortName>Commitments and Contingences (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>2426402 - Disclosure - Commitments and Contingencies Commitments and Contingencies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1</Role>
      <ShortName>Commitments and Contingencies Commitments and Contingencies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="biib-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>2427401 - Disclosure - Subsequent Events Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents</ParentRole>
      <Position>87</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">In ''Condensed Consolidated Balance Sheets (Unaudited)'', column(s) 2, 4, 5, 6 are contained in other reports, so were removed by flow through suppression.</Log>
    <Log type="Info">In ''Condensed Consolidated Statements of Cash Flows (Unaudited)'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression.</Log>
  </Logs>
  <InputFiles>
    <File>biib-20150930.xml</File>
    <File>biib-20150930_cal.xml</File>
    <File>biib-20150930_def.xml</File>
    <File>biib-20150930_lab.xml</File>
    <File>biib-20150930_pre.xml</File>
    <File>biib-20150930.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129120486752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">$ 28.3<span></span>
</td>
<td class="nump">$ 58.9<span></span>
</td>
<td class="nump">$ 167.6<span></span>
</td>
<td class="nump">$ 193.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(2.8)<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="num">(8.4)<span></span>
</td>
<td class="num">(7.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">25.5<span></span>
</td>
<td class="nump">56.6<span></span>
</td>
<td class="nump">159.2<span></span>
</td>
<td class="nump">186.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">7.3<span></span>
</td>
<td class="nump">7.1<span></span>
</td>
<td class="nump">33.4<span></span>
</td>
<td class="nump">30.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">30.4<span></span>
</td>
<td class="nump">28.2<span></span>
</td>
<td class="nump">94.1<span></span>
</td>
<td class="nump">86.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_CashSettledPerformanceSharesMember', window );">Cash settled performance shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">(9.5)<span></span>
</td>
<td class="nump">15.2<span></span>
</td>
<td class="nump">17.5<span></span>
</td>
<td class="nump">50.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=us-gaap_PerformanceSharesMember', window );">Performance units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">(2.8)<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
<td class="nump">11.6<span></span>
</td>
<td class="nump">16.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="nump">$ 11.0<span></span>
</td>
<td class="nump">$ 10.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of share-based compensation expense associated with different programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.F)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section F<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense, net of income tax, recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the compensation cost capitalized during the period arising from equity-based compensation arrangements (for example, shares of stock, units, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)(ii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129188077760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock', window );">Reconciliation of equity attributable to noncontrolling interests</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table reconciles equity attributable to noncontrolling interests (NCI):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NCI, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income (loss) attributable to NCI, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">53.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">49.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value of net assets and liabilities acquired and assigned to NCI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Distribution to NCI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(60.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(60.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Translation adjustment and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NCI, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(5.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(5.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation of equity attributable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140129197713008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Earnings&#160;per Share</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">965.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">856.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,715.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,051.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">232.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">234.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">232.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">234.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were not significant.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1278-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 52<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
